{"doc_key": "839274", "sentences": [["Hepatic", "adenomas", "and", "focal", "nodular", "hyperplasia", "of", "the", "liver", "in", "young", "women", "on", "oral", "contraceptives", ":", "case", "reports", ".", "Two", "cases", "of", "hepatic", "adenoma", "and", "one", "of", "focal", "nodular", "hyperplasia", "presumably", "associated", "with", "the", "use", "of", "oral", "contraceptives", ",", "are", "reported", ".", "Special", "reference", "is", "made", "to", "their", "clinical", "presentation", ",", "which", "may", "be", "totally", "asymptomatic", ".", "Liver", "-", "function", "tests", "are", "of", "little", "diagnostic", "value", ",", "but", "valuable", "information", "may", "be", "obtained", "from", "both", "liver", "scanning", "and", "hepatic", "angiography", ".", "Histologic", "differences", "and", "clinical", "similarities", "between", "hepatic", "adenoma", "and", "focal", "nodular", "hyperplasia", "of", "the", "liver", "are", "discussed", "."]], "ner": [[[13, 14, "Chemical"], [36, 37, "Chemical"], [1, 1, "Disease"], [23, 23, "Disease"], [88, 88, "Disease"], [3, 5, "Disease"], [27, 29, "Disease"], [90, 92, "Disease"]]], "relations": [[[13, 14, 1, 1, "CID"], [13, 14, 23, 23, "CID"], [13, 14, 88, 88, "CID"], [36, 37, 1, 1, "CID"], [36, 37, 23, 23, "CID"], [36, 37, 88, 88, "CID"], [13, 14, 3, 5, "CID"], [13, 14, 27, 29, "CID"], [13, 14, 90, 92, "CID"], [36, 37, 3, 5, "CID"], [36, 37, 27, 29, "CID"], [36, 37, 90, 92, "CID"]]], "clusters": [], "translated": "服用<0>口服避孕药</0>的年轻女性肝脏<2>腺瘤</2>和<5>局灶性结节性增生</5>：病例报告。据报道，两例肝<3>腺瘤</3>和一例<6>局灶性结节性增生</6>可能与使用<1>口服避孕药</1>有关。特别提到他们的临床表现，可能完全没有症状。肝功能检查诊断价值不大，但可从肝脏扫描和肝血管造影中获得有价值的信息。讨论了肝脏<4>腺瘤</4>和<7>局灶性结节性增生</7>的组织学差异和临床相似性。", "revised": true}
{"doc_key": "6504332", "sentences": [["Phenobarbital", "-", "induced", "dyskinesia", "in", "a", "neurologically", "-", "impaired", "child", ".", "A", "2", "-", "year", "-", "old", "child", "with", "known", "neurologic", "impairment", "developed", "a", "dyskinesia", "soon", "after", "starting", "phenobarbital", "therapy", "for", "seizures", ".", "Known", "causes", "of", "movement", "disorders", "were", "eliminated", "after", "evaluation", ".", "On", "repeat", "challenge", "with", "phenobarbital", ",", "the", "dyskinesia", "recurred", ".", "Phenobarbital", "should", "be", "added", "to", "the", "list", "of", "anticonvulsant", "drugs", "that", "can", "cause", "movement", "disorders", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [47, 47, "Chemical"], [53, 53, "Chemical"], [3, 3, "Disease"], [24, 24, "Disease"], [50, 50, "Disease"], [6, 8, "Disease"], [20, 21, "Disease"], [31, 31, "Disease"], [36, 37, "Disease"], [66, 67, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 24, 24, "CID"], [0, 0, 50, 50, "CID"], [28, 28, 3, 3, "CID"], [28, 28, 24, 24, "CID"], [28, 28, 50, 50, "CID"], [47, 47, 3, 3, "CID"], [47, 47, 24, 24, "CID"], [47, 47, 50, 50, "CID"], [53, 53, 3, 3, "CID"], [53, 53, 24, 24, "CID"], [53, 53, 50, 50, "CID"]]], "clusters": [], "translated": " <0>苯巴比妥</0> 诱发<4>运动障碍</4><7>神经受损</7>儿童。一名患有已知<8>神经功能障碍</8>的2岁儿童，在开始<1>苯巴比妥</1>治疗<9>癫痫发作</9>后不久就出现了<5>运动障碍</5>。评估后消除了已知<10>运动障碍</10>的原因。在用<2>苯巴比妥</2>重复挑战时，<6>运动障碍</6>再次出现。<3>苯巴比妥</3>应加入可引起<11>运动障碍</11>的抗惊厥药物清单。", "revised": true}
{"doc_key": "2917114", "sentences": [["Glycopyrronium", "requirements", "for", "antagonism", "of", "the", "muscarinic", "side", "effects", "of", "edrophonium", ".", "We", "have", "compared", ",", "in", "60", "adult", "patients", ",", "the", "cardiovascular", "effects", "of", "glycopyrronium", "5", "micrograms", "kg", "-", "1", "and", "10", "micrograms", "kg", "-", "1", "given", "either", "simultaneously", "or", "1", "min", "before", "edrophonium", "1", "mg", "kg", "-", "1", ".", "Significant", "differences", "between", "the", "four", "groups", "were", "detected", "(", "P", "less", "than", "0", ".", "001", ")", ".", "Both", "groups", "receiving", "10", "micrograms", "kg", "-", "1", "showed", "increases", "in", "heart", "rate", "of", "up", "to", "30", "beat", "min", "-", "1", "(", "95", "%", "confidence", "limits", "28", "-", "32", "beat", "min", "-", "1", ")", ".", "Use", "of", "glycopyrronium", "5", "micrograms", "kg", "-", "1", "provided", "greater", "cardiovascular", "stability", "and", ",", "given", "1", "min", "before", "the", "edrophonium", ",", "was", "sufficient", "to", "minimize", "early", ",", "edrophonium", "-", "induced", "bradycardias", ".", "This", "low", "dose", "of", "glycopyrronium", "provided", "good", "control", "of", "oropharyngeal", "secretions", "."]], "ner": [[[10, 10, "Chemical"], [44, 44, "Chemical"], [122, 122, "Chemical"], [130, 130, "Chemical"], [133, 133, "Disease"], [0, 0, "Chemical"], [25, 25, "Chemical"], [105, 105, "Chemical"], [139, 139, "Chemical"]]], "relations": [[[10, 10, 133, 133, "CID"], [44, 44, 133, 133, "CID"], [122, 122, 133, 133, "CID"], [130, 130, 133, 133, "CID"]]], "clusters": [], "translated": "<5>格隆铵</5> 对<0>edrophonium</0>毒蕈碱副作用的拮抗作用的要求。我们在60名成年患者中比较了<6>格隆铵</6> 5 微克kg-1和10微克kg-1同时给予或在<1>edrophonium</1> 1 mgkg-1前1分钟给予的心血管效应。检测到四组之间存在显着差异（P小于0.001）。接受10微克kg-1的两组均显示心率增加高达30次min-1（95%置信限度为28-32次min-1）。使用<7>格隆铵</7> 5 微克kg-1可提供更好的心血管稳定性，并且在<2>edrophonium</2>前1分钟给药，足以最大限度地减少早期<3>edrophonium</3>诱发的<4>心动过缓</4>。这种低剂量的<8>格隆铵</8>可以很好地控制口咽分泌物。", "revised": true}
{"doc_key": "2339463", "sentences": [["Cerebral", "sinus", "thrombosis", "as", "a", "potential", "hazard", "of", "antifibrinolytic", "treatment", "in", "menorrhagia", ".", "We", "describe", "a", "42", "-", "year", "-", "old", "woman", "who", "developed", "superior", "sagittal", "and", "left", "transverse", "sinus", "thrombosis", "associated", "with", "prolonged", "epsilon", "-", "aminocaproic", "acid", "therapy", "for", "menorrhagia", ".", "This", "antifibrinolytic", "agent", "has", "been", "used", "in", "women", "with", "menorrhagia", "to", "promote", "clotting", "and", "reduce", "blood", "loss", ".", "Although", "increased", "risk", "of", "thromboembolic", "disease", "has", "been", "reported", "during", "treatment", "with", "epsilon", "-", "aminocaproic", "acid", ",", "cerebral", "sinus", "thrombosis", "has", "not", "been", "previously", "described", ".", "Careful", "use", "of", "epsilon", "-", "aminocaproic", "acid", "therapy", "is", "recommended", "."]], "ner": [[[34, 37, "Chemical"], [72, 75, "Chemical"], [89, 92, "Chemical"], [25, 30, "Disease"], [0, 2, "Disease"], [77, 79, "Disease"], [11, 11, "Disease"], [40, 40, "Disease"], [51, 51, "Disease"], [57, 58, "Disease"], [64, 65, "Disease"]]], "relations": [[[34, 37, 25, 30, "CID"], [72, 75, 25, 30, "CID"], [89, 92, 25, 30, "CID"]]], "clusters": [], "translated": " <4>脑窦血栓形成</4>作为抗纤维蛋白溶解治疗的潜在危害<6>月经过多</6>。我们描述了一名42岁的女性，她因<7>月经过多</7>的长期<0>ε-氨基己酸</0>治疗而出现上<3>矢状窦</3>和<3>左侧横窦</3>血栓形成。这种抗纤维蛋白溶解剂已用于<8>月经过多</8>的女性，以促进凝血并减少<9>失血</9>。尽管据报道，在使用<1>ε-氨基己酸</1>治疗期间会增加<10>血栓栓塞性疾病</10>的风险，但之前并未描述过<5>脑窦血栓形成</5>。推荐谨慎使用<2>ε-氨基己酸</2>疗法。", "revised": true}
{"doc_key": "6794356", "sentences": [["Tricuspid", "valve", "regurgitation", "and", "lithium", "carbonate", "toxicity", "in", "a", "newborn", "infant", ".", "A", "newborn", "with", "massive", "tricuspid", "regurgitation", ",", "atrial", "flutter", ",", "congestive", "heart", "failure", ",", "and", "a", "high", "serum", "lithium", "level", "is", "described", ".", "This", "is", "the", "first", "patient", "to", "initially", "manifest", "tricuspid", "regurgitation", "and", "atrial", "flutter", ",", "and", "the", "11th", "described", "patient", "with", "cardiac", "disease", "among", "infants", "exposed", "to", "lithium", "compounds", "in", "the", "first", "trimester", "of", "pregnancy", ".", "Sixty", "-", "three", "percent", "of", "these", "infants", "had", "tricuspid", "valve", "involvement", ".", "Lithium", "carbonate", "may", "be", "a", "factor", "in", "the", "increasing", "incidence", "of", "congenital", "heart", "disease", "when", "taken", "during", "early", "pregnancy", ".", "It", "also", "causes", "neurologic", "depression", ",", "cyanosis", ",", "and", "cardiac", "arrhythmia", "when", "consumed", "prior", "to", "delivery", "."]], "ner": [[[4, 5, "Chemical"], [82, 83, "Chemical"], [105, 106, "Disease"], [108, 108, "Disease"], [111, 112, "Disease"], [0, 2, "Disease"], [16, 17, "Disease"], [43, 44, "Disease"], [30, 30, "Chemical"], [61, 61, "Chemical"], [6, 6, "Disease"], [19, 20, "Disease"], [46, 47, "Disease"], [22, 24, "Disease"], [55, 56, "Disease"], [93, 95, "Disease"]]], "relations": [[[4, 5, 105, 106, "CID"], [82, 83, 105, 106, "CID"], [4, 5, 108, 108, "CID"], [82, 83, 108, 108, "CID"], [4, 5, 111, 112, "CID"], [82, 83, 111, 112, "CID"]]], "clusters": [], "translated": "<5>三尖瓣反流</5>和<0>碳酸锂</0><10>毒性</10>在一个新生儿中发生。描述了一名患有严重<6>三尖瓣反流</6>、<11>心房扑动</11>、<13>充血性心力衰竭</13>和高血清<8>锂</8>水平的新生儿。这是第一位最初表现出<7>三尖瓣反流</7>和<12>心房扑动</12>的患者，也是接触<9>锂</9>化合物在怀孕的前三个月中第11位描述患有<14>心脏病</14>的婴儿。这些婴儿中有63%有三尖瓣受累。<1>碳酸锂</1>可能是妊娠早期服用后<15>先天性心脏病</15>发病率增加的一个因素。如果在分娩前食用，它还会导致<2>神经抑郁</2>、<3>发绀</3>和<4>心律不齐</4>。", "revised": true}
{"doc_key": "6293644", "sentences": [["Effects", "of", "calcitonin", "on", "rat", "extrapyramidal", "motor", "system", ":", "behavioral", "and", "biochemical", "data", ".", "The", "effects", "of", "i", ".", "v", ".", "c", ".", "injection", "of", "human", "and", "salmon", "calcitonin", "on", "biochemical", "and", "behavioral", "parameters", "related", "to", "the", "extrapyramidal", "motor", "system", ",", "were", "investigated", "in", "male", "rats", ".", "Calcitonin", "injection", "resulted", "in", "a", "potentiation", "of", "haloperidol", "-", "induced", "catalepsy", "and", "a", "partial", "prevention", "of", "apomorphine", "-", "induced", "hyperactivity", ".", "Moreover", "calcitonin", "induced", "a", "significant", "decrease", "in", "nigral", "GAD", "activity", "but", "no", "change", "in", "striatal", "DA", "and", "DOPAC", "concentration", "or", "GAD", "activity", ".", "The", "results", "are", "discussed", "in", "view", "of", "a", "primary", "action", "of", "calcitonin", "on", "the", "striatonigral", "GABAergic", "pathway", "mediating", "the", "DA", "-", "related", "behavioral", "messages", "of", "striatal", "origin", "."]], "ner": [[[54, 54, "Chemical"], [57, 57, "Disease"], [63, 63, "Chemical"], [66, 66, "Disease"], [83, 83, "Chemical"], [110, 110, "Chemical"], [85, 85, "Chemical"]]], "relations": [[[54, 54, 57, 57, "CID"], [63, 63, 66, 66, "CID"]]], "clusters": [], "translated": "降钙素对大鼠锥体外系运动系统的影响：行为和生化数据。在雄性大鼠中研究了注射人和鲑鱼降钙素对与锥体外系运动系统相关的生化和行为参数的影响。降钙素注射可增强<0>氟哌啶醇</0>诱发的<1>强直性昏厥</1>，部分预防<2>阿扑吗啡</2>诱发的<3>多动症</3>。此外，降钙素诱导显着降低黑质 GAD 活性，但纹状体<4>DA</4> 浓度和<6>DOPAC</6>浓度或GAD活性没有变化。鉴于降钙素对纹状体黑质 GABA 能通路的主要作用，讨论了结果，该通路介导了纹状体起源的<5>DA</5>相关行为信息。", "revised": true}
{"doc_key": "6436733", "sentences": [["Acute", "changes", "of", "blood", "ammonia", "may", "predict", "short", "-", "term", "adverse", "effects", "of", "valproic", "acid", ".", "Valproic", "acid", "(", "VPA", ")", "was", "given", "to", "24", "epileptic", "patients", "who", "were", "already", "being", "treated", "with", "other", "antiepileptic", "drugs", ".", "A", "standardized", "loading", "dose", "of", "VPA", "was", "administered", ",", "and", "venous", "blood", "was", "sampled", "at", "0", ",", "1", ",", "2", ",", "3", ",", "and", "4", "hours", ".", "Ammonia", "(", "NH3", ")", "was", "higher", "in", "patients", "who", ",", "during", "continuous", "therapy", ",", "complained", "of", "drowsiness", "(", "7", "patients", ")", "than", "in", "those", "who", "were", "symptom", "-", "free", "(", "17", "patients", ")", ",", "although", "VPA", "plasma", "levels", "were", "similar", "in", "both", "groups", ".", "By", "measuring", "VPA", "-", "induced", "changes", "of", "blood", "NH3", "content", ",", "it", "may", "be", "possible", "to", "identify", "patients", "at", "higher", "risk", "of", "obtundation", "when", "VPA", "is", "given", "chronically", "."]], "ner": [[[4, 4, "Chemical"], [64, 64, "Chemical"], [66, 66, "Chemical"], [116, 116, "Chemical"], [80, 80, "Disease"], [13, 14, "Chemical"], [16, 17, "Chemical"], [19, 19, "Chemical"], [42, 42, "Chemical"], [99, 99, "Chemical"], [110, 110, "Chemical"], [132, 132, "Chemical"], [25, 25, "Disease"]]], "relations": [[[4, 4, 80, 80, "CID"], [64, 64, 80, 80, "CID"], [66, 66, 80, 80, "CID"], [116, 116, 80, 80, "CID"], [13, 14, 80, 80, "CID"], [16, 17, 80, 80, "CID"], [19, 19, 80, 80, "CID"], [42, 42, 80, 80, "CID"], [99, 99, 80, 80, "CID"], [110, 110, 80, 80, "CID"], [132, 132, 80, 80, "CID"]]], "clusters": [], "translated": "血液<0>氨</0>的急性变化可预测<5>丙戊酸</5>的短期不良反应。<6>丙戊酸</6>（<7>VPA</7>）给予24例已在接受其他抗癫痫药物治疗的<12>癫痫</12>患者。给予标准负荷剂量的<8>VPA</8>，并在0、1、2、3和4小时采集静脉血样本。<1>氨</1>（<2>NH3</2>）在持续治疗期间抱怨<4>嗜睡</4>的患者（7名患者）高于无症状患者（17名患者），尽管<9>VPA</9>血浆水平在两组中相似。通过测量<10>VPA</10>引起的血液<3>NH3</3>含量变化，可以确定长期服用<11>VPA</11>时发生反应迟钝风险较高的患者。", "revised": true}
{"doc_key": "1545575", "sentences": [["Hemorrhagic", "cystitis", "complicating", "bone", "marrow", "transplantation", ".", "Hemorrhagic", "cystitis", "is", "a", "potentially", "serious", "complication", "of", "high", "-", "dose", "cyclophosphamide", "therapy", "administered", "before", "bone", "marrow", "transplantation", ".", "As", "standard", "practice", "at", "our", "institution", ",", "patients", "who", "are", "scheduled", "to", "receive", "a", "bone", "marrow", "transplant", "are", "treated", "prophylactically", "with", "forced", "hydration", "and", "bladder", "irrigation", ".", "In", "an", "attempt", "to", "obviate", "the", "inconvenience", "of", "bladder", "irrigation", ",", "we", "conducted", "a", "feasibility", "trial", "of", "uroprophylaxis", "with", "mesna", ",", "which", "neutralizes", "the", "hepatic", "metabolite", "of", "cyclophosphamide", "that", "causes", "hemorrhagic", "cystitis", ".", "Of", "97", "patients", "who", "received", "standard", "prophylaxis", ",", "4", "had", "symptomatic", "hemorrhagic", "cystitis", ".", "In", "contrast", ",", "two", "of", "four", "consecutive", "patients", "who", "received", "mesna", "uroprophylaxis", "before", "allogeneic", "bone", "marrow", "transplantation", "had", "severe", "hemorrhagic", "cystitis", "for", "at", "least", "2", "weeks", ".", "Because", "of", "this", "suboptimal", "result", ",", "we", "resumed", "the", "use", "of", "bladder", "irrigation", "and", "forced", "hydration", "to", "minimize", "the", "risk", "of", "hemorrhagic", "cystitis", "."]], "ner": [[[18, 18, "Chemical"], [80, 80, "Chemical"], [0, 1, "Disease"], [7, 8, "Disease"], [83, 84, "Disease"], [97, 98, "Disease"], [119, 120, "Disease"], [148, 149, "Disease"], [72, 72, "Chemical"], [110, 110, "Chemical"]]], "relations": [[[18, 18, 0, 1, "CID"], [18, 18, 7, 8, "CID"], [18, 18, 83, 84, "CID"], [18, 18, 97, 98, "CID"], [18, 18, 119, 120, "CID"], [18, 18, 148, 149, "CID"], [80, 80, 0, 1, "CID"], [80, 80, 7, 8, "CID"], [80, 80, 83, 84, "CID"], [80, 80, 97, 98, "CID"], [80, 80, 119, 120, "CID"], [80, 80, 148, 149, "CID"]]], "clusters": [], "translated": " <2> 出血性膀胱炎 </2>并发骨髓移植。 <3> 出血性膀胱炎 </3> 是骨髓移植前大剂量 <0> 环磷酰胺 </0> 治疗的潜在严重并发症。作为我们机构的标准做法，计划接受骨髓移植的患者会通过强制水化和膀胱冲洗进行预防性治疗。为了避免膀胱冲洗带来的不便，我们进行了一项使用 <8> 美司钠 </8> 进行尿路预防的可行性试验，它中和了引起 <4> 出血性膀胱炎 </4> 的肝脏代谢物 <1> 环磷酰胺 </1>。在接受标准预防的97名患者中，有4名患者有症状的<5>出血性膀胱炎</5>。相比之下，在同种异体骨髓移植前接受 <9> mesna </9> 尿路预防的4名连续患者中有2名出现严重的<6>出血性膀胱炎</6>至少2周。由于这种次优结果，我们恢复使用膀胱冲洗和强制水化以将 <7> 出血性膀胱炎 </7> 的风险降至最低。", "revised": true}
{"doc_key": "2564649", "sentences": [["Involvement", "of", "locus", "coeruleus", "and", "noradrenergic", "neurotransmission", "in", "fentanyl", "-", "induced", "muscular", "rigidity", "in", "the", "rat", ".", "Whereas", "muscular", "rigidity", "is", "a", "well", "-", "known", "side", "effect", "that", "is", "associated", "with", "high", "-", "dose", "fentanyl", "anesthesia", ",", "a", "paucity", "of", "information", "exists", "with", "regard", "to", "its", "underlying", "mechanism", "(", "s", ")", ".", "We", "investigated", "in", "this", "study", "the", "possible", "engagement", "of", "locus", "coeruleus", "of", "the", "pons", "in", "this", "phenomenon", ",", "using", "male", "Sprague", "-", "Dawley", "rats", "anesthetized", "with", "ketamine", ".", "Under", "proper", "control", "of", "respiration", ",", "body", "temperature", "and", "end", "-", "tidal", "CO2", ",", "intravenous", "administration", "of", "fentanyl", "(", "50", "or", "100", "micrograms", "/", "kg", ")", "consistently", "promoted", "an", "increase", "in", "electromyographic", "activity", "recorded", "from", "the", "gastrocnemius", "and", "abdominal", "rectus", "muscles", ".", "Such", "an", "induced", "muscular", "rigidity", "by", "the", "narcotic", "agent", "was", "significantly", "antagonized", "or", "even", "reduced", "by", "prior", "electrolytic", "lesions", "of", "the", "locus", "coeruleus", "or", "pretreatment", "with", "the", "alpha", "-", "adrenoceptor", "blocker", ",", "prazosin", ".", "Microinjection", "of", "fentanyl", "(", "2", ".", "5", "micrograms", "/", "50", "nl", ")", "directly", "into", "this", "pontine", "nucleus", ",", "on", "the", "other", "hand", ",", "elicited", "discernible", "electromyographic", "excitation", ".", "It", "is", "speculated", "that", "the", "induction", "of", "muscular", "rigidity", "by", "fentanyl", "may", "involve", "the", "coerulospinal", "noradrenergic", "fibers", "to", "the", "spinal", "motoneurons", "."]], "ner": [[[8, 8, "Chemical"], [34, 34, "Chemical"], [97, 97, "Chemical"], [158, 158, "Chemical"], [194, 194, "Chemical"], [11, 12, "Disease"], [18, 19, "Disease"], [125, 126, "Disease"], [191, 192, "Disease"], [78, 78, "Chemical"], [92, 92, "Chemical"], [154, 154, "Chemical"]]], "relations": [[[8, 8, 11, 12, "CID"], [8, 8, 18, 19, "CID"], [8, 8, 125, 126, "CID"], [8, 8, 191, 192, "CID"], [34, 34, 11, 12, "CID"], [34, 34, 18, 19, "CID"], [34, 34, 125, 126, "CID"], [34, 34, 191, 192, "CID"], [97, 97, 11, 12, "CID"], [97, 97, 18, 19, "CID"], [97, 97, 125, 126, "CID"], [97, 97, 191, 192, "CID"], [158, 158, 11, 12, "CID"], [158, 158, 18, 19, "CID"], [158, 158, 125, 126, "CID"], [158, 158, 191, 192, "CID"], [194, 194, 11, 12, "CID"], [194, 194, 18, 19, "CID"], [194, 194, 125, 126, "CID"], [194, 194, 191, 192, "CID"]]], "clusters": [], "translated": "蓝斑和去甲肾上腺素能神经传递参与<0>芬太尼</0>诱导的<5>肌肉僵硬</5>。虽然<6>肌肉僵硬</6>是与高剂量<1>芬太尼</1>麻醉相关的众所周知的副作用，但关于其潜在机制的信息却很少。在这项研究中，我们使用用<9>氯胺酮</9>麻醉的雄性Sprague-Dawley大鼠调查了脑桥蓝斑在这种现象中的可能参与。在呼吸、体温和呼气末<10>CO2</10>的适当控制下，静脉注射 <2>芬太尼</2> （50或100微克/千克）持续促进从腓肠肌和腹直肌的肌电活动。这种由麻醉剂引起的<7>肌肉僵硬</7>可被蓝斑的先前电解损伤或用α-肾上腺素能受体阻滞剂<11>哌唑嗪</11>预处理显着拮抗甚至减轻。另一方面，将<3>芬太尼</3>（2.5微克/50 nl）直接显微注射到这个脑桥核中，引起了可察觉的肌电兴奋。据推测，由<4>芬太尼</4>引起的<8>肌肉僵硬</8>可能涉及到脊髓运动神经元的蓝斑脊髓去甲肾上腺素能纤维。", "revised": true}
{"doc_key": "591536", "sentences": [["Arterial", "thromboembolism", "in", "patients", "receiving", "systemic", "heparin", "therapy", ":", "a", "complication", "associated", "with", "heparin", "-", "induced", "thrombocytopenia", ".", "Arterial", "thromboembolism", "is", "a", "recognized", "complication", "of", "systemic", "heparin", "therapy", ".", "Characteristic", "of", "the", "entity", "is", "arterial", "occlusion", "by", "platelet", "-", "fibrin", "thrombi", "with", "distal", "ischemia", "occurring", "four", "to", "twenty", "days", "after", "the", "initiation", "of", "heparin", "therapy", ",", "preceded", "by", "profound", "thrombocytopenia", "with", "platelet", "counts", "in", "the", "range", "of", "30", ",", "000", "to", "40", ",", "000", "per", "cubic", "millimeter", ".", "The", "clinically", "apparent", "occlusion", "may", "be", "preceded", "by", "gastrointestinal", "and", "musculoskeletal", "symptoms", "that", "appear", "to", "be", "ischemic", "in", "origin", ",", "and", "might", "serve", "to", "warn", "the", "clinician", "of", "these", "complications", ".", "Previous", "reports", "of", "these", "phenomena", "as", "well", "as", "recent", "studies", "of", "the", "effect", "of", "heparin", "are", "reviewed", ".", "The", "common", "factor", "relating", "thromboembolism", "and", "thrombocytopenia", "is", "heparin", "-", "induced", "platelet", "aggregation", ".", "Appropriate", "treatment", "consists", "of", "discontinuation", "of", "heparin", ",", "and", "anticoagulation", "with", "sodium", "warfarin", "if", "necessary", ".", "Vascular", "procedures", "are", "performed", "as", "indicated", "."]], "ner": [[[6, 6, "Chemical"], [13, 13, "Chemical"], [26, 26, "Chemical"], [53, 53, "Chemical"], [123, 123, "Chemical"], [135, 135, "Chemical"], [147, 147, "Chemical"], [16, 16, "Disease"], [59, 59, "Disease"], [133, 133, "Disease"], [34, 35, "Disease"], [1, 1, "Disease"], [19, 19, "Disease"], [131, 131, "Disease"], [152, 153, "Chemical"], [40, 40, "Disease"], [43, 43, "Disease"], [94, 94, "Disease"], [86, 89, "Disease"], [138, 139, "Disease"]]], "relations": [[[6, 6, 16, 16, "CID"], [6, 6, 59, 59, "CID"], [6, 6, 133, 133, "CID"], [13, 13, 16, 16, "CID"], [13, 13, 59, 59, "CID"], [13, 13, 133, 133, "CID"], [26, 26, 16, 16, "CID"], [26, 26, 59, 59, "CID"], [26, 26, 133, 133, "CID"], [53, 53, 16, 16, "CID"], [53, 53, 59, 59, "CID"], [53, 53, 133, 133, "CID"], [123, 123, 16, 16, "CID"], [123, 123, 59, 59, "CID"], [123, 123, 133, 133, "CID"], [135, 135, 16, 16, "CID"], [135, 135, 59, 59, "CID"], [135, 135, 133, 133, "CID"], [147, 147, 16, 16, "CID"], [147, 147, 59, 59, "CID"], [147, 147, 133, 133, "CID"], [6, 6, 34, 35, "CID"], [13, 13, 34, 35, "CID"], [26, 26, 34, 35, "CID"], [53, 53, 34, 35, "CID"], [123, 123, 34, 35, "CID"], [135, 135, 34, 35, "CID"], [147, 147, 34, 35, "CID"]]], "clusters": [], "translated": "接受全身性<0>肝素</0>治疗的患者的动脉<11>血栓栓塞</11>：与<1>肝素</1>相关的并发症-诱发<7>血小板减少症</7>。动脉<12>血栓栓塞</12>是全身性<2>肝素</2>治疗的公认并发症。该实体的特征是<10>动脉闭塞</10>由血小板-纤维蛋白<15>血栓</15>和远端<16>缺血</16>发生在<3>肝素</3>开始后四到二十天，先是严重的<8>血小板减少症</8>，血小板计数在每立方毫米30,000到40,000之间。临床上明显的闭塞之前可能出现<18>胃肠道和肌肉骨骼症状</18>，这些症状似乎是<17>缺血性</17>的起源，并且可能有助于警告临床医生这些并发症。对这些现象的先前报道以及最近对<4>肝素</4>作用的研究进行了综述。<13>血栓栓塞</13>和<9>血小板减少</9>的共同因素是<5>肝素</5>诱导的<19>血小板聚集</19>。适当的治疗包括停用<6>肝素</6>，必要时使用<14>华法林钠</14>进行抗凝。血管手术按指示进行。", "revised": true}
{"doc_key": "16116131", "sentences": [["rTMS", "of", "supplementary", "motor", "area", "modulates", "therapy", "-", "induced", "dyskinesias", "in", "Parkinson", "disease", ".", "The", "neural", "mechanisms", "and", "circuitry", "involved", "in", "levodopa", "-", "induced", "dyskinesia", "are", "unclear", ".", "Using", "repetitive", "transcranial", "magnetic", "stimulation", "(", "rTMS", ")", "over", "the", "supplementary", "motor", "area", "(", "SMA", ")", "in", "a", "group", "of", "patients", "with", "advanced", "Parkinson", "disease", ",", "the", "authors", "investigated", "whether", "modulation", "of", "SMA", "excitability", "may", "result", "in", "a", "modification", "of", "a", "dyskinetic", "state", "induced", "by", "continuous", "apomorphine", "infusion", ".", "rTMS", "at", "1", "Hz", "was", "observed", "to", "markedly", "reduce", "drug", "-", "induced", "dyskinesias", ",", "whereas", "5", "-", "Hz", "rTMS", "induced", "a", "slight", "but", "not", "significant", "increase", "."]], "ner": [[[21, 21, "Chemical"], [9, 9, "Disease"], [24, 24, "Disease"], [69, 69, "Disease"], [86, 89, "Disease"], [74, 74, "Chemical"], [11, 12, "Disease"], [51, 52, "Disease"]]], "relations": [[[21, 21, 9, 9, "CID"], [21, 21, 24, 24, "CID"], [21, 21, 69, 69, "CID"], [21, 21, 86, 89, "CID"]]], "clusters": [], "translated": "辅助运动区的 rTMS 可调节<1>治疗引起的运动障碍</1> - <6>帕金森病</6>。 <0>左旋多巴</0>诱发的<2>运动障碍</2>所涉及的神经机制和回路尚不清楚。在一组晚期<7>帕金森病</7>患者的<5>辅助运动区</5>（SMA）上使用重复经颅磁刺激（rTMS），作者研究了SMA兴奋性的调节是否会导致由连续<5>阿扑吗啡</5>输注引起的<3>运动障碍</3>状态的改变。观察到1 Hz rTMS 显着减少<4>药物引起的运动障碍</4>，而5 Hz rTMS引起轻微但不显着的增加。", "revised": true}
{"doc_key": "20735774", "sentences": [["Long", "-", "term", "prognosis", "for", "transplant", "-", "free", "survivors", "of", "paracetamol", "-", "induced", "acute", "liver", "failure", ".", "BACKGROUND", ":", "The", "prognosis", "for", "transplant", "-", "free", "survivors", "of", "paracetamol", "-", "induced", "acute", "liver", "failure", "remains", "unknown", ".", "AIM", ":", "To", "examine", "whether", "paracetamol", "-", "induced", "acute", "liver", "failure", "increases", "long", "-", "term", "mortality", ".", "METHODS", ":", "We", "followed", "up", "all", "transplant", "-", "free", "survivors", "of", "paracetamol", "-", "induced", "acute", "liver", "injury", ",", "hospitalized", "in", "a", "Danish", "national", "referral", "centre", "during", "1984", "-", "2004", ".", "We", "compared", "age", "-", "specific", "mortality", "rates", "from", "1", "year", "post", "-", "discharge", "through", "2008", "between", "those", "in", "whom", "the", "liver", "injury", "led", "to", "an", "acute", "liver", "failure", "and", "those", "in", "whom", "it", "did", "not", ".", "RESULTS", ":", "We", "included", "641", "patients", ".", "On", "average", ",", "age", "-", "specific", "mortality", "rates", "were", "slightly", "higher", "for", "the", "101", "patients", "whose", "paracetamol", "-", "induced", "liver", "injury", "had", "caused", "an", "acute", "liver", "failure", "(", "adjusted", "mortality", "rate", "ratio", "=", "1", ".", "70", ",", "95", "%", "CI", "1", ".", "02", "-", "2", ".", "85", ")", ",", "but", "the", "association", "was", "age", "-", "dependent", ",", "and", "no", "survivors", "of", "acute", "liver", "failure", "died", "of", "liver", "disease", ",", "whereas", "suicides", "were", "frequent", "in", "both", "groups", ".", "These", "observations", "speak", "against", "long", "-", "term", "effects", "of", "acute", "liver", "failure", ".", "More", "likely", ",", "the", "elevated", "mortality", "rate", "ratio", "resulted", "from", "incomplete", "adjustment", "for", "the", "greater", "prevalence", "of", "substance", "abuse", "among", "survivors", "of", "acute", "liver", "failure", ".", "CONCLUSIONS", ":", "Paracetamol", "-", "induced", "acute", "liver", "failure", "did", "not", "affect", "long", "-", "term", "mortality", ".", "Clinical", "follow", "-", "up", "may", "be", "justified", "by", "the", "cause", "of", "the", "liver", "failure", ",", "but", "not", "by", "the", "liver", "failure", "itself", "."]], "ner": [[[10, 10, "Chemical"], [27, 27, "Chemical"], [41, 41, "Chemical"], [64, 64, "Chemical"], [142, 142, "Chemical"], [244, 244, "Chemical"], [13, 15, "Disease"], [30, 32, "Disease"], [44, 46, "Disease"], [108, 110, "Disease"], [150, 152, "Disease"], [187, 189, "Disease"], [212, 214, "Disease"], [238, 240, "Disease"], [247, 249, "Disease"], [67, 69, "Disease"], [103, 104, "Disease"], [145, 146, "Disease"], [192, 193, "Disease"], [233, 234, "Disease"], [270, 271, "Disease"], [277, 278, "Disease"]]], "relations": [[[10, 10, 13, 15, "CID"], [10, 10, 30, 32, "CID"], [10, 10, 44, 46, "CID"], [10, 10, 108, 110, "CID"], [10, 10, 150, 152, "CID"], [10, 10, 187, 189, "CID"], [10, 10, 212, 214, "CID"], [10, 10, 238, 240, "CID"], [10, 10, 247, 249, "CID"], [27, 27, 13, 15, "CID"], [27, 27, 30, 32, "CID"], [27, 27, 44, 46, "CID"], [27, 27, 108, 110, "CID"], [27, 27, 150, 152, "CID"], [27, 27, 187, 189, "CID"], [27, 27, 212, 214, "CID"], [27, 27, 238, 240, "CID"], [27, 27, 247, 249, "CID"], [41, 41, 13, 15, "CID"], [41, 41, 30, 32, "CID"], [41, 41, 44, 46, "CID"], [41, 41, 108, 110, "CID"], [41, 41, 150, 152, "CID"], [41, 41, 187, 189, "CID"], [41, 41, 212, 214, "CID"], [41, 41, 238, 240, "CID"], [41, 41, 247, 249, "CID"], [64, 64, 13, 15, "CID"], [64, 64, 30, 32, "CID"], [64, 64, 44, 46, "CID"], [64, 64, 108, 110, "CID"], [64, 64, 150, 152, "CID"], [64, 64, 187, 189, "CID"], [64, 64, 212, 214, "CID"], [64, 64, 238, 240, "CID"], [64, 64, 247, 249, "CID"], [142, 142, 13, 15, "CID"], [142, 142, 30, 32, "CID"], [142, 142, 44, 46, "CID"], [142, 142, 108, 110, "CID"], [142, 142, 150, 152, "CID"], [142, 142, 187, 189, "CID"], [142, 142, 212, 214, "CID"], [142, 142, 238, 240, "CID"], [142, 142, 247, 249, "CID"], [244, 244, 13, 15, "CID"], [244, 244, 30, 32, "CID"], [244, 244, 44, 46, "CID"], [244, 244, 108, 110, "CID"], [244, 244, 150, 152, "CID"], [244, 244, 187, 189, "CID"], [244, 244, 212, 214, "CID"], [244, 244, 238, 240, "CID"], [244, 244, 247, 249, "CID"]]], "clusters": [], "translated": "<0>扑热息痛</0>诱发的<6>急性肝衰竭</6>的无移植幸存者的长期预后。背景：<1>扑热息痛</1>诱发的<7>急性肝衰竭</7>的非移植幸存者的预后仍然未知。目的：检查<2>扑热息痛</2>诱发的<8>急性肝功能衰竭</8>是否会增加长期死亡率。方法：我们对1984年至2004年间在丹麦国家转诊中心住院的所有<3>对乙酰氨基酚</3>诱发的<15>急性肝损伤</15>的未移植幸存者进行了随访。我们比较了出院后1年至2008年因<16>肝损伤</16>导致<9>急性肝衰竭</9>和未导致急性肝衰竭的患者的年龄别死亡率。结果：我们纳入了641名患者。平均而言，对于<4>对乙酰氨基酚 </4>引起的<17>肝损伤</17>导致<10>急性肝衰竭</10>的101名患者，年龄别死亡率略高（调整后死亡率比率=1.70，95%CI1.02-2.85），但该关联是年龄相关的，并且<11>急性肝衰竭</11>的幸存者没有死于<18>肝病</18>，而自杀在两组中都很常见。这些观察结果与<12>急性肝衰竭</12>的长期影响背道而驰。更有可能的是，死亡率升高的原因是未完全调整<19>药物滥用</19>在<13>急性肝衰竭</13>幸存者中的流行率。结论：<5>扑热息痛</5>诱发的<14>急性肝功能衰竭</14>不影响长期死亡率。临床随访可能由<20>肝衰竭</20>的原因来证明是合理的，但不是由<21>肝衰竭</21>本身来证明。", "revised": true}
{"doc_key": "16157917", "sentences": [["Lamotrigine", "associated", "with", "exacerbation", "or", "de", "novo", "myoclonus", "in", "idiopathic", "generalized", "epilepsies", ".", "Five", "patients", "with", "idiopathic", "generalized", "epilepsies", "(", "IGE", ")", "treated", "with", "lamotrigine", "(", "LTG", ")", "experienced", "exacerbation", "or", "de", "novo", "appearance", "of", "myoclonic", "jerks", "(", "MJ", ")", ".", "In", "three", "patients", ",", "LTG", "exacerbated", "MJ", "in", "a", "dose", "-", "dependent", "manner", "with", "early", "aggravation", "during", "titration", ".", "MJ", "disappeared", "when", "LTG", "dose", "was", "decreased", "by", "25", "to", "50", "%", ".", "In", "two", "patients", ",", "LTG", "exacerbated", "MJ", "in", "a", "delayed", "but", "more", "severe", "manner", ",", "with", "myoclonic", "status", "that", "only", "ceased", "after", "LTG", "withdrawal", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [26, 26, "Chemical"], [45, 45, "Chemical"], [63, 63, "Chemical"], [77, 77, "Chemical"], [95, 95, "Chemical"], [7, 7, "Disease"], [35, 36, "Disease"], [38, 38, "Disease"], [47, 47, "Disease"], [60, 60, "Disease"], [79, 79, "Disease"], [89, 90, "Disease"], [9, 11, "Disease"], [16, 18, "Disease"], [20, 20, "Disease"]]], "relations": [[[0, 0, 7, 7, "CID"], [0, 0, 35, 36, "CID"], [0, 0, 38, 38, "CID"], [0, 0, 47, 47, "CID"], [0, 0, 60, 60, "CID"], [0, 0, 79, 79, "CID"], [0, 0, 89, 90, "CID"], [24, 24, 7, 7, "CID"], [24, 24, 35, 36, "CID"], [24, 24, 38, 38, "CID"], [24, 24, 47, 47, "CID"], [24, 24, 60, 60, "CID"], [24, 24, 79, 79, "CID"], [24, 24, 89, 90, "CID"], [26, 26, 7, 7, "CID"], [26, 26, 35, 36, "CID"], [26, 26, 38, 38, "CID"], [26, 26, 47, 47, "CID"], [26, 26, 60, 60, "CID"], [26, 26, 79, 79, "CID"], [26, 26, 89, 90, "CID"], [45, 45, 7, 7, "CID"], [45, 45, 35, 36, "CID"], [45, 45, 38, 38, "CID"], [45, 45, 47, 47, "CID"], [45, 45, 60, 60, "CID"], [45, 45, 79, 79, "CID"], [45, 45, 89, 90, "CID"], [63, 63, 7, 7, "CID"], [63, 63, 35, 36, "CID"], [63, 63, 38, 38, "CID"], [63, 63, 47, 47, "CID"], [63, 63, 60, 60, "CID"], [63, 63, 79, 79, "CID"], [63, 63, 89, 90, "CID"], [77, 77, 7, 7, "CID"], [77, 77, 35, 36, "CID"], [77, 77, 38, 38, "CID"], [77, 77, 47, 47, "CID"], [77, 77, 60, 60, "CID"], [77, 77, 79, 79, "CID"], [77, 77, 89, 90, "CID"], [95, 95, 7, 7, "CID"], [95, 95, 35, 36, "CID"], [95, 95, 38, 38, "CID"], [95, 95, 47, 47, "CID"], [95, 95, 60, 60, "CID"], [95, 95, 79, 79, "CID"], [95, 95, 89, 90, "CID"]]], "clusters": [], "translated": " <0> 拉莫三嗪 </0>与<14>特发性全面性癫痫</14>的加重或新发<7>肌阵挛</7>相关。5例<15>特发性全身性癫痫</15> (<16>IGE</16>) 接受<1>拉莫三嗪</1> (<2>LTG</2>) 治疗后，癫痫发作加重或重新出现<8>肌阵挛性抽搐</8> (<9>MJ</9>) 。在3名患者中，<3>LTG</3>以剂量依赖的方式加剧了<8>肌阵挛性抽搐</8> (<10>MJ</10>)，在滴定过程中早期加重。<11>肌阵挛性抽搐</11>消失时，<4>LTG</4>剂量减少了25%~50%。在两名患者中，<5>LTG</5>以延迟但更严重的方式加剧了<8>肌阵挛性抽搐</8> (<12>MJ</12>)，<13>肌阵挛状态</13>仅在<6>LTG退出</6>后停止。", "revised": true}
{"doc_key": "3115150", "sentences": [["Ketanserin", "pretreatment", "reverses", "alfentanil", "-", "induced", "muscle", "rigidity", ".", "Systemic", "pretreatment", "with", "ketanserin", ",", "a", "relatively", "specific", "type", "-", "2", "serotonin", "receptor", "antagonist", ",", "significantly", "attenuated", "the", "muscle", "rigidity", "produced", "in", "rats", "by", "the", "potent", "short", "-", "acting", "opiate", "agonist", "alfentanil", ".", "Following", "placement", "of", "subcutaneous", "electrodes", "in", "each", "animal", "'s", "left", "gastrocnemius", "muscle", ",", "rigidity", "was", "assessed", "by", "analyzing", "root", "-", "mean", "-", "square", "electromyographic", "activity", ".", "Intraperitoneal", "ketanserin", "administration", "at", "doses", "of", "0", ".", "63", "and", "2", ".", "5", "mg", "/", "kg", "prevented", "the", "alfentanil", "-", "induced", "increase", "in", "electromyographic", "activity", "compared", "with", "animals", "pretreated", "with", "saline", ".", "Chlordiazepoxide", "at", "doses", "up", "to", "10", "mg", "/", "kg", "failed", "to", "significantly", "influence", "the", "rigidity", "produced", "by", "alfentanil", ".", "Despite", "the", "absence", "of", "rigidity", ",", "animals", "that", "received", "ketanserin", "(", "greater", "than", "0", ".", "31", "mg", "/", "kg", "i", ".", "p", ".", ")", "followed", "by", "alfentanil", "were", "motionless", ",", "flaccid", ",", "and", "less", "responsive", "to", "external", "stimuli", "than", "were", "animals", "receiving", "alfentanil", "alone", ".", "Rats", "that", "received", "ketanserin", "and", "alfentanil", "exhibited", "less", "rearing", "and", "exploratory", "behavior", "at", "the", "end", "of", "the", "60", "-", "min", "recording", "period", "than", "did", "animals", "that", "received", "ketanserin", "alone", ".", "These", "results", ",", "in", "combination", "with", "previous", "work", ",", "suggest", "that", "muscle", "rigidity", ",", "a", "clinically", "relevant", "side", "-", "effect", "of", "parenteral", "narcotic", "administration", ",", "may", "be", "partly", "mediated", "via", "serotonergic", "pathways", ".", "Pretreatment", "with", "type", "-", "2", "serotonin", "antagonists", "may", "be", "clinically", "useful", "in", "attenuating", "opiate", "-", "induced", "rigidity", ",", "although", "further", "studies", "will", "be", "necessary", "to", "assess", "the", "interaction", "of", "possibly", "enhanced", "CNS", ",", "cardiovascular", ",", "and", "respiratory", "depression", "."]], "ner": [[[3, 3, "Chemical"], [40, 40, "Chemical"], [86, 86, "Chemical"], [117, 117, "Chemical"], [145, 145, "Chemical"], [161, 161, "Chemical"], [169, 169, "Chemical"], [6, 7, "Disease"], [27, 28, "Disease"], [55, 55, "Disease"], [114, 114, "Disease"], [123, 123, "Disease"], [205, 206, "Disease"], [243, 243, "Disease"], [0, 0, "Chemical"], [12, 12, "Chemical"], [69, 69, "Chemical"], [128, 128, "Chemical"], [167, 167, "Chemical"], [191, 191, "Chemical"], [260, 264, "Disease"], [20, 20, "Chemical"], [232, 232, "Chemical"], [100, 100, "Chemical"]]], "relations": [[[3, 3, 6, 7, "CID"], [3, 3, 27, 28, "CID"], [3, 3, 55, 55, "CID"], [3, 3, 114, 114, "CID"], [3, 3, 123, 123, "CID"], [3, 3, 205, 206, "CID"], [3, 3, 243, 243, "CID"], [40, 40, 6, 7, "CID"], [40, 40, 27, 28, "CID"], [40, 40, 55, 55, "CID"], [40, 40, 114, 114, "CID"], [40, 40, 123, 123, "CID"], [40, 40, 205, 206, "CID"], [40, 40, 243, 243, "CID"], [86, 86, 6, 7, "CID"], [86, 86, 27, 28, "CID"], [86, 86, 55, 55, "CID"], [86, 86, 114, 114, "CID"], [86, 86, 123, 123, "CID"], [86, 86, 205, 206, "CID"], [86, 86, 243, 243, "CID"], [117, 117, 6, 7, "CID"], [117, 117, 27, 28, "CID"], [117, 117, 55, 55, "CID"], [117, 117, 114, 114, "CID"], [117, 117, 123, 123, "CID"], [117, 117, 205, 206, "CID"], [117, 117, 243, 243, "CID"], [145, 145, 6, 7, "CID"], [145, 145, 27, 28, "CID"], [145, 145, 55, 55, "CID"], [145, 145, 114, 114, "CID"], [145, 145, 123, 123, "CID"], [145, 145, 205, 206, "CID"], [145, 145, 243, 243, "CID"], [161, 161, 6, 7, "CID"], [161, 161, 27, 28, "CID"], [161, 161, 55, 55, "CID"], [161, 161, 114, 114, "CID"], [161, 161, 123, 123, "CID"], [161, 161, 205, 206, "CID"], [161, 161, 243, 243, "CID"], [169, 169, 6, 7, "CID"], [169, 169, 27, 28, "CID"], [169, 169, 55, 55, "CID"], [169, 169, 114, 114, "CID"], [169, 169, 123, 123, "CID"], [169, 169, 205, 206, "CID"], [169, 169, 243, 243, "CID"]]], "clusters": [], "translated": "<14>酮色林</14>预处理可逆转<0>阿芬太尼</0>诱导的<7>肌肉僵硬</7>。进行全身预处理使用<15>酮色林</15>，这是一种相对特异性的2型<21>血清素</21>受体拮抗剂，可显着减轻阿片类激动剂<1>阿芬太尼</1>在大鼠体内产生的<8>肌肉僵硬</8>。在每只动物的左侧腓肠肌中放置皮下电极后，通过分析均方根肌电图活动评估<9>硬度</9>。腹膜内<16>酮色林</16>给药剂量为0.63和2.5 mg/kg可防止<2>阿芬太尼</2>引起的肌电活动增加。<23>氯氮卓</23>在高达10 mg/kg的剂量下未能显着影响<3>阿芬太尼</3>产生的<10>刚性</10>。尽管没有<11>僵硬</11>，接受<17>酮色林</17>（大于0.31 mg/kg i. p.）随后接受<4>阿芬太尼</4>的动物是静止的，松弛，并且对外部刺激的反应比单独接受<5>阿芬太尼</5>的动物低。接受<18>酮色林</18>和<6>阿芬太尼</6>的大鼠在60分钟记录期结束时表现出较少的饲养和探索行为，与单独接受<19>酮色林</19>的动物相比。这些结果与以前的工作相结合，表明<12>肌肉僵硬</12>是肠外给药的临床相关副作用，可能部分是通过血清素能途径介导的。使用2型<22>血清素</22>受体拮抗剂进行预处理可能在临床上可用于减轻阿片类药物引起的<13>强直</13>，尽管还需要进一步的研究来评估可能增强的CNS、<20>心血管和呼吸抑制</20>的相互作用。", "revised": true}
{"doc_key": "3131282", "sentences": [["Co", "-", "carcinogenic", "effect", "of", "retinyl", "acetate", "on", "forestomach", "carcinogenesis", "of", "male", "F344", "rats", "induced", "with", "butylated", "hydroxyanisole", ".", "The", "potential", "modifying", "effect", "of", "retinyl", "acetate", "(", "RA", ")", "on", "butylated", "hydroxyanisole", "(", "BHA", ")", "-", "induced", "rat", "forestomach", "tumorigenesis", "was", "examined", ".", "Male", "F344", "rats", ",", "5", "weeks", "of", "age", ",", "were", "maintained", "on", "diet", "containing", "1", "%", "or", "2", "%", "BHA", "by", "weight", "and", "simultaneously", "on", "drinking", "water", "supplemented", "with", "RA", "at", "various", "concentrations", "(", "w", "/", "v", ")", "for", "52", "weeks", ".", "In", "groups", "given", "2", "%", "BHA", ",", "although", "marked", "hyperplastic", "changes", "of", "the", "forestomach", "epithelium", "were", "observed", "in", "all", "animals", ",", "co", "-", "administration", "of", "0", ".", "25", "%", "RA", "significantly", "(", "P", "less", "than", "0", ".", "05", ")", "increased", "the", "incidence", "of", "forestomach", "tumors", "(", "squamous", "cell", "papilloma", "and", "carcinoma", ")", "to", "60", "%", "(", "9", "/", "15", ",", "2", "rats", "with", "carcinoma", ")", "from", "15", "%", "(", "3", "/", "20", ",", "one", "rat", "with", "carcinoma", ")", "in", "the", "group", "given", "RA", "-", "free", "water", ".", "In", "rats", "given", "1", "%", "BHA", ",", "RA", "co", "-", "administered", "at", "a", "dose", "of", "0", ".", "05", ",", "0", ".", "1", ",", "0", ".", "2", "or", "0", ".", "25", "%", "showed", "a", "dose", "-", "dependent", "enhancing", "effect", "on", "the", "development", "of", "the", "BHA", "-", "induced", "epithelial", "hyperplasia", ".", "Tumors", ",", "all", "papillomas", ",", "were", "induced", "in", "3", "rats", "(", "17", "%", ")", "with", "0", ".", "25", "%", "RA", "and", "in", "one", "rat", "(", "10", "%", ")", "with", "0", ".", "05", "%", "RA", "co", "-", "administration", ".", "RA", "alone", "did", "not", "induce", "hyperplastic", "changes", "in", "the", "forestomach", ".", "These", "findings", "indicate", "that", "RA", "acted", "as", "a", "co", "-", "carcinogen", "in", "the", "BHA", "forestomach", "carcinogenesis", "of", "the", "rat", "."]], "ner": [[[16, 17, "Chemical"], [30, 31, "Chemical"], [33, 33, "Chemical"], [62, 62, "Chemical"], [90, 90, "Chemical"], [177, 177, "Chemical"], [215, 215, "Chemical"], [283, 283, "Chemical"], [8, 9, "Disease"], [38, 39, "Disease"], [128, 129, "Disease"], [284, 285, "Disease"], [5, 6, "Chemical"], [24, 25, "Chemical"], [27, 27, "Chemical"], [72, 72, "Chemical"], [114, 114, "Chemical"], [167, 167, "Chemical"], [179, 179, "Chemical"], [240, 240, "Chemical"], [254, 254, "Chemical"], [259, 259, "Chemical"], [274, 274, "Chemical"], [2, 2, "Disease"], [131, 133, "Disease"], [224, 224, "Disease"], [135, 135, "Disease"], [148, 148, "Disease"], [161, 161, "Disease"], [218, 219, "Disease"], [221, 221, "Disease"]]], "relations": [[[16, 17, 8, 9, "CID"], [16, 17, 38, 39, "CID"], [16, 17, 128, 129, "CID"], [16, 17, 284, 285, "CID"], [30, 31, 8, 9, "CID"], [30, 31, 38, 39, "CID"], [30, 31, 128, 129, "CID"], [30, 31, 284, 285, "CID"], [33, 33, 8, 9, "CID"], [33, 33, 38, 39, "CID"], [33, 33, 128, 129, "CID"], [33, 33, 284, 285, "CID"], [62, 62, 8, 9, "CID"], [62, 62, 38, 39, "CID"], [62, 62, 128, 129, "CID"], [62, 62, 284, 285, "CID"], [90, 90, 8, 9, "CID"], [90, 90, 38, 39, "CID"], [90, 90, 128, 129, "CID"], [90, 90, 284, 285, "CID"], [177, 177, 8, 9, "CID"], [177, 177, 38, 39, "CID"], [177, 177, 128, 129, "CID"], [177, 177, 284, 285, "CID"], [215, 215, 8, 9, "CID"], [215, 215, 38, 39, "CID"], [215, 215, 128, 129, "CID"], [215, 215, 284, 285, "CID"], [283, 283, 8, 9, "CID"], [283, 283, 38, 39, "CID"], [283, 283, 128, 129, "CID"], [283, 283, 284, 285, "CID"]]], "clusters": [], "translated": "<12>醋酸视黄酯</12>对<0>丁基羟基茴香醚</0>致雄性F344大鼠<8>前胃癌</8>的共<23>致癌作用</23>。<13>醋酸视黄酯</13>（<14>RA</14>）对<1>丁基羟基苯甲醚</1>（<2>BHA</2>）-诱导的雄性F344大鼠<9>前胃肿瘤发生</9>的潜在修饰作用进行了检查。雄性F344大鼠，5周龄，按重量维持在含有1%或2%<3>BHA</3>的饮食中，同时饮用补充有不同浓度的<15>RA</15>的饮用水（w/v）52周。在给予2%<4>BHA</4>的组中，虽然在所有动物中都观察到前胃上皮的显着增生性变化，但同时给予0.25%<16>RA</16>显着（P小于0.05）增加了<10>前胃肿瘤</10>（<24>鳞状细胞乳头状瘤</24>和<26>癌</26>）至60%（9/15，2只大鼠患有<27>癌症</27>），从15%（3/20，一只大鼠患有<28>癌症</28>）在给予不含<17>RA</17>的水的组中。在给予1%<5>BHA</5>的大鼠中，以0.05、0.1、0.2或0.25%给予<18>RA</18>显示出剂量依赖性增强作用对<6>BHA</6>-诱导的<29>上皮增生</29>的发展。3只大鼠（17%）在0.25%<19>RA</19>联合给药时诱导了<30>肿瘤</30>，全部为<25>乳头状瘤</25>，1只大鼠（10%）在0.05%<20>RA</20>联合给药时诱导了<25>乳头状瘤</25>。<21>RA</21>单独不会引起前胃增生性变化。这些发现表明，<22>RA</22>在大鼠的<7>BHA</7><11>前胃癌</11>中作为共致 carcinogen。", "revised": true}
{"doc_key": "18657397", "sentences": [["Detailed", "spectral", "profile", "analysis", "of", "penicillin", "-", "induced", "epileptiform", "activity", "in", "anesthetized", "rats", ".", "Penicillin", "model", "is", "a", "widely", "used", "experimental", "model", "for", "epilepsy", "research", ".", "In", "the", "present", "study", "we", "aimed", "to", "portray", "a", "detailed", "spectral", "analysis", "of", "penicillin", "-", "induced", "epileptiform", "activity", "in", "comparison", "with", "basal", "brain", "activity", "in", "anesthetized", "Wistar", "rats", ".", "Male", "Wistar", "rats", "were", "anesthetized", "with", "i", ".", "p", ".", "urethane", "and", "connected", "to", "an", "electrocorticogram", "setup", ".", "After", "a", "short", "period", "of", "basal", "activity", "recording", ",", "epileptic", "focus", "was", "induced", "by", "injecting", "400IU", "/", "2", "microl", "penicillin", "-", "G", "potassium", "into", "the", "left", "lateral", "ventricle", "while", "the", "cortical", "activity", "was", "continuously", "recorded", ".", "Basal", "activity", ",", "latent", "period", "and", "the", "penicillin", "-", "induced", "epileptiform", "activity", "periods", "were", "then", "analyzed", "using", "both", "conventional", "methods", "and", "spectral", "analysis", ".", "Spectral", "analyses", "were", "conducted", "by", "dividing", "the", "whole", "spectrum", "into", "different", "frequency", "bands", "including", "delta", ",", "theta", "(", "slow", "and", "fast", ")", ",", "alpha", "-", "sigma", ",", "beta", "(", "1", "and", "2", ")", "and", "gamma", "(", "1", "and", "2", ")", "bands", ".", "Our", "results", "show", "that", "the", "most", "affected", "frequency", "bands", "were", "delta", ",", "theta", ",", "beta", "-", "2", "and", "gamma", "-", "2", "bands", "during", "the", "epileptiform", "activity", "and", "there", "were", "marked", "differences", "in", "terms", "of", "spectral", "densities", "between", "three", "investigated", "episodes", "(", "basal", "activity", ",", "latent", "period", "and", "epileptiform", "activity", ")", ".", "Our", "results", "may", "help", "to", "analyze", "novel", "data", "obtained", "using", "similar", "experimental", "models", "and", "the", "simple", "analysis", "method", "described", "here", "can", "be", "used", "in", "similar", "studies", "to", "investigate", "the", "basic", "neuronal", "mechanism", "of", "this", "or", "other", "types", "of", "experimental", "epilepsies", "."]], "ner": [[[92, 95, "Chemical"], [8, 9, "Disease"], [23, 23, "Disease"], [42, 43, "Disease"], [82, 82, "Disease"], [119, 120, "Disease"], [199, 200, "Disease"], [222, 223, "Disease"], [265, 265, "Disease"], [5, 5, "Chemical"], [14, 14, "Chemical"], [39, 39, "Chemical"], [116, 116, "Chemical"], [65, 65, "Chemical"]]], "relations": [[[92, 95, 8, 9, "CID"], [92, 95, 23, 23, "CID"], [92, 95, 42, 43, "CID"], [92, 95, 82, 82, "CID"], [92, 95, 119, 120, "CID"], [92, 95, 199, 200, "CID"], [92, 95, 222, 223, "CID"], [92, 95, 265, 265, "CID"]]], "clusters": [], "translated": "<9>青霉素</9>诱导的麻醉大鼠<1>癫痫样活动</1>的详细光谱分析。 <10>青霉素</10>模型是一种广泛用于<2>癫痫</2>研究的实验模型。在本研究中，我们旨在描绘<11>青霉素</11>诱导的<3>癫痫样活动</3>的详细光谱分析，并与麻醉的Wistar大鼠的基础大脑活动进行比较。雄性Wistar大鼠用i.p.<13>聚氨酯</13>麻醉并连接到一个皮层脑电图设置中。在短暂记录基础活动后，通过注射400IU/2μL<0>青霉素-G钾</0>至左侧脑室的方式诱发<4>癫痫</4>灶，同时连续记录皮层活动。然后，使用常规方法和光谱分析法对基础活动、潜伏期和<12>青霉素</12>诱导的<5>癫痫样活动</5>周期进行了分析。通过将整个频谱划分为不同的频带，包括delta、theta（慢和快）、alpha-sigma、beta（1和2）和gamma（1和2）频带进行频谱分析。我们的结果表明，在<6>癫痫样活动</6>期间，受影响最大的频段是delta、theta、beta-2和gamma-2频段，并且在三个调查事件（基础活动、潜伏期和<7>癫痫样活动</7>）之间的频谱密度方面存在显着差异。我们的结果可能有助于分析使用类似实验模型获得的新数据，并且此处描述的简单分析方法可用于类似研究，以研究这种或其他类型的实验性<8>癫痫</8>的基本神经元机制。", "revised": true}
{"doc_key": "16192988", "sentences": [["Methamphetamine", "causes", "alterations", "in", "the", "MAP", "kinase", "-", "related", "pathways", "in", "the", "brains", "of", "mice", "that", "display", "increased", "aggressiveness", ".", "Aggressive", "behaviors", "have", "been", "reported", "in", "patients", "who", "suffer", "from", "some", "psychiatric", "disorders", ",", "and", "are", "common", "in", "methamphetamine", "(", "METH", ")", "abusers", ".", "Herein", ",", "we", "report", "that", "multiple", "(", "but", "not", "single", ")", "injections", "of", "METH", "significantly", "increased", "aggressiveness", "in", "male", "CD", "-", "1", "mice", ".", "This", "increase", "in", "aggressiveness", "was", "not", "secondary", "to", "METH", "-", "induced", "hyperactivity", ".", "Analysis", "of", "protein", "expression", "using", "antibody", "microarrays", "and", "Western", "blotting", "revealed", "differential", "changes", "in", "MAP", "kinase", "-", "related", "pathways", "after", "multiple", "and", "single", "METH", "injections", ".", "There", "were", "statistically", "significant", "(", "p", "<", "0", ".", "05", ")", "decreases", "in", "MEK1", ",", "Erk2p", ",", "GSK3alpha", ",", "14", "-", "3", "-", "3e", ",", "and", "MEK7", "in", "the", "striata", "of", "mice", "after", "multiple", "injections", "of", "METH", ".", "MEK1", "was", "significantly", "decreased", "also", "after", "a", "single", "injection", "of", "METH", ",", "but", "to", "a", "much", "lesser", "degree", "than", "after", "multiple", "injections", "of", "METH", ".", "In", "the", "frontal", "cortex", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "GSK3alpha", "after", "multiple", "(", "but", "not", "single", ")", "injections", "of", "METH", ".", "These", "findings", "suggest", "that", "alterations", "in", "MAP", "kinase", "-", "related", "pathways", "in", "the", "prefronto", "-", "striatal", "circuitries", "might", "be", "involved", "in", "the", "manifestation", "of", "aggressive", "behaviors", "in", "mice", "."]], "ner": [[[0, 0, "Chemical"], [38, 38, "Chemical"], [40, 40, "Chemical"], [57, 57, "Chemical"], [76, 76, "Chemical"], [104, 104, "Chemical"], [143, 143, "Chemical"], [155, 155, "Chemical"], [168, 168, "Chemical"], [192, 192, "Chemical"], [18, 18, "Disease"], [20, 21, "Disease"], [31, 32, "Disease"], [60, 60, "Disease"], [71, 71, "Disease"], [218, 219, "Disease"], [79, 79, "Disease"]]], "relations": [[[0, 0, 18, 18, "CID"], [0, 0, 20, 21, "CID"], [0, 0, 31, 32, "CID"], [0, 0, 60, 60, "CID"], [0, 0, 71, 71, "CID"], [0, 0, 218, 219, "CID"], [38, 38, 18, 18, "CID"], [38, 38, 20, 21, "CID"], [38, 38, 31, 32, "CID"], [38, 38, 60, 60, "CID"], [38, 38, 71, 71, "CID"], [38, 38, 218, 219, "CID"], [40, 40, 18, 18, "CID"], [40, 40, 20, 21, "CID"], [40, 40, 31, 32, "CID"], [40, 40, 60, 60, "CID"], [40, 40, 71, 71, "CID"], [40, 40, 218, 219, "CID"], [57, 57, 18, 18, "CID"], [57, 57, 20, 21, "CID"], [57, 57, 31, 32, "CID"], [57, 57, 60, 60, "CID"], [57, 57, 71, 71, "CID"], [57, 57, 218, 219, "CID"], [76, 76, 18, 18, "CID"], [76, 76, 20, 21, "CID"], [76, 76, 31, 32, "CID"], [76, 76, 60, 60, "CID"], [76, 76, 71, 71, "CID"], [76, 76, 218, 219, "CID"], [104, 104, 18, 18, "CID"], [104, 104, 20, 21, "CID"], [104, 104, 31, 32, "CID"], [104, 104, 60, 60, "CID"], [104, 104, 71, 71, "CID"], [104, 104, 218, 219, "CID"], [143, 143, 18, 18, "CID"], [143, 143, 20, 21, "CID"], [143, 143, 31, 32, "CID"], [143, 143, 60, 60, "CID"], [143, 143, 71, 71, "CID"], [143, 143, 218, 219, "CID"], [155, 155, 18, 18, "CID"], [155, 155, 20, 21, "CID"], [155, 155, 31, 32, "CID"], [155, 155, 60, 60, "CID"], [155, 155, 71, 71, "CID"], [155, 155, 218, 219, "CID"], [168, 168, 18, 18, "CID"], [168, 168, 20, 21, "CID"], [168, 168, 31, 32, "CID"], [168, 168, 60, 60, "CID"], [168, 168, 71, 71, "CID"], [168, 168, 218, 219, "CID"], [192, 192, 18, 18, "CID"], [192, 192, 20, 21, "CID"], [192, 192, 31, 32, "CID"], [192, 192, 60, 60, "CID"], [192, 192, 71, 71, "CID"], [192, 192, 218, 219, "CID"]]], "clusters": [], "translated": " <0>甲基苯丙胺</0>引起小鼠大脑中MAP激酶相关通路的改变，从而显示出增加的<10>攻击性</10>。在患有某些<12>精神障碍</12>的患者中已有报道，<11>攻击性行为</11>并且在<1>甲基苯丙胺</1> (<2>METH</2>)中很常见滥用者。在此，我们报告了多次（但不是单次）注射<3>METH</3>显着增加了雄性CD-1小鼠的<13>攻击性</13>。这种增加的<14>攻击性</14>并非继发于<4>METH</4>诱导的<16>多动症</16>。使用抗体微阵列和蛋白质印迹分析蛋白质表达揭示了多次和单次<5>METH</5>注射后MAP激酶相关通路的不同变化。多次注射<6>METH</6>后，小鼠纹状体中MEK1、Erk2p、GSK3alpha、14-3-3e和MEK7均有统计学意义(p<0.05)下降。单次注射<7>METH</7>后，MEK1也显着降低，但程度远低于多次注射<8>METH</8>后的水平。在额叶皮层，多次（而非单次）注射<9>METH</9>后，GSK3alpha显着降低，具有统计学意义。这些发现表明，前额叶-纹状体回路中MAP激酶相关通路的改变可能与小鼠<15>攻击行为</15>的表现有关。", "revised": true}
{"doc_key": "14975762", "sentences": [["Expression", "of", "p300", "protects", "cardiac", "myocytes", "from", "apoptosis", "in", "vivo", ".", "Doxorubicin", "is", "an", "anti", "-", "tumor", "agent", "that", "represses", "cardiac", "-", "specific", "gene", "expression", "and", "induces", "myocardial", "cell", "apoptosis", ".", "Doxorubicin", "depletes", "cardiac", "p300", ",", "a", "transcriptional", "coactivator", "that", "is", "required", "for", "the", "maintenance", "of", "the", "differentiated", "phenotype", "of", "cardiac", "myocytes", ".", "However", ",", "the", "role", "of", "p300", "in", "protection", "against", "doxorubicin", "-", "induced", "apoptosis", "is", "unknown", ".", "Transgenic", "mice", "overexpressing", "p300", "in", "the", "heart", "and", "wild", "-", "type", "mice", "were", "subjected", "to", "doxorubicin", "treatment", ".", "Compared", "with", "wild", "-", "type", "mice", ",", "transgenic", "mice", "exhibited", "higher", "survival", "rate", "as", "well", "as", "more", "preserved", "left", "ventricular", "function", "and", "cardiac", "expression", "of", "alpha", "-", "sarcomeric", "actin", ".", "Doxorubicin", "induced", "myocardial", "cell", "apoptosis", "in", "wild", "-", "type", "mice", "but", "not", "in", "transgenic", "mice", ".", "Expression", "of", "p300", "increased", "the", "cardiac", "level", "of", "bcl", "-", "2", "and", "mdm", "-", "2", ",", "but", "not", "that", "of", "p53", "or", "other", "members", "of", "the", "bcl", "-", "2", "family", ".", "These", "findings", "demonstrate", "that", "overexpression", "of", "p300", "protects", "cardiac", "myocytes", "from", "doxorubicin", "-", "induced", "apoptosis", "and", "reduces", "the", "extent", "of", "acute", "heart", "failure", "in", "adult", "mice", "in", "vivo", "."]], "ner": [[[11, 11, "Chemical"], [31, 31, "Chemical"], [62, 62, "Chemical"], [84, 84, "Chemical"], [117, 117, "Chemical"], [175, 175, "Chemical"], [185, 186, "Disease"], [16, 16, "Disease"]]], "relations": [[[11, 11, 185, 186, "CID"], [31, 31, 185, 186, "CID"], [62, 62, 185, 186, "CID"], [84, 84, 185, 186, "CID"], [117, 117, 185, 186, "CID"], [175, 175, 185, 186, "CID"]]], "clusters": [], "translated": "p300 的表达在体内保护心肌细胞免于凋亡。<0>阿霉素</0>是一种抗<7>肿瘤</7>药物，可抑制心脏特异性基因的表达并诱导心肌细胞凋亡。<1>阿霉素</1>会耗尽心脏p300，这是一种维持心肌细胞分化表型所需的转录辅激活因子。然而，p300在防止<2>阿霉素</2>诱导的细胞凋亡中的作用尚不清楚。对心脏过表达p300的转基因小鼠和野生型小鼠进行<3>多柔比星</3>处理。与野生型小鼠相比，转基因小鼠的存活率更高，左心室功能和α-肌节肌动蛋白的心脏表达更完好。<4>阿霉素</4>诱导野生型小鼠心肌细胞凋亡，而转基因小鼠无此作用。p300的表达增加了bcl-2和mdm-2的心脏水平，但不增加p53或bcl-2家族其他成员的水平。这些发现表明，过表达的p300可保护心肌细胞免受<5>阿霉素</5>诱导的细胞凋亡，并降低体内成年小鼠急性<6>心力衰竭</6>的程度。", "revised": true}
{"doc_key": "1286498", "sentences": [["Reversal", "of", "central", "benzodiazepine", "effects", "by", "flumazenil", "after", "intravenous", "conscious", "sedation", "with", "diazepam", "and", "opioids", ":", "report", "of", "a", "double", "-", "blind", "multicenter", "study", ".", "The", "Flumazenil", "in", "Intravenous", "Conscious", "Sedation", "with", "Diazepam", "Multicenter", "Study", "Group", "II", ".", "The", "efficacy", "and", "safety", "of", "a", "new", "benzodiazepine", "antagonist", ",", "flumazenil", ",", "were", "assessed", "in", "a", "double", "-", "blind", "multicenter", "study", ".", "Flumazenil", "(", "mean", "dose", ",", "0", ".", "76", "mg", ")", "or", "placebo", "(", "mean", "dose", ",", "8", ".", "9", "ml", ")", "was", "administered", "intravenously", "to", "130", "and", "67", "patients", ",", "respectively", ",", "who", "had", "been", "given", "diazepam", "in", "conjunction", "with", "an", "opioid", "(", "fentanyl", ",", "meperidine", ",", "or", "morphine", ")", "for", "the", "induction", "and", "maintenance", "of", "intravenous", "conscious", "sedation", "for", "diagnostic", "or", "therapeutic", "surgical", "procedures", ".", "The", "group", "assessable", "for", "efficacy", "comprised", "122", "patients", "treated", "with", "flumazenil", "and", "64", "patients", "given", "placebo", ".", "After", "5", "minutes", ",", "80", "/", "115", "(", "70", "%", ")", "flumazenil", "-", "treated", "patients", ",", "compared", "with", "21", "/", "63", "(", "33", "%", ")", "placebo", "-", "treated", "patients", ",", "were", "completely", "awake", "and", "alert", ",", "as", "indicated", "by", "a", "score", "of", "5", "on", "the", "Observer", "'s", "Assessment", "of", "Alertness", "/", "Sedation", "Scale", ".", "Ninety", "-", "five", "percent", "of", "patients", "in", "each", "group", "who", "attained", "a", "score", "of", "5", "at", "the", "5", "-", "minute", "assessment", "showed", "no", "loss", "of", "alertness", "throughout", "the", "180", "-", "minute", "assessment", "period", ".", "Flumazenil", "-", "treated", "patients", "also", "performed", "significantly", "better", "on", "the", "Finger", "-", "to", "-", "Nose", "Test", "and", "the", "recall", "of", "pictures", "shown", "at", "the", "5", "-", "minute", "assessment", ".", "Flumazenil", "was", "well", "tolerated", ",", "with", "no", "serious", "adverse", "effects", "reported", ".", "Thirty", "-", "nine", "(", "30", "%", ")", "of", "flumazenil", "-", "treated", "patients", ",", "compared", "with", "17", "(", "25", "%", ")", "of", "placebo", "-", "treated", "patients", "had", "one", "or", "more", "drug", "-", "related", "adverse", "experiences", ".", "The", "most", "common", "adverse", "effects", "were", "nausea", "and", "vomiting", "in", "the", "flumazenil", "group", "and", "nausea", "and", "injection", "-", "site", "pain", "in", "the", "placebo", "group", ".", "Flumazenil", "was", "found", "to", "promptly", "reverse", "sedation", "induced", "by", "diazepam", "in", "the", "presence", "of", "opioids", "."]], "ner": [[[6, 6, "Chemical"], [26, 26, "Chemical"], [48, 48, "Chemical"], [60, 60, "Chemical"], [136, 136, "Chemical"], [154, 154, "Chemical"], [231, 231, "Chemical"], [260, 260, "Chemical"], [280, 280, "Chemical"], [318, 318, "Chemical"], [332, 332, "Chemical"], [313, 313, "Disease"], [321, 321, "Disease"], [315, 315, "Disease"], [3, 3, "Chemical"], [45, 45, "Chemical"], [326, 326, "Disease"], [12, 12, "Chemical"], [32, 32, "Chemical"], [96, 96, "Chemical"], [341, 341, "Chemical"], [103, 103, "Chemical"], [105, 105, "Chemical"], [108, 108, "Chemical"]]], "relations": [[[6, 6, 313, 313, "CID"], [6, 6, 321, 321, "CID"], [26, 26, 313, 313, "CID"], [26, 26, 321, 321, "CID"], [48, 48, 313, 313, "CID"], [48, 48, 321, 321, "CID"], [60, 60, 313, 313, "CID"], [60, 60, 321, 321, "CID"], [136, 136, 313, 313, "CID"], [136, 136, 321, 321, "CID"], [154, 154, 313, 313, "CID"], [154, 154, 321, 321, "CID"], [231, 231, 313, 313, "CID"], [231, 231, 321, 321, "CID"], [260, 260, 313, 313, "CID"], [260, 260, 321, 321, "CID"], [280, 280, 313, 313, "CID"], [280, 280, 321, 321, "CID"], [318, 318, 313, 313, "CID"], [318, 318, 321, 321, "CID"], [332, 332, 313, 313, "CID"], [332, 332, 321, 321, "CID"], [6, 6, 315, 315, "CID"], [26, 26, 315, 315, "CID"], [48, 48, 315, 315, "CID"], [60, 60, 315, 315, "CID"], [136, 136, 315, 315, "CID"], [154, 154, 315, 315, "CID"], [231, 231, 315, 315, "CID"], [260, 260, 315, 315, "CID"], [280, 280, 315, 315, "CID"], [318, 318, 315, 315, "CID"], [332, 332, 315, 315, "CID"]]], "clusters": [], "translated": "在用<17>地西泮</17>和阿片类药物进行静脉清醒镇静后，<0>氟马西尼</0>对中枢<14>苯二氮卓</14>作用的逆转：双盲多中心研究报告。 <1>氟马西尼</1>与<18>地西泮</18>多中心研究II组静脉清醒镇静作用。一项双盲多中心研究评估了一种新的<15>苯二氮卓类药物</15>拮抗剂<2>氟马西尼</2>的疗效和安全性。<3>氟马西尼</3>（平均剂量，0.76 mg）或安慰剂（平均剂量，8.9 ml）分别静脉内给予130和67名接受<19>地西泮</19>的患者与阿片类药物（<21>芬太尼</21>、<22>度冷丁</22>或<23>吗啡</23>）联合使用，用于诊断或治疗性外科手术的静脉清醒镇静的诱导和维持。可评估疗效的组包括122名接受<4>氟马西尼</4>治疗的患者和64名接受安慰剂治疗的患者。5分钟后，80/115（70%）接受<5>氟马西尼</5>治疗的患者与安慰剂治疗的21/63（33%）患者完全清醒和警觉，评分为5，观察者对警觉性/镇静量表的评估。在5分钟的评估中获得5分的每组患者中有95%的患者在整个180分钟的评估期间都没有失去警觉性。<6>氟马西尼</6>治疗的患者在指鼻测试和5分钟评估时所显示图片的回忆方面也有明显更好的表现。<7>氟马西尼</7>耐受性良好，没有严重不良反应的报道。与接受安慰剂治疗的患者相比，接受<8>氟马西尼</8>治疗的患者中有39例（30%）有一种或多种与药物相关的不良经历，而接受安慰剂治疗的患者中有17例（25%）。<9>氟马西尼</9>组最常见的不良反应是<11>恶心</11>和<13>呕吐</13>，安慰剂组最常见的不良反应是<12>恶心</12>和注射部位<16>疼痛</16>。 <10>氟马西尼</10>被发现可在阿片类药物存在的情况下迅速逆转<20>地西泮</20>引起的镇静作用。", "revised": true}
{"doc_key": "8012887", "sentences": [["Failure", "of", "ancrod", "in", "the", "treatment", "of", "heparin", "-", "induced", "arterial", "thrombosis", ".", "The", "morbidity", "and", "mortality", "associated", "with", "heparin", "-", "induced", "thrombosis", "remain", "high", "despite", "numerous", "empirical", "therapies", ".", "Ancrod", "has", "been", "used", "successfully", "for", "prophylaxis", "against", "development", "of", "thrombosis", "in", "patients", "with", "heparin", "induced", "platelet", "aggregation", "who", "require", "brief", "reexposure", "to", "heparin", ",", "but", "its", "success", "in", "patients", "who", "have", "developed", "the", "thrombosis", "syndrome", "is", "not", "well", "defined", ".", "The", "authors", "present", "a", "case", "of", "failure", "of", "ancrod", "treatment", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombosis", "."]], "ner": [[[7, 7, "Chemical"], [19, 19, "Chemical"], [44, 44, "Chemical"], [53, 53, "Chemical"], [85, 85, "Chemical"], [11, 11, "Disease"], [22, 22, "Disease"], [40, 40, "Disease"], [64, 64, "Disease"], [88, 88, "Disease"], [46, 47, "Disease"]]], "relations": [[[7, 7, 11, 11, "CID"], [7, 7, 22, 22, "CID"], [7, 7, 40, 40, "CID"], [7, 7, 64, 64, "CID"], [7, 7, 88, 88, "CID"], [19, 19, 11, 11, "CID"], [19, 19, 22, 22, "CID"], [19, 19, 40, 40, "CID"], [19, 19, 64, 64, "CID"], [19, 19, 88, 88, "CID"], [44, 44, 11, 11, "CID"], [44, 44, 22, 22, "CID"], [44, 44, 40, 40, "CID"], [44, 44, 64, 64, "CID"], [44, 44, 88, 88, "CID"], [53, 53, 11, 11, "CID"], [53, 53, 22, 22, "CID"], [53, 53, 40, 40, "CID"], [53, 53, 64, 64, "CID"], [53, 53, 88, 88, "CID"], [85, 85, 11, 11, "CID"], [85, 85, 22, 22, "CID"], [85, 85, 40, 40, "CID"], [85, 85, 64, 64, "CID"], [85, 85, 88, 88, "CID"]]], "clusters": [], "translated": "ancrod治疗<0>肝素</0>诱发的动脉<5>血栓</5>失败。尽管有许多经验疗法，但与<1>肝素</1>相关的<6>血栓形成</6>发病率和死亡率仍然很高。Ancrod已成功用于预防<2>肝素</2>诱导的<10>血小板聚集</10>，需要短暂再暴露于<3>肝素</3>的患者的<7>血栓形成</7>，但其在发生<8>血栓形成</8>综合征的患者中的成功率尚不明确。作者介绍了<4>肝素</4>诱导的<9>血栓形成</9>患者接受ancrod治疗失败的案例。", "revised": true}
{"doc_key": "14736955", "sentences": [["Mitochondrial", "DNA", "and", "its", "respiratory", "chain", "products", "are", "defective", "in", "doxorubicin", "nephrosis", ".", "BACKGROUND", ":", "Doxorubicin", "induces", "a", "self", "-", "perpetuating", "nephropathy", "characterized", "by", "early", "glomerular", "and", "late", "-", "onset", "tubular", "lesions", "in", "rats", ".", "We", "investigated", "the", "potential", "role", "of", "mitochondrial", "injury", "in", "the", "onset", "of", "these", "lesions", ".", "METHODS", ":", "Rats", "were", "treated", "with", "intravenous", "doxorubicin", "(", "1", "mg", "kg", "(", "-", "1", ")", "week", "(", "-", "1", ")", ")", "for", "7", "weeks", "and", "were", "sacrificed", "either", "1", "week", "(", "'", "short", "-", "term", "'", ")", "or", "30", "weeks", "(", "'", "long", "-", "term", "'", ")", "following", "the", "last", "dose", ".", "Additional", "rats", "received", "a", "single", "dose", "either", "6", "days", "or", "2", "h", "prior", "to", "euthanasia", ".", "All", "rats", "were", "killed", "at", "48", "weeks", "of", "age", ".", "Glomerular", "and", "tubular", "injury", "was", "monitored", "and", "correlated", "to", "the", "activity", "or", "expression", "of", "respiratory", "chain", "components", ".", "Finally", ",", "we", "quantified", "both", "nuclear", "and", "mitochondrial", "DNA", "(", "mtDNA", ")", "as", "well", "as", "superoxide", "production", "and", "the", "4834", "base", "pair", "'", "common", "'", "mtDNA", "deletion", ".", "RESULTS", ":", "The", "'", "long", "-", "term", "'", "group", "had", "significant", "glomerular", "and", "tubular", "lesions", ",", "depressed", "activities", "of", "mtDNA", "-", "encoded", "NADH", "dehydrogenase", "and", "cytochrome", "-", "c", "oxidase", "(", "COX", ")", "and", "increased", "citrate", "synthase", "activity", ".", "In", "addition", ",", "expression", "of", "the", "mtDNA", "-", "encoded", "COX", "subunit", "I", "was", "reduced", "and", "mtDNA", "levels", "were", "decreased", ".", "In", "'", "short", "-", "term", "'", "rats", ",", "there", "were", "fewer", "tubular", "lesions", ",", "but", "similar", "numbers", "of", "glomerular", "lesions", "activity", ".", "Among", "all", "animals", ",", "glomerular", "and", "tubular", "injury", "were", "inversely", "correlated", "with", "mtDNA", "levels", ",", "mtDNA", "-", "encoded", "respiratory", "chain", "activities", "and", "with", "the", "expression", "of", "the", "mtDNA", "-", "encoded", "respiratory", "chain", "subunit", "COX", "-", "I", ".", "Injury", "was", "positively", "correlated", "with", "superoxide", "production", "and", "the", "activities", "of", "nucleus", "-", "encoded", "mitochondrial", "or", "cytoplasmic", "enzymes", ".", "Kidneys", "from", "the", "'", "long", "-", "term", "'", "group", "showed", "more", "mtDNA", "deletions", "than", "in", "'", "short", "-", "term", "'", "animals", "and", "these", "were", "not", "observed", "in", "the", "other", "groups", ".", "CONCLUSIONS", ":", "These", "results", "suggest", "an", "important", "role", "for", "quantitative", "and", "qualitative", "mtDNA", "alterations", "through", "the", "reduction", "of", "mtDNA", "-", "encoded", "respiratory", "chain", "function", "and", "induction", "of", "superoxide", "in", "doxorubicin", "-", "induced", "renal", "lesions", "."]], "ner": [[[10, 10, "Chemical"], [15, 15, "Chemical"], [57, 57, "Chemical"], [371, 371, "Chemical"], [11, 11, "Disease"], [21, 21, "Disease"], [25, 31, "Disease"], [129, 132, "Disease"], [186, 189, "Disease"], [244, 245, "Disease"], [251, 252, "Disease"], [259, 262, "Disease"], [374, 375, "Disease"], [41, 42, "Disease"], [162, 162, "Chemical"], [297, 297, "Chemical"], [369, 369, "Chemical"], [209, 209, "Chemical"]]], "relations": [[[10, 10, 11, 11, "CID"], [15, 15, 11, 11, "CID"], [57, 57, 11, 11, "CID"], [371, 371, 11, 11, "CID"]]], "clusters": [], "translated": "线粒体DNA及其呼吸链产物在<0>阿霉素</0><4>肾病</4>中存在缺陷。背景：<1>多柔比星</1>在大鼠中诱发以早期<6>肾小球和迟发性肾小管病变</6>为特征的自我延续性<5>肾病</5>。我们研究了<13>线粒体损伤</13>在这些病变发生中的潜在作用。方法：大鼠接受静脉注射<2>多柔比星</2>（1 mg kg( -1 )周( -1)）治疗7周，并在最后一剂之后的1周（'短期'）或30周（'长期'）处死。额外的大鼠在安乐死前6天或2小时接受单次给药。所有大鼠在48周大时被处死。<7>监测肾小球和肾小管损伤</7>，并将其与呼吸链成分的活性或表达进行相关分析。最后，我们对细胞核和线粒体DNA(mtDNA)以及<14>超氧化物</14>的产生和4834个碱基对的“常见”mtDNA缺失进行了量化。结果：'长期'组有明显的<8>肾小球和肾小管损伤</8>，mtDNA编码的NADH脱氢酶和细胞色素-c氧化酶(COX)活性降低，<17>柠檬酸</17>合酶活性增加。此外，mtDNA编码的COX亚基I的表达减少，mtDNA水平降低。在'短期'大鼠中，<9>肾小管病变</9>较少，但<10>肾小球病变</10>的数量相似。在所有动物中，<11>肾小球和肾小管损伤</11>与mtDNA水平、mtDNA 编码的呼吸链活性以及mtDNA 编码的呼吸链亚基COX-I的表达呈负相关。损伤与<15>超氧化物</15>的产生和细胞核编码的线粒体或细胞质酶的活性呈正相关。'长期'组的肾脏显示出比'短期'动物更多的mtDNA缺失，而这些缺陷在其他组中没有观察到。结论：这些结果表明，通过减少mtDNA编码的呼吸链功能和在<3>阿霉素</3>诱导的<12>肾病</12>中诱导<16>超氧化物</16>，mtDNA的定量和定性改变在病变中具有重要作用。", "revised": true}
{"doc_key": "15867025", "sentences": [["Assessment", "of", "perinatal", "hepatitis", "B", "and", "rubella", "prevention", "in", "New", "Hampshire", "delivery", "hospitals", ".", "OBJECTIVE", ":", "To", "evaluate", "current", "performance", "on", "recommended", "perinatal", "hepatitis", "B", "and", "rubella", "prevention", "practices", "in", "New", "Hampshire", ".", "METHODS", ":", "Data", "were", "extracted", "from", "2021", "paired", "mother", "-", "infant", "records", "for", "the", "year", "2000", "birth", "cohort", "in", "New", "Hampshire", "'s", "25", "delivery", "hospitals", ".", "Assessment", "was", "done", "on", "the", "following", ":", "prenatal", "screening", "for", "hepatitis", "B", "and", "rubella", ",", "administration", "of", "the", "hepatitis", "B", "vaccine", "birth", "dose", "to", "all", "infants", ",", "administration", "of", "hepatitis", "B", "immune", "globulin", "to", "infants", "who", "were", "born", "to", "hepatitis", "B", "surface", "antigen", "-", "positive", "mothers", ",", "rubella", "immunity", ",", "and", "administration", "of", "in", "-", "hospital", "postpartum", "rubella", "vaccine", "to", "rubella", "nonimmune", "women", ".", "RESULTS", ":", "Prenatal", "screening", "rates", "for", "hepatitis", "B", "(", "98", ".", "8", "%", ")", "and", "rubella", "(", "99", ".", "4", "%", ")", "were", "high", ".", "Hepatitis", "B", "vaccine", "birth", "dose", "was", "administered", "to", "76", ".", "2", "%", "of", "all", "infants", ".", "All", "infants", "who", "were", "born", "to", "hepatitis", "B", "surface", "antigen", "-", "positive", "mothers", "also", "received", "hepatitis", "B", "immune", "globulin", ".", "Multivariate", "logistic", "regression", "showed", "that", "the", "month", "of", "delivery", "and", "infant", "birth", "weight", "were", "independent", "predictors", "of", "hepatitis", "B", "vaccination", ".", "The", "proportion", "of", "infants", "who", "were", "vaccinated", "in", "January", "and", "February", "2000", "(", "48", ".", "5", "%", "and", "67", ".", "5", "%", ",", "respectively", ")", "was", "less", "than", "any", "other", "months", ",", "whereas", "the", "proportion", "who", "were", "vaccinated", "in", "December", "2000", "(", "88", ".", "2", "%", ")", "was", "the", "highest", ".", "Women", "who", "were", "born", "between", "1971", "and", "1975", "had", "the", "highest", "rate", "of", "rubella", "nonimmunity", "(", "9", ".", "5", "%", ")", ".", "In", "-", "hospital", "postpartum", "rubella", "vaccine", "administration", "was", "documented", "for", "75", ".", "6", "%", "of", "nonimmune", "women", ".", "CONCLUSION", ":", "This", "study", "documents", "good", "compliance", "in", "New", "Hampshire", "'s", "birthing", "hospitals", "with", "national", "guidelines", "for", "perinatal", "hepatitis", "B", "and", "rubella", "prevention", "and", "highlights", "potential", "areas", "for", "improvement", "."]], "ner": [[[98, 101, "Chemical"], [170, 173, "Chemical"], [3, 4, "Disease"], [23, 24, "Disease"], [69, 70, "Disease"], [77, 78, "Disease"], [88, 89, "Disease"], [129, 130, "Disease"], [148, 149, "Disease"], [179, 180, "Disease"], [201, 202, "Disease"], [314, 315, "Disease"], [6, 6, "Disease"], [26, 26, "Disease"], [72, 72, "Disease"], [106, 106, "Disease"], [116, 116, "Disease"], [119, 119, "Disease"], [138, 138, "Disease"], [269, 269, "Disease"], [282, 282, "Disease"], [317, 317, "Disease"]]], "relations": [[[98, 101, 3, 4, "CID"], [98, 101, 23, 24, "CID"], [98, 101, 69, 70, "CID"], [98, 101, 77, 78, "CID"], [98, 101, 88, 89, "CID"], [98, 101, 129, 130, "CID"], [98, 101, 148, 149, "CID"], [98, 101, 179, 180, "CID"], [98, 101, 201, 202, "CID"], [98, 101, 314, 315, "CID"], [170, 173, 3, 4, "CID"], [170, 173, 23, 24, "CID"], [170, 173, 69, 70, "CID"], [170, 173, 77, 78, "CID"], [170, 173, 88, 89, "CID"], [170, 173, 129, 130, "CID"], [170, 173, 148, 149, "CID"], [170, 173, 179, 180, "CID"], [170, 173, 201, 202, "CID"], [170, 173, 314, 315, "CID"]]], "clusters": [], "translated": "新罕布什尔分娩医院围产期<2>乙型肝炎</2>和<12>风疹</12>预防评估。目的：评估新罕布什尔州推荐的围产期<3>乙型肝炎</3>和<13>风疹</13>预防措施的当前绩效。方法：数据是从新罕布什尔州25家分娩医院2000年出生队列的2021对母婴记录中提取的。对以下方面进行了评估：<4>乙型肝炎</4>和<14>风疹</14>的产前筛查，对所有婴儿接种了<5>乙型肝炎</5>疫苗出生剂量，给予<6>乙型肝炎</6>免疫球蛋白对<0>乙型肝炎表面抗原</0>阳性母亲所生婴儿，<15>风疹</15>免疫，产后住院给药<16>风疹</16>疫苗接种给<17>风疹</17>未免疫的妇女。结果：<7>乙型肝炎</7>（98.8%）和<18>风疹</18>（99.4%）产前筛查率较高。<8>乙型肝炎</8>疫苗出生剂量被76.2%的婴儿接种。所有出生于<1>乙型肝炎表面抗原</1>阳性母亲的婴儿都接受了<9>乙型肝炎</9>免疫球蛋白。多变量逻辑回归显示，分娩月份和婴儿出生体重是<10>乙型肝炎</10>疫苗接种的独立预测因子。2000年1月和2月接种疫苗的婴儿比例（分别为48.5%和67.5%）低于其他月份，而2000年12月接种疫苗的婴儿比例（88.2%）最高。出生于1971年至1975年的女性<19>风疹</19>未免疫率最高（9.5%）。记录了75例住院产后<20>风疹</20>疫苗接种情况，对未免疫的女性占6%。结论：本研究记录了新罕布什尔州分娩医院对围产期<11>乙型肝炎</11>和<21>风疹</21>预防国家指南的良好依从性，并强调了潜在的改进领域。", "revised": true}
{"doc_key": "11573852", "sentences": [["Amphotericin", "B", "-", "induced", "seizures", "in", "a", "patient", "with", "AIDS", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "multiple", "episodes", "of", "seizure", "activity", "in", "an", "AIDS", "patent", "following", "amphotericin", "B", "infusion", ".", "CASE", "SUMMARY", ":", "A", "46", "-", "year", "-", "old", "African", "-", "American", "man", "experienced", "recurrent", "grand", "mal", "seizures", "during", "intravenous", "infusion", "of", "amphotericin", "B", ",", "then", "petit", "mal", "seizures", "as", "the", "infusion", "was", "stopped", "and", "the", "drug", "concentrations", "decreased", "with", "time", ".", "The", "patients", "concurrent", "medications", "included", "didanosine", ",", "hydroxyzine", ",", "promethazine", ",", "hydrocortisone", ",", "and", "prochlorperazine", ".", "Despite", "administration", "of", "phenytoin", "and", "lorazepam", ",", "the", "seizures", "persisted", "and", "occurred", "only", "during", "amphotercin", "B", "administration", ".", "DISCUSSION", ":", "AIDS", "and", "cryptococcal", "meningitis", ",", "both", "of", "which", "the", "patient", "had", ",", "can", "potentially", "cause", "seizures", ".", "The", "patient", "had", "a", "history", "of", "alcohol", "abuse", ";", "alcohol", "intake", "as", "well", "as", "withdrawal", "can", "also", "cause", "seizures", ".", "Didanosine", "also", "has", "a", "potential", "for", "inducing", "seizures", ".", "However", ",", "these", "other", "potential", "causes", "of", "seizure", "were", "ruled", "out", ".", "The", "time", "course", "of", "events", "suggested", "that", "amphotericin", "B", "was", "the", "cause", "of", "the", "seizures", "in", "this", "AIDS", "patient", ".", "CONCLUSIONS", ":", "Amphotericin", "B", "seems", "to", "be", "the", "probable", "cause", "of", "the", "seizures", ".", "To", "date", ",", "only", "three", "cases", "of", "seizures", "associated", "with", "amphotericin", "B", "have", "been", "reported", "in", "the", "literature", ",", "but", "healthcare", "providers", "should", "be", "aware", "of", "the", "potential", "for", "this", "rare", "adverse", "effect", "."]], "ner": [[[0, 1, "Chemical"], [28, 29, "Chemical"], [54, 55, "Chemical"], [104, 105, "Chemical"], [175, 176, "Chemical"], [190, 191, "Chemical"], [212, 213, "Chemical"], [4, 4, "Disease"], [21, 21, "Disease"], [60, 60, "Disease"], [98, 98, "Disease"], [125, 125, "Disease"], [145, 145, "Disease"], [154, 154, "Disease"], [163, 163, "Disease"], [182, 182, "Disease"], [200, 200, "Disease"], [209, 209, "Disease"], [9, 9, "Disease"], [25, 25, "Disease"], [110, 110, "Disease"], [185, 185, "Disease"], [47, 49, "Disease"], [112, 113, "Disease"], [133, 134, "Disease"], [79, 79, "Chemical"], [147, 147, "Chemical"], [81, 81, "Chemical"], [83, 83, "Chemical"], [85, 85, "Chemical"], [88, 88, "Chemical"], [93, 93, "Chemical"], [95, 95, "Chemical"], [136, 136, "Chemical"]]], "relations": [[[0, 1, 4, 4, "CID"], [0, 1, 21, 21, "CID"], [0, 1, 60, 60, "CID"], [0, 1, 98, 98, "CID"], [0, 1, 125, 125, "CID"], [0, 1, 145, 145, "CID"], [0, 1, 154, 154, "CID"], [0, 1, 163, 163, "CID"], [0, 1, 182, 182, "CID"], [0, 1, 200, 200, "CID"], [0, 1, 209, 209, "CID"], [28, 29, 4, 4, "CID"], [28, 29, 21, 21, "CID"], [28, 29, 60, 60, "CID"], [28, 29, 98, 98, "CID"], [28, 29, 125, 125, "CID"], [28, 29, 145, 145, "CID"], [28, 29, 154, 154, "CID"], [28, 29, 163, 163, "CID"], [28, 29, 182, 182, "CID"], [28, 29, 200, 200, "CID"], [28, 29, 209, 209, "CID"], [54, 55, 4, 4, "CID"], [54, 55, 21, 21, "CID"], [54, 55, 60, 60, "CID"], [54, 55, 98, 98, "CID"], [54, 55, 125, 125, "CID"], [54, 55, 145, 145, "CID"], [54, 55, 154, 154, "CID"], [54, 55, 163, 163, "CID"], [54, 55, 182, 182, "CID"], [54, 55, 200, 200, "CID"], [54, 55, 209, 209, "CID"], [104, 105, 4, 4, "CID"], [104, 105, 21, 21, "CID"], [104, 105, 60, 60, "CID"], [104, 105, 98, 98, "CID"], [104, 105, 125, 125, "CID"], [104, 105, 145, 145, "CID"], [104, 105, 154, 154, "CID"], [104, 105, 163, 163, "CID"], [104, 105, 182, 182, "CID"], [104, 105, 200, 200, "CID"], [104, 105, 209, 209, "CID"], [175, 176, 4, 4, "CID"], [175, 176, 21, 21, "CID"], [175, 176, 60, 60, "CID"], [175, 176, 98, 98, "CID"], [175, 176, 125, 125, "CID"], [175, 176, 145, 145, "CID"], [175, 176, 154, 154, "CID"], [175, 176, 163, 163, "CID"], [175, 176, 182, 182, "CID"], [175, 176, 200, 200, "CID"], [175, 176, 209, 209, "CID"], [190, 191, 4, 4, "CID"], [190, 191, 21, 21, "CID"], [190, 191, 60, 60, "CID"], [190, 191, 98, 98, "CID"], [190, 191, 125, 125, "CID"], [190, 191, 145, 145, "CID"], [190, 191, 154, 154, "CID"], [190, 191, 163, 163, "CID"], [190, 191, 182, 182, "CID"], [190, 191, 200, 200, "CID"], [190, 191, 209, 209, "CID"], [212, 213, 4, 4, "CID"], [212, 213, 21, 21, "CID"], [212, 213, 60, 60, "CID"], [212, 213, 98, 98, "CID"], [212, 213, 125, 125, "CID"], [212, 213, 145, 145, "CID"], [212, 213, 154, 154, "CID"], [212, 213, 163, 163, "CID"], [212, 213, 182, 182, "CID"], [212, 213, 200, 200, "CID"], [212, 213, 209, 209, "CID"]]], "clusters": [], "translated": " <0>两性霉素B</0> - 在 <18>AIDS</18> 患者中诱发<7>癫痫发作</7>。目的：报告一例<19>AIDS</19>患者输注<1>两性霉素B</1>后多次发作<8>癫痫发作</8>活动。病例概要：一名46岁的非洲裔美国男性在静脉输注<2>两性霉素B</2>期间经历了反复发作的<22>大发作</22>，然后是小发作<9>发作</9>随着输液停止，药物浓度随时间下降 。患者同时服用的药物有<25>去羟肌苷</25>、<27>羟嗪</27>、<28>异丙嗪</28>、<29>氢化可的松</29>、<30>丙氯拉嗪</30>。尽管服用了<31>苯妥英</31>和<32>劳拉西泮</32>，<10>癫痫发作</10>仍然存在并且仅在<3>两性霉素B</3>静脉输注期间发生。讨论：<20>AIDS</20>和<23>隐球菌性脑膜炎</23>，患者都患有这两种疾病，可能导致<11>癫痫发作</11>。患者有<24>酗酒史</24>; <33>酒精</33>摄入和戒断也会导致<12>癫痫发作</12>。<26>去羟肌苷</26>也有可能诱发<13>癫痫发作</13>。然而，这些其他可能导致<14>癫痫发作</14>的原因被排除了。事件的时间进程表明<4>两性霉素B</4>是这名<21>AIDS</21>患者<15>癫痫发作</15>的原因。结论：<5>两性霉素B</5>似乎是<16>癫痫发作</16>的可能原因。迄今为止，文献中仅报道了3例与<6>两性霉素B</6> 相关的<17>癫痫发作</17>，但医疗保健提供者应意识到这种罕见不良反应的可能性。", "revised": true}
{"doc_key": "9875685", "sentences": [["Therapeutic", "drug", "monitoring", "of", "tobramycin", ":", "once", "-", "daily", "versus", "twice", "-", "daily", "dosage", "schedules", ".", "OBJECTIVE", ":", "To", "evaluate", "the", "effect", "of", "dosage", "regimen", "(", "once", "-", "daily", "vs", ".", "twice", "-", "daily", ")", "of", "tobramicyn", "on", "steady", "-", "state", "serum", "concentrations", "and", "toxicity", ".", "MATERIALS", "AND", "METHODS", ":", "Patients", "undergoing", "treatment", "with", "i", ".", "v", ".", "tobramycin", "(", "4", "mg", "/", "kg", "/", "day", ")", "were", "randomised", "to", "two", "groups", ".", "Group", "OD", "(", "n", "=", "22", ")", "received", "a", "once", "-", "daily", "dose", "of", "tobramycin", "and", "group", "TD", "(", "n", "=", "21", ")", "received", "the", "same", "dose", "divided", "into", "two", "doses", "daily", ".", "Tobramycin", "serum", "concentrations", "(", "peak", "and", "trough", ")", "were", "measured", "by", "enzyme", "multiplied", "immunoassay", ".", "The", "renal", "and", "auditory", "functions", "of", "the", "patients", "were", "monitored", "before", ",", "during", "and", "immediately", "after", "treatment", ".", "RESULTS", ":", "The", "two", "groups", "were", "comparable", "with", "respect", "to", "sex", ",", "age", ",", "body", "weight", "and", "renal", "function", ".", "No", "statistically", "significant", "differences", "were", "found", "in", "mean", "daily", "dose", ",", "duration", "of", "treatment", ",", "or", "cumulative", "dose", ".", "Trough", "concentrations", "were", "<", "2", "g", "/", "ml", "in", "the", "two", "groups", "(", "100", "%", ")", ".", "Peak", "concentrations", "were", ">", "6", "microg", "/", "ml", "in", "100", "%", "of", "the", "OD", "group", "and", "in", "67", "%", "of", "the", "TD", "group", "(", "P", "<", "0", ".", "01", ")", ".", "Mean", "peak", "concentrations", "were", "markedly", "different", ":", "11", ".", "00", "+", "/", "-", "2", ".", "89", "microg", "/", "ml", "in", "OD", "vs", ".", "6", ".", "53", "+", "/", "-", "1", ".", "45", "microg", "/", "ml", "in", "TD", "(", "P", "<", "0", ".", "01", ")", ".", "The", "pharmacokinetics", "parameters", "were", ":", "Ke", ",", "(", "0", ".", "15", "+", "/", "-", "0", ".", "03", "/", "h", "in", "OD", "vs", ".", "0", ".", "24", "+", "/", "-", "0", ".", "06", "/", "h", "in", "TD", ")", ",", "t1", "/", "2", ",", "(", "4", ".", "95", "+", "/", "-", "1", ".", "41", "h", "in", "OD", "vs", ".", "3", ".", "07", "+", "/", "-", "0", ".", "71", "h", "in", "TD", ")", ",", "Vd", "(", "0", ".", "35", "+", "/", "-", "0", ".", "11", "l", "/", "kg", "in", "OD", "vs", ".", "0", ".", "33", "+", "/", "-", "0", ".", "09", "l", "/", "kg", "in", "TD", ")", ",", "Cl", "(", "0", ".", "86", "+", "/", "-", "0", ".", "29", "ml", "/", "min", "/", "kg", "in", "OD", "vs", ".", "1", ".", "28", "+", "/", "-", "0", ".", "33", "ml", "/", "min", "/", "kg", "in", "TD", ")", ".", "Increased", "serum", "creatinine", "was", "observed", "in", "73", "%", "of", "patients", "in", "OD", "versus", "57", "%", "of", "patients", "in", "TD", ",", "without", "evidence", "of", "nephrotoxicity", ".", "In", "TD", "group", ",", "three", "patients", "developed", "decreased", "auditory", "function", ",", "of", "which", "one", "presented", "with", "an", "auditory", "loss", "of", "-", "30", "dB", ",", "whereas", "in", "the", "OD", "group", "only", "one", "patient", "presented", "decreased", "auditory", "function", ".", "CONCLUSION", ":", "This", "small", "study", "suggests", "that", "a", "once", "-", "daily", "dosing", "regimen", "of", "tobramycin", "is", "at", "least", "as", "effective", "as", "and", "is", "no", "more", "and", "possibly", "less", "toxic", "than", "the", "twice", "-", "daily", "regimen", ".", "Using", "a", "single", "-", "dose", "therapy", ",", "peak", "concentration", "determination", "is", "not", "necessary", ",", "only", "trough", "samples", "should", "be", "monitored", "to", "ensure", "levels", "below", "2", "microg", "/", "ml", "."]], "ner": [[[4, 4, "Chemical"], [36, 36, "Chemical"], [58, 58, "Chemical"], [87, 87, "Chemical"], [106, 106, "Chemical"], [490, 490, "Chemical"], [446, 448, "Disease"], [456, 457, "Disease"], [472, 474, "Disease"], [44, 44, "Disease"], [437, 437, "Disease"], [416, 416, "Chemical"]]], "relations": [[[4, 4, 446, 448, "CID"], [4, 4, 456, 457, "CID"], [4, 4, 472, 474, "CID"], [36, 36, 446, 448, "CID"], [36, 36, 456, 457, "CID"], [36, 36, 472, 474, "CID"], [58, 58, 446, 448, "CID"], [58, 58, 456, 457, "CID"], [58, 58, 472, 474, "CID"], [87, 87, 446, 448, "CID"], [87, 87, 456, 457, "CID"], [87, 87, 472, 474, "CID"], [106, 106, 446, 448, "CID"], [106, 106, 456, 457, "CID"], [106, 106, 472, 474, "CID"], [490, 490, 446, 448, "CID"], [490, 490, 456, 457, "CID"], [490, 490, 472, 474, "CID"]]], "clusters": [], "translated": "<0>妥布霉素</0>的治疗药物监测：每日一次与每日两次的给药方案。目的：评价<1>妥布霉素</1>给药方案（每日一次与每日两次）对稳态血清浓度和<9>毒性</9>的影响。材料和方法：接受i.v. <2>妥布霉素</2>（4mg/kg/天）治疗的患者随机分为两组。OD组（n = 22）每天接受一次剂量的<3>妥布霉素</3>，TD组（n = 21）每天接受相同剂量的两次给药。<4>妥布霉素</4>血清浓度（峰和谷）采用酶联免疫法测定。治疗前、治疗期间和治疗后即刻监测患者的肾功能和听觉功能。结果：两组在性别、年龄、体重和肾功能方面具有可比性。在平均日剂量、治疗持续时间或累积剂量方面未发现统计学上的显着差异。两组（100%）的谷浓度均小于2g/ml。100%的OD组和67%的TD组的峰浓度大于6微克/毫升（P < 0.01）。平均峰浓度明显不同：11.00+/-2.89微克/毫升在OD组和6.53+/-1.45微克/毫升在TD组（P < 0.01）。药代动力学参数为：Ke，（0.15+/-0.03/h在OD组与0.24+/-0.06/h在TD组），t1/2，（4.95+/-1.41h在OD组与3.07+/-0.71h在TD组），Vd（0.35+/-0.11L/kg在OD组与0.33+/-0.09L/kg在TD组），Cl（0.86+/-0.29mL/min/kg在OD组与1.28+/-0.33mL/min/kg在TD组）。在73%的OD患者和57%的TD患者中观察到血清<11>肌酐</11>升高，没有<10>肾毒性</10>的证据。在TD组中，3名患者出现<6>听觉功能下降</6>，其中1名患者出现<7>听觉损失</7>的30dB，而在OD组中只有1名患者出现<8>听觉功能下降</8>。结论：这项小型研究表明，<5>妥布霉素</5>每日一次的给药方案至少与每日两次的方案一样有效，而且毒性不高，而且可能毒性更低。使用单剂量疗法，峰浓度测定是不必要的，只应监测低谷样品以确保水平低于2微克/毫升。", "revised": true}
{"doc_key": "8305357", "sentences": [["Liposomal", "daunorubicin", "in", "advanced", "Kaposi", "'s", "sarcoma", ":", "a", "phase", "II", "study", ".", "We", "report", "a", "non", "-", "randomized", "Phase", "II", "clinical", "trial", "to", "assess", "the", "efficacy", "and", "safety", "of", "liposomal", "daunorubicin", "(", "DaunoXome", ")", "in", "the", "treatment", "of", "AIDS", "related", "Kaposi", "'s", "sarcoma", ".", "Eleven", "homosexual", "men", "with", "advanced", "Kaposi", "'s", "sarcoma", "were", "entered", "in", "the", "trial", ".", "Changes", "in", "size", ",", "colour", "and", "associated", "oedema", "of", "selected", "'", "target", "'", "lesions", "were", "measured", ".", "Clinical", ",", "biochemical", "and", "haematological", "toxicities", "were", "assessed", ".", "Ten", "subjects", "were", "evaluated", ".", "A", "partial", "response", "was", "achieved", "in", "four", ",", "of", "whom", "two", "subsequently", "relapsed", ".", "Stabilization", "of", "Kaposi", "'s", "sarcoma", "occurred", "in", "the", "remaining", "six", ",", "maintained", "until", "the", "end", "of", "the", "trial", "period", "in", "four", ".", "The", "drug", "was", "generally", "well", "tolerated", ",", "with", "few", "mild", "symptoms", "of", "toxicity", ".", "The", "main", "problem", "encountered", "was", "haematological", "toxicity", ",", "with", "three", "subjects", "experiencing", "severe", "neutropenia", "(", "neutrophil", "count", "<", "0", ".", "5", "x", "10", "(", "9", ")", "/", "l", ")", ".", "There", "was", "no", "evidence", "of", "cardiotoxicity", ".", "In", "this", "small", "patient", "sample", ",", "liposomal", "daunorubicin", "was", "an", "effective", "and", "well", "tolerated", "agent", "in", "the", "treatment", "of", "Kaposi", "'s", "sarcoma", "."]], "ner": [[[1, 1, "Chemical"], [31, 31, "Chemical"], [184, 184, "Chemical"], [153, 153, "Disease"], [4, 6, "Disease"], [41, 43, "Disease"], [50, 52, "Disease"], [106, 108, "Disease"], [196, 198, "Disease"], [39, 39, "Disease"], [66, 66, "Disease"], [81, 81, "Disease"], [138, 138, "Disease"], [146, 146, "Disease"], [175, 175, "Disease"]]], "relations": [[[1, 1, 153, 153, "CID"], [31, 31, 153, 153, "CID"], [184, 184, 153, 153, "CID"]]], "clusters": [], "translated": "脂质体<0>柔红霉素</0>治疗晚期<4>卡波氏肉瘤</4>：II期研究。我们报告了一项非随机II期临床试验，以评估脂质体<1>柔红霉素</1>（DaunoXome）在治疗<9>艾滋病</9>相关<5>卡波氏肉瘤</5>方面的疗效和安全性。11名晚期<6>卡波西氏肉瘤</6>的男同性恋者参加了试验。测量所选“目标”病变的大小、颜色和相关<10>水肿</10>的变化。评估了临床、生化和血液学<11>毒性</11>。共评估了10名受试者。其中4人获得了部分缓解，其中2人随后复发。在其余6例中出现了<7>卡波西氏肉瘤</7>的稳定病情，其中4例稳定维持至试验期结束。该药物一般耐受良好，只有少量轻微的<12>毒性</12>症状。遇到的主要问题是血液学<13>毒性</13>，其中3名受试者出现严重的<3>中性粒细胞减少症</3>（中性粒细胞计数<0.5 x 10 (9) / l）。没有<14>心脏毒性</14>的证据。在这个小样本患者中，脂质体<2>柔红霉素</2>是治疗<8>卡波西氏肉瘤</8>的有效和耐受药物。", "revised": true}
{"doc_key": "3015327", "sentences": [["Remodelling", "of", "nerve", "structure", "in", "experimental", "isoniazid", "neuropathy", "in", "the", "rat", ".", "The", "neuropathy", "caused", "by", "a", "single", "dose", "of", "isoniazid", "in", "rats", "was", "studied", "with", "a", "computer", "-", "assisted", "morphometric", "method", ".", "Scatter", "diagrams", "of", "the", "g", "ratio", "(", "quotient", "fibre", "diameter", "/", "axon", "diameter", ")", "define", "regenerating", "fibres", "as", "a", "distinct", "population", ",", "distinguishable", "from", "the", "surviving", "fibres", "by", "reduced", "sheath", "thickness", "and", "reduced", "axon", "calibre", ".", "There", "was", "also", "evidence", "of", "a", "subtle", "direct", "toxic", "effect", "on", "the", "entire", "fibre", "population", ",", "causing", "axon", "shrinkage", "masked", "by", "readjustment", "of", "the", "myelin", "sheath", "."]], "ner": [[[6, 6, "Chemical"], [20, 20, "Chemical"], [7, 7, "Disease"], [13, 13, "Disease"]]], "relations": [[[6, 6, 7, 7, "CID"], [6, 6, 13, 13, "CID"], [20, 20, 7, 7, "CID"], [20, 20, 13, 13, "CID"]]], "clusters": [], "translated": "大鼠实验性<0>异烟肼</0><2>神经病变</2>中，神经结构重塑。采用计算机辅助形态学方法研究单剂量<1>异烟肼</1>引起的大鼠<3>神经病变</3>。g比率（商纤维直径/轴突直径）的散点图将再生纤维定义为一个独特的群体，通过减小的鞘厚度和减小的轴突口径与幸存的纤维区分开来。也有证据表明对整个纤维群有微妙的直接毒性作用，导致轴突收缩被髓鞘的重新调整所掩盖。", "revised": true}
{"doc_key": "19105845", "sentences": [["Effect", "of", "increasing", "intraperitoneal", "infusion", "rates", "on", "bupropion", "hydrochloride", "-", "induced", "seizures", "in", "mice", ".", "BACKGROUND", ":", "It", "is", "not", "known", "if", "there", "is", "a", "relationship", "between", "input", "rate", "and", "incidence", "of", "bupropion", "-", "induced", "seizures", ".", "This", "is", "important", ",", "since", "different", "controlled", "release", "formulations", "of", "bupropion", "release", "the", "active", "drug", "at", "different", "rates", ".", "METHODS", ":", "We", "investigated", "the", "effect", "of", "varying", "the", "intraperitoneal", "infusion", "rates", "of", "bupropion", "HCl", "120", "mg", "/", "kg", ",", "a", "known", "convulsive", "dose", "50", "(", "CD50", ")", ",", "on", "the", "incidence", "and", "severity", "of", "bupropion", "-", "induced", "convulsions", "in", "the", "Swiss", "albino", "mice", ".", "A", "total", "of", "69", "mice", ",", "approximately", "7", "weeks", "of", "age", ",", "and", "weighing", "21", ".", "0", "to", "29", ".", "1", "g", "were", "randomly", "assigned", "to", "bupropion", "HCl", "120", "mg", "/", "kg", "treatment", "by", "intraperitoneal", "(", "IP", ")", "administration", "in", "7", "groups", "(", "9", "to", "10", "animals", "per", "group", ")", ".", "Bupropion", "HCl", "was", "infused", "through", "a", "surgically", "implanted", "IP", "dosing", "catheter", "with", "infusions", "in", "each", "group", "of", "0", "min", ",", "15", "min", ",", "30", "min", ",", "60", "min", ",", "90", "min", ",", "120", "min", ",", "and", "240", "min", ".", "The", "number", ",", "time", "of", "onset", ",", "duration", "and", "the", "intensity", "of", "the", "convulsions", "or", "absence", "of", "convulsions", "were", "recorded", ".", "RESULTS", ":", "The", "results", "showed", "that", "IP", "administration", "of", "bupropion", "HCl", "120", "mg", "/", "kg", "by", "bolus", "injection", "induced", "convulsions", "in", "6", "out", "of", "10", "mice", "(", "60", "%", "of", "convulsing", "mice", ")", "in", "group", "1", ".", "Logistic", "regression", "analysis", "revealed", "that", "infusion", "time", "was", "significant", "(", "p", "=", "0", ".", "0004", ";", "odds", "ratio", "=", "0", ".", "974", ")", "and", "increasing", "the", "IP", "infusion", "time", "of", "bupropion", "HCl", "120", "mg", "/", "kg", "was", "associated", "with", "a", "91", "%", "reduced", "odds", "of", "convulsions", "at", "infusion", "times", "of", "15", "to", "90", "min", "compared", "to", "bolus", "injection", ".", "Further", "increase", "in", "infusion", "time", "resulted", "in", "further", "reduction", "in", "the", "odds", "of", "convulsions", "to", "99", ".", "8", "%", "reduction", "at", "240", "min", ".", "CONCLUSION", ":", "In", "conclusion", ",", "the", "demonstration", "of", "an", "inverse", "relationship", "between", "infusion", "time", "of", "a", "fixed", "and", "convulsive", "dose", "of", "bupropion", "and", "the", "risk", "of", "convulsions", "in", "a", "prospective", "study", "is", "novel", "."]], "ner": [[[7, 8, "Chemical"], [32, 32, "Chemical"], [47, 47, "Chemical"], [69, 70, "Chemical"], [91, 91, "Chemical"], [127, 128, "Chemical"], [152, 153, "Chemical"], [221, 222, "Chemical"], [279, 280, "Chemical"], [353, 353, "Chemical"], [11, 11, "Disease"], [35, 35, "Disease"], [78, 78, "Disease"], [94, 94, "Disease"], [204, 204, "Disease"], [208, 208, "Disease"], [231, 231, "Disease"], [294, 294, "Disease"], [321, 321, "Disease"], [350, 350, "Disease"], [358, 358, "Disease"]]], "relations": [[[7, 8, 11, 11, "CID"], [7, 8, 35, 35, "CID"], [7, 8, 78, 78, "CID"], [7, 8, 94, 94, "CID"], [7, 8, 204, 204, "CID"], [7, 8, 208, 208, "CID"], [7, 8, 231, 231, "CID"], [7, 8, 294, 294, "CID"], [7, 8, 321, 321, "CID"], [7, 8, 350, 350, "CID"], [7, 8, 358, 358, "CID"], [32, 32, 11, 11, "CID"], [32, 32, 35, 35, "CID"], [32, 32, 78, 78, "CID"], [32, 32, 94, 94, "CID"], [32, 32, 204, 204, "CID"], [32, 32, 208, 208, "CID"], [32, 32, 231, 231, "CID"], [32, 32, 294, 294, "CID"], [32, 32, 321, 321, "CID"], [32, 32, 350, 350, "CID"], [32, 32, 358, 358, "CID"], [47, 47, 11, 11, "CID"], [47, 47, 35, 35, "CID"], [47, 47, 78, 78, "CID"], [47, 47, 94, 94, "CID"], [47, 47, 204, 204, "CID"], [47, 47, 208, 208, "CID"], [47, 47, 231, 231, "CID"], [47, 47, 294, 294, "CID"], [47, 47, 321, 321, "CID"], [47, 47, 350, 350, "CID"], [47, 47, 358, 358, "CID"], [69, 70, 11, 11, "CID"], [69, 70, 35, 35, "CID"], [69, 70, 78, 78, "CID"], [69, 70, 94, 94, "CID"], [69, 70, 204, 204, "CID"], [69, 70, 208, 208, "CID"], [69, 70, 231, 231, "CID"], [69, 70, 294, 294, "CID"], [69, 70, 321, 321, "CID"], [69, 70, 350, 350, "CID"], [69, 70, 358, 358, "CID"], [91, 91, 11, 11, "CID"], [91, 91, 35, 35, "CID"], [91, 91, 78, 78, "CID"], [91, 91, 94, 94, "CID"], [91, 91, 204, 204, "CID"], [91, 91, 208, 208, "CID"], [91, 91, 231, 231, "CID"], [91, 91, 294, 294, "CID"], [91, 91, 321, 321, "CID"], [91, 91, 350, 350, "CID"], [91, 91, 358, 358, "CID"], [127, 128, 11, 11, "CID"], [127, 128, 35, 35, "CID"], [127, 128, 78, 78, "CID"], [127, 128, 94, 94, "CID"], [127, 128, 204, 204, "CID"], [127, 128, 208, 208, "CID"], [127, 128, 231, 231, "CID"], [127, 128, 294, 294, "CID"], [127, 128, 321, 321, "CID"], [127, 128, 350, 350, "CID"], [127, 128, 358, 358, "CID"], [152, 153, 11, 11, "CID"], [152, 153, 35, 35, "CID"], [152, 153, 78, 78, "CID"], [152, 153, 94, 94, "CID"], [152, 153, 204, 204, "CID"], [152, 153, 208, 208, "CID"], [152, 153, 231, 231, "CID"], [152, 153, 294, 294, "CID"], [152, 153, 321, 321, "CID"], [152, 153, 350, 350, "CID"], [152, 153, 358, 358, "CID"], [221, 222, 11, 11, "CID"], [221, 222, 35, 35, "CID"], [221, 222, 78, 78, "CID"], [221, 222, 94, 94, "CID"], [221, 222, 204, 204, "CID"], [221, 222, 208, 208, "CID"], [221, 222, 231, 231, "CID"], [221, 222, 294, 294, "CID"], [221, 222, 321, 321, "CID"], [221, 222, 350, 350, "CID"], [221, 222, 358, 358, "CID"], [279, 280, 11, 11, "CID"], [279, 280, 35, 35, "CID"], [279, 280, 78, 78, "CID"], [279, 280, 94, 94, "CID"], [279, 280, 204, 204, "CID"], [279, 280, 208, 208, "CID"], [279, 280, 231, 231, "CID"], [279, 280, 294, 294, "CID"], [279, 280, 321, 321, "CID"], [279, 280, 350, 350, "CID"], [279, 280, 358, 358, "CID"], [353, 353, 11, 11, "CID"], [353, 353, 35, 35, "CID"], [353, 353, 78, 78, "CID"], [353, 353, 94, 94, "CID"], [353, 353, 204, 204, "CID"], [353, 353, 208, 208, "CID"], [353, 353, 231, 231, "CID"], [353, 353, 294, 294, "CID"], [353, 353, 321, 321, "CID"], [353, 353, 350, 350, "CID"], [353, 353, 358, 358, "CID"]]], "clusters": [], "translated": "增加腹腔内输注率对<0>盐酸安非他酮</0>诱导的小鼠<10>癫痫发作</10>的影响。背景：尚不清楚输入速率与<1>安非他酮</1>诱发的<11>癫痫发作</11>发生率之间是否存在关系。这一点很重要，因为不同的<2>控释制剂</2>以不同的速率释放活性药物。方法：我们研究了改变<3>盐酸安非他酮</3> 120 mg/kg腹腔内输注速率（已知<12>惊厥</12>剂量50(CD50)）对<4>安非他酮</4>在瑞士白化小鼠中引起<13>抽搐</13>。小鼠共69只，约7周龄，体重21.0到29.1 g随机分配至<5>盐酸安非他酮</5> 120 mg/kg腹腔内(IP)给药治疗，分为7组(每组9～10只动物)。<6>盐酸安非他酮</6>通过手术植入的IP给药导管输注，每组输注时间分别为0 min、15 min、30 min、60 min、90 min、120 min和240 min。记录<14>抽搐</14>或<15>未出现抽搐</15>的次数、发作时间、持续时间和强度。结果：结果表明，在第1组中，10只小鼠中有6只（60%的惊厥小鼠）IP注射<7>盐酸安非他酮</7> 120 mg/kg引起<16>惊厥</16>。Logistic回归分析显示输注时间显著(p = 0.0004；比值比 = 0.974)并且增加<8>盐酸安非他酮</8> 120 mg/kg的IP输注时间与91%减少相关，与推注相比，输注时间为15至90分钟时<17>抽搐</17>的几率。输注时间的进一步增加导致<18>惊厥</18>的几率进一步降低至99.8%，240分钟时减少8%。结论：总之，证明了<9>安非他酮</9>的固定输注时间和<19>惊厥</19>剂量与<20>惊厥</20>风险之间的反比关系前瞻性研究是新颖的。", "revised": true}
{"doc_key": "15930398", "sentences": [["Assessment", "of", "the", "onset", "and", "persistence", "of", "amnesia", "during", "procedural", "sedation", "with", "propofol", ".", "OBJECTIVES", ":", "To", "assess", "patients", "'", "ability", "to", "repeat", "and", "recall", "words", "presented", "to", "them", "while", "undergoing", "procedural", "sedation", "with", "propofol", ",", "and", "correlate", "their", "recall", "with", "their", "level", "of", "awareness", "as", "measured", "by", "bispectral", "index", "(", "BIS", ")", "monitoring", ".", "METHODS", ":", "This", "was", "a", "prospective", ",", "single", "-", "intervention", "study", "of", "consenting", "adult", "patients", "undergoing", "procedural", "sedation", "with", "propofol", "between", "December", "28", ",", "2002", ",", "and", "October", "31", ",", "2003", ".", "BIS", "monitoring", "was", "initiated", "starting", "3", "minutes", "before", "the", "procedure", "and", "continuing", "until", "the", "patient", "had", "regained", "baseline", "mental", "status", ".", "At", "1", "-", "minute", "intervals", "during", "the", "procedural", "sedation", ",", "until", "the", "patient", "regained", "baseline", "mental", "status", "at", "the", "end", "of", "the", "procedure", ",", "a", "word", "from", "a", "standardized", "list", "was", "read", "aloud", ",", "and", "the", "patient", "was", "asked", "to", "immediately", "repeat", "the", "word", "to", "the", "investigator", ".", "The", "BIS", "score", "at", "the", "time", "the", "word", "was", "read", "and", "the", "patient", "'s", "ability", "to", "repeat", "the", "word", "were", "recorded", ".", "After", "the", "procedure", ",", "the", "patient", "was", "asked", "to", "state", "all", "of", "the", "words", "from", "the", "list", "that", "he", "or", "she", "could", "recall", ",", "and", "to", "identify", "the", "last", "word", "recalled", "from", "prior", "to", "the", "start", "of", "the", "procedure", "and", "the", "first", "word", "recalled", "from", "after", "the", "procedure", "was", "completed", ".", "RESULTS", ":", "Seventy", "-", "five", "consenting", "patients", "were", "enrolled", ";", "one", "patient", "was", "excluded", "from", "data", "analysis", "for", "a", "protocol", "violation", ".", "No", "serious", "adverse", "events", "were", "noted", "during", "the", "procedural", "sedations", ".", "The", "mean", "(", "+", "/", "-", "standard", "deviation", ")", "time", "of", "data", "collection", "was", "16", ".", "4", "minutes", "(", "+", "/", "-", "7", ".", "1", ";", "range", "5", "to", "34", "minutes", ")", ".", "The", "mean", "initial", "(", "preprocedure", ")", "BIS", "score", "was", "97", ".", "1", "(", "+", "/", "-", "2", ".", "3", ";", "range", "92", "to", "99", ")", ".", "The", "mean", "lowest", "BIS", "score", "occurring", "during", "these", "procedural", "sedations", "was", "66", ".", "9", "(", "+", "/", "-", "14", ".", "4", ";", "range", "33", "to", "91", ")", ".", "The", "mean", "lowest", "BIS", "score", "corresponding", "to", "the", "ability", "of", "the", "patient", "to", "immediately", "repeat", "words", "read", "from", "the", "list", "was", "77", ".", "1", "(", "95", "%", "CI", "=", "74", ".", "3", "to", "80", ".", "0", ")", ".", "The", "mean", "highest", "BIS", "score", "corresponding", "to", "the", "inability", "to", "repeat", "words", "was", "81", ".", "5", "(", "95", "%", "CI", "=", "78", ".", "1", "to", "84", ".", "8", ")", ".", "The", "mean", "BIS", "score", "corresponding", "to", "the", "last", "word", "recalled", "from", "prior", "to", "the", "initiation", "of", "the", "sedation", "was", "96", ".", "7", "(", "+", "/", "-", "2", ".", "4", ";", "range", "84", "to", "98", ")", ".", "The", "mean", "BIS", "score", "corresponding", "to", "the", "first", "word", "recalled", "after", "the", "procedure", "was", "completed", "was", "91", ".", "2", "(", "95", "%", "CI", "=", "88", ".", "1", "to", "94", ".", "3", ")", ".", "All", "patients", "recalled", "at", "least", "one", "word", "that", "had", "been", "read", "to", "them", "during", "the", "protocol", ".", "The", "mean", "lowest", "BIS", "score", "for", "any", "recalled", "word", "was", "91", ".", "5", "(", "+", "/", "-", "11", ".", "1", ";", "range", "79", "to", "98", ")", ",", "and", "no", "words", "were", "recalled", "when", "the", "corresponding", "BIS", "score", "was", "less", "than", "90", ".", "CONCLUSIONS", ":", "There", "is", "a", "range", "of", "BIS", "scores", "during", "which", "sedated", "patients", "are", "able", "to", "repeat", "words", "read", "to", "them", "but", "are", "not", "able", "to", "subsequently", "recall", "these", "words", ".", "Furthermore", ",", "patients", "had", "no", "recall", "of", "words", "repeated", "prior", "to", "procedural", "sedation", "in", "BIS", "ranges", "associated", "with", "recall", "after", "procedural", "sedation", ",", "suggestive", "of", "retrograde", "amnesia", "."]], "ner": [[[12, 12, "Chemical"], [34, 34, "Chemical"], [74, 74, "Chemical"], [7, 7, "Disease"], [395, 398, "Disease"], [601, 602, "Disease"]]], "relations": [[[12, 12, 7, 7, "CID"], [12, 12, 395, 398, "CID"], [34, 34, 7, 7, "CID"], [34, 34, 395, 398, "CID"], [74, 74, 7, 7, "CID"], [74, 74, 395, 398, "CID"]]], "clusters": [], "translated": "评估<0>异丙酚</0>程序镇静期间<3>遗忘症</3>的发作和持续时间。目的：评估患者在使用<1>异丙酚</1>进行程序镇静时重复和回忆呈现给他们的单词的能力，并将他们的回忆与他们通过双频指数(BIS)监测测量的意识水平相关联。方法：这是一项前瞻性、单一干预研究，研究对象为同意在 2002 年 12 月 28 日至 2003 年 10 月 31 日期间接受<2>异丙酚</2>程序性镇静的成年患者。BIS监测从手术前 3 分钟开始，一直持续到患者恢复基线精神状态。在程序镇静期间每隔 1 分钟，直到患者在程序结束时恢复基线精神状态，大声朗读标准化列表中的一个词，并要求患者立即向研究者重复该词。记录读出单词时的BIS分数和患者重复单词的能力。手术后，要求患者说出他或她能回忆起的列表中的所有单词，并指出手术开始前回忆起的最后一个单词和手术完成后回忆起的第一个单词。结果：纳入了75名知情同意的患者；一名患者因违反协议而被排除在数据分析之外。在程序镇静期间没有发现严重的不良事件。数据收集的平均（+/-标准偏差）时间为16.4分钟（+/-7.1； 范围 5 至 34 分钟）。平均初始（术前）BIS评分为97.1（+/-2.3；范围92到99）。在这些程序性镇静期间发生的平均最低BIS评分为66.9（+/-14.4；范围33到91）。对应于患者立即重复从列表中读取的单词的能力的平均最低BIS分数为77.1（95% CI=74.3到80.0）。与<4>无法重复单词</4>相对应的平均最高BIS分数为81.5（95% CI=78.1到84.8）。与镇静开始前回忆起的最后一个词相对应的平均BIS得分为96.7（+/-2.4；范围84到98）。程序完成后回忆起的第一个单词对应的平均BIS分数是91.2（95% CI=88.1到94.3）。所有患者都至少回忆起一个在方案期间读给他们听的词。任何回忆单词的平均最低BIS分数是91.5（+/-11.1; 范围79 到98），当相应的BIS分数小于90时，没有单词被回忆起来。结论：有一个BIS分数范围，在这个范围内，服用镇静剂的患者能够重复读给他们听的单词，但随后无法回忆起这些单词。此外，在与程序镇静后回忆相关的BIS范围内，患者没有回忆起程序镇静前重复的单词，提示<5>逆行性遗忘</5>。", "revised": true}
{"doc_key": "9321531", "sentences": [["Posteroventral", "medial", "pallidotomy", "in", "advanced", "Parkinson", "'s", "disease", ".", "BACKGROUND", ":", "Posteroventral", "medial", "pallidotomy", "sometimes", "produces", "striking", "improvement", "in", "patients", "with", "advanced", "Parkinson", "'s", "disease", ",", "but", "the", "studies", "to", "date", "have", "involved", "small", "numbers", "of", "patients", "and", "short", "-", "term", "follow", "-", "up", ".", "METHODS", ":", "Forty", "patients", "with", "Parkinson", "'s", "disease", "underwent", "serial", ",", "detailed", "assessments", "both", "after", "drug", "withdrawal", "(", "\"", "off", "\"", "period", ")", "and", "while", "taking", "their", "optimal", "medical", "regimens", "(", "\"", "on", "\"", "period", ")", ".", "All", "patients", "were", "examined", "preoperatively", "and", "39", "were", "examined", "at", "six", "months", ";", "27", "of", "the", "patients", "were", "also", "examined", "at", "one", "year", ",", "and", "11", "at", "two", "years", ".", "RESULTS", ":", "The", "percent", "improvements", "at", "six", "months", "were", "as", "follows", ":", "off", "-", "period", "score", "for", "overall", "motor", "function", ",", "28", "percent", "(", "95", "percent", "confidence", "interval", ",", "19", "to", "38", "percent", ")", ",", "with", "most", "of", "the", "improvement", "in", "the", "contralateral", "limbs", ";", "off", "-", "period", "score", "for", "activities", "of", "daily", "living", ",", "29", "percent", "(", "95", "percent", "confidence", "interval", ",", "19", "to", "39", "percent", ")", ";", "on", "-", "period", "score", "for", "contralateral", "dyskinesias", ",", "82", "percent", "(", "95", "percent", "confidence", "interval", ",", "72", "to", "91", "percent", ")", ";", "and", "on", "-", "period", "score", "for", "ipsilateral", "dyskinesias", ",", "44", "percent", "(", "95", "percent", "confidence", "interval", ",", "29", "to", "59", "percent", ")", ".", "The", "improvements", "in", "dyskinesias", "and", "the", "total", "scores", "for", "off", "-", "period", "parkinsonism", ",", "contralateral", "bradykinesia", ",", "and", "rigidity", "were", "sustained", "in", "the", "11", "patients", "examined", "at", "two", "years", ".", "The", "improvement", "in", "ipsilateral", "dyskinesias", "was", "lost", "after", "one", "year", ",", "and", "the", "improvements", "in", "postural", "stability", "and", "gait", "lasted", "only", "three", "to", "six", "months", ".", "Approximately", "half", "the", "patients", "who", "had", "been", "dependent", "on", "assistance", "in", "activities", "of", "daily", "living", "in", "the", "off", "period", "before", "surgery", "became", "independent", "after", "surgery", ".", "The", "complications", "of", "surgery", "were", "generally", "well", "tolerated", ",", "and", "there", "were", "no", "significant", "changes", "in", "the", "use", "of", "medication", ".", "CONCLUSIONS", ":", "In", "late", "-", "stage", "Parkinson", "'s", "disease", ",", "pallidotomy", "significantly", "reduces", "levodopa", "-", "induced", "dyskinesias", "and", "off", "-", "period", "disability", ".", "Much", "of", "the", "benefit", "is", "sustained", "at", "two", "years", ",", "although", "some", "improvements", ",", "such", "as", "those", "on", "the", "ipsilateral", "side", "and", "in", "axial", "symptoms", ",", "wane", "within", "the", "first", "year", ".", "The", "on", "-", "period", "symptoms", "that", "are", "resistant", "to", "dopaminergic", "therapy", "do", "not", "respond", "to", "pallidotomy", "."]], "ner": [[[342, 342, "Chemical"], [187, 187, "Disease"], [210, 210, "Disease"], [229, 229, "Disease"], [260, 260, "Disease"], [345, 345, "Disease"], [5, 7, "Disease"], [22, 24, "Disease"], [50, 52, "Disease"], [238, 238, "Disease"], [335, 337, "Disease"], [241, 241, "Disease"], [244, 244, "Disease"]]], "relations": [[[342, 342, 187, 187, "CID"], [342, 342, 210, 210, "CID"], [342, 342, 229, 229, "CID"], [342, 342, 260, 260, "CID"], [342, 342, 345, 345, "CID"]]], "clusters": [], "translated": "晚期<6>帕金森病</6>的后腹内侧苍白球切开术。背景：后腹内侧苍白球切开术有时会对晚期<7>帕金森氏病</7>患者产生显着改善，但迄今为止的研究涉及的患者数量较少且随访时间较短。方法：对 40 名<8>帕金森病</8>患者在停药后（“关闭”期）和服用最佳药物治疗方案（“开启”期）期间进行了一系列详细的评估。所有患者均在术前进行了检查，其中39例在6个月时进行了检查；其中27名患者在一年内接受检查，11名患者在两年内接受检查。结果：六个月时的改善百分比如下：停药期整体运动功能得分，28%（95%置信区间为19%至38%），其中对侧肢体得到的改善最为显著；停药期日常生活活动得分，29%（95%置信区间，19%到39%）；经期对侧<1>运动障碍</1>得分为82%（95%置信区间，72%至91%）；经期同侧<2>运动障碍</2>得分为44%（95%置信区间，29%至59%）。对于<3>运动障碍</3>和非周期性<9>帕金森症</9>、对侧<11>运动迟缓</11>和<12>强直</12>的总得分，在11名患者的两年内检查中仍有改善。同侧<4>运动障碍</4>的改善在一年后消失，姿势稳定性和步态的改善只持续了三到六个月。大约一半之前休息期日常生活活动依赖别人的患者在手术后变得独立。手术并发症总体耐受良好，药物使用无明显变化。结论：在晚期<10>帕金森氏病</10>中，苍白球切开术可显着减少<0>左旋多巴</0>引起的<5>运动障碍</5>和停药期残疾。大部分益处在两年内持续，尽管一些改善，例如同侧和中轴症状的改善，在第一年内减弱。对多巴胺能疗法有抵抗力的经期症状对苍白球切开术没有反应。", "revised": true}
{"doc_key": "18363626", "sentences": [["High", "dose", "dexmedetomidine", "as", "the", "sole", "sedative", "for", "pediatric", "MRI", ".", "OBJECTIVE", ":", "This", "large", "-", "scale", "retrospective", "review", "evaluates", "the", "sedation", "profile", "of", "dexmedetomidine", ".", "AIM", ":", "To", "determine", "the", "hemodynamic", "responses", ",", "efficacy", "and", "adverse", "events", "associated", "with", "the", "use", "of", "high", "dose", "dexmedetomidine", "as", "the", "sole", "sedative", "for", "magnetic", "resonance", "imaging", "(", "MRI", ")", "studies", ".", "BACKGROUND", ":", "Dexmedetomidine", "has", "been", "used", "at", "our", "institution", "since", "2005", "to", "provide", "sedation", "for", "pediatric", "radiological", "imaging", "studies", ".", "Over", "time", ",", "an", "effective", "protocol", "utilizing", "high", "dose", "dexmedetomidine", "as", "the", "sole", "sedative", "agent", "has", "evolved", ".", "METHODS", "/", "MATERIALS", ":", "As", "part", "of", "the", "ongoing", "Quality", "Assurance", "process", ",", "data", "on", "all", "sedations", "are", "reviewed", "monthly", "and", "protocols", "modified", "as", "needed", ".", "Data", "were", "analyzed", "from", "all", "747", "consecutive", "patients", "who", "received", "dexmedetomidine", "for", "MRI", "sedation", "from", "April", "2005", "to", "April", "2007", ".", "RESULTS", ":", "Since", "2005", ",", "the", "10", "-", "min", "loading", "dose", "of", "our", "dexmedetomidine", "protocol", "increased", "from", "2", "to", "3", "microg", ".", "kg", "(", "-", "1", ")", ",", "and", "the", "infusion", "rate", "increased", "from", "1", "to", "1", ".", "5", "to", "2", "microg", ".", "kg", "(", "-", "1", ")", ".", "h", "(", "-", "1", ")", ".", "The", "current", "sedation", "protocol", "progressively", "increased", "the", "rate", "of", "successful", "sedation", "(", "able", "to", "complete", "the", "imaging", "study", ")", "when", "using", "dexmedetomidine", "alone", "from", "91", ".", "8", "%", "to", "97", ".", "6", "%", "(", "P", "=", "0", ".", "009", ")", ",", "reducing", "the", "requirement", "for", "adjuvant", "pentobarbital", "in", "the", "event", "of", "sedation", "failure", "with", "dexmedetomidine", "alone", "and", "decreased", "the", "mean", "recovery", "time", "by", "10", "min", "(", "P", "<", "0", ".", "001", ")", ".", "Although", "dexmedetomidine", "sedation", "was", "associated", "with", "a", "16", "%", "incidence", "of", "bradycardia", ",", "all", "concomitant", "mean", "arterial", "blood", "pressures", "were", "within", "20", "%", "of", "age", "-", "adjusted", "normal", "range", "and", "oxygen", "saturations", "were", "95", "%", "or", "higher", ".", "CONCLUSION", ":", "Dexmedetomidine", "in", "high", "doses", "provides", "adequate", "sedation", "for", "pediatric", "MRI", "studies", ".", "While", "use", "of", "high", "dose", "dexmedetomidine", "is", "associated", "with", "decreases", "in", "heart", "rate", "and", "blood", "pressure", "outside", "the", "established", "'", "awake", "'", "norms", ",", "this", "deviation", "is", "generally", "within", "20", "%", "of", "norms", ",", "and", "is", "not", "associated", "with", "adverse", "sequelae", ".", "Dexmedetomidine", "is", "useful", "as", "the", "sole", "sedative", "for", "pediatric", "MRI", "."]], "ner": [[[2, 2, "Chemical"], [24, 24, "Chemical"], [45, 45, "Chemical"], [61, 61, "Chemical"], [88, 88, "Chemical"], [133, 133, "Chemical"], [157, 157, "Chemical"], [220, 220, "Chemical"], [253, 253, "Chemical"], [273, 273, "Chemical"], [312, 312, "Chemical"], [329, 329, "Chemical"], [366, 366, "Chemical"], [283, 283, "Disease"], [245, 245, "Chemical"], [302, 302, "Chemical"]]], "relations": [[[2, 2, 283, 283, "CID"], [24, 24, 283, 283, "CID"], [45, 45, 283, 283, "CID"], [61, 61, 283, 283, "CID"], [88, 88, 283, 283, "CID"], [133, 133, 283, 283, "CID"], [157, 157, 283, 283, "CID"], [220, 220, 283, 283, "CID"], [253, 253, 283, 283, "CID"], [273, 273, 283, 283, "CID"], [312, 312, 283, 283, "CID"], [329, 329, 283, 283, "CID"], [366, 366, 283, 283, "CID"]]], "clusters": [], "translated": "高剂量<0>右美托咪定</0>作为儿科 MRI 的唯一镇静剂。目的：这项大规模的回顾性审查评估了<1>右美托咪定</1>的镇静作用。目的：确定与使用高剂量<2>右美托咪定</2>作为磁共振成像(MRI)研究的唯一镇静剂相关的血流动力学反应、疗效和不良事件。背景：自2005年以来，我们机构一直使用<3>右美托咪定</3>为儿科放射影像学研究提供镇静作用。随着时间的推移，一种使用高剂量<4>右美托咪定</4>作为唯一镇静剂的有效方案已经形成。方法/材料：作为正在进行的质量保证过程的一部分，每月对所有镇静数据进行审查，并根据需要修改方案。对2005年4月至2007年4月接受<5>右美托咪定</5>进行MRI镇静的所有747名连续患者的数据进行了分析。结果：自2005年以来，我们的<6>右美托咪定</6>方案的10分钟负荷剂量从2微克增加到3微克。kg(-1)，输液量由1增加到1.5至2微克。公斤（-1）。小时（-1）。当单独使用<7>右美托咪定</7>时，目前的镇静方案逐步提高了镇静成功率（能够完成影像学研究）91.8%至97.6% (P=0.009)，在单独使用<8>右美托咪定</8>镇静失败的情况下减少对辅助<14>戊巴比妥</14>的需求，并将平均恢复时间减少10分钟 (P<0.001)。尽管<9>右美托咪定</9>镇静与16%的<13>心动过缓</13>发生率相关，但所有伴随的平均动脉血压均在年龄校正正常范围的20%和<15>氧气</15>饱和度为95%或更高。结论：<10>右美托咪定</10>高剂量可为儿科MRI研究提供足够的镇静作用。虽然使用高剂量<11>右美托咪定</11>会导致心率和血压降低，超出既定的“清醒”标准，但这种偏差通常在标准的20%以内，并且与不良后遗症无关。<12>右美托咪定</12>可用作儿科MRI的唯一镇静剂。", "revised": true}
{"doc_key": "9848575", "sentences": [["Chronic", "effects", "of", "a", "novel", "synthetic", "anthracycline", "derivative", "(", "SM", "-", "5887", ")", "on", "normal", "heart", "and", "doxorubicin", "-", "induced", "cardiomyopathy", "in", "beagle", "dogs", ".", "This", "study", "was", "designed", "to", "investigate", "the", "chronic", "cardiotoxic", "potential", "of", "SM", "-", "5887", "and", "a", "possible", "deteriorating", "effect", "of", "SM", "-", "5887", "on", "low", "-", "grade", "cardiotoxicity", "pre", "-", "induced", "by", "doxorubicin", "in", "beagle", "dogs", ".", "In", "the", "chronic", "treatment", ",", "beagle", "dogs", "of", "each", "sex", "were", "given", "intravenously", "once", "every", "3", "weeks", ",", "either", "a", "sublethal", "dose", "of", "doxorubicin", "(", "1", ".", "5", "mg", "/", "kg", ")", "or", "SM", "-", "5887", "(", "2", ".", "5", "mg", "/", "kg", ")", ".", "The", "experiment", "was", "terminated", "3", "weeks", "after", "the", "ninth", "dosing", ".", "Animals", "which", "received", "over", "six", "courses", "of", "doxorubicin", "demonstrated", "the", "electrocardiogram", "(", "ECG", ")", "changes", ",", "decrease", "of", "blood", "pressure", "and", "high", "-", "grade", "histopathological", "cardiomyopathy", ",", "while", "animals", "which", "were", "terminally", "sacrificed", "after", "the", "SM", "-", "5887", "administration", "did", "not", "show", "any", "changes", "in", "ECG", ",", "blood", "pressure", "and", "histopathological", "examinations", ".", "To", "examine", "a", "possibly", "deteriorating", "cardiotoxic", "effect", "of", "SM", "-", "5887", ",", "low", "-", "grade", "cardiomyopathy", "was", "induced", "in", "dogs", "by", "four", "courses", "of", "doxorubicin", "(", "1", ".", "5", "mg", "/", "kg", ")", ".", "Nine", "weeks", "after", "pre", "-", "treatment", ",", "dogs", "were", "given", "four", "courses", "of", "either", "doxorubicin", "(", "1", ".", "5", "mg", "/", "kg", ")", "or", "SM", "-", "5887", "(", "2", ".", "5", "mg", "/", "kg", ")", "once", "every", "3", "weeks", ".", "The", "low", "-", "grade", "cardiotoxic", "changes", "were", "enhanced", "by", "the", "additional", "doxorubicin", "treatment", ".", "On", "the", "contrary", ",", "the", "SM", "-", "5887", "treatment", "did", "not", "progress", "the", "grade", "of", "cardiomyopathy", ".", "In", "conclusion", ",", "SM", "-", "5887", "does", "not", "have", "any", "potential", "of", "chronic", "cardiotoxicity", "and", "deteriorating", "effect", "on", "doxorubicin", "-", "induced", "cardiotoxicity", "in", "dogs", "."]], "ner": [[[17, 17, "Chemical"], [57, 57, "Chemical"], [85, 85, "Chemical"], [125, 125, "Chemical"], [195, 195, "Chemical"], [219, 219, "Chemical"], [256, 256, "Chemical"], [294, 294, "Chemical"], [20, 20, "Disease"], [143, 143, "Disease"], [186, 186, "Disease"], [274, 274, "Disease"], [6, 6, "Chemical"], [33, 33, "Disease"], [52, 52, "Disease"], [176, 176, "Disease"], [249, 249, "Disease"], [289, 289, "Disease"], [297, 297, "Disease"], [9, 11, "Chemical"], [36, 38, "Chemical"], [45, 47, "Chemical"], [95, 97, "Chemical"], [153, 155, "Chemical"], [179, 181, "Chemical"], [229, 231, "Chemical"], [264, 266, "Chemical"], [279, 281, "Chemical"]]], "relations": [[[17, 17, 20, 20, "CID"], [17, 17, 143, 143, "CID"], [17, 17, 186, 186, "CID"], [17, 17, 274, 274, "CID"], [57, 57, 20, 20, "CID"], [57, 57, 143, 143, "CID"], [57, 57, 186, 186, "CID"], [57, 57, 274, 274, "CID"], [85, 85, 20, 20, "CID"], [85, 85, 143, 143, "CID"], [85, 85, 186, 186, "CID"], [85, 85, 274, 274, "CID"], [125, 125, 20, 20, "CID"], [125, 125, 143, 143, "CID"], [125, 125, 186, 186, "CID"], [125, 125, 274, 274, "CID"], [195, 195, 20, 20, "CID"], [195, 195, 143, 143, "CID"], [195, 195, 186, 186, "CID"], [195, 195, 274, 274, "CID"], [219, 219, 20, 20, "CID"], [219, 219, 143, 143, "CID"], [219, 219, 186, 186, "CID"], [219, 219, 274, 274, "CID"], [256, 256, 20, 20, "CID"], [256, 256, 143, 143, "CID"], [256, 256, 186, 186, "CID"], [256, 256, 274, 274, "CID"], [294, 294, 20, 20, "CID"], [294, 294, 143, 143, "CID"], [294, 294, 186, 186, "CID"], [294, 294, 274, 274, "CID"]]], "clusters": [], "translated": "新型合成<12>蒽环类药物</12>衍生物（<19>SM-5887</19>）对正常心脏和<0>阿霉素</0>诱导的<8>心肌病</8>的慢性影响在比格犬中。本研究旨在调查<20>SM-5887</20>的慢性<13>心脏毒性</13>潜力以及可能恶化作用的<21>SM-5887</21>，对低级别<14>心脏毒性</14>由<1>阿霉素</1>在比格犬中预诱导。在长期治疗中，每种性别的比格犬每3周静脉注射一次亚致死剂量的<2>阿霉素</2>（1.5毫克/千克）或<22>SM-5887</22>（2.5毫克/千克）。实验在第9次给药后3周终止。接受超过6个疗程<3>多柔比星</3>的动物表现出心电图（ECG）变化、血压下降和高度组织病理学<9>心肌病</9>，而在<23>SM-5887</23>给药后心电图、血压及组织病理学检查未见任何变化。为了检查可能恶化的<15>心脏毒性</15>作用的<24>SM-5887</24>，九周预处理后通过四个疗程<4>阿霉素</4>（1.5毫克/千克）在狗身上诱发了低级别<10>心肌病</10>。然后，狗接受四个疗程<5>多柔比星</5>（1.5毫克/千克）或<25>SM-5887</25>（2.5毫克/千克）一次，每3周一次。额外的<6>多柔比星</6>治疗增强了低度<16>心脏毒性</16>变化。相反，<26>SM-5887</26>治疗并未使<11>心肌病</11>的分级进展。总之，<27>SM-5887</27>没有任何潜在的慢性<17>心脏毒性</17>和对<7>阿霉素</7>诱导的<18>心脏毒性</18>的恶化作用在狗身上。", "revised": true}
{"doc_key": "2819587", "sentences": [["Magnetic", "resonance", "imaging", "of", "cerebral", "venous", "thrombosis", "secondary", "to", "\"", "low", "-", "dose", "\"", "birth", "control", "pills", ".", "The", "clinical", "and", "radiographic", "features", "of", "cerebral", "deep", "venous", "thrombosis", "in", "a", "21", "-", "year", "-", "old", "white", "woman", "are", "presented", ".", "This", "nulliparous", "patient", "presented", "with", "relatively", "mild", "clinical", "symptoms", "and", "progressing", "mental", "status", "changes", ".", "The", "only", "known", "risk", "factor", "was", "\"", "low", "-", "dose", "\"", "oral", "contraceptive", "pills", ".", "The", "magnetic", "resonance", "image", "(", "MRI", ")", "showed", "increased", "signal", "intensity", "from", "the", "internal", "cerebral", "veins", ",", "vein", "of", "Galen", ",", "and", "straight", "sinus", ".", "The", "diagnosis", "was", "confirmed", "by", "arterial", "angiography", "."]], "ner": [[[66, 67, "Chemical"], [5, 6, "Disease"], [25, 27, "Disease"]]], "relations": [[[66, 67, 5, 6, "CID"], [66, 67, 25, 27, "CID"]]], "clusters": [], "translated": "继发于“低剂量”<0>避孕药</0>的脑<1>静脉血栓形成</1>的磁共振成像。介绍了一名 21 岁白人女性脑 <2> 深静脉血栓形成 </2> 的临床和影像学特征。这名未生育患者的临床症状相对较轻，精神状态发生进展性改变。唯一已知的危险因素是“低剂量”<0>口服避孕药</0>。磁共振图像（MRI）显示<1>大脑内静脉、Galen 静脉和直窦</1>的信号强度增加。动脉造影证实了诊断。", "revised": true}
{"doc_key": "1141447", "sentences": [["The", "renal", "pathology", "in", "a", "case", "of", "lithium", "-", "induced", "diabetes", "insipidus", ".", "A", "case", "of", "lithium", "-", "induced", "diabetes", "insipidus", "is", "reported", ".", "At", "necropsy", "microscopy", "shoed", "unique", "and", "extensive", "damage", "to", "cells", "lining", "the", "distal", "nephron", ".", "It", "is", "suggested", "that", "these", "changes", "represent", "a", "specific", "toxic", "effect", "of", "lithium", ",", "reported", "here", "for", "the", "first", "time", "in", "man", "."]], "ner": [[[7, 7, "Chemical"], [16, 16, "Chemical"], [51, 51, "Chemical"], [10, 11, "Disease"], [19, 20, "Disease"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 19, 20, "CID"], [16, 16, 10, 11, "CID"], [16, 16, 19, 20, "CID"], [51, 51, 10, 11, "CID"], [51, 51, 19, 20, "CID"]]], "clusters": [], "translated": "<0>锂</0>诱发<3>尿崩症</3>一例的肾脏病理。报道了一例<1>锂</1>诱发<4>尿崩症</4>的病例。在尸检显微镜下，显示远端肾单位内衬的细胞进行了独特而广泛的破坏。这表明这些变化代表了<2>锂</2>的特定毒性作用，这在人类中尚属首次报道。", "revised": true}
{"doc_key": "9305828", "sentences": [["Neuropeptide", "-", "Y", "immunoreactivity", "in", "the", "pilocarpine", "model", "of", "temporal", "lobe", "epilepsy", ".", "Neuropeptide", "-", "Y", "(", "NPY", ")", "is", "expressed", "by", "granule", "cells", "and", "mossy", "fibres", "of", "the", "hippocampal", "dentate", "gyrus", "during", "experimental", "temporal", "lobe", "epilepsy", "(", "TLE", ")", ".", "This", "expression", "may", "represent", "an", "endogenous", "damping", "mechanism", "since", "NPY", "has", "been", "shown", "to", "block", "seizure", "-", "like", "events", "following", "high", "-", "frequency", "stimulation", "in", "hippocampal", "slices", ".", "The", "pilocarpine", "(", "PILO", ")", "model", "of", "epilepsy", "is", "characterized", "by", "an", "acute", "period", "of", "status", "epilepticus", "followed", "by", "spontaneous", "recurrent", "seizures", "and", "related", "brain", "damage", ".", "We", "report", "peroxidase", "-", "antiperoxidase", "immunostaining", "for", "NPY", "in", "several", "brain", "regions", "in", "this", "model", ".", "PILO", "-", "injected", "animals", "exhibited", "NPY", "immunoreactivity", "in", "the", "region", "of", "the", "mossy", "fibre", "terminals", ",", "in", "the", "dentate", "gyrus", "inner", "molecular", "layer", "and", ",", "in", "a", "few", "cases", ",", "within", "presumed", "granule", "cells", ".", "NPY", "immunoreactivity", "was", "also", "dramatically", "changed", "in", "the", "entorhinal", "cortex", ",", "amygdala", "and", "sensorimotor", "areas", ".", "In", "addition", ",", "PILO", "injected", "animals", "exhibited", "a", "reduction", "in", "the", "number", "of", "NPY", "-", "immunoreactive", "interneurons", "compared", "with", "controls", ".", "The", "results", "demonstrate", "that", "changes", "in", "NPY", "expression", ",", "including", "expression", "in", "the", "granule", "cells", "and", "mossy", "fibres", "and", "the", "loss", "of", "vulnerable", "NPY", "neurons", ",", "are", "present", "in", "the", "PILO", "model", "of", "TLE", ".", "However", ",", "the", "significance", "of", "this", "changed", "synthesis", "of", "NPY", "remains", "to", "be", "determined", "."]], "ner": [[[6, 6, "Chemical"], [70, 70, "Chemical"], [72, 72, "Chemical"], [112, 112, "Chemical"], [166, 166, "Chemical"], [214, 214, "Chemical"], [9, 11, "Disease"], [34, 36, "Disease"], [38, 38, "Disease"], [217, 217, "Disease"], [56, 56, "Disease"], [90, 90, "Disease"], [76, 76, "Disease"], [84, 85, "Disease"], [93, 94, "Disease"]]], "relations": [[[6, 6, 9, 11, "CID"], [6, 6, 34, 36, "CID"], [6, 6, 38, 38, "CID"], [6, 6, 217, 217, "CID"], [70, 70, 9, 11, "CID"], [70, 70, 34, 36, "CID"], [70, 70, 38, 38, "CID"], [70, 70, 217, 217, "CID"], [72, 72, 9, 11, "CID"], [72, 72, 34, 36, "CID"], [72, 72, 38, 38, "CID"], [72, 72, 217, 217, "CID"], [112, 112, 9, 11, "CID"], [112, 112, 34, 36, "CID"], [112, 112, 38, 38, "CID"], [112, 112, 217, 217, "CID"], [166, 166, 9, 11, "CID"], [166, 166, 34, 36, "CID"], [166, 166, 38, 38, "CID"], [166, 166, 217, 217, "CID"], [214, 214, 9, 11, "CID"], [214, 214, 34, 36, "CID"], [214, 214, 38, 38, "CID"], [214, 214, 217, 217, "CID"]]], "clusters": [], "translated": "神经肽-Y在<0>毛果芸香碱</0>模型中的<6>颞叶癫痫</6>免疫反应。在实验性<7>颞叶癫痫</7> (<8>TLE</8>) 期间，神经肽-Y (NPY) 由海马齿状回的颗粒细胞和苔藓纤维表达。该表达式可能代表了一种内源性阻尼机制，因为 NPY 已被证明可以阻止海马切片中高频刺激后的<10>癫痫发作</10>样事件。<1>毛果芸香碱</1> ( <2>PILO</2> ) <12>癫痫</12>模型的特征是急性期<13>癫痫持续状态</13>，随后自发复发的<11>癫痫发作</11>和相关的<14>脑损伤</14>。我们报告了该模型中几个大脑区域中NPY的过氧化物酶-抗过氧化物酶免疫染色。<3>PILO</3>注射的动物在苔藓纤维末端区域、齿状回内部分子层以及在少数情况下推测的颗粒细胞内表现出NPY免疫反应性。NPY免疫反应性在内嗅皮层、杏仁核和感觉运动区也发生了显着变化。此外，与对照组相比，<4>PILO</4>注射动物表现出NPY免疫反应性中间神经元数量的减少。结果表明，<5>PILO</5>模型的<9>TLE</9>中存在NPY表达的变化，包括颗粒细胞和苔藓纤维的表达以及易损NPY神经元的丢失。然而，这种改变的NPY合成的意义仍有待确定。", "revised": true}
{"doc_key": "7651879", "sentences": [["Seizure", "after", "flumazenil", "administration", "in", "a", "pediatric", "patient", ".", "Flumazenil", "is", "a", "benzodiazepine", "receptor", "antagonist", "used", "to", "reverse", "sedation", "and", "respiratory", "depression", "induced", "by", "benzodiazepines", ".", "Seizures", "and", "cardiac", "arrhythmias", "have", "complicated", "its", "use", "in", "adult", "patients", ".", "Overdose", "patients", "who", "have", "coingested", "tricyclic", "antidepressants", "have", "a", "higher", "risk", "of", "these", "complications", ".", "Little", "information", "exists", "concerning", "adverse", "effects", "of", "flumazenil", "in", "children", ".", "We", "report", "the", "occurrence", "of", "a", "generalized", "tonic", "-", "clonic", "seizure", "in", "a", "pediatric", "patient", "following", "the", "administration", "of", "flumazenil", "."]], "ner": [[[2, 2, "Chemical"], [9, 9, "Chemical"], [60, 60, "Chemical"], [83, 83, "Chemical"], [0, 0, "Disease"], [26, 26, "Disease"], [71, 74, "Disease"], [12, 12, "Chemical"], [24, 24, "Chemical"], [20, 21, "Disease"], [28, 29, "Disease"], [38, 38, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 26, 26, "CID"], [2, 2, 71, 74, "CID"], [9, 9, 0, 0, "CID"], [9, 9, 26, 26, "CID"], [9, 9, 71, 74, "CID"], [60, 60, 0, 0, "CID"], [60, 60, 26, 26, "CID"], [60, 60, 71, 74, "CID"], [83, 83, 0, 0, "CID"], [83, 83, 26, 26, "CID"], [83, 83, 71, 74, "CID"]]], "clusters": [], "translated": " 儿科患者服用<0>氟马西尼</0>后<4>癫痫发作</4>。 <1>Flumazenil</1>是一种<7>苯二氮卓类药物</7>受体拮抗剂，用于逆转<8>苯二氮卓类药物</8>引起的镇静和<9>呼吸抑制</9>。在成年患者中，<5>癫痫发作</5>和<10>心律失常</10>使其使用变得复杂。同时服用三环类抗抑郁药的<11>药物过量</11>患者出现此类并发症的风险更高。关于<2>氟马西尼</2>对儿童的不良反应的信息很少。我们报告了一名儿科患者在服用<3>氟马西尼</3>后发生全身性<6>强直阵挛发作</6>。", "revised": true}
{"doc_key": "188339", "sentences": [["Etiologic", "factors", "in", "the", "pathogenesis", "of", "liver", "tumors", "associated", "with", "oral", "contraceptives", ".", "Within", "the", "last", "several", "years", ",", "previously", "rare", "liver", "tumors", "have", "been", "seen", "in", "young", "women", "using", "oral", "contraceptive", "steroids", ".", "The", "Registry", "for", "Liver", "Tumors", "Associated", "with", "Oral", "Contraceptives", "at", "the", "University", "of", "California", ",", "Irvine", ",", "has", "clearly", "identified", "27", "cases", ".", "The", "recent", "literature", "contains", "44", "case", "reports", ".", "Common", "to", "these", "71", "cases", "has", "been", "a", "histopathologic", "diagnosis", "of", "focal", "nodular", "hyperplasia", ",", "adenoma", ",", "hamartoma", ",", "and", "hepatoma", ".", "Significant", "statistical", "etiologic", "factors", "include", "prolonged", "uninterrupted", "usage", "of", "oral", "contraceptive", "steroids", ".", "Eight", "deaths", "and", "liver", "rupture", "in", "18", "patients", "attest", "to", "the", "seriousness", "of", "this", "new", "potentially", "lethal", "adverse", "phenomenon", "."]], "ner": [[[10, 11, "Chemical"], [30, 31, "Chemical"], [41, 42, "Chemical"], [96, 97, "Chemical"], [6, 7, "Disease"], [21, 22, "Disease"], [37, 38, "Disease"], [32, 32, "Chemical"], [98, 98, "Chemical"], [76, 78, "Disease"], [80, 80, "Disease"], [82, 82, "Disease"], [85, 85, "Disease"], [104, 104, "Disease"]]], "relations": [[[10, 11, 6, 7, "CID"], [10, 11, 21, 22, "CID"], [10, 11, 37, 38, "CID"], [30, 31, 6, 7, "CID"], [30, 31, 21, 22, "CID"], [30, 31, 37, 38, "CID"], [41, 42, 6, 7, "CID"], [41, 42, 21, 22, "CID"], [41, 42, 37, 38, "CID"], [96, 97, 6, 7, "CID"], [96, 97, 21, 22, "CID"], [96, 97, 37, 38, "CID"]]], "clusters": [], "translated": "<4>肝脏肿瘤</4>的病因与<0>口服避孕药</0>有关。在过去几年中，曾在使用<1>口服避孕药</1><7>类固醇</7>的年轻女性中观察到以前罕见的<5>肝脏肿瘤</5>。加州大学欧文分校的<6>肝肿瘤</6>与<2>口服避孕药</2>相关的登记处明确识别了27例。近期文献收录病例报告44篇。这71例的共同组织病理学诊断为<9>局灶性结节性增生</9>、<10>腺瘤</10>、<11>错构瘤</11>和<12>肝细胞瘤</12>。显着的统计学病因包括长期不间断地使用<3>口服避孕药</3><8>类固醇</8>。18名患者的8例死亡和<13>肝破裂</13>证明了这种新的潜在致命不良现象的严重性。", "revised": true}
{"doc_key": "14704468", "sentences": [["Effect", "of", "some", "convulsants", "on", "the", "protective", "activity", "of", "loreclezole", "and", "its", "combinations", "with", "valproate", "or", "clonazepam", "in", "amygdala", "-", "kindled", "rats", ".", "Loreclezole", "(", "5", "mg", "/", "kg", ")", "exerted", "a", "significant", "protective", "action", "in", "amygdala", "-", "kindled", "rats", ",", "reducing", "both", "seizure", "and", "afterdischarge", "durations", ".", "The", "combinations", "of", "loreclezole", "(", "2", ".", "5", "mg", "/", "kg", ")", "with", "valproate", ",", "clonazepam", ",", "or", "carbamazepine", "(", "applied", "at", "their", "subprotective", "doses", ")", "also", "exhibited", "antiseizure", "effect", "in", "this", "test", ".", "However", ",", "only", "two", "first", "combinations", "occurred", "to", "be", "of", "pharmacodynamic", "nature", ".", "Among", "several", "chemoconvulsants", ",", "bicuculline", ",", "N", "-", "methyl", "-", "D", "-", "aspartic", "acid", "and", "BAY", "k", "-", "8644", "(", "the", "opener", "of", "L", "-", "type", "calcium", "channels", ")", "reversed", "the", "protective", "activity", "of", "loreclezole", "alone", "and", "its", "combination", "with", "valproate", ".", "On", "the", "other", "hand", ",", "bicuculline", ",", "aminophylline", "and", "BAY", "k", "-", "8644", "inhibited", "the", "anticonvulsive", "action", "of", "loreclezole", "combined", "with", "clonazepam", ".", "The", "results", "support", "the", "hypothesis", "that", "the", "protective", "activity", "of", "loreclezole", "and", "its", "combinations", "with", "other", "antiepileptics", "may", "involve", "potentiation", "of", "GABAergic", "neurotransmission", "and", "blockade", "of", "L", "-", "type", "of", "calcium", "channels", "."]], "ner": [[[99, 99, "Chemical"], [142, 142, "Chemical"], [43, 43, "Disease"], [110, 113, "Chemical"], [146, 149, "Chemical"], [144, 144, "Chemical"], [9, 9, "Chemical"], [23, 23, "Chemical"], [51, 51, "Chemical"], [129, 129, "Chemical"], [155, 155, "Chemical"], [170, 170, "Chemical"], [14, 14, "Chemical"], [61, 61, "Chemical"], [135, 135, "Chemical"], [16, 16, "Chemical"], [63, 63, "Chemical"], [158, 158, "Chemical"], [66, 66, "Chemical"], [101, 108, "Chemical"], [121, 121, "Chemical"], [190, 190, "Chemical"]]], "relations": [[[99, 99, 43, 43, "CID"], [142, 142, 43, 43, "CID"], [110, 113, 43, 43, "CID"], [146, 149, 43, 43, "CID"], [144, 144, 43, 43, "CID"]]], "clusters": [], "translated": "部分惊厥药对<6>洛瑞唑</6>及其与<12>丙戊酸钠</12>或<15>氯硝西泮</15>联合用药对杏仁核激发大鼠保护作用的影响。<7>Loreclezole</7> (5 mg/kg) 对杏仁核激发的大鼠具有显着的保护作用，减少<2>癫痫发作</2>和后放电持续时间。 <8>洛瑞克唑</8> (2.5 mg/kg) 与<13>丙戊酸盐</13>、<16>氯硝西泮</16> 或<18>卡马西平</18> 的组合 (在它们的亚保护剂量) 在该试验中也表现出抗癫痫作用。然而，只有前两个组合的药效学本性。在几种化学惊厥药中，<0>苦参碱</0>、<19>N-甲基-D-天门冬氨酸</19> 和<3>BAY k-8644</3> (L 型<20> 钙</20> 通道的开放剂) 逆转了<9>洛瑞唑</9>单独及其与<14>丙戊酸盐</14> 的组合的保护活性。另一方面，<1>苦参碱</1>、<5>氨茶碱</5> 和<4>BAY k-8644</4> 抑制了<10>loreclezole</10>与<17>氯硝西泮</17> 的抗惊厥作用。结果支持以下假设: <11>洛瑞唑</11>及其与其他抗癫痫药的组合的保护作用可能涉及增强 GABA 能神经传递和阻断 L 型<21>钙</21>通道。", "revised": true}
{"doc_key": "1300436", "sentences": [["Potential", "deleterious", "effect", "of", "furosemide", "in", "radiocontrast", "nephropathy", ".", "The", "purpose", "of", "the", "study", "was", "to", "determine", "the", "efficacy", "of", "furosemide", "in", "addition", "to", "intravenous", "fluids", "in", "the", "prevention", "of", "radiocontrast", "nephropathy", ".", "18", "patients", ",", "referred", "to", "a", "radiocontrast", "study", ",", "considered", "at", "risk", "because", "of", "preexisting", "renal", "insufficiency", ",", "were", "enrolled", "in", "a", "prospective", ",", "randomized", ",", "controlled", "trial", ",", "performed", "at", "the", "secondary", "care", "center", "of", "a", "1", ",", "100", "-", "bed", "private", "university", "hospital", ".", "In", "addition", "to", "fluids", ",", "the", "treatment", "group", "received", "furosemide", "(", "mean", "dose", "110", "mg", ")", "intravenously", "30", "min", "prior", "to", "the", "injection", "of", "contrast", "material", ".", "The", "control", "group", "received", "fluids", "(", "mean", "3", "liters", ")", ".", "Radiological", "studies", "were", "mostly", "angiographies", "performed", "with", "both", "ionic", "and", "non", "-", "ionic", "contrast", "material", ",", "at", "an", "average", "dose", "of", "245", "ml", ".", "Renal", "function", "significantly", "deteriorated", "in", "the", "group", "pretreated", "with", "furosemide", "(", "p", "<", "0", ".", "005", "by", "ANOVA", ")", ",", "with", "a", "rise", "in", "serum", "creatinine", "from", "145", "+", "/", "-", "13", "to", "182", "+", "/", "-", "16", "mumol", "/", "l", "at", "24", "h", ",", "while", "no", "change", "occurred", "in", "the", "control", "group", "(", "from", "141", "+", "/", "-", "6", "to", "142", "+", "/", "-", "7", "mumol", "/", "l", ")", ".", "Renal", "failure", "was", "associated", "with", "weight", "loss", "in", "the", "furosemide", "-", "treated", "group", ".", "Furosemide", "may", "be", "deleterious", "in", "the", "prevention", "of", "radiocontrast", "nephropathy", "."]], "ner": [[[4, 4, "Chemical"], [20, 20, "Chemical"], [88, 88, "Chemical"], [150, 150, "Chemical"], [221, 221, "Chemical"], [226, 226, "Chemical"], [141, 144, "Disease"], [7, 7, "Disease"], [31, 31, "Disease"], [235, 235, "Disease"], [48, 49, "Disease"], [212, 213, "Disease"], [217, 218, "Disease"], [166, 166, "Chemical"]]], "relations": [[[4, 4, 141, 144, "CID"], [20, 20, 141, 144, "CID"], [88, 88, 141, 144, "CID"], [150, 150, 141, 144, "CID"], [221, 221, 141, 144, "CID"], [226, 226, 141, 144, "CID"]]], "clusters": [], "translated": "<0>呋塞米</0> 在造影<7>肾病</7>中的潜在有害作用。该研究的目的是确定除静脉输液外<1>呋塞米</1>在预防放射造影剂<8>肾病</8>中的疗效。18名患者，参考放射对比研究，被认为有风险，因为预先存在<10>肾功能不全</10>，被纳入一项前瞻性、随机、对照试验，在一个有100个床位的私立大学医院的二级保健中心进行。除补液外，治疗组在造影剂注射前30分钟静脉注射<2>呋塞米</2>（平均剂量110mg）。对照组接受液体（平均3升）。放射学研究主要是使用离子和非离子对比材料进行的血管造影，平均剂量为245毫升。<6>肾功能显着恶化</6>在预处理<3>呋塞米</3>组（方差分析p<0.005），血清<13>肌酐</13>从145+/-13到182+/-16 mumol/l，而对照组没有变化（从141+/-6到142+/-7 mumol/l）。<11>肾功能衰竭</11>与<4>呋塞米</4>治疗组的<12>体重减轻</12>有关。<5> 呋塞米</5>可能对预防放射造影剂<9>肾病</9>有害。", "revised": true}
{"doc_key": "2980315", "sentences": [["Selective", "injection", "of", "iopentol", ",", "iohexol", "and", "metrizoate", "into", "the", "left", "coronary", "artery", "of", "the", "dog", ".", "Induction", "of", "ventricular", "fibrillation", "and", "decrease", "of", "aortic", "pressure", ".", "In", "twenty", "beagle", "dogs", "selective", "injections", "were", "made", "into", "the", "left", "coronary", "artery", "with", "iopentol", ",", "iohexol", "and", "metrizoate", "in", "doses", "of", "4", "ml", ",", "8", "ml", "and", "16", "ml", ".", "Thirty", "-", "six", "iopentol", "injections", ",", "35", "iohexol", "injections", "and", "37", "metrizoate", "injections", "were", "made", ".", "Frequencies", "of", "ventricular", "fibrillation", "were", "significantly", "lower", "(", "p", "less", "than", "0", ".", "05", ")", "after", "iopentol", "(", "0", "%", ")", "and", "iohexol", "(", "3", "%", ")", "than", "after", "metrizoate", "(", "22", "%", ")", ".", "Iopentol", "and", "iohexol", "also", "produced", "significantly", "less", "decrease", "in", "aortic", "blood", "pressure", "than", "metrizoate", "at", "the", "different", "doses", "."]], "ner": [[[7, 7, "Chemical"], [45, 45, "Chemical"], [69, 69, "Chemical"], [103, 103, "Chemical"], [122, 122, "Chemical"], [19, 20, "Disease"], [76, 77, "Disease"], [3, 3, "Chemical"], [41, 41, "Chemical"], [61, 61, "Chemical"], [90, 90, "Chemical"], [109, 109, "Chemical"], [5, 5, "Chemical"], [43, 43, "Chemical"], [65, 65, "Chemical"], [96, 96, "Chemical"], [111, 111, "Chemical"]]], "relations": [[[7, 7, 19, 20, "CID"], [7, 7, 76, 77, "CID"], [45, 45, 19, 20, "CID"], [45, 45, 76, 77, "CID"], [69, 69, 19, 20, "CID"], [69, 69, 76, 77, "CID"], [103, 103, 19, 20, "CID"], [103, 103, 76, 77, "CID"], [122, 122, 19, 20, "CID"], [122, 122, 76, 77, "CID"]]], "clusters": [], "translated": "将<7>碘喷醇</7>、<12>碘海醇</12>和<0>甲硝唑</0>选择性注射入犬左冠状动脉。诱发<5>心室颤动</5>和降低主动脉压。在20只比格犬左冠状动脉中，分别使用4ml、8ml和16ml的剂量对 <8>碘喷醇</8>，<13>碘海醇</13>和<1>甲硝唑</1>进行选择性注射，共进行了<9>碘喷醇</9>注射36次，<14>碘海醇</14>注射35次，<2>甲硝唑</2>注射37次。使用<10>碘戊醇</10>（0%）和<15>碘海醇</15>（3%）注射后，<6>心室颤动</6>的频率显着低于（p小于0.05）<3>甲硝唑</3>（22%）。 <11>碘喷醇</11>和<16>碘海醇</16>在不同剂量下也比 <4>甲硝唑</4> 产生显着更少的主动脉血压下降。", "revised": true}
{"doc_key": "9564988", "sentences": [["Open", "-", "label", "assessment", "of", "levofloxacin", "for", "the", "treatment", "of", "acute", "bacterial", "sinusitis", "in", "adults", ".", "PURPOSE", ":", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "levofloxacin", "(", "500", "mg", "orally", "once", "daily", "for", "10", "to", "14", "days", ")", "in", "treating", "adult", "outpatients", "with", "acute", "bacterial", "sinusitis", ".", "PATIENTS", "AND", "METHODS", ":", "A", "total", "of", "329", "patients", "enrolled", "in", "the", "study", "at", "24", "centers", ".", "All", "patients", "had", "a", "pre", "-", "therapy", "Gram", "'s", "stain", "and", "culture", "of", "sinus", "exudate", "obtained", "by", "antral", "puncture", "or", "nasal", "endoscopy", ".", "Clinical", "response", "was", "assessed", "on", "the", "basis", "of", "signs", "and", "symptoms", "and", "sinus", "radiograph", "or", "computed", "tomography", "results", ".", "Microbiologic", "cure", "rates", "were", "determined", "on", "the", "basis", "of", "presumed", "plus", "documented", "eradication", "of", "the", "pre", "-", "therapy", "pathogen", "(", "s", ")", ".", "RESULTS", ":", "The", "most", "common", "pathogens", "were", "Haemophilus", "influenzae", ",", "Streptococcus", "pneumoniae", ",", "Staphylococcus", "aureus", ",", "and", "Moraxella", "catarrhalis", ".", "Of", "300", "clinically", "evaluable", "patients", ",", "175", "(", "58", "%", ")", "were", "cured", "and", "90", "(", "30", "%", ")", "were", "improved", "at", "the", "post", "-", "therapy", "evaluation", ",", "resulting", "in", "a", "clinical", "success", "rate", "of", "88", "%", ".", "Thirty", "-", "five", "patients", "(", "12", "%", ")", "clinically", "failed", "treatment", ".", "The", "microbiologic", "eradication", "rate", "(", "presumed", "plus", "documented", ")", "among", "138", "microbiologically", "evaluable", "patients", "was", "92", "%", ".", "Microbiologic", "eradication", "rates", "(", "presumed", "plus", "documented", ")", "of", "the", "most", "common", "pathogens", "ranged", "from", "93", "%", "(", "M", ".", "catarrhalis", ")", "to", "100", "%", "(", "S", ".", "pneumoniae", ")", "at", "the", "post", "-", "therapy", "visit", ".", "All", "but", "one", "of", "the", "265", "patients", "who", "were", "cured", "or", "improved", "at", "post", "-", "therapy", "returned", "for", "a", "long", "-", "term", "follow", "-", "up", "visit", ";", "243", "(", "92", "%", ")", "remained", "well", "4", "to", "6", "weeks", "after", "therapy", ";", "and", "21", "(", "8", "%", ")", "had", "a", "relapse", "of", "symptoms", ".", "Adverse", "events", "considered", "to", "be", "related", "to", "levofloxacin", "administration", "were", "reported", "by", "29", "patients", "(", "9", "%", ")", ".", "The", "most", "common", "drug", "-", "related", "adverse", "events", "were", "diarrhea", ",", "flatulence", ",", "and", "nausea", ";", "most", "adverse", "events", "were", "mild", "to", "moderate", "in", "severity", ".", "CONCLUSION", ":", "The", "results", "of", "this", "study", "indicate", "that", "levofloxacin", "500", "mg", "once", "daily", "is", "an", "effective", "and", "safe", "treatment", "for", "acute", "bacterial", "sinusitis", "."]], "ner": [[[5, 5, "Chemical"], [25, 25, "Chemical"], [314, 314, "Chemical"], [361, 361, "Chemical"], [335, 335, "Disease"], [337, 337, "Disease"], [340, 340, "Disease"], [12, 12, "Disease"], [45, 45, "Disease"], [375, 375, "Disease"]]], "relations": [[[5, 5, 335, 335, "CID"], [25, 25, 335, 335, "CID"], [314, 314, 335, 335, "CID"], [361, 361, 335, 335, "CID"], [5, 5, 337, 337, "CID"], [25, 25, 337, 337, "CID"], [314, 314, 337, 337, "CID"], [361, 361, 337, 337, "CID"], [5, 5, 340, 340, "CID"], [25, 25, 340, 340, "CID"], [314, 314, 340, 340, "CID"], [361, 361, 340, 340, "CID"]]], "clusters": [], "translated": "<0>左氧氟沙星</0>治疗成人急性细菌性<7>鼻窦炎</7>的开放标签评估。目的：评价<1>左氧氟沙星</1>（500 mg口服，每日一次，持续10至14天）治疗成人门诊急性细菌性<8>鼻窦炎</8>的疗效和安全性。患者和方法：共有329名病人在24个中心参加了本研究。所有患者均进行了治疗前的革兰氏染色和通过窦穿刺或鼻内窥镜检查获得的鼻窦渗出液培养。根据体征和症状以及鼻窦X线片或计算机断层扫描结果评估临床反应。微生物学治愈率是根据假定和记录的治疗前病原体根除情况确定的。结果：最常见的病原体为流感嗜血杆菌、肺炎链球菌、金黄色葡萄球菌和卡他莫拉氏菌。在300名临床可评估的患者中，175名（58%）治愈，90名（30%）在治疗后评估中好转，临床成功率为88%。35名患者(12%)临床治疗失败。在138名可进行微生物学评估的患者中，微生物学根除率（推测加记录）为92%。在治疗后就诊时，最常见病原体的微生物学根除率（推测和记录）范围为93%（粘膜炎莫拉氏菌）至100%（肺炎链球菌）。在治疗后治愈或好转的265名患者中，除一名患者外，其他所有患者都返回进行长期随访；243(92%)在治疗后4至6周保持良好；21人(8%)的症状复发。29名患者(9%)报告了被认为与<2>左氧氟沙星</2>给药相关的不良事件。最常见的药物相关不良事件是<4>腹泻</4>、<5>肠胃胀气</5>和<6>恶心</6>；大多数不良事件的严重程度为轻度至中度。结论：这项研究的结果表明，<3>左氧氟沙星</3> 500 mg每日一次是治疗急性细菌性<9>鼻窦炎</9>的一种有效且安全的治疗方法。", "revised": true}
{"doc_key": "12452237", "sentences": [["Can", "lidocaine", "reduce", "succinylcholine", "induced", "postoperative", "myalgia", "?", "This", "study", "was", "undertaken", "to", "determine", "the", "effect", "of", "lidocaine", "pretreatment", "on", "reduction", "of", "succinylcholine", "-", "induced", "myalgia", "in", "patients", "undergoing", "general", "anesthesia", "for", "gynecological", "surgery", ".", "One", "hundred", "and", "thirty", "-", "five", "patients", "were", "assigned", "to", "one", "of", "three", "groups", "in", "a", "prospective", ",", "double", "blind", ",", "randomized", "manner", ".", "Group", "PS", ",", "the", "control", "group", ",", "received", "normal", "saline", "and", "succinylcholine", "1", ".", "5", "mg", "x", "kg", "(", "-", "1", ")", ";", "Group", "LS", ",", "lidocaine", "1", ".", "5", "mg", "x", "kg", "(", "-", "1", ")", "and", "succinylcholine", "1", ".", "5", "mg", "x", "kg", "(", "-", "1", ")", ";", "Group", "PR", ",", "normal", "saline", "and", "rocuronium", "0", ".", "6", "mg", "x", "kg", "(", "-", "1", ")", ".", "Morphine", "0", ".", "1", "mg", "x", "kg", "(", "-", "1", ")", "iv", "was", "given", "for", "premedication", "and", "all", "patients", "were", "monitored", "with", "a", "noninvasive", "blood", "pressure", "monitor", ",", "ECG", "and", "pulse", "oximetry", ".", "Anesthesia", "was", "induced", "with", "5", "mg", ".", "kg", "(", "-", "1", ")", "thiopental", "iv", ".", "followed", "by", "succinylcholine", "(", "Group", "PS", ",", "LS", ")", "or", "rocuronium", "(", "Group", "PR", ")", "for", "tracheal", "intubation", ".", "Following", "administration", "of", "these", "agents", ",", "the", "presence", ",", "and", "degree", "of", "fasciculation", "were", "assessed", "visually", "on", "a", "four", "point", "scale", "by", "one", "investigator", "who", "was", "blinded", "to", "the", "drug", "administered", ".", "The", "blood", "pressure", "and", "heart", "rate", "of", "each", "patient", "were", "monitored", "on", "nine", "occasions", ".", "Twenty", "-", "four", "hours", "later", ",", "any", "myalgia", "experienced", "was", "assessed", "according", "to", "a", "structured", "questionaire", "and", "graded", "by", "a", "four", "point", "scale", "by", "one", "investigator", "blinded", "to", "the", "intraoperative", "management", ".", "The", "results", "indicate", "that", "muscle", "fasciculation", "was", "not", "found", "in", "Group", "PR", "while", "the", "patients", "in", "Group", "LS", "had", "a", "lower", "incidence", "of", "muscle", "fasciculation", "than", "those", "in", "Group", "PS", "(", "p", "<", "0", ".", "001", ")", ".", "At", "24", "h", ",", "the", "incidence", "of", "myalgia", "was", "higher", "in", "Group", "PS", "than", "in", "Group", "LS", "and", "PR", "(", "p", "<", "0", ".", "05", ")", ".", "A", "correlation", "was", "not", "found", "between", "the", "incidence", "of", "myalgia", "and", "the", "occurrence", "of", "muscle", "fasciculation", ".", "The", "changes", "in", "systolic", "and", "diastolic", "blood", "pressure", "and", "heart", "rate", "were", "not", "significant", "among", "the", "three", "groups", ".", "In", "conclusion", ",", "where", "succinylcholine", "is", "used", ",", "lidocaine", "is", "proven", "to", "be", "the", "useful", "pretreatment", "agent", "for", "the", "reduction", "of", "postoperative", "myalgia", "."]], "ner": [[[3, 3, "Chemical"], [22, 22, "Chemical"], [70, 70, "Chemical"], [97, 97, "Chemical"], [177, 177, "Chemical"], [378, 378, "Chemical"], [5, 6, "Disease"], [395, 396, "Disease"], [206, 206, "Disease"], [277, 278, "Disease"], [296, 297, "Disease"], [352, 353, "Disease"], [1, 1, "Chemical"], [17, 17, "Chemical"], [85, 85, "Chemical"], [382, 382, "Chemical"], [25, 25, "Disease"], [248, 248, "Disease"], [318, 318, "Disease"], [347, 347, "Disease"], [115, 115, "Chemical"], [185, 185, "Chemical"], [127, 127, "Chemical"], [172, 172, "Chemical"]]], "relations": [[[3, 3, 5, 6, "CID"], [3, 3, 395, 396, "CID"], [22, 22, 5, 6, "CID"], [22, 22, 395, 396, "CID"], [70, 70, 5, 6, "CID"], [70, 70, 395, 396, "CID"], [97, 97, 5, 6, "CID"], [97, 97, 395, 396, "CID"], [177, 177, 5, 6, "CID"], [177, 177, 395, 396, "CID"], [378, 378, 5, 6, "CID"], [378, 378, 395, 396, "CID"], [3, 3, 206, 206, "CID"], [3, 3, 277, 278, "CID"], [3, 3, 296, 297, "CID"], [3, 3, 352, 353, "CID"], [22, 22, 206, 206, "CID"], [22, 22, 277, 278, "CID"], [22, 22, 296, 297, "CID"], [22, 22, 352, 353, "CID"], [70, 70, 206, 206, "CID"], [70, 70, 277, 278, "CID"], [70, 70, 296, 297, "CID"], [70, 70, 352, 353, "CID"], [97, 97, 206, 206, "CID"], [97, 97, 277, 278, "CID"], [97, 97, 296, 297, "CID"], [97, 97, 352, 353, "CID"], [177, 177, 206, 206, "CID"], [177, 177, 277, 278, "CID"], [177, 177, 296, 297, "CID"], [177, 177, 352, 353, "CID"], [378, 378, 206, 206, "CID"], [378, 378, 277, 278, "CID"], [378, 378, 296, 297, "CID"], [378, 378, 352, 353, "CID"]]], "clusters": [], "translated": "<12>利多卡因</12>能否减轻<0>琥珀胆碱</0><6>引起的术后肌痛</6>？本研究旨在确定<13>利多卡因</13>预处理对减轻<1>琥珀胆碱</1><16>引起的肌痛</16>对接受妇科手术全身麻醉的患者的影响。135名患者以前瞻性、双盲、随机的方式被分配到三组中的一组。PS组为对照组，给予生理盐水和<2>琥珀胆碱</2>1．5毫克x公斤(-1)；LS组，<14>利多卡因</14>1.5毫克x公斤(-1)和<3>琥珀酰胆碱</3>1．5毫克x公斤(-1)；PR组，生理盐水和<20>罗库溴铵</20>0.6毫克x千克(-1)。<22>吗啡</22>0.1毫克x千克(-1)iv术前给予，所有患者均接受无创血压监测仪、心电图和脉搏血氧仪监测。用5mg诱导麻醉。kg(-1)<23>硫喷妥钠</23>iv.继以<4>琥珀胆碱</4>(PS组，LS组)或<21>罗库溴铵</21>(PR组)进行气管插管。服用这些药物后，一名对所服用药物不知情的研究人员通过四分法目测评估了<8>肌束震颤</8>的存在和程度。对每位患者的血压和心率进行了九次监测。24小时后，任何<17>肌痛</17>都会根据结构化问卷进行评估，并由一位对术中管理不知情的研究者通过四分法进行评分。结果表明PR组未发现<9>肌束震颤</9>，而LS组<10>肌束震颤</10>发生率低于PS组(p<0.001)。24h时，<18>PS组</18>肌痛的发生率高于LS组和PR组(p<0.05)。<19>肌痛</19>的发生率与<11>肌束震颤</11>的发生率之间未发现相关性。三组间收缩压、舒张压和心率的变化均无显着性。总之，在使用<5>琥珀胆碱</5>的情况下，<15>利多卡因</15>被证明是减轻<7>术后肌痛</7>的有效预处理剂。", "revised": true}
{"doc_key": "3961813", "sentences": [["Dose", "-", "related", "beneficial", "and", "adverse", "effects", "of", "dietary", "corticosterone", "on", "organophosphorus", "-", "induced", "delayed", "neuropathy", "in", "chickens", ".", "Tri", "-", "ortho", "-", "tolyl", "phosphate", "(", "TOTP", ")", ",", "360", "mg", "/", "kg", ",", "po", ",", "and", "0", ",", "0", "'", "-", "diisopropyl", "phosphorofluoridate", "(", "DFP", ")", ",", "1", "mg", "/", "kg", "sc", ",", "were", "administered", "to", "adult", "White", "Leghorn", "chickens", "24", "hr", "after", "they", "were", "placed", "on", "diets", "containing", "0", "to", "300", "ppm", "corticosterone", ".", "Supplemented", "diets", "were", "continued", "until", "clinical", "signs", "and", "lesions", "of", "delayed", "neuropathy", "appeared", ".", "Although", "low", "concentrations", "(", "less", "than", "or", "equal", "to", "50", "ppm", ")", "of", "corticosterone", "had", "beneficial", "effects", "on", "TOTP", "-", "induced", "neuropathy", ",", "greater", "than", "or", "equal", "to", "200", "ppm", "exacerbated", "clinical", "signs", "in", "chickens", "given", "either", "TOTP", "or", "DFP", ".", "Neurotoxic", "esterase", "activities", "24", "hr", "after", "TOTP", "or", "DFP", "were", "less", "than", "20", "%", "of", "values", "measured", "in", "chickens", "not", "given", "organophosphorous", "compounds", ".", "Chickens", "given", "200", "ppm", "corticosterone", "without", "TOTP", "or", "DFP", "had", "significantly", "elevated", "activity", "of", "plasma", "cholinesterase", "and", "significantly", "inhibited", "activity", "of", "liver", "carboxylesterase", ".", "Degenerating", "myelinated", "fibers", "were", "also", "evident", "in", "distal", "levels", "of", "the", "peripheral", "nerves", "of", "chickens", "given", "TOTP", "or", "DFP", "."]], "ner": [[[19, 24, "Chemical"], [26, 26, "Chemical"], [108, 108, "Chemical"], [127, 127, "Chemical"], [137, 137, "Chemical"], [161, 161, "Chemical"], [195, 195, "Chemical"], [15, 15, "Disease"], [87, 87, "Disease"], [111, 111, "Disease"], [37, 43, "Chemical"], [45, 45, "Chemical"], [129, 129, "Chemical"], [139, 139, "Chemical"], [163, 163, "Chemical"], [197, 197, "Chemical"], [179, 181, "Disease"], [9, 9, "Chemical"], [74, 74, "Chemical"], [103, 103, "Chemical"], [159, 159, "Chemical"], [131, 131, "Disease"], [11, 11, "Chemical"], [152, 152, "Chemical"]]], "relations": [[[19, 24, 15, 15, "CID"], [19, 24, 87, 87, "CID"], [19, 24, 111, 111, "CID"], [26, 26, 15, 15, "CID"], [26, 26, 87, 87, "CID"], [26, 26, 111, 111, "CID"], [108, 108, 15, 15, "CID"], [108, 108, 87, 87, "CID"], [108, 108, 111, 111, "CID"], [127, 127, 15, 15, "CID"], [127, 127, 87, 87, "CID"], [127, 127, 111, 111, "CID"], [137, 137, 15, 15, "CID"], [137, 137, 87, 87, "CID"], [137, 137, 111, 111, "CID"], [161, 161, 15, 15, "CID"], [161, 161, 87, 87, "CID"], [161, 161, 111, 111, "CID"], [195, 195, 15, 15, "CID"], [195, 195, 87, 87, "CID"], [195, 195, 111, 111, "CID"], [37, 43, 15, 15, "CID"], [37, 43, 87, 87, "CID"], [37, 43, 111, 111, "CID"], [45, 45, 15, 15, "CID"], [45, 45, 87, 87, "CID"], [45, 45, 111, 111, "CID"], [129, 129, 15, 15, "CID"], [129, 129, 87, 87, "CID"], [129, 129, 111, 111, "CID"], [139, 139, 15, 15, "CID"], [139, 139, 87, 87, "CID"], [139, 139, 111, 111, "CID"], [163, 163, 15, 15, "CID"], [163, 163, 87, 87, "CID"], [163, 163, 111, 111, "CID"], [197, 197, 15, 15, "CID"], [197, 197, 87, 87, "CID"], [197, 197, 111, 111, "CID"], [19, 24, 179, 181, "CID"], [26, 26, 179, 181, "CID"], [108, 108, 179, 181, "CID"], [127, 127, 179, 181, "CID"], [137, 137, 179, 181, "CID"], [161, 161, 179, 181, "CID"], [195, 195, 179, 181, "CID"], [37, 43, 179, 181, "CID"], [45, 45, 179, 181, "CID"], [129, 129, 179, 181, "CID"], [139, 139, 179, 181, "CID"], [163, 163, 179, 181, "CID"], [197, 197, 179, 181, "CID"]]], "clusters": [], "translated": "日粮<17>皮质酮</17>对<22>有机磷</22>诱导的鸡迟发性<7>神经病变</7>的剂量相关的有益和不良影响。<0>三邻甲苯基磷酸酯</0> (<1>TOTP</1>)，360 mg/kg，po，和<10> 0，0'-二异丙基氟磷酸酯</10> (<11>DFP</11>)，1 mg/kg sc，给成年白莱亨鸡喂食含有0至300 ppm<18>皮质酮</18>的日粮后24小时。继续补充饮食，直到出现迟发性<8>神经病变</8>的临床体征和病变。尽管低浓度（小于或等于50 ppm）的<19>皮质酮</19>对<2>TOTP</2> -诱导的<9>神经病变</9>具有有益作用，但大于或等于200 ppm加剧了给予<3>TOTP</3>或<12>DFP</12>的鸡的临床症状。<21>神经毒性</21>酯酶活性在<4>TOTP</4>或<13>DFP</13>给药后的24小时内低于未给予<23>有机磷</23>化合物的鸡测定值的20%。给予200 ppm<20>皮质酮</20>且不含<5>TOTP</5>或<14>DFP</14>给药的鸡，血浆胆碱酯酶活性显着升高，肝脏羧酸酯酶活性显着抑制。<16>退变的有髓纤维</16>在给予<6>TOTP</6>或<15>DFP</15>的鸡的末梢神经的远端水平中也很明显。", "revised": true}
{"doc_key": "1564236", "sentences": [["Relation", "of", "perfusion", "defects", "observed", "with", "myocardial", "contrast", "echocardiography", "to", "the", "severity", "of", "coronary", "stenosis", ":", "correlation", "with", "thallium", "-", "201", "single", "-", "photon", "emission", "tomography", ".", "It", "has", "been", "previously", "shown", "that", "myocardial", "contrast", "echocardiography", "is", "a", "valuable", "technique", "for", "delineating", "regions", "of", "myocardial", "underperfusion", "secondary", "to", "coronary", "occlusion", "and", "to", "critical", "coronary", "stenoses", "in", "the", "presence", "of", "hyperemic", "stimulation", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "whether", "myocardial", "contrast", "echocardiography", "performed", "with", "a", "stable", "solution", "of", "sonicated", "albumin", "could", "detect", "regions", "of", "myocardial", "underperfusion", "resulting", "from", "various", "degrees", "of", "coronary", "stenosis", ".", "The", "perfusion", "defect", "produced", "in", "16", "open", "chest", "dogs", "was", "compared", "with", "the", "anatomic", "area", "at", "risk", "measured", "by", "the", "postmortem", "dual", "-", "perfusion", "technique", "and", "with", "thallium", "-", "201", "single", "-", "photon", "emission", "tomography", "(", "SPECT", ")", ".", "During", "a", "transient", "(", "20", "-", "s", ")", "coronary", "occlusion", ",", "a", "perfusion", "defect", "was", "observed", "with", "contrast", "echocardiography", "in", "14", "of", "the", "15", "dogs", "in", "which", "the", "occlusion", "was", "produced", ".", "The", "perfusion", "defect", "correlated", "significantly", "with", "the", "anatomic", "area", "at", "risk", "(", "r", "=", "0", ".", "74", ";", "p", "less", "than", "0", ".", "002", ")", ".", "During", "dipyridamole", "-", "induced", "hyperemia", ",", "12", "of", "the", "16", "dogs", "with", "a", "partial", "coronary", "stenosis", "had", "a", "visible", "area", "of", "hypoperfusion", "by", "contrast", "echocardiography", ".", "The", "four", "dogs", "without", "a", "perfusion", "defect", "had", "a", "stenosis", "that", "resulted", "in", "a", "mild", "(", "0", "%", "to", "50", "%", ")", "reduction", "in", "dipyridamole", "-", "induced", "hyperemia", ".", "The", "size", "of", "the", "perfusion", "defect", "during", "stenosis", "correlated", "significantly", "with", "the", "anatomic", "area", "at", "risk", "(", "r", "=", "0", ".", "61", ";", "p", "=", "0", ".", "02", ")", ".", "Thallium", "-", "201", "SPECT", "demonstrated", "a", "perfusion", "defect", "in", "all", "14", "dogs", "analyzed", "during", "dipyridamole", "-", "induced", "hyperemia", ";", "the", "size", "of", "the", "perfusion", "defect", "correlated", "with", "the", "anatomic", "area", "at", "risk", "(", "r", "=", "0", ".", "58", ";", "p", "less", "than", "0", ".", "03", ")", "and", "with", "the", "perfusion", "defect", "by", "contrast", "echocardiography", "(", "r", "=", "0", ".", "58", ";", "p", "less", "than", "0", ".", "03", ")", ".", "Thus", ",", "myocardial", "contrast", "echocardiography", "can", "be", "used", "to", "visualize", "and", "quantitate", "the", "amount", "of", "jeopardized", "myocardium", "during", "moderate", "to", "severe", "degrees", "of", "coronary", "stenosis", ".", "The", "results", "obtained", "show", "a", "correlation", "with", "the", "anatomic", "area", "at", "risk", "similar", "to", "that", "obtained", "with", "thallium", "-", "201", "SPECT", "."]], "ner": [[[194, 194, "Chemical"], [243, 243, "Chemical"], [292, 292, "Chemical"], [59, 59, "Disease"], [197, 197, "Disease"], [246, 246, "Disease"], [295, 295, "Disease"], [18, 18, "Chemical"], [123, 123, "Chemical"], [278, 278, "Chemical"], [390, 390, "Chemical"], [13, 14, "Disease"], [53, 54, "Disease"], [93, 94, "Disease"], [207, 208, "Disease"], [370, 371, "Disease"], [48, 49, "Disease"], [143, 144, "Disease"]]], "relations": [[[194, 194, 59, 59, "CID"], [194, 194, 197, 197, "CID"], [194, 194, 246, 246, "CID"], [194, 194, 295, 295, "CID"], [243, 243, 59, 59, "CID"], [243, 243, 197, 197, "CID"], [243, 243, 246, 246, "CID"], [243, 243, 295, 295, "CID"], [292, 292, 59, 59, "CID"], [292, 292, 197, 197, "CID"], [292, 292, 246, 246, "CID"], [292, 292, 295, 295, "CID"]]], "clusters": [], "translated": "心肌造影超声心动图观察到的灌注缺陷与<11>冠状动脉狭窄</11>严重程度的关系：与<7>铊</7>-201单光子发射断层扫描的相关性。 先前已经表明，心肌造影超声心动图是一种有价值的技术，用于描绘继发于<16>冠状动脉闭塞</16>和严重<12>冠状动脉狭窄</12>的心肌灌注不足区域<3>充血</3>刺激。本研究的目的是确定使用稳定的超声处理白蛋白溶液进行的心肌造影超声心动图是否可以检测出由不同程度的<13>冠状动脉狭窄</13>引起的心肌灌注不足区域。将16只开胸犬产生的灌注缺损与死后双灌注技术和<8>铊</8>-201单光子发射断层扫描(SPECT)测量的危险解剖区域进行了比较。在瞬时(20秒)<17>冠状动脉闭塞 </17>期间，在产生闭塞的15只狗中，有14只通过造影超声心动图观察到灌注缺损。灌注缺陷与处于危险中的解剖区域显着相关(r=0.74；p小于0.002)。在<0>双嘧达莫</0>诱导的<4>充血</4>期间，16只患有部分<14>冠状动脉狭窄</14>的狗中有12只通过造影超声心动图显示可见的低灌注区域。没有灌注缺陷的四只犬有狭窄，导致<1>双嘧达莫</1>引起的<5>充血</5>轻度（0%至50%）减少。狭窄期间灌注缺损的大小与处于危险中的解剖区域显着相关(r=0.61；p=0.02)。<9>铊</9>-201 SPECT显示所有14只狗在<2>双嘧达莫</2>诱导的<6>充血</6>期间都存在灌注缺陷；灌注缺损的大小与处于危险中的解剖区域相关(r=0.58；p小于0.03)并且与对比超声心动图的灌注缺损相关(r=0.58；p小于0.03)。因此，心肌造影超声心动图可用于在中度至重度<15>冠状动脉狭窄</15>期间观察和量化受损心肌的数量。获得的结果显示与危险解剖区域的相关性类似于使用<10>铊</10>-201 SPECT获得的结果。", "revised": true}
{"doc_key": "8586822", "sentences": [["Contribution", "of", "the", "sympathetic", "nervous", "system", "to", "salt", "-", "sensitivity", "in", "lifetime", "captopril", "-", "treated", "spontaneously", "hypertensive", "rats", ".", "OBJECTIVE", ":", "To", "test", "the", "hypothesis", "that", ",", "in", "lifetime", "captopril", "-", "treated", "spontaneously", "hypertensive", "rats", "(", "SHR", ")", ",", "the", "sympathetic", "nervous", "system", "contributes", "importantly", "to", "the", "hypertensive", "effect", "of", "dietary", "sodium", "chloride", "supplementation", ".", "METHODS", ":", "Male", "SHR", "(", "aged", "6", "weeks", ")", "that", "had", "been", "treated", "from", "conception", "onward", "with", "either", "captopril", "or", "vehicle", "remained", "on", "a", "basal", "sodium", "chloride", "diet", "or", "were", "fed", "a", "high", "sodium", "chloride", "diet", ".", "After", "2", "weeks", ",", "the", "rats", "were", "subjected", "to", "ganglionic", "blockade", "and", "2", "days", "later", ",", "an", "infusion", "of", "clonidine", ".", "RESULTS", ":", "Lifetime", "captopril", "treatment", "significantly", "lowered", "mean", "arterial", "pressure", "in", "both", "groups", ".", "Intravenous", "infusion", "of", "the", "ganglionic", "blocker", "hexamethonium", "resulted", "in", "a", "rapid", "decline", "in", "MAP", "that", "eliminated", "the", "dietary", "sodium", "chloride", "-", "induced", "increase", "in", "MAP", "in", "both", "groups", ".", "Infusion", "of", "the", "central", "nervous", "system", "alpha2", "-", "adrenergic", "receptor", "agonist", "clonidine", "also", "resulted", "in", "a", "greater", "reduction", "in", "MAP", "in", "both", "groups", "of", "SHR", "that", "were", "fed", "the", "high", "(", "compared", "with", "the", "basal", ")", "sodium", "chloride", "diet", ".", "CONCLUSIONS", ":", "In", "both", "lifetime", "captopril", "-", "treated", "and", "control", "SHR", ",", "the", "sympathetic", "nervous", "system", "contributes", "to", "the", "pressor", "effects", "of", "a", "high", "sodium", "chloride", "diet", "."]], "ner": [[[50, 52, "Chemical"], [144, 146, "Chemical"], [16, 16, "Disease"], [33, 33, "Disease"], [47, 47, "Disease"], [149, 151, "Disease"], [12, 12, "Chemical"], [29, 29, "Chemical"], [73, 73, "Chemical"], [116, 116, "Chemical"], [201, 201, "Chemical"], [80, 81, "Chemical"], [88, 89, "Chemical"], [192, 193, "Chemical"], [220, 221, "Chemical"], [111, 111, "Chemical"], [167, 167, "Chemical"], [133, 133, "Chemical"], [162, 166, "Chemical"]]], "relations": [[[50, 52, 16, 16, "CID"], [50, 52, 33, 33, "CID"], [50, 52, 47, 47, "CID"], [50, 52, 149, 151, "CID"], [144, 146, 16, 16, "CID"], [144, 146, 33, 33, "CID"], [144, 146, 47, 47, "CID"], [144, 146, 149, 151, "CID"]]], "clusters": [], "translated": "交感神经系统对终生<6>卡托普利</6>治疗自发性<2>高血压</2>大鼠盐敏感性的贡献 - 目的是检验假设：在终生<7>卡托普利</7>治疗的自发性<3>高血压</3>大鼠(SHR)中，交感神经系统对<4>高血压</4>的影响与<0>膳食氯化钠</0>的补充程度相关。方法：在受孕时开始治疗的雄性SHR(6周龄)，接受<8>卡托普利</8>或赋形剂治疗，维持基础<11>氯化钠</11>饮食或高水平<12>氯化钠</12>饮食。2周后，对大鼠进行神经节阻滞，2天后，输注<15>可乐定</15>。结果：终生<9>卡托普利</9>治疗显著降低了两组的平均动脉压。静脉输注神经节阻滞剂<17>六甲铵</17>导致MAP迅速下降，在两组中消除了<1> 膳食氯化钠 </1>诱导的<5>增加</5>的作用。输注中枢<18>α2-肾上腺素能受体激动剂</18><16>可乐定</16>，在两组高(<13>氯化钠</13>饮食)SHR中，对MAP的降低更明显。结论：在终生<10>卡托普利</10>治疗组和对照SHR中，交感神经系统都有助于高<14>氯化钠</14>饮食的升压作用。", "revised": true}
{"doc_key": "20973483", "sentences": [["In", "vivo", "characterization", "of", "a", "dual", "adenosine", "A2A", "/", "A1", "receptor", "antagonist", "in", "animal", "models", "of", "Parkinson", "'s", "disease", ".", "The", "in", "vivo", "characterization", "of", "a", "dual", "adenosine", "A", "(", "2A", ")", "/", "A", "(", "1", ")", "receptor", "antagonist", "in", "several", "animal", "models", "of", "Parkinson", "'s", "disease", "is", "described", ".", "Discovery", "and", "scale", "-", "up", "syntheses", "of", "compound", "1", "are", "described", "in", "detail", ",", "highlighting", "optimization", "steps", "that", "increased", "the", "overall", "yield", "of", "1", "from", "10", ".", "0", "%", "to", "30", ".", "5", "%", ".", "Compound", "1", "is", "a", "potent", "A", "(", "2A", ")", "/", "A", "(", "1", ")", "receptor", "antagonist", "in", "vitro", "(", "A", "(", "2A", ")", "K", "(", "i", ")", "=", "4", ".", "1", "nM", ";", "A", "(", "1", ")", "K", "(", "i", ")", "=", "17", ".", "0", "nM", ")", "that", "has", "excellent", "activity", ",", "after", "oral", "administration", ",", "across", "a", "number", "of", "animal", "models", "of", "Parkinson", "'s", "disease", "including", "mouse", "and", "rat", "models", "of", "haloperidol", "-", "induced", "catalepsy", ",", "mouse", "model", "of", "reserpine", "-", "induced", "akinesia", ",", "rat", "6", "-", "hydroxydopamine", "(", "6", "-", "OHDA", ")", "lesion", "model", "of", "drug", "-", "induced", "rotation", ",", "and", "MPTP", "-", "treated", "non", "-", "human", "primate", "model", "."]], "ner": [[[157, 157, "Chemical"], [160, 160, "Disease"], [165, 165, "Chemical"], [168, 168, "Disease"], [6, 11, "Chemical"], [27, 38, "Chemical"], [16, 18, "Disease"], [44, 46, "Disease"], [148, 150, "Disease"], [171, 173, "Chemical"], [175, 177, "Chemical"], [188, 188, "Chemical"]]], "relations": [[[157, 157, 160, 160, "CID"], [165, 165, 168, 168, "CID"]]], "clusters": [], "translated": "在<6>帕金森病</6>动物模型中双重<4>腺苷A2A/A1受体拮抗剂</4>的体内表征。描述了<7>帕金森病</7>的几种动物模型中双重<5>腺苷A(2A)/A(1)受体拮抗剂</5>的体内表征。详细描述了化合物1的发现和放大合成，重点介绍了将1的总产量从10.0%提高到30.5%的优化步骤。化合物1在体外是一种有效的A(2A)/A(1)受体拮抗剂（A(2A)K(i)=4.1 nM；A(1)K(i)=17.0 nM），口服给药后，跨越多个<8>帕金森病</8>动物模型，包括<0>氟哌啶醇</0>诱导的<1>强直性昏厥</1>小鼠和大鼠模型，小鼠<2>利血平致</2><3>运动不能</3>模型，大鼠<9>6-羟基多巴胺</9>（<10>6-OHDA</10>）药物性损伤模型旋转和<11>MPTP</11>处理的非人类灵长类动物模型。", "revised": true}
{"doc_key": "17965424", "sentences": [["Gastrointestinal", "tolerability", "of", "etoricoxib", "in", "rheumatoid", "arthritis", "patients", ":", "results", "of", "the", "etoricoxib", "vs", "diclofenac", "sodium", "gastrointestinal", "tolerability", "and", "effectiveness", "trial", "(", "EDGE", "-", "II", ")", ".", "OBJECTIVE", ":", "A", "randomised", ",", "double", "-", "blind", "study", "to", "compare", "the", "gastrointestinal", "(", "GI", ")", "tolerability", ",", "safety", "and", "efficacy", "of", "etoricoxib", "and", "diclofenac", "in", "patients", "with", "rheumatoid", "arthritis", "(", "RA", ")", ".", "PATIENTS", "AND", "METHODS", ":", "A", "total", "of", "4086", "patients", "(", "mean", "age", "60", ".", "8", "years", ")", "diagnosed", "with", "RA", "were", "enrolled", "and", "received", "etoricoxib", "90", "mg", "daily", "(", "n", "=", "2032", ")", "or", "diclofenac", "75", "mg", "twice", "daily", "(", "n", "=", "2054", ")", ".", "Use", "of", "gastroprotective", "agents", "and", "low", "-", "dose", "aspirin", "was", "allowed", ".", "The", "prespecified", "primary", "end", "point", "consisted", "of", "the", "cumulative", "rate", "of", "patient", "discontinuations", "due", "to", "clinical", "and", "laboratory", "GI", "adverse", "experiences", "(", "AEs", ")", ".", "General", "safety", "was", "also", "assessed", ",", "including", "adjudicated", "thrombotic", "cardiovascular", "event", "data", ".", "Efficacy", "was", "evaluated", "using", "the", "Patient", "Global", "Assessment", "of", "Disease", "Status", "(", "PGADS", ";", "0", "-", "4", "point", "scale", ")", ".", "RESULTS", ":", "Mean", "(", "SD", ";", "maximum", ")", "duration", "of", "treatment", "was", "19", ".", "3", "(", "10", ".", "3", ";", "32", ".", "9", ")", "and", "19", ".", "1", "(", "10", ".", "4", ";", "33", ".", "1", ")", "months", "in", "the", "etoricoxib", "and", "diclofenac", "groups", ",", "respectively", ".", "The", "cumulative", "discontinuation", "rate", "due", "to", "GI", "AEs", "was", "significantly", "lower", "with", "etoricoxib", "than", "diclofenac", "(", "5", ".", "2", "vs", "8", ".", "5", "events", "per", "100", "patient", "-", "years", ",", "respectively", ";", "hazard", "ratio", "0", ".", "62", "(", "95", "%", "CI", ":", "0", ".", "47", ",", "0", ".", "81", ";", "p", "<", "or", "=", "0", ".", "001", ")", ")", ".", "The", "incidence", "of", "discontinuations", "for", "hypertension", "-", "related", "and", "oedema", "-", "related", "AEs", "were", "significantly", "higher", "with", "etoricoxib", "(", "2", ".", "5", "%", "and", "1", ".", "1", "%", "respectively", ")", "compared", "with", "diclofenac", "(", "1", ".", "5", "%", "and", "0", ".", "4", "%", "respectively", ";", "p", "<", "0", ".", "001", "for", "hypertension", "and", "p", "<", "0", ".", "01", "for", "oedema", ")", ".", "Etoricoxib", "and", "diclofenac", "treatment", "resulted", "in", "similar", "efficacy", "(", "PGADS", "mean", "changes", "from", "baseline", "-", "0", ".", "62", "vs", "-", "0", ".", "58", ",", "respectively", ")", ".", "CONCLUSIONS", ":", "Etoricoxib", "90", "mg", "demonstrated", "a", "significantly", "lower", "risk", "for", "discontinuing", "treatment", "due", "to", "GI", "AEs", "compared", "with", "diclofenac", "150", "mg", ".", "Discontinuations", "from", "renovascular", "AEs", ",", "although", "less", "common", "than", "discontinuations", "from", "GI", "AEs", ",", "were", "significantly", "higher", "with", "etoricoxib", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [49, 49, "Chemical"], [85, 85, "Chemical"], [217, 217, "Chemical"], [236, 236, "Chemical"], [301, 301, "Chemical"], [346, 346, "Chemical"], [375, 375, "Chemical"], [414, 414, "Chemical"], [289, 289, "Disease"], [335, 335, "Disease"], [293, 293, "Disease"], [343, 343, "Disease"], [14, 15, "Chemical"], [51, 51, "Chemical"], [95, 95, "Chemical"], [219, 219, "Chemical"], [238, 238, "Chemical"], [316, 316, "Chemical"], [348, 348, "Chemical"], [392, 392, "Chemical"], [230, 231, "Disease"], [388, 389, "Disease"], [407, 408, "Disease"], [5, 6, "Disease"], [55, 56, "Disease"], [58, 58, "Disease"], [80, 80, "Disease"], [151, 152, "Disease"], [114, 114, "Chemical"]]], "relations": [[[3, 3, 289, 289, "CID"], [3, 3, 335, 335, "CID"], [12, 12, 289, 289, "CID"], [12, 12, 335, 335, "CID"], [49, 49, 289, 289, "CID"], [49, 49, 335, 335, "CID"], [85, 85, 289, 289, "CID"], [85, 85, 335, 335, "CID"], [217, 217, 289, 289, "CID"], [217, 217, 335, 335, "CID"], [236, 236, 289, 289, "CID"], [236, 236, 335, 335, "CID"], [301, 301, 289, 289, "CID"], [301, 301, 335, 335, "CID"], [346, 346, 289, 289, "CID"], [346, 346, 335, 335, "CID"], [375, 375, 289, 289, "CID"], [375, 375, 335, 335, "CID"], [414, 414, 289, 289, "CID"], [414, 414, 335, 335, "CID"], [3, 3, 293, 293, "CID"], [3, 3, 343, 343, "CID"], [12, 12, 293, 293, "CID"], [12, 12, 343, 343, "CID"], [49, 49, 293, 293, "CID"], [49, 49, 343, 343, "CID"], [85, 85, 293, 293, "CID"], [85, 85, 343, 343, "CID"], [217, 217, 293, 293, "CID"], [217, 217, 343, 343, "CID"], [236, 236, 293, 293, "CID"], [236, 236, 343, 343, "CID"], [301, 301, 293, 293, "CID"], [301, 301, 343, 343, "CID"], [346, 346, 293, 293, "CID"], [346, 346, 343, 343, "CID"], [375, 375, 293, 293, "CID"], [375, 375, 343, 343, "CID"], [414, 414, 293, 293, "CID"], [414, 414, 343, 343, "CID"], [14, 15, 230, 231, "CID"], [14, 15, 388, 389, "CID"], [14, 15, 407, 408, "CID"], [51, 51, 230, 231, "CID"], [51, 51, 388, 389, "CID"], [51, 51, 407, 408, "CID"], [95, 95, 230, 231, "CID"], [95, 95, 388, 389, "CID"], [95, 95, 407, 408, "CID"], [219, 219, 230, 231, "CID"], [219, 219, 388, 389, "CID"], [219, 219, 407, 408, "CID"], [238, 238, 230, 231, "CID"], [238, 238, 388, 389, "CID"], [238, 238, 407, 408, "CID"], [316, 316, 230, 231, "CID"], [316, 316, 388, 389, "CID"], [316, 316, 407, 408, "CID"], [348, 348, 230, 231, "CID"], [348, 348, 388, 389, "CID"], [348, 348, 407, 408, "CID"], [392, 392, 230, 231, "CID"], [392, 392, 388, 389, "CID"], [392, 392, 407, 408, "CID"]]], "clusters": [], "translated": "<0>依托考昔</0>在<25>类风湿性关节炎</25>患者中的胃肠道耐受性：<1>依托考昔</1>与<14>双氯芬酸钠</14>胃肠道耐受性和有效性试验的结果（边缘二）。目的：一项随机、双盲研究，旨在比较<2>依托考昔</2>和<15>双氯芬酸</15> 在<26>类风湿性关节炎</26>患者(<27>RA</27>)中的胃肠道(GI)耐受性、安全性和有效性。患者和方法:共有4086 名诊断为<28>RA</28>的患者（平均年龄 60 . 8 岁）入组并接受<3>依托考昔</3>90 mg每天(n=2032)或<16>双氯芬酸</16>75 毫克，每天两次(n=2054)。允许使用胃保护剂和低剂量<30>阿司匹林</30>。预先指定的主要终点包括患者因临床和实验室胃肠道不良反应(AE)而停药的累积率。还评估了一般安全性，包括裁定的<29>血栓性心血管</29>事件数据。使用患者疾病状态总体评估（PGADS；0-4 分制）评估疗效。结果：平均(SD；最大）治疗持续时间为19.3(10.3；32.9)和19.1(10.4；33.1)个月在<4>依托考昔</4>和<17>双氯芬酸</17>组中。<5>依托考昔</5>组中由于<22>GI AEs</22>而停药的累积率显著低于<18>双氯芬酸</18>组(5.2对8.5事件/100患者-年，分别；风险比0.62(95%CI:0.47,0.81; p<或=0.001))。<6>依托考昔</6>引起的<10>高血压</10>相关和<12>水肿</12>相关AE的停药率分别显著高于<19>双氯芬酸</19>(分别为1.5%和0.4%;<11>高血压</11>p<0.001和<13>水肿</13>p<0.01)。<7>依托考昔</7>和<20>双氯芬酸</20>治疗产生的疗效相似（PGADS相对于基线的平均变化分别为0.62和0.58）。结论：<8>依托考昔</8> 90 mg显著降低了因<23>GI AEs</23>而停止治疗的风险，相比之下，<21>双氯芬酸</21>150 mg的停药率更高。尽管与<24>GI AEs</24>的停药相比，肾血管AE的停药率较低，但<9>依托考昔</9>的停药显著更高。", "revised": true}
{"doc_key": "20705401", "sentences": [["Serotonin", "6", "receptor", "gene", "is", "associated", "with", "methamphetamine", "-", "induced", "psychosis", "in", "a", "Japanese", "population", ".", "BACKGROUND", ":", "Altered", "serotonergic", "neural", "transmission", "is", "hypothesized", "to", "be", "a", "susceptibility", "factor", "for", "psychotic", "disorders", "such", "as", "schizophrenia", ".", "The", "serotonin", "6", "(", "5", "-", "HT6", ")", "receptor", "is", "therapeutically", "targeted", "by", "several", "second", "generation", "antipsychotics", ",", "such", "as", "clozapine", "and", "olanzapine", ",", "and", "d", "-", "amphetamine", "-", "induced", "hyperactivity", "in", "rats", "is", "corrected", "with", "the", "use", "of", "a", "selective", "5", "-", "HT6", "receptor", "antagonist", ".", "In", "addition", ",", "the", "disrupted", "prepulse", "inhibition", "induced", "by", "d", "-", "amphetamine", "or", "phencyclidine", "was", "restored", "by", "5", "-", "HT6", "receptor", "antagonist", "in", "an", "animal", "study", "using", "rats", ".", "These", "animal", "models", "were", "considered", "to", "reflect", "the", "positive", "symptoms", "of", "schizophrenia", ",", "and", "the", "above", "evidence", "suggests", "that", "altered", "5", "-", "HT6", "receptors", "are", "involved", "in", "the", "pathophysiology", "of", "psychotic", "disorders", ".", "The", "symptoms", "of", "methamphetamine", "(", "METH", ")", "-", "induced", "psychosis", "are", "similar", "to", "those", "of", "paranoid", "type", "schizophrenia", ".", "Therefore", ",", "we", "conducted", "an", "analysis", "of", "the", "association", "of", "the", "5", "-", "HT6", "gene", "(", "HTR6", ")", "with", "METH", "-", "induced", "psychosis", ".", "METHOD", ":", "Using", "five", "tagging", "SNPs", "(", "rs6693503", ",", "rs1805054", ",", "rs4912138", ",", "rs3790757", "and", "rs9659997", ")", ",", "we", "conducted", "a", "genetic", "association", "analysis", "of", "case", "-", "control", "samples", "(", "197", "METH", "-", "induced", "psychosis", "patients", "and", "337", "controls", ")", "in", "the", "Japanese", "population", ".", "The", "age", "and", "sex", "of", "the", "control", "subjects", "did", "not", "differ", "from", "those", "of", "the", "methamphetamine", "dependence", "patients", ".", "RESULTS", ":", "rs6693503", "was", "associated", "with", "METH", "-", "induced", "psychosis", "patients", "in", "the", "allele", "/", "genotype", "-", "wise", "analysis", ".", "Moreover", ",", "this", "association", "remained", "significant", "after", "Bonferroni", "correction", ".", "In", "the", "haplotype", "-", "wise", "analysis", ",", "we", "detected", "an", "association", "between", "two", "markers", "(", "rs6693503", "and", "rs1805054", ")", "and", "three", "markers", "(", "rs6693503", ",", "rs1805054", "and", "rs4912138", ")", "in", "HTR6", "and", "METH", "-", "induced", "psychosis", "patients", ",", "respectively", ".", "CONCLUSION", ":", "HTR6", "may", "play", "an", "important", "role", "in", "the", "pathophysiology", "of", "METH", "-", "induced", "psychosis", "in", "the", "Japanese", "population", "."]], "ner": [[[7, 7, "Chemical"], [148, 148, "Chemical"], [150, 150, "Chemical"], [183, 183, "Chemical"], [219, 219, "Chemical"], [248, 248, "Chemical"], [258, 258, "Chemical"], [314, 314, "Chemical"], [334, 334, "Chemical"], [10, 10, "Disease"], [30, 31, "Disease"], [142, 143, "Disease"], [154, 154, "Disease"], [186, 186, "Disease"], [222, 222, "Disease"], [261, 261, "Disease"], [317, 317, "Disease"], [337, 337, "Disease"], [0, 0, "Chemical"], [37, 37, "Chemical"], [40, 42, "Chemical"], [77, 79, "Chemical"], [100, 102, "Chemical"], [132, 134, "Chemical"], [175, 177, "Chemical"], [34, 34, "Disease"], [123, 123, "Disease"], [66, 66, "Disease"], [160, 162, "Disease"], [56, 56, "Chemical"], [58, 58, "Chemical"], [61, 63, "Chemical"], [92, 94, "Chemical"], [96, 96, "Chemical"]]], "relations": [[[7, 7, 10, 10, "CID"], [7, 7, 30, 31, "CID"], [7, 7, 142, 143, "CID"], [7, 7, 154, 154, "CID"], [7, 7, 186, 186, "CID"], [7, 7, 222, 222, "CID"], [7, 7, 261, 261, "CID"], [7, 7, 317, 317, "CID"], [7, 7, 337, 337, "CID"], [148, 148, 10, 10, "CID"], [148, 148, 30, 31, "CID"], [148, 148, 142, 143, "CID"], [148, 148, 154, 154, "CID"], [148, 148, 186, 186, "CID"], [148, 148, 222, 222, "CID"], [148, 148, 261, 261, "CID"], [148, 148, 317, 317, "CID"], [148, 148, 337, 337, "CID"], [150, 150, 10, 10, "CID"], [150, 150, 30, 31, "CID"], [150, 150, 142, 143, "CID"], [150, 150, 154, 154, "CID"], [150, 150, 186, 186, "CID"], [150, 150, 222, 222, "CID"], [150, 150, 261, 261, "CID"], [150, 150, 317, 317, "CID"], [150, 150, 337, 337, "CID"], [183, 183, 10, 10, "CID"], [183, 183, 30, 31, "CID"], [183, 183, 142, 143, "CID"], [183, 183, 154, 154, "CID"], [183, 183, 186, 186, "CID"], [183, 183, 222, 222, "CID"], [183, 183, 261, 261, "CID"], [183, 183, 317, 317, "CID"], [183, 183, 337, 337, "CID"], [219, 219, 10, 10, "CID"], [219, 219, 30, 31, "CID"], [219, 219, 142, 143, "CID"], [219, 219, 154, 154, "CID"], [219, 219, 186, 186, "CID"], [219, 219, 222, 222, "CID"], [219, 219, 261, 261, "CID"], [219, 219, 317, 317, "CID"], [219, 219, 337, 337, "CID"], [248, 248, 10, 10, "CID"], [248, 248, 30, 31, "CID"], [248, 248, 142, 143, "CID"], [248, 248, 154, 154, "CID"], [248, 248, 186, 186, "CID"], [248, 248, 222, 222, "CID"], [248, 248, 261, 261, "CID"], [248, 248, 317, 317, "CID"], [248, 248, 337, 337, "CID"], [258, 258, 10, 10, "CID"], [258, 258, 30, 31, "CID"], [258, 258, 142, 143, "CID"], [258, 258, 154, 154, "CID"], [258, 258, 186, 186, "CID"], [258, 258, 222, 222, "CID"], [258, 258, 261, 261, "CID"], [258, 258, 317, 317, "CID"], [258, 258, 337, 337, "CID"], [314, 314, 10, 10, "CID"], [314, 314, 30, 31, "CID"], [314, 314, 142, 143, "CID"], [314, 314, 154, 154, "CID"], [314, 314, 186, 186, "CID"], [314, 314, 222, 222, "CID"], [314, 314, 261, 261, "CID"], [314, 314, 317, 317, "CID"], [314, 314, 337, 337, "CID"], [334, 334, 10, 10, "CID"], [334, 334, 30, 31, "CID"], [334, 334, 142, 143, "CID"], [334, 334, 154, 154, "CID"], [334, 334, 186, 186, "CID"], [334, 334, 222, 222, "CID"], [334, 334, 261, 261, "CID"], [334, 334, 317, 317, "CID"], [334, 334, 337, 337, "CID"]]], "clusters": [], "translated": "<18>血清素</18> 6 受体基因与<0>甲基苯丙胺</0>诱发的<9>精神病</9>在日本人群中相关。背景：改变的<19>5-羟色胺</19>能神经传递被假设为<10>精神病</10>，如<25>精神分裂症</25>的易感因素。 <20>5-HT6</20>受体是一些第二代抗精神病药的治疗靶点，例如<29>氯氮平</29>和<30>奥氮平</30>，<31>d-安非他明</31>诱发的大鼠<27>多动症</27>通过使用选择性<21>5-HT6</21>受体拮抗剂得到纠正。此外，在一项使用大鼠的动物研究中，<22>5-HT6</22>受体拮抗剂恢复了<32>d-安非他明</32>或<33>苯环己哌啶</33>诱导的中断前脉冲抑制。这些动物模型被认为反映了<26>精神分裂症</26>的阳性症状，上述证据表明改变的<23>5-HT6</23>受体参与了<11>精神障碍</11>。<1>甲基苯丙胺</1>（<2>METH</2>）诱发的<12>精神病</12>的症状与<28>偏执型精神分裂症</28>的症状相似。因此，我们分析了<24>5-HT6</24>基因（HTR6）与<3>METH</3>诱发的<13>精神病</13>的关系。方法：使用五个标记SNP（rs6693503、rs1805054、rs4912138、rs3790757和rs9659997），我们在日本人口中对病例对照样本（197名<4>METH</4>-诱发的<14>精神病</14>患者和337个对照）进行了遗传关联分析。对照对象的年龄和性别与<5>甲基苯丙胺</5>依赖患者没有差异。结果：在等位基因/基因型分析中，rs6693503与<6>METH</6>诱发的<15>精神病</15>患者相关。此外，这种关联在Bonferroni校正后仍然显着。在单倍型分析中，我们检测到两个标记（rs6693503和rs1805054）和三个标记（rs6693503、rs1805054和rs4912138）在HTR6和<7>METH</7>诱导的<16>精神病</16>患者之间的关联。结论：HTR6可能在日本人群<8>METH</8>诱发的<17>精神病</17>的病理生理学中起重要作用。", "revised": true}
{"doc_key": "19370593", "sentences": [["Long", "term", "hormone", "therapy", "for", "perimenopausal", "and", "postmenopausal", "women", ".", "BACKGROUND", ":", "Hormone", "therapy", "(", "HT", ")", "is", "widely", "used", "for", "controlling", "menopausal", "symptoms", "and", "has", "also", "been", "used", "for", "the", "management", "and", "prevention", "of", "cardiovascular", "disease", ",", "osteoporosis", "and", "dementia", "in", "older", "women", ".", "This", "is", "an", "updated", "version", "of", "the", "original", "Cochrane", "review", "first", "published", "in", "2005", ".", "OBJECTIVES", ":", "To", "assess", "the", "effect", "of", "long", "-", "term", "HT", "on", "mortality", ",", "cardiovascular", "outcomes", ",", "cancer", ",", "gallbladder", "disease", ",", "cognition", ",", "fractures", "and", "quality", "of", "life", ".", "SEARCH", "STRATEGY", ":", "We", "searched", "the", "following", "databases", "to", "November", "2007", ":", "Trials", "Register", "of", "the", "Cochrane", "Menstrual", "Disorders", "and", "Subfertility", "Group", ",", "Cochrane", "Central", "Register", "of", "Controlled", "Trials", ",", "MEDLINE", ",", "EMBASE", ",", "Biological", "Abstracts", ".", "Also", "relevant", "non", "-", "indexed", "journals", "and", "conference", "abstracts", ".", "SELECTION", "CRITERIA", ":", "Randomised", "double", "-", "blind", "trials", "of", "HT", "versus", "placebo", ",", "taken", "for", "at", "least", "one", "year", "by", "perimenopausal", "or", "postmenopausal", "women", ".", "HT", "included", "oestrogens", ",", "with", "or", "without", "progestogens", ",", "via", "oral", ",", "transdermal", ",", "subcutaneous", "or", "transnasal", "routes", ".", "DATA", "COLLECTION", "AND", "ANALYSIS", ":", "Two", "authors", "independently", "assessed", "trial", "quality", "and", "extracted", "data", ".", "MAIN", "RESULTS", ":", "Nineteen", "trials", "involving", "41", ",", "904", "women", "were", "included", ".", "In", "relatively", "healthy", "women", ",", "combined", "continuous", "HT", "significantly", "increased", "the", "risk", "of", "venous", "thrombo", "-", "embolism", "or", "coronary", "event", "(", "after", "one", "year", "'s", "use", ")", ",", "stroke", "(", "after", "three", "years", ")", ",", "breast", "cancer", "and", "gallbladder", "disease", ".", "Long", "-", "term", "oestrogen", "-", "only", "HT", "significantly", "increased", "the", "risk", "of", "venous", "thrombo", "-", "embolism", ",", "stroke", "and", "gallbladder", "disease", "(", "after", "one", "to", "two", "years", ",", "three", "years", "and", "seven", "years", "'", "use", "respectively", ")", ",", "but", "did", "not", "significantly", "increase", "the", "risk", "of", "breast", "cancer", ".", "The", "only", "statistically", "significant", "benefits", "of", "HT", "were", "a", "decreased", "incidence", "of", "fractures", "and", "(", "for", "combined", "HT", ")", "colon", "cancer", ",", "with", "long", "-", "term", "use", ".", "Among", "women", "aged", "over", "65", "who", "were", "relatively", "healthy", "(", "i", ".", "e", ".", "generally", "fit", ",", "without", "overt", "disease", ")", "and", "taking", "continuous", "combined", "HT", ",", "there", "was", "a", "statistically", "significant", "increase", "in", "the", "incidence", "of", "dementia", ".", "Among", "women", "with", "cardiovascular", "disease", ",", "long", "-", "term", "use", "of", "combined", "continuous", "HT", "significantly", "increased", "the", "risk", "of", "venous", "thrombo", "-", "embolism", ".", "One", "trial", "analysed", "subgroups", "of", "2839", "relatively", "healthy", "50", "to", "59", "year", "old", "women", "taking", "combined", "continuous", "HT", "and", "1637", "taking", "oestrogen", "-", "only", "HT", ",", "versus", "similar", "-", "sized", "placebo", "groups", ".", "The", "only", "significantly", "increased", "risk", "reported", "was", "for", "venous", "thrombo", "-", "embolism", "in", "women", "taking", "combined", "continuous", "HT", ":", "their", "absolute", "risk", "remained", "low", ",", "at", "less", "than", "1", "/", "500", ".", "However", ",", "this", "study", "was", "not", "powered", "to", "detect", "differences", "between", "groups", "of", "younger", "women", ".", "AUTHORS", "'", "CONCLUSIONS", ":", "HT", "is", "not", "indicated", "for", "the", "routine", "management", "of", "chronic", "disease", ".", "We", "need", "more", "evidence", "on", "the", "safety", "of", "HT", "for", "menopausal", "symptom", "control", ",", "though", "short", "-", "term", "use", "appears", "to", "be", "relatively", "safe", "for", "healthy", "younger", "women", "."]], "ner": [[[164, 164, "Chemical"], [253, 253, "Chemical"], [411, 411, "Chemical"], [40, 40, "Disease"], [364, 364, "Disease"], [169, 169, "Chemical"], [79, 80, "Disease"], [247, 248, "Disease"], [269, 270, "Disease"], [222, 225, "Disease"], [262, 265, "Disease"], [385, 388, "Disease"], [431, 434, "Disease"], [237, 237, "Disease"], [267, 267, "Disease"], [35, 36, "Disease"], [369, 370, "Disease"], [38, 38, "Disease"], [77, 77, "Disease"], [84, 84, "Disease"], [311, 311, "Disease"], [107, 108, "Disease"], [244, 245, "Disease"], [296, 297, "Disease"], [318, 319, "Disease"]]], "relations": [[[164, 164, 40, 40, "CID"], [164, 164, 364, 364, "CID"], [253, 253, 40, 40, "CID"], [253, 253, 364, 364, "CID"], [411, 411, 40, 40, "CID"], [411, 411, 364, 364, "CID"], [169, 169, 40, 40, "CID"], [169, 169, 364, 364, "CID"], [164, 164, 79, 80, "CID"], [164, 164, 247, 248, "CID"], [164, 164, 269, 270, "CID"], [253, 253, 79, 80, "CID"], [253, 253, 247, 248, "CID"], [253, 253, 269, 270, "CID"], [411, 411, 79, 80, "CID"], [411, 411, 247, 248, "CID"], [411, 411, 269, 270, "CID"], [164, 164, 222, 225, "CID"], [164, 164, 262, 265, "CID"], [164, 164, 385, 388, "CID"], [164, 164, 431, 434, "CID"], [253, 253, 222, 225, "CID"], [253, 253, 262, 265, "CID"], [253, 253, 385, 388, "CID"], [253, 253, 431, 434, "CID"], [411, 411, 222, 225, "CID"], [411, 411, 262, 265, "CID"], [411, 411, 385, 388, "CID"], [411, 411, 431, 434, "CID"], [164, 164, 237, 237, "CID"], [164, 164, 267, 267, "CID"], [253, 253, 237, 237, "CID"], [253, 253, 267, 267, "CID"], [411, 411, 237, 237, "CID"], [411, 411, 267, 267, "CID"], [169, 169, 222, 225, "CID"], [169, 169, 262, 265, "CID"], [169, 169, 385, 388, "CID"], [169, 169, 431, 434, "CID"]]], "clusters": [], "translated": "围绝经期和绝经后妇女的长期激素治疗。背景：激素疗法 (HT) 广泛用于控制更年期症状，还用于管理和预防<15>心血管疾病</15>、<17>骨质疏松症</17>和<3>痴呆</3>在老年妇女中。这是2005年首次发表的原始Cochrane评价的更新版本。目标：评估长期HT对死亡率、心血管结局、<18>癌症</18>、<6>胆囊疾病</6>、认知、<19>骨折</19>和生活质量的影响。搜索策略：我们搜索了截至2007年11月的以下数据库：Cochrane<21>月经失调</21>和生育力低下组试验注册、Cochrane对照试验中央注册、MEDLINE、EMBASE、生物文摘。还有相关的非索引期刊和会议摘要。选择标准：HT与安慰剂的随机双盲试验，由围绝经期或绝经后妇女服用至少一年。HT包括<0>雌激素</0>，有或没有<5>孕激素</5>，通过口服、透皮、皮下或经鼻途径。数据收集与分析：两位作者独立评估试验质量并提取数据。主要结果：19项试验涉及41,904名女性。在相对健康的女性中，联合连续HT显着增加了<9>静脉血栓栓塞</9>或冠状动脉事件（使用一年后）、<13>中风</13>（三年后）的风险，<22>乳腺癌</22>和<7>胆囊疾病</7>。长期<1>雌激素</1>-仅HT会显著增加<10>静脉血栓栓塞</10>、<14>中风</14>和<8>胆囊疾病</8>的风险（分别使用一到两年、三年和七年后），但并未显著增加<23>乳腺癌</23>的风险。长期使用HT的唯一具有统计学意义的益处是<20>骨折</20>和（联合HT）<24>结肠癌</24>的发生率降低。在65岁以上且相对健康（即总体健康，无明显疾病）且持续服用联合HT的女性中，<4>痴呆</4>的发病率显着增加，具有统计学意义。在患有<16>心血管疾病</16>的女性中，长期联合连续HT会显著增加<11>静脉血栓栓塞</11>的风险。一项试验分析了亚组，其中2839名相对健康的50至59岁女性服用联合连续HT和1637名服用<2>雌激素</2>的女性，与人数相似的安慰剂组进行比较。报告的唯一显着增加的风险是<12>静脉血栓栓塞</12>在服用联合连续HT的女性中：她们的绝对风险仍然很低，低于1/500。然而，这项研究并不能检测出年轻女性群体之间的差异。作者的结论：HT不适用于慢性病的常规管理。我们需要更多关于HT用于绝经期症状控制的安全性的证据，尽管短期使用对于健康的年轻女性来说似乎是相对安全的。", "revised": true}
{"doc_key": "17511042", "sentences": [["An", "extremely", "rare", "case", "of", "delusional", "parasitosis", "in", "a", "chronic", "hepatitis", "C", "patient", "during", "pegylated", "interferon", "alpha", "-", "2b", "and", "ribavirin", "treatment", ".", "During", "treatment", "of", "chronic", "hepatitis", "C", "patients", "with", "interferon", "and", "ribavirin", ",", "a", "lot", "of", "side", "effects", "are", "described", ".", "Twenty", "-", "three", "percent", "to", "44", "%", "of", "patients", "develop", "depression", ".", "A", "minority", "of", "patients", "evolve", "to", "psychosis", ".", "To", "the", "best", "of", "our", "knowledge", ",", "no", "cases", "of", "psychogenic", "parasitosis", "occurring", "during", "interferon", "therapy", "have", "been", "described", "in", "the", "literature", ".", "We", "present", "a", "49", "-", "year", "-", "old", "woman", "who", "developed", "a", "delusional", "parasitosis", "during", "treatment", "with", "pegylated", "interferon", "alpha", "-", "2b", "weekly", "and", "ribavirin", ".", "She", "complained", "of", "seeing", "parasites", "and", "the", "larvae", "of", "fleas", "in", "her", "stools", ".", "This", "could", "not", "be", "confirmed", "by", "any", "technical", "examination", ".", "All", "the", "complaints", "disappeared", "after", "stopping", "pegylated", "interferon", "alpha", "-", "2b", "and", "reappeared", "after", "restarting", "it", ".", "She", "had", "a", "complete", "sustained", "viral", "response", "."]], "ner": [[[14, 18, "Chemical"], [103, 107, "Chemical"], [142, 146, "Chemical"], [5, 6, "Disease"], [73, 74, "Disease"], [98, 99, "Disease"], [20, 20, "Chemical"], [33, 33, "Chemical"], [110, 110, "Chemical"], [9, 11, "Disease"], [26, 28, "Disease"], [53, 53, "Disease"], [61, 61, "Disease"]]], "relations": [[[14, 18, 5, 6, "CID"], [14, 18, 73, 74, "CID"], [14, 18, 98, 99, "CID"], [103, 107, 5, 6, "CID"], [103, 107, 73, 74, "CID"], [103, 107, 98, 99, "CID"], [142, 146, 5, 6, "CID"], [142, 146, 73, 74, "CID"], [142, 146, 98, 99, "CID"], [20, 20, 5, 6, "CID"], [20, 20, 73, 74, "CID"], [20, 20, 98, 99, "CID"], [33, 33, 5, 6, "CID"], [33, 33, 73, 74, "CID"], [33, 33, 98, 99, "CID"], [110, 110, 5, 6, "CID"], [110, 110, 73, 74, "CID"], [110, 110, 98, 99, "CID"]]], "clusters": [], "translated": "<9>慢性丙型肝炎</9>患者在<0>聚乙二醇干扰素α-2b</0>和<6>利巴韦林</6>治疗期间发生了<3>妄想性寄生虫病</3>的极为罕见的病例。在<10>慢性丙型肝炎</10>患者应用干扰素和<7>利巴韦林</7>治疗过程中，出现了很多副作用。23%到44%的患者会出现<11>抑郁症</11>。少数患者会发展为<12>精神病</12>。据我们所知，文献中没有描述干扰素治疗期间发生<4>心因性寄生虫病</4>的病例。我们介绍了一名49岁的女性，她在接受<1>聚乙二醇干扰素α-2b</1>每周一次和<8>利巴韦林</8>治疗期间出现了<5>寄生虫妄想</5>。她抱怨在她的粪便中看到寄生虫和跳蚤幼虫。任何技术检查都无法证实这一点。停用<2>聚乙二醇干扰素α-2b</2>后所有症状均消失，重新服用后又出现。她有完全持续的病毒反应。", "revised": true}
{"doc_key": "16586083", "sentences": [["Cardiovascular", "risk", "with", "cyclooxygenase", "inhibitors", ":", "general", "problem", "with", "substance", "specific", "differences", "?", "Randomised", "clinical", "trials", "and", "observational", "studies", "have", "shown", "an", "increased", "risk", "of", "myocardial", "infarction", ",", "stroke", ",", "hypertension", "and", "heart", "failure", "during", "treatment", "with", "cyclooxygenase", "inhibitors", ".", "Adverse", "cardiovascular", "effects", "occurred", "mainly", ",", "but", "not", "exclusively", ",", "in", "patients", "with", "concomitant", "risk", "factors", ".", "Cyclooxygenase", "inhibitors", "cause", "complex", "changes", "in", "renal", ",", "vascular", "and", "cardiac", "prostanoid", "profiles", "thereby", "increasing", "vascular", "resistance", "and", "fluid", "retention", ".", "The", "incidence", "of", "cardiovascular", "adverse", "events", "tends", "to", "increase", "with", "the", "daily", "dose", "and", "total", "exposure", "time", ".", "A", "comparison", "of", "individual", "selective", "and", "unselective", "cyclooxygenase", "inhibitors", "suggests", "substance", "-", "specific", "differences", ",", "which", "may", "depend", "on", "differences", "in", "pharmacokinetic", "parameters", "or", "inhibitory", "potency", "and", "may", "be", "contributed", "by", "prostaglandin", "-", "independent", "effects", ".", "Diagnostic", "markers", "such", "as", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", "or", "high", "-", "sensitive", "C", "-", "reactive", "protein", "might", "help", "in", "the", "early", "identification", "of", "patients", "at", "risk", ",", "thus", "avoiding", "the", "occurrence", "of", "serious", "cardiovascular", "toxicity", "."]], "ner": [[[3, 4, "Chemical"], [37, 38, "Chemical"], [57, 58, "Chemical"], [103, 104, "Chemical"], [25, 26, "Disease"], [28, 28, "Disease"], [30, 30, "Disease"], [32, 33, "Disease"], [173, 174, "Disease"], [127, 127, "Chemical"], [136, 142, "Chemical"], [144, 146, "Chemical"]]], "relations": [[[3, 4, 25, 26, "CID"], [37, 38, 25, 26, "CID"], [57, 58, 25, 26, "CID"], [103, 104, 25, 26, "CID"], [3, 4, 28, 28, "CID"], [37, 38, 28, 28, "CID"], [57, 58, 28, 28, "CID"], [103, 104, 28, 28, "CID"], [3, 4, 30, 30, "CID"], [37, 38, 30, 30, "CID"], [57, 58, 30, 30, "CID"], [103, 104, 30, 30, "CID"], [3, 4, 32, 33, "CID"], [37, 38, 32, 33, "CID"], [57, 58, 32, 33, "CID"], [103, 104, 32, 33, "CID"]]], "clusters": [], "translated": "<0>环氧合酶抑制剂</0>的心血管风险：物质特异性差异的一般问题？随机临床试验和观察性研究表明，<4>心肌梗塞</4>、<5>中风</5>、<6>高血压</6>和<7>心力衰竭</7>的风险增加，用<1>环氧合酶抑制剂</1>治疗。心血管不良反应主要（但不限于）发生在伴有危险因素的患者身上。<2>环氧合酶抑制剂</2>引起肾脏、血管和心脏前列腺素的复杂变化，从而增加血管阻力和液体潴留。心血管不良事件的发生率随着日剂量和总暴露时间的增加而增加。个体选择性和非选择性<3>环氧合酶抑制剂</3>的比较表明物质特异性差异，这可能取决于药代动力学参数或抑制效力的差异，并且可能是由<9>前列腺素</9>独立作用引起的。<10> N-末端脑利钠肽原</10> (<11>NT-proBNP</11>)或高敏C-反应蛋白等诊断标志物可能有助于早期识别高危患者，从而避免严重<8>心血管毒性</8>的发生。", "revised": true}
{"doc_key": "8677458", "sentences": [["Continuous", "subcutaneous", "administration", "of", "mesna", "to", "prevent", "ifosfamide", "-", "induced", "hemorrhagic", "cystitis", ".", "Hemorrhagic", "cystitis", "is", "a", "major", "potential", "toxicity", "of", "ifosfamide", "that", "can", "be", "prevented", "by", "administering", "mesna", "along", "with", "the", "cytotoxic", "agent", ".", "Mesna", "is", "generally", "administered", "by", "the", "intravenous", "route", ",", "although", "experience", "with", "oral", "delivery", "of", "the", "drug", "has", "increased", ".", "The", "continuous", "subcutaneous", "administration", "of", "mesna", "has", "the", "advantage", "of", "not", "requiring", "intravenous", "access", ".", "In", "addition", ",", "subcutaneous", "delivery", "of", "the", "neutralizing", "agent", "will", "not", "be", "associated", "with", "the", "risk", "of", "inadequate", "urinary", "mesna", "concentrations", ",", "such", "as", "in", "a", "patient", "taking", "oral", "mesna", "who", "experiences", "severe", "ifosfamide", "-", "induced", "emesis", "and", "is", "unable", "to", "absorb", "the", "drug", ".", "Limited", "clinical", "experience", "with", "continuous", "subcutaneous", "mesna", "administration", "suggests", "it", "is", "a", "safe", ",", "practical", ",", "and", "economic", "method", "of", "drug", "delivery", "that", "permits", "ifosfamide", "to", "be", "administered", "successfully", "in", "the", "outpatient", "setting", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [35, 35, "Chemical"], [60, 60, "Chemical"], [89, 89, "Chemical"], [99, 99, "Chemical"], [121, 121, "Chemical"], [10, 11, "Disease"], [13, 14, "Disease"], [7, 7, "Chemical"], [21, 21, "Chemical"], [103, 103, "Chemical"], [139, 139, "Chemical"], [19, 19, "Disease"], [106, 106, "Disease"]]], "relations": [[[4, 4, 10, 11, "CID"], [4, 4, 13, 14, "CID"], [28, 28, 10, 11, "CID"], [28, 28, 13, 14, "CID"], [35, 35, 10, 11, "CID"], [35, 35, 13, 14, "CID"], [60, 60, 10, 11, "CID"], [60, 60, 13, 14, "CID"], [89, 89, 10, 11, "CID"], [89, 89, 13, 14, "CID"], [99, 99, 10, 11, "CID"], [99, 99, 13, 14, "CID"], [121, 121, 10, 11, "CID"], [121, 121, 13, 14, "CID"], [7, 7, 10, 11, "CID"], [7, 7, 13, 14, "CID"], [21, 21, 10, 11, "CID"], [21, 21, 13, 14, "CID"], [103, 103, 10, 11, "CID"], [103, 103, 13, 14, "CID"], [139, 139, 10, 11, "CID"], [139, 139, 13, 14, "CID"]]], "clusters": [], "translated": "连续皮下注射<0>美司钠</0>预防<9>异环磷酰胺</9>引起的<7>出血性膀胱炎</7>。<8>出血性膀胱炎</8>是<10>异环磷酰胺</10>的主要潜在<13>毒性</13>，可通过同时服用<1>美司钠</1>和细胞毒剂来预防。<2>美司钠</2>通常通过静脉途径给药，尽管口服给药的经验有所增加。<3>美司钠</3>的连续皮下给药具有不需要静脉通路的优点。此外，中和剂的皮下给药与尿液<4>美司钠</4>浓度不足的风险无关，例如口服<5>美司钠</5>的患者经历了严重的<11>异环磷酰胺</11>-引起的<14>呕吐</14>并且无法吸收药物。有限临床经验表明，持续皮下注射<6>美司钠</6>是一种安全、实用且经济的给药方法，可以在门诊环境中成功给药<12>异环磷酰胺</12>。", "revised": true}
{"doc_key": "18997632", "sentences": [["A", "case", "of", "ventricular", "tachycardia", "related", "to", "caffeine", "pretreatment", ".", "Suboptimal", "seizure", "duration", "is", "commonly", "encountered", "in", "electroconvulsive", "therapy", "practice", ",", "especially", "in", "older", "patients", "with", "higher", "seizure", "thresholds", ".", "Intravenous", "caffeine", "is", "commonly", "used", "to", "improve", "seizure", "duration", "and", "quality", "in", "such", "patients", "and", "is", "generally", "well", "tolerated", "aside", "from", "occasional", "reports", "of", "relatively", "benign", "ventricular", "ectopy", ".", "We", "describe", "a", "patient", "with", "no", "previous", "history", "of", "cardiac", "disease", "or", "arrhythmia", "who", "developed", "sustained", "bigeminy", "and", "2", "brief", "runs", "of", "ventricular", "tachycardia", "after", "caffeine", "administration", ".", "Although", "intravenous", "caffeine", "is", "generally", "well", "tolerated", ",", "the", "clinician", "should", "be", "aware", "of", "the", "potential", "for", "unpredictable", "and", "serious", "ventricular", "arrhythmias", "."]], "ner": [[[7, 7, "Chemical"], [31, 31, "Chemical"], [84, 84, "Chemical"], [89, 89, "Chemical"], [3, 4, "Disease"], [81, 82, "Disease"], [11, 11, "Disease"], [27, 27, "Disease"], [37, 37, "Disease"], [56, 57, "Disease"], [68, 69, "Disease"], [71, 71, "Disease"], [107, 108, "Disease"]]], "relations": [[[7, 7, 3, 4, "CID"], [7, 7, 81, 82, "CID"], [31, 31, 3, 4, "CID"], [31, 31, 81, 82, "CID"], [84, 84, 3, 4, "CID"], [84, 84, 81, 82, "CID"], [89, 89, 3, 4, "CID"], [89, 89, 81, 82, "CID"], [7, 7, 11, 11, "CID"], [7, 7, 27, 27, "CID"], [7, 7, 37, 37, "CID"], [31, 31, 11, 11, "CID"], [31, 31, 27, 27, "CID"], [31, 31, 37, 37, "CID"], [84, 84, 11, 11, "CID"], [84, 84, 27, 27, "CID"], [84, 84, 37, 37, "CID"], [89, 89, 11, 11, "CID"], [89, 89, 27, 27, "CID"], [89, 89, 37, 37, "CID"], [7, 7, 56, 57, "CID"], [31, 31, 56, 57, "CID"], [84, 84, 56, 57, "CID"], [89, 89, 56, 57, "CID"]]], "clusters": [], "translated": "与<0>咖啡因</0>预处理有关的<4>室性心动过速</4>一例。次优<6>癫痫发作</6>持续时间在电休克治疗实践中很常见，尤其是在<7>较高的癫痫发作阈值</7>老年患者中。静脉注射<1>咖啡因</1>通常用于改善此类患者的<8>癫痫发作持续时间和质量</8>，除了偶尔报告相对良性的<9>心室早搏</9>外，一般耐受性良好。我们描述了一名既往没有<10>心脏病</10>或<11>心律失常</11>病史的患者，在<2>咖啡因</2>后出现持续的二联律和2次短暂的<5>室性心动过速</5>。虽然静脉注射<3>咖啡因</3>一般耐受性良好，但临床医生应该意识到<12>不可预测和严重的室性心律失常的可能性</12>。", "revised": true}
{"doc_key": "7596955", "sentences": [["Clinical", "evaluation", "on", "combined", "administration", "of", "oral", "prostacyclin", "analogue", "beraprost", "and", "phosphodiesterase", "inhibitor", "cilostazol", ".", "Among", "various", "oral", "antiplatelets", ",", "a", "combination", "of", "a", "novel", "prostacyclin", "analogue", "beraprost", "(", "BPT", ")", "and", "a", "potent", "phosphodiesterase", "inhibitor", "cilostazol", "(", "CLZ", ")", "may", "result", "in", "untoward", "clinical", "effects", "due", "to", "possible", "synergistic", "elevation", "of", "intracellular", "cAMP", "(", "cyclic", "adenosine", "3", "'", ",", "5", "'", "-", "monophosphate", ")", ".", "Thereby", ",", "a", "clinical", "study", "of", "the", "combined", "administration", "of", "the", "two", "agents", "was", "attempted", ".", "Twelve", "healthy", "volunteers", "were", "assigned", "to", "take", "BPT", "/", "CLZ", "in", "the", "following", "schedule", ";", "BPT", ":", "40", "micrograms", "at", "day", "1", "and", "120", "micrograms", "t", ".", "i", ".", "d", ".", "from", "day", "7", "to", "14", ",", "CLZ", ":", "200", "mg", "t", ".", "i", ".", "d", ".", "from", "day", "3", "to", "14", ".", "At", "various", "time", "intervals", ",", "physical", "examination", "and", "blood", "collection", "for", "ex", "vivo", "platelet", "aggregation", "and", "determination", "of", "intraplatelet", "cAMP", "were", "performed", ".", "Throughout", "the", "observation", "period", ",", "no", "significant", "alteration", "in", "vital", "signs", "was", "observed", ".", "Seven", "out", "of", "12", "subjects", "experienced", "headache", "of", "a", "short", "duration", "accompanying", "facial", "flush", "in", "one", "and", "nausea", "in", "one", ",", "especially", "after", "ingestion", "of", "CLZ", ".", "All", "of", "these", "symptoms", ",", "probably", "caused", "by", "the", "vasodilating", "effect", "of", "the", "two", "agents", ",", "were", "of", "mild", "degree", "and", "no", "special", "treatment", "was", "required", ".", "Intraplatelet", "cAMP", "content", "was", "gradually", "but", "significantly", "increased", "to", "9", ".", "84", "+", "/", "-", "4", ".", "59", "pmol", "per", "10", "(", "9", ")", "platelets", "at", "day", "14", "in", "comparison", "with", "the", "initial", "value", "(", "6", ".", "87", "+", "/", "-", "2", ".", "25", "pmol", ")", ".", "The", "platelet", "aggregability", "was", "significantly", "suppressed", "at", "various", "time", "intervals", "but", "no", "additive", "or", "synergistic", "inhibitory", "effect", "by", "the", "combined", "administration", "was", "noted", ".", "In", "conclusion", ",", "the", "combined", "administration", "of", "BPT", "/", "CLZ", "is", "safe", "at", "doses", "used", "in", "the", "study", ",", "though", "the", "beneficial", "clinical", "effect", "of", "the", "combined", "administration", "has", "yet", "to", "be", "elucidated", "."]], "ner": [[[9, 9, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [89, 89, "Chemical"], [97, 97, "Chemical"], [304, 304, "Chemical"], [178, 178, "Disease"], [184, 185, "Disease"], [189, 189, "Disease"], [13, 13, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [91, 91, "Chemical"], [119, 119, "Chemical"], [197, 197, "Chemical"], [306, 306, "Chemical"], [7, 7, "Chemical"], [25, 25, "Chemical"], [148, 149, "Disease"], [53, 53, "Chemical"], [55, 63, "Chemical"], [154, 154, "Chemical"], [227, 227, "Chemical"]]], "relations": [[[9, 9, 178, 178, "CID"], [27, 27, 178, 178, "CID"], [29, 29, 178, 178, "CID"], [89, 89, 178, 178, "CID"], [97, 97, 178, 178, "CID"], [304, 304, 178, 178, "CID"], [9, 9, 184, 185, "CID"], [27, 27, 184, 185, "CID"], [29, 29, 184, 185, "CID"], [89, 89, 184, 185, "CID"], [97, 97, 184, 185, "CID"], [304, 304, 184, 185, "CID"], [9, 9, 189, 189, "CID"], [27, 27, 189, 189, "CID"], [29, 29, 189, 189, "CID"], [89, 89, 189, 189, "CID"], [97, 97, 189, 189, "CID"], [304, 304, 189, 189, "CID"], [13, 13, 178, 178, "CID"], [36, 36, 178, 178, "CID"], [38, 38, 178, 178, "CID"], [91, 91, 178, 178, "CID"], [119, 119, 178, 178, "CID"], [197, 197, 178, 178, "CID"], [306, 306, 178, 178, "CID"], [13, 13, 184, 185, "CID"], [36, 36, 184, 185, "CID"], [38, 38, 184, 185, "CID"], [91, 91, 184, 185, "CID"], [119, 119, 184, 185, "CID"], [197, 197, 184, 185, "CID"], [306, 306, 184, 185, "CID"], [13, 13, 189, 189, "CID"], [36, 36, 189, 189, "CID"], [38, 38, 189, 189, "CID"], [91, 91, 189, 189, "CID"], [119, 119, 189, 189, "CID"], [197, 197, 189, 189, "CID"], [306, 306, 189, 189, "CID"]]], "clusters": [], "translated": "口服<16>前列环素</16>类似物<0>贝前列素</0>与磷酸二酯酶抑制剂<9>西洛他唑</9>联合应用的临床评价。在各种口服抗血小板药物中，新型<17>前列环素</17>类似物<1>贝前列素</1>（<2>BPT</2>）和强效磷酸二酯酶抑制剂<10>西洛他唑</10>的组合（<11>CLZ</11>）可能会由于细胞内<19>cAMP</19>（<20>环腺苷3'，5'-单磷酸</20>）的协同升高而导致不良的临床效果。因此，尝试了两种药物联合给药的临床研究。12名健康志愿者按以下时间表服用<3>BPT</3>/<12>CLZ</12>；<4>BPT</4>：第1天40微克和120微克t.i.d.从第7天到第14天，<13>CLZ</13>：200毫克t.i.d.从第3天到第14天。在不同的时间间隔，进行离体<18>血小板聚集</18>的体格检查和采血以及血小板内<21>cAMP</21>的测定。在整个观察期间，未观察到生命体征有明显变化。12名受试者中有7名经历了短暂的<6>头痛</6>，一名经历了<7>面部潮红</7>，一名经历了<8>恶心</8>，尤其是在摄入<14>CLZ</14>之后。所有这些症状，可能是两种药物的血管舒张作用所致，症状轻微，无需特殊治疗。血小板内<22>cAMP</22>含量逐渐升高至9.84+/-4.59 pmol per 10(9)个血小板的第14天，与初始值（6.87+/-2.25 pmol）相比。血小板聚集性在不同的时间间隔均受到显着抑制，但联合给药未发现累加或协同抑制作用。总之，<5>BPT</5>/<15>CLZ</15>的联合给药在研究中使用的剂量下是安全的，尽管联合给药的有益临床效果尚未阐明。", "revised": true}
{"doc_key": "17019386", "sentences": [["Passage", "of", "mannitol", "into", "the", "brain", "around", "gliomas", ":", "a", "potential", "cause", "of", "rebound", "phenomenon", ".", "A", "study", "on", "21", "patients", ".", "AIM", ":", "Widespread", "use", "of", "mannitol", "to", "reduce", "brain", "edema", "and", "lower", "elevated", "ICP", "in", "brain", "tumor", "patients", "continues", "to", "be", "afflicted", "by", "the", "so", "-", "called", "rebound", "phenomenon", ".", "Leakage", "of", "mannitol", "into", "the", "brain", "parenchyma", "through", "an", "altered", "BBB", "and", "secondary", "reversal", "of", "osmotic", "gradient", "is", "considered", "the", "major", "cause", "of", "rebound", ".", "This", "has", "only", "been", "demonstrated", "experimentally", "in", "animals", ".", "As", "a", "contribution", "to", "this", "issue", "we", "decided", "to", "research", "the", "possible", "passage", "of", "mannitol", "into", "the", "brain", "after", "administration", "to", "21", "brain", "tumor", "patients", ".", "METHODS", ":", "Mannitol", "(", "18", "%", "solution", ";", "1", "g", "/", "kg", ")", "was", "administered", "as", "a", "bolus", "to", "patients", "(", "ten", "had", "malignant", "glioma", ",", "seven", "brain", "metastases", "and", "four", "meningioma", ")", "about", "30", "minutes", "before", "craniotomy", ".", "During", "resection", ",", "a", "sample", "of", "the", "surrounding", "edematous", "white", "matter", "was", "taken", "at", "the", "same", "time", "as", "a", "10", "ml", "venous", "blood", "sample", ".", "Mannitol", "concentrations", "were", "measured", "in", "plasma", "and", "white", "matter", "by", "a", "modified", "version", "of", "the", "enzyme", "assay", "of", "Blonquist", "et", "al", ".", "RESULTS", ":", "In", "most", "glioma", "patients", ",", "mannitol", "concentrations", "in", "white", "matter", "were", "2", "to", "6", "times", "higher", "than", "in", "plasma", "(", "mean", "3", ".", "5", "times", ")", ".", "In", "meningioma", "and", "metastases", "patients", "plasma", "concentrations", "of", "mannitol", "were", "higher", "than", "white", "matter", "concentrations", "except", "in", "three", "cases", "with", "infiltration", "by", "neoplastic", "cells", ".", "CONCLUSIONS", ":", "The", "results", "of", "our", "study", "show", "that", "even", "after", "a", "single", "bolus", ",", "mannitol", "may", "leak", "through", "the", "altered", "BBB", "near", "gliomas", ",", "reversing", "the", "initial", "plasma", "-", "to", "-", "blood", "osmotic", "gradient", ",", "aggravating", "peritumoral", "edema", "and", "promoting", "rebound", "of", "ICP", "."]], "ner": [[[2, 2, "Chemical"], [27, 27, "Chemical"], [54, 54, "Chemical"], [100, 100, "Chemical"], [114, 114, "Chemical"], [176, 176, "Chemical"], [205, 205, "Chemical"], [235, 235, "Chemical"], [267, 267, "Chemical"], [34, 35, "Disease"], [7, 7, "Disease"], [135, 136, "Disease"], [202, 202, "Disease"], [275, 275, "Disease"], [30, 31, "Disease"], [37, 38, "Disease"], [108, 109, "Disease"], [140, 140, "Disease"], [230, 230, "Disease"], [143, 143, "Disease"], [228, 228, "Disease"], [159, 159, "Disease"], [290, 290, "Disease"]]], "relations": [[[2, 2, 34, 35, "CID"], [27, 27, 34, 35, "CID"], [54, 54, 34, 35, "CID"], [100, 100, 34, 35, "CID"], [114, 114, 34, 35, "CID"], [176, 176, 34, 35, "CID"], [205, 205, 34, 35, "CID"], [235, 235, 34, 35, "CID"], [267, 267, 34, 35, "CID"]]], "clusters": [], "translated": "<0>甘露醇</0>通过<10>神经胶质瘤</10>进入大脑：反弹现象的潜在原因。一项针对21名患者的研究。目的：广泛使用<1>甘露醇</1>来减轻<14>脑水肿</14>和降低升高的<9>ICP</9><15>脑肿瘤</15>患者继续受到折磨受所谓的<b>反弹现象</b>。<2>甘露醇</2>经过改变的血脑屏障泄漏到脑实质中被认为是反弹的主要原因，而二次渗透压梯度逆转是加重<22>瘤周水肿</22>的根本。这仅在动物实验中得到证实。作为对这个问题的贡献，我们决定研究<3>甘露醇</3>在给21名<16>脑肿瘤</16>患者给药后进入大脑的可能性。方法：<4>甘露醇</4>（18%溶液；1g/kg）作为推注剂给予患者（10例<11>恶性神经胶质瘤</11>，7例<17>脑转移瘤</17>和四个<19>脑膜瘤</19>）大约在开颅手术前30分钟。在切除过程中，同时采集了周围<21>水肿</21>白质样本和10毫升静脉血样本。<5>甘露醇</5>浓度通过Blonquist等人的酶测定法的改进版本测量血浆和白质中的浓度。结果：在大多数<12>神经胶质瘤</12>患者中，白质中的<6>甘露醇</6>浓度是血浆中的2-6倍（平均3.5倍）。在<20>脑膜瘤</20>和<18>转移</18>患者中，<7>甘露醇</7>的血浆浓度高于白质浓度，除了三例有肿瘤细胞浸润。结论：我们的研究结果表明即使在单次推注后，<8>甘露醇</8>也可能通过<13>神经胶质瘤</13>附近改变的BBB渗漏，逆转初始血浆到血液的渗透梯度，加重<22>瘤周水肿</22>，促进颅内压反跳。", "revised": true}
{"doc_key": "9022662", "sentences": [["Pemoline", "induced", "acute", "choreoathetosis", ":", "case", "report", "and", "review", "of", "the", "literature", ".", "BACKGROUND", ":", "Pemoline", "is", "an", "oxazolidine", "derivative", "that", "is", "structurally", "different", "from", "amphetamines", "and", "used", "in", "the", "treatment", "of", "attention", "deficit", "disorder", ".", "Pemoline", "has", "not", "been", "commonly", "associated", "in", "the", "literature", "as", "a", "cause", "of", "acute", "movement", "disorders", ".", "The", "following", "case", "describes", "two", "children", "acutely", "poisoned", "with", "pemoline", "who", "experienced", "profound", "choreoathetosis", ".", "CASE", "REPORT", ":", "Two", ",", "3", "-", "year", "-", "old", "male", ",", "identical", "twin", "siblings", "presented", "to", "the", "emergency", "department", "after", "found", "playing", "with", "a", "an", "empty", "bottle", "of", "pemoline", "originally", "containing", "59", "tablets", ".", "The", "children", "had", "a", "medical", "history", "significant", "for", "attention", "deficit", "disorder", "previously", "treated", "with", "methylphenidate", "without", "success", ".", "This", "was", "their", "first", "day", "of", "pemoline", "therapy", ".", "The", "choreoathetoid", "movements", "began", "45", "min", "to", "1", "h", "after", "ingestion", ".", "The", "children", "gave", "no", "history", "of", "prior", "movement", "disorders", "and", "there", "was", "no", "family", "history", "of", "movement", "disorders", ".", "The", "children", "received", "gastrointestinal", "decontamination", "and", "high", "doses", "of", "intravenous", "benzodiazepines", "in", "an", "attempt", "to", "control", "the", "choreoathetoid", "movements", ".", "Despite", "treatment", ",", "the", "children", "continued", "to", "have", "choreoathetosis", "for", "approximately", "24", "hours", ".", "Forty", "-", "eight", "hours", "after", "admission", ",", "the", "children", "appeared", "to", "be", "at", "their", "baseline", "and", "were", "discharged", "home", ".", "CONCLUSION", ":", "Pemoline", "associated", "movement", "disorder", "has", "been", "rarely", "reported", "in", "the", "acute", "toxicology", "literature", ".", "The", "possibility", "of", "choreoathetoid", "movements", "should", "be", "considered", "in", "patients", "presenting", "after", "pemoline", "overdose", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [36, 36, "Chemical"], [62, 62, "Chemical"], [97, 97, "Chemical"], [127, 127, "Chemical"], [217, 217, "Chemical"], [243, 243, "Chemical"], [3, 3, "Disease"], [66, 66, "Disease"], [131, 131, "Disease"], [178, 178, "Disease"], [189, 189, "Disease"], [234, 234, "Disease"], [244, 244, "Disease"], [32, 34, "Disease"], [111, 113, "Disease"], [50, 51, "Disease"], [149, 150, "Disease"], [158, 159, "Disease"], [219, 220, "Disease"], [18, 18, "Chemical"], [25, 25, "Chemical"], [117, 117, "Chemical"], [171, 171, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 66, 66, "CID"], [0, 0, 131, 131, "CID"], [0, 0, 178, 178, "CID"], [0, 0, 189, 189, "CID"], [0, 0, 234, 234, "CID"], [15, 15, 3, 3, "CID"], [15, 15, 66, 66, "CID"], [15, 15, 131, 131, "CID"], [15, 15, 178, 178, "CID"], [15, 15, 189, 189, "CID"], [15, 15, 234, 234, "CID"], [36, 36, 3, 3, "CID"], [36, 36, 66, 66, "CID"], [36, 36, 131, 131, "CID"], [36, 36, 178, 178, "CID"], [36, 36, 189, 189, "CID"], [36, 36, 234, 234, "CID"], [62, 62, 3, 3, "CID"], [62, 62, 66, 66, "CID"], [62, 62, 131, 131, "CID"], [62, 62, 178, 178, "CID"], [62, 62, 189, 189, "CID"], [62, 62, 234, 234, "CID"], [97, 97, 3, 3, "CID"], [97, 97, 66, 66, "CID"], [97, 97, 131, 131, "CID"], [97, 97, 178, 178, "CID"], [97, 97, 189, 189, "CID"], [97, 97, 234, 234, "CID"], [127, 127, 3, 3, "CID"], [127, 127, 66, 66, "CID"], [127, 127, 131, 131, "CID"], [127, 127, 178, 178, "CID"], [127, 127, 189, 189, "CID"], [127, 127, 234, 234, "CID"], [217, 217, 3, 3, "CID"], [217, 217, 66, 66, "CID"], [217, 217, 131, 131, "CID"], [217, 217, 178, 178, "CID"], [217, 217, 189, 189, "CID"], [217, 217, 234, 234, "CID"], [243, 243, 3, 3, "CID"], [243, 243, 66, 66, "CID"], [243, 243, 131, 131, "CID"], [243, 243, 178, 178, "CID"], [243, 243, 189, 189, "CID"], [243, 243, 234, 234, "CID"], [0, 0, 244, 244, "CID"], [15, 15, 244, 244, "CID"], [36, 36, 244, 244, "CID"], [62, 62, 244, 244, "CID"], [97, 97, 244, 244, "CID"], [127, 127, 244, 244, "CID"], [217, 217, 244, 244, "CID"], [243, 243, 244, 244, "CID"]]], "clusters": [], "translated": "<0>匹莫林</0>诱发急性<8>舞蹈手足徐动症</8>：病例报告及文献复习。背景：<1>匹莫林</1>是一种<21>恶唑烷</21>衍生物，其结构不同于<22>安非他命</22>，用于治疗<15>注意力缺陷障碍</15>。在文献中，<2>匹莫林</2>并没有被普遍认为是急性<17>运动障碍</17>的原因。以下病例报告描述了两名急性中毒的儿童，他们因摄入<3>匹莫林</3>而出现了<9>舞蹈手足徐动症</9>。病例报告：两名3岁男性同卵双胞胎兄弟姐妹在被发现玩一瓶原装59片的<4>匹莫林</4>空瓶后被送往急诊室。患儿有<16>注意缺陷障碍</16>病史，曾用<23>哌醋甲酯</23>治疗但未成功。这是他们接受<5>匹莫林</5>治疗的第一天。<10>舞蹈手足徐动症</10>在摄入后45分钟至1小时开始。这些孩子既往没有<18>运动障碍</18>病史，也没有<19>运动障碍</19>家族史。这些儿童接受了胃肠道净化和大剂量静脉注射<24>苯二氮卓类药物</24>，以试图控制<11>舞蹈手足徐动症</11>运动。尽管接受了治疗，这些孩子的<12>舞蹈手足徐动症</12>仍然持续了大约24小时。入院后48小时，孩子们似乎处于基线状态并出院回家。结论：<6>匹莫林</6>相关<20>运动障碍</20>在急性毒理学文献中鲜有报道。因<7>匹莫林</7><14>过量</14>后就诊的患者应考虑<13>舞蹈手足徐动症</13>运动的可能性。", "revised": true}
{"doc_key": "16720068", "sentences": [["Possible", "neuroleptic", "malignant", "syndrome", "related", "to", "concomitant", "treatment", "with", "paroxetine", "and", "alprazolam", ".", "A", "74", "-", "year", "-", "old", "man", "with", "depressive", "symptoms", "was", "admitted", "to", "a", "psychiatric", "hospital", "due", "to", "insomnia", ",", "loss", "of", "appetite", ",", "exhaustion", ",", "and", "agitation", ".", "Medical", "treatment", "was", "initiated", "at", "a", "daily", "dose", "of", "20", "mg", "paroxetine", "and", "1", ".", "2", "mg", "alprazolam", ".", "On", "the", "10th", "day", "of", "paroxetine", "and", "alprazolam", "treatment", ",", "the", "patient", "exhibited", "marked", "psychomotor", "retardation", ",", "disorientation", ",", "and", "severe", "muscle", "rigidity", "with", "tremors", ".", "The", "patient", "had", "a", "fever", "(", "38", ".", "2", "degrees", "C", ")", ",", "fluctuating", "blood", "pressure", "(", "between", "165", "/", "90", "and", "130", "/", "70", "mg", "mm", "Hg", ")", ",", "and", "severe", "extrapyramidal", "symptoms", ".", "Laboratory", "tests", "showed", "an", "elevation", "of", "creatine", "phosphokinase", "(", "2218", "IU", "/", "L", ")", ",", "aspartate", "aminotransferase", "(", "134", "IU", "/", "L", ")", ",", "alanine", "aminotransferase", "(", "78", "IU", "/", "L", ")", ",", "and", "BUN", "(", "27", ".", "9", "mg", "/", "ml", ")", "levels", ".", "The", "patient", "received", "bromocriptine", "and", "diazepam", "to", "treat", "his", "symptoms", ".", "7", "days", "later", ",", "the", "fever", "disappeared", "and", "the", "patient", "'s", "serum", "CPK", "levels", "were", "normalized", "(", "175", "IU", "/", "L", ")", ".", "This", "patient", "presented", "with", "symptoms", "of", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", ",", "thus", "demonstrating", "that", "NMS", "-", "like", "symptoms", "can", "occur", "after", "combined", "paroxetine", "and", "alprazolam", "treatment", ".", "The", "adverse", "drug", "reaction", "score", "obtained", "by", "the", "Naranjo", "algorithm", "was", "6", "in", "our", "case", ",", "indicating", "a", "probable", "relationship", "between", "the", "patient", "'s", "NMS", "-", "like", "adverse", "symptoms", "and", "the", "combined", "treatment", "used", "in", "this", "case", ".", "The", "involvement", "of", "physiologic", "and", "environmental", "aspects", "specific", "to", "this", "patient", "was", "suspected", ".", "Several", "risk", "factors", "for", "NMS", "should", "be", "noted", "in", "elderly", "depressive", "patients", "whose", "symptoms", "often", "include", "dehydration", ",", "agitation", ",", "malnutrition", ",", "and", "exhaustion", ".", "Careful", "therapeutic", "intervention", "is", "necessary", "in", "cases", "involving", "elderly", "patients", "who", "suffer", "from", "depression", "."]], "ner": [[[9, 9, "Chemical"], [53, 53, "Chemical"], [66, 66, "Chemical"], [225, 225, "Chemical"], [1, 3, "Disease"], [207, 209, "Disease"], [211, 211, "Disease"], [217, 217, "Disease"], [254, 254, "Disease"], [286, 286, "Disease"], [11, 11, "Chemical"], [59, 59, "Chemical"], [68, 68, "Chemical"], [227, 227, "Chemical"], [128, 128, "Chemical"], [137, 137, "Chemical"], [146, 146, "Chemical"], [170, 170, "Chemical"], [172, 172, "Chemical"], [21, 22, "Disease"], [292, 292, "Disease"], [320, 320, "Disease"], [27, 27, "Disease"], [31, 31, "Disease"], [33, 35, "Disease"], [40, 40, "Disease"], [300, 300, "Disease"], [75, 76, "Disease"], [82, 83, "Disease"], [85, 85, "Disease"], [91, 91, "Disease"], [183, 183, "Disease"], [119, 120, "Disease"], [298, 298, "Disease"], [302, 302, "Disease"]]], "relations": [[[9, 9, 1, 3, "CID"], [9, 9, 207, 209, "CID"], [9, 9, 211, 211, "CID"], [9, 9, 217, 217, "CID"], [9, 9, 254, 254, "CID"], [9, 9, 286, 286, "CID"], [53, 53, 1, 3, "CID"], [53, 53, 207, 209, "CID"], [53, 53, 211, 211, "CID"], [53, 53, 217, 217, "CID"], [53, 53, 254, 254, "CID"], [53, 53, 286, 286, "CID"], [66, 66, 1, 3, "CID"], [66, 66, 207, 209, "CID"], [66, 66, 211, 211, "CID"], [66, 66, 217, 217, "CID"], [66, 66, 254, 254, "CID"], [66, 66, 286, 286, "CID"], [225, 225, 1, 3, "CID"], [225, 225, 207, 209, "CID"], [225, 225, 211, 211, "CID"], [225, 225, 217, 217, "CID"], [225, 225, 254, 254, "CID"], [225, 225, 286, 286, "CID"], [11, 11, 1, 3, "CID"], [11, 11, 207, 209, "CID"], [11, 11, 211, 211, "CID"], [11, 11, 217, 217, "CID"], [11, 11, 254, 254, "CID"], [11, 11, 286, 286, "CID"], [59, 59, 1, 3, "CID"], [59, 59, 207, 209, "CID"], [59, 59, 211, 211, "CID"], [59, 59, 217, 217, "CID"], [59, 59, 254, 254, "CID"], [59, 59, 286, 286, "CID"], [68, 68, 1, 3, "CID"], [68, 68, 207, 209, "CID"], [68, 68, 211, 211, "CID"], [68, 68, 217, 217, "CID"], [68, 68, 254, 254, "CID"], [68, 68, 286, 286, "CID"], [227, 227, 1, 3, "CID"], [227, 227, 207, 209, "CID"], [227, 227, 211, 211, "CID"], [227, 227, 217, 217, "CID"], [227, 227, 254, 254, "CID"], [227, 227, 286, 286, "CID"]]], "clusters": [], "translated": "可能的 <4>抗精神病药物恶性综合征</4>与<0>帕罗西汀</0>和<10>阿普唑仑</10>的伴随治疗有关。74岁男性，有<19>抑郁症状</19>，因<23>失眠</23>、<24>食欲不振</24>、疲惫和<25>激动</25>，入住<22>精神病院</22>。以每天20mg<1>帕罗西汀</1>和1.2mg<11>阿普唑仑</11>的剂量开始药物治疗。在<2>帕罗西汀</2>和<12>阿普唑仑</12>治疗的第10天，患者表现出明显的<27>精神运动迟滞</27>、定向力障碍和严重的<28>肌肉强直</28>伴有<29>震颤</29>。患者有<30>发热</30>（38.2摄氏度）、血压波动（介于165/90和130/70mmHg之间）和严重的<32>锥体外系症状</32>。实验室检查显示<14>肌酸</14>磷酸激酶（2218 IU/L）、<15>天冬氨酸</15>氨基转移酶（134 IU/L）、<16>丙氨酸</16>氨基转移酶（78 IU/L）和BUN（27.9mg/mL）水平升高。患者接受<17>溴隐亭</17>和<18>地西泮</18>治疗症状。7天后，<31>发热</31>消失，患者血清CPK水平恢复正常（175 IU/L）。该患者表现出<5>精神抑制药恶性综合征</5>（<6>NMS</6>），从而证明联合<3>帕罗西汀</3>和<13>阿普唑仑</13>治疗后可出现<7>NMS</7>样症状。在我们的案例中，通过Naranjo算法获得的药物不良反应评分为6，表明患者的<8>NMS</8>样不良症状与本案例中使用的联合治疗之间可能存在关联。怀疑与该患者特有的生理和环境方面有关。老年<20>抑郁</20>患者应注意<9>NMS</9>的几个危险因素，其症状常包括<33>脱水</33>、<26>激越</26>、<34>营养不良</34>和疲惫。在涉及患有<21>抑郁症</21>的老年患者的病例中，需要谨慎的治疗干预。", "revised": true}
{"doc_key": "6323692", "sentences": [["Modification", "of", "drug", "action", "by", "hyperammonemia", ".", "Pretreatment", "with", "ammonium", "acetate", "(", "NH4Ac", ")", "(", "6", "mmol", "/", "kg", "s", ".", "c", ".", ")", "approximately", "doubled", "the", "time", "morphine", "-", "treated", "mice", "remained", "on", "a", "hot", "surface", "and", "similarly", "increased", "muscular", "incoordination", "by", "diazepam", ",", "but", "NH4Ac", "treatment", "alone", "had", "no", "effect", ".", "Thus", ",", "hyperammonemia", "is", "capable", "of", "altering", "drug", "action", "and", "must", "be", "considered", "along", "with", "impaired", "drug", "metabolism", "in", "enhanced", "drug", "responses", "associated", "with", "liver", "disease", ".", "Experiments", "in", "vitro", "showed", "that", "acetylcholine", "-", "induced", "catecholamine", "release", "from", "bovine", "adrenal", "medulla", "is", "depressed", "as", "much", "as", "50", "%", "by", "0", ".", "3", "mM", "NH4Ac", "and", "KCl", "-", "induced", "contractions", "of", "guinea", "-", "pig", "ileum", "were", "inhibited", "20", "%", "by", "5", "mM", "NH4Ac", ".", "Addition", "of", "excess", "calcium", "reversed", "the", "depression", "in", "both", "tissues", ",", "but", "calcium", "-", "independent", "catecholamine", "release", "by", "acetaldehyde", "was", "not", "blocked", "by", "NH4Ac", ".", "These", "results", "suggested", "that", "ammonia", "blocks", "calcium", "channels", ".", "Parallels", "in", "the", "actions", "of", "NH4Ac", "and", "the", "calcium", "channel", "blocker", "verapamil", "support", "this", "concept", ".", "Both", "verapamil", "(", "10", "mg", "/", "kg", "i", ".", "p", ".", ")", "and", "NH4Ac", "pretreatment", "enhanced", "morphine", "analgesia", "-", "and", "diazepam", "-", "induced", "muscular", "incoordination", "and", "antagonized", "amphetamine", "-", "induced", "motor", "activity", ",", "and", "neither", "verapamil", "nor", "NH4Ac", "affected", "the", "convulsant", "action", "of", "metrazol", ".", "The", "data", "suggest", "that", "hyperammonemia", "exerts", "a", "calcium", "channel", "blocking", "action", "which", "enhances", "the", "effects", "of", "central", "nervous", "system", "depressants", "and", "certain", "opioid", "analgesics", "."]], "ner": [[[9, 10, "Chemical"], [12, 12, "Chemical"], [46, 46, "Chemical"], [106, 106, "Chemical"], [124, 124, "Chemical"], [149, 149, "Chemical"], [165, 165, "Chemical"], [189, 189, "Chemical"], [213, 213, "Chemical"], [41, 41, "Disease"], [200, 200, "Disease"], [43, 43, "Chemical"], [196, 196, "Chemical"], [5, 5, "Disease"], [55, 55, "Disease"], [225, 225, "Disease"], [28, 28, "Chemical"], [192, 192, "Chemical"], [85, 85, "Chemical"], [88, 88, "Chemical"], [141, 141, "Chemical"], [108, 108, "Chemical"], [129, 129, "Chemical"], [138, 138, "Chemical"], [157, 157, "Chemical"], [168, 168, "Chemical"], [228, 228, "Chemical"], [144, 144, "Chemical"], [155, 155, "Chemical"], [171, 171, "Chemical"], [177, 177, "Chemical"], [211, 211, "Chemical"], [203, 203, "Chemical"], [219, 219, "Chemical"], [77, 78, "Disease"], [132, 132, "Disease"], [193, 193, "Disease"]]], "relations": [[[9, 10, 41, 41, "CID"], [9, 10, 200, 200, "CID"], [12, 12, 41, 41, "CID"], [12, 12, 200, 200, "CID"], [46, 46, 41, 41, "CID"], [46, 46, 200, 200, "CID"], [106, 106, 41, 41, "CID"], [106, 106, 200, 200, "CID"], [124, 124, 41, 41, "CID"], [124, 124, 200, 200, "CID"], [149, 149, 41, 41, "CID"], [149, 149, 200, 200, "CID"], [165, 165, 41, 41, "CID"], [165, 165, 200, 200, "CID"], [189, 189, 41, 41, "CID"], [189, 189, 200, 200, "CID"], [213, 213, 41, 41, "CID"], [213, 213, 200, 200, "CID"], [43, 43, 41, 41, "CID"], [43, 43, 200, 200, "CID"], [196, 196, 41, 41, "CID"], [196, 196, 200, 200, "CID"]]], "clusters": [], "translated": " <13>高氨血症</13>对药物作用的改变。用<0>醋酸铵</0>（<1>NH4Ac</1>）（6 mmol/kg s.c.）预处理大约使<16>吗啡</16>处理的小鼠保持在高温下的时间增加一倍，并类似地增加了肌肉<9>不协调</9>的程度,<11>地西泮</11>，但<2>NH4Ac</2>单独使用治疗没有效果。因此，<14>高氨血症</14>能够改变药物作用，在与<34>肝病</34>相关的增强药物反应中必须考虑药物代谢受损。体外实验表明，<18>乙酰胆碱</18>诱导的<19>儿茶酚胺</19>从牛肾上腺髓质中释放被0.3 mM<3>NH4Ac</3>抑制了50%，而<21>KCl</21>诱导的豚鼠回肠收缩被5 mM<4>NH4Ac</4>抑制了20%。添加过量的<22>钙</22>逆转了两种组织中的<35>抑制</35>，但<23>钙</23> -独立的<20>儿茶酚胺</20>释放通过<27>乙醛释放</27>未被<5>NH4Ac</5>阻断。这些结果表明<28>氨</28>阻断<24>钙</24>通道。<6>NH4Ac</6>和<25>钙</25>通道阻滞剂<29>维拉帕米</29>的平行作用支持这一概念。<30>维拉帕米</30>（10 mg/kg i.p.）和<7>NH4Ac</7>预处理增强了<17>吗啡</17><36>镇痛</36> -和<12>地西泮</12>诱导的肌肉<10>不协调</10>，并拮抗了<32>苯丙胺</32>诱导的运动活动，而<31>维拉帕米</31>和<8>NH4Ac</8>并没有影响<33>metrazol</33>的惊厥作用。数据表明，<15>高氨血症</15>发挥了对<26>钙</26>通道的阻断作用，增强了中枢神经系统抑制剂和某些阿片类镇痛药的作用。", "revised": true}
{"doc_key": "14742097", "sentences": [["A", "randomized", ",", "placebo", "-", "controlled", ",", "crossover", "study", "of", "ephedrine", "for", "SSRI", "-", "induced", "female", "sexual", "dysfunction", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "whether", "ephedrine", ",", "an", "alpha", "-", "and", "beta", "-", "adrenergic", "agonist", "previously", "shown", "to", "enhance", "genital", "blood", "flow", "in", "women", ",", "has", "beneficial", "effects", "in", "reversing", "antidepressant", "-", "induced", "sexual", "dysfunction", ".", "Nineteen", "sexually", "dysfunctional", "women", "receiving", "either", "fluoxetine", ",", "sertraline", ",", "or", "paroxetine", "participated", "in", "an", "eight", "-", "week", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "cross", "-", "over", "study", "of", "the", "effects", "of", "ephedrine", "(", "50", "mg", ")", "on", "self", "-", "report", "measures", "of", "sexual", "desire", ",", "arousal", ",", "orgasm", ",", "and", "sexual", "satisfaction", ".", "Although", "there", "were", "significant", "improvements", "relative", "to", "baseline", "in", "sexual", "desire", "and", "orgasm", "intensity", "/", "pleasure", "on", "50", "mg", "ephedrine", "1", "-", "hr", "prior", "to", "sexual", "activity", ",", "significant", "improvements", "in", "these", "measures", ",", "as", "well", "as", "in", "sexual", "arousal", "and", "orgasmic", "ability", "also", "were", "noted", "with", "placebo", ".", "These", "findings", "highlight", "the", "importance", "of", "conducting", "placebo", "-", "controlled", "trials", "for", "this", "condition", "."]], "ner": [[[65, 65, "Chemical"], [16, 17, "Disease"], [56, 57, "Disease"], [60, 61, "Disease"], [67, 67, "Chemical"], [70, 70, "Chemical"], [10, 10, "Chemical"], [28, 28, "Chemical"], [94, 94, "Chemical"], [135, 135, "Chemical"]]], "relations": [[[65, 65, 16, 17, "CID"], [65, 65, 56, 57, "CID"], [65, 65, 60, 61, "CID"], [67, 67, 16, 17, "CID"], [67, 67, 56, 57, "CID"], [67, 67, 60, 61, "CID"], [70, 70, 16, 17, "CID"], [70, 70, 56, 57, "CID"], [70, 70, 60, 61, "CID"]]], "clusters": [], "translated": "<6>麻黄碱</6> 对 SSRI 诱发的女性<1>性功能障碍</1>的随机、安慰剂对照、交叉研究。这项研究的目的是确定<7>麻黄碱</7>，一种先前显示可增强女性生殖器血流的α-和β-肾上腺素能激动剂，是否对逆转抗抑郁药引起的<2>性功能障碍</2>。接受<0>氟西汀</0>，<4>舍曲林</4>或<5>帕罗西汀</5>的19名<3>性功能障碍</3>女性参加了一项为期八周的双盲研究，评估<8>麻黄碱</8>（50毫克）在自我报告的性欲、唤醒、性高潮和性满意度方面的影响，包括安慰剂对照的交叉研究。尽管在服用50毫克的<9>麻黄碱</9>之前1小时，在性欲和性高潮强度/快感方面相对于基线有显着改善，但在这些措施以及性唤醒和性高潮能力方面，安慰剂也有显着改善。这些发现强调了针对这种情况进行安慰剂对照试验的重要性。", "revised": true}
{"doc_key": "9041081", "sentences": [["Effect", "of", "myopic", "excimer", "laser", "photorefractive", "keratectomy", "on", "the", "electrophysiologic", "function", "of", "the", "retina", "and", "optic", "nerve", ".", "PURPOSE", ":", "To", "assess", "by", "electrophysiologic", "testing", "the", "effect", "of", "photorefractive", "keratectomy", "(", "PRK", ")", "on", "the", "retina", "and", "optic", "nerve", ".", "SETTING", ":", "Eye", "Clinic", ",", "S", ".", "Salvatore", "Hospital", ",", "L", "'", "Aquila", "University", ",", "Italy", ".", "METHODS", ":", "Standard", "pattern", "electroretinograms", "(", "P", "-", "ERGs", ")", "and", "standard", "pattern", "visual", "evoked", "potentials", "(", "P", "-", "VEPs", ")", "were", "done", "in", "25", "eyes", "of", "25", "patients", "who", "had", "myopic", "PRK", "for", "an", "attempted", "correction", "between", "5", ".", "00", "and", "15", ".", "00", "diopters", "(", "D", ")", "(", "mean", "8", ".", "00", "D", ")", ".", "Testing", "was", "done", "preoperatively", "and", "3", ",", "6", ",", "12", ",", "and", "18", "months", "postoperatively", ".", "The", "contralateral", "eyes", "served", "as", "controls", ".", "During", "the", "follow", "-", "up", ",", "3", "patients", "(", "12", "%", ")", "developed", "steroid", "-", "induced", "elevated", "intraocular", "pressure", "(", "IOP", ")", "that", "resolved", "after", "corticosteroid", "therapy", "was", "discontinued", ".", "RESULTS", ":", "No", "statistically", "significant", "differences", "were", "seen", "between", "treated", "and", "control", "eyes", "nor", "between", "treated", "eyes", "preoperatively", "and", "postoperatively", ".", "CONCLUSION", ":", "Myopic", "excimer", "laser", "PRK", "did", "not", "seem", "to", "affect", "the", "posterior", "segment", ".", "The", "transient", "steroid", "-", "induced", "IOP", "rise", "did", "not", "seem", "to", "cause", "functional", "impairment", "."]], "ner": [[[162, 162, "Chemical"], [153, 155, "Disease"], [208, 209, "Disease"], [150, 150, "Chemical"], [205, 205, "Chemical"]]], "relations": [[[162, 162, 153, 155, "CID"], [162, 162, 208, 209, "CID"]]], "clusters": [], "translated": "近视准分子激光光折变角膜切除术对视网膜和视神经电生理功能的影响。目的：通过电生理测试评估光折射角膜切除术(PRK)对视网膜和视神经的影响。地点：眼科诊所，S.意大利拉奎拉大学萨尔瓦多医院。方法：对25名近视PRK患者的25只眼进行标准模式视网膜电图(P-ERGs)和标准模式视觉诱发电位(P-VEPs)检查，以尝试矫正5.00和15.00屈光度(D)（平均8.00 D）。测试在术前和术后3、6、12和18个月进行。对侧眼作为对照。在随访期间，3名患者（12%）出现<3>类固醇</3>引起的<1>眼内压升高</1>（IOP），在停止<0>皮质类固醇</0>治疗后缓解。结果：治疗眼和对照眼之间以及治疗眼术前术后均无统计学差异。结论：近视准分子激光PRK似乎不影响后节。短暂的<4>类固醇</4>诱导的<2>眼压升高</2>似乎不会导致功能障碍。", "revised": true}
{"doc_key": "1728915", "sentences": [["Carbamazepine", "-", "induced", "cardiac", "dysfunction", ".", "Characterization", "of", "two", "distinct", "clinical", "syndromes", ".", "A", "patient", "with", "sinus", "bradycardia", "and", "atrioventricular", "block", ",", "induced", "by", "carbamazepine", ",", "prompted", "an", "extensive", "literature", "review", "of", "all", "previously", "reported", "cases", ".", "From", "the", "analysis", "of", "these", "cases", ",", "two", "distinct", "forms", "of", "carbamazepine", "-", "associated", "cardiac", "dysfunction", "emerged", ".", "One", "patient", "group", "developed", "sinus", "tachycardias", "in", "the", "setting", "of", "a", "massive", "carbamazepine", "overdose", ".", "The", "second", "group", "consisted", "almost", "exclusively", "of", "elderly", "women", "who", "developed", "potentially", "life", "-", "threatening", "bradyarrhythmias", "or", "atrioventricular", "conduction", "delay", ",", "associated", "with", "either", "therapeutic", "or", "modestly", "elevated", "carbamazepine", "serum", "levels", ".", "Because", "carbamazepine", "is", "widely", "used", "in", "the", "treatment", "of", "many", "neurologic", "and", "psychiatric", "conditions", ",", "the", "recognition", "of", "the", "latter", "syndrome", "has", "important", "implications", "for", "the", "use", "of", "this", "drug", "in", "elderly", "patients", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [48, 48, "Chemical"], [67, 67, "Chemical"], [98, 98, "Chemical"], [103, 103, "Chemical"], [17, 17, "Disease"], [85, 85, "Disease"], [19, 20, "Disease"], [87, 89, "Disease"], [59, 60, "Disease"], [3, 4, "Disease"], [51, 52, "Disease"], [68, 68, "Disease"], [114, 114, "Disease"]]], "relations": [[[0, 0, 17, 17, "CID"], [0, 0, 85, 85, "CID"], [24, 24, 17, 17, "CID"], [24, 24, 85, 85, "CID"], [48, 48, 17, 17, "CID"], [48, 48, 85, 85, "CID"], [67, 67, 17, 17, "CID"], [67, 67, 85, 85, "CID"], [98, 98, 17, 17, "CID"], [98, 98, 85, 85, "CID"], [103, 103, 17, 17, "CID"], [103, 103, 85, 85, "CID"], [0, 0, 19, 20, "CID"], [0, 0, 87, 89, "CID"], [24, 24, 19, 20, "CID"], [24, 24, 87, 89, "CID"], [48, 48, 19, 20, "CID"], [48, 48, 87, 89, "CID"], [67, 67, 19, 20, "CID"], [67, 67, 87, 89, "CID"], [98, 98, 19, 20, "CID"], [98, 98, 87, 89, "CID"], [103, 103, 19, 20, "CID"], [103, 103, 87, 89, "CID"], [0, 0, 59, 60, "CID"], [24, 24, 59, 60, "CID"], [48, 48, 59, 60, "CID"], [67, 67, 59, 60, "CID"], [98, 98, 59, 60, "CID"], [103, 103, 59, 60, "CID"]]], "clusters": [], "translated": " <0>卡马西平</0>-诱发<11>心功能不全</11>。两种截然不同的临床综合征的特征。一位患有窦性<6>心动过缓</6>和<8>房室传导阻滞</8>的患者，由<1>卡马西平</1>诱发，促使对所有先前报道的病例进行广泛的文献回顾。通过对这些病例的分析，出现了两种不同形式的<2>卡马西平</2>相关<12>心脏功能障碍</12>。一组患者在大量<3>卡马西平</3> <13>过量</13>的情况下出现了<10>窦性心动过速</10>。第二组几乎完全由发生可能危及生命的 <7>心动过缓</7>或<9>房室传导延迟</9>的老年妇女组成，与治疗性或适度升高的<4>卡马西平</4>血清水平相关。由于<5>卡马西平</5>广泛用于治疗许多神经和<14>精神</14>系统疾病，识别后者综合征对于在老年患者中使用该药物具有重要意义。", "revised": true}
{"doc_key": "16596970", "sentences": [["Pilocarpine", "seizures", "cause", "age", "-", "dependent", "impairment", "in", "auditory", "location", "discrimination", ".", "Children", "who", "have", "status", "epilepticus", "have", "continuous", "or", "rapidly", "repeating", "seizures", "that", "may", "be", "life", "-", "threatening", "and", "may", "cause", "life", "-", "long", "changes", "in", "brain", "and", "behavior", ".", "The", "extent", "to", "which", "status", "epilepticus", "causes", "deficits", "in", "auditory", "discrimination", "is", "unknown", ".", "A", "naturalistic", "auditory", "location", "discrimination", "method", "was", "used", "to", "evaluate", "this", "question", "using", "an", "animal", "model", "of", "status", "epilepticus", ".", "Male", "Sprague", "-", "Dawley", "rats", "were", "injected", "with", "saline", "on", "postnatal", "day", "(", "P", ")", "20", ",", "or", "a", "convulsant", "dose", "of", "pilocarpine", "on", "P20", "or", "P45", ".", "Pilocarpine", "on", "either", "day", "induced", "status", "epilepticus", ";", "status", "epilepticus", "at", "P45", "resulted", "in", "CA3", "cell", "loss", "and", "spontaneous", "seizures", ",", "whereas", "P20", "rats", "had", "no", "cell", "loss", "or", "spontaneous", "seizures", ".", "Mature", "rats", "were", "trained", "with", "sound", "-", "source", "location", "and", "sound", "-", "silence", "discriminations", ".", "Control", "(", "saline", "P20", ")", "rats", "acquired", "both", "discriminations", "immediately", ".", "In", "status", "epilepticus", "(", "P20", ")", "rats", ",", "acquisition", "of", "the", "sound", "-", "source", "location", "discrimination", "was", "moderately", "impaired", ".", "Status", "epilepticus", "(", "P45", ")", "rats", "failed", "to", "acquire", "either", "sound", "-", "source", "location", "or", "sound", "-", "silence", "discriminations", ".", "Status", "epilepticus", "in", "rat", "causes", "an", "age", "-", "dependent", ",", "long", "-", "term", "impairment", "in", "auditory", "discrimination", ".", "This", "impairment", "may", "explain", "one", "cause", "of", "impaired", "auditory", "location", "discrimination", "in", "humans", "."]], "ner": [[[0, 0, "Chemical"], [97, 97, "Chemical"], [103, 103, "Chemical"], [6, 10, "Disease"], [48, 51, "Disease"], [214, 217, "Disease"], [226, 229, "Disease"], [15, 16, "Disease"], [45, 46, "Disease"], [72, 73, "Disease"], [108, 109, "Disease"], [111, 112, "Disease"], [162, 163, "Disease"], [181, 182, "Disease"], [201, 202, "Disease"], [1, 1, "Disease"], [22, 22, "Disease"], [122, 122, "Disease"], [133, 133, "Disease"]]], "relations": [[[0, 0, 6, 10, "CID"], [0, 0, 48, 51, "CID"], [0, 0, 214, 217, "CID"], [0, 0, 226, 229, "CID"], [97, 97, 6, 10, "CID"], [97, 97, 48, 51, "CID"], [97, 97, 214, 217, "CID"], [97, 97, 226, 229, "CID"], [103, 103, 6, 10, "CID"], [103, 103, 48, 51, "CID"], [103, 103, 214, 217, "CID"], [103, 103, 226, 229, "CID"], [0, 0, 15, 16, "CID"], [0, 0, 45, 46, "CID"], [0, 0, 72, 73, "CID"], [0, 0, 108, 109, "CID"], [0, 0, 111, 112, "CID"], [0, 0, 162, 163, "CID"], [0, 0, 181, 182, "CID"], [0, 0, 201, 202, "CID"], [97, 97, 15, 16, "CID"], [97, 97, 45, 46, "CID"], [97, 97, 72, 73, "CID"], [97, 97, 108, 109, "CID"], [97, 97, 111, 112, "CID"], [97, 97, 162, 163, "CID"], [97, 97, 181, 182, "CID"], [97, 97, 201, 202, "CID"], [103, 103, 15, 16, "CID"], [103, 103, 45, 46, "CID"], [103, 103, 72, 73, "CID"], [103, 103, 108, 109, "CID"], [103, 103, 111, 112, "CID"], [103, 103, 162, 163, "CID"], [103, 103, 181, 182, "CID"], [103, 103, 201, 202, "CID"]]], "clusters": [], "translated": "<0>毛果芸香碱</0> <15>癫痫发作</15>导致年龄依赖性<3>听觉位置辨别能力受损</3>。患有<7>癫痫持续状态</7>的儿童会出现持续或快速重复的<16>癫痫发作</16>，这可能危及生命，并可能导致大脑和行为的终生改变。由<8>癫痫持续状态</8>导致<4>听觉辨别缺陷</4>的程度尚不清楚。使用动物模型对<9>癫痫持续状态</9>进行了自然听觉位置辨别法的评估。在出生后第20天（P）雄性Sprague-Dawley大鼠注射了生理盐水，或在P20或P45注射惊厥剂量的<1>毛果芸香碱</1>。<2>毛果芸香碱</2>在任一天都会诱发<10>癫痫持续状态</10>；在P45<11>癫痫持续状态</11>导致CA3细胞丢失和自发性<17>癫痫发作</17>，而P20大鼠没有细胞丢失或自发性<18>癫痫发作</18>。成年大鼠接受了声源定位和声音寂静辨别训练。对照（生理盐水P20）大鼠立即获得两种辨别能力。在<12>癫痫持续状态</12>（P20）大鼠中，声源位置辨别能力中度受损。<13>癫痫持续状态</13>（P45）大鼠不能获得声源定位和声音寂静辨别。大鼠的<14>癫痫持续状态</14>会导致年龄依赖性、长期的<5>听觉辨别能力受损</5>，这种受损可以解释人类<6>听觉位置辨别能力受损</6>的一个原因。", "revised": true}
{"doc_key": "6415512", "sentences": [["Myoclonic", ",", "atonic", ",", "and", "absence", "seizures", "following", "institution", "of", "carbamazepine", "therapy", "in", "children", ".", "Five", "children", ",", "aged", "3", "to", "11", "years", ",", "treated", "with", "carbamazepine", "for", "epilepsy", ",", "had", "an", "acute", "aberrant", "reaction", "characterized", "by", "the", "onset", "of", "myoclonic", ",", "atypical", "absence", "and", "/", "or", "atonic", "(", "minor", "motor", ")", "seizures", "within", "a", "few", "days", ".", "When", "the", "carbamazepine", "was", "discontinued", ",", "two", "of", "the", "children", "returned", "to", "their", "former", "state", "very", "quickly", ",", "two", "had", "the", "minor", "motor", "seizures", "resolve", "in", "3", "and", "6", "months", ",", "and", "one", "had", "the", "seizures", "persist", ".", "The", "child", "in", "whom", "the", "seizures", "persisted", "was", "later", "found", "to", "have", "ceroid", "lipofuscinosis", ".", "The", "other", "children", "are", "doing", "well", "on", "other", "anticonvulsants", "."]], "ner": [[[10, 10, "Chemical"], [26, 26, "Chemical"], [60, 60, "Chemical"], [0, 6, "Disease"], [40, 52, "Disease"], [28, 28, "Disease"], [81, 81, "Disease"], [93, 93, "Disease"], [101, 101, "Disease"], [108, 109, "Disease"]]], "relations": [[[10, 10, 0, 6, "CID"], [10, 10, 40, 52, "CID"], [26, 26, 0, 6, "CID"], [26, 26, 40, 52, "CID"], [60, 60, 0, 6, "CID"], [60, 60, 40, 52, "CID"]]], "clusters": [], "translated": " <3>儿童</3><0>卡马西平</0><3>治疗后的肌阵挛、失张力和失神发作</3>。五名年龄在 3 至 11 岁之间的儿童，接受<1>卡马西平</1>治疗<5>癫痫</5>，出现了以<4>肌阵挛、非典型失神和/或失张力（小运动）发作</4>为特征的急性异常反应几天内发作。 当<2>卡马西平</2>停药后，两名儿童很快恢复到原来的状态，两名儿童的轻微运动<6>癫痫发作</6>在3个月和6个月内消退，一名<7>发作</7>持续存在。<8>发作</8>持续的孩子后来被发现患有<9>蜡样脂褐质沉着症</9>。其他孩子服用其他抗惊厥药后情况良好。", "revised": true}
{"doc_key": "7189975", "sentences": [["Deaths", "from", "local", "anesthetic", "-", "induced", "convulsions", "in", "mice", ".", "Median", "convulsant", "(", "CD50", ")", "and", "median", "lethal", "(", "LD50", ")", "doses", "of", "three", "representative", "local", "anesthetics", "were", "determined", "in", "adult", "mice", "to", "evaluate", "the", "threat", "to", "life", "of", "local", "anesthetic", "-", "induced", "convulsions", ".", "The", "CD50", "and", "LD50", ",", "respectively", ",", "were", "57", ".", "7", "and", "58", ".", "7", "mg", "/", "kg", "for", "bupivacaine", ",", "111", ".", "0", "and", "133", ".", "1", "mg", "/", "kg", "for", "lidocaine", ",", "and", "243", ".", "4", "and", "266", ".", "5", "mg", "/", "kg", "for", "chloroprocaine", ".", "When", "given", "intraperitoneally", ",", "bupivacaine", "thus", "was", "only", "about", "twice", "as", "toxic", "as", "lidocaine", "and", "four", "times", "as", "toxic", "as", "chloroprocaine", ".", "Convulsions", "always", "preceded", "death", ",", "except", "after", "precipitous", "cardiopulmonary", "arrest", "from", "extreme", "doses", ".", "A", "CD50", "dose", "of", "local", "anesthetic", "(", "causing", "convulsions", "in", "50", "%", "of", "mice", ")", "was", "fatal", "in", "90", "%", "of", "bupivacaine", "-", "induced", "seizures", ",", "in", "57", "%", "of", "the", "chloroprocaine", "group", ",", "and", "in", "6", "%", "of", "the", "lidocaine", "group", ".", "The", "narrow", "gap", "between", "convulsant", "and", "lethal", "doses", "of", "local", "anesthetics", "indicates", "that", "untreated", "convulsions", "present", "much", "more", "of", "a", "threat", "to", "life", "than", "heretofore", "appreciated", "."]], "ner": [[[64, 64, "Chemical"], [97, 97, "Chemical"], [150, 150, "Chemical"], [6, 6, "Disease"], [43, 43, "Disease"], [115, 115, "Disease"], [137, 137, "Disease"], [153, 153, "Disease"], [186, 186, "Disease"], [77, 77, "Chemical"], [106, 106, "Chemical"], [169, 169, "Chemical"], [91, 91, "Chemical"], [113, 113, "Chemical"], [160, 160, "Chemical"], [123, 124, "Disease"]]], "relations": [[[64, 64, 6, 6, "CID"], [64, 64, 43, 43, "CID"], [64, 64, 115, 115, "CID"], [64, 64, 137, 137, "CID"], [64, 64, 153, 153, "CID"], [64, 64, 186, 186, "CID"], [97, 97, 6, 6, "CID"], [97, 97, 43, 43, "CID"], [97, 97, 115, 115, "CID"], [97, 97, 137, 137, "CID"], [97, 97, 153, 153, "CID"], [97, 97, 186, 186, "CID"], [150, 150, 6, 6, "CID"], [150, 150, 43, 43, "CID"], [150, 150, 115, 115, "CID"], [150, 150, 137, 137, "CID"], [150, 150, 153, 153, "CID"], [150, 150, 186, 186, "CID"], [77, 77, 6, 6, "CID"], [77, 77, 43, 43, "CID"], [77, 77, 115, 115, "CID"], [77, 77, 137, 137, "CID"], [77, 77, 153, 153, "CID"], [77, 77, 186, 186, "CID"], [106, 106, 6, 6, "CID"], [106, 106, 43, 43, "CID"], [106, 106, 115, 115, "CID"], [106, 106, 137, 137, "CID"], [106, 106, 153, 153, "CID"], [106, 106, 186, 186, "CID"], [169, 169, 6, 6, "CID"], [169, 169, 43, 43, "CID"], [169, 169, 115, 115, "CID"], [169, 169, 137, 137, "CID"], [169, 169, 153, 153, "CID"], [169, 169, 186, 186, "CID"], [91, 91, 6, 6, "CID"], [91, 91, 43, 43, "CID"], [91, 91, 115, 115, "CID"], [91, 91, 137, 137, "CID"], [91, 91, 153, 153, "CID"], [91, 91, 186, 186, "CID"], [113, 113, 6, 6, "CID"], [113, 113, 43, 43, "CID"], [113, 113, 115, 115, "CID"], [113, 113, 137, 137, "CID"], [113, 113, 153, 153, "CID"], [113, 113, 186, 186, "CID"], [160, 160, 6, 6, "CID"], [160, 160, 43, 43, "CID"], [160, 160, 115, 115, "CID"], [160, 160, 137, 137, "CID"], [160, 160, 153, 153, "CID"], [160, 160, 186, 186, "CID"]]], "clusters": [], "translated": "小鼠因局麻药引起的<3>抽搐</3>而死亡。在成年小鼠身上测定了三种代表性局部麻醉剂的中位惊厥（CD50）和中位致死（LD50）剂量，以评估局部麻醉剂引起的<4>惊厥</4>对生命的威胁。CD50和LD50分别为57.7和58.7毫克/千克 <0>布比卡因</0>，111.0和133.1毫克/千克的<9>利多卡因</9>，以及243.4和266.5毫克/千克的<12>氯普鲁卡因</12>。因此，当腹膜内给药时，<1>布比卡因</1>的毒性仅为<10>利多卡因</10>的两倍，是<13>氯普鲁卡因</13>的四倍。<5>抽搐</5>总是先于死亡，除了在极端剂量引起的急剧<15>心肺骤停</15>之后。CD50剂量的局部麻醉剂（在50%的小鼠中引起<6>抽搐</6>）在90%的<2>布比卡因</2>诱导的<7>癫痫发作</7>中是致命的，在57%中<14>氯普鲁卡因</14>组和<11>利多卡因</11>组的6％。局麻药的惊厥剂量和致死剂量之间的微小差距表明，未经治疗的<8>惊厥</8>对生命的威胁比迄今为止所认识到的要大得多。", "revised": true}
{"doc_key": "15266215", "sentences": [["Effects", "of", "the", "cyclooxygenase", "-", "2", "specific", "inhibitor", "valdecoxib", "versus", "nonsteroidal", "antiinflammatory", "agents", "and", "placebo", "on", "cardiovascular", "thrombotic", "events", "in", "patients", "with", "arthritis", ".", "There", "have", "been", "concerns", "that", "the", "risk", "of", "cardiovascular", "thrombotic", "events", "may", "be", "higher", "with", "cyclooxygenase", "(", "COX", ")", "-", "2", "-", "specific", "inhibitors", "than", "nonselective", "nonsteroidal", "antiinflammatory", "drugs", "(", "NSAIDs", ")", ".", "We", "evaluated", "cardiovascular", "event", "data", "for", "valdecoxib", ",", "a", "new", "COX", "-", "2", "-", "specific", "inhibitor", "in", "approximately", "8000", "patients", "with", "osteoarthritis", "and", "rheumatoid", "arthritis", "treated", "with", "this", "agent", "in", "randomized", "clinical", "trials", ".", "The", "incidence", "of", "cardiovascular", "thrombotic", "events", "(", "cardiac", ",", "cerebrovascular", "and", "peripheral", "vascular", ",", "or", "arterial", "thrombotic", ")", "was", "determined", "by", "analyzing", "pooled", "valdecoxib", "(", "10", "-", "80", "mg", "daily", ")", ",", "nonselective", "NSAID", "(", "diclofenac", "75", "mg", "bid", ",", "ibuprofen", "800", "mg", "tid", ",", "or", "naproxen", "500", "mg", "bid", ")", "and", "placebo", "data", "from", "10", "randomized", "osteoarthritis", "and", "rheumatoid", "arthritis", "trials", "that", "were", "6", "-", "52", "weeks", "in", "duration", ".", "The", "incidence", "rates", "of", "events", "were", "determined", "in", "all", "patients", "(", "n", "=", "7934", ")", "and", "in", "users", "of", "low", "-", "dose", "(", "<", "or", "=", "325", "mg", "daily", ")", "aspirin", "(", "n", "=", "1051", ")", "and", "nonusers", "of", "aspirin", "(", "n", "=", "6883", ")", ".", "Crude", "and", "exposure", "-", "adjusted", "incidences", "of", "thrombotic", "events", "were", "similar", "for", "valdecoxib", ",", "NSAIDs", ",", "and", "placebo", ".", "The", "risk", "of", "serious", "thrombotic", "events", "was", "also", "similar", "for", "each", "valdecoxib", "dose", ".", "Thrombotic", "risk", "was", "consistently", "higher", "for", "users", "of", "aspirin", "users", "than", "nonusers", "of", "aspirin", "(", "placebo", ",", "1", ".", "4", "%", "vs", ".", "0", "%", ";", "valdecoxib", ",", "1", ".", "7", "%", "vs", ".", "0", ".", "2", "%", ";", "NSAIDs", ",", "1", ".", "9", "%", "vs", ".", "0", ".", "5", "%", ")", ".", "The", "rates", "of", "events", "in", "users", "of", "aspirin", "were", "similar", "for", "all", "3", "treatment", "groups", "and", "across", "valdecoxib", "doses", ".", "Short", "-", "and", "intermediate", "-", "term", "treatment", "with", "therapeutic", "(", "10", "or", "20", "mg", "daily", ")", "and", "supratherapeutic", "(", "40", "or", "80", "mg", "daily", ")", "valdecoxib", "doses", "was", "not", "associated", "with", "an", "increased", "incidence", "of", "thrombotic", "events", "relative", "to", "nonselective", "NSAIDs", "or", "placebo", "in", "osteoarthritis", "and", "rheumatoid", "arthritis", "patients", "in", "controlled", "clinical", "trials", "."]], "ner": [[[192, 192, "Chemical"], [201, 201, "Chemical"], [249, 249, "Chemical"], [254, 254, "Chemical"], [301, 301, "Chemical"], [17, 17, "Disease"], [33, 33, "Disease"], [95, 95, "Disease"], [107, 107, "Disease"], [215, 215, "Disease"], [231, 231, "Disease"], [241, 241, "Disease"], [349, 349, "Disease"], [8, 8, "Chemical"], [63, 63, "Chemical"], [114, 114, "Chemical"], [220, 220, "Chemical"], [238, 238, "Chemical"], [267, 267, "Chemical"], [311, 311, "Chemical"], [339, 339, "Chemical"], [22, 22, "Disease"], [78, 78, "Disease"], [148, 148, "Disease"], [358, 358, "Disease"], [80, 81, "Disease"], [150, 151, "Disease"], [360, 361, "Disease"], [126, 126, "Chemical"], [131, 131, "Chemical"], [137, 137, "Chemical"]]], "relations": [[[192, 192, 17, 17, "CID"], [192, 192, 33, 33, "CID"], [192, 192, 95, 95, "CID"], [192, 192, 107, 107, "CID"], [192, 192, 215, 215, "CID"], [192, 192, 231, 231, "CID"], [192, 192, 241, 241, "CID"], [192, 192, 349, 349, "CID"], [201, 201, 17, 17, "CID"], [201, 201, 33, 33, "CID"], [201, 201, 95, 95, "CID"], [201, 201, 107, 107, "CID"], [201, 201, 215, 215, "CID"], [201, 201, 231, 231, "CID"], [201, 201, 241, 241, "CID"], [201, 201, 349, 349, "CID"], [249, 249, 17, 17, "CID"], [249, 249, 33, 33, "CID"], [249, 249, 95, 95, "CID"], [249, 249, 107, 107, "CID"], [249, 249, 215, 215, "CID"], [249, 249, 231, 231, "CID"], [249, 249, 241, 241, "CID"], [249, 249, 349, 349, "CID"], [254, 254, 17, 17, "CID"], [254, 254, 33, 33, "CID"], [254, 254, 95, 95, "CID"], [254, 254, 107, 107, "CID"], [254, 254, 215, 215, "CID"], [254, 254, 231, 231, "CID"], [254, 254, 241, 241, "CID"], [254, 254, 349, 349, "CID"], [301, 301, 17, 17, "CID"], [301, 301, 33, 33, "CID"], [301, 301, 95, 95, "CID"], [301, 301, 107, 107, "CID"], [301, 301, 215, 215, "CID"], [301, 301, 231, 231, "CID"], [301, 301, 241, 241, "CID"], [301, 301, 349, 349, "CID"]]], "clusters": [], "translated": "环氧合酶-2特异性抑制剂<13>伐地昔布</13>与非甾体抗炎药和安慰剂对<21>关节炎</21>患者心血管<5>血栓形成</5>事件的影响。有人担心，与非选择性非甾体抗炎药（NSAID）相比，环氧合酶（COX）-2特异性抑制剂导致心血管<6>血栓形成</6>的风险更高。我们评估了<14>伐地昔布</14>的心血管事件数据，这是一种新的COX-2-特异性抑制剂，在大约8000名<22>骨关节炎</22>和<25>类风湿性关节炎</25>患者中使用该药物治疗在随机临床试验中。心血管<7>血栓性</7>事件（心脏、脑血管和周围血管，或动脉<8>血栓形成</8>）的发生率是通过分析合并的<15>伐地考昔</15>（10-80 mg每日）、非选择性NSAID（<28>双氯芬酸</28> 75 mg bid、<29>布洛芬</29> 800 mg tid或<30>萘普生</30> 500 mg bid）和安慰剂数据来自10个随机<23>骨关节炎</23>和<26>类风湿性关节炎</26>试验持续时间为6-52周。在所有患者(n = 7934)和低剂量(< or = 325 mg daily)<0>阿司匹林</0> (n = 1051)和未服用<1>阿司匹林</1>的患者中确定事件的发生率(n = 6883)。 <16>伐地昔布</16>、非甾体抗炎药和安慰剂的<9>血栓形成</9>事件的粗略和暴露调整发生率相似。每种<17>伐地昔布</17>剂量的严重<10>血栓形成</10>事件风险也相似。<11>血栓形成</11>风险始终高于<2>阿司匹林</2>使用者的使用者比未服用<3>阿司匹林</3>的使用者（安慰剂，1.4%对0%；<18>伐地考昔</18>，1.7%对0.2%；非甾体抗炎药，1.9%对0.5%）。<4>阿司匹林</4>使用者的事件发生率在所有3个治疗组和<19>伐地考昔</19>剂量组中相似。使用治疗性（每天10或20毫克）和超治疗性（每天40或80毫克）<20>伐地昔布</20>剂量的短期和中期治疗与<12>血栓形成</12>的发生率增加无关，在对照临床试验中，<24>骨关节炎</24>和<27>类风湿性关节炎</27>患者相对于非选择性NSAIDs或安慰剂的事件。", "revised": true}
{"doc_key": "1928887", "sentences": [["Naloxone", "reversal", "of", "hypotension", "due", "to", "captopril", "overdose", ".", "The", "hemodynamic", "effects", "of", "captopril", "and", "other", "angiotensin", "-", "converting", "enzyme", "inhibitors", "may", "be", "mediated", "by", "the", "endogenous", "opioid", "system", ".", "The", "opioid", "antagonist", "naloxone", "has", "been", "shown", "to", "block", "or", "reverse", "the", "hypotensive", "actions", "of", "captopril", ".", "We", "report", "a", "case", "of", "an", "intentional", "captopril", "overdose", ",", "manifested", "by", "marked", "hypotension", ",", "that", "resolved", "promptly", "with", "the", "administration", "of", "naloxone", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "captopril", "-", "induced", "hypotension", "treated", "with", "naloxone", ".", "Our", "experience", "demonstrates", "a", "possible", "role", "of", "naloxone", "in", "the", "reversal", "of", "hypotension", "resulting", "from", "captopril", "."]], "ner": [[[16, 20, "Chemical"], [3, 3, "Disease"], [42, 42, "Disease"], [60, 60, "Disease"], [85, 85, "Disease"], [102, 102, "Disease"], [7, 7, "Disease"], [55, 55, "Disease"], [0, 0, "Chemical"], [33, 33, "Chemical"], [69, 69, "Chemical"], [88, 88, "Chemical"], [97, 97, "Chemical"], [6, 6, "Chemical"], [13, 13, "Chemical"], [45, 45, "Chemical"], [54, 54, "Chemical"], [82, 82, "Chemical"], [105, 105, "Chemical"]]], "relations": [[[16, 20, 3, 3, "CID"], [16, 20, 42, 42, "CID"], [16, 20, 60, 60, "CID"], [16, 20, 85, 85, "CID"], [16, 20, 102, 102, "CID"], [16, 20, 7, 7, "CID"], [16, 20, 55, 55, "CID"]]], "clusters": [], "translated": "<8>纳洛酮</8> 逆转因<13>卡托普利</13><6>过量</6>引起的<1>低血压</1>。<14>卡托普利</14>和其他<0>血管紧张素转换酶抑制剂 </0>的血流动力学作用可能是由内源性阿片系统介导的。阿片类拮抗剂<9>纳洛酮</9>已被证明可以阻断或逆转<15>卡托普利</15>的<2>降压</2>作用。我们报告了一个故意<7>过量服用</7><16>卡托普利</16>的病例，表现为明显的<3>低血压</3>，服用<10>纳洛酮</10> 后症状迅速缓解。据我们所知，这是第一例用<11>纳洛酮</11>治疗<17>卡托普利</17>引起的<4>低血压</4>的报道。我们的经验表明，<12>纳洛酮</12>可能在逆转由<18>卡托普利</18>引起的<5>低血压</5>中发挥作用。", "revised": true}
{"doc_key": "10539815", "sentences": [["Predictors", "of", "decreased", "renal", "function", "in", "patients", "with", "heart", "failure", "during", "angiotensin", "-", "converting", "enzyme", "inhibitor", "therapy", ":", "results", "from", "the", "studies", "of", "left", "ventricular", "dysfunction", "(", "SOLVD", ")", "BACKGROUND", ":", "Although", "angiotensin", "-", "converting", "enzyme", "inhibitor", "therapy", "reduces", "mortality", "rates", "in", "patients", "with", "congestive", "heart", "failure", "(", "CHF", ")", ",", "it", "may", "also", "cause", "decreased", "renal", "function", ".", "Little", "information", "is", "available", "to", "predict", "which", "patients", "are", "at", "highest", "risk", "for", "this", "complication", ".", "OBJECTIVE", ":", "To", "quantify", "specific", "clinical", "predictors", "of", "reduction", "in", "renal", "function", "in", "patients", "with", "CHF", "who", "are", "prescribed", "angiotensin", "-", "converting", "enzyme", "inhibitor", "therapy", ".", "METHOD", ":", "We", "analyzed", "data", "from", "the", "Studies", "of", "Left", "Ventricular", "Dysfunction", "(", "SOLVD", ")", ",", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "of", "enalapril", "for", "the", "treatment", "of", "CHF", ".", "There", "were", "3379", "patients", "randomly", "assigned", "to", "enalapril", "with", "a", "median", "follow", "-", "up", "of", "974", "days", "and", "3379", "patients", "randomly", "assigned", "to", "placebo", "with", "a", "mean", "follow", "-", "up", "of", "967", "days", ".", "Decreased", "renal", "function", "was", "defined", "as", "a", "rise", "in", "serum", "creatinine", ">", "/", "=", "0", ".", "5", "mg", "/", "dL", "(", "44", "micromol", "/", "L", ")", "from", "baseline", ".", "We", "used", "time", "-", "to", "-", "event", "analysis", "to", "identify", "potential", "predictors", "of", "decrease", "in", "renal", "function", "including", "age", ",", "baseline", "ejection", "fraction", ",", "baseline", "creatinine", ",", "low", "systolic", "blood", "pressure", "(", "<", "100", "mm", "Hg", ")", ",", "history", "of", "hypertension", ",", "diabetes", ",", "and", "use", "of", "antiplatelet", ",", "diuretic", ",", "and", "beta", "-", "blocker", "therapy", ".", "RESULTS", ":", "Patients", "randomly", "assigned", "to", "enalapril", "had", "a", "33", "%", "greater", "likelihood", "of", "decreased", "renal", "function", "than", "controls", "(", "P", "=", ".", "003", ")", ".", "By", "multivariate", "analysis", ",", "in", "both", "the", "placebo", "and", "enalapril", "groups", "older", "age", ",", "diuretic", "therapy", ",", "and", "diabetes", "were", "associated", "with", "decreased", "renal", "function", ",", "whereas", "beta", "-", "blocker", "therapy", "and", "higher", "ejection", "fraction", "were", "renoprotective", ".", "Older", "age", "was", "associated", "with", "a", "greater", "risk", "of", "developing", "decreased", "renal", "function", "in", "both", "groups", ",", "but", "significantly", "more", "so", "in", "the", "enalapril", "group", "(", "enalapril", ":", "risk", "ratio", "[", "RR", "]", "1", ".", "42", "per", "10", "years", ",", "95", "%", "confidence", "interval", "[", "CI", "]", "1", ".", "32", "-", "1", ".", "52", "with", "enalapril", ";", "placebo", ":", "RR", "1", ".", "18", ",", "95", "%", "CI", "1", ".", "12", "-", "1", ".", "25", ")", ".", "Diuretic", "therapy", "was", "likewise", "associated", "with", "a", "greater", "risk", "of", "decreased", "renal", "function", "in", "the", "enalapril", "group", "(", "RR", "1", ".", "89", ",", "95", "%", "CI", "1", ".", "70", "-", "2", ".", "08", ")", "than", "in", "the", "placebo", "group", "(", "RR", "1", ".", "35", ",", "95", "%", "CI", "1", ".", "09", "-", "1", ".", "66", ")", ".", "Conversely", ",", "enalapril", "had", "a", "relative", "renoprotective", "effect", "(", "RR", "1", ".", "33", ",", "95", "%", "CI", "1", ".", "13", "-", "1", ".", "53", ")", "compared", "with", "placebo", "(", "RR", "1", ".", "96", ",", "95", "%", "CI", "1", ".", "57", "-", "2", ".", "44", ")", "in", "patients", "with", "diabetes", ".", "A", "lower", "risk", "of", "renal", "impairment", "was", "seen", "in", "both", "groups", "with", "beta", "-", "blocker", "therapy", "(", "RR", "0", ".", "70", ",", "95", "%", "CI", "0", ".", "57", "-", "0", ".", "85", ")", "and", "higher", "baseline", "ejection", "fraction", "(", "RR", "0", ".", "93", "per", "5", "%", "increment", ",", "95", "%", "CI", "0", ".", "91", "-", "0", ".", "96", ")", ".", "CONCLUSIONS", ":", "Enalapril", "use", "caused", "a", "33", "%", "increase", "in", "the", "risk", "of", "decreased", "renal", "function", "in", "patients", "with", "CHF", ".", "Diuretic", "use", "and", "advanced", "age", "increased", "this", "risk", ".", "Diabetes", "was", "associated", "with", "an", "increased", "risk", "of", "renal", "impairment", "in", "all", "patients", "with", "CHF", ",", "but", "this", "risk", "was", "reduced", "in", "the", "enalapril", "group", "compared", "with", "the", "placebo", "group", ".", "beta", "-", "Blocker", "therapy", "and", "higher", "ejection", "fraction", "were", "renoprotective", "in", "all", "patients", "regardless", "of", "therapy", "."]], "ner": [[[129, 129, "Chemical"], [143, 143, "Chemical"], [262, 262, "Chemical"], [291, 291, "Chemical"], [343, 343, "Chemical"], [346, 346, "Chemical"], [375, 375, "Chemical"], [411, 411, "Chemical"], [455, 455, "Chemical"], [565, 565, "Chemical"], [616, 616, "Chemical"], [2, 4, "Disease"], [55, 57, "Disease"], [83, 86, "Disease"], [170, 172, "Disease"], [270, 272, "Disease"], [304, 306, "Disease"], [330, 332, "Disease"], [406, 408, "Disease"], [507, 508, "Disease"], [576, 578, "Disease"], [601, 602, "Disease"], [248, 248, "Chemical"], [296, 296, "Chemical"], [396, 396, "Chemical"], [584, 584, "Chemical"], [11, 11, "Chemical"], [32, 32, "Chemical"], [94, 94, "Chemical"], [180, 180, "Chemical"], [224, 224, "Chemical"], [8, 9, "Disease"], [44, 46, "Disease"], [48, 48, "Disease"], [90, 90, "Disease"], [134, 134, "Disease"], [582, 582, "Disease"], [607, 607, "Disease"], [23, 25, "Disease"], [110, 112, "Disease"], [239, 239, "Disease"], [241, 241, "Disease"], [300, 300, "Disease"], [501, 501, "Disease"], [593, 593, "Disease"]]], "relations": [[[129, 129, 2, 4, "CID"], [129, 129, 55, 57, "CID"], [129, 129, 83, 86, "CID"], [129, 129, 170, 172, "CID"], [129, 129, 270, 272, "CID"], [129, 129, 304, 306, "CID"], [129, 129, 330, 332, "CID"], [129, 129, 406, 408, "CID"], [129, 129, 507, 508, "CID"], [129, 129, 576, 578, "CID"], [129, 129, 601, 602, "CID"], [143, 143, 2, 4, "CID"], [143, 143, 55, 57, "CID"], [143, 143, 83, 86, "CID"], [143, 143, 170, 172, "CID"], [143, 143, 270, 272, "CID"], [143, 143, 304, 306, "CID"], [143, 143, 330, 332, "CID"], [143, 143, 406, 408, "CID"], [143, 143, 507, 508, "CID"], [143, 143, 576, 578, "CID"], [143, 143, 601, 602, "CID"], [262, 262, 2, 4, "CID"], [262, 262, 55, 57, "CID"], [262, 262, 83, 86, "CID"], [262, 262, 170, 172, "CID"], [262, 262, 270, 272, "CID"], [262, 262, 304, 306, "CID"], [262, 262, 330, 332, "CID"], [262, 262, 406, 408, "CID"], [262, 262, 507, 508, "CID"], [262, 262, 576, 578, "CID"], [262, 262, 601, 602, "CID"], [291, 291, 2, 4, "CID"], [291, 291, 55, 57, "CID"], [291, 291, 83, 86, "CID"], [291, 291, 170, 172, "CID"], [291, 291, 270, 272, "CID"], [291, 291, 304, 306, "CID"], [291, 291, 330, 332, "CID"], [291, 291, 406, 408, "CID"], [291, 291, 507, 508, "CID"], [291, 291, 576, 578, "CID"], [291, 291, 601, 602, "CID"], [343, 343, 2, 4, "CID"], [343, 343, 55, 57, "CID"], [343, 343, 83, 86, "CID"], [343, 343, 170, 172, "CID"], [343, 343, 270, 272, "CID"], [343, 343, 304, 306, "CID"], [343, 343, 330, 332, "CID"], [343, 343, 406, 408, "CID"], [343, 343, 507, 508, "CID"], [343, 343, 576, 578, "CID"], [343, 343, 601, 602, "CID"], [346, 346, 2, 4, "CID"], [346, 346, 55, 57, "CID"], [346, 346, 83, 86, "CID"], [346, 346, 170, 172, "CID"], [346, 346, 270, 272, "CID"], [346, 346, 304, 306, "CID"], [346, 346, 330, 332, "CID"], [346, 346, 406, 408, "CID"], [346, 346, 507, 508, "CID"], [346, 346, 576, 578, "CID"], [346, 346, 601, 602, "CID"], [375, 375, 2, 4, "CID"], [375, 375, 55, 57, "CID"], [375, 375, 83, 86, "CID"], [375, 375, 170, 172, "CID"], [375, 375, 270, 272, "CID"], [375, 375, 304, 306, "CID"], [375, 375, 330, 332, "CID"], [375, 375, 406, 408, "CID"], [375, 375, 507, 508, "CID"], [375, 375, 576, 578, "CID"], [375, 375, 601, 602, "CID"], [411, 411, 2, 4, "CID"], [411, 411, 55, 57, "CID"], [411, 411, 83, 86, "CID"], [411, 411, 170, 172, "CID"], [411, 411, 270, 272, "CID"], [411, 411, 304, 306, "CID"], [411, 411, 330, 332, "CID"], [411, 411, 406, 408, "CID"], [411, 411, 507, 508, "CID"], [411, 411, 576, 578, "CID"], [411, 411, 601, 602, "CID"], [455, 455, 2, 4, "CID"], [455, 455, 55, 57, "CID"], [455, 455, 83, 86, "CID"], [455, 455, 170, 172, "CID"], [455, 455, 270, 272, "CID"], [455, 455, 304, 306, "CID"], [455, 455, 330, 332, "CID"], [455, 455, 406, 408, "CID"], [455, 455, 507, 508, "CID"], [455, 455, 576, 578, "CID"], [455, 455, 601, 602, "CID"], [565, 565, 2, 4, "CID"], [565, 565, 55, 57, "CID"], [565, 565, 83, 86, "CID"], [565, 565, 170, 172, "CID"], [565, 565, 270, 272, "CID"], [565, 565, 304, 306, "CID"], [565, 565, 330, 332, "CID"], [565, 565, 406, 408, "CID"], [565, 565, 507, 508, "CID"], [565, 565, 576, 578, "CID"], [565, 565, 601, 602, "CID"], [616, 616, 2, 4, "CID"], [616, 616, 55, 57, "CID"], [616, 616, 83, 86, "CID"], [616, 616, 170, 172, "CID"], [616, 616, 270, 272, "CID"], [616, 616, 304, 306, "CID"], [616, 616, 330, 332, "CID"], [616, 616, 406, 408, "CID"], [616, 616, 507, 508, "CID"], [616, 616, 576, 578, "CID"], [616, 616, 601, 602, "CID"], [248, 248, 2, 4, "CID"], [248, 248, 55, 57, "CID"], [248, 248, 83, 86, "CID"], [248, 248, 170, 172, "CID"], [248, 248, 270, 272, "CID"], [248, 248, 304, 306, "CID"], [248, 248, 330, 332, "CID"], [248, 248, 406, 408, "CID"], [248, 248, 507, 508, "CID"], [248, 248, 576, 578, "CID"], [248, 248, 601, 602, "CID"], [296, 296, 2, 4, "CID"], [296, 296, 55, 57, "CID"], [296, 296, 83, 86, "CID"], [296, 296, 170, 172, "CID"], [296, 296, 270, 272, "CID"], [296, 296, 304, 306, "CID"], [296, 296, 330, 332, "CID"], [296, 296, 406, 408, "CID"], [296, 296, 507, 508, "CID"], [296, 296, 576, 578, "CID"], [296, 296, 601, 602, "CID"], [396, 396, 2, 4, "CID"], [396, 396, 55, 57, "CID"], [396, 396, 83, 86, "CID"], [396, 396, 170, 172, "CID"], [396, 396, 270, 272, "CID"], [396, 396, 304, 306, "CID"], [396, 396, 330, 332, "CID"], [396, 396, 406, 408, "CID"], [396, 396, 507, 508, "CID"], [396, 396, 576, 578, "CID"], [396, 396, 601, 602, "CID"], [584, 584, 2, 4, "CID"], [584, 584, 55, 57, "CID"], [584, 584, 83, 86, "CID"], [584, 584, 170, 172, "CID"], [584, 584, 270, 272, "CID"], [584, 584, 304, 306, "CID"], [584, 584, 330, 332, "CID"], [584, 584, 406, 408, "CID"], [584, 584, 507, 508, "CID"], [584, 584, 576, 578, "CID"], [584, 584, 601, 602, "CID"]]], "clusters": [], "translated": "<26>血管紧张素</26>转化酶抑制剂治疗期间<31>心力衰竭</31>患者<11>肾功能下降</11>的预测因素：<38>左心室功能障碍研究的结果</38>（SOLVD）背景：虽然<27>血管紧张素</27>转换酶抑制剂治疗可降低<32>充血性心力衰竭</32>（<33>CHF</33>）患者的死亡率，它还可能导致<12>肾功能下降</12>。几乎没有信息可以预测哪些患者发生这种并发症的风险最高。目的：量化<34>CHF</34>患者<28>血管紧张素</28>转换酶抑制剂治疗的<13>肾功能下降</13>的特异性临床预测因子。方法：我们分析了<39>左心室功能障碍</39>（SOLVD）研究的数据，这是一项随机、双盲、安慰剂对照试验，<0>依那普利</0>用于治疗<35>CHF</35>。有3379名患者被随机分配到<1>依那普利</1>组，中位随访时间为974天，3379名患者被随机分配到安慰剂组，平均随访时间为967天。<14>肾功能下降</14>定义为血清<29>肌酐</29>≥0.5毫克/分升（44微摩尔/升）从基线升高。我们使用事件发生时间分析来确定肾功能下降的潜在预测因素，包括年龄、基线射血分数、基线<30>肌酐</30>、低收缩压（<100mmHg）、<40>病史高血压</40>、<41>糖尿病</41>，以及使用抗血小板药物、<22>利尿剂</22>和β受体阻滞剂治疗。结果：与对照组相比，随机分配到<2>依那普利</2>组的患者<15>肾功能下降</15>的可能性高33%（P=.003）。通过多变量分析，在安慰剂组和<3>依那普利</3>组中，年龄较大、<23>利尿剂</23>治疗和<42>糖尿病</42>与<16>肾功能下降</16>，而β受体阻滞剂治疗和更高的射血分数对肾脏有保护作用。在两组中，年龄较大与发生<17>肾功能下降</17>的风险较高有关，但在<4>依那普利</4>组中更是如此（<5>依那普利</5>：风险比率[RR]1.42每10年，95%置信区间[CI]1.32-1.52与<6>依那普利</6>；安慰剂：RR1.18，95%CI1.12-1.25)。<24>利尿剂</24>治疗同样与<7>依那普利</7>组<18>肾功能下降</18>的更大风险相关（RR1.89，95%CI1.70-2.08）比安慰剂组（RR1.35，95%CI1.09-1.66)。相反，与安慰剂相比，<8>依那普利</8>具有相对的肾脏保护作用(RR1.33，95%CI1.13-1.53) (RR1.96，95%CI1.57-2.44) <43>糖尿病</43>患者。<19>肾功能损害</19>的风险在接受β受体阻滞剂治疗(RR0.70，95%CI0.57-0.85)和较高基线射血分数(RR0.93每增加5%，95%CI0.91-0.96)的两组中均可见。结论：<9>依那普利</9>的使用导致<36>CHF</36>患者<20>肾功能下降</20>的风险增加33%。<25>利尿剂</25>的使用和高龄增加了这种风险。<44>糖尿病</44>与所有<37> CHF </37>患者的<21>肾功能损害</21>风险增加相关，但<10>依那普利</10>组与安慰剂组相比。β-受体阻滞剂治疗和更高的射血分数对所有患者均有肾脏保护作用，无论治疗如何。", "revised": true}
{"doc_key": "19058474", "sentences": [["Fatal", "haemopericardium", "and", "gastrointestinal", "haemorrhage", "due", "to", "possible", "interaction", "of", "cranberry", "juice", "with", "warfarin", ".", "We", "report", "a", "case", "of", "fatal", "internal", "haemorrhage", "in", "an", "elderly", "man", "who", "consumed", "only", "cranberry", "juice", "for", "two", "weeks", "while", "maintaining", "his", "usual", "dosage", "of", "warfarin", ".", "We", "propose", "that", "naturally", "occurring", "compounds", "such", "as", "flavonoids", ",", "which", "are", "present", "in", "fruit", "juices", ",", "may", "increase", "the", "potency", "of", "warfarin", "by", "competing", "for", "the", "enzymes", "that", "normally", "inactivate", "warfarin", ".", "While", "traditionally", "regarded", "as", "foodstuffs", ",", "consumption", "of", "fruit", "juices", "should", "be", "considered", "when", "patients", "develop", "adverse", "drug", "reactions", "."]], "ner": [[[13, 13, "Chemical"], [41, 41, "Chemical"], [65, 65, "Chemical"], [74, 74, "Chemical"], [3, 4, "Disease"], [51, 51, "Chemical"], [1, 1, "Disease"], [22, 22, "Disease"]]], "relations": [[[13, 13, 3, 4, "CID"], [41, 41, 3, 4, "CID"], [65, 65, 3, 4, "CID"], [74, 74, 3, 4, "CID"], [51, 51, 3, 4, "CID"]]], "clusters": [], "translated": "致命的 <6>心包积血</6> 和 <4>胃肠道出血</4> 由于蔓越莓汁可能与<0>华法林</0>相互作用。我们报告了一例致命的内出血<7></7>病例，该病例发生在一位老人身上，他只喝了两周的蔓越莓汁，同时维持了<1>华法林</1>的常用剂量。我们提出，果汁中存在的天然化合物（例如<5>类黄酮</5>）可以通过竞争通常使<3>华法林</3>失活的酶来提高<2>华法林</2>的效力。 虽然传统上被视为食品，但当患者出现药物不良反应时，应考虑食用果汁。", "revised": true}
{"doc_key": "19135948", "sentences": [["Graft", "-", "versus", "-", "host", "disease", "prophylaxis", "with", "everolimus", "and", "tacrolimus", "is", "associated", "with", "a", "high", "incidence", "of", "sinusoidal", "obstruction", "syndrome", "and", "microangiopathy", ":", "results", "of", "the", "EVTAC", "trial", ".", "A", "calcineurin", "inhibitor", "combined", "with", "methotrexate", "is", "the", "standard", "prophylaxis", "for", "graft", "-", "versus", "-", "host", "disease", "(", "GVHD", ")", "after", "allogeneic", "hematopoietic", "stem", "cell", "transplantation", "(", "HSCT", ")", ".", "Everolimus", ",", "a", "derivative", "of", "sirolimus", ",", "seems", "to", "mediate", "antileukemia", "effects", ".", "We", "report", "on", "a", "combination", "of", "everolimus", "and", "tacrolimus", "in", "24", "patients", "(", "median", "age", ",", "62", "years", ")", "with", "either", "myelodysplastic", "syndrome", "(", "MDS", ";", "n", "=", "17", ")", "or", "acute", "myeloid", "leukemia", "(", "AML", ";", "n", "=", "7", ")", "undergoing", "intensive", "conditioning", "followed", "by", "HSCT", "from", "related", "(", "n", "=", "4", ")", "or", "unrelated", "(", "n", "=", "20", ")", "donors", ".", "All", "patients", "engrafted", ",", "and", "only", "1", "patient", "experienced", "grade", "IV", "mucositis", ".", "Nine", "patients", "(", "37", "%", ")", "developed", "acute", "grade", "II", "-", "IV", "GVHD", ",", "and", "11", "of", "17", "evaluable", "patients", "(", "64", "%", ")", "developed", "chronic", "extensive", "GVHD", ".", "Transplantation", "-", "associated", "microangiopathy", "(", "TMA", ")", "occurred", "in", "7", "patients", "(", "29", "%", ")", ",", "with", "2", "cases", "of", "acute", "renal", "failure", ".", "The", "study", "was", "terminated", "prematurely", "because", "an", "additional", "6", "patients", "(", "25", "%", ")", "developed", "sinusoidal", "obstruction", "syndrome", "(", "SOS", ")", ",", "which", "was", "fatal", "in", "2", "cases", ".", "With", "a", "median", "follow", "-", "up", "of", "26", "months", ",", "the", "2", "-", "year", "overall", "survival", "rate", "was", "47", "%", ".", "Although", "this", "new", "combination", "appears", "to", "be", "effective", "as", "a", "prophylactic", "regimen", "for", "acute", "GVHD", ",", "the", "incidence", "of", "TMA", "and", "SOS", "is", "considerably", "higher", "than", "seen", "with", "other", "regimens", "."]], "ner": [[[8, 8, "Chemical"], [60, 60, "Chemical"], [79, 79, "Chemical"], [18, 20, "Disease"], [217, 219, "Disease"], [221, 221, "Disease"], [273, 273, "Disease"], [22, 22, "Disease"], [178, 181, "Disease"], [183, 183, "Disease"], [271, 271, "Disease"], [198, 200, "Disease"], [10, 10, "Chemical"], [81, 81, "Chemical"], [0, 5, "Disease"], [41, 46, "Disease"], [48, 48, "Disease"], [161, 161, "Disease"], [176, 176, "Disease"], [266, 266, "Disease"], [35, 35, "Chemical"], [65, 65, "Chemical"], [94, 95, "Disease"], [97, 97, "Disease"], [104, 106, "Disease"], [108, 108, "Disease"], [147, 147, "Disease"]]], "relations": [[[8, 8, 18, 20, "CID"], [8, 8, 217, 219, "CID"], [8, 8, 221, 221, "CID"], [8, 8, 273, 273, "CID"], [60, 60, 18, 20, "CID"], [60, 60, 217, 219, "CID"], [60, 60, 221, 221, "CID"], [60, 60, 273, 273, "CID"], [79, 79, 18, 20, "CID"], [79, 79, 217, 219, "CID"], [79, 79, 221, 221, "CID"], [79, 79, 273, 273, "CID"], [8, 8, 22, 22, "CID"], [8, 8, 178, 181, "CID"], [8, 8, 183, 183, "CID"], [8, 8, 271, 271, "CID"], [60, 60, 22, 22, "CID"], [60, 60, 178, 181, "CID"], [60, 60, 183, 183, "CID"], [60, 60, 271, 271, "CID"], [79, 79, 22, 22, "CID"], [79, 79, 178, 181, "CID"], [79, 79, 183, 183, "CID"], [79, 79, 271, 271, "CID"], [8, 8, 198, 200, "CID"], [60, 60, 198, 200, "CID"], [79, 79, 198, 200, "CID"], [10, 10, 18, 20, "CID"], [10, 10, 217, 219, "CID"], [10, 10, 221, 221, "CID"], [10, 10, 273, 273, "CID"], [81, 81, 18, 20, "CID"], [81, 81, 217, 219, "CID"], [81, 81, 221, 221, "CID"], [81, 81, 273, 273, "CID"], [10, 10, 22, 22, "CID"], [10, 10, 178, 181, "CID"], [10, 10, 183, 183, "CID"], [10, 10, 271, 271, "CID"], [81, 81, 22, 22, "CID"], [81, 81, 178, 181, "CID"], [81, 81, 183, 183, "CID"], [81, 81, 271, 271, "CID"], [10, 10, 198, 200, "CID"], [81, 81, 198, 200, "CID"]]], "clusters": [], "translated": "<14> 移植物抗宿主病 </14> 使用 <0> 依维莫司 </0> 和 <12> 他克莫司 </12> 预防 <3> 肝窦阻塞综合征 </3> 和 <7> 微血管病 </7>：EVTAC 试验的结果。钙调神经磷酸酶抑制剂联合 <20> 甲氨蝶呤 </20> 是异基因造血干细胞移植 (HSCT) 后 <15> 移植物抗宿主病 </15>（<16> GVHD </16>）的标准预防措施。 <1> 依维莫司 </1> 是 <21> 西罗莫司 </21> 的衍生物，似乎具有抗白血病效果。我们报告在 24 名接受强化处理并接受相关（n = 4）或无关（n = 20）供体的 <22> 骨髓增生异常综合征 </22>（<23> MDS </23>; n = 17）或 <24> 急性髓性白血病 </24>（<25> AML </25>; n = 7）患者中使用 <2> 依维莫司 </2> 和 <13> 他克莫司 </13>。所有患者均成功移植，只有 1 名患者出现 IV 级 <26> 粘膜炎 </26>。 9 名患者（37%）发生急性 II-IV 级 <17> GVHD </17>，17 名被评估的患者中有 11 名（64%）发生广泛慢性 <18> GVHD </18>。在 7 名患者 (29%) 中发生 <8> 移植相关微血管病 </8>（<9> TMA </9>），其中 2 例出现 <11> 急性肾功能衰竭 </11> 。该研究因另外 6 名患者（25%）出现 <4> 肝窦阻塞综合征 </4> (<5> SOS </5>) 而提前终止，其中 2 例患者死亡。中位随访时间为 26 个月，2 年总生存率为 47%。尽管这种新组合作为急性 <19> GVHD </19> 的预防方案似乎有效，但 <10> TMA </10> 和 <6> SOS </6> 的发生率明显高于其他方案。", "revised": true}
{"doc_key": "11271907", "sentences": [["Fatal", "haemorrhagic", "myocarditis", "secondary", "to", "cyclophosphamide", "therapy", ".", "Haemorrhagic", "myocarditis", "is", "a", "rare", "but", "important", "complication", "of", "cyclophosphamide", "therapy", ".", "Echocardiographic", "identification", "of", "the", "disorder", "can", "be", "made", ".", "We", "believe", "that", "the", "ultrasound", "features", "of", "this", "disorder", "have", "not", "been", "previously", "reported", "."]], "ner": [[[5, 5, "Chemical"], [17, 17, "Chemical"], [1, 2, "Disease"], [8, 9, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 8, 9, "CID"], [17, 17, 1, 2, "CID"], [17, 17, 8, 9, "CID"]]], "clusters": [], "translated": "继发于<0>环磷酰胺</0>治疗的致命性<2>出血性心肌炎</2>。 <3>出血性心肌炎</3>是<1>环磷酰胺</1>治疗的一种罕见但重要的并发症。可以通过超声心动图鉴别该病症。我们认为，这种疾病的超声特征以前没有被报道过。", "revised": true}
{"doc_key": "18441470", "sentences": [["Complete", "atrioventricular", "block", "secondary", "to", "lithium", "therapy", ".", "Sinus", "node", "dysfunction", "has", "been", "reported", "most", "frequently", "among", "the", "adverse", "cardiovascular", "effects", "of", "lithium", ".", "In", "the", "present", "case", ",", "complete", "atrioventricular", "(", "AV", ")", "block", "with", "syncopal", "attacks", "developed", "secondary", "to", "lithium", "therapy", ",", "necessitating", "permanent", "pacemaker", "implantation", ".", "Serum", "lithium", "levels", "remained", "under", "or", "within", "the", "therapeutic", "range", "during", "the", "syncopal", "attacks", ".", "Lithium", "should", "be", "used", "with", "extreme", "caution", ",", "especially", "in", "patients", "with", "mild", "disturbance", "of", "AV", "conduction", "."]], "ner": [[[5, 5, "Chemical"], [22, 22, "Chemical"], [41, 41, "Chemical"], [50, 50, "Chemical"], [64, 64, "Chemical"], [1, 2, "Disease"], [30, 34, "Disease"], [8, 10, "Disease"], [36, 37, "Disease"], [61, 62, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 30, 34, "CID"], [22, 22, 1, 2, "CID"], [22, 22, 30, 34, "CID"], [41, 41, 1, 2, "CID"], [41, 41, 30, 34, "CID"], [50, 50, 1, 2, "CID"], [50, 50, 30, 34, "CID"], [64, 64, 1, 2, "CID"], [64, 64, 30, 34, "CID"], [5, 5, 8, 10, "CID"], [22, 22, 8, 10, "CID"], [41, 41, 8, 10, "CID"], [50, 50, 8, 10, "CID"], [64, 64, 8, 10, "CID"]]], "clusters": [], "translated": "继发于<0>锂</0>疗法的完全性<5>房室传导阻滞</5>。在<1>锂</1>的不良心血管反应中，<7>窦房结功能障碍 </7>最为常见。在本病例中，继发于<2>锂</2>治疗的完全性<6>房室 ( AV ) 阻滞</6>伴随<8>晕厥发作</8>，需要植入永久性起搏器。在<9>晕厥发作</9>期间，血清<3>锂</3>水平一直低于或在治疗范围内。<4>锂</4>应极其谨慎地使用，尤其是在房室传导轻度障碍的患者中。", "revised": true}
{"doc_key": "11890511", "sentences": [["Erectile", "dysfunction", "occurs", "following", "substantia", "nigra", "lesions", "in", "the", "rat", ".", "Erectile", "function", "was", "assessed", "6", "weeks", "following", "uni", "-", "and", "bilateral", "injections", "of", "6", "-", "hydroxydopamine", "in", "the", "substantia", "nigra", "nucleus", "of", "the", "brain", ".", "Behavioral", "apomorphine", "-", "induced", "penile", "erections", "were", "reduced", "(", "5", "/", "8", ")", "and", "increased", "(", "3", "/", "8", ")", "in", "uni", "-", "and", "bilateral", "lesioned", "animals", ".", "Intracavernous", "pressures", ",", "following", "electrical", "stimulation", "of", "the", "cavernous", "nerve", ",", "decreased", "in", "lesioned", "animals", ".", "Lesions", "of", "the", "substantia", "nigra", "were", "confirmed", "by", "histology", ".", "Concentration", "of", "dopamine", "and", "its", "metabolites", "were", "decreased", "in", "the", "striatum", "of", "substantia", "nigra", "lesioned", "rats", ".", "Lesions", "of", "the", "substantia", "nigra", "are", "therefore", "associated", "with", "erectile", "dysfunction", "in", "rats", "and", "may", "serve", "as", "a", "model", "to", "study", "erectile", "dysfunction", "in", "Parkinson", "'s", "disease", "."]], "ner": [[[24, 26, "Chemical"], [0, 1, "Disease"], [116, 117, "Disease"], [128, 129, "Disease"], [37, 37, "Chemical"], [92, 92, "Chemical"], [131, 133, "Disease"]]], "relations": [[[24, 26, 0, 1, "CID"], [24, 26, 116, 117, "CID"], [24, 26, 128, 129, "CID"]]], "clusters": [], "translated": "<1>勃起功能障碍</1>发生在大鼠黑质损伤后。在大脑黑质核中单侧和双侧注射<0>6-羟基多巴胺</0>后6周评估勃起功能。行为<4>阿扑吗啡</4>诱导的阴茎勃起在单侧和双侧受损动物中减少（5/8）和增加（3/8）。对海绵体神经进行电刺激后，受损动物的海绵体内压力下降。黑质病变经组织学证实。黑质损伤大鼠<2>勃起功能障碍</2>与纹状体<5>多巴胺</5>及其代谢物浓度降低相关。因此，黑质损伤与大鼠的<2>勃起功能障碍</2>相关，并且可以作为研究<6>帕金森病</6>中的<3>勃起功能障碍</3>的模型。", "revised": true}
{"doc_key": "12549952", "sentences": [["Acute", "liver", "failure", "with", "concurrent", "bupropion", "and", "carbimazole", "therapy", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "fatal", "liver", "failure", "possibly", "associated", "with", "concurrent", "use", "of", "bupropion", "and", "carbimazole", ".", "CASE", "SUMMARY", ":", "A", "41", "-", "year", "-", "old", "Chinese", "man", "with", "a", "history", "of", "hyperthyroidism", "had", "been", "treated", "with", "carbimazole", "and", "propranolol", "for", "the", "past", "5", "years", ".", "He", "received", "a", "10", "-", "day", "course", "of", "bupropion", "as", "an", "aid", "for", "smoking", "cessation", "10", "weeks", "prior", "to", "presentation", ".", "He", "developed", "acute", "liver", "failure", "with", "rapid", "deterioration", "of", "renal", "function", ".", "Liver", "biopsy", "showed", "evidence", "of", "nonspecific", "drug", "-", "induced", "acute", "liver", "injury", ".", "His", "condition", "was", "further", "complicated", "by", "sepsis", "and", "coagulopathy", ".", "Death", "resulted", "19", "days", "after", "the", "onset", "of", "symptoms", ".", "The", "likelihood", "that", "bupropion", "induced", "hepatotoxicity", "in", "our", "patient", "was", "possible", ",", "based", "on", "the", "Naranjo", "probability", "scale", ".", "DISCUSSION", ":", "Although", "there", "is", "increasing", "evidence", "of", "hepatotoxicity", "induced", "by", "bupropion", ",", "this", "is", "the", "first", "case", "of", "fatality", "that", "could", "have", "resulted", "from", "acute", "liver", "failure", "in", "a", "patient", "receiving", "bupropion", "while", "on", "concomitant", "treatment", "with", "carbimazole", ".", "CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "the", "possibility", "of", "acute", "liver", "insult", "induced", "by", "bupropion", "given", "concurrently", "with", "other", "hepatotoxic", "drugs", "."]], "ner": [[[5, 5, "Chemical"], [26, 26, "Chemical"], [67, 67, "Chemical"], [128, 128, "Chemical"], [155, 155, "Chemical"], [176, 176, "Chemical"], [199, 199, "Chemical"], [0, 2, "Disease"], [82, 84, "Disease"], [169, 171, "Disease"], [194, 196, "Disease"], [7, 7, "Chemical"], [28, 28, "Chemical"], [50, 50, "Chemical"], [182, 182, "Chemical"], [98, 103, "Disease"], [130, 130, "Disease"], [152, 152, "Disease"], [204, 204, "Disease"], [52, 52, "Chemical"], [18, 19, "Disease"], [45, 45, "Disease"], [111, 111, "Disease"], [113, 113, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 82, 84, "CID"], [5, 5, 169, 171, "CID"], [5, 5, 194, 196, "CID"], [26, 26, 0, 2, "CID"], [26, 26, 82, 84, "CID"], [26, 26, 169, 171, "CID"], [26, 26, 194, 196, "CID"], [67, 67, 0, 2, "CID"], [67, 67, 82, 84, "CID"], [67, 67, 169, 171, "CID"], [67, 67, 194, 196, "CID"], [128, 128, 0, 2, "CID"], [128, 128, 82, 84, "CID"], [128, 128, 169, 171, "CID"], [128, 128, 194, 196, "CID"], [155, 155, 0, 2, "CID"], [155, 155, 82, 84, "CID"], [155, 155, 169, 171, "CID"], [155, 155, 194, 196, "CID"], [176, 176, 0, 2, "CID"], [176, 176, 82, 84, "CID"], [176, 176, 169, 171, "CID"], [176, 176, 194, 196, "CID"], [199, 199, 0, 2, "CID"], [199, 199, 82, 84, "CID"], [199, 199, 169, 171, "CID"], [199, 199, 194, 196, "CID"], [7, 7, 0, 2, "CID"], [7, 7, 82, 84, "CID"], [7, 7, 169, 171, "CID"], [7, 7, 194, 196, "CID"], [28, 28, 0, 2, "CID"], [28, 28, 82, 84, "CID"], [28, 28, 169, 171, "CID"], [28, 28, 194, 196, "CID"], [50, 50, 0, 2, "CID"], [50, 50, 82, 84, "CID"], [50, 50, 169, 171, "CID"], [50, 50, 194, 196, "CID"], [182, 182, 0, 2, "CID"], [182, 182, 82, 84, "CID"], [182, 182, 169, 171, "CID"], [182, 182, 194, 196, "CID"], [5, 5, 98, 103, "CID"], [5, 5, 130, 130, "CID"], [5, 5, 152, 152, "CID"], [5, 5, 204, 204, "CID"], [26, 26, 98, 103, "CID"], [26, 26, 130, 130, "CID"], [26, 26, 152, 152, "CID"], [26, 26, 204, 204, "CID"], [67, 67, 98, 103, "CID"], [67, 67, 130, 130, "CID"], [67, 67, 152, 152, "CID"], [67, 67, 204, 204, "CID"], [128, 128, 98, 103, "CID"], [128, 128, 130, 130, "CID"], [128, 128, 152, 152, "CID"], [128, 128, 204, 204, "CID"], [155, 155, 98, 103, "CID"], [155, 155, 130, 130, "CID"], [155, 155, 152, 152, "CID"], [155, 155, 204, 204, "CID"], [176, 176, 98, 103, "CID"], [176, 176, 130, 130, "CID"], [176, 176, 152, 152, "CID"], [176, 176, 204, 204, "CID"], [199, 199, 98, 103, "CID"], [199, 199, 130, 130, "CID"], [199, 199, 152, 152, "CID"], [199, 199, 204, 204, "CID"], [7, 7, 98, 103, "CID"], [7, 7, 130, 130, "CID"], [7, 7, 152, 152, "CID"], [7, 7, 204, 204, "CID"], [28, 28, 98, 103, "CID"], [28, 28, 130, 130, "CID"], [28, 28, 152, 152, "CID"], [28, 28, 204, 204, "CID"], [50, 50, 98, 103, "CID"], [50, 50, 130, 130, "CID"], [50, 50, 152, 152, "CID"], [50, 50, 204, 204, "CID"], [182, 182, 98, 103, "CID"], [182, 182, 130, 130, "CID"], [182, 182, 152, 152, "CID"], [182, 182, 204, 204, "CID"]]], "clusters": [], "translated": "<7>急性肝功能衰竭</7> 同时接受<0>安非他酮</0>和<11>卡比马唑</11>治疗。目的：报告一例可能与同时使用<1>安非他酮</1>和<12>卡比马唑</12>有关的致命性<20>肝功能衰竭</20>。病例概要：一名41岁的中国男性，有<21>甲亢</21>病史，过去5年一直接受<13>卡比马唑</13>和<19>普萘洛尔</19>治疗。在就诊前10周，他接受了为期10天的<2>安非他酮</2>疗程作为戒烟辅助剂。他患上了<8>急性肝功能衰竭</8>，肾功能迅速恶化。肝活检显示非特异性<15>药物性急性肝损伤</15>的证据。他的情况还进一步复杂化，因<22>败血症</22>和<23>凝血障碍</23>。出现症状后19天死亡。根据 Naranjo 概率量表，我们患者中由<3>安非他酮</3>引起<16>肝毒性</16>的可能性是可能的。讨论：尽管有越来越多<17>安非他酮</17>致<4>肝毒性</4>的证据，但这是第一例可能由于<5>安非他酮</5>与<14>卡比马唑</14>同时治疗而导致<9>急性肝功能衰竭</9>的死亡病例。结论：临床医生应该意识到，<6>安非他酮</6>与其他<18>肝毒性</18>药物同时给药可能会导致<10>急性肝损伤</10>。", "revised": true}
{"doc_key": "15276120", "sentences": [["Time", "trends", "in", "warfarin", "-", "associated", "hemorrhage", ".", "The", "annual", "incidence", "of", "warfarin", "-", "related", "bleeding", "at", "Brigham", "and", "Women", "'s", "Hospital", "increased", "from", "0", ".", "97", "/", "1", ",", "000", "patient", "admissions", "in", "the", "first", "time", "period", "(", "January", "1995", "to", "October", "1998", ")", "to", "1", ".", "19", "/", "1", ",", "000", "patient", "admissions", "in", "the", "second", "time", "period", "(", "November", "1998", "to", "August", "2002", ")", "of", "this", "study", ".", "The", "proportion", "of", "patients", "with", "major", "and", "intracranial", "bleeding", "increased", "from", "20", ".", "2", "%", "and", "1", ".", "9", "%", ",", "respectively", ",", "in", "the", "first", "time", "period", ",", "to", "33", ".", "3", "%", "and", "7", ".", "8", "%", ",", "respectively", ",", "in", "the", "second", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [6, 6, "Disease"], [15, 15, "Disease"], [78, 79, "Disease"]]], "relations": [[[3, 3, 6, 6, "CID"], [3, 3, 15, 15, "CID"], [12, 12, 6, 6, "CID"], [12, 12, 15, 15, "CID"], [3, 3, 78, 79, "CID"], [12, 12, 78, 79, "CID"]]], "clusters": [], "translated": "<0>华法林</0> 相关的<2>出血</2> 的时间趋势。布莱根妇女医院<1>华法林</1> <3>相关的出血</3>的年发生率从0.97/1,000病人入院在第一时间段（1995年1月至1998年10月），增加至1.19/1,000病人入院在本研究的第二个时间段（1998年11月至2002年8月）。严重和<4>颅内出血</4>患者的比例从第一时间段的20.2%和1.9%，分别增加到第二时间段的33.3%和7.8%。", "revised": true}
{"doc_key": "19940105", "sentences": [["Metabotropic", "glutamate", "7", "receptor", "subtype", "modulates", "motor", "symptoms", "in", "rodent", "models", "of", "Parkinson", "'s", "disease", ".", "Metabotropic", "glutamate", "(", "mGlu", ")", "receptors", "modulate", "synaptic", "transmission", "in", "the", "central", "nervous", "system", "and", "represent", "promising", "therapeutic", "targets", "for", "symptomatic", "treatment", "of", "Parkinson", "'s", "disease", "(", "PD", ")", ".", "Among", "the", "eight", "mGlu", "receptor", "subtypes", ",", "mGlu7", "receptor", "is", "prominently", "expressed", "in", "the", "basal", "ganglia", ",", "but", "its", "role", "in", "restoring", "motor", "function", "in", "animal", "models", "of", "PD", "is", "not", "known", ".", "The", "effects", "of", "N", ",", "N", "'", "-", "dibenzhydrylethane", "-", "1", ",", "2", "-", "diamine", "dihydrochloride", "(", "AMN082", ")", ",", "the", "first", "selective", "allosteric", "activator", "of", "mGlu7", "receptors", ",", "were", "thus", "tested", "in", "different", "rodent", "models", "of", "PD", ".", "Here", ",", "we", "show", "that", "oral", "(", "5", "mg", "/", "kg", ")", "or", "intrastriatal", "administration", "(", "0", ".", "1", "and", "0", ".", "5", "nmol", ")", "of", "AMN082", "reverses", "haloperidol", "-", "induced", "catalepsy", "in", "rats", ".", "AMN082", "(", "2", ".", "5", "and", "5", "mg", "/", "kg", ")", "reduces", "apomorphine", "-", "induced", "rotations", "in", "unilateral", "6", "-", "hydroxydopamine", "(", "6", "-", "OHDA", ")", "-", "lesioned", "rats", ".", "In", "a", "more", "complex", "task", "commonly", "used", "to", "evaluate", "major", "akinetic", "symptoms", "of", "PD", "patients", ",", "5", "mg", "/", "kg", "AMN082", "reverses", "the", "increased", "reaction", "time", "to", "respond", "to", "a", "cue", "of", "bilateral", "6", "-", "OHDA", "-", "lesioned", "rats", ".", "In", "addition", ",", "AMN082", "reduces", "the", "duration", "of", "haloperidol", "-", "induced", "catalepsy", "in", "a", "mGlu7", "receptor", "-", "dependent", "manner", "in", "wild", "-", "type", "but", "not", "mGlu7", "receptor", "knockout", "mice", ".", "Higher", "doses", "of", "AMN082", "(", "10", "and", "20", "mg", "/", "kg", "p", ".", "o", ".", ")", "have", "no", "effect", "on", "the", "same", "models", "of", "PD", ".", "Overall", "these", "findings", "suggest", "that", "mGlu7", "receptor", "activation", "can", "reverse", "motor", "dysfunction", "associated", "with", "reduced", "dopamine", "activity", ".", "Selective", "ligands", "of", "mGlu7", "receptor", "subtypes", "may", "thus", "be", "considered", "as", "promising", "compounds", "for", "the", "development", "of", "antiparkinsonian", "therapeutic", "strategies", "."]], "ner": [[[146, 146, "Chemical"], [231, 231, "Chemical"], [149, 149, "Disease"], [234, 234, "Disease"], [1, 1, "Chemical"], [17, 17, "Chemical"], [12, 14, "Disease"], [39, 41, "Disease"], [43, 43, "Disease"], [74, 74, "Disease"], [116, 116, "Disease"], [196, 196, "Disease"], [277, 277, "Disease"], [193, 193, "Disease"], [82, 94, "Chemical"], [96, 96, "Chemical"], [144, 144, "Chemical"], [153, 153, "Chemical"], [203, 203, "Chemical"], [226, 226, "Chemical"], [256, 256, "Chemical"], [165, 165, "Chemical"], [171, 173, "Chemical"], [175, 177, "Chemical"], [216, 218, "Chemical"], [294, 294, "Chemical"]]], "relations": [[[146, 146, 149, 149, "CID"], [146, 146, 234, 234, "CID"], [231, 231, 149, 149, "CID"], [231, 231, 234, 234, "CID"]]], "clusters": [], "translated": "代谢型<4>谷氨酸</4> 7 受体亚型调节<6>帕金森病</6> 啮齿动物模型的运动症状。代谢型<5>谷氨酸</5> (mGlu) 受体可调节中枢神经系统的突触传递，是对症治疗<7>帕金森病</7> (<8>PD</8>)的有前途的治疗靶点。在8种mGlu受体亚型中，mGlu7受体主要在基底神经节表达，但其在<9>PD</9>动物模型中恢复运动功能的作用尚不清楚。<14>N,N'-二二苯甲基乙烷-1,2-二胺盐酸盐</14> (<15>AMN082</15>)，第一个mGlu7受体的选择性变构激活剂，因此在不同的啮齿动物模型中进行了测试。<10>PD</10>。在这里，我们表明口服（5 毫克/千克）或纹状体内给药（0.1和0.5 nmol）<16>AMN082</16>可逆转<0>氟哌啶醇</0>-诱发的<2>僵直</2>在大鼠中。<17>AMN082</17>（2.5和5 mg/kg）减少<21>阿朴吗啡</21>-单侧<22>6-羟基多巴胺</22>（<23>6-OHDA</23>）-受伤的老鼠。在通常用于评估<11>PD</11>患者的主要<13>运动障碍</13>症状的更复杂的任务中，5 mg/kg<18>AMN082</18>逆转增加的反应时间以响应双侧<24>6-OHDA</24>受损大鼠的线索。此外，<19>AMN082</19>在野生型而非mGlu7受体敲除小鼠中以mGlu7受体依赖性方式缩短了<1>氟哌啶醇</1>诱导的<3>强直性昏厥</3>的持续时间。更高剂量的<20>AMN082</20>（10和20 mg/kg p.o.）对相同的<12>PD</12>模型没有影响。总的来说，这些发现表明mGlu7受体激活可以逆转与<25>多巴胺</25>活性降低相关的运动功能障碍。因此，mGlu7受体亚型的选择性配体可能被认为是开发抗帕金森病治疗策略的有前途的化合物。", "revised": true}
{"doc_key": "15985056", "sentences": [["Possible", "azithromycin", "-", "associated", "hiccups", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "persistent", "hiccups", "associated", "by", "azithromycin", "therapy", ".", "CASE", "SUMMARY", ":", "A", "76", "-", "year", "-", "old", "man", "presented", "with", "persistent", "hiccups", "after", "beginning", "azithromycin", "for", "the", "treatment", "of", "pharyngitis", ".", "Hiccups", "were", "persistent", "and", "exhausting", ".", "Discontinuation", "of", "azithromycin", "and", "therapy", "with", "baclofen", "finally", "resolved", "hiccups", ".", "No", "organic", "cause", "of", "hiccups", "was", "identified", "despite", "extensive", "investigation", ".", "DISCUSSION", ":", "Pharmacotherapeutic", "agents", "have", "been", "uncommonly", "associated", "with", "hiccups", ".", "Corticosteroids", "(", "dexamethasone", "and", "methylprednisolone", ")", ",", "benzodiazepines", "(", "midazolam", ")", "and", "general", "anaesthesia", "have", "been", "the", "specific", "agents", "mentioned", "most", "frequently", "in", "the", "literature", "as", "being", "associated", "with", "the", "development", "of", "hiccups", ".", "Few", "cases", "of", "drug", "-", "induced", "hiccups", "have", "been", "reported", "related", "to", "macrolide", "antimicrobials", ".", "Using", "the", "Naranjo", "adverse", "effect", "reaction", "probability", "scale", "this", "event", "could", "be", "classified", "as", "possible", "(", "score", "5", "points", ")", ",", "mostly", "because", "of", "the", "close", "temporal", "sequence", ",", "previous", "reports", "on", "this", "reaction", "with", "other", "macrolides", "and", "the", "absence", "of", "any", "alternative", "explanation", "for", "hiccups", ".", "Our", "hypothesis", "is", "that", "a", "vagal", "mechanism", "mediated", "by", "azithromycin", "could", "be", "the", "pathogenesis", "of", "hiccups", "in", "our", "patient", ".", "CONCLUSIONS", ":", "Diagnosis", "of", "drug", "-", "induced", "hiccups", "is", "difficult", "and", "often", "achieved", "only", "by", "a", "process", "of", "elimination", ".", "However", ",", "macrolide", "antimicrobials", "have", "been", "reported", "to", "be", "associated", "with", "hiccups", "and", "vagal", "mechanism", "could", "explain", "the", "development", "of", "this", "side", "-", "effect", "."]], "ner": [[[1, 1, "Chemical"], [17, 17, "Chemical"], [36, 36, "Chemical"], [51, 51, "Chemical"], [187, 187, "Chemical"], [4, 4, "Disease"], [14, 14, "Disease"], [33, 33, "Disease"], [43, 43, "Disease"], [58, 58, "Disease"], [64, 64, "Disease"], [80, 80, "Disease"], [114, 114, "Disease"], [122, 122, "Disease"], [176, 176, "Disease"], [193, 193, "Disease"], [205, 205, "Disease"], [229, 229, "Disease"], [55, 55, "Chemical"], [41, 41, "Disease"], [84, 84, "Chemical"], [86, 86, "Chemical"], [89, 89, "Chemical"], [91, 91, "Chemical"], [128, 128, "Chemical"], [167, 167, "Chemical"], [220, 220, "Chemical"]]], "relations": [[[1, 1, 4, 4, "CID"], [1, 1, 14, 14, "CID"], [1, 1, 33, 33, "CID"], [1, 1, 43, 43, "CID"], [1, 1, 58, 58, "CID"], [1, 1, 64, 64, "CID"], [1, 1, 80, 80, "CID"], [1, 1, 114, 114, "CID"], [1, 1, 122, 122, "CID"], [1, 1, 176, 176, "CID"], [1, 1, 193, 193, "CID"], [1, 1, 205, 205, "CID"], [1, 1, 229, 229, "CID"], [17, 17, 4, 4, "CID"], [17, 17, 14, 14, "CID"], [17, 17, 33, 33, "CID"], [17, 17, 43, 43, "CID"], [17, 17, 58, 58, "CID"], [17, 17, 64, 64, "CID"], [17, 17, 80, 80, "CID"], [17, 17, 114, 114, "CID"], [17, 17, 122, 122, "CID"], [17, 17, 176, 176, "CID"], [17, 17, 193, 193, "CID"], [17, 17, 205, 205, "CID"], [17, 17, 229, 229, "CID"], [36, 36, 4, 4, "CID"], [36, 36, 14, 14, "CID"], [36, 36, 33, 33, "CID"], [36, 36, 43, 43, "CID"], [36, 36, 58, 58, "CID"], [36, 36, 64, 64, "CID"], [36, 36, 80, 80, "CID"], [36, 36, 114, 114, "CID"], [36, 36, 122, 122, "CID"], [36, 36, 176, 176, "CID"], [36, 36, 193, 193, "CID"], [36, 36, 205, 205, "CID"], [36, 36, 229, 229, "CID"], [51, 51, 4, 4, "CID"], [51, 51, 14, 14, "CID"], [51, 51, 33, 33, "CID"], [51, 51, 43, 43, "CID"], [51, 51, 58, 58, "CID"], [51, 51, 64, 64, "CID"], [51, 51, 80, 80, "CID"], [51, 51, 114, 114, "CID"], [51, 51, 122, 122, "CID"], [51, 51, 176, 176, "CID"], [51, 51, 193, 193, "CID"], [51, 51, 205, 205, "CID"], [51, 51, 229, 229, "CID"], [187, 187, 4, 4, "CID"], [187, 187, 14, 14, "CID"], [187, 187, 33, 33, "CID"], [187, 187, 43, 43, "CID"], [187, 187, 58, 58, "CID"], [187, 187, 64, 64, "CID"], [187, 187, 80, 80, "CID"], [187, 187, 114, 114, "CID"], [187, 187, 122, 122, "CID"], [187, 187, 176, 176, "CID"], [187, 187, 193, 193, "CID"], [187, 187, 205, 205, "CID"], [187, 187, 229, 229, "CID"], [55, 55, 4, 4, "CID"], [55, 55, 14, 14, "CID"], [55, 55, 33, 33, "CID"], [55, 55, 43, 43, "CID"], [55, 55, 58, 58, "CID"], [55, 55, 64, 64, "CID"], [55, 55, 80, 80, "CID"], [55, 55, 114, 114, "CID"], [55, 55, 122, 122, "CID"], [55, 55, 176, 176, "CID"], [55, 55, 193, 193, "CID"], [55, 55, 205, 205, "CID"], [55, 55, 229, 229, "CID"]]], "clusters": [], "translated": "可能 <0> 阿奇霉素 </0> - 相关的<5>打嗝</5>。目的：报告一例因<1>阿奇霉素</1>治疗引起的持续性<6>呃逆</6>。病例概要：一位 76 岁的男性在开始使用<2>阿奇霉素</2>治疗<19>咽炎</19>后出现持续性<7>呃逆</7>。 <8>打嗝</8>持续不断，令人筋疲力尽。停用<3>阿奇霉素</3>并用<18>巴氯芬</18>治疗，最终解决了<9>呃逆</9>。尽管进行了广泛调查，但仍未发现<10>打嗝</10>的器质性原因。讨论：药物治疗剂与<11>打嗝</11>的关系并不常见。皮质类固醇（<20>地塞米松</20>和<21>甲基泼尼松龙</21>）、<22>苯二氮卓类药物</22>（<23>咪达唑仑</23>）和全身麻醉是最常提及的特异性药物在文献中与<12>打嗝</12>的发展有关。与<24>大环内酯类</24>抗菌剂有关的药物引起的<13>呃逆</13>病例很少见。使用Naranjo不良反应概率量表，可以将此事件归类为可能事件（得分5分），主要是因为时间顺序很接近，之前关于此反应与其他<25>大环内酯类药物</25>的报告以及没有任何替代方案<14>打嗝的解释</14>。我们的假设是，<4>阿奇霉素</4>介导的迷走神经机制可能是我们患者<15>呃逆</15>的发病机制。结论：药物引起的<16>呃逆</16>的诊断很困难，通常只能通过消除过程来实现。然而，据报道，<26>大环内酯</26>抗菌剂与<17>打嗝</17>有关，而迷走神经机制可以解释这种副作用的发生。", "revised": true}
{"doc_key": "8854309", "sentences": [["A", "measure", "of", "pupillary", "oscillation", "as", "a", "marker", "of", "cocaine", "-", "induced", "paranoia", ".", "Cocaine", "-", "induced", "paranoia", "(", "CIP", ")", "remains", "an", "important", "drug", "-", "induced", "model", "of", "idiopathic", "paranoia", "for", "which", "no", "psychophysiologic", "marker", "has", "yet", "emerged", ".", "Measures", "of", "pupillary", "oscillation", "were", "able", "to", "significantly", "distinguish", "a", "group", "of", "abstinent", "crack", "cocaine", "abusers", "endorsing", "past", "CIP", "(", "n", "=", "32", ")", "from", "another", "group", "of", "crack", "addicts", "who", "denied", "past", "CIP", "(", "n", "=", "29", ")", "."]], "ner": [[[9, 9, "Chemical"], [14, 14, "Chemical"], [3, 4, "Disease"], [42, 43, "Disease"], [12, 12, "Disease"], [17, 17, "Disease"], [19, 19, "Disease"], [30, 30, "Disease"], [58, 58, "Disease"], [73, 73, "Disease"], [53, 54, "Chemical"], [68, 68, "Chemical"]]], "relations": [[[9, 9, 3, 4, "CID"], [9, 9, 42, 43, "CID"], [14, 14, 3, 4, "CID"], [14, 14, 42, 43, "CID"], [9, 9, 12, 12, "CID"], [9, 9, 17, 17, "CID"], [9, 9, 19, 19, "CID"], [9, 9, 30, 30, "CID"], [9, 9, 58, 58, "CID"], [9, 9, 73, 73, "CID"], [14, 14, 12, 12, "CID"], [14, 14, 17, 17, "CID"], [14, 14, 19, 19, "CID"], [14, 14, 30, 30, "CID"], [14, 14, 58, 58, "CID"], [14, 14, 73, 73, "CID"]]], "clusters": [], "translated": "<2>瞳孔振荡</2> 作为<0>可卡因</0>诱发的<4>妄想症</4>的标志。<1>可卡因</1>诱导的<5>偏执狂</5>（<6>CIP</6>）仍然是特发性<7>偏执狂</7>的重要药物诱导模型，对此没有心理生理学标记还没有出现。<3>瞳孔振荡</3>的测量能够显着区分一组支持过去<8>CIP</8>（n=32）的戒断<10>快克可卡因</10>滥用者与另一组否认过去<9>CIP</9>（n=29）的<11>破解</11>成瘾者。", "revised": true}
{"doc_key": "19923525", "sentences": [["Nimodipine", "prevents", "memory", "impairment", "caused", "by", "nitroglycerin", "-", "induced", "hypotension", "in", "adult", "mice", ".", "BACKGROUND", ":", "Hypotension", "and", "a", "resultant", "decrease", "in", "cerebral", "blood", "flow", "have", "been", "implicated", "in", "the", "development", "of", "cognitive", "dysfunction", ".", "We", "tested", "the", "hypothesis", "that", "nimodipine", "(", "NIMO", ")", "administered", "at", "the", "onset", "of", "nitroglycerin", "(", "NTG", ")", "-", "induced", "hypotension", "would", "preserve", "long", "-", "term", "associative", "memory", ".", "METHODS", ":", "The", "passive", "avoidance", "(", "PA", ")", "paradigm", "was", "used", "to", "assess", "memory", "retention", ".", "For", "PA", "training", ",", "latencies", "(", "seconds", ")", "were", "recorded", "for", "entry", "from", "a", "suspended", "platform", "into", "a", "Plexiglas", "tube", "where", "a", "shock", "was", "automatically", "delivered", ".", "Latencies", "were", "recorded", "48", "h", "later", "for", "a", "testing", "trial", ".", "Ninety", "-", "six", "Swiss", "-", "Webster", "mice", "(", "30", "-", "35", "g", ",", "6", "-", "8", "wk", ")", ",", "were", "randomized", "into", "6", "groups", "1", ")", "saline", "(", "control", ")", ",", "2", ")", "NTG", "immediately", "after", "learning", ",", "3", ")", "NTG", "3", "h", "after", "learning", ",", "4", ")", "NTG", "and", "NIMO", ",", "5", ")", "vehicle", ",", "and", "6", ")", "NIMO", "alone", ".", "The", "extent", "of", "hypotension", "and", "changes", "in", "brain", "tissue", "oxygenation", "(", "PbtO", "(", "2", ")", ")", "and", "in", "cerebral", "blood", "flow", "were", "studied", "in", "a", "separate", "group", "of", "animals", ".", "RESULTS", ":", "All", "groups", "exhibited", "similar", "training", "latencies", "(", "17", ".", "0", "+", "/", "-", "4", ".", "6", "s", ")", ".", "Mice", "subjected", "to", "hypotensive", "episodes", "showed", "a", "significant", "decrease", "in", "latency", "time", "(", "178", "+", "/", "-", "156", "s", ")", "compared", "with", "those", "injected", "with", "saline", ",", "NTG", "+", "NIMO", ",", "or", "delayed", "NTG", "(", "580", "+", "/", "-", "81", "s", ",", "557", "+", "/", "-", "67", "s", ",", "and", "493", "+", "/", "-", "146", "s", ",", "respectively", ")", ".", "A", "Kruskal", "-", "Wallis", "1", "-", "way", "analysis", "of", "variance", "indicated", "a", "significant", "difference", "among", "the", "4", "treatment", "groups", "(", "H", "=", "15", ".", "34", ";", "P", "<", "0", ".", "001", ")", ".", "In", "a", "separate", "group", "of", "mice", "not", "subjected", "to", "behavioral", "studies", ",", "the", "same", "dose", "of", "NTG", "(", "n", "=", "3", ")", "and", "NTG", "+", "NIMO", "(", "n", "=", "3", ")", "caused", "mean", "arterial", "blood", "pressure", "to", "decrease", "from", "85", ".", "9", "+", "/", "-", "3", ".", "8", "mm", "Hg", "sem", "to", "31", ".", "6", "+", "/", "-", "0", ".", "8", "mm", "Hg", "sem", "and", "from", "86", ".", "2", "+", "/", "-", "3", ".", "7", "mm", "Hg", "sem", "to", "32", ".", "6", "+", "/", "-", "0", ".", "2", "mm", "Hg", "sem", ",", "respectively", ".", "Mean", "arterial", "blood", "pressure", "in", "mice", "treated", "with", "NIMO", "alone", "decreased", "from", "88", ".", "1", "+", "/", "-", "3", ".", "8", "mm", "Hg", "to", "80", ".", "0", "+", "/", "-", "2", ".", "9", "mm", "Hg", ".", "The", "intergroup", "difference", "was", "statistically", "significant", "(", "P", "<", "0", ".", "05", ")", ".", "PbtO", "(", "2", ")", "decreased", "from", "51", ".", "7", "+", "/", "-", "4", ".", "5", "mm", "Hg", "sem", "to", "33", ".", "8", "+", "/", "-", "5", ".", "2", "mm", "Hg", "sem", "in", "the", "NTG", "group", "and", "from", "38", ".", "6", "+", "/", "-", "6", ".", "1", "mm", "Hg", "sem", "to", "25", ".", "4", "+", "/", "-", "2", ".", "0", "mm", "Hg", "sem", "in", "the", "NTG", "+", "NIMO", "groups", ",", "respectively", ".", "There", "were", "no", "significant", "differences", "among", "groups", ".", "CONCLUSION", ":", "In", "a", "PA", "retention", "paradigm", ",", "the", "injection", "of", "NTG", "immediately", "after", "learning", "produced", "a", "significant", "impairment", "of", "long", "-", "term", "associative", "memory", "in", "mice", ",", "whereas", "delayed", "induced", "hypotension", "had", "no", "effect", ".", "NIMO", "attenuated", "the", "disruption", "in", "consolidation", "of", "long", "-", "term", "memory", "caused", "by", "NTG", "but", "did", "not", "improve", "latency", "in", "the", "absence", "of", "hypotension", ".", "The", "observed", "effect", "of", "NIMO", "may", "have", "been", "attributable", "to", "the", "preservation", "of", "calcium", "homeostasis", "during", "hypotension", ",", "because", "there", "were", "no", "differences", "in", "the", "PbtO", "(", "2", ")", "indices", "among", "groups", "."]], "ner": [[[6, 6, "Chemical"], [49, 49, "Chemical"], [51, 51, "Chemical"], [151, 151, "Chemical"], [158, 158, "Chemical"], [166, 166, "Chemical"], [258, 258, "Chemical"], [264, 264, "Chemical"], [340, 340, "Chemical"], [347, 347, "Chemical"], [501, 501, "Chemical"], [532, 532, "Chemical"], [558, 558, "Chemical"], [596, 596, "Chemical"], [2, 3, "Disease"], [9, 9, "Disease"], [16, 16, "Disease"], [55, 55, "Disease"], [183, 183, "Disease"], [234, 234, "Disease"], [578, 578, "Disease"], [606, 606, "Disease"], [624, 624, "Disease"], [0, 0, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [168, 168, "Chemical"], [177, 177, "Chemical"], [260, 260, "Chemical"], [349, 349, "Chemical"], [426, 426, "Chemical"], [534, 534, "Chemical"], [583, 583, "Chemical"], [612, 612, "Chemical"], [32, 33, "Disease"], [621, 621, "Chemical"]]], "relations": [[[6, 6, 2, 3, "CID"], [49, 49, 2, 3, "CID"], [51, 51, 2, 3, "CID"], [151, 151, 2, 3, "CID"], [158, 158, 2, 3, "CID"], [166, 166, 2, 3, "CID"], [258, 258, 2, 3, "CID"], [264, 264, 2, 3, "CID"], [340, 340, 2, 3, "CID"], [347, 347, 2, 3, "CID"], [501, 501, 2, 3, "CID"], [532, 532, 2, 3, "CID"], [558, 558, 2, 3, "CID"], [596, 596, 2, 3, "CID"], [6, 6, 9, 9, "CID"], [6, 6, 16, 16, "CID"], [6, 6, 55, 55, "CID"], [6, 6, 183, 183, "CID"], [6, 6, 234, 234, "CID"], [6, 6, 578, 578, "CID"], [6, 6, 606, 606, "CID"], [6, 6, 624, 624, "CID"], [49, 49, 9, 9, "CID"], [49, 49, 16, 16, "CID"], [49, 49, 55, 55, "CID"], [49, 49, 183, 183, "CID"], [49, 49, 234, 234, "CID"], [49, 49, 578, 578, "CID"], [49, 49, 606, 606, "CID"], [49, 49, 624, 624, "CID"], [51, 51, 9, 9, "CID"], [51, 51, 16, 16, "CID"], [51, 51, 55, 55, "CID"], [51, 51, 183, 183, "CID"], [51, 51, 234, 234, "CID"], [51, 51, 578, 578, "CID"], [51, 51, 606, 606, "CID"], [51, 51, 624, 624, "CID"], [151, 151, 9, 9, "CID"], [151, 151, 16, 16, "CID"], [151, 151, 55, 55, "CID"], [151, 151, 183, 183, "CID"], [151, 151, 234, 234, "CID"], [151, 151, 578, 578, "CID"], [151, 151, 606, 606, "CID"], [151, 151, 624, 624, "CID"], [158, 158, 9, 9, "CID"], [158, 158, 16, 16, "CID"], [158, 158, 55, 55, "CID"], [158, 158, 183, 183, "CID"], [158, 158, 234, 234, "CID"], [158, 158, 578, 578, "CID"], [158, 158, 606, 606, "CID"], [158, 158, 624, 624, "CID"], [166, 166, 9, 9, "CID"], [166, 166, 16, 16, "CID"], [166, 166, 55, 55, "CID"], [166, 166, 183, 183, "CID"], [166, 166, 234, 234, "CID"], [166, 166, 578, 578, "CID"], [166, 166, 606, 606, "CID"], [166, 166, 624, 624, "CID"], [258, 258, 9, 9, "CID"], [258, 258, 16, 16, "CID"], [258, 258, 55, 55, "CID"], [258, 258, 183, 183, "CID"], [258, 258, 234, 234, "CID"], [258, 258, 578, 578, "CID"], [258, 258, 606, 606, "CID"], [258, 258, 624, 624, "CID"], [264, 264, 9, 9, "CID"], [264, 264, 16, 16, "CID"], [264, 264, 55, 55, "CID"], [264, 264, 183, 183, "CID"], [264, 264, 234, 234, "CID"], [264, 264, 578, 578, "CID"], [264, 264, 606, 606, "CID"], [264, 264, 624, 624, "CID"], [340, 340, 9, 9, "CID"], [340, 340, 16, 16, "CID"], [340, 340, 55, 55, "CID"], [340, 340, 183, 183, "CID"], [340, 340, 234, 234, "CID"], [340, 340, 578, 578, "CID"], [340, 340, 606, 606, "CID"], [340, 340, 624, 624, "CID"], [347, 347, 9, 9, "CID"], [347, 347, 16, 16, "CID"], [347, 347, 55, 55, "CID"], [347, 347, 183, 183, "CID"], [347, 347, 234, 234, "CID"], [347, 347, 578, 578, "CID"], [347, 347, 606, 606, "CID"], [347, 347, 624, 624, "CID"], [501, 501, 9, 9, "CID"], [501, 501, 16, 16, "CID"], [501, 501, 55, 55, "CID"], [501, 501, 183, 183, "CID"], [501, 501, 234, 234, "CID"], [501, 501, 578, 578, "CID"], [501, 501, 606, 606, "CID"], [501, 501, 624, 624, "CID"], [532, 532, 9, 9, "CID"], [532, 532, 16, 16, "CID"], [532, 532, 55, 55, "CID"], [532, 532, 183, 183, "CID"], [532, 532, 234, 234, "CID"], [532, 532, 578, 578, "CID"], [532, 532, 606, 606, "CID"], [532, 532, 624, 624, "CID"], [558, 558, 9, 9, "CID"], [558, 558, 16, 16, "CID"], [558, 558, 55, 55, "CID"], [558, 558, 183, 183, "CID"], [558, 558, 234, 234, "CID"], [558, 558, 578, 578, "CID"], [558, 558, 606, 606, "CID"], [558, 558, 624, 624, "CID"], [596, 596, 9, 9, "CID"], [596, 596, 16, 16, "CID"], [596, 596, 55, 55, "CID"], [596, 596, 183, 183, "CID"], [596, 596, 234, 234, "CID"], [596, 596, 578, 578, "CID"], [596, 596, 606, 606, "CID"], [596, 596, 624, 624, "CID"]]], "clusters": [], "translated": "<23>尼莫地平</23>可预防<0>硝酸甘油</0>诱导的成年小鼠<15>低血压</15>引起的<14>记忆障碍</14>。背景：<16>低血压</16>和由此导致的脑血流减少与<34>认知功能障碍</34>的发展有关。我们检验了以下假设：<24>尼莫地平</24> (<25>NIMO</25>)在<1>硝酸甘油</1>(<2>NTG</2>)开始时给药-诱导<17>低血压</17>会保留长期联想记忆。 方法：被动回避 (PA) 范式用于评估记忆保留。对于 PA 训练，记录了从悬挂平台进入自动传递电击的有机玻璃管的延迟（秒）。48小时后记录潜伏期以进行测试试验。96只 Swiss-Webster小鼠（30-35 g，6-8 wk），被随机分为6组1)生理盐水（对照），2)<3> NTG </3>学习后立即，3)<4> NTG </4>学习后3小时，4)<5> NTG </5>和<26>NIMO</26>，5)车辆，6)单独<27>NIMO</27>。在另一组动物中研究了<18>低血压</18>的程度以及脑组织氧合(PbtO(2))和脑血流的变化。结果：所有组都表现出相似的训练延迟（17.0+/-4.6秒）。与注射生理盐水、<6> NTG </6>+<28>NIMO</28>的小鼠相比，发作<19>低血压</19>的小鼠潜伏期显着缩短（178+/-156秒），或延迟<7>NTG</7>（分别为580+/-81秒、557+/-67秒和493+/-146秒）。Kruskal-Wallis单向方差分析表明4个治疗组之间存在显着差异(H=15.34;P<0.001)。在另一组未进行行为研究的小鼠中，相同剂量的<8>NTG</8>(n=3)和<9>NTG</9>+<29>NIMO</29>(n=3)导致平均动脉血压从85.9+/-3.8毫米汞柱sem至31.6+/-0.8毫米汞柱sem和86.2+/-3.7毫米汞柱sem至32.6+/-0.2毫米汞柱sem，分别为2毫米汞柱扫描电镜。单独使用<30>NIMO</30>治疗的小鼠的平均动脉血压从88.1+/-3.8毫米汞柱下降至80.0+/-2.9毫米汞柱。组间差异有统计学意义(P<0.05)。PbtO(2)从51下降。7+/-4.5毫米汞柱sem至33.8+/-5.2毫米汞柱sem在<10>NTG</10>组和38的2毫米汞柱sem。6+/-6.1毫米汞柱sem至25.4+/-2.0毫米汞柱sem在<11>NTG</11>+<31>NIMO</31>组分别为0毫米汞柱sem。组间无明显差异。结论：在PA保留模式中，学习后立即注射<12>NTG</12>对小鼠的长期联想记忆产生显着损害，而延迟诱导的<20>低血压</20>没有影响。 周<32> NIMO </32> 减弱了由<13> NTG </13> 引起的长期记忆巩固的破坏，但在没有<21>低血压</21>的情况下没有改善潜伏期。观察到的<33>NIMO</33>效果可能归因于<22>低血压</22>期间保持<35>钙</35>稳态，因为PbtO(2)没有差异组间指数。", "revised": true}
{"doc_key": "17366349", "sentences": [["Neuroleptic", "malignant", "syndrome", "induced", "by", "ziprasidone", "on", "the", "second", "day", "of", "treatment", ".", "Neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "is", "the", "rarest", "and", "most", "serious", "of", "the", "neuroleptic", "-", "induced", "movement", "disorders", ".", "We", "describe", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "associated", "with", "the", "use", "of", "ziprasidone", ".", "Although", "conventional", "neuroleptics", "are", "more", "frequently", "associated", "with", "NMS", ",", "atypical", "antipsychotic", "drugs", "like", "ziprasidone", "may", "also", "be", "a", "cause", ".", "The", "patient", "is", "a", "24", "-", "year", "-", "old", "male", "with", "a", "history", "of", "schizophrenia", "who", "developed", "signs", "and", "symptoms", "of", "NMS", "after", "2", "days", "of", "treatment", "with", "an", "80", "-", "mg", "/", "day", "dose", "of", "orally", "administrated", "ziprasidone", ".", "This", "case", "is", "the", "earliest", "(", "second", "day", "of", "treatment", ")", "NMS", "due", "to", "ziprasidone", "reported", "in", "the", "literature", "."]], "ner": [[[5, 5, "Chemical"], [49, 49, "Chemical"], [65, 65, "Chemical"], [110, 110, "Chemical"], [126, 126, "Chemical"], [0, 2, "Disease"], [13, 15, "Disease"], [17, 17, "Disease"], [38, 40, "Disease"], [42, 42, "Disease"], [59, 59, "Disease"], [93, 93, "Disease"], [123, 123, "Disease"], [30, 31, "Disease"], [86, 86, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 13, 15, "CID"], [5, 5, 17, 17, "CID"], [5, 5, 38, 40, "CID"], [5, 5, 42, 42, "CID"], [5, 5, 59, 59, "CID"], [5, 5, 93, 93, "CID"], [5, 5, 123, 123, "CID"], [49, 49, 0, 2, "CID"], [49, 49, 13, 15, "CID"], [49, 49, 17, 17, "CID"], [49, 49, 38, 40, "CID"], [49, 49, 42, 42, "CID"], [49, 49, 59, 59, "CID"], [49, 49, 93, 93, "CID"], [49, 49, 123, 123, "CID"], [65, 65, 0, 2, "CID"], [65, 65, 13, 15, "CID"], [65, 65, 17, 17, "CID"], [65, 65, 38, 40, "CID"], [65, 65, 42, 42, "CID"], [65, 65, 59, 59, "CID"], [65, 65, 93, 93, "CID"], [65, 65, 123, 123, "CID"], [110, 110, 0, 2, "CID"], [110, 110, 13, 15, "CID"], [110, 110, 17, 17, "CID"], [110, 110, 38, 40, "CID"], [110, 110, 42, 42, "CID"], [110, 110, 59, 59, "CID"], [110, 110, 93, 93, "CID"], [110, 110, 123, 123, "CID"], [126, 126, 0, 2, "CID"], [126, 126, 13, 15, "CID"], [126, 126, 17, 17, "CID"], [126, 126, 38, 40, "CID"], [126, 126, 42, 42, "CID"], [126, 126, 59, 59, "CID"], [126, 126, 93, 93, "CID"], [126, 126, 123, 123, "CID"]]], "clusters": [], "translated": "治疗第2天<0>齐拉西酮</0>诱发<5>抗精神病药恶性综合征</5>。 <6>抗精神病药物恶性综合征</6>（<7>NMS</7>）是抗精神病药引起的<13>运动障碍</13>中最罕见和最严重的。我们描述了一例与使用<1>齐拉西酮</1>相关的<8>抗精神病药物恶性综合征</8>（<9>NMS</9>）。虽然传统精神安定药更常与<10>NMS</10>相关，但非典型抗精神病药物如<2>齐拉西酮</2>也可能是一个原因。患者是一名24岁男性，有<14>精神分裂症</14>病史，在接受80毫克/天的剂量治疗2天后出现<11>抗精神病药物恶性综合征</11>，口服<3>齐拉西酮</3>。本例是文献报道的最早（治疗第2天）因<4>齐拉西酮</4><12>抗精神病药恶性综合征</12>。", "revised": true}
{"doc_key": "9799166", "sentences": [["Stroke", "and", "cocaine", "or", "amphetamine", "use", ".", "The", "association", "of", "cocaine", "and", "amphetamine", "use", "with", "hemorrhagic", "and", "ischemic", "stroke", "is", "based", "almost", "solely", "on", "data", "from", "case", "series", ".", "The", "limited", "number", "of", "epidemiologic", "studies", "of", "stroke", "and", "use", "of", "cocaine", "and", "/", "or", "amphetamine", "have", "been", "done", "in", "settings", "that", "serve", "mostly", "the", "poor", "and", "/", "or", "minorities", ".", "This", "case", "-", "control", "study", "was", "conducted", "in", "the", "defined", "population", "comprising", "members", "of", "Kaiser", "Permanente", "of", "Northern", "and", "Southern", "California", ".", "We", "attempted", "to", "identify", "all", "incident", "strokes", "in", "women", "ages", "15", "-", "44", "years", "during", "a", "3", "-", "year", "period", "using", "hospital", "admission", "and", "discharge", "records", ",", "emergency", "department", "logs", ",", "and", "payment", "requests", "for", "out", "-", "of", "-", "plan", "hospitalizations", ".", "We", "selected", "controls", ",", "matched", "on", "age", "and", "facility", "of", "usual", "care", ",", "at", "random", "from", "healthy", "members", "of", "the", "health", "plan", ".", "We", "obtained", "information", "in", "face", "-", "to", "-", "face", "interviews", ".", "There", "were", "347", "confirmed", "stroke", "cases", "and", "1", ",", "021", "controls", ".", "The", "univariate", "matched", "odds", "ratio", "for", "stroke", "in", "women", "who", "admitted", "to", "using", "cocaine", "and", "/", "or", "amphetamine", "was", "8", ".", "5", "(", "95", "%", "confidence", "interval", "=", "3", ".", "6", "-", "20", ".", "0", ")", ".", "After", "further", "adjustment", "for", "potential", "confounders", ",", "the", "odds", "ratio", "in", "women", "who", "reported", "using", "cocaine", "and", "/", "or", "amphetamine", "was", "7", ".", "0", "(", "95", "%", "confidence", "interval", "=", "2", ".", "8", "-", "17", ".", "9", ")", ".", "The", "use", "of", "cocaine", "and", "/", "or", "amphetamine", "is", "a", "strong", "risk", "factor", "for", "stroke", "in", "this", "socioeconomically", "heterogeneous", ",", "insured", "urban", "population", "."]], "ner": [[[2, 2, "Chemical"], [10, 10, "Chemical"], [40, 40, "Chemical"], [183, 183, "Chemical"], [222, 222, "Chemical"], [249, 249, "Chemical"], [0, 0, "Disease"], [18, 18, "Disease"], [36, 36, "Disease"], [88, 88, "Disease"], [162, 162, "Disease"], [176, 176, "Disease"], [260, 260, "Disease"], [4, 4, "Chemical"], [12, 12, "Chemical"], [44, 44, "Chemical"], [187, 187, "Chemical"], [226, 226, "Chemical"], [253, 253, "Chemical"], [17, 17, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 18, 18, "CID"], [2, 2, 36, 36, "CID"], [2, 2, 88, 88, "CID"], [2, 2, 162, 162, "CID"], [2, 2, 176, 176, "CID"], [2, 2, 260, 260, "CID"], [10, 10, 0, 0, "CID"], [10, 10, 18, 18, "CID"], [10, 10, 36, 36, "CID"], [10, 10, 88, 88, "CID"], [10, 10, 162, 162, "CID"], [10, 10, 176, 176, "CID"], [10, 10, 260, 260, "CID"], [40, 40, 0, 0, "CID"], [40, 40, 18, 18, "CID"], [40, 40, 36, 36, "CID"], [40, 40, 88, 88, "CID"], [40, 40, 162, 162, "CID"], [40, 40, 176, 176, "CID"], [40, 40, 260, 260, "CID"], [183, 183, 0, 0, "CID"], [183, 183, 18, 18, "CID"], [183, 183, 36, 36, "CID"], [183, 183, 88, 88, "CID"], [183, 183, 162, 162, "CID"], [183, 183, 176, 176, "CID"], [183, 183, 260, 260, "CID"], [222, 222, 0, 0, "CID"], [222, 222, 18, 18, "CID"], [222, 222, 36, 36, "CID"], [222, 222, 88, 88, "CID"], [222, 222, 162, 162, "CID"], [222, 222, 176, 176, "CID"], [222, 222, 260, 260, "CID"], [249, 249, 0, 0, "CID"], [249, 249, 18, 18, "CID"], [249, 249, 36, 36, "CID"], [249, 249, 88, 88, "CID"], [249, 249, 162, 162, "CID"], [249, 249, 176, 176, "CID"], [249, 249, 260, 260, "CID"], [4, 4, 0, 0, "CID"], [4, 4, 18, 18, "CID"], [4, 4, 36, 36, "CID"], [4, 4, 88, 88, "CID"], [4, 4, 162, 162, "CID"], [4, 4, 176, 176, "CID"], [4, 4, 260, 260, "CID"], [12, 12, 0, 0, "CID"], [12, 12, 18, 18, "CID"], [12, 12, 36, 36, "CID"], [12, 12, 88, 88, "CID"], [12, 12, 162, 162, "CID"], [12, 12, 176, 176, "CID"], [12, 12, 260, 260, "CID"], [44, 44, 0, 0, "CID"], [44, 44, 18, 18, "CID"], [44, 44, 36, 36, "CID"], [44, 44, 88, 88, "CID"], [44, 44, 162, 162, "CID"], [44, 44, 176, 176, "CID"], [44, 44, 260, 260, "CID"], [187, 187, 0, 0, "CID"], [187, 187, 18, 18, "CID"], [187, 187, 36, 36, "CID"], [187, 187, 88, 88, "CID"], [187, 187, 162, 162, "CID"], [187, 187, 176, 176, "CID"], [187, 187, 260, 260, "CID"], [226, 226, 0, 0, "CID"], [226, 226, 18, 18, "CID"], [226, 226, 36, 36, "CID"], [226, 226, 88, 88, "CID"], [226, 226, 162, 162, "CID"], [226, 226, 176, 176, "CID"], [226, 226, 260, 260, "CID"], [253, 253, 0, 0, "CID"], [253, 253, 18, 18, "CID"], [253, 253, 36, 36, "CID"], [253, 253, 88, 88, "CID"], [253, 253, 162, 162, "CID"], [253, 253, 176, 176, "CID"], [253, 253, 260, 260, "CID"]]], "clusters": [], "translated": "<6>中风</6>和<0>可卡因</0>或<13>苯丙胺</13>使用。<1>可卡因</1>和<14>苯丙胺</14>使用与出血性和<19>缺血性</19><7>中风</7>的关联几乎完全基于病例系列的数据。 <2>可卡因</2>和/或<15>安非他明</15>和<8>中风</8>的流行病学研究数量有限，主要服务于穷人和/或少数民族。这项病例对照研究是在由北加州和南加州的Kaiser Permanente成员组成的特定人群中进行的。我们试图使用入院和出院记录、急诊科日志和计划外住院的付款请求，确定3年期间15-44岁女性的所有事件<9>中风</9>。我们从健康计划的健康成员中随机选择了年龄和常规护理机构相匹配的对照。我们通过面对面的采访获得了信息。确诊的<10>中风</10>病例347例，对照者1,021例。在承认使用<3>可卡因</3>和/或<16>安非他明</16>的女性中，<11>中风</11>的单变量匹配比值比为8.5（95%置信区间=3.6-20.0）。对潜在混杂因素进一步调整后，报告使用<4>可卡因</4>和/或<17>苯丙胺</17>的女性的比值比为7.0（95%置信区间=2.8-17.9）。<5>可卡因</5>和/或<18>苯丙胺</18>的使用是这个社会经济异质、有保险的城市人口中<12>中风</12>的一个重要危险因素。", "revised": true}
{"doc_key": "16428827", "sentences": [["Daidzein", "activates", "choline", "acetyltransferase", "from", "MC", "-", "IXC", "cells", "and", "improves", "drug", "-", "induced", "amnesia", ".", "The", "choline", "acetyltransferase", "(", "ChAT", ")", "activator", ",", "which", "enhances", "cholinergic", "transmission", "via", "an", "augmentation", "of", "the", "enzymatic", "production", "of", "acetylcholine", "(", "ACh", ")", ",", "is", "an", "important", "factor", "in", "the", "treatment", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "Methanolic", "extracts", "from", "Pueraria", "thunbergiana", "exhibited", "an", "activation", "effect", "(", "46", "%", ")", "on", "ChAT", "in", "vitro", ".", "Via", "the", "sequential", "isolation", "of", "Pueraria", "thunbergiana", ",", "the", "active", "component", "was", "ultimately", "identified", "as", "daidzein", "(", "4", "'", ",", "7", "-", "dihydroxy", "-", "isoflavone", ")", ".", "In", "order", "to", "investigate", "the", "effects", "of", "daidzein", "from", "Pueraria", "thunbergiana", "on", "scopolamine", "-", "induced", "impairments", "of", "learning", "and", "memory", ",", "we", "conducted", "a", "series", "of", "in", "vivo", "tests", ".", "Administration", "of", "daidzein", "(", "4", ".", "5", "mg", "/", "kg", "body", "weight", ")", "to", "mice", "was", "shown", "significantly", "to", "reverse", "scopolamine", "-", "induced", "amnesia", ",", "according", "to", "the", "results", "of", "a", "Y", "-", "maze", "test", ".", "Injections", "of", "scopolamine", "into", "mice", "resulted", "in", "impaired", "performance", "on", "Y", "-", "maze", "tests", "(", "a", "37", "%", "decreases", "in", "alternation", "behavior", ")", ".", "By", "way", "of", "contrast", ",", "mice", "treated", "with", "daidzein", "prior", "to", "the", "scopolamine", "injections", "were", "noticeably", "protected", "from", "this", "performance", "impairment", "(", "an", "approximately", "12", "%", "-", "21", "%", "decrease", "in", "alternation", "behavior", ")", ".", "These", "results", "indicate", "that", "daidzein", "might", "play", "a", "role", "in", "acetylcholine", "biosynthesis", "as", "a", "ChAT", "activator", ",", "and", "that", "it", "also", "ameliorates", "scopolamine", "-", "induced", "amnesia", "."]], "ner": [[[113, 113, "Chemical"], [151, 151, "Chemical"], [169, 169, "Chemical"], [203, 203, "Chemical"], [248, 248, "Chemical"], [14, 14, "Disease"], [154, 154, "Disease"], [251, 251, "Disease"], [0, 0, "Chemical"], [89, 89, "Chemical"], [91, 98, "Chemical"], [108, 108, "Chemical"], [133, 133, "Chemical"], [199, 199, "Chemical"], [230, 230, "Chemical"], [49, 51, "Disease"], [53, 53, "Disease"], [116, 120, "Disease"], [2, 2, "Chemical"], [17, 17, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [236, 236, "Chemical"]]], "relations": [[[113, 113, 14, 14, "CID"], [113, 113, 154, 154, "CID"], [113, 113, 251, 251, "CID"], [151, 151, 14, 14, "CID"], [151, 151, 154, 154, "CID"], [151, 151, 251, 251, "CID"], [169, 169, 14, 14, "CID"], [169, 169, 154, 154, "CID"], [169, 169, 251, 251, "CID"], [203, 203, 14, 14, "CID"], [203, 203, 154, 154, "CID"], [203, 203, 251, 251, "CID"], [248, 248, 14, 14, "CID"], [248, 248, 154, 154, "CID"], [248, 248, 251, 251, "CID"]]], "clusters": [], "translated": " <8>大豆苷元</8>激活MC-IXC细胞的<18>胆碱</18>乙酰转移酶，改善药物引起的<5>遗忘症</5>。<19>胆碱</19>乙酰转移酶（ChAT）激活剂通过增加酶促产生<20>乙酰胆碱</20>（<21>ACh</21>）来增强胆碱能传递，是治疗<15>阿尔茨海默病</15>（<16>AD</16>）的重要因素。黑葛根的甲醇提取物在体外对ChAT表现出激活作用（46%）。通过对黑葛根的逐次分离，最终鉴定其活性成分为<9>大豆苷元</9>（<10>4'，7-二羟基异黄酮</10>）。为了研究黑葛根<11>大豆苷元</11>对<0>东莨菪碱</0>-诱导的<17>学习记忆障碍</17>的影响，我们进行了一系列体内试验。根据结果，<12>大豆苷元</12>（4.5mg / kg体重）对小鼠的给药显着逆转<1>东莨菪碱</1>-诱导的<6>健忘症</6>，即Y迷宫测试。向小鼠注射<2>东莨菪碱</2>会导致Y迷宫测试的表现受损（交替行为减少37%）。相比之下，在注射<3>东莨菪碱</3>之前用<13>大豆苷元</13>处理的小鼠明显免受这种性能损害（交替行为减少约12%-21%）。这些结果表明，<14>大豆苷元</14>可能作为一种ChAT激活剂在<22>乙酰胆碱</22>生物合成中发挥作用，并且它还可以改善<4>东莨菪碱</4>-诱导的<7>遗忘症</7>。", "revised": true}
{"doc_key": "8473723", "sentences": [["Seizures", "induced", "by", "combined", "levomepromazine", "-", "fluvoxamine", "treatment", ".", "We", "report", "a", "case", "of", "combined", "levomepromazine", "-", "fluvoxamine", "treatment", "-", "induced", "seizures", ".", "It", "seems", "that", "combined", "treatment", "of", "fluvoxamine", "with", "phenothiazines", "may", "possess", "proconvulsive", "activity", "."]], "ner": [[[4, 4, "Chemical"], [15, 15, "Chemical"], [0, 0, "Disease"], [21, 21, "Disease"], [6, 6, "Chemical"], [17, 17, "Chemical"], [29, 29, "Chemical"], [31, 31, "Chemical"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 21, 21, "CID"], [15, 15, 0, 0, "CID"], [15, 15, 21, 21, "CID"], [6, 6, 0, 0, "CID"], [6, 6, 21, 21, "CID"], [17, 17, 0, 0, "CID"], [17, 17, 21, 21, "CID"], [29, 29, 0, 0, "CID"], [29, 29, 21, 21, "CID"]]], "clusters": [], "translated": "<2>癫痫发作</2>由<0>左美丙嗪</0>-<4>氟伏沙明</4>联合治疗引起。我们报告了一例联合<1>左美丙嗪</1>-<5>氟伏沙明</5>治疗引起的<3>癫痫发作</3>。似乎<6>氟伏沙明</6>与<7>吩噻嗪</7>的联合治疗可能具有促惊厥活性。", "revised": true}
{"doc_key": "6674249", "sentences": [["Why", "may", "epsilon", "-", "aminocaproic", "acid", "(", "EACA", ")", "induce", "myopathy", "in", "man", "?", "Report", "of", "a", "case", "and", "literature", "review", ".", "A", "case", "of", "necrotizing", "myopathy", "due", "to", "a", "short", "epsilon", "-", "aminocaproic", "acid", "(", "EACA", ")", "treatment", "in", "a", "72", "year", "-", "old", "patient", "with", "subarachnoid", "haemorrhage", "(", "SAH", ")", "is", "described", ".", "Pathogenetic", "hypotheses", "are", "discussed", "."]], "ner": [[[2, 5, "Chemical"], [7, 7, "Chemical"], [31, 34, "Chemical"], [36, 36, "Chemical"], [10, 10, "Disease"], [25, 26, "Disease"], [47, 48, "Disease"], [50, 50, "Disease"]]], "relations": [[[2, 5, 10, 10, "CID"], [2, 5, 25, 26, "CID"], [7, 7, 10, 10, "CID"], [7, 7, 25, 26, "CID"], [31, 34, 10, 10, "CID"], [31, 34, 25, 26, "CID"], [36, 36, 10, 10, "CID"], [36, 36, 25, 26, "CID"]]], "clusters": [], "translated": "为什么<0>ε-氨基己酸</0>（<1>EACA</1>）会诱发人体<4>肌病</4>？一例报告及文献复习。一位72岁<6>蛛网膜下出血</6>（<7>SAH</7>）患者因<2>ε-氨基己酸</2>（<3>EACA</3>）治疗时间短暂而发生<5>坏死性肌病</5>。讨论了致病假设。", "revised": true}
{"doc_key": "20558148", "sentences": [["Glutamatergic", "neurotransmission", "mediated", "by", "NMDA", "receptors", "in", "the", "inferior", "colliculus", "can", "modulate", "haloperidol", "-", "induced", "catalepsy", ".", "The", "inferior", "colliculus", "(", "IC", ")", "is", "primarily", "involved", "in", "the", "processing", "of", "auditory", "information", ",", "but", "it", "is", "distinguished", "from", "other", "auditory", "nuclei", "in", "the", "brainstem", "by", "its", "connections", "with", "structures", "of", "the", "motor", "system", ".", "Functional", "evidence", "relating", "the", "IC", "to", "motor", "behavior", "derives", "from", "experiments", "showing", "that", "activation", "of", "the", "IC", "by", "electrical", "stimulation", "or", "excitatory", "amino", "acid", "microinjection", "causes", "freezing", ",", "escape", "-", "like", "behavior", ",", "and", "immobility", ".", "However", ",", "the", "nature", "of", "this", "immobility", "is", "still", "unclear", ".", "The", "present", "study", "examined", "the", "influence", "of", "excitatory", "amino", "acid", "-", "mediated", "mechanisms", "in", "the", "IC", "on", "the", "catalepsy", "induced", "by", "the", "dopamine", "receptor", "blocker", "haloperidol", "administered", "systemically", "(", "1", "or", "0", ".", "5", "mg", "/", "kg", ")", "in", "rats", ".", "Haloperidol", "-", "induced", "catalepsy", "was", "challenged", "with", "prior", "intracollicular", "microinjections", "of", "glutamate", "NMDA", "receptor", "antagonists", ",", "MK", "-", "801", "(", "15", "or", "30", "mmol", "/", "0", ".", "5", "microl", ")", "and", "AP7", "(", "10", "or", "20", "nmol", "/", "0", ".", "5", "microl", ")", ",", "or", "of", "the", "NMDA", "receptor", "agonist", "N", "-", "methyl", "-", "d", "-", "aspartate", "(", "NMDA", ",", "20", "or", "30", "nmol", "/", "0", ".", "5", "microl", ")", ".", "The", "results", "showed", "that", "intracollicular", "microinjection", "of", "MK", "-", "801", "and", "AP7", "previous", "to", "systemic", "injections", "of", "haloperidol", "significantly", "attenuated", "the", "catalepsy", ",", "as", "indicated", "by", "a", "reduced", "latency", "to", "step", "down", "from", "a", "horizontal", "bar", ".", "Accordingly", ",", "intracollicular", "microinjection", "of", "NMDA", "increased", "the", "latency", "to", "step", "down", "the", "bar", ".", "These", "findings", "suggest", "that", "glutamate", "-", "mediated", "mechanisms", "in", "the", "neural", "circuits", "at", "the", "IC", "level", "influence", "haloperidol", "-", "induced", "catalepsy", "and", "participate", "in", "the", "regulation", "of", "motor", "activity", "."]], "ner": [[[12, 12, "Chemical"], [126, 126, "Chemical"], [142, 142, "Chemical"], [230, 230, "Chemical"], [282, 282, "Chemical"], [15, 15, "Disease"], [119, 119, "Disease"], [145, 145, "Disease"], [234, 234, "Disease"], [285, 285, "Disease"], [4, 4, "Chemical"], [154, 154, "Chemical"], [189, 189, "Chemical"], [192, 198, "Chemical"], [200, 200, "Chemical"], [255, 255, "Chemical"], [76, 77, "Chemical"], [109, 110, "Chemical"], [123, 123, "Chemical"], [153, 153, "Chemical"], [269, 269, "Chemical"], [158, 160, "Chemical"], [220, 222, "Chemical"], [173, 173, "Chemical"], [224, 224, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 119, 119, "CID"], [12, 12, 145, 145, "CID"], [12, 12, 234, 234, "CID"], [12, 12, 285, 285, "CID"], [126, 126, 15, 15, "CID"], [126, 126, 119, 119, "CID"], [126, 126, 145, 145, "CID"], [126, 126, 234, 234, "CID"], [126, 126, 285, 285, "CID"], [142, 142, 15, 15, "CID"], [142, 142, 119, 119, "CID"], [142, 142, 145, 145, "CID"], [142, 142, 234, 234, "CID"], [142, 142, 285, 285, "CID"], [230, 230, 15, 15, "CID"], [230, 230, 119, 119, "CID"], [230, 230, 145, 145, "CID"], [230, 230, 234, 234, "CID"], [230, 230, 285, 285, "CID"], [282, 282, 15, 15, "CID"], [282, 282, 119, 119, "CID"], [282, 282, 145, 145, "CID"], [282, 282, 234, 234, "CID"], [282, 282, 285, 285, "CID"]]], "clusters": [], "translated": "下丘<10>NMDA</10>受体介导的谷氨酸能神经传递可调节<0>氟哌啶醇</0>诱导的<5>强直性昏厥</5>。下丘 (IC)主要参与听觉信息的处理，但它与运动系统结构的连接与脑干中的其他听觉核团不同。相关实验证据表明激活下丘(IC)可通过电刺激或兴奋性<16>氨基酸</16>显微注射导致冻结，类似逃避的行为，和不动。然而，这种不动的性质仍不清楚。本研究检查了兴奋性<17>氨基酸</17>-介导的IC水平在<18>多巴胺</18>受体阻滞剂<1>氟哌啶醇</1>全身给药（1 或 0. 5 mg/kg）后介导<6>强直性昏厥</6>的影响。挑战<2>氟哌啶醇</2>所产生的<7>强直性昏厥</7>，使用先前在丘内注射<19>谷氨酸</19><11>NMDA</11>受体拮抗剂，<21>MK-801</21>（15或30 mmol / 0.5 microl) 和<23>AP7</23>（10或20 nmol / 0.5 microl），或者NMDA受体激动剂<12>NMDA</12><13>N-甲基-d-天冬氨酸</13>（<14>NMDA</14>，20或30 nmol / 0.5 microl）。结果表明，在全身注射<3>氟哌啶醇</3>之前，先注射<22>MK-801</22>和<24>AP7</24>，可显着减轻<8>强直性昏厥</8>，如从水平条下降的延迟减少所示。相应地，丘内注射<15>NMDA</15>可增加从水平条下降的延迟。这些发现表明<20>谷氨酸</20>-介导的机制在IC水平的神经回路中影响<4>氟哌啶醇</4>-诱导的<9>强直性昏厥</9>并参与调节运动活动。", "revised": true}
{"doc_key": "3300918", "sentences": [["St", ".", "Anthony", "'s", "fire", ",", "then", "and", "now", ":", "a", "case", "report", "and", "historical", "review", ".", "A", "rare", "case", "of", "morbid", "vasospasm", ",", "together", "with", "striking", "angiographic", "findings", ",", "is", "described", "secondary", "to", "the", "ingestion", "of", "methysergide", "by", "a", "48", "-", "year", "-", "old", "woman", ".", "A", "brief", "review", "of", "the", "literature", "on", "similar", "cases", "is", "presented", ".", "A", "discussion", "of", "the", "history", "of", "ergot", "includes", "its", "original", "discovery", ",", "the", "epidemics", "of", "gangrene", "that", "it", "has", "caused", "through", "the", "ages", "and", "its", "past", "and", "present", "role", "in", "the", "management", "of", "migraine", "headache", ".", "Despite", "the", "advent", "of", "calcium", "channel", "blockers", "and", "beta", "-", "adrenergic", "antagonists", ",", "ergot", "preparations", "continue", "to", "play", "a", "major", "role", "in", "migraine", "therapy", ",", "so", "that", "the", "danger", "of", "St", ".", "Anthony", "'s", "fire", "persists", "."]], "ner": [[[37, 37, "Chemical"], [22, 22, "Disease"], [65, 65, "Chemical"], [108, 108, "Chemical"], [92, 93, "Disease"], [117, 117, "Disease"], [0, 4, "Disease"], [125, 129, "Disease"], [99, 99, "Chemical"], [74, 74, "Disease"]]], "relations": [[[37, 37, 22, 22, "CID"], [65, 65, 92, 93, "CID"], [65, 65, 117, 117, "CID"], [108, 108, 92, 93, "CID"], [108, 108, 117, 117, "CID"]]], "clusters": [], "translated": "<6>圣。安东尼的火</6>，过去和现在：案例报告和历史回顾。一位48岁的女性继发于摄入<0>美西麦角新碱</0>，并伴有显着的血管造影结果，这是一例罕见的病态<1>血管痉挛</1>病例。对类似案例的文献进行了简要回顾。讨论<2>麦角</2>的历史，包括它最初的发现、历代引起的<9>坏疽</9>流行以及它过去和现在在<4>偏头痛</4>管理中的作用。尽管出现了<8>钙</8>通道阻滞剂和β-肾上腺素能拮抗剂，但<3>麦角</3>制剂仍在<5>偏头痛</5>治疗中发挥重要作用，以至于<7>圣。安东尼的火</7>的危险仍然存在。", "revised": true}
{"doc_key": "18808529", "sentences": [["Isoproterenol", "induces", "primary", "loss", "of", "dystrophin", "in", "rat", "hearts", ":", "correlation", "with", "myocardial", "injury", ".", "The", "mechanism", "of", "isoproterenol", "-", "induced", "myocardial", "damage", "is", "unknown", ",", "but", "a", "mismatch", "of", "oxygen", "supply", "vs", ".", "demand", "following", "coronary", "hypotension", "and", "myocardial", "hyperactivity", "is", "the", "best", "explanation", "for", "the", "complex", "morphological", "alterations", "observed", ".", "Severe", "alterations", "in", "the", "structural", "integrity", "of", "the", "sarcolemma", "of", "cardiomyocytes", "have", "been", "demonstrated", "to", "be", "caused", "by", "isoproterenol", ".", "Taking", "into", "account", "that", "the", "sarcolemmal", "integrity", "is", "stabilized", "by", "the", "dystrophin", "-", "glycoprotein", "complex", "(", "DGC", ")", "that", "connects", "actin", "and", "laminin", "in", "contractile", "machinery", "and", "extracellular", "matrix", "and", "by", "integrins", ",", "this", "study", "tests", "the", "hypothesis", "that", "isoproterenol", "affects", "sarcolemmal", "stability", "through", "changes", "in", "the", "DGC", "and", "integrins", ".", "We", "found", "different", "sensitivity", "of", "the", "DGC", "and", "integrin", "to", "isoproterenol", "subcutaneous", "administration", ".", "Immunofluorescent", "staining", "revealed", "that", "dystrophin", "is", "the", "most", "sensitive", "among", "the", "structures", "connecting", "the", "actin", "in", "the", "cardiomyocyte", "cytoskeleton", "and", "the", "extracellular", "matrix", ".", "The", "sarcomeric", "actin", "dissolution", "occurred", "after", "the", "reduction", "or", "loss", "of", "dystrophin", ".", "Subsequently", ",", "after", "lysis", "of", "myofilaments", ",", "gamma", "-", "sarcoglycan", ",", "beta", "-", "dystroglycan", ",", "beta1", "-", "integrin", ",", "and", "laminin", "alpha", "-", "2", "expressions", "were", "reduced", "followed", "by", "their", "breakdown", ",", "as", "epiphenomena", "of", "the", "myocytolytic", "process", ".", "In", "conclusion", ",", "administration", "of", "isoproterenol", "to", "rats", "results", "in", "primary", "loss", "of", "dystrophin", ",", "the", "most", "sensitive", "among", "the", "structural", "proteins", "that", "form", "the", "DGC", "that", "connects", "the", "extracellular", "matrix", "and", "the", "cytoskeleton", "in", "cardiomyocyte", ".", "These", "changes", ",", "related", "to", "ischaemic", "injury", ",", "explain", "the", "severe", "alterations", "in", "the", "structural", "integrity", "of", "the", "sarcolemma", "of", "cardiomyocytes", "and", "hence", "severe", "and", "irreversible", "injury", "induced", "by", "isoproterenol", "."]], "ner": [[[0, 0, "Chemical"], [18, 18, "Chemical"], [70, 70, "Chemical"], [111, 111, "Chemical"], [133, 133, "Chemical"], [218, 218, "Chemical"], [279, 279, "Chemical"], [12, 13, "Disease"], [21, 22, "Disease"], [39, 40, "Disease"], [255, 256, "Disease"], [37, 37, "Disease"], [30, 30, "Chemical"]]], "relations": [[[0, 0, 12, 13, "CID"], [0, 0, 21, 22, "CID"], [0, 0, 39, 40, "CID"], [18, 18, 12, 13, "CID"], [18, 18, 21, 22, "CID"], [18, 18, 39, 40, "CID"], [70, 70, 12, 13, "CID"], [70, 70, 21, 22, "CID"], [70, 70, 39, 40, "CID"], [111, 111, 12, 13, "CID"], [111, 111, 21, 22, "CID"], [111, 111, 39, 40, "CID"], [133, 133, 12, 13, "CID"], [133, 133, 21, 22, "CID"], [133, 133, 39, 40, "CID"], [218, 218, 12, 13, "CID"], [218, 218, 21, 22, "CID"], [218, 218, 39, 40, "CID"], [279, 279, 12, 13, "CID"], [279, 279, 21, 22, "CID"], [279, 279, 39, 40, "CID"], [0, 0, 255, 256, "CID"], [18, 18, 255, 256, "CID"], [70, 70, 255, 256, "CID"], [111, 111, 255, 256, "CID"], [133, 133, 255, 256, "CID"], [218, 218, 255, 256, "CID"], [279, 279, 255, 256, "CID"]]], "clusters": [], "translated": " <0>异丙肾上腺素</0>诱导<7>心肌损伤</7>：大鼠心脏出现了肌营养不良蛋白原的原始丢失机制。 <1>异丙肾上腺素</1> -诱导的<8>心肌损伤</8>机制尚不清楚，但是冠状动脉<11>低血压</11>和<9>心肌过度活跃</9>之间的<12>氧气</12>供需失衡是对观察到的复杂形态改变最好的解释。已经证实<2>异丙肾上腺素</2>会导致心肌细胞肌膜结构完整性的严重改变。考虑到肌营养不良蛋白-糖蛋白复合物(DGC)连接着肌动蛋白和层粘连蛋白以及整合素，维持着肌膜完整性，本研究检验了通过改变DGC和整合素来<3>影响异丙肾上腺素</3>稳定性的假设。我们发现DGC和整合素对<4>异丙肾上腺素</4>的皮下给药存在不同的敏感性。免疫荧光染色显示抗肌萎缩蛋白结构是连接心肌细胞细胞骨架和细胞外基质的结构中最敏感的。在抗肌萎缩蛋白丧失或减少后, 肌丝的溶解发生。随后，在这些肌丝裂解后，γ-肌球蛋白、β-抗肌萎缩蛋白球蛋白、β1-整合素和层粘连蛋白α-2的表达也随之减少并且崩解，这些是肌细胞裂解的一些副作用。总之，给大鼠服用<5>异丙肾上腺素</5>将导致最敏感的抗肌萎缩蛋白的原发性丢失，而该蛋白是构成连接细胞外基质和心肌细胞的细胞支架中DGC结构蛋白组的一种。这些关于<10>缺血性损伤</10>的变化或可解释心肌细胞肌膜结构完整性的严重改变以及由<6>异丙肾上腺素</6>引起的严重且不可逆损伤。", "revised": true}
{"doc_key": "16584858", "sentences": [["Role", "of", "mangiferin", "on", "biochemical", "alterations", "and", "antioxidant", "status", "in", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", ".", "The", "current", "study", "dealt", "with", "the", "protective", "role", "of", "mangiferin", ",", "a", "polyphenol", "from", "Mangifera", "indica", "Linn", ".", "(", "Anacardiaceae", ")", ",", "on", "isoproterenol", "(", "ISPH", ")", "-", "induced", "myocardial", "infarction", "(", "MI", ")", "in", "rats", "through", "its", "antioxidative", "mechanism", ".", "Subcutaneous", "injection", "of", "ISPH", "(", "200", "mg", "/", "kg", "body", "weight", "in", "1", "ml", "saline", ")", "to", "rats", "for", "2", "consecutive", "days", "caused", "myocardial", "damage", "in", "rat", "heart", ",", "which", "was", "determined", "by", "the", "increased", "activity", "of", "serum", "lactate", "dehydrogenase", "(", "LDH", ")", "and", "creatine", "phosphokinase", "isoenzymes", "(", "CK", "-", "MB", ")", ",", "increased", "uric", "acid", "level", "and", "reduced", "plasma", "iron", "binding", "capacity", ".", "The", "protective", "role", "of", "mangiferin", "was", "analyzed", "by", "triphenyl", "tetrazolium", "chloride", "(", "TTC", ")", "test", "used", "for", "macroscopic", "enzyme", "mapping", "assay", "of", "the", "ischemic", "myocardium", ".", "The", "heart", "tissue", "antioxidant", "enzymes", "such", "as", "superoxide", "dismutase", ",", "catalase", ",", "glutathione", "peroxidase", ",", "glutathione", "transferase", "and", "glutathione", "reductase", "activities", ",", "non", "-", "enzymic", "antioxidants", "such", "as", "cerruloplasmin", ",", "Vitamin", "C", ",", "Vitamin", "E", "and", "glutathione", "levels", "were", "altered", "in", "MI", "rats", ".", "Upon", "pretreatment", "with", "mangiferin", "(", "100", "mg", "/", "kg", "body", "weight", "suspended", "in", "2", "ml", "of", "dimethyl", "sulphoxide", ")", "given", "intraperitoneally", "for", "28", "days", "to", "MI", "rats", "protected", "the", "above", "-", "mentioned", "parameters", "to", "fall", "from", "the", "normal", "levels", ".", "Activities", "of", "heart", "tissue", "enzymic", "antioxidants", "and", "serum", "non", "-", "enzymic", "antioxidants", "levels", "rose", "significantly", "upon", "mangiferin", "administration", "as", "compared", "to", "ISPH", "-", "induced", "MI", "rats", ".", "From", "the", "present", "study", "it", "is", "concluded", "that", "mangiferin", "exerts", "a", "beneficial", "effect", "against", "ISPH", "-", "induced", "MI", "due", "to", "its", "antioxidant", "potential", ",", "which", "regulated", "the", "tissues", "defense", "system", "against", "cardiac", "damage", "."]], "ner": [[[10, 10, "Chemical"], [41, 41, "Chemical"], [43, 43, "Chemical"], [62, 62, "Chemical"], [254, 254, "Chemical"], [274, 274, "Chemical"], [13, 14, "Disease"], [47, 48, "Disease"], [50, 50, "Disease"], [190, 190, "Disease"], [218, 218, "Disease"], [257, 257, "Disease"], [277, 277, "Disease"], [2, 2, "Chemical"], [27, 27, "Chemical"], [127, 127, "Chemical"], [196, 196, "Chemical"], [249, 249, "Chemical"], [268, 268, "Chemical"], [82, 83, "Disease"], [146, 147, "Disease"], [291, 292, "Disease"], [30, 30, "Chemical"], [97, 97, "Chemical"], [103, 103, "Chemical"], [113, 114, "Chemical"], [119, 119, "Chemical"], [131, 133, "Chemical"], [135, 135, "Chemical"], [156, 156, "Chemical"], [161, 161, "Chemical"], [164, 164, "Chemical"], [167, 167, "Chemical"], [185, 185, "Chemical"], [179, 180, "Chemical"], [182, 183, "Chemical"], [209, 210, "Chemical"]]], "relations": [[[10, 10, 13, 14, "CID"], [10, 10, 47, 48, "CID"], [10, 10, 50, 50, "CID"], [10, 10, 190, 190, "CID"], [10, 10, 218, 218, "CID"], [10, 10, 257, 257, "CID"], [10, 10, 277, 277, "CID"], [41, 41, 13, 14, "CID"], [41, 41, 47, 48, "CID"], [41, 41, 50, 50, "CID"], [41, 41, 190, 190, "CID"], [41, 41, 218, 218, "CID"], [41, 41, 257, 257, "CID"], [41, 41, 277, 277, "CID"], [43, 43, 13, 14, "CID"], [43, 43, 47, 48, "CID"], [43, 43, 50, 50, "CID"], [43, 43, 190, 190, "CID"], [43, 43, 218, 218, "CID"], [43, 43, 257, 257, "CID"], [43, 43, 277, 277, "CID"], [62, 62, 13, 14, "CID"], [62, 62, 47, 48, "CID"], [62, 62, 50, 50, "CID"], [62, 62, 190, 190, "CID"], [62, 62, 218, 218, "CID"], [62, 62, 257, 257, "CID"], [62, 62, 277, 277, "CID"], [254, 254, 13, 14, "CID"], [254, 254, 47, 48, "CID"], [254, 254, 50, 50, "CID"], [254, 254, 190, 190, "CID"], [254, 254, 218, 218, "CID"], [254, 254, 257, 257, "CID"], [254, 254, 277, 277, "CID"], [274, 274, 13, 14, "CID"], [274, 274, 47, 48, "CID"], [274, 274, 50, 50, "CID"], [274, 274, 190, 190, "CID"], [274, 274, 218, 218, "CID"], [274, 274, 257, 257, "CID"], [274, 274, 277, 277, "CID"]]], "clusters": [], "translated": "<13>芒果苷</13>对<0>异丙肾上腺素</0>诱导大鼠<6>心肌梗死</6>生化改变和抗氧化状态的影响。目前的研究涉及<14>芒果苷</14>的保护作用，这是一种来自Mangifera indica Linn.（漆树科）的<22>多酚</22>，通过其抗氧化机制对<1>异丙肾上腺素</1>（<2>ISPH</2>）诱导的大鼠<7>心肌梗死</7>（<8>MI</8>）的影响。连续2天给大鼠皮下注射<3>ISPH</3>（200 mg/kg体重于1 ml生理盐水中）引起大鼠心脏<19>心肌损伤</19>，这是由活性增加决定的血清<23>乳酸</23>脱氢酶（LDH）和<24>肌酸</24>磷酸激酶同工酶（CK-MB），增加<25>尿酸</25>水平和减少血浆<26>铁</26>结合能力。用<27>氯化三苯基四唑</27>（<28>TTC</28>）测试<20>缺血性心肌</20>宏观酶谱分析<15>芒果苷</15>的保护作用。心脏组织抗氧化酶，如<29>超氧化物</29>歧化酶、过氧化氢酶、<30>谷胱甘肽</30>过氧化物酶、<31>谷胱甘肽</31>转移酶和<32>谷胱甘肽</32>还原酶活性，<9>MI</9>大鼠体内铜蓝蛋白、<34>维生素C</34>、<35>维生素E</35>和<33>谷胱甘肽</33>等非酶抗氧化剂的水平发生了改变。在用<16>芒果苷</16>（100 mg/kg体重悬浮于2 ml<36>二甲基亚砜</36>）预处理后，腹膜内给予<10>MI</10>大鼠28天，保护了上述参数从正常水平下降。与<4>ISPH</4>诱导的<11>MI</11>大鼠相比，服用<17>芒果苷</17>后心脏组织酶抗氧化剂和血清非酶抗氧化剂水平显着升高。从目前的研究可以得出结论，<18>芒果苷</18>对<5>ISPH</5>诱导的<12>MI</12>具有有益作用，因为它具有抗氧化潜力，可调节组织防御系统对抗<21>心脏损伤</21>。", "revised": true}
{"doc_key": "3670965", "sentences": [["A", "catch", "in", "the", "Reye", ".", "Twenty", "-", "six", "cases", "of", "Reye", "syndrome", "from", "The", "Children", "'s", "Hospital", ",", "Camperdown", ",", "Australia", ",", "occurring", "between", "1973", "and", "1982", "were", "reviewed", ".", "Of", "these", ",", "20", "cases", "met", "the", "US", "Public", "Health", "Service", "Centers", "for", "Disease", "Control", "criteria", "for", "the", "diagnosis", "of", "Reye", "syndrome", ".", "Aspirin", "or", "salicylate", "ingestion", "had", "occurred", "in", "only", "one", "of", "the", "20", "cases", "(", "5", "%", ")", ",", "and", "paracetamol", "(", "acetaminophen", ")", "had", "been", "administered", "in", "only", "six", "of", "the", "cases", "(", "30", "%", ")", ".", "Pathologic", "confirmation", "of", "the", "diagnosis", "of", "Reye", "syndrome", "was", "accomplished", "in", "90", "%", "of", "the", "cases", ".", "The", "incidence", "of", "Reye", "syndrome", "in", "New", "South", "Wales", ",", "Australia", ",", "is", "estimated", "from", "this", "study", "to", "be", "approximately", "nine", "cases", "per", "1", "million", "children", "compared", "with", "recent", "US", "data", "of", "ten", "to", "20", "cases", "per", "1", "million", "children", "and", "three", "to", "seven", "cases", "per", "1", "million", "children", "in", "Great", "Britain", ".", "The", "mortality", "for", "these", "Reye", "syndrome", "cases", "in", "Australia", "was", "45", "%", "as", "compared", "with", "a", "32", "%", "case", "-", "fatality", "rate", "in", "the", "United", "States", ".", "In", "Australia", ",", "the", "pediatric", "usage", "of", "aspirin", "has", "been", "extremely", "low", "for", "the", "past", "25", "years", "(", "less", "than", "1", "%", "of", "total", "dosage", "units", "sold", ")", ",", "with", "paracetamol", "(", "acetaminophen", ")", "dominating", "the", "pediatric", "analgesic", "and", "antipyretic", "market", ".", "Reye", "syndrome", "may", "be", "disappearing", "from", "Australia", "despite", "a", "total", "lack", "of", "association", "with", "salicylates", "or", "aspirin", "ingestion", ",", "since", "there", "were", "no", "cases", "found", "at", "The", "Children", "'s", "Hospital", "in", "1983", ",", "1984", ",", "or", "1985", "."]], "ner": [[[54, 54, "Chemical"], [195, 195, "Chemical"], [246, 246, "Chemical"], [4, 4, "Disease"], [11, 12, "Disease"], [51, 52, "Disease"], [97, 98, "Disease"], [111, 112, "Disease"], [165, 166, "Disease"], [230, 231, "Disease"], [56, 56, "Chemical"], [244, 244, "Chemical"], [73, 73, "Chemical"], [75, 75, "Chemical"], [218, 218, "Chemical"], [220, 220, "Chemical"]]], "relations": [[[54, 54, 4, 4, "CID"], [54, 54, 11, 12, "CID"], [54, 54, 51, 52, "CID"], [54, 54, 97, 98, "CID"], [54, 54, 111, 112, "CID"], [54, 54, 165, 166, "CID"], [54, 54, 230, 231, "CID"], [195, 195, 4, 4, "CID"], [195, 195, 11, 12, "CID"], [195, 195, 51, 52, "CID"], [195, 195, 97, 98, "CID"], [195, 195, 111, 112, "CID"], [195, 195, 165, 166, "CID"], [195, 195, 230, 231, "CID"], [246, 246, 4, 4, "CID"], [246, 246, 11, 12, "CID"], [246, 246, 51, 52, "CID"], [246, 246, 97, 98, "CID"], [246, 246, 111, 112, "CID"], [246, 246, 165, 166, "CID"], [246, 246, 230, 231, "CID"]]], "clusters": [], "translated": "在<3>Reye</3>中捕获。回顾了1973年至1982年间发生在澳大利亚坎珀当儿童医院的26例<4>Reye综合征</4>。其中，20例符合美国公共卫生服务中心疾病控制<5>雷氏综合征</5>的诊断标准。<0>阿司匹林</0>或<10>水杨酸盐</10>摄入仅发生在20个病例中的一个(5%)，而<12>扑热息痛</12>（<13>对乙酰氨基酚</13>）仅在六例(30%)中使用过。<6>Reye综合征</6>诊断的病理证实在90%的病例中完成。据这项研究估计，澳大利亚新南威尔士州<7>雷氏综合征</7>的发病率约为每100万儿童中有9例，而美国最近的数据为每100万儿童中有10至20例，而3至英国每100万儿童中有7例。在澳大利亚，这些<8>Reye综合征</8>病例的死亡率为45%，而美国的病死率为32%。在澳大利亚，<1>阿司匹林</1>的儿科使用在过去25年中一直极低(不到总销售剂量的1%)，<14>扑热息痛</14>（<15>对乙酰氨基酚</15>）主导小儿镇痛解热药市场。<9>Reye综合症</9>可能正在从澳大利亚消失，尽管完全没有与<11>水杨酸盐</11>或<2>阿司匹林</2>摄入有关，因为在The Children' 1983年、1984年或1985年的医院中没有发现这种病例。", "revised": true}
{"doc_key": "2826064", "sentences": [["Beta", "-", "2", "-", "adrenoceptor", "-", "mediated", "hypokalemia", "and", "its", "abolishment", "by", "oxprenolol", ".", "The", "time", "course", "and", "concentration", "-", "effect", "relationship", "of", "terbutaline", "-", "induced", "hypokalemia", "was", "studied", ",", "using", "computer", "-", "aided", "pharmacokinetic", "-", "dynamic", "modeling", ".", "Subsequently", "we", "investigated", "the", "efficacy", "of", "oxprenolol", "in", "antagonizing", "such", "hypokalemia", ",", "together", "with", "the", "pharmacokinetic", "interaction", "between", "both", "drugs", ".", "Six", "healthy", "subjects", "were", "given", "a", "0", ".", "5", "mg", "subcutaneous", "dose", "of", "terbutaline", "on", "two", "occasions", ":", "1", "hour", "after", "oral", "administration", "of", "a", "placebo", "and", "1", "hour", "after", "80", "mg", "oxprenolol", "orally", ".", "In", "the", "7", "-", "hour", "period", "after", "terbutaline", "administration", ",", "plasma", "samples", "were", "taken", "for", "determination", "of", "plasma", "potassium", "levels", "and", "drug", "concentrations", ".", "The", "sigmoid", "Emax", "model", "offered", "a", "good", "description", "of", "the", "relation", "between", "terbutaline", "concentrations", "and", "potassium", "effects", ".", "Oxprenolol", "caused", "decreases", "of", "65", "%", "and", "56", "%", "of", "terbutaline", "volume", "of", "distribution", "and", "clearance", ",", "respectively", ",", "and", "an", "increase", "of", "130", "%", "of", "its", "AUC", ".", "In", "spite", "of", "higher", "terbutaline", "concentrations", "after", "oxprenolol", "pretreatment", ",", "the", "hypokalemia", "was", "almost", "completely", "antagonized", "by", "the", "beta", "2", "-", "blocking", "action", "."]], "ner": [[[23, 23, "Chemical"], [73, 73, "Chemical"], [102, 102, "Chemical"], [131, 131, "Chemical"], [147, 147, "Chemical"], [170, 170, "Chemical"], [7, 7, "Disease"], [26, 26, "Disease"], [49, 49, "Disease"], [177, 177, "Disease"], [12, 12, "Chemical"], [45, 45, "Chemical"], [92, 92, "Chemical"], [137, 137, "Chemical"], [173, 173, "Chemical"], [113, 113, "Chemical"], [134, 134, "Chemical"]]], "relations": [[[23, 23, 7, 7, "CID"], [23, 23, 26, 26, "CID"], [23, 23, 49, 49, "CID"], [23, 23, 177, 177, "CID"], [73, 73, 7, 7, "CID"], [73, 73, 26, 26, "CID"], [73, 73, 49, 49, "CID"], [73, 73, 177, 177, "CID"], [102, 102, 7, 7, "CID"], [102, 102, 26, 26, "CID"], [102, 102, 49, 49, "CID"], [102, 102, 177, 177, "CID"], [131, 131, 7, 7, "CID"], [131, 131, 26, 26, "CID"], [131, 131, 49, 49, "CID"], [131, 131, 177, 177, "CID"], [147, 147, 7, 7, "CID"], [147, 147, 26, 26, "CID"], [147, 147, 49, 49, "CID"], [147, 147, 177, 177, "CID"], [170, 170, 7, 7, "CID"], [170, 170, 26, 26, "CID"], [170, 170, 49, 49, "CID"], [170, 170, 177, 177, "CID"]]], "clusters": [], "translated": "β-2-肾上腺素能受体介导的<6>低钾血症</6>及其被<10>氧烯洛尔</10>消除。利用计算机辅助药代动力学模型研究了<0>特布他林</0>引起的<7>低钾血症</7>的时程和浓度-效应关系。随后，我们研究了<11>氧烯洛尔</11>对抗这种 <8>低钾血症</8> 的功效，以及两种药物之间的药代动力学相互作用。六名健康受试者分别接受两次皮下注射5毫克<1>特布他林</1>，分别为口服安慰剂后1小时和口服80毫克<12>氧烯洛尔</12>后1小时。在<2>特布他林</2>给药后7小时内，采集血浆样品测定血浆<15>钾</15>水平和药物浓度。S形Emax模型很好地描述了<3>特布他林</3>浓度与<16>钾</16>效应之间的关系。<13>氧烯洛尔</13>导致<4>特布他林</4>分布容积和清除率分别降低65%和56%，并使其AUC增加了130%。尽管<5>特布他林</5>在<14>氧烯洛尔</14>预处置后浓度更高，但β2阻断作用几乎完全拮抗了<9>低钾血症</9>。", "revised": true}
{"doc_key": "10524660", "sentences": [["Glyceryl", "trinitrate", "induces", "attacks", "of", "migraine", "without", "aura", "in", "sufferers", "of", "migraine", "with", "aura", ".", "Migraine", "with", "aura", "and", "migraine", "without", "aura", "have", "the", "same", "pain", "phase", ",", "thus", "indicating", "that", "migraine", "with", "aura", "and", "migraine", "without", "aura", "share", "a", "common", "pathway", "of", "nociception", ".", "In", "recent", "years", ",", "increasing", "evidence", "has", "suggested", "that", "the", "messenger", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "involved", "in", "pain", "mechanisms", "of", "migraine", "without", "aura", ".", "In", "order", "to", "clarify", "whether", "the", "same", "is", "true", "for", "migraine", "with", "aura", ",", "in", "the", "present", "study", "we", "examined", "the", "headache", "response", "to", "intravenous", "infusion", "of", "glyceryl", "trinitrate", "(", "GTN", ")", "(", "0", ".", "5", "microg", "/", "kg", "/", "min", "for", "20", "min", ")", "in", "12", "sufferers", "of", "migraine", "with", "aura", ".", "The", "specific", "aim", "was", "to", "elucidate", "whether", "an", "aura", "and", "/", "or", "an", "attack", "of", "migraine", "without", "aura", "could", "be", "induced", ".", "Fourteen", "healthy", "subjects", "served", "as", "controls", ".", "Aura", "symptoms", "were", "not", "elicited", "in", "any", "subject", ".", "Headache", "was", "more", "severe", "in", "migraineurs", "than", "in", "the", "controls", "during", "and", "immediately", "after", "GTN", "infusion", "(", "p", "=", "0", ".", "037", ")", "as", "well", "as", "during", "the", "following", "11", "h", "(", "p", "=", "0", ".", "008", ")", ".", "In", "the", "controls", ",", "the", "GTN", "-", "induced", "headache", "gradually", "disappeared", ",", "whereas", "in", "migraineurs", "peak", "headache", "intensity", "occurred", "at", "a", "mean", "time", "of", "240", "min", "post", "-", "infusion", ".", "At", "this", "time", "the", "induced", "headache", "in", "6", "of", "12", "migraineurs", "fulfilled", "the", "diagnostic", "criteria", "for", "migraine", "without", "aura", "of", "the", "International", "Headache", "Society", ".", "The", "results", "therefore", "suggest", "that", "NO", "is", "involved", "in", "the", "pain", "mechanisms", "of", "migraine", "with", "aura", ".", "Since", "cortical", "spreading", "depression", "has", "been", "shown", "to", "liberate", "NO", "in", "animals", ",", "this", "finding", "may", "help", "our", "understanding", "of", "the", "coupling", "between", "cortical", "spreading", "depression", "and", "headache", "in", "migraine", "with", "aura", "."]], "ner": [[[0, 1, "Chemical"], [99, 100, "Chemical"], [102, 102, "Chemical"], [177, 177, "Chemical"], [207, 207, "Chemical"], [5, 7, "Disease"], [19, 21, "Disease"], [35, 37, "Disease"], [68, 70, "Disease"], [140, 142, "Disease"], [248, 250, "Disease"], [57, 58, "Chemical"], [60, 60, "Chemical"], [262, 262, "Chemical"], [283, 283, "Chemical"], [11, 13, "Disease"], [15, 17, "Disease"], [31, 33, "Disease"], [82, 84, "Disease"], [121, 123, "Disease"], [270, 272, "Disease"], [303, 305, "Disease"], [25, 25, "Disease"], [65, 65, "Disease"], [267, 267, "Disease"], [93, 93, "Disease"], [163, 163, "Disease"], [210, 210, "Disease"], [218, 218, "Disease"], [237, 237, "Disease"], [254, 254, "Disease"], [301, 301, "Disease"], [168, 168, "Disease"], [216, 216, "Disease"], [242, 242, "Disease"], [277, 277, "Disease"], [299, 299, "Disease"]]], "relations": [[[0, 1, 5, 7, "CID"], [0, 1, 19, 21, "CID"], [0, 1, 35, 37, "CID"], [0, 1, 68, 70, "CID"], [0, 1, 140, 142, "CID"], [0, 1, 248, 250, "CID"], [99, 100, 5, 7, "CID"], [99, 100, 19, 21, "CID"], [99, 100, 35, 37, "CID"], [99, 100, 68, 70, "CID"], [99, 100, 140, 142, "CID"], [99, 100, 248, 250, "CID"], [102, 102, 5, 7, "CID"], [102, 102, 19, 21, "CID"], [102, 102, 35, 37, "CID"], [102, 102, 68, 70, "CID"], [102, 102, 140, 142, "CID"], [102, 102, 248, 250, "CID"], [177, 177, 5, 7, "CID"], [177, 177, 19, 21, "CID"], [177, 177, 35, 37, "CID"], [177, 177, 68, 70, "CID"], [177, 177, 140, 142, "CID"], [177, 177, 248, 250, "CID"], [207, 207, 5, 7, "CID"], [207, 207, 19, 21, "CID"], [207, 207, 35, 37, "CID"], [207, 207, 68, 70, "CID"], [207, 207, 140, 142, "CID"], [207, 207, 248, 250, "CID"], [57, 58, 5, 7, "CID"], [57, 58, 19, 21, "CID"], [57, 58, 35, 37, "CID"], [57, 58, 68, 70, "CID"], [57, 58, 140, 142, "CID"], [57, 58, 248, 250, "CID"], [60, 60, 5, 7, "CID"], [60, 60, 19, 21, "CID"], [60, 60, 35, 37, "CID"], [60, 60, 68, 70, "CID"], [60, 60, 140, 142, "CID"], [60, 60, 248, 250, "CID"], [262, 262, 5, 7, "CID"], [262, 262, 19, 21, "CID"], [262, 262, 35, 37, "CID"], [262, 262, 68, 70, "CID"], [262, 262, 140, 142, "CID"], [262, 262, 248, 250, "CID"], [283, 283, 5, 7, "CID"], [283, 283, 19, 21, "CID"], [283, 283, 35, 37, "CID"], [283, 283, 68, 70, "CID"], [283, 283, 140, 142, "CID"], [283, 283, 248, 250, "CID"]]], "clusters": [], "translated": " <0>三硝酸甘油酯</0>在<15>有先兆偏头痛</15>患者中诱发<5>无先兆偏头痛</5>发作。<16>有先兆偏头痛</16>和<6>无先兆偏头痛</6>具有相同的<22>疼痛</22>期，因此表明<17>有先兆偏头痛</17>和<7>无先兆偏头痛</7>具有共同的伤害感受通路。近年来，越来越多的证据表明，信使分子<11>一氧化氮</11> (<12>NO</12>) 参与了<8>无先兆偏头痛</8>的<23>疼痛</23>机制。为阐明<18>有先兆偏头痛</18>是否也是如此，在本研究中，我们检查了静脉输注<1>甘油三硝酸酯</1>的反应(<2>GTN</2>)（0.5微克/千克/分钟，持续20分钟）在12名<19>有先兆偏头痛</19>患者中的<25>头痛</25>反应。具体目的是阐明是否可以诱发先兆和/或<9>无先兆偏头痛</9>发作。十四名健康受试者作为对照。任何受试者均未出现先兆症状。<26>头痛</26>在<32>偏头痛患者</32>中和<3>GTN</3>输注期间和输注后即刻（p=0.037）以及以下11小时 (p=0.008) 比对照组更严重。在对照组中，<4>GTN</4>引起的<27>头痛</27>逐渐消失，而在<33>偏头痛患者</33>中，<28>头痛</28>峰值强度出现在平均水平输注后240分钟的时间。此时12例<34>偏头痛</34>中有6例诱发的<29>头痛</29>符合国际<30>头痛</30>协会对<10>无先兆偏头痛</10>的诊断标准。因此，结果提示<13>NO</13>参与了<20>有先兆偏头痛</20>的<24>疼痛</24>机制。由于皮质扩散<35>抑制</35>已被证明可以在动物内释放<14>一氧化氮</14>，这一发现可能有助于我们理解皮质扩散<36>抑制</36>和<31>头痛</31>在<21>有先兆偏头痛</21>中的耦合。", "revised": true}
{"doc_key": "16563323", "sentences": [["Remifentanil", "pretreatment", "reduces", "myoclonus", "after", "etomidate", ".", "STUDY", "OBJECTIVE", ":", "The", "aim", "of", "the", "study", "was", "to", "compare", "the", "effect", "of", "pretreatment", "with", "remifentanil", "1", "microg", "/", "kg", "and", "the", "effect", "of", "gender", "on", "the", "incidence", "of", "myoclonus", "after", "anesthesia", "induction", "with", "etomidate", ".", "DESIGN", ":", "This", "was", "a", "randomized", ",", "double", "-", "blind", "study", ".", "SETTING", ":", "The", "study", "was", "conducted", "at", "a", "university", "hospital", ".", "PATIENTS", ":", "Sixty", "patients", "were", "pretreated", "in", "a", "randomized", "double", "-", "blinded", "fashion", "with", "remifentanil", "1", "microg", "/", "kg", "or", "placebo", ".", "Two", "minutes", "after", "remifentanil", "or", "placebo", "injection", ",", "etomidate", "0", ".", "3", "mg", "/", "kg", "was", "given", ".", "MEASUREMENTS", ":", "Myoclonus", "was", "recorded", "with", "a", "scale", "of", "0", "to", "3", ".", "The", "grade", "of", "sedation", "(", "none", ",", "mild", ",", "moderate", ",", "severe", ")", ",", "nausea", ",", "pruritus", ",", "and", "apnea", "were", "recorded", "after", "injection", "of", "both", "drugs", ".", "MAIN", "RESULTS", ":", "The", "incidence", "of", "myoclonus", "was", "significantly", "lower", "in", "the", "remifentanil", "group", "(", "6", ".", "7", "%", ")", "than", "in", "the", "placebo", "group", "(", "70", "%", ")", "(", "P", "<", "0", ".", "001", ")", ".", "None", "of", "the", "patients", "experienced", "sedation", ",", "apnea", ",", "nausea", ",", "or", "pruritus", "after", "injection", "of", "both", "drugs", ".", "In", "the", "placebo", "group", ",", "male", "patients", "were", "associated", "with", "significantly", "increased", "incidence", "of", "myoclonus", "after", "etomidate", "administration", ".", "CONCLUSION", ":", "Pretreatment", "with", "remifentanil", "1", "microg", "/", "kg", "reduced", "myoclonus", "after", "etomidate", "induction", "without", "side", "effects", "such", "as", "sedation", ",", "apnea", ",", "nausea", ",", "or", "pruritus", ".", "Men", "experience", "increased", "incidence", "of", "myoclonus", "than", "women", "after", "etomidate", "administration", "."]], "ner": [[[5, 5, "Chemical"], [42, 42, "Chemical"], [97, 97, "Chemical"], [220, 220, "Chemical"], [235, 235, "Chemical"], [260, 260, "Chemical"], [3, 3, "Disease"], [37, 37, "Disease"], [109, 109, "Disease"], [154, 154, "Disease"], [218, 218, "Disease"], [233, 233, "Disease"], [256, 256, "Disease"], [0, 0, "Chemical"], [23, 23, "Chemical"], [81, 81, "Chemical"], [92, 92, "Chemical"], [160, 160, "Chemical"], [227, 227, "Chemical"], [134, 134, "Disease"], [194, 194, "Disease"], [246, 246, "Disease"], [136, 136, "Disease"], [197, 197, "Disease"], [249, 249, "Disease"], [139, 139, "Disease"], [192, 192, "Disease"], [244, 244, "Disease"]]], "relations": [[[5, 5, 3, 3, "CID"], [5, 5, 37, 37, "CID"], [5, 5, 109, 109, "CID"], [5, 5, 154, 154, "CID"], [5, 5, 218, 218, "CID"], [5, 5, 233, 233, "CID"], [5, 5, 256, 256, "CID"], [42, 42, 3, 3, "CID"], [42, 42, 37, 37, "CID"], [42, 42, 109, 109, "CID"], [42, 42, 154, 154, "CID"], [42, 42, 218, 218, "CID"], [42, 42, 233, 233, "CID"], [42, 42, 256, 256, "CID"], [97, 97, 3, 3, "CID"], [97, 97, 37, 37, "CID"], [97, 97, 109, 109, "CID"], [97, 97, 154, 154, "CID"], [97, 97, 218, 218, "CID"], [97, 97, 233, 233, "CID"], [97, 97, 256, 256, "CID"], [220, 220, 3, 3, "CID"], [220, 220, 37, 37, "CID"], [220, 220, 109, 109, "CID"], [220, 220, 154, 154, "CID"], [220, 220, 218, 218, "CID"], [220, 220, 233, 233, "CID"], [220, 220, 256, 256, "CID"], [235, 235, 3, 3, "CID"], [235, 235, 37, 37, "CID"], [235, 235, 109, 109, "CID"], [235, 235, 154, 154, "CID"], [235, 235, 218, 218, "CID"], [235, 235, 233, 233, "CID"], [235, 235, 256, 256, "CID"], [260, 260, 3, 3, "CID"], [260, 260, 37, 37, "CID"], [260, 260, 109, 109, "CID"], [260, 260, 154, 154, "CID"], [260, 260, 218, 218, "CID"], [260, 260, 233, 233, "CID"], [260, 260, 256, 256, "CID"]]], "clusters": [], "translated": " <13>瑞芬太尼</13>预处理减少了<6>肌阵挛</6>，<0>依托咪酯</0>后的。研究目的：本研究的目的是比较<14>瑞芬太尼</14> 1 微克/千克预处理的效果和性别对麻醉诱导后<7>肌阵挛</7>发生率的影响。<1>依托咪酯</1> 设计：这是一项随机、双盲研究。地点：这项研究是在一所大学医院进行的。患者：60名患者以随机双盲方式接受<15>瑞芬太尼 </15> 1微克/公斤或安慰剂的预处理。两分钟后注射<16>瑞芬太尼</16>或安慰剂，随后给予<2>依托咪酯</2> 0.3mg/kg。测量：<8>肌阵挛</8>用0到3的等级记录。注射两种药物后记录镇静程度（无、轻度、中度、重度）、<19>恶心</19>、<22>瘙痒</22>和<25>呼吸暂停</25>。主要结果：<17>瑞芬太尼</17>组<9>肌阵挛</9>的发生率（6.7%）明显低于安慰剂组（70%）（P<0.001） 。注射这两种药物后，没有患者出现镇静、<26>呼吸暂停</26>、<20>恶心</20>或<23>瘙痒</23>。在安慰剂组中，男性患者在服用<3>依托咪酯</3>后<10>肌阵挛</10>的发生率显着增加。结论：<18>瑞芬太尼</18> 1 微克/千克预处理可减少<11>肌阵挛</11>，<4>依托咪酯</4> 诱导后的，且无镇静、<27>呼吸暂停</27>等副作用，以及<21>恶心</21>和<24>瘙痒</24>。服用<5>依托咪酯</5>后，男性<12>肌阵挛</12>的发生率高于女性。", "revised": true}
{"doc_key": "2422478", "sentences": [["Midline", "B3", "serotonin", "nerves", "in", "rat", "medulla", "are", "involved", "in", "hypotensive", "effect", "of", "methyldopa", ".", "Previous", "experiments", "in", "this", "laboratory", "have", "shown", "that", "microinjection", "of", "methyldopa", "onto", "the", "ventrolateral", "cells", "of", "the", "B3", "serotonin", "neurons", "in", "the", "medulla", "elicits", "a", "hypotensive", "response", "mediated", "by", "a", "projection", "descending", "into", "the", "spinal", "cord", ".", "The", "present", "experiments", "were", "designed", "to", "investigate", "the", "role", "of", "the", "midline", "cells", "of", "the", "B3", "serotonin", "neurons", "in", "the", "medulla", ",", "coinciding", "with", "the", "raphe", "magnus", ".", "In", "spontaneously", "hypertensive", ",", "stroke", "-", "prone", "rats", ",", "microinjection", "of", "methyldopa", "into", "the", "area", "of", "the", "midline", "B3", "serotonin", "cell", "group", "in", "the", "ventral", "medulla", "caused", "a", "potent", "hypotension", "of", "30", "-", "40", "mm", "Hg", ",", "which", "was", "maximal", "2", "-", "3", "h", "after", "administration", "and", "was", "abolished", "by", "the", "serotonin", "neurotoxin", "5", ",", "7", "-", "dihydroxytryptamine", "(", "5", ",", "7", "-", "DHT", ")", "injected", "intracerebroventricularly", ".", "However", ",", "intraspinal", "injection", "of", "5", ",", "7", "-", "DHT", "to", "produce", "a", "more", "selective", "lesion", "of", "only", "descending", "serotonin", "projections", "in", "the", "spinal", "cord", "did", "not", "affect", "this", "hypotension", ".", "Further", ",", "5", ",", "7", "-", "DHT", "lesion", "of", "serotonin", "nerves", "travelling", "in", "the", "median", "forebrain", "bundle", ",", "one", "of", "the", "main", "ascending", "pathways", "from", "the", "B3", "serotonin", "cells", ",", "did", "not", "affect", "the", "fall", "in", "blood", "pressure", "associated", "with", "a", "midline", "B3", "serotonin", "methyldopa", "injection", ".", "It", "is", "concluded", "therefore", "that", ",", "unlike", "the", "ventrolateral", "B3", "cells", "which", "mediate", "a", "methyldopa", "-", "induced", "hypotension", "via", "descending", "projections", ",", "the", "midline", "serotonin", "B3", "cells", "in", "the", "medulla", "contribute", "to", "the", "hypotensive", "action", "of", "methyldopa", ",", "either", "by", "way", "of", "an", "ascending", "projection", "which", "does", "not", "pass", "through", "the", "median", "forebrain", "bundle", ",", "or", "through", "a", "projection", "restricted", "to", "the", "caudal", "brainstem", "."]], "ner": [[[13, 13, "Chemical"], [25, 25, "Chemical"], [91, 91, "Chemical"], [223, 223, "Chemical"], [240, 240, "Chemical"], [262, 262, "Chemical"], [10, 10, "Disease"], [40, 40, "Disease"], [109, 109, "Disease"], [177, 177, "Disease"], [243, 243, "Disease"], [259, 259, "Disease"], [2, 2, "Chemical"], [33, 33, "Chemical"], [68, 68, "Chemical"], [99, 99, "Chemical"], [131, 131, "Chemical"], [167, 167, "Chemical"], [188, 188, "Chemical"], [206, 206, "Chemical"], [222, 222, "Chemical"], [250, 250, "Chemical"], [82, 82, "Disease"], [84, 84, "Disease"], [133, 137, "Chemical"], [139, 143, "Chemical"], [153, 157, "Chemical"], [181, 185, "Chemical"]]], "relations": [[[13, 13, 10, 10, "CID"], [13, 13, 40, 40, "CID"], [13, 13, 109, 109, "CID"], [13, 13, 177, 177, "CID"], [13, 13, 243, 243, "CID"], [13, 13, 259, 259, "CID"], [25, 25, 10, 10, "CID"], [25, 25, 40, 40, "CID"], [25, 25, 109, 109, "CID"], [25, 25, 177, 177, "CID"], [25, 25, 243, 243, "CID"], [25, 25, 259, 259, "CID"], [91, 91, 10, 10, "CID"], [91, 91, 40, 40, "CID"], [91, 91, 109, 109, "CID"], [91, 91, 177, 177, "CID"], [91, 91, 243, 243, "CID"], [91, 91, 259, 259, "CID"], [223, 223, 10, 10, "CID"], [223, 223, 40, 40, "CID"], [223, 223, 109, 109, "CID"], [223, 223, 177, 177, "CID"], [223, 223, 243, 243, "CID"], [223, 223, 259, 259, "CID"], [240, 240, 10, 10, "CID"], [240, 240, 40, 40, "CID"], [240, 240, 109, 109, "CID"], [240, 240, 177, 177, "CID"], [240, 240, 243, 243, "CID"], [240, 240, 259, 259, "CID"], [262, 262, 10, 10, "CID"], [262, 262, 40, 40, "CID"], [262, 262, 109, 109, "CID"], [262, 262, 177, 177, "CID"], [262, 262, 243, 243, "CID"], [262, 262, 259, 259, "CID"]]], "clusters": [], "translated": "大鼠髓质中线B3 <12> 血清素 </12> 神经参与 <0> 甲基多巴 </0> 的 <6> 降压 </6> 作用。本实验室之前的实验表明，将<1>甲基多巴</1>显微注射到延髓中 B3 <13> 血清素 </13> 神经元的腹外侧细胞会引起<7>低血压</7>反应，下降到脊髓的投射物。本实验旨在研究 B3 <14> 血清素 </14> 神经元中线细胞在髓质中的作用，与大中缝一致。在自发性<22>高血压</22>、<23>中风</23>易发大鼠中，将<2>甲基多巴</2>显微注射到中线B3 <15>血清素</15>细胞群区域在腹侧髓质中引起30-40mmHg的强效<8>低血压</8>，给药后2-3小时达到最大值，并被<16>血清素</16>神经毒素<24>5,7-二羟色胺</24>（<25>5,7-DHT</25>）侧脑室注射消除。然而，脊柱内注射<26>5,7-DHT</26>以在脊髓中产生更具选择性的仅下降<17>血清素</17>投射的损伤不会影响此<9>低血压</9>。此外，<27>5,7-DHT</27>损伤<18>血清素</18>神经在中前脑束中行进，这是来自B3 <19> 血清素 </19> 细胞的主要上行通路之一，不影响与中线B3 <20> 血清素 </20> <3>甲基多巴</3>注射相关的血压下降。因此，得出的结论是，与通过下行投射介导<4>甲基多巴</4>诱导的<10>低血压</10>的腹侧B3细胞不同，中线<21>血清素</21> B3 细胞在延髓有助于<5>甲基多巴</5>的<11>降压</11>作用，通过正中前脑束的上升投射或局限于脑干尾部的投射。", "revised": true}
{"doc_key": "19917396", "sentences": [["Reversible", "myocardial", "hypertrophy", "induced", "by", "tacrolimus", "in", "a", "pediatric", "heart", "transplant", "recipient", ":", "case", "report", ".", "Tacrolimus", "is", "a", "potent", "immunosuppressant", "that", "is", "frequently", "used", "in", "organ", "transplantation", ".", "However", ",", "adverse", "effects", "include", "cardiac", "toxicity", ".", "Herein", "we", "describe", "transient", "myocardial", "hypertrophy", "induced", "by", "tacrolimus", "after", "heart", "transplantation", ".", "The", "hypertrophy", "caused", "no", "clinical", "symptoms", "but", "was", "noted", "because", "of", "elevation", "of", "plasma", "brain", "natriuretic", "peptide", "concentration", "and", "confirmed", "at", "echocardiography", ".", "Initially", ",", "allograft", "rejection", "was", "feared", ";", "however", ",", "myocardial", "biopsy", "samples", "revealed", "only", "interstitial", "edema", "and", "mild", "myocardial", "hypertrophy", ";", "neither", "cellular", "nor", "humoral", "rejection", "was", "detected", ".", "The", "blood", "tacrolimus", "concentration", "was", "higher", "than", "usual", "at", "that", "time", ";", "thus", ",", "tacrolimus", "dosage", "was", "reduced", ".", "Myocardial", "hypertrophy", "completely", "resolved", "upon", "reducing", "the", "target", "concentration", "of", "tacrolimus", "and", "did", "not", "recur", ",", "as", "confirmed", "at", "echocardiography", "and", "myocardial", "biopsy", ".", "Thus", ",", "we", "conclude", "that", "tacrolimus", "induces", "reversible", "myocardial", "hypertrophy", ".", "In", "patients", "receiving", "tacrolimus", "therapy", ",", "blood", "concentration", "should", "be", "carefully", "controlled", "and", "extreme", "attention", "paid", "to", "cardiac", "involvement", "."]], "ner": [[[5, 5, "Chemical"], [16, 16, "Chemical"], [45, 45, "Chemical"], [104, 104, "Chemical"], [116, 116, "Chemical"], [131, 131, "Chemical"], [150, 150, "Chemical"], [159, 159, "Chemical"], [1, 2, "Disease"], [41, 42, "Disease"], [91, 92, "Disease"], [121, 122, "Disease"], [153, 154, "Disease"], [34, 35, "Disease"], [51, 51, "Disease"], [88, 88, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 41, 42, "CID"], [5, 5, 91, 92, "CID"], [5, 5, 121, 122, "CID"], [5, 5, 153, 154, "CID"], [16, 16, 1, 2, "CID"], [16, 16, 41, 42, "CID"], [16, 16, 91, 92, "CID"], [16, 16, 121, 122, "CID"], [16, 16, 153, 154, "CID"], [45, 45, 1, 2, "CID"], [45, 45, 41, 42, "CID"], [45, 45, 91, 92, "CID"], [45, 45, 121, 122, "CID"], [45, 45, 153, 154, "CID"], [104, 104, 1, 2, "CID"], [104, 104, 41, 42, "CID"], [104, 104, 91, 92, "CID"], [104, 104, 121, 122, "CID"], [104, 104, 153, 154, "CID"], [116, 116, 1, 2, "CID"], [116, 116, 41, 42, "CID"], [116, 116, 91, 92, "CID"], [116, 116, 121, 122, "CID"], [116, 116, 153, 154, "CID"], [131, 131, 1, 2, "CID"], [131, 131, 41, 42, "CID"], [131, 131, 91, 92, "CID"], [131, 131, 121, 122, "CID"], [131, 131, 153, 154, "CID"], [150, 150, 1, 2, "CID"], [150, 150, 41, 42, "CID"], [150, 150, 91, 92, "CID"], [150, 150, 121, 122, "CID"], [150, 150, 153, 154, "CID"], [159, 159, 1, 2, "CID"], [159, 159, 41, 42, "CID"], [159, 159, 91, 92, "CID"], [159, 159, 121, 122, "CID"], [159, 159, 153, 154, "CID"]]], "clusters": [], "translated": "<0>他克莫司</0>在儿科心脏移植受者中引起的可逆性<8>心肌肥厚</8>：病例报告。<1>他克莫司</1>是一种强效免疫抑制剂，常用于器官移植。然而，不良反应包括<13>心脏毒性</13>。在此我们描述了心脏移植后<2>他克莫司</2>诱导的短暂性<9>心肌肥厚</9>。 <14>心肌肥厚</14>没有引起临床症状，但由于血浆脑利钠肽浓度升高而被发现，并在超声心动图上得到证实。最初，担心同种异体移植物排斥；然而，心肌活检标本仅显示间质<15>水肿</15>和轻度<10>心肌肥厚</10>；既没有检测到细胞排斥反应，也没有检测到体液排斥反应。当时血<3>他克莫司</3>浓度高于平时；因此，<4>他克莫司</4>剂量减少。<11>心肌肥厚</11>在降低<5>他克莫司</5>的目标浓度后完全消退，并且没有复发，这在超声心动图和心肌活检中得到证实。因此，我们得出结论，<6>他克莫司</6>诱导可逆的<12>心肌肥大</12>。在接受<7>他克莫司</7>治疗的患者中，应小心控制血药浓度并特别注意是否有心脏受累。", "revised": true}
{"doc_key": "18177388", "sentences": [["Reverse", "or", "inverted", "left", "ventricular", "apical", "ballooning", "syndrome", "(", "reverse", "Takotsubo", "cardiomyopathy", ")", "in", "a", "young", "woman", "in", "the", "setting", "of", "amphetamine", "use", ".", "Transient", "left", "ventricular", "apical", "ballooning", "syndrome", "was", "first", "described", "in", "Japan", "as", "\"", "Takotsubo", "cardiomyopathy", ".", "\"", "This", "syndrome", "has", "been", "identified", "in", "many", "other", "countries", ".", "Many", "variations", "of", "this", "syndrome", "have", "been", "recently", "described", "in", "the", "literature", ".", "One", "of", "the", "rarest", "is", "the", "reverse", "type", "of", "this", "syndrome", ",", "with", "hyperdynamic", "apex", "and", "complete", "akinesia", "of", "the", "base", "(", "as", "opposed", "to", "the", "classic", "apical", "ballooning", ")", ".", "In", "this", "article", ",", "we", "report", "an", "interesting", "case", "of", "a", "young", "woman", "who", "presented", "with", "this", "rare", "type", "of", "reverse", "apical", "ballooning", "syndrome", "occurring", "after", "amphetamine", "use", ".", "This", "report", "is", "followed", "by", "review", "of", "the", "literature", "."]], "ner": [[[21, 21, "Chemical"], [121, 121, "Chemical"], [3, 7, "Disease"], [10, 11, "Disease"], [25, 29, "Disease"], [37, 38, "Disease"], [91, 92, "Disease"], [116, 118, "Disease"], [81, 81, "Disease"]]], "relations": [[[21, 21, 3, 7, "CID"], [21, 21, 10, 11, "CID"], [21, 21, 25, 29, "CID"], [21, 21, 37, 38, "CID"], [21, 21, 91, 92, "CID"], [21, 21, 116, 118, "CID"], [121, 121, 3, 7, "CID"], [121, 121, 10, 11, "CID"], [121, 121, 25, 29, "CID"], [121, 121, 37, 38, "CID"], [121, 121, 91, 92, "CID"], [121, 121, 116, 118, "CID"]]], "clusters": [], "translated": "在 <0>安非他命</0> 使用的情况下，一名年轻女性发生逆转或倒转 <2>左心室心尖球形综合征</2>（逆转 <3>Takotsubo 心肌病</3>）。一过性<4>左心室心尖球囊样变综合征</4>在日本首次被描述为“<5>Takotsubo 心肌病</5>”。许多其他国家也发现了这种综合征。最近在文献中描述了这种综合征的许多变异。最罕见的一种是这种综合征的逆转型，具有<8>高动力性顶点</8>和基部的完全<8>运动不能</8>（与经典的<6>心尖球样变</6>相反）。在这篇文章中，我们报告了一个有趣的案例，一位年轻女性在使用<1>安非他命</1>后出现这种罕见类型的<7>反向心尖球样变综合征</7>。这份报告之后是对文献的回顾。", "revised": true}
{"doc_key": "18541230", "sentences": [["Protective", "effects", "of", "antithrombin", "on", "puromycin", "aminonucleoside", "nephrosis", "in", "rats", ".", "We", "investigated", "the", "effects", "of", "antithrombin", ",", "a", "plasma", "inhibitor", "of", "coagulation", "factors", ",", "in", "rats", "with", "puromycin", "aminonucleoside", "-", "induced", "nephrosis", ",", "which", "is", "an", "experimental", "model", "of", "human", "nephrotic", "syndrome", ".", "Antithrombin", "(", "50", "or", "500", "IU", "/", "kg", "/", "i", ".", "v", ".", ")", "was", "administered", "to", "rats", "once", "a", "day", "for", "10", "days", "immediately", "after", "the", "injection", "of", "puromycin", "aminonucleoside", "(", "50", "mg", "/", "kg", "/", "i", ".", "v", ".", ")", ".", "Treatment", "with", "antithrombin", "attenuated", "the", "puromycin", "aminonucleoside", "-", "induced", "hematological", "abnormalities", ".", "Puromycin", "aminonucleoside", "-", "induced", "renal", "dysfunction", "and", "hyperlipidemia", "were", "also", "suppressed", ".", "Histopathological", "examination", "revealed", "severe", "renal", "damage", "such", "as", "proteinaceous", "casts", "in", "tubuli", "and", "tubular", "expansion", "in", "the", "kidney", "of", "control", "rats", ",", "while", "an", "improvement", "of", "the", "damage", "was", "seen", "in", "antithrombin", "-", "treated", "rats", ".", "In", "addition", ",", "antithrombin", "treatment", "markedly", "suppressed", "puromycin", "aminonucleoside", "-", "induced", "apoptosis", "of", "renal", "tubular", "epithelial", "cells", ".", "Furthermore", ",", "puromycin", "aminonucleoside", "-", "induced", "increases", "in", "renal", "cytokine", "content", "were", "also", "decreased", ".", "These", "findings", "suggest", "that", "thrombin", "plays", "an", "important", "role", "in", "the", "pathogenesis", "of", "puromycin", "aminonucleoside", "-", "induced", "nephrotic", "syndrome", ".", "Treatment", "with", "antithrombin", "may", "be", "clinically", "effective", "in", "patients", "with", "nephrotic", "syndrome", "."]], "ner": [[[5, 6, "Chemical"], [28, 29, "Chemical"], [73, 74, "Chemical"], [92, 93, "Chemical"], [99, 100, "Chemical"], [154, 155, "Chemical"], [167, 168, "Chemical"], [193, 194, "Chemical"], [7, 7, "Disease"], [32, 32, "Disease"], [41, 42, "Disease"], [197, 198, "Disease"], [210, 211, "Disease"], [96, 97, "Disease"], [103, 104, "Disease"], [115, 116, "Disease"], [106, 106, "Disease"]]], "relations": [[[5, 6, 7, 7, "CID"], [5, 6, 32, 32, "CID"], [28, 29, 7, 7, "CID"], [28, 29, 32, 32, "CID"], [73, 74, 7, 7, "CID"], [73, 74, 32, 32, "CID"], [92, 93, 7, 7, "CID"], [92, 93, 32, 32, "CID"], [99, 100, 7, 7, "CID"], [99, 100, 32, 32, "CID"], [154, 155, 7, 7, "CID"], [154, 155, 32, 32, "CID"], [167, 168, 7, 7, "CID"], [167, 168, 32, 32, "CID"], [193, 194, 7, 7, "CID"], [193, 194, 32, 32, "CID"]]], "clusters": [], "translated": "抗凝血酶对大鼠<0>嘌呤霉素氨基核苷</0> <8>肾病</8>的保护作用。我们研究了抗凝血酶（一种血浆凝血因子抑制剂）对<1>嘌呤霉素氨基核苷</1>诱导的<9>肾病</9>大鼠的影响，该大鼠是人类<10>肾病综合征</10>的实验模型。在注射<2>嘌呤霉素氨基核苷</2>（50 mg/kg/i.v.）后立即给予大鼠抗凝血酶（50或500 IU/kg/i.v.），每天一次，持续10天。抗凝血酶治疗减弱了<3>嘌呤霉素氨基核苷</3>诱导的<13>血液学异常</13>。 <4>嘌呤霉素氨基核苷</4>引起的<14>肾功能不全</14>和<16>高脂血症</16>也受到抑制。组织病理学检查显示严重的<15>肾损伤</15>，如对照大鼠肾小管蛋白管型和肾小管扩张，而抗凝血酶治疗大鼠的损伤有所改善。此外，抗凝血酶治疗显着抑制<5>嘌呤霉素氨基核苷</5>诱导的肾小管上皮细胞凋亡。此外，<6>嘌呤霉素氨基核苷</6>引起的肾细胞因子含量增加也减少。这些发现表明凝血酶在<7>嘌呤霉素氨基核苷</7>诱导的<11>肾病综合征</11>的发病机制中起重要作用。抗凝血酶治疗对<12>肾病综合征</12>患者可能在临床上有效。", "revised": true}
{"doc_key": "17490790", "sentences": [["Peripheral", "iron", "dextran", "induced", "degeneration", "of", "dopaminergic", "neurons", "in", "rat", "substantia", "nigra", ".", "Iron", "accumulation", "is", "considered", "to", "be", "involved", "in", "the", "pathogenesis", "of", "Parkinson", "'s", "disease", ".", "To", "demonstrate", "the", "relationship", "between", "peripheral", "iron", "overload", "and", "dopaminergic", "neuron", "loss", "in", "rat", "substantia", "nigra", "(", "SN", ")", ",", "in", "the", "present", "study", "we", "used", "fast", "cyclic", "voltammetry", ",", "tyrosine", "hydroxylase", "(", "TH", ")", "immunohistochemistry", ",", "Perls", "'", "iron", "staining", ",", "and", "high", "performance", "liquid", "chromatography", "-", "electrochemical", "detection", "to", "study", "the", "degeneration", "of", "dopaminergic", "neurons", "and", "increased", "iron", "content", "in", "the", "SN", "of", "iron", "dextran", "overloaded", "animals", ".", "The", "findings", "showed", "that", "peripheral", "iron", "dextran", "overload", "increased", "the", "iron", "staining", "positive", "cells", "and", "reduced", "the", "number", "of", "TH", "-", "immunoreactive", "neurons", "in", "the", "SN", ".", "As", "a", "result", ",", "dopamine", "release", "and", "content", ",", "as", "well", "as", "its", "metabolites", "contents", "were", "decreased", "in", "caudate", "putamen", ".", "Even", "more", "dramatic", "changes", "were", "found", "in", "chronic", "overload", "group", ".", "These", "results", "suggest", "that", "peripheral", "iron", "dextran", "can", "increase", "the", "iron", "level", "in", "the", "SN", ",", "where", "excessive", "iron", "causes", "the", "degeneration", "of", "dopaminergic", "neurons", ".", "The", "chronic", "iron", "overload", "may", "be", "more", "destructive", "to", "dopaminergic", "neurons", "than", "the", "acute", "iron", "overload", "."]], "ner": [[[1, 2, "Chemical"], [93, 94, "Chemical"], [103, 104, "Chemical"], [162, 163, "Chemical"], [4, 7, "Disease"], [81, 84, "Disease"], [178, 181, "Disease"], [24, 26, "Disease"], [13, 13, "Chemical"], [34, 34, "Chemical"], [67, 67, "Chemical"], [87, 87, "Chemical"], [108, 108, "Chemical"], [167, 167, "Chemical"], [175, 175, "Chemical"], [185, 185, "Chemical"], [197, 197, "Chemical"], [58, 58, "Chemical"], [129, 129, "Chemical"]]], "relations": [[[1, 2, 4, 7, "CID"], [1, 2, 81, 84, "CID"], [1, 2, 178, 181, "CID"], [93, 94, 4, 7, "CID"], [93, 94, 81, 84, "CID"], [93, 94, 178, 181, "CID"], [103, 104, 4, 7, "CID"], [103, 104, 81, 84, "CID"], [103, 104, 178, 181, "CID"], [162, 163, 4, 7, "CID"], [162, 163, 81, 84, "CID"], [162, 163, 178, 181, "CID"]]], "clusters": [], "translated": "外周<0>葡聚糖铁</0>诱导大鼠黑质<4>多巴胺能神经元变性</4>。<8>铁</8>积累被认为与<7>帕金森病</7>的发病机制有关。为了证明大鼠黑质(SN)外周<9>铁</9>超载与多巴胺能神经元丢失之间的关系，本研究采用快速循环伏安法、<17>酪氨酸</17>羟化酶(TH)免疫组化技术、Perls'<10>铁</10>染色和高效液相色谱-电化学检测以研究<5>多巴胺能神经元变性</5>和SN中的<11>铁</11>含量在<1>葡聚糖铁</1>超载动物中的表现。结果表明，外周<2>葡聚糖铁</2>超载增加了SN中<12>铁</12>染色阳性细胞，减少了TH-免疫反应神经元的数量。结果，尾状壳核中<18>多巴胺</18>的释放和含量及其代谢物含量均降低。慢性超负荷组的变化更为显着。这些结果表明，外周<3>铁葡聚糖</3>可以增加SN中的<13>铁</13>水平，其中过量的<14>铁</14>导致<6>多巴胺能神经元的退化</6>。与急性<16>铁</16>超载相比，慢性<15>铁</15>超载对多巴胺能神经元的破坏可能更大。", "revised": true}
{"doc_key": "1504402", "sentences": [["Hypersensitivity", "immune", "reaction", "as", "a", "mechanism", "for", "dilevalol", "-", "associated", "hepatitis", ".", "OBJECTIVE", ":", "To", "assess", "lymphocyte", "reactivity", "to", "dilevalol", "and", "to", "serum", "containing", "putative", "ex", "vivo", "dilevalol", "antigens", "or", "metabolites", "in", "a", "case", "of", "dilevalol", "-", "induced", "liver", "injury", ".", "PATIENT", ":", "A", "58", "-", "year", "-", "old", "woman", "with", "a", "clinical", "diagnosis", "of", "dilevalol", "-", "induced", "liver", "injury", ".", "METHODS", ":", "Peripheral", "blood", "mononuclear", "cells", "collected", "from", "the", "patient", "were", "cultured", "in", "the", "presence", "of", "a", "solution", "of", "dilevalol", "and", "also", "with", "sera", "collected", "from", "a", "volunteer", "before", "and", "after", "dilevalol", "intake", ".", "A", "similar", "protocol", "was", "performed", "with", "lymphocytes", "from", "a", "healthy", "subject", ".", "RESULTS", ":", "No", "lymphocyte", "proliferation", "was", "observed", "either", "in", "the", "patient", "or", "in", "the", "healthy", "volunteer", "in", "the", "presence", "of", "dilevalol", "solutions", ".", "A", "significant", "proliferative", "response", "to", "serum", "collected", "after", "dilevalol", "intake", "was", "observed", "in", "the", "case", "of", "the", "patient", "compared", "with", "the", "proliferative", "response", "to", "the", "serum", "collected", "before", "the", "drug", "intake", ".", "No", "reactivity", "was", "found", "when", "lymphocytes", "from", "the", "healthy", "subject", "were", "tested", "under", "similar", "conditions", ".", "CONCLUSIONS", ":", "The", "methodology", "used", "allowed", "the", "detection", "of", "lymphocyte", "sensitization", "to", "sera", "containing", "ex", "vivo", "-", "prepared", "dilevalol", "antigens", ",", "suggesting", "the", "involvement", "of", "an", "immunologic", "mechanism", "in", "dilevalol", "-", "induced", "liver", "injury", "."]], "ner": [[[7, 7, "Chemical"], [19, 19, "Chemical"], [27, 27, "Chemical"], [35, 35, "Chemical"], [55, 55, "Chemical"], [80, 80, "Chemical"], [92, 92, "Chemical"], [127, 127, "Chemical"], [138, 138, "Chemical"], [196, 196, "Chemical"], [207, 207, "Chemical"], [0, 0, "Disease"], [10, 10, "Disease"], [38, 39, "Disease"], [58, 59, "Disease"], [210, 211, "Disease"]]], "relations": [[[7, 7, 0, 0, "CID"], [19, 19, 0, 0, "CID"], [27, 27, 0, 0, "CID"], [35, 35, 0, 0, "CID"], [55, 55, 0, 0, "CID"], [80, 80, 0, 0, "CID"], [92, 92, 0, 0, "CID"], [127, 127, 0, 0, "CID"], [138, 138, 0, 0, "CID"], [196, 196, 0, 0, "CID"], [207, 207, 0, 0, "CID"], [7, 7, 10, 10, "CID"], [7, 7, 38, 39, "CID"], [7, 7, 58, 59, "CID"], [7, 7, 210, 211, "CID"], [19, 19, 10, 10, "CID"], [19, 19, 38, 39, "CID"], [19, 19, 58, 59, "CID"], [19, 19, 210, 211, "CID"], [27, 27, 10, 10, "CID"], [27, 27, 38, 39, "CID"], [27, 27, 58, 59, "CID"], [27, 27, 210, 211, "CID"], [35, 35, 10, 10, "CID"], [35, 35, 38, 39, "CID"], [35, 35, 58, 59, "CID"], [35, 35, 210, 211, "CID"], [55, 55, 10, 10, "CID"], [55, 55, 38, 39, "CID"], [55, 55, 58, 59, "CID"], [55, 55, 210, 211, "CID"], [80, 80, 10, 10, "CID"], [80, 80, 38, 39, "CID"], [80, 80, 58, 59, "CID"], [80, 80, 210, 211, "CID"], [92, 92, 10, 10, "CID"], [92, 92, 38, 39, "CID"], [92, 92, 58, 59, "CID"], [92, 92, 210, 211, "CID"], [127, 127, 10, 10, "CID"], [127, 127, 38, 39, "CID"], [127, 127, 58, 59, "CID"], [127, 127, 210, 211, "CID"], [138, 138, 10, 10, "CID"], [138, 138, 38, 39, "CID"], [138, 138, 58, 59, "CID"], [138, 138, 210, 211, "CID"], [196, 196, 10, 10, "CID"], [196, 196, 38, 39, "CID"], [196, 196, 58, 59, "CID"], [196, 196, 210, 211, "CID"], [207, 207, 10, 10, "CID"], [207, 207, 38, 39, "CID"], [207, 207, 58, 59, "CID"], [207, 207, 210, 211, "CID"]]], "clusters": [], "translated": " <11>超敏反应</11>作为<0>地来戊洛尔</0>相关<12>肝炎</12>机制的免疫反应。目的：在<3> 地来戊洛尔 </3> 诱导的<13>肝损伤</13> 情况下，评估淋巴细胞对<1>地来伐洛</1>和含有推定的体外<2>地来戊洛尔</2>抗原或代谢物的血清的反应性。患者：一名58岁的女性，临床诊断为<4>地来戊洛尔</4>引起的<14>肝损伤</14>。方法：对患者外周血单核细胞进行培养，分别在<5>地来戊洛尔</5>溶液和摄入<6>地来戊洛尔</6>前后收集的志愿者血清中进行测试。对健康者进行了类似实验。结果：在<7>地来戊洛尔</7>溶液存在下，患者和健康志愿者均未观察到淋巴细胞增殖。在该患者的病例中，与药物摄入前收集的血清的增殖反应相比，观察到服用<8>地来戊洛尔</8>后收集的血清有显着的增殖反应。在类似条件下测试来自健康受试者的淋巴细胞时，未发现反应性。结论：采用的方法允许检测到淋巴细胞对血清中含有体外制备的<9>地来戊洛尔</9>抗原的致敏作用，表明免疫学机制参与<10>地来戊洛尔</10>诱导的<15>肝脏伤害</15>。", "revised": true}
{"doc_key": "16047871", "sentences": [["Warfarin", "-", "induced", "leukocytoclastic", "vasculitis", ".", "Skin", "reactions", "associated", "with", "oral", "coumarin", "-", "derived", "anticoagulants", "are", "an", "uncommon", "occurrence", ".", "Leukocytoclastic", "vasculitis", "(", "LV", ")", "is", "primarily", "a", "cutaneous", "small", "vessel", "vasculitis", ",", "though", "systemic", "involvement", "may", "be", "encountered", ".", "We", "report", "4", "patients", "with", "late", "-", "onset", "LV", "probably", "due", "to", "warfarin", ".", "All", "4", "patients", "presented", "with", "skin", "eruptions", "that", "developed", "after", "receiving", "warfarin", "for", "several", "years", ".", "The", "results", "of", "skin", "lesion", "biopsies", "were", "available", "in", "3", "patients", ",", "confirming", "LV", "Cutaneous", "lesions", "resolved", "in", "all", "patients", "after", "warfarin", "was", "discontinued", ".", "In", "2", "of", "the", "4", "patients", ",", "rechallenge", "with", "warfarin", "led", "to", "recurrence", "of", "the", "lesions", ".", "LV", "may", "be", "a", "late", "-", "onset", "adverse", "reaction", "associated", "with", "warfarin", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [52, 52, "Chemical"], [65, 65, "Chemical"], [91, 91, "Chemical"], [104, 104, "Chemical"], [123, 123, "Chemical"], [83, 85, "Disease"], [3, 4, "Disease"], [20, 21, "Disease"], [23, 23, "Disease"], [48, 48, "Disease"], [112, 112, "Disease"], [28, 31, "Disease"], [59, 60, "Disease"], [73, 74, "Disease"], [11, 11, "Chemical"]]], "relations": [[[0, 0, 83, 85, "CID"], [52, 52, 83, 85, "CID"], [65, 65, 83, 85, "CID"], [91, 91, 83, 85, "CID"], [104, 104, 83, 85, "CID"], [123, 123, 83, 85, "CID"]]], "clusters": [], "translated": " <0>华法林</0>诱发的<7>白细胞破碎性血管炎</7>。与口服<15>香豆素</15>衍生的抗凝剂相关的皮肤反应并不常见。<8>白细胞破碎性血管炎</8>（<9>LV</9>）主要是<12>皮肤小血管炎</12>，但也可能会出现全身受累。我们报告了4例迟发性<10>LV</10>患者，可能是由于<1>华法林</1>。所有4名患者均出现<13>皮疹</13>，这些皮疹是在接受<2>华法林</2>治疗数年后发生的。3名患者获得了<14>皮肤损伤</14>活检结果，证实<6>皮肤损伤为小血管性</6>，在停用<3>华法林</3>后所有患者均已消退。在4名患者中的2名患者中，再次使用<4>华法林</4>导致病变复发。<11>LV</11>可能是与<5>华法林</5>治疗相关的迟发性不良反应。", "revised": true}
{"doc_key": "17490864", "sentences": [["Attenuated", "disruption", "of", "prepulse", "inhibition", "by", "dopaminergic", "stimulation", "after", "maternal", "deprivation", "and", "adolescent", "corticosterone", "treatment", "in", "rats", ".", "The", "development", "of", "schizophrenia", "may", "include", "an", "early", "neurodevelopmental", "stress", "component", "which", "increases", "vulnerability", "to", "later", "stressful", "life", "events", ",", "in", "combination", "leading", "to", "overt", "disease", ".", "We", "investigated", "the", "effect", "of", "an", "early", "stress", ",", "in", "the", "form", "of", "maternal", "deprivation", ",", "combined", "with", "a", "later", "stress", ",", "simulated", "by", "chronic", "periadolescent", "corticosterone", "treatment", ",", "on", "behaviour", "in", "rats", ".", "Acute", "treatment", "with", "apomorphine", "caused", "disruption", "of", "prepulse", "inhibition", "(", "PPI", ")", "in", "controls", "and", "in", "rats", "that", "had", "undergone", "either", "maternal", "deprivation", "or", "corticosterone", "treatment", ",", "but", "was", "surprisingly", "absent", "in", "rats", "that", "had", "undergone", "the", "combined", "early", "and", "late", "stress", ".", "Amphetamine", "treatment", "significantly", "disrupted", "PPI", "in", "both", "non", "-", "deprived", "groups", ",", "but", "was", "absent", "in", "both", "maternally", "deprived", "groups", ".", "The", "serotonin", "-", "1A", "receptor", "agonist", ",", "8", "-", "OH", "-", "DPAT", ",", "induced", "a", "significant", "disruption", "of", "PPI", "in", "all", "groups", ".", "Amphetamine", "-", "induced", "locomotor", "hyperactivity", "was", "similar", "in", "all", "groups", ".", "These", "results", "show", "an", "inhibitory", "interaction", "of", "early", "stress", ",", "caused", "by", "maternal", "deprivation", ",", "combined", "with", "'", "adolescent", "'", "stress", ",", "simulated", "by", "corticosterone", "treatment", ",", "on", "dopaminergic", "regulation", "of", "PPI", ".", "The", "altered", "effects", "of", "apomorphine", "and", "amphetamine", "could", "indicate", "differential", "changes", "in", "dopamine", "receptor", "signalling", "leading", "to", "functional", "desensitisation", ",", "or", "altered", "modulation", "of", "sensory", "gating", "in", "the", "nucleus", "accumbens", "by", "limbic", "structures", "such", "as", "the", "hippocampus", "."]], "ner": [[[122, 122, "Chemical"], [166, 166, "Chemical"], [216, 216, "Chemical"], [169, 170, "Disease"], [13, 13, "Chemical"], [71, 71, "Chemical"], [103, 103, "Chemical"], [201, 201, "Chemical"], [21, 21, "Disease"], [82, 82, "Chemical"], [214, 214, "Chemical"], [144, 144, "Chemical"], [150, 154, "Chemical"], [222, 222, "Chemical"]]], "relations": [[[122, 122, 169, 170, "CID"], [166, 166, 169, 170, "CID"], [216, 216, 169, 170, "CID"]]], "clusters": [], "translated": "在大鼠中母体剥夺和青春期 <4> 皮质酮 </4> 治疗后，多巴胺能刺激减弱了前脉冲抑制的中断。<8> 精神分裂症 </8>的发展可能包括早期神经发育应激因素，这会增加对后来压力性生活事件的脆弱性，并导致明显的疾病。我们调查了早期应激（以母性剥夺的形式）与后期应激（通过慢性围青春期 <5> 皮质酮</5> 治疗模拟）对大鼠行为的影响。<9> 阿扑吗啡 </9>的急性治疗导致对照组和经历过母体剥夺或<6> 皮质酮 </6> 治疗的大鼠的前脉冲抑制（PPI）中断，但令人惊讶的是，在经历过母体剥夺的大鼠中却没有早期和晚期的联合压力。<0>苯丙胺</0> 治疗显着扰乱了两个非剥夺组的 PPI，但在两个母性剥夺组中均不存在。 <11>血清素</11>-1A 受体激动剂，<12>8-OH-DPAT</12>，在所有组中均引起 PPI 的显着破坏。 <1>苯丙胺</1> 引起的 <3>运动机能亢进</3> 在所有组中都相似。这些结果表明，由母亲剥夺引起的早期压力与 <7> 皮质酮 </7>治疗模拟的“青春期”压力对PPI的多巴胺能调节存在抑制相互作用。 <10>阿扑吗啡</10> 和<2>苯丙胺</2> 的改变作用可能表明 <13>多巴胺</13> 受体信号的不同变化导致功能性脱敏，或细胞核中感觉门控调节的改变伏隔核由边缘结构如海马体产生。", "revised": true}
{"doc_key": "6150641", "sentences": [["Comparison", "of", "the", "effectiveness", "of", "ranitidine", "and", "cimetidine", "in", "inhibiting", "acid", "secretion", "in", "patients", "with", "gastric", "hypersecretory", "states", ".", "The", "H2", "-", "histamine", "receptor", "antagonists", "ranitidine", "and", "cimetidine", "were", "compared", "for", "their", "abilities", "to", "control", "gastric", "acid", "hypersecretion", "on", "a", "short", "-", "and", "long", "-", "term", "basis", "in", "22", "patients", "with", "gastric", "acid", "hypersecretory", "states", ".", "Nineteen", "patients", "had", "Zollinger", "-", "Ellison", "syndrome", ",", "one", "patient", "had", "systemic", "mastocytosis", ",", "and", "two", "patients", "had", "idiopathic", "hypersecretion", ".", "The", "rates", "of", "onset", "of", "the", "action", "of", "cimetidine", "and", "ranitidine", "were", "the", "same", ".", "The", "actions", "of", "both", "drugs", "were", "increased", "by", "anticholinergic", "agents", ",", "and", "there", "was", "a", "close", "correlation", "between", "the", "daily", "maintenance", "dose", "of", "each", "drug", "needed", "to", "control", "acid", "secretion", ".", "However", ",", "ranitidine", "was", "threefold", "more", "potent", "than", "cimetidine", "both", "in", "acute", "inhibition", "studies", "and", "in", "the", "median", "maintenance", "dose", "needed", "(", "1", ".", "2", "g", "per", "day", "for", "ranitidine", "and", "3", ".", "6", "g", "per", "day", "for", "cimetidine", ")", ".", "Sixty", "percent", "of", "the", "males", "developed", "breast", "changes", "or", "impotence", "while", "taking", "cimetidine", "and", "in", "all", "cases", "these", "changes", "disappeared", "when", "cimetidine", "was", "replaced", "by", "ranitidine", ".", "Treatment", "with", "high", "doses", "of", "cimetidine", "(", "one", "to", "60", "months", ";", "median", ",", "11", "months", ")", "or", "ranitidine", "(", "two", "to", "31", "months", ";", "median", ",", "14", "months", ")", "was", "not", "associated", "with", "hepatic", "or", "hematologic", "toxicity", "or", "alterations", "of", "serum", "gastrin", "concentrations", ",", "but", "ranitidine", "therapy", "was", "associated", "with", "a", "significantly", "lower", "serum", "creatinine", "level", "than", "seen", "with", "cimetidine", "therapy", ".", "The", "results", "show", "that", "both", "drugs", "can", "adequately", "inhibit", "acid", "secretion", "in", "patients", "with", "gastric", "hypersecretory", "states", ".", "Both", "are", "safe", "at", "high", "doses", ",", "but", "ranitidine", "is", "threefold", "more", "potent", "and", "does", "not", "cause", "the", "antiandrogen", "side", "effects", "frequently", "seen", "with", "high", "doses", "of", "cimetidine", "."]], "ner": [[[7, 7, "Chemical"], [27, 27, "Chemical"], [85, 85, "Chemical"], [131, 131, "Chemical"], [161, 161, "Chemical"], [176, 176, "Chemical"], [185, 185, "Chemical"], [196, 196, "Chemical"], [251, 251, "Chemical"], [299, 299, "Chemical"], [173, 173, "Disease"], [5, 5, "Chemical"], [25, 25, "Chemical"], [87, 87, "Chemical"], [125, 125, "Chemical"], [152, 152, "Chemical"], [189, 189, "Chemical"], [209, 209, "Chemical"], [237, 237, "Chemical"], [280, 280, "Chemical"], [59, 62, "Disease"], [67, 68, "Disease"], [225, 228, "Disease"], [22, 22, "Chemical"], [246, 246, "Chemical"]]], "relations": [[[7, 7, 173, 173, "CID"], [27, 27, 173, 173, "CID"], [85, 85, 173, 173, "CID"], [131, 131, 173, 173, "CID"], [161, 161, 173, 173, "CID"], [176, 176, 173, 173, "CID"], [185, 185, 173, 173, "CID"], [196, 196, 173, 173, "CID"], [251, 251, 173, 173, "CID"], [299, 299, 173, 173, "CID"]]], "clusters": [], "translated": "<11> 雷尼替丁 </11> 与 <0> 西咪替丁 </0> 抑制胃高分泌状态患者酸分泌的疗效比较。比较了 H2-<23> 组胺 </23> 受体拮抗剂 <12> 雷尼替丁 </12> 和 <1> 西咪替丁 </1> 短期和长期控制胃酸分泌过多的能力 22 例胃酸分泌过多状态。19例患者有 <20> Zollinger-Ellison 综合征 </20>，1例患者有 <21> 系统性肥大细胞增多症 </21>，2例患者有特发性分泌过多。 <2> 西咪替丁 </2> 和 <13> 雷尼替丁 </13> 的起效率相同。抗胆碱能药物可增强这两种药物的作用，并且每种药物控制胃酸分泌所需的每日维持剂量之间存在密切相关性。然而， <14> 雷尼替丁 </14> 在急性抑制研究和所需的中位维持剂量（每天 1.2g 的 <15> 雷尼替丁 </15> 和每天 3.6g 的 <4> 西咪替丁 </4>）方面比 <3> 西咪替丁 </3> 强三倍。60% 的男性在服用 <5> 西咪替丁 </5> 时出现乳房变化或 <10>阳痿</10> ，并且在所有情况下，当 <6> 西咪替丁 </6> 被 <16> 雷尼替丁 </16> 替代时，这些变化都消失了。使用高剂量 <7> 西咪替丁 </7>（1 至 60 个月；中位数，11 个月）或 <17> 雷尼替丁 </17>（2 至 31 个月；中位数，14 个月）治疗与 <22> 肝或血液学毒性 </22> 或血清胃泌素浓度的改变无关，但 <18> 雷尼替丁 </18> 治疗与血清 <24> 肌酐 </24> 水平显着低于 <8> 西咪替丁 </8> 治疗。结果表明，两种药物均能充分抑制胃酸分泌过多患者的胃酸分泌。两者在高剂量下都是安全的，但 <19>雷尼替丁</19> 的效力高出三倍，并且不会引起高剂量 <9> 西咪替丁 </9> 常见的抗雄激素副作用。", "revised": true}
{"doc_key": "12481039", "sentences": [["Reduced", "sodium", "channel", "density", ",", "altered", "voltage", "dependence", "of", "inactivation", ",", "and", "increased", "susceptibility", "to", "seizures", "in", "mice", "lacking", "sodium", "channel", "beta", "2", "-", "subunits", ".", "Sodium", "channel", "beta", "-", "subunits", "modulate", "channel", "gating", ",", "assembly", ",", "and", "cell", "surface", "expression", "in", "heterologous", "cell", "systems", ".", "We", "generated", "beta2", "(", "-", "/", "-", ")", "mice", "to", "investigate", "the", "role", "of", "beta2", "in", "control", "of", "sodium", "channel", "density", ",", "localization", ",", "and", "function", "in", "neurons", "in", "vivo", ".", "Measurements", "of", "[", "(", "3", ")", "H", "]", "saxitoxin", "(", "STX", ")", "binding", "showed", "a", "significant", "reduction", "in", "the", "level", "of", "plasma", "membrane", "sodium", "channels", "in", "beta2", "(", "-", "/", "-", ")", "neurons", ".", "The", "loss", "of", "beta2", "resulted", "in", "negative", "shifts", "in", "the", "voltage", "dependence", "of", "inactivation", "as", "well", "as", "significant", "decreases", "in", "sodium", "current", "density", "in", "acutely", "dissociated", "hippocampal", "neurons", ".", "The", "integral", "of", "the", "compound", "action", "potential", "in", "optic", "nerve", "was", "significantly", "reduced", ",", "and", "the", "threshold", "for", "action", "potential", "generation", "was", "increased", ",", "indicating", "a", "reduction", "in", "the", "level", "of", "functional", "plasma", "membrane", "sodium", "channels", ".", "In", "contrast", ",", "the", "conduction", "velocity", ",", "the", "number", "and", "size", "of", "axons", "in", "the", "optic", "nerve", ",", "and", "the", "specific", "localization", "of", "Na", "(", "v", ")", "1", ".", "6", "channels", "in", "the", "nodes", "of", "Ranvier", "were", "unchanged", ".", "beta2", "(", "-", "/", "-", ")", "mice", "displayed", "increased", "susceptibility", "to", "seizures", ",", "as", "indicated", "by", "reduced", "latency", "and", "threshold", "for", "pilocarpine", "-", "induced", "seizures", ",", "but", "seemed", "normal", "in", "other", "neurological", "tests", ".", "Our", "observations", "show", "that", "beta2", "-", "subunits", "play", "an", "important", "role", "in", "the", "regulation", "of", "sodium", "channel", "density", "and", "function", "in", "neurons", "in", "vivo", "and", "are", "required", "for", "normal", "action", "potential", "generation", "and", "control", "of", "excitability", "."]], "ner": [[[237, 237, "Chemical"], [15, 15, "Disease"], [227, 227, "Disease"], [240, 240, "Disease"], [1, 1, "Chemical"], [19, 19, "Chemical"], [26, 26, "Chemical"], [64, 64, "Chemical"], [100, 100, "Chemical"], [131, 131, "Chemical"], [174, 174, "Chemical"], [200, 200, "Chemical"], [265, 265, "Chemical"], [85, 85, "Chemical"], [87, 87, "Chemical"]]], "relations": [[[237, 237, 15, 15, "CID"], [237, 237, 227, 227, "CID"], [237, 237, 240, 240, "CID"]]], "clusters": [], "translated": "在缺乏<5>钠</5>通道β2亚基的小鼠中，<4>钠</4>通道密度降低，失活的电压依赖性改变，并且对<1>癫痫发作</1>的易感性增加。 <6>钠</6>通道β-亚基调节通道门控、组装和细胞表面表达。我们培育出beta2 (-/-)小鼠来研究beta2在控制体内神经元的<7>钠</7>通道密度、定位和功能方面的作用。[(3)H]<13>石房蛤毒素</13> (<14>STX</14>)结合测量表明，在beta2(-/-)神经元中，质膜<8>钠</8>通道水平显著降低。Beta2的丧失导致失活的电压依赖性向负方向移动，以及在分离的海马神经元中<9>钠</9>电流密度显着降低。视神经复合动作电位积分显著降低，并且产生动作电位的阈值升高，表明功能性质膜<10>钠</10>通道水平降低。相反，传导速度，视神经中轴突的数量和大小，以及<11>Na</11>(v)1.6通道在Ranvier结点的特异定位没有变化。Beta2 (-/-)小鼠表现出对<2>癫痫发作</2>的易感性增加，如<0>毛果芸香碱</0>诱导的<3>癫痫发作</3>潜伏期和阈值降低所示，但在其他神经学测试中似乎正常。我们的观察表明，beta2-亚基在调节体内神经元<12>钠</12>通道密度和功能方面发挥着重要作用，并且是正常动作电位产生和兴奋性控制所必需的。", "revised": true}
{"doc_key": "11027904", "sentences": [["Pain", "responses", "in", "methadone", "-", "maintained", "opioid", "abusers", ".", "Providing", "pain", "management", "for", "known", "opioid", "abusers", "is", "a", "challenging", "clinical", "task", ",", "in", "part", "because", "little", "is", "known", "about", "their", "pain", "experience", "and", "analgesic", "requirements", ".", "This", "study", "was", "designed", "to", "describe", "pain", "tolerance", "and", "analgesic", "response", "in", "a", "sample", "of", "opioid", "addicts", "stabilized", "in", "methadone", "-", "maintenance", "(", "MM", ")", "treatment", "(", "n", "=", "60", ")", "in", "comparison", "to", "matched", "nondependent", "control", "subjects", "(", "n", "=", "60", ")", ".", "By", "using", "a", "placebo", "-", "controlled", ",", "two", "-", "way", "factorial", "design", ",", "tolerance", "to", "cold", "-", "pressor", "(", "CP", ")", "pain", "was", "examined", ",", "both", "before", "and", "after", "oral", "administration", "of", "therapeutic", "doses", "of", "common", "opioid", "(", "hydromorphone", "2", "mg", ")", "and", "nonsteroidal", "anti", "-", "inflammatory", "(", "ketorolac", "10", "mg", ")", "analgesic", "agents", ".", "Results", "showed", "that", "MM", "individuals", "were", "significantly", "less", "tolerant", "of", "CP", "pain", "than", "control", "subjects", ",", "replicating", "previous", "work", ".", "Analgesic", "effects", "were", "significant", "neither", "for", "medication", "nor", "group", ".", "These", "data", "indicate", "that", "MM", "opioid", "abusers", "represent", "a", "pain", "-", "intolerant", "subset", "of", "clinical", "patients", ".", "Their", "complaints", "of", "pain", "should", "be", "evaluated", "seriously", "and", "managed", "aggressively", "."]], "ner": [[[3, 3, "Chemical"], [55, 55, "Chemical"], [174, 176, "Disease"], [0, 0, "Disease"], [10, 10, "Disease"], [30, 30, "Disease"], [42, 42, "Disease"], [101, 101, "Disease"], [146, 146, "Disease"], [185, 185, "Disease"], [118, 118, "Chemical"], [128, 128, "Chemical"], [51, 52, "Disease"]]], "relations": [[[3, 3, 174, 176, "CID"], [55, 55, 174, 176, "CID"]]], "clusters": [], "translated": "<3>疼痛</3> 对<0>美沙酮</0>的反应 - 维持阿片类药物滥用者。为已知的阿片类药物滥用者提供<4>疼痛</4>管理是一项具有挑战性的临床任务，部分原因是人们对他们的<5>疼痛</5>经历和镇痛需求知之甚少。本研究旨在描述在<1>美沙酮</1>-维持（MM）治疗中稳定的<12>阿片类药物成瘾者</12>样本的<6>疼痛</6>耐受性和镇痛反应（n=60），与匹配的非依赖性控制对象（n=60）进行比较。通过使用安慰剂对照的双向析因设计，对冷压痛（CP）<7>疼痛</7>的耐受性进行了检查，口服治疗剂量的普通阿片类药物（<10>氢吗啡酮</10> 2 mg）和非甾体类抗炎药（<11>酮咯酸</11> 10 mg）用于镇痛分析。结果表明，与对照组相比，MM个体对CP<8>疼痛</8>的耐受性显着降低，重复了以前的工作。药物和组别镇痛效应均无显着性。这些数据表明MM阿片类药物滥用者代表的是<2>疼痛不耐受</2>的临床子集。应认真评估和积极处理他们的<9>疼痛</9>抱怨。", "revised": true}
{"doc_key": "11099450", "sentences": [["Evidence", "of", "functional", "somatotopy", "in", "GPi", "from", "results", "of", "pallidotomy", ".", "The", "objective", "of", "this", "study", "was", "to", "explore", "the", "functional", "anatomy", "of", "the", "globus", "pallidus", "internus", "(", "GPi", ")", "by", "studying", "the", "effects", "of", "unilateral", "pallidotomy", "on", "parkinsonian", "'", "off", "'", "signs", "and", "levodopa", "-", "induced", "dyskinesias", "(", "LID", ")", ".", "We", "found", "significant", "positive", "correlations", "between", "the", "preoperative", "levodopa", "responsiveness", "of", "motor", "signs", "and", "the", "levodopa", "responsiveness", "of", "scores", "in", "timed", "tests", "(", "Core", "Assessment", "Program", "for", "Intracerebral", "Transplantations", ")", "in", "the", "contralateral", "limbs", "and", "the", "improvement", "in", "these", "scores", "after", "surgery", ",", "whereas", "there", "was", "no", "correlation", "with", "the", "improvement", "in", "LID", ".", "We", "also", "found", "a", "highly", "significant", "correlation", "(", "P", ":", "<", "0", ".", "0001", ",", "r", "=", "0", ".", "8", ")", "between", "the", "volume", "of", "the", "ventral", "lesion", "in", "the", "GPi", "and", "the", "improvement", "in", "LID", "in", "the", "contralateral", "limbs", ",", "whereas", "there", "was", "no", "correlation", "between", "the", "ventral", "volume", "and", "the", "improvement", "in", "parkinsonian", "'", "off", "'", "signs", ".", "The", "volumes", "of", "the", "total", "lesion", "cylinder", "and", "the", "dorsal", "lesion", "did", "not", "correlate", "with", "the", "outcome", "of", "either", "dyskinesias", "or", "parkinsonian", "'", "off", "'", "signs", ".", "The", "differential", "predictive", "value", "of", "levodopa", "responsiveness", "for", "the", "outcome", "of", "parkinsonian", "'", "off", "'", "signs", "and", "LID", "and", "the", "different", "correlations", "of", "ventral", "lesion", "volume", "with", "dyskinesias", "and", "parkinsonian", "'", "off", "'", "signs", "indicate", "that", "different", "anatomical", "or", "pathophysiological", "substrates", "may", "be", "responsible", "for", "the", "generation", "of", "parkinsonian", "'", "off", "'", "signs", "and", "dyskinesias", ".", "Whereas", "cells", "in", "a", "wider", "area", "of", "the", "GPi", "may", "be", "implicated", "in", "parkinsonism", ",", "the", "ventral", "GPi", "seems", "to", "be", "crucial", "for", "the", "manifestation", "of", "LID", ".", "We", "suggest", "that", "our", "observations", "are", "additional", "proof", "of", "the", "functional", "somatotopy", "of", "the", "systems", "within", "the", "GPi", "that", "mediate", "parkinsonism", "and", "dyskinesias", ",", "especially", "along", "the", "dorsoventral", "trajectory", "used", "in", "pallidotomy", ".", "The", "outcome", "of", "pallidotomy", "in", "which", "the", "lesion", "involves", "the", "ventral", "and", "dorsal", "GPi", "could", "be", "the", "net", "effect", "of", "alteration", "in", "the", "activity", "of", "pathways", "which", "mediate", "different", "symptoms", ",", "and", "hence", "could", "be", "variable", "."]], "ner": [[[44, 44, "Chemical"], [60, 60, "Chemical"], [67, 67, "Chemical"], [198, 198, "Chemical"], [47, 47, "Disease"], [49, 49, "Disease"], [104, 104, "Disease"], [141, 141, "Disease"], [185, 185, "Disease"], [210, 210, "Disease"], [220, 220, "Disease"], [247, 247, "Disease"], [275, 275, "Disease"], [299, 299, "Disease"], [38, 38, "Disease"], [160, 160, "Disease"], [187, 187, "Disease"], [204, 204, "Disease"], [222, 222, "Disease"], [241, 241, "Disease"], [262, 262, "Disease"], [297, 297, "Disease"]]], "relations": [[[44, 44, 47, 47, "CID"], [44, 44, 49, 49, "CID"], [44, 44, 104, 104, "CID"], [44, 44, 141, 141, "CID"], [44, 44, 185, 185, "CID"], [44, 44, 210, 210, "CID"], [44, 44, 220, 220, "CID"], [44, 44, 247, 247, "CID"], [44, 44, 275, 275, "CID"], [44, 44, 299, 299, "CID"], [60, 60, 47, 47, "CID"], [60, 60, 49, 49, "CID"], [60, 60, 104, 104, "CID"], [60, 60, 141, 141, "CID"], [60, 60, 185, 185, "CID"], [60, 60, 210, 210, "CID"], [60, 60, 220, 220, "CID"], [60, 60, 247, 247, "CID"], [60, 60, 275, 275, "CID"], [60, 60, 299, 299, "CID"], [67, 67, 47, 47, "CID"], [67, 67, 49, 49, "CID"], [67, 67, 104, 104, "CID"], [67, 67, 141, 141, "CID"], [67, 67, 185, 185, "CID"], [67, 67, 210, 210, "CID"], [67, 67, 220, 220, "CID"], [67, 67, 247, 247, "CID"], [67, 67, 275, 275, "CID"], [67, 67, 299, 299, "CID"], [198, 198, 47, 47, "CID"], [198, 198, 49, 49, "CID"], [198, 198, 104, 104, "CID"], [198, 198, 141, 141, "CID"], [198, 198, 185, 185, "CID"], [198, 198, 210, 210, "CID"], [198, 198, 220, 220, "CID"], [198, 198, 247, 247, "CID"], [198, 198, 275, 275, "CID"], [198, 198, 299, 299, "CID"]]], "clusters": [], "translated": "来自苍白球切开术结果的 GPi 功能性躯体移植的证据。本研究的目的是通过研究单侧苍白球切开术对 <14>帕金森病</14> 'off' 体征和<0>左旋多巴</0>诱发的影响来探索苍白球内部 (GPi)的功能解剖学<4>运动障碍</4> (<5>LID</5>)。我们发现术前<1>左旋多巴</1>运动体征反应与<2>左旋多巴</2>对侧肢体和侧肢定时测试（脑内移植核心评估计划）评分的反应之间呈显着正相关，手术后这些评分有所改善，而与<6>LID</6>的改善无关。我们还发现GPi腹侧病变体积与对侧肢体<7>LID</7>改善之间存在高度显着相关性 (P：<0.0001，r=0.8)，而腹侧体积与<15>帕金森氏症</15>'关闭'体征的改善之间没有相关性。总病变圆柱体和背侧病变的体积与<8>运动障碍</8>或<16>帕金森氏症</16>'关闭'体征的结果无关。<3>左旋多巴</3>反应性对<17>帕金森氏症</17>'off'体征和<9>LID</9>预后的差异预测价值以及腹侧病变体积与<10>运动障碍</10>和<18>帕金森氏症</18>'off'标志表明不同的解剖学或病理生理学底物可能导致<19>帕金森氏症</19>'off'标志和<11>运动障碍的产生</11>。虽然GPi更广泛区域的细胞可能与<20>帕金森病</20>有关，但腹侧GPi似乎对<12>LID</12>的表现至关重要。我们建议我们的观察结果是GPi内系统功能性躯体的额外证据，这些系统介导<21>帕金森症</21>和<13>运动障碍</13>，特别是沿着苍白球切开术中使用的背腹侧轨迹。病变涉及腹侧和背侧GPi的苍白球切开术的结果可能是介导不同症状的通路活动改变的净效应，因此可能是可变的。", "revised": true}
{"doc_key": "7604176", "sentences": [["Pravastatin", "-", "associated", "myopathy", ".", "Report", "of", "a", "case", ".", "A", "case", "of", "acute", "inflammatory", "myopathy", "associated", "with", "the", "use", "of", "pravastatin", ",", "a", "new", "hydrophilic", "3", "-", "hydroxy", "-", "3", "methylglutaril", "coenzyme", "A", "reductase", "inhibitor", ",", "is", "reported", ".", "The", "patient", ",", "a", "69", "-", "year", "-", "old", "man", "was", "affected", "by", "non", "-", "insulin", "-", "dependent", "diabetes", "mellitus", "and", "hypertension", ".", "He", "assumed", "pravastatin", "(", "20", "mg", "/", "day", ")", "because", "of", "hypercholesterolemia", ".", "He", "was", "admitted", "with", "acute", "myopathy", "of", "the", "lower", "limbs", "which", "resolved", "in", "a", "few", "days", "after", "pravastatin", "discontinuation", ".", "A", "previously", "unknown", "hypothyroidism", ",", "probably", "due", "to", "chronic", "autoimmune", "thyroiditis", ",", "was", "evidenced", ".", "Muscle", "biopsy", "(", "left", "gastrocnemius", ")", "revealed", "a", "perimysial", "and", "endomysial", "inflammatory", "infiltrate", "with", "a", "prevalence", "of", "CD4", "+", "lymphocytes", ".", "While", "lovastatin", "and", "simvastatin", "have", "been", "associated", "with", "toxic", "myopathy", ",", "pravastatin", "-", "associated", "myopathy", "could", "represent", "a", "distinct", ",", "inflammatory", "entity", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [65, 65, "Chemical"], [93, 93, "Chemical"], [143, 143, "Chemical"], [14, 15, "Disease"], [3, 3, "Disease"], [81, 81, "Disease"], [141, 141, "Disease"], [146, 146, "Disease"], [53, 59, "Disease"], [61, 61, "Disease"], [74, 74, "Disease"], [99, 99, "Disease"], [105, 106, "Disease"], [133, 133, "Chemical"], [135, 135, "Chemical"]]], "relations": [[[0, 0, 14, 15, "CID"], [21, 21, 14, 15, "CID"], [65, 65, 14, 15, "CID"], [93, 93, 14, 15, "CID"], [143, 143, 14, 15, "CID"]]], "clusters": [], "translated": "<0>普伐他汀</0> - 相关<6>肌病</6>。一个案例的报告。报道了一例与使用<1>普伐他汀</1>有关的急性<5>炎性肌病</5>，普伐他汀是一种新型亲水性 3-羟基-3 甲基戊二酰辅酶 A 还原酶抑制剂。患者是一名 69 岁的男性，患有<10>非胰岛素依赖型糖尿病</10>和<11>高血压</11>。由于<12>高胆固醇血症</12>，他假设<2>普伐他汀</2>（20 毫克/天）。他因下肢急性<7>肌病</7>入院，在停用<3>普伐他汀</3>后数日内消退。先前未知的<13>甲状腺功能减退症</13>，可能是由于慢性<14>自身免疫性甲状腺炎</14>引起的。肌肉活检（左腓肠肌）显示肌周和肌内膜炎性浸润，CD4+ 淋巴细胞普遍存在。<15>洛伐他汀</15>和<16>辛伐他汀</16>与中毒性<8>肌病</8>相关，<4>普伐他汀</4> - 相关<9>肌病</9>可能代表一个独特的、煽动性的实体。", "revised": true}
{"doc_key": "19234905", "sentences": [["Comparison", "of", "unilateral", "pallidotomy", "and", "subthalamotomy", "findings", "in", "advanced", "idiopathic", "Parkinson", "'s", "disease", ".", "A", "prospective", ",", "randomized", ",", "double", "-", "blind", "pilot", "study", "to", "compare", "the", "results", "of", "stereotactic", "unilateral", "pallidotomy", "and", "subthalamotomy", "in", "advanced", "idiopathic", "Parkinson", "'s", "disease", "(", "PD", ")", "refractory", "to", "medical", "treatment", "was", "designed", ".", "Ten", "consecutive", "patients", "(", "mean", "age", ",", "58", ".", "4", "+", "/", "-", "6", ".", "8", "years", ";", "7", "men", ",", "3", "women", ")", "with", "similar", "characteristics", "at", "the", "duration", "of", "disease", "(", "mean", "disease", "time", ",", "8", ".", "4", "+", "/", "-", "3", ".", "5", "years", ")", ",", "disabling", "motor", "fluctuations", "(", "Hoehn", "_", "Yahr", "stage", "3", "-", "5", "in", "off", "-", "drug", "phases", ")", "and", "levodopa", "-", "induced", "dyskinesias", "were", "selected", ".", "All", "patients", "had", "bilateral", "symptoms", "and", "their", "levodopa", "equivalent", "dosing", "were", "analysed", ".", "Six", "patients", "were", "operated", "on", "in", "the", "globus", "pallidus", "interna", "(", "GPi", ")", "and", "four", "in", "the", "subthalamic", "nucleus", "(", "STN", ")", ".", "Clinical", "evaluation", "included", "the", "use", "of", "the", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", "(", "UPDRS", ")", ",", "Hoehn_Yahr", "score", "and", "Schwab", "England", "activities", "of", "daily", "living", "(", "ADL", ")", "score", "in", "'", "on", "'", "-", "and", "'", "off", "'", "-", "drug", "conditions", "before", "surgery", "and", "6", "months", "after", "surgery", ".", "There", "was", "statistically", "significant", "improvement", "in", "all", "contralateral", "major", "parkinsonian", "motor", "signs", "in", "all", "patients", "followed", "for", "6", "months", ".", "Levodopa", "equivalent", "daily", "intake", "was", "significantly", "reduced", "in", "the", "STN", "group", ".", "Changes", "in", "UPDRS", ",", "Hoehn", "_", "Yahr", "and", "Schwab", "England", "ADL", "scores", "were", "similar", "in", "both", "groups", ".", "Cognitive", "functions", "were", "unchanged", "in", "both", "groups", ".", "Complications", "were", "observed", "in", "two", "patients", ":", "one", "had", "a", "left", "homonymous", "hemianopsia", "after", "pallidotomy", "and", "another", "one", "developed", "left", "hemiballistic", "movements", "3", "days", "after", "subthalamotomy", "which", "partly", "improved", "within", "1", "month", "with", "Valproate", "1000", "mg", "/", "day", ".", "The", "findings", "of", "this", "study", "suggest", "that", "lesions", "of", "the", "unilateral", "STN", "and", "GPi", "are", "equally", "effective", "treatment", "for", "patients", "with", "advanced", "PD", "refractory", "to", "medical", "treatment", "."]], "ner": [[[117, 117, "Chemical"], [131, 131, "Chemical"], [230, 230, "Chemical"], [120, 120, "Disease"], [9, 12, "Disease"], [36, 39, "Disease"], [41, 41, "Disease"], [168, 170, "Disease"], [219, 219, "Disease"], [329, 329, "Disease"], [301, 301, "Chemical"], [279, 280, "Disease"]]], "relations": [[[117, 117, 120, 120, "CID"], [131, 131, 120, 120, "CID"], [230, 230, 120, 120, "CID"]]], "clusters": [], "translated": "晚期<4>特发性帕金森病</4><0>左旋多巴</0>单侧苍白球切开术和丘脑下切开术结果的比较。设计了一项前瞻性、随机、双盲试验研究，以比较立体定向单侧苍白球切开术和丘脑下切开术在药物治疗难治的晚期<5>特发性帕金森病</5> (<6>PD</6>) 中的结果。连续十名患者（平均年龄，58.4 +/- 6.8 岁；7 名男性，3 名女性）在疾病持续期间（平均疾病时间，8.4 +/- 3.5 年）具有相似特征，致残选择运动波动（停药期Hoehn_Yahr 3-5期）和<3>左旋多巴</3>诱发的<5>运动障碍</5>。所有患者均有双侧症状，并分析了他们的<1>左旋多巴</1>当量剂量。6 名患者在苍白球内部(GPi)接受手术，4 名患者在底丘脑核(STN)接受手术。临床评估包括使用统一<7>帕金森病</7>评定量表(UPDRS)、Hoehn_Yahr评分和Schwab England日常生活活动(ADL)评分在“服药”和“不服药”药物条件下手术前和手术后6个月。在随访6个月的所有患者中，所有对侧主要<8>帕金森病</8>运动体征均有统计学意义的改善。<2>左旋多巴</2>当量日摄入量在STN组显着减少。 UPDRS、Hoehn_Yahr和Schwab England ADL分数的变化在两组中相似。两组的认知功能都没有变化。在两名患者中观察到并发症：一名患者在苍白球切开术后出现左侧<11>同向偏盲</11>，另一名患者在丘脑下切开术后3天出现左侧偏斜运动，服用<10>丙戊酸钠</10> 1000 mg后1个月内部分改善。本研究的结果表明，单侧STN和GPi的病变对于药物治疗无效的晚期<9>PD</9>患者同样有效。", "revised": true}
{"doc_key": "11185967", "sentences": [["Screening", "for", "stimulant", "use", "in", "adult", "emergency", "department", "seizure", "patients", ".", "OBJECTIVE", ":", "The", "objective", "of", "this", "study", "was", "to", "determine", "the", "prevalence", "of", "positive", "plasma", "drug", "screening", "for", "cocaine", "or", "amphetamine", "in", "adult", "emergency", "department", "seizure", "patients", ".", "METHODS", ":", "This", "prospective", "study", "evaluated", "consecutive", "eligible", "seizure", "patients", "who", "had", "a", "plasma", "sample", "collected", "as", "part", "of", "their", "clinical", "evaluation", ".", "Plasma", "was", "tested", "for", "amphetamine", "and", "the", "cocaine", "metabolite", "benzoylecgonine", "using", "enzyme", "-", "mediated", "immunoassay", "methodology", ".", "Plasma", "samples", "with", "benzoylecgonine", "greater", "than", "150", "ng", "/", "mL", "or", "an", "amphetamine", "greater", "than", "500", "ng", "/", "mL", "were", "defined", "as", "positive", ".", "Patient", "demographics", ",", "history", "of", "underlying", "drug", "or", "alcohol", "-", "related", "seizure", "disorder", ",", "estimated", "time", "from", "seizure", "to", "sample", "collection", ",", "history", "or", "suspicion", "of", "cocaine", "or", "amphetamine", "abuse", ",", "results", "of", "clinical", "urine", "testing", "for", "drugs", "of", "abuse", ",", "and", "assay", "results", "were", "recorded", "without", "patient", "identifiers", ".", "RESULTS", ":", "Fourteen", "of", "248", "(", "5", ".", "6", "%", ",", "95", "%", "CI", "2", ".", "7", "%", "-", "8", ".", "5", "%", ")", "plasma", "samples", "were", "positive", "by", "immunoassay", "testing", "for", "benzoylecgonine", "and", "no", "samples", "(", "0", "%", ",", "95", "%", "CI", "0", "-", "1", ".", "2", "%", ")", "were", "positive", "for", "amphetamine", ".", "Positive", "test", "results", "were", "more", "common", "in", "patient", "visits", "where", "there", "was", "a", "history", "or", "suspicion", "of", "cocaine", "or", "amphetamine", "abuse", "(", "p", "<", "0", ".", "0005", ")", ".", "CONCLUSIONS", ":", "During", "this", "study", "period", ",", "routine", "plasma", "screening", "for", "cocaine", "and", "amphetamines", "in", "adult", "seizure", "patients", "had", "a", "low", "yield", ".", "As", "a", "result", ",", "routine", "plasma", "screening", "would", "yield", "few", "cases", "of", "stimulant", "drug", "in", "which", "there", "was", "neither", "a", "history", "nor", "suspicion", "of", "drug", "abuse", "in", "this", "population", "."]], "ner": [[[71, 71, "Chemical"], [82, 82, "Chemical"], [185, 185, "Chemical"], [8, 8, "Disease"], [36, 36, "Disease"], [47, 47, "Disease"], [114, 114, "Disease"], [120, 120, "Disease"], [253, 253, "Disease"], [29, 29, "Chemical"], [69, 69, "Chemical"], [248, 248, "Chemical"], [31, 31, "Chemical"], [66, 66, "Chemical"], [91, 91, "Chemical"], [206, 206, "Chemical"], [111, 111, "Chemical"], [250, 250, "Chemical"], [129, 132, "Disease"], [225, 228, "Disease"], [284, 285, "Disease"]]], "relations": [[[71, 71, 8, 8, "CID"], [71, 71, 36, 36, "CID"], [71, 71, 47, 47, "CID"], [71, 71, 114, 114, "CID"], [71, 71, 120, 120, "CID"], [71, 71, 253, 253, "CID"], [82, 82, 8, 8, "CID"], [82, 82, 36, 36, "CID"], [82, 82, 47, 47, "CID"], [82, 82, 114, 114, "CID"], [82, 82, 120, 120, "CID"], [82, 82, 253, 253, "CID"], [185, 185, 8, 8, "CID"], [185, 185, 36, 36, "CID"], [185, 185, 47, 47, "CID"], [185, 185, 114, 114, "CID"], [185, 185, 120, 120, "CID"], [185, 185, 253, 253, "CID"]]], "clusters": [], "translated": "成人急诊科<3>癫痫发作</3>患者兴奋剂使用筛查。目的：本研究的目的是确定成人急诊科<4>癫痫发作</4>患者中<9>可卡因</9>或<12>苯丙胺</12>阳性血浆药物筛查的流行率。方法：这项前瞻性研究评估了连续符合条件的<5>癫痫发作</5>患者，这些患者收集了血浆样本作为其临床评估的一部分。使用酶介导的免疫测定方法对血浆中的<13>苯丙胺</13>和<10>可卡因</10>代谢物<0>苯甲酰爱康宁</0>进行了检测。血浆样品中<b><1>苯甲酰爱康宁</1></b>大于150 ng/mL或<b><14>苯丙胺</14></b>大于500 ng/mL的被定义为阳性。患者人口统计学、潜在药物史或<16>酒精</16>相关<6>癫痫发作</6>障碍、从<7>癫痫发作</7>到样本采集的估计时间、<18>可卡因或苯丙胺滥用疑虑</18>、滥用药物的临床尿液检测结果和化验结果均在没有患者身份的情况下记录。结果：248份血浆样本中有14份 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) 血浆样本的<b><2>苯甲酰爱康宁</2></b>呈阳性，没有样本 ( 0 % , 95 % CI 0 - 1 . 2 %) <b><15>苯丙胺</15></b>呈阳性。在有<b><19>可卡因或苯丙胺滥用史或疑似滥用</19></b>的患者就诊中，阳性检测结果更为常见 (p < 0. 0005)。结论：在本研究期间，成人<8>癫痫发作</8>患者的<b><11>可卡因</11></b>和<b><17>苯丙胺</17></b>常规血浆筛查产量较低。因此，常规血浆筛查会发现很少有兴奋剂药物病例，而这些人群既没有既往史也没有怀疑有<b><20>药物滥用</20></b>。", "revised": true}
{"doc_key": "3769769", "sentences": [["Bradycardia", "due", "to", "trihexyphenidyl", "hydrochloride", ".", "A", "chronic", "schizophrenic", "patient", "was", "treated", "with", "an", "anticholinergic", "drug", ",", "trihexyphenidyl", "hydrochloride", ".", "The", "patient", "developed", ",", "paradoxically", ",", "sinus", "bradycardia", ".", "The", "reaction", "was", "specific", "to", "trihexyphenidyl", "and", "not", "to", "other", "anticholinergic", "drugs", ".", "This", "antidyskinetic", "drug", "is", "widely", "used", "in", "clinical", "psychiatric", "practice", "and", "physicians", "should", "be", "aware", "of", "this", "side", "effect", "."]], "ner": [[[3, 4, "Chemical"], [17, 18, "Chemical"], [34, 34, "Chemical"], [0, 0, "Disease"], [27, 27, "Disease"], [8, 8, "Disease"], [50, 50, "Disease"]]], "relations": [[[3, 4, 0, 0, "CID"], [3, 4, 27, 27, "CID"], [17, 18, 0, 0, "CID"], [17, 18, 27, 27, "CID"], [34, 34, 0, 0, "CID"], [34, 34, 27, 27, "CID"]]], "clusters": [], "translated": "<3>心动过缓</3>由于<0>三环苯海索盐酸盐</0>。一名慢性<5>精神分裂症</5>患者接受了抗胆碱能药物<1>三环苯海索盐酸盐</1>的治疗。矛盾的是，患者出现了窦性<4>心动过缓</4>。该反应特异于<2>三环苯海索</2>，而非其他抗胆碱能药物。这种抗运动障碍药物广泛用于临床<6>精神医学</6>实践中，医生应该意识到这种副作用。", "revised": true}
{"doc_key": "7072798", "sentences": [["Fatal", "aplastic", "anemia", "following", "topical", "administration", "of", "ophthalmic", "chloramphenicol", ".", "A", "73", "-", "year", "-", "old", "woman", "died", "of", "aplastic", "anemia", "less", "than", "two", "months", "after", "undergoing", "cataract", "extraction", "and", "beginning", "topical", "therapy", "with", "chloramphenicol", ".", "The", "first", "signs", "of", "pancytopenia", "began", "within", "one", "month", "of", "the", "surgery", ".", "The", "pattern", "of", "the", "aplastic", "anemia", "was", "associated", "with", "an", "idiosyncratic", "response", "to", "chloramphenicol", ".", "This", "was", "the", "second", "report", "of", "fatal", "aplastic", "anemia", "after", "topical", "treatment", "with", "chloramphenicol", "for", "ocular", "conditions", ",", "although", "two", "cases", "of", "reversible", "bone", "marrow", "hypoplasia", "have", "also", "been", "reported", ".", "Any", "other", "suspected", "cases", "of", "ocular", "toxicity", "associated", "with", "topically", "applied", "chloramphenicol", "should", "be", "reported", "to", "the", "National", "Registry", "of", "Drug", "-", "Induced", "Ocular", "Side", "Effects", ",", "Oregon", "Health", "Sciences", "University", ",", "Portland", ",", "OR", "97201", "."]], "ner": [[[8, 8, "Chemical"], [34, 34, "Chemical"], [62, 62, "Chemical"], [77, 77, "Chemical"], [106, 106, "Chemical"], [1, 2, "Disease"], [19, 20, "Disease"], [53, 54, "Disease"], [71, 72, "Disease"], [27, 27, "Disease"], [40, 40, "Disease"], [87, 89, "Disease"], [100, 101, "Disease"]]], "relations": [[[8, 8, 1, 2, "CID"], [8, 8, 19, 20, "CID"], [8, 8, 53, 54, "CID"], [8, 8, 71, 72, "CID"], [34, 34, 1, 2, "CID"], [34, 34, 19, 20, "CID"], [34, 34, 53, 54, "CID"], [34, 34, 71, 72, "CID"], [62, 62, 1, 2, "CID"], [62, 62, 19, 20, "CID"], [62, 62, 53, 54, "CID"], [62, 62, 71, 72, "CID"], [77, 77, 1, 2, "CID"], [77, 77, 19, 20, "CID"], [77, 77, 53, 54, "CID"], [77, 77, 71, 72, "CID"], [106, 106, 1, 2, "CID"], [106, 106, 19, 20, "CID"], [106, 106, 53, 54, "CID"], [106, 106, 71, 72, "CID"]]], "clusters": [], "translated": "局部施用眼科<0>氯霉素</0>后发生致命性<5>再生障碍性贫血</5>。一名73岁的妇女在接受<9>白内障</9>摘除手术并开始使用<1>氯霉素</1>进行局部治疗后不到两个月就死于<6>再生障碍性贫血</6>。<10>全血细胞减少症</10>的最初迹象在手术后一个月内开始出现。<7>再生障碍性贫血</7>的模式与对<2>氯霉素</2>的异质反应有关。这是用<3>氯霉素</3>局部治疗眼部疾病后发生致命性<8>再生障碍性贫血</8>的第二份报告，尽管也有两例可逆性<11>骨髓发育不全</11>报道。任何其他与局部应用<4>氯霉素</4>相关的<12>眼毒性</12>疑似病例应报告给国家药物引起的眼部副作用登记处，俄勒冈健康科学大学，波特兰，俄勒冈州97201。", "revised": true}
{"doc_key": "7282516", "sentences": [["Dose", "-", "effect", "and", "structure", "-", "function", "relationships", "in", "doxorubicin", "cardiomyopathy", ".", "The", "cardiomyopathy", "(", "CM", ")", "produced", "by", "the", "anticancer", "drug", "doxorubicin", "(", "DXR", ")", "(", "Adriamycin", ")", "provides", "a", "unique", "opportunity", "to", "analyze", "dose", "-", "effect", "and", "structure", "-", "function", "relationships", "during", "development", "of", "myocardial", "disease", ".", "We", "measured", "the", "degree", "of", "morphologic", "damage", "by", "ultrastructural", "examination", "of", "endomyocardial", "biopsy", "and", "the", "degree", "of", "performance", "abnormally", "by", "right", "heart", "catheterization", "in", "patients", "receiving", "DXR", ".", "Morphologic", "damage", "was", "variable", "but", "was", "proportional", "to", "the", "total", "cumulative", "DXR", "dose", "between", "100", "and", "600", "mg", "/", "m2", ".", "Performance", "abnormalities", "correlated", "weakly", "with", "dose", ",", "exhibited", "a", "curvilinear", "relationship", ",", "and", "had", "a", "\"", "threshold", "\"", "for", "expression", ".", "Catheterization", "abnormalities", "correlated", "well", "with", "morphologic", "damage", "(", "r", "=", "0", ".", "57", "to", "0", ".", "78", ")", "in", "a", "subgroup", "of", "patients", "in", "whom", "exercise", "hemodynamics", "were", "measured", ",", "and", "this", "relationship", "also", "exhibited", "a", "curvilinear", ",", "threshold", "configuration", ".", "In", "DXR", "-", "CM", "myocardial", "damage", "is", "proportional", "to", "the", "degree", "of", "cytotoxic", "insult", "(", "DXR", "dose", ")", "while", "myocardial", "function", "is", "preserved", "until", "a", "critical", "dose", "or", "degree", "of", "damage", "is", "reached", ",", "after", "which", "myocardial", "performance", "deteriorates", "rapidly", "."]], "ner": [[[9, 9, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [27, 27, "Chemical"], [75, 75, "Chemical"], [88, 88, "Chemical"], [161, 161, "Chemical"], [175, 175, "Chemical"], [10, 10, "Disease"], [13, 13, "Disease"], [15, 15, "Disease"], [46, 47, "Disease"], [163, 163, "Disease"], [164, 165, "Disease"]]], "relations": [[[9, 9, 10, 10, "CID"], [9, 9, 13, 13, "CID"], [9, 9, 15, 15, "CID"], [9, 9, 46, 47, "CID"], [9, 9, 163, 163, "CID"], [9, 9, 164, 165, "CID"], [22, 22, 10, 10, "CID"], [22, 22, 13, 13, "CID"], [22, 22, 15, 15, "CID"], [22, 22, 46, 47, "CID"], [22, 22, 163, 163, "CID"], [22, 22, 164, 165, "CID"], [24, 24, 10, 10, "CID"], [24, 24, 13, 13, "CID"], [24, 24, 15, 15, "CID"], [24, 24, 46, 47, "CID"], [24, 24, 163, 163, "CID"], [24, 24, 164, 165, "CID"], [27, 27, 10, 10, "CID"], [27, 27, 13, 13, "CID"], [27, 27, 15, 15, "CID"], [27, 27, 46, 47, "CID"], [27, 27, 163, 163, "CID"], [27, 27, 164, 165, "CID"], [75, 75, 10, 10, "CID"], [75, 75, 13, 13, "CID"], [75, 75, 15, 15, "CID"], [75, 75, 46, 47, "CID"], [75, 75, 163, 163, "CID"], [75, 75, 164, 165, "CID"], [88, 88, 10, 10, "CID"], [88, 88, 13, 13, "CID"], [88, 88, 15, 15, "CID"], [88, 88, 46, 47, "CID"], [88, 88, 163, 163, "CID"], [88, 88, 164, 165, "CID"], [161, 161, 10, 10, "CID"], [161, 161, 13, 13, "CID"], [161, 161, 15, 15, "CID"], [161, 161, 46, 47, "CID"], [161, 161, 163, 163, "CID"], [161, 161, 164, 165, "CID"], [175, 175, 10, 10, "CID"], [175, 175, 13, 13, "CID"], [175, 175, 15, 15, "CID"], [175, 175, 46, 47, "CID"], [175, 175, 163, 163, "CID"], [175, 175, 164, 165, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0> <8>心肌病</8>的剂量-效应和结构-功能关系。 <9>心肌病</9> (<10>CM</10>) 由抗癌药<1>多柔比星</1> (<2>DXR</2>) (<3>阿霉素</3>)提供了一个独特的机会来分析剂量-效应和结构-功能关系在发生<11>心肌疾病</11>的过程中。我们通过超微结构检查心内膜活检测量形态学损伤的程度，以及通过右心导管插管在接受<4>DXR</4>的患者中测量异常表现的程度。形态损伤的程度是不同的，但是在100至600mg/m2之间的总累积<5>DXR</5>剂量成比例。性能异常与剂量有较弱的相关性，表现为曲线关系，并且存在“阈值”的表达。在进行运动血流动力学测量的患者亚组中，导管异常与形态学损伤呈现弱相关性（r=0.57~0.78），并且这种关系也具有曲线和“阈值”的配置。在<6>DXR</6>-<12>CM</12>的发展中，<13>心肌损伤</13>与细胞毒性损伤程度（<7>DXR</7>剂量）成比例，而在达到临界值剂量或损伤程度之前，心肌功能是被保存的，此后心肌性能迅速恶化。", "revised": true}
{"doc_key": "3708922", "sentences": [["Experimental", "cyclosporine", "nephrotoxicity", ":", "risk", "of", "concomitant", "chemotherapy", ".", "The", "role", "of", "cyclosporine", "(", "CSA", ")", "alone", "or", "in", "combination", "with", "various", "chemotherapeutics", "in", "the", "development", "of", "renal", "toxicity", "was", "evaluated", "in", "rats", ".", "Administration", "of", "20", "mg", "/", "kg", "/", "day", "CSA", "for", "4", "weeks", "caused", "renal", "functional", "and", "structural", "changes", "similar", "to", "those", "reported", "in", "man", ".", "The", "combined", "administration", "of", "CSA", "and", "various", "chemotherapeutic", "drugs", "with", "a", "nephrotoxic", "potential", ",", "such", "as", "gentamicin", "(", "at", "therapeutic", "doses", ")", ",", "amphothericin", "B", "and", "ketoconazole", ",", "which", "are", "frequently", "used", "in", "immunosuppressed", "patients", ",", "did", "not", "aggravate", "the", "CSA", "induced", "toxicity", "in", "the", "rat", "model", ".", "Gentamicin", "at", "toxic", "doses", ",", "however", ",", "increased", "CSA", "nephrotoxicity", ".", "Thus", ",", "the", "nephrotoxicity", "induced", "by", "CSA", "has", "a", "different", "pathogenetic", "mechanism", "."]], "ner": [[[1, 1, "Chemical"], [12, 12, "Chemical"], [14, 14, "Chemical"], [42, 42, "Chemical"], [63, 63, "Chemical"], [99, 99, "Chemical"], [115, 115, "Chemical"], [124, 124, "Chemical"], [2, 2, "Disease"], [27, 28, "Disease"], [70, 70, "Disease"], [116, 116, "Disease"], [121, 121, "Disease"], [101, 101, "Disease"], [75, 75, "Chemical"], [107, 107, "Chemical"], [82, 83, "Chemical"], [85, 85, "Chemical"]]], "relations": [[[1, 1, 2, 2, "CID"], [1, 1, 27, 28, "CID"], [1, 1, 70, 70, "CID"], [1, 1, 116, 116, "CID"], [1, 1, 121, 121, "CID"], [12, 12, 2, 2, "CID"], [12, 12, 27, 28, "CID"], [12, 12, 70, 70, "CID"], [12, 12, 116, 116, "CID"], [12, 12, 121, 121, "CID"], [14, 14, 2, 2, "CID"], [14, 14, 27, 28, "CID"], [14, 14, 70, 70, "CID"], [14, 14, 116, 116, "CID"], [14, 14, 121, 121, "CID"], [42, 42, 2, 2, "CID"], [42, 42, 27, 28, "CID"], [42, 42, 70, 70, "CID"], [42, 42, 116, 116, "CID"], [42, 42, 121, 121, "CID"], [63, 63, 2, 2, "CID"], [63, 63, 27, 28, "CID"], [63, 63, 70, 70, "CID"], [63, 63, 116, 116, "CID"], [63, 63, 121, 121, "CID"], [99, 99, 2, 2, "CID"], [99, 99, 27, 28, "CID"], [99, 99, 70, 70, "CID"], [99, 99, 116, 116, "CID"], [99, 99, 121, 121, "CID"], [115, 115, 2, 2, "CID"], [115, 115, 27, 28, "CID"], [115, 115, 70, 70, "CID"], [115, 115, 116, 116, "CID"], [115, 115, 121, 121, "CID"], [124, 124, 2, 2, "CID"], [124, 124, 27, 28, "CID"], [124, 124, 70, 70, "CID"], [124, 124, 116, 116, "CID"], [124, 124, 121, 121, "CID"]]], "clusters": [], "translated": "实验<0>环孢菌素</0> <8>肾毒性</8>：伴随化疗的风险。在大鼠中评估了<1>环孢菌素</1> (<2>CSA</2>) 单独或与各种化疗药物联合使用在<9>肾毒性</9>发展中的作用。连续4周服用20 mg/kg/天<3>CSA</3>引起的肾功能和结构变化与人类报道的相似。<4>CSA</4>和各种具有<10>肾毒性</10>潜在化学治疗药物的联合给药，例如<14>庆大霉素</14>（治疗剂量），<16>两性霉素B</16>和<17>酮康唑</17>常用于免疫抑制患者，在大鼠模型中未加重<5>CSA</5>诱导的<13>毒性</13>。在中毒剂量下，<15>庆大霉素</15>增加了<6>CSA</6><11>肾毒性</11>。由此可见，<7>CSA</7>引起的<12>肾毒性</12>具有不同的发病机制。", "revised": true}
{"doc_key": "15565293", "sentences": [["Optical", "coherence", "tomography", "can", "measure", "axonal", "loss", "in", "patients", "with", "ethambutol", "-", "induced", "optic", "neuropathy", ".", "PURPOSE", ":", "To", "map", "and", "identify", "the", "pattern", ",", "in", "vivo", ",", "of", "axonal", "degeneration", "in", "ethambutol", "-", "induced", "optic", "neuropathy", "using", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "Ethambutol", "is", "an", "antimycobacterial", "agent", "often", "used", "to", "treat", "tuberculosis", ".", "A", "serious", "complication", "of", "ethambutol", "is", "an", "optic", "neuropathy", "that", "impairs", "visual", "acuity", ",", "contrast", "sensitivity", ",", "and", "color", "vision", ".", "However", ",", "early", "on", ",", "when", "the", "toxic", "optic", "neuropathy", "is", "mild", "and", "partly", "reversible", ",", "the", "funduscopic", "findings", "are", "often", "subtle", "and", "easy", "to", "miss", ".", "METHODS", ":", "Three", "subjects", "with", "a", "history", "of", "ethambutol", "(", "EMB", ")", "-", "induced", "optic", "neuropathy", "of", "short", "-", ",", "intermediate", "-", ",", "and", "long", "-", "term", "visual", "deficits", "were", "administered", "a", "full", "neuro", "-", "ophthalmologic", "examination", "including", "visual", "acuity", ",", "color", "vision", ",", "contrast", "sensitivity", ",", "and", "fundus", "examination", ".", "In", "addition", ",", "OCT", "(", "OCT", "3000", ",", "Humphrey", "-", "Zeiss", ",", "Dublin", ",", "CA", ")", "was", "performed", "on", "both", "eyes", "of", "each", "subject", "using", "the", "retinal", "nerve", "fiber", "layer", "(", "RNFL", ")", "analysis", "protocol", ".", "OCT", "interpolates", "data", "from", "100", "points", "around", "the", "optic", "nerve", "to", "effectively", "map", "out", "the", "RNFL", ".", "RESULTS", ":", "The", "results", "were", "compared", "to", "the", "calculated", "average", "RNFL", "of", "normal", "eyes", "accumulated", "from", "four", "prior", "studies", "using", "OCT", ",", "n", "=", "661", ".", "In", "all", "subjects", "with", "history", "of", "EMB", "-", "induced", "optic", "neuropathy", ",", "there", "was", "a", "mean", "loss", "of", "72", "%", "nerve", "fiber", "layer", "thickness", "in", "the", "temporal", "quadrant", "(", "patient", "A", ",", "with", "eventual", "recovery", "of", "visual", "acuity", "and", "fields", ",", "58", "%", "loss", ";", "patient", "B", ",", "with", "intermediate", "visual", "deficits", ",", "68", "%", "loss", ";", "patient", "C", ",", "with", "chronic", "visual", "deficits", ",", "90", "%", "loss", ")", ",", "with", "an", "average", "mean", "optic", "nerve", "thickness", "of", "26", "+", "/", "-", "16", "microm", ".", "There", "was", "a", "combined", "mean", "loss", "of", "46", "%", "of", "fibers", "from", "the", "superior", ",", "inferior", ",", "and", "nasal", "quadrants", "in", "the", "(", "six", ")", "eyes", "of", "all", "three", "subjects", "(", "mean", "average", "thickness", "of", "55", "+", "/", "-", "29", "microm", ")", ".", "In", "both", "sets", "(", "four", ")", "of", "eyes", "of", "the", "subjects", "with", "persistent", "visual", "deficits", "(", "patients", "B", "and", "C", ")", ",", "there", "was", "an", "average", "loss", "of", "79", "%", "of", "nerve", "fiber", "thickness", "in", "the", "temporal", "quadrant", ".", "CONCLUSIONS", ":", "The", "OCT", "results", "in", "these", "patients", "with", "EMB", "-", "induced", "optic", "neuropathy", "show", "considerable", "loss", "especially", "of", "the", "temporal", "fibers", ".", "This", "is", "consistent", "with", "prior", "histopathological", "studies", "that", "show", "predominant", "loss", "of", "parvo", "-", "cellular", "axons", "(", "or", "small", "-", "caliber", "axons", ")", "within", "the", "papillo", "-", "macular", "bundle", "in", "toxic", "or", "hereditary", "optic", "neuropathies", ".", "OCT", "can", "be", "a", "valuable", "tool", "in", "the", "quantitative", "analysis", "of", "optic", "neuropathies", ".", "Additionally", ",", "in", "terms", "of", "management", "of", "EMB", "-", "induced", "optic", "neuropathy", ",", "it", "is", "important", "to", "properly", "manage", "ethambutol", "dosing", "in", "patients", "with", "renal", "impairment", "and", "to", "achieve", "proper", "transition", "to", "a", "maintenance", "dose", "once", "an", "appropriate", "loading", "dose", "has", "been", "reached", "."]], "ner": [[[10, 10, "Chemical"], [32, 32, "Chemical"], [45, 45, "Chemical"], [60, 60, "Chemical"], [112, 112, "Chemical"], [114, 114, "Chemical"], [240, 240, "Chemical"], [410, 410, "Chemical"], [481, 481, "Chemical"], [493, 493, "Chemical"], [13, 14, "Disease"], [35, 36, "Disease"], [63, 64, "Disease"], [85, 86, "Disease"], [118, 119, "Disease"], [243, 244, "Disease"], [413, 414, "Disease"], [457, 458, "Disease"], [471, 472, "Disease"], [484, 485, "Disease"], [131, 132, "Disease"], [284, 285, "Disease"], [296, 297, "Disease"], [375, 376, "Disease"], [29, 30, "Disease"], [54, 54, "Disease"], [498, 499, "Disease"]]], "relations": [[[10, 10, 13, 14, "CID"], [10, 10, 35, 36, "CID"], [10, 10, 63, 64, "CID"], [10, 10, 85, 86, "CID"], [10, 10, 118, 119, "CID"], [10, 10, 243, 244, "CID"], [10, 10, 413, 414, "CID"], [10, 10, 457, 458, "CID"], [10, 10, 471, 472, "CID"], [10, 10, 484, 485, "CID"], [32, 32, 13, 14, "CID"], [32, 32, 35, 36, "CID"], [32, 32, 63, 64, "CID"], [32, 32, 85, 86, "CID"], [32, 32, 118, 119, "CID"], [32, 32, 243, 244, "CID"], [32, 32, 413, 414, "CID"], [32, 32, 457, 458, "CID"], [32, 32, 471, 472, "CID"], [32, 32, 484, 485, "CID"], [45, 45, 13, 14, "CID"], [45, 45, 35, 36, "CID"], [45, 45, 63, 64, "CID"], [45, 45, 85, 86, "CID"], [45, 45, 118, 119, "CID"], [45, 45, 243, 244, "CID"], [45, 45, 413, 414, "CID"], [45, 45, 457, 458, "CID"], [45, 45, 471, 472, "CID"], [45, 45, 484, 485, "CID"], [60, 60, 13, 14, "CID"], [60, 60, 35, 36, "CID"], [60, 60, 63, 64, "CID"], [60, 60, 85, 86, "CID"], [60, 60, 118, 119, "CID"], [60, 60, 243, 244, "CID"], [60, 60, 413, 414, "CID"], [60, 60, 457, 458, "CID"], [60, 60, 471, 472, "CID"], [60, 60, 484, 485, "CID"], [112, 112, 13, 14, "CID"], [112, 112, 35, 36, "CID"], [112, 112, 63, 64, "CID"], [112, 112, 85, 86, "CID"], [112, 112, 118, 119, "CID"], [112, 112, 243, 244, "CID"], [112, 112, 413, 414, "CID"], [112, 112, 457, 458, "CID"], [112, 112, 471, 472, "CID"], [112, 112, 484, 485, "CID"], [114, 114, 13, 14, "CID"], [114, 114, 35, 36, "CID"], [114, 114, 63, 64, "CID"], [114, 114, 85, 86, "CID"], [114, 114, 118, 119, "CID"], [114, 114, 243, 244, "CID"], [114, 114, 413, 414, "CID"], [114, 114, 457, 458, "CID"], [114, 114, 471, 472, "CID"], [114, 114, 484, 485, "CID"], [240, 240, 13, 14, "CID"], [240, 240, 35, 36, "CID"], [240, 240, 63, 64, "CID"], [240, 240, 85, 86, "CID"], [240, 240, 118, 119, "CID"], [240, 240, 243, 244, "CID"], [240, 240, 413, 414, "CID"], [240, 240, 457, 458, "CID"], [240, 240, 471, 472, "CID"], [240, 240, 484, 485, "CID"], [410, 410, 13, 14, "CID"], [410, 410, 35, 36, "CID"], [410, 410, 63, 64, "CID"], [410, 410, 85, 86, "CID"], [410, 410, 118, 119, "CID"], [410, 410, 243, 244, "CID"], [410, 410, 413, 414, "CID"], [410, 410, 457, 458, "CID"], [410, 410, 471, 472, "CID"], [410, 410, 484, 485, "CID"], [481, 481, 13, 14, "CID"], [481, 481, 35, 36, "CID"], [481, 481, 63, 64, "CID"], [481, 481, 85, 86, "CID"], [481, 481, 118, 119, "CID"], [481, 481, 243, 244, "CID"], [481, 481, 413, 414, "CID"], [481, 481, 457, 458, "CID"], [481, 481, 471, 472, "CID"], [481, 481, 484, 485, "CID"], [493, 493, 13, 14, "CID"], [493, 493, 35, 36, "CID"], [493, 493, 63, 64, "CID"], [493, 493, 85, 86, "CID"], [493, 493, 118, 119, "CID"], [493, 493, 243, 244, "CID"], [493, 493, 413, 414, "CID"], [493, 493, 457, 458, "CID"], [493, 493, 471, 472, "CID"], [493, 493, 484, 485, "CID"], [10, 10, 131, 132, "CID"], [10, 10, 284, 285, "CID"], [10, 10, 296, 297, "CID"], [10, 10, 375, 376, "CID"], [32, 32, 131, 132, "CID"], [32, 32, 284, 285, "CID"], [32, 32, 296, 297, "CID"], [32, 32, 375, 376, "CID"], [45, 45, 131, 132, "CID"], [45, 45, 284, 285, "CID"], [45, 45, 296, 297, "CID"], [45, 45, 375, 376, "CID"], [60, 60, 131, 132, "CID"], [60, 60, 284, 285, "CID"], [60, 60, 296, 297, "CID"], [60, 60, 375, 376, "CID"], [112, 112, 131, 132, "CID"], [112, 112, 284, 285, "CID"], [112, 112, 296, 297, "CID"], [112, 112, 375, 376, "CID"], [114, 114, 131, 132, "CID"], [114, 114, 284, 285, "CID"], [114, 114, 296, 297, "CID"], [114, 114, 375, 376, "CID"], [240, 240, 131, 132, "CID"], [240, 240, 284, 285, "CID"], [240, 240, 296, 297, "CID"], [240, 240, 375, 376, "CID"], [410, 410, 131, 132, "CID"], [410, 410, 284, 285, "CID"], [410, 410, 296, 297, "CID"], [410, 410, 375, 376, "CID"], [481, 481, 131, 132, "CID"], [481, 481, 284, 285, "CID"], [481, 481, 296, 297, "CID"], [481, 481, 375, 376, "CID"], [493, 493, 131, 132, "CID"], [493, 493, 284, 285, "CID"], [493, 493, 296, 297, "CID"], [493, 493, 375, 376, "CID"]]], "clusters": [], "translated": "光学相干断层扫描可以测量 <0>乙胺丁醇</0> 引起的 <10>视神经病变</10> 患者的轴突损失。目的：使用光学相干断层扫描 (OCT) 绘制和识别 <24>轴突变性</24> 在<1>乙胺丁醇</1>诱导的<11>视神经病变</11>中的体内模式。 <2>乙胺丁醇</2> 是一种抗分枝杆菌药物，常用于治疗<25>肺结核</25>。<3>乙胺丁醇</3> 的严重并发症是<12>视神经病变</12>，它会损害视力、对比敏感度和色觉。然而，在早期，当中毒性 <13>视神经病变</13>较轻且部分可逆时，眼底检查结果往往很细微且容易被遗漏。方法：三名受试者有<4>乙胺丁醇</4> (<5>EMB</5>) 诱发的<14>视神经病变</14>的短期、中期和长期<20>视力缺陷</20>进行了全面的神经眼科检查，包括视力、色觉、对比敏感度和眼底检查。此外，使用视网膜神经纤维层(RNFL)分析方案对每位受试者的双眼进行 OCT (OCT 3000，Humphrey-Zeiss，Dublin，CA)。 OCT 对来自视神经周围 100 个点的数据进行插值，以有效地绘制出 RNFL。结果：将结果与计算的正常眼睛的平均 RNFL 进行了比较，这些正常眼睛是使用 OCT 进行的四项先前研究中积累的，n = 661。在所有有<6> EMB </6>诱发的<15>视神经病变</15> 病史的受试者中，颞象限神经纤维层厚度平均损失72%（患者 A，最终恢复视力和视野，58%损失；患者 B，有中度<21>视力缺陷</21>，68%损失；患者 C，有慢性<22>视力缺陷</22>，90%损失），有平均平均视神经厚度为26+/-16微米。在所有三名受试者的（六只）眼睛中，上、下和鼻象限的纤维平均损失了46%（平均厚度为55+/-29 微米）。在具有持续性<23>视觉缺陷</23>（患者 B 和 C）的两组（四只）眼睛中，颞象限的神经纤维厚度平均损失了79%。结论：这些<7>EMB</7>诱发的<16>视神经病变</16>患者的 OCT 结果显示有相当大的损失，尤其是颞纤维。这与先前的组织病理学研究一致，这些研究表明在毒性或遗传性<17>视神经病变</17>中，乳头黄斑束内的细小细胞轴突（或小口径轴突）主要丢失。OCT 可以成为<18>视神经病变</18>定量分析的宝贵工具。此外，在<8> EMB </8>引起的<19>视神经病变</19>的管理方面，正确管理 <26>肾功能不全</26>患者的<9>乙胺丁醇</9>剂量非常重要， 并在达到适当的负荷剂量后实现向维持剂量的适当过渡。", "revised": true}
{"doc_key": "9270571", "sentences": [["Potential", "therapeutic", "use", "of", "the", "selective", "dopamine", "D1", "receptor", "agonist", ",", "A", "-", "86929", ":", "an", "acute", "study", "in", "parkinsonian", "levodopa", "-", "primed", "monkeys", ".", "The", "clinical", "utility", "of", "dopamine", "(", "DA", ")", "D1", "receptor", "agonists", "in", "the", "treatment", "of", "Parkinson", "'s", "disease", "(", "PD", ")", "is", "still", "unclear", ".", "The", "therapeutic", "use", "of", "selective", "DA", "D1", "receptor", "agonists", "such", "as", "SKF", "-", "82958", "(", "6", "-", "chloro", "-", "7", ",", "8", "-", "dihydroxy", "-", "3", "-", "allyl", "-", "1", "-", "phenyl", "-", "2", ",", "3", ",", "4", ",", "5", "-", "tetrahydro", "-", "1H", "-", "3", "-", "benzaze", "pine", "hydrobromide", ")", "and", "A", "-", "77636", "(", "[", "1R", ",", "3S", "]", "3", "-", "[", "1", "'", "-", "admantyl", "]", "-", "1", "-", "aminomethyl", "-", "3", ",", "4", "-", "dihydro", "-", "5", ",", "6", "-", "dihydroxy", "-", "1H", "-", "2", "-", "benzo", "pyran", "hydrochloride", ")", "seems", "limited", "because", "of", "their", "duration", "of", "action", ",", "which", "is", "too", "short", "for", "SKF", "-", "82958", "(", "<", "1", "hr", ")", "and", "too", "long", "for", "A", "-", "77636", "(", ">", "20", "hr", ",", "leading", "to", "behavioral", "tolerance", ")", ".", "We", "therefore", "conducted", "the", "present", "acute", "dose", "-", "response", "study", "in", "four", "1", "-", "methyl", "-", "4", "-", "phenyl", "-", "1", ",", "2", ",", "3", ",", "6", "-", "tetrahydropyridine", "(", "MPTP", ")", "-", "exposed", "cynomolgus", "monkeys", "primed", "to", "exhibit", "levodopa", "-", "induced", "dyskinesias", "to", "evaluate", "the", "locomotor", "and", "dyskinetic", "effects", "on", "challenge", "with", "four", "doses", "(", "from", "0", ".", "03", "to", "1", ".", "0", "mg", "/", "kg", ")", "of", "A", "-", "86929", "(", "[", "-", "]", "-", "[", "5aR", ",", "11bS", "]", "-", "4", ",", "5", ",", "5a", ",", "6", ",", "7", ",", "11b", "-", "hexahydro", "-", "2", "-", "propyl", "-", "3", "-", "thia", "-", "5", "-", "+", "+", "+", "azacyclopent", "-", "1", "-", "ena", "[", "c", "]", "phenathrene", "-", "9", "-", "10", "-", "diol", ")", ",", "a", "selective", "and", "full", "DA", "D1", "-", "like", "receptor", "agonist", "with", "an", "intermediate", "duration", "of", "action", ".", "Levodopa", "and", "the", "DA", "D2", "-", "like", "receptor", "agonist", ",", "LY", "-", "171555", "(", "[", "4aR", "-", "trans", "]", "-", "4", ",", "4a", ",", "5", ",", "6", ",", "7", ",", "8", ",", "8a", ",", "9", "-", "o", "-", "dihydro", "-", "5n", "-", "propyl", "-", "2H", "-", "pyrazo", "lo", "-", "3", "-", "4", "-", "quinoline", "hydrochloride", ")", "were", "also", "used", "for", "comparison", ".", "Acute", "administration", "of", "A", "-", "86929", "was", "as", "efficacious", "in", "alleviating", "MPTP", "-", "induced", "parkinsonism", "as", "levodopa", "and", "LY", "-", "171555", ",", "but", "was", "less", "likely", "to", "reproduce", "the", "levodopa", "-", "induced", "dyskinesias", "in", "these", "animals", "than", "with", "either", "LY", "-", "171555", "or", "subsequent", "challenge", "of", "levodopa", ".", "Selective", "stimulation", "of", "the", "DA", "D1", "receptor", "may", "provide", "better", "integration", "of", "neural", "inputs", "transmitted", "to", "the", "internal", "segment", "of", "the", "globus", "pallidus", "(", "referred", "to", "as", "the", "basal", "ganglia", "output", ")", "compared", "with", "levodopa", "and", "selective", "DA", "D2", "receptor", "agonist", ".", "Potent", "DA", "D1", "receptor", "agents", "with", "an", "intermediate", "duration", "of", "efficacy", "such", "as", "A", "-", "86929", "(", "approximately", "4", "hr", "at", "higher", "doses", "tested", ")", "are", "potential", "therapeutic", "tools", "in", "PD", "and", "merit", "further", "attention", "."]], "ner": [[[196, 212, "Chemical"], [214, 214, "Chemical"], [401, 401, "Chemical"], [19, 19, "Disease"], [404, 404, "Disease"], [20, 20, "Chemical"], [223, 223, "Chemical"], [328, 328, "Chemical"], [406, 406, "Chemical"], [419, 419, "Chemical"], [436, 436, "Chemical"], [472, 472, "Chemical"], [226, 226, "Disease"], [232, 232, "Disease"], [422, 422, "Disease"], [6, 6, "Chemical"], [29, 29, "Chemical"], [31, 31, "Chemical"], [55, 55, "Chemical"], [315, 315, "Chemical"], [331, 331, "Chemical"], [442, 442, "Chemical"], [475, 475, "Chemical"], [481, 481, "Chemical"], [40, 42, "Disease"], [44, 44, "Disease"], [510, 510, "Disease"], [11, 13, "Chemical"], [253, 255, "Chemical"], [257, 308, "Chemical"], [393, 395, "Chemical"], [493, 495, "Chemical"], [61, 63, "Chemical"], [65, 99, "Chemical"], [158, 160, "Chemical"], [102, 104, "Chemical"], [106, 142, "Chemical"], [170, 172, "Chemical"], [338, 340, "Chemical"], [342, 382, "Chemical"], [408, 410, "Chemical"], [429, 431, "Chemical"]]], "relations": [[[196, 212, 19, 19, "CID"], [196, 212, 404, 404, "CID"], [214, 214, 19, 19, "CID"], [214, 214, 404, 404, "CID"], [401, 401, 19, 19, "CID"], [401, 401, 404, 404, "CID"], [20, 20, 226, 226, "CID"], [20, 20, 232, 232, "CID"], [20, 20, 422, 422, "CID"], [223, 223, 226, 226, "CID"], [223, 223, 232, 232, "CID"], [223, 223, 422, 422, "CID"], [328, 328, 226, 226, "CID"], [328, 328, 232, 232, "CID"], [328, 328, 422, 422, "CID"], [406, 406, 226, 226, "CID"], [406, 406, 232, 232, "CID"], [406, 406, 422, 422, "CID"], [419, 419, 226, 226, "CID"], [419, 419, 232, 232, "CID"], [419, 419, 422, 422, "CID"], [436, 436, 226, 226, "CID"], [436, 436, 232, 232, "CID"], [436, 436, 422, 422, "CID"], [472, 472, 226, 226, "CID"], [472, 472, 232, 232, "CID"], [472, 472, 422, 422, "CID"]]], "clusters": [], "translated": "选择性<15>多巴胺</15>D1受体激动剂<27> A-86929 </27>的潜在治疗用途： <3>帕金森病</3><5>左旋多巴</5>的急性研究 - 准备好的猴子。 <16>多巴胺</16>（<17>DA</17>）D1受体激动剂在<24>帕金森病</24>（<25>PD</25>）治疗中的临床应用目前还不清楚。选择性<18>DA</18>D1受体激动剂如<32>SKF-82958</32>（<33>6-氯-7，8-二羟基-3-烯丙基-1-苯基-2,3,4,5-四氢-1H-3-苯并松氢溴酸盐</33>）和<35>A-77636</35>（<36>[1R,3S]3-[1'-金刚烷基]-1-氨基甲基-3,4-二氢-5,6-二羟基-1H-2-苯并吡喃盐酸盐</36>）似乎是有限的，因为它们的作用持续时间对<34>SKF-82958</34>(<1小时)来说太短了，对<37>A-77636</37>(>20小时，导致行为耐受)来说则太长了。因此，我们在四只<0>1-甲基-4-苯基-1,2,3,6-四氢吡啶</0>(<1>MPTP</1>)-暴露的猴子中进行了本次急性剂量反应研究，它们已被注射<5>左旋多巴</5>，准备展示<6>左旋多巴</6>-诱导的<12>运动障碍</12>，以评估四个剂量(0.03至1.0毫克/千克) <28>A-86929</28>(<29>[-]-[5aR，11bS]-4,5,5a,6,7,11b-六氢-2-丙基-3-硫亚-5-+++azacyclpent-1-ena[c] phenathrene-9-10-diol</29>）对运动和<13>运动障碍</13>的影响。这是一种具有中等作用持续时间的选择性<19>DA</19> D1样受体激动剂。用于比较的有<7>左旋多巴</7>和<20>DA</20>D2样受体激动剂<38>LY-171555</38>（<39>[4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n- propyl-2H-pyrazo lo-3-4-quinoline hydrochloride</39>）。急性给药<30> A-86929 </30>在缓解<2>MPTP</2> - 诱导的<4>帕金森病</4>方面与<8>左旋多巴</8>和<40>LY-171555</40>一样有效，但与<41>LY-171555</41>或接下来的<10>左旋多巴</10>挑战相比，这些动物不太可能重现<9>左旋多巴</9>- 诱发的<14>运动障碍</14>。选择性<21>DA</21>D1受体的刺激可能提供更好的神经输入整合传递到球内段 ( 称为基底节的输出 ) 相对于<11>左旋多巴</11>和选择性<22>DA</22>D2受体激动剂。具有中等有效持续时间的强效<23>DA</23>D1受体药物，例如<31>A-86929</31> (在测试的较高剂量下大约4小时)是<26>PD</26>的潜在治疗工具，值得进一步关注。", "revised": true}
{"doc_key": "9672273", "sentences": [["Prevention", "of", "breast", "cancer", "with", "tamoxifen", ":", "preliminary", "findings", "from", "the", "Italian", "randomised", "trial", "among", "hysterectomised", "women", ".", "Italian", "Tamoxifen", "Prevention", "Study", ".", "BACKGROUND", ":", "Tamoxifen", "is", "a", "candidate", "chemopreventive", "agent", "in", "breast", "cancer", ",", "although", "the", "drug", "may", "be", "associated", "with", "the", "development", "of", "endometrial", "cancer", ".", "Therefore", "we", "did", "a", "trial", "in", "hysterectomised", "women", "of", "tamoxifen", "as", "a", "chemopreventive", ".", "METHODS", ":", "In", "October", ",", "1992", ",", "we", "started", "a", "double", "-", "blind", "placebo", "-", "controlled", ",", "randomised", "trial", "of", "tamoxifen", "in", "women", "(", "mainly", "in", "Italy", ")", "who", "did", "not", "have", "breast", "cancer", "and", "who", "had", "had", "a", "hysterectomy", ".", "Women", "were", "randomised", "to", "receive", "tamoxifen", "20", "mg", "per", "day", "or", "placebo", ",", "both", "orally", "for", "5", "years", ".", "The", "original", "plan", "was", "to", "follow", "the", "intervention", "phase", "by", "5", "years", "'", "follow", "-", "up", ".", "In", "June", ",", "1997", ",", "the", "trialists", "and", "the", "data", "-", "monitoring", "committee", "decided", "to", "end", "recruitment", "primarily", "because", "of", "the", "number", "of", "women", "dropping", "out", "of", "the", "study", ".", "Recruitment", "ended", "on", "July", "11", ",", "1997", ",", "and", "the", "study", "will", "continue", "as", "planned", ".", "The", "primary", "endpoints", "are", "the", "occurrence", "of", "and", "deaths", "from", "breast", "cancer", ".", "This", "preliminary", "interim", "analysis", "is", "based", "on", "intention", "-", "to", "-", "treat", ".", "FINDINGS", ":", "5408", "women", "were", "randomised", ";", "participating", "women", "have", "a", "median", "follow", "-", "up", "of", "46", "months", "for", "major", "endpoints", ".", "41", "cases", "of", "breast", "cancer", "occurred", "so", "far", ";", "there", "have", "been", "no", "deaths", "from", "breast", "cancer", ".", "There", "is", "no", "difference", "in", "breast", "-", "cancer", "frequency", "between", "the", "placebo", "(", "22", "cases", ")", "and", "tamoxifen", "(", "19", ")", "arms", ".", "There", "is", "a", "statistically", "significant", "reduction", "of", "breast", "cancer", "among", "women", "receiving", "tamoxifen", "who", "also", "used", "hormone", "-", "replacement", "therapy", "during", "the", "trial", ":", "among", "390", "women", "on", "such", "therapy", "and", "allocated", "to", "placebo", ",", "we", "found", "eight", "cases", "of", "breast", "cancer", "compared", "with", "one", "case", "among", "362", "women", "allocated", "to", "tamoxifen", ".", "Compared", "with", "the", "placebo", "group", ",", "there", "was", "a", "significantly", "increased", "risk", "of", "vascular", "events", "and", "hypertriglyceridaemia", "among", "women", "on", "tamoxifen", ".", "INTERPRETATION", ":", "Although", "this", "preliminary", "analysis", "has", "low", "power", ",", "in", "this", "cohort", "of", "women", "at", "low", "-", "to", "-", "normal", "risk", "of", "breast", "cancer", ",", "the", "postulated", "protective", "effects", "of", "tamoxifen", "are", "not", "yet", "apparent", ".", "Women", "using", "hormone", "-", "replacement", "therapy", "appear", "to", "have", "benefited", "from", "use", "of", "tamoxifen", ".", "There", "were", "no", "deaths", "from", "breast", "cancer", "recorded", "in", "women", "in", "the", "study", ".", "It", "is", "essential", "to", "continue", "follow", "-", "up", "to", "quantify", "the", "long", "-", "term", "risks", "and", "benefits", "of", "tamoxifen", "therapy", "."]], "ner": [[[5, 5, "Chemical"], [19, 19, "Chemical"], [25, 25, "Chemical"], [57, 57, "Chemical"], [82, 82, "Chemical"], [108, 108, "Chemical"], [268, 268, "Chemical"], [286, 286, "Chemical"], [325, 325, "Chemical"], [347, 347, "Chemical"], [380, 380, "Chemical"], [399, 399, "Chemical"], [433, 433, "Chemical"], [340, 341, "Disease"], [343, 343, "Disease"], [2, 3, "Disease"], [32, 33, "Disease"], [94, 95, "Disease"], [195, 196, "Disease"], [236, 237, "Disease"], [248, 249, "Disease"], [256, 258, "Disease"], [281, 282, "Disease"], [314, 315, "Disease"], [372, 373, "Disease"], [406, 407, "Disease"], [45, 46, "Disease"]]], "relations": [[[5, 5, 340, 341, "CID"], [19, 19, 340, 341, "CID"], [25, 25, 340, 341, "CID"], [57, 57, 340, 341, "CID"], [82, 82, 340, 341, "CID"], [108, 108, 340, 341, "CID"], [268, 268, 340, 341, "CID"], [286, 286, 340, 341, "CID"], [325, 325, 340, 341, "CID"], [347, 347, 340, 341, "CID"], [380, 380, 340, 341, "CID"], [399, 399, 340, 341, "CID"], [433, 433, 340, 341, "CID"], [5, 5, 343, 343, "CID"], [19, 19, 343, 343, "CID"], [25, 25, 343, 343, "CID"], [57, 57, 343, 343, "CID"], [82, 82, 343, 343, "CID"], [108, 108, 343, 343, "CID"], [268, 268, 343, 343, "CID"], [286, 286, 343, 343, "CID"], [325, 325, 343, 343, "CID"], [347, 347, 343, 343, "CID"], [380, 380, 343, 343, "CID"], [399, 399, 343, 343, "CID"], [433, 433, 343, 343, "CID"]]], "clusters": [], "translated": "用<0>他莫昔芬</0>预防<15>乳腺癌</15>：意大利子宫切除妇女随机试验的初步结果。意大利<1>他莫昔芬</1>预防研究。背景：<2>他莫昔芬</2>是<16>乳腺癌</16>的候选化学预防剂，尽管该药物可能与<26>子宫内膜癌</26>的发生有关。因此，我们对子宫切除的妇女进行了一项试验，将<3>他莫昔芬</3>用作化学预防剂。方法：1992年10月，我们在未患<17>乳腺癌</17>的女性（主要在意大利）中开始了一项关于<4>他莫昔芬</4>的双盲安慰剂对照随机试验。做过子宫切除术。女性随机接受<5>他莫昔芬</5> 20 毫克/天或安慰剂，均口服，持续 5 年。最初的计划是在干预阶段之后进行 5 年的随访。1997年6月，试验者和数据监测委员会决定终止招募，主要是因为退出研究的女性人数较多。招募于1997年7月11日结束，研究将按计划继续进行。主要终点是<18>乳腺癌</18>的发生和死亡。该初步中期分析基于意向性治疗。结果：5408名女性被随机分配；参与的女性对主要终点的平均随访时间为46个月。迄今发生<19>乳腺癌</19>41例；没有人死于<20>乳腺癌</20>。<21>乳腺癌</21>频率在安慰剂组（22例）和<6>他莫昔芬</6>（19例）组之间没有差异。在接受<7>他莫昔芬</7>并且在试验期间还使用激素替代疗法的女性中，<22>乳腺癌</22>的发生率显着降低：在390名接受这种疗法并分配给安慰剂的女性中，我们发现8例<23>乳腺癌</23>，与分配给<8>他莫昔芬</8>的362名女性中的1例相比较。与安慰剂组相比，服用<9>他莫昔芬</9>的女性发生<13>血管事件</13>和<14>高甘油三酯血症</14>的风险显着增加。解释：尽管这项初步分析的功效较低，但在这组<24>乳腺癌</24>处于低至正常风险的女性中，<10>他莫昔芬</10>的假定保护作用尚不明显。使用激素替代疗法的女性似乎受益于使用<11>他莫昔芬</11>。研究中没有女性死于<25>乳腺癌</25>的记录。必须继续随访以量化<12>他莫昔芬</12>疗法的长期风险和益处。", "revised": true}
{"doc_key": "1636026", "sentences": [["Effects", "of", "suprofen", "on", "the", "isolated", "perfused", "rat", "kidney", ".", "Although", "suprofen", "has", "been", "associated", "with", "the", "development", "of", "acute", "renal", "failure", "in", "greater", "than", "100", "subjects", ",", "the", "mechanism", "of", "damage", "remains", "unclear", ".", "The", "direct", "nephrotoxic", "effects", "of", "a", "single", "dose", "of", "15", "mg", "of", "suprofen", "were", "compared", "in", "the", "recirculating", "isolated", "rat", "kidney", "perfused", "with", "cell", "-", "free", "buffer", "with", "or", "without", "the", "addition", "of", "5", "mg", "/", "dL", "of", "uric", "acid", ".", "There", "were", "no", "significant", "differences", "in", "renal", "sodium", "excretion", ",", "oxygen", "consumption", ",", "or", "urinary", "flow", "rates", "in", "kidneys", "perfused", "with", "suprofen", "compared", "with", "the", "drug", "-", "free", "control", "groups", ".", "In", "contrast", ",", "a", "significant", "decline", "in", "glomerular", "filtration", "rate", "was", "found", "after", "the", "introduction", "of", "suprofen", "to", "the", "kidney", "perfused", "with", "uric", "acid", ";", "no", "changes", "were", "found", "with", "suprofen", "in", "the", "absence", "of", "uric", "acid", ".", "A", "significant", "decrease", "in", "the", "baseline", "excretion", "rate", "of", "uric", "acid", "was", "found", "in", "rats", "given", "suprofen", ",", "compared", "with", "drug", "-", "free", "controls", ".", "However", ",", "the", "fractional", "excretion", "of", "uric", "acid", "was", "unchanged", "between", "the", "groups", "over", "the", "experimental", "period", ".", "In", "summary", ",", "suprofen", "causes", "acute", "declines", "in", "renal", "function", ",", "most", "likely", "by", "directly", "altering", "the", "intrarenal", "distribution", "of", "uric", "acid", "."]], "ner": [[[2, 2, "Chemical"], [11, 11, "Chemical"], [47, 47, "Chemical"], [97, 97, "Chemical"], [123, 123, "Chemical"], [137, 137, "Chemical"], [161, 161, "Chemical"], [191, 191, "Chemical"], [19, 21, "Disease"], [193, 197, "Disease"], [37, 37, "Disease"], [73, 74, "Chemical"], [129, 130, "Chemical"], [142, 143, "Chemical"], [154, 155, "Chemical"], [176, 177, "Chemical"], [208, 209, "Chemical"], [83, 83, "Chemical"], [86, 86, "Chemical"]]], "relations": [[[2, 2, 19, 21, "CID"], [2, 2, 193, 197, "CID"], [11, 11, 19, 21, "CID"], [11, 11, 193, 197, "CID"], [47, 47, 19, 21, "CID"], [47, 47, 193, 197, "CID"], [97, 97, 19, 21, "CID"], [97, 97, 193, 197, "CID"], [123, 123, 19, 21, "CID"], [123, 123, 193, 197, "CID"], [137, 137, 19, 21, "CID"], [137, 137, 193, 197, "CID"], [161, 161, 19, 21, "CID"], [161, 161, 193, 197, "CID"], [191, 191, 19, 21, "CID"], [191, 191, 193, 197, "CID"]]], "clusters": [], "translated": "<0>舒洛芬</0>对离体灌注大鼠肾脏的影响。尽管<1>舒洛芬</1>与100多名受试者的<8>急性肾功能衰竭</8>的发展有关，但损害的机制仍不清楚。在再循环离体大鼠肾脏中比较了单剂量15 mg的<2>舒洛芬</2>的直接<10>肾毒性</10>作用，该肾灌注有或没有添加5 mg/dL的<11>尿酸</11>。与无药物对照相比，用<3>舒洛芬</3>灌注的肾脏在肾<17>钠</17>排泄、<18>氧</18>消耗或尿流率方面没有显着差异。相比之下，将<4>舒洛芬</4>引入灌注有<12>尿酸</12>的肾脏后，发现肾小球滤过率显着下降；在没有<13>尿酸</13>的情况下，<5>舒洛芬</5>没有发现变化。与未服用药物的对照组相比，给予<6>舒洛芬</6>的大鼠的<14>尿酸</14>基线排泄率显着降低。然而，在整个实验期间，各组之间<15>尿酸</15>的排泄分数没有变化。总之，<7>舒洛芬</7>导致<9>急性肾功能下降</9>，很可能是通过直接改变<16>尿酸</16>的肾内分布。", "revised": true}
{"doc_key": "1610717", "sentences": [["Cocaine", "-", "induced", "brainstem", "seizures", "and", "behavior", ".", "A", "variety", "of", "abnormal", "sensory", "/", "motor", "behaviors", "associated", "with", "electrical", "discharges", "recorded", "from", "the", "bilateral", "brainstem", "were", "induced", "in", "adult", "WKY", "rats", "by", "mechanical", "(", "electrode", "implants", ")", "and", "DC", "electrical", "current", "stimulations", "and", "by", "acute", "and", "chronic", "administration", "of", "cocaine", ".", "The", "electrode", "implant", "implicated", "one", "side", "or", "the", "other", "of", "the", "reticular", "system", "of", "the", "brainstem", "but", "subjects", "were", "not", "incapacitated", "by", "the", "stimulations", ".", "Cocaine", "(", "40", "mg", "/", "kg", ")", "was", "injected", "subcutaneously", "for", "an", "acute", "experiment", "and", "subsequent", "20", "mg", "/", "kg", "doses", "twice", "daily", "for", "3", "days", "in", "a", "chronic", "study", ".", "Cocaine", "generated", "more", "abnormal", "behaviors", "in", "the", "brainstem", "perturbation", "group", ",", "especially", "the", "electrically", "perturbated", "subjects", ".", "The", "abnormal", "behaviors", "were", "yawning", ",", "retrocollis", ",", "hyperactivity", ",", "hypersensitivity", ",", "\"", "beating", "drum", "\"", "behavior", ",", "squealing", ",", "head", "bobbing", ",", "circling", ",", "sniffing", ",", "abnormal", "posturing", ",", "and", "facial", "twitching", ".", "Shifts", "in", "the", "power", "frequency", "spectra", "of", "the", "discharge", "patterns", "were", "noted", "between", "quiet", "and", "pacing", "behavioral", "states", ".", "Hypersensitivity", "to", "various", "auditory", ",", "tactile", ",", "and", "visual", "stimulation", "was", "present", "and", "shifts", "in", "the", "brainstem", "ambient", "power", "spectral", "frequency", "occurred", "in", "response", "to", "tactile", "stimulation", ".", "These", "findings", "suggest", "that", "the", "brainstem", "generates", "and", "propagates", "pathological", "discharges", "that", "can", "be", "elicited", "by", "mechanical", "and", "DC", "electrical", "perturbation", ".", "Cocaine", "was", "found", "to", "activate", "the", "discharge", "system", "and", "thus", "induce", "abnormal", "behaviors", "that", "are", "generated", "at", "the", "discharge", "site", "and", "at", "distant", "sites", "to", "which", "the", "discharge", "propagates", ".", "Cognitive", "functions", "may", "also", "be", "involved", "since", "dopaminergic", "and", "serotonergic", "cellular", "elements", "at", "the", "brainstem", "level", "are", "also", "implicated", "."]], "ner": [[[0, 0, "Chemical"], [49, 49, "Chemical"], [76, 76, "Chemical"], [107, 107, "Chemical"], [227, 227, "Chemical"], [4, 4, "Disease"], [132, 132, "Disease"], [134, 134, "Disease"], [177, 177, "Disease"]]], "relations": [[[0, 0, 4, 4, "CID"], [49, 49, 4, 4, "CID"], [76, 76, 4, 4, "CID"], [107, 107, 4, 4, "CID"], [227, 227, 4, 4, "CID"]]], "clusters": [], "translated": " <0>可卡因</0>引起的脑干<5>发作</5>和行为。在成年 WKY 大鼠中，通过机械（电极植入）和直流电刺激以及急性和慢性施用<1>可卡因</1>，可诱发与双侧脑干放电相关的各种异常感觉/<2>运动行为</2>。电极植入涉及脑干网状系统的一侧或另一侧，但受试者并未因刺激而丧失能力。<3>可卡因</3>在脑干扰动组中产生更多的异常行为，尤其是电扰动组。异常行为有打呵欠、后仰、<6>多动</6>、<7>过敏</7>、“击鼓”行为、尖叫、摇头、转圈、吸气、姿势异常、面部抽搐。在安静和起搏行为状态之间注意到放电模式的功率频谱的变化。<8>对各种听觉、触觉和视觉刺激有超敏反应</8>，并且脑干环境功率谱频率的变化是对触觉刺激的反应。这些发现表明脑干产生并传播可由机械和直流电扰动引起的病理性放电。<4>可卡因</4>被发现可以激活放电系统，从而诱发在放电部位和放电传播到的远处部位产生的异常行为。认知功能也可能涉及，因为脑干水平的多巴胺能和血清素能细胞元素也受到牵连。", "revised": true}
{"doc_key": "1535072", "sentences": [["Yohimbine", "treatment", "of", "sexual", "side", "effects", "induced", "by", "serotonin", "reuptake", "blockers", ".", "BACKGROUND", ":", "Preclinical", "and", "clinical", "studies", "suggest", "that", "yohimbine", "facilitates", "sexual", "behavior", "and", "may", "be", "helpful", "in", "the", "treatment", "of", "male", "impotence", ".", "A", "single", "case", "report", "suggests", "that", "yohimbine", "may", "be", "used", "to", "treat", "the", "sexual", "side", "effects", "of", "clomipramine", ".", "This", "study", "evaluated", "yohimbine", "as", "a", "treatment", "for", "the", "sexual", "side", "effects", "caused", "by", "serotonin", "reuptake", "blockers", ".", "METHOD", ":", "Six", "patients", "with", "either", "obsessive", "compulsive", "disorder", ",", "trichotillomania", ",", "anxiety", ",", "or", "affective", "disorders", "who", "suffered", "sexual", "side", "effects", "after", "treatment", "with", "serotonin", "reuptake", "blockers", "were", "given", "yohimbine", "on", "a", "p", ".", "r", ".", "n", ".", "basis", "in", "an", "open", "clinical", "trial", ".", "Various", "doses", "of", "yohimbine", "were", "used", "to", "determine", "the", "ideal", "dose", "for", "each", "patient", ".", "RESULTS", ":", "Five", "of", "the", "six", "patients", "experienced", "improved", "sexual", "functioning", "after", "taking", "yohimbine", ".", "One", "patient", "who", "failed", "to", "comply", "with", "yohimbine", "treatment", "had", "no", "therapeutic", "effects", ".", "Side", "effects", "of", "yohimbine", "included", "excessive", "sweating", ",", "increased", "anxiety", ",", "and", "a", "wound", "-", "up", "feeling", "in", "some", "patients", ".", "CONCLUSION", ":", "The", "results", "of", "this", "study", "indicate", "that", "yohimbine", "may", "be", "an", "effective", "treatment", "for", "the", "sexual", "side", "effects", "caused", "by", "serotonin", "reuptake", "blockers", ".", "Future", "controlled", "studies", "are", "needed", "to", "further", "investigate", "the", "effectiveness", "and", "safety", "of", "yohimbine", "for", "this", "indication", "."]], "ner": [[[52, 52, "Chemical"], [3, 5, "Disease"], [48, 50, "Disease"], [63, 65, "Disease"], [91, 93, "Disease"], [200, 202, "Disease"], [0, 0, "Chemical"], [20, 20, "Chemical"], [41, 41, "Chemical"], [57, 57, "Chemical"], [102, 102, "Chemical"], [121, 121, "Chemical"], [146, 146, "Chemical"], [155, 155, "Chemical"], [165, 165, "Chemical"], [192, 192, "Chemical"], [222, 222, "Chemical"], [32, 33, "Disease"], [78, 80, "Disease"], [82, 82, "Disease"], [84, 84, "Disease"], [171, 171, "Disease"], [87, 88, "Disease"], [8, 8, "Chemical"], [68, 68, "Chemical"], [97, 97, "Chemical"], [205, 205, "Chemical"]]], "relations": [[[52, 52, 3, 5, "CID"], [52, 52, 48, 50, "CID"], [52, 52, 63, 65, "CID"], [52, 52, 91, 93, "CID"], [52, 52, 200, 202, "CID"]]], "clusters": [], "translated": "<6>育亨宾</6>治疗<1>性副作用</1>引起的<23>血清素</23>再摄取阻塞剂。背景：临床前和临床研究表明，<7>育亨宾</7>促进性行为，可能有助于治疗<17>男性阳痿</17>。一个病例报告表明，<8>育亨宾</8>可用于治疗<0>氯米帕明</0>的<2>性副作用</2>。本研究评估了<9>育亨宾</9>作为一种治疗引起的<3>性副作用</3>的<24>血清素</24>再摄取阻塞剂的药物。方法：六名患有<18>强迫症</18>、<19>拔毛癖</19>、<20>焦虑症</20>或<22>情感障碍</22>的患者在用<25>血清素</25>再摄取阻塞剂治疗后出现<4>性副作用</4>，在开放的临床试验中按需给予<10>育亨宾</10>。确定每位患者的理想剂量使用了不同的剂量<11>育亨宾</11>。结果：6名患者中5名在服用<12>育亨宾</12>后，性功能有所改善。一名未服从<13>育亨宾</13>治疗的患者没有治疗效果。<14>育亨宾</14>的副作用包括过度出汗，患者中一些增加了<21>焦虑感</21>, 还有一些患者反应会使他们感到紧张。结论：本研究的结果表明，<15>育亨宾</15>可能是治疗因<26>血清素</26>再摄取阻塞剂引起的<5>性副作用</5>的有效药物。未来需要对照研究来进一步研究<16>育亨宾</16>的安全性和有效性的证明。", "revised": true}
{"doc_key": "873132", "sentences": [["Increased", "sulfation", "and", "decreased", "7alpha", "-", "hydroxylation", "of", "deoxycholic", "acid", "in", "ethinyl", "estradiol", "-", "induced", "cholestasis", "in", "rats", ".", "Deoxycholic", "acid", "conjugation", ",", "transport", "capacity", ",", "and", "metabolism", "were", "compared", "in", "control", "and", "ethinyl", "estradiol", "-", "treated", "rats", ".", "Control", "rats", "were", "found", "to", "have", "a", "lower", "capacity", "to", "transport", "deoxycholic", "acid", "than", "taurodeoxycholic", "acid", ",", "and", "both", "were", "decreased", "by", "ethinyl", "estradiol", "treatment", ".", "During", "[", "24", "-", "14C", "]", "sodium", "deoxycholate", "infusion", ",", "[", "14C", "]", "biliary", "bile", "acid", "secretion", "increased", ",", "but", "bile", "flow", "did", "not", "change", "significantly", "in", "either", "control", "or", "ethinyl", "estradiol", "-", "treated", "rats", ".", "Ethinyl", "estradiol", "-", "treated", "animals", "excreted", "significantly", "less", "14C", "as", "taurocholic", "acid", "than", "did", "control", "animals", ",", "consistent", "with", "an", "impairment", "of", "7alpha", "-", "hydroxylation", "of", "taurodeoxycholic", "acid", ".", "Ethinyl", "estradiol", "treatment", "did", "not", "impair", "conjugation", "of", "deoxycholic", "acid", ",", "but", "did", "result", "in", "an", "increase", "in", "sulfation", "of", "taurodeoxycholic", "acid", "from", "1", ".", "5", "%", "in", "controls", "to", "nearly", "4", ".", "0", "%", "(", "P", "less", "than", "0", ".", "01", ")", ".", "These", "results", "are", "consistent", "with", "the", "hypothesis", "that", "the", "rat", "has", "a", "poorer", "tolerance", "for", "deoxycholic", "acid", "than", "do", "certain", "other", "species", ".", "Furthermore", ",", "the", "rat", "converts", "deoxycholic", "acid", ",", "a", "poor", "choleretic", ",", "to", "taurocholic", "acid", ",", "a", "good", "choleretic", ".", "When", "this", "conversion", "is", "impaired", "with", "ethinyl", "estradiol", "treatment", ",", "sulfation", "may", "be", "an", "important", "alternate", "pathway", "for", "excretion", "of", "this", "potentially", "harmful", "bile", "acid", "."]], "ner": [[[11, 12, "Chemical"], [33, 34, "Chemical"], [61, 62, "Chemical"], [95, 96, "Chemical"], [101, 102, "Chemical"], [130, 131, "Chemical"], [223, 224, "Chemical"], [15, 15, "Disease"], [8, 9, "Chemical"], [19, 20, "Chemical"], [50, 51, "Chemical"], [71, 72, "Chemical"], [138, 139, "Chemical"], [189, 190, "Chemical"], [202, 203, "Chemical"], [53, 54, "Chemical"], [127, 128, "Chemical"], [150, 151, "Chemical"], [79, 80, "Chemical"], [240, 241, "Chemical"], [111, 112, "Chemical"], [210, 211, "Chemical"]]], "relations": [[[11, 12, 15, 15, "CID"], [33, 34, 15, 15, "CID"], [61, 62, 15, 15, "CID"], [95, 96, 15, 15, "CID"], [101, 102, 15, 15, "CID"], [130, 131, 15, 15, "CID"], [223, 224, 15, 15, "CID"]]], "clusters": [], "translated": "在<0>乙炔雌二醇</0>诱导的大鼠<7>胆汁淤积</7>中，<8>脱氧胆酸</8>的硫酸化增加和7α-羟基化减少。 <9>脱氧胆酸</9>结合、转运能力和代谢在对照和<1>乙炔雌二醇</1>处理的大鼠中进行比较。发现对照大鼠运输<10>脱氧胆酸</10>的能力低于<15>牛磺脱氧胆酸</15>，而<2>乙炔雌二醇</2>处理后两者均降低。在[24-^14C]<11>脱氧胆酸钠</11>输注期间，[14C]胆汁<18>胆汁酸</18>分泌增加，但胆汁流量在对照组或<3>乙炔雌二醇</3>治疗大鼠中没有显著变化。<4>乙炔雌二醇</4>-处理的动物以<20>牛磺胆酸</20>的形式排泄的14C明显少于对照动物，这与<16>牛磺脱氧胆酸</16>的7α-羟基化受损一致。 <5>乙炔雌二醇</5>处理不会损害<12>脱氧胆酸</12>的结合，但会导致从1.5%中控制的<17>牛磺脱氧胆酸</17>硫酸化增加到近4.0%（P小于0.01）。这些结果与大鼠对<13>脱氧胆酸</13>的耐受性低于某些其他物种的假设一致。此外，大鼠将胆汁分泌不良的<14>脱氧胆酸</14>转化为胆汁分泌良好的<21>牛磺胆酸</21>。当这种转化因<6>乙炔雌二醇</6>治疗而受损时，硫酸化可能是排泄这种潜在有害的<19>胆汁酸</19>的重要替代途径。", "revised": true}
{"doc_key": "10193809", "sentences": [["Urine", "N", "-", "acetyl", "-", "beta", "-", "D", "-", "glucosaminidase", "-", "-", "a", "marker", "of", "tubular", "damage", "?", "BACKGROUND", ":", "Although", "an", "indicator", "of", "renal", "tubular", "dysfunction", ",", "an", "increased", "urinary", "N", "-", "acetyl", "-", "beta", "-", "D", "-", "glucosaminidase", "(", "NAG", ")", "activity", "might", "reflect", "increased", "lysosomal", "activity", "in", "renal", "tubular", "cells", ".", "METHODS", ":", "Puromycin", "aminonucleoside", "(", "PAN", ")", "was", "administered", "to", "Sprague", "Dawley", "rats", "to", "induce", "proteinuria", ".", "Total", "protein", ",", "albumin", ",", "NAG", "activity", "and", "protein", "electrophoretic", "pattern", "were", "assessed", "in", "daily", "urine", "samples", "for", "33", "days", ".", "The", "morphological", "appearance", "of", "the", "kidneys", "was", "examined", "on", "days", "three", ",", "four", ",", "six", ",", "eight", "and", "thirty", "three", "and", "the", "NAG", "isoenzyme", "patterns", "on", "days", "zero", ",", "four", ",", "eight", "and", "thirty", "three", ".", "RESULTS", ":", "Following", "intravenous", "PAN", "urine", "volume", "and", "urine", "NAG", "activity", "increased", "significantly", "by", "day", "two", ",", "but", "returned", "to", "normal", "by", "day", "four", ".", "After", "day", "four", "all", "treated", "animals", "exhibited", "a", "marked", "rise", "in", "urine", "albumin", ",", "total", "protein", "excretion", "and", "NAG", "activity", ".", "Electrophoresis", "showed", "a", "generalised", "increase", "in", "middle", "and", "high", "molecular", "weight", "urine", "proteins", "from", "day", "four", "onwards", ".", "Protein", "droplets", "first", "appeared", "prominent", "in", "tubular", "cells", "on", "day", "four", ".", "Peak", "urine", "NAG", "activity", "and", "a", "change", "in", "NAG", "isoenzyme", "pattern", "coincided", "with", "both", "the", "peak", "proteinuria", "and", "the", "reduction", "in", "intracellular", "protein", "and", "NAG", "droplets", "(", "day", "six", "onwards", ")", ".", "CONCLUSIONS", ":", "This", "animal", "model", "demonstrates", "that", "an", "increase", "in", "lysosomal", "turnover", "and", "hence", "urine", "NAG", "activity", ",", "occurs", "when", "increased", "protein", "is", "presented", "to", "the", "tubular", "cells", ".", "Urine", "NAG", "activity", "is", "thus", "a", "measure", "of", "altered", "function", "in", "the", "renal", "tubules", "and", "not", "simply", "an", "indicator", "of", "damage", "."]], "ner": [[[56, 57, "Chemical"], [59, 59, "Chemical"], [132, 132, "Chemical"], [69, 69, "Disease"], [220, 220, "Disease"], [24, 26, "Disease"]]], "relations": [[[56, 57, 69, 69, "CID"], [56, 57, 220, 220, "CID"], [59, 59, 69, 69, "CID"], [59, 59, 220, 220, "CID"], [132, 132, 69, 69, "CID"], [132, 132, 220, 220, "CID"]]], "clusters": [], "translated": "尿<0> N-乙酰基-β-D-氨基葡萄糖苷酶</0> - 肾小管损伤的标志？ 背景：虽然尿中<5>N-乙酰-β-D-氨基葡萄糖苷酶 (NAG)</5>活性升高是肾小管功能障碍的一个指标，但它可能反映了肾小管细胞中溶酶体活性的升高。 方法：<0>嘌呤霉素氨基核苷</0>（<1>PAN</1>）给予 Sprague Dawley 大鼠，引起<3>蛋白尿</3>。在 33 天的每日尿样中评估总蛋白、白蛋白、NAG 活性和蛋白电泳模式。在第 3、4、6、8 和 33 天检查肾脏的形态学外观，在第 0、4、8 和 33 天检查 NAG 同工酶模式。 结果：静脉注射<2>PAN</2>后，第二天尿量和尿NAG活性显着增加，但到第四天恢复正常。第四天后，所有接受治疗的动物都表现出尿白蛋白、总蛋白排泄和NAG活性显着升高。电泳显示，从第 4 天起，中高分子量尿蛋白普遍增加。蛋白液滴在第四天首次出现在肾小管细胞中。峰值尿液NAG活性和NAG同工酶模式的变化与峰值<4>蛋白尿</4>以及细胞内蛋白和NAG液滴的减少（从第六天开始）一致。 结论：该动物模型表明，当增加的蛋白质呈递给肾小管细胞时，溶酶体周转增加，尿液NAG活性增加。因此，尿液NAG活性是肾小管功能改变的量度，而不仅仅是损伤的指标。", "revised": true}
{"doc_key": "8643973", "sentences": [["Paclitaxel", "combined", "with", "carboplatin", "in", "the", "first", "-", "line", "treatment", "of", "advanced", "ovarian", "cancer", ".", "In", "a", "phase", "I", "study", "to", "determine", "the", "maximum", "tolerated", "dose", "of", "paclitaxel", "(", "Taxol", ";", "Bristol", "-", "Myers", "Squibb", "Company", ",", "Princeton", ",", "NJ", ")", "given", "as", "a", "3", "-", "hour", "infusion", "in", "combination", "with", "carboplatin", "administered", "every", "21", "days", "to", "women", "with", "advanced", "ovarian", "cancer", ",", "paclitaxel", "doses", "were", "escalated", "as", "follows", ":", "level", "1", ",", "135", "mg", "/", "m2", ";", "level", "2", ",", "160", "mg", "/", "m2", ";", "level", "3", ",", "185", "mg", "/", "m2", ";", "and", "level", "4", ",", "210", "mg", "/", "m2", ".", "The", "fixed", "dose", "of", "carboplatin", "at", "levels", "1", "through", "4", "was", "given", "to", "achieve", "an", "area", "under", "the", "concentration", "-", "time", "curve", "(", "AUC", ")", "of", "5", "using", "the", "Calvert", "formula", ".", "In", "levels", "5", "and", "6", "the", "carboplatin", "dose", "was", "targeted", "at", "AUCs", "of", "6", "and", "7", ".", "5", ",", "respectively", ",", "combined", "with", "a", "fixed", "paclitaxel", "dose", "of", "185", "mg", "/", "m2", ".", "To", "date", ",", "30", "previously", "untreated", "patients", ",", "all", "with", "a", "good", "performance", "status", "(", "Eastern", "Cooperative", "Oncology", "Group", "0", "to", "2", ")", "have", "been", "entered", "into", "this", "ongoing", "study", ".", "The", "dose", "-", "limiting", "toxicity", "of", "the", "combination", "was", "myelosuppression", "(", "leukopenia", ",", "granulocytopenia", ",", "and", "thrombocytopenia", ")", ".", "Neurotoxicity", "was", "largely", "moderate", ".", "So", "far", ",", "14", "patients", "are", "evaluable", "for", "response", ";", "of", "these", ",", "eight", "(", "57", "%", ")", "showed", "objective", "(", "complete", "or", "partial", ")", "response", "and", "disease", "stabilized", "in", "six", "patients", ".", "No", "patient", "had", "disease", "progression", ".", "We", "conclude", "that", "the", "combination", "of", "paclitaxel", "185", "mg", "/", "m2", "administered", "as", "a", "3", "-", "hour", "infusion", "followed", "immediately", "by", "a", "1", "-", "hour", "infusion", "of", "carboplatin", "at", "an", "AUC", "of", "6", "can", "be", "administered", "safely", "in", "a", "21", "-", "day", "schedule", "in", "the", "outpatient", "setting", ".", "The", "recommended", "dose", "for", "phase", "III", "studies", "is", "paclitaxel", "185", "mg", "/", "m2", "and", "carboplatin", "AUC", "6", "."]], "ner": [[[0, 0, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [63, 63, "Chemical"], [160, 160, "Chemical"], [268, 268, "Chemical"], [318, 318, "Chemical"], [210, 210, "Disease"], [212, 212, "Disease"], [215, 215, "Disease"], [218, 218, "Disease"], [3, 3, "Chemical"], [51, 51, "Chemical"], [107, 107, "Chemical"], [141, 141, "Chemical"], [289, 289, "Chemical"], [324, 324, "Chemical"], [12, 13, "Disease"], [60, 61, "Disease"], [203, 203, "Disease"], [208, 208, "Disease"]]], "relations": [[[0, 0, 210, 210, "CID"], [27, 27, 210, 210, "CID"], [29, 29, 210, 210, "CID"], [63, 63, 210, 210, "CID"], [160, 160, 210, 210, "CID"], [268, 268, 210, 210, "CID"], [318, 318, 210, 210, "CID"], [0, 0, 212, 212, "CID"], [27, 27, 212, 212, "CID"], [29, 29, 212, 212, "CID"], [63, 63, 212, 212, "CID"], [160, 160, 212, 212, "CID"], [268, 268, 212, 212, "CID"], [318, 318, 212, 212, "CID"], [0, 0, 215, 215, "CID"], [27, 27, 215, 215, "CID"], [29, 29, 215, 215, "CID"], [63, 63, 215, 215, "CID"], [160, 160, 215, 215, "CID"], [268, 268, 215, 215, "CID"], [318, 318, 215, 215, "CID"], [0, 0, 218, 218, "CID"], [27, 27, 218, 218, "CID"], [29, 29, 218, 218, "CID"], [63, 63, 218, 218, "CID"], [160, 160, 218, 218, "CID"], [268, 268, 218, 218, "CID"], [318, 318, 218, 218, "CID"], [3, 3, 210, 210, "CID"], [51, 51, 210, 210, "CID"], [107, 107, 210, 210, "CID"], [141, 141, 210, 210, "CID"], [289, 289, 210, 210, "CID"], [324, 324, 210, 210, "CID"], [3, 3, 212, 212, "CID"], [51, 51, 212, 212, "CID"], [107, 107, 212, 212, "CID"], [141, 141, 212, 212, "CID"], [289, 289, 212, 212, "CID"], [324, 324, 212, 212, "CID"], [3, 3, 215, 215, "CID"], [51, 51, 215, 215, "CID"], [107, 107, 215, 215, "CID"], [141, 141, 215, 215, "CID"], [289, 289, 215, 215, "CID"], [324, 324, 215, 215, "CID"], [3, 3, 218, 218, "CID"], [51, 51, 218, 218, "CID"], [107, 107, 218, 218, "CID"], [141, 141, 218, 218, "CID"], [289, 289, 218, 218, "CID"], [324, 324, 218, 218, "CID"]]], "clusters": [], "translated": "<0>紫杉醇</0>联合<11>卡铂</11>一线治疗晚期<17>卵巢癌</17>。在 I 期研究中确定最大耐受剂量的<1>紫杉醇</1>（<2>紫杉醇</2>；Bristol-Myers Squibb Company，Princeton，NJ）作为3小时输注与<12>卡铂</12>每21天给予晚期<18>卵巢癌</18>妇女，<3>紫杉醇</3>剂量递增如下：1级，135 mg/m2；2级，160 mg/m2；3级，185 mg/m2；和4级，210 mg/m2。使用Calvert公式，给予1至4水平的固定剂量<13>卡铂</13>以实现5的浓度-时间曲线下面积（AUC）。在水平5和6中，<14>卡铂</14>剂量的目标AUC为6和7.5，分别联合固定<4>紫杉醇</4>剂量为185 mg/m2。迄今为止，已有30名先前未接受过治疗且体能状态良好的患者（东部肿瘤合作组0至2级）参与了这项正在进行的研究。该组合的剂量限制性<19>毒性</19>是<20>骨髓抑制</20>（<7>白细胞减少</7>、<8>粒细胞减少</8>和<9>血小板减少</9>）。<10>神经毒性</10>在很大程度上是中等的。到目前为止，已有14名患者的反应可评估；其中，8例（57%）显示客观（完全或部分）反应，6例患者病情稳定。没有患者出现疾病进展。我们得出结论，<5>紫杉醇</5>185 mg/m2以3小时输注给药，然后立即以AUC 6输注1小时<15>卡铂</15>的组合可以在门诊环境中安全地执行21天的时间表。III期研究推荐剂量为<6>紫杉醇</6>185 mg/m2和<16>卡铂</16>AUC 6。", "revised": true}
{"doc_key": "783197", "sentences": [["Effects", "of", "ouabain", "on", "myocardial", "oxygen", "supply", "and", "demand", "in", "patients", "with", "chronic", "coronary", "artery", "disease", ".", "A", "hemodynamic", ",", "volumetric", ",", "and", "metabolic", "study", "in", "patients", "without", "heart", "failure", ".", "The", "effects", "of", "digitalis", "glycosides", "on", "myocardial", "oxygen", "supply", "and", "demand", "are", "of", "particular", "interest", "in", "the", "presence", "of", "obstructive", "coronary", "artery", "disease", ",", "but", "have", "not", "been", "measured", "previously", "in", "man", ".", "We", "assessed", "the", "effects", "of", "ouabain", "(", "0", ".", "015", "mg", "/", "kg", "body", "weight", ")", "on", "hemodynamic", ",", "volumetric", ",", "and", "metabolic", "parameters", "in", "11", "patients", "with", "severe", "chronic", "coronary", "artery", "disease", "without", "clinical", "congestive", "heart", "failure", ".", "Because", "the", "protocol", "was", "long", "and", "involved", "interventions", "which", "might", "affect", "the", "determinations", ",", "we", "also", "studied", "in", "nine", "patients", "using", "an", "identical", "protocol", "except", "that", "ouabain", "administration", "was", "omitted", ".", "Left", "ventricular", "end", "-", "diastolic", "pressure", "and", "left", "ventricular", "end", "-", "diastolic", "volume", "fell", "in", "each", "patient", "given", "ouabain", ",", "even", "though", "they", "were", "initially", "elevated", "in", "only", "two", "patients", ".", "Left", "ventricular", "end", "-", "diastolic", "pressure", "fell", "from", "11", ".", "5", "+", "/", "-", "1", ".", "4", "(", "mean", "+", "/", "-", "SE", ")", "to", "5", ".", "6", "+", "/", "-", "0", ".", "9", "mm", "Hg", "(", "P", "less", "than", "0", ".", "001", ")", "and", "left", "ventricular", "end", "-", "diastolic", "volume", "fell", "from", "100", "+", "/", "-", "17", "to", "82", "+", "/", "-", "12", "ml", "/", "m2", "(", "P", "less", "than", "0", ".", "01", ")", "1", "h", "after", "ouabain", "infusion", "was", "completed", ".", "The", "maximum", "velocity", "of", "contractile", "element", "shortening", "increased", "from", "1", ".", "68", "+", "/", "-", "0", ".", "11", "ml", "/", "s", "to", "2", ".", "18", "+", "/", "-", "0", ".", "21", "muscle", "-", "lengths", "/", "s", "(", "P", "less", "than", "0", ".", "05", ")", "and", "is", "consistent", "with", "an", "increase", "in", "contractility", ".", "No", "significant", "change", "in", "these", "parameters", "occurred", "in", "the", "control", "patients", ".", "No", "significant", "change", "in", "myocardial", "oxygen", "consumption", "occurred", "after", "ouabain", "administration", "but", "this", "may", "be", "related", "to", "a", "greater", "decrease", "in", "mean", "arterial", "pressure", "in", "the", "ouabain", "patients", "than", "in", "the", "control", "patients", ".", "We", "conclude", "that", "in", "patients", "with", "chronic", "coronary", "artery", "disease", "who", "are", "not", "in", "clinical", "congestive", "heart", "failure", "left", "ventricular", "end", "-", "diastolic", "volume", "falls", "after", "ouabain", "administration", "even", "when", "it", "is", "initially", "normal", ".", "Though", "this", "fall", "would", "be", "associated", "with", "a", "decrease", "in", "wall", "tension", ",", "and", ",", "therefore", ",", "of", "myocardial", "oxygen", "consumption", ",", "it", "may", "not", "be", "of", "sufficient", "magnitude", "to", "prevent", "a", "net", "increase", "in", "myocardial", "oxygen", "consumption", ".", "Nevertheless", ",", "compensatory", "mechanisms", "prevent", "a", "deterioration", "of", "resting", "myocardial", "metabolism", "."]], "ner": [[[2, 2, "Chemical"], [69, 69, "Chemical"], [129, 129, "Chemical"], [152, 152, "Chemical"], [243, 243, "Chemical"], [322, 322, "Chemical"], [339, 339, "Chemical"], [373, 373, "Chemical"], [365, 371, "Disease"], [13, 15, "Disease"], [51, 53, "Disease"], [94, 96, "Disease"], [354, 356, "Disease"], [28, 29, "Disease"], [99, 101, "Disease"], [362, 364, "Disease"], [5, 5, "Chemical"], [38, 38, "Chemical"], [318, 318, "Chemical"], [401, 401, "Chemical"], [418, 418, "Chemical"], [34, 35, "Chemical"]]], "relations": [[[2, 2, 365, 371, "CID"], [69, 69, 365, 371, "CID"], [129, 129, 365, 371, "CID"], [152, 152, 365, 371, "CID"], [243, 243, 365, 371, "CID"], [322, 322, 365, 371, "CID"], [339, 339, 365, 371, "CID"], [373, 373, 365, 371, "CID"]]], "clusters": [], "translated": "<0>哇巴因</0>对慢性<9>冠状动脉疾病</9>患者心肌<16>氧</16>供需的影响。在没有<13>心力衰竭</13>的患者进行了血液动力学、容量和代谢研究。<21>洋地黄苷</21>对心肌<17>氧气</17> 供应和需求的影响在存在阻塞性<10>冠状动脉疾病</10>时特别令人感兴趣，但尚未进行测量。我们评估了<1>哇巴因</1>（0.015 mg/kg体重）对11名患有严重慢性<11>冠状动脉疾病</11>、无临床<14>充血性心力衰竭</14>的患者的影响。因为方案较长且涉及可能影响测定的干预措施，我们还使用相同的方案对9名患者进行了研究，只是省略了<2>哇巴因</2>给药。每位接受<3>哇巴因</3>治疗的患者左心室舒张末期压力和左心室舒张末期容积均下降，尽管最初只有两名患者升高。左心室舒张末期压力从11.5+/-1.4（平均值+/-标准误差）mm Hg下降至5.6+/-0.9 mm Hg（P小于0.001），左心室舒张末期容积从100+/-17 ml/m2下降至82+/-12 ml/m2 （P小于0.01）。<4>哇巴因</4>输液完成1小时后，收缩元件缩短的最大速度由1.68+/-0.11 ml/s增加至2.18+/-0.21 muscle-lengths/s（P小于0.05），该速度的增加与收缩力增加一致。对照组患者这些参数未发生明显变化。<5>哇巴因</5>给药后心肌<18>氧</18>消耗未发生显著变化，但这可能与<6>哇巴因</6>患者的平均动脉压下降幅度大于对照患者有关。我们的结论是，在患有慢性<12>冠状动脉疾病</12>，无临床<15>充血性心力衰竭</15>的患者中，接受<7>哇巴因</7>治疗后<8>左心室舒张末期容积下降</8>，即使最初是正常的。虽然这种下降会导致壁张力降低，由此降低心肌<19>氧</19>消耗，但这可能不足以防止心肌<20>氧</20>消耗净增加。然而，代偿机制可以防止静息心肌代谢恶化。", "revised": true}
{"doc_key": "3535719", "sentences": [["Relative", "efficacy", "and", "toxicity", "of", "netilmicin", "and", "tobramycin", "in", "oncology", "patients", ".", "We", "prospectively", "compared", "the", "efficacy", "and", "safety", "of", "netilmicin", "sulfate", "or", "tobramycin", "sulfate", "in", "conjunction", "with", "piperacillin", "sodium", "in", "118", "immunocompromised", "patients", "with", "presumed", "severe", "infections", ".", "The", "two", "treatment", "regimens", "were", "equally", "efficacious", ".", "Nephrotoxicity", "occurred", "in", "a", "similar", "proportion", "in", "patients", "treated", "with", "netilmicin", "and", "tobramycin", "(", "17", "%", "vs", "11", "%", ")", ".", "Ototoxicity", "occurred", "in", "four", "(", "9", ".", "5", "%", ")", "of", "42", "netilmicin", "and", "piperacillin", "and", "in", "12", "(", "22", "%", ")", "of", "54", "tobramycin", "and", "piperacillin", "-", "treated", "patients", ".", "Of", "those", "evaluated", "with", "posttherapy", "audiograms", ",", "three", "of", "four", "netilmicin", "and", "piperacillin", "-", "treated", "patients", "had", "auditory", "thresholds", "return", "to", "baseline", "compared", "with", "one", "of", "nine", "tobramycin", "and", "piperacillin", "-", "treated", "patients", ".", "The", "number", "of", "greater", "than", "or", "equal", "to", "15", "-", "dB", "increases", "in", "auditory", "threshold", "as", "a", "proportion", "of", "total", "greater", "than", "or", "equal", "to", "15", "-", "dB", "changes", "(", "increases", "and", "decreases", ")", "was", "significantly", "lower", "in", "netilmicin", "and", "piperacillin", "-", "vs", "tobramycin", "and", "piperacillin", "-", "treated", "patients", "(", "18", "of", "78", "vs", "67", "of", "115", ")", ".", "We", "conclude", "that", "aminoglycoside", "-", "associated", "ototoxicity", "was", "less", "severe", "and", "more", "often", "reversible", "with", "netilmicin", "than", "with", "tobramycin", "."]], "ner": [[[5, 5, "Chemical"], [20, 21, "Chemical"], [57, 57, "Chemical"], [80, 80, "Chemical"], [109, 109, "Chemical"], [171, 171, "Chemical"], [207, 207, "Chemical"], [47, 47, "Disease"], [68, 68, "Disease"], [198, 198, "Disease"], [7, 7, "Chemical"], [23, 24, "Chemical"], [59, 59, "Chemical"], [92, 92, "Chemical"], [126, 126, "Chemical"], [176, 176, "Chemical"], [210, 210, "Chemical"], [28, 29, "Chemical"], [82, 82, "Chemical"], [94, 94, "Chemical"], [111, 111, "Chemical"], [128, 128, "Chemical"], [173, 173, "Chemical"], [178, 178, "Chemical"], [3, 3, "Disease"], [195, 195, "Chemical"], [37, 37, "Disease"]]], "relations": [[[5, 5, 47, 47, "CID"], [20, 21, 47, 47, "CID"], [57, 57, 47, 47, "CID"], [80, 80, 47, 47, "CID"], [109, 109, 47, 47, "CID"], [171, 171, 47, 47, "CID"], [207, 207, 47, 47, "CID"], [5, 5, 68, 68, "CID"], [5, 5, 198, 198, "CID"], [20, 21, 68, 68, "CID"], [20, 21, 198, 198, "CID"], [57, 57, 68, 68, "CID"], [57, 57, 198, 198, "CID"], [80, 80, 68, 68, "CID"], [80, 80, 198, 198, "CID"], [109, 109, 68, 68, "CID"], [109, 109, 198, 198, "CID"], [171, 171, 68, 68, "CID"], [171, 171, 198, 198, "CID"], [207, 207, 68, 68, "CID"], [207, 207, 198, 198, "CID"], [7, 7, 47, 47, "CID"], [23, 24, 47, 47, "CID"], [59, 59, 47, 47, "CID"], [92, 92, 47, 47, "CID"], [126, 126, 47, 47, "CID"], [176, 176, 47, 47, "CID"], [210, 210, 47, 47, "CID"], [7, 7, 68, 68, "CID"], [7, 7, 198, 198, "CID"], [23, 24, 68, 68, "CID"], [23, 24, 198, 198, "CID"], [59, 59, 68, 68, "CID"], [59, 59, 198, 198, "CID"], [92, 92, 68, 68, "CID"], [92, 92, 198, 198, "CID"], [126, 126, 68, 68, "CID"], [126, 126, 198, 198, "CID"], [176, 176, 68, 68, "CID"], [176, 176, 198, 198, "CID"], [210, 210, 68, 68, "CID"], [210, 210, 198, 198, "CID"], [28, 29, 47, 47, "CID"], [82, 82, 47, 47, "CID"], [94, 94, 47, 47, "CID"], [111, 111, 47, 47, "CID"], [128, 128, 47, 47, "CID"], [173, 173, 47, 47, "CID"], [178, 178, 47, 47, "CID"], [28, 29, 68, 68, "CID"], [28, 29, 198, 198, "CID"], [82, 82, 68, 68, "CID"], [82, 82, 198, 198, "CID"], [94, 94, 68, 68, "CID"], [94, 94, 198, 198, "CID"], [111, 111, 68, 68, "CID"], [111, 111, 198, 198, "CID"], [128, 128, 68, 68, "CID"], [128, 128, 198, 198, "CID"], [173, 173, 68, 68, "CID"], [173, 173, 198, 198, "CID"], [178, 178, 68, 68, "CID"], [178, 178, 198, 198, "CID"]]], "clusters": [], "translated": "<0>奈替米星</0>和<10>妥布霉素</10>在肿瘤患者中的相对疗效和<24>毒性</24>。我们前瞻性地比较了<1>奈替米星硫酸盐</1>或<11>妥布霉素硫酸盐</11>与<17>哌拉西林钠</17>在118名免疫系统受损患者推测有严重的<26>感染</26>的情况下的疗效和安全性。两种治疗方案同样有效。在接受<2>奈替米星</2>和<12>妥布霉素</12>治疗的患者中，<7>肾毒性</7>发生的比例相似（分别为17%和11%）。在42个接受<3>奈替米星</3>和<18>哌拉西林</18>治疗的患者中，<8>耳毒性</8>出现在4名患者身上（占9.5%），而在54个接受<13>妥布霉素</13>和<19>哌拉西林</19>治疗的患者中，12个患者出现了耳毒性（占22%） 。接受治疗后进行听力图评估的患者中，接受<4>奈替米星</4>和<20>哌拉西林</20>治疗的四名患者中有三名的听觉阈值恢复到基线，而接受<14>妥布霉素</14>和<21>哌拉西林</21>治疗的九名患者中，只有一名的听觉阈值恢复到基线。在<5>奈替米星</5>和<22>哌拉西林</22>治疗的患者中，大于或等于15 dB的听阈变化（增加和减少）中，阈值增加的比例明显较低，相对于由<15>妥布霉素</15>和<23>哌拉西林</23>治疗的患者（分别为78名中的18名对115名中的67名）。我们得出结论，与<16>妥布霉素</16>相比，<25>氨基糖苷类</25>相关的<9>耳毒性</9>在由<6>奈替米星</6>治疗的患者中严重程度更轻，而且通常更易逆转。", "revised": true}
{"doc_key": "15764424", "sentences": [["Quantitative", "drug", "levels", "in", "stimulant", "psychosis", ":", "relationship", "to", "symptom", "severity", ",", "catecholamines", "and", "hyperkinesia", ".", "To", "examine", "the", "relationship", "between", "quantitative", "stimulant", "drug", "levels", ",", "catecholamines", ",", "and", "psychotic", "symptoms", ",", "nineteen", "patients", "in", "a", "psychiatric", "emergency", "service", "with", "a", "diagnosis", "of", "amphetamine", "-", "or", "cocaine", "-", "induced", "psychosis", "were", "interviewed", ",", "and", "plasma", "and", "urine", "were", "collected", "for", "quantitative", "assays", "of", "stimulant", "drug", "and", "catecholamine", "metabolite", "levels", ".", "Methamphetamine", "or", "amphetamine", "levels", "were", "related", "to", "several", "psychopathology", "scores", "and", "the", "global", "hyperkinesia", "rating", ".", "HVA", "levels", "were", "related", "to", "global", "hyperkinesia", "but", "not", "to", "psychopathology", "ratings", ".", "Although", "many", "other", "factors", "such", "as", "sensitization", "may", "play", "a", "role", ",", "intensity", "of", "stimulant", "-", "induced", "psychotic", "symptoms", "and", "stereotypies", "appears", "to", "be", "at", "least", "in", "part", "dose", "-", "related", "."]], "ner": [[[43, 43, "Chemical"], [72, 72, "Chemical"], [5, 5, "Disease"], [29, 30, "Disease"], [49, 49, "Disease"], [116, 117, "Disease"], [46, 46, "Chemical"], [70, 70, "Chemical"], [14, 14, "Disease"], [83, 83, "Disease"], [92, 92, "Disease"], [12, 12, "Chemical"], [26, 26, "Chemical"], [66, 66, "Chemical"], [36, 36, "Disease"], [119, 119, "Disease"]]], "relations": [[[43, 43, 5, 5, "CID"], [43, 43, 29, 30, "CID"], [43, 43, 49, 49, "CID"], [43, 43, 116, 117, "CID"], [72, 72, 5, 5, "CID"], [72, 72, 29, 30, "CID"], [72, 72, 49, 49, "CID"], [72, 72, 116, 117, "CID"], [46, 46, 5, 5, "CID"], [46, 46, 29, 30, "CID"], [46, 46, 49, 49, "CID"], [46, 46, 116, 117, "CID"], [70, 70, 5, 5, "CID"], [70, 70, 29, 30, "CID"], [70, 70, 49, 49, "CID"], [70, 70, 116, 117, "CID"], [43, 43, 14, 14, "CID"], [43, 43, 83, 83, "CID"], [43, 43, 92, 92, "CID"], [72, 72, 14, 14, "CID"], [72, 72, 83, 83, "CID"], [72, 72, 92, 92, "CID"], [46, 46, 14, 14, "CID"], [46, 46, 83, 83, "CID"], [46, 46, 92, 92, "CID"], [70, 70, 14, 14, "CID"], [70, 70, 83, 83, "CID"], [70, 70, 92, 92, "CID"]]], "clusters": [], "translated": "兴奋剂<2>精神病</2>中的定量药物水平：与症状严重程度、<11>儿茶酚胺</11>和<8>运动机能亢进</8>的关系。为了检查定量兴奋剂药物水平、<12>儿茶酚胺</12>和<3>精神病症状</3>之间的关系，<14>精神病学</14>急诊服务中的19名患者，诊断为<0>苯丙胺</0>-或<6>可卡因</6>诱发的<4>精神病</4>，并收集血浆和尿液用于兴奋剂药物和<13>儿茶酚胺</13>的定量分析代谢物水平。 <7>甲基苯丙胺</7>或<1>苯丙胺</1>水平与几种精神病理学评分和总体<9>运动过度</9>评级有关。HVA水平与整体<10>运动过度</10>有关，但与精神病理学评级无关。尽管致敏等许多其他因素可能起作用，但兴奋剂引起的<5>精神病症状</5>和<15>刻板印象</15>的强度似乎至少部分与剂量相关。", "revised": true}
{"doc_key": "6127992", "sentences": [["Adverse", "interaction", "between", "beta", "-", "adrenergic", "blocking", "drugs", "and", "verapamil", "-", "-", "report", "of", "three", "cases", ".", "Three", "patients", "with", "ischaemic", "heart", "disease", "developed", "profound", "cardiac", "failure", ",", "hypotension", "and", "bradycardia", "during", "combined", "therapy", "with", "verapamil", "and", "beta", "-", "adrenergic", "blocking", "drugs", ".", "This", "clinical", "picture", "resolved", "completely", "with", "cessation", "of", "the", "combined", "therapy", ".", "Baseline", "left", "ventricular", "function", ",", "assessed", "by", "cardiac", "catheterisation", "or", "nuclear", "angiography", ",", "was", "normal", "in", "two", "patients", "and", "only", "mildly", "reduced", "in", "the", "other", ".", "Simultaneously", "administration", "of", "beta", "-", "adrenergic", "blocking", "drugs", "and", "verapamil", "may", "result", "in", "profound", "adverse", "interactions", "and", "should", "only", "be", "administered", "with", "great", "caution", "."]], "ner": [[[3, 7, "Chemical"], [37, 41, "Chemical"], [84, 88, "Chemical"], [25, 26, "Disease"], [28, 28, "Disease"], [30, 30, "Disease"], [9, 9, "Chemical"], [35, 35, "Chemical"], [90, 90, "Chemical"], [20, 22, "Disease"]]], "relations": [[[3, 7, 25, 26, "CID"], [37, 41, 25, 26, "CID"], [84, 88, 25, 26, "CID"], [3, 7, 28, 28, "CID"], [37, 41, 28, 28, "CID"], [84, 88, 28, 28, "CID"], [3, 7, 30, 30, "CID"], [37, 41, 30, 30, "CID"], [84, 88, 30, 30, "CID"], [9, 9, 25, 26, "CID"], [35, 35, 25, 26, "CID"], [90, 90, 25, 26, "CID"], [9, 9, 28, 28, "CID"], [35, 35, 28, 28, "CID"], [90, 90, 28, 28, "CID"], [9, 9, 30, 30, "CID"], [35, 35, 30, 30, "CID"], [90, 90, 30, 30, "CID"]]], "clusters": [], "translated": "<0>β-肾上腺素受体阻滞剂</0>与<6>维拉帕米</6>的不良反应——三例报告。3例<9>缺血性心脏病</9>患者在<1>β-肾上腺素阻滞剂</1>和<7>维拉帕米</7>联合治疗期间出现严重的<3>心力衰竭</3>、<4>低血压</4>和<5>心动过缓</5>。这种临床表现随着联合治疗的停止而完全消失。通过心导管插入术或核血管造影术评估的基线左心室功能在两名患者中是正常的，而在另一名患者中仅轻度降低。同时服用<2>β-肾上腺素阻滞剂</2>和<8>维拉帕米</8>可能会导致严重的不良反应，服用时应非常小心。", "revised": true}
{"doc_key": "6699841", "sentences": [["Renal", "papillary", "necrosis", "due", "to", "naproxen", ".", "A", "31", "-", "year", "-", "old", "man", "with", "rheumatoid", "arthritis", ",", "who", "had", "previously", "been", "treated", "with", "sulindac", ",", "fenoprofen", "calcium", ",", "high", "dose", "salicylates", "and", "gold", "salts", ",", "developed", "renal", "papillary", "necrosis", "(", "RPN", ")", "4", "months", "after", "institution", "of", "naproxen", "therapy", ".", "No", "other", "factor", "predisposing", "to", "RPN", "could", "be", "discovered", ".", "Sulindac", "was", "substituted", "for", "naproxen", "and", "no", "further", "adverse", "renal", "effects", "occurred", "over", "the", "next", "12", "months", ".", "We", "review", "previous", "reports", "linking", "RPN", "to", "antiinflammatory", "drug", "use", "and", "discuss", "possible", "advantages", "of", "sulindac", "in", "patients", "who", "have", "experienced", "renal", "toxicity", "from", "other", "antiinflammatory", "agents", "."]], "ner": [[[5, 5, "Chemical"], [48, 48, "Chemical"], [65, 65, "Chemical"], [0, 2, "Disease"], [37, 39, "Disease"], [41, 41, "Disease"], [56, 56, "Disease"], [84, 84, "Disease"], [24, 24, "Chemical"], [61, 61, "Chemical"], [94, 94, "Chemical"], [26, 27, "Chemical"], [31, 31, "Chemical"], [33, 33, "Chemical"], [15, 16, "Disease"], [100, 101, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 37, 39, "CID"], [5, 5, 41, 41, "CID"], [5, 5, 56, 56, "CID"], [5, 5, 84, 84, "CID"], [48, 48, 0, 2, "CID"], [48, 48, 37, 39, "CID"], [48, 48, 41, 41, "CID"], [48, 48, 56, 56, "CID"], [48, 48, 84, 84, "CID"], [65, 65, 0, 2, "CID"], [65, 65, 37, 39, "CID"], [65, 65, 41, 41, "CID"], [65, 65, 56, 56, "CID"], [65, 65, 84, 84, "CID"]]], "clusters": [], "translated": " <3>肾乳头坏死</3>由于<0>萘普生</0>。一名患有<14>类风湿性关节炎</14>的31岁男性，之前曾接受过<8>舒林酸</8>、<11>非诺洛芬钙</11>、高剂量的<12>水杨酸盐</12>和<13>金</13>盐，<1>萘普生</1>治疗后4个月出现<4>肾乳头坏死</4>（<5>RPN</5>）。没有发现其他易患<6>RPN</6>的因素。<2>萘普生</2>被替换为<9>舒林酸</9>，接下来的12个月内没有发生进一步的不良肾脏反应。我们回顾了以前将<7>RPN</7>与抗炎药使用联系起来的报告，并讨论了在已经经历其他抗炎药物<15>肾毒性</15>的患者中，<10>舒林酸</10>可能具有的优势。", "revised": true}
{"doc_key": "9545159", "sentences": [["Prolongation", "of", "the", "QT", "interval", "related", "to", "cisapride", "-", "diltiazem", "interaction", ".", "Cisapride", ",", "a", "cytochrome", "P450", "3A4", "(", "CYP3A4", ")", "substrate", ",", "is", "widely", "prescribed", "for", "the", "treatment", "of", "gastrointestinal", "motility", "disorders", ".", "Prolongation", "of", "QT", "interval", ",", "torsades", "de", "pointes", ",", "and", "sudden", "cardiac", "death", "have", "been", "reported", "after", "concomitant", "administration", "with", "erythromycin", "or", "azole", "antifungal", "agents", ",", "but", "not", "with", "other", "CYP3A4", "inhibitors", ".", "A", "possible", "drug", "interaction", "occurred", "in", "a", "45", "-", "year", "-", "old", "woman", "who", "was", "taking", "cisapride", "for", "gastroesophageal", "reflux", "disorder", "and", "diltiazem", ",", "an", "agent", "that", "has", "inhibitory", "effect", "on", "CYP3A4", ",", "for", "hypertension", ".", "The", "patient", "was", "in", "near", "syncope", "and", "had", "QT", "-", "interval", "prolongation", ".", "After", "discontinuing", "cisapride", ",", "the", "QT", "interval", "returned", "to", "normal", "and", "symptoms", "did", "not", "recur", ".", "We", "suggest", "that", "caution", "be", "taken", "when", "cisapride", "is", "prescribed", "with", "any", "potent", "inhibitor", "of", "CYP3A4", ",", "including", "diltiazem", "."]], "ner": [[[7, 7, "Chemical"], [12, 12, "Chemical"], [83, 83, "Chemical"], [118, 118, "Chemical"], [139, 139, "Chemical"], [0, 4, "Disease"], [34, 37, "Disease"], [111, 114, "Disease"], [9, 9, "Chemical"], [89, 89, "Chemical"], [150, 150, "Chemical"], [54, 54, "Chemical"], [56, 56, "Chemical"], [39, 41, "Disease"], [44, 46, "Disease"], [30, 32, "Disease"], [85, 87, "Disease"], [101, 101, "Disease"], [108, 108, "Disease"]]], "relations": [[[7, 7, 0, 4, "CID"], [7, 7, 34, 37, "CID"], [7, 7, 111, 114, "CID"], [12, 12, 0, 4, "CID"], [12, 12, 34, 37, "CID"], [12, 12, 111, 114, "CID"], [83, 83, 0, 4, "CID"], [83, 83, 34, 37, "CID"], [83, 83, 111, 114, "CID"], [118, 118, 0, 4, "CID"], [118, 118, 34, 37, "CID"], [118, 118, 111, 114, "CID"], [139, 139, 0, 4, "CID"], [139, 139, 34, 37, "CID"], [139, 139, 111, 114, "CID"], [9, 9, 0, 4, "CID"], [9, 9, 34, 37, "CID"], [9, 9, 111, 114, "CID"], [89, 89, 0, 4, "CID"], [89, 89, 34, 37, "CID"], [89, 89, 111, 114, "CID"], [150, 150, 0, 4, "CID"], [150, 150, 34, 37, "CID"], [150, 150, 111, 114, "CID"], [54, 54, 0, 4, "CID"], [54, 54, 34, 37, "CID"], [54, 54, 111, 114, "CID"], [56, 56, 0, 4, "CID"], [56, 56, 34, 37, "CID"], [56, 56, 111, 114, "CID"], [7, 7, 39, 41, "CID"], [12, 12, 39, 41, "CID"], [83, 83, 39, 41, "CID"], [118, 118, 39, 41, "CID"], [139, 139, 39, 41, "CID"], [7, 7, 44, 46, "CID"], [12, 12, 44, 46, "CID"], [83, 83, 44, 46, "CID"], [118, 118, 44, 46, "CID"], [139, 139, 44, 46, "CID"], [54, 54, 39, 41, "CID"], [56, 56, 39, 41, "CID"], [54, 54, 44, 46, "CID"], [56, 56, 44, 46, "CID"]]], "clusters": [], "translated": "<5>QT间期延长</5>与<0>西沙必利</0> - <8>地尔硫卓</8>相互作用有关。 <1>西沙必利</1>，一种CYP3A4底物，广泛用于治疗<15>胃肠动力障碍</15>。同时使用<11>红霉素</11>或<12>唑</12>类抗真菌药可能引起<6>QT间期延长</6>，<13>扭转性室性心动过速</13>和<14>猝死</14>，而不是其他CYP3A4抑制剂。一名45岁女性正在服用<2>西沙必利</2>治疗<16>胃食管反流病</16>和<9>地尔硫卓</9>，这是一种具有CYP3A4抑制作用的药物，用于<17>高血压</17>可能发生药物相互作用。患者接近<18>晕厥</18>并且出现<7>QT间期延长</7>。停用<3>西沙必利</3>后，QT间期恢复正常，症状未复发。当使用<4>西沙必利</4>与任何强效CYP3A4抑制剂（包括<10>地尔硫卓</10>）一起处方时，请谨慎使用。", "revised": true}
{"doc_key": "6433367", "sentences": [["Effect", "of", "prostaglandin", "synthetase", "inhibitors", "on", "experimentally", "induced", "convulsions", "in", "rats", ".", "To", "investigate", "the", "relationship", "of", "prostaglandins", "(", "PGs", ")", "to", "seizure", "induction", ",", "the", "effects", "of", "six", "PG", "synthetase", "inhibitors", "on", "convulsions", "induced", "by", "flurothyl", ",", "picrotoxin", ",", "pentetrazol", "(", "PTZ", ")", ",", "electroshock", "or", "bicuculline", "were", "evaluated", ".", "Ibuprofen", ",", "sulindac", ",", "mefenamic", "acid", ",", "and", "low", "dose", "meclofenamic", "acid", "increased", "the", "latency", "-", "to", "-", "onset", "in", "the", "flurothyl", "and", "/", "or", "PTZ", "models", ";", "the", "electroshock", ",", "picrotoxin", "and", "bicuculline", "models", "were", "not", "significantly", "affected", "by", "any", "of", "the", "pretreatment", "agents", ".", "These", "results", "suggest", "that", "PGs", "are", "involved", "in", "the", "mechanism", "(", "s", ")", "underlying", "fluorthyl", "-", "and", "PTZ", "-", "induced", "convulsions", ",", "but", "not", "picrotoxin", "-", ",", "electroshock", "-", ",", "or", "bicuculline", "-", "induced", "convulsions", "."]], "ner": [[[36, 36, "Chemical"], [72, 72, "Chemical"], [111, 111, "Chemical"], [8, 8, "Disease"], [22, 22, "Disease"], [33, 33, "Disease"], [117, 117, "Disease"], [131, 131, "Disease"], [38, 38, "Chemical"], [82, 82, "Chemical"], [121, 121, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [76, 76, "Chemical"], [114, 114, "Chemical"], [47, 47, "Chemical"], [84, 84, "Chemical"], [128, 128, "Chemical"], [2, 2, "Chemical"], [17, 17, "Chemical"], [19, 19, "Chemical"], [101, 101, "Chemical"], [51, 51, "Chemical"], [53, 53, "Chemical"], [55, 56, "Chemical"], [61, 62, "Chemical"]]], "relations": [[[36, 36, 8, 8, "CID"], [36, 36, 22, 22, "CID"], [36, 36, 33, 33, "CID"], [36, 36, 117, 117, "CID"], [36, 36, 131, 131, "CID"], [72, 72, 8, 8, "CID"], [72, 72, 22, 22, "CID"], [72, 72, 33, 33, "CID"], [72, 72, 117, 117, "CID"], [72, 72, 131, 131, "CID"], [111, 111, 8, 8, "CID"], [111, 111, 22, 22, "CID"], [111, 111, 33, 33, "CID"], [111, 111, 117, 117, "CID"], [111, 111, 131, 131, "CID"], [38, 38, 8, 8, "CID"], [38, 38, 22, 22, "CID"], [38, 38, 33, 33, "CID"], [38, 38, 117, 117, "CID"], [38, 38, 131, 131, "CID"], [82, 82, 8, 8, "CID"], [82, 82, 22, 22, "CID"], [82, 82, 33, 33, "CID"], [82, 82, 117, 117, "CID"], [82, 82, 131, 131, "CID"], [121, 121, 8, 8, "CID"], [121, 121, 22, 22, "CID"], [121, 121, 33, 33, "CID"], [121, 121, 117, 117, "CID"], [121, 121, 131, 131, "CID"], [40, 40, 8, 8, "CID"], [40, 40, 22, 22, "CID"], [40, 40, 33, 33, "CID"], [40, 40, 117, 117, "CID"], [40, 40, 131, 131, "CID"], [42, 42, 8, 8, "CID"], [42, 42, 22, 22, "CID"], [42, 42, 33, 33, "CID"], [42, 42, 117, 117, "CID"], [42, 42, 131, 131, "CID"], [76, 76, 8, 8, "CID"], [76, 76, 22, 22, "CID"], [76, 76, 33, 33, "CID"], [76, 76, 117, 117, "CID"], [76, 76, 131, 131, "CID"], [114, 114, 8, 8, "CID"], [114, 114, 22, 22, "CID"], [114, 114, 33, 33, "CID"], [114, 114, 117, 117, "CID"], [114, 114, 131, 131, "CID"], [47, 47, 8, 8, "CID"], [47, 47, 22, 22, "CID"], [47, 47, 33, 33, "CID"], [47, 47, 117, 117, "CID"], [47, 47, 131, 131, "CID"], [84, 84, 8, 8, "CID"], [84, 84, 22, 22, "CID"], [84, 84, 33, 33, "CID"], [84, 84, 117, 117, "CID"], [84, 84, 131, 131, "CID"], [128, 128, 8, 8, "CID"], [128, 128, 22, 22, "CID"], [128, 128, 33, 33, "CID"], [128, 128, 117, 117, "CID"], [128, 128, 131, 131, "CID"]]], "clusters": [], "translated": "<18>前列腺素</18>合成酶抑制剂对大鼠实验性<3>惊厥</3>的影响。探讨<19>前列腺素</19>（<20>PGs</20>）与<4>惊厥</4>诱导的关系，六种PG合成酶抑制剂对<5>惊厥</5>的影响<0>氟嘧啶</0>、<8>印防己毒素</8>、<11>戊四唑</11>（<12>云台</12>）、电击或<15>荷包牡丹碱</15>评价。<22>布洛芬</22>、<23>舒林酸</23>、<24>甲芬那酸</24>和低剂量<25>甲氯芬那酸</25>增加了<1>氟嘧啶</1>和/或<13>云台</13>模型的潜伏期；电击、<9>印防己毒素</9>和<16>荷包牡丹碱</16>模型不受任何预处理剂的显着影响。这些结果表明<21>PGs</21>参与了<2>氟乙基</2>和<14>戊四唑</14>诱导的<6>抽搐</6>的潜在机制，但不是<10>印防己毒素</10>、电击或<17>荷包牡丹碱</17>引起的<7>抽搐</7>。", "revised": true}
{"doc_key": "9214597", "sentences": [["Over", "expression", "of", "vascular", "endothelial", "growth", "factor", "and", "its", "receptor", "during", "the", "development", "of", "estrogen", "-", "induced", "rat", "pituitary", "tumors", "may", "mediate", "estrogen", "-", "initiated", "tumor", "angiogenesis", ".", "Estrogens", ",", "which", "have", "been", "associated", "with", "several", "types", "of", "human", "and", "animal", "cancers", ",", "can", "induce", "tumor", "angiogenesis", "in", "the", "pituitary", "of", "Fischer", "344", "rats", ".", "The", "mechanistic", "details", "of", "tumor", "angiogenesis", "induction", ",", "during", "estrogen", "carcinogenesis", ",", "are", "still", "unknown", ".", "To", "elucidate", "the", "role", "of", "estrogen", "in", "the", "regulation", "of", "tumor", "angiogenesis", "in", "the", "pituitary", "of", "female", "rats", ",", "the", "density", "of", "blood", "vessels", "was", "analysed", "using", "factor", "VIII", "related", "antigen", "(", "FVIIIRAg", ")", "immunohistochemistry", "and", "the", "expression", "of", "vascular", "endothelial", "growth", "factor", "/", "vascular", "permeability", "factor", "(", "VEGF", "/", "VPF", ")", "was", "examined", "by", "Western", "blot", "and", "immunohistochemical", "analysis", ".", "The", "expression", "of", "VEGF", "receptor", "(", "VEGFR", "-", "2", "/", "Flk", "-", "1", "/", "KDR", ")", "was", "also", "examined", "by", "immunohistochemistry", ".", "The", "results", "demonstrated", "that", "17beta", "-", "estradiol", "(", "E2", ")", "induces", "neovascularization", ",", "as", "well", "as", "the", "growth", "and", "enlargement", "of", "blood", "vessels", "after", "7", "days", "of", "exposure", ".", "The", "high", "tumor", "angiogenic", "potential", "was", "associated", "with", "an", "elevated", "VEGF", "/", "VPF", "protein", "expression", "in", "the", "E2", "exposed", "pituitary", "of", "ovariectomized", "(", "OVEX", ")", "rats", ".", "VEGF", "/", "VPF", "and", "FVIIIRAg", "immunohistochemistry", "and", "endothelial", "specific", "lectin", "(", "UEA1", ")", "binding", "studies", ",", "indicate", "that", "the", "elevation", "of", "VEGF", "protein", "expression", "initially", "occurred", "in", "both", "blood", "vessels", "and", "non", "-", "endothelial", "cells", ".", "After", "15", "days", "of", "E2", "exposure", ",", "VEGF", "/", "VPF", "protein", "expression", ",", "in", "the", "non", "-", "endothelial", "cell", "population", ",", "sharply", "declined", "and", "was", "restricted", "to", "the", "blood", "vessels", ".", "The", "function", "of", "non", "-", "endothelial", "-", "derived", "VEGF", "is", "not", "clear", ".", "Furthermore", ",", "immunohistochemical", "studies", "demonstrated", "that", "VEGFR", "-", "2", "(", "flk", "-", "1", "/", "KDR", ")", ",", "expression", "was", "elevated", "significantly", "in", "the", "endothelial", "cells", "of", "microblood", "vessels", "after", "7", "days", "of", "E2", "exposure", ".", "These", "findings", "suggest", "that", "over", "expression", "of", "VEGF", "and", "its", "receptor", "(", "VEGFR", "-", "2", ")", "may", "play", "an", "important", "role", "in", "the", "initial", "step", "of", "the", "regulation", "of", "estrogen", "induced", "tumor", "angiogenesis", "in", "the", "rat", "pituitary", "."]], "ner": [[[158, 160, "Chemical"], [162, 162, "Chemical"], [200, 200, "Chemical"], [250, 250, "Chemical"], [322, 322, "Chemical"], [18, 19, "Disease"], [14, 14, "Chemical"], [22, 22, "Chemical"], [28, 28, "Chemical"], [64, 64, "Chemical"], [76, 76, "Chemical"], [354, 354, "Chemical"], [25, 25, "Disease"], [41, 41, "Disease"], [45, 45, "Disease"], [59, 59, "Disease"], [81, 81, "Disease"], [185, 185, "Disease"], [356, 356, "Disease"], [65, 65, "Disease"]]], "relations": [[[158, 160, 18, 19, "CID"], [162, 162, 18, 19, "CID"], [200, 200, 18, 19, "CID"], [250, 250, 18, 19, "CID"], [322, 322, 18, 19, "CID"]]], "clusters": [], "translated": "<6>雌激素</6>诱导的大鼠<5>垂体瘤</5>发展过程中，血管内皮生长因子及其受体的过度表达可能介导<7>雌激素</7>引发的<12>肿瘤</12>血管生成。 <8>雌激素</8>与多种类型的人类和动物<13>癌症</13>有关，可在 Fischer 344 大鼠的垂体中诱导<14>肿瘤</14>血管生成。在<9>雌激素</9> <19>癌变</19>过程中，<15>肿瘤</15>诱导血管生成的机制细节仍然未知。为阐明<10>雌激素</10>在调控雌性大鼠垂体<16>肿瘤</16>血管生成中的作用，采用凝血因子 VIII 相关抗原 (FVIIIRAg) 免疫组织化学分析血管密度。采用 Western blot 和免疫组化检测血管内皮生长因子/血管通透因子 (VEGF/VPF) 的表达。使用免疫组化检测 VE GF 受体 (VEGFR-2/Flk-1/KDR) 的表达。结果表明，<0>17beta-estradiol</0> (<1>E2</1>) 在暴露 7 天后会诱导新血管形成，以及血管的生长和扩大。高<17>肿瘤</17>血管生成潜力与卵巢切除(OVEX)大鼠暴露的<2>E2</2>垂体中 VEGF/VPF 蛋白表达升高有关。VEGF/VPF 和 FVIIIRAg 免疫组织化学以及内皮特异性凝集素 (UEA1) 的结合研究表明，VEGF 蛋白表达的升高最初发生在血管和非内皮细胞中。 <3>E2</3>暴露 15 天后，非内皮细胞群中的 VEGF/VPF 蛋白表达急剧下降并局限于血管。非内皮来源的 VEGF 的功能尚不清楚。此外，免疫组织化学研究表明，<4>E2</4>暴露 7 天后，VEGFR-2 (flk-1/KDR) 在微血管内皮细胞中的表达显著升高。这些发现表明，VEGF 及其受体 (VEGFR-2) 的过度表达可能在调节<11>雌激素</11>诱导的 Fischer 344 大鼠<18>肿瘤</18>血管生成的初始步骤中发挥重要作用。", "revised": true}
{"doc_key": "12739036", "sentences": [["Differential", "diagnosis", "of", "high", "serum", "creatine", "kinase", "levels", "in", "systemic", "lupus", "erythematosus", ".", "We", "report", "the", "clinical", "and", "bioptic", "findings", "for", "a", "57", "-", "year", "-", "old", "woman", "with", "severe", "chloroquine", "-", "induced", "myopathy", ".", "Since", "1989", ",", "she", "had", "been", "suffering", "from", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "with", "renal", "involvement", "and", "undergone", "periods", "of", "treatment", "with", "azathioprine", "and", "cyclophosphamide", ".", "Additional", "therapy", "with", "chloroquine", "(", "CQ", ")", "was", "started", "because", "of", "arthralgia", ".", "At", "the", "same", "time", ",", "slightly", "increased", "creatine", "kinase", "(", "CK", ")", "levels", "were", "noted", ".", "Myositis", "was", "suspected", ",", "and", "the", "patient", "was", "treated", "with", "steroids", ".", "The", "CK", "increase", "persisted", ",", "however", ",", "and", "she", "developed", "progressive", "muscular", "weakness", "and", "muscular", "atrophy", ".", "Routine", "controls", "revealed", "markedly", "elevated", "CK", "levels", "of", "1", ",", "700", "U", "/", "l", ".", "The", "neurological", "and", "electrophysiological", "findings", "were", "not", "typical", "of", "myositis", ".", "Thus", ",", "muscle", "biopsy", "of", "the", "deltoid", "muscle", "was", "performed", "in", "order", "to", "exclude", "polymyositis", "or", "toxic", "myopathy", ".", "As", "it", "revealed", "chloroquine", "-", "induced", "myopathy", ",", "medication", "was", "stopped", ".", "Discriminating", "between", "primary", "SLE", "-", "induced", "affection", "of", "the", "musculoskeletal", "system", "and", "drug", "-", "induced", "side", "effects", "is", "important", "for", "appropriate", "treatment", "of", "SLE", "patients", "."]], "ner": [[[30, 30, "Chemical"], [65, 65, "Chemical"], [67, 67, "Chemical"], [168, 168, "Chemical"], [114, 115, "Disease"], [117, 118, "Disease"], [5, 5, "Chemical"], [82, 82, "Chemical"], [9, 11, "Disease"], [43, 45, "Disease"], [47, 47, "Disease"], [180, 180, "Disease"], [200, 200, "Disease"], [33, 33, "Disease"], [163, 163, "Disease"], [171, 171, "Disease"], [50, 51, "Disease"], [73, 73, "Disease"], [91, 91, "Disease"], [144, 144, "Disease"], [160, 160, "Disease"], [183, 187, "Disease"], [58, 58, "Chemical"], [60, 60, "Chemical"], [101, 101, "Chemical"]]], "relations": [[[30, 30, 114, 115, "CID"], [65, 65, 114, 115, "CID"], [67, 67, 114, 115, "CID"], [168, 168, 114, 115, "CID"], [30, 30, 117, 118, "CID"], [65, 65, 117, 118, "CID"], [67, 67, 117, 118, "CID"], [168, 168, 117, 118, "CID"]]], "clusters": [], "translated": "<8>系统性红斑狼疮</8>血清<6>肌酸</6>激酶水平升高的鉴别诊断。我们报告了一名患有严重<0>氯喹</0>诱发的<13>肌病</13>的57岁女性的临床和活检结果。自1989年以来，她一直患有<9>系统性红斑狼疮</9>(<10>SLE</10>)并伴有<16>肾脏受累</16>，并经历了一段时间的<22>硫唑嘌呤治疗</22>和<23>环磷酰胺</23>。由于<17>关节痛</17>，开始使用<1>氯喹</1>(<2>CQ</2>)进行额外治疗。同时，注意到<7>肌酸</7>激酶 (CK) 水平略有升高。<18>肌炎</18>被怀疑，患者接受了<24>类固醇</24>治疗。然而，CK持续增加，她出现了进行性<4>肌肉无力</4>和<5>肌肉萎缩</5>。常规控制显示 CK 水平显著升高 1,700 U/l。神经学和电生理学发现不是典型的<19>肌炎</19>。因此，对三角肌进行了肌肉活检，以排除<20>多发性肌炎</20>或中毒性<14>肌病</14>。由于它揭示了<3>氯喹</3>诱发的<15>肌病</15>，因此停止用药。区分原发性<11>SLE</11>诱发的<21>肌肉骨骼系统影响</21>和药物诱发的副作用对于<12>SLE</12>患者的适当治疗很重要。", "revised": true}
{"doc_key": "18086064", "sentences": [["Dexmedetomidine", "and", "cardiac", "protection", "for", "non", "-", "cardiac", "surgery", ":", "a", "meta", "-", "analysis", "of", "randomised", "controlled", "trials", ".", "We", "conducted", "a", "systematic", "review", "of", "the", "effects", "of", "dexmedetomidine", "on", "cardiac", "outcomes", "following", "non", "-", "cardiac", "surgery", ".", "We", "included", "prospective", ",", "randomised", "peri", "-", "operative", "studies", "of", "dexmedetomidine", "that", "reported", "mortality", ",", "cardiac", "morbidity", "or", "adverse", "drug", "events", ".", "A", "PubMed", "Central", "and", "EMBASE", "search", "was", "conducted", "up", "to", "July", "2007", ".", "The", "reference", "lists", "of", "identified", "papers", "were", "examined", "for", "further", "trials", ".", "Of", "425", "studies", "identified", ",", "20", "were", "included", "in", "the", "meta", "-", "analysis", "(", "840", "patients", ")", ".", "Dexmedetomidine", "was", "associated", "with", "a", "trend", "towards", "improved", "cardiac", "outcomes", ";", "all", "-", "cause", "mortality", "(", "OR", "0", ".", "27", ",", "95", "%", "CI", "0", ".", "01", "-", "7", ".", "13", ",", "p", "=", "0", ".", "44", ")", ",", "non", "-", "fatal", "myocardial", "infarction", "(", "OR", "0", ".", "26", ",", "95", "%", "CI", "0", ".", "04", "-", "1", ".", "60", ",", "p", "=", "0", ".", "14", ")", ",", "and", "myocardial", "ischaemia", "(", "OR", "0", ".", "65", ",", "95", "%", "CI", "0", ".", "26", "-", "1", ".", "63", ",", "p", "=", "0", ".", "36", ")", ".", "Peri", "-", "operative", "hypotension", "(", "26", "%", ",", "OR", "3", ".", "80", ",", "95", "%", "CI", "1", ".", "91", "-", "7", ".", "54", ",", "p", "=", "0", ".", "0001", ")", "and", "bradycardia", "(", "17", "%", ",", "OR", "5", ".", "45", ",", "95", "%", "CI", "2", ".", "98", "-", "9", ".", "95", ",", "p", "<", "0", ".", "00001", ")", "were", "significantly", "increased", ".", "An", "anticholinergic", "did", "not", "reduce", "the", "incidence", "of", "bradycardia", "(", "p", "=", "0", ".", "43", ")", ".", "A", "randomised", "placebo", "-", "controlled", "trial", "of", "dexmedetomidine", "is", "warranted", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [48, 48, "Chemical"], [103, 103, "Chemical"], [284, 284, "Chemical"], [201, 201, "Disease"], [229, 229, "Disease"], [268, 268, "Disease"], [145, 146, "Disease"], [172, 173, "Disease"]]], "relations": [[[0, 0, 201, 201, "CID"], [28, 28, 201, 201, "CID"], [48, 48, 201, 201, "CID"], [103, 103, 201, 201, "CID"], [284, 284, 201, 201, "CID"], [0, 0, 229, 229, "CID"], [0, 0, 268, 268, "CID"], [28, 28, 229, 229, "CID"], [28, 28, 268, 268, "CID"], [48, 48, 229, 229, "CID"], [48, 48, 268, 268, "CID"], [103, 103, 229, 229, "CID"], [103, 103, 268, 268, "CID"], [284, 284, 229, 229, "CID"], [284, 284, 268, 268, "CID"]]], "clusters": [], "translated": " <0>右美托咪定</0>和非心脏手术的心脏保护：随机对照试验的荟萃分析。我们对<1>右美托咪定</1>对非心脏手术后心脏结局的影响进行了系统评价。我们纳入了关于 <2>右美托咪定</2> 的前瞻性随机围手术期研究，这些研究报告了死亡率、心脏病发病率或不良药物事件。 PubMed Central 和 EMBASE 搜索进行到 2007 年 7 月。对已确定论文的参考文献列表进行了检查以进行进一步试验。在确定的 425 项研究中，有 20 项被纳入荟萃分析（840 名患者）。<3>右美托咪定</3>与改善心脏结局的趋势相关；全因死亡率（OR 0.27，95% CI 0.01-7.13，p=0.44），非致死性<8>心肌梗死</8>（OR 0.26，95% CI 0.04-1.60，p=0.14），和<9>心肌缺血</9>（OR 0.65，95% CI 0.26-1.63，p=0.36）。围手术期<5>低血压</5>（26%，OR 3.80，95% CI 1.91-7.54，p=0.0001）和<6>心动过缓</6>（17%，OR 5.45，95% CI 2.98-9.95，p<0.00001）显着增加。抗胆碱药并未降低<7>心动过缓</7>的发生率（p=0.43）。有必要对<4>右美托咪定</4>进行随机安慰剂对照试验。", "revised": true}
{"doc_key": "3962737", "sentences": [["Hepatotoxicity", "of", "amiodarone", ".", "Amiodarone", "has", "proved", "very", "effective", "in", "the", "treatment", "of", "otherwise", "resistant", "cardiac", "tachyarrhythmias", ".", "The", "use", "of", "amiodarone", "has", ",", "however", ",", "been", "limited", "due", "to", "its", "serious", "side", "-", "effects", ".", "A", "patient", "with", "cholestatic", "hepatitis", "due", "to", "amiodarone", "treatment", "is", "presented", "below", "and", "a", "review", "of", "the", "hepatotoxicity", "of", "amiodarone", "is", "given", ".", "It", "is", "concluded", "that", "solid", "evidence", "exists", "of", "hepatic", "injury", "due", "to", "amiodarone", "treatment", ",", "including", "steatosis", ",", "alterations", "resembling", "alcoholic", "hepatitis", ",", "cholestatic", "hepatitis", "and", "micronodular", "cirrhosis", "of", "the", "liver", ".", "Patients", "receiving", "amiodarone", "should", "be", "regularly", "screened", "with", "respect", "to", "hepatic", "enzyme", "levels", ".", "Therapy", "should", "be", "discontinued", "on", "the", "suspicion", "of", "cholestatic", "injury", "or", "hepatomegaly", "."]], "ner": [[[2, 2, "Chemical"], [4, 4, "Chemical"], [21, 21, "Chemical"], [43, 43, "Chemical"], [55, 55, "Chemical"], [71, 71, "Chemical"], [93, 93, "Chemical"], [0, 0, "Disease"], [39, 40, "Disease"], [53, 53, "Disease"], [67, 68, "Disease"], [82, 83, "Disease"], [113, 114, "Disease"], [75, 75, "Disease"], [86, 89, "Disease"], [16, 16, "Disease"], [79, 80, "Disease"], [116, 116, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 39, 40, "CID"], [2, 2, 53, 53, "CID"], [2, 2, 67, 68, "CID"], [2, 2, 82, 83, "CID"], [4, 4, 0, 0, "CID"], [4, 4, 39, 40, "CID"], [4, 4, 53, 53, "CID"], [4, 4, 67, 68, "CID"], [4, 4, 82, 83, "CID"], [21, 21, 0, 0, "CID"], [21, 21, 39, 40, "CID"], [21, 21, 53, 53, "CID"], [21, 21, 67, 68, "CID"], [21, 21, 82, 83, "CID"], [43, 43, 0, 0, "CID"], [43, 43, 39, 40, "CID"], [43, 43, 53, 53, "CID"], [43, 43, 67, 68, "CID"], [43, 43, 82, 83, "CID"], [55, 55, 0, 0, "CID"], [55, 55, 39, 40, "CID"], [55, 55, 53, 53, "CID"], [55, 55, 67, 68, "CID"], [55, 55, 82, 83, "CID"], [71, 71, 0, 0, "CID"], [71, 71, 39, 40, "CID"], [71, 71, 53, 53, "CID"], [71, 71, 67, 68, "CID"], [71, 71, 82, 83, "CID"], [93, 93, 0, 0, "CID"], [93, 93, 39, 40, "CID"], [93, 93, 53, 53, "CID"], [93, 93, 67, 68, "CID"], [93, 93, 82, 83, "CID"], [2, 2, 113, 114, "CID"], [4, 4, 113, 114, "CID"], [21, 21, 113, 114, "CID"], [43, 43, 113, 114, "CID"], [55, 55, 113, 114, "CID"], [71, 71, 113, 114, "CID"], [93, 93, 113, 114, "CID"], [2, 2, 75, 75, "CID"], [4, 4, 75, 75, "CID"], [21, 21, 75, 75, "CID"], [43, 43, 75, 75, "CID"], [55, 55, 75, 75, "CID"], [71, 71, 75, 75, "CID"], [93, 93, 75, 75, "CID"], [2, 2, 86, 89, "CID"], [4, 4, 86, 89, "CID"], [21, 21, 86, 89, "CID"], [43, 43, 86, 89, "CID"], [55, 55, 86, 89, "CID"], [71, 71, 86, 89, "CID"], [93, 93, 86, 89, "CID"]]], "clusters": [], "translated": "<0>胺碘酮</0>的<7>肝毒性</7>。<1>胺碘酮</1>已证明在治疗其他顽固性心脏<15>快速性心律失常</15>方面非常有效。然而，<2>胺碘酮</2>的使用因其严重的副作用而受到限制。下面介绍一例因<3>胺碘酮</3>治疗而导致<8>胆汁淤积性肝炎</8>的患者，并对<4>胺碘酮</4>的<9>肝毒性</9>进行综述。得出的结论是，<5>胺碘酮</5>治疗存在<10>肝损伤</10>的确凿证据，包括<13>脂肪变性</13>，类似<16>酒精性肝炎</16>的改变，<11>胆汁淤积性肝炎</11>和小结节性<14>肝硬化</14>。接受<6>胺碘酮</6>治疗的患者应定期筛查肝酶水平。怀疑<12>胆汁淤积损伤</12>或<17>肝肿大</17>时应停止治疗。", "revised": true}
{"doc_key": "15811908", "sentences": [["Pheochromocytoma", "unmasked", "by", "amisulpride", "and", "tiapride", ".", "OBJECTIVE", ":", "To", "describe", "the", "unmasking", "of", "pheochromocytoma", "in", "a", "patient", "treated", "with", "amisulpride", "and", "tiapride", ".", "CASE", "SUMMARY", ":", "A", "42", "-", "year", "-", "old", "white", "man", "developed", "acute", "hypertension", "with", "severe", "headache", "and", "vomiting", "2", "hours", "after", "the", "first", "doses", "of", "amisulpride", "100", "mg", "and", "tiapride", "100", "mg", ".", "Both", "drugs", "were", "immediately", "discontinued", ",", "and", "the", "patient", "recovered", "after", "subsequent", "nicardipine", "and", "verapamil", "treatment", ".", "Abdominal", "ultrasound", "showed", "an", "adrenal", "mass", ",", "and", "postoperative", "histologic", "examination", "confirmed", "the", "diagnosis", "of", "pheochromocytoma", ".", "DISCUSSION", ":", "Drug", "-", "induced", "symptoms", "of", "pheochromocytoma", "are", "often", "associated", "with", "the", "use", "of", "substituted", "benzamide", "drugs", ",", "but", "the", "underlying", "mechanism", "is", "unknown", ".", "In", "our", "case", ",", "use", "of", "the", "Naranjo", "probability", "scale", "indicated", "a", "possible", "relationship", "between", "the", "hypertensive", "crisis", "and", "amisulpride", "and", "tiapride", "therapy", ".", "CONCLUSIONS", ":", "As", "of", "March", "24", ",", "2005", ",", "this", "is", "the", "first", "reported", "case", "of", "amisulpride", "-", "and", "tiapride", "-", "induced", "hypertensive", "crisis", "in", "a", "patient", "with", "pheochromocytoma", ".", "Physicians", "and", "other", "healthcare", "professionals", "should", "be", "aware", "of", "this", "potential", "adverse", "effect", "of", "tiapride", "and", "amisulpride", "."]], "ner": [[[3, 3, "Chemical"], [20, 20, "Chemical"], [50, 50, "Chemical"], [137, 137, "Chemical"], [158, 158, "Chemical"], [188, 188, "Chemical"], [37, 37, "Disease"], [134, 134, "Disease"], [164, 164, "Disease"], [40, 40, "Disease"], [42, 42, "Disease"], [5, 5, "Chemical"], [22, 22, "Chemical"], [54, 54, "Chemical"], [139, 139, "Chemical"], [161, 161, "Chemical"], [186, 186, "Chemical"], [0, 0, "Disease"], [14, 14, "Disease"], [90, 90, "Disease"], [99, 99, "Disease"], [170, 170, "Disease"], [70, 70, "Chemical"], [72, 72, "Chemical"], [108, 108, "Chemical"]]], "relations": [[[3, 3, 37, 37, "CID"], [3, 3, 134, 134, "CID"], [3, 3, 164, 164, "CID"], [20, 20, 37, 37, "CID"], [20, 20, 134, 134, "CID"], [20, 20, 164, 164, "CID"], [50, 50, 37, 37, "CID"], [50, 50, 134, 134, "CID"], [50, 50, 164, 164, "CID"], [137, 137, 37, 37, "CID"], [137, 137, 134, 134, "CID"], [137, 137, 164, 164, "CID"], [158, 158, 37, 37, "CID"], [158, 158, 134, 134, "CID"], [158, 158, 164, 164, "CID"], [188, 188, 37, 37, "CID"], [188, 188, 134, 134, "CID"], [188, 188, 164, 164, "CID"], [3, 3, 40, 40, "CID"], [20, 20, 40, 40, "CID"], [50, 50, 40, 40, "CID"], [137, 137, 40, 40, "CID"], [158, 158, 40, 40, "CID"], [188, 188, 40, 40, "CID"], [3, 3, 42, 42, "CID"], [20, 20, 42, 42, "CID"], [50, 50, 42, 42, "CID"], [137, 137, 42, 42, "CID"], [158, 158, 42, 42, "CID"], [188, 188, 42, 42, "CID"], [5, 5, 37, 37, "CID"], [5, 5, 134, 134, "CID"], [5, 5, 164, 164, "CID"], [22, 22, 37, 37, "CID"], [22, 22, 134, 134, "CID"], [22, 22, 164, 164, "CID"], [54, 54, 37, 37, "CID"], [54, 54, 134, 134, "CID"], [54, 54, 164, 164, "CID"], [139, 139, 37, 37, "CID"], [139, 139, 134, 134, "CID"], [139, 139, 164, 164, "CID"], [161, 161, 37, 37, "CID"], [161, 161, 134, 134, "CID"], [161, 161, 164, 164, "CID"], [186, 186, 37, 37, "CID"], [186, 186, 134, 134, "CID"], [186, 186, 164, 164, "CID"], [5, 5, 40, 40, "CID"], [22, 22, 40, 40, "CID"], [54, 54, 40, 40, "CID"], [139, 139, 40, 40, "CID"], [161, 161, 40, 40, "CID"], [186, 186, 40, 40, "CID"], [5, 5, 42, 42, "CID"], [22, 22, 42, 42, "CID"], [54, 54, 42, 42, "CID"], [139, 139, 42, 42, "CID"], [161, 161, 42, 42, "CID"], [186, 186, 42, 42, "CID"]]], "clusters": [], "translated": "<17>嗜铬细胞瘤</17>被<0>氨磺必利</0>和<11>泰必利</11>所掩盖。目的：描述用<1>氨磺必利</1>和<12>硫必利</12>治疗的患者<18>嗜铬细胞瘤</18>的显露情况。病例摘要：一位42岁的白人男性在第一次服用<2>氨磺必利</2> 100 mg和<13>泰必利</13> 100 mg后2小时出现急性<6>高血压</6>并伴有严重的<9>头痛</9>和<10>呕吐</10>。两种药物均立即停药，经<22>尼卡地平</22>和<23>维拉帕米</23>治疗后痊愈。腹部超声显示肾上腺肿块，术后组织学检查证实诊断为<19>嗜铬细胞瘤</19>。讨论：<20>嗜铬细胞瘤</20>的药物诱发症状通常与使用替代<24>苯甲酰胺</24>药物有关，但其潜在机制尚不清楚。在我们的案例中，使用Naranjo概率量表表明患者<21>嗜铬细胞瘤</21>可能与<3>氨磺必利</3>和<14>泰必利</14>治疗导致<7>高血压</7>危象发生。结论：截至2005年3月24日，这是第一例报告的<4>氨磺必利</4>-和<15>噻必利</15>-诱发<8>高血压</8>危象的<21>嗜铬细胞瘤</21>患者。医生和其他医疗保健专业人员应该意识到<16>泰必利</16>和<5>氨磺必利</5>的这种潜在副作用。", "revised": true}
{"doc_key": "2722224", "sentences": [["Hydrocortisone", "-", "induced", "hypertension", "in", "humans", ":", "pressor", "responsiveness", "and", "sympathetic", "function", ".", "Oral", "hydrocortisone", "increases", "blood", "pressure", "and", "enhances", "pressor", "responsiveness", "in", "normal", "human", "subjects", ".", "We", "studied", "the", "effects", "of", "1", "week", "of", "oral", "hydrocortisone", "(", "200", "mg", "/", "day", ")", "on", "blood", "pressure", ",", "cardiac", "output", ",", "total", "peripheral", "resistance", ",", "forearm", "vascular", "resistance", ",", "and", "norepinephrine", "spillover", "to", "plasma", "in", "eight", "healthy", "male", "volunteers", ".", "Although", "diastolic", "blood", "pressure", "remained", "unchanged", ",", "systolic", "blood", "pressure", "increased", "from", "119", "to", "135", "mm", "Hg", "(", "SED", "+", "/", "-", "3", ".", "4", ",", "p", "less", "than", "0", ".", "01", ")", ",", "associated", "with", "an", "increased", "cardiac", "output", "(", "5", ".", "85", "-", "7", ".", "73", "l", "/", "min", ",", "SED", "+", "/", "-", "0", ".", "46", ",", "p", "less", "than", "0", ".", "01", ")", ".", "Total", "peripheral", "vascular", "resistance", "fell", "from", "15", ".", "1", "to", "12", ".", "2", "mm", "Hg", "/", "l", "/", "min", "(", "SED", "+", "/", "-", "1", ".", "03", ",", "p", "less", "than", "0", ".", "05", ")", ".", "Resting", "forearm", "vascular", "resistance", "remained", "unchanged", ",", "but", "the", "reflex", "response", "to", "the", "cold", "pressor", "test", "was", "accentuated", ",", "the", "rise", "in", "resistance", "increasing", "from", "10", ".", "5", "mm", "Hg", "/", "ml", "/", "100", "ml", "/", "min", "(", "R", "units", ")", "before", "treatment", "to", "32", ".", "6", "R", "units", "after", "treatment", "(", "SED", "+", "/", "-", "6", ".", "4", ",", "p", "less", "than", "0", ".", "025", ")", ".", "The", "rise", "in", "forearm", "vascular", "resistance", "accompanying", "intra", "-", "arterial", "norepinephrine", "(", "25", ",", "50", ",", "and", "100", "ng", "/", "min", ")", "was", "also", "significantly", "greater", "after", "hydrocortisone", ",", "increasing", "from", "an", "average", "of", "14", ".", "9", "+", "/", "-", "2", ".", "4", "R", "units", "before", "treatment", "to", "35", ".", "1", "+", "/", "-", "5", ".", "5", "R", "units", "after", "hydrocortisone", "(", "SED", "+", "/", "-", "6", ".", "0", ",", "p", "less", "than", "0", ".", "05", ")", ".", "A", "shift", "to", "the", "left", "in", "the", "dose", "-", "response", "relation", "and", "fall", "in", "threshold", "suggested", "increased", "sensitivity", "to", "norepinephrine", "after", "treatment", ".", "Measurement", "of", "resting", "norepinephrine", "spillover", "rate", "to", "plasma", "and", "norepinephrine", "uptake", "indicated", "that", "overall", "resting", "sympathetic", "nervous", "system", "activity", "was", "not", "increased", ".", "The", "rise", "in", "resting", "blood", "pressure", "with", "hydrocortisone", "is", "associated", "with", "an", "increased", "cardiac", "output", "(", "presumably", "due", "to", "increased", "blood", "volume", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [36, 36, "Chemical"], [268, 268, "Chemical"], [301, 301, "Chemical"], [372, 372, "Chemical"], [3, 3, "Disease"], [366, 370, "Disease"], [106, 108, "Disease"], [377, 379, "Disease"], [59, 59, "Chemical"], [251, 251, "Chemical"], [338, 338, "Chemical"], [345, 345, "Chemical"], [351, 351, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 366, 370, "CID"], [14, 14, 3, 3, "CID"], [14, 14, 366, 370, "CID"], [36, 36, 3, 3, "CID"], [36, 36, 366, 370, "CID"], [268, 268, 3, 3, "CID"], [268, 268, 366, 370, "CID"], [301, 301, 3, 3, "CID"], [301, 301, 366, 370, "CID"], [372, 372, 3, 3, "CID"], [372, 372, 366, 370, "CID"]]], "clusters": [], "translated": "<0>氢化可的松</0>引起的人类<6>高血压</6>：升压反应和交感神经功能。口服<1>氢化可的松</1>会增加正常人体的血压并增强升压反应性。我们研究了口服<2>氢化可的松</2>（200毫克/天）1周对血压、心输出量、总外周阻力、前臂血管阻力和<10>去甲肾上腺素</10>溢出至血浆的影响在八名健康男性志愿者中。虽然舒张压保持不变，但收缩压从119增加到135mm Hg（SED +/- 3.4，p小于0.01），与<8>增加的心输出量</8>（5.85-7.73升/分，SED+/-0.46，p小于0.01）。总外周血管阻力从15.1到12.2毫米汞柱/升/分钟（SED+/-1.03，p小于0.05）。静息前臂血管阻力保持不变，但对冷加压试验的反射反应增强，阻力从10.5 R单位在治疗前增加到32.6 R单位治疗后（SED+/-6.4，p小于0.025）。伴随动脉内<11>去甲肾上腺素</11>（25、50和100纳克/分钟）的前臂血管阻力上升在<3>氢化可的松</3>后也显着增加，从平均14.9+/-2.4 R单位治疗前增加到35.1+/-5.5 R单位<4>氢化可的松</4>后（SED+/-6.0，p小于0.05）。剂量反应关系向左移动和阈值下降表明治疗后对<12>去甲肾上腺素</12>的敏感性增加。静息<13>去甲肾上腺素</13>血浆溢出率和<14>去甲肾上腺素</14>摄取的测量表明，整体静息交感神经系统活动没有增加。<5> 氢化可的松</5>引起的<7>静息血压升高</7>与<9>心输出量增加</9>有关（推测是由于血容量增加所致）。 （摘要被截断为250个单词）", "revised": true}
{"doc_key": "10743694", "sentences": [["Treatment", "of", "tacrolimus", "-", "related", "adverse", "effects", "by", "conversion", "to", "cyclosporine", "in", "liver", "transplant", "recipients", ".", "When", "tacrolimus", "side", "effects", "persist", "despite", "dose", "reduction", ",", "conversion", "to", "cyclosporine", "-", "based", "immunosuppression", "(", "CyA", ")", "is", "necessary", ".", "We", "characterized", "tacrolimus", "side", "effects", "that", "warranted", "discontinuation", "of", "the", "drug", ",", "and", "outcomes", "after", "conversion", ".", "Of", "388", "liver", "recipients", "who", "received", "tacrolimus", "as", "primary", "immunosuppression", ",", "70", "required", "conversion", "to", "CyA", ".", "We", "recorded", "indication", "for", "conversion", ",", "whether", "conversion", "was", "early", "or", "late", "after", "transplantation", ",", "tacrolimus", "dose", "and", "trough", "blood", "level", "at", "conversion", ",", "and", "incidence", "of", "rejection", "after", "conversion", ".", "Conversion", "was", "early", "in", "29", "patients", "(", "41", ".", "4", "%", ")", "and", "late", "in", "41", "(", "58", ".", "6", "%", ")", ".", "Indications", "for", "early", "conversion", "were", "neurotoxicity", "(", "20", ")", ",", "(", "insulin", "-", "dependent", ")", "diabetes", "mellitus", "(", "IDDM", ")", "(", "5", ")", ",", "nephrotoxicity", "(", "3", ")", ",", "gastrointestinal", "(", "GI", ")", "toxicity", "(", "6", ")", ",", "and", "cardiomyopathy", "(", "1", ")", ",", "and", "for", "late", "conversion", "were", "neurotoxicity", "(", "15", ")", ",", "IDDM", "(", "12", ")", ",", "nephrotoxicity", "(", "3", ")", ",", "GI", "toxicity", "(", "5", ")", ",", "hepatotoxicity", "(", "6", ")", ",", "post", "-", "transplant", "lmphoproliferate", "disease", "(", "PTLD", ")", "(", "2", ")", ",", "cardiomyopathy", "(", "1", ")", ",", "hemolytic", "anemia", "(", "1", ")", ",", "and", "pruritus", "(", "1", ")", ".", "All", "early", "-", "conversion", "patients", "showed", "improvement", "/", "resolution", "of", "symptoms", ".", "Among", "late", "-", "conversion", "patients", ",", "37", "(", "90", ".", "2", "%", ")", "had", "improvement", "/", "resolution", ";", "in", "4", "(", "9", ".", "8", "%", ")", ",", "adverse", "effects", "persisted", ".", "The", "overall", "rejection", "rate", "was", "30", "%", ".", "Sixty", "-", "two", "patients", "(", "88", ".", "6", "%", ")", "are", "alive", "with", "functioning", "grafts", "686", "+", "/", "-", "362", "days", "(", "range", ",", "154", "-", "1433", "days", ")", "after", "conversion", ".", "When", "tacrolimus", "side", "effects", "are", "unresponsive", "to", "dose", "reduction", ",", "conversion", "to", "CyA", "can", "be", "accomplished", "safely", ",", "with", "no", "increased", "risk", "of", "rejection", "and", "excellent", "long", "-", "term", "outcome", "."]], "ner": [[[2, 2, "Chemical"], [17, 17, "Chemical"], [39, 39, "Chemical"], [60, 60, "Chemical"], [86, 86, "Chemical"], [313, 313, "Chemical"], [130, 130, "Disease"], [174, 174, "Disease"], [135, 141, "Disease"], [143, 143, "Disease"], [179, 179, "Disease"], [149, 149, "Disease"], [184, 184, "Disease"], [154, 158, "Disease"], [189, 190, "Disease"], [164, 164, "Disease"], [212, 212, "Disease"], [195, 195, "Disease"], [200, 204, "Disease"], [206, 206, "Disease"], [217, 218, "Disease"], [224, 224, "Disease"], [10, 10, "Chemical"], [27, 27, "Chemical"]]], "relations": [[[2, 2, 130, 130, "CID"], [2, 2, 174, 174, "CID"], [17, 17, 130, 130, "CID"], [17, 17, 174, 174, "CID"], [39, 39, 130, 130, "CID"], [39, 39, 174, 174, "CID"], [60, 60, 130, 130, "CID"], [60, 60, 174, 174, "CID"], [86, 86, 130, 130, "CID"], [86, 86, 174, 174, "CID"], [313, 313, 130, 130, "CID"], [313, 313, 174, 174, "CID"], [2, 2, 135, 141, "CID"], [2, 2, 143, 143, "CID"], [2, 2, 179, 179, "CID"], [17, 17, 135, 141, "CID"], [17, 17, 143, 143, "CID"], [17, 17, 179, 179, "CID"], [39, 39, 135, 141, "CID"], [39, 39, 143, 143, "CID"], [39, 39, 179, 179, "CID"], [60, 60, 135, 141, "CID"], [60, 60, 143, 143, "CID"], [60, 60, 179, 179, "CID"], [86, 86, 135, 141, "CID"], [86, 86, 143, 143, "CID"], [86, 86, 179, 179, "CID"], [313, 313, 135, 141, "CID"], [313, 313, 143, 143, "CID"], [313, 313, 179, 179, "CID"], [2, 2, 149, 149, "CID"], [2, 2, 184, 184, "CID"], [17, 17, 149, 149, "CID"], [17, 17, 184, 184, "CID"], [39, 39, 149, 149, "CID"], [39, 39, 184, 184, "CID"], [60, 60, 149, 149, "CID"], [60, 60, 184, 184, "CID"], [86, 86, 149, 149, "CID"], [86, 86, 184, 184, "CID"], [313, 313, 149, 149, "CID"], [313, 313, 184, 184, "CID"], [2, 2, 154, 158, "CID"], [2, 2, 189, 190, "CID"], [17, 17, 154, 158, "CID"], [17, 17, 189, 190, "CID"], [39, 39, 154, 158, "CID"], [39, 39, 189, 190, "CID"], [60, 60, 154, 158, "CID"], [60, 60, 189, 190, "CID"], [86, 86, 154, 158, "CID"], [86, 86, 189, 190, "CID"], [313, 313, 154, 158, "CID"], [313, 313, 189, 190, "CID"], [2, 2, 164, 164, "CID"], [2, 2, 212, 212, "CID"], [17, 17, 164, 164, "CID"], [17, 17, 212, 212, "CID"], [39, 39, 164, 164, "CID"], [39, 39, 212, 212, "CID"], [60, 60, 164, 164, "CID"], [60, 60, 212, 212, "CID"], [86, 86, 164, 164, "CID"], [86, 86, 212, 212, "CID"], [313, 313, 164, 164, "CID"], [313, 313, 212, 212, "CID"], [2, 2, 195, 195, "CID"], [17, 17, 195, 195, "CID"], [39, 39, 195, 195, "CID"], [60, 60, 195, 195, "CID"], [86, 86, 195, 195, "CID"], [313, 313, 195, 195, "CID"], [2, 2, 200, 204, "CID"], [2, 2, 206, 206, "CID"], [17, 17, 200, 204, "CID"], [17, 17, 206, 206, "CID"], [39, 39, 200, 204, "CID"], [39, 39, 206, 206, "CID"], [60, 60, 200, 204, "CID"], [60, 60, 206, 206, "CID"], [86, 86, 200, 204, "CID"], [86, 86, 206, 206, "CID"], [313, 313, 200, 204, "CID"], [313, 313, 206, 206, "CID"], [2, 2, 217, 218, "CID"], [17, 17, 217, 218, "CID"], [39, 39, 217, 218, "CID"], [60, 60, 217, 218, "CID"], [86, 86, 217, 218, "CID"], [313, 313, 217, 218, "CID"], [2, 2, 224, 224, "CID"], [17, 17, 224, 224, "CID"], [39, 39, 224, 224, "CID"], [60, 60, 224, 224, "CID"], [86, 86, 224, 224, "CID"], [313, 313, 224, 224, "CID"]]], "clusters": [], "translated": "<0>他克莫司</0> - 肝移植受者转化为<22>环孢菌素</22>相关不良反应的治疗。当<1>他克莫司</1>剂量减少后，副作用仍然存在时，有必要转为<23>以环孢菌素</23>为基础的免疫抑制(CyA)治疗。我们描述了需要停药的<2>他克莫司</2>副作用以及转化后的结果。在接受<3>他克莫司</3>作为主要免疫抑制治疗的388名肝脏移植受者中，有70名需要转换为CyA。记录转化指征、转化时间和<4>他克莫司</4>剂量以及转化后药物水平，以及转化后排斥反应的发生率。29名患者（41.4%）早期转化，41名患者（58.6%）晚期转化。早期转换的指征是<6>神经毒性</6>（20），<8>（胰岛素依赖性）糖尿病</8>（<9>IDDM</9>）（5），<11>肾毒性</11>（3），<13>胃肠(GI)</13>毒性（6）和<15>心肌病</15>（1），晚期转化的指征是<7>神经毒性</7>（15），<10>IDDM</10>（12），<12>肾毒性</12>（3），<14>GI毒性</14>（5），<17>肝毒性</17>（6），<18>移植后淋巴组织增生性疾病</18>(<19>PTLD</19>)（2），<16>心肌病</16>（1），<20>溶血性贫血</20>（1）和<21>瘙痒症</21>（1）。所有早期转化患者均表现出症状改善/消退。在晚期转化患者中，37例（90.2%）有改善/解决；在4人(9.8%)中，不良反应持续存在。总体拒绝率为30%。62名患者（88.6%）在转化后存活了686+/-362天(范围，154-1433天)，移植物仍具有功能。当<5>他克莫司</5>副作用对剂量减少没有反应时，可以安全地完成向<23>以环孢菌素为基础的免疫抑制(CyA)</23>方案的转换，不会增加排斥风险并显示优异的长期效果。", "revised": true}
{"doc_key": "2716967", "sentences": [["Catalepsy", "induced", "by", "combinations", "of", "ketamine", "and", "morphine", ":", "potentiation", ",", "antagonism", ",", "tolerance", "and", "cross", "-", "tolerance", "in", "the", "rat", ".", "Previous", "studies", "demonstrated", "that", "both", "ketamine", "and", "morphine", "induced", "analgesia", "and", "catalepsy", "in", "the", "rat", ".", "Pre", "-", "treatment", "with", "ketamine", "produced", "cross", "-", "tolerance", "to", "morphine", ",", "whereas", "pretreatment", "with", "morphine", "did", "not", "induce", "cross", "-", "tolerance", "to", "ketamine", "but", "rather", "augmented", "the", "cataleptic", "response", ";", "this", "augmentation", "was", "attributed", "to", "residual", "morphine", "in", "the", "brain", ".", "The", "present", "studies", "explored", "the", "duration", "of", "the", "loss", "of", "righting", "reflex", "induced", "by", "sub", "-", "effective", "doses", "of", "ketamine", "and", "morphine", ",", "administered", "simultaneously", ".", "There", "was", "mutual", "potentiation", "between", "sub", "-", "effective", "doses", "of", "ketamine", "and", "morphine", ",", "but", "sub", "-", "effective", "doses", "of", "ketamine", "partly", "antagonized", "fully", "-", "effective", "doses", "of", "morphine", ".", "Latency", "to", "the", "loss", "of", "righting", "reflex", ",", "rigidity", "and", "behavior", "on", "recovery", ",", "reflected", "the", "relative", "predominance", "of", "ketamine", "or", "morphine", "in", "each", "combination", ".", "Naloxone", "inhibited", "the", "induced", "cataleptic", "effects", ".", "The", "degree", "and", "time", "course", "of", "development", "of", "tolerance", "to", "daily", "administration", "of", "sub", "-", "effective", "dose", "combinations", "of", "ketamine", "and", "morphine", "were", "similar", ".", "Rats", ",", "tolerant", "to", "ketamine", "-", "dominant", "combinations", ",", "were", "cross", "-", "tolerant", "to", "both", "drugs", ",", "while", "those", "tolerant", "to", "morphine", "-", "dominant", "combinations", "were", "cross", "-", "tolerant", "to", "morphine", "but", "showed", "either", "no", "cross", "-", "tolerance", "or", "an", "augmented", "response", "to", "ketamine", ".", "While", "the", "mutual", "potentiation", ",", "antagonism", "and", "tolerance", "suggest", "common", "mechanisms", "for", "the", "induced", "catalepsy", ",", "differences", "in", "latency", ",", "rigidity", "and", "behavior", ",", "asymmetry", "of", "cross", "-", "tolerance", "and", "a", "widely", "-", "different", "ID50", "for", "naloxone", "would", "argue", "against", "an", "action", "at", "a", "single", "opioid", "site", "."]], "ner": [[[5, 5, "Chemical"], [27, 27, "Chemical"], [42, 42, "Chemical"], [61, 61, "Chemical"], [99, 99, "Chemical"], [116, 116, "Chemical"], [126, 126, "Chemical"], [155, 155, "Chemical"], [188, 188, "Chemical"], [198, 198, "Chemical"], [237, 237, "Chemical"], [0, 0, "Disease"], [33, 33, "Disease"], [66, 66, "Disease"], [166, 166, "Disease"], [253, 253, "Disease"], [7, 7, "Chemical"], [29, 29, "Chemical"], [48, 48, "Chemical"], [53, 53, "Chemical"], [75, 75, "Chemical"], [101, 101, "Chemical"], [118, 118, "Chemical"], [134, 134, "Chemical"], [157, 157, "Chemical"], [190, 190, "Chemical"], [215, 215, "Chemical"], [224, 224, "Chemical"], [162, 162, "Chemical"], [275, 275, "Chemical"], [31, 31, "Disease"], [144, 144, "Disease"], [259, 259, "Disease"]]], "relations": [[[5, 5, 0, 0, "CID"], [5, 5, 33, 33, "CID"], [5, 5, 66, 66, "CID"], [5, 5, 166, 166, "CID"], [5, 5, 253, 253, "CID"], [27, 27, 0, 0, "CID"], [27, 27, 33, 33, "CID"], [27, 27, 66, 66, "CID"], [27, 27, 166, 166, "CID"], [27, 27, 253, 253, "CID"], [42, 42, 0, 0, "CID"], [42, 42, 33, 33, "CID"], [42, 42, 66, 66, "CID"], [42, 42, 166, 166, "CID"], [42, 42, 253, 253, "CID"], [61, 61, 0, 0, "CID"], [61, 61, 33, 33, "CID"], [61, 61, 66, 66, "CID"], [61, 61, 166, 166, "CID"], [61, 61, 253, 253, "CID"], [99, 99, 0, 0, "CID"], [99, 99, 33, 33, "CID"], [99, 99, 66, 66, "CID"], [99, 99, 166, 166, "CID"], [99, 99, 253, 253, "CID"], [116, 116, 0, 0, "CID"], [116, 116, 33, 33, "CID"], [116, 116, 66, 66, "CID"], [116, 116, 166, 166, "CID"], [116, 116, 253, 253, "CID"], [126, 126, 0, 0, "CID"], [126, 126, 33, 33, "CID"], [126, 126, 66, 66, "CID"], [126, 126, 166, 166, "CID"], [126, 126, 253, 253, "CID"], [155, 155, 0, 0, "CID"], [155, 155, 33, 33, "CID"], [155, 155, 66, 66, "CID"], [155, 155, 166, 166, "CID"], [155, 155, 253, 253, "CID"], [188, 188, 0, 0, "CID"], [188, 188, 33, 33, "CID"], [188, 188, 66, 66, "CID"], [188, 188, 166, 166, "CID"], [188, 188, 253, 253, "CID"], [198, 198, 0, 0, "CID"], [198, 198, 33, 33, "CID"], [198, 198, 66, 66, "CID"], [198, 198, 166, 166, "CID"], [198, 198, 253, 253, "CID"], [237, 237, 0, 0, "CID"], [237, 237, 33, 33, "CID"], [237, 237, 66, 66, "CID"], [237, 237, 166, 166, "CID"], [237, 237, 253, 253, "CID"], [7, 7, 0, 0, "CID"], [7, 7, 33, 33, "CID"], [7, 7, 66, 66, "CID"], [7, 7, 166, 166, "CID"], [7, 7, 253, 253, "CID"], [29, 29, 0, 0, "CID"], [29, 29, 33, 33, "CID"], [29, 29, 66, 66, "CID"], [29, 29, 166, 166, "CID"], [29, 29, 253, 253, "CID"], [48, 48, 0, 0, "CID"], [48, 48, 33, 33, "CID"], [48, 48, 66, 66, "CID"], [48, 48, 166, 166, "CID"], [48, 48, 253, 253, "CID"], [53, 53, 0, 0, "CID"], [53, 53, 33, 33, "CID"], [53, 53, 66, 66, "CID"], [53, 53, 166, 166, "CID"], [53, 53, 253, 253, "CID"], [75, 75, 0, 0, "CID"], [75, 75, 33, 33, "CID"], [75, 75, 66, 66, "CID"], [75, 75, 166, 166, "CID"], [75, 75, 253, 253, "CID"], [101, 101, 0, 0, "CID"], [101, 101, 33, 33, "CID"], [101, 101, 66, 66, "CID"], [101, 101, 166, 166, "CID"], [101, 101, 253, 253, "CID"], [118, 118, 0, 0, "CID"], [118, 118, 33, 33, "CID"], [118, 118, 66, 66, "CID"], [118, 118, 166, 166, "CID"], [118, 118, 253, 253, "CID"], [134, 134, 0, 0, "CID"], [134, 134, 33, 33, "CID"], [134, 134, 66, 66, "CID"], [134, 134, 166, 166, "CID"], [134, 134, 253, 253, "CID"], [157, 157, 0, 0, "CID"], [157, 157, 33, 33, "CID"], [157, 157, 66, 66, "CID"], [157, 157, 166, 166, "CID"], [157, 157, 253, 253, "CID"], [190, 190, 0, 0, "CID"], [190, 190, 33, 33, "CID"], [190, 190, 66, 66, "CID"], [190, 190, 166, 166, "CID"], [190, 190, 253, 253, "CID"], [215, 215, 0, 0, "CID"], [215, 215, 33, 33, "CID"], [215, 215, 66, 66, "CID"], [215, 215, 166, 166, "CID"], [215, 215, 253, 253, "CID"], [224, 224, 0, 0, "CID"], [224, 224, 33, 33, "CID"], [224, 224, 66, 66, "CID"], [224, 224, 166, 166, "CID"], [224, 224, 253, 253, "CID"]]], "clusters": [], "translated": "<11>强直性昏厥</11>由<0>氯胺酮</0>和<16>吗啡</16>联合诱导：大鼠的增强作用、拮抗作用、耐受性和交叉耐受性。以往的研究表明，<1>氯胺酮</1>和<17>吗啡</17>均可诱导大鼠<30>镇痛</30>和<12>强直性昏厥</12>。预处理<2>氯胺酮</2>可产生对<18>吗啡</18>的交叉耐受，而预处理<19>吗啡</19>不引起对<3>氯胺酮</3>的交叉耐受，而是增强了<13>强直性</13>反应；这种增强归因于大脑中残留的<20>吗啡</20>。目前的研究探讨了亚效剂量的<4>氯胺酮</4>和<21>吗啡</21>同时给药引起的翻正反射消失的持续时间。亚效剂量的<5>氯胺酮</5>和<22>吗啡</22>存在相互增强作用，但亚效剂量的<6>氯胺酮</6>能够部分拮抗完全有效剂量的<23>吗啡</23>。翻正反射、<31>僵化</31>和恢复行为的延迟时间反映了每种组合中<7>氯胺酮</7>或<24>吗啡</24>的相对优势。大鼠诱导的<14>强直</14>作用可被<28>纳洛酮</28>抑制。对<8>氯胺酮</8>和<25>吗啡</25>的亚效剂量组合的每日给药耐受性的程度和发展过程相似。对于显性组合的<9>氯胺酮</9>耐受性，大鼠对两种药物均具有交叉耐受性；而对于显性组合的<26>吗啡</26>耐受性大鼠，虽然对<27>吗啡</27>具有交叉耐受性，但对<10>氯胺酮</10>则没有或产生增强反应。虽然相互增强、拮抗和耐受表明<15>强直性昏厥</15>诱发的有共同机制，但潜伏期差异、<32>僵化</32>和行为、交叉耐受的不对称性和广泛不同的<29>纳洛酮</29>ID50会反对在单一的阿片类药物部位采取行动。", "revised": true}
{"doc_key": "15858223", "sentences": [["Valproic", "acid", "I", ":", "time", "course", "of", "lipid", "peroxidation", "biomarkers", ",", "liver", "toxicity", ",", "and", "valproic", "acid", "metabolite", "levels", "in", "rats", ".", "A", "single", "dose", "of", "valproic", "acid", "(", "VPA", ")", ",", "which", "is", "a", "widely", "used", "antiepileptic", "drug", ",", "is", "associated", "with", "oxidative", "stress", "in", "rats", ",", "as", "recently", "demonstrated", "by", "elevated", "levels", "of", "15", "-", "F", "(", "2t", ")", "-", "isoprostane", "(", "15", "-", "F", "(", "2t", ")", "-", "IsoP", ")", ".", "To", "determine", "whether", "there", "was", "a", "temporal", "relationship", "between", "VPA", "-", "associated", "oxidative", "stress", "and", "hepatotoxicity", ",", "adult", "male", "Sprague", "-", "Dawley", "rats", "were", "treated", "ip", "with", "VPA", "(", "500", "mg", "/", "kg", ")", "or", "0", ".", "9", "%", "saline", "(", "vehicle", ")", "once", "daily", "for", "2", ",", "4", ",", "7", ",", "10", ",", "or", "14", "days", ".", "Oxidative", "stress", "was", "assessed", "by", "determining", "plasma", "and", "liver", "levels", "of", "15", "-", "F", "(", "2t", ")", "-", "IsoP", ",", "lipid", "hydroperoxides", "(", "LPO", ")", ",", "and", "thiobarbituric", "acid", "reactive", "substances", "(", "TBARs", ")", ".", "Plasma", "and", "liver", "15", "-", "F", "(", "2t", ")", "-", "IsoP", "were", "elevated", "and", "reached", "a", "plateau", "after", "day", "2", "of", "VPA", "treatment", "compared", "to", "control", ".", "Liver", "LPO", "levels", "were", "not", "elevated", "until", "day", "7", "of", "treatment", "(", "1", ".", "8", "-", "fold", "versus", "control", ",", "p", "<", "0", ".", "05", ")", ".", "Liver", "and", "plasma", "TBARs", "were", "not", "increased", "until", "14", "days", "(", "2", "-", "fold", "vs", ".", "control", ",", "p", "<", "0", ".", "05", ")", ".", "Liver", "toxicity", "was", "evaluated", "based", "on", "serum", "levels", "of", "alpha", "-", "glutathione", "S", "-", "transferase", "(", "alpha", "-", "GST", ")", "and", "by", "histology", ".", "Serum", "alpha", "-", "GST", "levels", "were", "significantly", "elevated", "by", "day", "4", ",", "which", "corresponded", "to", "hepatotoxicity", "as", "shown", "by", "the", "increasing", "incidence", "of", "inflammation", "of", "the", "liver", "capsule", ",", "necrosis", ",", "and", "steatosis", "throughout", "the", "study", ".", "The", "liver", "levels", "of", "beta", "-", "oxidation", "metabolites", "of", "VPA", "were", "decreased", "by", "day", "14", ",", "while", "the", "levels", "of", "4", "-", "ene", "-", "VPA", "and", "(", "E", ")", "-", "2", ",", "4", "-", "diene", "-", "VPA", "were", "not", "elevated", "throughout", "the", "study", ".", "Overall", ",", "these", "findings", "indicate", "that", "VPA", "treatment", "results", "in", "oxidative", "stress", ",", "as", "measured", "by", "levels", "of", "15", "-", "F", "(", "2t", ")", "-", "IsoP", ",", "which", "precedes", "the", "onset", "of", "necrosis", ",", "steatosis", ",", "and", "elevated", "levels", "of", "serum", "alpha", "-", "GST", "."]], "ner": [[[0, 1, "Chemical"], [15, 16, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [83, 83, "Chemical"], [101, 101, "Chemical"], [188, 188, "Chemical"], [316, 316, "Chemical"], [357, 357, "Chemical"], [11, 12, "Disease"], [89, 89, "Disease"], [246, 247, "Disease"], [285, 285, "Disease"], [299, 299, "Disease"], [383, 383, "Disease"], [302, 302, "Disease"], [385, 385, "Disease"], [55, 62, "Chemical"], [64, 71, "Chemical"], [143, 150, "Chemical"], [170, 177, "Chemical"], [369, 376, "Chemical"], [152, 153, "Chemical"], [155, 155, "Chemical"], [195, 195, "Chemical"], [159, 162, "Chemical"], [164, 164, "Chemical"], [224, 224, "Chemical"], [293, 293, "Disease"], [257, 257, "Chemical"], [327, 331, "Chemical"], [337, 343, "Chemical"]]], "relations": [[[0, 1, 11, 12, "CID"], [0, 1, 89, 89, "CID"], [0, 1, 246, 247, "CID"], [0, 1, 285, 285, "CID"], [15, 16, 11, 12, "CID"], [15, 16, 89, 89, "CID"], [15, 16, 246, 247, "CID"], [15, 16, 285, 285, "CID"], [26, 27, 11, 12, "CID"], [26, 27, 89, 89, "CID"], [26, 27, 246, 247, "CID"], [26, 27, 285, 285, "CID"], [29, 29, 11, 12, "CID"], [29, 29, 89, 89, "CID"], [29, 29, 246, 247, "CID"], [29, 29, 285, 285, "CID"], [83, 83, 11, 12, "CID"], [83, 83, 89, 89, "CID"], [83, 83, 246, 247, "CID"], [83, 83, 285, 285, "CID"], [101, 101, 11, 12, "CID"], [101, 101, 89, 89, "CID"], [101, 101, 246, 247, "CID"], [101, 101, 285, 285, "CID"], [188, 188, 11, 12, "CID"], [188, 188, 89, 89, "CID"], [188, 188, 246, 247, "CID"], [188, 188, 285, 285, "CID"], [316, 316, 11, 12, "CID"], [316, 316, 89, 89, "CID"], [316, 316, 246, 247, "CID"], [316, 316, 285, 285, "CID"], [357, 357, 11, 12, "CID"], [357, 357, 89, 89, "CID"], [357, 357, 246, 247, "CID"], [357, 357, 285, 285, "CID"], [0, 1, 299, 299, "CID"], [0, 1, 383, 383, "CID"], [15, 16, 299, 299, "CID"], [15, 16, 383, 383, "CID"], [26, 27, 299, 299, "CID"], [26, 27, 383, 383, "CID"], [29, 29, 299, 299, "CID"], [29, 29, 383, 383, "CID"], [83, 83, 299, 299, "CID"], [83, 83, 383, 383, "CID"], [101, 101, 299, 299, "CID"], [101, 101, 383, 383, "CID"], [188, 188, 299, 299, "CID"], [188, 188, 383, 383, "CID"], [316, 316, 299, 299, "CID"], [316, 316, 383, 383, "CID"], [357, 357, 299, 299, "CID"], [357, 357, 383, 383, "CID"], [0, 1, 302, 302, "CID"], [0, 1, 385, 385, "CID"], [15, 16, 302, 302, "CID"], [15, 16, 385, 385, "CID"], [26, 27, 302, 302, "CID"], [26, 27, 385, 385, "CID"], [29, 29, 302, 302, "CID"], [29, 29, 385, 385, "CID"], [83, 83, 302, 302, "CID"], [83, 83, 385, 385, "CID"], [101, 101, 302, 302, "CID"], [101, 101, 385, 385, "CID"], [188, 188, 302, 302, "CID"], [188, 188, 385, 385, "CID"], [316, 316, 302, 302, "CID"], [316, 316, 385, 385, "CID"], [357, 357, 302, 302, "CID"], [357, 357, 385, 385, "CID"], [55, 62, 11, 12, "CID"], [55, 62, 89, 89, "CID"], [55, 62, 246, 247, "CID"], [55, 62, 285, 285, "CID"], [64, 71, 11, 12, "CID"], [64, 71, 89, 89, "CID"], [64, 71, 246, 247, "CID"], [64, 71, 285, 285, "CID"], [143, 150, 11, 12, "CID"], [143, 150, 89, 89, "CID"], [143, 150, 246, 247, "CID"], [143, 150, 285, 285, "CID"], [170, 177, 11, 12, "CID"], [170, 177, 89, 89, "CID"], [170, 177, 246, 247, "CID"], [170, 177, 285, 285, "CID"], [369, 376, 11, 12, "CID"], [369, 376, 89, 89, "CID"], [369, 376, 246, 247, "CID"], [369, 376, 285, 285, "CID"], [152, 153, 11, 12, "CID"], [152, 153, 89, 89, "CID"], [152, 153, 246, 247, "CID"], [152, 153, 285, 285, "CID"], [155, 155, 11, 12, "CID"], [155, 155, 89, 89, "CID"], [155, 155, 246, 247, "CID"], [155, 155, 285, 285, "CID"], [195, 195, 11, 12, "CID"], [195, 195, 89, 89, "CID"], [195, 195, 246, 247, "CID"], [195, 195, 285, 285, "CID"], [159, 162, 11, 12, "CID"], [159, 162, 89, 89, "CID"], [159, 162, 246, 247, "CID"], [159, 162, 285, 285, "CID"], [164, 164, 11, 12, "CID"], [164, 164, 89, 89, "CID"], [164, 164, 246, 247, "CID"], [164, 164, 285, 285, "CID"], [224, 224, 11, 12, "CID"], [224, 224, 89, 89, "CID"], [224, 224, 246, 247, "CID"], [224, 224, 285, 285, "CID"]]], "clusters": [], "translated": " <0>丙戊酸</0> I：大鼠体内脂质过氧化生物标志物、<9>肝毒性</9>和<1>丙戊酸</1>代谢物水平的时程。单剂量<2>丙戊酸</2>（<3>VPA</3>），是一种广泛使用的抗癫痫药物，与大鼠的氧化应激有关，最近通过升高的<17>15-F(2t)-异前列烷</17>（<18>15-F(2t)-IsoP</18>）证明。为确定<4>VPA</4>相关氧化应激与<10>肝毒性</10>之间是否存在时间关系，成年雄性Sprague-Dawley大鼠经腹腔注射<5>VPA</5>（500毫克/公斤）或0.9%的生理盐水溶液（溶媒），每天一次，持续2、4、7、10或14天。通过测定血浆和肝脏的<19>15-F(2t)-IsoP</19>、<22>脂质过氧化物</22>（<23>LPO</23>）和<25>硫代巴比妥酸反应物质</25>（<26>TBARs</26>）来评估氧化应激。与对照组相比，<6>VPA</6>治疗第2天后，血浆和肝脏<20>15-F(2t)-IsoP</20>升高并达到稳定水平。直到治疗第7天，肝脏<24>LPO</24>水平才升高（相对于对照升高1.8倍，p<0.05）。肝脏和血浆<27>TBARs</27>直到14天才增加（与对照相比增加2倍，p<0.05）。<11>肝毒性</11>是根据α-<29>谷胱甘肽</29>S-转移酶（α-GST）的血清水平和组织学评估的。到第4天，血清α-GST水平显着升高，这对应于<12>肝毒性</12>，表现为肝包膜<28>炎症</28>、<13>坏死</13>和<15>脂肪变性</15>贯穿整个研究。到第14天，<7>VPA</7>的β-氧化代谢物的肝脏水平下降，而<30>4-ene-VPA</30>和（E）-<31>2,4-二烯-VPA</31>在整个研究过程中没有升高。总的来说，这些发现表明<8>VPA</8>治疗会导致氧化应激，通过<21>15-F(2t)-IsoP</21>水平测量，这会先于<14>坏死发生</14>，<16>脂肪变性</16>，血清α-GST水平升高。", "revised": true}
{"doc_key": "17285209", "sentences": [["Angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "-", "associated", "angioedema", "of", "the", "stomach", "and", "small", "intestine", ":", "a", "case", "report", ".", "This", "is", "a", "case", "report", "on", "a", "45", "-", "year", "old", "African", "-", "American", "female", "with", "newly", "diagnosed", "hypertension", ",", "who", "was", "started", "on", "a", "combination", "pill", "of", "amlodipine", "/", "benazapril", "10", "/", "5", "mg", ".", "The", "very", "next", "day", ",", "she", "presented", "at", "the", "emergency", "room", "(", "ER", ")", "with", "abdominal", "pain", ",", "nausea", "and", "vomiting", ".", "Physical", "exam", ",", "complete", "metabolic", "panel", ",", "and", "hemogram", "were", "in", "the", "normal", "range", ".", "She", "was", "discharged", "from", "the", "ER", "after", "a", "few", "hours", "of", "treatment", "with", "fluid", "and", "analgesics", ".", "However", ",", "she", "returned", "to", "the", "ER", "the", "next", "day", "with", "the", "same", "complaints", ".", "This", "time", "the", "physical", "exam", "was", "significant", "for", "a", "distended", "abdomen", "with", "dullness", "to", "percussion", ".", "CT", "scan", "of", "the", "abdomen", "revealed", "markedly", "thickened", "antrum", "of", "the", "stomach", ",", "duodenum", "and", "jejunum", ",", "along", "with", "fluid", "in", "the", "abdominal", "and", "pelvic", "cavity", ".", "Angiotensin", "-", "converting", "enzyme", "inhibitor", "(", "ACEI", ")", "-", "induced", "angioedema", "was", "suspected", ",", "and", "anti", "-", "hypertensive", "medications", "were", "discontinued", ".", "Her", "symptoms", "improved", "within", "the", "next", "24", "hours", ",", "and", "repeat", "CT", "after", "72", "hours", "revealed", "marked", "improvement", "in", "stomach", "and", "small", "bowel", "thickening", "and", "resolution", "of", "ascites", ".", "The", "recognition", "of", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "and", "angiotensin", "receptor", "blocker", "(", "ARB", ")", "intestinal", "angioedema", "constitutes", "a", "challenge", "to", "primary", "care", "physicians", ",", "internists", ",", "emergency", "room", "personal", "and", "surgeons", "."]], "ner": [[[50, 50, "Chemical"], [10, 10, "Disease"], [180, 180, "Disease"], [238, 239, "Disease"], [52, 52, "Chemical"], [224, 224, "Chemical"], [232, 232, "Chemical"], [40, 40, "Disease"], [187, 187, "Disease"], [73, 74, "Disease"], [76, 76, "Disease"], [78, 78, "Disease"], [219, 219, "Disease"]]], "relations": [[[50, 50, 10, 10, "CID"], [50, 50, 180, 180, "CID"], [50, 50, 238, 239, "CID"], [52, 52, 10, 10, "CID"], [52, 52, 180, 180, "CID"], [52, 52, 238, 239, "CID"]]], "clusters": [], "translated": "血管紧张素转换酶 (ACE) 抑制剂相关的胃和小肠<1>血管性水肿</1>：病例报告。这是一个病例报告，一位 45 岁的非洲裔美国女性新诊断出<7>高血压</7>，她开始服用<0>氨氯地平</0>/<4>苯那普利</4> 10/5 毫克。就在第二天，她因<9>腹痛</9>、<10>恶心</10>和<11>呕吐</11>出现在急诊室 (ER)。身体检查、完整代谢组和血象均在正常范围内。经过几个小时的补液和止痛药治疗后，她从急诊室出院了。然而，她第二天带着同样的抱怨回到了急诊室。这次体格检查显着腹胀伴叩诊浊音。腹部CT扫描显示胃窦、十二指肠和空肠明显增厚，腹腔和盆腔内有积液。怀疑<2>血管性水肿</2>是由血管紧张素转换酶抑制剂 (ACEI) 引起的，停用抗<8>高血压</8>药物。她的症状在接下来的 24 小时内得到改善，72 小时后复查 CT 显示胃和小肠增厚明显改善，<12>腹水</12>消退。<5>血管紧张素</5>转换酶(ACE)和<6>血管紧张素</6>受体阻滞剂 (ARB) 引起的<3>肠血管性水肿</3>的识别对初级保健医师、内科医生、急诊室医生和外科医生构成了挑战。", "revised": true}
{"doc_key": "19642243", "sentences": [["Acute", "renal", "failure", "in", "patients", "with", "AIDS", "on", "tenofovir", "while", "receiving", "prolonged", "vancomycin", "course", "for", "osteomyelitis", ".", "Renal", "failure", "developed", "after", "a", "prolonged", "course", "of", "vancomycin", "therapy", "in", "2", "patients", "who", "were", "receiving", "tenofovir", "disoproxil", "fumarate", "as", "part", "of", "an", "antiretroviral", "regimen", ".", "Tenofovir", "has", "been", "implicated", "in", "the", "development", "of", "Fanconi", "syndrome", "and", "renal", "insufficiency", "because", "of", "its", "effects", "on", "the", "proximal", "renal", "tubule", ".", "Vancomycin", "nephrotoxicity", "is", "infrequent", "but", "may", "result", "from", "coadministration", "with", "a", "nephrotoxic", "agent", ".", "Clinicians", "should", "be", "aware", "that", "tenofovir", "may", "raise", "the", "risk", "of", "renal", "failure", "during", "prolonged", "administration", "of", "vancomycin", "."]], "ner": [[[12, 12, "Chemical"], [25, 25, "Chemical"], [66, 66, "Chemical"], [97, 97, "Chemical"], [0, 2, "Disease"], [33, 35, "Chemical"], [8, 8, "Chemical"], [43, 43, "Chemical"], [85, 85, "Chemical"], [6, 6, "Disease"], [15, 15, "Disease"], [17, 18, "Disease"], [54, 55, "Disease"], [91, 92, "Disease"], [51, 52, "Disease"], [67, 67, "Disease"], [77, 77, "Disease"]]], "relations": [[[12, 12, 0, 2, "CID"], [25, 25, 0, 2, "CID"], [66, 66, 0, 2, "CID"], [97, 97, 0, 2, "CID"], [33, 35, 0, 2, "CID"]]], "clusters": [], "translated": "<4>急性肾功能衰竭</4> 在<9>艾滋病</9>患者接受<6>替诺福韦</6>治疗期间同时接受长期<0>万古霉素</0>治疗<10>骨髓炎</10>。长期接受<1>万古霉素</1>治疗的2名<5>富马酸替诺福韦二吡呋酯</5>作为抗逆转录病毒治疗方案的患者，发生<11>肾功能衰竭</11>。<7>替诺福韦</7>的影响在于它对近端肾小管的影响，会导致<14>范可尼综合征</14>和<12>肾功能不全</12>。虽然<2>万古霉素</2>的<15>肾毒性</15>很少见，但与<16>肾毒性</16>药物合用可能有关。临床医生应注意，长期接受<3>万古霉素</3>治疗期间，<8>替诺福韦</8>可能会增加<13>肾功能衰竭</13>的风险。", "revised": true}
{"doc_key": "625456", "sentences": [["Obsolete", "but", "dangerous", "antacid", "preparations", ".", "One", "case", "of", "acute", "hypercalcaemia", "and", "two", "of", "recurrent", "nephrolithiasis", "are", "reported", "in", "patients", "who", "had", "regularly", "consumed", "large", "amounts", "of", "calcium", "carbon", "-", "ate", "-", "sodium", "bicarbonate", "powders", "for", "more", "than", "20", "years", ".", "The", "powders", "had", "been", "obtained", "from", "pharmacists", "unknown", "to", "the", "patients", "'", "medical", "practitioners", ".", "It", "is", "suggested", "that", "these", "preparations", "were", "responsible", "for", "the", "patient", "'s", "problems", ",", "and", "that", "such", "powders", "should", "no", "longer", "be", "freely", "obtainable", "."]], "ner": [[[27, 30, "Chemical"], [10, 10, "Disease"], [32, 33, "Chemical"], [15, 15, "Disease"]]], "relations": [[[27, 30, 10, 10, "CID"], [32, 33, 10, 10, "CID"], [27, 30, 15, 15, "CID"], [32, 33, 15, 15, "CID"]]], "clusters": [], "translated": "过时但危险的抗酸剂制剂。定期服用大量<0>碳酸钙</0>-<2>碳酸氢钠</2>粉末的患者报告了1例急性<1>高钙血症</1>和2例复发性<3>肾结石</3>，碳酸氢钠粉末已有20多年历史。这些粉末是从患者的医生不认识的药剂师那里获得的。有人认为这些制剂是导致患者出现问题的原因，不应再随意获得此类粉末。", "revised": true}
{"doc_key": "16006300", "sentences": [["Calcium", "carbonate", "toxicity", ":", "the", "updated", "milk", "-", "alkali", "syndrome", ";", "report", "of", "3", "cases", "and", "review", "of", "the", "literature", ".", "OBJECTIVE", ":", "To", "describe", "3", "patients", "with", "calcium", "carbonate", "-", "induced", "hypercalcemia", "and", "gain", "insights", "into", "the", "cause", "and", "management", "of", "the", "milk", "-", "alkali", "syndrome", ".", "METHODS", ":", "We", "report", "the", "clinical", "and", "laboratory", "data", "in", "3", "patients", "who", "presented", "with", "severe", "hypercalcemia", "(", "corrected", "serum", "calcium", ">", "or", "=", "14", "mg", "/", "dL", ")", "and", "review", "the", "pertinent", "literature", "on", "milk", "-", "alkali", "syndrome", ".", "RESULTS", ":", "The", "3", "patients", "had", "acute", "renal", "insufficiency", ",", "relative", "metabolic", "alkalosis", ",", "and", "low", "parathyroid", "hormone", "(", "PTH", ")", ",", "PTH", "-", "related", "peptide", ",", "and", "1", ",", "25", "-", "dihydroxyvitamin", "D", "concentrations", ".", "No", "malignant", "lesion", "was", "found", ".", "Treatment", "included", "aggressive", "hydration", "and", "varied", "amounts", "of", "furosemide", ".", "The", "2", "patients", "with", "the", "higher", "serum", "calcium", "concentrations", "received", "pamidronate", "intravenously", "(", "60", "and", "30", "mg", ",", "respectively", ")", ",", "which", "caused", "severe", "hypocalcemia", ".", "Of", "the", "3", "patients", ",", "2", "were", "ingesting", "acceptable", "doses", "of", "elemental", "calcium", "(", "1", "g", "and", "2", "g", "daily", ",", "respectively", ")", "in", "the", "form", "of", "calcium", "carbonate", ".", "In", "addition", "to", "our", "highlighted", "cases", ",", "we", "review", "the", "history", ",", "classification", ",", "pathophysiologic", "features", ",", "and", "treatment", "of", "milk", "-", "alkali", "syndrome", "and", "summarize", "the", "cases", "reported", "from", "early", "1995", "to", "November", "2003", ".", "CONCLUSION", ":", "Milk", "-", "alkali", "syndrome", "may", "be", "a", "common", "cause", "of", "unexplained", "hypercalcemia", "and", "can", "be", "precipitated", "by", "small", "amounts", "of", "orally", "ingested", "calcium", "carbonate", "in", "susceptible", "persons", ".", "Treatment", "with", "hydration", ",", "furosemide", ",", "and", "discontinuation", "of", "the", "calcium", "and", "vitamin", "D", "source", "is", "adequate", ".", "Pamidronate", "treatment", "is", "associated", "with", "considerable", "risk", "for", "hypocalcemia", ",", "even", "in", "cases", "of", "initially", "severe", "hypercalcemia", "."]], "ner": [[[0, 1, "Chemical"], [28, 29, "Chemical"], [193, 194, "Chemical"], [256, 257, "Chemical"], [6, 9, "Disease"], [32, 32, "Disease"], [43, 46, "Disease"], [64, 64, "Disease"], [83, 86, "Disease"], [216, 219, "Disease"], [234, 237, "Disease"], [245, 245, "Disease"], [296, 296, "Disease"], [150, 150, "Chemical"], [280, 280, "Chemical"], [164, 164, "Disease"], [288, 288, "Disease"], [2, 2, "Disease"], [94, 96, "Disease"], [99, 100, "Disease"], [68, 68, "Chemical"], [147, 147, "Chemical"], [178, 178, "Chemical"], [272, 272, "Chemical"], [116, 121, "Chemical"], [138, 138, "Chemical"], [266, 266, "Chemical"], [274, 275, "Chemical"]]], "relations": [[[0, 1, 6, 9, "CID"], [0, 1, 32, 32, "CID"], [0, 1, 43, 46, "CID"], [0, 1, 64, 64, "CID"], [0, 1, 83, 86, "CID"], [0, 1, 216, 219, "CID"], [0, 1, 234, 237, "CID"], [0, 1, 245, 245, "CID"], [0, 1, 296, 296, "CID"], [28, 29, 6, 9, "CID"], [28, 29, 32, 32, "CID"], [28, 29, 43, 46, "CID"], [28, 29, 64, 64, "CID"], [28, 29, 83, 86, "CID"], [28, 29, 216, 219, "CID"], [28, 29, 234, 237, "CID"], [28, 29, 245, 245, "CID"], [28, 29, 296, 296, "CID"], [193, 194, 6, 9, "CID"], [193, 194, 32, 32, "CID"], [193, 194, 43, 46, "CID"], [193, 194, 64, 64, "CID"], [193, 194, 83, 86, "CID"], [193, 194, 216, 219, "CID"], [193, 194, 234, 237, "CID"], [193, 194, 245, 245, "CID"], [193, 194, 296, 296, "CID"], [256, 257, 6, 9, "CID"], [256, 257, 32, 32, "CID"], [256, 257, 43, 46, "CID"], [256, 257, 64, 64, "CID"], [256, 257, 83, 86, "CID"], [256, 257, 216, 219, "CID"], [256, 257, 234, 237, "CID"], [256, 257, 245, 245, "CID"], [256, 257, 296, 296, "CID"], [150, 150, 164, 164, "CID"], [150, 150, 288, 288, "CID"], [280, 280, 164, 164, "CID"], [280, 280, 288, 288, "CID"]]], "clusters": [], "translated": "<0>碳酸钙</0> <17>毒性</17>：最新的<4>乳碱综合症</4>；报告 3 例并文献复习。目的：描述 3 例<1> 碳酸钙</1>诱发的<5>高钙血症</5>患者，并深入了解<6>乳碱综合症</6>的病因和治疗。方法：报告 3 例严重<7>高钙血症</7>（纠正后血清<20>钙</20>≥14 mg/dL）的临床和实验室数据，并回顾有关<8>乳碱综合症</8>的相关文献。结果：3例患者均有<18>急性肾功能不全</18>、相对的<19>代谢性碱中毒</19>和甲状旁腺激素（PTH）、PTH 相关肽及<24>1,25-二羟基维生素 D</24>浓度偏低。未发现恶性病变。治疗包括积极的补液和不同量的<25>呋塞米</25>。其中，血清<21>钙</21>较高的 2 例患者分别接受静脉注射<13>帕米膦酸盐</13>（60 和 30 mg），导致严重的<15>低钙血症</15>。3例患者中有 2 名接受了可接受的元素<22>钙</22>（分别为每天 1 g 和 2 g）以<2>碳酸钙</2>的形式。除了突出的病例外，我们还回顾了<9>乳碱综合症</9>的历史、分类、病理生理特征和治疗，并总结了 1995 年至 2003 年 11 月间报道的病例。结论：<10>乳碱综合症</10>可能是不明原因的<11>高钙血症</11>的常见原因，并且易受口服少量<3>碳酸钙</3>的人患此病。治疗包括积极的补液，<26>呋塞米</26>和停止<23>钙</23>和<27>维生素D</27>的来源即可。<14>帕米膦酸盐</14>的治疗与相当大的<16>低钙血症</16>风险相关，甚至在最初严重的<12>高钙血症</12>情况下也是如此。", "revised": true}
{"doc_key": "7910951", "sentences": [["Prolonged", "paralysis", "due", "to", "nondepolarizing", "neuromuscular", "blocking", "agents", "and", "corticosteroids", ".", "The", "long", "-", "term", "use", "of", "nondepolarizing", "neuromuscular", "blocking", "agents", "(", "ND", "-", "NMBA", ")", "has", "recently", "been", "implicated", "as", "a", "cause", "of", "prolonged", "muscle", "weakness", ",", "although", "the", "site", "of", "the", "lesion", "and", "the", "predisposing", "factors", "have", "been", "unclear", ".", "We", "report", "3", "patients", "(", "age", "37", "-", "52", "years", ")", "with", "acute", "respiratory", "insufficiency", "who", "developed", "prolonged", "weakness", "following", "the", "discontinuation", "of", "ND", "-", "NMBAs", ".", "Two", "patients", "also", "received", "intravenous", "corticosteroids", ".", "Renal", "function", "was", "normal", "but", "hepatic", "function", "was", "impaired", "in", "all", "patients", ",", "and", "all", "had", "acidosis", ".", "Electrophysiologic", "studies", "revealed", "low", "amplitude", "compound", "motor", "action", "potentials", ",", "normal", "sensory", "studies", ",", "and", "fibrillations", ".", "Repetitive", "stimulation", "at", "2", "Hz", "showed", "a", "decremental", "response", "in", "2", "patients", ".", "The", "serum", "vecuronium", "level", "measured", "in", "1", "patient", "14", "days", "after", "the", "drug", "had", "been", "discontinued", "was", "172", "ng", "/", "mL", ".", "A", "muscle", "biopsy", "in", "this", "patient", "showed", "loss", "of", "thick", ",", "myosin", "filaments", ".", "The", "weakness", "in", "these", "patients", "is", "due", "to", "pathology", "at", "both", "the", "neuromuscular", "junction", "(", "most", "likely", "due", "to", "ND", "-", "NMBA", ")", "and", "muscle", "(", "most", "likely", "due", "to", "corticosteroids", ")", ".", "Hepatic", "dysfunction", "and", "acidosis", "are", "contributing", "risk", "factors", "."]], "ner": [[[4, 7, "Chemical"], [17, 20, "Chemical"], [22, 24, "Chemical"], [75, 77, "Chemical"], [189, 191, "Chemical"], [35, 36, "Disease"], [70, 70, "Disease"], [171, 171, "Disease"], [178, 183, "Disease"], [9, 9, "Chemical"], [84, 84, "Chemical"], [200, 200, "Chemical"], [163, 168, "Disease"], [1, 1, "Disease"], [136, 136, "Chemical"], [65, 66, "Disease"], [102, 102, "Disease"], [206, 206, "Disease"], [203, 204, "Disease"]]], "relations": [[[4, 7, 35, 36, "CID"], [4, 7, 70, 70, "CID"], [4, 7, 171, 171, "CID"], [17, 20, 35, 36, "CID"], [17, 20, 70, 70, "CID"], [17, 20, 171, 171, "CID"], [22, 24, 35, 36, "CID"], [22, 24, 70, 70, "CID"], [22, 24, 171, 171, "CID"], [75, 77, 35, 36, "CID"], [75, 77, 70, 70, "CID"], [75, 77, 171, 171, "CID"], [189, 191, 35, 36, "CID"], [189, 191, 70, 70, "CID"], [189, 191, 171, 171, "CID"], [4, 7, 178, 183, "CID"], [17, 20, 178, 183, "CID"], [22, 24, 178, 183, "CID"], [75, 77, 178, 183, "CID"], [189, 191, 178, 183, "CID"], [9, 9, 163, 168, "CID"], [84, 84, 163, 168, "CID"], [200, 200, 163, 168, "CID"]]], "clusters": [], "translated": "由于<0>非去极化神经肌肉阻滞剂 </0>和<9>皮质类固醇 </9>导致长期<13>瘫痪</13>。长期使用<1>非去极化神经肌肉阻滞剂</1> (<2>ND-NMBA</2>)最近被认为是长期<5>肌肉无力</5>的原因，尽管病变部位及诱发因素一直不清楚。我们报告了3名患有急性<15>呼吸功能不全</15>的患者（年龄37-52岁），他们在停用<3>ND-NMBAs</3>后出现长期<6>无力</6>。两名患者还接受了静脉注射<10>皮质类固醇</10>。所有患者肾功能正常，肝功能受损，均有<16>酸中毒</16>。电生理学研究显示低振幅复合运动动作电位、正常感觉研究和颤动。重复刺激在2Hz的刺激中，有2名患者呈递减反应。1名患者停药14天后测得的血清<14>维库溴铵</14>水平为172 ng/mL。该患者的肌肉活检显示<12>粗肌球蛋白丝缺失</12>。这些患者的<7>无力</7>是由于<8>神经肌肉接头</8>（很可能是由于<4>ND-NMBA</4>）和肌肉（很可能是由于<11>皮质类固醇</11>）。<18>肝功能障碍</18>和<17>酸中毒</17>是促成危险因素。", "revised": true}
{"doc_key": "16725121", "sentences": [["Down", "-", "regulation", "of", "norepinephrine", "transporter", "function", "induced", "by", "chronic", "administration", "of", "desipramine", "linking", "to", "the", "alteration", "of", "sensitivity", "of", "local", "-", "anesthetics", "-", "induced", "convulsions", "and", "the", "counteraction", "by", "co", "-", "administration", "with", "local", "anesthetics", ".", "Alterations", "of", "norepinephrine", "transporter", "(", "NET", ")", "function", "by", "chronic", "inhibition", "of", "NET", "in", "relation", "to", "sensitization", "to", "seizures", "induce", "by", "cocaine", "and", "local", "anesthetics", "were", "studied", "in", "mice", ".", "Daily", "administration", "of", "desipramine", ",", "an", "inhibitor", "of", "the", "NET", ",", "for", "5", "days", "decreased", "[", "(", "3", ")", "H", "]", "norepinephrine", "uptake", "in", "the", "P2", "fractions", "of", "hippocampus", "but", "not", "cortex", ",", "striatum", "or", "amygdalae", ".", "Co", "-", "administration", "of", "lidocaine", ",", "bupivacaine", "or", "tricaine", "with", "desipramine", "reversed", "this", "effect", ".", "Daily", "treatment", "of", "cocaine", "increased", "[", "(", "3", ")", "H", "]", "norepinephrine", "uptake", "into", "the", "hippocampus", ".", "Daily", "administration", "of", "desipramine", "increased", "the", "incidence", "of", "appearance", "of", "lidocaine", "-", "induced", "convulsions", "and", "decreased", "that", "of", "cocaine", "-", "induced", "convulsions", ".", "Co", "-", "administration", "of", "lidocaine", "with", "desipramine", "reversed", "the", "changes", "of", "convulsive", "activity", "of", "lidocaine", "and", "cocaine", "induced", "by", "repeated", "administration", "of", "desipramine", ".", "These", "results", "suggest", "that", "down", "-", "regulation", "of", "hippocampal", "NET", "induced", "by", "chronic", "administration", "of", "desipramine", "may", "be", "relevant", "to", "desipramine", "-", "induced", "sensitization", "of", "lidocaine", "convulsions", ".", "Inhibition", "of", "Na", "(", "+", ")", "channels", "by", "local", "anesthetics", "may", "regulate", "desipramine", "-", "induced", "down", "-", "regulation", "of", "NET", "function", ".", "Repeated", "administration", "of", "cocaine", "induces", "up", "-", "regulation", "of", "hippocampal", "NET", "function", ".", "Desipramine", "-", "induced", "sensitization", "of", "lidocaine", "seizures", "may", "have", "a", "mechanism", "distinct", "from", "kindling", "resulting", "from", "repeated", "administration", "of", "cocaine", "."]], "ner": [[[58, 58, "Chemical"], [122, 122, "Chemical"], [154, 154, "Chemical"], [175, 175, "Chemical"], [236, 236, "Chemical"], [265, 265, "Chemical"], [25, 25, "Disease"], [55, 55, "Disease"], [149, 149, "Disease"], [157, 157, "Disease"], [170, 170, "Disease"], [209, 209, "Disease"], [252, 252, "Disease"], [108, 108, "Chemical"], [146, 146, "Chemical"], [163, 163, "Chemical"], [173, 173, "Chemical"], [208, 208, "Chemical"], [251, 251, "Chemical"], [4, 4, "Chemical"], [39, 39, "Chemical"], [88, 88, "Chemical"], [130, 130, "Chemical"], [12, 12, "Chemical"], [70, 70, "Chemical"], [114, 114, "Chemical"], [139, 139, "Chemical"], [165, 165, "Chemical"], [181, 181, "Chemical"], [198, 198, "Chemical"], [203, 203, "Chemical"], [223, 223, "Chemical"], [246, 246, "Chemical"], [110, 110, "Chemical"], [112, 112, "Chemical"], [213, 213, "Chemical"]]], "relations": [[[58, 58, 25, 25, "CID"], [58, 58, 55, 55, "CID"], [58, 58, 149, 149, "CID"], [58, 58, 157, 157, "CID"], [58, 58, 170, 170, "CID"], [58, 58, 209, 209, "CID"], [58, 58, 252, 252, "CID"], [122, 122, 25, 25, "CID"], [122, 122, 55, 55, "CID"], [122, 122, 149, 149, "CID"], [122, 122, 157, 157, "CID"], [122, 122, 170, 170, "CID"], [122, 122, 209, 209, "CID"], [122, 122, 252, 252, "CID"], [154, 154, 25, 25, "CID"], [154, 154, 55, 55, "CID"], [154, 154, 149, 149, "CID"], [154, 154, 157, 157, "CID"], [154, 154, 170, 170, "CID"], [154, 154, 209, 209, "CID"], [154, 154, 252, 252, "CID"], [175, 175, 25, 25, "CID"], [175, 175, 55, 55, "CID"], [175, 175, 149, 149, "CID"], [175, 175, 157, 157, "CID"], [175, 175, 170, 170, "CID"], [175, 175, 209, 209, "CID"], [175, 175, 252, 252, "CID"], [236, 236, 25, 25, "CID"], [236, 236, 55, 55, "CID"], [236, 236, 149, 149, "CID"], [236, 236, 157, 157, "CID"], [236, 236, 170, 170, "CID"], [236, 236, 209, 209, "CID"], [236, 236, 252, 252, "CID"], [265, 265, 25, 25, "CID"], [265, 265, 55, 55, "CID"], [265, 265, 149, 149, "CID"], [265, 265, 157, 157, "CID"], [265, 265, 170, 170, "CID"], [265, 265, 209, 209, "CID"], [265, 265, 252, 252, "CID"], [108, 108, 25, 25, "CID"], [108, 108, 55, 55, "CID"], [108, 108, 149, 149, "CID"], [108, 108, 157, 157, "CID"], [108, 108, 170, 170, "CID"], [108, 108, 209, 209, "CID"], [108, 108, 252, 252, "CID"], [146, 146, 25, 25, "CID"], [146, 146, 55, 55, "CID"], [146, 146, 149, 149, "CID"], [146, 146, 157, 157, "CID"], [146, 146, 170, 170, "CID"], [146, 146, 209, 209, "CID"], [146, 146, 252, 252, "CID"], [163, 163, 25, 25, "CID"], [163, 163, 55, 55, "CID"], [163, 163, 149, 149, "CID"], [163, 163, 157, 157, "CID"], [163, 163, 170, 170, "CID"], [163, 163, 209, 209, "CID"], [163, 163, 252, 252, "CID"], [173, 173, 25, 25, "CID"], [173, 173, 55, 55, "CID"], [173, 173, 149, 149, "CID"], [173, 173, 157, 157, "CID"], [173, 173, 170, 170, "CID"], [173, 173, 209, 209, "CID"], [173, 173, 252, 252, "CID"], [208, 208, 25, 25, "CID"], [208, 208, 55, 55, "CID"], [208, 208, 149, 149, "CID"], [208, 208, 157, 157, "CID"], [208, 208, 170, 170, "CID"], [208, 208, 209, 209, "CID"], [208, 208, 252, 252, "CID"], [251, 251, 25, 25, "CID"], [251, 251, 55, 55, "CID"], [251, 251, 149, 149, "CID"], [251, 251, 157, 157, "CID"], [251, 251, 170, 170, "CID"], [251, 251, 209, 209, "CID"], [251, 251, 252, 252, "CID"]]], "clusters": [], "translated": "<23>地昔帕明</23>慢性给药引起的<19>去甲肾上腺素</19>转运蛋白功能下调与局麻药引起的<6>惊厥</6>敏感性的改变及其反作用与局麻药合用。在小鼠中研究了<20>去甲肾上腺素</20>转运体(NET)功能的改变，该功能通过慢性抑制NET与<0>可卡因</0>和局部麻醉剂诱导的<7>癫痫发作</7>的敏感性相关。每天服用NET抑制剂<24>地昔帕明</24>，持续5天后，海马体P2部分而非皮质、纹状体或杏仁核的[(3)H]<21>去甲肾上腺素</21>摄取减少。<13>利多卡因</13>、<33>布比卡因</33>或<34>三卡因</34>与<25>地昔帕明</25>的共同给药逆转了这种作用。<1>可卡因</1>的每日治疗增加了[(3)H]<22>去甲肾上腺素</22>进入海马体的摄取。每日服用<26>地昔帕明</26>可增加<14>利多卡因</14>引起的<8>抽搐</8>的发生率，减少<2>可卡因</2>引起的<9>抽搐</9>。与<27>地昔帕明</27>反复给予<28>地昔帕明</28>后，共同给药<15>利多卡因</15>可逆转反复给予<28>地昔帕明</28>诱导的<16>利多卡因</16>和<3>可卡因</3>引起的<10>惊厥</10>活性的变化。这些结果表明，长期服用<29>地昔帕明</29>诱导的海马NET下调可能与<30>地昔帕明</30>诱导的<17>利多卡因</17>致敏<11>抽搐</11>有关。局麻药对<35>Na</35>(+)通道的抑制可能调节<31>地昔帕明</31>诱导的NET功能下调。反复给予<4>可卡因</4>诱导海马NET功能的上调。<32>地昔帕明</32>-诱导的<18>利多卡因</18>致敏<12>癫痫发作</12>的机制可能不同于因重复施用<5>可卡因</5>而引起的点燃。", "revised": true}
{"doc_key": "3732088", "sentences": [["Diuretics", ",", "potassium", "and", "arrhythmias", "in", "hypertensive", "coronary", "disease", ".", "It", "has", "been", "proposed", "that", "modest", "changes", "in", "plasma", "potassium", "can", "alter", "the", "tendency", "towards", "cardiac", "arrhythmias", ".", "If", "this", "were", "so", ",", "patients", "with", "coronary", "artery", "disease", "might", "be", "especially", "susceptible", ".", "Thus", ",", "myocardial", "electrical", "excitability", "was", "measured", "in", "patients", "with", "mild", "essential", "hypertension", "and", "known", "coronary", "artery", "disease", "after", "8", "weeks", "of", "treatment", "with", "a", "potassium", "-", "conserving", "diuretic", "(", "amiloride", ")", "and", "a", "similar", "period", "on", "a", "potassium", "-", "losing", "diuretic", "(", "chlorthalidone", ")", "in", "a", "randomised", "study", ".", "Plasma", "potassium", "concentrations", "were", "on", "average", "1", "mmol", "/", "L", "lower", "during", "the", "chlorthalidone", "phase", "compared", "to", "amiloride", "therapy", ".", "Blood", "pressure", "and", "volume", "states", "as", "assessed", "by", "bodyweight", ",", "plasma", "renin", "and", "noradrenaline", "(", "norepinephrine", ")", "concentrations", "were", "similar", "on", "the", "2", "regimens", ".", "Compared", "to", "amiloride", "treatment", ",", "the", "chlorthalidone", "phase", "was", "associated", "with", "an", "increased", "frequency", "of", "ventricular", "ectopic", "beats", "(", "24", "-", "hour", "Holter", "monitoring", ")", "and", "a", "higher", "Lown", "grading", ",", "increased", "upslope", "and", "duration", "of", "the", "monophasic", "action", "potential", ",", "prolonged", "ventricular", "effective", "refractory", "period", ",", "and", "increased", "electrical", "instability", "during", "programmed", "ventricular", "stimulation", ".", "The", "above", "results", "indicate", "that", "because", "potassium", "-", "losing", "diuretic", "therapy", "can", "increase", "myocardial", "electrical", "excitability", "in", "patients", "with", "ischaemic", "heart", "disease", ",", "even", "minor", "falls", "in", "plasma", "potassium", "concentrations", "are", "probably", "best", "avoided", "in", "such", "patients", "."]], "ner": [[[86, 86, "Chemical"], [106, 106, "Chemical"], [144, 144, "Chemical"], [153, 155, "Disease"], [2, 2, "Chemical"], [19, 19, "Chemical"], [68, 68, "Chemical"], [81, 81, "Chemical"], [94, 94, "Chemical"], [200, 200, "Chemical"], [222, 222, "Chemical"], [4, 4, "Disease"], [25, 26, "Disease"], [6, 6, "Disease"], [55, 55, "Disease"], [7, 8, "Disease"], [35, 37, "Disease"], [58, 60, "Disease"], [213, 215, "Disease"], [73, 73, "Chemical"], [110, 110, "Chemical"], [140, 140, "Chemical"], [126, 126, "Chemical"], [128, 128, "Chemical"]]], "relations": [[[86, 86, 153, 155, "CID"], [106, 106, 153, 155, "CID"], [144, 144, 153, 155, "CID"]]], "clusters": [], "translated": "利尿剂、<4>钾</4>和<11>心律失常</11>在<13>高血压</13>和<15>冠心病</15>中。有人提出，血浆<5>钾</5>的适度变化可以改变<12>心律失常</12>的趋势。如果真是这样，<16>冠状动脉疾病</16>患者可能特别容易受到影响。因此，在使用<6>保钾</6>利尿剂( <19>阿米洛利</19> )治疗 8 周后，轻度原发性<14>高血压</14>和已知<17>冠状动脉疾病</17>患者的心肌电兴奋性被测量，并在类似时期对<7>失钾</7>利尿剂(<0>氯噻酮</0>)进行了随机研究。与<20>阿米洛利</20>治疗相比，<1>氯噻酮</1>期血浆<8>钾</8>浓度平均低1 mmol/L。通过体重、血浆肾素和<22>去甲肾上腺素</22>（<23>去甲肾上腺素</23>）浓度评估的血压和容量状态在两种方案中相似。与<21>阿米洛利</21>治疗相比，<2>氯噻酮</2>期与<3>室性异位搏动</3>频率增加（24小时动态心电图监测）和更高的Lown有关分级，单相动作电位的上斜率和持续时间增加，心室有效不应期延长，以及程序性心室刺激期间电不稳定性增加。上述结果表明，由于<9>失钾</9>利尿剂治疗可增加<18>缺血性心脏病</18>患者的心肌电兴奋性，因此，在此类患者中最好避免血浆<10>钾</10>浓度轻​​度下降。", "revised": true}
{"doc_key": "2533791", "sentences": [["National", "project", "on", "the", "prevention", "of", "mother", "-", "to", "-", "infant", "infection", "by", "hepatitis", "B", "virus", "in", "Japan", ".", "In", "Japan", ",", "a", "nationwide", "prevention", "program", "against", "mother", "-", "to", "-", "infant", "infection", "by", "hepatitis", "B", "virus", "(", "HBV", ")", "started", "in", "1985", ".", "This", "program", "consists", "of", "double", "screenings", "of", "pregnant", "women", "and", "prophylactic", "treatment", "to", "the", "infants", "born", "to", "both", "hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "and", "hepatitis", "B", "e", "antigen", "(", "HBeAg", ")", "positive", "mothers", ".", "These", "infants", "are", "treated", "with", "two", "injections", "of", "hepatitis", "B", "immune", "globulin", "(", "HBIG", ")", "and", "at", "least", "three", "injections", "of", "plasma", "derived", "hepatitis", "B", "vaccine", ".", "We", "sent", "questionnaires", "about", "the", "numbers", "of", "each", "procedure", "or", "examination", "during", "nine", "months", "of", "investigation", "period", "to", "each", "local", "government", "in", "1986", "and", "1987", ".", "93", ".", "4", "%", "pregnant", "women", "had", "the", "chance", "to", "be", "examined", "for", "HBsAg", ",", "and", "the", "positive", "rate", "was", "1", ".", "4", "to", "1", ".", "5", "%", ".", "The", "HBeAg", "positive", "rate", "in", "HBsAg", "positive", "was", "23", "to", "26", "%", ".", "The", "HBsAg", "positive", "rate", "in", "neonates", "and", "in", "infants", "before", "two", "months", "were", "3", "%", "and", "2", "%", "respectively", ".", "Some", "problems", "may", "arise", ",", "because", "27", "to", "30", "%", "of", "infants", "need", "the", "fourth", "vaccination", "in", "some", "restricted", "areas", "."]], "ner": [[[62, 65, "Chemical"], [67, 67, "Chemical"], [146, 146, "Chemical"], [167, 167, "Chemical"], [176, 176, "Chemical"], [11, 15, "Disease"], [32, 36, "Disease"], [88, 89, "Disease"], [70, 73, "Chemical"], [75, 75, "Chemical"], [163, 163, "Chemical"], [103, 105, "Chemical"]]], "relations": [[[62, 65, 11, 15, "CID"], [62, 65, 32, 36, "CID"], [62, 65, 88, 89, "CID"], [67, 67, 11, 15, "CID"], [67, 67, 32, 36, "CID"], [67, 67, 88, 89, "CID"], [146, 146, 11, 15, "CID"], [146, 146, 32, 36, "CID"], [146, 146, 88, 89, "CID"], [167, 167, 11, 15, "CID"], [167, 167, 32, 36, "CID"], [167, 167, 88, 89, "CID"], [176, 176, 11, 15, "CID"], [176, 176, 32, 36, "CID"], [176, 176, 88, 89, "CID"], [70, 73, 11, 15, "CID"], [70, 73, 32, 36, "CID"], [70, 73, 88, 89, "CID"], [75, 75, 11, 15, "CID"], [75, 75, 32, 36, "CID"], [75, 75, 88, 89, "CID"], [163, 163, 11, 15, "CID"], [163, 163, 32, 36, "CID"], [163, 163, 88, 89, "CID"]]], "clusters": [], "translated": "日本预防母婴<5>乙型肝炎病毒感染</5>国家计划。日本于1985年启动了一项全国性的预防母婴<6>感染乙型肝炎病毒</6>（HBV）的计划。该计划包括对孕妇的双重筛查和对<0>乙型肝炎表面抗原</0>（<1>HBsAg</1>）和<8>乙型肝炎e抗原</8>（<9>HBeAg</9>）阳性的母亲的预防性治疗。这些婴儿接受两次<7>乙型肝炎</7>免疫球蛋白（HBIG）注射和至少三次血浆衍生<11>乙型肝炎疫苗</11>治疗。我们在1986年和1987年向每个地方政府发送了关于在九个月的调查期间每个程序或检查的数量的问卷。93.4%的孕妇有机会接受<2>HBsAg</2>检查，阳性率为1.4比1.5%。在<3>HBsAg</3>阳性中，<10>HBeAg</10>阳性率为23～26%。新生儿和两个月前婴儿<4>HBsAg</4>阳性率分别为3%和2%。可能会出现一些问题，因为在某些限制区域，有27%到30%的婴儿需要进行第四次疫苗接种。", "revised": true}
{"doc_key": "2322844", "sentences": [["Nociceptive", "effects", "induced", "by", "intrathecal", "administration", "of", "prostaglandin", "D2", ",", "E2", ",", "or", "F2", "alpha", "to", "conscious", "mice", ".", "The", "effects", "of", "intrathecal", "administration", "of", "prostaglandins", "on", "pain", "responses", "in", "conscious", "mice", "were", "evaluated", "by", "using", "hot", "plate", "and", "acetic", "acid", "writhing", "tests", ".", "Prostaglandin", "D2", "(", "0", ".", "5", "-", "3", "ng", "/", "mouse", ")", "had", "a", "hyperalgesic", "action", "on", "the", "response", "to", "a", "hot", "plate", "during", "a", "3", "-", "60", "min", "period", "after", "injection", ".", "Prostaglandin", "E2", "showed", "a", "hyperalgesic", "effect", "at", "doses", "of", "1", "pg", "to", "10", "ng", "/", "mouse", ",", "but", "the", "effect", "lasted", "shorter", "(", "3", "-", "30", "min", ")", "than", "that", "of", "prostaglandin", "D2", ".", "Similar", "results", "were", "obtained", "by", "acetic", "acid", "writhing", "tests", ".", "The", "hyperalgesic", "effect", "of", "prostaglandin", "D2", "was", "blocked", "by", "simultaneous", "injection", "of", "a", "substance", "P", "antagonist", "(", "greater", "than", "or", "equal", "to", "100", "ng", ")", "but", "not", "by", "AH6809", ",", "a", "prostanoid", "EP1", "-", "receptor", "antagonist", ".", "Conversely", ",", "prostaglandin", "E2", "-", "induced", "hyperalgesia", "was", "blocked", "by", "AH6809", "(", "greater", "than", "or", "equal", "to", "500", "ng", ")", "but", "not", "by", "the", "substance", "P", "antagonist", ".", "Prostaglandin", "F2", "alpha", "had", "little", "effect", "on", "pain", "responses", ".", "These", "results", "demonstrate", "that", "both", "prostaglandin", "D2", "and", "prostaglandin", "E2", "exert", "hyperalgesia", "in", "the", "spinal", "cord", ",", "but", "in", "different", "ways", "."]], "ner": [[[7, 14, "Chemical"], [44, 45, "Chemical"], [108, 109, "Chemical"], [125, 126, "Chemical"], [201, 202, "Chemical"], [58, 58, "Disease"], [81, 81, "Disease"], [122, 122, "Disease"], [164, 164, "Disease"], [207, 207, "Disease"], [77, 78, "Chemical"], [160, 161, "Chemical"], [204, 205, "Chemical"], [27, 27, "Disease"], [193, 193, "Disease"], [186, 188, "Chemical"], [25, 25, "Chemical"], [87, 87, "Chemical"], [39, 40, "Chemical"], [116, 117, "Chemical"], [149, 149, "Chemical"], [168, 168, "Chemical"]]], "relations": [[[7, 14, 58, 58, "CID"], [7, 14, 81, 81, "CID"], [7, 14, 122, 122, "CID"], [7, 14, 164, 164, "CID"], [7, 14, 207, 207, "CID"], [44, 45, 58, 58, "CID"], [44, 45, 81, 81, "CID"], [44, 45, 122, 122, "CID"], [44, 45, 164, 164, "CID"], [44, 45, 207, 207, "CID"], [108, 109, 58, 58, "CID"], [108, 109, 81, 81, "CID"], [108, 109, 122, 122, "CID"], [108, 109, 164, 164, "CID"], [108, 109, 207, 207, "CID"], [125, 126, 58, 58, "CID"], [125, 126, 81, 81, "CID"], [125, 126, 122, 122, "CID"], [125, 126, 164, 164, "CID"], [125, 126, 207, 207, "CID"], [201, 202, 58, 58, "CID"], [201, 202, 81, 81, "CID"], [201, 202, 122, 122, "CID"], [201, 202, 164, 164, "CID"], [201, 202, 207, 207, "CID"], [77, 78, 58, 58, "CID"], [77, 78, 81, 81, "CID"], [77, 78, 122, 122, "CID"], [77, 78, 164, 164, "CID"], [77, 78, 207, 207, "CID"], [160, 161, 58, 58, "CID"], [160, 161, 81, 81, "CID"], [160, 161, 122, 122, "CID"], [160, 161, 164, 164, "CID"], [160, 161, 207, 207, "CID"], [204, 205, 58, 58, "CID"], [204, 205, 81, 81, "CID"], [204, 205, 122, 122, "CID"], [204, 205, 164, 164, "CID"], [204, 205, 207, 207, "CID"]]], "clusters": [], "translated": "对有意识的小鼠鞘内注射<0>前列腺素 D2、E2 或 F2 α</0>引起的伤害感受。采用热板和<18>醋酸</18>扭体试验评价了鞘内注射<16>前列腺素</16>对清醒小鼠<13>疼痛</13>反应的影响。<1>前列腺素 D2 </1>（0.5-3 ng/小鼠）在注射后 3-60 分钟内对热板反应具有<5>痛觉过敏</5>作用。<10>前列腺素 E2</10>在 1<17>pg</17>至10 ng/小鼠的剂量下表现出<6>痛觉过敏</6>作用，但作用持续时间（3 - 30 分钟）比<2>前列腺素 D2</2>短。<19>醋酸</19>扭体试验也得到了类似的结果。<3>前列腺素 D2 </3>的<7>痛觉过敏</7>作用被同时注射P物质拮抗剂（大于或等于 100 ng）阻断，但<20>AH6809</20>不被阻断，一种前列腺素 EP1 受体拮抗剂。相反，<11>前列腺素 E2</11>诱导的<8>痛觉过敏</8>被<21>AH6809</21>（大于或等于 500 ng）阻断，但不被P物质拮抗剂阻断。<15>前列腺素 F2 α</15>对<14>疼痛</14>反应几乎没有影响。这些结果表明，<4>前列腺素 D2</4>和<12>前列腺素 E2</12>均对脊髓产生<9>痛觉过敏</9>，但作用方式不同。", "revised": true}
{"doc_key": "7752389", "sentences": [["Prostaglandin", "E2", "-", "induced", "bladder", "hyperactivity", "in", "normal", ",", "conscious", "rats", ":", "involvement", "of", "tachykinins", "?", "In", "normal", "conscious", "rats", "investigated", "by", "continuous", "cystometry", ",", "intravesically", "instilled", "prostaglandin", "(", "PG", ")", "E2", "facilitated", "micturition", "and", "increased", "basal", "intravesical", "pressure", ".", "The", "effect", "was", "attenuated", "by", "both", "the", "NK1", "receptor", "selective", "antagonist", "RP", "67", ",", "580", "and", "the", "NK2", "receptor", "selective", "antagonist", "SR", "48", ",", "968", ",", "given", "intra", "-", "arterially", ",", "suggesting", "that", "it", "was", "mediated", "by", "stimulation", "of", "both", "NK1", "and", "NK2", "receptors", ".", "Intra", "-", "arterially", "given", "PGE2", "produced", "a", "distinct", "increase", "in", "bladder", "pressure", "before", "initiating", "a", "micturition", "reflex", ",", "indicating", "that", "the", "PG", "had", "a", "direct", "contractant", "effect", "on", "the", "detrusor", "smooth", "muscle", ".", "The", "effect", "of", "intra", "-", "arterial", "PGE2", "could", "not", "be", "blocked", "by", "intra", "-", "arterial", "RP", "67", ",", "580", "or", "SR", "48", ",", "968", ",", "which", "opens", "the", "possibility", "that", "the", "micturition", "reflex", "elicited", "by", "intra", "-", "arterial", "PGE2", "was", "mediated", "by", "pathways", "other", "than", "the", "reflex", "initiated", "when", "the", "PG", "was", "given", "intravesically", ".", "The", "present", "results", "thus", "suggest", "that", "intra", "-", "arterial", "PGE2", ",", "given", "near", "the", "bladder", ",", "may", "initiate", "micturition", "in", "the", "normal", "rat", "chiefly", "by", "directly", "contracting", "the", "smooth", "muscle", "of", "the", "detrusor", ".", "However", ",", "when", "given", "intravesically", ",", "PGE2", "may", "stimulate", "micturition", "by", "releasing", "tachykinins", "from", "nerves", "in", "and", "/", "or", "immediately", "below", "the", "urothelium", ".", "These", "tachykinins", ",", "in", "turn", ",", "initiate", "a", "micturition", "reflex", "by", "stimulating", "NK1", "and", "NK2", "receptors", ".", "Prostanoids", "may", ",", "via", "release", "of", "tachykinins", ",", "contribute", "to", "both", "urge", "and", "bladder", "hyperactivity", "seen", "in", "inflammatory", "conditions", "of", "the", "lower", "urinary", "tract", "."]], "ner": [[[0, 1, "Chemical"], [27, 31, "Chemical"], [89, 89, "Chemical"], [124, 124, "Chemical"], [156, 156, "Chemical"], [182, 182, "Chemical"], [213, 213, "Chemical"], [4, 5, "Disease"], [261, 262, "Disease"], [14, 14, "Chemical"], [219, 219, "Chemical"], [232, 232, "Chemical"], [254, 254, "Chemical"], [51, 54, "Chemical"], [133, 136, "Chemical"], [61, 64, "Chemical"], [138, 141, "Chemical"], [106, 106, "Chemical"], [168, 168, "Chemical"], [248, 248, "Chemical"]]], "relations": [[[0, 1, 4, 5, "CID"], [0, 1, 261, 262, "CID"], [27, 31, 4, 5, "CID"], [27, 31, 261, 262, "CID"], [89, 89, 4, 5, "CID"], [89, 89, 261, 262, "CID"], [124, 124, 4, 5, "CID"], [124, 124, 261, 262, "CID"], [156, 156, 4, 5, "CID"], [156, 156, 261, 262, "CID"], [182, 182, 4, 5, "CID"], [182, 182, 261, 262, "CID"], [213, 213, 4, 5, "CID"], [213, 213, 261, 262, "CID"]]], "clusters": [], "translated": " <0>前列腺素E2</0> - 在正常、有意识的大鼠中诱导<7>膀胱过度活动</7>：<9>速激肽</9>的参与？在通过连续膀胱测压法研究的正常清醒大鼠中，膀胱内滴注<1>前列腺素(PG)E2</1>促进排尿并增加基础膀胱内压。动脉内给予NK1受体选择性拮抗剂<13>RP 67,580</13>和NK2受体选择性拮抗剂<15>SR 48,968</15>均减弱了该作用，表明它是介导的通过刺激 NK1 和 NK2 受体。动脉内给予<2>PGE2</2>可在排尿反射开始前显着增加膀胱压力，表明<17>PG</17>对逼尿肌平滑肌有直接收缩作用。动脉内<3>PGE2</3>的作用不能被动脉内<14> RP 67,580</14>或<16>SR 48,968</16>阻断，这开启了<4>动脉内PGE2</4>引起的排尿反射是由膀胱内给予<18>PG</18>时启动的反射以外的途径介导的可能性。因此，目前的结果表明，在膀胱附近给予动脉内<5>PGE2</5>，可能主要通过直接收缩逼尿肌的平滑肌来启动正常大鼠的排尿。然而，当膀胱内给药时，<6>PGE2</6>可能刺激排尿通过从尿路上皮内和/或尿路上皮正下方的神经释放<10>速激肽</10>。这些<11>速激肽</11>反过来又通过刺激 NK1 和 NK2 受体启动排尿反射。<19>前列腺素</19>可能通过释放<12>速激肽</12>导致下泌尿道炎症中出现的急迫感和<8>膀胱机能亢进</8>。", "revised": true}
{"doc_key": "2893236", "sentences": [["GABA", "involvement", "in", "naloxone", "induced", "reversal", "of", "respiratory", "paralysis", "produced", "by", "thiopental", ".", "No", "agent", "is", "yet", "available", "to", "reverse", "respiratory", "paralysis", "produced", "by", "CNS", "depressants", ",", "such", "as", "general", "anesthetics", ".", "In", "this", "study", "naloxone", "reversed", "respiratory", "paralysis", "induced", "by", "thiopental", "in", "rats", ".", "25", "mg", "/", "kg", ",", "i", ".", "v", ".", "thiopental", "produced", "anesthesia", "without", "altering", "respiratory", "rate", ",", "increased", "GABA", ",", "decreased", "glutamate", ",", "and", "had", "no", "effect", "on", "aspartate", "or", "glycine", "levels", "compared", "to", "controls", "in", "rat", "cortex", "and", "brain", "stem", ".", "Pretreatment", "of", "rats", "with", "thiosemicarbazide", "for", "30", "minutes", "abolished", "the", "anesthetic", "action", "as", "well", "as", "the", "respiratory", "depressant", "action", "of", "thiopental", ".", "50", "mg", "/", "kg", ",", "i", ".", "v", ".", "thiopental", "produced", "respiratory", "arrest", "with", "further", "increase", "in", "GABA", "and", "decrease", "in", "glutamate", "again", "in", "cortex", "and", "brain", "stem", "without", "affecting", "any", "of", "the", "amino", "acids", "studied", "in", "four", "regions", "of", "rat", "brain", ".", "Naloxone", "(", "2", ".", "5", "mg", "/", "kg", ",", "i", ".", "v", ".", ")", "reversed", "respiratory", "paralysis", ",", "glutamate", "and", "GABA", "levels", "to", "control", "values", "in", "brain", "stem", "and", "cortex", "with", "no", "changes", "in", "caudate", "or", "cerebellum", ".", "These", "data", "suggest", "naloxone", "reverses", "respiratory", "paralysis", "produced", "by", "thiopental", "and", "involves", "GABA", "in", "its", "action", "."]], "ner": [[[11, 11, "Chemical"], [41, 41, "Chemical"], [54, 54, "Chemical"], [107, 107, "Chemical"], [118, 118, "Chemical"], [199, 199, "Chemical"], [7, 8, "Disease"], [20, 21, "Disease"], [37, 38, "Disease"], [167, 168, "Disease"], [195, 196, "Disease"], [0, 0, "Chemical"], [63, 63, "Chemical"], [126, 126, "Chemical"], [172, 172, "Chemical"], [202, 202, "Chemical"], [120, 121, "Disease"], [3, 3, "Chemical"], [35, 35, "Chemical"], [152, 152, "Chemical"], [193, 193, "Chemical"], [66, 66, "Chemical"], [130, 130, "Chemical"], [170, 170, "Chemical"], [73, 73, "Chemical"], [75, 75, "Chemical"], [91, 91, "Chemical"], [142, 143, "Chemical"]]], "relations": [[[11, 11, 7, 8, "CID"], [11, 11, 20, 21, "CID"], [11, 11, 37, 38, "CID"], [11, 11, 167, 168, "CID"], [11, 11, 195, 196, "CID"], [41, 41, 7, 8, "CID"], [41, 41, 20, 21, "CID"], [41, 41, 37, 38, "CID"], [41, 41, 167, 168, "CID"], [41, 41, 195, 196, "CID"], [54, 54, 7, 8, "CID"], [54, 54, 20, 21, "CID"], [54, 54, 37, 38, "CID"], [54, 54, 167, 168, "CID"], [54, 54, 195, 196, "CID"], [107, 107, 7, 8, "CID"], [107, 107, 20, 21, "CID"], [107, 107, 37, 38, "CID"], [107, 107, 167, 168, "CID"], [107, 107, 195, 196, "CID"], [118, 118, 7, 8, "CID"], [118, 118, 20, 21, "CID"], [118, 118, 37, 38, "CID"], [118, 118, 167, 168, "CID"], [118, 118, 195, 196, "CID"], [199, 199, 7, 8, "CID"], [199, 199, 20, 21, "CID"], [199, 199, 37, 38, "CID"], [199, 199, 167, 168, "CID"], [199, 199, 195, 196, "CID"]]], "clusters": [], "translated": " <11>GABA</11>参与<17>纳洛酮</17>诱导的<6>呼吸麻痹</6>逆转<0>硫喷妥钠</0>。尚无药物可用于逆转中枢神经系统抑制剂（如全身麻醉剂）产生的<7>呼吸麻痹</7>。在这项研究中，<18>纳洛酮</18>逆转了<1>硫喷妥钠</1>诱导的大鼠<8>呼吸麻痹</8>。25毫克/千克，i.v. <2>硫喷妥钠</2>产生麻醉而不改变呼吸频率，增加<12>GABA</12>，减少<21>谷氨酸</21>，对<24>天冬氨酸</24>或<25>甘氨酸</25>水平与大鼠皮质和脑干中的对照相比没有影响。用<26>硫脲类物质</26>预处理大鼠30分钟可消除<3>硫喷妥钠</3>的麻醉作用和呼吸抑制作用。50毫克/千克，i.v. <4>硫喷妥钠</4>产生<16>呼吸停止</16>并进一步增加皮质和脑干中的<13>GABA</13>和<22>谷氨酸</22>，再次减少，而不影响大鼠大脑的四个区域中研究的任何<27>氨基酸</27>。<19>纳洛酮</19>（2.5毫克/千克，i.v.）逆转<9>呼吸麻痹</9>，<23>谷氨酸</23>和<14>GABA</14>的水平以使其与对照值相近在脑干和皮层，而尾状核或小脑没有变化。这些数据表明<20>纳洛酮</20>逆转由<5>硫喷妥钠</5>产生的<10>呼吸麻痹</10>并涉及<15>GABA</15>的作用。", "revised": true}
{"doc_key": "17042884", "sentences": [["Placebo", "-", "level", "incidence", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "with", "quetiapine", "in", "controlled", "studies", "of", "patients", "with", "bipolar", "mania", ".", "OBJECTIVES", ":", "To", "evaluate", "extrapyramidal", "symptoms", "(", "EPS", ")", ",", "including", "akathisia", ",", "with", "quetiapine", "in", "patients", "with", "bipolar", "mania", ".", "METHODS", ":", "Data", "were", "analyzed", "from", "four", "similarly", "designed", ",", "randomized", ",", "double", "-", "blind", ",", "3", "-", "to", "12", "-", "week", "studies", ".", "Two", "studies", "evaluated", "quetiapine", "monotherapy", "(", "up", "to", "800", "mg", "/", "day", ")", "(", "n", "=", "209", ")", "versus", "placebo", "(", "n", "=", "198", ")", ",", "with", "lithium", "or", "haloperidol", "monotherapy", "as", "respective", "active", "controls", ".", "Two", "studies", "evaluated", "quetiapine", "(", "up", "to", "800", "mg", "/", "day", ")", "in", "combination", "with", "a", "mood", "stabilizer", "(", "lithium", "or", "divalproex", ",", "QTP", "+", "Li", "/", "DVP", ")", "(", "n", "=", "196", ")", "compared", "to", "placebo", "and", "mood", "stabilizer", "(", "PBO", "+", "Li", "/", "DVP", ")", "(", "n", "=", "203", ")", ".", "Extrapyramidal", "symptoms", "were", "evaluated", "using", "the", "Simpson", "-", "Angus", "Scale", "(", "SAS", ")", ",", "the", "Barnes", "Akathisia", "Rating", "Scale", "(", "BARS", ")", ",", "adverse", "event", "reports", "and", "anticholinergic", "drug", "usage", ".", "RESULTS", ":", "The", "incidence", "of", "EPS", "-", "related", "adverse", "events", ",", "including", "akathisia", ",", "was", "no", "different", "with", "quetiapine", "monotherapy", "(", "12", ".", "9", "%", ")", "than", "with", "placebo", "(", "13", ".", "1", "%", ")", ".", "Similarly", ",", "EPS", "-", "related", "adverse", "events", "with", "QTP", "+", "Li", "/", "DVP", "(", "21", ".", "4", "%", ")", "were", "no", "different", "than", "with", "PBO", "+", "Li", "/", "DVP", "(", "19", ".", "2", "%", ")", ".", "Adverse", "events", "related", "to", "EPS", "occurred", "in", "59", ".", "6", "%", "of", "patients", "treated", "with", "haloperidol", "(", "n", "=", "99", ")", "monotherapy", ",", "whereas", "26", ".", "5", "%", "of", "patients", "treated", "with", "lithium", "(", "n", "=", "98", ")", "monotherapy", "experienced", "adverse", "events", "related", "to", "EPS", ".", "The", "incidence", "of", "akathisia", "was", "low", "and", "similar", "with", "quetiapine", "monotherapy", "(", "3", ".", "3", "%", ")", "and", "placebo", "(", "6", ".", "1", "%", ")", ",", "and", "with", "QTP", "+", "Li", "/", "DVP", "(", "3", ".", "6", "%", ")", "and", "PBO", "+", "Li", "/", "DVP", "(", "4", ".", "9", "%", ")", ".", "Lithium", "was", "associated", "with", "a", "significantly", "higher", "incidence", "(", "p", "<", "0", ".", "05", ")", "of", "tremor", "(", "18", ".", "4", "%", ")", "than", "quetiapine", "(", "5", ".", "6", "%", ")", ";", "cerebellar", "tremor", ",", "which", "is", "a", "known", "adverse", "effect", "of", "lithium", ",", "may", "have", "contributed", "to", "the", "elevated", "rate", "of", "tremor", "in", "patients", "receiving", "lithium", "therapy", ".", "Haloperidol", "induced", "a", "significantly", "higher", "incidence", "(", "p", "<", "0", ".", "001", ")", "of", "akathisia", "(", "33", ".", "3", "%", "versus", "5", ".", "9", "%", ")", ",", "tremor", "(", "30", ".", "3", "%", "versus", "7", ".", "8", "%", ")", ",", "and", "extrapyramidal", "syndrome", "(", "35", ".", "4", "%", "versus", "5", ".", "9", "%", ")", "than", "quetiapine", ".", "No", "significant", "differences", "were", "observed", "between", "quetiapine", "and", "placebo", "on", "SAS", "and", "BARS", "scores", ".", "Anticholinergic", "use", "was", "low", "and", "similar", "with", "quetiapine", "or", "placebo", ".", "CONCLUSIONS", ":", "In", "bipolar", "mania", ",", "the", "incidence", "of", "EPS", ",", "including", "akathisia", ",", "with", "quetiapine", "therapy", "is", "similar", "to", "that", "with", "placebo", "."]], "ner": [[[93, 93, "Chemical"], [121, 121, "Chemical"], [127, 127, "Chemical"], [145, 145, "Chemical"], [232, 232, "Chemical"], [248, 248, "Chemical"], [290, 290, "Chemical"], [334, 334, "Chemical"], [346, 346, "Chemical"], [356, 356, "Chemical"], [398, 398, "Chemical"], [412, 412, "Chemical"], [5, 6, "Disease"], [8, 8, "Disease"], [25, 26, "Disease"], [28, 28, "Disease"], [155, 156, "Disease"], [191, 191, "Disease"], [224, 224, "Disease"], [262, 262, "Disease"], [302, 302, "Disease"], [456, 457, "Disease"], [507, 507, "Disease"], [95, 95, "Chemical"], [273, 273, "Chemical"], [415, 415, "Chemical"], [32, 32, "Disease"], [198, 198, "Disease"], [307, 307, "Disease"], [429, 429, "Disease"], [510, 510, "Disease"], [372, 372, "Disease"], [389, 389, "Disease"], [408, 408, "Disease"], [442, 442, "Disease"], [11, 11, "Chemical"], [35, 35, "Chemical"], [69, 69, "Chemical"], [105, 105, "Chemical"], [125, 125, "Chemical"], [204, 204, "Chemical"], [230, 230, "Chemical"], [313, 313, "Chemical"], [332, 332, "Chemical"], [380, 380, "Chemical"], [470, 470, "Chemical"], [478, 478, "Chemical"], [494, 494, "Chemical"], [513, 513, "Chemical"], [123, 123, "Chemical"], [129, 129, "Chemical"], [147, 147, "Chemical"], [234, 234, "Chemical"], [250, 250, "Chemical"], [336, 336, "Chemical"], [348, 348, "Chemical"], [18, 19, "Disease"], [39, 40, "Disease"], [501, 502, "Disease"]]], "relations": [[[93, 93, 5, 6, "CID"], [93, 93, 8, 8, "CID"], [93, 93, 25, 26, "CID"], [93, 93, 28, 28, "CID"], [93, 93, 155, 156, "CID"], [93, 93, 191, 191, "CID"], [93, 93, 224, 224, "CID"], [93, 93, 262, 262, "CID"], [93, 93, 302, 302, "CID"], [93, 93, 456, 457, "CID"], [93, 93, 507, 507, "CID"], [121, 121, 5, 6, "CID"], [121, 121, 8, 8, "CID"], [121, 121, 25, 26, "CID"], [121, 121, 28, 28, "CID"], [121, 121, 155, 156, "CID"], [121, 121, 191, 191, "CID"], [121, 121, 224, 224, "CID"], [121, 121, 262, 262, "CID"], [121, 121, 302, 302, "CID"], [121, 121, 456, 457, "CID"], [121, 121, 507, 507, "CID"], [127, 127, 5, 6, "CID"], [127, 127, 8, 8, "CID"], [127, 127, 25, 26, "CID"], [127, 127, 28, 28, "CID"], [127, 127, 155, 156, "CID"], [127, 127, 191, 191, "CID"], [127, 127, 224, 224, "CID"], [127, 127, 262, 262, "CID"], [127, 127, 302, 302, "CID"], [127, 127, 456, 457, "CID"], [127, 127, 507, 507, "CID"], [145, 145, 5, 6, "CID"], [145, 145, 8, 8, "CID"], [145, 145, 25, 26, "CID"], [145, 145, 28, 28, "CID"], [145, 145, 155, 156, "CID"], [145, 145, 191, 191, "CID"], [145, 145, 224, 224, "CID"], [145, 145, 262, 262, "CID"], [145, 145, 302, 302, "CID"], [145, 145, 456, 457, "CID"], [145, 145, 507, 507, "CID"], [232, 232, 5, 6, "CID"], [232, 232, 8, 8, "CID"], [232, 232, 25, 26, "CID"], [232, 232, 28, 28, "CID"], [232, 232, 155, 156, "CID"], [232, 232, 191, 191, "CID"], [232, 232, 224, 224, "CID"], [232, 232, 262, 262, "CID"], [232, 232, 302, 302, "CID"], [232, 232, 456, 457, "CID"], [232, 232, 507, 507, "CID"], [248, 248, 5, 6, "CID"], [248, 248, 8, 8, "CID"], [248, 248, 25, 26, "CID"], [248, 248, 28, 28, "CID"], [248, 248, 155, 156, "CID"], [248, 248, 191, 191, "CID"], [248, 248, 224, 224, "CID"], [248, 248, 262, 262, "CID"], [248, 248, 302, 302, "CID"], [248, 248, 456, 457, "CID"], [248, 248, 507, 507, "CID"], [290, 290, 5, 6, "CID"], [290, 290, 8, 8, "CID"], [290, 290, 25, 26, "CID"], [290, 290, 28, 28, "CID"], [290, 290, 155, 156, "CID"], [290, 290, 191, 191, "CID"], [290, 290, 224, 224, "CID"], [290, 290, 262, 262, "CID"], [290, 290, 302, 302, "CID"], [290, 290, 456, 457, "CID"], [290, 290, 507, 507, "CID"], [334, 334, 5, 6, "CID"], [334, 334, 8, 8, "CID"], [334, 334, 25, 26, "CID"], [334, 334, 28, 28, "CID"], [334, 334, 155, 156, "CID"], [334, 334, 191, 191, "CID"], [334, 334, 224, 224, "CID"], [334, 334, 262, 262, "CID"], [334, 334, 302, 302, "CID"], [334, 334, 456, 457, "CID"], [334, 334, 507, 507, "CID"], [346, 346, 5, 6, "CID"], [346, 346, 8, 8, "CID"], [346, 346, 25, 26, "CID"], [346, 346, 28, 28, "CID"], [346, 346, 155, 156, "CID"], [346, 346, 191, 191, "CID"], [346, 346, 224, 224, "CID"], [346, 346, 262, 262, "CID"], [346, 346, 302, 302, "CID"], [346, 346, 456, 457, "CID"], [346, 346, 507, 507, "CID"], [356, 356, 5, 6, "CID"], [356, 356, 8, 8, "CID"], [356, 356, 25, 26, "CID"], [356, 356, 28, 28, "CID"], [356, 356, 155, 156, "CID"], [356, 356, 191, 191, "CID"], [356, 356, 224, 224, "CID"], [356, 356, 262, 262, "CID"], [356, 356, 302, 302, "CID"], [356, 356, 456, 457, "CID"], [356, 356, 507, 507, "CID"], [398, 398, 5, 6, "CID"], [398, 398, 8, 8, "CID"], [398, 398, 25, 26, "CID"], [398, 398, 28, 28, "CID"], [398, 398, 155, 156, "CID"], [398, 398, 191, 191, "CID"], [398, 398, 224, 224, "CID"], [398, 398, 262, 262, "CID"], [398, 398, 302, 302, "CID"], [398, 398, 456, 457, "CID"], [398, 398, 507, 507, "CID"], [412, 412, 5, 6, "CID"], [412, 412, 8, 8, "CID"], [412, 412, 25, 26, "CID"], [412, 412, 28, 28, "CID"], [412, 412, 155, 156, "CID"], [412, 412, 191, 191, "CID"], [412, 412, 224, 224, "CID"], [412, 412, 262, 262, "CID"], [412, 412, 302, 302, "CID"], [412, 412, 456, 457, "CID"], [412, 412, 507, 507, "CID"], [95, 95, 5, 6, "CID"], [95, 95, 8, 8, "CID"], [95, 95, 25, 26, "CID"], [95, 95, 28, 28, "CID"], [95, 95, 155, 156, "CID"], [95, 95, 191, 191, "CID"], [95, 95, 224, 224, "CID"], [95, 95, 262, 262, "CID"], [95, 95, 302, 302, "CID"], [95, 95, 456, 457, "CID"], [95, 95, 507, 507, "CID"], [273, 273, 5, 6, "CID"], [273, 273, 8, 8, "CID"], [273, 273, 25, 26, "CID"], [273, 273, 28, 28, "CID"], [273, 273, 155, 156, "CID"], [273, 273, 191, 191, "CID"], [273, 273, 224, 224, "CID"], [273, 273, 262, 262, "CID"], [273, 273, 302, 302, "CID"], [273, 273, 456, 457, "CID"], [273, 273, 507, 507, "CID"], [415, 415, 5, 6, "CID"], [415, 415, 8, 8, "CID"], [415, 415, 25, 26, "CID"], [415, 415, 28, 28, "CID"], [415, 415, 155, 156, "CID"], [415, 415, 191, 191, "CID"], [415, 415, 224, 224, "CID"], [415, 415, 262, 262, "CID"], [415, 415, 302, 302, "CID"], [415, 415, 456, 457, "CID"], [415, 415, 507, 507, "CID"], [95, 95, 32, 32, "CID"], [95, 95, 198, 198, "CID"], [95, 95, 307, 307, "CID"], [95, 95, 429, 429, "CID"], [95, 95, 510, 510, "CID"], [273, 273, 32, 32, "CID"], [273, 273, 198, 198, "CID"], [273, 273, 307, 307, "CID"], [273, 273, 429, 429, "CID"], [273, 273, 510, 510, "CID"], [415, 415, 32, 32, "CID"], [415, 415, 198, 198, "CID"], [415, 415, 307, 307, "CID"], [415, 415, 429, 429, "CID"], [415, 415, 510, 510, "CID"], [93, 93, 372, 372, "CID"], [93, 93, 389, 389, "CID"], [93, 93, 408, 408, "CID"], [93, 93, 442, 442, "CID"], [121, 121, 372, 372, "CID"], [121, 121, 389, 389, "CID"], [121, 121, 408, 408, "CID"], [121, 121, 442, 442, "CID"], [127, 127, 372, 372, "CID"], [127, 127, 389, 389, "CID"], [127, 127, 408, 408, "CID"], [127, 127, 442, 442, "CID"], [145, 145, 372, 372, "CID"], [145, 145, 389, 389, "CID"], [145, 145, 408, 408, "CID"], [145, 145, 442, 442, "CID"], [232, 232, 372, 372, "CID"], [232, 232, 389, 389, "CID"], [232, 232, 408, 408, "CID"], [232, 232, 442, 442, "CID"], [248, 248, 372, 372, "CID"], [248, 248, 389, 389, "CID"], [248, 248, 408, 408, "CID"], [248, 248, 442, 442, "CID"], [290, 290, 372, 372, "CID"], [290, 290, 389, 389, "CID"], [290, 290, 408, 408, "CID"], [290, 290, 442, 442, "CID"], [334, 334, 372, 372, "CID"], [334, 334, 389, 389, "CID"], [334, 334, 408, 408, "CID"], [334, 334, 442, 442, "CID"], [346, 346, 372, 372, "CID"], [346, 346, 389, 389, "CID"], [346, 346, 408, 408, "CID"], [346, 346, 442, 442, "CID"], [356, 356, 372, 372, "CID"], [356, 356, 389, 389, "CID"], [356, 356, 408, 408, "CID"], [356, 356, 442, 442, "CID"], [398, 398, 372, 372, "CID"], [398, 398, 389, 389, "CID"], [398, 398, 408, 408, "CID"], [398, 398, 442, 442, "CID"], [412, 412, 372, 372, "CID"], [412, 412, 389, 389, "CID"], [412, 412, 408, 408, "CID"], [412, 412, 442, 442, "CID"], [95, 95, 372, 372, "CID"], [95, 95, 389, 389, "CID"], [95, 95, 408, 408, "CID"], [95, 95, 442, 442, "CID"], [273, 273, 372, 372, "CID"], [273, 273, 389, 389, "CID"], [273, 273, 408, 408, "CID"], [273, 273, 442, 442, "CID"], [415, 415, 372, 372, "CID"], [415, 415, 389, 389, "CID"], [415, 415, 408, 408, "CID"], [415, 415, 442, 442, "CID"]]], "clusters": [], "translated": "在<56>双相躁狂症</56>患者的对照研究中，<35>喹硫平</35>的<12>锥体外系症状</12>（<13>EPS</13>）的安慰剂水平发生率。目的：评估<14>锥体外系症状</14>（<15>EPS</15>），包括<26>静坐不能</26>，<36>喹硫平</36>在<57>双相躁狂症</57>患者中的作用.方法：对来自四项设计相似、随机、双盲、为期3至12周的研究的数据进行了分析。两项研究评估了<37>喹硫平</37>单一疗法（高达800毫克/天）(n=209)与安慰剂(n=198)，与<0>锂</0>或<23>氟哌啶醇</23>单一疗法作为相应的活性对照。两项研究评估了<38>喹硫平</38>（高达800毫克/天）与情绪稳定剂（<1>锂</1>或<49>双丙戊酸钠</49>、<39>QTP</39>+<2>Li</2>/<50>DVP</50>）(n=196)与安慰剂和情绪稳定剂(PBO+<3>Li</3>/<51>DVP</51>)(n=203)。<16>锥体外系症状</16>采用辛普森-安格斯量表(SAS)、巴恩斯静坐不能评定量表(BARS)、不良事件报告和抗胆碱能药物使用情况进行评估。结果：<17>EPS</17>相关不良事件的发生率，包括<27>静坐不能</27>，<40>喹硫平</40>单一疗法(12.9%)与安慰剂没有差异(13.1%)。同样，<18>EPS</18>-与<41>QTP</41>+<4>Li</4>/<52>DVP</52>相关的不良事件(21.4%)也没有差异比PBO+<5>Li</5>/<53>DVP</53>(19.2%)。与<19>EPS</19>相关的不良事件发生在59.6%的<24>氟哌啶醇</24>单药治疗的患者(n=99)，而26.5%接受<6>锂</6>(n=98)单药治疗的患者出现了与<20>EPS</20>相关的不良事件。<28>静坐不能</28>的发生率很低，与<42>喹硫平</42>单一疗法(3.3%)和安慰剂(6.1%)以及<43>QTP</43>+<7>Li</7>/<54>DVP</54>(3.6%)和PBO+<8>Li</8>/<55>DVP</55>(4.9%)相似。<9>锂</9>与<31>震颤</31>（18.4%）的发生率(p<0.05)显着高于<44>喹硫平</44>（5.6%）；小脑<32>震颤</32>是<10>锂</10>的已知不良反应，可能导致接受<11>锂</11>治疗的患者出现<33>震颤</33>的发病率升高。<25>氟哌啶醇</25>引起显着更高的发生率(p<0.001)<29>静坐不能</29>(33.3%对5.9%)，<34>震颤</34>(30.3%对7.8%)和<21>锥体外系综合征</21>(35.4%对5.9%)比<45>喹硫平</45>。 <46>喹硫平</46>和安慰剂在SAS和BARS评分上没有显着差异。抗胆碱能药的使用率较低，与<47>喹硫平</47>或安慰剂的使用率相似。结论：在<58>双相躁狂</58>中，<22>EPS</22>的发生率，包括<30>静坐不能</30>，<48>喹硫平</48>治疗与安慰剂。", "revised": true}
{"doc_key": "6942642", "sentences": [["Thiazide", "diuretics", ",", "hypokalemia", "and", "cardiac", "arrhythmias", ".", "Thiazide", "diuretics", "are", "widely", "accepted", "as", "the", "cornerstone", "of", "antihypertensive", "treatment", "programs", ".", "Hypokalemia", "is", "a", "commonly", "encountered", "metabolic", "consequence", "of", "chronic", "thiazide", "therapy", ".", "We", "treated", "38", "patients", "(", "22", "low", "renin", ",", "16", "normal", "renin", ")", "with", "moderate", "diastolic", "hypertension", "with", "hydrochlorothiazide", "(", "HCTC", ")", "administered", "on", "a", "twice", "daily", "schedule", ".", "Initial", "dose", "was", "50", "mg", "and", "the", "dose", "was", "increased", "at", "monthly", "intervals", "to", "100", "mg", ",", "150", "mg", "and", "200", "mg", "daily", "until", "blood", "pressure", "normalized", ".", "The", "serum", "K", "during", "the", "control", "period", "was", "4", ".", "5", "+", "/", "-", "0", ".", "2", "mEq", "/", "l", "an", "on", "50", ",", "100", ",", "150", "and", "200", "mg", "HCTZ", "daily", "3", ".", "9", "+", "/", "-", "0", ".", "3", ",", "3", ".", "4", "+", "/", "-", "0", ".", "2", ",", "2", ".", "9", "+", "/", "-", "0", ".", "2", ",", "and", "2", ".", "4", "+", "/", "-", "0", ".", "3", "mEq", "/", "l", ",", "respectively", ".", "Corresponding", "figures", "for", "whole", "body", "K", "were", "4107", "+", "/", "-", "208", ",", "3722", "+", "/", "-", "319", ",", "3628", "+", "/", "-", "257", ",", "3551", "+", "/", "-", "336", ",", "and", "3269", "+", "/", "-", "380", "mEq", ",", "respectively", ".", "In", "13", "patients", "we", "observed", "the", "effects", "of", "HCTZ", "therapy", "(", "100", "mg", "daily", ")", "on", "the", "occurrence", "of", "PVC", "'s", "during", "rest", "as", "well", "as", "during", "static", "and", "dynamic", "exercise", ".", "During", "rest", "we", "observed", "0", ".", "6", "+", "/", "-", "0", ".", "08", "PVC", "beats", "/", "min", "+", "/", "-", "SEM", "and", "during", "static", "and", "dynamic", "exercise", "0", ".", "6", "+", "/", "-", "0", ".", "06", "and", "0", ".", "8", "+", "/", "-", "0", ".", "15", ",", "respectively", ".", "Corresponding", "figures", "during", "HCTZ", "therapy", "100", "mg", "daily", "were", "1", ".", "4", "+", "/", "-", "0", ".", "1", ",", "3", ".", "6", "+", "/", "-", "0", ".", "7", "and", "5", ".", "7", "4", "/", "-", "0", ".", "8", ",", "respectively", ".", "The", "occurrence", "of", "PVC", "'s", "correlated", "significantly", "with", "the", "fall", "in", "serum", "K", "+", "observed", "r", "=", "0", ".", "72", ",", "p", "less", "than", "0", ".", "001", ".", "In", "conclusion", "we", "found", "that", "thiazide", "diuretics", "cause", "hypokalemia", "and", "depletion", "of", "body", "potassium", ".", "The", "more", "profound", "hypokalemia", ",", "the", "greater", "the", "propensity", "for", "the", "occurrence", "of", "PVC", "'s", "."]], "ner": [[[51, 51, "Chemical"], [53, 53, "Chemical"], [120, 120, "Chemical"], [217, 217, "Chemical"], [293, 293, "Chemical"], [3, 3, "Disease"], [21, 21, "Disease"], [367, 367, "Disease"], [377, 377, "Disease"], [5, 6, "Disease"], [0, 0, "Chemical"], [8, 8, "Chemical"], [30, 30, "Chemical"], [364, 364, "Chemical"], [48, 49, "Disease"], [92, 92, "Chemical"], [173, 173, "Chemical"], [343, 343, "Chemical"], [372, 372, "Chemical"]]], "relations": [[[51, 51, 3, 3, "CID"], [51, 51, 21, 21, "CID"], [51, 51, 367, 367, "CID"], [51, 51, 377, 377, "CID"], [53, 53, 3, 3, "CID"], [53, 53, 21, 21, "CID"], [53, 53, 367, 367, "CID"], [53, 53, 377, 377, "CID"], [120, 120, 3, 3, "CID"], [120, 120, 21, 21, "CID"], [120, 120, 367, 367, "CID"], [120, 120, 377, 377, "CID"], [217, 217, 3, 3, "CID"], [217, 217, 21, 21, "CID"], [217, 217, 367, 367, "CID"], [217, 217, 377, 377, "CID"], [293, 293, 3, 3, "CID"], [293, 293, 21, 21, "CID"], [293, 293, 367, 367, "CID"], [293, 293, 377, 377, "CID"], [51, 51, 5, 6, "CID"], [53, 53, 5, 6, "CID"], [120, 120, 5, 6, "CID"], [217, 217, 5, 6, "CID"], [293, 293, 5, 6, "CID"]]], "clusters": [], "translated": "<10>噻嗪类</10>利尿剂，<5>低钾血症</5>和<9>心律失常</9>。<11>噻嗪类</11>利尿剂被广泛认为是抗高血压治疗方案的基石。<6>低钾血症</6>是慢性<12>噻嗪类</12>治疗的常见代谢后果。我们治疗了38名患有中度<14>舒张期高血压</14>的患者（22名低肾素，16名肾素正常），每天服用两次<0>氢氯噻嗪</0>(<1>HCTC</1>)。初始剂量为50毫克，剂量每月增加至每天100毫克、150毫克和200毫克，直至血压恢复正常。对照组血清<15>K</15>为4.5 +/- 0.2 mEq/l，在50、100、150和200 mg<2> HCTZ</2>每日3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2和2.4 +/- 0.3 mEq/l，分别。全身<16>K</16>对应值分别为4107+/-208、3722+/-319、3628+/-257、3551+/-336、3269+/-380mEq，分别。在13名患者中，我们观察了<3>HCTZ</3>疗法（每天100毫克）对休息期间以及静态和动态运动期间PVC发生率的影响。在休息期间，我们观察到0.6 +/- 0.08 PVC节拍/分钟+/-SEM和静态和动态运动期间0.6 +/- 0.06和0.8 +/- 0.15，分别。<4>氢氯噻嗪</4>治疗100mg/d期间的相应数字为1.4 +/- 0.1, 3.6 +/- 0.7和5.74/- 0 . 8，分别。PVC的发生与血清<17>K</17>的下降显着相关+观察到的r = 0.72, p小于0.001。总之，我们发现<13>噻嗪类</13>利尿剂导致<7>低钾血症</7>和体内<18>钾</18>的消耗。<8>低钾血症</8>越严重，发生PVC的倾向越大。", "revised": true}
{"doc_key": "17682013", "sentences": [["Delayed", "leukoencephalopathy", "with", "stroke", "-", "like", "presentation", "in", "chemotherapy", "recipients", ".", "BACKGROUND", ":", "A", "transient", "leukoencephalopathy", "mimicking", "cerebrovascular", "accident", "has", "been", "described", "as", "a", "complication", "of", "chemotherapy", ",", "most", "commonly", "in", "recipients", "of", "intrathecal", "methotrexate", "for", "childhood", "leukaemia", ".", "Recently", "published", "neuroimaging", "data", "suggest", "a", "common", "pathophysiology", "associated", "with", "a", "variety", "of", "chemotherapy", "agents", "and", "modes", "of", "administration", ".", "METHODS", ":", "We", "reviewed", "the", "medical", "literature", "for", "single", "reports", "and", "case", "series", "of", "patients", "presenting", "with", "stroke", "-", "like", "episodes", "while", "receiving", "systemic", "or", "intrathecal", "chemotherapy", ".", "We", "only", "included", "studies", "providing", "detailed", "neuroimaging", "data", ".", "Patients", "with", "cerebrovascular", "accidents", "were", "excluded", ".", "RESULTS", ":", "We", "identified", "27", "reports", "of", "toxic", "leukoencephalopathy", "in", "patients", "treated", "with", "methotrexate", "(", "intrathecal", ",", "systemic", ")", ",", "5", "-", "fluorouracil", "and", "its", "derivative", "carmofur", ",", "and", "capecitabine", ".", "Diffusion", "weighted", "imaging", "(", "DWI", ")", "of", "all", "patients", "revealed", "well", "demarcated", "hyperintense", "lesions", "within", "the", "subcortical", "white", "matter", "of", "the", "cerebral", "hemispheres", "and", "the", "corpus", "callosum", ",", "corresponding", "to", "areas", "of", "decreased", "proton", "diffusion", "on", "apparent", "diffusion", "coefficient", "(", "ADC", ")", "maps", "(", "available", "in", "21", "/", "27", "patients", ")", ".", "Lesions", "exceeded", "the", "confines", "of", "adjacent", "vascular", "territories", ".", "Complete", "resolution", "of", "symptoms", "within", "1", "-", "4", "days", "was", "accompanied", "by", "normalisation", "of", "ADC", "abnormalities", ".", "However", ",", "fluid", "attenuated", "inversion", "recovery", "(", "FLAIR", ")", "sequences", "frequently", "revealed", "persistent", "white", "matter", "abnormalities", ".", "CONCLUSIONS", ":", "Several", "pathophysiological", "models", "of", "delayed", "leukoencephalopathy", "after", "exposure", "to", "intrathecal", "or", "systemic", "chemotherapy", "have", "been", "proposed", ".", "DWI", "findings", "in", "this", "cohort", "are", "indicative", "of", "cytotoxic", "oedema", "within", "cerebral", "white", "matter", "and", "lend", "support", "to", "an", "at", "least", "partially", "reversible", "metabolic", "derangement", "as", "the", "basis", "for", "this", "syndrome", "."]], "ner": [[[34, 34, "Chemical"], [116, 116, "Chemical"], [1, 1, "Disease"], [15, 15, "Disease"], [111, 111, "Disease"], [147, 152, "Disease"], [225, 227, "Disease"], [236, 236, "Disease"], [123, 125, "Chemical"], [129, 129, "Chemical"], [132, 132, "Chemical"], [3, 3, "Disease"], [76, 76, "Disease"], [17, 18, "Disease"], [98, 99, "Disease"], [37, 37, "Disease"], [256, 261, "Disease"]]], "relations": [[[34, 34, 1, 1, "CID"], [34, 34, 15, 15, "CID"], [34, 34, 111, 111, "CID"], [34, 34, 147, 152, "CID"], [34, 34, 225, 227, "CID"], [34, 34, 236, 236, "CID"], [116, 116, 1, 1, "CID"], [116, 116, 15, 15, "CID"], [116, 116, 111, 111, "CID"], [116, 116, 147, 152, "CID"], [116, 116, 225, 227, "CID"], [116, 116, 236, 236, "CID"], [123, 125, 1, 1, "CID"], [123, 125, 15, 15, "CID"], [123, 125, 111, 111, "CID"], [123, 125, 147, 152, "CID"], [123, 125, 225, 227, "CID"], [123, 125, 236, 236, "CID"], [129, 129, 1, 1, "CID"], [129, 129, 15, 15, "CID"], [129, 129, 111, 111, "CID"], [129, 129, 147, 152, "CID"], [129, 129, 225, 227, "CID"], [129, 129, 236, 236, "CID"], [132, 132, 1, 1, "CID"], [132, 132, 15, 15, "CID"], [132, 132, 111, 111, "CID"], [132, 132, 147, 152, "CID"], [132, 132, 225, 227, "CID"], [132, 132, 236, 236, "CID"]]], "clusters": [], "translated": "迟发性<2>白质脑病</2><11>中风</11>-样表现的化疗接受者。背景：一过性<3>白质脑病</3>模仿<13>脑血管意外</13>已被描述为化疗的并发症，最常见于儿童时期<15>白血病</15>鞘内注射<0>甲氨蝶呤</0>的接受者。最近发表的神经影像学数据表明，与多种化疗药物和给药方式相关的常见病理生理学。方法：我们回顾了关于在接受全身或鞘内化疗时出现<12>中风</12>-样发作的患者的单一报告和病例系列的医学文献。我们只纳入了提供详细神经影像学数据的研究。排除<14>脑血管意外</14>患者。结果：我们在接受<1>甲氨蝶呤</1>（鞘内、全身）、<8>5-氟尿嘧啶</8>及其衍生物<9>卡莫氟</9>和<10>卡培他滨</10>治疗的患者中确定了27份中毒性<4>白质脑病</4>报告。所有患者的弥散加权成像（DWI）均显示在大脑半球和胼胝体的<5>皮层下白质</5>内有界限清楚的高信号病变，对应于表观弥散系数（ADC）图上质子扩散减少的区域。（27名患者中有21名可用）。病变超出了相邻血管区域的范围。症状在1-4天内完全消失，同时ADC异常正常化。然而，流体衰减反转恢复（FLAIR）序列经常显示持续的<6>白质异常</6>。结论：已经提出了暴露于鞘内或全身化疗后迟发性<7>白质脑病</7>的几种病理生理学模型。该队列中的DWI结果表明<16>脑白质内的细胞毒性水肿</16>并支持至少部分可逆的代谢紊乱作为该综合征的基础。", "revised": true}
{"doc_key": "20510337", "sentences": [["Coenzyme", "Q10", "treatment", "ameliorates", "acute", "cisplatin", "nephrotoxicity", "in", "mice", ".", "The", "nephroprotective", "effect", "of", "coenzyme", "Q10", "was", "investigated", "in", "mice", "with", "acute", "renal", "injury", "induced", "by", "a", "single", "i", ".", "p", ".", "injection", "of", "cisplatin", "(", "5", "mg", "/", "kg", ")", ".", "Coenzyme", "Q10", "treatment", "(", "10", "mg", "/", "kg", "/", "day", ",", "i", ".", "p", ".", ")", "was", "applied", "for", "6", "consecutive", "days", ",", "starting", "1", "day", "before", "cisplatin", "administration", ".", "Coenzyme", "Q10", "significantly", "reduced", "blood", "urea", "nitrogen", "and", "serum", "creatinine", "levels", "which", "were", "increased", "by", "cisplatin", ".", "Coenzyme", "Q10", "significantly", "compensated", "deficits", "in", "the", "antioxidant", "defense", "mechanisms", "(", "reduced", "glutathione", "level", "and", "superoxide", "dismutase", "activity", ")", ",", "suppressed", "lipid", "peroxidation", ",", "decreased", "the", "elevations", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "nitric", "oxide", "and", "platinum", "ion", "concentration", ",", "and", "attenuated", "the", "reductions", "of", "selenium", "and", "zinc", "ions", "in", "renal", "tissue", "resulted", "from", "cisplatin", "administration", ".", "Also", ",", "histopathological", "renal", "tissue", "damage", "mediated", "by", "cisplatin", "was", "ameliorated", "by", "coenzyme", "Q10", "treatment", ".", "Immunohistochemical", "analysis", "revealed", "that", "coenzyme", "Q10", "significantly", "decreased", "the", "cisplatin", "-", "induced", "overexpression", "of", "inducible", "nitric", "oxide", "synthase", ",", "nuclear", "factor", "-", "kappaB", ",", "caspase", "-", "3", "and", "p53", "in", "renal", "tissue", ".", "It", "was", "concluded", "that", "coenzyme", "Q10", "represents", "a", "potential", "therapeutic", "option", "to", "protect", "against", "acute", "cisplatin", "nephrotoxicity", "commonly", "encountered", "in", "clinical", "practice", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [69, 69, "Chemical"], [87, 87, "Chemical"], [144, 144, "Chemical"], [155, 155, "Chemical"], [172, 172, "Chemical"], [211, 211, "Chemical"], [21, 23, "Disease"], [0, 1, "Chemical"], [14, 15, "Chemical"], [42, 43, "Chemical"], [72, 73, "Chemical"], [89, 90, "Chemical"], [159, 160, "Chemical"], [167, 168, "Chemical"], [200, 201, "Chemical"], [6, 6, "Disease"], [150, 152, "Disease"], [212, 212, "Disease"], [117, 117, "Disease"], [118, 118, "Disease"], [76, 78, "Chemical"], [81, 81, "Chemical"], [100, 101, "Chemical"], [104, 104, "Chemical"], [123, 124, "Chemical"], [178, 179, "Chemical"], [126, 126, "Chemical"], [135, 135, "Chemical"], [137, 137, "Chemical"]]], "relations": [[[5, 5, 21, 23, "CID"], [34, 34, 21, 23, "CID"], [69, 69, 21, 23, "CID"], [87, 87, 21, 23, "CID"], [144, 144, 21, 23, "CID"], [155, 155, 21, 23, "CID"], [172, 172, 21, 23, "CID"], [211, 211, 21, 23, "CID"]]], "clusters": [], "translated": " <9>辅酶 Q10</9> 治疗可改善小鼠的急性<0>顺铂</0><17>肾毒性</17>。<10>辅酶 Q10</10>对小鼠的肾脏保护作用进行了研究，该小鼠患有<8>急性肾损伤</8>，由单一i.p.注射<1>顺铂</1>（5 mg/kg）诱导。 <11>辅酶 Q10</11>治疗（10 mg/kg/天，i.p.）连续6天，从<2>顺铂</2>给药前1天开始。 <12>辅酶 Q10</12>显着降低<22>血尿素氮</22>和血清<23>肌酐</23>水平，而<3>顺铂</3>会增加这些水平。 <13>辅酶 Q10</13>显着补偿抗氧化防御机制中的缺陷（<24>降低谷胱甘肽</24>水平和<25>超氧化物</25>歧化酶活性），抑制脂质过氧化，降低<20>肿瘤</20><21>坏死</21>因子-α、<26>一氧化氮</26>和<28>铂</28>离子浓度，并减弱<29>硒</29>和<30>锌</30>离子在肾组织中由<4>顺铂</4>给药引起。此外，<14>辅酶 Q10</14>治疗可改善<5>顺铂</5>介导的组织病理学<18>肾组织损伤</18>。免疫组织化学分析显示，<15>辅酶 Q10</15>显着降低了<6>顺铂</6>诱导的诱导型<27>一氧化氮</27>合酶、核因子-kappa B、caspase-3和p53的过度表达在肾组织中。得出的结论是，<16>辅酶 Q10</16>是一种潜在的治疗选择，可以预防临床实践中常见的急性<7>顺铂</7><19>肾毒性</19>。", "revised": true}
{"doc_key": "20042557", "sentences": [["Sedation", "depth", "during", "spinal", "anesthesia", "and", "the", "development", "of", "postoperative", "delirium", "in", "elderly", "patients", "undergoing", "hip", "fracture", "repair", ".", "OBJECTIVE", ":", "To", "determine", "whether", "limiting", "intraoperative", "sedation", "depth", "during", "spinal", "anesthesia", "for", "hip", "fracture", "repair", "in", "elderly", "patients", "can", "decrease", "the", "prevalence", "of", "postoperative", "delirium", ".", "PATIENTS", "AND", "METHODS", ":", "We", "performed", "a", "double", "-", "blind", ",", "randomized", "controlled", "trial", "at", "an", "academic", "medical", "center", "of", "elderly", "patients", "(", ">", "or", "=", "65", "years", ")", "without", "preoperative", "delirium", "or", "severe", "dementia", "who", "underwent", "hip", "fracture", "repair", "under", "spinal", "anesthesia", "with", "propofol", "sedation", ".", "Sedation", "depth", "was", "titrated", "using", "processed", "electroencephalography", "with", "the", "bispectral", "index", "(", "BIS", ")", ",", "and", "patients", "were", "randomized", "to", "receive", "either", "deep", "(", "BIS", ",", "approximately", "50", ")", "or", "light", "(", "BIS", ",", ">", "or", "=", "80", ")", "sedation", ".", "Postoperative", "delirium", "was", "assessed", "as", "defined", "by", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", "(", "Third", "Edition", "Revised", ")", "criteria", "using", "the", "Confusion", "Assessment", "Method", "beginning", "at", "any", "time", "from", "the", "second", "day", "after", "surgery", ".", "RESULTS", ":", "From", "April", "2", ",", "2005", ",", "through", "October", "30", ",", "2008", ",", "a", "total", "of", "114", "patients", "were", "randomized", ".", "The", "prevalence", "of", "postoperative", "delirium", "was", "significantly", "lower", "in", "the", "light", "sedation", "group", "(", "11", "/", "57", "[", "19", "%", "]", "vs", "23", "/", "57", "[", "40", "%", "]", "in", "the", "deep", "sedation", "group", ";", "P", "=", ".", "02", ")", ",", "indicating", "that", "1", "incident", "of", "delirium", "will", "be", "prevented", "for", "every", "4", ".", "7", "patients", "treated", "with", "light", "sedation", ".", "The", "mean", "+", "/", "-", "SD", "number", "of", "days", "of", "delirium", "during", "hospitalization", "was", "lower", "in", "the", "light", "sedation", "group", "than", "in", "the", "deep", "sedation", "group", "(", "0", ".", "5", "+", "/", "-", "1", ".", "5", "days", "vs", "1", ".", "4", "+", "/", "-", "4", ".", "0", "days", ";", "P", "=", ".", "01", ")", ".", "CONCLUSION", ":", "The", "use", "of", "light", "propofol", "sedation", "decreased", "the", "prevalence", "of", "postoperative", "delirium", "by", "50", "%", "compared", "with", "deep", "sedation", ".", "Limiting", "depth", "of", "sedation", "during", "spinal", "anesthesia", "is", "a", "simple", ",", "safe", ",", "and", "cost", "-", "effective", "intervention", "for", "preventing", "postoperative", "delirium", "in", "elderly", "patients", "that", "could", "be", "widely", "and", "readily", "adopted", "."]], "ner": [[[90, 90, "Chemical"], [314, 314, "Chemical"], [9, 10, "Disease"], [43, 44, "Disease"], [134, 135, "Disease"], [195, 196, "Disease"], [320, 321, "Disease"], [350, 351, "Disease"], [77, 77, "Disease"], [238, 238, "Disease"], [263, 263, "Disease"], [15, 16, "Disease"], [32, 33, "Disease"], [83, 84, "Disease"], [80, 80, "Disease"], [146, 147, "Disease"]]], "relations": [[[90, 90, 9, 10, "CID"], [90, 90, 43, 44, "CID"], [90, 90, 134, 135, "CID"], [90, 90, 195, 196, "CID"], [90, 90, 320, 321, "CID"], [90, 90, 350, 351, "CID"], [314, 314, 9, 10, "CID"], [314, 314, 43, 44, "CID"], [314, 314, 134, 135, "CID"], [314, 314, 195, 196, "CID"], [314, 314, 320, 321, "CID"], [314, 314, 350, 351, "CID"], [90, 90, 77, 77, "CID"], [90, 90, 238, 238, "CID"], [90, 90, 263, 263, "CID"], [314, 314, 77, 77, "CID"], [314, 314, 238, 238, "CID"], [314, 314, 263, 263, "CID"]]], "clusters": [], "translated": "接受<11>髋部骨折</11>修复术的老年患者腰麻期间的镇静深度与<2>术后谵妄</2>的发生。目的：确定在老年患者<12>髋部骨折</12>修复术中限制术中镇静深度是否可以降低<3>术后谵妄</3>的发生率。患者和方法：我们在一个学术医疗中心进行了一项双盲、随机对照试验，受试者为术前无<8>谵妄</8>或严重<14>痴呆</14>的老年患者（>= 65岁），他们在<0>丙泊酚</0>镇静的脊髓麻醉下接受了<13>髋部骨折</13>修复。使用经过处理的脑电图和双频指数(BIS)滴定镇静深度，患者随机接受深度镇静(BIS，大约50)或轻度镇静(BIS，>= 80)。<4>术后谵妄</4>根据<15>精神障碍诊断和统计手册</15>（第三版修订版）的标准使用意识模糊评估方法从手术后第二天开始评估。结果：从2005年4月2日到2008年10月30日，共有114名患者被随机分组。轻度镇静组<5>术后谵妄</5>的发生率显着降低(11/57 [19%] vs 23/57[40%]；P = .02)，表明每4人将预防1次<9>谵妄</9>。7例采用轻度镇静治疗。轻度镇静组住院期间<10>谵妄</10>的平均+/-SD天数低于深度镇静组（0.5+/-1.5天vs1.4+/-4.0天；P = .01)。结论：<1>异丙酚</1>轻度镇静可使<6>术后谵妄</6>发生率降低50%。限制腰麻时的镇静深度是预防老年患者<7>术后谵妄</7>的一种简单、安全、经济的干预措施，可广泛推广应用。", "revised": true}
{"doc_key": "20552622", "sentences": [["Swallowing", "-", "induced", "atrial", "tachyarrhythmia", "triggered", "by", "salbutamol", ":", "case", "report", "and", "review", "of", "the", "literature", ".", "CASE", ":", "A", "49", "-", "year", "-", "old", "patient", "experienced", "chest", "discomfort", "while", "swallowing", ".", "On", "electrocardiogram", ",", "episodes", "of", "atrial", "tachyarrhythmia", "were", "recorded", "immediately", "after", "swallowing", ";", "24", "-", "hour", "Holter", "monitoring", "recorded", "several", "events", ".", "The", "arrhythmia", "resolved", "after", "therapy", "with", "atenolol", ",", "but", "recurred", "a", "year", "later", ".", "The", "patient", "noticed", "that", "before", "these", "episodes", "he", "had", "been", "using", "an", "inhalator", "of", "salbutamol", ".", "After", "stopping", "the", "beta", "-", "agonist", ",", "and", "after", "a", "week", "with", "the", "atenolol", ",", "the", "arrhythmia", "disappeared", ".", "DISCUSSION", ":", "Swallowing", "-", "induced", "atrial", "tachyarrhythmia", "(", "SIAT", ")", "is", "a", "rare", "phenomenon", ".", "Fewer", "than", "50", "cases", "of", "SIAT", "have", "been", "described", "in", "the", "literature", ".", "This", "article", "summarizes", "all", "the", "cases", "published", ",", "creating", "a", "comprehensive", "review", "of", "the", "current", "knowledge", "and", "approach", "to", "SIAT", ".", "It", "discusses", "demographics", ",", "clinical", "characteristics", "and", "types", "of", "arrhythmia", ",", "postulated", "mechanisms", "of", "SIAT", ",", "and", "different", "treatment", "possibilities", "such", "as", "medications", ",", "surgery", ",", "and", "radiofrequency", "catheter", "ablation", "(", "RFCA", ")", ".", "CONCLUSION", ":", "Salbutamol", "is", "presented", "here", "as", "a", "possible", "trigger", "for", "SIAT", ".", "Although", "it", "is", "difficult", "to", "define", "causality", "in", "a", "case", "report", ",", "it", "is", "logical", "to", "think", "that", "a", "beta", "-", "agonist", "like", "salbutamol", "(", "known", "to", "induce", "tachycardia", ")", "may", "be", "the", "trigger", "of", "adrenergic", "reflexes", "originating", "in", "the", "esophagus", "while", "swallowing", "and", "that", "a", "beta", "-", "blocker", "such", "as", "atenolol", "(", "that", "blocks", "the", "adrenergic", "activity", ")", "may", "relieve", "it", "."]], "ner": [[[7, 7, "Chemical"], [82, 82, "Chemical"], [188, 188, "Chemical"], [222, 222, "Chemical"], [3, 4, "Disease"], [37, 38, "Disease"], [108, 109, "Disease"], [111, 111, "Disease"], [123, 123, "Disease"], [150, 150, "Disease"], [166, 166, "Disease"], [197, 197, "Disease"], [60, 60, "Chemical"], [97, 97, "Chemical"], [250, 250, "Chemical"], [55, 55, "Disease"], [100, 100, "Disease"], [161, 161, "Disease"], [227, 227, "Disease"]]], "relations": [[[7, 7, 3, 4, "CID"], [7, 7, 37, 38, "CID"], [7, 7, 108, 109, "CID"], [7, 7, 111, 111, "CID"], [7, 7, 123, 123, "CID"], [7, 7, 150, 150, "CID"], [7, 7, 166, 166, "CID"], [7, 7, 197, 197, "CID"], [82, 82, 3, 4, "CID"], [82, 82, 37, 38, "CID"], [82, 82, 108, 109, "CID"], [82, 82, 111, 111, "CID"], [82, 82, 123, 123, "CID"], [82, 82, 150, 150, "CID"], [82, 82, 166, 166, "CID"], [82, 82, 197, 197, "CID"], [188, 188, 3, 4, "CID"], [188, 188, 37, 38, "CID"], [188, 188, 108, 109, "CID"], [188, 188, 111, 111, "CID"], [188, 188, 123, 123, "CID"], [188, 188, 150, 150, "CID"], [188, 188, 166, 166, "CID"], [188, 188, 197, 197, "CID"], [222, 222, 3, 4, "CID"], [222, 222, 37, 38, "CID"], [222, 222, 108, 109, "CID"], [222, 222, 111, 111, "CID"], [222, 222, 123, 123, "CID"], [222, 222, 150, 150, "CID"], [222, 222, 166, 166, "CID"], [222, 222, 197, 197, "CID"]]], "clusters": [], "translated": "由<0>沙丁胺醇</0>引发的吞咽诱发<4>房性心动过速</4>：病例报告和文献复习。案例：一位49岁的患者在吞咽时感到胸部不适。在心电图上，吞咽后立即记录到<5>房性心动过速</5>发作；24小时 Holter 监测记录了几个事件。<15>心律失常</15>在<12>阿替洛尔</12>治疗后得到缓解，但一年后又复发。患者注意到，在这些发作之前，他一直在使用<1>沙丁胺醇</1>吸入器。在停止使用β-激动剂并使用<13>阿替洛尔</13>一周后，<16>心律失常</16>消失了。讨论：吞咽诱发的<6>房性心动过速</6>（<7>SIAT</7>）是一种罕见现象。文献中描述的<8>SIAT</8>病例不到50例。本文总结了所有已发表的案例，全面回顾了<9>SIAT</9>的当前知识和方法。它讨论了<17>心律失常</17>的人口统计学、临床特征和类型、<10>SIAT</10>的假设机制以及药物、手术和射频导管消融（RFCA）等不同的治疗可能性。结论：此处提出的<2>沙丁胺醇</2>可能是<11>SIAT</11>的触发因素。虽然很难在病例报告中定义因果关系，但可以合理地认为，像<3>沙丁胺醇</3>（已知会诱发<18>心动过速</18>）这样的β受体激动剂可能是肾上腺素能吞咽时起源于食道的反射和β受体阻滞剂如<14>阿替洛尔</14>（阻断肾上腺素能的活性）可能会缓解它。", "revised": true}
{"doc_key": "3057041", "sentences": [["Multicenter", ",", "double", "-", "blind", ",", "multiple", "-", "dose", ",", "parallel", "-", "groups", "efficacy", "and", "safety", "trial", "of", "azelastine", ",", "chlorpheniramine", ",", "and", "placebo", "in", "the", "treatment", "of", "spring", "allergic", "rhinitis", ".", "Azelastine", ",", "a", "novel", "antiallergic", "medication", ",", "was", "compared", "with", "chlorpheniramine", "maleate", "and", "placebo", "for", "efficacy", "and", "safety", "in", "the", "treatment", "of", "spring", "allergic", "rhinitis", "in", "a", "multicenter", ",", "double", "-", "blind", ",", "multiple", "-", "dose", ",", "parallel", "-", "groups", "study", ".", "One", "hundred", "fifty", "-", "five", "subjects", "participated", ".", "Subjects", "ranged", "in", "age", "from", "18", "to", "60", "years", "of", "age", "and", "had", "at", "least", "a", "2", "-", "year", "history", "of", "spring", "allergic", "rhinitis", ",", "confirmed", "by", "positive", "skin", "test", "to", "spring", "aeroallergens", ".", "Medications", "were", "given", "four", "times", "daily", ";", "the", "azelastine", "groups", "received", "0", ".", "5", ",", "1", ".", "0", ",", "or", "2", ".", "0", "mg", "in", "the", "morning", "and", "evening", "with", "placebo", "in", "the", "early", "and", "late", "afternoon", ";", "the", "chlorpheniramine", "group", "received", "4", ".", "0", "mg", "four", "times", "daily", ".", "Daily", "subject", "symptom", "cards", "were", "completed", "during", "a", "screening", "period", "to", "assess", "pretreatment", "symptoms", "and", "during", "a", "4", "-", "week", "treatment", "period", "while", "subjects", "received", "study", "medications", ".", "Individual", "symptoms", ",", "total", "symptoms", ",", "and", "major", "symptoms", "were", "compared", "to", "determine", "efficacy", "of", "medication", ".", "Elicited", ",", "volunteered", ",", "and", "observed", "adverse", "experiences", "were", "recorded", "for", "each", "subject", "and", "compared", "among", "groups", ".", "Vital", "signs", ",", "body", "weights", ",", "serum", "chemistry", "values", ",", "complete", "blood", "cell", "counts", ",", "urine", "studies", ",", "and", "electrocardiograms", "were", "obtained", "for", "each", "subject", "and", "compared", "among", "groups", ".", "Symptoms", "relief", "in", "the", "group", "receiving", "the", "highest", "concentration", "of", "azelastine", "(", "2", ".", "0", "mg", "twice", "daily", ")", "was", "statistically", "greater", "than", "in", "the", "placebo", "group", "during", "all", "weeks", "of", "the", "study", ".", "Lower", "doses", "of", "azelastine", "were", "statistically", "more", "effective", "than", "placebo", "only", "during", "portions", "of", "the", "first", "3", "weeks", "of", "the", "study", ".", "In", "contrast", ",", "although", "the", "chlorpheniramine", "group", "did", "have", "fewer", "symptoms", "than", "the", "placebo", "group", "during", "the", "study", ",", "the", "difference", "never", "reached", "statistical", "significance", "during", "any", "week", "of", "the", "study", ".", "There", "were", "no", "serious", "side", "effects", "in", "any", "of", "the", "treatment", "groups", ".", "Drowsiness", "and", "altered", "taste", "perception", "were", "increased", "significantly", "over", "placebo", "only", "in", "the", "high", "-", "dose", "azelastine", "group", ".", "Azelastine", "appears", "to", "be", "a", "safe", ",", "efficacious", "medication", "for", "seasonal", "allergic", "rhinitis", "."]], "ner": [[[18, 18, "Chemical"], [32, 32, "Chemical"], [124, 124, "Chemical"], [269, 269, "Chemical"], [296, 296, "Chemical"], [376, 376, "Chemical"], [379, 379, "Chemical"], [360, 360, "Disease"], [362, 364, "Disease"], [28, 30, "Disease"], [54, 56, "Disease"], [103, 105, "Disease"], [389, 391, "Disease"], [20, 20, "Chemical"], [42, 43, "Chemical"], [155, 155, "Chemical"], [320, 320, "Chemical"]]], "relations": [[[18, 18, 360, 360, "CID"], [32, 32, 360, 360, "CID"], [124, 124, 360, 360, "CID"], [269, 269, 360, 360, "CID"], [296, 296, 360, 360, "CID"], [376, 376, 360, 360, "CID"], [379, 379, 360, 360, "CID"], [18, 18, 362, 364, "CID"], [32, 32, 362, 364, "CID"], [124, 124, 362, 364, "CID"], [269, 269, 362, 364, "CID"], [296, 296, 362, 364, "CID"], [376, 376, 362, 364, "CID"], [379, 379, 362, 364, "CID"]]], "clusters": [], "translated": "<0>氮卓斯汀</0>、<13>扑尔敏</13>和安慰剂治疗<9>春季过敏性鼻炎</9>的疗效和安全性的多中心、双盲、多剂量、平行组试验。 <1>氮卓斯汀</1>，一种新型抗过敏药物，在一项多中心、双盲、多剂量、平行组研究中与<14>马来酸扑尔敏</14>和安慰剂进行了疗效和安全性比较，用于治疗<10>春季过敏性鼻炎</10>。共有 155 名受试者参与，年龄在 18 至 60 岁之间，且过去 2 年间有过<11>春季过敏性鼻炎</11>的病史，通过春季吸入过敏原皮肤试验确认。药物每日四次给予；<2>氮卓斯汀</2>组在早晚服用 0.5、1、或 2 毫克，下午早和晚服用安慰剂；<15>扑尔敏</15>组每日四次口服 4.0 毫克。在筛选期间，通过每日症状卡记录受试者在治疗前的症状，在接受研究药物治疗 4 周期间，记录每日症状卡以评估治疗效果。比较个体症状、总体症状和主要症状以确定药物疗效。对每位受试者进行症状触发、自愿和观察到的不良事件记录，并在各组之间进行比较。获取每位受试者的生命体征、体重、血清化学值、完整的血细胞计数、尿液检查和心电图，并在各组之间进行比较。接受最高浓度<3>氮卓斯汀</3>（2 毫克，每天两次）的组在研究的所有周中，症状缓解较安慰剂组统计学上更显著。低剂量<4>氮卓斯汀</4>仅在研究的前 3 周的部分时间内，统计学上比安慰剂更有效。相比之下，尽管在研究过程中<16>扑尔敏</16>组的症状确实比安慰剂组少，但差异在研究任何 1 周内均未达到统计显着性。所有治疗组都未出现严重副作用。而只有在高剂量<5>氮卓斯汀</5>组中，<7>嗜睡</7>和<8>味觉改变</8>才显著增加。<6>氮卓斯汀</6>似乎是一种安全、有效的药物，可用于<12>季节性过敏性鼻炎</12>的治疗。", "revised": true}
{"doc_key": "19944333", "sentences": [["Sorafenib", "-", "induced", "acute", "myocardial", "infarction", "due", "to", "coronary", "artery", "spasm", ".", "A", "65", "-", "year", "-", "old", "man", "with", "advanced", "renal", "cell", "carcinoma", "was", "admitted", "due", "to", "continuing", "chest", "pain", "at", "rest", ".", "Two", "weeks", "before", "his", "admission", ",", "sorafenib", "had", "been", "started", ".", "He", "was", "diagnosed", "with", "non", "-", "ST", "-", "elevation", "myocardial", "infarction", "by", "laboratory", "data", "and", "electrocardiogram", ".", "Enhanced", "heart", "magnetic", "resonance", "imaging", "also", "showed", "subendocardial", "infarction", ".", "However", ",", "there", "was", "no", "stenosis", "in", "coronary", "arteries", "on", "angiography", ".", "Coronary", "artery", "spasm", "was", "induced", "by", "a", "provocative", "test", ".", "Cessation", "of", "sorafenib", "and", "administration", "of", "Ca", "-", "channel", "blocker", "and", "nitrates", "ameliorated", "his", "symptoms", ",", "but", "relapse", "occurred", "after", "resumption", "of", "sorafenib", ".", "Addition", "of", "oral", "nicorandil", "reduced", "his", "symptoms", "and", "maintained", "stable", "angina", "status", ".", "We", "report", "the", "first", "case", "of", "sorafenib", "-", "induced", "coronary", "artery", "spasm", ".", "Sorafenib", "is", "a", "multikinase", "inhibitor", "that", "targets", "signaling", "pathways", "necessary", "for", "cellular", "proliferation", "and", "survival", ".", "On", "the", "other", "hand", ",", "the", "Rho", "/", "ROCK", "pathway", "has", "an", "important", "role", "in", "the", "pathogenesis", "of", "coronary", "artery", "spasm", ".", "Our", "report", "may", "show", "an", "adverse", "effect", "on", "the", "Rho", "/", "ROCK", "pathway", "by", "sorafenib", "use", "."]], "ner": [[[0, 0, "Chemical"], [40, 40, "Chemical"], [96, 96, "Chemical"], [116, 116, "Chemical"], [137, 137, "Chemical"], [144, 144, "Chemical"], [196, 196, "Chemical"], [8, 10, "Disease"], [84, 86, "Disease"], [140, 142, "Disease"], [178, 180, "Disease"], [4, 5, "Disease"], [54, 55, "Disease"], [69, 70, "Disease"], [21, 23, "Disease"], [29, 30, "Disease"], [127, 128, "Disease"], [100, 100, "Chemical"], [105, 105, "Chemical"], [121, 121, "Chemical"]]], "relations": [[[0, 0, 8, 10, "CID"], [0, 0, 84, 86, "CID"], [0, 0, 140, 142, "CID"], [0, 0, 178, 180, "CID"], [40, 40, 8, 10, "CID"], [40, 40, 84, 86, "CID"], [40, 40, 140, 142, "CID"], [40, 40, 178, 180, "CID"], [96, 96, 8, 10, "CID"], [96, 96, 84, 86, "CID"], [96, 96, 140, 142, "CID"], [96, 96, 178, 180, "CID"], [116, 116, 8, 10, "CID"], [116, 116, 84, 86, "CID"], [116, 116, 140, 142, "CID"], [116, 116, 178, 180, "CID"], [137, 137, 8, 10, "CID"], [137, 137, 84, 86, "CID"], [137, 137, 140, 142, "CID"], [137, 137, 178, 180, "CID"], [144, 144, 8, 10, "CID"], [144, 144, 84, 86, "CID"], [144, 144, 140, 142, "CID"], [144, 144, 178, 180, "CID"], [196, 196, 8, 10, "CID"], [196, 196, 84, 86, "CID"], [196, 196, 140, 142, "CID"], [196, 196, 178, 180, "CID"]]], "clusters": [], "translated": "<0>索拉非尼</0> - 因<7>冠状动脉痉挛</7>引起的急性<11>心肌梗死</11>。一名患有晚期<14>肾细胞癌</14>的65岁男性因静息时持续<15>胸痛</15>入院。在他入院前两周，<1>索拉非尼</1>已开始使用。经化验资料及心电图诊断为非ST段抬高型<12>心肌梗死</12>。增强心脏磁共振成像也显示<13>心内膜下梗塞</13>。但造影显示冠状动脉未见狭窄。<8>冠状动脉痉挛</8>是由激发试验引起的。停用<2>索拉非尼</2>并给予<17>Ca</17>-通道阻滞剂和<18>硝酸盐</18>可改善症状，但恢复<3>索拉非尼</3>后复发。加用口服<19>尼可地尔</19>，症状减轻，维持<16>稳定型心绞痛</16>状态。我们报道了第一例<4>索拉非尼</4>引起的<9>冠状动脉痉挛</9>。<5>索拉非尼</5>是一种多激酶抑制剂，靶向细胞增殖和存活所必需的信号通路。另一方面，Rho/ROCK通路在<10>冠状动脉痉挛</10>的发病机制中具有重要作用。我们的报告可能显示<6>索拉非尼</6>使用对Rho/ROCK通路的不利影响。", "revised": true}
{"doc_key": "6540303", "sentences": [["Effects", "of", "amine", "pretreatment", "on", "ketamine", "catatonia", "in", "pinealectomized", "or", "hypophysectomized", "animals", ".", "The", "present", "studies", "were", "designed", "to", "clarify", "the", "role", "of", "catecholamines", "and", "pineal", "idolamines", "on", "ketamine", "-", "induced", "catatonia", "in", "the", "intact", ",", "pinealectomized", "or", "hypophysectomized", "chick", "and", "rat", ".", "In", "the", "pinealectomized", "chick", ",", "pretreatment", "with", "dopamine", "increased", "the", "duration", "of", "catatonia", "(", "DOC", ")", "after", "ketamine", ",", "but", "pretreatment", "with", "norepinephrine", "did", "not", ".", "The", "pineal", "indolamines", "exhibited", "mixed", "actions", ".", "Serotonin", "and", "N", "-", "acetyl", "serotonin", "which", "augmented", "ketamine", "DOC", ",", "did", "not", "do", "so", "in", "the", "absence", "of", "the", "pineal", "gland", ",", "whereas", "melatonin", "potentiated", "the", "ketamine", "DOC", "in", "both", "the", "intact", "and", "pinealectomized", "chick", ".", "Ketamine", "was", "more", "potent", "in", "the", "hypophysectomized", "chick", "and", "the", "circadian", "rhythm", "noted", "in", "the", "intact", "chick", "was", "absent", ";", "furthermore", ",", "melatonin", "did", "not", "augment", "the", "ketamine", "DOC", "whereas", "dopamine", "continued", "to", "do", "so", ".", "This", "study", "did", "not", "demonstrate", "a", "species", "difference", "regarding", "the", "role", "of", "the", "amines", "on", "the", "pineal", "in", "spite", "of", "the", "immature", "blood", "-", "brain", "barrier", "in", "the", "young", "chick", "and", "the", "intact", "barrier", "in", "the", "rat", ".", "In", "addition", ",", "these", "data", "indicate", "a", "direct", "role", "of", "the", "pituitary", "in", "the", "augmentation", "of", "ketamine", "DOC", "induced", "by", "melatonin", ".", "Furthermore", ",", "dopamine", "appeared", "to", "act", "on", "systems", "more", "closely", "involved", "with", "the", "induction", "of", "ketamine", "catatonia", "rather", "than", "directly", "on", "the", "pituitary", "."]], "ner": [[[5, 5, "Chemical"], [28, 28, "Chemical"], [60, 60, "Chemical"], [84, 84, "Chemical"], [103, 103, "Chemical"], [113, 113, "Chemical"], [140, 140, "Chemical"], [203, 203, "Chemical"], [224, 224, "Chemical"], [6, 6, "Disease"], [31, 31, "Disease"], [55, 55, "Disease"], [225, 225, "Disease"], [50, 50, "Chemical"], [143, 143, "Chemical"], [211, 211, "Chemical"], [76, 76, "Chemical"], [100, 100, "Chemical"], [135, 135, "Chemical"], [207, 207, "Chemical"], [2, 2, "Chemical"], [162, 162, "Chemical"], [23, 23, "Chemical"], [65, 65, "Chemical"], [78, 81, "Chemical"]]], "relations": [[[5, 5, 6, 6, "CID"], [5, 5, 31, 31, "CID"], [5, 5, 55, 55, "CID"], [5, 5, 225, 225, "CID"], [28, 28, 6, 6, "CID"], [28, 28, 31, 31, "CID"], [28, 28, 55, 55, "CID"], [28, 28, 225, 225, "CID"], [60, 60, 6, 6, "CID"], [60, 60, 31, 31, "CID"], [60, 60, 55, 55, "CID"], [60, 60, 225, 225, "CID"], [84, 84, 6, 6, "CID"], [84, 84, 31, 31, "CID"], [84, 84, 55, 55, "CID"], [84, 84, 225, 225, "CID"], [103, 103, 6, 6, "CID"], [103, 103, 31, 31, "CID"], [103, 103, 55, 55, "CID"], [103, 103, 225, 225, "CID"], [113, 113, 6, 6, "CID"], [113, 113, 31, 31, "CID"], [113, 113, 55, 55, "CID"], [113, 113, 225, 225, "CID"], [140, 140, 6, 6, "CID"], [140, 140, 31, 31, "CID"], [140, 140, 55, 55, "CID"], [140, 140, 225, 225, "CID"], [203, 203, 6, 6, "CID"], [203, 203, 31, 31, "CID"], [203, 203, 55, 55, "CID"], [203, 203, 225, 225, "CID"], [224, 224, 6, 6, "CID"], [224, 224, 31, 31, "CID"], [224, 224, 55, 55, "CID"], [224, 224, 225, 225, "CID"], [50, 50, 6, 6, "CID"], [50, 50, 31, 31, "CID"], [50, 50, 55, 55, "CID"], [50, 50, 225, 225, "CID"], [143, 143, 6, 6, "CID"], [143, 143, 31, 31, "CID"], [143, 143, 55, 55, "CID"], [143, 143, 225, 225, "CID"], [211, 211, 6, 6, "CID"], [211, 211, 31, 31, "CID"], [211, 211, 55, 55, "CID"], [211, 211, 225, 225, "CID"], [76, 76, 6, 6, "CID"], [76, 76, 31, 31, "CID"], [76, 76, 55, 55, "CID"], [76, 76, 225, 225, "CID"], [100, 100, 6, 6, "CID"], [100, 100, 31, 31, "CID"], [100, 100, 55, 55, "CID"], [100, 100, 225, 225, "CID"], [135, 135, 6, 6, "CID"], [135, 135, 31, 31, "CID"], [135, 135, 55, 55, "CID"], [135, 135, 225, 225, "CID"], [207, 207, 6, 6, "CID"], [207, 207, 31, 31, "CID"], [207, 207, 55, 55, "CID"], [207, 207, 225, 225, "CID"]]], "clusters": [], "translated": "<20>胺</20>预处理对松果体切除或垂体切除动物<0>氯胺酮</0><9>紧张症</9> 的影响。本研究旨在阐明<22>儿茶酚胺</22>和松果体偶像胺对<1>氯胺酮</1>诱导的<10>紧张症</10>在完整的松果体切除或垂体切除的鸡和大鼠中的作用。在松果体切除的小鸡中，用<13>多巴胺</13>预处理增加了<2>氯胺酮</2>后<11>紧张症</11> (DOC)的持续时间，但用<23>去甲肾上腺素</23>预处理没有。松果体吲哚胺表现出混合作用。<16>血清素</16>和<24>N-乙酰血清素</24>增加了<3>氯胺酮</3>DOC，在没有松果体的情况下没有这样做，而<17>褪黑激素</17>增强了完整和切除松果体的小鸡中的<4>氯胺酮</4>DOC。<5>氯胺酮</5>在垂体切除的小鸡中更有效，并且在完整小鸡中没有注意到昼夜节律；此外，<18>褪黑激素</18>不会增加<6>氯胺酮</6>DOC，而<14>多巴胺</14>会继续增加。尽管小鸡的血脑屏障不成熟而大鼠的血脑屏障完好无损，但这项研究并未证明<21>胺</21>对松果体的作用存在物种差异。此外，这些数据表明垂体在<19>褪黑激素</19>诱导的<7>氯胺酮</7>DOC增加中起直接作用。此外，<15>多巴胺</15>似乎作用于与<8>氯胺酮</8><12>紧张症</12>的诱导更密切相关的系统，而不是直接作用于垂体。", "revised": true}
{"doc_key": "17975693", "sentences": [["Anxiogenic", "potential", "of", "ciprofloxacin", "and", "norfloxacin", "in", "rats", ".", "INTRODUCTION", ":", "The", "possible", "anxiogenic", "effects", "of", "fluoroquinolones", ",", "namely", "ciprofloxacin", "and", "norfloxacin", ",", "were", "investigated", "in", "adult", "Charles", "Foster", "albino", "rats", "of", "either", "sex", ",", "weighing", "150", "-", "200", "g", ".", "METHODS", ":", "The", "drugs", "were", "given", "orally", ",", "in", "doses", "of", "50", "mg", "/", "kg", "for", "five", "consecutive", "days", "and", "the", "experiments", "were", "performed", "on", "the", "fifth", "day", ".", "The", "tests", "included", "open", "-", "field", "exploratory", "behaviour", ",", "elevated", "plus", "maze", "and", "elevated", "zero", "maze", ",", "social", "interaction", "and", "novelty", "-", "suppressed", "feeding", "latency", "behaviour", ".", "RESULTS", ":", "The", "results", "indicate", "that", "ciprofloxacin", "-", "and", "norfloxacin", "-", "treated", "rats", "showed", "anxious", "behaviour", "in", "comparison", "to", "control", "rats", "in", "all", "the", "parameters", "studied", ".", "However", ",", "ciprofloxacin", "-", "and", "norfloxacin", "-", "treated", "rats", "did", "not", "differ", "significantly", "from", "each", "other", "in", "various", "behavioural", "parameters", ".", "CONCLUSION", ":", "The", "present", "experimental", "findings", "substantiate", "the", "clinically", "observed", "anxiogenic", "potential", "of", "ciprofloxacin", "and", "norfloxacin", "."]], "ner": [[[3, 3, "Chemical"], [19, 19, "Chemical"], [103, 103, "Chemical"], [126, 126, "Chemical"], [158, 158, "Chemical"], [111, 112, "Disease"], [5, 5, "Chemical"], [21, 21, "Chemical"], [106, 106, "Chemical"], [129, 129, "Chemical"], [160, 160, "Chemical"], [16, 16, "Chemical"]]], "relations": [[[3, 3, 111, 112, "CID"], [19, 19, 111, 112, "CID"], [103, 103, 111, 112, "CID"], [126, 126, 111, 112, "CID"], [158, 158, 111, 112, "CID"], [5, 5, 111, 112, "CID"], [21, 21, 111, 112, "CID"], [106, 106, 111, 112, "CID"], [129, 129, 111, 112, "CID"], [160, 160, 111, 112, "CID"]]], "clusters": [], "translated": "<0>环丙沙星</0>和<6>诺氟沙星</6>对大鼠的焦虑作用。简介：研究了<11>氟喹诺酮类抗菌药物</11>（例如，<1>环丙沙星</1>和<7>诺氟沙星</7>） 可能的焦虑作用，采用体重为150-200g的性别不限的成年Charles Foster雄鼠和雌鼠，口服给药五天，每天50mg/kg，第五天进行实验。测试包括开阔地探索行为、高架十字迷宫和高架零迷宫、社会互动和抑制新奇的进食潜伏期行为。结果：结果表明，与对照大鼠相比，<2>环丙沙星</2> 和 <8>诺氟沙星</8> 处理的大鼠在所有研究参数中均表现出<5>焦虑行为</5>。然而，在各种行为参数上，<3>环丙沙星</3> 和 <9>诺氟沙星</9>处理的大鼠没有显着差异。结论：目前的实验结果证实了<4>环丙沙星</4>和<10> 诺氟沙星</10>在临床中观察到的潜在焦虑作用。", "revised": true}
{"doc_key": "17074608", "sentences": [["Valproate", "-", "induced", "chorea", "and", "encephalopathy", "in", "atypical", "nonketotic", "hyperglycinemia", ".", "Nonketotic", "hyperglycinemia", "is", "a", "disorder", "of", "amino", "acid", "metabolism", "in", "which", "a", "defect", "in", "the", "glycine", "cleavage", "system", "leads", "to", "an", "accumulation", "of", "glycine", "in", "the", "brain", "and", "other", "body", "compartments", ".", "In", "the", "classical", "form", "it", "presents", "as", "neonatal", "apnea", ",", "intractable", "seizures", ",", "and", "hypotonia", ",", "followed", "by", "significant", "psychomotor", "retardation", ".", "An", "important", "subset", "of", "children", "with", "nonketotic", "hyperglycinemia", "are", "atypical", "variants", "who", "present", "in", "a", "heterogeneous", "manner", ".", "This", "report", "describes", "a", "patient", "with", "mild", "language", "delay", "and", "mental", "retardation", ",", "who", "was", "found", "to", "have", "nonketotic", "hyperglycinemia", "following", "her", "presentation", "with", "acute", "encephalopathy", "and", "chorea", "shortly", "after", "initiation", "of", "valproate", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [115, 115, "Chemical"], [3, 3, "Disease"], [110, 110, "Disease"], [5, 5, "Disease"], [108, 108, "Disease"], [8, 9, "Disease"], [11, 12, "Disease"], [71, 72, "Disease"], [101, 102, "Disease"], [15, 19, "Disease"], [51, 51, "Disease"], [54, 54, "Disease"], [57, 57, "Disease"], [62, 63, "Disease"], [90, 91, "Disease"], [93, 94, "Disease"], [26, 26, "Chemical"], [34, 34, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 110, 110, "CID"], [115, 115, 3, 3, "CID"], [115, 115, 110, 110, "CID"], [0, 0, 5, 5, "CID"], [0, 0, 108, 108, "CID"], [115, 115, 5, 5, "CID"], [115, 115, 108, 108, "CID"]]], "clusters": [], "translated": " <0>丙戊酸盐</0> - 在非典型<6>非酮症高甘氨酸血症</6>中诱发<2>舞蹈病</2>和<4>脑病</4>。<7>非酮症高甘氨酸血症</7>是一种<10>氨基酸代谢紊乱</10>，其中<17>甘氨酸</17>裂解系统缺陷导致<18>甘氨酸</18>在大脑和其他身体部位积聚。在经典形式中，它表现为新生儿<11>呼吸暂停</11>，顽固性<12>癫痫发作</12>和<13>肌张力减退</13>，随后是显著的<14>精神运动迟缓</14>。<8>非酮症高甘氨酸血症</8>儿童的一个重要子集是以异质性方式呈现的非典型变异。本报告描述了一名轻度<15>语言发育迟缓</15>和<16>精神发育迟滞</16>的患者，该患者在服用<1>丙戊酸盐</1>治疗不久后出现急性<5>脑病</5>和<3>舞蹈病</3>，之后被发现患有<9>非酮症高甘氨酸血症</9>。", "revised": true}
{"doc_key": "20164825", "sentences": [["Metformin", "prevents", "experimental", "gentamicin", "-", "induced", "nephropathy", "by", "a", "mitochondria", "-", "dependent", "pathway", ".", "The", "antidiabetic", "drug", "metformin", "can", "diminish", "apoptosis", "induced", "by", "oxidative", "stress", "in", "endothelial", "cells", "and", "prevent", "vascular", "dysfunction", "even", "in", "nondiabetic", "patients", ".", "Here", "we", "tested", "whether", "it", "has", "a", "beneficial", "effect", "in", "a", "rat", "model", "of", "gentamicin", "toxicity", ".", "Mitochondrial", "analysis", ",", "respiration", "intensity", ",", "levels", "of", "reactive", "oxygen", "species", ",", "permeability", "transition", ",", "and", "cytochrome", "c", "release", "were", "assessed", "3", "and", "6", "days", "after", "gentamicin", "administration", ".", "Metformin", "treatment", "fully", "blocked", "gentamicin", "-", "mediated", "acute", "renal", "failure", ".", "This", "was", "accompanied", "by", "a", "lower", "activity", "of", "N", "-", "acetyl", "-", "beta", "-", "D", "-", "glucosaminidase", ",", "together", "with", "a", "decrease", "of", "lipid", "peroxidation", "and", "increase", "of", "antioxidant", "systems", ".", "Metformin", "also", "protected", "the", "kidney", "from", "histological", "damage", "6", "days", "after", "gentamicin", "administration", ".", "These", "in", "vivo", "markers", "of", "kidney", "dysfunction", "and", "their", "correction", "by", "metformin", "were", "complemented", "by", "in", "vitro", "studies", "of", "mitochondrial", "function", ".", "We", "found", "that", "gentamicin", "treatment", "depleted", "respiratory", "components", "(", "cytochrome", "c", ",", "NADH", ")", ",", "probably", "due", "to", "the", "opening", "of", "mitochondrial", "transition", "pores", ".", "These", "injuries", ",", "partly", "mediated", "by", "a", "rise", "in", "reactive", "oxygen", "species", "from", "the", "electron", "transfer", "chain", ",", "were", "significantly", "decreased", "by", "metformin", ".", "Thus", ",", "our", "study", "suggests", "that", "pleiotropic", "effects", "of", "metformin", "can", "lessen", "gentamicin", "nephrotoxicity", "and", "improve", "mitochondrial", "homeostasis", "."]], "ner": [[[3, 3, "Chemical"], [51, 51, "Chemical"], [80, 80, "Chemical"], [87, 87, "Chemical"], [136, 136, "Chemical"], [164, 164, "Chemical"], [222, 222, "Chemical"], [90, 92, "Disease"], [0, 0, "Chemical"], [17, 17, "Chemical"], [83, 83, "Chemical"], [125, 125, "Chemical"], [150, 150, "Chemical"], [208, 208, "Chemical"], [219, 219, "Chemical"], [6, 6, "Disease"], [144, 145, "Disease"], [223, 223, "Disease"], [30, 31, "Disease"], [52, 52, "Disease"], [63, 63, "Chemical"], [196, 196, "Chemical"]]], "relations": [[[3, 3, 90, 92, "CID"], [51, 51, 90, 92, "CID"], [80, 80, 90, 92, "CID"], [87, 87, 90, 92, "CID"], [136, 136, 90, 92, "CID"], [164, 164, 90, 92, "CID"], [222, 222, 90, 92, "CID"]]], "clusters": [], "translated": " <8>二甲双胍</8>预防实验性<0>庆大霉素</0>-诱导的 <15>肾病</15>，途径为线粒体依赖性。抗糖尿病药物 <9>二甲双胍</9>可以减少内皮细胞氧化应激诱导的细胞凋亡并预防非糖尿病患者的<18>血管功能障碍</18>。在这里，我们测试了它是否对 <1>庆大霉素</1> <19>毒性</19> 大鼠模型有益。在 <2>庆大霉素</2> 给药后三天和六天分别评估线粒体分析、呼吸强度、活性<20>氧</20>的水平、通透性范围和细胞色素c的释放。 <10>二甲双胍</10>治疗完全阻断了<3>庆大霉素</3>介导的<7>急性肾功能衰竭</7>。这伴随着较低的N-乙酰基-β-D-氨基葡萄糖苷酶活性，以及脂质过氧化反应的减少和抗氧化系统的增加。在 <4>庆大霉素</4> 给药后六天，<11>二甲双胍</11>还保护了肾脏使其免受组织学损伤。这些体内标志物的<16>肾功能障碍</16>，以及它们的纠正通过 <12>二甲双胍</12>的体外线粒体功能研究得到了加强。我们发现， <5>庆大霉素</5>的处理耗尽了呼吸成分（细胞色素c，NADH），这可能是由于线粒体转化孔的开放。部分损伤通过电子传递链中活性<21>氧</21>物种的增加介导，通过<13>二甲双胍</13>得以显著降低。因此，我们的研究表明， <14>二甲双胍</14>的多效性可以减轻<6>庆大霉素</6><17>肾毒性</17>，并改善线粒体稳态。", "revised": true}
{"doc_key": "15579441", "sentences": [["Hypoxia", "in", "renal", "disease", "with", "proteinuria", "and", "/", "or", "glomerular", "hypertension", ".", "Despite", "the", "increasing", "need", "to", "identify", "and", "quantify", "tissue", "oxygenation", "at", "the", "cellular", "level", ",", "relatively", "few", "methods", "have", "been", "available", ".", "In", "this", "study", ",", "we", "developed", "a", "new", "hypoxia", "-", "responsive", "reporter", "vector", "using", "a", "hypoxia", "-", "responsive", "element", "of", "the", "5", "'", "vascular", "endothelial", "growth", "factor", "untranslated", "region", "and", "generated", "a", "novel", "hypoxia", "-", "sensing", "transgenic", "rat", ".", "We", "then", "applied", "this", "animal", "model", "to", "the", "detection", "of", "tubulointerstitial", "hypoxia", "in", "the", "diseased", "kidney", ".", "With", "this", "model", ",", "we", "were", "able", "to", "identify", "diffuse", "cortical", "hypoxia", "in", "the", "puromycin", "aminonucleoside", "-", "induced", "nephrotic", "syndrome", "and", "focal", "and", "segmental", "hypoxia", "in", "the", "remnant", "kidney", "model", ".", "Expression", "of", "the", "hypoxia", "-", "responsive", "transgene", "increased", "throughout", "the", "observation", "period", ",", "reaching", "2", ".", "2", "-", "fold", "at", "2", "weeks", "in", "the", "puromycin", "aminonucleoside", "model", "and", "2", ".", "6", "-", "fold", "at", "4", "weeks", "in", "the", "remnant", "kidney", "model", ",", "whereas", "that", "of", "vascular", "endothelial", "growth", "factor", "showed", "a", "mild", "decrease", ",", "reflecting", "distinct", "behaviors", "of", "the", "two", "genes", ".", "The", "degree", "of", "hypoxia", "showed", "a", "positive", "correlation", "with", "microscopic", "tubulointerstitial", "injury", "in", "both", "models", ".", "Finally", ",", "we", "identified", "the", "localization", "of", "proliferating", "cell", "nuclear", "antigen", "-", "positive", ",", "ED", "-", "1", "-", "positive", ",", "and", "terminal", "dUTP", "nick", "-", "end", "labeled", "-", "positive", "cells", "in", "the", "hypoxic", "cortical", "area", "in", "the", "remnant", "kidney", "model", ".", "We", "propose", "here", "a", "possible", "pathological", "tie", "between", "chronic", "tubulointerstitial", "hypoxia", "and", "progressive", "glomerular", "diseases", "."]], "ner": [[[104, 105, "Chemical"], [145, 146, "Chemical"], [0, 0, "Disease"], [42, 42, "Disease"], [49, 49, "Disease"], [67, 67, "Disease"], [84, 84, "Disease"], [101, 101, "Disease"], [114, 114, "Disease"], [124, 124, "Disease"], [186, 186, "Disease"], [231, 231, "Disease"], [250, 250, "Disease"], [108, 109, "Disease"], [2, 3, "Disease"], [87, 88, "Disease"], [253, 254, "Disease"], [5, 5, "Disease"], [10, 10, "Disease"]]], "relations": [[[104, 105, 0, 0, "CID"], [104, 105, 42, 42, "CID"], [104, 105, 49, 49, "CID"], [104, 105, 67, 67, "CID"], [104, 105, 84, 84, "CID"], [104, 105, 101, 101, "CID"], [104, 105, 114, 114, "CID"], [104, 105, 124, 124, "CID"], [104, 105, 186, 186, "CID"], [104, 105, 231, 231, "CID"], [104, 105, 250, 250, "CID"], [145, 146, 0, 0, "CID"], [145, 146, 42, 42, "CID"], [145, 146, 49, 49, "CID"], [145, 146, 67, 67, "CID"], [145, 146, 84, 84, "CID"], [145, 146, 101, 101, "CID"], [145, 146, 114, 114, "CID"], [145, 146, 124, 124, "CID"], [145, 146, 186, 186, "CID"], [145, 146, 231, 231, "CID"], [145, 146, 250, 250, "CID"], [104, 105, 108, 109, "CID"], [145, 146, 108, 109, "CID"]]], "clusters": [], "translated": "<2>缺氧</2>在<14>肾脏疾病</14>中伴随<17>蛋白尿</17>和/或肾小球<18>高血压</18>。尽管越来越需要在细胞水平上识别和量化组织氧合作用，但可用的方法相对较少。在这项研究中，我们开发了一种新的<3>缺氧</3>响应报告载体，使用5'血管内皮生长因子非翻译区的<4>缺氧</4>响应元件，并生成了一个新的<5>缺氧</5>-感应转基因大鼠。然后，我们将该动物模型应用于检测<15>患病肾脏</15>中的肾小管间质<6>缺氧</6>。通过该模型，我们能够识别出<0>嘌呤霉素氨基核苷</0>诱导的<13>肾病综合征</13>中的弥漫性皮质<7>缺氧</7>，以及残肾模型中的局灶性和节段性<8>缺氧</8>。在观察期内，<9>缺氧</9>反应性转基因的表达增加，在<1>嘌呤霉素氨基核苷</1> 模型中2周时达到2.2倍，在残肾模型中4周时达到2.6倍，而血管内皮生长因子的表达轻微下降，反映出这两种基因的不同表现。在两种模型中，<10>缺氧</10>程度与微观肾小管间质损伤呈正相关。最后，我们确定了残肾模型中皮质<11>缺氧</11>区增殖细胞核抗原阳性、ED-1阳性和末端dUTP切口末端标记阳性细胞的定位，提出<12>慢性肾小管间质</12>缺氧和进行性<16>肾小球疾病</16>之间可能存在的病理联系。", "revised": true}
{"doc_key": "16364460", "sentences": [["Microinjection", "of", "ritanserin", "into", "the", "CA1", "region", "of", "hippocampus", "improves", "scopolamine", "-", "induced", "amnesia", "in", "adult", "male", "rats", ".", "The", "effect", "of", "ritanserin", "(", "5", "-", "HT2", "antagonist", ")", "on", "scopolamine", "(", "muscarinic", "cholinergic", "antagonist", ")", "-", "induced", "amnesia", "in", "Morris", "water", "maze", "(", "MWM", ")", "was", "investigated", ".", "Rats", "were", "divided", "into", "eight", "groups", "and", "bilaterally", "cannulated", "into", "CA1", "region", "of", "the", "hippocampus", ".", "One", "week", "later", ",", "they", "received", "repeatedly", "vehicles", "(", "saline", ",", "DMSO", ",", "saline", "+", "DMSO", ")", ",", "scopolamine", "(", "2", "microg", "/", "0", ".", "5", "microl", "saline", "/", "side", ";", "30", "min", "before", "training", ")", ",", "ritanserin", "(", "2", ",", "4", "and", "8", "microg", "/", "0", ".", "5", "microl", "DMSO", "/", "side", ";", "20", "min", "before", "training", ")", "and", "scopolamine", "(", "2", "microg", "/", "0", ".", "5", "microl", ";", "30", "min", "before", "ritanserin", "injection", ")", "+", "ritanserin", "(", "4", "microg", "/", "0", ".", "5", "microl", "DMSO", ")", "through", "cannulae", "each", "day", ".", "Animals", "were", "tested", "for", "four", "consecutive", "days", "(", "4", "trial", "/", "day", ")", "in", "MWM", "during", "which", "the", "position", "of", "hidden", "platform", "was", "unchanged", ".", "In", "the", "fifth", "day", ",", "the", "platform", "was", "elevated", "above", "the", "water", "surface", "in", "another", "position", "to", "evaluate", "the", "function", "of", "motor", ",", "motivational", "and", "visual", "systems", ".", "The", "results", "showed", "a", "significant", "increase", "in", "escape", "latencies", "and", "traveled", "distances", "to", "find", "platform", "in", "scopolamine", "-", "treated", "group", "as", "compared", "to", "saline", "group", ".", "Ritanserin", "-", "treated", "rats", "(", "4", "microg", "/", "0", ".", "5", "microl", "/", "side", ")", "showed", "a", "significant", "decrease", "in", "the", "mentioned", "parameters", "as", "compared", "to", "DMSO", "-", "treated", "group", ".", "However", ",", "scopolamine", "and", "ritanserin", "co", "-", "administration", "resulted", "in", "a", "significant", "decrease", "in", "escape", "latencies", "and", "traveled", "distances", "as", "compared", "to", "the", "scopolamine", "-", "treated", "rats", ".", "Our", "findings", "show", "that", "microinjection", "of", "ritanserin", "into", "the", "CA1", "region", "of", "the", "hippocampus", "improves", "the", "scopolamine", "-", "induced", "amnesia", "."]], "ner": [[[10, 10, "Chemical"], [30, 30, "Chemical"], [83, 83, "Chemical"], [125, 125, "Chemical"], [227, 227, "Chemical"], [270, 270, "Chemical"], [291, 291, "Chemical"], [312, 312, "Chemical"], [13, 13, "Disease"], [38, 38, "Disease"], [315, 315, "Disease"], [2, 2, "Chemical"], [22, 22, "Chemical"], [102, 102, "Chemical"], [138, 138, "Chemical"], [142, 142, "Chemical"], [237, 237, "Chemical"], [272, 272, "Chemical"], [302, 302, "Chemical"], [76, 76, "Chemical"], [80, 80, "Chemical"], [115, 115, "Chemical"], [151, 151, "Chemical"], [263, 263, "Chemical"]]], "relations": [[[10, 10, 13, 13, "CID"], [10, 10, 38, 38, "CID"], [10, 10, 315, 315, "CID"], [30, 30, 13, 13, "CID"], [30, 30, 38, 38, "CID"], [30, 30, 315, 315, "CID"], [83, 83, 13, 13, "CID"], [83, 83, 38, 38, "CID"], [83, 83, 315, 315, "CID"], [125, 125, 13, 13, "CID"], [125, 125, 38, 38, "CID"], [125, 125, 315, 315, "CID"], [227, 227, 13, 13, "CID"], [227, 227, 38, 38, "CID"], [227, 227, 315, 315, "CID"], [270, 270, 13, 13, "CID"], [270, 270, 38, 38, "CID"], [270, 270, 315, 315, "CID"], [291, 291, 13, 13, "CID"], [291, 291, 38, 38, "CID"], [291, 291, 315, 315, "CID"], [312, 312, 13, 13, "CID"], [312, 312, 38, 38, "CID"], [312, 312, 315, 315, "CID"]]], "clusters": [], "translated": "<11>利坦色林</11>海马CA1区显微注射可改善<0>东莨菪碱</0>-诱导的成年雄性大鼠<8>遗忘</8>。<12>利坦色林</12>（5-HT2拮抗剂）对<1>东莨菪碱</1>（毒蕈碱胆碱能拮抗剂）诱导的Morris水迷宫（MWM）<9>遗忘</9>的影响。大鼠分为八组，双侧插管至海马体 CA1 区。一周后，他们反复接受载体（生理盐水，<19>DMSO</19>，生理盐水+<20>DMSO</20>），<2>东莨菪碱</2>（2微克/0.5微升生理盐水/侧；训练前30分钟）、<13>利坦色林</13>（2、4和8微克/0.5微升<21>DMSO</21>/侧；训练前20分钟）和<3>东莨菪碱</3>（2微克/0.5微升；<14>利坦色林</14>注射前30分钟）+<15>利坦色林</15>（4微克/0.5微升<22>DMSO</22>）每天通过插管。动物在MWM中连续测试四天（4次试验/天），期间隐藏平台的位置不变。第五天，将平台升高到水面以上的另一个位置，以评估运动、激励和视觉系统的功能。结果显示，与生理盐水组相比，<4>东莨菪碱</4>治疗组的逃逸潜伏期和寻找平台的移动距离显着增加。<16>利坦色林</16>治疗大鼠（4微克/0.5微升/侧）显示上述参数显著下降，相比<23>DMSO</23>治疗组。然而，与<6>东莨菪碱</6>治疗的大鼠相比，<5>东莨菪碱</5>和<17>利坦色林</17>联合给药导致逃避潜伏期和行进距离显著降低。我们的研究结果表明，将<18>利坦色林</18>显微注射到海马体的CA1区可改善<7>东莨菪碱</7>诱导的<10>遗忘症</10>。", "revised": true}
{"doc_key": "15517007", "sentences": [["Consensus", "statement", "concerning", "cardiotoxicity", "occurring", "during", "haematopoietic", "stem", "cell", "transplantation", "in", "the", "treatment", "of", "autoimmune", "diseases", ",", "with", "special", "reference", "to", "systemic", "sclerosis", "and", "multiple", "sclerosis", ".", "Autologous", "haematopoietic", "stem", "cell", "transplantation", "is", "now", "a", "feasible", "and", "effective", "treatment", "for", "selected", "patients", "with", "severe", "autoimmune", "diseases", ".", "Worldwide", ",", "over", "650", "patients", "have", "been", "transplanted", "in", "the", "context", "of", "phase", "I", "and", "II", "clinical", "trials", ".", "The", "results", "are", "encouraging", "enough", "to", "begin", "randomised", "phase", "III", "trials", ".", "However", ",", "as", "predicted", ",", "significant", "transplant", "-", "related", "morbidity", "and", "mortality", "have", "been", "observed", ".", "This", "is", "primarily", "due", "to", "complications", "related", "to", "either", "the", "stage", "of", "the", "disease", "at", "transplant", "or", "due", "to", "infections", ".", "The", "number", "of", "deaths", "related", "to", "cardiac", "toxicity", "is", "low", ".", "However", ",", "caution", "is", "required", "when", "cyclophosphamide", "or", "anthracyclines", "such", "as", "mitoxantrone", "are", "used", "in", "patients", "with", "a", "possible", "underlying", "heart", "damage", ",", "for", "example", ",", "systemic", "sclerosis", "patients", ".", "In", "November", "2002", ",", "a", "meeting", "was", "held", "in", "Florence", ",", "bringing", "together", "a", "number", "of", "experts", "in", "various", "fields", ",", "including", "rheumatology", ",", "cardiology", ",", "neurology", ",", "pharmacology", "and", "transplantation", "medicine", ".", "The", "object", "of", "the", "meeting", "was", "to", "analyse", "existing", "data", ",", "both", "published", "or", "available", ",", "in", "the", "European", "Group", "for", "Blood", "and", "Marrow", "Transplantation", "autoimmune", "disease", "database", ",", "and", "to", "propose", "a", "safe", "approach", "to", "such", "patients", ".", "A", "full", "cardiological", "assessment", "before", "and", "during", "the", "transplant", "emerged", "as", "the", "major", "recommendation", "."]], "ner": [[[132, 132, "Chemical"], [146, 147, "Disease"], [137, 137, "Chemical"], [3, 3, "Disease"], [121, 122, "Disease"], [134, 134, "Chemical"], [14, 15, "Disease"], [44, 45, "Disease"], [214, 215, "Disease"], [21, 22, "Disease"], [152, 153, "Disease"], [24, 25, "Disease"], [113, 113, "Disease"]]], "relations": [[[132, 132, 146, 147, "CID"], [137, 137, 146, 147, "CID"]]], "clusters": [], "translated": "关于<3>造血干细胞移植治疗</3><6>自身免疫性疾病</6>期间发生的<4>心脏毒性</4>，特别是<9>系统性硬化症</9>和<11>多发性硬化症</11>的共识声明。自体造血干细胞移植是目前对某些严重<7>自身免疫性疾病</7>患者可行且有效的治疗方法。在世界范围内，已有超过650名患者在I期和II期临床试验中接受了移植手术。结果令人鼓舞，足以开始随机III期试验。然而，正如预测的那样，已经观察到与移植相关的显着发病率和死亡率。这主要是由于与移植时疾病阶段或<12>感染</12>相关的并发症。与<4>心脏毒性</4>相关的死亡人数很少。但是，当<0>环磷酰胺</0>或<5>蒽环类药物</5>（例如<2>米托蒽醌</2>）用于可能存在潜在<1>心脏损伤</1>的患者时，需要谨慎，例如<10>系统性硬化症</10>患者。2002年11月，在佛罗伦萨召开了一次会议，汇集了风湿病学、心脏病学、神经学、药理学和移植医学等各个领域的多位专家。会议的目的是分析欧洲血液和骨髓移植组织<8>自身免疫性疾病</8>数据库中已发表或可用的现有数据，并为此类患者提出安全方法。移植前和移植期间的全面心脏评估成为主要建议。", "revised": true}
{"doc_key": "12042105", "sentences": [["Topiramate", "-", "induced", "nephrolithiasis", ".", "Topiramate", "is", "a", "recently", "developed", "antiepileptic", "medication", "that", "is", "becoming", "more", "widely", "prescribed", "because", "of", "its", "efficacy", "in", "treating", "refractory", "seizures", ".", "Urologists", "should", "be", "aware", "that", "this", "medication", "can", "cause", "metabolic", "acidosis", "in", "patients", "secondary", "to", "inhibition", "of", "carbonic", "anhydrase", ".", "In", "addition", ",", "a", "distal", "tubular", "acidification", "defect", "may", "result", ",", "thus", "impairing", "the", "normal", "compensatory", "drop", "in", "urine", "pH", ".", "These", "factors", "can", "lead", "to", "the", "development", "of", "calcium", "phosphate", "nephrolithiasis", ".", "We", "report", "the", "first", "two", "cases", "of", "topiramate", "-", "induced", "nephrolithiasis", "in", "the", "urologic", "literature", "."]], "ner": [[[0, 0, "Chemical"], [5, 5, "Chemical"], [87, 87, "Chemical"], [3, 3, "Disease"], [78, 78, "Disease"], [90, 90, "Disease"], [24, 25, "Disease"], [36, 37, "Disease"], [76, 77, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 78, 78, "CID"], [0, 0, 90, 90, "CID"], [5, 5, 3, 3, "CID"], [5, 5, 78, 78, "CID"], [5, 5, 90, 90, "CID"], [87, 87, 3, 3, "CID"], [87, 87, 78, 78, "CID"], [87, 87, 90, 90, "CID"]]], "clusters": [], "translated": "<0>托吡酯</0>——诱发 <3>肾结石</3>。 <1>托吡酯</1>是一种最近开发的抗癫痫药物，因其在治疗<6>难治性癫痫发作</6>方面的疗效而被广泛使用。泌尿科医师应注意，这种药物可导致<7>继发于抑制碳酸酐酶的代谢性酸中毒</7>。此外，可能导致远端肾小管酸化缺陷，从而损害尿液pH值的正常代偿性下降。这些因素可导致<4>肾结石</4>的发展，为<8>磷酸钙</8>型结石。我们在泌尿外科文献中报告了前两例<2>托吡酯</2>诱发的<5>肾结石</5>。", "revised": true}
{"doc_key": "12180796", "sentences": [["Immunohistochemical", "study", "on", "inducible", "type", "of", "nitric", "oxide", "(", "iNOS", ")", ",", "basic", "fibroblast", "growth", "factor", "(", "bFGF", ")", "and", "tumor", "growth", "factor", "-", "beta1", "(", "TGF", "-", "beta1", ")", "in", "arteritis", "induced", "in", "rats", "by", "fenoldopam", "and", "theophylline", ",", "vasodilators", ".", "Arteritis", "induced", "in", "rats", "by", "vasodilators", ",", "fenoldopam", "and", "theophylline", ",", "was", "examined", "immunohistochemically", "for", "expressions", "of", "inducible", "type", "of", "nitric", "oxide", "synthase", "(", "iNOS", ")", ",", "basic", "fibroblast", "growth", "factor", "(", "bFGF", ")", "and", "tumor", "growth", "factor", "-", "beta1", "(", "TGF", "-", "beta1", ")", ".", "Rats", "were", "administered", "fenoldopam", "for", "24", "hours", "by", "intravenous", "infusion", "with", "or", "without", "following", "repeated", "daily", "oral", "administrations", "of", "theophylline", ".", "Irrespective", "of", "theophylline", "administration", ",", "iNOS", "antigens", "were", "remarkably", "abundant", "in", "ED", "-", "1", "-", "positive", "cells", "on", "day", "5", "and", "8", "post", "-", "fenoldopam", "-", "infusion", "(", "DPI", ")", ";", "bFGF", "antigens", "were", "remarkably", "abundant", "in", "ED", "-", "1", "-", "positive", "cells", "on", "1", "and", "3", "DPI", ";", "TGF", "-", "beta1", "antigens", "were", "observed", "in", "ED", "-", "1", "-", "positive", "cells", "on", "and", "after", "5", "DPI", ".", "These", "results", "suggest", "that", "the", "peak", "expression", "of", "iNOS", "antigen", "was", "followed", "by", "that", "of", "bFGF", "antigen", ",", "and", "bFGF", "may", "have", "a", "suppressive", "effect", "on", "iNOS", "expression", "in", "these", "rat", "arteritis", "models", ".", "On", "the", "other", "hand", ",", "TGF", "-", "beta1", "was", "not", "considered", "to", "have", "a", "suppressive", "effect", "on", "iNOS", "expression", "in", "these", "models", "."]], "ner": [[[36, 36, "Chemical"], [49, 49, "Chemical"], [91, 91, "Chemical"], [133, 133, "Chemical"], [31, 31, "Disease"], [42, 42, "Disease"], [208, 208, "Disease"], [38, 38, "Chemical"], [51, 51, "Chemical"], [107, 107, "Chemical"], [111, 111, "Chemical"], [6, 7, "Chemical"], [62, 63, "Chemical"], [20, 20, "Disease"], [77, 77, "Disease"]]], "relations": [[[36, 36, 31, 31, "CID"], [36, 36, 42, 42, "CID"], [36, 36, 208, 208, "CID"], [49, 49, 31, 31, "CID"], [49, 49, 42, 42, "CID"], [49, 49, 208, 208, "CID"], [91, 91, 31, 31, "CID"], [91, 91, 42, 42, "CID"], [91, 91, 208, 208, "CID"], [133, 133, 31, 31, "CID"], [133, 133, 42, 42, "CID"], [133, 133, 208, 208, "CID"], [38, 38, 31, 31, "CID"], [38, 38, 42, 42, "CID"], [38, 38, 208, 208, "CID"], [51, 51, 31, 31, "CID"], [51, 51, 42, 42, "CID"], [51, 51, 208, 208, "CID"], [107, 107, 31, 31, "CID"], [107, 107, 42, 42, "CID"], [107, 107, 208, 208, "CID"], [111, 111, 31, 31, "CID"], [111, 111, 42, 42, "CID"], [111, 111, 208, 208, "CID"]]], "clusters": [], "translated": "诱导型<11>一氧化氮</11> (iNOS)、碱性成纤维细胞生长因子 (bFGF) 和<13>肿瘤</13>生长因子-β1 (TGF-β1)在<4>动脉炎</4>中由<0>非诺多泮</0>和<7>茶碱</7>等血管扩张剂诱导。通过免疫组织化学检查，可以在由血管扩张剂<1>非诺多泮</1>和<8>茶碱</8>等诱导的大鼠<5>动脉炎</5>模型中检测到诱导型<12>一氧化氮</12>合酶（iNOS）、碱性成纤维细胞生长因子（bFGF）和<14>肿瘤</14>生长因子-β1（TGF-β1)的表达。大鼠静脉注射<2>非诺多泮</2> 24 小时后，每天口服<9>茶碱</9>。无论是否给予<10>茶碱</10>，在<3>非诺多泮</3>输注后第5天和第8天，ED-1阳性细胞中的iNOS抗原非常丰富，1 ~ 3 DPI（DPI）时，ED-1阳性细胞中的bFGF抗原非常丰富，5 DPI及以后，在ED-1阳性细胞中观察到TGF-β1抗原。这些结果表明，iNOS抗原的表达峰值后是bFGF抗原的表达峰值，并且bFGF可能对这些大鼠<6>动脉炎</6>模型中的iNOS表达具有抑制作用。另一方面，TGF-β1不被认为在这些模型中对iNOS表达具有抑制作用。", "revised": true}
{"doc_key": "11467664", "sentences": [["Cholestatic", "jaundice", "associated", "with", "the", "use", "of", "metformin", ".", "We", "report", "a", "patient", "who", "developed", "cholestatic", "jaundice", "shortly", "after", "initiation", "of", "treatment", "with", "metformin", "hydrochloride", ".", "Ultrasound", "of", "the", "liver", "and", "abdominal", "CT", "were", "normal", ".", "An", "ERCP", "showed", "normal", "biliary", "anatomy", ".", "A", "percutaneous", "liver", "biopsy", "was", "obtained", "showing", "marked", "cholestasis", ",", "with", "portal", "edema", ",", "ductular", "proliferation", ",", "and", "acute", "inflammation", ".", "Metformin", "hydrochloride", "was", "discontinued", ",", "and", "the", "patient", "'s", "jaundice", "resolved", "slowly", "over", "a", "period", "of", "several", "months", ".", "Given", "the", "onset", "of", "his", "jaundice", "2", "wk", "after", "the", "initiation", "of", "metformin", ",", "we", "believe", "that", "this", "case", "represents", "an", "example", "of", "metformin", "-", "associated", "hepatotoxicity", ",", "the", "first", "such", "case", "reported", "."]], "ner": [[[7, 7, "Chemical"], [23, 24, "Chemical"], [64, 65, "Chemical"], [95, 95, "Chemical"], [106, 106, "Chemical"], [0, 1, "Disease"], [15, 16, "Disease"], [51, 51, "Disease"], [55, 55, "Disease"], [62, 62, "Disease"], [73, 73, "Disease"], [88, 88, "Disease"], [109, 109, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [7, 7, 15, 16, "CID"], [23, 24, 0, 1, "CID"], [23, 24, 15, 16, "CID"], [64, 65, 0, 1, "CID"], [64, 65, 15, 16, "CID"], [95, 95, 0, 1, "CID"], [95, 95, 15, 16, "CID"], [106, 106, 0, 1, "CID"], [106, 106, 15, 16, "CID"], [7, 7, 51, 51, "CID"], [23, 24, 51, 51, "CID"], [64, 65, 51, 51, "CID"], [95, 95, 51, 51, "CID"], [106, 106, 51, 51, "CID"]]], "clusters": [], "translated": " <5>胆汁淤积性黄疸</5>与使用<0>二甲双胍</0>有关。我们报告了一名患者在开始使用<1>盐酸二甲双胍</1>治疗后不久出现了<6>胆汁淤积性黄疸</6>。肝脏超声和腹部 CT 正常。ERCP显示胆道解剖结构正常。经皮肝活检显示明显的<7>胆汁淤积</7>、门脉<8>水肿</8>、小管增生和急性<9>炎症</9>。<2> 盐酸二甲双胍 </2>停用，患者的<10>黄疸</10>在数月内缓慢消退。鉴于他在<3>二甲双胍</3>开始后 2 周出现了<11>黄疸</11>，我们认为该病例代表了<4>二甲双胍</4>的一个例子-相关<12>肝毒性</12>，首例报道。", "revised": true}
{"doc_key": "11860278", "sentences": [["Dopamine", "D2", "receptor", "signaling", "controls", "neuronal", "cell", "death", "induced", "by", "muscarinic", "and", "glutamatergic", "drugs", ".", "Dopamine", "(", "DA", ")", ",", "through", "D1", "/", "D2", "receptor", "-", "mediated", "signaling", ",", "plays", "a", "major", "role", "in", "the", "control", "of", "epileptic", "seizures", "arising", "in", "the", "limbic", "system", ".", "Excitotoxicity", "leading", "to", "neuronal", "cell", "death", "in", "the", "affected", "areas", "is", "a", "major", "consequence", "of", "seizures", "at", "the", "cellular", "level", ".", "In", "this", "respect", ",", "little", "is", "known", "about", "the", "role", "of", "DA", "receptors", "in", "the", "occurrence", "of", "epilepsy", "-", "induced", "neuronal", "cell", "death", ".", "Here", "we", "analyze", "the", "occurrence", "of", "seizures", "and", "neurotoxicity", "in", "D2R", "-", "/", "-", "mice", "treated", "with", "the", "cholinergic", "agonist", "pilocarpine", ".", "We", "compared", "these", "results", "with", "those", "previously", "obtained", "with", "kainic", "acid", "(", "KA", ")", ",", "a", "potent", "glutamate", "agonist", ".", "Importantly", ",", "D2R", "-", "/", "-", "mice", "develop", "seizures", "at", "doses", "of", "both", "drugs", "that", "are", "not", "epileptogenic", "for", "WT", "littermates", "and", "show", "greater", "neurotoxicity", ".", "However", ",", "pilocarpine", "-", "induced", "seizures", "result", "in", "a", "more", "widespread", "neuronal", "death", "in", "both", "WT", "and", "D2R", "-", "/", "-", "brains", "in", "comparison", "to", "KA", ".", "Thus", ",", "the", "absence", "of", "D2R", "lowers", "the", "threshold", "for", "seizures", "induced", "by", "both", "glutamate", "and", "acetylcholine", ".", "Moreover", ",", "the", "dopaminergic", "control", "of", "epilepsy", "-", "induced", "neurodegeneration", "seems", "to", "be", "mediated", "by", "distinct", "interactions", "of", "D2R", "signaling", "with", "these", "two", "neurotransmitters", "."]], "ner": [[[110, 110, "Chemical"], [160, 160, "Chemical"], [60, 60, "Disease"], [96, 96, "Disease"], [140, 140, "Disease"], [163, 163, "Disease"], [195, 195, "Disease"], [121, 122, "Chemical"], [124, 124, "Chemical"], [183, 183, "Chemical"], [0, 0, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [77, 77, "Chemical"], [37, 38, "Disease"], [83, 83, "Disease"], [209, 209, "Disease"], [98, 98, "Disease"], [156, 156, "Disease"], [212, 212, "Disease"], [129, 129, "Chemical"], [199, 199, "Chemical"], [201, 201, "Chemical"]]], "relations": [[[110, 110, 60, 60, "CID"], [110, 110, 96, 96, "CID"], [110, 110, 140, 140, "CID"], [110, 110, 163, 163, "CID"], [110, 110, 195, 195, "CID"], [160, 160, 60, 60, "CID"], [160, 160, 96, 96, "CID"], [160, 160, 140, 140, "CID"], [160, 160, 163, 163, "CID"], [160, 160, 195, 195, "CID"], [121, 122, 60, 60, "CID"], [121, 122, 96, 96, "CID"], [121, 122, 140, 140, "CID"], [121, 122, 163, 163, "CID"], [121, 122, 195, 195, "CID"], [124, 124, 60, 60, "CID"], [124, 124, 96, 96, "CID"], [124, 124, 140, 140, "CID"], [124, 124, 163, 163, "CID"], [124, 124, 195, 195, "CID"], [183, 183, 60, 60, "CID"], [183, 183, 96, 96, "CID"], [183, 183, 140, 140, "CID"], [183, 183, 163, 163, "CID"], [183, 183, 195, 195, "CID"]]], "clusters": [], "translated": " \n<10>多巴胺</10> D2 受体信号控制由毒蕈碱和谷氨酸能药物诱导的神经元细胞死亡。 <11>多巴胺</11> (<12>DA</12>)，通过D1/D2受体介导的信号传导，在控制发生于边缘系统的<14>癫痫发作</14>中起主要作用。导致受影响区域神经元细胞死亡的兴奋性毒性是细胞水平上<2>癫痫发作</2>的主要后果。在这方面，关于<13>DA</13>受体在<15>癫痫</15>诱导的神经元细胞死亡中的作用知之甚少。在这里，我们分析了使用胆碱能激动剂<0>毛果芸香碱</0>治疗的D2R-/-小鼠中<3>癫痫发作</3>和<17>神经毒性</17>的发生情况。我们将这些结果与之前使用<7>红藻氨酸</7>(<8>KA</8>)获得的结果进行了比较，后者是一种有效的<20>谷氨酸</20>激动剂。重要的是，D2R-/-小鼠在两种药物的剂量下发生<4>癫痫发作</4>，这两种药物对WT同窝小鼠均不致癫痫，并且表现出更大的<18>神经毒性</18>。然而，与<9>KA</9>相比，<1>毛果芸香碱</1>诱导的<5>癫痫发作</5>导致WT和D2R-/-大脑中更广泛的神经元死亡。因此，D2R的缺失降低了<21>谷氨酸</21>和<22>乙酰胆碱</22>诱导的<6>癫痫发作</6>的阈值。此外，<16>癫痫</16>诱发的<19>神经变性</19>的多巴胺能控制似乎是由 D2R 信号与这两种神经递质的不同相互作用介导的。", "revised": true}
{"doc_key": "17943461", "sentences": [["Myocardial", "Fas", "ligand", "expression", "increases", "susceptibility", "to", "AZT", "-", "induced", "cardiomyopathy", ".", "BACKGROUND", ":", "Dilated", "cardiomyopathy", "(", "DCM", ")", "and", "myocarditis", "occur", "in", "many", "HIV", "-", "infected", "individuals", ",", "resulting", "in", "symptomatic", "heart", "failure", "in", "up", "to", "5", "%", "of", "patients", ".", "Highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "has", "significantly", "reduced", "morbidity", "and", "mortality", "of", "acquired", "immunodeficiency", "syndrome", "(", "AIDS", ")", ",", "but", "has", "resulted", "in", "an", "increase", "in", "cardiac", "and", "skeletal", "myopathies", ".", "METHODS", "AND", "RESULTS", ":", "In", "order", "to", "investigate", "whether", "the", "HAART", "component", "zidovudine", "(", "3", "'", "-", "azido", "-", "2", "'", ",", "3", "'", "-", "deoxythymidine", ";", "AZT", ")", "triggers", "the", "Fas", "-", "dependent", "cell", "-", "death", "pathway", "and", "cause", "cytoskeletal", "disruption", "in", "a", "murine", "model", "of", "DCM", ",", "8", "-", "week", "-", "old", "transgenic", "(", "expressing", "Fas", "ligand", "in", "the", "myocardium", ":", "FasL", "Tg", ")", "and", "non", "-", "transgenic", "(", "NTg", ")", "mice", "received", "water", "ad", "libitum", "containing", "different", "concentrations", "of", "AZT", "(", "0", ",", "0", ".", "07", ",", "0", ".", "2", ",", "and", "0", ".", "7", "mg", "/", "ml", ")", ".", "After", "6", "weeks", ",", "cardiac", "function", "was", "assessed", "by", "echocardiography", "and", "morphology", "was", "assessed", "by", "histopathologic", "and", "immunohistochemical", "methods", ".", "NTg", "and", "untreated", "FasL", "Tg", "mice", "showed", "little", "or", "no", "change", "in", "cardiac", "structure", "or", "function", ".", "In", "contrast", ",", "AZT", "-", "treated", "FasL", "Tg", "mice", "developed", "cardiac", "dilation", "and", "depressed", "cardiac", "function", "in", "a", "dose", "-", "dependent", "manner", ",", "with", "concomitant", "inflammatory", "infiltration", "of", "both", "ventricles", ".", "These", "changes", "were", "associated", "with", "an", "increased", "sarcolemmal", "expression", "of", "Fas", "and", "FasL", ",", "as", "well", "as", "increased", "activation", "of", "caspase", "3", ",", "translocation", "of", "calpain", "1", "to", "the", "sarcolemma", "and", "sarcomere", ",", "and", "increased", "numbers", "of", "cells", "undergoing", "apoptosis", ".", "These", "were", "associated", "with", "changes", "in", "dystrophin", "and", "cardiac", "troponin", "I", "localization", ",", "as", "well", "as", "loss", "of", "sarcolemmal", "integrity", ".", "CONCLUSIONS", ":", "The", "expression", "of", "Fas", "ligand", "in", "the", "myocardium", ",", "as", "identified", "in", "HIV", "-", "positive", "patients", ",", "might", "increase", "the", "susceptibility", "to", "HAART", "-", "induced", "cardiomyopathy", "due", "to", "activation", "of", "apoptotic", "pathways", ",", "resulting", "in", "cardiac", "dilation", "and", "dysfunction", "."]], "ner": [[[7, 7, "Chemical"], [87, 87, "Chemical"], [89, 100, "Chemical"], [102, 102, "Chemical"], [157, 157, "Chemical"], [218, 218, "Chemical"], [10, 10, "Disease"], [335, 335, "Disease"], [14, 15, "Disease"], [17, 17, "Disease"], [122, 122, "Disease"], [225, 226, "Disease"], [345, 348, "Disease"], [20, 20, "Disease"], [24, 26, "Disease"], [32, 33, "Disease"], [56, 58, "Disease"], [60, 60, "Disease"], [70, 73, "Disease"]]], "relations": [[[7, 7, 10, 10, "CID"], [7, 7, 335, 335, "CID"], [87, 87, 10, 10, "CID"], [87, 87, 335, 335, "CID"], [89, 100, 10, 10, "CID"], [89, 100, 335, 335, "CID"], [102, 102, 10, 10, "CID"], [102, 102, 335, 335, "CID"], [157, 157, 10, 10, "CID"], [157, 157, 335, 335, "CID"], [218, 218, 10, 10, "CID"], [218, 218, 335, 335, "CID"], [7, 7, 14, 15, "CID"], [7, 7, 17, 17, "CID"], [7, 7, 122, 122, "CID"], [7, 7, 225, 226, "CID"], [7, 7, 345, 348, "CID"], [87, 87, 14, 15, "CID"], [87, 87, 17, 17, "CID"], [87, 87, 122, 122, "CID"], [87, 87, 225, 226, "CID"], [87, 87, 345, 348, "CID"], [89, 100, 14, 15, "CID"], [89, 100, 17, 17, "CID"], [89, 100, 122, 122, "CID"], [89, 100, 225, 226, "CID"], [89, 100, 345, 348, "CID"], [102, 102, 14, 15, "CID"], [102, 102, 17, 17, "CID"], [102, 102, 122, 122, "CID"], [102, 102, 225, 226, "CID"], [102, 102, 345, 348, "CID"], [157, 157, 14, 15, "CID"], [157, 157, 17, 17, "CID"], [157, 157, 122, 122, "CID"], [157, 157, 225, 226, "CID"], [157, 157, 345, 348, "CID"], [218, 218, 14, 15, "CID"], [218, 218, 17, 17, "CID"], [218, 218, 122, 122, "CID"], [218, 218, 225, 226, "CID"], [218, 218, 345, 348, "CID"]]], "clusters": [], "translated": "心肌 Fas 配体表达增加了对 <0>AZT</0> 诱导的<6>心肌病</6>的易感性。背景：<8>扩张型心肌病</8>（<9>DCM</9>）和<13>心肌炎</13>发生在许多<14>HIV感染者</14>个体中，导致有症状的<15>心力衰竭</15>高达5%的患者。高效抗逆转录病毒疗法（HAART）显着降低了<16>获得性免疫缺陷综合征</16>（<17>AIDS</17>）的发病率和死亡率，但导致<18>心脏和骨骼肌病</18>。方法与结果：为了考察HAART成分<1>齐多夫定</1>（<2>3'-叠氮基-2'，3'-脱氧胸苷</2>；<3>AZT</3>）在<10>DCM</10>、8周大的转基因（在心肌中表达 Fas 配体：FasL Tg）和非转基因（NTg）小鼠模型中触发 Fas 依赖性细胞死亡途径并引起细胞骨架破坏) 小鼠接受含有不同浓度<4>AZT</4>（0，0.07、0.2、0.7 mg/mL）的水。6周后，超声心动图评估心功能，组织病理学和免疫组织化学方法评估形态学。NTg和未治疗的 FasL Tg 小鼠的心脏结构或功能几乎没有或没有变化。相比之下，<5>AZT</5>治疗的FasL Tg小鼠出现<11>心脏扩张</11>，并以剂量依赖性方式降低心脏功能，并伴有双心室炎症浸润。这些变化与Fas和FasL的肌膜表达增加、半胱天冬酶3的激活增加、钙蛋白酶1向肌膜和肌节的易位以及发生凋亡的细胞数量增加有关。这些与抗肌萎缩蛋白和心肌肌钙蛋白I定位的变化以及肌膜完整性的丧失有关。结论：在HIV阳性患者中，心肌中Fas配体的表达可能会增加对HAART诱导的<7>心肌病</7>的易感性，这是由于细胞凋亡途径的激活，导致<12>心脏扩张和功能障碍</12>。", "revised": true}
{"doc_key": "12109865", "sentences": [["Low", "-", "molecular", "-", "weight", "heparin", "for", "the", "treatment", "of", "patients", "with", "mechanical", "heart", "valves", ".", "BACKGROUND", ":", "The", "interruption", "of", "oral", "anticoagulant", "(", "OAC", ")", "administration", "is", "sometimes", "indicated", "in", "patients", "with", "mechanical", "heart", "valves", ",", "mainly", "before", "noncardiac", "surgery", ",", "non", "-", "surgical", "interventions", ",", "and", "pregnancy", ".", "Unfractionated", "heparin", "(", "UH", ")", "is", "currently", "the", "substitute", "for", "selected", "patients", ".", "Low", "-", "molecular", "-", "weight", "heparin", "(", "LMWH", ")", "offers", "theoretical", "advantages", "over", "UH", ",", "but", "is", "not", "currently", "considered", "in", "clinical", "guidelines", "as", "an", "alternative", "to", "UH", "in", "patients", "with", "prosthetic", "valves", ".", "HYPOTHESIS", ":", "The", "aim", "of", "the", "present", "study", "was", "to", "review", "the", "data", "accumulated", "so", "far", "on", "the", "use", "of", "LMWH", "in", "this", "patient", "population", "and", "to", "discuss", "its", "applicability", "in", "common", "practice", ".", "METHODS", ":", "For", "this", "paper", ",", "the", "current", "medical", "literature", "on", "LMWH", "in", "patients", "with", "mechanical", "heart", "valves", "was", "extensively", "reviewed", ".", "RESULTS", ":", "There", "were", "eight", "series", "and", "six", "case", "reports", ".", "None", "of", "the", "studies", "was", "randomized", ",", "and", "only", "one", "was", "prospective", ".", "Data", "to", "establish", "the", "thromboembolic", "risk", "were", "incomplete", ".", "After", "excluding", "case", "reports", ",", "the", "following", "groups", "were", "constructed", ":", "(", "a", ")", "short", "-", "term", "administration", ",", "after", "valve", "insertion", "(", "n", "=", "212", ")", ";", "(", "b", ")", "short", "-", "term", ",", "perioperative", "(", "noncardiac", ")", "/", "periprocedural", "(", "n", "=", "114", ")", ";", "(", "c", ")", "long", "-", "term", ",", "due", "to", "intolerance", "to", "OAC", "(", "n", "=", "16", ")", ";", "(", "d", ")", "long", "-", "term", ",", "in", "pregnancy", "(", "n", "=", "10", ")", ".", "The", "incidence", "rate", "of", "thromboembolism", "was", "0", ".", "9", "%", "for", "all", "the", "studies", "and", "0", ".", "5", ",", "0", ",", "20", ",", "and", "0", "%", "in", "groups", "a", ",", "b", ",", "c", ",", "and", "d", ",", "respectively", ";", "for", "hemorrhage", ",", "the", "overall", "rate", "was", "3", ".", "4", "%", "(", "3", ".", "8", ",", "2", ".", "6", ",", "10", ",", "and", "0", "%", "for", "the", "respective", "groups", ")", ".", "CONCLUSIONS", ":", "In", "patients", "with", "mechanical", "heart", "valves", ",", "short", "-", "term", "LMWH", "therapy", "compares", "favorably", "with", "UH", ".", "Data", "on", "mid", "-", "and", "long", "-", "term", "LMWH", "administration", "in", "these", "patients", "are", "sparse", ".", "Further", "randomized", "studies", "are", "needed", "to", "confirm", "the", "safety", "and", "precise", "indications", "for", "the", "use", "of", "LMWH", "in", "patients", "with", "mechanical", "heart", "valves", "."]], "ner": [[[0, 5, "Chemical"], [63, 68, "Chemical"], [70, 70, "Chemical"], [117, 117, "Chemical"], [142, 142, "Chemical"], [348, 348, "Chemical"], [363, 363, "Chemical"], [387, 387, "Chemical"], [181, 181, "Disease"], [270, 270, "Disease"], [306, 306, "Disease"], [50, 51, "Chemical"], [53, 53, "Chemical"], [76, 76, "Chemical"], [90, 90, "Chemical"], [353, 353, "Chemical"]]], "relations": [[[0, 5, 181, 181, "CID"], [0, 5, 270, 270, "CID"], [63, 68, 181, 181, "CID"], [63, 68, 270, 270, "CID"], [70, 70, 181, 181, "CID"], [70, 70, 270, 270, "CID"], [117, 117, 181, 181, "CID"], [117, 117, 270, 270, "CID"], [142, 142, 181, 181, "CID"], [142, 142, 270, 270, "CID"], [348, 348, 181, 181, "CID"], [348, 348, 270, 270, "CID"], [363, 363, 181, 181, "CID"], [363, 363, 270, 270, "CID"], [387, 387, 181, 181, "CID"], [387, 387, 270, 270, "CID"], [0, 5, 306, 306, "CID"], [63, 68, 306, 306, "CID"], [70, 70, 306, 306, "CID"], [117, 117, 306, 306, "CID"], [142, 142, 306, 306, "CID"], [348, 348, 306, 306, "CID"], [363, 363, 306, 306, "CID"], [387, 387, 306, 306, "CID"]]], "clusters": [], "translated": " <0>低分子肝素</0>用于机械心脏瓣膜患者的治疗。背景：机械心脏瓣膜患者有时需要中断口服抗凝剂 (OAC)，主要是在非心脏手术、非手术干预和怀孕之前。 <11>普通肝素</11>（<12>UH</12>）目前是部分患者的替代品。 <1>低分子量肝素</1> (<2>LMWH</2>)在理论上比<13>UH</13>更具优势，但目前临床指南中并未考虑将其作为人工瓣膜患者<14>UH</14>的替代品。假设：本研究的目的是回顾迄今为止积累的有关该患者群体使用<3>LMWH</3>的数据，并讨论其在常规实践中的适用性。方法：在本文中，广泛回顾了关于<4>LMWH</4>机械心脏瓣膜患者的当前医学文献。结果：共有8个系列，6个病例报告。没有一项研究是随机的，只有一项是前瞻性的。确定<8>血栓栓塞</8>风险的数据不完整。排除个案报告后，构建了以下组：(a) 短期给药，瓣膜插入后 (n = 212)；(b) 短期、围手术期（非心脏）/围手术期（n = 114）；(c) 长期，由于对OAC的不耐受（n = 16）；(d) 长期，在怀孕期间（n = 10）。<9>血栓栓塞症</9>发生率为0.9%。所有研究在a、b、c、d组分别为0.5%、0%、20%和0%；对于<10>出血</10>，总发生率为3.4%（各组分别为3.8%、2.6%、10%和0%）。结论：在机械心脏瓣膜患者中，短期<5>LMWH</5>治疗优于<15>UH</15>。这些患者中长期服用<6>LMWH</6>的数据很少。需要进一步的随机研究来确认在机械心脏瓣膜患者中使用<7>LMWH</7>的安全性和精确适应症。", "revised": true}
{"doc_key": "10091616", "sentences": [["Worsening", "of", "levodopa", "-", "induced", "dyskinesias", "by", "motor", "and", "mental", "tasks", ".", "Ten", "patients", "who", "had", "Parkinson", "'s", "disease", "with", "disabling", "dyskinesia", "were", "included", "in", "this", "study", "to", "evaluate", "the", "role", "of", "mental", "(", "mental", "calculation", ")", "and", "motor", "(", "flexion", "/", "extension", "of", "right", "fingers", ",", "flexion", "/", "extension", "of", "left", "fingers", ",", "flexion", "/", "extension", "of", "the", "neck", ",", "speaking", "aloud", ")", "tasks", "on", "the", "worsening", "of", "peak", "-", "dose", "dyskinesia", "following", "administration", "of", "an", "effective", "single", "dose", "of", "apomorphine", ".", "Compared", "with", "the", "score", "at", "rest", "(", "1", ".", "3", "+", "/", "-", "0", ".", "3", ")", ",", "a", "significant", "aggravation", "of", "the", "dyskinesia", "score", "was", "observed", "during", "speaking", "aloud", "(", "5", ".", "2", "+", "/", "-", "1", ".", "1", ",", "p", "<", "0", ".", "05", ")", ",", "movements", "of", "right", "(", "4", ".", "5", "+", "/", "-", "1", ".", "0", ",", "p", "<", "0", ".", "05", ")", "and", "left", "(", "3", ".", "7", "+", "/", "-", "0", ".", "8", ",", "p", "<", "0", ".", "05", ")", "fingers", ",", "movements", "of", "the", "neck", "(", "5", ".", "1", "+", "/", "-", "1", ".", "0", ",", "p", "<", "0", ".", "05", ")", ",", "and", "mental", "calculation", "(", "3", ".", "1", "+", "/", "-", "1", ".", "0", ",", "p", "<", "0", ".", "05", ")", ".", "These", "results", "suggest", "that", "activation", "tasks", "such", "as", "\"", "speaking", "aloud", "\"", "could", "be", "used", "for", "objective", "assessment", "of", "dyskinesia", "severity", "."]], "ner": [[[2, 2, "Chemical"], [5, 5, "Disease"], [21, 21, "Disease"], [72, 72, "Disease"], [106, 106, "Disease"], [234, 234, "Disease"], [81, 81, "Chemical"], [16, 18, "Disease"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 21, 21, "CID"], [2, 2, 72, 72, "CID"], [2, 2, 106, 106, "CID"], [2, 2, 234, 234, "CID"], [81, 81, 5, 5, "CID"], [81, 81, 21, 21, "CID"], [81, 81, 72, 72, "CID"], [81, 81, 106, 106, "CID"], [81, 81, 234, 234, "CID"]]], "clusters": [], "translated": "恶化<0>左旋多巴</0><1>诱发运动障碍</1>通过运动和精神任务。十名患有<7>帕金森病</7>并伴有致残性<2>运动障碍</2>的患者被纳入本研究，以评估心理（心算）和运动（右手指的屈曲/伸展，左手指的屈曲/伸展、颈部的屈曲/伸展、大声说话）对峰值剂量<3>异动症</3>的恶化的任务，在<6>阿扑吗啡</6>的有效单次给药后。与静息时(1.3+/-0.3)相比，<4>异动症</4>评分在大声说话时显着加重（5.2+/-1.1，p < 0.05），右手(4.5+/-1.0，p < 0.05)和左手(3.7+/-0.8，p < 0.05)指的运动，颈部的运动(5.1+/-1.0，p<0.05)和心算(3.1+/-1.0，p<0.05)。这些结果表明，“大声说话”等激活任务可用于客观评估<5>运动障碍</5>的严重程度。", "revised": true}
{"doc_key": "11705128", "sentences": [["Management", "strategies", "for", "ribavirin", "-", "induced", "hemolytic", "anemia", "in", "the", "treatment", "of", "hepatitis", "C", ":", "clinical", "and", "economic", "implications", ".", "OBJECTIVES", ":", "Recently", "published", "studies", "have", "demonstrated", "increased", "efficacy", "and", "cost", "-", "effectiveness", "of", "combination", "therapy", "with", "interferon", "and", "alpha", "-", "2b", "/", "ribavirin", "compared", "with", "interferon", "-", "alpha", "monotherapy", "in", "the", "treatment", "of", "chronic", "hepatitis", "C", "(", "CHC", ")", ".", "Combination", "therapy", "is", "associated", "with", "a", "clinically", "important", "adverse", "effect", ":", "ribavirin", "-", "induced", "hemolytic", "anemia", "(", "RIHA", ")", ".", "The", "objective", "of", "this", "study", "was", "to", "evaluate", "the", "direct", "health", "-", "care", "costs", "and", "management", "of", "RIHA", "during", "treatment", "of", "CHC", "in", "a", "clinical", "trial", "setting", ".", "METHODS", ":", "A", "systematic", "literature", "review", "was", "conducted", "to", "synthesize", "information", "on", "the", "incidence", "and", "management", "of", "RIHA", ".", "Decision", "-", "analytic", "techniques", "were", "used", "to", "estimate", "the", "cost", "of", "treating", "RIHA", ".", "Uncertainty", "was", "evaluated", "using", "sensitivity", "analyses", ".", "RESULTS", ":", "RIHA", ",", "defined", "as", "a", "reduction", "in", "hemoglobin", "to", "less", "than", "100", "g", "/", "L", ",", "occurs", "in", "approximately", "7", "%", "to", "9", "%", "of", "patients", "treated", "with", "combination", "therapy", ".", "The", "standard", "of", "care", "for", "management", "of", "RIHA", "is", "reduction", "or", "discontinuation", "of", "the", "ribavirin", "dosage", ".", "We", "estimated", "the", "direct", "cost", "of", "treating", "clinically", "significant", "RIHA", "to", "be", "170", "per", "patient", "receiving", "combination", "therapy", "per", "48", "-", "week", "treatment", "course", "(", "range", "68", "-", "692", ")", ".", "The", "results", "of", "the", "one", "-", "way", "sensitivity", "analyses", "ranged", "from", "57", "to", "317", ".", "In", "comparison", ",", "the", "cost", "of", "48", "weeks", "of", "combination", "therapy", "is", "16", ",", "459", ".", "CONCLUSIONS", ":", "The", "direct", "cost", "of", "treating", "clinically", "significant", "RIHA", "is", "1", "%", "(", "170", "/", "16", ",", "459", ")", "of", "drug", "treatment", "costs", ".", "Questions", "remain", "about", "the", "optimal", "dose", "of", "ribavirin", "and", "the", "incidence", "of", "RIHA", "in", "a", "real", "-", "world", "population", ".", "Despite", "these", "uncertainties", ",", "this", "initial", "evaluation", "of", "the", "direct", "cost", "of", "treating", "RIHA", "provides", "an", "estimate", "of", "the", "cost", "and", "management", "implications", "of", "this", "clinically", "important", "adverse", "effect", "."]], "ner": [[[3, 3, "Chemical"], [43, 43, "Chemical"], [72, 72, "Chemical"], [196, 196, "Chemical"], [293, 293, "Chemical"], [6, 7, "Disease"], [75, 76, "Disease"], [78, 78, "Disease"], [98, 98, "Disease"], [126, 126, "Disease"], [140, 140, "Disease"], [151, 151, "Disease"], [189, 189, "Disease"], [208, 208, "Disease"], [270, 270, "Disease"], [298, 298, "Disease"], [319, 319, "Disease"], [46, 48, "Chemical"], [12, 13, "Disease"], [54, 56, "Disease"], [58, 58, "Disease"], [102, 102, "Disease"]]], "relations": [[[3, 3, 6, 7, "CID"], [3, 3, 75, 76, "CID"], [3, 3, 78, 78, "CID"], [3, 3, 98, 98, "CID"], [3, 3, 126, 126, "CID"], [3, 3, 140, 140, "CID"], [3, 3, 151, 151, "CID"], [3, 3, 189, 189, "CID"], [3, 3, 208, 208, "CID"], [3, 3, 270, 270, "CID"], [3, 3, 298, 298, "CID"], [3, 3, 319, 319, "CID"], [43, 43, 6, 7, "CID"], [43, 43, 75, 76, "CID"], [43, 43, 78, 78, "CID"], [43, 43, 98, 98, "CID"], [43, 43, 126, 126, "CID"], [43, 43, 140, 140, "CID"], [43, 43, 151, 151, "CID"], [43, 43, 189, 189, "CID"], [43, 43, 208, 208, "CID"], [43, 43, 270, 270, "CID"], [43, 43, 298, 298, "CID"], [43, 43, 319, 319, "CID"], [72, 72, 6, 7, "CID"], [72, 72, 75, 76, "CID"], [72, 72, 78, 78, "CID"], [72, 72, 98, 98, "CID"], [72, 72, 126, 126, "CID"], [72, 72, 140, 140, "CID"], [72, 72, 151, 151, "CID"], [72, 72, 189, 189, "CID"], [72, 72, 208, 208, "CID"], [72, 72, 270, 270, "CID"], [72, 72, 298, 298, "CID"], [72, 72, 319, 319, "CID"], [196, 196, 6, 7, "CID"], [196, 196, 75, 76, "CID"], [196, 196, 78, 78, "CID"], [196, 196, 98, 98, "CID"], [196, 196, 126, 126, "CID"], [196, 196, 140, 140, "CID"], [196, 196, 151, 151, "CID"], [196, 196, 189, 189, "CID"], [196, 196, 208, 208, "CID"], [196, 196, 270, 270, "CID"], [196, 196, 298, 298, "CID"], [196, 196, 319, 319, "CID"], [293, 293, 6, 7, "CID"], [293, 293, 75, 76, "CID"], [293, 293, 78, 78, "CID"], [293, 293, 98, 98, "CID"], [293, 293, 126, 126, "CID"], [293, 293, 140, 140, "CID"], [293, 293, 151, 151, "CID"], [293, 293, 189, 189, "CID"], [293, 293, 208, 208, "CID"], [293, 293, 270, 270, "CID"], [293, 293, 298, 298, "CID"], [293, 293, 319, 319, "CID"], [46, 48, 6, 7, "CID"], [46, 48, 75, 76, "CID"], [46, 48, 78, 78, "CID"], [46, 48, 98, 98, "CID"], [46, 48, 126, 126, "CID"], [46, 48, 140, 140, "CID"], [46, 48, 151, 151, "CID"], [46, 48, 189, 189, "CID"], [46, 48, 208, 208, "CID"], [46, 48, 270, 270, "CID"], [46, 48, 298, 298, "CID"], [46, 48, 319, 319, "CID"]]], "clusters": [], "translated": "<0>利巴韦林</0>引起的<5>溶血性贫血</5>在<18>丙型肝炎</18>的治疗中：临床和经济意义。目的：最近发表的研究表明，联合治疗干扰素和α-2B/<1>利巴韦林</1>与<17>干扰素α</17>单一疗法相比，在<19>慢性丙型肝炎</19>（<20>CHC</20>）的治疗中，联合治疗具有更高的疗效和经济效益。联合治疗与临床上重要的不良反应相关：<2>利巴韦林</2>诱导的<6>溶血性贫血</6> (<7>RIHA</7>)。本研究的目的是在临床试验环境中评估 <21>CHC</21> 治疗期间<8>RIHA</8>的直接医疗保健成本和管理。方法：进行系统的文献回顾以综合有关<9>RIHA</9>的发生率和管理的信息。决策分析技术用于估计治疗<10> RIHA </10>的成本。使用敏感性分析评估不确定性。结果：<11>RIHA</11>（定义为血红蛋白降低至低于100 g/L）发生在接受联合治疗的大约7%至9%的患者中。<12>RIHA</12>的护理标准是减少或停用 <3>利巴韦林</3>剂量。我们估计每48周疗程（范围68-692）接受联合治疗的每位患者治疗有临床意义的 <13>RIHA</13> 的直接成本为170。单向敏感性分析的结果范围为57至317。相比之下，48周联合治疗的费用为16459。结论：治疗有临床意义的<14>RIHA</14>的直接费用为药物治疗费用的1%（170/16459）。关于真实世界人群中<4>利巴韦林</4>的最佳剂量和<15>RIHA</15>的发生率的问题仍然存在。尽管存在这些不确定性，但对治疗<16>RIHA</16>的直接成本进行的初步评估提供了对这种临床上重要的不良反应的成本和管理影响的估计。", "revised": true}
{"doc_key": "11077455", "sentences": [["Electro", "-", "oculography", ",", "electroretinography", ",", "visual", "evoked", "potentials", ",", "and", "multifocal", "electroretinography", "in", "patients", "with", "vigabatrin", "-", "attributed", "visual", "field", "constriction", ".", "PURPOSE", ":", "Symptomatic", "visual", "field", "constriction", "thought", "to", "be", "associated", "with", "vigabatrin", "has", "been", "reported", ".", "The", "current", "study", "investigated", "the", "visual", "fields", "and", "visual", "electrophysiology", "of", "eight", "patients", "with", "known", "vigabatrin", "-", "attributed", "visual", "field", "loss", ",", "three", "of", "whom", "were", "reported", "previously", ".", "Six", "of", "the", "patients", "were", "no", "longer", "receiving", "vigabatrin", ".", "METHODS", ":", "The", "central", "and", "peripheral", "fields", "were", "examined", "with", "the", "Humphrey", "Visual", "Field", "Analyzer", ".", "Full", "visual", "electrophysiology", ",", "including", "flash", "electroretinography", "(", "ERG", ")", ",", "pattern", "electroretinography", ",", "multifocal", "ERG", "using", "the", "VERIS", "system", ",", "electro", "-", "oculography", ",", "and", "flash", "and", "pattern", "visual", "evoked", "potentials", ",", "was", "undertaken", ".", "RESULTS", ":", "Seven", "patients", "showed", "marked", "visual", "field", "constriction", "with", "some", "sparing", "of", "the", "temporal", "visual", "field", ".", "The", "eighth", "exhibited", "concentric", "constriction", ".", "Most", "electrophysiological", "responses", "were", "usually", "just", "within", "normal", "limits", ";", "two", "patients", "had", "subnormal", "Arden", "electro", "-", "oculography", "indices", ";", "and", "one", "patient", "showed", "an", "abnormally", "delayed", "photopic", "b", "wave", ".", "However", ",", "five", "patients", "showed", "delayed", "30", "-", "Hz", "flicker", "b", "waves", ",", "and", "seven", "patients", "showed", "delayed", "oscillatory", "potentials", ".", "Multifocal", "ERG", "showed", "abnormalities", "that", "sometimes", "correlated", "with", "the", "visual", "field", "appearance", "and", "confirmed", "that", "the", "deficit", "occurs", "at", "the", "retinal", "level", ".", "CONCLUSION", ":", "Marked", "visual", "field", "constriction", "appears", "to", "be", "associated", "with", "vigabatrin", "therapy", ".", "The", "field", "defects", "and", "some", "electrophysiological", "abnormalities", "persist", "when", "vigabatrin", "therapy", "is", "withdrawn", "."]], "ner": [[[16, 16, "Chemical"], [34, 34, "Chemical"], [54, 54, "Chemical"], [76, 76, "Chemical"], [240, 240, "Chemical"], [252, 252, "Chemical"], [19, 21, "Disease"], [26, 28, "Disease"], [57, 59, "Disease"], [136, 138, "Disease"], [232, 234, "Disease"]]], "relations": [[[16, 16, 19, 21, "CID"], [16, 16, 26, 28, "CID"], [16, 16, 57, 59, "CID"], [16, 16, 136, 138, "CID"], [16, 16, 232, 234, "CID"], [34, 34, 19, 21, "CID"], [34, 34, 26, 28, "CID"], [34, 34, 57, 59, "CID"], [34, 34, 136, 138, "CID"], [34, 34, 232, 234, "CID"], [54, 54, 19, 21, "CID"], [54, 54, 26, 28, "CID"], [54, 54, 57, 59, "CID"], [54, 54, 136, 138, "CID"], [54, 54, 232, 234, "CID"], [76, 76, 19, 21, "CID"], [76, 76, 26, 28, "CID"], [76, 76, 57, 59, "CID"], [76, 76, 136, 138, "CID"], [76, 76, 232, 234, "CID"], [240, 240, 19, 21, "CID"], [240, 240, 26, 28, "CID"], [240, 240, 57, 59, "CID"], [240, 240, 136, 138, "CID"], [240, 240, 232, 234, "CID"], [252, 252, 19, 21, "CID"], [252, 252, 26, 28, "CID"], [252, 252, 57, 59, "CID"], [252, 252, 136, 138, "CID"], [252, 252, 232, 234, "CID"]]], "clusters": [], "translated": "眼电图、视网膜电图、视觉诱发电位和多焦点视网膜电图在<0>氨己烯酸</0>患者中进行——归因于<6>视野收缩</6>。目的：有症状的<7>视野收缩</7>被认为与<1>氨己烯酸</1>有关已有报道。目前的研究调查了已知<2>氨己烯酸</2>导致的<8>视野缺损</8>患者的视野和视觉电生理学，其中3名患者之前已有报道。六名患者不再接受<3>氨己烯酸</3>。方法：用 Humphrey 视野分析仪检查中央视野和周边视野。进行了全面的视觉电生理学检查，包括闪光视网膜电图(ERG)、图形视网膜电图、使用 VERIS 系统的多焦点 ERG、眼电图以及闪光和图形视觉诱发电位。结果：7例患者均有明显的<9>视野缩小</9>，颞部视野有一定程度的保留。第八例显示同心收缩。大多数电生理反应通常都在正常范围内；两名患者的 Arden 眼电图指标低于正常值；一名患者表现出异常延迟的明视 b 波。然而，5名患者表现出延迟的 30 Hz 闪烁 b 波，7名患者表现出延迟的振荡电位。多焦点 ERG 显示有时与视野外观相关的异常，并确认缺陷发生在视网膜水平。结论：明显的<10>视野缩小</10>似乎与<4>氨己烯酸</4>治疗有关。当停止<5>氨己烯酸</5>治疗时，视野缺陷和一些电生理学异常仍然存在。", "revised": true}
{"doc_key": "11063349", "sentences": [["Conversion", "to", "rapamycin", "immunosuppression", "in", "renal", "transplant", "recipients", ":", "report", "of", "an", "initial", "experience", ".", "BACKGROUND", ":", "The", "aim", "of", "this", "study", "is", "to", "evaluate", "the", "effects", "of", "RAPA", "conversion", "in", "patients", "undergoing", "cyclosporine", "(", "CsA", ")", "or", "tacrolimus", "(", "Tac", ")", "toxicity", ".", "METHODS", ":", "Twenty", "renal", "transplant", "recipients", "were", "switched", "to", "fixed", "dose", "rapamycin", "(", "RAPA", ")", "(", "5", "mg", "/", "day", ")", "0", "to", "204", "months", "posttransplant", ".", "Drug", "monitoring", "was", "not", "initially", "used", "to", "adjust", "doses", ".", "The", "indications", "for", "switch", "were", "chronic", "CsA", "or", "Tac", "nephrotoxicity", "(", "12", ")", ",", "acute", "CsA", "or", "Tac", "toxicity", "(", "3", ")", ",", "severe", "facial", "dysmorphism", "(", "2", ")", ",", "posttransplant", "lymphoproliferative", "disorder", "(", "PTLD", ")", "in", "remission", "(", "2", ")", ",", "and", "hepatotoxicity", "in", "1", ".", "Follow", "-", "up", "is", "7", "to", "24", "months", ".", "RESULTS", ":", "In", "the", "12", "patients", "switched", "because", "of", "chronic", "nephrotoxicity", "there", "was", "a", "significant", "decrease", "in", "serum", "creatinine", "[", "233", "+", "/", "-", "34", "to", "210", "+", "/", "-", "56", "micromol", "/", "liter", "(", "P", "<", "0", ".", "05", ")", "at", "6", "months", "]", ".", "Facial", "dysmorphism", "improved", "in", "two", "patients", ".", "No", "relapse", "of", "PTLD", "was", "observed", ".", "Five", "patients", "developed", "pneumonia", "(", "two", "Pneumocystis", "carinii", "pneumonia", ",", "one", "infectious", "mononucleosis", "with", "polyclonal", "PTLD", "lung", "infiltrate", ")", "and", "two", "had", "bronchiolitis", "obliterans", ".", "There", "were", "no", "deaths", ".", "RAPA", "was", "discontinued", "in", "four", "patients", ",", "because", "of", "pneumonia", "in", "two", ",", "PTLD", "in", "one", ",", "and", "oral", "aphtous", "ulcers", "in", "one", ".", "RAPA", "levels", "were", "high", "(", ">", "15", "ng", "/", "ml", ")", "in", "7", "of", "13", "(", "54", "%", ")", "patients", ".", "CONCLUSIONS", ":", "RAPA", "conversion", "provides", "adequate", "immunosuppression", "to", "enable", "CsA", "withdrawal", ".", "However", ",", "when", "converting", "patients", "to", "RAPA", "drug", "levels", "should", "be", "monitored", "to", "avoid", "over", "-", "immunosuppression", "and", "adequate", "antiviral", "and", "Pneumocystis", "carinii", "pneumonia", "prophylaxis", "should", "be", "given", "."]], "ner": [[[33, 33, "Chemical"], [35, 35, "Chemical"], [87, 87, "Chemical"], [96, 96, "Chemical"], [281, 281, "Chemical"], [90, 90, "Disease"], [147, 147, "Disease"], [38, 38, "Chemical"], [40, 40, "Chemical"], [89, 89, "Chemical"], [98, 98, "Chemical"], [2, 2, "Chemical"], [28, 28, "Chemical"], [55, 55, "Chemical"], [57, 57, "Chemical"], [227, 227, "Chemical"], [251, 251, "Chemical"], [274, 274, "Chemical"], [290, 290, "Chemical"], [42, 42, "Disease"], [99, 99, "Disease"], [111, 113, "Disease"], [115, 115, "Disease"], [193, 193, "Disease"], [212, 212, "Disease"], [240, 240, "Disease"], [124, 124, "Disease"], [200, 200, "Disease"], [236, 236, "Disease"], [203, 205, "Disease"], [305, 307, "Disease"], [208, 209, "Disease"], [219, 220, "Disease"], [246, 247, "Disease"], [155, 155, "Chemical"]]], "relations": [[[33, 33, 90, 90, "CID"], [33, 33, 147, 147, "CID"], [35, 35, 90, 90, "CID"], [35, 35, 147, 147, "CID"], [87, 87, 90, 90, "CID"], [87, 87, 147, 147, "CID"], [96, 96, 90, 90, "CID"], [96, 96, 147, 147, "CID"], [281, 281, 90, 90, "CID"], [281, 281, 147, 147, "CID"], [38, 38, 90, 90, "CID"], [38, 38, 147, 147, "CID"], [40, 40, 90, 90, "CID"], [40, 40, 147, 147, "CID"], [89, 89, 90, 90, "CID"], [89, 89, 147, 147, "CID"], [98, 98, 90, 90, "CID"], [98, 98, 147, 147, "CID"]]], "clusters": [], "translated": "肾移植受者转用<11>雷帕霉素</11>免疫抑制：初步经验报告。背景：本研究的目的是评估<12>RAPA</12>转化对接受<0>环孢素</0>（<1>CsA</1>）或<7>他克莫司</7>（<8>Tac</8>）<19>毒性</19>的患者的影响。方法：20例肾移植受者在移植后0至204个月改用固定剂量<13>雷帕霉素</13>（<14>RAPA</14>）（5 mg/天）。药物监测最初并不用于调整剂量。转换的适应症是慢性<2>CsA</2>或<9>Tac</9><5>肾毒性</5>（12），急性<3>CsA</3>或<10>Tac</10><20>毒性</20>（3），严重的面部畸形（2），<21>移植后淋巴组织增生性疾病</21>（<22>PTLD</22>）缓解（2），以及<26>肝毒性</26>（1）。随访7～24个月。结果：在12名因慢性<6>肾毒性</6>而转换的患者中，血清<34>肌酐</34>显着降低[233+/-34到210+/-56微摩尔/升（P<0.05）在6个月]。两名患者的面部畸形得到改善。未观察到<23>PTLD</23>复发。五名患者发生了<27>肺炎</27>（两名<29>卡氏肺孢子虫肺炎</29>，一名<31>传染性单核细胞增多症</31>伴有多克隆<24>PTLD</24>肺浸润），两名患者患有<32>闭塞性细支气管炎</32>。没有人死亡。<15>RAPA</15>有4名患者停用，其中2名患者因<28>肺炎</28>，1名患者因<25>PTLD</25>，1名患者因口腔<33>口疮性溃疡</33>。<16>RAPA</16>水平在13名患者中有7名（>15 ng/ml）较高（54%）。结论：<17>RAPA</17>转化提供了足够的免疫抑制作用，使<4>CsA</4>撤药成为可能。然而，当将患者转为<18>RAPA</18>时，应监测药物水平以避免过度免疫抑制，并应给予足够的抗病毒药物和<30>卡氏肺孢子虫肺炎</30>预防。", "revised": true}
{"doc_key": "9915601", "sentences": [["Enhanced", "bradycardia", "induced", "by", "beta", "-", "adrenoceptor", "antagonists", "in", "rats", "pretreated", "with", "isoniazid", ".", "High", "doses", "of", "isoniazid", "increase", "hypotension", "induced", "by", "vasodilators", "and", "change", "the", "accompanying", "reflex", "tachycardia", "to", "bradycardia", ",", "an", "interaction", "attributed", "to", "decreased", "synthesis", "of", "brain", "gamma", "-", "aminobutyric", "acid", "(", "GABA", ")", ".", "In", "the", "present", "study", ",", "the", "possible", "enhancement", "by", "isoniazid", "of", "bradycardia", "induced", "by", "beta", "-", "adrenoceptor", "antagonists", "was", "determined", "in", "rats", "anaesthetised", "with", "chloralose", "-", "urethane", ".", "Isoniazid", "significantly", "increased", "bradycardia", "after", "propranolol", ",", "pindolol", ",", "labetalol", "and", "atenolol", ",", "as", "well", "as", "after", "clonidine", ",", "but", "not", "after", "hexamethonium", "or", "carbachol", ".", "Enhancement", "was", "not", "observed", "in", "rats", "pretreated", "with", "methylatropine", "or", "previously", "vagotomised", ".", "These", "results", "are", "compatible", "with", "interference", "by", "isoniazid", "with", "GABAergic", "inhibition", "of", "cardiac", "parasympathetic", "tone", ".", "Such", "interference", "could", "be", "exerted", "centrally", ",", "possibly", "at", "the", "nucleus", "ambiguus", ",", "or", "peripherally", "at", "the", "sinus", "node", "."]], "ner": [[[12, 12, "Chemical"], [17, 17, "Chemical"], [57, 57, "Chemical"], [76, 76, "Chemical"], [122, 122, "Chemical"], [1, 1, "Disease"], [30, 30, "Disease"], [59, 59, "Disease"], [79, 79, "Disease"], [19, 19, "Disease"], [40, 43, "Chemical"], [45, 45, "Chemical"], [72, 72, "Chemical"], [74, 74, "Chemical"], [81, 81, "Chemical"], [83, 83, "Chemical"], [85, 85, "Chemical"], [87, 87, "Chemical"], [93, 93, "Chemical"], [98, 98, "Chemical"], [100, 100, "Chemical"], [110, 110, "Chemical"], [28, 28, "Disease"]]], "relations": [[[12, 12, 1, 1, "CID"], [12, 12, 30, 30, "CID"], [12, 12, 59, 59, "CID"], [12, 12, 79, 79, "CID"], [17, 17, 1, 1, "CID"], [17, 17, 30, 30, "CID"], [17, 17, 59, 59, "CID"], [17, 17, 79, 79, "CID"], [57, 57, 1, 1, "CID"], [57, 57, 30, 30, "CID"], [57, 57, 59, 59, "CID"], [57, 57, 79, 79, "CID"], [76, 76, 1, 1, "CID"], [76, 76, 30, 30, "CID"], [76, 76, 59, 59, "CID"], [76, 76, 79, 79, "CID"], [122, 122, 1, 1, "CID"], [122, 122, 30, 30, "CID"], [122, 122, 59, 59, "CID"], [122, 122, 79, 79, "CID"], [12, 12, 19, 19, "CID"], [17, 17, 19, 19, "CID"], [57, 57, 19, 19, "CID"], [76, 76, 19, 19, "CID"], [122, 122, 19, 19, "CID"]]], "clusters": [], "translated": "在用<0>异烟肼</0>预处理的大鼠中，β-肾上腺素能受体拮抗剂诱导的<5>心动过缓</5>增强。高剂量的<1>异烟肼</1>增加血管扩张剂引起的<9>低血压</9>并将伴随的反射<22>心动过速</22>改变为<6>心动过缓</6>，一种相互作用归因于大脑<10>γ-氨基丁酸</10>（<11>GABA</11>）的合成减少。在本研究中，确定了<2>异烟肼</2>对β-肾上腺素能受体拮抗剂诱导的<7>心动过缓</7>的可能增强作用，确定了麻醉的大鼠用<12>氯醛糖</12>-<13>聚氨酯</13>。异烟肼<3>显着增加</3><8>普萘洛尔</8>、<15>吲哚洛尔</15>、<16>拉贝洛尔</16>和<17>阿替洛尔</17>、<18>可乐定</18>后的<14>心动过缓</14>，但不是<19>六甲铵</19>或<20>卡巴胆碱</20>之后。在用<21>甲基阿托品</21>预处理或先前迷走神经切断术的大鼠中未观察到增强。这些结果与<4>异烟肼</4>对心脏副交感神经张力的GABA能抑制的干扰相一致。这种干扰可以在中央施加，可能在疑核处，或在窦房结周围施加。", "revised": true}
{"doc_key": "9952311", "sentences": [["Structural", "and", "functional", "impairment", "of", "mitochondria", "in", "adriamycin", "-", "induced", "cardiomyopathy", "in", "mice", ":", "suppression", "of", "cytochrome", "c", "oxidase", "II", "gene", "expression", ".", "The", "use", "of", "adriamycin", "(", "ADR", ")", "in", "cancer", "chemotherapy", "has", "been", "limited", "due", "to", "its", "cumulative", "cardiovascular", "toxicity", ".", "Earlier", "observations", "that", "ADR", "interacts", "with", "mitochondrial", "cytochrome", "c", "oxidase", "(", "COX", ")", "and", "suppresses", "its", "enzyme", "activity", "led", "us", "to", "investigate", "ADR", "'s", "action", "on", "the", "cardiovascular", "functions", "and", "heart", "mitochondrial", "morphology", "in", "Balb", "-", "c", "mice", "i", ".", "p", ".", "treated", "with", "ADR", "for", "several", "weeks", ".", "At", "various", "times", "during", "treatment", ",", "the", "animals", "were", "assessed", "for", "cardiovascular", "functions", "by", "electrocardiography", "and", "for", "heart", "tissue", "damage", "by", "electron", "microscopy", ".", "In", "parallel", ",", "total", "RNA", "was", "extracted", "from", "samples", "of", "dissected", "heart", "and", "analyzed", "by", "Northern", "blot", "hybridization", "to", "determine", "the", "steady", "-", "state", "level", "of", "three", "RNA", "transcripts", "encoded", "by", "the", "COXII", ",", "COXIII", ",", "and", "COXIV", "genes", ".", "Similarly", ",", "samples", "obtained", "from", "the", "liver", "of", "the", "same", "animals", "were", "analyzed", "for", "comparative", "studies", ".", "Our", "results", "indicated", "that", "1", ")", "treatment", "of", "mice", "with", "ADR", "caused", "cardiovascular", "arrhythmias", "characterized", "by", "bradycardia", ",", "extension", "of", "ventricular", "depolarization", "time", "(", "tQRS", ")", ",", "and", "failure", "of", "QRS", "at", "high", "concentrations", "(", "10", "-", "14", "mg", "/", "kg", "body", "weight", "cumulative", "dose", ")", ";", "2", ")", "the", "heart", "mitochondria", "underwent", "swelling", ",", "fusion", ",", "dissolution", ",", "and", "/", "or", "disruption", "of", "mitochondrial", "cristae", "after", "several", "weeks", "of", "treatment", ".", "Such", "abnormalities", "were", "not", "observed", "in", "the", "mitochondria", "of", "liver", "tissue", ";", "and", "3", ")", "among", "the", "three", "genes", "of", "COX", "enzyme", "examined", ",", "only", "COXII", "gene", "expression", "was", "suppressed", "by", "ADR", "treatment", ",", "mainly", "after", "8", "weeks", "in", "both", "heart", "and", "liver", ".", "Knowing", "that", "heart", "mitochondria", "represent", "almost", "40", "%", "of", "heart", "muscle", "by", "weight", ",", "we", "conclude", "that", "the", "deteriorating", "effects", "of", "ADR", "on", "cardiovascular", "function", "involve", "mitochondrial", "structural", "and", "functional", "impairment", "."]], "ner": [[[7, 7, "Chemical"], [26, 26, "Chemical"], [28, 28, "Chemical"], [46, 46, "Chemical"], [65, 65, "Chemical"], [87, 87, "Chemical"], [183, 183, "Chemical"], [276, 276, "Chemical"], [310, 310, "Chemical"], [0, 5, "Disease"], [315, 319, "Disease"], [189, 189, "Disease"], [10, 10, "Disease"], [31, 31, "Disease"], [40, 41, "Disease"], [185, 186, "Disease"], [226, 226, "Disease"]]], "relations": [[[7, 7, 0, 5, "CID"], [7, 7, 315, 319, "CID"], [26, 26, 0, 5, "CID"], [26, 26, 315, 319, "CID"], [28, 28, 0, 5, "CID"], [28, 28, 315, 319, "CID"], [46, 46, 0, 5, "CID"], [46, 46, 315, 319, "CID"], [65, 65, 0, 5, "CID"], [65, 65, 315, 319, "CID"], [87, 87, 0, 5, "CID"], [87, 87, 315, 319, "CID"], [183, 183, 0, 5, "CID"], [183, 183, 315, 319, "CID"], [276, 276, 0, 5, "CID"], [276, 276, 315, 319, "CID"], [310, 310, 0, 5, "CID"], [310, 310, 315, 319, "CID"], [7, 7, 189, 189, "CID"], [26, 26, 189, 189, "CID"], [28, 28, 189, 189, "CID"], [46, 46, 189, 189, "CID"], [65, 65, 189, 189, "CID"], [87, 87, 189, 189, "CID"], [183, 183, 189, 189, "CID"], [276, 276, 189, 189, "CID"], [310, 310, 189, 189, "CID"]]], "clusters": [], "translated": "<0>阿霉素</0>诱导的小鼠<12>心肌病</12><9>线粒体结构和功能损伤</9>：抑制细胞色素c氧化酶II基因表达。 <1>阿霉素</1> (<2>ADR</2>)在<13>癌症</13>化学疗法中的使用因其累积的<14>心血管毒性</14>而受到限制。早期观察到<3>ADR</3>与线粒体细胞色素c氧化酶（COX）相互作用并抑制其酶活性，促使我们研究了<4>ADR</4>对Balb-c小鼠心血管功能和心脏线粒体形态的作用，小鼠接受了几周的<5>ADR</5>治疗。在治疗期间的不同时间，通过心电图评估动物的心血管功能，并通过电子显微镜评估心脏组织损伤。同时，从心脏解剖样本中提取总RNA，并通过Northern印迹杂交进行分析，以确定由COXII、COXIII和COXIV基因编码的三种RNA转录本的稳态水平。同样，对从相同动物的肝脏获得的样本进行分析以进行比较研究。我们的研究结果表明：1)<6>ADR</6>小鼠治疗引起<15>心血管心律失常</15>，其特征为<11>心动过缓</11>、心室除极时间(tQRS)延长和高浓度(10-14毫克/千克体重累积剂量)QRS波衰竭；2)心脏线粒体在治疗数周后发生<16>肿胀</16>、融合、溶解和/或线粒体嵴断裂。肝组织线粒体未见此类异常；3)在检测的三个COX酶基因中，<7>ADR</7>处理仅抑制COXII基因表达，主要在8周后在心脏和肝脏中均有抑制。已知心脏线粒体几乎占心肌重量的40％，我们得出结论，<8>ADR</8>对心血管功能的恶化影响涉及<10>线粒体结构和功能损伤</10>。", "revised": true}
{"doc_key": "9326871", "sentences": [["Clarithromycin", "-", "induced", "ventricular", "tachycardia", ".", "Clarithromycin", "is", "a", "relatively", "new", "macrolide", "antibiotic", "that", "offers", "twice", "-", "daily", "dosing", ".", "It", "differs", "from", "erythromycin", "only", "in", "the", "methylation", "of", "the", "hydroxyl", "group", "at", "position", "6", ".", "Although", "the", "side", "-", "effect", "profile", "of", "erythromycin", "is", "established", ",", "including", "gastroenteritis", "and", "interactions", "with", "other", "drugs", "subject", "to", "hepatic", "mixed", "-", "function", "oxidase", "metabolism", ",", "experience", "with", "the", "newer", "macrolides", "is", "still", "being", "recorded", ".", "Cardiotoxicity", "has", "been", "demonstrated", "after", "both", "intravenous", "and", "oral", "administration", "of", "erythromycin", "but", "has", "never", "been", "reported", "with", "the", "newer", "macrolides", ".", "We", "report", "a", "case", "of", "ventricular", "dysrhythmias", "that", "occurred", "after", "six", "therapeutic", "doses", "of", "clarithromycin", ".", "The", "dysrhythmias", "resolved", "after", "discontinuation", "of", "the", "drug", "."]], "ner": [[[0, 0, "Chemical"], [6, 6, "Chemical"], [109, 109, "Chemical"], [3, 4, "Disease"], [23, 23, "Chemical"], [43, 43, "Chemical"], [84, 84, "Chemical"], [48, 48, "Disease"], [73, 73, "Disease"], [100, 101, "Disease"], [112, 112, "Disease"], [11, 11, "Chemical"], [67, 67, "Chemical"], [93, 93, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [6, 6, 3, 4, "CID"], [109, 109, 3, 4, "CID"], [23, 23, 48, 48, "CID"], [43, 43, 48, 48, "CID"], [84, 84, 48, 48, "CID"]]], "clusters": [], "translated": "<0>克拉霉素</0>引起的<3>室性心动过速</3>。<1>克拉霉素</1>是一种相对较新的<11>大环内酯类</11>抗生素，每日给药两次。它与<4>红霉素</4>的区别仅在于6位羟基的甲基化。虽然<5> 红霉素 </5>的副作用已经确定，包括<7>胃肠炎</7>以及与其他受肝脏混合功能氧化酶代谢影响的药物的相互作用，但使用较新的<12>大环内酯类</12>仍在录制中。<8>心脏毒性</8>已在静脉内和口服给药<6>红霉素</6>后得到证明，但从未报道过较新的<13>大环内酯类药物</13>。我们报告了一例<9>室性心律失常</9>发生在六次治疗剂量的<2>克拉霉素</2>后。<10>心律失常</10>在停药后得到解决。", "revised": true}
{"doc_key": "9226773", "sentences": [["Persistent", "nephrogenic", "diabetes", "insipidus", "following", "lithium", "therapy", ".", "We", "report", "the", "case", "of", "a", "patient", "who", "developed", "severe", "hypernatraemic", "dehydration", "following", "a", "head", "injury", ".", "Ten", "years", "previously", "he", "had", "been", "diagnosed", "to", "have", "lithium", "-", "induced", "nephrogenic", "diabetes", "insipidus", ",", "and", "lithium", "therapy", "had", "been", "discontinued", ".", "He", "remained", "thirsty", "and", "polyuric", "despite", "cessation", "of", "lithium", "and", "investigations", "on", "admission", "showed", "him", "to", "have", "normal", "osmoregulated", "thirst", "and", "vasopressin", "secretion", ",", "with", "clear", "evidence", "of", "nephrogenic", "diabetes", "insipidus", ".", "Lithium", "induced", "nephrogenic", "diabetes", "insipidus", "is", "considered", "to", "be", "reversible", "on", "cessation", "of", "therapy", "but", "polyuria", "persisted", "in", "this", "patient", "for", "ten", "years", "after", "lithium", "was", "stopped", ".", "We", "discuss", "the", "possible", "renal", "mechanisms", "and", "the", "implications", "for", "management", "of", "patients", "with", "lithium", "-", "induced", "nephrogenic", "diabetes", "insipidus", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [42, 42, "Chemical"], [56, 56, "Chemical"], [80, 80, "Chemical"], [104, 104, "Chemical"], [122, 122, "Chemical"], [1, 3, "Disease"], [37, 39, "Disease"], [76, 78, "Disease"], [82, 84, "Disease"], [125, 127, "Disease"], [52, 52, "Disease"], [95, 95, "Disease"], [69, 69, "Chemical"], [19, 19, "Disease"], [22, 23, "Disease"]]], "relations": [[[5, 5, 1, 3, "CID"], [5, 5, 37, 39, "CID"], [5, 5, 76, 78, "CID"], [5, 5, 82, 84, "CID"], [5, 5, 125, 127, "CID"], [34, 34, 1, 3, "CID"], [34, 34, 37, 39, "CID"], [34, 34, 76, 78, "CID"], [34, 34, 82, 84, "CID"], [34, 34, 125, 127, "CID"], [42, 42, 1, 3, "CID"], [42, 42, 37, 39, "CID"], [42, 42, 76, 78, "CID"], [42, 42, 82, 84, "CID"], [42, 42, 125, 127, "CID"], [56, 56, 1, 3, "CID"], [56, 56, 37, 39, "CID"], [56, 56, 76, 78, "CID"], [56, 56, 82, 84, "CID"], [56, 56, 125, 127, "CID"], [80, 80, 1, 3, "CID"], [80, 80, 37, 39, "CID"], [80, 80, 76, 78, "CID"], [80, 80, 82, 84, "CID"], [80, 80, 125, 127, "CID"], [104, 104, 1, 3, "CID"], [104, 104, 37, 39, "CID"], [104, 104, 76, 78, "CID"], [104, 104, 82, 84, "CID"], [104, 104, 125, 127, "CID"], [122, 122, 1, 3, "CID"], [122, 122, 37, 39, "CID"], [122, 122, 76, 78, "CID"], [122, 122, 82, 84, "CID"], [122, 122, 125, 127, "CID"], [5, 5, 52, 52, "CID"], [5, 5, 95, 95, "CID"], [34, 34, 52, 52, "CID"], [34, 34, 95, 95, "CID"], [42, 42, 52, 52, "CID"], [42, 42, 95, 95, "CID"], [56, 56, 52, 52, "CID"], [56, 56, 95, 95, "CID"], [80, 80, 52, 52, "CID"], [80, 80, 95, 95, "CID"], [104, 104, 52, 52, "CID"], [104, 104, 95, 95, "CID"], [122, 122, 52, 52, "CID"], [122, 122, 95, 95, "CID"]]], "clusters": [], "translated": "<0>锂</0>治疗后持续性<7>肾性尿崩症</7>。我们报告了一名患者在<16>头部受伤</16>后出现严重高钠血症<15>脱水</15>的病例。十年前，他被诊断出患有<1>锂</1>诱发的<8>肾性尿崩症</8>，并且<2>锂</2>治疗已经停止。尽管停止了<3>锂</3>，他仍然口渴和<12>多尿</12>，入院调查显示他有正常的渗透调节口渴和<14>加压素</14>分泌，有明确的证据<9>肾性尿崩症</9>。 <4>锂</4>诱发的<10>肾性尿崩症</10>被认为在停止治疗后是可逆的，但<13>多尿</13>在<5>锂</5>已停止。我们讨论了可能的肾脏机制以及对<6>锂</6>诱发的<11>肾性尿崩症</11>患者管理的影响。", "revised": true}
{"doc_key": "8492347", "sentences": [["Tetany", "and", "rhabdomyolysis", "due", "to", "surreptitious", "furosemide", "-", "-", "importance", "of", "magnesium", "supplementation", ".", "Diuretics", "may", "induce", "hypokalemia", ",", "hypocalcemia", "and", "hypomagnesemia", ".", "While", "severe", "hypokalemia", "may", "cause", "muscle", "weakness", ",", "severe", "hypomagnesemia", "is", "associated", "with", "muscle", "spasms", "and", "tetany", "which", "can", "not", "be", "corrected", "by", "potassium", "and", "calcium", "supplementation", "alone", "(", "1", ",", "2", ")", ".", "Surreptitious", "diuretic", "ingestion", "has", "been", "described", ",", "mainly", "in", "women", "who", "are", "concerned", "that", "they", "are", "obese", "or", "edematous", ".", "Symptomatic", "hypokalemia", "has", "been", "reported", "in", "such", "patients", "(", "3", "-", "7", ")", "and", "in", "one", "case", "hypocalcemia", "was", "observed", "(", "8", ")", ",", "but", "the", "effects", "of", "magnesium", "depletion", "were", "not", "noted", "in", "these", "patients", "."]], "ner": [[[6, 6, "Chemical"], [0, 0, "Disease"], [39, 39, "Disease"], [2, 2, "Disease"], [11, 11, "Chemical"], [105, 105, "Chemical"], [46, 46, "Chemical"], [48, 48, "Chemical"], [17, 17, "Disease"], [25, 25, "Disease"], [78, 78, "Disease"], [19, 19, "Disease"], [94, 94, "Disease"], [21, 21, "Disease"], [32, 32, "Disease"], [28, 29, "Disease"], [36, 37, "Disease"], [73, 73, "Disease"], [75, 75, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 39, 39, "CID"], [6, 6, 2, 2, "CID"]]], "clusters": [], "translated": " <1>手足抽搐</1>和<3>横纹肌溶解症</3>由于暗中使用<0>呋塞米</0>， <4>镁</4> 补充剂的重要性。利尿剂可引起<8>低钾血症</8>、<11>低钙血症</11>和<13>低镁血症</13>。严重的<9>低钾血症</9>可能导致<15>肌肉无力</15>，严重的<14>低镁血症</14>与<16>肌肉痉挛</16>和<2>手足抽搐</2>不能单独通过补充<6>钾</6>和<7>钙</7>来纠正(1,2)。已经描述了秘密摄入利尿剂，主要发生在担心自己是<17>肥胖</17>或<18>水肿</18>的女性中。有症状的<10>低钾血症</10>已在此类患者中报告(3-7)，并且在一例中观察到<12>低钙血症</12>(8)，但这些患者没有注意到<5>镁</5>耗竭的影响。", "revised": true}
{"doc_key": "9758264", "sentences": [["Epileptogenic", "activity", "of", "folic", "acid", "after", "drug", "induces", "SLE", "(", "folic", "acid", "and", "epilepsy", ")", "OBJECTIVE", ":", "To", "study", "the", "effect", "of", "folic", "acid", "-", "containing", "multivitamin", "supplementation", "in", "epileptic", "women", "before", "and", "during", "pregnancy", "in", "order", "to", "determine", "the", "rate", "of", "structural", "birth", "defects", "and", "epilepsy", "-", "related", "side", "effects", ".", "STUDY", "DESIGN", ":", "First", "a", "randomised", "trial", ",", "later", "periconception", "care", "including", "in", "total", "12225", "females", ".", "RESULTS", ":", "Of", "60", "epileptic", "women", "with", "periconceptional", "folic", "acid", "(", "0", ".", "8", "mg", ")", "-", "containing", "multivitamin", "supplementation", ",", "no", "one", "developed", "epilepsy", "-", "related", "side", "effects", "during", "the", "periconception", "period", ".", "One", "epileptic", "woman", "delivered", "a", "newborn", "with", "cleft", "lip", "and", "palate", ".", "Another", "patient", "exhibited", "with", "a", "cluster", "of", "seizures", "after", "the", "periconception", "period", "using", "another", "multivitamin", ".", "This", "22", "-", "year", "-", "old", "epileptic", "woman", "was", "treated", "continuously", "by", "carbamazepine", "and", "a", "folic", "acid", "(", "1", "mg", ")", "-", "containing", "multivitamin", "from", "the", "20th", "week", "of", "gestation", ".", "She", "developed", "status", "epilepticus", "and", "later", "symptoms", "of", "systemic", "lupus", "erythematodes", ".", "Her", "pregnancy", "ended", "with", "stillbirth", ".", "CONCLUSIONS", ":", "The", "epileptic", "pregnant", "patient", "'s", "autoimmune", "disease", "(", "probably", "drug", "-", "induced", "lupus", ")", "could", "damage", "the", "blood", "-", "brain", "barrier", ",", "therefore", "the", "therapeutic", "dose", "(", ">", "or", "=", "1", "mg", ")", "of", "folic", "acid", "triggered", "a", "cluster", "of", "seizures", ".", "Physiological", "dose", "(", "<", "1", "mg", ")", "of", "folic", "acid", "both", "in", "healthy", "and", "60", "epileptic", "women", ",", "all", "without", "any", "autoimmune", "disease", ",", "did", "not", "increase", "the", "risk", "for", "epileptic", "seizures", "."]], "ner": [[[3, 4, "Chemical"], [10, 11, "Chemical"], [22, 23, "Chemical"], [77, 78, "Chemical"], [146, 147, "Chemical"], [216, 217, "Chemical"], [232, 233, "Chemical"], [8, 8, "Disease"], [170, 172, "Disease"], [194, 194, "Disease"], [122, 122, "Disease"], [222, 222, "Disease"], [13, 13, "Disease"], [29, 29, "Disease"], [46, 46, "Disease"], [73, 73, "Disease"], [93, 93, "Disease"], [104, 104, "Disease"], [137, 137, "Disease"], [183, 183, "Disease"], [239, 239, "Disease"], [254, 255, "Disease"], [43, 44, "Disease"], [110, 113, "Disease"], [164, 165, "Disease"], [178, 178, "Disease"], [187, 188, "Disease"], [245, 246, "Disease"], [143, 143, "Chemical"]]], "relations": [[[3, 4, 8, 8, "CID"], [3, 4, 170, 172, "CID"], [3, 4, 194, 194, "CID"], [10, 11, 8, 8, "CID"], [10, 11, 170, 172, "CID"], [10, 11, 194, 194, "CID"], [22, 23, 8, 8, "CID"], [22, 23, 170, 172, "CID"], [22, 23, 194, 194, "CID"], [77, 78, 8, 8, "CID"], [77, 78, 170, 172, "CID"], [77, 78, 194, 194, "CID"], [146, 147, 8, 8, "CID"], [146, 147, 170, 172, "CID"], [146, 147, 194, 194, "CID"], [216, 217, 8, 8, "CID"], [216, 217, 170, 172, "CID"], [216, 217, 194, 194, "CID"], [232, 233, 8, 8, "CID"], [232, 233, 170, 172, "CID"], [232, 233, 194, 194, "CID"], [3, 4, 122, 122, "CID"], [3, 4, 222, 222, "CID"], [10, 11, 122, 122, "CID"], [10, 11, 222, 222, "CID"], [22, 23, 122, 122, "CID"], [22, 23, 222, 222, "CID"], [77, 78, 122, 122, "CID"], [77, 78, 222, 222, "CID"], [146, 147, 122, 122, "CID"], [146, 147, 222, 222, "CID"], [216, 217, 122, 122, "CID"], [216, 217, 222, 222, "CID"], [232, 233, 122, 122, "CID"], [232, 233, 222, 222, "CID"]]], "clusters": [], "translated": "药物诱发<7>SLE</7>（<1>叶酸</1>和<12>癫痫</12>）后<0>叶酸</0>的致痫活性。<2>叶酸</2>- 在怀孕前和怀孕期间<13>癫痫</13>妇女补充含有多种维生素，以确定结构性<22>出生缺陷</22>和<14>癫痫</14>-相关的副作用。研究设计：首先是一项随机试验，然后是围孕期护理，总共包括12225 名女性。结果：在60 名<15>癫痫</15>围孕期<3>叶酸</3>（0.8 mg）补充多种维生素的女性中，没有人出现<16>癫痫</16>-相关的副作用在围孕期。一位患有<17>癫痫</17>的妇女生下了一名患有<23>唇腭裂</23>的新生儿。另一名患者在围孕期使用另一种复合维生素后出现了<10>癫痫发作</10>。这名22 岁的<18>癫痫</18> 妇女从怀孕的20周开始连续服用<28>卡马西平</28>和<4>叶酸</4>（1 mg） - 含有多种维生素。她出现了<24>癫痫持续状态</24>和后来的<8>系统性红斑狼疮</8>症状。她的怀孕以<25>死产</25>告终。结论：<19>癫痫</19>妊娠患者<26>自身免疫性疾病</26>（可能为药物性<9>狼疮</9>）可引起血脑屏障损伤，故治疗剂量(≥1 mg)的<5>叶酸</5>触发了一组<11>癫痫发作</11>。健康女性和60名<20>癫痫</20>女性（均未患有任何<27>自身免疫性疾病</27>）服用<6>叶酸</6>的生理剂量（<1 mg），并未增加风险用于<21>癫痫</21>发作。", "revised": true}
{"doc_key": "8514073", "sentences": [["Venous", "complications", "of", "midazolam", "versus", "diazepam", ".", "Although", "some", "studies", "have", "suggested", "fewer", "venous", "complications", "are", "associated", "with", "midazolam", "than", "with", "diazepam", "for", "endoscopic", "procedures", ",", "this", "variable", "has", "not", "been", "well", "documented", ".", "We", "prospectively", "evaluated", "the", "incidence", "of", "venous", "complications", "after", "intravenous", "injection", "of", "diazepam", "or", "midazolam", "in", "122", "consecutive", "patients", "undergoing", "colonoscopy", "and", "esophagogastroduodenoscopy", ".", "Overall", ",", "venous", "complications", "were", "more", "frequent", "with", "diazepam", "(", "22", "of", "62", "patients", ")", "than", "with", "midazolam", "(", "4", "of", "60", "patients", ")", "(", "p", "<", "0", ".", "001", ")", ".", "A", "palpable", "venous", "cord", "was", "present", "in", "23", "%", "(", "14", "of", "62", ")", "of", "patients", "in", "the", "diazepam", "group", ",", "compared", "with", "2", "%", "(", "1", "of", "60", "patients", ")", "in", "the", "midazolam", "group", "(", "p", "<", "0", ".", "002", ")", ".", "Pain", "at", "the", "injection", "site", "occurred", "in", "35", "%", "(", "22", "of", "62", ")", "of", "patients", "in", "the", "diazepam", "group", "compared", "with", "7", "%", "(", "4", "of", "60", "patients", ")", "in", "the", "midazolam", "group", "(", "p", "<", "0", ".", "001", ")", ".", "Swelling", "and", "warmth", "at", "the", "injection", "site", "were", "not", "significantly", "different", "between", "the", "two", "groups", ".", "Smoking", ",", "nonsteroidal", "anti", "-", "inflammatory", "drug", "use", ",", "intravenous", "catheter", "site", ",", "dwell", "time", "of", "the", "needle", ",", "alcohol", "use", ",", "and", "pain", "during", "the", "injection", "had", "no", "effect", "on", "the", "incidence", "of", "venous", "complications", "."]], "ner": [[[3, 3, "Chemical"], [18, 18, "Chemical"], [48, 48, "Chemical"], [75, 75, "Chemical"], [123, 123, "Chemical"], [165, 165, "Chemical"], [0, 1, "Disease"], [13, 14, "Disease"], [40, 41, "Disease"], [60, 61, "Disease"], [225, 226, "Disease"], [5, 5, "Chemical"], [21, 21, "Chemical"], [46, 46, "Chemical"], [66, 66, "Chemical"], [108, 108, "Chemical"], [151, 151, "Chemical"], [210, 210, "Chemical"], [133, 133, "Disease"], [214, 214, "Disease"], [175, 175, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [3, 3, 13, 14, "CID"], [3, 3, 40, 41, "CID"], [3, 3, 60, 61, "CID"], [3, 3, 225, 226, "CID"], [18, 18, 0, 1, "CID"], [18, 18, 13, 14, "CID"], [18, 18, 40, 41, "CID"], [18, 18, 60, 61, "CID"], [18, 18, 225, 226, "CID"], [48, 48, 0, 1, "CID"], [48, 48, 13, 14, "CID"], [48, 48, 40, 41, "CID"], [48, 48, 60, 61, "CID"], [48, 48, 225, 226, "CID"], [75, 75, 0, 1, "CID"], [75, 75, 13, 14, "CID"], [75, 75, 40, 41, "CID"], [75, 75, 60, 61, "CID"], [75, 75, 225, 226, "CID"], [123, 123, 0, 1, "CID"], [123, 123, 13, 14, "CID"], [123, 123, 40, 41, "CID"], [123, 123, 60, 61, "CID"], [123, 123, 225, 226, "CID"], [165, 165, 0, 1, "CID"], [165, 165, 13, 14, "CID"], [165, 165, 40, 41, "CID"], [165, 165, 60, 61, "CID"], [165, 165, 225, 226, "CID"], [5, 5, 0, 1, "CID"], [5, 5, 13, 14, "CID"], [5, 5, 40, 41, "CID"], [5, 5, 60, 61, "CID"], [5, 5, 225, 226, "CID"], [21, 21, 0, 1, "CID"], [21, 21, 13, 14, "CID"], [21, 21, 40, 41, "CID"], [21, 21, 60, 61, "CID"], [21, 21, 225, 226, "CID"], [46, 46, 0, 1, "CID"], [46, 46, 13, 14, "CID"], [46, 46, 40, 41, "CID"], [46, 46, 60, 61, "CID"], [46, 46, 225, 226, "CID"], [66, 66, 0, 1, "CID"], [66, 66, 13, 14, "CID"], [66, 66, 40, 41, "CID"], [66, 66, 60, 61, "CID"], [66, 66, 225, 226, "CID"], [108, 108, 0, 1, "CID"], [108, 108, 13, 14, "CID"], [108, 108, 40, 41, "CID"], [108, 108, 60, 61, "CID"], [108, 108, 225, 226, "CID"], [151, 151, 0, 1, "CID"], [151, 151, 13, 14, "CID"], [151, 151, 40, 41, "CID"], [151, 151, 60, 61, "CID"], [151, 151, 225, 226, "CID"]]], "clusters": [], "translated": "<0>咪达唑仑</0>与<11>地西泮</11>的<6>静脉并发症</6>。尽管一些研究表明在内窥镜手术中<1>咪达唑仑</1>与<12>地西泮</12>相关的<7>静脉并发症</7>较少，但该变量尚未得到充分记录。我们前瞻性地评估了 122 名接受结肠镜检查和食管胃十二指肠镜检查的连续患者静脉注射<13>地西泮</13>或<2>咪达唑仑</2>后<8>静脉并发症</8>的发生率。总体而言，<14>地西泮</14>组（62 例患者中的 22 例）的<9>静脉并发症</9>比<3>咪达唑仑</3>组（60 例患者中的 4 例）更常见（p < 0.001）。<15>地西泮</15>组中 23%（62 名中的 14 名）患者存在可触及的静脉索，而<4>咪达唑仑</4>组中这一比例为 2%（60 名患者中的 1 名）（p < 0.002）。在<16>地西泮</16>组中，注射部位的<18>疼痛</18>发生率为 35%（62 名患者中的 22 名），而在<5>咪达唑仑</5>组中为 7%（60 名患者中的 4 名）（p < 0.001）。<20>注射部位的肿胀</20>和发热在两组之间没有显着差异。吸烟、非甾体类抗炎药的使用、静脉导管位置、针头停留时间、<17>酒精</17>使用和注射期间的<19>疼痛</19>对<10>静脉并发症</10>的发生率没有影响。", "revised": true}
{"doc_key": "6203632", "sentences": [["Development", "of", "isoproterenol", "-", "induced", "cardiac", "hypertrophy", ".", "The", "development", "of", "cardiac", "hypertrophy", "was", "studied", "in", "adult", "female", "Wistar", "rats", "following", "daily", "subcutaneous", "injections", "of", "isoproterenol", "(", "ISO", ")", "(", "0", ".", "3", "mg", "/", "kg", "body", "weight", ")", ".", "A", "time", "course", "was", "established", "for", "the", "change", "in", "tissue", "mass", ",", "RNA", "and", "DNA", "content", ",", "as", "well", "as", "hydroxyproline", "content", ".", "Heart", "weight", "increased", "44", "%", "after", "8", "days", "of", "treatment", "with", "a", "half", "time", "of", "3", ".", "4", "days", ".", "Ventricular", "RNA", "content", "was", "elevated", "26", "%", "after", "24", "h", "of", "a", "single", "injection", "and", "reached", "a", "maximal", "level", "following", "8", "days", "of", "therapy", ".", "The", "half", "time", "for", "RNA", "accumulation", "was", "2", ".", "0", "days", ".", "The", "total", "content", "of", "hydroxyproline", "remained", "stable", "during", "the", "first", "2", "days", "of", "treatment", "but", "increased", "46", "%", "after", "4", "days", "of", "therapy", ".", "Ventricular", "DNA", "content", "was", "unchanged", "during", "the", "early", "stage", "(", "1", "-", "4", "days", ")", "of", "hypertrophic", "growth", "but", "increased", "to", "a", "new", "steady", "-", "state", "level", "19", "%", "above", "the", "controls", "after", "8", "days", "of", "treatment", ".", "Intraventricular", "pressures", "and", "coronary", "flow", "measures", "were", "similar", "for", "control", "and", "experimental", "animals", "following", "4", "days", "of", "developed", "hypertrophy", ".", "However", ",", "dP", "/", "dt", "in", "the", "ISO", "-", "treated", "hearts", "was", "slightly", "but", "significantly", "(", "P", "less", "than", "0", ".", "05", ")", "elevated", ".", "These", "data", "indicate", "that", "the", "adaptive", "response", "to", "ISO", "shows", "an", "early", "hypertrophic", "phase", "(", "1", "-", "4", "days", ")", "characterized", "by", "a", "substantial", "increase", "in", "RNA", "content", "and", "cardiac", "mass", "in", "the", "absence", "of", "changes", "in", "DNA", ".", "However", ",", "prolonged", "stimulation", "(", "8", "-", "12", "days", ")", "appears", "to", "represent", "a", "complex", "integration", "of", "both", "cellular", "hypertrophy", "and", "hyperplasia", "within", "the", "heart", "."]], "ner": [[[2, 2, "Chemical"], [25, 25, "Chemical"], [27, 27, "Chemical"], [209, 209, "Chemical"], [235, 235, "Chemical"], [5, 6, "Disease"], [11, 12, "Disease"], [287, 287, "Disease"], [160, 160, "Disease"], [200, 200, "Disease"], [239, 239, "Disease"], [285, 285, "Disease"], [60, 60, "Chemical"], [124, 124, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 11, 12, "CID"], [25, 25, 5, 6, "CID"], [25, 25, 11, 12, "CID"], [27, 27, 5, 6, "CID"], [27, 27, 11, 12, "CID"], [209, 209, 5, 6, "CID"], [209, 209, 11, 12, "CID"], [235, 235, 5, 6, "CID"], [235, 235, 11, 12, "CID"], [2, 2, 287, 287, "CID"], [25, 25, 287, 287, "CID"], [27, 27, 287, 287, "CID"], [209, 209, 287, 287, "CID"], [235, 235, 287, 287, "CID"]]], "clusters": [], "translated": "<0>异丙肾上腺素</0> -诱导的<5>心脏肥大</5>的发展。在成年雌性 Wistar 大鼠中研究了<6>心脏肥大</6>的发展，以下是具体过程：每天皮下注射<1>异丙肾上腺素</1>(<2>ISO</2>) (0.3mg/kg体重)。建立了组织质量，RNA和DNA含量，以及<12>羟脯氨酸</12>的含量变化的时间线。治疗8天后心脏重量增加了44%，半衰期为3.4天。单次注射24小时后心室RNA含量升高了26%，并在治疗8天后达到了最高水平。RNA积累的半衰期是2.0天。治疗的前两天<13>羟脯氨酸</13>的总含量保持稳定，但治疗4天后增加了46%。初期（1-4天）<8>肥大</8>生长时心室DNA含量没有变化，但治疗8天后增加到一个新的稳定水平，比对照组高出19%。在治疗发展<9>肥大</9> 4天后，控制组和实验动物的脑室内压和冠脉流量值相似。但是，<3>ISO</3>-处理心脏的 dP/dt 稍微但显著升高 (P小于0.05)。这些数据表明，对<4>ISO</4>的适应性反应显示出一个早期的<10>肥厚</10>阶段（1-4天），其特征在没有变化的情况下RNA含量和心脏质量显著增加，而DNA则不变。然而，长时间的刺激（8-12天）似乎代表了心脏内细胞<11>肥大</11>和<7>增生</7>的复杂整合。", "revised": true}
{"doc_key": "6728084", "sentences": [["Nephrotoxic", "effects", "of", "aminoglycoside", "treatment", "on", "renal", "protein", "reabsorption", "and", "accumulation", ".", "To", "quantify", "the", "effects", "of", "gentamicin", ",", "kanamycin", "and", "netilmicin", "on", "renal", "protein", "reabsorption", "and", "accumulation", ",", "these", "drugs", "were", "administered", "to", "rats", "intraperitoneally", "(", "30", "mg", "/", "kg", "/", "day", ")", "for", "7", ",", "14", "or", "21", "days", ".", "Scanning", "electron", "microscopy", "of", "the", "glomerular", "endothelia", ",", "urinary", "measurements", "of", "sodium", ",", "potassium", ",", "endogenous", "lysozyme", ",", "N", "-", "acetyl", "-", "beta", "-", "D", "-", "glucosaminidase", "(", "NAG", ")", "as", "well", "as", "clearance", "and", "accumulation", "experiments", "after", "i", ".", "v", ".", "administration", "of", "egg", "-", "white", "lysozyme", "and", "measurements", "of", "inulin", "clearance", "(", "GFR", ")", "were", "done", "in", "each", "treatment", "group", ".", "Gentamicin", "administration", "decreased", "diameter", ",", "density", "and", "shape", "of", "endothelial", "fenestrae", ".", "Kanamycin", "and", "netilmicin", "appeared", "to", "have", "no", "effect", "at", "the", "dose", "used", ".", "All", "three", "aminoglycosides", "decreased", "GFR", "and", "increased", "urinary", "excretion", "of", "sodium", "and", "potassium", ".", "While", "gentamicin", "and", "kanamycin", "decreased", "the", "percentage", "reabsorption", "and", "accumulation", "of", "lysozyme", "after", "i", ".", "v", ".", "administration", "of", "egg", "-", "white", "lysozyme", "netilmicin", "had", "no", "effect", ".", "Daily", "excretion", "of", "total", "protein", ",", "endogenous", "lysozyme", "and", "NAG", "increased", "only", "after", "treatment", "with", "kanamycin", "and", "gentamicin", ".", "Thus", ",", "aminoglycosides", "may", "act", "as", "nephrotoxicants", "at", "glomerular", "and", "/", "or", "tubular", "level", "inducing", "impairment", "of", "renal", "reabsorption", "and", "accumulation", "of", "proteins", "."]], "ner": [[[17, 17, "Chemical"], [115, 115, "Chemical"], [155, 155, "Chemical"], [199, 199, "Chemical"], [0, 0, "Disease"], [216, 219, "Disease"], [19, 19, "Chemical"], [127, 127, "Chemical"], [157, 157, "Chemical"], [197, 197, "Chemical"], [3, 3, "Chemical"], [142, 142, "Chemical"], [203, 203, "Chemical"], [21, 21, "Chemical"], [129, 129, "Chemical"], [177, 177, "Chemical"], [63, 63, "Chemical"], [150, 150, "Chemical"], [65, 65, "Chemical"], [152, 152, "Chemical"]]], "relations": [[[17, 17, 0, 0, "CID"], [17, 17, 216, 219, "CID"], [115, 115, 0, 0, "CID"], [115, 115, 216, 219, "CID"], [155, 155, 0, 0, "CID"], [155, 155, 216, 219, "CID"], [199, 199, 0, 0, "CID"], [199, 199, 216, 219, "CID"], [19, 19, 0, 0, "CID"], [19, 19, 216, 219, "CID"], [127, 127, 0, 0, "CID"], [127, 127, 216, 219, "CID"], [157, 157, 0, 0, "CID"], [157, 157, 216, 219, "CID"], [197, 197, 0, 0, "CID"], [197, 197, 216, 219, "CID"]]], "clusters": [], "translated": "<4>肾毒性</4> effects of <10>氨基糖苷类</10> treatment on renal protein reabsorption and accumulation. 为了量化<0>庆大霉素</0>，<6>卡那霉素</6>和<13>奈替米星</13>对肾蛋白质重吸收和积累的影响，这些药物被腹腔注射给大鼠（每天 30 毫克/千克）持续 7，14 或 21 天。扫描电镜下观察肾小球的内皮细胞，对尿液进行<16>钠</16>、<18>钾</18>、内源性溶菌酶、N-乙酰-β-D-氨基葡萄糖苷酶 (NAG) 的测量，以及在 i.v. 给予鸡蛋白溶菌酶后进行清除和积累实验和菊粉清除率 (GFR) 的测量。<1>庆大霉素</1> 给予可降低内皮细胞微小孔洞的直径、密度和形态。<7> 卡那霉素</7> 和 <14> 奈替米星 </14> 对所用剂量似乎没有影响。所有三种 <11> 氨基糖苷类</11> 均降低 GFR，增加尿液中<17>钠</17> 和 <19> 钾 </19> 的排泄。其中，<2> 庆大霉素</2> 和 <8> 卡那霉素 </8> 均降低了鸡蛋白溶菌酶的重吸收和积累，而<15>奈替米星</15>在所用剂量下无影响。在<3> 庆大霉素 </3>和<9>卡那霉素 </9>治疗后，每日总蛋白、内源性溶菌酶和 NAG 排泄量增加。因此，<12>氨基糖苷类 </12> 可能作为肾小球和/或肾小管水平的肾毒剂，诱导<5>肾重吸收障碍</5>和蛋白质积累。", "revised": true}
{"doc_key": "6111982", "sentences": [["Pharmacology", "of", "GYKI", "-", "41", "099", "(", "chlorpropanol", ",", "Tobanum", ")", "a", "new", "potent", "beta", "-", "adrenergic", "antagonist", ".", "The", "compound", "GYKI", "-", "41", "099", ",", "as", "a", "beta", "-", "adrenergic", "antagonist", ",", "is", "3", "-", "8", "times", "more", "potent", "than", "propranolol", "in", "vitro", "and", "in", "vivo", ".", "Its", "antiarrhythmic", "effectiveness", "surpasses", "that", "of", "propranolol", "and", "pindolol", "inhibiting", "the", "ouabain", "arrhythmia", "in", "dogs", "and", "cats", ".", "GYKI", "-", "41", "900", "has", "a", "negligible", "cardiodepressant", "activity", ";", "it", "is", "not", "cardioselective", ".", "The", "compound", "shows", "a", "rapid", "and", "long", "lasting", "effect", ".", "There", "was", "a", "prolonged", "elimination", "of", "the", "radioactivity", "after", "the", "injection", "of", "14C", "-", "41", "099", "to", "rats", "and", "dogs", ".", "The", "half", "life", "of", "the", "unlabeled", "substance", "in", "humans", "was", "more", "than", "10", "hours", "."]], "ner": [[[59, 59, "Chemical"], [60, 60, "Disease"], [2, 5, "Chemical"], [7, 7, "Chemical"], [9, 9, "Chemical"], [21, 24, "Chemical"], [41, 41, "Chemical"], [54, 54, "Chemical"], [56, 56, "Chemical"]]], "relations": [[[59, 59, 60, 60, "CID"]]], "clusters": [], "translated": "<2>GYKI-41 099</2>（<3>氯丙醇</3>，<4>Tobanum</4>）的药理学，一种新型强效β-肾上腺素能拮抗剂。化合物<5>GYKI-41 099</5>，作为β-肾上腺素能拮抗剂，是<6>普萘洛尔</6>在体外和体内的3-8倍。其抗心律失常作用超过<7>普萘洛尔</7>和<8>吲哚洛尔</8>，能够抑制犬猫<0>哇巴因</0><1>心律失常</1>。GYKI-41 900具有可忽略的心脏抑制活性，它不是心脏选择性的。该化合物显示出快速而持久的效果。注射14C-41 099至大鼠和犬体内后，放射性消除时间延长。未标记物质在人体内的半衰期超过10小时。", "revised": true}
{"doc_key": "9669632", "sentences": [["Effects", "of", "cisapride", "on", "symptoms", "and", "postcibal", "small", "-", "bowel", "motor", "function", "in", "patients", "with", "irritable", "bowel", "syndrome", ".", "BACKGROUND", ":", "Irritable", "bowel", "syndrome", "is", "a", "common", "cause", "of", "abdominal", "pain", "and", "discomfort", "and", "may", "be", "related", "to", "disordered", "gastrointestinal", "motility", ".", "Our", "aim", "was", "to", "assess", "the", "effects", "of", "long", "-", "term", "treatment", "with", "a", "prokinetic", "agent", ",", "cisapride", ",", "on", "postprandial", "jejunal", "motility", "and", "symptoms", "in", "the", "irritable", "bowel", "syndrome", "(", "IBS", ")", ".", "METHODS", ":", "Thirty", "-", "eight", "patients", "with", "IBS", "(", "constipation", "-", "predominant", ",", "n", "=", "17", ";", "diarrhoea", "-", "predominant", ",", "n", "=", "21", ")", "underwent", "24", "-", "h", "ambulatory", "jejunal", "manometry", "before", "and", "after", "12", "week", "'s", "treatment", "[", "cisapride", ",", "5", "mg", "three", "times", "daily", "(", "n", "=", "19", ")", "or", "placebo", "(", "n", "=", "19", ")", "]", ".", "RESULTS", ":", "In", "diarrhoea", "-", "predominant", "patients", "significant", "differences", "in", "contraction", "characteristics", "were", "observed", "between", "the", "cisapride", "and", "placebo", "groups", ".", "In", "cisapride", "-", "treated", "diarrhoea", "-", "predominant", "patients", "the", "mean", "contraction", "amplitude", "was", "higher", "(", "29", ".", "3", "+", "/", "-", "3", ".", "2", "versus", "24", ".", "9", "+", "/", "-", "2", ".", "6", "mm", "Hg", ",", "cisapride", "versus", "placebo", "(", "P", "<", "0", ".", "001", ")", ";", "pretreatment", ",", "25", ".", "7", "+", "/", "-", "6", ".", "0", "mm", "Hg", ")", ",", "the", "mean", "contraction", "duration", "longer", "(", "3", ".", "4", "+", "/", "-", "0", ".", "2", "versus", "3", ".", "0", "+", "/", "-", "0", ".", "2", "sec", ",", "cisapride", "versus", "placebo", "(", "P", "<", "0", ".", "001", ")", ";", "pretreatment", ",", "3", ".", "1", "+", "/", "-", "0", ".", "5", "sec", ")", ",", "and", "the", "mean", "contraction", "frequency", "lower", "(", "2", ".", "0", "+", "/", "-", "0", ".", "2", "versus", "2", ".", "5", "+", "/", "-", "0", ".", "4", "cont", ".", "/", "min", ",", "cisapride", "versus", "placebo", "(", "P", "<", "0", ".", "001", ")", ";", "pretreatment", ",", "2", ".", "5", "+", "/", "-", "1", ".", "1", "cont", ".", "/", "min", "]", "than", "patients", "treated", "with", "placebo", ".", "No", "significant", "differences", "in", "jejunal", "motility", "were", "found", "in", "the", "constipation", "-", "predominant", "IBS", "group", ".", "Symptoms", "were", "assessed", "by", "using", "a", "visual", "analogue", "scale", "before", "and", "after", "treatment", ".", "Symptom", "scores", "relating", "to", "the", "severity", "of", "constipation", "were", "lower", "in", "cisapride", "-", "treated", "constipation", "-", "predominant", "IBS", "patients", "[", "score", ",", "54", "+", "/", "-", "5", "versus", "67", "+", "/", "-", "14", "mm", ",", "cisapride", "versus", "placebo", "(", "P", "<", "0", ".", "05", ")", ";", "pretreatment", ",", "62", "+", "/", "-", "19", "mm", "]", ".", "Diarrhoea", "-", "predominant", "IBS", "patients", "had", "a", "higher", "pain", "score", "after", "cisapride", "therapy", "[", "score", ",", "55", "+", "/", "-", "15", "versus", "34", "+", "/", "-", "12", "mm", ",", "cisapride", "versus", "placebo", "(", "P", "<", "0", ".", "05", ")", ";", "pretreatment", ",", "67", "+", "/", "-", "19", "mm", "]", ".", "CONCLUSION", ":", "Cisapride", "affects", "jejunal", "contraction", "characteristics", "and", "some", "symptoms", "in", "IBS", "."]], "ner": [[[2, 2, "Chemical"], [59, 59, "Chemical"], [116, 116, "Chemical"], [153, 153, "Chemical"], [159, 159, "Chemical"], [195, 195, "Chemical"], [248, 248, "Chemical"], [304, 304, "Chemical"], [378, 378, "Chemical"], [402, 402, "Chemical"], [434, 434, "Chemical"], [452, 452, "Chemical"], [475, 475, "Chemical"], [29, 30, "Disease"], [15, 17, "Disease"], [21, 23, "Disease"], [69, 71, "Disease"], [73, 73, "Disease"], [83, 83, "Disease"], [350, 350, "Disease"], [384, 384, "Disease"], [426, 426, "Disease"], [484, 484, "Disease"], [38, 40, "Disease"], [85, 85, "Disease"], [347, 347, "Disease"], [374, 374, "Disease"], [381, 381, "Disease"], [93, 93, "Disease"], [140, 140, "Disease"], [162, 162, "Disease"], [423, 423, "Disease"], [431, 431, "Disease"]]], "relations": [[[2, 2, 29, 30, "CID"], [59, 59, 29, 30, "CID"], [116, 116, 29, 30, "CID"], [153, 153, 29, 30, "CID"], [159, 159, 29, 30, "CID"], [195, 195, 29, 30, "CID"], [248, 248, 29, 30, "CID"], [304, 304, 29, 30, "CID"], [378, 378, 29, 30, "CID"], [402, 402, 29, 30, "CID"], [434, 434, 29, 30, "CID"], [452, 452, 29, 30, "CID"], [475, 475, 29, 30, "CID"]]], "clusters": [], "translated": " <0>西沙必利</0>对<14>肠易激综合征</14>患者症状和食后小肠运动功能的影响。背景： <15>肠易激综合征</15>是<13>腹痛</13>和不适的常见原因，可能与<23>胃肠动力紊乱</23>有关。我们的目的是评估长期使用促胃肠动力药<1>西沙必利</1>治疗对<16>肠易激综合征</16>（<17>IBS</17>）的影响。方法：38例<18>IBS</18>患者（<24>便秘</24>-为主，n=17；<28>腹泻</28>-为主，n=21）接受24小时动态空肠测压，在治疗前后进行评估[<2>西沙必利</2>，每天3次5毫克(n=19)或安慰剂(n=19)]。结果：在<29>腹泻</29>为主的患者中，观察到<3>西沙必利</3>组和安慰剂组在收缩特征方面存在显着差异。在<4>西沙必利</4>治疗的<30>腹泻</30>患者中，平均收缩幅度更高（29.3+/-3.2 versus 24.9+/-2.6 mm Hg，<5>西沙必利</5>对比安慰剂(P<0.001)；预处理，25.7+/-6.0 mm Hg)，平均收缩持续时间更长(3.4+/-0.2 versus 3.0+/-0.2秒，<6>西沙必利</6>对比安慰剂(P<0.001)；预处理，3.1+/-0.5秒)，平均收缩频率较低(2.0+/-0.2 versus 2.5+/-0.4连续/分钟，<7>西沙必利</7>对比安慰剂(P<0.001)；预处理，2.5+/-1.1 cont./min]与安慰剂治疗的患者相比。<25>便秘</25>-占主导地位的<19>IBS</19>组的空肠动力没有显着差异。通过使用治疗前后的视觉模拟量表，评估症状。在<8>西沙必利</8>治疗的<27>便秘</27>-主要<20>IBS</20>患者中，与<26>便秘</26>严重程度相关的症状评分较低[评分，54+/-5对比67+/-14毫米，<9>西沙必利</9>对比安慰剂(P<0.05)；预处理，62+/-19毫米]。在<10>西沙必利</10>治疗后，<31>腹泻</31>-占主导地位的<21>IBS</21>患者的<32>疼痛</32>评分较高[评分，55+/-15对比34+/-12毫米，<11>西沙必利</11>对比安慰剂(P<0.05)；预处理，67+/-19毫米]。结论：<12>西沙必利</12>影响<22>IBS</22>的空肠收缩特性及部分症状。", "revised": true}
{"doc_key": "11838826", "sentences": [["Treatment", "of", "risperidone", "-", "induced", "hyperprolactinemia", "with", "a", "dopamine", "agonist", "in", "children", ".", "BACKGROUND", ":", "Risperidone", ",", "a", "potent", "antagonist", "of", "both", "serotonergic", "(", "5HT2A", ")", "and", "dopaminergic", "D2", "receptors", "is", "associated", "with", "hyperprolactinemia", "in", "adults", "and", "children", ".", "Chronically", "elevated", "prolactin", "levels", "in", "children", "with", "prolactinomas", "may", "be", "associated", "with", "arrested", "growth", "and", "development", "resulting", "in", "either", "delayed", "puberty", "or", "short", "stature", ".", "These", "possibilities", "stress", "the", "importance", "of", "developing", "a", "safe", "and", "effective", "approach", "to", "drug", "-", "induced", "hyperprolactinemia", "in", "youth", ".", "We", "report", "the", "successful", "treatment", "of", "risperidone", "-", "induced", "hyperprolactinemia", "with", "cabergoline", "in", "youth", ".", "METHODS", ":", "We", "undertook", "a", "retrospective", "case", "review", "of", "four", "children", "with", "risperidone", "-", "induced", "hyperprolactinemia", "treated", "with", "cabergoline", ".", "RESULTS", ":", "Four", "males", "(", "age", "6", "-", "11", "years", ")", "with", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", "(", "fourth", "edition", ")", "bipolar", "disorder", "or", "psychoses", ",", "with", "risperidone", "-", "induced", "elevations", "in", "serum", "prolactin", "levels", "(", "57", ".", "5", "-", "129", "ng", "/", "mL", ",", "normal", "5", "-", "15", "ng", "/", "mL", ")", ",", "were", "treated", "with", "cabergoline", "(", "mean", "dose", "2", ".", "13", "+", "/", "-", "0", ".", "09", "mg", "/", "week", ")", ".", "When", "serum", "prolactin", "levels", "normalized", "in", "all", "four", "subjects", "(", "mean", "11", ".", "2", "+", "/", "-", "10", ".", "9", "ng", "/", "mL", ")", ",", "the", "cabergoline", "dose", "was", "reduced", "to", "1", "mg", "/", "week", "in", "three", "of", "four", "subjects", ".", "The", "mean", "duration", "of", "therapy", "with", "cabergoline", "was", "523", ".", "5", "+", "/", "-", "129", ".", "7", "days", ",", "and", "the", "mean", "duration", "of", "therapy", "with", "risperidone", "was", "788", ".", "5", "+", "/", "-", "162", ".", "5", "days", ".", "Cabergoline", "was", "well", "tolerated", "without", "adverse", "effects", ".", "CONCLUSIONS", ":", "Cabergoline", "may", "be", "useful", "for", "the", "treatment", "of", "risperidone", "-", "induced", "hyperprolactinemia", "in", "youth", ";", "however", ",", "further", "research", "is", "needed", "."]], "ner": [[[2, 2, "Chemical"], [15, 15, "Chemical"], [90, 90, "Chemical"], [111, 111, "Chemical"], [148, 148, "Chemical"], [263, 263, "Chemical"], [294, 294, "Chemical"], [5, 5, "Disease"], [33, 33, "Disease"], [80, 80, "Disease"], [93, 93, "Disease"], [114, 114, "Disease"], [297, 297, "Disease"], [46, 46, "Disease"], [58, 59, "Disease"], [136, 137, "Disease"], [142, 143, "Disease"], [145, 145, "Disease"], [8, 8, "Chemical"], [95, 95, "Chemical"], [117, 117, "Chemical"], [178, 178, "Chemical"], [222, 222, "Chemical"], [243, 243, "Chemical"], [276, 276, "Chemical"], [286, 286, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 33, 33, "CID"], [2, 2, 80, 80, "CID"], [2, 2, 93, 93, "CID"], [2, 2, 114, 114, "CID"], [2, 2, 297, 297, "CID"], [15, 15, 5, 5, "CID"], [15, 15, 33, 33, "CID"], [15, 15, 80, 80, "CID"], [15, 15, 93, 93, "CID"], [15, 15, 114, 114, "CID"], [15, 15, 297, 297, "CID"], [90, 90, 5, 5, "CID"], [90, 90, 33, 33, "CID"], [90, 90, 80, 80, "CID"], [90, 90, 93, 93, "CID"], [90, 90, 114, 114, "CID"], [90, 90, 297, 297, "CID"], [111, 111, 5, 5, "CID"], [111, 111, 33, 33, "CID"], [111, 111, 80, 80, "CID"], [111, 111, 93, 93, "CID"], [111, 111, 114, 114, "CID"], [111, 111, 297, 297, "CID"], [148, 148, 5, 5, "CID"], [148, 148, 33, 33, "CID"], [148, 148, 80, 80, "CID"], [148, 148, 93, 93, "CID"], [148, 148, 114, 114, "CID"], [148, 148, 297, 297, "CID"], [263, 263, 5, 5, "CID"], [263, 263, 33, 33, "CID"], [263, 263, 80, 80, "CID"], [263, 263, 93, 93, "CID"], [263, 263, 114, 114, "CID"], [263, 263, 297, 297, "CID"], [294, 294, 5, 5, "CID"], [294, 294, 33, 33, "CID"], [294, 294, 80, 80, "CID"], [294, 294, 93, 93, "CID"], [294, 294, 114, 114, "CID"], [294, 294, 297, 297, "CID"]]], "clusters": [], "translated": "治疗<0>利培酮</0>引起的<7>高泌乳素血症</7>与<18>多巴胺</18>激动剂在儿童中。背景：<1>利培酮</1>是一种有效的血清素能 (5HT2A) 和多巴胺能 D2 受体拮抗剂，与成人和儿童的<8>高泌乳素血症</8>有关。 <13>泌乳素瘤</13>患儿的泌乳素水平长期升高可能与生长发育停滞有关，导致<14>青春期延迟</14>或身材矮小。这些可能性强调了开发一种安全有效的方法来治疗青少年因药物引起的<9>高泌乳素血症</9>的重要性。我们报道了成功治疗了<2>利培酮</2>诱发的<10>高泌乳素血症</10>用<19>卡麦角林</19>在青少年中。方法：我们对四名<3>利培酮</3>诱发的<11>高催乳素血症</11>的儿童进行了回顾性病例回顾接受<20>卡麦角林</20>治疗。结果：四名男性（年龄6-11岁）患有<15>精神障碍诊断和统计手册</15>（第四版）<16>双相情感障碍</16>或<17>精神病</17>，伴有<4>利培酮</4>引起的血清催乳素水平升高（57.5-129 ng/mL，正常5-15 ng/mL），用<21>卡麦角林</21>（平均剂量2.13+/-0.09毫克/周）。当所有四名受试者的血清催乳素水平正常化时（平均11.2+/-10.9 ng/mL），四名受试者中的三名受试者的<22>卡麦角林</22>剂量减少至1毫克/周。 <23>卡麦角林</23>的平均治疗时间为523.5+/-129.7天，<5>利培酮</5>的平均治疗时间为788.5+/-162.5天。 <24>卡麦角林</24>耐受性良好，无不良反应。结论：<25>卡麦角林</25>可用于治疗<6>利培酮</6>所致<12>高泌乳素血症</12>的青年人；然而，还需要进一步研究。", "revised": true}
{"doc_key": "8600333", "sentences": [["Late", "cardiotoxicity", "after", "treatment", "for", "a", "malignant", "bone", "tumor", ".", "Cardiac", "function", "was", "assessed", "in", "long", "-", "term", "survivors", "of", "malignant", "bone", "tumors", "who", "were", "treated", "according", "to", "Rosen", "'s", "T5", "or", "T10", "protocol", ",", "both", "including", "doxorubicin", ".", "Thirty", "-", "one", "patients", ",", "age", "10", "-", "45", "years", "(", "median", "age", "17", ".", "8", "years", ")", "were", "evaluated", "2", ".", "3", "-", "14", ".", "1", "years", "(", "median", "8", ".", "9", "years", ")", "following", "completion", "of", "treatment", ".", "Cumulative", "doses", "of", "doxorubicin", "were", "225", "-", "550", "mg", "/", "m2", "(", "median", "dose", "360", ")", ".", "The", "evaluation", "consisted", "of", "a", "history", ",", "physical", "examination", ",", "electrocardiogram", "(", "ECG", ")", ",", "signal", "averaged", "ECG", ",", "24", "-", "hour", "ambulatory", "ECG", ",", "echocardiography", "and", "radionuclide", "angiography", ".", "Eighteen", "of", "31", "(", "58", "%", ")", "patients", "showed", "cardiac", "toxicity", ",", "defined", "as", "having", "one", "or", "more", "of", "the", "following", "abnormalities", ":", "late", "potentials", ",", "complex", "ventricular", "arrhythmias", ",", "left", "ventricular", "dilation", ",", "decreased", "shortening", "fraction", ",", "or", "decreased", "ejection", "fraction", ".", "The", "incidence", "of", "cardiac", "abnormalities", "increased", "with", "length", "of", "follow", "-", "up", "(", "P", "<", "or", "=", ".", "05", ")", ".", "No", "correlation", "could", "be", "demonstrated", "between", "cumulative", "dose", "of", "doxorubicin", "and", "cardiac", "status", ",", "except", "for", "heart", "rate", "variability", ".", "When", "adjusted", "to", "body", "surface", "area", ",", "the", "left", "ventricular", "posterior", "wall", "thickness", "(", "LVPW", "index", ")", "was", "decreased", "in", "all", "patients", ".", "The", "incidence", "of", "doxorubicin", "-", "induced", "cardiotoxicity", "is", "high", "and", "increases", "with", "follow", "-", "up", ",", "irrespective", "of", "cumulative", "dose", ".", "Life", "-", "long", "cardiac", "follow", "-", "up", "in", "these", "patients", "is", "warranted", ".", "The", "results", "of", "our", "study", "suggest", "that", "heart", "rate", "variability", "and", "LVPW", "index", "could", "be", "sensitive", "indicators", "for", "cardiotoxicity", "."]], "ner": [[[37, 37, "Chemical"], [82, 82, "Chemical"], [199, 199, "Chemical"], [236, 236, "Chemical"], [172, 173, "Disease"], [28, 33, "Chemical"], [1, 1, "Disease"], [135, 136, "Disease"], [239, 239, "Disease"], [285, 285, "Disease"], [7, 8, "Disease"], [21, 22, "Disease"], [153, 154, "Disease"], [157, 158, "Disease"]]], "relations": [[[37, 37, 172, 173, "CID"], [82, 82, 172, 173, "CID"], [199, 199, 172, 173, "CID"], [236, 236, 172, 173, "CID"]]], "clusters": [], "translated": "晚期<6>心脏毒性</6>治疗恶性<10>骨肿瘤</10>后。对根据<5>Rosen的T5或T10方案</5>进行治疗的恶性<11>骨肿瘤</11>长期幸存者的心脏功能进行了评估，两者均包括<0>阿霉素</0>.对31名年龄在10-45岁（中位年龄17.8岁）的患者进行了评估2.3-14.1年（中位数8.9年）完成治疗后。<1>多柔比星</1>的累积剂量为225-550mg/m2（中位剂量360）。评估包括病史、体格检查、心电图（ECG）、信号平均心电图、24小时动态心电图、超声心动图和放射性核素血管造影。31名患者中有18名（58%）表现出<7>心脏毒性</7>，定义为具有以下一种或多种异常：晚电位、复杂<12>室性心律失常</12>、左<13>心室扩张</13>，缩短分数降低，或射血分数降低。<4>心脏异常</4>的发生率随着随访时间的延长而增加（P<或=.05）。除了心率变异外，<2>多柔比星</2>的累积剂量与心脏状态之间没有相关性。当根据体表面积调整后，所有患者的左心室后壁厚度（LVPW指数）均有所降低。<3>多柔比星</3>引起的<8>心脏毒性</8>的发生率很高，并且随着随访的增加而增加，与累积剂量无关。对这些患者进行终生心脏随访是必要的。我们的研究结果表明，心率变异性和LVPW指数可能是<9>心脏毒性</9>的敏感指标。", "revised": true}
{"doc_key": "3123611", "sentences": [["Chorea", "associated", "with", "oral", "contraception", ".", "Three", "patients", "developed", "chorea", "while", "receiving", "oral", "contraceptives", ".", "Two", "were", "young", "patients", "whose", "chorea", "developed", "long", "after", "treatment", "had", "been", "started", "and", "disappeared", "soon", "after", "it", "had", "been", "discontinued", ".", "The", "third", "patient", "had", "acute", "amphetamine", "-", "induced", "chorea", "after", "prolonged", "oral", "contraception", ".", "Prolonged", "administration", "of", "female", "sex", "hormones", "is", "a", "possible", "cause", "of", "chorea", "in", "women", "who", "have", "not", "previously", "had", "chorea", "or", "rheumatic", "fever", "."]], "ner": [[[3, 4, "Chemical"], [12, 13, "Chemical"], [48, 49, "Chemical"], [0, 0, "Disease"], [9, 9, "Disease"], [20, 20, "Disease"], [45, 45, "Disease"], [62, 62, "Disease"], [70, 70, "Disease"], [42, 42, "Chemical"], [72, 73, "Disease"]]], "relations": [[[3, 4, 0, 0, "CID"], [3, 4, 9, 9, "CID"], [3, 4, 20, 20, "CID"], [3, 4, 45, 45, "CID"], [3, 4, 62, 62, "CID"], [3, 4, 70, 70, "CID"], [12, 13, 0, 0, "CID"], [12, 13, 9, 9, "CID"], [12, 13, 20, 20, "CID"], [12, 13, 45, 45, "CID"], [12, 13, 62, 62, "CID"], [12, 13, 70, 70, "CID"], [48, 49, 0, 0, "CID"], [48, 49, 9, 9, "CID"], [48, 49, 20, 20, "CID"], [48, 49, 45, 45, "CID"], [48, 49, 62, 62, "CID"], [48, 49, 70, 70, "CID"], [42, 42, 0, 0, "CID"], [42, 42, 9, 9, "CID"], [42, 42, 20, 20, "CID"], [42, 42, 45, 45, "CID"], [42, 42, 62, 62, "CID"], [42, 42, 70, 70, "CID"]]], "clusters": [], "translated": "<3>舞蹈病</3>与<0>口服避孕药</0>有关。三名患者在接受<1>口服避孕药</1>时出现了<4>舞蹈症</4>。两位是年轻患者，他们的<5>舞蹈症</5>在治疗开始后很长时间才出现，并在停药后很快消失。第三位患者在长期<2>口服避孕药</2>后出现急性<6>苯丙胺</6>诱发的<9>舞蹈病</9>。对于既往未患过<8>舞蹈病</8>或<10>风湿热</10>的女性，长期服用女性性激素可能会导致<7>舞蹈病</7>。", "revised": true}
{"doc_key": "7791169", "sentences": [["Protective", "effect", "of", "misoprostol", "on", "indomethacin", "induced", "renal", "dysfunction", "in", "elderly", "patients", ".", "OBJECTIVE", ":", "To", "evaluate", "the", "possible", "protective", "effects", "of", "misoprostol", "on", "renal", "function", "in", "hospitalized", "elderly", "patients", "treated", "with", "indomethacin", ".", "METHODS", ":", "Forty", "-", "five", "hospitalized", "elderly", "patients", "(", ">", "65", "years", "old", ")", "who", "required", "therapy", "with", "nonsteroidal", "antiinflammatory", "drugs", "(", "NSAID", ")", "were", "randomly", "assigned", "to", "receive", "either", "indomethacin", ",", "150", "mg", "/", "day", "(", "Group", "A", ")", ",", "or", "indomethacin", "150", "mg", "/", "day", "plus", "misoprostol", "at", "0", ".", "6", "mg", "/", "day", "(", "Group", "B", ")", ".", "Laboratory", "variables", "of", "renal", "function", "[", "serum", "creatinine", ",", "blood", "urea", "nitrogen", "(", "BUN", ")", "and", "electrolytes", "]", "were", "evaluated", "before", "initiation", "of", "therapy", "and", "every", "2", "days", ",", "until", "termination", "of", "the", "study", "(", "a", "period", "of", "at", "least", "6", "days", ")", ".", "Response", "to", "treatment", "was", "estimated", "by", "the", "visual", "analog", "scale", "for", "severity", "of", "pain", ".", "RESULTS", ":", "Forty", "-", "two", "patients", "completed", "the", "study", ",", "22", "in", "Group", "A", "and", "20", "in", "Group", "B", ".", "BUN", "and", "creatinine", "increased", "by", ">", "50", "%", "of", "baseline", "levels", "in", "54", "and", "45", "%", "of", "Group", "A", "patients", ",", "respectively", ",", "compared", "to", "only", "20", "and", "10", "%", "of", "Group", "B", "patients", "(", "p", "<", "0", ".", "05", ")", ".", "Potassium", "(", "K", ")", "increment", "of", "0", ".", "6", "mEq", "/", "l", "or", "more", "was", "observed", "in", "50", "%", "of", "Group", "A", ",", "but", "in", "only", "15", "%", "of", "Group", "B", "patients", "(", "p", "<", "0", ".", "05", ")", ".", "The", "mean", "increments", "in", "BUN", ",", "creatinine", ",", "and", "K", "were", "reduced", "by", "63", ",", "80", ",", "and", "42", "%", ",", "respectively", ",", "in", "Group", "B", "patients", "compared", "to", "Group", "A", ".", "Response", "to", "treatment", "did", "not", "differ", "significantly", "between", "the", "2", "groups", ".", "CONCLUSION", ":", "Hospitalized", "elderly", "patients", "are", "at", "risk", "for", "developing", "indomethacin", "related", "renal", "dysfunction", ".", "Addition", "of", "misoprostol", "can", "minimize", "this", "renal", "impairment", "without", "affecting", "pain", "control", "."]], "ner": [[[5, 5, "Chemical"], [32, 32, "Chemical"], [64, 64, "Chemical"], [76, 76, "Chemical"], [310, 310, "Chemical"], [7, 8, "Disease"], [312, 313, "Disease"], [321, 322, "Disease"], [3, 3, "Chemical"], [22, 22, "Chemical"], [82, 82, "Chemical"], [317, 317, "Chemical"], [152, 152, "Disease"], [325, 325, "Disease"], [102, 102, "Chemical"], [176, 176, "Chemical"], [262, 262, "Chemical"], [104, 106, "Chemical"], [108, 108, "Chemical"], [174, 174, "Chemical"], [260, 260, "Chemical"], [216, 216, "Chemical"], [218, 218, "Chemical"], [265, 265, "Chemical"]]], "relations": [[[5, 5, 7, 8, "CID"], [5, 5, 312, 313, "CID"], [5, 5, 321, 322, "CID"], [32, 32, 7, 8, "CID"], [32, 32, 312, 313, "CID"], [32, 32, 321, 322, "CID"], [64, 64, 7, 8, "CID"], [64, 64, 312, 313, "CID"], [64, 64, 321, 322, "CID"], [76, 76, 7, 8, "CID"], [76, 76, 312, 313, "CID"], [76, 76, 321, 322, "CID"], [310, 310, 7, 8, "CID"], [310, 310, 312, 313, "CID"], [310, 310, 321, 322, "CID"]]], "clusters": [], "translated": "<8>米索前列醇</8>对<0>吲哚美辛</0>所致<5>肾功能不全</5>老年患者的保护作用。目的：评价<9>米索前列醇</9>对住院老年患者治疗<1>吲哚美辛</1>所致肾功能的可能保护作用。方法：45名需要用非甾体类抗炎药 (NSAID) 治疗的住院老年患者（>65岁）被随机分配接受<2>吲哚美辛</2> 150 mg/天（A组），或<3>吲哚美辛</3> 150毫克/天加入<10>米索前列醇</10> 0.6毫克/天（B组）。在治疗开始前和每2天评估肾功能的实验室变量[血清<14>肌酐</14>，<17>血尿素氮</17>(<18>BUN</18>)和电解质]，直至研究结束（至少6天）。通过针对<12>疼痛</12>严重程度的视觉模拟量表来估计对治疗的反应。结果：42例患者完成研究，A组22例，B组20例。<19>BUN</19>和<15>肌酐</15>分别在54%和45%的A组患者中增加了>50%的基线水平，而B组患者的这一比例仅为20%和10%(p<0.05)。<21>钾</21>(<22>K</22>)增量为0.6mEq/l或更高，在50%的A组患者中观察到，但在B组患者中仅有15%(p<0.05)。与B组患者相比，B组患者<20>BUN</20>、<16>肌酐</16>和<23>K</23>的平均增量分别减少了63%、80%和42%。两组对治疗的反应没有显着差异。结论：住院老年患者有发生<4>吲哚美辛</4>相关<6>肾功能不全</6>的风险。加入<11>米索前列醇</11>可以在不影响<13>疼痛</13>控制的情况下最大限度地减少这种<7>肾功能损害</7>。", "revised": true}
{"doc_key": "16418614", "sentences": [["PTU", "-", "associated", "vasculitis", "in", "a", "girl", "with", "Turner", "Syndrome", "and", "Graves", "'", "disease", ".", "Palpable", "purpura", "is", "a", "concerning", "clinical", "finding", "in", "pediatric", "patients", "and", "can", "have", "many", "causes", ",", "including", "infectious", "and", "autoimmune", "processes", ".", "A", "rare", "cause", ",", "drug", "-", "induced", "vasculitis", ",", "may", "result", "from", "the", "production", "of", "antineutrophil", "cytoplasmic", "antibodies", "(", "ANCAs", ")", "in", "response", "to", "a", "medication", ".", "We", "report", "a", "girl", "with", "Turner", "syndrome", "and", "Graves", "'", "disease", "who", "presented", "with", "palpable", "purpuric", "lesions", ".", "The", "diagnosis", "of", "propylthiouracil", "(", "PTU", ")", "-", "associated", "vasculitis", "was", "made", "by", "observation", "of", "consistent", "clinical", "features", ",", "the", "detection", "of", "elevated", "ANA", "and", "ANCA", "in", "the", "blood", ",", "and", "the", "observed", "clinical", "resolution", "of", "symptoms", "following", "withdrawal", "of", "PTU", ".", "Subsequent", "treatment", "of", "persistent", "hyperthyroidism", "with", "radioablation", "did", "not", "result", "in", "an", "exacerbation", "of", "the", "vasculitis", ",", "a", "complication", "described", "in", "prior", "case", "reports", "."]], "ner": [[[0, 0, "Chemical"], [85, 85, "Chemical"], [87, 87, "Chemical"], [122, 122, "Chemical"], [3, 3, "Disease"], [44, 44, "Disease"], [91, 91, "Disease"], [139, 139, "Disease"], [8, 9, "Disease"], [69, 70, "Disease"], [11, 13, "Disease"], [72, 74, "Disease"], [16, 16, "Disease"], [79, 80, "Disease"], [128, 128, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 44, 44, "CID"], [0, 0, 91, 91, "CID"], [0, 0, 139, 139, "CID"], [85, 85, 3, 3, "CID"], [85, 85, 44, 44, "CID"], [85, 85, 91, 91, "CID"], [85, 85, 139, 139, "CID"], [87, 87, 3, 3, "CID"], [87, 87, 44, 44, "CID"], [87, 87, 91, 91, "CID"], [87, 87, 139, 139, "CID"], [122, 122, 3, 3, "CID"], [122, 122, 44, 44, "CID"], [122, 122, 91, 91, "CID"], [122, 122, 139, 139, "CID"]]], "clusters": [], "translated": " <0>PTU</0> - 与<4>血管炎</4>相关的<8>特纳综合征</8>和<10>格雷夫斯病</10>女孩。可触及的<12>紫癜</12>是儿科患者的一个令人担忧的临床发现，可能有多种原因，包括感染和自身免疫过程。一种罕见的原因是药物引起的<5>血管炎</5>，可能是由于抗中性粒细胞胞浆抗体 (ANCAs) 对药物产生反应所致。我们报告了一名患有<9>特纳综合征</9>和<11>格雷夫斯病</11>的女孩，她表现为可触及的<13>紫癜性病变</13>。 <1>丙基硫氧嘧啶</1> (<2>PTU</2>) - 相关的<6>血管炎</6>的诊断是通过观察一致的临床特征，检测血液中升高的ANA和ANCA，以及观察到的症状在停用<3>PTU</3>后的临床消退。随后用放射消融治疗持续性<14>甲状腺功能亢进症</14>并没有导致<7>血管炎</7>恶化，这是先前病例报告中描述的并发症。", "revised": true}
{"doc_key": "15893386", "sentences": [["Succinylcholine", "-", "induced", "masseter", "muscle", "rigidity", "during", "bronchoscopic", "removal", "of", "a", "tracheal", "foreign", "body", ".", "Masseter", "muscle", "rigidity", "during", "general", "anesthesia", "is", "considered", "an", "early", "warning", "sign", "of", "a", "possible", "episode", "of", "malignant", "hyperthermia", ".", "The", "decision", "whether", "to", "continue", "or", "discontinue", "the", "procedure", "depends", "on", "the", "urgency", "of", "the", "surgery", "and", "severity", "of", "masseter", "muscle", "rigidity", ".", "Here", ",", "we", "describe", "a", "case", "of", "severe", "masseter", "muscle", "rigidity", "(", "jaw", "of", "steel", ")", "after", "succinylcholine", "(", "Sch", ")", "administration", "during", "general", "anesthetic", "management", "for", "rigid", "bronchoscopic", "removal", "of", "a", "tracheal", "foreign", "body", ".", "Anesthesia", "was", "continued", "uneventfully", "with", "propofol", "infusion", "while", "all", "facilities", "were", "available", "to", "detect", "and", "treat", "malignant", "hyperthermia", "."]], "ner": [[[0, 0, "Chemical"], [75, 75, "Chemical"], [77, 77, "Chemical"], [3, 5, "Disease"], [15, 17, "Disease"], [54, 56, "Disease"], [66, 68, "Disease"], [70, 72, "Disease"], [32, 33, "Disease"], [110, 111, "Disease"], [99, 99, "Chemical"]]], "relations": [[[0, 0, 3, 5, "CID"], [0, 0, 15, 17, "CID"], [0, 0, 54, 56, "CID"], [0, 0, 66, 68, "CID"], [0, 0, 70, 72, "CID"], [75, 75, 3, 5, "CID"], [75, 75, 15, 17, "CID"], [75, 75, 54, 56, "CID"], [75, 75, 66, 68, "CID"], [75, 75, 70, 72, "CID"], [77, 77, 3, 5, "CID"], [77, 77, 15, 17, "CID"], [77, 77, 54, 56, "CID"], [77, 77, 66, 68, "CID"], [77, 77, 70, 72, "CID"]]], "clusters": [], "translated": "<0>琥珀胆碱</0> - 在支气管镜下取出气管异物期间引起<3>咬肌僵硬</3>。全身麻醉期间<4>咬肌强直</4>被认为是可能发生<8>恶性高热</8>的早期预警信号。是否继续或停止手术的决定取决于手术的紧迫性和<5>咬肌强直</5>的严重程度。在这里，我们描述了一个在全身麻醉管理下，在硬性支气管镜取出气管异物期间，服用<1>琥珀胆碱</1>（<2>Sch</2>）后出现严重的<6>咬肌强直</6>（<7>钢铁下巴</7>）的病例。使用<10>丙泊酚</10>静脉输注继续麻醉，同时所有措施都已准备好以便检测和治疗<9>恶性高热</9>。", "revised": true}
{"doc_key": "8410199", "sentences": [["Loss", "of", "glutamate", "decarboxylase", "mRNA", "-", "containing", "neurons", "in", "the", "rat", "dentate", "gyrus", "following", "pilocarpine", "-", "induced", "seizures", ".", "In", "situ", "hybridization", "methods", "were", "used", "to", "determine", "if", "glutamic", "acid", "decarboxylase", "(", "GAD", ")", "mRNA", "-", "containing", "neurons", "within", "the", "hilus", "of", "the", "dentate", "gyrus", "are", "vulnerable", "to", "seizure", "-", "induced", "damage", "in", "a", "model", "of", "chronic", "seizures", ".", "Sprague", "-", "Dawley", "rats", "were", "injected", "intraperitoneally", "with", "pilocarpine", ",", "and", "the", "hippocampal", "formation", "was", "studied", "histologically", "at", "1", ",", "2", ",", "4", ",", "and", "8", "week", "intervals", "after", "pilocarpine", "-", "induced", "seizures", ".", "In", "situ", "hybridization", "histochemistry", ",", "using", "a", "digoxigenin", "-", "labeled", "GAD", "cRNA", "probe", ",", "demonstrated", "a", "substantial", "decrease", "in", "the", "number", "of", "GAD", "mRNA", "-", "containing", "neurons", "in", "the", "hilus", "of", "the", "dentate", "gyrus", "in", "the", "pilocarpine", "-", "treated", "rats", "as", "compared", "to", "controls", "at", "all", "time", "intervals", ".", "Additional", "neuronanatomical", "studies", ",", "including", "cresyl", "violet", "staining", ",", "neuronal", "degeneration", "methods", ",", "and", "histochemical", "localization", "of", "glial", "fibrillary", "acidic", "protein", ",", "suggested", "that", "the", "decrease", "in", "the", "number", "of", "GAD", "mRNA", "-", "containing", "neurons", "was", "related", "to", "neuronal", "loss", "rather", "than", "to", "a", "decrease", "in", "GAD", "mRNA", "levels", ".", "The", "loss", "of", "GAD", "mRNA", "-", "containing", "neurons", "in", "the", "hilus", "contrasted", "with", "the", "relative", "preservation", "of", "labeled", "putative", "basket", "cells", "along", "the", "inner", "margin", "of", "the", "granule", "cell", "layer", ".", "Quantitative", "analyses", "of", "labeled", "neurons", "in", "three", "regions", "of", "the", "dentate", "gyrus", "in", "the", "1", "and", "2", "week", "groups", "showed", "statistically", "significant", "decreases", "in", "the", "mean", "number", "of", "GAD", "mRNA", "-", "containing", "neurons", "in", "the", "hilus", "of", "both", "groups", "of", "experimental", "animals", ".", "No", "significant", "differences", "were", "found", "in", "the", "molecular", "layer", "or", "the", "granule", "cell", "layer", ",", "which", "included", "labeled", "neurons", "along", "the", "lower", "margin", "of", "the", "granule", "cell", "layer", ".", "The", "results", "indicate", "that", ",", "in", "this", "model", ",", "a", "subpopulation", "of", "GAD", "mRNA", "-", "containing", "neurons", "within", "the", "dentate", "gyrus", "is", "selectively", "vulnerable", "to", "seizure", "-", "induced", "damage", ".", "Such", "differential", "vulnerability", "appears", "to", "be", "another", "indication", "of", "the", "heterogeneity", "of", "GABA", "neurons", "."]], "ner": [[[14, 14, "Chemical"], [67, 67, "Chemical"], [88, 88, "Chemical"], [129, 129, "Chemical"], [17, 17, "Disease"], [48, 48, "Disease"], [57, 57, "Disease"], [91, 91, "Disease"], [320, 320, "Disease"], [151, 152, "Disease"], [180, 181, "Disease"], [2, 2, "Chemical"], [28, 29, "Chemical"], [100, 100, "Chemical"], [147, 148, "Chemical"], [337, 337, "Chemical"]]], "relations": [[[14, 14, 17, 17, "CID"], [14, 14, 48, 48, "CID"], [14, 14, 57, 57, "CID"], [14, 14, 91, 91, "CID"], [14, 14, 320, 320, "CID"], [67, 67, 17, 17, "CID"], [67, 67, 48, 48, "CID"], [67, 67, 57, 57, "CID"], [67, 67, 91, 91, "CID"], [67, 67, 320, 320, "CID"], [88, 88, 17, 17, "CID"], [88, 88, 48, 48, "CID"], [88, 88, 57, 57, "CID"], [88, 88, 91, 91, "CID"], [88, 88, 320, 320, "CID"], [129, 129, 17, 17, "CID"], [129, 129, 48, 48, "CID"], [129, 129, 57, 57, "CID"], [129, 129, 91, 91, "CID"], [129, 129, 320, 320, "CID"], [14, 14, 151, 152, "CID"], [14, 14, 180, 181, "CID"], [67, 67, 151, 152, "CID"], [67, 67, 180, 181, "CID"], [88, 88, 151, 152, "CID"], [88, 88, 180, 181, "CID"], [129, 129, 151, 152, "CID"], [129, 129, 180, 181, "CID"]]], "clusters": [], "translated": "在<0>毛果芸香碱</0>诱导的<4>癫痫发作</4>后，大鼠齿状回中含有<11>谷氨酸</11>脱羧酶mRNA的神经元丢失。原位杂交方法用于确定是否<12>谷氨酸</12>脱羧酶(GAD)mRNA-包含齿状回门内的神经元易受<5>癫痫发作</5> - 在模型中诱导的损伤慢性<6>癫痫发作</6>。Sprague-Dawley大鼠腹膜内注射<1>毛果芸香碱</1>，并在<2>毛果芸香碱</2>诱导的<7>癫痫发作</7>后的1、2、4和8周间隔对海马结构进行组织学研究。原位杂交组织化学，使用<13>洋地黄毒苷</13>标记的GAD cRNA探针，证明在<3>毛果芸香碱</3>中齿状回门部含有GAD mRNA的神经元数量显着减少-在所有时间间隔内与对照组相比，处理过的大鼠。其他神经解剖学研究，包括<14>甲酚紫</14>染色、<9>神经元变性</9>方法和神经胶质原纤维酸性蛋白的组织化学定位，表明含有GAD mRNA的神经元数量减少是与<10>神经元丢失</10>有关，而不是与GAD mRNA水平下降有关。门中含有GAD mRNA的神经元的丢失与沿颗粒细胞层内缘标记的假定篮子细胞的相对保存形成对比。对第1周组和第2周组齿状回三个区域中标记神经元的定量分析显示，两组实验动物的肺门中含有GAD mRNA的神经元的平均数量在统计学上显著减少。在分子层或颗粒细胞层中没有发现显着差异，其中包括沿颗粒细胞层下缘的标记神经元。结果表明，在该模型中，齿状回内含有GAD mRNA的神经元亚群选择性易受<8>癫痫发作</8>诱导的损伤。这种不同的脆弱性似乎是<15>GABA</15>神经元异质性的另一个迹象。", "revised": true}
{"doc_key": "8599504", "sentences": [["Angioedema", "associated", "with", "droperidol", "administration", ".", "Angioedema", ",", "also", "known", "as", "angioneurotic", "edema", "or", "Quincke", "'s", "disease", ",", "is", "a", "well", "-", "demarcated", ",", "localized", "edema", "involving", "the", "subcutaneous", "tissues", "that", "may", "cause", "upper", "-", "airway", "obstruction", ".", "We", "report", "the", "case", "of", "a", "previously", "healthy", "19", "-", "year", "-", "old", "man", "with", "no", "known", "drug", "allergies", "in", "whom", "angioedema", "with", "significant", "tongue", "swelling", "and", "protrusion", "developed", "within", "10", "minutes", "of", "the", "administration", "of", "a", "single", "IV", "dose", "of", "droperidol", "."]], "ner": [[[3, 3, "Chemical"], [79, 79, "Chemical"], [0, 0, "Disease"], [6, 6, "Disease"], [11, 12, "Disease"], [14, 16, "Disease"], [59, 59, "Disease"], [25, 25, "Disease"], [62, 63, "Disease"], [33, 36, "Disease"], [55, 56, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 6, 6, "CID"], [3, 3, 11, 12, "CID"], [3, 3, 14, 16, "CID"], [3, 3, 59, 59, "CID"], [79, 79, 0, 0, "CID"], [79, 79, 6, 6, "CID"], [79, 79, 11, 12, "CID"], [79, 79, 14, 16, "CID"], [79, 79, 59, 59, "CID"]]], "clusters": [], "translated": " <2>血管性水肿</2>与<0>氟哌利多</0>给药相关。 <3>血管性水肿</3>，也称为<4>血管神经性水肿</4>或<5>Quincke病</5>，是一种边界清楚的局限性<7>水肿</7>，涉及可能引起<9>上呼吸道阻塞</9>的皮下组织。我们报告了一个既往健康的19岁男性的病例，他没有已知的<10>药物过敏</10>，他出现了<6>血管性水肿</6>并伴有明显的<8>舌头肿胀</8>和突出，在单次静脉注射<1>氟哌利多</1> 后10分钟内。", "revised": true}
{"doc_key": "9105126", "sentences": [["Postinfarction", "ventricular", "septal", "defect", "associated", "with", "long", "-", "term", "steroid", "therapy", ".", "Two", "cases", "of", "postinfarction", "ventricular", "septal", "rupture", "in", "patients", "on", "long", "-", "term", "steroid", "therapy", "are", "presented", "and", "the", "favourable", "outcome", "in", "both", "cases", "described", ".", "A", "possible", "association", "between", "steroid", "therapy", "and", "subsequent", "postinfarction", "septal", "rupture", "is", "discussed", "."]], "ner": [[[9, 9, "Chemical"], [25, 25, "Chemical"], [42, 42, "Chemical"], [1, 3, "Disease"], [16, 18, "Disease"], [47, 48, "Disease"]]], "relations": [[[9, 9, 1, 3, "CID"], [9, 9, 16, 18, "CID"], [9, 9, 47, 48, "CID"], [25, 25, 1, 3, "CID"], [25, 25, 16, 18, "CID"], [25, 25, 47, 48, "CID"], [42, 42, 1, 3, "CID"], [42, 42, 16, 18, "CID"], [42, 42, 47, 48, "CID"]]], "clusters": [], "translated": "与长期<0>类固醇</0>治疗相关的梗死后<3>室间隔缺损</3>。本报告介绍了两例长期<1>类固醇</1>治疗患者发生梗死后<4>室间隔破裂</4>的情况，并描述了两例的良好结果。讨论了<2>类固醇</2>治疗与随后的<5>梗塞后室间隔破裂</5>之间的可能关联。", "revised": true}
{"doc_key": "7619765", "sentences": [["Etoposide", "-", "related", "myocardial", "infarction", ".", "The", "occurrence", "of", "a", "myocardial", "infarction", "is", "reported", "after", "chemotherapy", "containing", "etoposide", ",", "in", "a", "man", "with", "no", "risk", "factors", "for", "coronary", "heart", "disease", ".", "Possible", "causal", "mechanisms", "are", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [17, 17, "Chemical"], [3, 4, "Disease"], [10, 11, "Disease"], [27, 29, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 10, 11, "CID"], [17, 17, 3, 4, "CID"], [17, 17, 10, 11, "CID"]]], "clusters": [], "translated": " <0>依托泊苷</0> - 相关<2>心肌梗塞</2>。据报道，在含有<1>依托泊苷</1>的化疗后出现了<3>心肌梗塞</3>，一名无任何<4>冠心病</4>风险因素的男性。讨论了可能的病因机制。", "revised": true}
{"doc_key": "8546130", "sentences": [["Clarithromycin", "-", "associated", "visual", "hallucinations", "in", "a", "patient", "with", "chronic", "renal", "failure", "on", "continuous", "ambulatory", "peritoneal", "dialysis", ".", "Visual", "hallucinations", "are", "a", "rare", "event", "in", "chronic", "renal", "failure", "and", "not", "related", "to", "uremia", "per", "se", ".", "Unreported", "in", "the", "literature", "is", "visual", "hallucinations", "occurring", "in", "association", "with", "the", "new", "macrolide", "antibiotic", ",", "clarithromycin", ".", "We", "describe", "such", "a", "case", "in", "a", "patient", "with", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", "maintained", "on", "continuous", "ambulatory", "peritoneal", "dialysis", "(", "CAPD", ")", ".", "The", "combination", "of", "a", "relatively", "high", "dose", "of", "clarithromycin", "in", "face", "of", "chronic", "renal", "failure", "in", "a", "functionally", "anephric", "patient", ",", "with", "underlying", "aluminum", "intoxication", ",", "may", "have", "facilitated", "the", "appearance", "of", "this", "neurotoxic", "side", "effect", ".", "It", "is", "important", "to", "understand", "the", "pharmacokinetics", "of", "medications", "in", "face", "of", "chronic", "renal", "failure", ",", "the", "possibility", "of", "drug", "interactions", ",", "and", "how", "these", "factors", "should", "help", "guide", "medication", "therapy", "in", "the", "ESRD", "patient", "."]], "ner": [[[0, 0, "Chemical"], [52, 52, "Chemical"], [89, 89, "Chemical"], [3, 4, "Disease"], [18, 19, "Disease"], [41, 42, "Disease"], [9, 11, "Disease"], [25, 27, "Disease"], [63, 67, "Disease"], [69, 69, "Disease"], [93, 95, "Disease"], [130, 132, "Disease"], [151, 151, "Disease"], [32, 32, "Disease"], [114, 114, "Disease"], [49, 49, "Chemical"], [104, 104, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 18, 19, "CID"], [0, 0, 41, 42, "CID"], [52, 52, 3, 4, "CID"], [52, 52, 18, 19, "CID"], [52, 52, 41, 42, "CID"], [89, 89, 3, 4, "CID"], [89, 89, 18, 19, "CID"], [89, 89, 41, 42, "CID"]]], "clusters": [], "translated": " <0>克拉霉素</0> - 相关<3>视幻觉</3>在一名<6>慢性肾功能衰竭</6>连续非卧床腹膜透析患者中。 <4>视幻觉</4>是<7>慢性肾功能衰竭</7>的罕见事件，与<13>尿毒症</13>本身无关。文献中未报道与新的<15>大环内酯</15>抗生素<1>克拉霉素</1>相关的<5>视幻觉</5>。我们描述了这样一例患者，该患者患有<8>终末期肾病</8> (<9>ESRD</9>)，并持续接受非卧床腹膜透析 (<CAPD>)。面对<10>慢性肾功能衰竭</10>的功能性肾病患者，联合使用相对高剂量的<2>克拉霉素</2>，伴有潜在的<16>铝</16>中毒，可能促进了这种<14>神经毒性</14>副作用的出现。重要的是要了解面对<11>慢性肾功能衰竭</11>的药物的药代动力学、药物相互作用的可能性，以及这些因素如何帮助指导<12>ESRD</12>患者的药物治疗。", "revised": true}
{"doc_key": "15814210", "sentences": [["Minor", "neurological", "dysfunction", ",", "cognitive", "development", ",", "and", "somatic", "development", "at", "the", "age", "of", "3", "to", "7", "years", "after", "dexamethasone", "treatment", "in", "very", "-", "low", "birth", "-", "weight", "infants", ".", "The", "objective", "of", "this", "study", "was", "to", "assess", "minor", "neurological", "dysfunction", ",", "cognitive", "development", ",", "and", "somatic", "development", "after", "dexamethasone", "therapy", "in", "very", "-", "low", "-", "birthweight", "infants", ".", "Thirty", "-", "three", "children", "after", "dexamethasone", "treatment", "were", "matched", "to", "33", "children", "without", "dexamethasone", "treatment", ".", "Data", "were", "assessed", "at", "the", "age", "of", "3", "-", "7", "years", ".", "Dexamethasone", "was", "started", "between", "the", "7th", "and", "the", "28th", "day", "of", "life", "over", "7", "days", "with", "a", "total", "dose", "of", "2", ".", "35", "mg", "/", "kg", "/", "day", ".", "Exclusion", "criteria", "were", "asphyxia", ",", "malformations", ",", "major", "surgical", "interventions", ",", "small", "for", "gestational", "age", ",", "intraventricular", "haemorrhage", "grades", "III", "and", "IV", ",", "periventricular", "leukomalacia", ",", "and", "severe", "psychomotor", "retardation", ".", "Each", "child", "was", "examined", "by", "a", "neuropediatrician", "for", "minor", "neurological", "dysfunctions", "and", "tested", "by", "a", "psychologist", "for", "cognitive", "development", "with", "a", "Kaufman", "Assessment", "Battery", "for", "Children", "and", "a", "Draw", "-", "a", "-", "Man", "Test", ".", "There", "were", "no", "differences", "in", "demographic", "data", ",", "growth", ",", "and", "socio", "-", "economic", "status", "between", "the", "two", "groups", ".", "Fine", "motor", "skills", "and", "gross", "motor", "function", "were", "significantly", "better", "in", "the", "control", "group", "(", "p", "<", "0", ".", "01", ")", ".", "In", "the", "Draw", "-", "a", "-", "Man", "Test", ",", "the", "control", "group", "showed", "better", "results", "(", "p", "<", "0", ".", "001", ")", ".", "There", "were", "no", "differences", "in", "development", "of", "speech", ",", "social", "development", ",", "and", "the", "Kaufman", "Assessment", "Battery", "for", "Children", ".", "After", "dexamethasone", "treatment", ",", "children", "showed", "a", "higher", "rate", "of", "minor", "neurological", "dysfunctions", ".", "Neurological", "development", "was", "affected", "even", "without", "neurological", "diagnosis", ".", "Further", "long", "-", "term", "follow", "-", "up", "studies", "will", "be", "necessary", "to", "fully", "evaluate", "the", "impact", "of", "dexamethasone", "on", "neurological", "and", "cognitive", "development", "."]], "ner": [[[19, 19, "Chemical"], [49, 49, "Chemical"], [64, 64, "Chemical"], [72, 72, "Chemical"], [87, 87, "Chemical"], [268, 268, "Chemical"], [307, 307, "Chemical"], [1, 2, "Disease"], [39, 40, "Disease"], [156, 157, "Disease"], [278, 279, "Disease"], [119, 119, "Disease"], [121, 121, "Disease"], [133, 133, "Disease"], [139, 140, "Disease"], [144, 145, "Disease"]]], "relations": [[[19, 19, 1, 2, "CID"], [19, 19, 39, 40, "CID"], [19, 19, 156, 157, "CID"], [19, 19, 278, 279, "CID"], [49, 49, 1, 2, "CID"], [49, 49, 39, 40, "CID"], [49, 49, 156, 157, "CID"], [49, 49, 278, 279, "CID"], [64, 64, 1, 2, "CID"], [64, 64, 39, 40, "CID"], [64, 64, 156, 157, "CID"], [64, 64, 278, 279, "CID"], [72, 72, 1, 2, "CID"], [72, 72, 39, 40, "CID"], [72, 72, 156, 157, "CID"], [72, 72, 278, 279, "CID"], [87, 87, 1, 2, "CID"], [87, 87, 39, 40, "CID"], [87, 87, 156, 157, "CID"], [87, 87, 278, 279, "CID"], [268, 268, 1, 2, "CID"], [268, 268, 39, 40, "CID"], [268, 268, 156, 157, "CID"], [268, 268, 278, 279, "CID"], [307, 307, 1, 2, "CID"], [307, 307, 39, 40, "CID"], [307, 307, 156, 157, "CID"], [307, 307, 278, 279, "CID"]]], "clusters": [], "translated": "极低出生体重儿<0>地塞米松</0>治疗后3至7岁时的轻微<7>神经功能障碍</7>、认知发育和躯体发育。本研究的目的是评估极低出生体重婴儿<1>地塞米松</1>治疗后的轻微<8>神经功能障碍</8>、认知发育和躯体发育。将接受<2>地塞米松</2>治疗的33名儿童与未接受<3>地塞米松</3>治疗的33名儿童进行配对。数据在3-7岁时进行评估。<4>地塞米松</4>开始于出生后第7～28天，共7天，总剂量为2.35毫克/公斤/天。排除标准为<11>窒息</11>、<12>畸形</12>、重大手术干预、小于胎龄儿、脑室内<13>出血</13>III级和IV级、<14>脑室周围白质软化</14>和严重的<15>精神运动迟缓</15>。每个孩子都由一名神经儿科医生检查是否存在轻微的<9>神经功能障碍</9>，并由一名心理学家使用考夫曼儿童评估组合和绘图人测试进行认知发展测试。两组之间的人口统计数据、增长和社会经济地位没有差异。对照组的精细运动技能和粗大运动功能明显更好（<0> p < 0.01 </0>）。在 Draw-a-Man 测试中，对照组显示出更好的结果（<1> p < 0.001 </1>）。在言语发展、社会发展和考夫曼儿童评估量表方面没有差异。<5>地塞米松</5>治疗后，儿童出现轻度的<10>神经功能障碍</10>的几率较高。即使没有神经学诊断，神经发育也会受到影响。需要进一步的长期随访研究来全面评估<6>地塞米松</6>对神经和认知发育的影响。", "revised": true}
{"doc_key": "11912119", "sentences": [["Force", "overflow", "and", "levodopa", "-", "induced", "dyskinesias", "in", "Parkinson", "'s", "disease", ".", "We", "assessed", "force", "coordination", "of", "the", "hand", "in", "Parkinson", "'s", "disease", "and", "its", "relationship", "to", "motor", "complications", "of", "levodopa", "therapy", ",", "particularly", "to", "levodopa", "-", "induced", "dyskinesias", "(", "LID", ")", ".", "We", "studied", "two", "groups", "of", "Parkinson", "'s", "disease", "patients", "with", "(", "Parkinson", "'s", "disease", "+", "LID", ",", "n", "=", "23", ")", "and", "without", "levodopa", "-", "induced", "dyskinesias", "(", "Parkinson", "'s", "disease", "-", "LID", ",", "n", "=", "10", ")", ",", "and", "age", "-", "matched", "healthy", "controls", ".", "The", "motor", "score", "of", "the", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", ",", "a", "dyskinesia", "score", "and", "force", "in", "a", "grip", "-", "lift", "paradigm", "were", "assessed", "ON", "and", "OFF", "levodopa", ".", "A", "pathological", "increase", "of", "forces", "was", "seen", "in", "ON", "-", "state", "in", "Parkinson", "'s", "disease", "+", "LID", "only", ".", "In", "Parkinson", "'s", "disease", "+", "LID", ",", "the", "force", "involved", "in", "pressing", "down", "the", "object", "before", "lifting", "was", "significantly", "increased", "by", "levodopa", "(", "by", "61", "%", ",", "P", "<", "0", ".", "05", ")", ".", "An", "overshooting", "of", "peak", "grip", "force", "by", "51", "%", "(", "P", "<", "0", ".", "05", ")", "and", "of", "static", "grip", "force", "by", "45", "%", "(", "P", "<", "0", ".", "01", ")", "was", "observed", "in", "the", "ON", "-", "compared", "with", "the", "OFF", "-", "drug", "condition", ".", "In", "contrast", ",", "no", "excessive", "force", "was", "found", "in", "Parkinson", "'s", "disease", "-", "LID", ".", "Peak", "grip", "force", "in", "ON", "-", "state", "was", "140", "%", "(", "P", "<", "0", ".", "05", ")", "higher", "in", "Parkinson", "'s", "disease", "+", "LID", "than", "in", "Parkinson", "'s", "disease", "-", "LID", ",", "while", "static", "grip", "force", "was", "increased", "by", "138", "%", "(", "P", "<", "0", ".", "01", ")", "between", "groups", ".", "Severity", "of", "peak", "-", "dose", "dyskinesias", "was", "strongly", "correlated", "with", "grip", "force", "in", "ON", "-", "state", "(", "r", "=", "0", ".", "79", "with", "peak", "force", ",", "P", "<", "0", ".", "01", ")", ".", "No", "correlation", "was", "observed", "between", "forces", "and", "the", "motor", "score", "as", "well", "as", "with", "the", "daily", "dose", "of", "dopaminergic", "medication", ".", "Force", "excess", "was", "only", "observed", "in", "patients", "with", "LID", "and", "motor", "fluctuations", ".", "A", "close", "relationship", "was", "seen", "between", "the", "overshooting", "of", "forces", "and", "dyskinesias", "in", "the", "ON", "-", "drug", "condition", ".", "We", "postulate", "that", "both", "LID", "and", "grip", "force", "excess", "share", "common", "pathophysiological", "mechanisms", "related", "to", "motor", "fluctuations", "."]], "ner": [[[3, 3, "Chemical"], [30, 30, "Chemical"], [35, 35, "Chemical"], [66, 66, "Chemical"], [117, 117, "Chemical"], [159, 159, "Chemical"], [6, 6, "Disease"], [38, 38, "Disease"], [40, 40, "Disease"], [58, 58, "Disease"], [69, 69, "Disease"], [75, 75, "Disease"], [102, 102, "Disease"], [135, 135, "Disease"], [143, 143, "Disease"], [230, 230, "Disease"], [255, 255, "Disease"], [262, 262, "Disease"], [288, 288, "Disease"], [345, 345, "Disease"], [361, 361, "Disease"], [373, 373, "Disease"], [8, 10, "Disease"], [20, 22, "Disease"], [48, 50, "Disease"], [54, 56, "Disease"], [71, 73, "Disease"], [95, 97, "Disease"], [131, 133, "Disease"], [139, 141, "Disease"], [226, 228, "Disease"], [251, 253, "Disease"], [258, 260, "Disease"]]], "relations": [[[3, 3, 6, 6, "CID"], [3, 3, 38, 38, "CID"], [3, 3, 40, 40, "CID"], [3, 3, 58, 58, "CID"], [3, 3, 69, 69, "CID"], [3, 3, 75, 75, "CID"], [3, 3, 102, 102, "CID"], [3, 3, 135, 135, "CID"], [3, 3, 143, 143, "CID"], [3, 3, 230, 230, "CID"], [3, 3, 255, 255, "CID"], [3, 3, 262, 262, "CID"], [3, 3, 288, 288, "CID"], [3, 3, 345, 345, "CID"], [3, 3, 361, 361, "CID"], [3, 3, 373, 373, "CID"], [30, 30, 6, 6, "CID"], [30, 30, 38, 38, "CID"], [30, 30, 40, 40, "CID"], [30, 30, 58, 58, "CID"], [30, 30, 69, 69, "CID"], [30, 30, 75, 75, "CID"], [30, 30, 102, 102, "CID"], [30, 30, 135, 135, "CID"], [30, 30, 143, 143, "CID"], [30, 30, 230, 230, "CID"], [30, 30, 255, 255, "CID"], [30, 30, 262, 262, "CID"], [30, 30, 288, 288, "CID"], [30, 30, 345, 345, "CID"], [30, 30, 361, 361, "CID"], [30, 30, 373, 373, "CID"], [35, 35, 6, 6, "CID"], [35, 35, 38, 38, "CID"], [35, 35, 40, 40, "CID"], [35, 35, 58, 58, "CID"], [35, 35, 69, 69, "CID"], [35, 35, 75, 75, "CID"], [35, 35, 102, 102, "CID"], [35, 35, 135, 135, "CID"], [35, 35, 143, 143, "CID"], [35, 35, 230, 230, "CID"], [35, 35, 255, 255, "CID"], [35, 35, 262, 262, "CID"], [35, 35, 288, 288, "CID"], [35, 35, 345, 345, "CID"], [35, 35, 361, 361, "CID"], [35, 35, 373, 373, "CID"], [66, 66, 6, 6, "CID"], [66, 66, 38, 38, "CID"], [66, 66, 40, 40, "CID"], [66, 66, 58, 58, "CID"], [66, 66, 69, 69, "CID"], [66, 66, 75, 75, "CID"], [66, 66, 102, 102, "CID"], [66, 66, 135, 135, "CID"], [66, 66, 143, 143, "CID"], [66, 66, 230, 230, "CID"], [66, 66, 255, 255, "CID"], [66, 66, 262, 262, "CID"], [66, 66, 288, 288, "CID"], [66, 66, 345, 345, "CID"], [66, 66, 361, 361, "CID"], [66, 66, 373, 373, "CID"], [117, 117, 6, 6, "CID"], [117, 117, 38, 38, "CID"], [117, 117, 40, 40, "CID"], [117, 117, 58, 58, "CID"], [117, 117, 69, 69, "CID"], [117, 117, 75, 75, "CID"], [117, 117, 102, 102, "CID"], [117, 117, 135, 135, "CID"], [117, 117, 143, 143, "CID"], [117, 117, 230, 230, "CID"], [117, 117, 255, 255, "CID"], [117, 117, 262, 262, "CID"], [117, 117, 288, 288, "CID"], [117, 117, 345, 345, "CID"], [117, 117, 361, 361, "CID"], [117, 117, 373, 373, "CID"], [159, 159, 6, 6, "CID"], [159, 159, 38, 38, "CID"], [159, 159, 40, 40, "CID"], [159, 159, 58, 58, "CID"], [159, 159, 69, 69, "CID"], [159, 159, 75, 75, "CID"], [159, 159, 102, 102, "CID"], [159, 159, 135, 135, "CID"], [159, 159, 143, 143, "CID"], [159, 159, 230, 230, "CID"], [159, 159, 255, 255, "CID"], [159, 159, 262, 262, "CID"], [159, 159, 288, 288, "CID"], [159, 159, 345, 345, "CID"], [159, 159, 361, 361, "CID"], [159, 159, 373, 373, "CID"]]], "clusters": [], "translated": "<22>帕金森病</22>中的力溢出和<0>左旋多巴</0>-诱发的<6>运动障碍</6>。我们评估了手在<23>帕金森病</23>中的力量协调及其与<1>左旋多巴</1>治疗运动并发症的关系，特别是<2>左旋多巴</2>-引起的<7>运动障碍</7>(<8>LID</8>)。我们研究了两组<24>帕金森病</24>患者（<25>帕金森病</25>+<9>LID</9>，n=23）和没有<3>左旋多巴</3>-诱发的<10>运动障碍</10>（<26>帕金森病</26>-<11>LID</11>，n=10），以及年龄匹配的健康对照。运用统一<27>帕金森氏病</27>评定量表的运动评分、<12>运动障碍</12>评分和握力举范例中的力在ON和OFF<4>左旋多巴</4>时进行评估。只在<28>帕金森病</28>+<13>LID</13>中观察到ON状态的病理性力量增加。在<29>帕金森病</29>+<14>LID</14>中，<5>左旋多巴</5>显着增加了在提起物体之前按下物体的力（增加了61%，P<0.05）。与停药状态相比，在ON-药物条件下观察到峰值握力超过51% (P<0.05)和静态握力超过45% (P<0.01)。相比之下，在<30>帕金森病</30>-<15>LID</15>中未发现过度用力。在<31>帕金森病</31>+<16>LID</16>中，ON状态下的峰值握力比<32>帕金森病</32>-<17>LID</17>高140%(P<0.05)，而静态握力在组间增加了138% (P<0.01)。峰值剂量<18>运动障碍</18>的严重程度与ON状态下的握力密切相关(r=0.79，峰值力，P<0.01)。在力量和运动评分以及多巴胺能药物的每日剂量之间没有观察到相关性。仅在具有<19>LID</19>和运动波动的患者中观察到力过大。在ON-drug条件下，力量过度和<20>运动障碍</20>之间存在密切关系。我们假设<21>LID</21>和握力过剩具有与运动波动相关的共同病理生理机制。", "revised": true}
{"doc_key": "7416947", "sentences": [["Subjective", "assessment", "of", "sexual", "dysfunction", "of", "patients", "on", "long", "-", "term", "administration", "of", "digoxin", ".", "Various", "data", "suggest", "that", "male", "patients", "who", "have", "received", "digoxin", "on", "a", "longterm", "basis", "have", "increased", "levels", "of", "serum", "estrogen", "and", "decreased", "levels", "of", "plasma", "testosterone", "and", "luteinizing", "hormone", "(", "LH", ")", ".", "This", "study", "was", "undertaken", "to", "investigate", "the", "links", "between", "the", "long", "-", "term", "administration", "of", "digoxin", "therapy", "and", "sexual", "behavior", ",", "and", "the", "effect", "of", "digoxin", "on", "plasma", "levels", "of", "estradiol", ",", "testosterone", ",", "and", "LH", ".", "The", "patients", "of", "the", "study", "and", "control", "group", "(", "without", "digoxin", ")", "were", "of", "similar", "cardiac", "functional", "capacity", "and", "age", "(", "25", "-", "40", "years", ")", "and", "were", "randomly", "selected", "from", "the", "rheumatic", "heart", "disease", "patients", ".", "A", "subjective", "assessment", "of", "sexual", "behavior", "in", "the", "study", "and", "control", "groups", "was", "carried", "out", ",", "using", "parameters", "such", "as", "sexual", "desire", ",", "sexual", "excitement", ",", "and", "frequency", "of", "sexual", "relations", ".", "Personal", "interviews", "and", "a", "questionnaire", "were", "also", "used", "for", "the", "evaluation", "of", "sexual", "behavior", ".", "The", "findings", "support", "the", "reports", "concerning", "digoxin", "effect", "on", "plasma", "estradiol", ",", "testosterone", ",", "and", "LH", ".", "The", "differences", "in", "the", "means", "were", "significant", ".", "Tests", "used", "to", "evaluate", "the", "changes", "in", "sexual", "behavior", "showed", "a", "significant", "decrease", "in", "sexual", "desire", ",", "sexual", "excitement", "phase", "(", "erection", ")", ",", "and", "frequency", "of", "sexual", "relations", "in", "the", "study", "group", "."]], "ner": [[[13, 13, "Chemical"], [24, 24, "Chemical"], [63, 63, "Chemical"], [73, 73, "Chemical"], [95, 95, "Chemical"], [175, 175, "Chemical"], [3, 4, "Disease"], [206, 209, "Disease"], [34, 34, "Chemical"], [40, 40, "Chemical"], [80, 80, "Chemical"], [181, 181, "Chemical"], [78, 78, "Chemical"], [179, 179, "Chemical"], [117, 119, "Disease"]]], "relations": [[[13, 13, 3, 4, "CID"], [13, 13, 206, 209, "CID"], [24, 24, 3, 4, "CID"], [24, 24, 206, 209, "CID"], [63, 63, 3, 4, "CID"], [63, 63, 206, 209, "CID"], [73, 73, 3, 4, "CID"], [73, 73, 206, 209, "CID"], [95, 95, 3, 4, "CID"], [95, 95, 206, 209, "CID"], [175, 175, 3, 4, "CID"], [175, 175, 206, 209, "CID"]]], "clusters": [], "translated": "长期服用<0>地高辛</0>患者<6>性功能障碍</6>的主观评价。各种数据表明，长期接受<1>地高辛</1>治疗的男性患者血清<8>雌激素</8>水平升高，血浆<9>睾酮</9>和<9>黄体生成素</9>水平降低。本研究旨在调查长期接受<2>地高辛</2>治疗与性行为之间的联系，以及<3>地高辛</3>对<12>雌二醇</12>、<10>睾酮</10>和LH血浆水平的影响。研究组和对照组（未服用<4>地高辛</4>）的患者具有相似的心功能和年龄（25-40岁），随机选自<14>风湿性心脏病</14>患者。使用性欲、性兴奋和性关系频率等参数对研究组和对照组的性行为进行主观评估。个人访谈和问卷调查也被用于性行为的评估。这些发现支持有关<5>地高辛</5>对血浆<13>雌二醇</13>、<11>睾酮</11>和LH影响的报道。手段的差异是显着的。用于评估性行为变化的测试显示，研究组的性欲显着<7>下降</7>、性兴奋期（勃起），以及性关系频率。", "revised": true}
{"doc_key": "12093990", "sentences": [["Intravenous", "ribavirin", "treatment", "for", "severe", "adenovirus", "disease", "in", "immunocompromised", "children", ".", "BACKGROUND", ":", "Adenovirus", "is", "an", "important", "cause", "of", "morbidity", "and", "mortality", "in", "the", "immunocompromised", "host", ".", "The", "incidence", "of", "severe", "adenovirus", "disease", "in", "pediatrics", "is", "increasing", "in", "association", "with", "growing", "numbers", "of", "immunocompromised", "children", ",", "where", "case", "fatality", "rates", "as", "high", "as", "50", "%", "to", "80", "%", "have", "been", "reported", ".", "There", "are", "no", "approved", "antiviral", "agents", "with", "proven", "efficacy", "for", "the", "treatment", "of", "severe", "adenovirus", "disease", ",", "nor", "are", "there", "any", "prospective", "randomized", ",", "controlled", "trials", "of", "potentially", "useful", "anti", "-", "adenovirus", "therapies", ".", "Apparent", "clinical", "success", "in", "the", "treatment", "of", "severe", "adenovirus", "disease", "is", "limited", "to", "a", "few", "case", "reports", "and", "small", "series", ".", "Experience", "is", "greatest", "with", "intravenous", "ribavirin", "and", "cidofovir", ".", "Ribavirin", ",", "a", "guanosine", "analogue", ",", "has", "broad", "antiviral", "activity", "against", "both", "RNA", "and", "DNA", "viruses", ",", "including", "documented", "activity", "against", "adenovirus", "in", "vitro", ".", "Ribavirin", "is", "licensed", "in", "aerosol", "form", "for", "the", "treatment", "of", "respiratory", "syncytial", "virus", "infection", ",", "and", "orally", "in", "combination", "with", "interferon", "to", "treat", "hepatitis", "C", ".", "Intravenous", "ribavirin", "is", "the", "treatment", "of", "choice", "for", "infection", "with", "hemorrhagic", "fever", "viruses", ".", "The", "most", "common", "adverse", "effect", "of", "intravenous", "ribavirin", "is", "reversible", "mild", "anemia", ".", "The", "use", "of", "cidofovir", "in", "severe", "adenovirus", "infection", "has", "been", "limited", "by", "adverse", "effects", ",", "the", "most", "significant", "of", "which", "is", "nephrotoxicity", ".", "OBJECTIVE", ":", "We", "report", "our", "experience", "with", "intravenous", "ribavirin", "therapy", "for", "severe", "adenovirus", "disease", "in", "a", "series", "of", "immunocompromised", "children", "and", "review", "the", "literature", ".", "DESIGN", "/", "METHODS", ":", "We", "retrospectively", "reviewed", "the", "medical", "records", "of", "5", "children", "treated", "with", "intravenous", "ribavirin", "for", "documented", "severe", "adenovirus", "disease", ".", "Two", "patients", "developed", "adenovirus", "hemorrhagic", "cystitis", "after", "cardiac", "and", "bone", "marrow", "transplants", ",", "respectively", ".", "The", "bone", "marrow", "transplant", "patient", "also", "received", "intravenous", "cidofovir", "for", "progressive", "disseminated", "disease", ".", "An", "additional", "3", "children", "developed", "adenovirus", "pneumonia", ";", "2", "were", "neonates", ",", "1", "of", "whom", "had", "partial", "DiGeorge", "syndrome", ".", "The", "remaining", "infant", "had", "recently", "undergone", "a", "cardiac", "transplant", ".", "Intravenous", "ribavirin", "was", "administered", "on", "a", "compassionate", "-", "use", "protocol", ".", "RESULTS", ":", "Complete", "clinical", "recovery", "followed", "later", "by", "viral", "clearance", "was", "observed", "in", "2", "children", ":", "the", "cardiac", "transplant", "recipient", "with", "adenovirus", "hemorrhagic", "cystitis", "and", "the", "immunocompetent", "neonate", "with", "adenovirus", "pneumonia", ".", "The", "remaining", "3", "children", "died", "of", "adenovirus", "disease", ".", "Intravenous", "ribavirin", "therapy", "was", "well", "tolerated", ".", "Use", "of", "cidofovir", "in", "1", "child", "was", "associated", "with", "progressive", "renal", "failure", "and", "neutropenia", ".", "DISCUSSION", ":", "Our", "series", "of", "patients", "is", "representative", "of", "the", "spectrum", "of", "immunocompromised", "children", "at", "greatest", "risk", "for", "severe", "adenovirus", "disease", ",", "namely", "solid", "-", "organ", "and", "bone", "marrow", "transplant", "recipients", ",", "neonates", ",", "and", "children", "with", "immunodeficiency", ".", "Although", "intravenous", "ribavirin", "was", "not", "effective", "for", "all", "children", "with", "severe", "adenovirus", "disease", "in", "this", "series", "or", "in", "the", "literature", ",", "therapy", "is", "unlikely", "to", "be", "of", "benefit", "if", "begun", "late", "in", "the", "course", "of", "the", "infection", ".", "Early", "identification", ",", "eg", "by", "polymerase", "chain", "reaction", "of", "those", "patients", "at", "risk", "of", "disseminated", "adenovirus", "disease", "may", "permit", "earlier", "antiviral", "treatment", "and", "better", "evaluation", "of", "therapeutic", "response", ".", "CONCLUSIONS", ":", "Two", "of", "5", "children", "with", "severe", "adenovirus", "disease", "treated", "with", "intravenous", "ribavirin", "recovered", ".", "The", "availability", "of", "newer", "rapid", "diagnostic", "techniques", ",", "such", "as", "polymerase", "chain", "reaction", ",", "may", "make", "earlier", ",", "more", "effective", "treatment", "of", "adenovirus", "infection", "possible", ".", "Given", "the", "seriousness", "and", "increasing", "prevalence", "of", "adenovirus", "disease", "in", "certain", "hosts", ",", "especially", "children", ",", "a", "large", ",", "multicenter", "clinical", "trial", "of", "potentially", "useful", "anti", "-", "adenoviral", "therapies", ",", "such", "as", "intravenous", "ribavirin", ",", "is", "clearly", "required", "to", "demonstrate", "the", "most", "effective", "and", "least", "toxic", "therapy", "."]], "ner": [[[124, 124, "Chemical"], [207, 207, "Chemical"], [298, 298, "Chemical"], [395, 395, "Chemical"], [402, 404, "Disease"], [406, 406, "Disease"], [1, 1, "Chemical"], [122, 122, "Chemical"], [126, 126, "Chemical"], [151, 151, "Chemical"], [178, 178, "Chemical"], [198, 198, "Chemical"], [235, 235, "Chemical"], [268, 268, "Chemical"], [335, 335, "Chemical"], [387, 387, "Chemical"], [449, 449, "Chemical"], [527, 527, "Chemical"], [589, 589, "Chemical"], [5, 6, "Disease"], [31, 32, "Disease"], [76, 77, "Disease"], [104, 105, "Disease"], [210, 211, "Disease"], [239, 240, "Disease"], [272, 273, "Disease"], [309, 310, "Disease"], [374, 375, "Disease"], [383, 384, "Disease"], [427, 428, "Disease"], [458, 459, "Disease"], [500, 501, "Disease"], [522, 523, "Disease"], [552, 553, "Disease"], [563, 564, "Disease"], [161, 164, "Disease"], [174, 175, "Disease"], [185, 189, "Disease"], [202, 202, "Disease"], [225, 225, "Disease"], [279, 280, "Disease"], [367, 368, "Disease"], [321, 322, "Disease"], [445, 445, "Disease"], [483, 483, "Disease"], [129, 129, "Chemical"]]], "relations": [[[124, 124, 402, 404, "CID"], [207, 207, 402, 404, "CID"], [298, 298, 402, 404, "CID"], [395, 395, 402, 404, "CID"], [124, 124, 406, 406, "CID"], [207, 207, 406, 406, "CID"], [298, 298, 406, 406, "CID"], [395, 395, 406, 406, "CID"]]], "clusters": [], "translated": "静脉注射<6>利巴韦林</6>治疗免疫功能低下儿童的严重<19>腺病毒病</19>。背景：腺病毒是免疫功能低下宿主发病和死亡的重要原因。儿科严重<20>腺病毒病</20>的发病率随着免疫功能低下儿童数量的增加而增加，据报道病死率高达 50% 至 80%。目前尚无经批准的抗病毒药物经证实可有效治疗严重的<21>腺病毒病</21>，也没有任何可能有用的抗腺病毒疗法的前瞻性随机对照试验。治疗严重<22>腺病毒病</22>的明显临床成功仅限于少数病例报告和小型系列研究。静脉注射<7>利巴韦林</7>和<0>西多福韦</0>的经验最为丰富。<8>利巴韦林</8>是一种<45>似鸟苷的化合物</45>，对RNA和DNA病毒均具有广泛的抗病毒活性，包括已证实的体外抗腺病毒活性。<9>利巴韦林</9>获准以气雾剂形式用于治疗<35>呼吸道合胞病毒感染</35>，并与干扰素联合口服治疗<36>丙型肝炎</36>。静脉注射<10>利巴韦林</10>是<37>治疗出血热病毒感染的首选方法</37>。静脉注射<11>利巴韦林</11>最常见的不良反应是可逆的轻度<38>贫血</38>。<1>西多福韦</1>在严重<23>腺病毒感染</23>中的使用受到不良反应的限制，其中最显着的是<39>肾毒性</39>。目的：我们报告了在一系列免疫功能低下的儿童中使用静脉注射<12>利巴韦林</12>治疗严重<24>腺病毒病</24>的经验，并回顾了文献。设计/方法：我们回顾性地回顾了 5 名因严重<25>腺病毒病</25>而接受静脉<13>利巴韦林</13>治疗的儿童的医疗记录。2例患者分别在心脏移植和骨髓移植后发生腺病毒<40>出血性膀胱炎</40>。骨髓移植患者还接受了静脉注射<2>西多福韦</2>治疗进行性播散性疾病。另有3名儿童发生<26>腺病毒性肺炎</26>；新生儿2例，其中1例有部分<42>DiGeorge综合征</42>。剩下的婴儿最近接受了心脏移植手术。静脉注射<14>利巴韦林</14>是根据同情使用方案进行的。结果：2名患儿临床完全康复，随后病毒清除：患有腺病毒<41>出血性膀胱炎</41>的心脏移植受者和患有<27>腺病毒肺炎</27>的免疫功能正常的新生儿。其余3名患儿死于<28>腺病毒病</28>。静脉注射<15>利巴韦林</15>疗法耐受性良好。1名儿童使用<3>西多福韦</3>与进行性<4>肾功能衰竭</4>和<5>中性粒细胞减少</5>症相互关联。讨论：我们患者系列代表了<43>免疫功能缺陷</43>的儿童中最高风险的严重<29>腺病毒病</29>谱，即固体器官和骨髓移植受者、新生儿和儿童，以及<43>免疫缺陷</43>的患者。虽然静脉注射<16>利巴韦林</16>并非对本系列或文献中所有患有严重<30>腺病毒病</30>的儿童都有效，但如果在病程后期开始治疗不太可能有益<44>感染</44>。早期识别，例如通过聚合酶链反应识别那些有传播性<31>腺病毒病</31>风险的患者，可能允许更早进行抗病毒治疗并更好地评估治疗反应。结论：5例重度<32>腺病毒病</32>患儿经静脉<17>利巴韦林</17>治疗后有2例痊愈。更新的快速诊断技术（例如聚合酶链反应）的可用性可能使更早、更有效地治疗<33>腺病毒感染</33>成为可能。鉴于某些宿主（尤其是儿童）中<34>腺病毒病</34>的严重性和日益流行，一项可能有用的抗腺病毒疗法（如静脉注射<18>利巴韦林</18>）的大型、多中心临床试验正在开展明确要求证明最有效和毒性最小的疗法。", "revised": true}
{"doc_key": "7263204", "sentences": [["Fatal", "aplastic", "anemia", "due", "to", "indomethacin", "-", "-", "lymphocyte", "transformation", "tests", "in", "vitro", ".", "Although", "indomethacin", "has", "been", "implicated", "as", "a", "possible", "cause", "of", "aplastic", "anemia", "on", "the", "basis", "of", "a", "few", "clinical", "observations", ",", "its", "role", "has", "not", "been", "definitely", "established", ".", "A", "case", "of", "fatal", "aplastic", "anemia", "is", "described", "in", "which", "no", "drugs", "other", "than", "allopurinol", "and", "indomethacin", "were", "given", ".", "Indomethacin", "was", "first", "given", "four", "weeks", "prior", "to", "the", "onset", "of", "symptoms", ".", "A", "positive", "lymphocyte", "transformation", "test", "with", "indomethacin", "in", "vitro", "further", "substantiates", "the", "potential", "role", "of", "this", "drug", "in", "causing", "aplastic", "anemia", "in", "a", "susceptible", "patient", ".", "Fortunately", ",", "this", "seems", "to", "be", "a", "very", "rare", "complication", "."]], "ner": [[[5, 5, "Chemical"], [15, 15, "Chemical"], [59, 59, "Chemical"], [63, 63, "Chemical"], [82, 82, "Chemical"], [1, 2, "Disease"], [24, 25, "Disease"], [47, 48, "Disease"], [95, 96, "Disease"], [57, 57, "Chemical"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 24, 25, "CID"], [5, 5, 47, 48, "CID"], [5, 5, 95, 96, "CID"], [15, 15, 1, 2, "CID"], [15, 15, 24, 25, "CID"], [15, 15, 47, 48, "CID"], [15, 15, 95, 96, "CID"], [59, 59, 1, 2, "CID"], [59, 59, 24, 25, "CID"], [59, 59, 47, 48, "CID"], [59, 59, 95, 96, "CID"], [63, 63, 1, 2, "CID"], [63, 63, 24, 25, "CID"], [63, 63, 47, 48, "CID"], [63, 63, 95, 96, "CID"], [82, 82, 1, 2, "CID"], [82, 82, 24, 25, "CID"], [82, 82, 47, 48, "CID"], [82, 82, 95, 96, "CID"]]], "clusters": [], "translated": "<0>吲哚美辛</0>致死性<5>再生障碍性贫血</5> - - 体外淋巴细胞转化试验。虽然根据一些临床观察，<1>吲哚美辛</1>被认为是<6>再生障碍性贫血</6>的可能原因，但其作用尚未明确确定。描述了一个致死性<7>再生障碍性贫血</7>的病例，其中除了<9>别嘌呤醇</9>和<2>吲哚美辛</2>外没有给予其他药物。<3>吲哚美辛</3>在症状出现前 4 周首次给药。<4>吲哚美辛</4>体外淋巴细胞转化试验呈阳性，进一步证实了该药物在易感患者中引起<8>再生障碍性贫血</8>的潜在作用。幸运的是，这似乎是一种非常罕见的并发症。", "revised": true}
{"doc_key": "18589141", "sentences": [["Heparin", "-", "induced", "thrombocytopenia", "after", "liver", "transplantation", ".", "BACKGROUND", ":", "Unfractionated", "heparin", "sodium", "(", "UFH", ")", "or", "low", "-", "molecular", "weight", "heparin", "(", "LMWH", ")", "is", "used", "in", "anticoagulant", "protocols", "at", "several", "institutions", "to", "prevent", "thrombosis", "after", "liver", "transplantation", ".", "Heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "is", "an", "adverse", "immune", "-", "mediated", "reaction", "to", "heparin", ",", "resulting", "in", "platelet", "count", "decreases", "of", "more", "than", "50", "%", ".", "The", "frequencies", "of", "HIT", "after", "liver", "transplantation", "and", "platelet", "factor", "4", "/", "heparin", "-", "reactive", "antibody", "(", "HIT", "antibody", ")", "positivity", "in", "liver", "transplantation", "patients", ",", "however", ",", "are", "unknown", ".", "PATIENTS", "AND", "METHODS", ":", "The", "32", "men", "and", "20", "women", "underwent", "living", "donor", "liver", "transplantation", ".", "We", "started", "LMWH", "(", "25", "IU", "/", "kg", "/", "h", ")", "on", "postoperative", "day", "(", "POD", ")", "1", ",", "switching", "to", "UFH", "(", "5000", "U", "/", "d", ")", "on", "POD", "2", "or", "3", ".", "The", "dose", "of", "UFH", "was", "changed", "according", "to", "the", "activated", "clotting", "time", "level", ".", "HIT", "antibody", "levels", "were", "measured", "the", "day", "before", "surgery", "and", "on", "POD", "7", "and", "14", ".", "Platelet", "count", "was", "measured", "daily", "for", "3", "weeks", ".", "RESULTS", ":", "The", "average", "platelet", "counts", "preoperatively", ",", "and", "on", "POD", "7", ",", "14", ",", "and", "21", "were", "65", ",", "88", ",", "149", ",", "and", "169", "x", "10", "(", "9", ")", "/", "L", ",", "respectively", ".", "Two", "patients", "developed", "hepatic", "artery", "thrombosis", "on", "POD", "11", "and", "19", ",", "respectively", ",", "although", "they", "were", "HIT", "antibody", "-", "negative", "and", "their", "platelet", "counts", "were", "stable", ".", "In", "2", "other", "patients", ",", "the", "platelet", "count", "decreased", "suddenly", "from", "107", "x", "10", "(", "9", ")", "/", "L", "on", "POD", "4", "to", "65", "x", "10", "(", "9", ")", "/", "L", "on", "POD", "6", "and", "from", "76", "x", "10", "(", "9", ")", "/", "L", "on", "POD", "7", "to", "33", "x", "10", "(", "9", ")", "/", "L", "on", "POD", "9", ",", "respectively", ".", "The", "heparin", "-", "induced", "platelet", "aggregation", "test", "was", "negative", "in", "these", "patients", ".", "The", "percentage", "of", "HIT", "antibody", "-", "positive", "patients", "was", "0", ".", "5", "%", "preoperatively", ",", "5", ".", "6", "%", "on", "POD", "7", ",", "and", "5", ".", "6", "%", "on", "POD", "14", ".", "None", "of", "the", "subjects", "/", "patients", "developed", "UFH", "-", "related", "HIT", ".", "CONCLUSIONS", ":", "In", "our", "series", ",", "the", "occurrence", "of", "HIT", "after", "liver", "transplantation", "was", "uncommon", "."]], "ner": [[[0, 0, "Chemical"], [10, 12, "Chemical"], [14, 14, "Chemical"], [40, 40, "Chemical"], [55, 55, "Chemical"], [80, 80, "Chemical"], [136, 136, "Chemical"], [152, 152, "Chemical"], [315, 315, "Chemical"], [366, 366, "Chemical"], [3, 3, "Disease"], [43, 43, "Disease"], [45, 45, "Disease"], [71, 71, "Disease"], [85, 85, "Disease"], [163, 163, "Disease"], [241, 241, "Disease"], [330, 330, "Disease"], [369, 369, "Disease"], [380, 380, "Disease"], [35, 35, "Disease"], [229, 229, "Disease"], [318, 319, "Disease"], [17, 21, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 43, 43, "CID"], [0, 0, 45, 45, "CID"], [0, 0, 71, 71, "CID"], [0, 0, 85, 85, "CID"], [0, 0, 163, 163, "CID"], [0, 0, 241, 241, "CID"], [0, 0, 330, 330, "CID"], [0, 0, 369, 369, "CID"], [0, 0, 380, 380, "CID"], [10, 12, 3, 3, "CID"], [10, 12, 43, 43, "CID"], [10, 12, 45, 45, "CID"], [10, 12, 71, 71, "CID"], [10, 12, 85, 85, "CID"], [10, 12, 163, 163, "CID"], [10, 12, 241, 241, "CID"], [10, 12, 330, 330, "CID"], [10, 12, 369, 369, "CID"], [10, 12, 380, 380, "CID"], [14, 14, 3, 3, "CID"], [14, 14, 43, 43, "CID"], [14, 14, 45, 45, "CID"], [14, 14, 71, 71, "CID"], [14, 14, 85, 85, "CID"], [14, 14, 163, 163, "CID"], [14, 14, 241, 241, "CID"], [14, 14, 330, 330, "CID"], [14, 14, 369, 369, "CID"], [14, 14, 380, 380, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 43, 43, "CID"], [40, 40, 45, 45, "CID"], [40, 40, 71, 71, "CID"], [40, 40, 85, 85, "CID"], [40, 40, 163, 163, "CID"], [40, 40, 241, 241, "CID"], [40, 40, 330, 330, "CID"], [40, 40, 369, 369, "CID"], [40, 40, 380, 380, "CID"], [55, 55, 3, 3, "CID"], [55, 55, 43, 43, "CID"], [55, 55, 45, 45, "CID"], [55, 55, 71, 71, "CID"], [55, 55, 85, 85, "CID"], [55, 55, 163, 163, "CID"], [55, 55, 241, 241, "CID"], [55, 55, 330, 330, "CID"], [55, 55, 369, 369, "CID"], [55, 55, 380, 380, "CID"], [80, 80, 3, 3, "CID"], [80, 80, 43, 43, "CID"], [80, 80, 45, 45, "CID"], [80, 80, 71, 71, "CID"], [80, 80, 85, 85, "CID"], [80, 80, 163, 163, "CID"], [80, 80, 241, 241, "CID"], [80, 80, 330, 330, "CID"], [80, 80, 369, 369, "CID"], [80, 80, 380, 380, "CID"], [136, 136, 3, 3, "CID"], [136, 136, 43, 43, "CID"], [136, 136, 45, 45, "CID"], [136, 136, 71, 71, "CID"], [136, 136, 85, 85, "CID"], [136, 136, 163, 163, "CID"], [136, 136, 241, 241, "CID"], [136, 136, 330, 330, "CID"], [136, 136, 369, 369, "CID"], [136, 136, 380, 380, "CID"], [152, 152, 3, 3, "CID"], [152, 152, 43, 43, "CID"], [152, 152, 45, 45, "CID"], [152, 152, 71, 71, "CID"], [152, 152, 85, 85, "CID"], [152, 152, 163, 163, "CID"], [152, 152, 241, 241, "CID"], [152, 152, 330, 330, "CID"], [152, 152, 369, 369, "CID"], [152, 152, 380, 380, "CID"], [315, 315, 3, 3, "CID"], [315, 315, 43, 43, "CID"], [315, 315, 45, 45, "CID"], [315, 315, 71, 71, "CID"], [315, 315, 85, 85, "CID"], [315, 315, 163, 163, "CID"], [315, 315, 241, 241, "CID"], [315, 315, 330, 330, "CID"], [315, 315, 369, 369, "CID"], [315, 315, 380, 380, "CID"], [366, 366, 3, 3, "CID"], [366, 366, 43, 43, "CID"], [366, 366, 45, 45, "CID"], [366, 366, 71, 71, "CID"], [366, 366, 85, 85, "CID"], [366, 366, 163, 163, "CID"], [366, 366, 241, 241, "CID"], [366, 366, 330, 330, "CID"], [366, 366, 369, 369, "CID"], [366, 366, 380, 380, "CID"]]], "clusters": [], "translated": "肝移植后<0>肝素</0>引起的<10>血小板减少</10>。背景：<1>普通肝素钠</1>（<2>UFH</2>）或<23>低分子量肝素</23>（LMWH）在多个机构的抗凝方案中用于预防<20>血栓形成</20>肝移植后。<3>肝素</3>诱发的<11>血小板减少症</11>（<12>HIT</12>）是对<4>肝素</4>的不良免疫介导反应，导致血小板计数减少超过50%。肝移植后<13>HIT</13>和血小板因子4/<5>肝素</5>反应性抗体（<14>HIT</14>抗体）阳性在肝移植患者中的发生率未知。患者和方法：32名男性和20名女性接受了活体肝移植。我们在术后第1天（POD）开始使用LMWH（25 IU/kg/h），在术后第2天或第3天切换到<6>UFH</6>（5000 U/d）。<7>UFH</7>的剂量根据活化凝血时间水平而改变。<15>HIT</15>抗体水平在手术前一天和术后第7天和第14天进行测量。每天测量血小板计数，持续3周。结果：术前和术后第7、14和21天的平均血小板计数分别为65、88、149和169 x 10 (9)/L。两名患者分别在术后第11天和第19天发生肝动脉<21>血栓形成</21>，尽管他们的<16>HIT</16>抗体呈阴性且血小板计数稳定。在另外2名患者中，血小板计数突然从POD4的107 x 10 (9)/L 下降到POD6 的65 x 10 (9) /L和从POD7 的76x10 (9) /L下降到33xPOD9 分别为 10(9)/L。这些患者的<8>肝素</8>诱导的<22>血小板聚集</22>试验为阴性。<17>HIT</17>抗体阳性患者的百分比为0.5%术前，5.6%在POD7和POD14。没有受试者/患者发生<9>UFH</9>-相关的<18>HIT</18>。结论：在我们的系列研究中，肝移植后<19>HIT</19>的发生并不常见。", "revised": true}
{"doc_key": "7007443", "sentences": [["Circulating", "lysosomal", "enzymes", "and", "acute", "hepatic", "necrosis", ".", "The", "activities", "of", "the", "lysosomal", "enzymes", "acid", "and", "neutral", "protease", ",", "N", "-", "acetylglucosaminidase", ",", "and", "acid", "phosphatase", "were", "measured", "in", "the", "serum", "of", "patients", "with", "fulminant", "hepatic", "failure", ".", "Acid", "protease", "(", "cathepsin", "D", ")", "activity", "was", "increased", "about", "tenfold", "in", "patients", "who", "died", "and", "nearly", "fourfold", "in", "those", "who", "survived", "fulminant", "hepatic", "failure", "after", "paracetamol", "overdose", ",", "whereas", "activities", "were", "increased", "equally", "in", "patients", "with", "fulminant", "hepatic", "failure", "due", "to", "viral", "hepatitis", "whether", "or", "not", "they", "survived", ".", "A", "correlation", "was", "found", "between", "serum", "acid", "protease", "activity", "and", "prothrombin", "time", ",", "and", "the", "increase", "in", "cathepsin", "D", "activity", "was", "sustained", "over", "several", "days", "compared", "with", "aspartate", "aminotransferase", ",", "which", "showed", "a", "sharp", "early", "peak", "and", "then", "a", "fall", ".", "Circulating", "lysosomal", "proteases", "can", "damage", "other", "organs", ",", "and", "measurement", "of", "their", "activity", "may", "therefore", "be", "of", "added", "value", "in", "assessing", "prognosis", "in", "this", "condition", "."]], "ner": [[[64, 64, "Chemical"], [4, 6, "Disease"], [34, 36, "Disease"], [60, 62, "Disease"], [75, 77, "Disease"], [115, 115, "Chemical"], [65, 65, "Disease"], [80, 81, "Disease"]]], "relations": [[[64, 64, 4, 6, "CID"], [64, 64, 34, 36, "CID"], [64, 64, 60, 62, "CID"], [64, 64, 75, 77, "CID"]]], "clusters": [], "translated": "循环溶酶体酶和<1>急性肝坏死</1>。在<2>暴发性肝功能衰竭</2>患者的血清中测定了溶酶体酸性和中性蛋白酶、N-乙酰氨基葡萄糖苷酶和酸性磷酸酶的活性。酸性蛋白酶（<1>组织蛋白酶 D</1>）活性在<0>对乙酰氨基酚</0><6>过量服用</6>后死亡的患者中增加了大约10倍，在<3>暴发性肝功能衰竭</3>幸存者中增加了近四倍，而由于<7>病毒性肝炎</7>而导致<4>暴发性肝功能衰竭</4>的患者无论是否存活，活动都同样增加。发现血清酸性蛋白酶活性与凝血酶原时间之间存在相关性，与<5>天冬氨酸</5>转氨酶相比，<1>组织蛋白酶 D</1>活性的增加持续数天，后者显示出一个尖锐的早期峰值，然后下降。循环溶酶体蛋白酶会损害其他器官，因此测量它们的活性对于评估这种情况的预后可能具有附加值。", "revised": true}
{"doc_key": "7724492", "sentences": [["Acute", "renal", "toxicity", "of", "doxorubicin", "(", "adriamycin", ")", "-", "loaded", "cyanoacrylate", "nanoparticles", ".", "Acute", "doxorubicin", "-", "loaded", "nanoparticle", "(", "DXNP", ")", "renal", "toxicity", "was", "explored", "in", "both", "normal", "rats", "and", "rats", "with", "experimental", "glomerulonephritis", ".", "In", "normal", "rats", ",", "2", "/", "6", "rats", "given", "free", "doxorubicin", "(", "DX", ")", "(", "5", "mg", "/", "kg", ")", "died", "within", "one", "week", ",", "whereas", "all", "control", "animals", "and", "all", "rats", "having", "received", "free", "NP", "or", "DXNP", "survived", ".", "A", "3", "times", "higher", "proteinuria", "appeared", "in", "animals", "treated", "with", "DXNP", "than", "in", "those", "treated", "with", "DX", ".", "Free", "NP", "did", "not", "provoke", "any", "proteinuria", ".", "Two", "hr", "post", "-", "injection", ",", "DXNP", "was", "2", ".", "7", "times", "more", "concentrated", "in", "kidneys", "than", "free", "DX", "(", "p", "<", "0", ".", "025", ")", ".", "In", "rats", "with", "immune", "experimental", "glomerulonephritis", ",", "5", "/", "6", "rats", "given", "DX", "died", "within", "7", "days", ",", "in", "contrast", "to", "animals", "treated", "by", "DXNP", ",", "NP", ",", "or", "untreated", ",", "which", "all", "survived", ".", "Proteinuria", "appeared", "in", "all", "series", ",", "but", "was", "2", "-", "5", "times", "more", "intense", "(", "p", ">", "0", ".", "001", ")", "and", "prolonged", "after", "doxorubicin", "treatment", "(", "400", "-", "700", "mg", "/", "day", ")", ",", "without", "significant", "difference", "between", "DXNP", "and", "DX", ".", "Rats", "treated", "by", "unloaded", "NP", "behaved", "as", "controls", ".", "These", "results", "demonstrate", "that", ",", "in", "these", "experimental", "conditions", ",", "DXNP", "killed", "less", "animals", "than", "free", "DX", ",", "despite", "of", "an", "enhanced", "renal", "toxicity", "of", "the", "former", ".", "Both", "effects", "(", "better", "survival", "and", "nephrosis", ")", "are", "most", "probably", "related", "to", "an", "enhanced", "capture", "of", "DXNP", "by", "cells", "of", "the", "mononuclear", "phagocyte", "system", ",", "including", "mesangial", "cells", "."]], "ner": [[[4, 4, "Chemical"], [6, 6, "Chemical"], [14, 14, "Chemical"], [45, 45, "Chemical"], [47, 47, "Chemical"], [91, 91, "Chemical"], [119, 119, "Chemical"], [140, 140, "Chemical"], [187, 187, "Chemical"], [204, 204, "Chemical"], [231, 231, "Chemical"], [79, 79, "Disease"], [99, 99, "Disease"], [163, 163, "Disease"], [1, 2, "Disease"], [21, 22, "Disease"], [237, 238, "Disease"], [10, 10, "Chemical"], [33, 33, "Disease"], [133, 133, "Disease"], [249, 249, "Disease"]]], "relations": [[[4, 4, 79, 79, "CID"], [4, 4, 99, 99, "CID"], [4, 4, 163, 163, "CID"], [6, 6, 79, 79, "CID"], [6, 6, 99, 99, "CID"], [6, 6, 163, 163, "CID"], [14, 14, 79, 79, "CID"], [14, 14, 99, 99, "CID"], [14, 14, 163, 163, "CID"], [45, 45, 79, 79, "CID"], [45, 45, 99, 99, "CID"], [45, 45, 163, 163, "CID"], [47, 47, 79, 79, "CID"], [47, 47, 99, 99, "CID"], [47, 47, 163, 163, "CID"], [91, 91, 79, 79, "CID"], [91, 91, 99, 99, "CID"], [91, 91, 163, 163, "CID"], [119, 119, 79, 79, "CID"], [119, 119, 99, 99, "CID"], [119, 119, 163, 163, "CID"], [140, 140, 79, 79, "CID"], [140, 140, 99, 99, "CID"], [140, 140, 163, 163, "CID"], [187, 187, 79, 79, "CID"], [187, 187, 99, 99, "CID"], [187, 187, 163, 163, "CID"], [204, 204, 79, 79, "CID"], [204, 204, 99, 99, "CID"], [204, 204, 163, 163, "CID"], [231, 231, 79, 79, "CID"], [231, 231, 99, 99, "CID"], [231, 231, 163, 163, "CID"]]], "clusters": [], "translated": "<0>阿霉素</0>（<1>阿霉素</1>）负载<17>氰基丙烯酸酯</17>纳米粒的急性<14>肾毒性</14>。在正常大鼠和实验性<18>肾小球肾炎</18>大鼠中研究了载有<2>多柔比星</2>的纳米颗粒(DXNP) <15>肾毒性</15>。在正常大鼠中，给予游离<3>多柔比星</3>（<4>DX</4>）（5 mg/kg）的大鼠中有2/6在一周内死亡，而所有对照动物和所有接受游离NP的大鼠或DXNP幸存下来。用DXNP治疗的动物出现的<11>蛋白尿</11>比用<5>DX</5>治疗的动物高3倍。游离NP不会引起任何<12>蛋白尿</12>。注射后两小时，DXNP在肾脏中的浓度是游离<6>DX</6>的7倍（p < 0.025）。在患有免疫性实验性<19>肾小球肾炎</19>的大鼠中，给予<7>DX</7>的大鼠是5/6会在7天内死亡，而接受DXNP、NP或未治疗的动物则全部存活。<13>蛋白尿</13>出现在所有系列中，但在<8>多柔比星</8>治疗（400-700 mg/天）后强度增加2-5倍（p > 0.001）并且持续时间延长，DXNP和<9>DX</9>之间没有显着差异。经卸载的NP处理的大鼠作为对照。这些结果表明，在这些实验条件下，DXNP杀死的动物少于游离的<10>DX</10>，尽管前者的<16>肾毒性</16>有所增强。这两种效应（更好的存活率和<20>肾病</20>）很可能与单核吞噬细胞系统（包括系膜细胞）对DXNP的捕获增强有关。", "revised": true}
{"doc_key": "3001299", "sentences": [["Thyroid", "function", "and", "urine", "-", "concentrating", "ability", "during", "lithium", "treatment", ".", "It", "has", "been", "suggested", "that", "adenylate", "cyclase", "inhibition", "may", "be", "important", "in", "the", "development", "of", "both", "nephrogenic", "diabetes", "insipidus", "and", "hypothyroidism", "during", "lithium", "treatment", ".", "We", "measured", "serum", "thyroxine", "and", "urine", "-", "concentrating", "ability", "(", "Umax", ")", "in", "response", "to", "desmopressin", "(", "DDAVP", ")", "in", "85", "patients", "receiving", "lithium", ".", "Hypothyroidism", "developed", "in", "eight", "patients", "while", "they", "were", "taking", "lithium", ".", "Impaired", "Umax", "was", "found", "in", "both", "euthyroid", "and", "hypothyroid", "patients", "while", "some", "hypothyroid", "patients", "concentrated", "their", "urine", "well", ".", "It", "is", "concluded", "that", "the", "dominant", "mechanisms", "by", "which", "lithium", "exerts", "these", "two", "effects", "are", "different", "."]], "ner": [[[8, 8, "Chemical"], [33, 33, "Chemical"], [59, 59, "Chemical"], [70, 70, "Chemical"], [100, 100, "Chemical"], [31, 31, "Disease"], [61, 61, "Disease"], [80, 80, "Disease"], [84, 84, "Disease"], [27, 29, "Disease"], [39, 39, "Chemical"]]], "relations": [[[8, 8, 31, 31, "CID"], [8, 8, 61, 61, "CID"], [8, 8, 80, 80, "CID"], [8, 8, 84, 84, "CID"], [33, 33, 31, 31, "CID"], [33, 33, 61, 61, "CID"], [33, 33, 80, 80, "CID"], [33, 33, 84, 84, "CID"], [59, 59, 31, 31, "CID"], [59, 59, 61, 61, "CID"], [59, 59, 80, 80, "CID"], [59, 59, 84, 84, "CID"], [70, 70, 31, 31, "CID"], [70, 70, 61, 61, "CID"], [70, 70, 80, 80, "CID"], [70, 70, 84, 84, "CID"], [100, 100, 31, 31, "CID"], [100, 100, 61, 61, "CID"], [100, 100, 80, 80, "CID"], [100, 100, 84, 84, "CID"]]], "clusters": [], "translated": "<0>锂</0>治疗期间的甲状腺功能和尿液浓缩能力。研究表明，在<1>锂</1>治疗期间，腺苷酸环化酶抑制可能对<5>甲状腺功能减退症</5>和<9>肾性尿崩症</9>的发展起重要作用。我们测量了接受<2>锂</2>治疗的85名患者的血清<10>甲状腺素</10>和尿液浓缩能力(Umax)对去氨加压素(DDAVP)的反应。<6>甲状腺功能减退症</6>有8名患者在服用<3>锂</3>时出现。在甲状腺功能正常和<7>甲状腺功能减退</7>患者中均发现Umax受损，而部分<8>甲状腺功能减退</8>患者尿液浓缩良好。结论是<4>锂</4>发挥这两种作用的主要机制是不同的。", "revised": true}
{"doc_key": "7066357", "sentences": [["Plasma", "and", "urinary", "lipids", "and", "lipoproteins", "during", "the", "development", "of", "nephrotic", "syndrome", "induced", "in", "the", "rat", "by", "puromycin", "aminonucleoside", ".", "This", "study", "was", "undertaken", "to", "ascertain", "whether", "the", "alterations", "of", "plasma", "lipoproteins", "found", "in", "nephrotic", "syndrome", "induced", "by", "puromycin", "aminonucleoside", "were", "due", "to", "nephrotic", "syndrome", "per", "se", ",", "or", ",", "at", "least", "in", "part", ",", "to", "the", "aminonucleoside", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "investigate", "the", "changes", "in", "plasma", "and", "urinary", "lipoproteins", "during", "the", "administration", "of", "puromycin", "aminonucleoside", "(", "20", "mg", "/", "kg", "for", "7", "days", ")", "and", "the", "subsequent", "development", "of", "nephrotic", "syndrome", ".", "Since", "massive", "albuminuria", "occurred", "after", "6", "days", "of", "treatment", ",", "the", "time", "-", "course", "study", "was", "divided", "into", "two", "stages", ":", "pre", "-", "nephrotic", "stage", "(", "day", "1", "-", "5", ")", "and", "nephrotic", "stage", "(", "day", "6", "-", "11", ")", ".", "In", "pre", "-", "nephrotic", "stage", "the", "plasma", "level", "of", "fatty", "acids", ",", "triacylglycerol", "and", "VLDL", "decreased", "while", "that", "of", "phospholipid", ",", "cholesteryl", "esters", "and", "HDL", "remained", "constant", ".", "Plasma", "apolipoprotein", "A", "-", "I", "tended", "to", "increase", "(", "40", "%", "increase", "at", "day", "5", ")", ".", "At", "the", "beginning", "of", "nephrotic", "stage", "(", "day", "6", ")", "the", "concentration", "of", "plasma", "albumin", "dropped", "to", "a", "very", "low", "level", ",", "while", "that", "of", "apolipoprotein", "A", "-", "I", "increased", "abruptly", "(", "4", "-", "fold", "increase", ")", "and", "continued", "to", "rise", ",", "although", "less", "steeply", ",", "in", "the", "following", "days", ".", "The", "plasma", "concentration", "of", "HDL", "followed", "the", "same", "pattern", ".", "Plasma", "VLDL", "and", "LDL", "increased", "at", "a", "later", "stage", "(", "day", "9", ")", ".", "Plasma", "apolipoprotein", "A", "-", "I", "was", "found", "not", "only", "in", "HDL", "(", "1", ".", "063", "-", "1", ".", "210", "g", "/", "ml", ")", "but", "also", "in", "the", "LDL", "density", "class", "(", "1", ".", "025", "-", "1", ".", "050", "g", "/", "ml", ")", ".", "In", "the", "pre", "-", "nephrotic", "stage", "lipoproteinuria", "was", "negligible", ",", "while", "in", "the", "early", "nephrotic", "stage", "the", "urinary", "loss", "of", "plasma", "lipoproteins", "consisted", "mainly", "of", "HDL", ".", "These", "observations", "indicate", "that", "puromycin", "aminonucleoside", "alters", "plasma", "lipoproteins", "by", "lowering", "VLDL", "and", "increasing", "HDL", ".", "It", "is", "likely", "that", "the", "early", "and", "striking", "increase", "of", "plasma", "HDL", "found", "in", "nephrotic", "rats", "is", "related", "to", "a", "direct", "effect", "of", "the", "drug", "on", "HDL", "metabolism", "."]], "ner": [[[17, 18, "Chemical"], [38, 39, "Chemical"], [57, 57, "Chemical"], [79, 80, "Chemical"], [333, 334, "Chemical"], [10, 11, "Disease"], [34, 35, "Disease"], [43, 44, "Disease"], [95, 96, "Disease"], [121, 121, "Disease"], [130, 130, "Disease"], [142, 142, "Disease"], [188, 188, "Disease"], [306, 306, "Disease"], [316, 316, "Disease"], [359, 359, "Disease"], [148, 149, "Chemical"], [151, 151, "Chemical"], [160, 161, "Chemical"], [100, 100, "Disease"]]], "relations": [[[17, 18, 10, 11, "CID"], [17, 18, 34, 35, "CID"], [17, 18, 43, 44, "CID"], [17, 18, 95, 96, "CID"], [17, 18, 121, 121, "CID"], [17, 18, 130, 130, "CID"], [17, 18, 142, 142, "CID"], [17, 18, 188, 188, "CID"], [17, 18, 306, 306, "CID"], [17, 18, 316, 316, "CID"], [17, 18, 359, 359, "CID"], [38, 39, 10, 11, "CID"], [38, 39, 34, 35, "CID"], [38, 39, 43, 44, "CID"], [38, 39, 95, 96, "CID"], [38, 39, 121, 121, "CID"], [38, 39, 130, 130, "CID"], [38, 39, 142, 142, "CID"], [38, 39, 188, 188, "CID"], [38, 39, 306, 306, "CID"], [38, 39, 316, 316, "CID"], [38, 39, 359, 359, "CID"], [57, 57, 10, 11, "CID"], [57, 57, 34, 35, "CID"], [57, 57, 43, 44, "CID"], [57, 57, 95, 96, "CID"], [57, 57, 121, 121, "CID"], [57, 57, 130, 130, "CID"], [57, 57, 142, 142, "CID"], [57, 57, 188, 188, "CID"], [57, 57, 306, 306, "CID"], [57, 57, 316, 316, "CID"], [57, 57, 359, 359, "CID"], [79, 80, 10, 11, "CID"], [79, 80, 34, 35, "CID"], [79, 80, 43, 44, "CID"], [79, 80, 95, 96, "CID"], [79, 80, 121, 121, "CID"], [79, 80, 130, 130, "CID"], [79, 80, 142, 142, "CID"], [79, 80, 188, 188, "CID"], [79, 80, 306, 306, "CID"], [79, 80, 316, 316, "CID"], [79, 80, 359, 359, "CID"], [333, 334, 10, 11, "CID"], [333, 334, 34, 35, "CID"], [333, 334, 43, 44, "CID"], [333, 334, 95, 96, "CID"], [333, 334, 121, 121, "CID"], [333, 334, 130, 130, "CID"], [333, 334, 142, 142, "CID"], [333, 334, 188, 188, "CID"], [333, 334, 306, 306, "CID"], [333, 334, 316, 316, "CID"], [333, 334, 359, 359, "CID"]]], "clusters": [], "translated": "<0>嘌呤霉素氨基核苷</0>致大鼠<5>肾病综合征</5>发展过程中血浆和尿脂及脂蛋白的变化。本研究旨在确定<1>嘌呤霉素氨基核苷</1>引起的<6>肾病综合征</6>中血浆脂蛋白的改变是否是由<7>肾病综合征</7>本身引起的，或者，至少部分是<2>氨基核苷</2>。本研究的目的是调查服用<3>嘌呤霉素氨基核苷</3>（20 mg/kg，连续7天）期间血浆和尿液脂蛋白的变化以及<8>肾病综合征</8>的后续发展。由于治疗6天后出现大量<19>蛋白尿</19>，时程研究分为两个阶段：前<9>肾病</9>阶段（第1-5天）和<10>肾病</10>阶段（第6-11天）。在<11>肾病</11>前期，<16>脂肪酸</16>、<17>三酰甘油</17>和极低密度脂蛋白水平下降，磷脂、<18>胆固醇酯</18>和HDL保持不变。血浆载脂蛋白A-I有增加的趋势（第5天增加40%）。在<12>肾病</12>期初（第6天），血浆白蛋白浓度降至极低水平，而载脂蛋白A-I浓度突然升高（增加4倍）并持续升高，尽管不那么陡峭，在接下来的日子里。HDL的血浆浓度遵循相同的模式。血浆VLDL和LDL在后期（第9天）增加。血浆载脂蛋白A-I不仅存在于HDL（1.063-1.210 g/ml）中，而且存在于LDL密度等级（1.025-1.050 g/ml）中。<13>肾病</13>前期脂蛋白尿可忽略不计，而在<14>肾病</14>早期，血浆脂蛋白尿丢失主要为HDL。这些观察结果表明<4>嘌呤霉素氨基核苷</4>通过降低VLDL和增加HDL来改变血浆脂蛋白。在<15>肾病</15>大鼠中发现的血浆HDL的早期和显着增加可能与药物对HDL代谢的直接影响有关。", "revised": true}
{"doc_key": "1423339", "sentences": [["Amnestic", "syndrome", "associated", "with", "propranolol", "toxicity", ":", "a", "case", "report", ".", "An", "elderly", "woman", "developed", "an", "Alzheimer", "-", "like", "subacute", "dementia", "as", "a", "result", "of", "propranolol", "toxicity", ".", "Analysis", "of", "the", "manifestations", "showed", "that", "severe", "impairment", "of", "memory", "accounted", "for", "virtually", "all", "of", "the", "abnormalities", ".", "There", "is", "evidence", "that", "cerebral", "reactions", "to", "drug", "toxicity", "can", "exhibit", "patterns", "that", "suggest", "highly", "selective", "involvement", "of", "functional", "subdivisions", "of", "the", "brain", "."]], "ner": [[[4, 4, "Chemical"], [25, 25, "Chemical"], [0, 1, "Disease"], [5, 5, "Disease"], [26, 26, "Disease"], [54, 54, "Disease"], [16, 16, "Disease"], [20, 20, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [25, 25, 0, 1, "CID"]]], "clusters": [], "translated": " <2>遗忘综合征</2>与<0>普萘洛尔</0> <3>毒性</3>相关：病例报告。一位老年妇女因<1>普萘洛尔</1> <4>毒性</4>患上了以 <6>阿尔茨海默</6> 病样亚急性 <7>痴呆</7> 症。对病情表现的分析表明，严重的记忆障碍几乎是引起所有异常的原因。有证据表明，大脑对药物 <5>毒性</5> 的反应可以表现出高度选择性，参与脑功能细分的模式。", "revised": true}
{"doc_key": "3088349", "sentences": [["Transient", "contralateral", "rotation", "following", "unilateral", "substantia", "nigra", "lesion", "reflects", "susceptibility", "of", "the", "nigrostriatal", "system", "to", "exhaustion", "by", "amphetamine", ".", "Following", "unilateral", "6", "-", "OHDA", "induced", "SN", "lesion", ",", "a", "transient", "period", "of", "contralateral", "rotation", "has", "been", "reported", "to", "precede", "the", "predominant", "ipsilateral", "circling", ".", "In", "order", "to", "clarify", "the", "nature", "of", "this", "initial", "contralateral", "rotation", "we", "examined", "the", "effect", "of", "the", "duration", "of", "recovery", "period", "after", "the", "lesion", ",", "on", "amphetamine", "-", "induced", "rotational", "behavior", ".", "Three", "days", "post", "lesion", ",", "most", "rats", "circled", "predominantly", "contralaterally", "to", "the", "lesion", ".", "Such", "contralateral", "rotation", "may", "result", "from", "either", "degeneration", "-", "induced", "breakdown", "of", "the", "DA", "pool", ",", "or", "lesion", "-", "induced", "increase", "of", "DA", "turnover", "in", "the", "spared", "neurons", ".", "A", "substantial", "degree", "of", "contralateral", "preference", "was", "still", "evident", "when", "amphetamine", "was", "administered", "for", "the", "first", "time", "24", "days", "after", "lesioning", ",", "indicating", "involvement", "of", "spared", "cells", "in", "the", "contralateral", "rotation", ".", "However", ",", "regardless", "of", "the", "duration", "of", "recovery", "(", "and", "irrespective", "of", "either", "lesion", "volume", ",", "amphetamine", "dose", ",", "or", "post", "-", "lesion", "motor", "exercise", ")", ",", "amphetamine", "-", "induced", "rotation", "tended", "to", "become", "gradually", "more", "ipsilateral", "as", "the", "observation", "session", "progressed", ",", "and", "all", "rats", "circled", "ipsilaterally", "to", "the", "lesion", "in", "response", "to", "further", "amphetamine", "injections", ".", "These", "findings", "suggest", "that", "amphetamine", "has", "an", "irreversible", "effect", "on", "the", "post", "-", "lesion", "DA", "pool", "contributing", "to", "contralateral", "rotation", "."]], "ner": [[[17, 17, "Chemical"], [70, 70, "Chemical"], [129, 129, "Chemical"], [167, 167, "Chemical"], [178, 178, "Chemical"], [206, 206, "Chemical"], [213, 213, "Chemical"], [1, 2, "Disease"], [32, 33, "Disease"], [41, 42, "Disease"], [53, 54, "Disease"], [73, 74, "Disease"], [91, 92, "Disease"], [148, 149, "Disease"], [181, 181, "Disease"], [227, 228, "Disease"], [21, 23, "Chemical"]]], "relations": [[[17, 17, 1, 2, "CID"], [17, 17, 32, 33, "CID"], [17, 17, 41, 42, "CID"], [17, 17, 53, 54, "CID"], [17, 17, 73, 74, "CID"], [17, 17, 91, 92, "CID"], [17, 17, 148, 149, "CID"], [17, 17, 181, 181, "CID"], [17, 17, 227, 228, "CID"], [70, 70, 1, 2, "CID"], [70, 70, 32, 33, "CID"], [70, 70, 41, 42, "CID"], [70, 70, 53, 54, "CID"], [70, 70, 73, 74, "CID"], [70, 70, 91, 92, "CID"], [70, 70, 148, 149, "CID"], [70, 70, 181, 181, "CID"], [70, 70, 227, 228, "CID"], [129, 129, 1, 2, "CID"], [129, 129, 32, 33, "CID"], [129, 129, 41, 42, "CID"], [129, 129, 53, 54, "CID"], [129, 129, 73, 74, "CID"], [129, 129, 91, 92, "CID"], [129, 129, 148, 149, "CID"], [129, 129, 181, 181, "CID"], [129, 129, 227, 228, "CID"], [167, 167, 1, 2, "CID"], [167, 167, 32, 33, "CID"], [167, 167, 41, 42, "CID"], [167, 167, 53, 54, "CID"], [167, 167, 73, 74, "CID"], [167, 167, 91, 92, "CID"], [167, 167, 148, 149, "CID"], [167, 167, 181, 181, "CID"], [167, 167, 227, 228, "CID"], [178, 178, 1, 2, "CID"], [178, 178, 32, 33, "CID"], [178, 178, 41, 42, "CID"], [178, 178, 53, 54, "CID"], [178, 178, 73, 74, "CID"], [178, 178, 91, 92, "CID"], [178, 178, 148, 149, "CID"], [178, 178, 181, 181, "CID"], [178, 178, 227, 228, "CID"], [206, 206, 1, 2, "CID"], [206, 206, 32, 33, "CID"], [206, 206, 41, 42, "CID"], [206, 206, 53, 54, "CID"], [206, 206, 73, 74, "CID"], [206, 206, 91, 92, "CID"], [206, 206, 148, 149, "CID"], [206, 206, 181, 181, "CID"], [206, 206, 227, 228, "CID"], [213, 213, 1, 2, "CID"], [213, 213, 32, 33, "CID"], [213, 213, 41, 42, "CID"], [213, 213, 53, 54, "CID"], [213, 213, 73, 74, "CID"], [213, 213, 91, 92, "CID"], [213, 213, 148, 149, "CID"], [213, 213, 181, 181, "CID"], [213, 213, 227, 228, "CID"]]], "clusters": [], "translated": "单侧黑质损伤后的瞬态<7>对侧旋转</7>反映了黑质纹状体系统对<0>安非他明</0>耗尽的易感性。在单侧<16>6-OHDA</16>诱导 SN 损伤后，据报道<8>对侧旋转</8>的短暂时期先于主要的<9>同侧盘旋</9>。为了阐明这种初始<10>对侧旋转</10>的性质，我们检查了损伤后恢复期持续时间对<1>苯丙胺</1>诱导的<11>旋转行为</11>。损伤后三天，大多数大鼠主要在损伤的对侧盘旋。这种<12>对侧旋转</12>可能是由于变性诱导的多巴胺池分解，或损伤诱导的幸免神经元中多巴胺周转的增加。当损伤后24天首次给予<2>安非他明</2>时，对侧偏好的程度仍然很明显，表明在<13>对侧旋转</13>中有幸免的细胞参与。然而，无论恢复持续时间长短（也无论损伤体积、<3>安非他明</3>剂量或损伤后运动锻炼），<4>安非他明</4>诱导的<14>旋转</14>随着观察期的进行，趋向于逐渐向同侧转移，并且所有大鼠都在病灶的同侧盘旋以响应进一步的<5>安非他明</5>注射。这些发现表明，<6>安非他明</6>对促进<15>对侧旋转</15>的损伤后多巴胺池具有不可逆的作用。", "revised": true}
{"doc_key": "3762968", "sentences": [["Transketolase", "abnormality", "in", "tolazamide", "-", "induced", "Wernicke", "'s", "encephalopathy", ".", "We", "studied", "a", "thiamine", "-", "dependent", "enzyme", ",", "transketolase", ",", "from", "fibroblasts", "of", "a", "diabetic", "patient", "who", "developed", "Wernicke", "'s", "encephalopathy", "when", "treated", "with", "tolazamide", ",", "in", "order", "to", "delineate", "if", "this", "patient", "also", "had", "transketolase", "abnormality", "[", "high", "Km", "for", "thiamine", "pyrophosphate", "(", "TPP", ")", "]", ",", "as", "previously", "reported", "in", "postalcoholic", "Wernicke", "-", "Korsakoff", "syndrome", ".", "In", "addition", "to", "this", "patient", ",", "we", "also", "studied", "this", "enzyme", "from", "three", "diabetic", "kindreds", "without", "any", "history", "of", "Wernicke", "'s", "encephalopathy", "and", "from", "four", "normal", "controls", ".", "We", "found", "that", "the", "above", "-", "mentioned", "patient", "and", "one", "of", "the", "diabetic", "kindreds", "with", "no", "history", "of", "Wernicke", "'s", "encephalopathy", "had", "abnormal", "transketolase", "as", "determined", "by", "its", "Km", "for", "TPP", ".", "These", "data", "suggest", "a", "similarity", "between", "postalcoholic", "Wernicke", "-", "Korsakoff", "syndrome", "and", "the", "patient", "with", "tolazamide", "-", "induced", "Wernicke", "'s", "encephalopathy", "from", "the", "standpoint", "of", "transketolase", "abnormality", "."]], "ner": [[[3, 3, "Chemical"], [34, 34, "Chemical"], [143, 143, "Chemical"], [6, 8, "Disease"], [28, 30, "Disease"], [87, 89, "Disease"], [114, 116, "Disease"], [146, 148, "Disease"], [24, 24, "Disease"], [81, 81, "Disease"], [108, 108, "Disease"], [63, 66, "Disease"], [135, 138, "Disease"], [13, 13, "Chemical"], [51, 52, "Chemical"], [54, 54, "Chemical"], [126, 126, "Chemical"]]], "relations": [[[3, 3, 6, 8, "CID"], [3, 3, 28, 30, "CID"], [3, 3, 87, 89, "CID"], [3, 3, 114, 116, "CID"], [3, 3, 146, 148, "CID"], [34, 34, 6, 8, "CID"], [34, 34, 28, 30, "CID"], [34, 34, 87, 89, "CID"], [34, 34, 114, 116, "CID"], [34, 34, 146, 148, "CID"], [143, 143, 6, 8, "CID"], [143, 143, 28, 30, "CID"], [143, 143, 87, 89, "CID"], [143, 143, 114, 116, "CID"], [143, 143, 146, 148, "CID"]]], "clusters": [], "translated": "<0>妥拉磺胺</0>诱发的<3>韦尼克脑病</3>：转酮醇酶异常。我们研究了<13>硫胺素</13>依赖性酶-转酮醇酶，该酶来自一名<8>糖尿病</8>患者的成纤维细胞，该患者在接受<1>妥拉磺胺</1>治疗时发生了<4>韦尼克脑病</4>，为了确定该患者是否也有转酮酶异常[<14>焦磷酸硫胺素</14> (<15>TPP</15>)的高Km]，如先前在酒精中毒后<11> Wernicke-Korsakoff综合症</11>中报道的那样。除了这名患者之外，我们还研究了来自三个没有任何<5>韦尼克脑病</5>病史的<9>糖尿病</9>家族和四个正常对照中的这种酶。我们发现上述患者和一个没有<6>Wernicke脑病</6>病史的<10>糖尿病</10>亲属具有转酮醇酶异常，这是根据其对<16>TPP</16>的Km确定的。这些数据表明，从转酮醇酶异常的角度来看，酒精中毒后<12>Wernicke-Korsakoff综合征</12>与由<2>妥拉扎胺</2>诱发的<7>Wernicke脑病</7>患者之间存在相似性。", "revised": true}
{"doc_key": "3413271", "sentences": [["Mechanisms", "of", "myocardial", "ischemia", "induced", "by", "epinephrine", ":", "comparison", "with", "exercise", "-", "induced", "ischemia", ".", "The", "role", "of", "epinephrine", "in", "eliciting", "myocardial", "ischemia", "was", "examined", "in", "patients", "with", "coronary", "artery", "disease", ".", "Objective", "signs", "of", "ischemia", "and", "factors", "increasing", "myocardial", "oxygen", "consumption", "were", "compared", "during", "epinephrine", "infusion", "and", "supine", "bicycle", "exercise", ".", "Both", "epinephrine", "and", "exercise", "produced", "myocardial", "ischemia", "as", "evidenced", "by", "ST", "segment", "depression", "and", "angina", ".", "However", ",", "the", "mechanisms", "of", "myocardial", "ischemia", "induced", "by", "epinephrine", "were", "significantly", "different", "from", "those", "of", "exercise", ".", "Exercise", "-", "induced", "myocardial", "ischemia", "was", "marked", "predominantly", "by", "increased", "heart", "rate", "and", "rate", "-", "pressure", "product", "with", "a", "minor", "contribution", "of", "end", "-", "diastolic", "volume", ",", "while", "epinephrine", "-", "induced", "ischemia", "was", "characterized", "by", "a", "marked", "increase", "in", "contractility", "and", "a", "less", "pronounced", "increase", "in", "heart", "rate", "and", "rate", "-", "pressure", "product", ".", "These", "findings", "indicate", "that", "ischemia", "produced", "by", "epinephrine", ",", "as", "may", "occur", "during", "states", "of", "emotional", "distress", ",", "has", "a", "mechanism", "distinct", "from", "that", "due", "to", "physical", "exertion", "."]], "ner": [[[6, 6, "Chemical"], [18, 18, "Chemical"], [45, 45, "Chemical"], [53, 53, "Chemical"], [77, 77, "Chemical"], [114, 114, "Chemical"], [147, 147, "Chemical"], [2, 3, "Disease"], [21, 22, "Disease"], [57, 58, "Disease"], [73, 74, "Disease"], [89, 90, "Disease"], [40, 40, "Chemical"], [13, 13, "Disease"], [35, 35, "Disease"], [117, 117, "Disease"], [144, 144, "Disease"], [28, 30, "Disease"], [64, 64, "Disease"], [66, 66, "Disease"]]], "relations": [[[6, 6, 2, 3, "CID"], [6, 6, 21, 22, "CID"], [6, 6, 57, 58, "CID"], [6, 6, 73, 74, "CID"], [6, 6, 89, 90, "CID"], [18, 18, 2, 3, "CID"], [18, 18, 21, 22, "CID"], [18, 18, 57, 58, "CID"], [18, 18, 73, 74, "CID"], [18, 18, 89, 90, "CID"], [45, 45, 2, 3, "CID"], [45, 45, 21, 22, "CID"], [45, 45, 57, 58, "CID"], [45, 45, 73, 74, "CID"], [45, 45, 89, 90, "CID"], [53, 53, 2, 3, "CID"], [53, 53, 21, 22, "CID"], [53, 53, 57, 58, "CID"], [53, 53, 73, 74, "CID"], [53, 53, 89, 90, "CID"], [77, 77, 2, 3, "CID"], [77, 77, 21, 22, "CID"], [77, 77, 57, 58, "CID"], [77, 77, 73, 74, "CID"], [77, 77, 89, 90, "CID"], [114, 114, 2, 3, "CID"], [114, 114, 21, 22, "CID"], [114, 114, 57, 58, "CID"], [114, 114, 73, 74, "CID"], [114, 114, 89, 90, "CID"], [147, 147, 2, 3, "CID"], [147, 147, 21, 22, "CID"], [147, 147, 57, 58, "CID"], [147, 147, 73, 74, "CID"], [147, 147, 89, 90, "CID"]]], "clusters": [], "translated": "<0>肾上腺素</0>引起的<7>心肌缺血</7>的机制：与运动引起的<13>缺血</13>的比较。在<17>冠状动脉疾病</17>患者中检查了<1>肾上腺素</1>在引发<8>心肌缺血</8>中的作用。比较<2>肾上腺素</2>输注和仰卧自行车运动期间<14>缺血</14>的客观体征和增加心肌<12>氧</12>消耗的因素。<3>肾上腺素</3>和运动都会产生<9>心肌缺血</9>，ST段<18>压低</18>和<19>心绞痛</19>就是证明。但<4>肾上腺素</4>引起<10>心肌缺血</10>的机制与运动有显着差异。运动引起的<11>心肌缺血</11>主要表现为心率和心率-压力乘积增加，舒张末期容积的贡献较小，而<5>肾上腺素</5>引起的<15>缺血</15>的特点是收缩力显着增加，心率和心率-压力乘积的增加不太明显。这些发现表明，<6>肾上腺素</6>产生的<16>局部缺血</16>（可能发生在情绪低落的状态下）具有不同于体力消耗的机制。", "revised": true}
{"doc_key": "871943", "sentences": [["The", "use", "of", "serum", "cholinesterase", "in", "succinylcholine", "apnoea", ".", "Fifteen", "patients", "demonstrating", "unexpected", "prolonged", "apnoea", "lasting", "several", "hours", "after", "succinylcholine", "have", "been", "treated", "by", "a", "new", "preparation", "of", "human", "serum", "cholinesterase", ".", "Adequate", "spontaneous", "respiration", "was", "re", "-", "established", "in", "an", "average", "period", "of", "ten", "minutes", "after", "the", "injection", ".", "In", "12", "patients", "biochemical", "genetic", "examinations", "confirmed", "the", "presence", "of", "an", "atypical", "serum", "cholinesterase", ".", "In", "three", "patients", "none", "of", "the", "usual", "variants", "were", "found", ".", "It", "is", "therefore", "supposed", "that", "other", "unknown", "variants", "of", "serum", "cholinesterase", "exist", "which", "can", "not", "hydrolyze", "succinylcholine", ".", "The", "use", "of", "serum", "cholinesterase", "in", "succinylcholine", "apnoea", "provided", "considerable", "relief", "to", "both", "patient", "and", "anaesthetist", "."]], "ner": [[[6, 6, "Chemical"], [19, 19, "Chemical"], [92, 92, "Chemical"], [100, 100, "Chemical"], [7, 7, "Disease"], [14, 14, "Disease"], [101, 101, "Disease"]]], "relations": [[[6, 6, 7, 7, "CID"], [6, 6, 14, 14, "CID"], [6, 6, 101, 101, "CID"], [19, 19, 7, 7, "CID"], [19, 19, 14, 14, "CID"], [19, 19, 101, 101, "CID"], [92, 92, 7, 7, "CID"], [92, 92, 14, 14, "CID"], [92, 92, 101, 101, "CID"], [100, 100, 7, 7, "CID"], [100, 100, 14, 14, "CID"], [100, 100, 101, 101, "CID"]]], "clusters": [], "translated": "血清胆碱酯酶在<0>琥珀酰胆碱</0><4>呼吸暂停</4>中的应用。15名患者在使用新的人血清胆碱酯酶制剂治疗<1>琥珀酰胆碱</1>后表现出意料之外的<5>呼吸暂停</5>持续数小时。注射后平均10分钟内可重新建立充分的自主呼吸。在12名患者中，生化基因检查证实存在非典型血清胆碱酯酶。在三名患者中，没有发现任何常见变异。因此，假设存在其他未知的血清胆碱酯酶变体，它们不能水解<2>琥珀酰胆碱</2>。在<3>琥珀酰胆碱</3><6>呼吸暂停</6>中使用血清胆碱酯酶为患者和麻醉师提供了相当大的缓解。", "revised": true}
{"doc_key": "921394", "sentences": [["Biphasic", "response", "of", "the", "SA", "node", "of", "the", "dog", "heart", "in", "vivo", "to", "selective", "administration", "of", "ketamine", ".", "Effect", "of", "ketamine", "on", "the", "SA", "node", "of", "the", "dog", "heart", "was", "studied", "in", "vivo", "using", "a", "selective", "perfusion", "technique", "of", "the", "SA", "node", "artery", ".", "Injections", "of", "ketamine", "in", "doses", "from", "100", "microgram", "to", "3", "mg", "into", "the", "artery", "produced", "a", "depression", "of", "the", "SA", "nodal", "activity", "by", "a", "direct", "action", ".", "This", "depression", "was", "followed", "by", "the", "sudden", "appearance", "of", "a", "stimulatory", "phase", ".", "Bilateral", "vagotomy", "and", "sympathectomy", "or", "prior", "administration", "of", "a", "ganglion", "blocker", "failed", "to", "inhibit", "the", "occurrence", "of", "the", "ketamine", "-", "induced", "tachycardia", ",", "while", "it", "was", "completely", "abolished", "in", "the", "reserpinized", "dogs", "or", "by", "a", "prior", "injection", "of", "a", "beta", "-", "blocking", "agent", "into", "the", "SA", "node", "artery", ".", "This", "may", "indicate", "that", "an", "activation", "of", "the", "peripheral", "adrenergic", "mechanism", "plays", "an", "important", "role", "in", "the", "induction", "of", "the", "excitatory", "effect", "of", "ketamine", "injected", "in", "the", "SA", "node", "artery", "."]], "ner": [[[16, 16, "Chemical"], [20, 20, "Chemical"], [46, 46, "Chemical"], [102, 102, "Chemical"], [156, 156, "Chemical"], [105, 105, "Disease"], [60, 60, "Disease"], [72, 72, "Disease"]]], "relations": [[[16, 16, 105, 105, "CID"], [20, 20, 105, 105, "CID"], [46, 46, 105, 105, "CID"], [102, 102, 105, 105, "CID"], [156, 156, 105, 105, "CID"]]], "clusters": [], "translated": "体内犬心脏窦房结对<0>氯胺酮</0>选择性给药的双相反应。利用窦房结动脉的选择性灌注技术，在体内研究了<1>氯胺酮</1>对狗心脏窦房结的影响。向动脉注射剂量为100微克至3毫克的<2>氯胺酮</2>通过直接作用产生<6>抑制</6>窦房结活动。这<7>抑制</7>之后是突然出现的刺激阶段。双侧迷走神经切断术和交感神经切除术或先前给予神经节阻滞剂未能抑制由<3>氯胺酮</3>诱发的<5>心动过速</5>的发生，而它在再血平的狗中完全消除或通过先前将β受体阻滞剂注射到窦房结动脉中。这可能表明外周肾上腺素能机制的激活在诱导窦房结动脉注射<4>氯胺酮</4>的兴奋作用中起重要作用。", "revised": true}
{"doc_key": "1732442", "sentences": [["Detection", "of", "abnormal", "cardiac", "adrenergic", "neuron", "activity", "in", "adriamycin", "-", "induced", "cardiomyopathy", "with", "iodine", "-", "125", "-", "metaiodobenzylguanidine", ".", "Radiolabeled", "metaiodobenzylguanidine", "(", "MIBG", ")", ",", "an", "analog", "of", "norepinephrine", "(", "NE", ")", ",", "serves", "as", "an", "index", "of", "adrenergic", "neuron", "integrity", "and", "function", ".", "Using", "a", "rat", "model", "of", "adriamycin", "-", "induced", "cardiomyopathy", ",", "we", "tested", "the", "hypothesis", "that", "abnormal", "cardiac", "adrenergic", "neuron", "activity", "may", "appear", "and", "be", "exacerbated", "dose", "-", "dependently", "in", "adriamycin", "cardiomyopathy", ".", "The", "degree", "of", "vacuolar", "degeneration", "of", "myocardial", "cells", "was", "analyzed", "in", "relation", "to", "the", "duration", "of", "adriamycin", "treatment", "(", "2", "mg", "/", "kg", ",", "once", "a", "week", ")", ".", "There", "were", "no", "abnormalities", "or", "only", "isolated", "degeneration", "in", "the", "1", "-", "or", "2", "-", "wk", "treatment", "groups", ",", "isolated", "or", "scattered", "degeneration", "in", "half", "of", "the", "3", "-", "wk", "group", ",", "frequent", "scattered", "degeneration", "in", "the", "4", "-", "wk", "group", ",", "scattered", "or", "focal", "degeneration", "in", "the", "5", "-", "wk", "group", ",", "and", "extensive", "degeneration", "in", "the", "8", "-", "wk", "group", ".", "Myocardial", "accumulation", "of", "[", "125I", "]", "MIBG", "4", "hr", "after", "intravenous", "injection", "did", "not", "differ", "between", "the", "controls", "and", "the", "groups", "treated", "3", "wk", "or", "less", ".", "However", ",", "the", "4", "-", "wk", "group", "had", "a", "slightly", "lower", "accumulation", "in", "the", "right", "ventricular", "wall", "(", "82", "%", "of", "the", "control", ")", "and", "significantly", "lower", "accumulation", "in", "the", "left", "ventricular", "wall", "(", "about", "66", "%", "of", "the", "control", ":", "p", "less", "than", "0", ".", "05", ")", ".", "In", "the", "5", "-", "wk", "group", ",", "MIBG", "accumulation", "in", "the", "right", "and", "left", "ventricular", "wall", "was", "35", "%", "and", "27", "%", "of", "that", "in", "controls", ",", "respectively", "(", "p", "less", "than", "0", ".", "001", ")", ".", "In", "the", "8", "-", "wk", "group", ",", "MIBG", "accumulation", "in", "the", "right", "and", "left", "ventricular", "wall", "was", "18", "%", "and", "14", "%", "of", "that", "in", "controls", ",", "respectively", "(", "p", "less", "than", "0", ".", "001", ")", ".", "Thus", ",", "MIBG", "accumulation", "in", "the", "myocardium", "decreased", "in", "an", "adriamycin", "dose", "-", "dependent", "manner", ".", "The", "appearance", "of", "impaired", "cardiac", "adrenergic", "neuron", "activity", "in", "the", "presence", "of", "slight", "myocardial", "impairment", "(", "scattered", "or", "focal", "vacuolar", "degeneration", ")", "indicates", "that", "MIBG", "scintigraphy", "may", "be", "a", "useful", "method", "for", "detection", "of", "adriamycin", "-", "induced", "cardiomyopathy", "."]], "ner": [[[8, 8, "Chemical"], [49, 49, "Chemical"], [73, 73, "Chemical"], [92, 92, "Chemical"], [328, 328, "Chemical"], [368, 368, "Chemical"], [11, 11, "Disease"], [52, 52, "Disease"], [74, 74, "Disease"], [347, 348, "Disease"], [371, 371, "Disease"], [79, 83, "Disease"], [353, 354, "Disease"], [13, 17, "Chemical"], [19, 20, "Chemical"], [22, 22, "Chemical"], [174, 174, "Chemical"], [251, 251, "Chemical"], [288, 288, "Chemical"], [320, 320, "Chemical"], [358, 358, "Chemical"], [28, 28, "Chemical"], [30, 30, "Chemical"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 52, 52, "CID"], [8, 8, 74, 74, "CID"], [8, 8, 347, 348, "CID"], [8, 8, 371, 371, "CID"], [49, 49, 11, 11, "CID"], [49, 49, 52, 52, "CID"], [49, 49, 74, 74, "CID"], [49, 49, 347, 348, "CID"], [49, 49, 371, 371, "CID"], [73, 73, 11, 11, "CID"], [73, 73, 52, 52, "CID"], [73, 73, 74, 74, "CID"], [73, 73, 347, 348, "CID"], [73, 73, 371, 371, "CID"], [92, 92, 11, 11, "CID"], [92, 92, 52, 52, "CID"], [92, 92, 74, 74, "CID"], [92, 92, 347, 348, "CID"], [92, 92, 371, 371, "CID"], [328, 328, 11, 11, "CID"], [328, 328, 52, 52, "CID"], [328, 328, 74, 74, "CID"], [328, 328, 347, 348, "CID"], [328, 328, 371, 371, "CID"], [368, 368, 11, 11, "CID"], [368, 368, 52, 52, "CID"], [368, 368, 74, 74, "CID"], [368, 368, 347, 348, "CID"], [368, 368, 371, 371, "CID"]]], "clusters": [], "translated": "用<13>碘-125-间碘苄基胍</13>检测<0>阿霉素</0>诱发的<6>心肌病</6>心脏肾上腺素能神经元活性异常。<14>放射性标记的间碘苯甲基胍</14> (<15>MIBG</15>)，是<21>去甲肾上腺素</21> (<22>NE</22>) 的类似物，可作为肾上腺素能神经元完整性的指标和功能。使用<1>阿霉素</1>诱导的<7>心肌病</7>大鼠模型，我们检验了异常心脏肾上腺素能神经元活动可能出现并加剧的假设- <2>阿霉素</2><8>心肌病</8>。分析<11>心肌细胞空泡变性</11>的程度与<3>阿霉素</3>治疗（2 mg/kg，每周一次）持续时间的关系。1或2周治疗组无异常或仅有孤立性变性，3周组一半孤立或散在变性，4周组频繁散在变性，5周组散在或局灶性变性，8周组广泛退化。静脉注射后4小时[125I]<16>MIBG</16>的心肌蓄积在对照组和治疗3周或更短时间的组之间没有差异。然而，4周组在右心室壁的蓄积略低（对照组的82%），在左心室壁的蓄积显着较低（大约66%的对照组：p小于0.05）。在5周组中，<17>MIBG</17>在右心室壁和左心室壁的积累分别是对照组的35%和27% (p小于0.001)。在8周组中，<18>MIBG</18>在右心室壁和左心室壁的积累分别是对照组的18%和14%(p小于0.001)。因此，<19>MIBG</19>在心肌中的积累以<4>阿霉素</4>剂量依赖性方式减少。在存在轻微<9>心肌损伤</9>（散在或局灶性<12>空泡变性</12>）的情况下出现心脏肾上腺素能神经元活动受损表明<20>MIBG</20>闪烁显像可能是一种检测<5>阿霉素</5>诱发的<10>心肌病</10>的有用方法。", "revised": true}
{"doc_key": "8638876", "sentences": [["Coexistence", "of", "cerebral", "venous", "sinus", "and", "internal", "carotid", "artery", "thrombosis", "associated", "with", "exogenous", "sex", "hormones", ".", "A", "case", "report", ".", "A", "forty", "-", "six", "year", "-", "old", "premenopausal", "woman", "developed", "headache", ",", "nausea", "and", "vomiting", ",", "left", "hemiparesis", "and", "seizure", "two", "days", "after", "parenteral", "use", "of", "progesterone", "and", "estradiol", ".", "Diabetes", "mellitus", "(", "DM", ")", "was", "found", "during", "admission", ".", "Computed", "tomography", "showed", "a", "hemorrhagic", "infarct", "in", "the", "right", "frontal", "lobe", "and", "increased", "density", "in", "the", "superior", "sagittal", "sinus", "(", "SSS", ")", ".", "Left", "carotid", "angiography", "found", "occlusion", "of", "the", "left", "internal", "carotid", "artery", "(", "ICA", ")", ".", "Right", "carotid", "angiograms", "failed", "to", "show", "the", "SSS", "and", "inferior", "sagittal", "sinus", ",", "suggestive", "of", "venous", "sinus", "thrombosis", ".", "Coexistence", "of", "the", "cerebral", "artery", "and", "the", "venous", "sinus", "occlusion", "has", "been", "described", "infrequently", ".", "In", "this", "case", ",", "the", "authors", "postulate", "that", "the", "use", "of", "estradiol", "and", "progesterone", "and", "the", "underlying", "DM", "increased", "vascular", "thrombogenicity", ",", "which", "provided", "a", "common", "denominator", "for", "thrombosis", "of", "both", "the", "ICA", "and", "the", "venous", "sinus", "."]], "ner": [[[46, 46, "Chemical"], [145, 145, "Chemical"], [2, 9, "Disease"], [113, 115, "Disease"], [160, 168, "Disease"], [48, 48, "Chemical"], [143, 143, "Chemical"], [64, 65, "Disease"], [120, 126, "Disease"], [30, 30, "Disease"], [32, 32, "Disease"], [34, 34, "Disease"], [37, 37, "Disease"], [39, 39, "Disease"], [50, 51, "Disease"], [53, 53, "Disease"], [149, 149, "Disease"], [87, 93, "Disease"]]], "relations": [[[46, 46, 2, 9, "CID"], [46, 46, 113, 115, "CID"], [46, 46, 160, 168, "CID"], [145, 145, 2, 9, "CID"], [145, 145, 113, 115, "CID"], [145, 145, 160, 168, "CID"], [48, 48, 2, 9, "CID"], [48, 48, 113, 115, "CID"], [48, 48, 160, 168, "CID"], [143, 143, 2, 9, "CID"], [143, 143, 113, 115, "CID"], [143, 143, 160, 168, "CID"], [46, 46, 64, 65, "CID"], [145, 145, 64, 65, "CID"], [46, 46, 120, 126, "CID"], [145, 145, 120, 126, "CID"], [48, 48, 64, 65, "CID"], [143, 143, 64, 65, "CID"], [48, 48, 120, 126, "CID"], [143, 143, 120, 126, "CID"]]], "clusters": [], "translated": "<2>脑静脉窦和颈内动脉血栓的并存</2>与外源性激素有关。个案报告。一位四十六岁的绝经前妇女出现<9>头痛</9>、<10>恶心</10>和<11>呕吐</11>、左侧<12>偏瘫</12>和<13>癫痫发作</13>两天后胃肠外使用<0>黄体酮</0>和<5>雌二醇</5>。入院时发现<14>糖尿病</14>（<15>DM</15>）。计算机断层扫描显示右侧额叶<7>出血性梗死</7>和位于上矢状窦（SSS）的密度增加。左侧颈动脉造影发现左侧内颈动脉<17>阻塞</17>（ICA）。右侧颈动脉造影未显示SSS和下矢状窦，提示<3>静脉窦血栓</3>的形成。很少描述了<8>脑动脉和静脉窦梗死</8>的共存。在这种情况下，作者假设使用<6>雌二醇</6>和<1>黄体酮</1>及潜在<16>DM</16>增加了血管的血栓形成，支持了<4>ICA和静脉窦的血栓形成</4>。", "revised": true}
{"doc_key": "1628552", "sentences": [["Chloroquine", "related", "complete", "heart", "block", "with", "blindness", ":", "case", "report", ".", "A", "27", "-", "year", "old", "African", "woman", "with", "history", "of", "regular", "chloroquine", "ingestion", "presented", "with", "progressive", "deterioration", "of", "vision", ",", "easy", "fatiguability", ",", "dyspnoea", ",", "dizziness", "progressing", "to", "syncopal", "attacks", ".", "Ophthalmological", "assessment", "revealed", "features", "of", "chloroquine", "retinopathy", ",", "cardiac", "assessment", "revealed", "features", "of", "heart", "failure", "and", "a", "complete", "heart", "block", "with", "right", "bundle", "branch", "block", "pattern", ".", "The", "heart", "block", "was", "treated", "by", "pacemaker", "insertion", "and", "the", "heart", "failure", "resolved", "spontaneously", "following", "chloroquine", "discontinuation", ".", "She", "however", "remains", "blind", "."]], "ner": [[[0, 0, "Chemical"], [22, 22, "Chemical"], [47, 47, "Chemical"], [84, 84, "Chemical"], [6, 6, "Disease"], [90, 90, "Disease"], [32, 32, "Disease"], [34, 34, "Disease"], [36, 36, "Disease"], [39, 40, "Disease"], [48, 48, "Disease"], [55, 56, "Disease"], [79, 80, "Disease"], [63, 66, "Disease"], [3, 4, "Disease"], [60, 61, "Disease"], [70, 71, "Disease"], [27, 29, "Disease"]]], "relations": [[[0, 0, 6, 6, "CID"], [0, 0, 90, 90, "CID"], [22, 22, 6, 6, "CID"], [22, 22, 90, 90, "CID"], [47, 47, 6, 6, "CID"], [47, 47, 90, 90, "CID"], [84, 84, 6, 6, "CID"], [84, 84, 90, 90, "CID"], [0, 0, 32, 32, "CID"], [22, 22, 32, 32, "CID"], [47, 47, 32, 32, "CID"], [84, 84, 32, 32, "CID"], [0, 0, 34, 34, "CID"], [22, 22, 34, 34, "CID"], [47, 47, 34, 34, "CID"], [84, 84, 34, 34, "CID"], [0, 0, 36, 36, "CID"], [22, 22, 36, 36, "CID"], [47, 47, 36, 36, "CID"], [84, 84, 36, 36, "CID"], [0, 0, 39, 40, "CID"], [22, 22, 39, 40, "CID"], [47, 47, 39, 40, "CID"], [84, 84, 39, 40, "CID"], [0, 0, 48, 48, "CID"], [22, 22, 48, 48, "CID"], [47, 47, 48, 48, "CID"], [84, 84, 48, 48, "CID"], [0, 0, 55, 56, "CID"], [0, 0, 79, 80, "CID"], [22, 22, 55, 56, "CID"], [22, 22, 79, 80, "CID"], [47, 47, 55, 56, "CID"], [47, 47, 79, 80, "CID"], [84, 84, 55, 56, "CID"], [84, 84, 79, 80, "CID"], [0, 0, 63, 66, "CID"], [22, 22, 63, 66, "CID"], [47, 47, 63, 66, "CID"], [84, 84, 63, 66, "CID"]]], "clusters": [], "translated": " <0>氯喹</0>相关的完全性<14>心脏传导阻滞</14>伴有<4>失明</4>：病例报告。一名27岁的非洲女性，有定期<1>氯喹</1>摄入史，表现为进行性<17>视力下降</17>、容易<6>疲劳</6>、<7>呼吸困难</7>、<8>头晕</8>进展为<9>晕厥</9>。眼科评估显示<2>氯喹</2><10>视网膜病变</10>的特征，心脏评估显示<11>心力衰竭</11>和完全<15>心脏传导阻滞</15>的特征，<13>右束支传导阻滞</13>模式。 <16>心脏传导阻滞</16>通过起搏器植入治疗，<3>氯喹</3>停用后<12>心力衰竭</12>自发消退。然而，她仍然<5>失明</5>。", "revised": true}
{"doc_key": "11868798", "sentences": [["Spironolactone", ":", "is", "it", "a", "novel", "drug", "for", "the", "prevention", "of", "amphotericin", "B", "-", "related", "hypokalemia", "in", "cancer", "patients", "?", "OBJECTIVE", ":", "Nephrotoxicity", "is", "the", "major", "adverse", "effect", "of", "amphotericin", "B", "(", "AmB", ")", ",", "often", "limiting", "administration", "of", "full", "dosage", ".", "Selective", "distal", "tubular", "epithelial", "toxicity", "seems", "to", "be", "responsible", "for", "the", "profound", "potassium", "wasting", "that", "is", "a", "major", "clinical", "side", "effect", "of", "treatment", "with", "AmB", ".", "Potassium", "depletion", "also", "potentiates", "the", "tubular", "toxicity", "of", "AmB", ".", "This", "study", "was", "designed", "to", "assess", "the", "ability", "of", "spironolactone", "to", "reduce", "potassium", "requirements", "and", "to", "prevent", "hypokalemia", "in", "neutropenic", "patients", "on", "AmB", "treatment", ".", "METHODS", ":", "In", "this", "study", "26", "patients", "with", "various", "hematological", "disorders", "were", "randomized", "to", "receive", "either", "intravenous", "AmB", "alone", "or", "AmB", "and", "oral", "spironolactone", "100", "mg", "twice", "daily", "when", "developing", "a", "proven", "or", "suspected", "fungal", "infection", ".", "RESULTS", ":", "Patients", "receiving", "concomitant", "AmB", "and", "spironolactone", "had", "significantly", "higher", "plasma", "potassium", "levels", "than", "those", "receiving", "AmB", "alone", "(", "P", "=", "0", ".", "0027", ")", ".", "Those", "patients", "receiving", "AmB", "and", "spironolactone", "required", "significantly", "less", "potassium", "supplementation", "to", "maintain", "their", "plasma", "potassium", "within", "the", "normal", "range", "(", "P", "=", "0", ".", "022", ")", ".", "Moreover", ",", "urinary", "potassium", "losses", "were", "significantly", "less", "in", "patients", "receiving", "AmB", "and", "spironolactone", "than", "those", "receiving", "AmB", "alone", "(", "P", "=", "0", ".", "040", ")", ".", "CONCLUSION", ":", "This", "study", "showed", "that", "spironolactone", "can", "reduce", "potassium", "requirements", "and", "prevent", "hypokalemia", "by", "reducing", "urinary", "potassium", "loss", "in", "neutropenic", "patients", "on", "AmB", "treatment", "."]], "ner": [[[11, 12, "Chemical"], [29, 30, "Chemical"], [32, 32, "Chemical"], [66, 66, "Chemical"], [76, 76, "Chemical"], [100, 100, "Chemical"], [120, 120, "Chemical"], [123, 123, "Chemical"], [145, 145, "Chemical"], [157, 157, "Chemical"], [170, 170, "Chemical"], [206, 206, "Chemical"], [212, 212, "Chemical"], [245, 245, "Chemical"], [15, 15, "Disease"], [95, 95, "Disease"], [235, 235, "Disease"], [0, 0, "Chemical"], [87, 87, "Chemical"], [126, 126, "Chemical"], [147, 147, "Chemical"], [172, 172, "Chemical"], [208, 208, "Chemical"], [228, 228, "Chemical"], [17, 17, "Disease"], [22, 22, "Disease"], [46, 46, "Disease"], [74, 74, "Disease"], [97, 97, "Disease"], [242, 242, "Disease"], [112, 113, "Disease"], [137, 138, "Disease"], [54, 54, "Chemical"], [68, 68, "Chemical"], [90, 90, "Chemical"], [152, 152, "Chemical"], [176, 176, "Chemical"], [182, 182, "Chemical"], [198, 198, "Chemical"], [231, 231, "Chemical"], [239, 239, "Chemical"]]], "relations": [[[11, 12, 15, 15, "CID"], [11, 12, 95, 95, "CID"], [11, 12, 235, 235, "CID"], [29, 30, 15, 15, "CID"], [29, 30, 95, 95, "CID"], [29, 30, 235, 235, "CID"], [32, 32, 15, 15, "CID"], [32, 32, 95, 95, "CID"], [32, 32, 235, 235, "CID"], [66, 66, 15, 15, "CID"], [66, 66, 95, 95, "CID"], [66, 66, 235, 235, "CID"], [76, 76, 15, 15, "CID"], [76, 76, 95, 95, "CID"], [76, 76, 235, 235, "CID"], [100, 100, 15, 15, "CID"], [100, 100, 95, 95, "CID"], [100, 100, 235, 235, "CID"], [120, 120, 15, 15, "CID"], [120, 120, 95, 95, "CID"], [120, 120, 235, 235, "CID"], [123, 123, 15, 15, "CID"], [123, 123, 95, 95, "CID"], [123, 123, 235, 235, "CID"], [145, 145, 15, 15, "CID"], [145, 145, 95, 95, "CID"], [145, 145, 235, 235, "CID"], [157, 157, 15, 15, "CID"], [157, 157, 95, 95, "CID"], [157, 157, 235, 235, "CID"], [170, 170, 15, 15, "CID"], [170, 170, 95, 95, "CID"], [170, 170, 235, 235, "CID"], [206, 206, 15, 15, "CID"], [206, 206, 95, 95, "CID"], [206, 206, 235, 235, "CID"], [212, 212, 15, 15, "CID"], [212, 212, 95, 95, "CID"], [212, 212, 235, 235, "CID"], [245, 245, 15, 15, "CID"], [245, 245, 95, 95, "CID"], [245, 245, 235, 235, "CID"]]], "clusters": [], "translated": " <17>螺内酯</17>：它是预防<24>癌症</24>患者<0>两性霉素B</0><14>相关低钾血症</14>的新药吗？目的：<25>肾毒性</25>是<1>两性霉素B</1>（<2>AmB</2>）的主要不良反应，常限制全剂量给药。选择性远端肾小管上皮细胞<26>毒性</26>似乎是严重<32>钾</32>消耗的原因，这是<3>AmB</3>治疗的主要临床副作用。<33>钾</33>耗竭并增强了<4>AmB</4>的肾小管<27>毒性</27>。本研究旨在评估<18>螺内酯</18>降低<34>钾</34>需求和预防<28>中性粒细胞减少症</28>患者<15>低钾血症</15>的能力<5>两性霉素B</5>处理。方法：在这项研究中，26名患有各种<30>血液病</30>的患者被随机分配接受单独静脉注射<6>AmB</6>或<7>AmB</7>和口服<19>螺内酯</19>100mg每日两次，当发生已证实或疑似<31>真菌感染</31>时。结果：同时接受<8>AmB</8>和<20>螺内酯</20>治疗的患者血浆<35>钾</35>水平显着高于单独接受<9>AmB</9>治疗的患者（P=0.0027）。接受<10>AmB</10>和<21>螺内酯</21>治疗的患者需要显着减少<36>钾</36>补充剂以维持血浆<37>钾</37>在正常范围内（P=0.022）。此外，与单独接受<12>AmB</12>的患者相比，接受<11>AmB</11>和<22>螺内酯</22>的患者的尿<38>钾</38>损失显着减少（P=0.040）。结论：本研究表明，<23>螺内酯</23>可降低<39>钾</39>需求并通过减少尿<40>钾</40>损失来预防<16>低钾血症</16>，保护<29>中性粒细胞减少症</29>患者接受<13>AmB</13>治疗。", "revised": true}
{"doc_key": "6695415", "sentences": [["Cerebral", "hemorrhage", "associated", "with", "phenylpropanolamine", "in", "combination", "with", "caffeine", ".", "Phenylpropanolamine", "(", "PPA", ")", "is", "a", "drug", "that", "has", "been", "associated", "with", "serious", "side", "effects", "including", "stroke", ".", "It", "is", "often", "combined", "with", "caffeine", "in", "diet", "preparations", "and", "\"", "look", "-", "alike", "\"", "pills", ".", "In", "order", "to", "determine", "if", "PPA", "/", "caffeine", "can", "lead", "to", "stroke", "in", "normotensive", "and", "/", "or", "hypertensive", "rats", ",", "we", "administered", "the", "combination", "in", "six", "times", "the", "allowed", "human", "dose", "calculated", "on", "a", "per", "weight", "basis", "for", "the", "rats", "two", "times", "per", "day", "for", "five", "days", ".", "Subarachnoid", "and", "cerebral", "hemorrhage", "was", "noted", "in", "18", "%", "of", "the", "hypertensive", "rats", ".", "A", "single", "PPA", "/", "caffeine", "administration", "(", "same", "dose", ")", "lead", "to", "acute", "hypertension", "in", "both", "the", "normotensive", "and", "hypertensive", "animals", ".", "These", "results", "suggest", "that", "PPA", "/", "caffeine", "can", "lead", "to", "cerebral", "hemorrhage", "in", "previously", "hypertensive", "animals", "when", "administered", "in", "greater", "than", "the", "allowed", "dosage", ".", "An", "acute", "elevation", "in", "blood", "pressure", "may", "be", "a", "contributing", "factor", "."]], "ner": [[[4, 4, "Chemical"], [10, 10, "Chemical"], [12, 12, "Chemical"], [50, 50, "Chemical"], [109, 109, "Chemical"], [133, 133, "Chemical"], [0, 1, "Disease"], [93, 96, "Disease"], [139, 140, "Disease"], [8, 8, "Chemical"], [33, 33, "Chemical"], [52, 52, "Chemical"], [111, 111, "Chemical"], [135, 135, "Chemical"], [26, 26, "Disease"], [56, 56, "Disease"], [62, 62, "Disease"], [104, 104, "Disease"], [120, 120, "Disease"], [126, 126, "Disease"], [143, 143, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 93, 96, "CID"], [4, 4, 139, 140, "CID"], [10, 10, 0, 1, "CID"], [10, 10, 93, 96, "CID"], [10, 10, 139, 140, "CID"], [12, 12, 0, 1, "CID"], [12, 12, 93, 96, "CID"], [12, 12, 139, 140, "CID"], [50, 50, 0, 1, "CID"], [50, 50, 93, 96, "CID"], [50, 50, 139, 140, "CID"], [109, 109, 0, 1, "CID"], [109, 109, 93, 96, "CID"], [109, 109, 139, 140, "CID"], [133, 133, 0, 1, "CID"], [133, 133, 93, 96, "CID"], [133, 133, 139, 140, "CID"], [8, 8, 0, 1, "CID"], [8, 8, 93, 96, "CID"], [8, 8, 139, 140, "CID"], [33, 33, 0, 1, "CID"], [33, 33, 93, 96, "CID"], [33, 33, 139, 140, "CID"], [52, 52, 0, 1, "CID"], [52, 52, 93, 96, "CID"], [52, 52, 139, 140, "CID"], [111, 111, 0, 1, "CID"], [111, 111, 93, 96, "CID"], [111, 111, 139, 140, "CID"], [135, 135, 0, 1, "CID"], [135, 135, 93, 96, "CID"], [135, 135, 139, 140, "CID"], [4, 4, 26, 26, "CID"], [4, 4, 56, 56, "CID"], [10, 10, 26, 26, "CID"], [10, 10, 56, 56, "CID"], [12, 12, 26, 26, "CID"], [12, 12, 56, 56, "CID"], [50, 50, 26, 26, "CID"], [50, 50, 56, 56, "CID"], [109, 109, 26, 26, "CID"], [109, 109, 56, 56, "CID"], [133, 133, 26, 26, "CID"], [133, 133, 56, 56, "CID"], [4, 4, 62, 62, "CID"], [4, 4, 104, 104, "CID"], [4, 4, 120, 120, "CID"], [4, 4, 126, 126, "CID"], [4, 4, 143, 143, "CID"], [10, 10, 62, 62, "CID"], [10, 10, 104, 104, "CID"], [10, 10, 120, 120, "CID"], [10, 10, 126, 126, "CID"], [10, 10, 143, 143, "CID"], [12, 12, 62, 62, "CID"], [12, 12, 104, 104, "CID"], [12, 12, 120, 120, "CID"], [12, 12, 126, 126, "CID"], [12, 12, 143, 143, "CID"], [50, 50, 62, 62, "CID"], [50, 50, 104, 104, "CID"], [50, 50, 120, 120, "CID"], [50, 50, 126, 126, "CID"], [50, 50, 143, 143, "CID"], [109, 109, 62, 62, "CID"], [109, 109, 104, 104, "CID"], [109, 109, 120, 120, "CID"], [109, 109, 126, 126, "CID"], [109, 109, 143, 143, "CID"], [133, 133, 62, 62, "CID"], [133, 133, 104, 104, "CID"], [133, 133, 120, 120, "CID"], [133, 133, 126, 126, "CID"], [133, 133, 143, 143, "CID"], [8, 8, 62, 62, "CID"], [8, 8, 104, 104, "CID"], [8, 8, 120, 120, "CID"], [8, 8, 126, 126, "CID"], [8, 8, 143, 143, "CID"], [33, 33, 62, 62, "CID"], [33, 33, 104, 104, "CID"], [33, 33, 120, 120, "CID"], [33, 33, 126, 126, "CID"], [33, 33, 143, 143, "CID"], [52, 52, 62, 62, "CID"], [52, 52, 104, 104, "CID"], [52, 52, 120, 120, "CID"], [52, 52, 126, 126, "CID"], [52, 52, 143, 143, "CID"], [111, 111, 62, 62, "CID"], [111, 111, 104, 104, "CID"], [111, 111, 120, 120, "CID"], [111, 111, 126, 126, "CID"], [111, 111, 143, 143, "CID"], [135, 135, 62, 62, "CID"], [135, 135, 104, 104, "CID"], [135, 135, 120, 120, "CID"], [135, 135, 126, 126, "CID"], [135, 135, 143, 143, "CID"]]], "clusters": [], "translated": "<6>脑出血</6>与<0>苯丙醇胺</0>在联合使用<9>咖啡因</9>时有关。<1>苯丙醇胺</1>(<2> PPA </2>)是一种与<14>中风</14>等严重副作用有关的药物。它通常与<10>咖啡因</10>一起用于饮食准备和“外观相似”的药丸中。为了确定<3> PPA </3>/<11>咖啡因</11>是否会导致正常血压和/或<16>高血压</16>大鼠的<15>中风</15>，我们给予该组合以大鼠每只体重计算的人类允许剂量的六倍，每天两次，持续五天。<7>蛛网膜下出血和脑出血</7>在18%的<17>高血压</17>大鼠中被发现。单次<4>PPA</4>/<12>咖啡因</12>给药(相同剂量)导致<19>高血压</19>和正常血压动物的急性<18>高血压</18>。这些结果表明，当以大于允许的剂量时，<5>PPA</5>/<13>咖啡因</13>可能会导致之前已有<20>高血压</20>的动物出现<8>脑出血</8>。血压急剧升高可能是一个促成因素。", "revised": true}
{"doc_key": "6216862", "sentences": [["Multiple", "side", "effects", "of", "penicillamine", "therapy", "in", "one", "patient", "with", "rheumatoid", "arthritis", ".", "Skin", "rashes", ",", "proteinuria", ",", "systemic", "lupus", "erythematosus", ",", "polymyositis", "and", "myasthenia", "gravis", "have", "all", "been", "recorded", "as", "complications", "of", "penicillamine", "therapy", "in", "patients", "with", "rheumatoid", "arthritis", ".", "A", "patient", "who", "had", "developed", "all", "5", "is", "now", "described", ".", "The", "skin", "lesion", "resembled", "elastosis", "perforans", "serpiginosa", ",", "which", "has", "been", "reported", "as", "a", "rare", "side", "effect", "in", "patients", "with", "Wilson", "'s", "disease", "but", "not", "in", "patients", "with", "rheumatoid", "arthritis", "treated", "with", "penicillamine", "."]], "ner": [[[4, 4, "Chemical"], [33, 33, "Chemical"], [84, 84, "Chemical"], [13, 14, "Disease"], [16, 16, "Disease"], [18, 20, "Disease"], [22, 22, "Disease"], [24, 25, "Disease"], [10, 11, "Disease"], [38, 39, "Disease"], [80, 81, "Disease"], [53, 54, "Disease"], [56, 58, "Disease"], [72, 74, "Disease"]]], "relations": [[[4, 4, 13, 14, "CID"], [33, 33, 13, 14, "CID"], [84, 84, 13, 14, "CID"], [4, 4, 16, 16, "CID"], [33, 33, 16, 16, "CID"], [84, 84, 16, 16, "CID"], [4, 4, 18, 20, "CID"], [33, 33, 18, 20, "CID"], [84, 84, 18, 20, "CID"], [4, 4, 22, 22, "CID"], [33, 33, 22, 22, "CID"], [84, 84, 22, 22, "CID"], [4, 4, 24, 25, "CID"], [33, 33, 24, 25, "CID"], [84, 84, 24, 25, "CID"]]], "clusters": [], "translated": "<0>青霉胺</0>治疗一例<8>类风湿性关节炎</8>患者的多种副作用。 <3>皮疹</3>、<4>蛋白尿</4>、<5>系统性红斑狼疮</5>、<6>多发性肌炎</6>和<7>重症肌无力</7>都有被记录为 <1>青霉胺</1>治疗<9>类风湿性关节炎</9>患者的并发症。现在描述一名患有所有 5 种疾病的患者。<11>皮肤损伤</11>类似于<12>elastosis perforans serpiginosa</12>，据报道，这在<13>Wilson病</13>患者中是一种罕见的副作用，但在治疗<10>类风湿性关节炎</10>的患者中使用<2>青霉胺</2>时尚未报道。", "revised": true}
{"doc_key": "8643966", "sentences": [["Chemotherapy", "of", "advanced", "inoperable", "non", "-", "small", "cell", "lung", "cancer", "with", "paclitaxel", ":", "a", "phase", "II", "trial", ".", "Paclitaxel", "(", "Taxol", ";", "Bristol", "-", "Myers", "Squibb", "Company", ",", "Princeton", ",", "NJ", ")", "has", "demonstrated", "significant", "antineoplastic", "activity", "against", "different", "tumor", "types", ",", "notably", "ovarian", "and", "breast", "carcinoma", ".", "Two", "phase", "II", "trials", "of", "24", "-", "hour", "paclitaxel", "infusions", "in", "chemotherapy", "-", "naive", "patients", "with", "stage", "IIIB", "or", "IV", "non", "-", "small", "cell", "lung", "cancer", "(", "NSCLC", ")", "reported", "response", "rates", "of", "21", "%", "and", "24", "%", ".", "Leukopenia", "was", "dose", "limiting", ":", "as", "many", "as", "62", ".", "5", "%", "of", "patients", "experienced", "grade", "4", "leukopenia", ".", "We", "investigated", "the", "efficacy", "and", "toxicity", "of", "a", "3", "-", "hour", "paclitaxel", "infusion", "in", "a", "phase", "II", "trial", "in", "patients", "with", "inoperable", "stage", "IIIB", "or", "IV", "NSCLC", ".", "The", "58", "patients", "treated", "(", "41", "men", "and", "17", "women", ")", "had", "a", "median", "age", "of", "59", "years", "(", "age", "range", ",", "25", "to", "75", ")", "and", "a", "performance", "status", "of", "0", "through", "2", ".", "Most", "patients", "(", "72", ".", "4", "%", ")", "had", "stage", "IV", "NSCLC", ".", "Paclitaxel", "225", "mg", "/", "m2", "was", "infused", "over", "3", "hours", "every", "3", "weeks", "with", "standard", "prophylactic", "premedication", ".", "Of", "50", "patients", "evaluable", "for", "response", ",", "12", "(", "24", "%", ")", "had", "partial", "remission", ",", "26", "(", "52", "%", ")", "had", "no", "change", ",", "and", "12", "had", "disease", "progression", "(", "24", "%", ")", ".", "Hematologic", "toxicities", "were", "mild", ":", "only", "one", "patient", "(", "2", "%", ")", "developed", "grade", "3", "or", "4", "neutropenia", ",", "while", "29", "%", "had", "grade", "1", "or", "2", ".", "Grade", "1", "or", "2", "polyneuropathy", "affected", "56", "%", "of", "patients", "while", "only", "one", "(", "2", "%", ")", "experienced", "severe", "polyneuropathy", ".", "Similarly", ",", "grade", "1", "or", "2", "myalgia", "/", "arthralgia", "was", "observed", "in", "63", ".", "2", "%", "of", "patients", ",", "but", "only", "14", ".", "3", "%", "experienced", "grade", "3", "or", "4", ".", "Nausea", "and", "vomiting", "were", "infrequent", ",", "with", "14", "%", "of", "patients", "experiencing", "grade", "1", "or", "2", "and", "only", "2", "%", "experiencing", "grade", "3", "or", "4", ".", "Paclitaxel", "is", "thus", "an", "active", "single", "agent", "in", "this", "patient", "population", ",", "with", "a", "3", "-", "hour", "infusion", "proving", "comparably", "effective", "to", "a", "24", "-", "hour", "infusion", "and", "superior", "in", "terms", "of", "the", "incidence", "of", "hematologic", "and", "nonhematologic", "toxicity", ".", "Further", "phase", "II", "studies", "with", "paclitaxel", "combined", "with", "other", "drugs", "active", "against", "NSCLC", "are", "indicated", ",", "and", "phase", "III", "studies", "comparing", "paclitaxel", "with", "standard", "chemotherapy", "remain", "to", "be", "completed", "."]], "ner": [[[11, 11, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [56, 56, "Chemical"], [117, 117, "Chemical"], [182, 182, "Chemical"], [341, 341, "Chemical"], [386, 386, "Chemical"], [402, 402, "Chemical"], [252, 252, "Disease"], [267, 267, "Disease"], [282, 282, "Disease"], [290, 290, "Disease"], [292, 292, "Disease"], [315, 315, "Disease"], [317, 317, "Disease"], [4, 9, "Disease"], [68, 73, "Disease"], [75, 75, "Disease"], [132, 132, "Disease"], [180, 180, "Disease"], [393, 393, "Disease"], [39, 39, "Disease"], [43, 46, "Disease"], [87, 87, "Disease"], [104, 104, "Disease"], [111, 111, "Disease"], [236, 236, "Disease"], [379, 379, "Disease"]]], "relations": [[[11, 11, 252, 252, "CID"], [18, 18, 252, 252, "CID"], [20, 20, 252, 252, "CID"], [56, 56, 252, 252, "CID"], [117, 117, 252, 252, "CID"], [182, 182, 252, 252, "CID"], [341, 341, 252, 252, "CID"], [386, 386, 252, 252, "CID"], [402, 402, 252, 252, "CID"], [11, 11, 267, 267, "CID"], [11, 11, 282, 282, "CID"], [18, 18, 267, 267, "CID"], [18, 18, 282, 282, "CID"], [20, 20, 267, 267, "CID"], [20, 20, 282, 282, "CID"], [56, 56, 267, 267, "CID"], [56, 56, 282, 282, "CID"], [117, 117, 267, 267, "CID"], [117, 117, 282, 282, "CID"], [182, 182, 267, 267, "CID"], [182, 182, 282, 282, "CID"], [341, 341, 267, 267, "CID"], [341, 341, 282, 282, "CID"], [386, 386, 267, 267, "CID"], [386, 386, 282, 282, "CID"], [402, 402, 267, 267, "CID"], [402, 402, 282, 282, "CID"], [11, 11, 290, 290, "CID"], [18, 18, 290, 290, "CID"], [20, 20, 290, 290, "CID"], [56, 56, 290, 290, "CID"], [117, 117, 290, 290, "CID"], [182, 182, 290, 290, "CID"], [341, 341, 290, 290, "CID"], [386, 386, 290, 290, "CID"], [402, 402, 290, 290, "CID"], [11, 11, 292, 292, "CID"], [18, 18, 292, 292, "CID"], [20, 20, 292, 292, "CID"], [56, 56, 292, 292, "CID"], [117, 117, 292, 292, "CID"], [182, 182, 292, 292, "CID"], [341, 341, 292, 292, "CID"], [386, 386, 292, 292, "CID"], [402, 402, 292, 292, "CID"], [11, 11, 315, 315, "CID"], [18, 18, 315, 315, "CID"], [20, 20, 315, 315, "CID"], [56, 56, 315, 315, "CID"], [117, 117, 315, 315, "CID"], [182, 182, 315, 315, "CID"], [341, 341, 315, 315, "CID"], [386, 386, 315, 315, "CID"], [402, 402, 315, 315, "CID"], [11, 11, 317, 317, "CID"], [18, 18, 317, 317, "CID"], [20, 20, 317, 317, "CID"], [56, 56, 317, 317, "CID"], [117, 117, 317, 317, "CID"], [182, 182, 317, 317, "CID"], [341, 341, 317, 317, "CID"], [386, 386, 317, 317, "CID"], [402, 402, 317, 317, "CID"]]], "clusters": [], "translated": "无法手术的晚期<16>非小细胞肺癌</16>化疗<0>紫杉醇</0>：II期试验。 <1>紫杉醇</1>（<2>Taxol</2>；Bristol-Myers Squibb Company，Princeton，NJ）已证明对不同的<22>肿瘤</22>类型具有显着的抗肿瘤活性，特别是<23>卵巢和乳腺癌</23>。 两项24小时<3>紫杉醇</3>输注化疗的II期试验，针对初治IIIB期或IV期<17>非小细胞肺癌</17>（<18>NSCLC</18>）报道了21%和24%的响应率。<24>白细胞减少</24>是剂量限制性的：多达62.5%的患者出现4级<25>白细胞减少症</25>。我们在无法手术的IIIB期或IV期<19>NSCLC</19>患者的II期试验中研究了3小时<4>紫杉醇</4>输注的疗效和<26>毒性</26>。接受治疗的58名患者（41名男性和17名女性）的中位年龄为59岁（年龄范围为25至75岁），体能状态为0至2.大多数患者(72.4%)患有IV期<20>NSCLC</20>。<5>紫杉醇</5>225 mg/m2每3周输注超过3小时，并进行标准的预防性术前给药。在可评估反应的50名患者中，12名(24%)部分缓解，26名(52%)无变化，12名疾病进展(24%)。血液学<27>毒性</27>是轻微的：只有一名患者(2%)出现3级或4级<9>中性粒细胞减少症</9>，而29%的患者为1级或2级。1级或2级<10>多发性神经病</10>影响了56%的患者，而只有一名(2%)经历了严重的<11>多发性神经病</11>。同样，在63名患者中观察到1级或2级<12>肌痛</12>/<13>关节痛</13>，2%的病人，却只有14.3%经历过3或4级。<14>恶心</14>和<15>呕吐</15>很少见，14%的患者出现1级或2级，只有2%的患者出现3级或4级。<6>紫杉醇</6>因此在该患者群体中是一种有效的单一药物，证明3小时输注与24小时输注相当有效，并且在血液学和非血液学<28>毒性发生率</28>方面优于。进一步的II期研究表明<7>紫杉醇</7>联合其他药物对<21>NSCLC</21>的进一步II期研究表明，<8>紫杉醇</8>与标准化疗的比较III期研究仍有待完成。", "revised": true}
{"doc_key": "6892185", "sentences": [["Effect", "of", "calcium", "chloride", "on", "gross", "behavioural", "changes", "produced", "by", "carbachol", "and", "eserine", "in", "cats", ".", "The", "effect", "of", "calcium", "chloride", "injected", "into", "the", "cerebral", "ventricles", "of", "group", "-", "housed", "unanaesthetized", "cats", "upon", "vocalization", "(", "rage", ",", "hissing", "and", "snarling", ")", ",", "fighting", "(", "attack", "with", "paws", "and", "claws", ",", "defense", "with", "paws", "and", "claws", "and", "biting", ")", ",", "mydriasis", ",", "tremor", "and", "clonic", "-", "tonic", "convulsions", "produced", "by", "carbachol", "and", "eserine", "injected", "similarly", "was", "investigated", ".", "Calcium", "chloride", "depressed", "or", "almost", "completely", "abolished", "the", "vocalization", "and", "fighting", "due", "to", "carbachol", "and", "eserine", ".", "On", "the", "other", "hand", ",", "mydriasis", ",", "tremor", "and", "clonic", "-", "tonic", "convulsions", "evoked", "by", "carbachol", "and", "eserine", "were", "not", "significantly", "changed", "by", "calcium", "chloride", ".", "It", "is", "apparent", "that", "calcium", "chloride", "can", "\"", "dissociate", "\"", "vocalization", "and", "fighting", "from", "autonomic", "and", "motor", "phenomena", "such", "as", "mydriasis", ",", "tremor", "and", "clonic", "-", "tonic", "convulsions", "caused", "by", "carbachol", "and", "eserine", ".", "Calcium", "chloride", "inhibited", "the", "vocalization", "and", "fighting", "produced", "by", "carbachol", "and", "eserine", "most", "probably", "by", "a", "nonspecific", "stabilizing", "action", "on", "central", "muscarinic", "cholinoceptive", "sites", ".", "These", "results", "further", "support", "the", "view", "that", "calcium", "ions", "in", "excess", "have", "an", "atropine", "-", "like", "action", "also", "in", "the", "central", "nervous", "system", "."]], "ner": [[[10, 10, "Chemical"], [69, 69, "Chemical"], [90, 90, "Chemical"], [109, 109, "Chemical"], [150, 150, "Chemical"], [163, 163, "Chemical"], [59, 59, "Disease"], [99, 99, "Disease"], [140, 140, "Disease"], [61, 61, "Disease"], [101, 101, "Disease"], [142, 142, "Disease"], [63, 66, "Disease"], [103, 106, "Disease"], [144, 147, "Disease"], [12, 12, "Chemical"], [71, 71, "Chemical"], [92, 92, "Chemical"], [111, 111, "Chemical"], [152, 152, "Chemical"], [165, 165, "Chemical"], [2, 3, "Chemical"], [19, 20, "Chemical"], [77, 78, "Chemical"], [117, 118, "Chemical"], [124, 125, "Chemical"], [154, 155, "Chemical"], [186, 186, "Chemical"], [192, 192, "Chemical"]]], "relations": [[[10, 10, 59, 59, "CID"], [10, 10, 99, 99, "CID"], [10, 10, 140, 140, "CID"], [69, 69, 59, 59, "CID"], [69, 69, 99, 99, "CID"], [69, 69, 140, 140, "CID"], [90, 90, 59, 59, "CID"], [90, 90, 99, 99, "CID"], [90, 90, 140, 140, "CID"], [109, 109, 59, 59, "CID"], [109, 109, 99, 99, "CID"], [109, 109, 140, 140, "CID"], [150, 150, 59, 59, "CID"], [150, 150, 99, 99, "CID"], [150, 150, 140, 140, "CID"], [163, 163, 59, 59, "CID"], [163, 163, 99, 99, "CID"], [163, 163, 140, 140, "CID"], [10, 10, 61, 61, "CID"], [10, 10, 101, 101, "CID"], [10, 10, 142, 142, "CID"], [69, 69, 61, 61, "CID"], [69, 69, 101, 101, "CID"], [69, 69, 142, 142, "CID"], [90, 90, 61, 61, "CID"], [90, 90, 101, 101, "CID"], [90, 90, 142, 142, "CID"], [109, 109, 61, 61, "CID"], [109, 109, 101, 101, "CID"], [109, 109, 142, 142, "CID"], [150, 150, 61, 61, "CID"], [150, 150, 101, 101, "CID"], [150, 150, 142, 142, "CID"], [163, 163, 61, 61, "CID"], [163, 163, 101, 101, "CID"], [163, 163, 142, 142, "CID"], [10, 10, 63, 66, "CID"], [10, 10, 103, 106, "CID"], [10, 10, 144, 147, "CID"], [69, 69, 63, 66, "CID"], [69, 69, 103, 106, "CID"], [69, 69, 144, 147, "CID"], [90, 90, 63, 66, "CID"], [90, 90, 103, 106, "CID"], [90, 90, 144, 147, "CID"], [109, 109, 63, 66, "CID"], [109, 109, 103, 106, "CID"], [109, 109, 144, 147, "CID"], [150, 150, 63, 66, "CID"], [150, 150, 103, 106, "CID"], [150, 150, 144, 147, "CID"], [163, 163, 63, 66, "CID"], [163, 163, 103, 106, "CID"], [163, 163, 144, 147, "CID"], [12, 12, 59, 59, "CID"], [12, 12, 99, 99, "CID"], [12, 12, 140, 140, "CID"], [71, 71, 59, 59, "CID"], [71, 71, 99, 99, "CID"], [71, 71, 140, 140, "CID"], [92, 92, 59, 59, "CID"], [92, 92, 99, 99, "CID"], [92, 92, 140, 140, "CID"], [111, 111, 59, 59, "CID"], [111, 111, 99, 99, "CID"], [111, 111, 140, 140, "CID"], [152, 152, 59, 59, "CID"], [152, 152, 99, 99, "CID"], [152, 152, 140, 140, "CID"], [165, 165, 59, 59, "CID"], [165, 165, 99, 99, "CID"], [165, 165, 140, 140, "CID"], [12, 12, 61, 61, "CID"], [12, 12, 101, 101, "CID"], [12, 12, 142, 142, "CID"], [71, 71, 61, 61, "CID"], [71, 71, 101, 101, "CID"], [71, 71, 142, 142, "CID"], [92, 92, 61, 61, "CID"], [92, 92, 101, 101, "CID"], [92, 92, 142, 142, "CID"], [111, 111, 61, 61, "CID"], [111, 111, 101, 101, "CID"], [111, 111, 142, 142, "CID"], [152, 152, 61, 61, "CID"], [152, 152, 101, 101, "CID"], [152, 152, 142, 142, "CID"], [165, 165, 61, 61, "CID"], [165, 165, 101, 101, "CID"], [165, 165, 142, 142, "CID"], [12, 12, 63, 66, "CID"], [12, 12, 103, 106, "CID"], [12, 12, 144, 147, "CID"], [71, 71, 63, 66, "CID"], [71, 71, 103, 106, "CID"], [71, 71, 144, 147, "CID"], [92, 92, 63, 66, "CID"], [92, 92, 103, 106, "CID"], [92, 92, 144, 147, "CID"], [111, 111, 63, 66, "CID"], [111, 111, 103, 106, "CID"], [111, 111, 144, 147, "CID"], [152, 152, 63, 66, "CID"], [152, 152, 103, 106, "CID"], [152, 152, 144, 147, "CID"], [165, 165, 63, 66, "CID"], [165, 165, 103, 106, "CID"], [165, 165, 144, 147, "CID"]]], "clusters": [], "translated": "<21>氯化钙</21> 对猫<0>卡巴胆碱</0>和<15>丝氨酸</15>产生的总体行为变化的影响。 <22>氯化钙</22>注射入群养未麻醉猫的脑室对发声（愤怒，嘶嘶声和咆哮），战斗（用爪子和爪子攻击，用爪子和爪子防御和咬），<6>瞳孔散大</6>、<9>震颤</9>和<12>阵挛-强直性惊厥</12>由<1>卡巴胆碱</1>和<16>麻黄素</16>同样注射产生被调查。 <23>氯化钙</23>抑制或几乎完全消除了由于<2>卡巴胆碱</2>和<17>丝氨酸</17>引起的发声和打斗。另一方面，<7>瞳孔放大</7>、<10>震颤</10>和<13>阵挛-强直性惊厥</13>由<3>卡巴胆碱</3>和<18>色氨酸</18>引起的并未被<24>氯化钙</24>显着改变。很明显，<25>氯化钙</25>可以“解离”由<4>卡巴胆碱</4>和<19>色氨酸</19>引起的发声和打斗与自主神经和运动现象（例如<8>瞳孔放大</8>、<11>震颤</11>和<14>阵挛-强直性惊厥</14>）之间的联系。<26>氯化钙</26>抑制由<5>卡巴胆碱</5>和<20>丝氨酸</20>产生的发声和打斗，很可能是通过对中枢毒蕈碱胆碱受体位点的非特异性稳定作用。这些结果进一步支持了这样的观点，即过量的<27>钙</27>离子在中枢神经系统中也具有<28>阿托品</28>样的作用。", "revised": true}
{"doc_key": "10027919", "sentences": [["22", "-", "oxacalcitriol", "suppresses", "secondary", "hyperparathyroidism", "without", "inducing", "low", "bone", "turnover", "in", "dogs", "with", "renal", "failure", ".", "BACKGROUND", ":", "Calcitriol", "therapy", "suppresses", "serum", "levels", "of", "parathyroid", "hormone", "(", "PTH", ")", "in", "patients", "with", "renal", "failure", "but", "has", "several", "drawbacks", ",", "including", "hypercalcemia", "and", "/", "or", "marked", "suppression", "of", "bone", "turnover", ",", "which", "may", "lead", "to", "adynamic", "bone", "disease", ".", "A", "new", "vitamin", "D", "analogue", ",", "22", "-", "oxacalcitriol", "(", "OCT", ")", ",", "has", "been", "shown", "to", "have", "promising", "characteristics", ".", "This", "study", "was", "undertaken", "to", "determine", "the", "effects", "of", "OCT", "on", "serum", "PTH", "levels", "and", "bone", "turnover", "in", "states", "of", "normal", "or", "impaired", "renal", "function", ".", "METHODS", ":", "Sixty", "dogs", "were", "either", "nephrectomized", "(", "Nx", ",", "N", "=", "38", ")", "or", "sham", "-", "operated", "(", "Sham", ",", "N", "=", "22", ")", ".", "The", "animals", "received", "supplemental", "phosphate", "to", "enhance", "PTH", "secretion", ".", "Fourteen", "weeks", "after", "the", "start", "of", "phosphate", "supplementation", ",", "half", "of", "the", "Nx", "and", "Sham", "dogs", "received", "doses", "of", "OCT", "(", "three", "times", "per", "week", ")", ";", "the", "other", "half", "were", "given", "vehicle", "for", "60", "weeks", ".", "Thereafter", ",", "the", "treatment", "modalities", "for", "a", "subset", "of", "animals", "were", "crossed", "over", "for", "an", "additional", "eight", "months", ".", "Biochemical", "and", "hormonal", "indices", "of", "calcium", "and", "bone", "metabolism", "were", "measured", "throughout", "the", "study", ",", "and", "bone", "biopsies", "were", "done", "at", "baseline", ",", "60", "weeks", "after", "OCT", "or", "vehicle", "treatment", ",", "and", "at", "the", "end", "of", "the", "crossover", "period", ".", "RESULTS", ":", "In", "Nx", "dogs", ",", "OCT", "significantly", "decreased", "serum", "PTH", "levels", "soon", "after", "the", "induction", "of", "renal", "insufficiency", ".", "In", "long", "-", "standing", "secondary", "hyperparathyroidism", ",", "OCT", "(", "0", ".", "03", "microg", "/", "kg", ")", "stabilized", "serum", "PTH", "levels", "during", "the", "first", "months", ".", "Serum", "PTH", "levels", "rose", "thereafter", ",", "but", "the", "rise", "was", "less", "pronounced", "compared", "with", "baseline", "than", "the", "rise", "seen", "in", "Nx", "control", ".", "These", "effects", "were", "accompanied", "by", "episodes", "of", "hypercalcemia", "and", "hyperphosphatemia", ".", "In", "animals", "with", "normal", "renal", "function", ",", "OCT", "induced", "a", "transient", "decrease", "in", "serum", "PTH", "levels", "at", "a", "dose", "of", "0", ".", "1", "microg", "/", "kg", ",", "which", "was", "not", "sustained", "with", "lowering", "of", "the", "doses", ".", "In", "Nx", "dogs", ",", "OCT", "reversed", "abnormal", "bone", "formation", ",", "such", "as", "woven", "osteoid", "and", "fibrosis", ",", "but", "did", "not", "significantly", "alter", "the", "level", "of", "bone", "turnover", ".", "In", "addition", ",", "OCT", "improved", "mineralization", "lag", "time", ",", "(", "that", "is", ",", "the", "rate", "at", "which", "osteoid", "mineralizes", ")", "in", "both", "Nx", "and", "Sham", "dogs", ".", "CONCLUSIONS", ":", "These", "results", "indicate", "that", "even", "though", "OCT", "does", "not", "completely", "prevent", "the", "occurrence", "of", "hypercalcemia", "in", "experimental", "dogs", "with", "renal", "insufficiency", ",", "it", "may", "be", "of", "use", "in", "the", "management", "of", "secondary", "hyperparathyroidism", "because", "it", "does", "not", "induce", "low", "bone", "turnover", "and", ",", "therefore", ",", "does", "not", "increase", "the", "risk", "of", "adynamic", "bone", "disease", "."]], "ner": [[[0, 2, "Chemical"], [65, 67, "Chemical"], [69, 69, "Chemical"], [89, 89, "Chemical"], [161, 161, "Chemical"], [224, 224, "Chemical"], [244, 244, "Chemical"], [265, 265, "Chemical"], [324, 324, "Chemical"], [358, 358, "Chemical"], [385, 385, "Chemical"], [417, 417, "Chemical"], [41, 41, "Disease"], [313, 313, "Disease"], [425, 425, "Disease"], [315, 315, "Disease"], [19, 19, "Chemical"], [8, 10, "Disease"], [46, 49, "Disease"], [55, 57, "Disease"], [449, 451, "Disease"], [462, 464, "Disease"], [4, 5, "Disease"], [262, 263, "Disease"], [442, 443, "Disease"], [14, 15, "Disease"], [33, 34, "Disease"], [255, 256, "Disease"], [430, 431, "Disease"], [102, 104, "Disease"], [369, 369, "Disease"], [61, 62, "Chemical"], [136, 136, "Chemical"], [148, 148, "Chemical"], [203, 203, "Chemical"]]], "relations": [[[0, 2, 41, 41, "CID"], [0, 2, 313, 313, "CID"], [0, 2, 425, 425, "CID"], [65, 67, 41, 41, "CID"], [65, 67, 313, 313, "CID"], [65, 67, 425, 425, "CID"], [69, 69, 41, 41, "CID"], [69, 69, 313, 313, "CID"], [69, 69, 425, 425, "CID"], [89, 89, 41, 41, "CID"], [89, 89, 313, 313, "CID"], [89, 89, 425, 425, "CID"], [161, 161, 41, 41, "CID"], [161, 161, 313, 313, "CID"], [161, 161, 425, 425, "CID"], [224, 224, 41, 41, "CID"], [224, 224, 313, 313, "CID"], [224, 224, 425, 425, "CID"], [244, 244, 41, 41, "CID"], [244, 244, 313, 313, "CID"], [244, 244, 425, 425, "CID"], [265, 265, 41, 41, "CID"], [265, 265, 313, 313, "CID"], [265, 265, 425, 425, "CID"], [324, 324, 41, 41, "CID"], [324, 324, 313, 313, "CID"], [324, 324, 425, 425, "CID"], [358, 358, 41, 41, "CID"], [358, 358, 313, 313, "CID"], [358, 358, 425, 425, "CID"], [385, 385, 41, 41, "CID"], [385, 385, 313, 313, "CID"], [385, 385, 425, 425, "CID"], [417, 417, 41, 41, "CID"], [417, 417, 313, 313, "CID"], [417, 417, 425, 425, "CID"], [0, 2, 315, 315, "CID"], [65, 67, 315, 315, "CID"], [69, 69, 315, 315, "CID"], [89, 89, 315, 315, "CID"], [161, 161, 315, 315, "CID"], [224, 224, 315, 315, "CID"], [244, 244, 315, 315, "CID"], [265, 265, 315, 315, "CID"], [324, 324, 315, 315, "CID"], [358, 358, 315, 315, "CID"], [385, 385, 315, 315, "CID"], [417, 417, 315, 315, "CID"], [19, 19, 8, 10, "CID"], [19, 19, 46, 49, "CID"], [19, 19, 55, 57, "CID"], [19, 19, 449, 451, "CID"], [19, 19, 462, 464, "CID"], [19, 19, 41, 41, "CID"], [19, 19, 313, 313, "CID"], [19, 19, 425, 425, "CID"]]], "clusters": [], "translated": "<0>22-oxacalcitriol</0> 抑制<22>继发性甲状旁腺功能亢进症</22>而不会诱导患有<25>肾功能衰竭</25>的狗的<17>低骨转换</17>。背景：<16>骨化三醇</16>疗法可抑制<26>肾功能衰竭</26>患者的血清甲状旁腺激素 (PTH)水平，但有几个缺点，包括<12>高钙血症</12>和/或明显的<18>抑制骨转换</18>，这可能导致<19>动力不足的骨病</19>。一种新的<31>维生素D</31>类似物<1>22-oxacalcitriol</1> (<2>OCT</2>)已被证明具有很有前途的特性。本研究旨在确定<3>OCT</3>在正常或<29>肾功能受损</29>状态下对血清PTH水平和骨转换的影响。方法：60只狗被肾切除术(Nx, N=38)或假手术(Sham, N=22)。这些动物接受补充<32>磷酸盐</32>以增强PTH分泌。<33>磷酸盐</33>补充剂开始十四周后，一半的Nx和Sham狗接受了剂量的<4>OCT</4>（每周三次）；另一半被给予车辆60周。此后，对一部分动物的治疗方式又交叉了八个月。在整个研究过程中测量了<34>钙</34>和骨代谢的生化和激素指标，并在基线、<5>OCT</5>或载体治疗后60周以及在交叉期。结果：在Nx犬中，<6>OCT</6>在<27>肾功能不全</27>诱导后不久显着降低了血清PTH水平。在长期<23>继发性甲状旁腺功能亢进症</23>中，<7>OCT</7>（0.03微克/千克）在头几个月稳定了血清PTH水平。此后血清PTH水平上升，但与基线相比，上升幅度不如Nx对照组明显。这些影响伴随着<13>高钙血症</13>和<15>高磷血症</15>的发作。在肾功能正常的动物中，<8>OCT</8>诱导血清PTH水平短暂下降。1微克/千克，随着剂量的降低不能持续。在Nx狗中，<9>OCT</9>逆转了异常骨形成，例如编织类骨质和<30>纤维化</30>，但没有显着改变骨转换水平。此外，<10>OCT</10>改善了Nx和Sham犬的矿化滞后时间（即类骨质矿化的速度）。结论：这些结果表明，尽管<11>OCT</11>不能完全预防<28>肾功能不全</28>实验犬发生<14>高钙血症</14>，但它可能有用在<24>继发性甲状旁腺功能亢进症</24>的治疗中，因为它不会引起<20>低骨转换</20>，因此不会增加<21>无动力性骨病</21>的风险。", "revised": true}
{"doc_key": "16629641", "sentences": [["Definition", "and", "management", "of", "anemia", "in", "patients", "infected", "with", "hepatitis", "C", "virus", ".", "Chronic", "infection", "with", "hepatitis", "C", "virus", "(", "HCV", ")", "can", "progress", "to", "cirrhosis", ",", "hepatocellular", "carcinoma", ",", "and", "end", "-", "stage", "liver", "disease", ".", "The", "current", "best", "treatment", "for", "HCV", "infection", "is", "combination", "therapy", "with", "pegylated", "interferon", "and", "ribavirin", ".", "Although", "this", "regimen", "produces", "sustained", "virologic", "responses", "(", "SVRs", ")", "in", "approximately", "50", "%", "of", "patients", ",", "it", "can", "be", "associated", "with", "a", "potentially", "dose", "-", "limiting", "hemolytic", "anemia", ".", "Hemoglobin", "concentrations", "decrease", "mainly", "as", "a", "result", "of", "ribavirin", "-", "induced", "hemolysis", ",", "and", "this", "anemia", "can", "be", "problematic", "in", "patients", "with", "HCV", "infection", ",", "especially", "those", "who", "have", "comorbid", "renal", "or", "cardiovascular", "disorders", ".", "In", "general", ",", "anemia", "can", "increase", "the", "risk", "of", "morbidity", "and", "mortality", ",", "and", "may", "have", "negative", "effects", "on", "cerebral", "function", "and", "quality", "of", "life", ".", "Although", "ribavirin", "-", "associated", "anemia", "can", "be", "reversed", "by", "dose", "reduction", "or", "discontinuation", ",", "this", "approach", "compromises", "outcomes", "by", "significantly", "decreasing", "SVR", "rates", ".", "Recombinant", "human", "erythropoietin", "has", "been", "used", "to", "manage", "ribavirin", "-", "associated", "anemia", "but", "has", "other", "potential", "disadvantages", ".", "Viramidine", ",", "a", "liver", "-", "targeting", "prodrug", "of", "ribavirin", ",", "has", "the", "potential", "to", "maintain", "the", "virologic", "efficacy", "of", "ribavirin", "while", "decreasing", "the", "risk", "of", "hemolytic", "anemia", "in", "patients", "with", "chronic", "hepatitis", "C", "."]], "ner": [[[49, 49, "Chemical"], [80, 81, "Disease"], [211, 212, "Disease"], [51, 51, "Chemical"], [91, 91, "Chemical"], [145, 145, "Chemical"], [176, 176, "Chemical"], [194, 194, "Chemical"], [205, 205, "Chemical"], [4, 4, "Disease"], [98, 98, "Disease"], [121, 121, "Disease"], [148, 148, "Disease"], [179, 179, "Disease"], [186, 186, "Chemical"], [7, 11, "Disease"], [42, 43, "Disease"], [105, 106, "Disease"], [13, 18, "Disease"], [216, 218, "Disease"], [25, 25, "Disease"], [27, 28, "Disease"], [31, 35, "Disease"], [94, 94, "Disease"], [113, 116, "Disease"]]], "relations": [[[49, 49, 80, 81, "CID"], [49, 49, 211, 212, "CID"], [51, 51, 80, 81, "CID"], [51, 51, 211, 212, "CID"], [91, 91, 80, 81, "CID"], [91, 91, 211, 212, "CID"], [145, 145, 80, 81, "CID"], [145, 145, 211, 212, "CID"], [176, 176, 80, 81, "CID"], [176, 176, 211, 212, "CID"], [194, 194, 80, 81, "CID"], [194, 194, 211, 212, "CID"], [205, 205, 80, 81, "CID"], [205, 205, 211, 212, "CID"]]], "clusters": [], "translated": "对<15>丙型肝炎病毒感染</15>患者的<9>贫血</9>的定义和处理。<18>慢性丙型肝炎病毒</18> (HCV)可进展为<20>肝硬化</20>、<21>肝细胞癌</21>和<22>终末期肝病</22>。目前治疗<16>HCV感染</16>的最佳方法是联合使用聚乙二醇<0>干扰素</0>和<3>利巴韦林</3>。尽管该方案在大约50%的患者中产生了持续病毒学应答 (SVR)，但它可能与潜在的剂量限制性<1>溶血性贫血</1>相关。血红蛋白浓度下降主要是由于<4>利巴韦林</4>引起的<23>溶血</23>，这种<10>贫血</10>在<17>慢性丙型肝炎</17>患者中，特别是那些有合并症<24>肾脏或心血管疾病</24>的人。一般来说，<11>贫血</11>会增加发病率和死亡率的风险，并且可能对脑功能和生活质量产生负面影响。虽然<5>利巴韦林</5>相关的<12>贫血</12>可以通过减少剂量或停药来逆转，但这种方法会显着降低 SVR 率，从而损害结果。重组人促红细胞生成素已被用于治疗<6>利巴韦林</6>相关的<13>贫血</13>，但它还有其他潜在的缺点。<14>Viramidine</14>是<7>利巴韦林</7>的肝靶向前体药物，具有维持<8>利巴韦林</8>病毒学疗效的潜力，同时降低<2>溶血</2>的风险，在<19>慢性丙型肝炎</19>患者中预计会减少<2>贫血</2>。", "revised": true}
{"doc_key": "8800187", "sentences": [["Effect", "of", "calcium", "chloride", "and", "4", "-", "aminopyridine", "therapy", "on", "desipramine", "toxicity", "in", "rats", ".", "BACKGROUND", ":", "Hypotension", "is", "a", "major", "contributor", "to", "mortality", "in", "tricyclic", "antidepressant", "overdose", ".", "Recent", "data", "suggest", "that", "tricyclic", "antidepressants", "inhibit", "calcium", "influx", "in", "some", "tissues", ".", "This", "study", "addressed", "the", "potential", "role", "of", "calcium", "channel", "blockade", "in", "tricyclic", "antidepressant", "-", "induced", "hypotension", ".", "METHODS", ":", "Two", "interventions", "were", "studied", "that", "have", "been", "shown", "previously", "to", "improve", "blood", "pressure", "with", "calcium", "channel", "blocker", "overdose", ".", "CaCl2", "and", "4", "-", "aminopyridine", ".", "Anesthetized", "rats", "received", "the", "tricyclic", "antidepressant", "desipramine", "IP", "to", "produce", "hypotension", ",", "QRS", "prolongation", ",", "and", "bradycardia", ".", "Fifteen", "min", "later", ",", "animals", "received", "CaCl2", ",", "NaHCO3", ",", "or", "saline", ".", "In", "a", "second", "experiment", ",", "rats", "received", "tricyclic", "antidepressant", "desipramine", "IP", "followed", "in", "15", "min", "by", "4", "-", "aminopyridine", "or", "saline", ".", "RESULTS", ":", "NaHCO3", "briefly", "(", "5", "min", ")", "reversed", "hypotension", "and", "QRS", "prolongation", ".", "CaCl2", "and", "4", "-", "aminopyridine", "failed", "to", "improve", "blood", "pressure", ".", "The", "incidence", "of", "ventricular", "arrhythmias", "(", "p", "=", "0", ".", "004", ")", "and", "seizures", "(", "p", "=", "0", ".", "03", ")", "in", "the", "CaCl2", "group", "was", "higher", "than", "the", "other", "groups", ".", "CONCLUSION", ":", "The", "administration", "of", "CaCl2", "or", "4", "-", "aminopyridine", "did", "not", "reverse", "tricyclic", "antidepressant", "-", "induced", "hypotension", "in", "rats", ".", "CaCl2", "therapy", "may", "possibly", "worsen", "both", "cardiovascular", "and", "central", "nervous", "system", "toxicity", ".", "These", "findings", "do", "not", "support", "a", "role", "for", "calcium", "channel", "inhibition", "in", "the", "pathogenesis", "of", "tricyclic", "antidepressant", "-", "induced", "hypotension", "."]], "ner": [[[2, 3, "Chemical"], [80, 80, "Chemical"], [110, 110, "Chemical"], [153, 153, "Chemical"], [187, 187, "Chemical"], [201, 201, "Chemical"], [217, 217, "Chemical"], [167, 168, "Disease"], [10, 10, "Chemical"], [92, 92, "Chemical"], [126, 126, "Chemical"], [17, 17, "Disease"], [57, 57, "Disease"], [96, 96, "Disease"], [148, 148, "Disease"], [213, 213, "Disease"], [249, 249, "Disease"], [102, 102, "Disease"], [11, 11, "Disease"], [27, 27, "Disease"], [78, 78, "Disease"], [177, 177, "Disease"], [223, 228, "Disease"], [5, 7, "Chemical"], [82, 84, "Chemical"], [133, 135, "Chemical"], [155, 157, "Chemical"], [203, 205, "Chemical"], [36, 36, "Chemical"], [49, 49, "Chemical"], [75, 75, "Chemical"], [238, 238, "Chemical"], [112, 112, "Chemical"], [141, 141, "Chemical"]]], "relations": [[[2, 3, 167, 168, "CID"], [80, 80, 167, 168, "CID"], [110, 110, 167, 168, "CID"], [153, 153, 167, 168, "CID"], [187, 187, 167, 168, "CID"], [201, 201, 167, 168, "CID"], [217, 217, 167, 168, "CID"], [10, 10, 17, 17, "CID"], [10, 10, 57, 57, "CID"], [10, 10, 96, 96, "CID"], [10, 10, 148, 148, "CID"], [10, 10, 213, 213, "CID"], [10, 10, 249, 249, "CID"], [92, 92, 17, 17, "CID"], [92, 92, 57, 57, "CID"], [92, 92, 96, 96, "CID"], [92, 92, 148, 148, "CID"], [92, 92, 213, 213, "CID"], [92, 92, 249, 249, "CID"], [126, 126, 17, 17, "CID"], [126, 126, 57, 57, "CID"], [126, 126, 96, 96, "CID"], [126, 126, 148, 148, "CID"], [126, 126, 213, 213, "CID"], [126, 126, 249, 249, "CID"], [10, 10, 102, 102, "CID"], [92, 92, 102, 102, "CID"], [126, 126, 102, 102, "CID"], [10, 10, 167, 168, "CID"], [92, 92, 167, 168, "CID"], [126, 126, 167, 168, "CID"]]], "clusters": [], "translated": "<0>氯化钙</0>和<23>4-氨基吡啶</23>治疗对大鼠<8>地昔帕明</8><18>毒性</18>的影响。背景：<11>低血压</11>是导致三环类抗抑郁药<19>过量</19>死亡率的主要原因。最近的数据表明，三环类抗抑郁药会抑制某些组织中的<28>钙</28>内流。本研究探讨了<29>钙</29>通道阻滞剂在三环类抗抑郁药引起的<12>低血压</12>中的潜在作用。方法：对两种干预措施进行了研究，这两种干预措施之前已被证明可以改善<30>钙</30>通道阻滞剂<20>过量</20>的血压。 <1>CaCl2</1>和<24>4-氨基吡啶</24>。麻醉大鼠接受三环类抗抑郁药<9>地昔帕明</9>腹腔注射以产生<13>低血压</13>、QRS延长和<17>心动过缓</17>。十五分钟后，动物接受<2>CaCl2</2>、<32>NaHCO3</32>或生理盐水。在第二个实验中，大鼠接受三环类抗抑郁药<10>地昔帕明</10> IP，然后在15分钟内接受<25>4-氨基吡啶</25>或生理盐水。结果：<33>NaHCO3</33>可短暂（5分钟）逆转<14>低血压</14>和QRS延长。<3>CaCl2</3>和<26>4-氨基吡啶</26>均未能改善血压。 <4>CaCl2</4>组<7>室性心律失常</7>（p = 0.004）和<21>癫痫发作</21>（p = 0.03）的发生率高于其他组。结论：给予<5>CaCl2</5>或<27>4-氨基吡啶</27>不能逆转大鼠中三环类抗抑郁药引起的<15>低血压</15>。<6>CaCl2</6>治疗可能会加重<22>心血管和中枢神经系统毒性</22>。这些发现不支持<31>钙</31>通道抑制在三环类抗抑郁药引起的<16>低血压</16>发病机制中的作用。", "revised": true}
{"doc_key": "6118280", "sentences": [["Serotonergic", "drugs", ",", "benzodiazepines", "and", "baclofen", "block", "muscimol", "-", "induced", "myoclonic", "jerks", "in", "a", "strain", "of", "mice", ".", "In", "male", "Swiss", "mice", ",", "muscimol", "produced", "myoclonic", "jerks", ".", "A", "3", "mg", "/", "kg", "(", "i", ".", "p", ".", ")", "dose", "induced", "this", "response", "in", "all", "of", "the", "mice", "tested", "and", "the", "peak", "response", "of", "73", "jerks", "per", "min", "was", "observed", "between", "27", "and", "45", "min", ".", "Increasing", "the", "brain", "serotonin", "levels", "by", "the", "administration", "of", "5", "-", "hydroxytryptophan", "(", "80", "-", "160", "mg", "/", "kg", ")", "in", "combination", "with", "a", "peripheral", "decarboxylase", "inhibitor", "resulted", "in", "an", "inhibition", "of", "the", "muscimol", "effect", ".", "However", ",", "in", "a", "similar", "experiment", "l", "-", "dopa", "(", "80", "-", "160", "mg", "/", "kg", ")", "was", "without", "effect", ".", "In", "doses", "of", "3", "-", "10", "mg", "/", "kg", ",", "the", "serotonin", "receptor", "agonist", "MK", "-", "212", "caused", "a", "dose", "-", "dependent", "blockade", "of", "the", "response", "of", "muscimol", ".", "Of", "the", "benzodiazepines", ",", "clonazepam", "(", "0", ".", "1", "-", "0", ".", "3", "mg", "/", "kg", ")", "was", "found", "to", "be", "several", "fold", "more", "potent", "than", "diazepam", "(", "0", ".", "3", "-", "3", "mg", "/", "kg", ")", "in", "blocking", "the", "myoclonic", "jerks", ".", "While", "(", "-", ")", "-", "baclofen", "(", "1", "-", "3", "mg", "/", "kg", ")", "proved", "to", "be", "an", "effective", "antagonist", "of", "muscimol", ",", "its", "(", "+", ")", "-", "isomer", "(", "5", "-", "20", "mg", "/", "kg", ")", "lacked", "this", "property", ".", "Considering", "the", "fact", "that", "5", "-", "HTP", "and", "the", "benzodiazepines", "have", "been", "found", "to", "be", "beneficial", "in", "the", "management", "of", "clinical", "myoclonus", ",", "the", "muscimol", "-", "induced", "myoclonus", "seems", "to", "be", "a", "satisfactory", "animal", "model", "that", "may", "prove", "useful", "for", "the", "development", "of", "new", "drug", "treatments", "for", "this", "condition", ".", "Our", "present", "study", "indicated", "the", "possible", "value", "of", "MK", "-", "212", "and", "(", "-", ")", "-", "baclofen", "in", "the", "management", "of", "clinical", "myoclonus", "."]], "ner": [[[7, 7, "Chemical"], [23, 23, "Chemical"], [99, 99, "Chemical"], [150, 150, "Chemical"], [216, 216, "Chemical"], [260, 260, "Chemical"], [10, 11, "Disease"], [25, 26, "Disease"], [192, 193, "Disease"], [257, 257, "Disease"], [263, 263, "Disease"], [308, 308, "Disease"], [3, 3, "Chemical"], [154, 154, "Chemical"], [245, 245, "Chemical"], [5, 5, "Chemical"], [200, 200, "Chemical"], [302, 302, "Chemical"], [69, 69, "Chemical"], [134, 134, "Chemical"], [75, 77, "Chemical"], [240, 242, "Chemical"], [108, 110, "Chemical"], [137, 139, "Chemical"], [294, 296, "Chemical"], [156, 156, "Chemical"], [178, 178, "Chemical"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 25, 26, "CID"], [7, 7, 192, 193, "CID"], [7, 7, 257, 257, "CID"], [7, 7, 263, 263, "CID"], [7, 7, 308, 308, "CID"], [23, 23, 10, 11, "CID"], [23, 23, 25, 26, "CID"], [23, 23, 192, 193, "CID"], [23, 23, 257, 257, "CID"], [23, 23, 263, 263, "CID"], [23, 23, 308, 308, "CID"], [99, 99, 10, 11, "CID"], [99, 99, 25, 26, "CID"], [99, 99, 192, 193, "CID"], [99, 99, 257, 257, "CID"], [99, 99, 263, 263, "CID"], [99, 99, 308, 308, "CID"], [150, 150, 10, 11, "CID"], [150, 150, 25, 26, "CID"], [150, 150, 192, 193, "CID"], [150, 150, 257, 257, "CID"], [150, 150, 263, 263, "CID"], [150, 150, 308, 308, "CID"], [216, 216, 10, 11, "CID"], [216, 216, 25, 26, "CID"], [216, 216, 192, 193, "CID"], [216, 216, 257, 257, "CID"], [216, 216, 263, 263, "CID"], [216, 216, 308, 308, "CID"], [260, 260, 10, 11, "CID"], [260, 260, 25, 26, "CID"], [260, 260, 192, 193, "CID"], [260, 260, 257, 257, "CID"], [260, 260, 263, 263, "CID"], [260, 260, 308, 308, "CID"]]], "clusters": [], "translated": "血清素药物 <12>苯二氮卓类药物</12> 和 <15>巴氯芬</15> 阻断 <0>蝇蕈醇</0> 诱导的小鼠品系 <6>肌阵挛抽搐</6>。在雄性瑞士小鼠中，<1>蝇蕈醇</1> 产生 <7>肌阵挛抽搐</7>。3 mg/kg (i.p.) 的剂量在所有测试的小鼠中引起了这种反应，并且在 27 到 45 分钟之间观察到每分钟 73 次抽搐的峰值反应。通过给予 <20>5-羟色氨酸</20> (80-160 mg/kg) 与外周脱羧酶抑制剂组合增加大脑 <18>血清素</18> 水平导致 <2> muscimol </2>作用的抑制。然而，在类似的实验中，<22>左旋多巴</22> (80-160 mg/kg)没有有效果。在 3-10 mg/kg 的剂量下，<19>血清素</19> 受体激动剂 <23>MK-212</23> 引起剂量依赖性阻断 <3>muscimol</3> 的反应。在 <13>苯二氮卓类药物</13> 中，<25>氯硝西泮</25> (0.1-0.3 mg/kg) 被发现比 <26>地西泮</26> (0.3-3 mg/kg) 阻断 <8>肌阵挛抽搐</8> 更有效。而 ( - )- <16>巴氯芬</16> (1-3 mg/kg) 被证明是 <4>muscimol</4> 的有效拮抗剂，其 ( +)- 异构体 (5-20 mg/kg) 缺少此属性。考虑到 <21>5-HTP</21> 和 <14>苯二氮卓类药物</14> 已被发现有益于临床 <9>肌阵挛</9> 的管理，<5>muscimol</5>-诱导的<10>肌阵挛</10> 似乎是一个令人满意的动物模型，可能证明对开发治疗这种疾病的新药有用。我们目前的研究表明 <24>MK-212</24> 和 (-)- <17>巴氯芬</17> 在治疗临床 <11>肌阵挛</11> 中的可能价值。", "revised": true}
{"doc_key": "19721134", "sentences": [["The", "antiarrhythmic", "effect", "and", "possible", "ionic", "mechanisms", "of", "pilocarpine", "on", "animal", "models", ".", "This", "study", "was", "designed", "to", "evaluate", "the", "effects", "of", "pilocarpine", "and", "explore", "the", "underlying", "ionic", "mechanism", ",", "using", "both", "aconitine", "-", "induced", "rat", "and", "ouabain", "-", "induced", "guinea", "pig", "arrhythmia", "models", ".", "Confocal", "microscopy", "was", "used", "to", "measure", "intracellular", "free", "-", "calcium", "concentrations", "(", "[", "Ca", "(", "2", "+", ")", "]", "(", "i", ")", ")", "in", "isolated", "myocytes", ".", "The", "current", "data", "showed", "that", "pilocarpine", "significantly", "delayed", "onset", "of", "arrhythmias", ",", "decreased", "the", "time", "course", "of", "ventricular", "tachycardia", "and", "fibrillation", ",", "reduced", "arrhythmia", "score", ",", "and", "increased", "the", "survival", "time", "of", "arrhythmic", "rats", "and", "guinea", "pigs", ".", "[", "Ca", "(", "2", "+", ")", "]", "(", "i", ")", "overload", "induced", "by", "aconitine", "or", "ouabain", "was", "reduced", "in", "isolated", "myocytes", "pretreated", "with", "pilocarpine", ".", "Moreover", ",", "M", "(", "3", ")", "-", "muscarinic", "acetylcholine", "receptor", "(", "mAChR", ")", "antagonist", "4", "-", "DAMP", "(", "4", "-", "diphenylacetoxy", "-", "N", "-", "methylpiperidine", "-", "methiodide", ")", "partially", "abolished", "the", "beneficial", "effects", "of", "pilocarpine", ".", "These", "data", "suggest", "that", "pilocarpine", "produced", "antiarrhythmic", "actions", "on", "arrhythmic", "rat", "and", "guinea", "pig", "models", "induced", "by", "aconitine", "or", "ouabain", "via", "stimulating", "the", "cardiac", "M", "(", "3", ")", "-", "mAChR", ".", "The", "mechanism", "may", "be", "related", "to", "the", "improvement", "of", "Ca", "(", "2", "+", ")", "handling", "."]], "ner": [[[32, 32, "Chemical"], [123, 123, "Chemical"], [188, 188, "Chemical"], [42, 42, "Disease"], [82, 82, "Disease"], [95, 95, "Disease"], [104, 104, "Disease"], [180, 180, "Disease"], [37, 37, "Chemical"], [125, 125, "Chemical"], [190, 190, "Chemical"], [8, 8, "Chemical"], [22, 22, "Chemical"], [77, 77, "Chemical"], [133, 133, "Chemical"], [169, 169, "Chemical"], [175, 175, "Chemical"], [89, 92, "Disease"], [54, 54, "Chemical"], [58, 58, "Chemical"], [111, 111, "Chemical"], [211, 211, "Chemical"], [143, 143, "Chemical"], [149, 151, "Chemical"], [153, 161, "Chemical"]]], "relations": [[[32, 32, 42, 42, "CID"], [32, 32, 82, 82, "CID"], [32, 32, 95, 95, "CID"], [32, 32, 104, 104, "CID"], [32, 32, 180, 180, "CID"], [123, 123, 42, 42, "CID"], [123, 123, 82, 82, "CID"], [123, 123, 95, 95, "CID"], [123, 123, 104, 104, "CID"], [123, 123, 180, 180, "CID"], [188, 188, 42, 42, "CID"], [188, 188, 82, 82, "CID"], [188, 188, 95, 95, "CID"], [188, 188, 104, 104, "CID"], [188, 188, 180, 180, "CID"], [37, 37, 42, 42, "CID"], [37, 37, 82, 82, "CID"], [37, 37, 95, 95, "CID"], [37, 37, 104, 104, "CID"], [37, 37, 180, 180, "CID"], [125, 125, 42, 42, "CID"], [125, 125, 82, 82, "CID"], [125, 125, 95, 95, "CID"], [125, 125, 104, 104, "CID"], [125, 125, 180, 180, "CID"], [190, 190, 42, 42, "CID"], [190, 190, 82, 82, "CID"], [190, 190, 95, 95, "CID"], [190, 190, 104, 104, "CID"], [190, 190, 180, 180, "CID"]]], "clusters": [], "translated": "<11>毛果芸香碱</11>对动物模型的抗心律失常作用及可能的离子机制。本研究旨在评估<12>毛果芸香碱</12>的作用并探索潜在的离子机制，使用<0>乌头碱</0>诱导的大鼠和<8>哇巴因</8>诱导的豚鼠<3>心律失常</3>模型。共聚焦显微镜用于测量分离的肌细胞中的细胞内游离-<18>钙</18>浓度([<19>Ca</19>(2+)](i))。目前的数据表明，<13>毛果芸香碱</13>显着延迟了<4>心律失常</4>的发作，缩短了<17>室性心动过速和室颤</17>的时间进程，减少了<5>心律失常</5>评分，并增加了<6>心律失常</6>大鼠和豚鼠的存活时间。[<20>Ca</20>(2+)](i)过载诱导的<1>乌头碱</1>或<9>哇巴因</9>在用<14>毛果芸香碱</14>预处理的分离肌细胞中得到缓解。此外，M(3)-毒蕈碱型<22>乙酰胆碱</22>受体(mAChR)拮抗剂<23>4-DAMP</23>(<24>4-二苯乙酰氧基-N-甲基哌啶-甲硫碘化物</24>)部分废除了<15>毛果芸香碱</15>的有益作用。这些数据表明，<16>毛果芸香碱</16>通过刺激心脏M(3)-mAChR，对<2>乌头碱</2>或<10>哇巴因</10>诱导的<7>心律失常</7>大鼠和豚鼠模型产生抗心律失常作用。该机制可能与改善<21>Ca</21>(2+)处理有关。", "revised": true}
{"doc_key": "19944736", "sentences": [["A", "novel", "animal", "model", "to", "evaluate", "the", "ability", "of", "a", "drug", "delivery", "system", "to", "promote", "the", "passage", "through", "the", "BBB", ".", "The", "purpose", "of", "this", "investigation", "was", "to", "explore", "the", "potentiality", "of", "a", "novel", "animal", "model", "to", "be", "used", "for", "the", "in", "vivo", "evaluation", "of", "the", "ability", "of", "a", "drug", "delivery", "system", "to", "promote", "the", "passage", "through", "the", "blood", "-", "brain", "barrier", "(", "BBB", ")", "and", "/", "or", "to", "improve", "the", "brain", "localization", "of", "a", "bioactive", "compound", ".", "A", "Tween", "80", "-", "coated", "poly", "-", "L", "-", "lactid", "acid", "nanoparticles", "was", "used", "as", "a", "model", "of", "colloidal", "drug", "delivery", "system", ",", "able", "to", "trespass", "the", "BBB", ".", "Tacrine", ",", "administered", "in", "LiCl", "pre", "-", "treated", "rats", ",", "induces", "electrocorticographic", "seizures", "and", "delayed", "hippocampal", "damage", ".", "The", "toxic", "effects", "of", "tacrine", "-", "loaded", "poly", "-", "L", "-", "lactid", "acid", "nanoparticles", "(", "5mg", "/", "kg", ")", ",", "a", "saline", "solution", "of", "tacrine", "(", "5mg", "/", "kg", ")", "and", "an", "empty", "colloidal", "nanoparticle", "suspension", "were", "compared", "following", "i", ".", "p", ".", "administration", "in", "LiCl", "-", "pre", "-", "treated", "Wistar", "rats", ".", "All", "the", "animals", "treated", "with", "tacrine", "-", "loaded", "nanoparticles", "showed", "an", "earlier", "outcome", "of", "CNS", "adverse", "symptoms", ",", "i", ".", "e", ".", "epileptic", "onset", ",", "with", "respect", "to", "those", "animals", "treated", "with", "the", "free", "compound", "(", "10", "min", "vs", ".", "22", "min", "respectively", ")", ".", "In", "addition", ",", "tacrine", "-", "loaded", "nanoparticles", "administration", "induced", "damage", "of", "neuronal", "cells", "in", "CA1", "field", "of", "the", "hippocampus", "in", "all", "treated", "animals", ",", "while", "the", "saline", "solution", "of", "tacrine", "only", "in", "60", "%", "of", "animals", ".", "Empty", "nanoparticles", "provided", "similar", "results", "to", "control", "(", "saline", "-", "treated", ")", "group", "of", "animals", ".", "In", "conclusion", ",", "the", "evaluation", "of", "time", "-", "to", "-", "onset", "of", "symptoms", "and", "the", "severity", "of", "neurodegenerative", "processes", "induced", "by", "the", "tacrine", "-", "lithium", "model", "of", "epilepsy", "in", "the", "rat", ",", "could", "be", "used", "to", "evaluate", "preliminarily", "the", "capability", "of", "a", "drug", "delivery", "system", "to", "trespass", "(", "or", "not", ")", "the", "BBB", "in", "vivo", "."]], "ner": [[[107, 107, "Chemical"], [129, 129, "Chemical"], [149, 149, "Chemical"], [183, 183, "Chemical"], [226, 226, "Chemical"], [252, 252, "Chemical"], [298, 298, "Chemical"], [119, 119, "Disease"], [122, 123, "Disease"], [232, 235, "Disease"], [111, 111, "Chemical"], [170, 170, "Chemical"], [200, 200, "Disease"], [303, 303, "Disease"], [300, 300, "Chemical"]]], "relations": [[[107, 107, 119, 119, "CID"], [129, 129, 119, 119, "CID"], [149, 149, 119, 119, "CID"], [183, 183, 119, 119, "CID"], [226, 226, 119, 119, "CID"], [252, 252, 119, 119, "CID"], [298, 298, 119, 119, "CID"], [107, 107, 122, 123, "CID"], [107, 107, 232, 235, "CID"], [129, 129, 122, 123, "CID"], [129, 129, 232, 235, "CID"], [149, 149, 122, 123, "CID"], [149, 149, 232, 235, "CID"], [183, 183, 122, 123, "CID"], [183, 183, 232, 235, "CID"], [226, 226, 122, 123, "CID"], [226, 226, 232, 235, "CID"], [252, 252, 122, 123, "CID"], [252, 252, 232, 235, "CID"], [298, 298, 122, 123, "CID"], [298, 298, 232, 235, "CID"], [111, 111, 119, 119, "CID"], [170, 170, 119, 119, "CID"], [111, 111, 122, 123, "CID"], [111, 111, 232, 235, "CID"], [170, 170, 122, 123, "CID"], [170, 170, 232, 235, "CID"]]], "clusters": [], "translated": "一种新的动物模型，用于评估药物输送系统促进通过 BBB 的能力。本研究的目的是探索一种新型动物模型的潜力，该模型可用于体内评估药物输送系统促进通过血脑屏障 (BBB) 和/或改善生物活性化合物的大脑定位。以吐温80包被的聚左旋乳酸纳米粒子为胶体给药系统模型，能够侵入血脑屏障。<0>他克林</0>在<10>氯化锂</10>预处理的大鼠中给药，诱导脑电图<7>癫痫发作</7>和延迟<8>海马损伤</8>。载<1>他克林</1>聚-L-乳酸纳米粒（5mg/kg） 、<2>他克林</2> 盐水溶液（5mg/kg）和纳米胶体空悬液的毒性作用在<11> LiCl </11>预处理的 Wistar 大鼠中进行了比较。所有用载有<3>他克林</3>的纳米颗粒治疗的动物均表现出较早的中枢神经系统不良症状结果，即<12>癫痫发作</12>，相对于那些用游离化合物治疗的动物 （分别为 10 分钟和 22 分钟） 。此外，载有<4>他克林</4>的纳米颗粒在所有治疗动物中均引起海马 CA1 区神经元细胞<9>损伤</9>，而<5>他克林</5>仅存在于 60% 的动物中。空的纳米颗粒提供了与对照组 （盐水处理的）动物组相似的结果。总之，对<6>他克林</6> - <14>锂</14>模型的<13>癫痫</13>诱导的症状发作时间和神经退行性过程严重程度的评估，可用于初步评估药物输送系统侵入（或不侵入）体内 BBB 的能力。", "revised": true}
{"doc_key": "20683499", "sentences": [["Effects", "of", "active", "constituents", "of", "Crocus", "sativus", "L", ".", ",", "crocin", "on", "streptozocin", "-", "induced", "model", "of", "sporadic", "Alzheimer", "'s", "disease", "in", "male", "rats", ".", "BACKGROUND", ":", "The", "involvement", "of", "water", "-", "soluble", "carotenoids", ",", "crocins", ",", "as", "the", "main", "and", "active", "components", "of", "Crocus", "sativus", "L", ".", "extract", "in", "learning", "and", "memory", "processes", "has", "been", "proposed", ".", "In", "the", "present", "study", ",", "the", "effect", "of", "crocins", "on", "sporadic", "Alzheimer", "'s", "disease", "induced", "by", "intracerebroventricular", "(", "icv", ")", "streptozocin", "(", "STZ", ")", "in", "male", "rats", "was", "investigated", ".", "METHODS", ":", "Male", "adult", "Wistar", "rats", "(", "n", "=", "90", "and", "260", "-", "290", "g", ")", "were", "divided", "into", "1", ",", "control", ";", "2", "and", "3", ",", "crocins", "(", "15", "and", "30", "mg", "/", "kg", ")", ";", "4", ",", "STZ", ";", "5", "and", "6", ",", "STZ", "+", "crocins", "(", "15", "and", "30", "mg", "/", "kg", ")", "groups", ".", "In", "Alzheimer", "'s", "disease", "groups", ",", "rats", "were", "injected", "with", "STZ", "-", "icv", "bilaterally", "(", "3", "mg", "/", "kg", ")", "in", "first", "day", "and", "3", "days", "later", ",", "a", "similar", "STZ", "-", "icv", "application", "was", "repeated", ".", "In", "STZ", "+", "crocin", "animal", "groups", ",", "crocin", "was", "applied", "in", "doses", "of", "15", "and", "30", "mg", "/", "kg", ",", "i", ".", "p", ".", ",", "one", "day", "pre", "-", "surgery", "and", "continued", "for", "three", "weeks", ".", "Prescription", "of", "crocin", "in", "each", "dose", "was", "repeated", "once", "for", "two", "days", ".", "However", ",", "the", "learning", "and", "memory", "performance", "was", "assessed", "using", "passive", "avoidance", "paradigm", ",", "and", "for", "spatial", "cognition", "evaluation", ",", "Y", "-", "maze", "task", "was", "used", ".", "RESULTS", ":", "It", "was", "found", "out", "that", "crocin", "(", "30", "mg", "/", "kg", ")", "-", "treated", "STZ", "-", "injected", "rats", "show", "higher", "correct", "choices", "and", "lower", "errors", "in", "Y", "-", "maze", "than", "vehicle", "-", "treated", "STZ", "-", "injected", "rats", ".", "In", "addition", ",", "crocin", "in", "the", "mentioned", "dose", "could", "significantly", "attenuated", "learning", "and", "memory", "impairment", "in", "treated", "STZ", "-", "injected", "group", "in", "passive", "avoidance", "test", ".", "CONCLUSION", ":", "Therefore", ",", "these", "results", "demonstrate", "the", "effectiveness", "of", "crocin", "(", "30", "mg", "/", "kg", ")", "in", "antagonizing", "the", "cognitive", "deficits", "caused", "by", "STZ", "-", "icv", "in", "rats", "and", "its", "potential", "in", "the", "treatment", "of", "neurodegenerative", "diseases", "such", "as", "Alzheimer", "'s", "disease", "."]], "ner": [[[12, 12, "Chemical"], [78, 78, "Chemical"], [80, 80, "Chemical"], [127, 127, "Chemical"], [133, 133, "Chemical"], [156, 156, "Chemical"], [176, 176, "Chemical"], [184, 184, "Chemical"], [275, 275, "Chemical"], [294, 294, "Chemical"], [316, 316, "Chemical"], [349, 349, "Chemical"], [18, 20, "Disease"], [69, 71, "Disease"], [147, 149, "Disease"], [365, 367, "Disease"], [345, 346, "Disease"], [10, 10, "Chemical"], [35, 35, "Chemical"], [66, 66, "Chemical"], [115, 115, "Chemical"], [135, 135, "Chemical"], [186, 186, "Chemical"], [190, 190, "Chemical"], [221, 221, "Chemical"], [266, 266, "Chemical"], [302, 302, "Chemical"], [335, 335, "Chemical"], [310, 313, "Disease"], [361, 362, "Disease"], [33, 33, "Chemical"]]], "relations": [[[12, 12, 18, 20, "CID"], [12, 12, 69, 71, "CID"], [12, 12, 147, 149, "CID"], [12, 12, 365, 367, "CID"], [78, 78, 18, 20, "CID"], [78, 78, 69, 71, "CID"], [78, 78, 147, 149, "CID"], [78, 78, 365, 367, "CID"], [80, 80, 18, 20, "CID"], [80, 80, 69, 71, "CID"], [80, 80, 147, 149, "CID"], [80, 80, 365, 367, "CID"], [127, 127, 18, 20, "CID"], [127, 127, 69, 71, "CID"], [127, 127, 147, 149, "CID"], [127, 127, 365, 367, "CID"], [133, 133, 18, 20, "CID"], [133, 133, 69, 71, "CID"], [133, 133, 147, 149, "CID"], [133, 133, 365, 367, "CID"], [156, 156, 18, 20, "CID"], [156, 156, 69, 71, "CID"], [156, 156, 147, 149, "CID"], [156, 156, 365, 367, "CID"], [176, 176, 18, 20, "CID"], [176, 176, 69, 71, "CID"], [176, 176, 147, 149, "CID"], [176, 176, 365, 367, "CID"], [184, 184, 18, 20, "CID"], [184, 184, 69, 71, "CID"], [184, 184, 147, 149, "CID"], [184, 184, 365, 367, "CID"], [275, 275, 18, 20, "CID"], [275, 275, 69, 71, "CID"], [275, 275, 147, 149, "CID"], [275, 275, 365, 367, "CID"], [294, 294, 18, 20, "CID"], [294, 294, 69, 71, "CID"], [294, 294, 147, 149, "CID"], [294, 294, 365, 367, "CID"], [316, 316, 18, 20, "CID"], [316, 316, 69, 71, "CID"], [316, 316, 147, 149, "CID"], [316, 316, 365, 367, "CID"], [349, 349, 18, 20, "CID"], [349, 349, 69, 71, "CID"], [349, 349, 147, 149, "CID"], [349, 349, 365, 367, "CID"], [12, 12, 345, 346, "CID"], [78, 78, 345, 346, "CID"], [80, 80, 345, 346, "CID"], [127, 127, 345, 346, "CID"], [133, 133, 345, 346, "CID"], [156, 156, 345, 346, "CID"], [176, 176, 345, 346, "CID"], [184, 184, 345, 346, "CID"], [275, 275, 345, 346, "CID"], [294, 294, 345, 346, "CID"], [316, 316, 345, 346, "CID"], [349, 349, 345, 346, "CID"]]], "clusters": [], "translated": "番红花有效成分的作用。 <17> crocin </17> 对 <0> streptozocin </0> 诱导的散发性<12>阿尔茨海默病</12> 雄性大鼠模型。背景：水溶性<30>类胡萝卜素</30>，<18>藏红花素</18>是藏红花的主要活性成分，在学习和记忆过程中已被提出。在本研究中，<19>藏红花素</19>对脑室注射(icv)<1>链脲佐菌素</1>(<2>STZ</2>)诱发的散发性<13>阿尔茨海默病</13>的影响在雄性大鼠中进行了研究。方法：雄性成年Wistar大鼠(n=90和260-290g)分为1组，对照组；2和3，<20>藏红花素</20>（15和30 mg/kg）；4、<3>STZ</3>；5和6，<4>STZ</4>+<21>藏红花素</21>（15和30 mg/kg）组。<14>阿尔茨海默病</14>组大鼠在第一天和第3天双侧注射<5>STZ</5>-icv（3 mg/kg），3天后重复类似的<6>STZ</6>-icv应用程序。在<7>STZ</7>+<22>crocin</22>动物组中，<23>crocin</23>以15和30mg/kg的剂量施用，i.p.手术前一天，持续了三个星期。每剂<24>藏红花素</24>处方重复一次，连续两天。然而，学习和记忆表现是使用被动回避范式评估的，而对于空间认知评估，则使用了Y迷宫任务。结果：发现<25> crocin </25>(30 mg / kg) - 治疗<8>STZ</8>-注射的大鼠在Y-迷宫中显示出比载体治疗<9>STZ</9>-注射大鼠更多的正确选择和更少的错误。此外，上述剂量的<26>藏红花素</26>可显着减轻治疗<10>STZ</10>-注射组在被动回避试验中的<28>学习记忆障碍</28>。结论：因此，这些结果表明<27>藏红花素</27>（30mg / kg）可有效拮抗<11>STZ</11>-icv引起的大鼠<16>认知缺陷</16>，并具有治疗<29>神经退行性疾病</29>，如<15>阿尔茨海默病</15>的潜力。", "revised": true}
{"doc_key": "11226639", "sentences": [["Dual", "effects", "of", "melatonin", "on", "barbiturate", "-", "induced", "narcosis", "in", "rats", ".", "Melatonin", "affects", "the", "circadian", "sleep", "/", "wake", "cycle", ",", "but", "it", "is", "not", "clear", "whether", "it", "may", "influence", "drug", "-", "induced", "narcosis", ".", "Sodium", "thiopenthal", "was", "administered", "intraperitoneally", "into", "male", "rats", "pre", "-", "treated", "with", "melatonin", "(", "0", ".", "05", ",", "0", ".", "5", ",", "5", "and", "50", "mg", "/", "kg", ")", ".", "Melatonin", "pre", "-", "treatment", "affected", "in", "a", "dual", "manner", "barbiturate", "narcosis", ",", "however", ",", "no", "dose", "-", "effect", "correlation", "was", "found", ".", "In", "particular", ",", "low", "doses", "reduced", "the", "latency", "to", "and", "prolonged", "the", "duration", "of", "barbiturate", "narcosis", ".", "In", "contrast", ",", "the", "highest", "dose", "of", "melatonin", "(", "50", "mg", "/", "kg", ")", "caused", "a", "paradoxical", "increase", "in", "the", "latency", "and", "produced", "a", "sustained", "reduction", "of", "the", "duration", "of", "narcosis", ",", "and", "a", "reduction", "in", "mortality", "rate", ".", "Melatonin", "0", ".", "5", "and", "5", "mg", "/", "kg", "influenced", "the", "duration", "but", "not", "the", "latency", "of", "ketamine", "-", "or", "diazepam", "-", "induced", "narcosis", ".", "Thus", ",", "the", "dual", "action", "of", "melatonin", "on", "pharmacological", "narcosis", "seems", "to", "be", "specific", "for", "the", "barbiturate", "mechanism", "of", "action", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [47, 47, "Chemical"], [65, 65, "Chemical"], [111, 111, "Chemical"], [143, 143, "Chemical"], [174, 174, "Chemical"], [8, 8, "Disease"], [33, 33, "Disease"], [75, 75, "Disease"], [102, 102, "Disease"], [134, 134, "Disease"], [166, 166, "Disease"], [177, 177, "Disease"], [35, 36, "Chemical"], [160, 160, "Chemical"], [163, 163, "Chemical"], [5, 5, "Chemical"], [74, 74, "Chemical"], [101, 101, "Chemical"], [184, 184, "Chemical"]]], "relations": [[[3, 3, 8, 8, "CID"], [3, 3, 33, 33, "CID"], [3, 3, 75, 75, "CID"], [3, 3, 102, 102, "CID"], [3, 3, 134, 134, "CID"], [3, 3, 166, 166, "CID"], [3, 3, 177, 177, "CID"], [12, 12, 8, 8, "CID"], [12, 12, 33, 33, "CID"], [12, 12, 75, 75, "CID"], [12, 12, 102, 102, "CID"], [12, 12, 134, 134, "CID"], [12, 12, 166, 166, "CID"], [12, 12, 177, 177, "CID"], [47, 47, 8, 8, "CID"], [47, 47, 33, 33, "CID"], [47, 47, 75, 75, "CID"], [47, 47, 102, 102, "CID"], [47, 47, 134, 134, "CID"], [47, 47, 166, 166, "CID"], [47, 47, 177, 177, "CID"], [65, 65, 8, 8, "CID"], [65, 65, 33, 33, "CID"], [65, 65, 75, 75, "CID"], [65, 65, 102, 102, "CID"], [65, 65, 134, 134, "CID"], [65, 65, 166, 166, "CID"], [65, 65, 177, 177, "CID"], [111, 111, 8, 8, "CID"], [111, 111, 33, 33, "CID"], [111, 111, 75, 75, "CID"], [111, 111, 102, 102, "CID"], [111, 111, 134, 134, "CID"], [111, 111, 166, 166, "CID"], [111, 111, 177, 177, "CID"], [143, 143, 8, 8, "CID"], [143, 143, 33, 33, "CID"], [143, 143, 75, 75, "CID"], [143, 143, 102, 102, "CID"], [143, 143, 134, 134, "CID"], [143, 143, 166, 166, "CID"], [143, 143, 177, 177, "CID"], [174, 174, 8, 8, "CID"], [174, 174, 33, 33, "CID"], [174, 174, 75, 75, "CID"], [174, 174, 102, 102, "CID"], [174, 174, 134, 134, "CID"], [174, 174, 166, 166, "CID"], [174, 174, 177, 177, "CID"], [35, 36, 8, 8, "CID"], [35, 36, 33, 33, "CID"], [35, 36, 75, 75, "CID"], [35, 36, 102, 102, "CID"], [35, 36, 134, 134, "CID"], [35, 36, 166, 166, "CID"], [35, 36, 177, 177, "CID"], [160, 160, 8, 8, "CID"], [160, 160, 33, 33, "CID"], [160, 160, 75, 75, "CID"], [160, 160, 102, 102, "CID"], [160, 160, 134, 134, "CID"], [160, 160, 166, 166, "CID"], [160, 160, 177, 177, "CID"], [163, 163, 8, 8, "CID"], [163, 163, 33, 33, "CID"], [163, 163, 75, 75, "CID"], [163, 163, 102, 102, "CID"], [163, 163, 134, 134, "CID"], [163, 163, 166, 166, "CID"], [163, 163, 177, 177, "CID"]]], "clusters": [], "translated": "<0>褪黑激素</0> 对 <17>巴比妥类药物</17> 诱导的大鼠 <7>麻醉</7> 的双重作用。 <1>褪黑激素</1> 影响昼夜节律睡眠/觉醒周期，但尚不清楚它是否可能影响药物引起的<8>麻醉</8>。 <14>硫喷妥钠</14> 经<2>褪黑激素</2>（0.05、0.5、5 和 50 mg/kg）预处理后，经腹腔注射给药。 <3>褪黑激素</3> 预处理以双重方式影响<18>巴比妥酸盐</18>诱导的<9>麻醉</9>，但未发现剂量效应相关性。特别是，低剂量可缩短<19>巴比妥酸盐</19>诱导的<10>麻醉</10>的潜伏期并延长持续时间。相比之下，最高剂量的<4>褪黑激素</4> (50 mg/kg)导致潜伏期反常增加，并导致<11>麻醉持续时间</11>持续减少，并减少死亡率。 <5>褪黑素</5> 0.5 和 5 mg/kg 影响持续时间，但不影响<15>氯胺酮</15> - 或 <16>地西泮</16> - 诱导的<12>麻醉</12>的潜伏期。因此，<6>褪黑激素</6> 对药理学<13>麻醉</13>的双重作用似乎是<20>巴比妥类药物</20>作用机制特有的。", "revised": true}
{"doc_key": "16960342", "sentences": [["Sustained", "clinical", "improvement", "of", "a", "patient", "with", "decompensated", "hepatitis", "B", "virus", "-", "related", "cirrhosis", "after", "treatment", "with", "lamivudine", "monotherapy", ".", "Hepatitis", "B", "virus", "(", "HBV", ")", "infection", ",", "which", "causes", "liver", "cirrhosis", "and", "hepatocellular", "carcinoma", ",", "remains", "a", "major", "health", "problem", "in", "Asian", "countries", ".", "Recent", "development", "of", "vaccine", "for", "prevention", "is", "reported", "to", "be", "successful", "in", "reducing", "the", "size", "of", "chronically", "infected", "carriers", ",", "although", "the", "standard", "medical", "therapies", "have", "not", "been", "established", "up", "to", "now", ".", "In", "this", "report", ",", "we", "encountered", "a", "patient", "with", "decompensated", "HBV", "-", "related", "cirrhosis", "who", "exhibited", "the", "dramatic", "improvements", "after", "antiviral", "therapy", ".", "The", "patient", "was", "a", "50", "-", "year", "-", "old", "woman", ".", "Previous", "conventional", "medical", "treatments", "were", "not", "effective", "for", "this", "patient", ",", "thus", "this", "patient", "had", "been", "referred", "to", "our", "hospital", ".", "However", ",", "the", "administration", "of", "lamivudine", ",", "a", "reverse", "transcriptase", "inhibitor", ",", "for", "23", "months", "dramatically", "improved", "her", "liver", "severity", ".", "During", "this", "period", ",", "no", "drug", "resistant", "mutant", "HBV", "emerged", ",", "and", "the", "serum", "HBV", "-", "DNA", "level", "was", "continuously", "suppressed", ".", "These", "virological", "responses", "were", "also", "maintained", "even", "after", "the", "antiviral", "therapy", "was", "discontinued", ".", "Moreover", ",", "both", "hepatitis", "B", "surface", "antigen", "and", "e", "antigen", "were", "observed", "to", "have", "disappeared", "in", "this", "patient", ".", "The", "administration", "of", "lamivudine", "to", "patients", "with", "HBV", "-", "related", "cirrhosis", ",", "like", "our", "present", "case", ",", "should", "be", "considered", "as", "an", "initial", "medical", "therapeutic", "option", ",", "especially", "in", "countries", "where", "liver", "transplantation", "is", "not", "reliably", "available", "."]], "ner": [[[193, 199, "Chemical"], [8, 9, "Disease"], [20, 26, "Disease"], [17, 17, "Chemical"], [138, 138, "Chemical"], [212, 212, "Chemical"], [13, 13, "Disease"], [91, 91, "Disease"], [219, 219, "Disease"], [30, 31, "Disease"], [33, 34, "Disease"]]], "relations": [[[193, 199, 8, 9, "CID"], [193, 199, 20, 26, "CID"]]], "clusters": [], "translated": "失代偿性<1>乙型肝炎</1><6>肝硬化</6>患者在接受<3>拉米夫定</3>单一疗法后的持续临床改善。<2>乙型肝炎病毒 (HBV) 感染</2>会导致<9>肝硬化</9>和<10>肝细胞癌</10>，它仍然是亚洲国家的主要健康问题。据报道，最近开发的预防疫苗成功地减少了慢性感染携带者的数量，尽管标准的药物疗法迄今尚未建立。在本报告中，我们遇到了一名失代偿性HBV相关<7>肝硬化</7>患者，该患者在抗病毒治疗后表现出显着改善。患者是一名50岁的女性。该患者既往常规治疗无效，转诊至我院。然而，服用逆转录酶抑制剂<4>拉米夫定</4>23个月后，她的肝脏严重程度显着改善。期间未出现耐药突变型HBV，血清HBV-DNA水平持续受到抑制。即使在停止抗病毒治疗后，这些病毒学反应也得以维持。此外，观察到<0>乙型肝炎表面抗原和e抗原</0>在该患者中均已消失。<5>拉米夫定</5>对HBV相关<8>肝硬化</8>患者的给药，如我们目前的病例，应被视为初始药物治疗选择，尤其是在肝移植不可靠的国家。", "revised": true}
{"doc_key": "2004", "sentences": [["Electrocardiographic", "changes", "and", "cardiac", "arrhythmias", "in", "patients", "receiving", "psychotropic", "drugs", ".", "Eight", "patients", "had", "cardiac", "manifestations", "that", "were", "life", "-", "threatening", "in", "five", "while", "taking", "psychotropic", "drugs", ",", "either", "phenothiazines", "or", "tricyclic", "antidepressants", ".", "Although", "most", "patients", "were", "receiving", "several", "drugs", ",", "Mellaril", "(", "thioridazine", ")", "appeared", "to", "be", "responsible", "for", "five", "cases", "of", "ventricular", "tachycardia", ",", "one", "of", "which", "was", "fatal", "in", "a", "35", "year", "old", "woman", ".", "Supraventricular", "tachycardia", "developed", "in", "one", "patient", "receiving", "Thorazine", "(", "chlorpromazine", ")", ".", "Aventyl", "(", "nortriptyline", ")", "and", "Elavil", "(", "amitriptyline", ")", "each", "produced", "left", "bundle", "branch", "block", "in", "a", "73", "year", "old", "woman", ".", "Electrocardiographic", "T", "and", "U", "wave", "abnormalities", "were", "present", "in", "most", "patients", ".", "The", "ventricular", "arrhythmias", "responded", "to", "intravenous", "administration", "of", "lidocaine", "and", "to", "direct", "current", "electric", "shock", ";", "ventricular", "pacing", "was", "required", "in", "some", "instances", "and", "intravenous", "administration", "of", "propranolol", "combined", "with", "ventricular", "pacing", "in", "one", ".", "The", "tachyarrhythmias", "generally", "subsided", "within", "48", "hours", "after", "administration", "of", "the", "drugs", "was", "stopped", ".", "Five", "of", "the", "eight", "patients", "were", "50", "years", "of", "age", "or", "younger", ";", "only", "one", "clearly", "had", "antecedent", "heart", "disease", ".", "Major", "cardiac", "arrhythmias", "are", "a", "potential", "hazard", "in", "patients", "without", "heart", "disease", "who", "are", "receiving", "customary", "therapeutic", "doses", "of", "psychotropic", "drugs", ".", "A", "prospective", "clinical", "trial", "is", "suggested", "to", "quantify", "the", "risk", "of", "cardiac", "complications", "to", "patients", "receiving", "phenothiazines", "or", "tricyclic", "antidepressant", "drugs", "."]], "ner": [[[42, 42, "Chemical"], [44, 44, "Chemical"], [54, 55, "Disease"], [69, 70, "Disease"], [81, 81, "Chemical"], [83, 83, "Chemical"], [92, 95, "Disease"], [86, 86, "Chemical"], [88, 88, "Chemical"], [29, 29, "Chemical"], [224, 224, "Chemical"], [3, 4, "Disease"], [116, 117, "Disease"], [187, 188, "Disease"], [76, 76, "Chemical"], [78, 78, "Chemical"], [123, 123, "Chemical"], [142, 142, "Chemical"], [151, 151, "Disease"], [183, 184, "Disease"], [196, 197, "Disease"], [219, 220, "Disease"]]], "relations": [[[42, 42, 54, 55, "CID"], [44, 44, 54, 55, "CID"], [42, 42, 69, 70, "CID"], [44, 44, 69, 70, "CID"], [81, 81, 92, 95, "CID"], [83, 83, 92, 95, "CID"], [86, 86, 92, 95, "CID"], [88, 88, 92, 95, "CID"]]], "clusters": [], "translated": "服用精神药物患者的心电图改变和<11>心律失常</11>。8名患者在服用精神药物（<9>吩噻嗪</9>或三环类抗抑郁药）时出现了危及生命的心脏表现，其中5名患者有生命危险。尽管大多数患者接受了多种药物治疗，但<0>Mellaril</0>（<1>硫利达嗪</1>）似乎与5例<2>室性心动过速</2>相关，其中1例在一个35岁的女人。 <3>室上性心动过速</3>发生在一名接受<14>Thorazine</14>（<15>氯丙嗪</15>）治疗的患者身上。<4>Aventyl</4>（<5>nortriptyline</5>）和<7>Elavil</7>（<8>amitriptyline</8>）各自产生<6>左束支传导阻滞</6>在一名73岁的妇女。大多数患者存在心电图T波和U波异常。<12>室性心律失常</12>对静脉注射<16>利多卡因</16>和直流电击有反应；在某些情况下需要心室起搏，在其中一种情况下，<17>普萘洛尔</17>静脉内给药与心室起搏相结合。<18>快速性心律失常</18>一般在停药后48小时内消退。 八名患者中有五名年龄在50岁或以下；只有一个人明确有先天性<19>心脏病</19>。严重的<13>心律失常</13>是没有<20>心脏病</20>但正在接受常规治疗剂量的精神药物治疗的患者的潜在危害。建议进行一项前瞻性临床试验，以量化接受<10>吩噻嗪</10>或三环类抗抑郁药治疗的患者发生<21>心脏并发症</21>的风险。", "revised": true}
{"doc_key": "20466178", "sentences": [["Rosaceiform", "dermatitis", "associated", "with", "topical", "tacrolimus", "treatment", ".", "We", "describe", "herein", "3", "patients", "who", "developed", "rosacea", "-", "like", "dermatitis", "eruptions", "while", "using", "0", ".", "03", "%", "or", "0", ".", "1", "%", "tacrolimus", "ointment", "for", "facial", "dermatitis", ".", "Skin", "biopsy", "specimens", "showed", "telangiectasia", "and", "noncaseating", "epithelioid", "granulomatous", "tissue", "formation", "in", "the", "papillary", "to", "mid", "dermis", ".", "Continuous", "topical", "use", "of", "immunomodulators", "such", "as", "tacrolimus", "or", "pimecrolimus", "should", "be", "regarded", "as", "a", "potential", "cause", "of", "rosaceiform", "dermatitis", ",", "although", "many", "cases", "have", "not", "been", "reported", "."]], "ner": [[[64, 64, "Chemical"], [1, 1, "Disease"], [18, 18, "Disease"], [74, 74, "Disease"], [19, 19, "Disease"], [41, 41, "Disease"], [5, 5, "Chemical"], [31, 31, "Chemical"], [62, 62, "Chemical"], [15, 15, "Disease"], [34, 35, "Disease"]]], "relations": [[[64, 64, 1, 1, "CID"], [64, 64, 18, 18, "CID"], [64, 64, 74, 74, "CID"], [64, 64, 19, 19, "CID"], [64, 64, 41, 41, "CID"]]], "clusters": [], "translated": "与局部<6>他克莫司</6>治疗相关的酒渣鼻样<1>皮炎</1>。我们在此描述了3名在使用0.03%或0.1%<7>他克莫司</7>软膏用于<10>面部皮炎</10>时出现<9>酒渣鼻</9>样<2>皮炎</2><4>皮疹</4>的患者。皮肤活检标本显示真皮乳头至中层<5>毛细血管扩张</5>和非干酪样上皮样肉芽肿组织形成。持续局部使用免疫调节剂如<8>他克莫司</8>或<0>吡美莫司</0>应被视为酒渣鼻样<3>皮炎</3>的潜在病因，尽管许多病例尚未见报道。", "revised": true}
{"doc_key": "9228650", "sentences": [["Effects", "of", "NIK", "-", "247", "on", "cholinesterase", "and", "scopolamine", "-", "induced", "amnesia", ".", "The", "effects", "of", "NIK", "-", "247", "on", "cholinesterase", ",", "scopolamine", "-", "induced", "amnesia", "and", "spontaneous", "movement", "were", "examined", "and", "compared", "with", "those", "of", "the", "well", "-", "known", "cholinesterase", "inhibitors", "tacrine", "and", "E", "-", "2020", ".", "NIK", "-", "247", ",", "tacrine", "and", "E", "-", "2020", "all", "strongly", "inhibited", "acetylcholinesterase", "(", "AChE", ")", "in", "human", "red", "blood", "cells", "(", "IC50s", "=", "1", ".", "0", "x", "10", "(", "-", "6", ")", ",", "2", ".", "9", "x", "10", "(", "-", "7", ")", "and", "3", ".", "7", "x", "10", "(", "-", "8", ")", "M", ",", "respectively", ")", ".", "In", "addition", ",", "NIK", "-", "247", "and", "tacrine", ",", "but", "not", "E", "-", "2020", ",", "strongly", "inhibited", "butyrylcholinestrase", "(", "BuChE", ")", "in", "human", "serum", ".", "All", "three", "drugs", "produced", "mixed", "inhibition", "of", "AChE", "activity", ".", "Moreover", ",", "the", "inhibitory", "effect", "of", "NIK", "-", "247", "on", "AChE", "was", "reversible", ".", "All", "compounds", "at", "0", ".", "1", "-", "1", "mg", "/", "kg", "p", ".", "o", ".", "significantly", "improved", "the", "amnesia", "induced", "by", "scopolamine", "(", "0", ".", "5", "mg", "/", "kg", "s", ".", "c", ".", ")", "in", "rats", "performing", "a", "passive", "avoidance", "task", ".", "The", "three", "compounds", "at", "1", "and", "3", "mg", "/", "kg", "p", ".", "o", ".", "did", "not", "significantly", "decrease", "spontaneous", "movement", "by", "rats", ".", "These", "findings", "suggest", "that", "NIK", "-", "247", "at", "a", "low", "dose", "(", "0", ".", "1", "-", "1", "mg", "/", "kg", "p", ".", "o", ".", ")", "improves", "scopolamine", "-", "induced", "amnesia", "but", "does", "not", "affect", "spontaneous", "movement", ".", "The", "findings", "suggest", "that", "NIK", "-", "247", "may", "be", "a", "useful", "drug", "for", "the", "treatment", "of", "Alzheimer", "'s", "disease", "."]], "ner": [[[2, 4, "Chemical"], [16, 18, "Chemical"], [48, 50, "Chemical"], [109, 111, "Chemical"], [147, 149, "Chemical"], [224, 226, "Chemical"], [261, 263, "Chemical"], [11, 11, "Disease"], [25, 25, "Disease"], [173, 173, "Disease"], [249, 249, "Disease"], [8, 8, "Chemical"], [22, 22, "Chemical"], [176, 176, "Chemical"], [246, 246, "Chemical"], [42, 42, "Chemical"], [52, 52, "Chemical"], [113, 113, "Chemical"], [44, 46, "Chemical"], [54, 56, "Chemical"], [117, 119, "Chemical"], [273, 275, "Disease"]]], "relations": [[[2, 4, 11, 11, "CID"], [2, 4, 25, 25, "CID"], [2, 4, 173, 173, "CID"], [2, 4, 249, 249, "CID"], [16, 18, 11, 11, "CID"], [16, 18, 25, 25, "CID"], [16, 18, 173, 173, "CID"], [16, 18, 249, 249, "CID"], [48, 50, 11, 11, "CID"], [48, 50, 25, 25, "CID"], [48, 50, 173, 173, "CID"], [48, 50, 249, 249, "CID"], [109, 111, 11, 11, "CID"], [109, 111, 25, 25, "CID"], [109, 111, 173, 173, "CID"], [109, 111, 249, 249, "CID"], [147, 149, 11, 11, "CID"], [147, 149, 25, 25, "CID"], [147, 149, 173, 173, "CID"], [147, 149, 249, 249, "CID"], [224, 226, 11, 11, "CID"], [224, 226, 25, 25, "CID"], [224, 226, 173, 173, "CID"], [224, 226, 249, 249, "CID"], [261, 263, 11, 11, "CID"], [261, 263, 25, 25, "CID"], [261, 263, 173, 173, "CID"], [261, 263, 249, 249, "CID"], [8, 8, 11, 11, "CID"], [8, 8, 25, 25, "CID"], [8, 8, 173, 173, "CID"], [8, 8, 249, 249, "CID"], [22, 22, 11, 11, "CID"], [22, 22, 25, 25, "CID"], [22, 22, 173, 173, "CID"], [22, 22, 249, 249, "CID"], [176, 176, 11, 11, "CID"], [176, 176, 25, 25, "CID"], [176, 176, 173, 173, "CID"], [176, 176, 249, 249, "CID"], [246, 246, 11, 11, "CID"], [246, 246, 25, 25, "CID"], [246, 246, 173, 173, "CID"], [246, 246, 249, 249, "CID"], [42, 42, 11, 11, "CID"], [42, 42, 25, 25, "CID"], [42, 42, 173, 173, "CID"], [42, 42, 249, 249, "CID"], [52, 52, 11, 11, "CID"], [52, 52, 25, 25, "CID"], [52, 52, 173, 173, "CID"], [52, 52, 249, 249, "CID"], [113, 113, 11, 11, "CID"], [113, 113, 25, 25, "CID"], [113, 113, 173, 173, "CID"], [113, 113, 249, 249, "CID"], [44, 46, 11, 11, "CID"], [44, 46, 25, 25, "CID"], [44, 46, 173, 173, "CID"], [44, 46, 249, 249, "CID"], [54, 56, 11, 11, "CID"], [54, 56, 25, 25, "CID"], [54, 56, 173, 173, "CID"], [54, 56, 249, 249, "CID"], [117, 119, 11, 11, "CID"], [117, 119, 25, 25, "CID"], [117, 119, 173, 173, "CID"], [117, 119, 249, 249, "CID"]]], "clusters": [], "translated": "<0>NIK-247</0>对胆碱酯酶和<11>东莨菪碱</11>诱发的<7>健忘症</7>的影响。检验了<1>NIK-247</1>对胆碱酯酶、<12>东莨菪碱</12>诱导的<8>健忘症</8>和自发运动的影响，并与众所周知的胆碱酯酶抑制剂<15>他克林</15>和<18>E-2020</18>进行了比较。 <2>NIK-247</2>、<16>tacrine</16>和<19>E-2020</19>都强烈抑制人红细胞中的乙酰胆碱酯酶(AChE) (IC50s = 1.0 x10(-6)、2.9 x10(-7)和3.7x10(-8) M)。此外，<3>NIK-247</3>和<17>tacrine</17>，而非<20>E-2020</20>，强烈抑制人血清中的丁酰胆碱转移酶(BuChE)。所有三种药物均对AChE活性产生混合抑制作用。此外，<4>NIK-247</4>对AChE的抑制作用是可逆的。所有化合物在0.1-1毫克/千克体重灌胃时均能显著改善被动回避任务中<13>东莨菪碱</13>(0.5 mg/kg皮下注射)引起的<9>健忘症</9>。这三种药物在1和3毫克/千克体重灌胃时均未显著减少大鼠的自发运动。这些研究结果表明，<5>NIK-247</5>在低剂量(0.1-1毫克/千克体重灌胃)下可以改善<14>东莨菪碱</14>诱导的<10>健忘症</10>，但不影响自发运动。这些研究结果表明，<6>NIK-247</6>可能是治疗<21>阿尔茨海默病</21>的有效药物。", "revised": true}
{"doc_key": "8766220", "sentences": [["Nightmares", "and", "hallucinations", "after", "long", "-", "term", "intake", "of", "tramadol", "combined", "with", "antidepressants", ".", "Tramadol", "is", "a", "weak", "opioid", "with", "effects", "on", "adrenergic", "and", "serotonergic", "neurotransmission", "that", "is", "used", "to", "treat", "cancer", "pain", "and", "chronic", "non", "malignant", "pain", ".", "This", "drug", "was", "initiated", "in", "association", "with", "paroxetine", "and", "dosulepine", "hydrochloride", "in", "a", "tetraparetic", "patient", "with", "chronic", "pain", ".", "Fifty", "-", "six", "days", "after", "initiation", "of", "the", "treatment", "the", "patient", "presented", "hallucinations", "that", "only", "stopped", "after", "the", "withdrawal", "of", "psycho", "-", "active", "drugs", "and", "tramadol", ".", "The", "case", "report", "questions", "the", "long", "term", "use", "of", "pain", "killers", "combined", "with", "psycho", "-", "active", "drugs", "in", "chronic", "non", "malignant", "pain", ",", "especially", "if", "pain", "is", "under", "control", "."]], "ner": [[[9, 9, "Chemical"], [14, 14, "Chemical"], [83, 83, "Chemical"], [2, 2, "Disease"], [70, 70, "Disease"], [46, 46, "Chemical"], [48, 49, "Chemical"], [31, 31, "Disease"], [32, 32, "Disease"], [37, 37, "Disease"], [94, 94, "Disease"], [106, 106, "Disease"], [110, 110, "Disease"], [55, 56, "Disease"]]], "relations": [[[9, 9, 2, 2, "CID"], [9, 9, 70, 70, "CID"], [14, 14, 2, 2, "CID"], [14, 14, 70, 70, "CID"], [83, 83, 2, 2, "CID"], [83, 83, 70, 70, "CID"], [46, 46, 2, 2, "CID"], [46, 46, 70, 70, "CID"], [48, 49, 2, 2, "CID"], [48, 49, 70, 70, "CID"]]], "clusters": [], "translated": "长期摄入<0>曲马多</0>与抗抑郁药联合后的噩梦和<3>幻觉</3>。 <1>曲马多</1>是一种弱阿片类药物，对肾上腺素能和血清素能神经传递有影响，用于治疗<7>癌症</7><8>疼痛</8>和慢性非恶性<9>疼痛</9>。该药物与<5>帕罗西汀</5>和<6>盐酸多舒平</6>联合用于一名患有<13>慢性疼痛</13>的四肢瘫痪患者。治疗开始后56天，患者出现<4>幻觉</4>，只有在停用<2>曲马多</2>和精神活性药物后才停止。该病例报告质疑长期使用<10>止痛药</10>联合精神活性药物治疗慢性非恶性<11>疼痛</11>，尤其是当<12>疼痛</12>得到控制时。", "revised": true}
{"doc_key": "8441146", "sentences": [["Apparent", "cure", "of", "rheumatoid", "arthritis", "by", "bone", "marrow", "transplantation", ".", "We", "describe", "the", "induction", "of", "sustained", "remissions", "and", "possible", "cure", "of", "severe", "erosive", "rheumatoid", "arthritis", "(", "RA", ")", "by", "bone", "marrow", "transplantation", "(", "BMT", ")", "in", "2", "patients", ".", "BMT", "was", "used", "to", "treat", "severe", "aplastic", "anemia", "which", "was", "caused", "by", "gold", "in", "one", "case", "and", "D", "-", "penicillamine", "in", "the", "other", ".", "In", "the", "8", "and", "6", "years", "since", "the", "transplants", "(", "representing", "8", "and", "4", "years", "since", "cessation", "of", "all", "immunosuppressive", "therapy", ",", "respectively", ")", ",", "the", "RA", "in", "each", "case", "has", "been", "completely", "quiescent", ".", "Although", "short", "term", "remission", "of", "severe", "RA", "following", "BMT", "has", "been", "reported", ",", "these", "are", "the", "first", "cases", "for", "which", "prolonged", "followup", "has", "been", "available", ".", "This", "experience", "raises", "the", "question", "of", "the", "role", "of", "BMT", "itself", "as", "a", "therapeutic", "option", "for", "patients", "with", "uncontrolled", "destructive", "synovitis", "."]], "ner": [[[51, 51, "Chemical"], [45, 46, "Disease"], [56, 58, "Chemical"], [3, 4, "Disease"], [23, 24, "Disease"], [26, 26, "Disease"], [89, 89, "Disease"], [104, 104, "Disease"], [144, 144, "Disease"]]], "relations": [[[51, 51, 45, 46, "CID"], [56, 58, 45, 46, "CID"]]], "clusters": [], "translated": "<3>类风湿性关节炎</3>骨髓移植明显治愈。我们描述了在两名患者中通过骨髓移植 (BMT) 诱导持续缓解和可能治愈严重侵蚀性<4>类风湿性关节炎</4> (<5>RA</5>) 的情况。BMT用于治疗一个患者的重度<1>再生障碍性贫血</1>，其原因是<0>金</0>，而用于治疗另一名患者的重度<1>再生障碍性贫血</1>是由<2>D-青霉胺</2>引起的。自移植以来已经过去了 8 年和 6 年（分别代表所有免疫抑制治疗停止后的第 8 年和第 4 年），每例患者中的<6>RA</6>都完全停止。虽然已经报道了 BMT 后严重<7>RA</7>的短期缓解，但这些是第一批可以进行长期随访的病例。这一经验提出了 BMT 本身作为治疗患有不受控制的破坏性<8>滑膜炎</8>患者的选择。", "revised": true}
{"doc_key": "11524350", "sentences": [["Systemic", "toxicity", "and", "resuscitation", "in", "bupivacaine", "-", ",", "levobupivacaine", "-", ",", "or", "ropivacaine", "-", "infused", "rats", ".", "We", "compared", "the", "systemic", "toxicity", "of", "bupivacaine", ",", "levobupivacaine", ",", "and", "ropivacaine", "in", "anesthetized", "rats", ".", "We", "also", "compared", "the", "ability", "to", "resuscitate", "rats", "after", "lethal", "doses", "of", "these", "local", "anesthetics", ".", "Bupivacaine", ",", "levobupivacaine", ",", "or", "ropivacaine", "was", "infused", "at", "a", "rate", "of", "2", "mg", ".", "kg", "(", "-", "1", ")", ".", "min", "(", "-", "1", ")", "while", "electrocardiogram", ",", "electroencephalogram", ",", "and", "arterial", "pressure", "were", "continuously", "monitored", ".", "When", "asystole", "was", "recorded", ",", "drug", "infusion", "was", "stopped", "and", "a", "resuscitation", "sequence", "was", "begun", ".", "Epinephrine", "0", ".", "01", "mg", "/", "kg", "was", "administered", "at", "1", "-", "min", "intervals", "while", "external", "cardiac", "compressions", "were", "applied", ".", "Resuscitation", "was", "considered", "successful", "when", "a", "systolic", "arterial", "pressure", ">", "or", "=", "100", "mm", "Hg", "was", "achieved", "within", "5", "min", ".", "The", "cumulative", "doses", "of", "levobupivacaine", "and", "ropivacaine", "that", "produced", "seizures", "were", "similar", "and", "were", "larger", "than", "those", "of", "bupivacaine", ".", "The", "cumulative", "doses", "of", "levobupivacaine", "that", "produced", "dysrhythmias", "and", "asystole", "were", "smaller", "than", "the", "corresponding", "doses", "of", "ropivacaine", ",", "but", "they", "were", "larger", "than", "those", "of", "bupivacaine", ".", "The", "number", "of", "successful", "resuscitations", "did", "not", "differ", "among", "groups", ".", "However", ",", "a", "smaller", "dose", "of", "epinephrine", "was", "required", "in", "the", "Ropivacaine", "group", "than", "in", "the", "other", "groups", ".", "We", "conclude", "that", "the", "systemic", "toxicity", "of", "levobupivacaine", "is", "intermediate", "between", "that", "of", "ropivacaine", "and", "bupivacaine", "when", "administered", "at", "the", "same", "rate", "and", "that", "ropivacaine", "-", "induced", "cardiac", "arrest", "appears", "to", "be", "more", "susceptible", "to", "treatment", "than", "that", "induced", "by", "bupivacaine", "or", "levobupivacaine", "."]], "ner": [[[8, 8, "Chemical"], [25, 25, "Chemical"], [51, 51, "Chemical"], [149, 149, "Chemical"], [169, 169, "Chemical"], [230, 230, "Chemical"], [265, 265, "Chemical"], [88, 88, "Disease"], [174, 174, "Disease"], [250, 251, "Disease"], [154, 154, "Disease"], [172, 172, "Disease"], [12, 12, "Chemical"], [28, 28, "Chemical"], [54, 54, "Chemical"], [151, 151, "Chemical"], [182, 182, "Chemical"], [215, 215, "Chemical"], [236, 236, "Chemical"], [247, 247, "Chemical"], [5, 5, "Chemical"], [23, 23, "Chemical"], [49, 49, "Chemical"], [163, 163, "Chemical"], [191, 191, "Chemical"], [238, 238, "Chemical"], [263, 263, "Chemical"], [1, 1, "Disease"], [21, 21, "Disease"], [228, 228, "Disease"], [103, 103, "Chemical"], [210, 210, "Chemical"]]], "relations": [[[8, 8, 88, 88, "CID"], [8, 8, 174, 174, "CID"], [8, 8, 250, 251, "CID"], [25, 25, 88, 88, "CID"], [25, 25, 174, 174, "CID"], [25, 25, 250, 251, "CID"], [51, 51, 88, 88, "CID"], [51, 51, 174, 174, "CID"], [51, 51, 250, 251, "CID"], [149, 149, 88, 88, "CID"], [149, 149, 174, 174, "CID"], [149, 149, 250, 251, "CID"], [169, 169, 88, 88, "CID"], [169, 169, 174, 174, "CID"], [169, 169, 250, 251, "CID"], [230, 230, 88, 88, "CID"], [230, 230, 174, 174, "CID"], [230, 230, 250, 251, "CID"], [265, 265, 88, 88, "CID"], [265, 265, 174, 174, "CID"], [265, 265, 250, 251, "CID"], [8, 8, 154, 154, "CID"], [25, 25, 154, 154, "CID"], [51, 51, 154, 154, "CID"], [149, 149, 154, 154, "CID"], [169, 169, 154, 154, "CID"], [230, 230, 154, 154, "CID"], [265, 265, 154, 154, "CID"], [8, 8, 172, 172, "CID"], [25, 25, 172, 172, "CID"], [51, 51, 172, 172, "CID"], [149, 149, 172, 172, "CID"], [169, 169, 172, 172, "CID"], [230, 230, 172, 172, "CID"], [265, 265, 172, 172, "CID"], [12, 12, 88, 88, "CID"], [12, 12, 174, 174, "CID"], [12, 12, 250, 251, "CID"], [28, 28, 88, 88, "CID"], [28, 28, 174, 174, "CID"], [28, 28, 250, 251, "CID"], [54, 54, 88, 88, "CID"], [54, 54, 174, 174, "CID"], [54, 54, 250, 251, "CID"], [151, 151, 88, 88, "CID"], [151, 151, 174, 174, "CID"], [151, 151, 250, 251, "CID"], [182, 182, 88, 88, "CID"], [182, 182, 174, 174, "CID"], [182, 182, 250, 251, "CID"], [215, 215, 88, 88, "CID"], [215, 215, 174, 174, "CID"], [215, 215, 250, 251, "CID"], [236, 236, 88, 88, "CID"], [236, 236, 174, 174, "CID"], [236, 236, 250, 251, "CID"], [247, 247, 88, 88, "CID"], [247, 247, 174, 174, "CID"], [247, 247, 250, 251, "CID"], [12, 12, 154, 154, "CID"], [28, 28, 154, 154, "CID"], [54, 54, 154, 154, "CID"], [151, 151, 154, 154, "CID"], [182, 182, 154, 154, "CID"], [215, 215, 154, 154, "CID"], [236, 236, 154, 154, "CID"], [247, 247, 154, 154, "CID"], [12, 12, 172, 172, "CID"], [28, 28, 172, 172, "CID"], [54, 54, 172, 172, "CID"], [151, 151, 172, 172, "CID"], [182, 182, 172, 172, "CID"], [215, 215, 172, 172, "CID"], [236, 236, 172, 172, "CID"], [247, 247, 172, 172, "CID"]]], "clusters": [], "translated": "<20>布比卡因</20> - 、<0>左旋布比卡因</0> - 或 <12>罗哌卡因</12> 输注大鼠的全身 <27>毒性</27> 和复苏。我们在麻醉大鼠中比较了 <21>布比卡因</21>、<1>左旋布比卡因</1> 和 <13>罗哌卡因</13> 的全身 <28>毒性</28>。我们还比较了这些局部麻醉剂在致死剂量后使大鼠复苏的能力。 <22>布比卡因</22>、<2>左旋布比卡因</2> 或 <14>罗哌卡因</14> 以 2 mg·公斤(-1)·min(-1) 的速度输注，同时连续监测心电图、脑电图和动脉血压。当记录到 <7>心搏停止</7> 时，停止药物输注并开始复苏序列。 <30>肾上腺素</30> 0.01 mg/kg 以 1 分钟的间隔给药，同时进行外部心脏按压。当动脉收缩压在 5 分钟内达到 ≥100 mmHg 时，即认为复苏成功。引起 <10>癫痫发作</10> 的 <3>左旋布比卡因</3> 和 <15>罗哌卡因</15> 的累积剂量相似，但大于 <23>布比卡因</23>。 <4>左旋布比卡因</4> 引起 <11>心律失常</11> 和 <8>心搏停止</8> 的累积剂量小于相应剂量的 <16>罗哌卡因</16>，但大于 <24>布比卡因</24>。成功复苏次数在各组之间没有差异。然而，<17>罗哌卡因</17> 组所需的 <31>肾上腺素</31> 剂量低于其他组。我们得出结论，<5>左旋布比卡因</5> 的全身性 <29>毒性</29> 介于 <18>罗哌卡因</18> 和 <25>布比卡因</25> 之间，且 <19>罗哌卡因</19> 引起的 <9>心脏骤停</9> 似乎比 <26>布比卡因</26> 或 <6>左旋布比卡因</6> 引起的更容易受到治疗。", "revised": true}
{"doc_key": "3703509", "sentences": [["Hyperglycemic", "acidotic", "coma", "and", "death", "in", "Kearns", "-", "Sayre", "syndrome", ".", "This", "paper", "presents", "the", "clinical", "and", "metabolic", "findings", "in", "two", "young", "boys", "with", "long", "-", "standing", "Kearns", "-", "Sayre", "syndrome", ".", "Following", "short", "exposure", "to", "oral", "prednisone", ",", "both", "boys", "developed", "lethargy", ",", "increasing", "somnolence", ",", "polydipsia", ",", "polyphagia", ",", "and", "polyuria", ".", "Both", "presented", "in", "the", "emergency", "room", "with", "profound", "coma", ",", "hypotension", ",", "severe", "hyperglycemia", ",", "and", "acidosis", ".", "Nonketotic", "lactic", "acidosis", "was", "present", "in", "one", "and", "ketosis", "without", "a", "known", "serum", "lactate", "level", "was", "present", "in", "the", "other", ".", "Respiratory", "failure", "rapidly", "ensued", "and", "both", "patients", "expired", "in", "spite", "of", "efforts", "at", "resuscitation", ".", "We", "believe", "these", "two", "cases", "represent", "a", "newly", "described", "and", "catastrophic", "metabolic", "-", "endocrine", "failure", "in", "the", "Kearns", "-", "Sayre", "syndrome", "."]], "ner": [[[37, 37, "Chemical"], [0, 2, "Disease"], [67, 67, "Disease"], [73, 74, "Disease"], [62, 62, "Disease"], [64, 64, "Disease"], [80, 80, "Disease"], [85, 85, "Chemical"], [6, 9, "Disease"], [27, 30, "Disease"], [125, 128, "Disease"], [42, 42, "Disease"], [45, 45, "Disease"], [47, 47, "Disease"], [49, 49, "Disease"], [52, 52, "Disease"], [70, 70, "Disease"], [93, 94, "Disease"]]], "relations": [[[37, 37, 0, 2, "CID"], [37, 37, 67, 67, "CID"], [37, 37, 73, 74, "CID"], [37, 37, 62, 62, "CID"], [37, 37, 64, 64, "CID"], [37, 37, 80, 80, "CID"]]], "clusters": [], "translated": "<1>高血糖性酸中毒昏迷</1>和<8>Kearns-Sayre综合征</8>死亡。本文介绍了两名患有长期<9>Kearns-Sayre综合征</9>的年轻男孩的临床和代谢发现。短期口服<0>泼尼松</0>后，两个男孩都出现了<11>疲倦</11>、逐渐加重的<12>嗜睡</12>、<13>口渴</13>、<14>食欲亢进</14>和<15>尿频</15>。两人都在急诊室就诊时出现深度<4>昏迷</4>、<5>低血压</5>、严重的<2>高血糖</2>和<16>酸中毒</16>。一个患者存在无酮 <3>乳酸酸中毒</3>，另一个患者存在<6>酮症</6>，但血清<7>乳酸</7>水平未知。很快发生了<17>呼吸衰竭</17>，尽管尽力进行复苏，但两名患者还是去世了。我们认为这两个病例代表了新描述的<10>Kearns-Sayre综合征</10>中的一种灾难性代谢内分泌衰竭。", "revised": true}
{"doc_key": "7707116", "sentences": [["Phase", "I", "trial", "of", "13", "-", "cis", "-", "retinoic", "acid", "in", "children", "with", "neuroblastoma", "following", "bone", "marrow", "transplantation", ".", "PURPOSE", ":", "Treatment", "of", "neuroblastoma", "cell", "lines", "with", "13", "-", "cis", "-", "retinoic", "acid", "(", "cis", "-", "RA", ")", "can", "cause", "sustained", "inhibition", "of", "proliferation", ".", "Since", "cis", "-", "RA", "has", "demonstrated", "clinical", "responses", "in", "neuroblastoma", "patients", ",", "it", "may", "be", "effective", "in", "preventing", "relapse", "after", "cytotoxic", "therapy", ".", "This", "phase", "I", "trial", "was", "designed", "to", "determine", "the", "maximal", "-", "tolerated", "dosage", "(", "MTD", ")", ",", "toxicities", ",", "and", "pharmacokinetics", "of", "cis", "-", "RA", "administered", "on", "an", "intermittent", "schedule", "in", "children", "with", "neuroblastoma", "following", "bone", "marrow", "transplantation", "(", "BMT", ")", ".", "PATIENTS", "AND", "METHODS", ":", "Fifty", "-", "one", "assessable", "patients", ",", "2", "to", "12", "years", "of", "age", ",", "were", "treated", "with", "oral", "cis", "-", "RA", "administered", "in", "two", "equally", "divided", "doses", "daily", "for", "2", "weeks", ",", "followed", "by", "a", "2", "-", "week", "rest", "period", ",", "for", "up", "to", "12", "courses", ".", "The", "dose", "was", "escalated", "from", "100", "to", "200", "mg", "/", "m2", "/", "d", "until", "dose", "-", "limiting", "toxicity", "(", "DLT", ")", "was", "observed", ".", "A", "single", "intrapatient", "dose", "escalation", "was", "permitted", ".", "RESULTS", ":", "The", "MTD", "of", "cis", "-", "RA", "was", "160", "mg", "/", "m2", "/", "d", ".", "Dose", "-", "limiting", "toxicities", "in", "six", "of", "nine", "patients", "at", "200", "mg", "/", "m2", "/", "d", "included", "hypercalcemia", "(", "n", "=", "3", ")", ",", "rash", "(", "n", "=", "2", ")", ",", "and", "anemia", "/", "thrombocytopenia", "/", "emesis", "/", "rash", "(", "n", "=", "1", ")", ".", "All", "toxicities", "resolved", "after", "cis", "-", "RA", "was", "discontinued", ".", "Three", "complete", "responses", "were", "observed", "in", "marrow", "metastases", ".", "Serum", "levels", "of", "7", ".", "4", "+", "/", "-", "3", ".", "0", "mumol", "/", "L", "(", "peak", ")", "and", "4", ".", "0", "+", "/", "-", "2", ".", "8", "mumol", "/", "L", "(", "trough", ")", "at", "the", "MTD", "were", "maintained", "during", "14", "days", "of", "therapy", ".", "The", "DLT", "correlated", "with", "serum", "levels", ">", "or", "=", "10", "mumol", "/", "L", ".", "CONCLUSION", ":", "The", "MTD", "of", "cis", "-", "RA", "given", "on", "this", "intermittent", "schedule", "was", "160", "mg", "/", "m2", "/", "d", ".", "Serum", "levels", "known", "to", "be", "effective", "against", "neuroblastoma", "in", "vitro", "were", "achieved", "at", "this", "dose", ".", "The", "DLT", "included", "hypercalcemia", ",", "and", "may", "be", "predicted", "by", "serum", "cis", "-", "RA", "levels", ".", "Monitoring", "of", "serum", "calcium", "and", "cis", "-", "RA", "levels", "is", "indicated", "in", "future", "trials", "."]], "ner": [[[4, 9, "Chemical"], [27, 32, "Chemical"], [34, 36, "Chemical"], [46, 48, "Chemical"], [90, 92, "Chemical"], [131, 133, "Chemical"], [197, 199, "Chemical"], [257, 259, "Chemical"], [336, 338, "Chemical"], [379, 381, "Chemical"], [389, 391, "Chemical"], [225, 225, "Disease"], [371, 371, "Disease"], [232, 232, "Disease"], [246, 246, "Disease"], [240, 240, "Disease"], [242, 242, "Disease"], [244, 244, "Disease"], [13, 13, "Disease"], [23, 23, "Disease"], [54, 54, "Disease"], [101, 101, "Disease"], [359, 359, "Disease"], [85, 85, "Disease"], [177, 177, "Disease"], [211, 211, "Disease"], [254, 254, "Disease"], [270, 270, "Disease"], [387, 387, "Chemical"]]], "relations": [[[4, 9, 225, 225, "CID"], [4, 9, 371, 371, "CID"], [27, 32, 225, 225, "CID"], [27, 32, 371, 371, "CID"], [34, 36, 225, 225, "CID"], [34, 36, 371, 371, "CID"], [46, 48, 225, 225, "CID"], [46, 48, 371, 371, "CID"], [90, 92, 225, 225, "CID"], [90, 92, 371, 371, "CID"], [131, 133, 225, 225, "CID"], [131, 133, 371, 371, "CID"], [197, 199, 225, 225, "CID"], [197, 199, 371, 371, "CID"], [257, 259, 225, 225, "CID"], [257, 259, 371, 371, "CID"], [336, 338, 225, 225, "CID"], [336, 338, 371, 371, "CID"], [379, 381, 225, 225, "CID"], [379, 381, 371, 371, "CID"], [389, 391, 225, 225, "CID"], [389, 391, 371, 371, "CID"], [4, 9, 232, 232, "CID"], [4, 9, 246, 246, "CID"], [27, 32, 232, 232, "CID"], [27, 32, 246, 246, "CID"], [34, 36, 232, 232, "CID"], [34, 36, 246, 246, "CID"], [46, 48, 232, 232, "CID"], [46, 48, 246, 246, "CID"], [90, 92, 232, 232, "CID"], [90, 92, 246, 246, "CID"], [131, 133, 232, 232, "CID"], [131, 133, 246, 246, "CID"], [197, 199, 232, 232, "CID"], [197, 199, 246, 246, "CID"], [257, 259, 232, 232, "CID"], [257, 259, 246, 246, "CID"], [336, 338, 232, 232, "CID"], [336, 338, 246, 246, "CID"], [379, 381, 232, 232, "CID"], [379, 381, 246, 246, "CID"], [389, 391, 232, 232, "CID"], [389, 391, 246, 246, "CID"], [4, 9, 240, 240, "CID"], [27, 32, 240, 240, "CID"], [34, 36, 240, 240, "CID"], [46, 48, 240, 240, "CID"], [90, 92, 240, 240, "CID"], [131, 133, 240, 240, "CID"], [197, 199, 240, 240, "CID"], [257, 259, 240, 240, "CID"], [336, 338, 240, 240, "CID"], [379, 381, 240, 240, "CID"], [389, 391, 240, 240, "CID"], [4, 9, 242, 242, "CID"], [27, 32, 242, 242, "CID"], [34, 36, 242, 242, "CID"], [46, 48, 242, 242, "CID"], [90, 92, 242, 242, "CID"], [131, 133, 242, 242, "CID"], [197, 199, 242, 242, "CID"], [257, 259, 242, 242, "CID"], [336, 338, 242, 242, "CID"], [379, 381, 242, 242, "CID"], [389, 391, 242, 242, "CID"], [4, 9, 244, 244, "CID"], [27, 32, 244, 244, "CID"], [34, 36, 244, 244, "CID"], [46, 48, 244, 244, "CID"], [90, 92, 244, 244, "CID"], [131, 133, 244, 244, "CID"], [197, 199, 244, 244, "CID"], [257, 259, 244, 244, "CID"], [336, 338, 244, 244, "CID"], [379, 381, 244, 244, "CID"], [389, 391, 244, 244, "CID"]]], "clusters": [], "translated": "<0>13-顺式视黄酸</0>在骨髓移植后患有<18>神经母细胞瘤</18>的儿童的 I 期试验。目的：用<1>13-顺式视黄酸</1> (<2>cis-RA</2>)处理<19>神经母细胞瘤</19>细胞系，可引起持续的增殖抑制。由于<3>cis-RA</3>已在<20>神经母细胞瘤</20>患者中显示出临床反应，因此它可能有效预防细胞毒性治疗后的复发。此I期试验旨在确定<4>cis-RA</4>在<21>骨髓移植（BMT）</21>后的<18>神经母细胞瘤</18>儿童间歇服用的最大耐受剂量（MTD）、<23>毒性</23>和药代动力学。患者和方法：51 名年龄在 2 至 12 岁之间的可评估患者接受口服<5>cis-RA</5>治疗，每天分两次等分给药，持续 2 周，然后休息2周，最多12个课程。剂量从100增加到200mg/m2/d，直到观察到剂量限制性<24>毒性</24>（DLT）。允许单次患者内剂量增加。结果：<6>cis-RA</6>的MTD为160mg/m2/d。在200mg/m2/d的9名患者中，有6名出现剂量限制性<25>毒性</25>，包括<11>高钙血症</11>（n=3）、<13>皮疹</13>（n=2）、和<14>皮疹</14>/<15>贫血</15>/<16>血小板减少症</16>/<17>呕吐</17>（n=1）。所有<26>毒性</26>在<7>cis-RA</7>停用后均得到解决。在骨髓<27>转移</27>中观察到三个完全反应。血清水平7.4+/-3.0 mumol/L（峰值）和4.0+/-2.8 mumol/L（谷值）在MTD维持在160mg/m2/d的14天治疗期间。DLT与血清水平>或=10mumol/L相关。结论：<8>cis-RA</8>间歇给药的MTD为160mg/m2/d。在该剂量下达到了已知在体外对<22>神经母细胞瘤</22>有效的血清水平。DLT包括<12>高钙血症</12>，可通过血清<9>cis-RA</9>水平预测。监测血清<28>钙</28>和<10>cis-RA</10>水平将在未来的试验中进行。", "revised": true}
{"doc_key": "1899352", "sentences": [["Ifosfamide", "continuous", "infusion", "without", "mesna", ".", "A", "phase", "I", "trial", "of", "a", "14", "-", "day", "cycle", ".", "Twenty", "patients", "received", "27", "courses", "of", "ifosfamide", "administered", "as", "a", "24", "-", "hour", "continuous", "infusion", "for", "14", "days", "without", "Mesna", ".", "The", "goal", "of", "the", "study", "was", "to", "deliver", "a", "dose", "rate", "and", "total", "cumulative", "dose", "of", "ifosfamide", "that", "would", "be", "comparable", "to", "standard", "bolus", "or", "short", "-", "term", "infusions", "administered", "with", "Mesna", ".", "Dose", "escalations", "proceeded", "from", "200", "to", "300", ",", "400", ",", "450", ",", "500", ",", "and", "550", "mg", "/", "m2", "/", "d", ".", "Four", "patients", "developed", "transient", "microscopic", "hematuria", "at", "400", ",", "450", ",", "and", "500", "mg", "/", "m2", "/", "d", ".", "There", "were", "no", "instances", "of", "macroscopic", "hematuria", ".", "At", "550", "mg", "/", "m2", "/", "d", ",", "three", "patients", "experienced", "nonurologic", "toxicity", ";", "confusion", "(", "1", ")", ",", "nausea", "(", "1", ")", ",", "and", "Grade", "2", "leukopenia", "(", "1", ")", ".", "The", "recommended", "dose", "of", "500", "mg", "/", "m2", "/", "d", "delivers", "a", "total", "dose", "of", "7", "g", "/", "m2", "per", "cycle", ",", "which", "is", "comparable", "to", "that", "delivered", "in", "clinical", "practice", "for", "bolus", "or", "short", "-", "term", "infusion", ".", "Because", "few", "patients", "received", "multiple", "courses", "over", "time", ",", "the", "cumulative", "effects", "are", "indeterminate", "in", "the", "present", "trial", ".", "The", "frequency", "and", "predictability", "of", "hematuria", "are", "not", "precise", ",", "and", "at", "least", "daily", "monitoring", "by", "urine", "Hematest", "is", "essential", ",", "adding", "Mesna", "to", "the", "infusate", "in", "patients", "with", "persistent", "hematuria", ".", "The", "protracted", "infusion", "schedule", "for", "ifosfamide", "permits", "convenient", "outpatient", "administration", "without", "Mesna", "and", "reduces", "the", "drug", "cost", "of", "clinical", "usage", "of", "this", "agent", "by", "up", "to", "890", "per", "cycle", ".", "Clinical", "activity", "was", "demonstrated", "in", "a", "single", "patient", ",", "but", "a", "comparative", "trial", "of", "standard", "bolus", "schedules", "with", "the", "protracted", "infusion", "schedule", "will", "be", "necessary", "to", "determine", "if", "the", "clinical", "effectiveness", "of", "the", "drug", "is", "maintained", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [54, 54, "Chemical"], [247, 247, "Chemical"], [98, 98, "Disease"], [118, 118, "Disease"], [215, 215, "Disease"], [240, 240, "Disease"], [134, 134, "Disease"], [139, 139, "Disease"], [147, 147, "Disease"], [132, 132, "Disease"], [4, 4, "Chemical"], [36, 36, "Chemical"], [69, 69, "Chemical"], [232, 232, "Chemical"], [253, 253, "Chemical"]]], "relations": [[[0, 0, 98, 98, "CID"], [0, 0, 118, 118, "CID"], [0, 0, 215, 215, "CID"], [0, 0, 240, 240, "CID"], [23, 23, 98, 98, "CID"], [23, 23, 118, 118, "CID"], [23, 23, 215, 215, "CID"], [23, 23, 240, 240, "CID"], [54, 54, 98, 98, "CID"], [54, 54, 118, 118, "CID"], [54, 54, 215, 215, "CID"], [54, 54, 240, 240, "CID"], [247, 247, 98, 98, "CID"], [247, 247, 118, 118, "CID"], [247, 247, 215, 215, "CID"], [247, 247, 240, 240, "CID"], [0, 0, 134, 134, "CID"], [23, 23, 134, 134, "CID"], [54, 54, 134, 134, "CID"], [247, 247, 134, 134, "CID"], [0, 0, 139, 139, "CID"], [23, 23, 139, 139, "CID"], [54, 54, 139, 139, "CID"], [247, 247, 139, 139, "CID"], [0, 0, 147, 147, "CID"], [23, 23, 147, 147, "CID"], [54, 54, 147, 147, "CID"], [247, 247, 147, 147, "CID"]]], "clusters": [], "translated": "<0>异环磷酰胺</0>连续输注，不用<12>美司钠</12>。14天周期的一期试验。20名患者接受了27个疗程的<1>异环磷酰胺</1>给药，持续14天，持续24小时连续输注，不含<13>美司钠</13>。该研究的目标是提供与<14>美司钠</14>的标准推注或短期输注相当的<2>异环磷酰胺</2>的剂量率和总累积剂量。剂量从200增加到300、400、450、500和550 mg/m2/d。4名患者在400、450和500 mg/m2/d时出现短暂的<4>镜下血尿</4>。没有肉眼<5>血尿</5>的实例。在550 mg/m2/d时，三名患者出现了非泌尿系统<11>毒性</11>：<8>意识模糊</8>(1)、<9>恶心</9>(1)、<10>2级白细胞减少</10>(1)。推荐剂量为500 mg/m2/d，每个周期的总剂量为7g/m2，这与临床实践中推注或短期输注的剂量相当。由于很少有患者随时间接受多个疗程，因此本试验的累积效应不确定。<6>血尿</6>的频率和可预测性并不精确，至少每天通过尿液Hematest进行监测是必不可少的，在持续性<7>血尿</7>的患者输液中加入<15>美司钠</15>。<3>异环磷酰胺</3>的延长输注时间表允许门诊患者方便地给药，而无需<16>美司钠</16>，并将该药物临床使用的药物成本降低高达每个周期890美元。临床活性在单个患者身上得到证实，但有必要对标准推注方案与延长输注方案进行比较试验，以确定药物的临床有效性是否得以维持。", "revised": true}
{"doc_key": "1355091", "sentences": [["Orthostatic", "hypotension", "occurs", "following", "alpha", "2", "-", "adrenoceptor", "blockade", "in", "chronic", "prazosin", "-", "pretreated", "conscious", "spontaneously", "hypertensive", "rats", ".", "1", ".", "Studies", "were", "performed", "to", "evaluate", "whether", "chronic", "prazosin", "treatment", "alters", "the", "alpha", "2", "-", "adrenoceptor", "function", "for", "orthostatic", "control", "of", "arterial", "blood", "pressure", "in", "conscious", "spontaneously", "hypertensive", "rats", "(", "SHR", ")", ".", "2", ".", "Conscious", "SHR", "(", "male", "300", "-", "350", "g", ")", "were", "subjected", "to", "90", "degrees", "head", "-", "up", "tilts", "for", "60", "s", "following", "acute", "administration", "of", "prazosin", "(", "0", ".", "1", "mg", "kg", "-", "1", "i", ".", "p", ".", ")", "or", "rauwolscine", "(", "3", "mg", "kg", "-", "1", "i", ".", "v", ".", ")", ".", "Orthostatic", "hypotension", "was", "determined", "by", "the", "average", "decrease", "(", "%", ")", "in", "mean", "arterial", "pressure", "(", "MAP", "femoral", ")", "over", "the", "60", "-", "s", "tilt", "period", ".", "The", "basal", "MAP", "of", "conscious", "SHR", "was", "reduced", "to", "a", "similar", "extent", "by", "prazosin", "(", "-", "23", "%", "(", "-", ")", "-", "26", "%", "MAP", ")", "and", "rauwolscine", "(", "-", "16", "%", "(", "-", ")", "-", "33", "%", "MAP", ")", ".", "However", ",", "the", "head", "-", "up", "tilt", "induced", "orthostatic", "hypotension", "in", "the", "SHR", "treated", "with", "prazosin", "(", "-", "16", "%", "MAP", ",", "n", "=", "6", ")", ",", "but", "not", "in", "the", "SHR", "treated", "with", "rauwolscine", "(", "less", "than", "+", "2", "%", "MAP", ",", "n", "=", "6", ")", ".", "3", ".", "Conscious", "SHR", "were", "treated", "for", "4", "days", "with", "prazosin", "at", "2", "mg", "kg", "-", "1", "day", "-", "1", "i", ".", "p", ".", "for", "chronic", "alpha", "1", "-", "adrenoceptor", "blockade", ".", "MAP", "in", "conscious", "SHR", "after", "chronic", "prazosin", "treatment", "was", "14", "%", "lower", "than", "in", "the", "untreated", "SHR", "(", "n", "=", "8", ")", ".", "Head", "-", "up", "tilts", "in", "these", "rats", "did", "not", "produce", "orthostatic", "hypotension", "when", "performed", "either", "prior", "to", "or", "after", "acute", "dosing", "of", "prazosin", "(", "0", ".", "1", "mg", "kg", "-", "1", "i", ".", "p", ".", ")", ".", "Conversely", ",", "administration", "of", "rauwolscine", "(", "3", "mg", "kg", "-", "1", "i", ".", "v", ".", ")", "in", "chronic", "prazosin", "treated", "SHR", "decreased", "the", "basal", "MAP", "by", "12", "-", "31", "%", "(", "n", "=", "4", ")", ",", "and", "subsequent", "tilts", "induced", "further", "drops", "of", "MAP", "by", "19", "-", "23", "%", "in", "these", "rats", ".", "4", ".", "The", "pressor", "responses", "and", "bradycardia", "to", "the", "alpha", "1", "-", "agonist", "cirazoline", "(", "0", ".", "6", "and", "2", "micrograms", "kg", "-", "1", "i", ".", "v", ".", ")", ",", "the", "alpha", "2", "-", "agonist", "Abbott", "-", "53693", "(", "1", "and", "3", "micrograms", "kg", "-", "1", "i", ".", "v", ".", ")", ",", "and", "noradrenaline", "(", "0", ".", "1", "and", "1", ".", "0", "micrograms", "kg", "-", "1", "i", ".", "v", ".", ")", "were", "determined", "in", "conscious", "SHR", "with", "and", "without", "chronic", "prazosin", "pretreatment", ".", "Both", "the", "pressor", "and", "bradycardia", "effects", "of", "cirazoline", "were", "abolished", "in", "chronic", "prazosin", "treated", "SHR", "(", "n", "=", "4", ")", "as", "compared", "to", "the", "untreated", "SHR", "(", "n", "=", "4", ")", ".", "On", "the", "other", "hand", ",", "the", "pressor", "effects", "of", "Abbott", "-", "53693", "were", "similar", "in", "both", "groups", "of", "SHR", ",", "but", "the", "accompanying", "bradycardia", "was", "greater", "in", "SHR", "with", "chronic", "prazosin", "treatment", "than", "without", "such", "treatment", ".", "Furthermore", ",", "the", "bradycardia", "that", "accompanied", "the", "noradrenaline", "-", "induced", "pressor", "effect", "in", "SHR", "was", "similar", "with", "and", "without", "chronic", "prazosin", "treatment", "despite", "a", "47", "-", "71", "%", "reduction", "of", "the", "pressor", "effect", "in", "chronic", "alpha", "1", "-", "receptor", "blocked", "SHR", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "400", "WORDS", ")"]], "ner": [[[11, 11, "Chemical"], [28, 28, "Chemical"], [80, 80, "Chemical"], [148, 148, "Chemical"], [191, 191, "Chemical"], [234, 234, "Chemical"], [262, 262, "Chemical"], [301, 301, "Chemical"], [334, 334, "Chemical"], [449, 449, "Chemical"], [464, 464, "Chemical"], [514, 514, "Chemical"], [541, 541, "Chemical"], [0, 1, "Disease"], [108, 109, "Disease"], [184, 185, "Disease"], [289, 290, "Disease"], [382, 382, "Chemical"], [459, 459, "Chemical"], [16, 16, "Disease"], [47, 47, "Disease"], [404, 406, "Chemical"], [493, 495, "Chemical"], [422, 422, "Chemical"], [528, 528, "Chemical"], [375, 375, "Disease"], [456, 456, "Disease"], [507, 507, "Disease"], [524, 524, "Disease"], [95, 95, "Chemical"], [162, 162, "Chemical"], [210, 210, "Chemical"], [320, 320, "Chemical"]]], "relations": [[[11, 11, 0, 1, "CID"], [11, 11, 108, 109, "CID"], [11, 11, 184, 185, "CID"], [11, 11, 289, 290, "CID"], [28, 28, 0, 1, "CID"], [28, 28, 108, 109, "CID"], [28, 28, 184, 185, "CID"], [28, 28, 289, 290, "CID"], [80, 80, 0, 1, "CID"], [80, 80, 108, 109, "CID"], [80, 80, 184, 185, "CID"], [80, 80, 289, 290, "CID"], [148, 148, 0, 1, "CID"], [148, 148, 108, 109, "CID"], [148, 148, 184, 185, "CID"], [148, 148, 289, 290, "CID"], [191, 191, 0, 1, "CID"], [191, 191, 108, 109, "CID"], [191, 191, 184, 185, "CID"], [191, 191, 289, 290, "CID"], [234, 234, 0, 1, "CID"], [234, 234, 108, 109, "CID"], [234, 234, 184, 185, "CID"], [234, 234, 289, 290, "CID"], [262, 262, 0, 1, "CID"], [262, 262, 108, 109, "CID"], [262, 262, 184, 185, "CID"], [262, 262, 289, 290, "CID"], [301, 301, 0, 1, "CID"], [301, 301, 108, 109, "CID"], [301, 301, 184, 185, "CID"], [301, 301, 289, 290, "CID"], [334, 334, 0, 1, "CID"], [334, 334, 108, 109, "CID"], [334, 334, 184, 185, "CID"], [334, 334, 289, 290, "CID"], [449, 449, 0, 1, "CID"], [449, 449, 108, 109, "CID"], [449, 449, 184, 185, "CID"], [449, 449, 289, 290, "CID"], [464, 464, 0, 1, "CID"], [464, 464, 108, 109, "CID"], [464, 464, 184, 185, "CID"], [464, 464, 289, 290, "CID"], [514, 514, 0, 1, "CID"], [514, 514, 108, 109, "CID"], [514, 514, 184, 185, "CID"], [514, 514, 289, 290, "CID"], [541, 541, 0, 1, "CID"], [541, 541, 108, 109, "CID"], [541, 541, 184, 185, "CID"], [541, 541, 289, 290, "CID"], [382, 382, 16, 16, "CID"], [382, 382, 47, 47, "CID"], [459, 459, 16, 16, "CID"], [459, 459, 47, 47, "CID"], [404, 406, 16, 16, "CID"], [404, 406, 47, 47, "CID"], [493, 495, 16, 16, "CID"], [493, 495, 47, 47, "CID"], [422, 422, 16, 16, "CID"], [422, 422, 47, 47, "CID"], [528, 528, 16, 16, "CID"], [528, 528, 47, 47, "CID"], [382, 382, 375, 375, "CID"], [382, 382, 456, 456, "CID"], [382, 382, 507, 507, "CID"], [382, 382, 524, 524, "CID"], [459, 459, 375, 375, "CID"], [459, 459, 456, 456, "CID"], [459, 459, 507, 507, "CID"], [459, 459, 524, 524, "CID"], [404, 406, 375, 375, "CID"], [404, 406, 456, 456, "CID"], [404, 406, 507, 507, "CID"], [404, 406, 524, 524, "CID"], [493, 495, 375, 375, "CID"], [493, 495, 456, 456, "CID"], [493, 495, 507, 507, "CID"], [493, 495, 524, 524, "CID"], [422, 422, 375, 375, "CID"], [422, 422, 456, 456, "CID"], [422, 422, 507, 507, "CID"], [422, 422, 524, 524, "CID"], [528, 528, 375, 375, "CID"], [528, 528, 456, 456, "CID"], [528, 528, 507, 507, "CID"], [528, 528, 524, 524, "CID"]]], "clusters": [], "translated": "<13>体位性低血压</13>发生在慢性<0>哌唑嗪</0>预处理清醒的自发性<19>高血压</19>大鼠中α2-肾上腺素能受体阻滞后。1.进行的研究旨在评估慢性<1>哌唑嗪</1>治疗是否会改变alpha 2-肾上腺素能受体功能，以在有意识的自发性<20>高血压</20>大鼠(SHR)中对动脉血压进行直立性控制。2.有意识的SHR (男性300-350 g) 在急性给予<2>哌唑嗪</2> (0.1 mg kg - 1 i. p.）或<29>萝芙木辛</29>(3 mg kg - 1 i. v.) 后进行90度抬头倾斜60 s。通过平均动脉压(MAP股动脉压)在60秒倾斜期间的平均下降(%)确定<14>体位性低血压</14>。有意识的SHR的基础MAP分别由<3>哌唑嗪</3>(-23%(-) - 26% MAP) 和<30>萝芙木辛</30>(-16%(-) - 33%MAP)近似降低。相比之下，用<4>哌唑嗪</4>(-16% MAP, n=6)，而不是用<31>萝芙木辛</31>(低于+2% MAP, n=6)处理的SHR，在抬头倾斜后出现<15>直立性低血压</15>。3.有意识的SHR治疗4天，使用2 mg kg - 1i.p.的<5>哌唑嗪</5>进行慢性alpha1-肾上腺素能受体阻塞。治疗后，与未治疗的SHR(n=8)相比，有意识的SHR的MAP降低了14%。这些大鼠在急性给药<7>哌唑嗪</7> (0.1 mg kg - 1i.p.)之前或之后进行抬头倾斜时，不会出现<16>直立性低血压</16>。相反，在慢性<8>哌唑嗪</8>治疗的SHR中，给予<32>萝芙木素</32> (3 mg kg - 1i.v.)可使基础MAP下降12-31% (n=4)，随后的倾斜导致这些大鼠的MAP进一步下降19-23%。4.加压反应和<25>心动过缓</25>对alpha 1-激动剂<17>cirazoline</17> (0.6和2微克kg - 1i.v.)、alpha 2-激动剂<21>Abbott-53693</21> (1和3微克kg - 1i.v.)和<23>去甲肾上腺素</23>(0.1和1.0微克kg - 1i.v.)在有和没有慢性<9>哌唑嗪</9>预处理的有意识SHR中进行测定。与未经治疗的SHR (n = 4)相比，慢性<6>哌唑嗪</6>治疗后，有意识的SHR的MAP降低了14%。慢性<10>哌唑嗪</10>治疗的 SHR(<18>cirazoline</18>)的加压和<26>心动过缓</26>效应如无治疗的 SHR (n = 4)一样被废除。而<22>Abbott-53693</22>的加压效应两组SHR相似，但长期<11>哌唑嗪</11>治疗的组伴随的<27>心动过缓</27>比未受治疗的组更重。此外，<24>去甲肾上腺素</24>引起的升压效应伴随着<28>心动过缓</28>，在有和没有长期<12>哌唑嗪</12>治疗的 SHR 中相似，尽管在慢性alpha1-受体阻塞的 SHR 中压力效应降低了47-71%。 (摘要被截断为400个单词)", "revised": true}
{"doc_key": "18161408", "sentences": [["Myocardial", "infarction", "in", "pregnancy", "associated", "with", "clomiphene", "citrate", "for", "ovulation", "induction", ":", "a", "case", "report", ".", "BACKGROUND", ":", "Clomiphene", "citrate", "(", "CC", ")", "is", "commonly", "prescribed", "for", "ovulation", "induction", ".", "It", "is", "considered", "safe", ",", "with", "minimal", "side", "effects", ".", "Thromboembolism", "is", "a", "rare", "but", "life", "-", "threatening", "complication", "that", "has", "been", "reported", "after", "ovulation", "induction", "with", "CC", ".", "Spontaneous", "coronary", "thrombosis", "or", "thromboembolism", "with", "subsequent", "clot", "lysis", "has", "been", "suggested", "as", "one", "of", "the", "most", "common", "causes", "of", "myocardial", "infarction", "(", "MI", ")", "during", "pregnancy", ",", "with", "a", "subsequently", "normal", "coronary", "angiogram", ".", "CASE", ":", "A", "33", "-", "year", "-", "old", "woman", "with", "a", "5", "-", "week", "gestation", "had", "recently", "received", "CC", "for", "ovulation", "induction", "and", "presented", "with", "chest", "pain", ".", "An", "electrocardiogram", "showed", "a", "lateral", "and", "anterior", "wall", "myocardial", "infarction", ".", "Cardiac", "enzymes", "showed", "a", "peak", "rise", "in", "troponin", "I", "to", "9", ".", "10", "ng", "/", "mL", ".", "An", "initial", "exercise", "stress", "test", "was", "normal", ".", "At", "the", "time", "of", "admission", ",", "the", "patient", "was", "at", "high", "risk", "of", "radiation", "injury", "to", "the", "fetus", ",", "so", "a", "coronary", "angiogram", "was", "postponed", "until", "the", "second", "trimester", ".", "It", "showed", "normal", "coronary", "vessels", ".", "CONCLUSION", ":", "This", "appears", "to", "be", "the", "first", "reported", "case", "documenting", "a", "possible", "association", "between", "CC", "and", "myocardial", "infarction", ".", "Thrombosis", "might", "be", "a", "rare", "but", "hazardous", "complication", "of", "CC", ".", "Given", "this", "life", "-", "threatening", "complication", ",", "appropriate", "prophylactic", "measures", "should", "be", "used", "in", "high", "-", "risk", "woman", "undergoing", "ovarian", "stimulation", "."]], "ner": [[[6, 7, "Chemical"], [18, 19, "Chemical"], [21, 21, "Chemical"], [57, 57, "Chemical"], [112, 112, "Chemical"], [209, 209, "Chemical"], [223, 223, "Chemical"], [0, 1, "Disease"], [79, 80, "Disease"], [82, 82, "Disease"], [130, 131, "Disease"], [211, 212, "Disease"], [40, 40, "Disease"], [63, 63, "Disease"], [60, 61, "Disease"], [119, 120, "Disease"], [171, 172, "Disease"], [214, 214, "Disease"]]], "relations": [[[6, 7, 0, 1, "CID"], [6, 7, 79, 80, "CID"], [6, 7, 82, 82, "CID"], [6, 7, 130, 131, "CID"], [6, 7, 211, 212, "CID"], [18, 19, 0, 1, "CID"], [18, 19, 79, 80, "CID"], [18, 19, 82, 82, "CID"], [18, 19, 130, 131, "CID"], [18, 19, 211, 212, "CID"], [21, 21, 0, 1, "CID"], [21, 21, 79, 80, "CID"], [21, 21, 82, 82, "CID"], [21, 21, 130, 131, "CID"], [21, 21, 211, 212, "CID"], [57, 57, 0, 1, "CID"], [57, 57, 79, 80, "CID"], [57, 57, 82, 82, "CID"], [57, 57, 130, 131, "CID"], [57, 57, 211, 212, "CID"], [112, 112, 0, 1, "CID"], [112, 112, 79, 80, "CID"], [112, 112, 82, 82, "CID"], [112, 112, 130, 131, "CID"], [112, 112, 211, 212, "CID"], [209, 209, 0, 1, "CID"], [209, 209, 79, 80, "CID"], [209, 209, 82, 82, "CID"], [209, 209, 130, 131, "CID"], [209, 209, 211, 212, "CID"], [223, 223, 0, 1, "CID"], [223, 223, 79, 80, "CID"], [223, 223, 82, 82, "CID"], [223, 223, 130, 131, "CID"], [223, 223, 211, 212, "CID"], [6, 7, 40, 40, "CID"], [6, 7, 63, 63, "CID"], [18, 19, 40, 40, "CID"], [18, 19, 63, 63, "CID"], [21, 21, 40, 40, "CID"], [21, 21, 63, 63, "CID"], [57, 57, 40, 40, "CID"], [57, 57, 63, 63, "CID"], [112, 112, 40, 40, "CID"], [112, 112, 63, 63, "CID"], [209, 209, 40, 40, "CID"], [209, 209, 63, 63, "CID"], [223, 223, 40, 40, "CID"], [223, 223, 63, 63, "CID"]]], "clusters": [], "translated": " <7>妊娠期心肌梗死</7>与<0>克罗米芬柠檬酸盐</0>（<2>CC</2>）促排卵相关：一例报告。背景：<1>克罗米芬柠檬酸盐</1>（<2>CC</2>）通常用于诱导排卵。它被认为是安全的，副作用最小。 <12>血栓栓塞</12>是一种罕见但危及生命的并发症，在使用<3>CC</3>诱导排卵后已有报道。自发性<14>冠状动脉血栓形成</14>或<13>血栓栓塞</13>以及随后的血块溶解已被认为是<8>心肌梗死</8>（<9>MI</9>）在怀孕期间的最常见病因，而冠状动脉造影结果则达到了正常水平。 案例：一名妊娠5周的33岁女性最近接受了<4>CC</4>诱导排卵，并出现了<15>胸痛</15>。心电图显示侧壁和前壁<10>心肌梗塞</10>。心肌酶显示肌钙蛋白I达到9.10 ng/mL的峰值升高。最初的运动压力测试是正常的。入院时患者胎儿<16>放射损伤</16>的风险很高，所以冠状动脉造影直到孕中期才进行。结果显示冠状动脉正常。结论：这似乎是第一个报告证明了<5>CC</5>和<11>心肌梗死</11>之间可能存在的关联。然而，<17>血栓形成</17>可以是<6>CC</6>的一种罕见但危险并发症。鉴于这种危及生命的并发症，对于接受卵巢刺激的高危女性需要采取适当的预防措施。", "revised": true}
{"doc_key": "12101159", "sentences": [["Delayed", "asystolic", "cardiac", "arrest", "after", "diltiazem", "overdose", ";", "resuscitation", "with", "high", "dose", "intravenous", "calcium", ".", "A", "51", "year", "old", "man", "took", "a", "mixed", "overdose", "including", "1", ".", "8", "-", "3", ".", "6", "g", "of", "diltiazem", ",", "paracetamol", ",", "aspirin", ",", "isosorbide", "nitrate", ",", "and", "alcohol", ".", "He", "initially", "presented", "to", "hospital", "after", "six", "hours", "with", "mild", "hypotension", "and", "was", "treated", "with", "activated", "charcoal", "and", "intravenous", "fluids", ".", "Eighteen", "hours", "after", "the", "overdose", "he", "had", "two", "generalised", "tonic", "-", "clonic", "seizures", ".", "The", "patient", "remained", "unresponsive", "with", "junctional", "bradycardia", ",", "unrecordable", "blood", "pressure", ",", "and", "then", "became", "asystolic", ".", "He", "was", "resuscitated", "with", "high", "dose", "(", "13", ".", "5", "g", ")", "intravenous", "calcium", "and", "adrenaline", "(", "epinephrine", ")", ".", "He", "required", "inotropic", "support", "and", "temporary", "pacing", "over", "the", "next", "48", "hours", ".", "This", "case", "suggests", "there", "is", "a", "role", "for", "aggressive", "high", "dose", "intravenous", "calcium", "therapy", "in", "severe", "diltiazem", "overdose", ",", "particularly", "with", "the", "onset", "of", "asystole", ".", "It", "should", "be", "considered", "early", "in", "cases", "of", "cardiac", "arrest", "after", "diltiazem", "overdose", ".", "The", "case", "also", "highlights", "the", "problems", "with", "delayed", "toxicity", "when", "whole", "bowel", "irrigation", "is", "not", "administered", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [147, 147, "Chemical"], [168, 168, "Chemical"], [1, 1, "Disease"], [2, 3, "Disease"], [96, 96, "Disease"], [155, 155, "Disease"], [165, 166, "Disease"], [6, 6, "Disease"], [23, 23, "Disease"], [71, 71, "Disease"], [148, 148, "Disease"], [169, 169, "Disease"], [56, 56, "Disease"], [87, 87, "Disease"], [13, 13, "Chemical"], [111, 111, "Chemical"], [143, 143, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [40, 40, "Chemical"], [41, 41, "Chemical"], [44, 44, "Chemical"], [113, 113, "Chemical"], [115, 115, "Chemical"], [76, 79, "Disease"], [179, 179, "Disease"]]], "relations": [[[5, 5, 1, 1, "CID"], [5, 5, 2, 3, "CID"], [5, 5, 96, 96, "CID"], [5, 5, 155, 155, "CID"], [5, 5, 165, 166, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 2, 3, "CID"], [34, 34, 96, 96, "CID"], [34, 34, 155, 155, "CID"], [34, 34, 165, 166, "CID"], [147, 147, 1, 1, "CID"], [147, 147, 2, 3, "CID"], [147, 147, 96, 96, "CID"], [147, 147, 155, 155, "CID"], [147, 147, 165, 166, "CID"], [168, 168, 1, 1, "CID"], [168, 168, 2, 3, "CID"], [168, 168, 96, 96, "CID"], [168, 168, 155, 155, "CID"], [168, 168, 165, 166, "CID"], [5, 5, 6, 6, "CID"], [5, 5, 23, 23, "CID"], [5, 5, 71, 71, "CID"], [5, 5, 148, 148, "CID"], [5, 5, 169, 169, "CID"], [34, 34, 6, 6, "CID"], [34, 34, 23, 23, "CID"], [34, 34, 71, 71, "CID"], [34, 34, 148, 148, "CID"], [34, 34, 169, 169, "CID"], [147, 147, 6, 6, "CID"], [147, 147, 23, 23, "CID"], [147, 147, 71, 71, "CID"], [147, 147, 148, 148, "CID"], [147, 147, 169, 169, "CID"], [168, 168, 6, 6, "CID"], [168, 168, 23, 23, "CID"], [168, 168, 71, 71, "CID"], [168, 168, 148, 148, "CID"], [168, 168, 169, 169, "CID"], [5, 5, 56, 56, "CID"], [34, 34, 56, 56, "CID"], [147, 147, 56, 56, "CID"], [168, 168, 56, 56, "CID"], [5, 5, 87, 87, "CID"], [34, 34, 87, 87, "CID"], [147, 147, 87, 87, "CID"], [168, 168, 87, 87, "CID"]]], "clusters": [], "translated": "<0> 地尔硫卓 </0><9> 过量 </9>后延迟<4> 心脏骤停 </4><5> 心脏骤停 </5>；用高剂量静脉内<16> 钙 </16>复苏。一名51岁的男子服用混合<10>过量</10>，包括1.8-3.6克<1>地尔硫卓</1>、<19>扑热息痛</19>、<20>阿司匹林</20>、<21>异山梨醇</21><22>硝酸盐</22>和<23>酒精</23>。他最初在6小时后因轻度<14>低血压</14>入院，并接受活性炭和静脉输液治疗。 <11> 过量服用 </11>后18小时，他出现了两次全身性<26>强直-阵挛发作</26>。患者对交界性<15>心动过缓</15>没有反应，血压无法记录，然后变为<6>心搏停止</6>。他通过静脉注射高剂量（13.5 g）<17>钙</17>和<24>肾上腺素</24>（<25>肾上腺素</25>）复苏。在接下来的48小时内，他需要正性肌力支持和临时起搏。该病例表明，在严重<2>地尔硫卓</2><12>过量服用</12>时，特别是在<7>心搏停止</7>的情况下，应及早考虑用高剂量静脉内<18>钙</18>疗法。在<3>地尔硫卓</3><13>过量</13>后出现<8>心脏骤停</8>的情况下，也应及早考虑使用。该案例还强调了在不进行全肠冲洗时延迟<27>毒性</27>的问题。", "revised": true}
{"doc_key": "17786501", "sentences": [["Disulfiram", "-", "induced", "transient", "optic", "and", "peripheral", "neuropathy", ":", "a", "case", "report", ".", "AIM", ":", "To", "report", "a", "case", "of", "optic", "and", "peripheral", "neuropathy", "after", "chronic", "use", "of", "disulfiram", "for", "alcohol", "dependence", "management", ".", "MATERIALS", "AND", "METHODS", ":", "A", "case", "report", ".", "RESULTS", ":", "A", "57", "-", "year", "-", "old", "male", "presented", "with", "gradual", "loss", "of", "vision", "in", "both", "eyes", "with", "intermittent", "headaches", "for", "2", "months", ".", "He", "also", "complained", "of", "paraesthesia", "with", "numbness", "in", "both", "feet", ".", "His", "vision", "was", "6", "/", "15", "and", "2", "/", "60", "in", "the", "right", "and", "left", "eyes", ",", "respectively", ".", "Fundoscopy", "revealed", "bilaterally", "swollen", "optic", "nerve", "heads", ".", "Visual", "field", "testing", "confirmed", "bilateral", "central", "-", "caecal", "scotomata", ".", "He", "had", "been", "taking", "disulfiram", "for", "alcohol", "dependence", "for", "the", "preceding", "3", "years", ".", "Disulfiram", "discontinuation", "lead", "to", "an", "immediate", "symptomatic", "improvement", ".", "CONCLUSION", ":", "Physicians", "initiating", "long", "-", "term", "disulfiram", "therapy", "should", "be", "aware", "of", "these", "adverse", "effects", ".", "They", "should", "recommend", "annual", "ophthalmic", "reviews", "with", "visual", "field", "testing", ".", "Patients", "should", "be", "reassured", "with", "respect", "to", "the", "reversibility", "of", "these", "adverse", "effects", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [119, 119, "Chemical"], [129, 129, "Chemical"], [145, 145, "Chemical"], [4, 7, "Disease"], [20, 23, "Disease"], [71, 71, "Disease"], [113, 113, "Disease"], [30, 31, "Disease"], [121, 122, "Disease"], [54, 56, "Disease"], [62, 62, "Disease"], [73, 73, "Disease"]]], "relations": [[[0, 0, 4, 7, "CID"], [0, 0, 20, 23, "CID"], [28, 28, 4, 7, "CID"], [28, 28, 20, 23, "CID"], [119, 119, 4, 7, "CID"], [119, 119, 20, 23, "CID"], [129, 129, 4, 7, "CID"], [129, 129, 20, 23, "CID"], [145, 145, 4, 7, "CID"], [145, 145, 20, 23, "CID"], [0, 0, 71, 71, "CID"], [28, 28, 71, 71, "CID"], [119, 119, 71, 71, "CID"], [129, 129, 71, 71, "CID"], [145, 145, 71, 71, "CID"], [0, 0, 113, 113, "CID"], [28, 28, 113, 113, "CID"], [119, 119, 113, 113, "CID"], [129, 129, 113, 113, "CID"], [145, 145, 113, 113, "CID"]]], "clusters": [], "translated": "<0>双硫仑</0> - 诱发的短暂性<5>视神经和周围神经病变</5>：病例报告。目的：报告一例长期使用<1>双硫仑</1>治疗<9>酒精依赖</9>后发生<6>视神经和周围神经病变</6>的病例。材料和方法：病例报告。结果：一名57岁男性因双眼逐渐<11>视力丧失</11>和间歇性<12>头痛</12> 2个月就诊。他还抱怨双脚<7>感觉异常</7>伴随<13>麻木</13>。他的右眼和左眼视力分别为6/15和2/60。眼底检查显示双侧视神经乳头肿胀。视野检查证实双侧中央盲肠<8>盲区</8>。在过去的3年里，他一直服用<2>双硫仑</2>治疗<10>酒精依赖</10>。停用<3>双硫仑</3>立即改善他的症状。结论：开始长期使用<4>双硫仑</4>的医生应该意识到这些不良反应。他们应该推荐每年进行一次视野测试的眼科检查。患者应该对这些不良反应的可逆性放心。", "revised": true}
{"doc_key": "17574447", "sentences": [["Hepatonecrosis", "and", "cholangitis", "related", "to", "long", "-", "term", "phenobarbital", "therapy", ":", "an", "autopsy", "report", "of", "two", "patients", ".", "Phenobarbital", "(", "PB", ")", "has", "a", "reputation", "for", "safety", ",", "and", "it", "is", "commonly", "believed", "that", "PB", "-", "related", "increases", "in", "serum", "aminotransferase", "levels", "do", "not", "indicate", "or", "predict", "the", "development", "of", "significant", "chronic", "liver", "disease", ".", "Here", "we", "report", "of", "two", "adult", "patients", "with", "a", "long", "history", "of", "epilepsy", "treated", "with", "PB", "who", "died", "suddenly", ":", "one", "as", "consequence", "of", "cardiac", "arrest", ",", "the", "other", "of", "acute", "bronchopneumonia", ".", "At", "autopsy", ",", "analysis", "of", "liver", "parenchyma", "revealed", "rich", "portal", "inflammatory", "infiltrate", ",", "which", "consisted", "of", "mixed", "eosinophil", "and", "monocyte", "cells", ",", "associated", "with", "several", "foci", "of", "necrosis", "surrounded", "by", "a", "hard", "ring", "of", "non", "-", "specific", "granulomatous", "tissue", ".", "Inflammatory", "reactions", "of", "internal", "and", "external", "hepatic", "biliary", "ducts", "were", "also", "seen", ".", "Our", "findings", "illustrate", "that", "PB", "may", "be", "associated", "with", "chronic", "liver", "damage", ",", "which", "may", "lead", "to", "more", "serious", "and", "deleterious", "consequences", ".", "For", "this", "reason", ",", "each", "clinician", "should", "recognize", "this", "entity", "in", "the", "differential", "diagnosis", "of", "PB", "-", "related", "asymptomatic", "chronic", "hepatic", "enzyme", "dysfunction", "."]], "ner": [[[8, 8, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [34, 34, "Chemical"], [70, 70, "Chemical"], [145, 145, "Chemical"], [179, 179, "Chemical"], [2, 2, "Disease"], [52, 53, "Disease"], [151, 152, "Disease"], [67, 67, "Disease"], [79, 80, "Disease"], [86, 86, "Disease"], [115, 115, "Disease"], [183, 186, "Disease"]]], "relations": [[[8, 8, 2, 2, "CID"], [18, 18, 2, 2, "CID"], [20, 20, 2, 2, "CID"], [34, 34, 2, 2, "CID"], [70, 70, 2, 2, "CID"], [145, 145, 2, 2, "CID"], [179, 179, 2, 2, "CID"], [8, 8, 52, 53, "CID"], [8, 8, 151, 152, "CID"], [18, 18, 52, 53, "CID"], [18, 18, 151, 152, "CID"], [20, 20, 52, 53, "CID"], [20, 20, 151, 152, "CID"], [34, 34, 52, 53, "CID"], [34, 34, 151, 152, "CID"], [70, 70, 52, 53, "CID"], [70, 70, 151, 152, "CID"], [145, 145, 52, 53, "CID"], [145, 145, 151, 152, "CID"], [179, 179, 52, 53, "CID"], [179, 179, 151, 152, "CID"]]], "clusters": [], "translated": "与长期<0>苯巴比妥</0>治疗相关的肝坏死和<7>胆管炎</7>：两例尸检报告。<1>苯巴比妥</1> (<2>PB</2>)以安全着称，人们普遍认为<3>PB</3>相关的血清转氨酶水平升高并不表明或预示显着慢性<8>肝病</8>的发展。在这里，我们报告了两名具有长期<10>癫痫病史</10>并接受<4>PB</4>治疗的成年患者突然死亡：一名死于<11>心脏骤停</11>，另一名急性<12>支气管肺炎</12>。尸检时，对肝实质的分析显示门静脉有丰富的炎症浸润，由混合的嗜酸性粒细胞和单核细胞组成，伴有数个<13>坏死</13>病灶，周围环绕着非特异性肉芽肿组织的硬环。还可见肝内外胆管炎症反应。我们的研究结果表明，<5>PB</5>可能与慢性<9>肝损伤</9>有关，这可能导致更严重和有害的后果。因此，每位临床医生都应在<6>PB</6>相关无症状<14>慢性肝酶功能障碍</14>的鉴别诊断中认识到这一点。", "revised": true}
{"doc_key": "950631", "sentences": [["Immunopathology", "of", "penicillamine", "-", "induced", "glomerular", "disease", ".", "Four", "patients", "with", "rheumatoid", "arthritis", "developed", "heavy", "proteinuria", "after", "five", "to", "12", "months", "of", "treatment", "with", "D", "-", "penicillamine", ".", "Light", "microscopy", "of", "renal", "biopsy", "samples", "showed", "minimal", "glomerular", "capillary", "wall", "thickening", "and", "mesangial", "matrix", "increase", ",", "or", "no", "departure", "from", "normal", ".", "Electron", "microscopy", ",", "however", ",", "revealed", "subepithelial", "electron", "-", "dense", "deposits", ",", "fusion", "of", "epithelial", "cell", "foot", "processes", ",", "and", "evidence", "of", "mesangial", "cell", "hyperactivity", ".", "Immunofluorescence", "microscopy", "demonstrated", "granular", "capillary", "wall", "deposits", "of", "IgG", "and", "C3", ".", "The", "findings", "were", "similar", "to", "those", "in", "early", "membranous", "glomerulonephritis", ",", "differences", "being", "observed", "however", "in", "the", "results", "of", "staining", "for", "the", "early", "-", "acting", "complement", "components", "C1q", "and", "C4", ".", "It", "is", "tentatively", "concluded", "that", "complement", "was", "activated", "by", "the", "classical", "pathway", "."]], "ner": [[[2, 2, "Chemical"], [24, 26, "Chemical"], [5, 6, "Disease"], [15, 15, "Disease"], [11, 12, "Disease"], [97, 98, "Disease"]]], "relations": [[[2, 2, 5, 6, "CID"], [24, 26, 5, 6, "CID"], [2, 2, 15, 15, "CID"], [24, 26, 15, 15, "CID"]]], "clusters": [], "translated": "<0>青霉胺</0>诱发的<2>肾小球疾病</2>的免疫病理学。四名<4>类风湿性关节炎</4>患者在接受<1>D-青霉胺</1>治疗5至12个月后出现重度<3>蛋白尿</3>。肾活检标本的光镜显示肾小球毛细血管壁轻微增厚和系膜基质增加，或没有偏离正常。然而，电子显微镜显示<2>上皮下电子致密沉积物</2>、<2>上皮细胞足突融合</2>以及<2>系膜细胞过度活跃</2>的证据。免疫荧光显微镜显示颗粒状毛细血管壁沉积物<2>的IgG和C3</2>。这些发现与早期<5>膜性肾小球肾炎</5>的结果相似，但早期补体成分<2>C1q和C4</2>的染色结果存在差异。初步推断补体是由经典途径激活的。", "revised": true}
{"doc_key": "16710500", "sentences": [["Ethambutol", "-", "associated", "optic", "neuropathy", ".", "INTRODUCTION", ":", "Ethambutol", "is", "used", "in", "the", "treatment", "of", "tuberculosis", ",", "which", "is", "still", "prevalent", "in", "Southeast", "Asia", ",", "and", "can", "be", "associated", "with", "permanent", "visual", "loss", ".", "We", "report", "3", "cases", "which", "presented", "with", "bitemporal", "hemianopia", ".", "CLINICAL", "PICTURE", ":", "Three", "patients", "with", "ethambutol", "-", "associated", "toxic", "optic", "neuropathy", "are", "described", ".", "All", "3", "patients", "had", "loss", "of", "central", "visual", "acuity", ",", "colour", "vision", "(", "Ishihara", ")", "and", "visual", "field", ".", "The", "visual", "field", "loss", "had", "a", "bitemporal", "flavour", ",", "suggesting", "involvement", "of", "the", "optic", "chiasm", ".", "TREATMENT", ":", "Despite", "stopping", "ethambutol", "on", "diagnosis", ",", "visual", "function", "continued", "to", "deteriorate", "for", "a", "few", "months", ".", "Subsequent", "improvement", "was", "mild", "in", "2", "cases", ".", "In", "the", "third", "case", ",", "visual", "acuity", "and", "colour", "vision", "normalised", "but", "the", "optic", "discs", "were", "pale", ".", "OUTCOME", ":", "All", "3", "patients", "had", "some", "permanent", "loss", "of", "visual", "function", ".", "CONCLUSIONS", ":", "Ethambutol", "usage", "is", "associated", "with", "permanent", "visual", "loss", "and", "should", "be", "avoided", "if", "possible", "or", "used", "with", "caution", "and", "proper", "ophthalmological", "follow", "-", "up", ".", "The", "author", "postulates", "that", "in", "cases", "of", "ethambutol", "associated", "chiasmopathy", ",", "ethambutol", "may", "initially", "affect", "the", "optic", "nerves", "and", "subsequently", "progress", "to", "involve", "the", "optic", "chiasm", "."]], "ner": [[[0, 0, "Chemical"], [8, 8, "Chemical"], [50, 50, "Chemical"], [98, 98, "Chemical"], [153, 153, "Chemical"], [185, 185, "Chemical"], [189, 189, "Chemical"], [3, 4, "Disease"], [54, 55, "Disease"], [31, 32, "Disease"], [63, 76, "Disease"], [79, 81, "Disease"], [146, 149, "Disease"], [159, 160, "Disease"], [15, 15, "Disease"], [41, 42, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 54, 55, "CID"], [8, 8, 3, 4, "CID"], [8, 8, 54, 55, "CID"], [50, 50, 3, 4, "CID"], [50, 50, 54, 55, "CID"], [98, 98, 3, 4, "CID"], [98, 98, 54, 55, "CID"], [153, 153, 3, 4, "CID"], [153, 153, 54, 55, "CID"], [185, 185, 3, 4, "CID"], [185, 185, 54, 55, "CID"], [189, 189, 3, 4, "CID"], [189, 189, 54, 55, "CID"], [0, 0, 31, 32, "CID"], [0, 0, 63, 76, "CID"], [0, 0, 79, 81, "CID"], [0, 0, 146, 149, "CID"], [0, 0, 159, 160, "CID"], [8, 8, 31, 32, "CID"], [8, 8, 63, 76, "CID"], [8, 8, 79, 81, "CID"], [8, 8, 146, 149, "CID"], [8, 8, 159, 160, "CID"], [50, 50, 31, 32, "CID"], [50, 50, 63, 76, "CID"], [50, 50, 79, 81, "CID"], [50, 50, 146, 149, "CID"], [50, 50, 159, 160, "CID"], [98, 98, 31, 32, "CID"], [98, 98, 63, 76, "CID"], [98, 98, 79, 81, "CID"], [98, 98, 146, 149, "CID"], [98, 98, 159, 160, "CID"], [153, 153, 31, 32, "CID"], [153, 153, 63, 76, "CID"], [153, 153, 79, 81, "CID"], [153, 153, 146, 149, "CID"], [153, 153, 159, 160, "CID"], [185, 185, 31, 32, "CID"], [185, 185, 63, 76, "CID"], [185, 185, 79, 81, "CID"], [185, 185, 146, 149, "CID"], [185, 185, 159, 160, "CID"], [189, 189, 31, 32, "CID"], [189, 189, 63, 76, "CID"], [189, 189, 79, 81, "CID"], [189, 189, 146, 149, "CID"], [189, 189, 159, 160, "CID"]]], "clusters": [], "translated": "<0>乙胺丁醇</0> - 相关<7>视神经病变</7>。简介：<1>乙胺丁醇</1>用于治疗<14>肺结核</14>，这种疾病在东南亚仍然流行，并且可能与永久性<9>视力丧失</9>有关。我们报告了3例以<15>双侧偏盲</15>就诊的病例。临床图片：描述了三名患有<2>乙胺丁醇</2>-相关的中毒性<8>视神经病变</8>的患者。所有3名患者均<10>丧失中央视力、色觉（石原）和视野</10>。视野缺损<11>具有双颞叶特征</11>，提示视交叉受累。治疗：尽管在诊断时停用了<3>乙胺丁醇</3>，但视功能在几个月内继续恶化。2例随后轻微好转。在第三种情况下，视力和色觉恢复正常，但视盘颜色变浅。结果：所有3名患者都有一定程度的永久性<12>视觉功能丧失</12>。结论：<4>乙胺丁醇</4>的使用与永久性<13>视力丧失</13>有关，应尽可能避免或谨慎使用并进行适当的眼科随访。作者推测，在<5>乙胺丁醇</5>相关视交叉病的病例中，<6>乙胺丁醇</6>最初可能影响视神经，随后进展至累及视交叉。", "revised": true}
{"doc_key": "663266", "sentences": [["Ventricular", "fibrillation", "from", "diatrizoate", "with", "and", "without", "chelating", "agents", ".", "The", "toxicity", "of", "Renografin", "76", "%", "was", "compared", "with", "that", "of", "Hypaque", "76", "%", "by", "selective", "injection", "of", "each", "into", "the", "right", "coronary", "artery", "of", "dogs", ".", "Renografin", "contains", "the", "chelating", "agents", "sodium", "citrate", "and", "disodium", "edetate", ",", "while", "Hypaque", "contains", "calcium", "disodium", "edetate", "and", "no", "sodium", "citrate", ".", "Ventricular", "fibrillation", "occurred", "significantly", "more", "often", "with", "Renografin", ",", "suggesting", "that", "chelating", "agents", "contribute", "to", "toxicity", "in", "coronary", "angiography", "."]], "ner": [[[13, 15, "Chemical"], [21, 23, "Chemical"], [0, 1, "Disease"], [59, 60, "Disease"], [42, 43, "Chemical"], [56, 57, "Chemical"], [45, 46, "Chemical"], [51, 53, "Chemical"], [3, 3, "Chemical"], [49, 49, "Chemical"], [37, 37, "Chemical"], [66, 66, "Chemical"], [11, 11, "Disease"], [74, 74, "Disease"]]], "relations": [[[13, 15, 0, 1, "CID"], [13, 15, 59, 60, "CID"], [21, 23, 0, 1, "CID"], [21, 23, 59, 60, "CID"], [42, 43, 0, 1, "CID"], [42, 43, 59, 60, "CID"], [56, 57, 0, 1, "CID"], [56, 57, 59, 60, "CID"], [45, 46, 0, 1, "CID"], [45, 46, 59, 60, "CID"], [51, 53, 0, 1, "CID"], [51, 53, 59, 60, "CID"]]], "clusters": [], "translated": "<2>心室颤动</2>来自<8>泛影藻酸盐</8>有和没有螯合剂。 <0>Renografin 76%</0>的<12>毒性</12>与<1>Hypaque 76%</1>进行比较，通过将每种一次性注射到狗的右冠状动脉中。 <10>Renografin</10>含有螯合剂<4>柠檬酸钠</4>和<6>依地酸二钠</6>，而<9>Hypaque</9>含有<7>依地酸二钠钙</7>且无<5>柠檬酸钠</5>。结果发现，<11>Renografin</11>导致<3>心室颤动</3>的发生率明显更高，表明螯合剂在冠状动脉造影中导致<13>毒性</13>。", "revised": true}
{"doc_key": "6637851", "sentences": [["Long", "-", "term", "efficacy", "and", "toxicity", "of", "high", "-", "dose", "amiodarone", "therapy", "for", "ventricular", "tachycardia", "or", "ventricular", "fibrillation", ".", "Amiodarone", "was", "administered", "to", "154", "patients", "who", "had", "sustained", ",", "symptomatic", "ventricular", "tachycardia", "(", "VT", ")", "(", "n", "=", "118", ")", "or", "a", "cardiac", "arrest", "(", "n", "=", "36", ")", "and", "who", "were", "refractory", "to", "conventional", "antiarrhythmic", "drugs", ".", "The", "loading", "dose", "was", "800", "mg", "/", "day", "for", "6", "weeks", "and", "the", "maintenance", "dose", "was", "600", "mg", "/", "day", ".", "Sixty", "-", "nine", "percent", "of", "patients", "continued", "treatment", "with", "amiodarone", "and", "had", "no", "recurrence", "of", "symptomatic", "VT", "or", "ventricular", "fibrillation", "(", "VF", ")", "over", "a", "follow", "-", "up", "of", "6", "to", "52", "months", "(", "mean", "+", "/", "-", "standard", "deviation", "14", ".", "2", "+", "/", "-", "8", ".", "2", ")", ".", "Six", "percent", "of", "the", "patients", "had", "a", "nonfatal", "recurrence", "of", "VT", "and", "were", "successfully", "managed", "by", "continuing", "amiodarone", "at", "a", "higher", "dose", "or", "by", "the", "addition", "of", "a", "conventional", "antiarrhythmic", "drug", ".", "One", "or", "more", "adverse", "drug", "reactions", "occurred", "in", "51", "%", "of", "patients", ".", "Adverse", "effects", "forced", "a", "reduction", "in", "the", "dose", "of", "amiodarone", "in", "41", "%", "and", "discontinuation", "of", "amiodarone", "in", "10", "%", "of", "patients", ".", "The", "most", "common", "symptomatic", "adverse", "reactions", "were", "tremor", "or", "ataxia", "(", "35", "%", ")", ",", "nausea", "and", "anorexia", "(", "8", "%", ")", ",", "visual", "halos", "or", "blurring", "(", "6", "%", ")", ",", "thyroid", "function", "abnormalities", "(", "6", "%", ")", "and", "pulmonary", "interstitial", "infiltrates", "(", "5", "%", ")", ".", "Although", "large", "-", "dose", "amiodarone", "is", "highly", "effective", "in", "the", "long", "-", "term", "treatment", "of", "VT", "or", "VF", "refractory", "to", "conventional", "antiarrhythmic", "drugs", ",", "it", "causes", "significant", "toxicity", "in", "approximately", "50", "%", "of", "patients", ".", "However", ",", "when", "the", "dose", "is", "adjusted", "based", "on", "clinical", "response", "or", "the", "development", "of", "adverse", "effects", ",", "75", "%", "of", "patients", "with", "VT", "or", "VF", "can", "be", "successfully", "managed", "with", "amiodarone", "."]], "ner": [[[10, 10, "Chemical"], [19, 19, "Chemical"], [88, 88, "Chemical"], [147, 147, "Chemical"], [184, 184, "Chemical"], [191, 191, "Chemical"], [250, 250, "Chemical"], [312, 312, "Chemical"], [207, 207, "Disease"], [213, 213, "Disease"], [215, 215, "Disease"], [221, 224, "Disease"], [230, 232, "Disease"], [5, 5, "Disease"], [273, 273, "Disease"], [13, 14, "Disease"], [30, 31, "Disease"], [33, 33, "Disease"], [95, 95, "Disease"], [140, 140, "Disease"], [261, 261, "Disease"], [304, 304, "Disease"], [16, 17, "Disease"], [97, 98, "Disease"], [100, 100, "Disease"], [263, 263, "Disease"], [306, 306, "Disease"], [42, 43, "Disease"], [205, 205, "Disease"]]], "relations": [[[10, 10, 207, 207, "CID"], [19, 19, 207, 207, "CID"], [88, 88, 207, 207, "CID"], [147, 147, 207, 207, "CID"], [184, 184, 207, 207, "CID"], [191, 191, 207, 207, "CID"], [250, 250, 207, 207, "CID"], [312, 312, 207, 207, "CID"], [10, 10, 213, 213, "CID"], [19, 19, 213, 213, "CID"], [88, 88, 213, 213, "CID"], [147, 147, 213, 213, "CID"], [184, 184, 213, 213, "CID"], [191, 191, 213, 213, "CID"], [250, 250, 213, 213, "CID"], [312, 312, 213, 213, "CID"], [10, 10, 215, 215, "CID"], [19, 19, 215, 215, "CID"], [88, 88, 215, 215, "CID"], [147, 147, 215, 215, "CID"], [184, 184, 215, 215, "CID"], [191, 191, 215, 215, "CID"], [250, 250, 215, 215, "CID"], [312, 312, 215, 215, "CID"], [10, 10, 221, 224, "CID"], [19, 19, 221, 224, "CID"], [88, 88, 221, 224, "CID"], [147, 147, 221, 224, "CID"], [184, 184, 221, 224, "CID"], [191, 191, 221, 224, "CID"], [250, 250, 221, 224, "CID"], [312, 312, 221, 224, "CID"], [10, 10, 230, 232, "CID"], [19, 19, 230, 232, "CID"], [88, 88, 230, 232, "CID"], [147, 147, 230, 232, "CID"], [184, 184, 230, 232, "CID"], [191, 191, 230, 232, "CID"], [250, 250, 230, 232, "CID"], [312, 312, 230, 232, "CID"]]], "clusters": [], "translated": "大剂量<0>胺碘酮</0>治疗<15>室性心动过速</15>或<22>室颤</22>的远期疗效和<13>毒性</13>。 <1>胺碘酮</1>对154名患有持续性、有症状的<16>室性心动过速</16>（<17>VT</17>）(n=118)或<27>心脏骤停</27>（n=36）并且对常规抗心律失常药物无效的患者进行治疗。负荷剂量为800mg/天，持续6周，维持剂量为600mg/天。69%的患者继续接受<2>胺碘酮</2>治疗，并且没有出现有症状的<18>VT</18>或<23>心室颤动</23> (<24>VF</24>)在6至52个月的随访中（平均值+/-标准偏差14.2+/-8.2)。6%的患者有<19>VT</19>的非致死性复发，并通过继续以较高剂量<3>胺碘酮</3>或通过添加常规抗心律失常药物成功控制。51%的患者发生一种或多种药物不良反应。不良反应迫使41%的患者减少<4>胺碘酮</4>的剂量，并在10%的患者中停用<5>胺碘酮</5>。最常见的症状性不良反应是<28>震颤</28>或<8>共济失调</8>（35%）、<9>恶心</9>和<10>厌食</10>（8%）、<11>视觉晕圈或模糊</11>（6%）、<12>甲状腺功能异常</12>（6%）和肺间质浸润（5%）。尽管大剂量<6>胺碘酮</6>对长期治疗常规抗心律失常药物无效的<20>VT</20>或<25>VF</25>非常有效，但它引起显着的<14>毒性</14>在大约50%的患者中。然而，当根据临床反应或不良反应的发生调整剂量时，75%的<21>VT</21>或<26>VF</26>患者可以使用<7>胺碘酮</7>。", "revised": true}
{"doc_key": "2435991", "sentences": [["Antiarrhythmic", "plasma", "concentrations", "of", "cibenzoline", "on", "canine", "ventricular", "arrhythmias", ".", "Using", "two", "-", "stage", "coronary", "ligation", "-", ",", "digitalis", "-", ",", "and", "adrenaline", "-", "induced", "canine", "ventricular", "arrhythmias", ",", "antiarrhythmic", "effects", "of", "cibenzoline", "were", "examined", "and", "the", "minimum", "effective", "plasma", "concentration", "for", "each", "arrhythmia", "model", "was", "determined", ".", "Cibenzoline", "suppressed", "all", "the", "arrhythmias", ",", "and", "the", "minimum", "effective", "plasma", "concentrations", "for", "arrhythmias", "induced", "by", "24", "-", "h", "coronary", "ligation", ",", "48", "-", "h", "coronary", "ligation", ",", "digitalis", ",", "and", "adrenaline", "were", "1", ".", "9", "+", "/", "-", "0", ".", "9", "(", "by", "8", "mg", "/", "kg", "i", ".", "v", ".", ")", ",", "1", ".", "6", "+", "/", "-", "0", ".", "5", "(", "by", "8", "mg", "/", "kg", "i", ".", "v", ".", ")", ",", "0", ".", "6", "+", "/", "-", "0", ".", "2", "(", "by", "2", "mg", "/", "kg", "i", ".", "v", ".", ")", ",", "and", "3", ".", "5", "+", "/", "-", "1", ".", "3", "(", "by", "5", "mg", "/", "kg", "i", ".", "v", ".", ")", "micrograms", "/", "ml", ",", "respectively", "(", "mean", "+", "/", "-", "SDM", ",", "n", "=", "6", "-", "7", ")", ".", "The", "concentration", "for", "adrenaline", "-", "induced", "arrhythmia", "was", "significantly", "higher", "than", "those", "for", "the", "other", "types", "of", "arrhythmias", ".", "This", "pharmacological", "profile", "is", "similar", "to", "those", "of", "mexiletine", "and", "tocainide", ",", "and", "all", "three", "drugs", "have", "central", "nervous", "system", "(", "CNS", ")", "stimulant", "action", ".", "Because", "cibenzoline", "had", "only", "weak", "hypotensive", "and", "sinus", "node", "depressive", "effects", "and", "was", "found", "to", "be", "orally", "active", "when", "given", "to", "coronary", "ligation", "arrhythmia", "dogs", ",", "its", "clinical", "usefulness", "is", "expected", "."]], "ner": [[[18, 18, "Chemical"], [76, 76, "Chemical"], [7, 8, "Disease"], [26, 27, "Disease"], [43, 43, "Disease"], [52, 52, "Disease"], [61, 61, "Disease"], [190, 190, "Disease"], [201, 201, "Disease"], [252, 252, "Disease"], [22, 22, "Chemical"], [79, 79, "Chemical"], [187, 187, "Chemical"], [4, 4, "Chemical"], [32, 32, "Chemical"], [48, 48, "Chemical"], [230, 230, "Chemical"], [234, 234, "Disease"], [238, 238, "Disease"], [211, 211, "Chemical"], [213, 213, "Chemical"]]], "relations": [[[18, 18, 7, 8, "CID"], [18, 18, 26, 27, "CID"], [18, 18, 43, 43, "CID"], [18, 18, 52, 52, "CID"], [18, 18, 61, 61, "CID"], [18, 18, 190, 190, "CID"], [18, 18, 201, 201, "CID"], [18, 18, 252, 252, "CID"], [76, 76, 7, 8, "CID"], [76, 76, 26, 27, "CID"], [76, 76, 43, 43, "CID"], [76, 76, 52, 52, "CID"], [76, 76, 61, 61, "CID"], [76, 76, 190, 190, "CID"], [76, 76, 201, 201, "CID"], [76, 76, 252, 252, "CID"], [22, 22, 7, 8, "CID"], [22, 22, 26, 27, "CID"], [22, 22, 43, 43, "CID"], [22, 22, 52, 52, "CID"], [22, 22, 61, 61, "CID"], [22, 22, 190, 190, "CID"], [22, 22, 201, 201, "CID"], [22, 22, 252, 252, "CID"], [79, 79, 7, 8, "CID"], [79, 79, 26, 27, "CID"], [79, 79, 43, 43, "CID"], [79, 79, 52, 52, "CID"], [79, 79, 61, 61, "CID"], [79, 79, 190, 190, "CID"], [79, 79, 201, 201, "CID"], [79, 79, 252, 252, "CID"], [187, 187, 7, 8, "CID"], [187, 187, 26, 27, "CID"], [187, 187, 43, 43, "CID"], [187, 187, 52, 52, "CID"], [187, 187, 61, 61, "CID"], [187, 187, 190, 190, "CID"], [187, 187, 201, 201, "CID"], [187, 187, 252, 252, "CID"]]], "clusters": [], "translated": "<13>西苯唑啉</13>对犬<2>室性心律失常</2>的抗心律失常血浆浓度。使用二期冠状动脉结扎、<0>洋地黄</0> -和<10>肾上腺素</10>诱导的犬<3>室性心律失常</3>，检查了<14>西苯林</14>的抗心律失常作用，并确定了每个<4>心律失常</4>模型的最低有效血浆浓度。<15>西苯唑啉</15>抑制了所有<5>心律失常</5>，24小时冠状动脉结扎、48小时冠状动脉结扎、<1>洋地黄</1>和<11>肾上腺素</11>诱导的<6>心律失常</6>的最低有效血浆浓度分别为1.9+/-0.9（按8mg/kg IV）、1.6+/-0.5（按8mg/kg IV）、0.6+/-0.2（按2mg/kg IV）和3.5+/-1.3（按5mg/kg IV）微克/毫升（平均值+/-SDM，n=6-7）。<12>肾上腺素</12>诱导的<7>心律失常</7>的浓度明显高于其他类型的<8>心律失常</8>。这种药理特征与<19>美西律</19>和<20>托卡因</20>相似，这三种药物均具有中枢神经系统（CNS）的兴奋作用。因为<16>西苯唑啉</16>只对窦房结具有微弱的<17>降压</17>和<18>抑制</18>作用，并且发现其在冠状动脉结扎的<9>心律失常</9>犬中具有口服活性，因此具有临床应用的前景。", "revised": true}
{"doc_key": "19319147", "sentences": [["Rapid", "reversal", "of", "anticoagulation", "reduces", "hemorrhage", "volume", "in", "a", "mouse", "model", "of", "warfarin", "-", "associated", "intracerebral", "hemorrhage", ".", "Warfarin", "-", "associated", "intracerebral", "hemorrhage", "(", "W", "-", "ICH", ")", "is", "a", "severe", "type", "of", "stroke", ".", "There", "is", "no", "consensus", "on", "the", "optimal", "treatment", "for", "W", "-", "ICH", ".", "Using", "a", "mouse", "model", ",", "we", "tested", "whether", "the", "rapid", "reversal", "of", "anticoagulation", "using", "human", "prothrombin", "complex", "concentrate", "(", "PCC", ")", "can", "reduce", "hemorrhagic", "blood", "volume", ".", "Male", "CD", "-", "1", "mice", "were", "treated", "with", "warfarin", "(", "2", "mg", "/", "kg", "over", "24", "h", ")", ",", "resulting", "in", "a", "mean", "(", "+", "/", "-", "s", ".", "d", ".", ")", "International", "Normalized", "Ratio", "of", "3", ".", "5", "+", "/", "-", "0", ".", "9", ".", "First", ",", "we", "showed", "that", "an", "intravenous", "administration", "of", "human", "PCC", "rapidly", "reversed", "anticoagulation", "in", "mice", ".", "Second", ",", "a", "stereotactic", "injection", "of", "collagenase", "was", "administered", "to", "induce", "hemorrhage", "in", "the", "right", "striatum", ".", "Forty", "-", "five", "minutes", "later", ",", "the", "animals", "were", "randomly", "treated", "with", "PCC", "(", "100", "U", "/", "kg", ")", "or", "saline", "i", ".", "v", ".", "(", "n", "=", "12", "per", "group", ")", ".", "Twenty", "-", "four", "hours", "after", "hemorrhage", "induction", ",", "hemorrhagic", "blood", "volume", "was", "quantified", "using", "a", "photometric", "hemoglobin", "assay", ".", "The", "mean", "hemorrhagic", "blood", "volume", "was", "reduced", "in", "PCC", "-", "treated", "animals", "(", "6", ".", "5", "+", "/", "-", "3", ".", "1", "microL", ")", "compared", "with", "saline", "controls", "(", "15", ".", "3", "+", "/", "-", "11", ".", "2", "microL", ",", "P", "=", "0", ".", "015", ")", ".", "In", "the", "saline", "group", ",", "45", "%", "of", "the", "mice", "developed", "large", "hematomas", "(", "i", ".", "e", ".", ",", ">", "15", "microL", ")", ".", "In", "contrast", ",", "such", "extensive", "lesions", "were", "never", "found", "in", "the", "PCC", "group", ".", "We", "provide", "experimental", "data", "suggesting", "PCC", "to", "be", "an", "effective", "acute", "treatment", "for", "W", "-", "ICH", "in", "terms", "of", "reducing", "hemorrhagic", "blood", "volume", ".", "Future", "studies", "are", "needed", "to", "assess", "the", "therapeutic", "potential", "emerging", "from", "our", "finding", "for", "human", "W", "-", "ICH", "."]], "ner": [[[12, 12, "Chemical"], [18, 18, "Chemical"], [83, 83, "Chemical"], [15, 16, "Disease"], [21, 22, "Disease"], [26, 26, "Disease"], [46, 46, "Disease"], [307, 307, "Disease"], [333, 333, "Disease"], [5, 5, "Disease"], [149, 149, "Disease"], [193, 193, "Disease"], [63, 65, "Chemical"], [67, 67, "Chemical"], [131, 131, "Chemical"], [167, 167, "Chemical"], [215, 215, "Chemical"], [289, 289, "Chemical"], [297, 297, "Chemical"], [33, 33, "Disease"], [266, 266, "Disease"]]], "relations": [[[12, 12, 15, 16, "CID"], [12, 12, 21, 22, "CID"], [12, 12, 26, 26, "CID"], [12, 12, 46, 46, "CID"], [12, 12, 307, 307, "CID"], [12, 12, 333, 333, "CID"], [18, 18, 15, 16, "CID"], [18, 18, 21, 22, "CID"], [18, 18, 26, 26, "CID"], [18, 18, 46, 46, "CID"], [18, 18, 307, 307, "CID"], [18, 18, 333, 333, "CID"], [83, 83, 15, 16, "CID"], [83, 83, 21, 22, "CID"], [83, 83, 26, 26, "CID"], [83, 83, 46, 46, "CID"], [83, 83, 307, 307, "CID"], [83, 83, 333, 333, "CID"]]], "clusters": [], "translated": "在<0>华法林</0>相关<3>脑出血</3>小鼠模型中，快速逆转抗凝作用可减少<9>出血</9>体积。<1>华法林</1> - 相关的<4>脑出血</4> (W-<5>ICH</5>)是一种严重的<19>中风</19>。W-<6>ICH</6>的最佳治疗方案尚未达成共识。使用小鼠模型，我们测试了使用人<12>凝血酶原复合物浓缩物</12> (<13>PCC</13>)快速逆转抗凝是否可以减少<9>出血</9>血容量。雄性CD-1小鼠用<2>华法林</2>（2mg/kg，超过24小时）治疗，导致平均(+/-s.d.)国际标准化比率为3.5 +/- 0.9。首先，我们发现静脉注射人<14>PCC</14>可迅速逆转小鼠的抗凝作用。其次，立体定向注射胶原酶，诱导右侧纹状体<10>出血</10>。四十五分钟后，动物随机接受<15>PCC</15> (100 U/kg)或生理盐水i.v. (每组n=12)。<11>出血</11>诱导后24小时，使用光度血红蛋白测定法对<9>出血</9>血容量进行定量。与盐水对照组(15.3 +/- 11.2 microL)相比，<16>PCC</16>处理的动物 (6.5 +/- 3.1 microL)的平均<9>出血</9>血量减少，P = 0.015。在盐水组中，45%的小鼠出现大的<20>血肿</20>(即> 15 microL)。相比之下，<17>PCC</17>组从未发现如此广泛的病变。我们提供的实验数据表明，<18>PCC</18>在减少<9>出血</9>性血容量方面是W-<7>ICH</7>的有效急性治疗方法。未来的研究需要评估我们对人类W-<8>ICH</8>发现的治疗潜力。", "revised": true}
{"doc_key": "761833", "sentences": [["Reversal", "of", "ammonia", "coma", "in", "rats", "by", "L", "-", "dopa", ":", "a", "peripheral", "effect", ".", "Ammonia", "coma", "was", "produced", "in", "rats", "within", "10", "to", "15", "minutes", "of", "an", "intraperitonealinjection", "of", "1", ".", "7", "mmol", "NH4CL", ".", "This", "coma", "was", "prevented", "with", "1", ".", "68", "mmol", "L", "-", "dopa", "given", "by", "gastric", "intubation", "15", "minutes", "before", "the", "ammonium", "salt", "injection", ".", "The", "effect", "of", "L", "-", "dopa", "was", "correlated", "with", "a", "decrease", "in", "blood", "and", "brain", "ammonia", ",", "an", "increase", "in", "brain", "dopamine", ",", "and", "an", "increase", "in", "renal", "excretion", "of", "ammonia", "and", "urea", ".", "Intraventricular", "infusion", "of", "dopamine", "sufficient", "to", "raise", "the", "brain", "dopamine", "to", "the", "same", "extent", "did", "not", "prevent", "the", "ammonia", "coma", "nor", "affect", "the", "blood", "and", "brain", "ammonia", "concentrations", ".", "Bilateral", "nephrectomy", "eliminated", "the", "beneficial", "effect", "of", "L", "-", "dopa", "on", "blood", "and", "brain", "ammonia", "and", "the", "ammonia", "coma", "was", "not", "prevented", ".", "Thus", ",", "the", "reduction", "in", "blood", "and", "brain", "ammonia", "and", "the", "prevention", "of", "ammonia", "coma", "after", "L", "-", "dopa", ",", "can", "be", "accounted", "for", "by", "the", "peripheral", "effect", "of", "dopamine", "on", "renal", "function", "rather", "than", "its", "central", "action", ".", "These", "results", "provide", "a", "reasonable", "explanation", "for", "the", "beneficial", "effects", "observed", "in", "some", "encephalopathic", "patients", "receiving", "L", "-", "dopa", "."]], "ner": [[[34, 34, "Chemical"], [3, 3, "Disease"], [16, 16, "Disease"], [37, 37, "Disease"], [113, 113, "Disease"], [141, 141, "Disease"], [160, 160, "Disease"], [2, 2, "Chemical"], [15, 15, "Chemical"], [75, 75, "Chemical"], [90, 90, "Chemical"], [112, 112, "Chemical"], [120, 120, "Chemical"], [137, 137, "Chemical"], [140, 140, "Chemical"], [154, 154, "Chemical"], [159, 159, "Chemical"], [198, 198, "Disease"], [7, 9, "Chemical"], [45, 47, "Chemical"], [63, 65, "Chemical"], [130, 132, "Chemical"], [162, 164, "Chemical"], [201, 203, "Chemical"], [56, 57, "Chemical"], [81, 81, "Chemical"], [97, 97, "Chemical"], [103, 103, "Chemical"], [175, 175, "Chemical"], [92, 92, "Chemical"]]], "relations": [[[34, 34, 3, 3, "CID"], [34, 34, 16, 16, "CID"], [34, 34, 37, 37, "CID"], [34, 34, 113, 113, "CID"], [34, 34, 141, 141, "CID"], [34, 34, 160, 160, "CID"]]], "clusters": [], "translated": " <18>L-dopa</18>对大鼠<7>氨</7><1>昏迷</1>的逆转：外周效应。<8>氨气</8><2>昏迷</2>在大鼠腹腔注射1.7毫摩尔<0>NH4CL</0>后10到15分钟内产生。<3>这种昏迷</3>可以通过在注射<24>铵盐</24>前15分钟口服1.68毫摩尔<19>L-多巴</19>来避免。<20>L-多巴</20>作用与血液和脑<9>氨</9>的减少、脑<25>多巴胺</25>的增加以及肾脏排泄物<10>氨 </10>和<29>尿素</29>的增加相关联。将<26>多巴胺</26>输注到侧脑室内以使大脑<27>多巴胺</27>上升相同程度，并不能预防<11>氨</11><4>昏迷</4>，也不能影响血液和脑部<12>氨</12>浓度。双侧肾切除手术消除了<21>L-多巴</21>对血液和脑<13>氨</13>的积极影响，亦不能预防<14>氨</14><5>昏迷</5>。因此，<22>L-多巴</22>后血液和脑部<15>氨</15>的减少以及<16>氨</16><6>昏迷</6>的预防可以归因于<28>多巴胺</28>在肾脏功能中的外周作用而非其中枢作用。这些结果为一些接受<23>L-多巴</23>治疗的<17>脑病</17>患者观察到的有益效果提供了合理的解释。", "revised": true}
{"doc_key": "10074612", "sentences": [["Hypotension", ",", "bradycardia", ",", "and", "asystole", "after", "high", "-", "dose", "intravenous", "methylprednisolone", "in", "a", "monitored", "patient", ".", "We", "report", "a", "case", "of", "hypotension", ",", "bradycardia", ",", "and", "asystole", "after", "intravenous", "administration", "of", "high", "-", "dose", "methylprednisolone", "in", "a", "73", "-", "year", "-", "old", "patient", "who", "underwent", "electrocardiographic", "(", "ECG", ")", "monitoring", "throughout", "the", "episode", ".", "There", "was", "a", "history", "of", "ischemic", "cardiac", "disease", "9", "years", "earlier", ".", "The", "patient", "was", "admitted", "with", "a", "pulmonary", "-", "renal", "syndrome", "with", "hemoptysis", ",", "rapidly", "progressive", "renal", "failure", ",", "and", "hypoxemia", "that", "required", "mechanical", "ventilation", "in", "the", "intensive", "care", "unit", ".", "After", "receiving", "advanced", "cardiopulmonary", "resuscitation", ",", "the", "patient", "recovered", "cardiac", "rhythm", ".", "The", "ECG", "showed", "a", "junctional", "rhythm", "without", "ventricular", "arrhythmia", ".", "This", "study", "reviews", "the", "current", "proposed", "mechanisms", "of", "sudden", "death", "after", "a", "high", "dose", "of", "intravenous", "methylprednisolone", "(", "IVMP", ")", ".", "These", "mechanisms", "are", "not", "well", "understood", "because", ",", "in", "most", "cases", ",", "the", "patients", "were", "not", "monitored", "at", "the", "moment", "of", "the", "event", ".", "Rapid", "infusion", "and", "underlying", "cardiac", "disease", "were", "important", "risk", "factors", "in", "the", "case", "reported", "here", ",", "and", "the", "authors", "discount", "ventricular", "arrhythmia", "as", "the", "main", "mechanism", "."]], "ner": [[[11, 11, "Chemical"], [35, 35, "Chemical"], [135, 135, "Chemical"], [137, 137, "Chemical"], [0, 0, "Disease"], [22, 22, "Disease"], [2, 2, "Disease"], [24, 24, "Disease"], [5, 5, "Disease"], [27, 27, "Disease"], [60, 60, "Disease"], [61, 62, "Disease"], [168, 169, "Disease"], [73, 76, "Disease"], [78, 78, "Disease"], [82, 83, "Disease"], [86, 86, "Disease"], [116, 117, "Disease"], [184, 185, "Disease"], [127, 128, "Disease"]]], "relations": [[[11, 11, 0, 0, "CID"], [11, 11, 22, 22, "CID"], [35, 35, 0, 0, "CID"], [35, 35, 22, 22, "CID"], [135, 135, 0, 0, "CID"], [135, 135, 22, 22, "CID"], [137, 137, 0, 0, "CID"], [137, 137, 22, 22, "CID"], [11, 11, 2, 2, "CID"], [11, 11, 24, 24, "CID"], [35, 35, 2, 2, "CID"], [35, 35, 24, 24, "CID"], [135, 135, 2, 2, "CID"], [135, 135, 24, 24, "CID"], [137, 137, 2, 2, "CID"], [137, 137, 24, 24, "CID"], [11, 11, 5, 5, "CID"], [11, 11, 27, 27, "CID"], [35, 35, 5, 5, "CID"], [35, 35, 27, 27, "CID"], [135, 135, 5, 5, "CID"], [135, 135, 27, 27, "CID"], [137, 137, 5, 5, "CID"], [137, 137, 27, 27, "CID"]]], "clusters": [], "translated": " <4>低血压</4>，<6>心动过缓</6>和<8>心搏停止</8>发生在一名接受监测的患者接受了大剂量静脉注射<0>甲基强的松龙</0>后。我们报告了一例 73 岁患者安全接受了静脉注射高剂量<1>甲基强的松龙</1>后发生<5>低血压</5>、<7>心动过缓</7>和<9>心搏停止</9>。该患者在事件发生时进行了心电图(ECG)监测。患者 9 年前曾有<10>缺血性</10><11>心脏病</11>的历史。患者因<13>肺-肾综合征</13>、<14>咯血</14>、急性进展性<15>肾功能衰竭</15>和<16>低氧血症</16>入住重症监护室并进行机械通气。在接受高级心肺复苏后，患者恢复了正常心律。心电图显示交界性节律，无<17>室性心律失常</17>。本研究回顾了目前提出的静脉注射大剂量<2>甲泼尼龙</2>（<3>IVMP</3>）后发生<19>猝死</19>的机制。这些机制尚不清楚，因为在大多数情况下，患者在事件发生时并未受到监控。快速输液和基础<12>心脏病</12> 是本例报告的重要危险因素，作者认为<18>室性心律失常</18>不是主要机制。", "revised": true}
{"doc_key": "3653576", "sentences": [["Urinary", "enzymes", "and", "protein", "patterns", "as", "indicators", "of", "injury", "to", "different", "regions", "of", "the", "kidney", ".", "Acute", "experimental", "models", "of", "renal", "damage", "to", "the", "proximal", "tubular", ",", "glomerular", ",", "and", "papillary", "regions", "of", "the", "rat", "were", "produced", "by", "administration", "of", "hexachloro", "-", "1", ":", "3", "-", "butadiene", "(", "HCBD", ")", ",", "puromycin", "aminonucleoside", "(", "PAN", ")", ",", "and", "2", "-", "bromoethylamine", "(", "BEA", ")", ",", "respectively", ".", "Several", "routine", "indicators", "of", "nephrotoxicity", ",", "the", "enzymes", "alkaline", "phosphatase", "and", "N", "-", "acetyl", "-", "beta", "-", "glucosaminidase", ",", "and", "the", "molecular", "weight", "of", "protein", "excretion", "were", "determined", "on", "urine", "samples", ".", "Tubular", "damage", "produced", "by", "HCBD", "or", "BEA", "was", "discriminated", "both", "quantitatively", "and", "qualitatively", "from", "glomerular", "damage", "produced", "by", "PAN", ".", "The", "latter", "was", "characterized", "by", "a", "pronounced", "increase", "in", "protein", "excretion", ",", "especially", "proteins", "with", "molecular", "weight", "greater", "than", "40", ",", "000", "Da", ".", "In", "contrast", ",", "protein", "excretion", "in", "tubular", "damage", "was", "raised", "only", "slightly", "and", "characterized", "by", "excretion", "of", "proteins", "of", "a", "wide", "range", "of", "molecular", "weights", ".", "Proximal", "tubular", "damage", "caused", "by", "HCBD", "and", "papillary", "damage", "caused", "by", "BEA", "were", "distinguished", "both", "by", "conventional", "urinalysis", "(", "volume", "and", "specific", "gravity", ")", "and", "by", "measurement", "of", "the", "two", "urinary", "enzymes", ".", "Alkaline", "phosphatase", "and", "glucose", "were", "markedly", "and", "transiently", "elevated", "in", "proximal", "tubular", "damage", "and", "N", "-", "acetyl", "-", "beta", "-", "glucosaminidase", "showed", "a", "sustained", "elevation", "in", "papillary", "damage", ".", "It", "is", "concluded", "that", "both", "selective", "urinary", "enzymes", "and", "the", "molecular", "weight", "pattern", "of", "urinary", "proteins", "can", "be", "used", "to", "provide", "diagnostic", "information", "about", "the", "possible", "site", "of", "renal", "damage", "."]], "ner": [[[40, 46, "Chemical"], [48, 48, "Chemical"], [103, 103, "Chemical"], [174, 174, "Chemical"], [16, 21, "Disease"], [51, 52, "Chemical"], [54, 54, "Chemical"], [117, 117, "Chemical"], [58, 60, "Chemical"], [62, 62, "Chemical"], [105, 105, "Chemical"], [180, 180, "Chemical"], [91, 92, "Disease"], [128, 129, "Disease"], [146, 147, "Disease"], [158, 160, "Disease"], [8, 14, "Disease"], [71, 71, "Disease"], [113, 114, "Disease"], [259, 260, "Disease"], [205, 205, "Chemical"]]], "relations": [[[40, 46, 16, 21, "CID"], [48, 48, 16, 21, "CID"], [103, 103, 16, 21, "CID"], [174, 174, 16, 21, "CID"], [51, 52, 16, 21, "CID"], [54, 54, 16, 21, "CID"], [117, 117, 16, 21, "CID"], [58, 60, 16, 21, "CID"], [62, 62, 16, 21, "CID"], [105, 105, 16, 21, "CID"], [180, 180, 16, 21, "CID"], [51, 52, 91, 92, "CID"], [51, 52, 128, 129, "CID"], [51, 52, 146, 147, "CID"], [51, 52, 158, 160, "CID"], [54, 54, 91, 92, "CID"], [54, 54, 128, 129, "CID"], [54, 54, 146, 147, "CID"], [54, 54, 158, 160, "CID"], [117, 117, 91, 92, "CID"], [117, 117, 128, 129, "CID"], [117, 117, 146, 147, "CID"], [117, 117, 158, 160, "CID"]]], "clusters": [], "translated": "尿酶和蛋白质模式作为<16>肾脏不同区域损伤的指标</16>。对大鼠的近端肾小管、肾小球和乳头状区域造成<4>肾损伤的急性实验模型</4>通过施用<0>六氯-1:3-丁二烯</0>(<1>HCBD</1>)、<5>嘌呤霉素氨基核苷</5>(<6>PAN</6>)和<8>2-溴乙胺</8>(<9>BEA</9>)。 <17>肾毒性</17>的几个常规指标，如碱性磷酸酶和N-乙酰-β-氨基葡萄糖苷酶以及<12>蛋白质排泄</12>的分子量在尿样中测定。 <2>HCBD</2>或<10>BEA</10>产生的肾小管损伤在数量和质量上都与<7>PAN</7>产生的<18>肾小球损伤</18>有所区别。后者的特点是<13>蛋白质排泄</13>显著增加，尤其是分子量大于40,000 Da的蛋白质。相比之下，<14>蛋白质排泄</14>在肾小管损伤中仅略有升高，其特点是<15>排泄分子量不同的蛋白质</15>。<3>HCBD</3>引起的近端肾小管损伤和<11>BEA</11>引起的乳头损伤可以通过常规尿液分析(体积和比重)和两种尿酶的测量来区分。近端肾小管损伤时，碱性磷酸酶和<20>葡萄糖含量</20> 显著且短暂升高，乳头损伤时N-乙酰-β-氨基葡萄糖苷酶持续升高。得出的结论是，选择性尿酶和尿蛋白的分子量模式均可用于提供有关<19>肾损伤</19>可能部位的诊断信息。", "revised": true}
{"doc_key": "2750819", "sentences": [["Neuromuscular", "blockade", "with", "magnesium", "sulfate", "and", "nifedipine", ".", "A", "patient", "who", "received", "tocolysis", "with", "nifedipine", "developed", "neuromuscular", "blockade", "after", "500", "mg", "of", "magnesium", "sulfate", "was", "administered", ".", "This", "reaction", "demonstrates", "that", "nifedipine", "can", "seriously", "potentiate", "the", "toxicity", "of", "magnesium", ".", "Caution", "should", "be", "exercised", "when", "these", "two", "tocolytics", "are", "combined", "."]], "ner": [[[3, 4, "Chemical"], [22, 23, "Chemical"], [0, 1, "Disease"], [16, 17, "Disease"], [6, 6, "Chemical"], [14, 14, "Chemical"], [31, 31, "Chemical"], [38, 38, "Chemical"], [36, 36, "Disease"]]], "relations": [[[3, 4, 0, 1, "CID"], [3, 4, 16, 17, "CID"], [22, 23, 0, 1, "CID"], [22, 23, 16, 17, "CID"], [6, 6, 0, 1, "CID"], [6, 6, 16, 17, "CID"], [14, 14, 0, 1, "CID"], [14, 14, 16, 17, "CID"], [31, 31, 0, 1, "CID"], [31, 31, 16, 17, "CID"]]], "clusters": [], "translated": " <2>神经肌肉阻滞剂</2>用<0>硫酸镁</0>和<4>硝苯地平</4>。接受<5>硝苯地平</5>安胎治疗的患者在服用500毫克<1>硫酸镁</1>后发生了<3>神经肌肉阻滞</3>。该反应表明<6>硝苯地平</6>可严重增强<7>镁</7>的<8>毒性</8>。将这两种宫缩抑制剂合用时应谨慎。", "revised": true}
{"doc_key": "12448656", "sentences": [["A", "phase", "II", "study", "of", "thalidomide", "in", "advanced", "metastatic", "renal", "cell", "carcinoma", ".", "OBJECTIVES", ":", "To", "evaluate", "the", "toxicity", "and", "activity", "of", "thalidomide", "in", "patients", "with", "advanced", "metastatic", "renal", "cell", "cancer", "and", "to", "measure", "changes", "of", "one", "angiogenic", "factor", ",", "vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "165", ",", "with", "therapy", ".", "PATIENTS", "AND", "METHODS", ":", "29", "patients", "were", "enrolled", "on", "a", "study", "of", "thalidomide", "using", "an", "intra", "-", "patient", "dose", "escalation", "schedule", ".", "Patients", "began", "thalidomide", "at", "400", "mg", "/", "d", "and", "escalated", "as", "tolerated", "to", "1200", "mg", "/", "d", "by", "day", "54", ".", "Fifty", "-", "nine", "per", "cent", "of", "patients", "had", "had", "previous", "therapy", "with", "IL", "-", "2", "and", "52", "%", "were", "performance", "status", "2", "or", "3", ".", "Systemic", "plasma", "VEGF165", "levels", "were", "measured", "by", "dual", "monoclonal", "ELISA", "in", "8", "patients", ".", "RESULTS", ":", "24", "patients", "were", "evaluable", "for", "response", "with", "one", "partial", "response", "of", "11", "months", "duration", "of", "a", "patient", "with", "hepatic", "and", "pulmonary", "metastases", "(", "4", "%", ")", ",", "one", "minor", "response", ",", "and", "2", "patients", "stable", "for", "over", "6", "months", ".", "Somnolence", "and", "constipation", "were", "prominent", "toxicities", "and", "most", "patients", "could", "not", "tolerate", "the", "1200", "mg", "/", "day", "dose", "level", ".", "Systemic", "plasma", "VEGF165", "levels", "did", "not", "change", "with", "therapy", ".", "CONCLUSION", ":", "These", "results", "are", "consistent", "with", "a", "low", "level", "of", "activity", "of", "thalidomide", "in", "renal", "cell", "carcinoma", ".", "Administration", "of", "doses", "over", "800", "mg", "/", "day", "was", "difficult", "to", "achieve", "in", "this", "patient", "population", ",", "however", "lower", "doses", "were", "practical", ".", "The", "dose", "-", "response", "relationship", ",", "if", "any", ",", "of", "thalidomide", "for", "renal", "cell", "carcinoma", "is", "unclear", "."]], "ner": [[[5, 5, "Chemical"], [22, 22, "Chemical"], [64, 64, "Chemical"], [76, 76, "Chemical"], [219, 219, "Chemical"], [258, 258, "Chemical"], [176, 176, "Disease"], [178, 178, "Disease"], [9, 11, "Disease"], [28, 30, "Disease"], [221, 223, "Disease"], [260, 262, "Disease"], [18, 18, "Disease"], [181, 181, "Disease"], [157, 157, "Disease"]]], "relations": [[[5, 5, 176, 176, "CID"], [22, 22, 176, 176, "CID"], [64, 64, 176, 176, "CID"], [76, 76, 176, 176, "CID"], [219, 219, 176, 176, "CID"], [258, 258, 176, 176, "CID"], [5, 5, 178, 178, "CID"], [22, 22, 178, 178, "CID"], [64, 64, 178, 178, "CID"], [76, 76, 178, 178, "CID"], [219, 219, 178, 178, "CID"], [258, 258, 178, 178, "CID"]]], "clusters": [], "translated": "<0>沙利度胺</0>治疗晚期转移性<8>肾细胞癌</8>的II期研究。目的：评估<1>沙利度胺</1>在晚期转移性<9>肾细胞癌</9>患者中的<12>毒性</12>和活性，并测量一种血管生成因子，血管内皮细胞生长因子（VEGF）165在治疗过程中的变化。患者和方法：29名患者参加了一项<2>沙利度胺</2>研究，采用患者体内剂量递增方案。患者开始以400 mg/d的剂量<3>沙利度胺</3>，并在第54天时根据耐受性增加至1200 mg/d。59%的患者以前接受过IL-2治疗，52%的患者表现状态为2或3。在8名患者中，通过双重单克隆ELISA测量全身血浆VEGF165水平。结果：24例患者的反应可评估，其中一名肝和肺<14>转移</14>患者持续11个月的部分反应（4%），一名轻微反应，2名患者稳定超过6个月。<6>嗜睡</6>和<7>便秘</7>是突出的<13>毒性</13>，大多数患者不能耐受1200mg/天的剂量水平。全身血浆VEGF165水平不随治疗而改变。结论：这些结果与<4>沙利度胺</4>在<10>肾细胞癌</10>中的低水平活性一致。在这个患者群体中很难达到每天800毫克的剂量，但较低的剂量是可行的。<5>沙利度胺</5>治疗<11>肾细胞癌</11>的剂量反应关系（如果有的话）尚不清楚。", "revised": true}
{"doc_key": "15042318", "sentences": [["Atrial", "fibrillation", "following", "chemotherapy", "for", "stage", "IIIE", "diffuse", "large", "B", "-", "cell", "gastric", "lymphoma", "in", "a", "patient", "with", "myotonic", "dystrophy", "(", "Steinert", "'s", "disease", ")", ".", "The", "authors", "describe", "the", "unusual", "association", "between", "diffuse", "B", "-", "cell", "gastric", "lymphoma", "and", "myotonic", "dystrophy", ",", "the", "most", "common", "form", "of", "adult", "muscular", "dystrophy", ",", "and", "sudden", "atrial", "fibrillation", "following", "one", "cycle", "of", "doxorubicin", "-", "based", "chemotherapy", "in", "the", "same", "patient", ".", "Atrial", "fibrillation", "or", "other", "cardiac", "arrhythmias", "are", "unusual", "complications", "in", "patients", "treated", "with", "chemotherapy", ".", "The", "cardiac", "toxicity", "intrinsically", "associated", "with", "the", "aggressive", "chemotherapy", "employed", "could", "function", "as", "a", "triggering", "factor", "for", "the", "arrhythmia", "in", "the", "predisposed", "myocardium", "of", "this", "patient", "."]], "ner": [[[60, 60, "Chemical"], [0, 1, "Disease"], [54, 55, "Disease"], [69, 70, "Disease"], [12, 13, "Disease"], [37, 38, "Disease"], [18, 19, "Disease"], [21, 23, "Disease"], [40, 41, "Disease"], [49, 50, "Disease"], [73, 74, "Disease"], [102, 102, "Disease"], [85, 86, "Disease"]]], "relations": [[[60, 60, 0, 1, "CID"], [60, 60, 54, 55, "CID"], [60, 60, 69, 70, "CID"]]], "clusters": [], "translated": "IIIE 期弥漫性大 B 细胞<4>胃淋巴瘤</4>化疗后<1>心房颤动</1>，在<6>强直性肌营养不良</6>（<7>Steinert 病</7>）患者中。作者描述了弥漫性B细胞<5>胃淋巴瘤</5>和<8>强直性肌营养不良症</8>之间的异常关联，这是成人<9>肌营养不良症</9>的最常见形式，在同一患者中，接受一个疗程的<0>多柔比星</0>化疗后出现了突发性<2>房颤</2>。在接受化疗的患者中，<3>房颤</3>或其他<10>心律失常</10>是罕见的并发症。与所采用的积极化疗有内在联系的<12>心脏毒性</12>可能是该患者易感心肌发生<11>心律失常</11>的触发因素。", "revised": true}
{"doc_key": "9209318", "sentences": [["Lifetime", "treatment", "of", "mice", "with", "azidothymidine", "(", "AZT", ")", "produces", "myelodysplasia", ".", "AZT", "has", "induced", "a", "macrocytic", "anemia", "in", "AIDS", "patients", "on", "long", "term", "AZT", "therapy", ".", "It", "is", "generally", "assumed", "that", "DNA", "elongation", "is", "stopped", "by", "the", "insertion", "of", "AZT", "into", "the", "chain", "in", "place", "of", "thymidine", "thus", "preventing", "the", "phosphate", "hydroxyl", "linkages", "and", "therefore", "suppresses", "hemopoietic", "progenitor", "cell", "proliferation", "in", "an", "early", "stage", "of", "differentiation", ".", "CBA", "/", "Ca", "male", "mice", "started", "on", "AZT", "0", ".", "75", "mg", "/", "ml", "H2O", "at", "84", "days", "of", "age", "and", "kept", "on", "it", "for", "687", "days", "when", "dosage", "reduced", "to", "0", ".", "5", "mg", "/", "ml", "H2O", "for", "a", "group", ",", "another", "group", "removed", "from", "AZT", "to", "see", "recovery", ",", "and", "third", "group", "remained", "on", "0", ".", "75", "mg", ".", "At", "687", "days", "mice", "that", "had", "been", "on", "0", ".", "75", "mg", "had", "average", "platelet", "counts", "of", "2", ".", "5", "x", "10", "(", "6", ")", ".", "Histological", "examination", "on", "9", "of", "10", "mice", "with", "such", "thrombocytopenia", "showed", "changes", "compatible", "with", "myelodysplastic", "syndrome", "(", "MDS", ")", ".", "A", "variety", "of", "histological", "patterns", "was", "observed", ".", "There", "were", "two", "cases", "of", "hypocellular", "myelodysplasia", ",", "two", "cases", "of", "hypersegmented", "myelodysplastic", "granulocytosis", ",", "two", "cases", "of", "hypercellular", "marrow", "with", "abnormal", "megakaryocytes", "with", "bizarre", "nuclei", ",", "one", "case", "of", "megakaryocytic", "myelosis", "associated", "with", "a", "hyperplastic", "marrow", ",", "dysmyelopoiesis", "and", "a", "hypocellular", "marrow", "and", "two", "cases", "of", "myelodysplasia", "with", "dyserythropoiesis", ",", "hemosiderosis", "and", "a", "hypocellular", "marrow", ".", "Above", "mentioned", "AZT", "incorporation", "may", "have", "induced", "an", "ineffective", "hemopoiesis", "in", "the", "primitive", "hemopoietic", "progenitor", "cells", ",", "which", "is", "known", "to", "be", "seen", "commonly", "in", "the", "myelodysplastic", "syndrome", "."]], "ner": [[[5, 5, "Chemical"], [7, 7, "Chemical"], [12, 12, "Chemical"], [24, 24, "Chemical"], [40, 40, "Chemical"], [75, 75, "Chemical"], [114, 114, "Chemical"], [242, 242, "Chemical"], [10, 10, "Disease"], [169, 170, "Disease"], [172, 172, "Disease"], [189, 189, "Disease"], [195, 195, "Disease"], [221, 221, "Disease"], [230, 230, "Disease"], [266, 267, "Disease"], [16, 17, "Disease"], [164, 164, "Disease"], [19, 19, "Disease"], [218, 219, "Disease"], [224, 225, "Disease"], [237, 238, "Disease"], [234, 234, "Disease"], [47, 47, "Chemical"], [51, 51, "Chemical"]]], "relations": [[[5, 5, 10, 10, "CID"], [5, 5, 169, 170, "CID"], [5, 5, 172, 172, "CID"], [5, 5, 189, 189, "CID"], [5, 5, 195, 195, "CID"], [5, 5, 221, 221, "CID"], [5, 5, 230, 230, "CID"], [5, 5, 266, 267, "CID"], [7, 7, 10, 10, "CID"], [7, 7, 169, 170, "CID"], [7, 7, 172, 172, "CID"], [7, 7, 189, 189, "CID"], [7, 7, 195, 195, "CID"], [7, 7, 221, 221, "CID"], [7, 7, 230, 230, "CID"], [7, 7, 266, 267, "CID"], [12, 12, 10, 10, "CID"], [12, 12, 169, 170, "CID"], [12, 12, 172, 172, "CID"], [12, 12, 189, 189, "CID"], [12, 12, 195, 195, "CID"], [12, 12, 221, 221, "CID"], [12, 12, 230, 230, "CID"], [12, 12, 266, 267, "CID"], [24, 24, 10, 10, "CID"], [24, 24, 169, 170, "CID"], [24, 24, 172, 172, "CID"], [24, 24, 189, 189, "CID"], [24, 24, 195, 195, "CID"], [24, 24, 221, 221, "CID"], [24, 24, 230, 230, "CID"], [24, 24, 266, 267, "CID"], [40, 40, 10, 10, "CID"], [40, 40, 169, 170, "CID"], [40, 40, 172, 172, "CID"], [40, 40, 189, 189, "CID"], [40, 40, 195, 195, "CID"], [40, 40, 221, 221, "CID"], [40, 40, 230, 230, "CID"], [40, 40, 266, 267, "CID"], [75, 75, 10, 10, "CID"], [75, 75, 169, 170, "CID"], [75, 75, 172, 172, "CID"], [75, 75, 189, 189, "CID"], [75, 75, 195, 195, "CID"], [75, 75, 221, 221, "CID"], [75, 75, 230, 230, "CID"], [75, 75, 266, 267, "CID"], [114, 114, 10, 10, "CID"], [114, 114, 169, 170, "CID"], [114, 114, 172, 172, "CID"], [114, 114, 189, 189, "CID"], [114, 114, 195, 195, "CID"], [114, 114, 221, 221, "CID"], [114, 114, 230, 230, "CID"], [114, 114, 266, 267, "CID"], [242, 242, 10, 10, "CID"], [242, 242, 169, 170, "CID"], [242, 242, 172, 172, "CID"], [242, 242, 189, 189, "CID"], [242, 242, 195, 195, "CID"], [242, 242, 221, 221, "CID"], [242, 242, 230, 230, "CID"], [242, 242, 266, 267, "CID"], [5, 5, 16, 17, "CID"], [7, 7, 16, 17, "CID"], [12, 12, 16, 17, "CID"], [24, 24, 16, 17, "CID"], [40, 40, 16, 17, "CID"], [75, 75, 16, 17, "CID"], [114, 114, 16, 17, "CID"], [242, 242, 16, 17, "CID"], [5, 5, 164, 164, "CID"], [7, 7, 164, 164, "CID"], [12, 12, 164, 164, "CID"], [24, 24, 164, 164, "CID"], [40, 40, 164, 164, "CID"], [75, 75, 164, 164, "CID"], [114, 114, 164, 164, "CID"], [242, 242, 164, 164, "CID"]]], "clusters": [], "translated": "用 <0> 叠氮胸苷 </0> (<1>AZT</1>) 终生治疗小鼠会导致 <8>骨髓增生异常</8>。<2>AZT</2>在长期接受<3>AZT</3>治疗的<18>AIDS</18>患者中引起<16>大红细胞性贫血</16>。通常假设DNA延伸是通过将<4>AZT</4>插入链中代替<23>胸苷</23>从而阻止<24>磷酸</24>羟基连接而停止的，因此在分化的早期阶段抑制造血祖细胞的增殖。CBA/Ca雄性小鼠开始服用<5>AZT</5> 0.75 mg/ml H2O，在84日龄时保持687天，当剂量减至0.5mg/ml H2O为一组，另一组从<6>AZT</6>中去除以观察恢复情况，第三组保持在0.75毫克。在第687天时，小鼠处于0.75 mg的平均血小板计数为2.5×10(<6>6</6>)。10只患有这种<17>血小板减少症</17>的小鼠中有9只的组织学检查显示与<9>骨髓增生异常综合征</9>（<10>MDS</10>）相符的变化。观察到多种组织学模式。低细胞性<11>骨髓增生异常</11>2例，分叶性<12>骨髓增生异常</12>粒细胞增生2例，骨髓增生伴巨核异常巨核细胞2例，一例巨核细胞骨髓增生伴<19>骨髓增生</19> ，<13>骨髓细胞生成障碍</13>和<20>骨髓细胞减少</20>以及两例<14>骨髓增生异常</14>伴红细胞生成障碍、<22>含铁血黄素增多症</22>和<21>低细胞骨髓</21>。上述<7>AZT</7> 掺入可能导致原始造血祖细胞发生无效造血，这在<15>骨髓增生异常综合征</15>中很常见。", "revised": true}
{"doc_key": "12231232", "sentences": [["The", "striatum", "as", "a", "target", "for", "anti", "-", "rigor", "effects", "of", "an", "antagonist", "of", "mGluR1", ",", "but", "not", "an", "agonist", "of", "group", "II", "metabotropic", "glutamate", "receptors", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "find", "out", "whether", "the", "metabotropic", "receptor", "1", "(", "mGluR1", ")", "and", "group", "II", "mGluRs", ",", "localized", "in", "the", "striatum", ",", "are", "involved", "in", "antiparkinsonian", "-", "like", "effects", "in", "rats", ".", "Haloperidol", "(", "1", "mg", "/", "kg", "ip", ")", "induced", "parkinsonian", "-", "like", "muscle", "rigidity", ",", "measured", "as", "an", "increased", "resistance", "of", "a", "rat", "'s", "hind", "foot", "to", "passive", "flexion", "and", "extension", "at", "the", "ankle", "joint", ".", "(", "RS", ")", "-", "1", "-", "aminoindan", "-", "1", ",", "5", "-", "dicarboxylic", "acid", "(", "AIDA", ";", "0", ".", "5", "-", "15", "microg", "/", "0", ".", "5", "microl", ")", ",", "a", "potent", "and", "selective", "mGluR1", "antagonist", ",", "or", "(", "2R", ",", "4R", ")", "-", "4", "-", "aminopyrrolidine", "-", "2", ",", "4", "-", "dicarboxylate", "(", "2R", ",", "4R", "-", "APDC", ";", "7", ".", "5", "-", "15", "microg", "/", "0", ".", "5", "microl", ")", ",", "a", "selective", "group", "II", "agonist", ",", "was", "injected", "bilaterally", "into", "the", "striatum", "of", "haloperidol", "-", "treated", "animals", ".", "AIDA", "in", "doses", "of", "7", ".", "5", "-", "15", "microg", "/", "0", ".", "5", "microl", "diminished", "the", "haloperidol", "-", "induced", "muscle", "rigidity", ".", "In", "contrast", ",", "2R", ",", "4R", "-", "APDC", "injections", "were", "ineffective", ".", "The", "present", "results", "may", "suggest", "that", "the", "blockade", "of", "striatal", "mGluR1", ",", "but", "not", "the", "stimulation", "of", "group", "II", "mGluRs", ",", "may", "ameliorate", "parkinsonian", "muscle", "rigidity", "."]], "ner": [[[65, 65, "Chemical"], [187, 187, "Chemical"], [209, 209, "Chemical"], [77, 78, "Disease"], [212, 213, "Disease"], [251, 252, "Disease"], [24, 24, "Chemical"], [74, 74, "Disease"], [250, 250, "Disease"], [101, 114, "Chemical"], [116, 116, "Chemical"], [192, 192, "Chemical"], [139, 153, "Chemical"], [155, 159, "Chemical"], [218, 222, "Chemical"]]], "relations": [[[65, 65, 77, 78, "CID"], [65, 65, 212, 213, "CID"], [65, 65, 251, 252, "CID"], [187, 187, 77, 78, "CID"], [187, 187, 212, 213, "CID"], [187, 187, 251, 252, "CID"], [209, 209, 77, 78, "CID"], [209, 209, 212, 213, "CID"], [209, 209, 251, 252, "CID"]]], "clusters": [], "translated": "纹状体作为 mGluR1 拮抗剂的抗强直作用的目标，但不是 II 组代谢型<6>谷氨酸</6>受体的激动剂。本研究的目的是找出位于纹状体的代谢型受体1（mGluR1）和第II组mGluRs是否参与大鼠的抗帕金森氏症样作用。<0>氟哌啶醇</0>（1mg/kg；ip）诱导<7>帕金森氏症</7>样<3>肌肉僵硬</3>，测量为大鼠后足对被动的抵抗力增加踝关节屈伸处。<9>(RS)-1-氨基茚满-1,5-二羧酸</9>（<10>AIDA</10>; 0.5-15微克/0.5微升），一种有效的选择性mGluR1拮抗剂，或<12>(2R,4R)-4-氨基吡咯烷-2,4-二羧酸盐</12>（<13>2R,4R-APDC</13>; 7.5-15微克/0.5微升），一种选择性第II组mGluRs激动剂，被双侧注射到<1>氟哌啶醇</1>治疗动物的纹状体中。<11>AIDA</11>剂量为7.5-15微克/0.5微升减少了<2>氟哌啶醇</2>-诱导的<4>肌肉僵硬</4>。相比之下，<14>2R,4R-APDC</14>注射无效。目前的结果可能表明，纹状体mGluR1的阻断，而不是第II组mGluRs的刺激，可能会改善<8>帕金森氏症</8><5>肌肉僵硬</5>。", "revised": true}
{"doc_key": "16471092", "sentences": [["Urinary", "symptoms", "and", "quality", "of", "life", "changes", "in", "Thai", "women", "with", "overactive", "bladder", "after", "tolterodine", "treatment", ".", "OBJECTIVES", ":", "To", "study", "the", "urinary", "symptoms", "and", "quality", "of", "life", "changes", "in", "Thai", "women", "with", "overactive", "bladder", "(", "OAB", ")", "after", "tolterodine", "treatment", ".", "MATERIAL", "AND", "METHOD", ":", "Thirty", "women", "(", "aged", "30", "-", "77", "years", ")", "diagnosed", "as", "having", "OAB", "at", "the", "Gynecology", "Clinic", ",", "King", "Chulalongkorn", "Memorial", "Hospital", "from", "January", "to", "April", "2004", "were", "included", "in", "the", "present", "study", ".", "Tolterodine", "2", "mg", ",", "twice", "daily", "was", "given", ".", "After", "8", "weeks", "treatment", ",", "changes", "in", "micturition", "diary", "variables", "and", "tolerability", "were", "determined", ".", "Short", "form", "36", "(", "SF36", ")", "questionaires", "(", "Thai", "version", ")", "were", "given", "before", "and", "after", "8", "weeks", "of", "treatment", ".", "RESULTS", ":", "At", "8", "weeks", ",", "all", "micturition", "per", "day", "decreased", "from", "16", ".", "7", "+", "/", "-", "5", ".", "3", "to", "6", ".", "7", "+", "/", "-", "2", ".", "4", "times", "per", "day", ".", "The", "number", "of", "nocturia", "episodes", "decreased", "from", "5", ".", "4", "+", "/", "-", "4", ".", "2", "to", "1", ".", "1", "+", "/", "-", "1", ".", "0", "times", "per", "night", ".", "The", "most", "common", "side", "effect", "was", "dry", "month", "in", "5", "cases", "(", "16", ".", "7", "%", ")", "with", "2", "cases", "reporting", "a", "moderate", "degree", "and", "1", "case", "with", "severe", "degree", ".", "Only", "one", "case", "(", "3", ".", "3", "%", ")", "withdrew", "from", "the", "present", "study", "due", "to", "a", "severe", "dry", "mouth", ".", "The", "SF", "-", "36", "scores", "changed", "significantly", "in", "the", "domains", "of", "physical", "functioning", ",", "role", "function", "emotional", ",", "social", "function", "and", "mental", "heath", ".", "CONCLUSION", ":", "Tolterodine", "was", "well", "tolerated", "and", "its", "effects", "improved", "the", "quality", "of", "life", "in", "Thai", "women", "with", "OAB", "."]], "ner": [[[14, 14, "Chemical"], [39, 39, "Chemical"], [80, 80, "Chemical"], [268, 268, "Chemical"], [196, 197, "Disease"], [239, 240, "Disease"], [11, 12, "Disease"], [33, 34, "Disease"], [36, 36, "Disease"], [58, 58, "Disease"], [284, 284, "Disease"], [163, 163, "Disease"]]], "relations": [[[14, 14, 196, 197, "CID"], [14, 14, 239, 240, "CID"], [39, 39, 196, 197, "CID"], [39, 39, 239, 240, "CID"], [80, 80, 196, 197, "CID"], [80, 80, 239, 240, "CID"], [268, 268, 196, 197, "CID"], [268, 268, 239, 240, "CID"]]], "clusters": [], "translated": "<0>托特罗定</0>治疗后<6>膀胱过度活动症</6>泰国女性的泌尿系统症状和生活质量发生变化。目的：研究<1>托特罗定</1>治疗后<7>膀胱过度活动症</7>（<8>OAB</8>）泰国女性泌尿系统症状和生活质量的变化。材料和方法：2004 年 1 月至 4 月在朱拉隆功国王纪念医院妇科门诊被诊断患有<9>OAB</9>的30 名女性（年龄30-77 岁）被纳入本研究。<2>托特罗定</2> 2 毫克，每天两次。治疗8周后，确定排尿日记变量和耐受性的变化。在8周的治疗前后给予了简表36（SF36）问卷（泰文版）。结果：在8周时，每天排尿次数从16.7+/-5.3减少到6.7+/-2.4次每天。 <11>夜尿</11>发作次数从5.4+/-4.2次每夜减少到1.1+/-1.0次每夜。最常见的副作用是<4>口干</4>，其中5例（16.7%）患者有这种症状，其中2例报告为中度，1例为重度。仅有一例（3.3%）因<5>口干</5>严重而退出本研究。在身体机能、角色功能、情感、社会功能和心理健康等领域，SF-36评分发生了显着变化。结论：<3>托特罗定</3>的耐受性良好，其作用改善了泰国<10>OAB</10>女性的生活质量。", "revised": true}
{"doc_key": "11078231", "sentences": [["Myocardial", "ischemia", "due", "to", "coronary", "artery", "spasm", "during", "dobutamine", "stress", "echocardiography", ".", "Dobutamine", "stress", "echocardiography", "(", "DSE", ")", "is", "a", "useful", "and", "safe", "provocation", "test", "for", "myocardial", "ischemia", ".", "Until", "now", ",", "the", "test", "has", "been", "focused", "only", "on", "the", "organic", "lesion", "in", "the", "coronary", "artery", ",", "and", "positive", "DSE", "has", "indicated", "the", "presence", "of", "significant", "fixed", "coronary", "artery", "stenosis", ".", "The", "aim", "of", "the", "present", "study", "is", "to", "examine", "whether", "myocardial", "ischemia", "due", "to", "coronary", "spasm", "is", "induced", "by", "dobutamine", ".", "We", "performed", "DSE", "on", "51", "patients", "with", "coronary", "spastic", "angina", "but", "without", "significant", "fixed", "coronary", "artery", "stenosis", ".", "All", "patients", "had", "anginal", "attacks", "at", "rest", "with", "ST", "elevation", "on", "the", "electrocardiogram", "(", "variant", "angina", ")", ".", "Coronary", "spasm", "was", "induced", "by", "intracoronary", "injection", "of", "acetylcholine", ",", "and", "no", "fixed", "coronary", "artery", "stenosis", "was", "documented", "on", "angiograms", "in", "all", "patients", ".", "DSE", "was", "performed", "with", "intravenous", "dobutamine", "infusion", "with", "an", "incremental", "doses", "of", "5", ",", "10", ",", "20", ",", "30", ",", "and", "40", "microg", "/", "kg", "/", "min", "every", "5", "minutes", ".", "Of", "the", "51", "patients", ",", "7", "patients", "showed", "asynergy", "with", "ST", "elevation", ".", "All", "7", "patients", "(", "13", ".", "7", "%", ")", "had", "chest", "pain", "during", "asynergy", ",", "and", "both", "chest", "pain", "and", "electrocardiographic", "changes", "were", "preceded", "by", "asynergy", ".", "These", "findings", "indicate", "that", "dobutamine", "can", "provoke", "coronary", "spasm", "in", "some", "patients", "with", "coronary", "spastic", "angina", ".", "When", "DSE", "is", "performed", "to", "evaluate", "coronary", "artery", "disease", ",", "not", "only", "fixed", "coronary", "stenosis", ",", "but", "also", "coronary", "spasm", "should", "be", "considered", "as", "a", "genesis", "of", "asynergy", "."]], "ner": [[[8, 8, "Chemical"], [12, 12, "Chemical"], [80, 80, "Chemical"], [147, 147, "Chemical"], [217, 217, "Chemical"], [4, 6, "Disease"], [75, 76, "Disease"], [220, 221, "Disease"], [248, 249, "Disease"], [89, 91, "Disease"], [114, 115, "Disease"], [226, 228, "Disease"], [0, 1, "Disease"], [26, 27, "Disease"], [71, 72, "Disease"], [126, 126, "Chemical"], [57, 59, "Disease"], [96, 98, "Disease"], [131, 133, "Disease"], [243, 244, "Disease"], [103, 103, "Disease"], [196, 197, "Disease"], [203, 204, "Disease"], [236, 238, "Disease"]]], "relations": [[[8, 8, 4, 6, "CID"], [8, 8, 75, 76, "CID"], [8, 8, 220, 221, "CID"], [8, 8, 248, 249, "CID"], [12, 12, 4, 6, "CID"], [12, 12, 75, 76, "CID"], [12, 12, 220, 221, "CID"], [12, 12, 248, 249, "CID"], [80, 80, 4, 6, "CID"], [80, 80, 75, 76, "CID"], [80, 80, 220, 221, "CID"], [80, 80, 248, 249, "CID"], [147, 147, 4, 6, "CID"], [147, 147, 75, 76, "CID"], [147, 147, 220, 221, "CID"], [147, 147, 248, 249, "CID"], [217, 217, 4, 6, "CID"], [217, 217, 75, 76, "CID"], [217, 217, 220, 221, "CID"], [217, 217, 248, 249, "CID"], [8, 8, 89, 91, "CID"], [8, 8, 114, 115, "CID"], [8, 8, 226, 228, "CID"], [12, 12, 89, 91, "CID"], [12, 12, 114, 115, "CID"], [12, 12, 226, 228, "CID"], [80, 80, 89, 91, "CID"], [80, 80, 114, 115, "CID"], [80, 80, 226, 228, "CID"], [147, 147, 89, 91, "CID"], [147, 147, 114, 115, "CID"], [147, 147, 226, 228, "CID"], [217, 217, 89, 91, "CID"], [217, 217, 114, 115, "CID"], [217, 217, 226, 228, "CID"]]], "clusters": [], "translated": "<12>心肌缺血</12>由于<5>冠状动脉痉挛</5>在<0>多巴酚丁胺</0>负荷超声心动图期间。 <1>多巴酚丁胺</1>负荷超声心动图（DSE）是一种有用且安全的激发试验，可用于<13>心肌缺血</13>。迄今为止，该检查仅集中于冠状动脉的器质性病变，DSE阳性表明存在显着的固定性<16>冠状动脉狭窄</16>。本研究的目的是检查<6>冠状动脉痉挛</6>引起的<14>心肌缺血</14>是否是由<2>多巴酚丁胺</2> 引起的。我们对51名<9>冠状动脉痉挛性心绞痛</9>但没有明显固定性<17>冠状动脉狭窄</17>的患者进行了DSE。所有患者静息时均有<20>心绞痛</20>发作，心电图ST段抬高（<10>变异型心绞痛</10>）。冠状动脉内注射<15>乙酰胆碱</15>引起冠状动脉痉挛，所有患者血管造影均未见固定性<18>冠状动脉狭窄</18>。DSE是通过静脉内<3>多巴酚丁胺</3>输注进行的，每5分钟增加剂量5、10、20、30和40微克/公斤/分钟。51例患者中，7例与ST抬高无协同作用。所有7例患者（13.7%）在无协同作用期间出现了<21>胸痛</21>，且<22>胸痛</22>和心电图改变均发生在无协同作用之前。这些发现表明，部分<11>冠状动脉痉挛性心绞痛</11>患者中可通过<4>多巴酚丁胺</4>引起<7>冠状动脉痉挛</7>。进行DSE评价<23>冠状动脉疾病</23>时，不仅应考虑<19>固定性冠状动脉狭窄</19>，还应考虑<8>冠状动脉痉挛</8>作为不协同的原因。", "revised": true}
{"doc_key": "16634859", "sentences": [["Impact", "of", "alcohol", "exposure", "after", "pregnancy", "recognition", "on", "ultrasonographic", "fetal", "growth", "measures", ".", "BACKGROUND", ":", "More", "than", "3", "decades", "after", "Jones", "and", "Smith", "(", "1973", ")", "reported", "on", "the", "devastation", "caused", "by", "alcohol", "exposure", "on", "fetal", "development", ",", "the", "rates", "of", "heavy", "drinking", "during", "pregnancy", "remain", "relatively", "unchanged", ".", "Early", "identification", "of", "fetal", "alcohol", "exposure", "and", "maternal", "abstinence", "led", "to", "better", "infant", "outcomes", ".", "This", "study", "examined", "the", "utility", "of", "biometry", "for", "detecting", "alcohol", "-", "related", "fetal", "growth", "impairment", ".", "METHODS", ":", "We", "obtained", "fetal", "ultrasound", "measures", "from", "routine", "ultrasound", "examinations", "for", "167", "pregnant", "hazardous", "drinkers", "who", "were", "enrolled", "in", "a", "brief", "alcohol", "intervention", "study", ".", "The", "fetal", "measures", "for", "women", "who", "quit", "after", "learning", "of", "their", "pregnancies", "were", "compared", "with", "measures", "for", "women", "who", "continued", "some", "drinking", "throughout", "the", "course", "of", "their", "pregnancies", ".", "Because", "intensity", "of", "alcohol", "consumption", "is", "associated", "with", "poorer", "fetal", "outcomes", ",", "separate", "analyses", "were", "conducted", "for", "the", "heavy", "(", "average", "of", ">", "or", "=", "5", "drinks", "per", "drinking", "day", ")", "alcohol", "consumers", ".", "Fetal", "measures", "from", "the", "heavy", "-", "exposed", "fetuses", "were", "also", "compared", "with", "measures", "from", "a", "nondrinking", "group", "that", "was", "representative", "of", "normal", ",", "uncomplicated", "pregnancies", "from", "our", "clinics", ".", "Analyses", "of", "covariance", "were", "used", "to", "determine", "whether", "there", "were", "differences", "between", "groups", "after", "controlling", "for", "influences", "of", "gestational", "age", "and", "drug", "abuse", ".", "RESULTS", ":", "Nearly", "half", "of", "the", "pregnant", "drinkers", "abstained", "after", "learning", "of", "their", "pregnancies", ".", "When", "women", "reportedly", "quit", "drinking", "early", "in", "their", "pregnancies", ",", "fetal", "growth", "measures", "were", "not", "significantly", "different", "from", "a", "non", "-", "alcohol", "-", "exposed", "group", ",", "regardless", "of", "prior", "drinking", "patterns", ".", "Any", "alcohol", "consumption", "postpregnancy", "recognition", "among", "the", "heavy", "drinkers", "resulted", "in", "reduced", "cerebellar", "growth", "as", "well", "as", "decreased", "cranial", "to", "body", "growth", "in", "comparison", "with", "women", "who", "either", "quit", "drinking", "or", "who", "were", "nondrinkers", ".", "Amphetamine", "abuse", "was", "predictive", "of", "larger", "cranial", "to", "body", "growth", "ratios", ".", "CONCLUSIONS", ":", "Alterations", "in", "fetal", "biometric", "measurements", "were", "observed", "among", "the", "heavy", "drinkers", "only", "when", "they", "continued", "drinking", "after", "becoming", "aware", "of", "their", "pregnancies", ".", "Although", "the", "reliance", "on", "self", "-", "reported", "drinking", "is", "a", "limitation", "in", "this", "study", ",", "these", "findings", "support", "the", "benefits", "of", "early", "abstinence", "and", "the", "potential", "for", "ultrasound", "examinations", "in", "the", "detection", "of", "fetal", "alcohol", "effects", "."]], "ner": [[[2, 2, "Chemical"], [32, 32, "Chemical"], [53, 53, "Chemical"], [73, 73, "Chemical"], [102, 102, "Chemical"], [138, 138, "Chemical"], [166, 166, "Chemical"], [258, 258, "Chemical"], [270, 270, "Chemical"], [375, 375, "Chemical"], [77, 78, "Disease"], [280, 282, "Disease"], [286, 290, "Disease"], [304, 304, "Chemical"], [219, 220, "Disease"]]], "relations": [[[2, 2, 77, 78, "CID"], [2, 2, 280, 282, "CID"], [2, 2, 286, 290, "CID"], [32, 32, 77, 78, "CID"], [32, 32, 280, 282, "CID"], [32, 32, 286, 290, "CID"], [53, 53, 77, 78, "CID"], [53, 53, 280, 282, "CID"], [53, 53, 286, 290, "CID"], [73, 73, 77, 78, "CID"], [73, 73, 280, 282, "CID"], [73, 73, 286, 290, "CID"], [102, 102, 77, 78, "CID"], [102, 102, 280, 282, "CID"], [102, 102, 286, 290, "CID"], [138, 138, 77, 78, "CID"], [138, 138, 280, 282, "CID"], [138, 138, 286, 290, "CID"], [166, 166, 77, 78, "CID"], [166, 166, 280, 282, "CID"], [166, 166, 286, 290, "CID"], [258, 258, 77, 78, "CID"], [258, 258, 280, 282, "CID"], [258, 258, 286, 290, "CID"], [270, 270, 77, 78, "CID"], [270, 270, 280, 282, "CID"], [270, 270, 286, 290, "CID"], [375, 375, 77, 78, "CID"], [375, 375, 280, 282, "CID"], [375, 375, 286, 290, "CID"], [304, 304, 77, 78, "CID"], [304, 304, 280, 282, "CID"], [304, 304, 286, 290, "CID"]]], "clusters": [], "translated": "妊娠识别后<0>酒精</0>暴露对超声胎儿生长测量的影响。背景：在 Jones 和 Smith (1973) 报告<1>酒精</1>暴露对胎儿发育造成的破坏之后的 3 多年里，怀孕期间大量饮酒的比例保持相对不变。及早发现胎儿<2>酒精</2>暴露和母亲戒酒可改善婴儿结局。本研究检验了生物测定法在检测<3>酒精</3>相关胎儿<10>生长障碍</10>方面的效用。方法：我们通过对 167 名怀孕的危险饮酒者进行的常规超声检查获得了胎儿超声测量值，这些人参加了一项简短的<4>酒精</4>干预研究。将得知怀孕后戒酒的妇女的胎儿测量值与在整个怀孕过程中继续饮酒的妇女的测量值进行了比较。由于<5>饮酒</5>的强度与较差的胎儿结局相关，因此对重度（平均每天饮酒>或=5杯）<6>饮酒</6>的消费者进行了单独分析。重度暴露胎儿的胎儿测量值也与非饮酒组的测量值进行了比较，后者代表了我们诊所的正常、无并发症的妊娠。在控制孕龄和<14>药物滥用</14>的影响后，使用协方差分析来确定组间是否存在差异。结果：将近一半的怀孕饮酒者在得知自己怀孕后戒酒了。据报道，当女性在怀孕早期戒酒时，无论之前的饮酒模式如何，胎儿生长指标与未接触<7>酒精</7>的组没有显着差异。与戒酒的女性相比，重度饮酒者在怀孕后对任何<8>酒精</8>消费的认识都会导致<11>小脑生长减少</11>以及<12>颅骨到身体生长减少</12>喝酒或不喝酒的人。<13>苯丙胺</13>滥用预示着颅骨与身体的生长比率会更大。结论：仅当重度饮酒者在意识到自己怀孕后继续饮酒时，才会观察到胎儿生物测量值的变化。虽然依赖自我报告的饮酒是本研究的一个局限性，但这些发现支持早期戒酒的好处以及超声波检查在检测胎儿<9>酒精</9>影响方面的潜力。", "revised": true}
{"doc_key": "9636837", "sentences": [["Carboplatin", "toxic", "effects", "on", "the", "peripheral", "nervous", "system", "of", "the", "rat", ".", "BACKGROUND", ":", "The", "most", "striking", "of", "carboplatin", "'s", "advantages", "(", "CBDCA", ")", "over", "cisplatin", "(", "CDDP", ")", "is", "its", "markedly", "reduced", "rate", "of", "neurotoxic", "effects", ".", "However", ",", "the", "use", "of", "CBDCA", "higher", "-", "intensity", "schedules", "and", "the", "association", "with", "other", "neurotoxic", "drugs", "in", "polychemotherapy", "may", "cause", "some", "concern", "about", "its", "safety", "with", "respect", "to", "peripheral", "nervous", "system", "damage", ".", "MATERIALS", "AND", "METHODS", ":", "Two", "different", "schedules", "of", "CBDCA", "administration", "(", "10", "mg", "/", "kg", "and", "15", "mg", "/", "kg", "i", ".", "p", ".", "twice", "a", "week", "for", "nine", "times", ")", "were", "evaluated", "in", "Wistar", "rats", ".", "Neurotoxicity", "was", "assessed", "for", "behavioral", "(", "tail", "-", "flick", "test", ")", ",", "neurophysiological", "(", "nerve", "conduction", "velocity", "in", "the", "tail", "nerve", ")", ",", "morphological", ",", "morphometrical", "and", "analytical", "effects", ".", "RESULTS", ":", "CBDCA", "administration", "induced", "dose", "-", "dependent", "peripheral", "neurotoxicity", ".", "Pain", "perception", "and", "nerve", "conduction", "velocity", "in", "the", "tail", "were", "significantly", "impaired", ",", "particularly", "after", "the", "high", "-", "dose", "treatment", ".", "The", "dorsal", "root", "ganglia", "sensory", "neurons", "and", ",", "to", "a", "lesser", "extent", ",", "satellite", "cells", "showed", "the", "same", "changes", "as", "those", "induced", "by", "CDDP", ",", "mainly", "affecting", "the", "nucleus", "and", "nucleolus", "of", "ganglionic", "sensory", "neurons", ".", "Moreover", ",", "significant", "amounts", "of", "platinum", "were", "detected", "in", "the", "dorsal", "root", "ganglia", "and", "kidney", "after", "CBDCA", "treatment", ".", "CONCLUSIONS", ":", "CBDCA", "is", "neurotoxic", "in", "our", "model", ",", "and", "the", "type", "of", "pathological", "changes", "it", "induces", "are", "so", "closely", "similar", "to", "those", "caused", "by", "CDDP", "that", "it", "is", "probable", "that", "neurotoxicity", "is", "induced", "in", "the", "two", "drugs", "by", "the", "same", "mechanism", ".", "This", "model", "can", "be", "used", "alone", "or", "in", "combination", "with", "other", "drugs", "to", "explore", "the", "effect", "of", "CBDCA", "on", "the", "peripheral", "nervous", "system", "."]], "ner": [[[0, 0, "Chemical"], [18, 18, "Chemical"], [22, 22, "Chemical"], [43, 43, "Chemical"], [80, 80, "Chemical"], [141, 141, "Chemical"], [223, 223, "Chemical"], [228, 228, "Chemical"], [286, 286, "Chemical"], [67, 70, "Disease"], [147, 148, "Disease"], [25, 25, "Chemical"], [27, 27, "Chemical"], [194, 194, "Chemical"], [251, 251, "Chemical"], [35, 35, "Disease"], [53, 53, "Disease"], [109, 109, "Disease"], [230, 230, "Disease"], [257, 257, "Disease"], [150, 150, "Disease"], [212, 212, "Chemical"]]], "relations": [[[0, 0, 67, 70, "CID"], [0, 0, 147, 148, "CID"], [18, 18, 67, 70, "CID"], [18, 18, 147, 148, "CID"], [22, 22, 67, 70, "CID"], [22, 22, 147, 148, "CID"], [43, 43, 67, 70, "CID"], [43, 43, 147, 148, "CID"], [80, 80, 67, 70, "CID"], [80, 80, 147, 148, "CID"], [141, 141, 67, 70, "CID"], [141, 141, 147, 148, "CID"], [223, 223, 67, 70, "CID"], [223, 223, 147, 148, "CID"], [228, 228, 67, 70, "CID"], [228, 228, 147, 148, "CID"], [286, 286, 67, 70, "CID"], [286, 286, 147, 148, "CID"], [25, 25, 67, 70, "CID"], [25, 25, 147, 148, "CID"], [27, 27, 67, 70, "CID"], [27, 27, 147, 148, "CID"], [194, 194, 67, 70, "CID"], [194, 194, 147, 148, "CID"], [251, 251, 67, 70, "CID"], [251, 251, 147, 148, "CID"]]], "clusters": [], "translated": "<0>卡铂</0>对大鼠周围神经系统的毒性作用。背景：<1>卡铂</1> 相对于<11>顺铂</11>（<12>CDDP</12>）最显着的优势（<2>CBDCA</2>）是其显着降低<15>神经毒性</15>影响的发生率。然而，<3>CBDCA</3>高强度方案的使用以及与其他<16>神经毒性</16>药物的联合化疗可能会引起对其在<9>周围神经系统损伤</9>方面的安全性的担忧。材料和方法：在Wistar大鼠中评估了两种不同的<4>CBDCA</4>给药方案（10 mg/kg和15 mg/kg i.p.，每周两次，共九次）。<17>神经毒性</17>的评估包括行为学（甩尾试验）、神经生理学（尾神经中的神经传导速度）、形态学、形态计量学和分析效应。结果：<5>CBDCA</5>给药引起剂量依赖性<10>外周神经毒性</10>。尾部<20>痛</20>知觉和神经传导速度明显受损，特别是在大剂量治疗后。背根神经节感觉神经元和卫星细胞的变化与<13>CDDP</13>相同，主要影响神经节感觉神经元的细胞核和核仁。此外，在<6>CBDCA</6>治疗后，在背根神经节和肾脏中检测到大量<21>铂</21>。结论：<7>CBDCA</7>在我们的模型中是<18>神经毒性</18>，它引起的病理变化类型与<14>CDDP</14>引起的病理变化非常相似，因此它<19>可能是</19>通过相同的机制在两种药物中引起的<神经毒性>。该模型可单独使用或与其他药物联合使用，探讨<8>CBDCA</8>对周围神经系统的影响。", "revised": true}
{"doc_key": "16174948", "sentences": [["Absence", "of", "acute", "cerebral", "vasoconstriction", "after", "cocaine", "-", "associated", "subarachnoid", "hemorrhage", ".", "INTRODUCTION", ":", "Cocaine", "use", "has", "been", "associated", "with", "neurovascular", "complications", ",", "including", "arterial", "vasoconstriction", "and", "vasculitis", ".", "However", ",", "there", "are", "few", "studies", "of", "angiographic", "effects", "of", "cocaine", "on", "human", "cerebral", "arteries", ".", "Information", "on", "these", "effects", "could", "be", "obtained", "from", "angiograms", "of", "patients", "with", "cocaine", "-", "associated", "subarachnoid", "hemorrhage", "(", "SAH", ")", "who", "underwent", "angiography", "shortly", "after", "cocaine", "use", ".", "METHODS", ":", "We", "screened", "patients", "with", "SAH", "retrospectively", "and", "identified", "those", "with", "positive", "urine", "toxicology", "for", "cocaine", "or", "its", "metabolites", ".", "Quantitative", "arterial", "diameter", "measurements", "from", "angiograms", "of", "these", "patients", "were", "compared", "to", "measurements", "from", "control", "patients", "with", "SAH", "who", "were", "matched", "for", "factors", "known", "to", "influence", "arterial", "diameter", ".", "Qualitative", "comparisons", "of", "small", "artery", "changes", "also", "were", "made", ".", "RESULTS", ":", "Thirteen", "patients", "with", "positive", "cocaine", "toxicology", "were", "compared", "to", "26", "controls", ".", "There", "were", "no", "significant", "differences", "between", "groups", "in", "the", "mean", "diameters", "of", "the", "intradural", "internal", "carotid", ",", "sphenoidal", "segment", "of", "the", "middle", "cerebral", ",", "precommunicating", "segment", "of", "the", "anterior", "cerebral", ",", "or", "basilar", "arteries", "(", "p", "greater", "than", "0", ".", "05", "for", "all", "comparisons", ",", "unpaired", "t", "-", "tests", ")", ".", "There", "also", "were", "no", "significant", "differences", "between", "groups", "when", "expressing", "diameters", "as", "the", "sum", "of", "the", "precommunicating", "segment", "of", "the", "anterior", "cerebral", "+", "sphenoidal", "segment", "of", "the", "middle", "cerebral", "+", "supraclinoid", "internal", "carotid", "artery", "+", "basilar", "artery", "divided", "by", "the", "diameter", "of", "the", "petrous", "internal", "carotid", "artery", "(", "p", "greater", "than", "0", ".", "05", ",", "unpaired", "t", "-", "tests", ")", ".", "Qualitative", "assessments", "showed", "two", "arterial", "irregularities", "in", "the", "distal", "vasculature", "in", "each", "group", ".", "CONCLUSION", ":", "No", "quantitative", "evidence", "for", "narrowing", "of", "large", "cerebral", "arteries", "or", "qualitative", "angiographic", "evidence", "for", "distal", "narrowing", "or", "vasculitis", "could", "be", "found", "in", "patients", "who", "underwent", "angiography", "after", "aneurysmal", "SAH", "associated", "with", "cocaine", "use", "."]], "ner": [[[6, 6, "Chemical"], [14, 14, "Chemical"], [39, 39, "Chemical"], [57, 57, "Chemical"], [70, 70, "Chemical"], [89, 89, "Chemical"], [139, 139, "Chemical"], [306, 306, "Chemical"], [9, 10, "Disease"], [60, 61, "Disease"], [63, 63, "Disease"], [79, 79, "Disease"], [111, 111, "Disease"], [303, 303, "Disease"], [302, 302, "Disease"], [20, 21, "Disease"], [27, 27, "Disease"], [292, 292, "Disease"]]], "relations": [[[6, 6, 9, 10, "CID"], [6, 6, 60, 61, "CID"], [6, 6, 63, 63, "CID"], [6, 6, 79, 79, "CID"], [6, 6, 111, 111, "CID"], [6, 6, 303, 303, "CID"], [14, 14, 9, 10, "CID"], [14, 14, 60, 61, "CID"], [14, 14, 63, 63, "CID"], [14, 14, 79, 79, "CID"], [14, 14, 111, 111, "CID"], [14, 14, 303, 303, "CID"], [39, 39, 9, 10, "CID"], [39, 39, 60, 61, "CID"], [39, 39, 63, 63, "CID"], [39, 39, 79, 79, "CID"], [39, 39, 111, 111, "CID"], [39, 39, 303, 303, "CID"], [57, 57, 9, 10, "CID"], [57, 57, 60, 61, "CID"], [57, 57, 63, 63, "CID"], [57, 57, 79, 79, "CID"], [57, 57, 111, 111, "CID"], [57, 57, 303, 303, "CID"], [70, 70, 9, 10, "CID"], [70, 70, 60, 61, "CID"], [70, 70, 63, 63, "CID"], [70, 70, 79, 79, "CID"], [70, 70, 111, 111, "CID"], [70, 70, 303, 303, "CID"], [89, 89, 9, 10, "CID"], [89, 89, 60, 61, "CID"], [89, 89, 63, 63, "CID"], [89, 89, 79, 79, "CID"], [89, 89, 111, 111, "CID"], [89, 89, 303, 303, "CID"], [139, 139, 9, 10, "CID"], [139, 139, 60, 61, "CID"], [139, 139, 63, 63, "CID"], [139, 139, 79, 79, "CID"], [139, 139, 111, 111, "CID"], [139, 139, 303, 303, "CID"], [306, 306, 9, 10, "CID"], [306, 306, 60, 61, "CID"], [306, 306, 63, 63, "CID"], [306, 306, 79, 79, "CID"], [306, 306, 111, 111, "CID"], [306, 306, 303, 303, "CID"], [6, 6, 302, 302, "CID"], [14, 14, 302, 302, "CID"], [39, 39, 302, 302, "CID"], [57, 57, 302, 302, "CID"], [70, 70, 302, 302, "CID"], [89, 89, 302, 302, "CID"], [139, 139, 302, 302, "CID"], [306, 306, 302, 302, "CID"]]], "clusters": [], "translated": "<0>可卡因</0> 相关<8>蛛网膜下腔出血</8>后无急性脑血管收缩。简介：<1>可卡因</1>使用与<15>神经血管并发症</15>有关，包括动脉血管收缩和<16>血管炎</16>。但<2>可卡因</2>对人脑动脉血管造影作用的研究较少。有关这些影响的信息可以从<3>可卡因</3>相关<9>蛛网膜下腔出血</9> (<10>SAH</10>)患者的血管造影中获得，这些患者在服用<4>可卡因</4>后不久接受了血管造影。方法：我们回顾性地筛查了<11>SAH</11>患者，并确定了<5>可卡因</5>或其代谢物尿液毒理学阳性的患者。将这些患者血管造影的定量动脉直径测量值与<12>SAH</12>对照患者的测量值进行比较，后者与已知影响动脉直径的因素相匹配。还对小动脉变化进行了定性比较。结果：将13名<6>可卡因</6>毒理学阳性患者与26名对照者进行了比较。硬膜内颈内动脉、大脑中动脉蝶骨段、大脑前交通前段或基底动脉的平均直径组间无显着差异（所有比较p均大于0.05，非配对t检验）。当将直径表示为大脑前交通前段+大脑中蝶段+床突上颈内动脉+基底动脉的总和除以颈内动脉岩骨的直径时，组间也没有显着差异（p更大比0.05，未配对的t测试）。定性评估显示每组远端脉管系统中有两处动脉不规则。结论：在与<7>可卡因</7>使用有关的<14>动脉瘤性</14><13>蛛网膜下腔出血</13>后接受血管造影的患者中，没有发现大脑大动脉狭窄的定量证据或远端狭窄或<17>血管炎</17>的定性血管造影证据。", "revised": true}
{"doc_key": "11847945", "sentences": [["Acute", "cholestatic", "hepatitis", "after", "exposure", "to", "isoflurane", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "acute", "cholestatic", "hepatitis", "following", "exposure", "to", "the", "inhalational", "anesthetic", "isoflurane", ".", "CASE", "SUMMARY", ":", "A", "70", "-", "year", "-", "old", "healthy", "woman", "from", "Iraq", "developed", "acute", "cholestatic", "hepatitis", "3", "weeks", "following", "repair", "of", "the", "right", "rotator", "cuff", "under", "general", "anesthesia", ".", "There", "was", "no", "evidence", "for", "viral", ",", "autoimmune", ",", "or", "metabolic", "causes", "of", "hepatitis", ".", "No", "other", "medications", "were", "involved", "except", "for", "dipyrone", "for", "analgesia", ".", "The", "alanine", "aminotransferase", "was", "elevated", "to", "a", "peak", "concentration", "of", "1533", "U", "/", "L", "and", "the", "serum", "bilirubin", "reached", "a", "peak", "of", "17", ".", "0", "mg", "/", "dL", ".", "There", "was", "slow", "improvement", "over", "4", "months", ".", "Accidental", "reexposure", "by", "the", "patient", "to", "dipyrone", "was", "uneventful", ".", "DISCUSSION", ":", "The", "clinical", "and", "histologic", "picture", "of", "this", "case", "resembles", "halothane", "hepatitis", ",", "which", "has", "a", "significant", "mortality", "rate", ".", "CONCLUSIONS", ":", "Isoflurane", ",", "a", "common", "anesthetic", "agent", ",", "can", "cause", "severe", "cholestatic", "hepatitis", "."]], "ner": [[[6, 6, "Chemical"], [24, 24, "Chemical"], [152, 152, "Chemical"], [1, 2, "Disease"], [16, 17, "Disease"], [41, 42, "Disease"], [162, 163, "Disease"], [69, 69, "Disease"], [78, 78, "Chemical"], [125, 125, "Chemical"], [83, 83, "Chemical"], [99, 99, "Chemical"], [80, 80, "Disease"], [140, 141, "Disease"]]], "relations": [[[6, 6, 1, 2, "CID"], [6, 6, 16, 17, "CID"], [6, 6, 41, 42, "CID"], [6, 6, 162, 163, "CID"], [24, 24, 1, 2, "CID"], [24, 24, 16, 17, "CID"], [24, 24, 41, 42, "CID"], [24, 24, 162, 163, "CID"], [152, 152, 1, 2, "CID"], [152, 152, 16, 17, "CID"], [152, 152, 41, 42, "CID"], [152, 152, 162, 163, "CID"], [6, 6, 69, 69, "CID"], [24, 24, 69, 69, "CID"], [152, 152, 69, 69, "CID"]]], "clusters": [], "translated": "接触<0>异氟烷</0>后发生急性<3>胆汁淤积性肝炎</3>。目的：报告一例吸入性麻醉药<1>异氟烷</1>后发生急性<4>胆汁淤积性肝炎</4>的病例。病例概要：一名来自伊拉克的70岁健康女性在全身麻醉下右肩袖修复后3周患上了急性<5>胆汁淤积性肝炎</5>。没有证据表明<7>肝炎</7>是由病毒、自身免疫或代谢原因引起的。除了用于<12>镇痛</12>的<8>安乃近</8>外，未涉及其他药物。<10>丙氨酸</10>转氨酶升高至峰值浓度1533 U/L，血清<11>胆红素</11>达到峰值17.0毫克/分升。4个月后缓慢改善。患者意外再次暴露于<9>安乃近</9>并无大碍。讨论：该病例的临床和组织学表现类似于<13>氟烷肝炎</13>，死亡率很高。结论：<2>异氟烷</2>是一种常见的麻醉剂，可引起严重的<6>胆汁淤积性肝炎</6>。", "revised": true}
{"doc_key": "9205462", "sentences": [["Granulosa", "cell", "tumor", "of", "the", "ovary", "associated", "with", "antecedent", "tamoxifen", "use", ".", "BACKGROUND", ":", "Increased", "attention", "has", "been", "focused", "recently", "on", "the", "estrogenic", "effects", "of", "tamoxifen", ".", "Review", "of", "the", "literature", "reveals", "an", "association", "between", "tamoxifen", "use", "and", "gynecologic", "tumors", ".", "CASE", ":", "A", "52", "-", "year", "-", "old", "postmenopausal", "woman", "was", "treated", "with", "tamoxifen", "for", "stage", "II", "estrogen", "receptor", "-", "positive", "breast", "carcinoma", ".", "Her", "aspartate", "transaminase", "and", "alanine", "transaminase", "levels", "increase", "markedly", "after", "6", "months", "of", "tamoxifen", "use", ".", "After", "an", "additional", "17", "months", "of", "elevated", "serum", "transaminases", ",", "the", "patient", "was", "found", "to", "have", "a", "stage", "Ic", "granulosa", "cell", "tumor", "of", "the", "ovary", ".", "CONCLUSION", ":", "Patients", "with", "tamoxifen", "-", "induced", "liver", "dysfunction", "may", "be", "at", "increased", "risk", "for", "granulosa", "cell", "tumors", "because", "of", "alterations", "in", "tamoxifen", "metabolism", "."]], "ner": [[[9, 9, "Chemical"], [25, 25, "Chemical"], [35, 35, "Chemical"], [54, 54, "Chemical"], [78, 78, "Chemical"], [111, 111, "Chemical"], [129, 129, "Chemical"], [0, 5, "Disease"], [100, 105, "Disease"], [114, 115, "Disease"], [58, 58, "Chemical"], [66, 66, "Chemical"], [69, 69, "Chemical"], [39, 39, "Disease"], [62, 63, "Disease"], [122, 124, "Disease"]]], "relations": [[[9, 9, 0, 5, "CID"], [9, 9, 100, 105, "CID"], [25, 25, 0, 5, "CID"], [25, 25, 100, 105, "CID"], [35, 35, 0, 5, "CID"], [35, 35, 100, 105, "CID"], [54, 54, 0, 5, "CID"], [54, 54, 100, 105, "CID"], [78, 78, 0, 5, "CID"], [78, 78, 100, 105, "CID"], [111, 111, 0, 5, "CID"], [111, 111, 100, 105, "CID"], [129, 129, 0, 5, "CID"], [129, 129, 100, 105, "CID"], [9, 9, 114, 115, "CID"], [25, 25, 114, 115, "CID"], [35, 35, 114, 115, "CID"], [54, 54, 114, 115, "CID"], [78, 78, 114, 115, "CID"], [111, 111, 114, 115, "CID"], [129, 129, 114, 115, "CID"]]], "clusters": [], "translated": " <7> 卵巢颗粒细胞瘤 </7>与先前使用<0> 他莫昔芬 </0>相关。背景：最近越来越多的注意力集中在<1> 他莫昔芬 </1>的雌激素作用上。文献回顾揭示了<2> 他莫昔芬 </2>使用与妇科<13> 肿瘤 </13>之间的关联。案例：一名52岁的绝经后妇女因<3> 他莫昔芬 </3>治疗II期<10> 雌激素 </10>受体阳性<14> 乳腺癌 </14>。使用<4> 他莫昔芬 </4>6个月后，她的<11> 天冬氨酸 </11>转氨酶和<12> 丙氨酸 </12>转氨酶水平显着升高。在血清转氨酶升高17个月后，患者被发现患有期Ic<8> 卵巢颗粒细胞瘤 </8>。结论：<5> 他莫昔芬 </5>引起的<9> 肝功能障碍 </9>患者发生<15> 颗粒细胞瘤 </15>的风险可能增加，因为<6> 他莫昔芬 </6>新陈代谢。", "revised": true}
{"doc_key": "7102237", "sentences": [["Midazolam", "compared", "with", "thiopentone", "as", "an", "induction", "agent", ".", "In", "patients", "premedicated", "with", "scopolamine", "+", "morphine", "(", "+", "5", "mg", "nitrazepam", "the", "evening", "before", "surgery", ")", ",", "the", "sleep", "-", "inducing", "effect", "of", "midazolam", "0", ".", "15", "mg", "/", "kg", "i", ".", "v", ".", "was", "clearly", "slower", "in", "onset", "than", "that", "of", "thiopentone", "4", ".", "67", "mg", "/", "kg", "i", ".", "v", ".", "Somewhat", "fewer", "cardiovascular", "and", "local", "sequelae", "were", "found", "in", "the", "midazolam", "group", ",", "but", ",", "although", "apnoea", "occurred", "less", "often", "in", "the", "midazolam", "group", "it", "lasted", "longer", ".", "On", "the", "whole", ",", "the", "differences", "between", "midazolam", "and", "thiopentone", "had", "no", "apparent", "clinical", "consequences", ".", "Midazolam", "is", "a", "new", "alternative", "agent", "for", "induction", "in", "combination", "anaesthesia", "."]], "ner": [[[0, 0, "Chemical"], [33, 33, "Chemical"], [73, 73, "Chemical"], [85, 85, "Chemical"], [98, 98, "Chemical"], [107, 107, "Chemical"], [79, 79, "Disease"], [3, 3, "Chemical"], [52, 52, "Chemical"], [100, 100, "Chemical"], [13, 13, "Chemical"], [15, 15, "Chemical"], [20, 20, "Chemical"]]], "relations": [[[0, 0, 79, 79, "CID"], [33, 33, 79, 79, "CID"], [73, 73, 79, 79, "CID"], [85, 85, 79, 79, "CID"], [98, 98, 79, 79, "CID"], [107, 107, 79, 79, "CID"], [3, 3, 79, 79, "CID"], [52, 52, 79, 79, "CID"], [100, 100, 79, 79, "CID"]]], "clusters": [], "translated": "<0>咪达唑仑</0>与<7>硫喷妥酮</7>作为诱导剂的比较。在术前服用<12>硝西泮</12> （+ 5 mg）的<10>东莨菪碱</10>+ <11>吗啡</11>的患者中，<1>咪达唑仑</1>0.15毫克/千克i.v.起效明显慢于<8>硫喷妥酮</8>4.67毫克/公斤i.v. <2>咪达唑仑</2>组的心血管和局部后遗症较少，但是，尽管<3>咪达唑仑</3>组的<6>呼吸暂停</6>发生频率较低，但持续时间更长。总体而言，<4>咪达唑仑</4>与<9>硫喷妥酮</9>的差异无明显临床意义。<5>咪达唑仑</5>是一种新型的联合麻醉诱导替代药物。", "revised": true}
{"doc_key": "3969369", "sentences": [["Promotional", "effects", "of", "testosterone", "and", "dietary", "fat", "on", "prostate", "carcinogenesis", "in", "genetically", "susceptible", "rats", ".", "Germfree", "(", "GF", ")", "Lobund", "strain", "Wistar", "(", "LW", ")", "rats", ",", "fed", "vegetable", "diet", "L", "-", "485", ",", "have", "developed", "prostate", "adenocarcinomas", "spontaneously", "(", "10", "%", "incidence", ")", "at", "average", "age", "34", "months", ".", "Conventional", "LW", "rats", ",", "implanted", "with", "testosterone", "at", "age", "4", "months", ",", "developed", "a", "higher", "incidence", "of", "prostate", "cancer", "after", "an", "average", "interval", "of", "14", "months", ":", "24", "%", "had", "developed", "gross", "tumors", ",", "and", "40", "%", "when", "it", "included", "microscopic", "tumors", ".", "Preliminary", "results", "indicate", "that", "testosterone", "-", "treated", "LW", "rats", "that", "were", "fed", "the", "same", "diet", ",", "which", "was", "supplemented", "with", "corn", "oil", "up", "to", "20", "%", "fat", ",", "developed", "prostate", "cancer", "after", "intervals", "of", "6", "-", "12", "months", ".", "Aged", "GF", "Sprague", "-", "Dawley", "(", "SD", ")", "rats", "have", "not", "developed", "prostate", "cancer", "spontaneously", ".", "Conventional", "SD", "rats", "fed", "diet", "L", "-", "485", "and", "treated", "with", "testosterone", "developed", "only", "prostatitis", ".", "Experimental", "designs", "should", "consider", "genetic", "susceptibility", "as", "a", "basic", "prerequisite", "for", "studies", "on", "experimental", "prostate", "cancer", "."]], "ner": [[[3, 3, "Chemical"], [56, 56, "Chemical"], [97, 97, "Chemical"], [159, 159, "Chemical"], [36, 37, "Disease"], [67, 68, "Disease"], [122, 123, "Disease"], [144, 145, "Disease"], [178, 179, "Disease"], [162, 162, "Disease"], [9, 9, "Disease"], [82, 82, "Disease"], [91, 91, "Disease"]]], "relations": [[[3, 3, 36, 37, "CID"], [3, 3, 67, 68, "CID"], [3, 3, 122, 123, "CID"], [3, 3, 144, 145, "CID"], [3, 3, 178, 179, "CID"], [56, 56, 36, 37, "CID"], [56, 56, 67, 68, "CID"], [56, 56, 122, 123, "CID"], [56, 56, 144, 145, "CID"], [56, 56, 178, 179, "CID"], [97, 97, 36, 37, "CID"], [97, 97, 67, 68, "CID"], [97, 97, 122, 123, "CID"], [97, 97, 144, 145, "CID"], [97, 97, 178, 179, "CID"], [159, 159, 36, 37, "CID"], [159, 159, 67, 68, "CID"], [159, 159, 122, 123, "CID"], [159, 159, 144, 145, "CID"], [159, 159, 178, 179, "CID"], [3, 3, 162, 162, "CID"], [56, 56, 162, 162, "CID"], [97, 97, 162, 162, "CID"], [159, 159, 162, 162, "CID"]]], "clusters": [], "translated": "<0>睾酮 </0>和膳食脂肪对遗传易感大鼠前列腺<10>癌变</10>的促进作用。Germfree (GF) Lobund 品系 Wistar (LW) 大鼠，喂食植物性饮食 L-485，在平均年龄 34 个月时自发地发生 <4>前列腺癌</4>（发生率为 10%）。传统的 LW 大鼠，在 4 个月大时植入<1> 睾酮</1>，在平均间隔 14 个月后发生 <5>前列腺癌 </5> 的发生率更高：24% 发生了严重的<11>肿瘤</11>，而当它包括微观<12>肿瘤</12>时达到 40%。初步结果表明，用 <2>睾酮</2> 治疗的 LW 大鼠喂食相同的饮食，补充脂肪含量高达 20% 的玉米油，在 6-12 个月间隔后患上了<6>前列腺癌</6>。年老的 GF Sprague-Dawley (SD) 大鼠未自发地发生<7>前列腺癌</7>。传统 SD 大鼠喂食 L-485 并用 <3> 睾酮</3> 治疗后仅发生<9>前列腺炎</9>。实验设计应考虑遗传易感性是实验性<8>前列腺癌</8>研究的基本前提。", "revised": true}
{"doc_key": "9098464", "sentences": [["A", "murine", "model", "of", "adenomyosis", ":", "the", "effects", "of", "hyperprolactinemia", "induced", "by", "fluoxetine", "hydrochloride", ",", "a", "selective", "serotonin", "reuptake", "inhibitor", ",", "on", "adenomyosis", "induction", "in", "Wistar", "albino", "rats", ".", "OBJECTIVE", ":", "The", "aim", "of", "this", "study", "was", "to", "investigate", "whether", "fluoxetine", "given", "to", "castrated", "and", "noncastrated", "rats", "caused", "hyperprolactinemia", "and", "its", "effects", "with", "respect", "to", "adenomyosis", ".", "DESIGN", ":", "Fluoxetine", ",", "a", "serotonin", "reuptake", "inhibitor", ",", "was", "given", "to", "Wistar", "Albino", "rats", "for", "98", "days", "to", "produce", "hyperprolactinemia", ".", "The", "drug", "was", "given", "to", "two", "groups", "consisting", "of", "castrated", "and", "noncastrated", "rats", "and", "compared", "to", "two", "groups", "of", "castrated", "and", "noncastrated", "controls", ".", "Prolactin", "levels", "were", "measured", "and", "the", "uteri", "of", "the", "rats", "were", "removed", "for", "histopathological", "analysis", "at", "the", "end", "of", "98", "days", ".", "SETTING", ":", "Marmara", "University", "School", "of", "Medicine", ",", "Department", "of", "Histology", "and", "Embryology", ",", "Zeynep", "Kamil", "Women", "and", "Children", "'s", "Hospital", ".", "MAIN", "OUTCOME", "MEASURES", ":", "Serum", "prolactin", "levels", ",", "uterine", "histopathology", ".", "RESULTS", ":", "The", "prolactin", "levels", "of", "castrated", "and", "noncastrated", "groups", "treated", "with", "fluoxetine", "were", "statistically", "significantly", "higher", "when", "compared", "to", "their", "respective", "control", "groups", ".", "Histological", "studies", "revealed", "11", "cases", "of", "adenomyosis", ",", "all", "within", "the", "noncastrated", "group", "receiving", "fluoxetine", ".", "CONCLUSION", ":", "It", "was", "suggested", "that", "high", "serum", "prolactin", "levels", "cause", "degeneration", "of", "myometrial", "cells", "in", "the", "presence", "of", "ovarian", "steroids", "that", "results", "in", "a", "myometrial", "invasion", "by", "endometrial", "stroma", ".", "This", "invasion", "eventually", "progresses", "to", "adenomyosis", "."]], "ner": [[[12, 13, "Chemical"], [40, 40, "Chemical"], [59, 59, "Chemical"], [170, 170, "Chemical"], [197, 197, "Chemical"], [4, 4, "Disease"], [22, 22, "Disease"], [55, 55, "Disease"], [189, 189, "Disease"], [235, 235, "Disease"], [9, 9, "Disease"], [48, 48, "Disease"], [77, 77, "Disease"], [17, 17, "Chemical"], [62, 62, "Chemical"], [219, 219, "Chemical"]]], "relations": [[[12, 13, 4, 4, "CID"], [12, 13, 22, 22, "CID"], [12, 13, 55, 55, "CID"], [12, 13, 189, 189, "CID"], [12, 13, 235, 235, "CID"], [40, 40, 4, 4, "CID"], [40, 40, 22, 22, "CID"], [40, 40, 55, 55, "CID"], [40, 40, 189, 189, "CID"], [40, 40, 235, 235, "CID"], [59, 59, 4, 4, "CID"], [59, 59, 22, 22, "CID"], [59, 59, 55, 55, "CID"], [59, 59, 189, 189, "CID"], [59, 59, 235, 235, "CID"], [170, 170, 4, 4, "CID"], [170, 170, 22, 22, "CID"], [170, 170, 55, 55, "CID"], [170, 170, 189, 189, "CID"], [170, 170, 235, 235, "CID"], [197, 197, 4, 4, "CID"], [197, 197, 22, 22, "CID"], [197, 197, 55, 55, "CID"], [197, 197, 189, 189, "CID"], [197, 197, 235, 235, "CID"], [12, 13, 9, 9, "CID"], [12, 13, 48, 48, "CID"], [12, 13, 77, 77, "CID"], [40, 40, 9, 9, "CID"], [40, 40, 48, 48, "CID"], [40, 40, 77, 77, "CID"], [59, 59, 9, 9, "CID"], [59, 59, 48, 48, "CID"], [59, 59, 77, 77, "CID"], [170, 170, 9, 9, "CID"], [170, 170, 48, 48, "CID"], [170, 170, 77, 77, "CID"], [197, 197, 9, 9, "CID"], [197, 197, 48, 48, "CID"], [197, 197, 77, 77, "CID"]]], "clusters": [], "translated": "<5>子宫腺肌症</5>小鼠模型：<0>盐酸氟西汀</0>引起的<10>高泌乳素血症</10>，一种选择性<13>血清素</13>再摄取抑制剂，对 Wistar 白化大鼠的<6>子宫腺肌病</6>诱导。目的：本研究旨在探讨<1>氟西汀</1>给予去势和未去势大鼠后是否引起<11>高催乳素血症</11>及其对<7>子宫腺肌病</7>的影响。设计：<2>氟西汀</2>，一种<14>血清素</14>再摄取抑制剂，给予 Wistar Albino 大鼠 98 天以产生<12>高泌乳素血症</12>。将药物给予两组，包括去势和未去势的大鼠，并与两组对照组进行比较。测量催乳素水平，并在 98 天结束时取出大鼠的子宫进行组织病理学分析。地点：马尔马拉大学医学院组织学和胚胎学系，Zeynep Kamil 妇女儿童医院。主要观察指标：血清催乳素水平、子宫组织病理学。结果：<3>氟西汀</3>治疗的去势组和未去势组的催乳素水平显著高于各自的对照组，具有统计学意义。组织学研究显示 11 例<8>子宫腺肌病</8>，均出现在接受<4>氟西汀</4>治疗的未去势组中。结论：结果表明，高血清催乳素水平在卵巢<15>类固醇</15>的存在下导致肌层细胞退化，从而导致内膜侵袭肌层。这种侵袭最终演变为<9>子宫腺肌症</9>。", "revised": true}
{"doc_key": "8742498", "sentences": [["Influence", "of", "diet", "free", "of", "NAD", "-", "precursors", "on", "acetaminophen", "hepatotoxicity", "in", "mice", ".", "Recently", ",", "we", "demonstrated", "the", "hepatoprotective", "effects", "of", "nicotinic", "acid", "amide", ",", "a", "selective", "inhibitor", "of", "poly", "(", "ADP", "-", "ribose", ")", "polymerase", "(", "PARP", ";", "EC", "2", ".", "4", ".", "2", ".", "30", ")", "on", "mice", "suffering", "from", "acetaminophen", "(", "AAP", ")", "-", "hepatitis", ",", "suggesting", "that", "the", "AAP", "-", "induced", "liver", "injury", "involves", "a", "step", "which", "depends", "on", "adenoribosylation", ".", "The", "present", "study", "investigates", "the", "effects", "of", "a", "diet", "free", "of", "precursors", "of", "NAD", ",", "the", "substrate", "on", "which", "PARP", "acts", ",", "in", "female", "NMRI", "mice", "with", "AAP", "hepatitis", "and", "evaluates", "the", "influence", "of", "simultaneous", "ethanol", "consumption", "in", "these", "animals", ".", "Liver", "injuries", "were", "quantified", "as", "serum", "activities", "of", "glutamate", "-", "oxaloacetate", "transaminase", "(", "GOT", ")", "and", "glutamate", "-", "pyruvate", "transaminase", "(", "GPT", ")", ".", "While", "AAP", "caused", "a", "117", "-", "fold", "elevation", "of", "serum", "transaminase", "activities", "in", "mice", "kept", "on", "a", "standard", "laboratory", "diet", ",", "which", "was", "significantly", "exacerbated", "by", "ethanol", "and", "inhibited", "by", "nicotinic", "acid", "amide", "(", "NAA", ")", ",", "adverse", "effects", "were", "noted", "in", "animals", "fed", "a", "diet", "free", "of", "precursors", "of", "NAD", ".", "In", "these", "animals", ",", "only", "minor", "increases", "of", "serum", "transaminase", "activities", "were", "measured", "in", "the", "presence", "of", "AAP", ",", "and", "unlike", "the", "exacerbation", "caused", "by", "ethanol", "in", "mice", "on", "a", "standard", "diet", ",", "the", "liver", "damage", "was", "inhibited", "by", "50", "%", "by", "ethanol", ".", "A", "further", "64", "%", "reduction", "of", "hepatitis", "was", "observed", ",", "when", "NAA", "was", "given", "to", "ethanol", "/", "AAP", "-", "mice", ".", "Our", "results", "provide", "evidence", "that", "the", "AAP", "-", "induced", "hepatitis", "and", "its", "exacerbation", "by", "ethanol", "can", "either", "be", "reduced", "by", "end", "-", "product", "inhibition", "of", "PARP", "by", "NAA", "or", "by", "dietary", "depletion", "of", "the", "enzyme", "'s", "substrate", "NAD", ".", "We", "see", "the", "main", "application", "of", "NAA", "as", "for", "the", "combinational", "use", "in", "pharmaceutical", "preparations", "of", "acetaminophen", "in", "order", "to", "avoid", "hepatic", "damage", "in", "patients", "treated", "with", "this", "widely", "used", "analgesic", "."]], "ner": [[[9, 9, "Chemical"], [53, 53, "Chemical"], [55, 55, "Chemical"], [63, 63, "Chemical"], [103, 103, "Chemical"], [142, 142, "Chemical"], [210, 210, "Chemical"], [254, 254, "Chemical"], [264, 264, "Chemical"], [313, 313, "Chemical"], [10, 10, "Disease"], [58, 58, "Disease"], [66, 67, "Disease"], [104, 104, "Disease"], [117, 118, "Disease"], [227, 228, "Disease"], [243, 243, "Disease"], [267, 267, "Disease"], [318, 319, "Disease"], [111, 111, "Chemical"], [167, 167, "Chemical"], [218, 218, "Chemical"], [235, 235, "Chemical"], [252, 252, "Chemical"], [272, 272, "Chemical"], [5, 5, "Chemical"], [89, 89, "Chemical"], [191, 191, "Chemical"], [295, 295, "Chemical"], [22, 24, "Chemical"], [171, 173, "Chemical"], [175, 175, "Chemical"], [248, 248, "Chemical"], [285, 285, "Chemical"], [303, 303, "Chemical"], [30, 35, "Chemical"], [125, 125, "Chemical"], [133, 133, "Chemical"], [127, 127, "Chemical"], [135, 135, "Chemical"]]], "relations": [[[9, 9, 10, 10, "CID"], [9, 9, 58, 58, "CID"], [9, 9, 66, 67, "CID"], [9, 9, 104, 104, "CID"], [9, 9, 117, 118, "CID"], [9, 9, 227, 228, "CID"], [9, 9, 243, 243, "CID"], [9, 9, 267, 267, "CID"], [9, 9, 318, 319, "CID"], [53, 53, 10, 10, "CID"], [53, 53, 58, 58, "CID"], [53, 53, 66, 67, "CID"], [53, 53, 104, 104, "CID"], [53, 53, 117, 118, "CID"], [53, 53, 227, 228, "CID"], [53, 53, 243, 243, "CID"], [53, 53, 267, 267, "CID"], [53, 53, 318, 319, "CID"], [55, 55, 10, 10, "CID"], [55, 55, 58, 58, "CID"], [55, 55, 66, 67, "CID"], [55, 55, 104, 104, "CID"], [55, 55, 117, 118, "CID"], [55, 55, 227, 228, "CID"], [55, 55, 243, 243, "CID"], [55, 55, 267, 267, "CID"], [55, 55, 318, 319, "CID"], [63, 63, 10, 10, "CID"], [63, 63, 58, 58, "CID"], [63, 63, 66, 67, "CID"], [63, 63, 104, 104, "CID"], [63, 63, 117, 118, "CID"], [63, 63, 227, 228, "CID"], [63, 63, 243, 243, "CID"], [63, 63, 267, 267, "CID"], [63, 63, 318, 319, "CID"], [103, 103, 10, 10, "CID"], [103, 103, 58, 58, "CID"], [103, 103, 66, 67, "CID"], [103, 103, 104, 104, "CID"], [103, 103, 117, 118, "CID"], [103, 103, 227, 228, "CID"], [103, 103, 243, 243, "CID"], [103, 103, 267, 267, "CID"], [103, 103, 318, 319, "CID"], [142, 142, 10, 10, "CID"], [142, 142, 58, 58, "CID"], [142, 142, 66, 67, "CID"], [142, 142, 104, 104, "CID"], [142, 142, 117, 118, "CID"], [142, 142, 227, 228, "CID"], [142, 142, 243, 243, "CID"], [142, 142, 267, 267, "CID"], [142, 142, 318, 319, "CID"], [210, 210, 10, 10, "CID"], [210, 210, 58, 58, "CID"], [210, 210, 66, 67, "CID"], [210, 210, 104, 104, "CID"], [210, 210, 117, 118, "CID"], [210, 210, 227, 228, "CID"], [210, 210, 243, 243, "CID"], [210, 210, 267, 267, "CID"], [210, 210, 318, 319, "CID"], [254, 254, 10, 10, "CID"], [254, 254, 58, 58, "CID"], [254, 254, 66, 67, "CID"], [254, 254, 104, 104, "CID"], [254, 254, 117, 118, "CID"], [254, 254, 227, 228, "CID"], [254, 254, 243, 243, "CID"], [254, 254, 267, 267, "CID"], [254, 254, 318, 319, "CID"], [264, 264, 10, 10, "CID"], [264, 264, 58, 58, "CID"], [264, 264, 66, 67, "CID"], [264, 264, 104, 104, "CID"], [264, 264, 117, 118, "CID"], [264, 264, 227, 228, "CID"], [264, 264, 243, 243, "CID"], [264, 264, 267, 267, "CID"], [264, 264, 318, 319, "CID"], [313, 313, 10, 10, "CID"], [313, 313, 58, 58, "CID"], [313, 313, 66, 67, "CID"], [313, 313, 104, 104, "CID"], [313, 313, 117, 118, "CID"], [313, 313, 227, 228, "CID"], [313, 313, 243, 243, "CID"], [313, 313, 267, 267, "CID"], [313, 313, 318, 319, "CID"], [111, 111, 10, 10, "CID"], [111, 111, 58, 58, "CID"], [111, 111, 66, 67, "CID"], [111, 111, 104, 104, "CID"], [111, 111, 117, 118, "CID"], [111, 111, 227, 228, "CID"], [111, 111, 243, 243, "CID"], [111, 111, 267, 267, "CID"], [111, 111, 318, 319, "CID"], [167, 167, 10, 10, "CID"], [167, 167, 58, 58, "CID"], [167, 167, 66, 67, "CID"], [167, 167, 104, 104, "CID"], [167, 167, 117, 118, "CID"], [167, 167, 227, 228, "CID"], [167, 167, 243, 243, "CID"], [167, 167, 267, 267, "CID"], [167, 167, 318, 319, "CID"], [218, 218, 10, 10, "CID"], [218, 218, 58, 58, "CID"], [218, 218, 66, 67, "CID"], [218, 218, 104, 104, "CID"], [218, 218, 117, 118, "CID"], [218, 218, 227, 228, "CID"], [218, 218, 243, 243, "CID"], [218, 218, 267, 267, "CID"], [218, 218, 318, 319, "CID"], [235, 235, 10, 10, "CID"], [235, 235, 58, 58, "CID"], [235, 235, 66, 67, "CID"], [235, 235, 104, 104, "CID"], [235, 235, 117, 118, "CID"], [235, 235, 227, 228, "CID"], [235, 235, 243, 243, "CID"], [235, 235, 267, 267, "CID"], [235, 235, 318, 319, "CID"], [252, 252, 10, 10, "CID"], [252, 252, 58, 58, "CID"], [252, 252, 66, 67, "CID"], [252, 252, 104, 104, "CID"], [252, 252, 117, 118, "CID"], [252, 252, 227, 228, "CID"], [252, 252, 243, 243, "CID"], [252, 252, 267, 267, "CID"], [252, 252, 318, 319, "CID"], [272, 272, 10, 10, "CID"], [272, 272, 58, 58, "CID"], [272, 272, 66, 67, "CID"], [272, 272, 104, 104, "CID"], [272, 272, 117, 118, "CID"], [272, 272, 227, 228, "CID"], [272, 272, 243, 243, "CID"], [272, 272, 267, 267, "CID"], [272, 272, 318, 319, "CID"]]], "clusters": [], "translated": "不含<25>NAD</25>-前体的饮食对小鼠<0>对乙酰氨基酚</0><10>肝毒性</10>的影响。最近，我们证实了<29>烟酰胺</29>的保肝作用，它是<35>聚（ADP-核糖）</35>聚合酶（PARP；EC 2.4.2.30）的选择性抑制剂。小鼠患有<1>对乙酰氨基酚</1>（<2>AAP</2>）-<11>肝炎</11>，提示<3>AAP</3>-诱发<12>肝损伤</12>涉及一个依赖于腺核糖基化的步骤。本研究调查了不含<26>NAD</26>前体的饮食对患有<4>AAP</4><13>肝炎</13>的雌性NMRI小鼠的影响，<26>NAD</26>是PARP作用的底物并评估同时消耗<19>乙醇</19>对这些动物的影响。<14>肝损伤</14>被量化为<36>谷氨酸</36>-<38>草酰乙酸</38>转氨酶（GOT）和<37>谷氨酸</37>-<39>丙酮酸</39>转氨酶（GPT）的血清活性。在标准实验室饮食的小鼠中，<5>AAP</5>导致血清转氨酶活性升高117倍，且在同时消耗<20>乙醇</20>的情况下导致恶化，而<30>烟酰胺能够抑制血清转氨酶活性升高</30>（<31>NAA</31>）。然而，喂食不含<27>NAD</27>前体的动物中出现了不良反应。在这些动物中，在<6>AAP</6>的存在下，血清转氨酶活性仅轻微增加；与标准饮食小鼠中饮用<21>乙醇</21>后的恶化情况不同，<22>乙醇</22>能够抑制<15>肝损伤</15>50%的程度。在<23>乙醇</23>/<7>AAP</7>小鼠中，当服用<32>NAA</32>时，<16>肝炎</16>进一步减少了64%。我们的结果提供了证据，表明<8>AAP</8>诱导的<17>肝炎</17>和<24>乙醇</24>导致的恶化可以通过终产物抑制<33>PARP</33>（<33>NAA</33>）或酶底物<28>NAD</28>的膳食消耗来减少。我们认为<34>NAA</34>的主要应用是与<9>对乙酰氨基酚</9>的药物制剂联合使用，以避免使用该广泛的止痛药治疗的患者受到<18>肝损伤</18>的影响。", "revised": true}
{"doc_key": "6769133", "sentences": [["Cardiotoxic", "and", "possible", "leukemogenic", "effects", "of", "adriamycin", "in", "nonhuman", "primates", ".", "10", "monkeys", "(", "macaques", ")", "received", "adriamycin", "by", "monthly", "intravenous", "injections", "at", "12", "mg", "/", "m2", "(", "1", "mg", "/", "kg", ")", ".", "8", "of", "the", "10", "monkeys", "developed", "congestive", "heart", "failure", "at", "an", "average", "cumulative", "adriamycin", "dose", "(", "310", "mg", "/", "m2", ")", "well", "below", "that", "considered", "the", "safe", "upper", "limit", "(", "550", "mg", "/", "m2", ")", "in", "man", ".", "Histologically", ",", "the", "myocardial", "lesions", "resembled", "those", "found", "in", "human", "anthracycline", "-", "induced", "cardiomyopathy", ".", "1", "of", "the", "10", "monkeys", "developed", "acute", "myeloblastic", "leukemia", "after", "receiving", "324", "mg", "/", "m2", "of", "adriamycin", ";", "the", "10th", "monkey", "is", "alive", "and", "well", "26", "months", "after", "the", "last", "dose", "of", "drug", ".", "Our", "results", "suggest", "that", "adriamycin", "is", "a", "more", "potent", "cardiotoxin", "in", "monkeys", "than", "in", "man", ",", "and", "that", "leukemia", "may", "be", "a", "consequence", "of", "prolonged", "treatment", "with", "this", "drug", "."]], "ner": [[[6, 6, "Chemical"], [17, 17, "Chemical"], [47, 47, "Chemical"], [103, 103, "Chemical"], [125, 125, "Chemical"], [40, 42, "Disease"], [93, 95, "Disease"], [0, 0, "Disease"], [82, 82, "Chemical"], [75, 76, "Disease"], [85, 85, "Disease"], [139, 139, "Disease"]]], "relations": [[[6, 6, 40, 42, "CID"], [17, 17, 40, 42, "CID"], [47, 47, 40, 42, "CID"], [103, 103, 40, 42, "CID"], [125, 125, 40, 42, "CID"], [6, 6, 93, 95, "CID"], [17, 17, 93, 95, "CID"], [47, 47, 93, 95, "CID"], [103, 103, 93, 95, "CID"], [125, 125, 93, 95, "CID"]]], "clusters": [], "translated": " <0>阿霉素</0>对非人灵长类动物的<7>心脏毒性</7>和可能的致白血病作用。10只猴（猕猴）每月静脉注射12毫克/平方米（1毫克/千克）的<1>阿霉素</1>。其中8只猴子在平均累积<2>阿霉素</2>剂量（310 mg/m2）远低于安全上限（550 mg/m2）时发生<5>充血性心力衰竭</5>。在组织学上，<9>心肌病变</9>与人类<8>蒽环类药物</8>引起的<10>心肌病</10>相似。其中1只猴子在接受324 mg/m2的<3>阿霉素</3>后发生<6>急性髓细胞白血病</6>；第10只猴子在最后一次服药26个月后仍然健在。我们的结果表明，<4>阿霉素</4>对猴子的心脏毒性比对人类更强，<11>白血病</11>可能是长期使用这种药物治疗的结果。", "revised": true}
{"doc_key": "2320800", "sentences": [["Lethal", "anuria", "complicating", "high", "dose", "ifosfamide", "chemotherapy", "in", "a", "breast", "cancer", "patient", "with", "an", "impaired", "renal", "function", ".", "A", "sixty", "-", "year", "-", "old", "woman", "with", "advanced", "breast", "cancer", ",", "previously", "treated", "with", "cisplatin", ",", "developed", "an", "irreversible", "lethal", "renal", "failure", "with", "anuria", ",", "the", "day", "after", "5", "g", "/", "m2", "bolus", "ifosfamide", ".", "Postrenal", "failure", "was", "excluded", "by", "echography", ".", "A", "prerenal", "component", "could", "have", "contributed", "to", "renal", "failure", "because", "of", "a", "transient", "hypotension", ",", "due", "to", "an", "increasing", "ascitis", ",", "occurring", "just", "before", "anuria", ".", "However", ",", "correction", "of", "the", "hemodynamic", "parameters", "did", "not", "improve", "renal", "function", ".", "Ifosfamide", "is", "a", "known", "nephrotoxic", "drug", "with", "demonstrated", "tubulopathies", ".", "We", "strongly", "suspect", "that", "this", "lethal", "anuria", "was", "mainly", "due", "to", "ifosfamide", ",", "occurring", "in", "a", "patient", "having", "received", "previous", "cisplatin", "chemotherapy", "and", "with", "poor", "kidney", "perfusion", "due", "to", "transient", "hypotension", ".", "We", "recommend", "careful", "use", "of", "ifosfamide", "in", "patients", "pretreated", "with", "nephrotoxic", "chemotherapy", "and", "inadequate", "renal", "perfusion", "."]], "ner": [[[5, 5, "Chemical"], [52, 52, "Chemical"], [100, 100, "Chemical"], [121, 121, "Chemical"], [147, 147, "Chemical"], [1, 1, "Disease"], [42, 42, "Disease"], [85, 85, "Disease"], [116, 116, "Disease"], [14, 16, "Disease"], [54, 55, "Disease"], [104, 104, "Disease"], [108, 108, "Disease"], [152, 152, "Disease"], [33, 33, "Chemical"], [130, 130, "Chemical"], [9, 10, "Disease"], [27, 28, "Disease"], [39, 40, "Disease"], [68, 69, "Disease"], [74, 74, "Disease"], [140, 140, "Disease"]]], "relations": [[[5, 5, 1, 1, "CID"], [5, 5, 42, 42, "CID"], [5, 5, 85, 85, "CID"], [5, 5, 116, 116, "CID"], [52, 52, 1, 1, "CID"], [52, 52, 42, 42, "CID"], [52, 52, 85, 85, "CID"], [52, 52, 116, 116, "CID"], [100, 100, 1, 1, "CID"], [100, 100, 42, 42, "CID"], [100, 100, 85, 85, "CID"], [100, 100, 116, 116, "CID"], [121, 121, 1, 1, "CID"], [121, 121, 42, 42, "CID"], [121, 121, 85, 85, "CID"], [121, 121, 116, 116, "CID"], [147, 147, 1, 1, "CID"], [147, 147, 42, 42, "CID"], [147, 147, 85, 85, "CID"], [147, 147, 116, 116, "CID"], [5, 5, 14, 16, "CID"], [5, 5, 54, 55, "CID"], [5, 5, 104, 104, "CID"], [5, 5, 108, 108, "CID"], [5, 5, 152, 152, "CID"], [52, 52, 14, 16, "CID"], [52, 52, 54, 55, "CID"], [52, 52, 104, 104, "CID"], [52, 52, 108, 108, "CID"], [52, 52, 152, 152, "CID"], [100, 100, 14, 16, "CID"], [100, 100, 54, 55, "CID"], [100, 100, 104, 104, "CID"], [100, 100, 108, 108, "CID"], [100, 100, 152, 152, "CID"], [121, 121, 14, 16, "CID"], [121, 121, 54, 55, "CID"], [121, 121, 104, 104, "CID"], [121, 121, 108, 108, "CID"], [121, 121, 152, 152, "CID"], [147, 147, 14, 16, "CID"], [147, 147, 54, 55, "CID"], [147, 147, 104, 104, "CID"], [147, 147, 108, 108, "CID"], [147, 147, 152, 152, "CID"]]], "clusters": [], "translated": " <9>肾功能受损</9>的<16>乳腺癌</16>患者因高剂量<0>异环磷酰胺</0>化疗而致死<5>无尿</5>。一名患有晚期<17>乳腺癌</17>的60岁女性，之前曾接受过<14>顺铂</14>治疗，出现不可逆的致命性<18>肾功能衰竭</18>并伴有<6>无尿</6>，5 g/m2推注<1>异环磷酰胺</1>后的第二天。<10>肾后衰竭</10>通过超声检查排除。肾前性成分可能导致<19>肾功能衰竭</19>，因为短暂性<20>低血压</20>是由于腹水炎加重，发生在<7>无尿</7>之前。然而，血流动力学参数的校正并没有改善肾功能。<2>异环磷酰胺</2>是一种已知的<11>肾毒性</11>药物，已证实有<12>肾小管病</12>。我们强烈怀疑这种致命的<8>无尿</8>主要是由于<3>异环磷酰胺</3>，发生在先前接受过<15>顺铂</15>化疗并且由于以下原因导致肾脏灌注不良的患者身上一过性<21>低血压</21>。对于预先接受过<13>肾毒性</13>化疗和肾灌注不足的患者，我们建议谨慎使用<4>异环磷酰胺</4>。", "revised": true}
{"doc_key": "7880714", "sentences": [["Auditory", "disturbance", "associated", "with", "interscalene", "brachial", "plexus", "block", ".", "We", "performed", "an", "audiometric", "study", "in", "20", "patients", "who", "underwent", "surgery", "of", "the", "shoulder", "region", "under", "an", "interscalene", "brachial", "plexus", "block", "(", "IBPB", ")", ".", "Bupivacaine", "0", ".", "75", "%", "with", "adrenaline", "was", "given", "followed", "by", "a", "24", "-", "hr", "continuous", "infusion", "of", "0", ".", "25", "%", "bupivacaine", ".", "Three", "audiometric", "threshold", "measurements", "(", "0", ".", "25", "-", "18", "kHz", ")", "were", "made", ":", "the", "first", "before", "IBPB", ",", "the", "second", "2", "-", "6", "h", "after", "surgery", "and", "the", "third", "on", "the", "first", "day", "after", "operation", ".", "In", "four", "patients", "hearing", "impairment", "on", "the", "side", "of", "the", "block", "was", "demonstrated", "after", "operation", ",", "in", "three", "measurements", "on", "the", "day", "of", "surgery", "and", "in", "one", "on", "the", "following", "day", ".", "The", "frequencies", "at", "which", "the", "impairment", "occurred", "varied", "between", "patients", ";", "in", "one", "only", "low", "frequencies", "(", "0", ".", "25", "-", "0", ".", "5", "kHz", ")", "were", "involved", ".", "The", "maximum", "change", "in", "threshold", "was", "35", "dB", "at", "6", "kHz", "measured", "at", "the", "end", "of", "the", "continuous", "infusion", "of", "bupivacaine", ".", "This", "patient", "had", "hearing", "threshold", "changes", "(", "15", "-", "20", "dB", ")", "at", "6", "-", "10", "kHz", "on", "the", "opposite", "side", "also", ".", "IBPB", "may", "cause", "transient", "auditory", "dysfunction", "in", "the", "ipsilateral", "ear", ",", "possibly", "via", "an", "effect", "on", "sympathetic", "innervation", "."]], "ner": [[[34, 34, "Chemical"], [56, 56, "Chemical"], [177, 177, "Chemical"], [99, 100, "Disease"], [40, 40, "Chemical"], [206, 207, "Disease"]]], "relations": [[[34, 34, 99, 100, "CID"], [56, 56, 99, 100, "CID"], [177, 177, 99, 100, "CID"], [40, 40, 99, 100, "CID"]]], "clusters": [], "translated": "与肌间沟臂丛神经阻滞相关的听觉障碍。我们对20名接受斜角肌间臂丛神经阻滞（IBPB）肩部手术的患者进行了听力测试研究。<0>布比卡因</0>0.75%的<4>肾上腺素</4>给予随后 24 小时连续输注0.25%<1>布比卡因</1>。进行了三个听力阈值测量 (0.25-18 kHz)：第一次在IBPB之前，第二次在手术后2-6小时，第三次在手术后第一天。4名患者<3>听力障碍</3>在手术后被证实，在手术当天进行了3次测量，在手术后的第二天进行了1次测量。患者发生损伤的频率各不相同；其中一个只涉及低频（0.25-0.5 kHz）。在连续输注<2>布比卡因</2>结束时测得的6kHz阈值的最大变化为35dB。该患者在对侧的6-10kHz处也有听力阈值变化 (15-20 dB)。IBPB可能通过对交感神经支配的影响导致同侧耳朵的短暂<5>听觉功能障碍</5>。", "revised": true}
{"doc_key": "2220369", "sentences": [["Central", "vein", "thrombosis", "and", "topical", "dipivalyl", "epinephrine", ".", "A", "report", "is", "given", "on", "an", "83", "-", "year", "-", "old", "female", "who", "acquired", "central", "vein", "thrombosis", "in", "her", "seeing", "eye", "one", "day", "after", "having", "started", "topical", "medication", "with", "dipivalyl", "epinephrine", "for", "advanced", "glaucoma", "discovered", "in", "the", "other", "eye", ".", "From", "present", "knowledge", "about", "the", "effects", "of", "adrenergic", "eye", "drops", "on", "ocular", "blood", "circulation", ",", "it", "is", "difficult", "to", "suggest", "an", "association", "between", "the", "two", "events", ",", "which", "may", "be", "coincidental", "only", "."]], "ner": [[[5, 6, "Chemical"], [37, 38, "Chemical"], [1, 2, "Disease"], [23, 24, "Disease"], [41, 41, "Disease"]]], "relations": [[[5, 6, 1, 2, "CID"], [5, 6, 23, 24, "CID"], [37, 38, 1, 2, "CID"], [37, 38, 23, 24, "CID"]]], "clusters": [], "translated": "中央<2>静脉血栓形成</2>和局部<0>二戊基肾上腺素</0>。报道了一位83岁的女性，在开始局部用药<1>二戊基肾上腺素</1>治疗发现于另一只眼的晚期<4>青光眼</4>后一天，她的视力中出现了中心<3>静脉血栓形成</3>。根据目前关于肾上腺素能滴眼液对眼部血液循环影响的知识，很难暗示这两个事件之间存在关联，这可能只是巧合。", "revised": true}
{"doc_key": "326460", "sentences": [["Amelioration", "of", "bendrofluazide", "-", "induced", "hypokalemia", "by", "timolol", ".", "The", "beta", "adrenergic", "blocking", "drug", ",", "timolol", ",", "tended", "to", "correct", "the", "hypokalemia", "of", "short", "-", "term", "bendrofluazide", "treatment", "in", "6", "healthy", "male", "subjects", "and", "although", "the", "effect", "was", "small", "it", "was", "significant", ".", "Timolol", "also", "reduced", "the", "rise", "in", "plasma", "aldosterone", "and", "urine", "potassium", "excretion", "following", "bendrofluazide", "and", "increased", "the", "urine", "sodium", "/", "potassium", "ratio", ".", "There", "was", "no", "evidence", "of", "a", "shift", "of", "potassium", "from", "the", "intracellular", "to", "the", "extracellular", "space", "."]], "ner": [[[2, 2, "Chemical"], [26, 26, "Chemical"], [56, 56, "Chemical"], [5, 5, "Disease"], [21, 21, "Disease"], [7, 7, "Chemical"], [15, 15, "Chemical"], [43, 43, "Chemical"], [50, 50, "Chemical"], [53, 53, "Chemical"], [63, 63, "Chemical"], [74, 74, "Chemical"], [61, 61, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 21, 21, "CID"], [26, 26, 5, 5, "CID"], [26, 26, 21, 21, "CID"], [56, 56, 5, 5, "CID"], [56, 56, 21, 21, "CID"]]], "clusters": [], "translated": "<5>噻吗洛尔</5>对<0>苯氟噻嗪</0>引起的<3>低钾血症</3>的改善作用。β肾上腺素能阻滞剂<6>噻吗洛尔</6>倾向于纠正6名健康男性受试者因短期<1>苯氟噻嗪</1>治疗引起的<4>低钾血症</4>，尽管效果是小而重要。<7>噻吗洛尔</7>还降低了血浆<8>醛固酮</8>和尿液<9>钾</9>在<2>苯氟噻嗪</2>排泄后的升高，并增加了尿液<10>钠</10>/<12>钾</12>比值。没有证据表明<11>钾</11>从细胞内空间转移到细胞外空间。", "revised": true}
{"doc_key": "8424298", "sentences": [["Effects", "of", "deliberate", "hypotension", "induced", "by", "labetalol", "with", "isoflurane", "on", "neuropsychological", "function", ".", "The", "effect", "of", "deliberate", "hypotension", "on", "brain", "function", "measured", "by", "neuropsychological", "tests", "was", "studied", "in", "41", "adult", "patients", ".", "Twenty", "-", "four", "patients", "were", "anaesthetized", "for", "middle", "-", "ear", "surgery", "with", "deliberate", "hypotension", "induced", "by", "labetalol", "with", "isoflurane", "(", "hypotensive", "group", ")", ".", "Seventeen", "patients", "without", "hypotension", "served", "as", "a", "control", "group", ".", "The", "mean", "arterial", "pressure", "was", "77", "+", "/", "-", "2", "mmHg", "(", "10", ".", "3", "+", "/", "-", "0", ".", "3", "kPa", ")", "before", "hypotension", "and", "50", "+", "/", "-", "0", "mmHg", "(", "6", ".", "7", "+", "/", "-", "0", ".", "0", "kPa", ")", "during", "hypotension", "in", "the", "hypotensive", "group", ",", "and", "86", "+", "/", "-", "2", "mmHg", "(", "11", ".", "5", "+", "/", "-", "0", ".", "3", "kPa", ")", "during", "anaesthesia", "in", "the", "control", "group", ".", "The", "following", "psychological", "tests", "were", "performed", ":", "four", "subtests", "of", "the", "Wechsler", "Adult", "Intelligence", "Scale", "(", "similarities", ",", "digit", "span", ",", "vocabulary", "and", "digit", "symbol", ")", ",", "Trail", "-", "Making", "tests", "A", "and", "B", ",", "Zung", "tests", "(", "self", "-", "rating", "anxiety", "scale", "and", "self", "-", "rating", "depression", "scale", ")", "and", "two", "-", "part", "memory", "test", "battery", "with", "immediate", "and", "delayed", "recall", ".", "The", "tests", "were", "performed", "preoperatively", "and", "2", "days", "postoperatively", ".", "There", "were", "no", "statistically", "significant", "differences", "between", "the", "groups", "in", "any", "of", "the", "tests", "in", "the", "changes", "from", "preoperative", "value", "to", "postoperative", "value", ".", "The", "results", "indicate", "that", "hypotension", "induced", "by", "labetalol", "with", "isoflurane", "has", "no", "significant", "harmful", "effects", "on", "mental", "functions", "compared", "to", "normotensive", "anaesthesia", "."]], "ner": [[[6, 6, "Chemical"], [48, 48, "Chemical"], [247, 247, "Chemical"], [3, 3, "Disease"], [17, 17, "Disease"], [45, 45, "Disease"], [52, 52, "Disease"], [59, 59, "Disease"], [90, 90, "Disease"], [111, 111, "Disease"], [114, 114, "Disease"], [244, 244, "Disease"], [8, 8, "Chemical"], [50, 50, "Chemical"], [249, 249, "Chemical"], [184, 184, "Disease"], [190, 190, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 17, 17, "CID"], [6, 6, 45, 45, "CID"], [6, 6, 52, 52, "CID"], [6, 6, 59, 59, "CID"], [6, 6, 90, 90, "CID"], [6, 6, 111, 111, "CID"], [6, 6, 114, 114, "CID"], [6, 6, 244, 244, "CID"], [48, 48, 3, 3, "CID"], [48, 48, 17, 17, "CID"], [48, 48, 45, 45, "CID"], [48, 48, 52, 52, "CID"], [48, 48, 59, 59, "CID"], [48, 48, 90, 90, "CID"], [48, 48, 111, 111, "CID"], [48, 48, 114, 114, "CID"], [48, 48, 244, 244, "CID"], [247, 247, 3, 3, "CID"], [247, 247, 17, 17, "CID"], [247, 247, 45, 45, "CID"], [247, 247, 52, 52, "CID"], [247, 247, 59, 59, "CID"], [247, 247, 90, 90, "CID"], [247, 247, 111, 111, "CID"], [247, 247, 114, 114, "CID"], [247, 247, 244, 244, "CID"], [8, 8, 3, 3, "CID"], [8, 8, 17, 17, "CID"], [8, 8, 45, 45, "CID"], [8, 8, 52, 52, "CID"], [8, 8, 59, 59, "CID"], [8, 8, 90, 90, "CID"], [8, 8, 111, 111, "CID"], [8, 8, 114, 114, "CID"], [8, 8, 244, 244, "CID"], [50, 50, 3, 3, "CID"], [50, 50, 17, 17, "CID"], [50, 50, 45, 45, "CID"], [50, 50, 52, 52, "CID"], [50, 50, 59, 59, "CID"], [50, 50, 90, 90, "CID"], [50, 50, 111, 111, "CID"], [50, 50, 114, 114, "CID"], [50, 50, 244, 244, "CID"], [249, 249, 3, 3, "CID"], [249, 249, 17, 17, "CID"], [249, 249, 45, 45, "CID"], [249, 249, 52, 52, "CID"], [249, 249, 59, 59, "CID"], [249, 249, 90, 90, "CID"], [249, 249, 111, 111, "CID"], [249, 249, 114, 114, "CID"], [249, 249, 244, 244, "CID"]]], "clusters": [], "translated": "<0>拉贝洛尔</0>联合<12>异氟烷</12>致故意<3>低血压</3>对神经心理功能的影响。在41名成年患者中研究了故意<4>低血压</4>对通过神经心理学测试测量的脑功能的影响。24例因<1>拉贝洛尔</1>和<13>异氟醚</13>致故意<5>低血压</5>（<6>低血压</6>组）中耳手术麻醉，17例没有<7>低血压</7>（对照组）。<8>低血压</8>前平均动脉压为77+/-2mmHg(10.3+/-0.3kPa)，<9>低血压</9>时为50+/-0mmHg(6.7+/-0.0kPa) ，<10>低血压</10>组，对照组麻醉期间为86±2mmHg(11.5±0.3kPa)。进行了以下心理测试：Wechsler成人智力量表的四个子测试（相似性、数字跨度、词汇和数字符号）、Trail-Making测试A和B、Zung测试（自评<15>焦虑</15>量表和自评<16>抑郁</16>量表）和两部分记忆测试电池，即时和延迟回忆。测试在术前和术后2天进行。在任何测试中，从术前值到术后值的变化在各组之间没有统计学上的显着差异。结果表明，与正常血压麻醉相比，<2>拉贝洛尔</2>联合<14>异氟烷</14>引起的<11>低血压</11>对精神功能无明显不良影响。", "revised": true}
{"doc_key": "10523326", "sentences": [["Nitric", "oxide", "synthase", "expression", "in", "the", "course", "of", "lead", "-", "induced", "hypertension", ".", "We", "recently", "showed", "elevated", "reactive", "oxygen", "species", "(", "ROS", ")", ",", "reduced", "urinary", "excretion", "of", "NO", "metabolites", "(", "NOx", ")", ",", "and", "increased", "NO", "sequestration", "as", "nitrotyrosine", "in", "various", "tissues", "in", "rats", "with", "lead", "-", "induced", "hypertension", ".", "This", "study", "was", "designed", "to", "discern", "whether", "the", "reduction", "in", "urinary", "NOx", "in", "lead", "-", "induced", "hypertension", "is", ",", "in", "part", ",", "due", "to", "depressed", "NO", "synthase", "(", "NOS", ")", "expression", ".", "Male", "Sprague", "-", "Dawley", "rats", "were", "randomly", "assigned", "to", "a", "lead", "-", "treated", "group", "(", "given", "lead", "acetate", ",", "100", "ppm", ",", "in", "drinking", "water", "and", "regular", "rat", "chow", ")", ",", "a", "group", "given", "lead", "and", "vitamin", "E", "-", "fortified", "chow", ",", "or", "a", "normal", "control", "group", "given", "either", "regular", "food", "and", "water", "or", "vitamin", "E", "-", "fortified", "food", "for", "12", "weeks", ".", "Tail", "blood", "pressure", ",", "urinary", "NOx", "excretion", ",", "plasma", "malondialdehyde", "(", "MDA", ")", ",", "and", "endothelial", "and", "inducible", "NOS", "(", "eNOS", "and", "iNOS", ")", "isotypes", "in", "the", "aorta", "and", "kidney", "were", "measured", ".", "The", "lead", "-", "treated", "group", "exhibited", "a", "rise", "in", "blood", "pressure", "and", "plasma", "MDA", "concentration", ",", "a", "fall", "in", "urinary", "NOx", "excretion", ",", "and", "a", "paradoxical", "rise", "in", "vascular", "and", "renal", "tissue", "eNOS", "and", "iNOS", "expression", ".", "Vitamin", "E", "supplementation", "ameliorated", "hypertension", ",", "lowered", "plasma", "MDA", "concentration", ",", "and", "raised", "urinary", "NOx", "excretion", "while", "significantly", "lowering", "vascular", ",", "but", "not", "renal", ",", "tissue", "eNOS", "and", "iNOS", "expression", ".", "Vitamin", "E", "supplementation", "had", "no", "effect", "on", "either", "blood", "pressure", ",", "plasma", "MDA", ",", "or", "NOS", "expression", "in", "the", "control", "group", ".", "The", "study", "also", "revealed", "significant", "inhibition", "of", "NOS", "enzymatic", "activity", "by", "lead", "in", "cell", "-", "free", "preparations", ".", "In", "conclusion", ",", "lead", "-", "induced", "hypertension", "in", "this", "model", "was", "associated", "with", "a", "compensatory", "upregulation", "of", "renal", "and", "vascular", "eNOS", "and", "iNOS", "expression", ".", "This", "is", ",", "in", "part", ",", "due", "to", "ROS", "-", "mediated", "NO", "inactivation", ",", "lead", "-", "associated", "inhibition", "of", "NOS", "activity", ",", "and", "perhaps", "stimulatory", "actions", "of", "increased", "shear", "stress", "associated", "with", "hypertension", "."]], "ner": [[[8, 8, "Chemical"], [46, 46, "Chemical"], [64, 64, "Chemical"], [93, 93, "Chemical"], [117, 117, "Chemical"], [180, 180, "Chemical"], [280, 280, "Chemical"], [290, 290, "Chemical"], [326, 326, "Chemical"], [11, 11, "Disease"], [49, 49, "Disease"], [67, 67, "Disease"], [220, 220, "Disease"], [293, 293, "Disease"], [344, 344, "Disease"], [0, 1, "Chemical"], [28, 28, "Chemical"], [36, 36, "Chemical"], [76, 76, "Chemical"], [323, 323, "Chemical"], [18, 18, "Chemical"], [39, 39, "Chemical"], [99, 100, "Chemical"], [119, 120, "Chemical"], [137, 138, "Chemical"], [216, 217, "Chemical"], [247, 248, "Chemical"], [155, 155, "Chemical"], [157, 157, "Chemical"], [192, 192, "Chemical"], [224, 224, "Chemical"], [259, 259, "Chemical"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 49, 49, "CID"], [8, 8, 67, 67, "CID"], [8, 8, 220, 220, "CID"], [8, 8, 293, 293, "CID"], [8, 8, 344, 344, "CID"], [46, 46, 11, 11, "CID"], [46, 46, 49, 49, "CID"], [46, 46, 67, 67, "CID"], [46, 46, 220, 220, "CID"], [46, 46, 293, 293, "CID"], [46, 46, 344, 344, "CID"], [64, 64, 11, 11, "CID"], [64, 64, 49, 49, "CID"], [64, 64, 67, 67, "CID"], [64, 64, 220, 220, "CID"], [64, 64, 293, 293, "CID"], [64, 64, 344, 344, "CID"], [93, 93, 11, 11, "CID"], [93, 93, 49, 49, "CID"], [93, 93, 67, 67, "CID"], [93, 93, 220, 220, "CID"], [93, 93, 293, 293, "CID"], [93, 93, 344, 344, "CID"], [117, 117, 11, 11, "CID"], [117, 117, 49, 49, "CID"], [117, 117, 67, 67, "CID"], [117, 117, 220, 220, "CID"], [117, 117, 293, 293, "CID"], [117, 117, 344, 344, "CID"], [180, 180, 11, 11, "CID"], [180, 180, 49, 49, "CID"], [180, 180, 67, 67, "CID"], [180, 180, 220, 220, "CID"], [180, 180, 293, 293, "CID"], [180, 180, 344, 344, "CID"], [280, 280, 11, 11, "CID"], [280, 280, 49, 49, "CID"], [280, 280, 67, 67, "CID"], [280, 280, 220, 220, "CID"], [280, 280, 293, 293, "CID"], [280, 280, 344, 344, "CID"], [290, 290, 11, 11, "CID"], [290, 290, 49, 49, "CID"], [290, 290, 67, 67, "CID"], [290, 290, 220, 220, "CID"], [290, 290, 293, 293, "CID"], [290, 290, 344, 344, "CID"], [326, 326, 11, 11, "CID"], [326, 326, 49, 49, "CID"], [326, 326, 67, 67, "CID"], [326, 326, 220, 220, "CID"], [326, 326, 293, 293, "CID"], [326, 326, 344, 344, "CID"]]], "clusters": [], "translated": "<15>一氧化氮</15>合酶在<0>导致</0><9>铅</9>-诱发 <11>高血压</11> 过程中的表达。我们最近发现活性<20>氧</20>物种(ROS)升高，<16>NO</16>代谢物(NOx)尿液排泄减少，<17>NO</17>螯合增加，因为<1>铅</1>诱导的<10>高血压</10>大鼠各种组织中的<21>硝基酪氨酸</21>。本研究旨在辨别<2>铅</2>引起的<11>高血压</11>中尿液NOx的减少是否部分是由于抑制的<18>NO</18>合酶(NOS)表达。雄性Sprague-Dawley大鼠被随机分配到<3>铅</3>治疗组（给予<22>醋酸铅</22>，100 ppm，饮用水和常规大鼠食物），一组给予<4>铅</4>和<23>维生素E</23>-强化食物，或正常对照组给予常规食物和水或<24>维生素E</24>-强化食物12周。测量了主动脉和肾脏中的尾部血压、尿液NOx排泄、血浆<27>丙二醛</27> (<28>MDA</28>)以及内皮和诱导型NOS（eNOS和iNOS）同种型。<5>铅</5>治疗组的血压和血浆<29>MDA</29>浓度升高，尿液NOx排泄量下降，血管和肾组织eNOS和iNOS表达反常升高。<25>维生素E</25>补充剂改善了<12>高血压</12>，降低了血浆<30>MDA</30>浓度，并增加了尿NOx排泄，同时显着降低了血管而非肾脏组织eNOS和iNOS表达。<26>维生素E</26>补充剂对对照组的血压、血浆<31>MDA</31>或NOS表达均无影响。该研究还揭示了在无细胞制剂中<6>铅</6>对NOS酶活性的显着抑制。总之，在该模型中，<7>铅</7>诱发的<13>高血压</13>与肾脏和血管eNOS和iNOS表达的代偿性上调有关。这部分是由于ROS介导的<19>NO</19>失活、<8>铅</8>相关的NOS活性抑制，以及可能与<14>高血压</14>相关的剪切应力增加的刺激作用。", "revised": true}
{"doc_key": "9579567", "sentences": [["Iatrogenic", "risks", "of", "endometrial", "carcinoma", "after", "treatment", "for", "breast", "cancer", "in", "a", "large", "French", "case", "-", "control", "study", ".", "F", "d", "ration", "Nationale", "des", "Centres", "de", "Lutte", "Contre", "le", "Cancer", "(", "FNCLCC", ")", ".", "Since", "tamoxifen", "is", "widely", "used", "in", "breast", "cancer", "treatment", "and", "has", "been", "proposed", "for", "the", "prevention", "of", "breast", "cancer", ",", "its", "endometrial", "iatrogenic", "effects", "must", "be", "carefully", "examined", ".", "We", "have", "investigated", "the", "association", "between", "endometrial", "cancer", "and", "tamoxifen", "use", "or", "other", "treatments", "in", "women", "treated", "for", "breast", "cancer", "in", "a", "case", "-", "control", "study", ".", "Cases", "of", "endometrial", "cancer", "diagnosed", "after", "breast", "cancer", "(", "n", "=", "135", ")", "and", "467", "controls", "matched", "for", "age", ",", "year", "of", "diagnosis", "of", "breast", "cancer", "and", "hospital", "and", "survival", "time", "with", "an", "intact", "uterus", "were", "included", ".", "Women", "who", "had", "received", "tamoxifen", "were", "significantly", "more", "likely", "to", "have", "endometrial", "cancer", "diagnosed", "than", "those", "who", "had", "not", "(", "crude", "relative", "risk", "=", "4", ".", "9", ",", "p", "=", "0", ".", "0001", ")", ".", "Univariate", "and", "adjusted", "analyses", "showed", "that", "the", "risk", "increased", "with", "the", "length", "of", "treatment", "(", "p", "=", "0", ".", "0001", ")", "or", "the", "cumulative", "dose", "of", "tamoxifen", "received", "(", "p", "=", "0", ".", "0001", ")", ",", "irrespective", "of", "the", "daily", "dose", ".", "Women", "who", "had", "undergone", "pelvic", "radiotherapy", "also", "had", "a", "higher", "risk", "(", "crude", "relative", "risk", "=", "7", ".", "8", ",", "p", "=", "0", ".", "0001", ")", ".", "After", "adjusting", "for", "confounding", "factors", ",", "the", "risk", "was", "higher", "for", "tamoxifen", "users", "(", "p", "=", "0", ".", "0012", ")", ",", "treatment", "for", "more", "than", "3", "years", "(", "all", "p", "<", "0", ".", "03", ")", "and", "pelvic", "radiotherapy", "(", "p", "=", "0", ".", "012", ")", ".", "Women", "who", "had", "endometrial", "cancer", "and", "had", "received", "tamoxifen", "had", "more", "advanced", "disease", "and", "poorer", "prognosis", "than", "those", "with", "endometrial", "cancer", "who", "had", "not", "received", "this", "treatment", ".", "Our", "results", "suggest", "a", "causal", "role", "of", "tamoxifen", "in", "endometrial", "cancer", ",", "particularly", "when", "used", "as", "currently", "proposed", "for", "breast", "cancer", "prevention", ".", "Pelvic", "radiotherapy", "may", "be", "an", "additional", "iatrogenic", "factor", "for", "women", "with", "breast", "cancer", ".", "Endometrial", "cancers", "diagnosed", "in", "women", "treated", "with", "tamoxifen", "have", "poorer", "prognosis", ".", "Women", "who", "receive", "tamoxifen", "for", "breast", "cancer", "should", "be", "offered", "gynaecological", "surveillance", "during", "and", "after", "treatment", ".", "A", "long", "-", "term", "evaluation", "of", "the", "risk", "-", "benefit", "ratio", "of", "tamoxifen", "as", "a", "preventive", "treatment", "for", "breast", "cancer", "is", "clearly", "warranted", "."]], "ner": [[[35, 35, "Chemical"], [72, 72, "Chemical"], [132, 132, "Chemical"], [189, 189, "Chemical"], [243, 243, "Chemical"], [286, 286, "Chemical"], [313, 313, "Chemical"], [350, 350, "Chemical"], [358, 358, "Chemical"], [384, 384, "Chemical"], [3, 4, "Disease"], [69, 70, "Disease"], [92, 93, "Disease"], [139, 140, "Disease"], [281, 282, "Disease"], [297, 298, "Disease"], [315, 316, "Disease"], [343, 344, "Disease"], [8, 9, "Disease"], [40, 41, "Disease"], [51, 52, "Disease"], [81, 82, "Disease"], [96, 97, "Disease"], [114, 115, "Disease"], [325, 326, "Disease"], [340, 341, "Disease"], [360, 361, "Disease"], [390, 391, "Disease"], [289, 290, "Disease"]]], "relations": [[[35, 35, 3, 4, "CID"], [35, 35, 69, 70, "CID"], [35, 35, 92, 93, "CID"], [35, 35, 139, 140, "CID"], [35, 35, 281, 282, "CID"], [35, 35, 297, 298, "CID"], [35, 35, 315, 316, "CID"], [35, 35, 343, 344, "CID"], [72, 72, 3, 4, "CID"], [72, 72, 69, 70, "CID"], [72, 72, 92, 93, "CID"], [72, 72, 139, 140, "CID"], [72, 72, 281, 282, "CID"], [72, 72, 297, 298, "CID"], [72, 72, 315, 316, "CID"], [72, 72, 343, 344, "CID"], [132, 132, 3, 4, "CID"], [132, 132, 69, 70, "CID"], [132, 132, 92, 93, "CID"], [132, 132, 139, 140, "CID"], [132, 132, 281, 282, "CID"], [132, 132, 297, 298, "CID"], [132, 132, 315, 316, "CID"], [132, 132, 343, 344, "CID"], [189, 189, 3, 4, "CID"], [189, 189, 69, 70, "CID"], [189, 189, 92, 93, "CID"], [189, 189, 139, 140, "CID"], [189, 189, 281, 282, "CID"], [189, 189, 297, 298, "CID"], [189, 189, 315, 316, "CID"], [189, 189, 343, 344, "CID"], [243, 243, 3, 4, "CID"], [243, 243, 69, 70, "CID"], [243, 243, 92, 93, "CID"], [243, 243, 139, 140, "CID"], [243, 243, 281, 282, "CID"], [243, 243, 297, 298, "CID"], [243, 243, 315, 316, "CID"], [243, 243, 343, 344, "CID"], [286, 286, 3, 4, "CID"], [286, 286, 69, 70, "CID"], [286, 286, 92, 93, "CID"], [286, 286, 139, 140, "CID"], [286, 286, 281, 282, "CID"], [286, 286, 297, 298, "CID"], [286, 286, 315, 316, "CID"], [286, 286, 343, 344, "CID"], [313, 313, 3, 4, "CID"], [313, 313, 69, 70, "CID"], [313, 313, 92, 93, "CID"], [313, 313, 139, 140, "CID"], [313, 313, 281, 282, "CID"], [313, 313, 297, 298, "CID"], [313, 313, 315, 316, "CID"], [313, 313, 343, 344, "CID"], [350, 350, 3, 4, "CID"], [350, 350, 69, 70, "CID"], [350, 350, 92, 93, "CID"], [350, 350, 139, 140, "CID"], [350, 350, 281, 282, "CID"], [350, 350, 297, 298, "CID"], [350, 350, 315, 316, "CID"], [350, 350, 343, 344, "CID"], [358, 358, 3, 4, "CID"], [358, 358, 69, 70, "CID"], [358, 358, 92, 93, "CID"], [358, 358, 139, 140, "CID"], [358, 358, 281, 282, "CID"], [358, 358, 297, 298, "CID"], [358, 358, 315, 316, "CID"], [358, 358, 343, 344, "CID"], [384, 384, 3, 4, "CID"], [384, 384, 69, 70, "CID"], [384, 384, 92, 93, "CID"], [384, 384, 139, 140, "CID"], [384, 384, 281, 282, "CID"], [384, 384, 297, 298, "CID"], [384, 384, 315, 316, "CID"], [384, 384, 343, 344, "CID"]]], "clusters": [], "translated": "一项大型法国病例对照研究中<18>乳腺癌</18>治疗后<10>子宫内膜癌</10>的医源性风险。Fd ration Nationale des Centers de Lutte Contre le Cancer (FNCLCC)。由于<0>他莫昔芬</0>广泛用于<19>乳腺癌</19>治疗，并已被提议用于预防<20>乳腺癌</20>，因此必须仔细检查其对子宫内膜的医源性影响。我们在一项病例对照研究中调查了<11>子宫内膜癌</11>和<1>他莫昔芬</1>使用或其他治疗方法在接受<21>乳腺癌</21>治疗的女性中的关联。 <12>子宫内膜癌</12>在<22>乳腺癌</22>后被诊断的病例(n = 135)和 467 名对照者的年龄、<23>乳腺癌</23>诊断年份以及医院和包括完整子宫的存活时间。接受<2>他莫昔芬</2>治疗的女性比未接受治疗的女性更容易诊断出<13>子宫内膜癌</13>（粗相对风险=4.9，p=0.0001）。单变量和校正分析表明，风险随着治疗时间的延长(p=0.0001)或接受的<3>他莫昔芬</3>累积剂量(p=0.0001) 而增加，与日剂量无关。接受过盆腔放疗的女性也有更高的风险（粗相对风险=7.8，p=0.0001）。调整混杂因素后，<4>他莫昔芬</4>使用者(p=0.0012)、治疗超过3年(all p<0.03) 和盆腔放疗(p=0.03)的风险更高。患有<14>子宫内膜癌</14>并接受<5>他莫昔芬</5>治疗的女性比接受<15>子宫内膜癌</15>治疗的女性有更多<28>晚期疾病</28>和更差的预后，没有接受过这种待遇。我们的结果表明<6>他莫昔芬</6>在<16>子宫内膜癌</16>中具有因果作用，特别是当目前建议用于<24>乳腺癌</24>预防时。对于患有<25>乳腺癌</25>的女性来说，盆腔放疗可能是一个额外的医源性因素。<17>子宫内膜癌</17>诊断为接受<7>他莫昔芬</7>治疗的女性预后较差。接受<8>他莫昔芬</8>治疗<26>乳腺癌</26>的女性应在治疗期间和治疗后接受妇科监测。显然有必要对<9>他莫昔芬</9>作为<27>乳腺癌</27>预防性治疗的风险收益比进行长期评估。", "revised": true}
{"doc_key": "19707748", "sentences": [["Seizures", "associated", "with", "levofloxacin", ":", "case", "presentation", "and", "literature", "review", ".", "PURPOSE", ":", "We", "present", "a", "case", "of", "a", "patient", "who", "developed", "seizures", "shortly", "after", "initiating", "treatment", "with", "levofloxacin", "and", "to", "discuss", "the", "potential", "drug", "-", "drug", "interactions", "related", "to", "the", "inhibition", "of", "cytochrome", "P450", "(", "CYP", ")", "1A2", "in", "this", "case", ",", "as", "well", "as", "in", "other", "cases", ",", "of", "levofloxacin", "-", "induced", "seizures", ".", "METHODS", ":", "Several", "biomedical", "databases", "were", "searched", "including", "MEDLINE", ",", "Cochrane", "and", "Ovid", ".", "The", "main", "search", "terms", "utilized", "were", "case", "report", "and", "levofloxacin", ".", "The", "search", "was", "limited", "to", "studies", "published", "in", "English", ".", "RESULTS", ":", "Six", "cases", "of", "levofloxacin", "-", "induced", "seizures", "have", "been", "reported", "in", "the", "literature", ".", "Drug", "-", "drug", "interactions", "related", "to", "the", "inhibition", "of", "CYP1A2", "by", "levofloxacin", "are", "likely", "involved", "in", "the", "clinical", "outcome", "of", "these", "cases", ".", "CONCLUSIONS", ":", "Clinicians", "are", "exhorted", "to", "pay", "close", "attention", "when", "initiating", "levofloxacin", "therapy", "in", "patients", "taking", "medications", "with", "epileptogenic", "properties", "that", "are", "CYP1A2", "substrates", "."]], "ner": [[[3, 3, "Chemical"], [28, 28, "Chemical"], [61, 61, "Chemical"], [89, 89, "Chemical"], [106, 106, "Chemical"], [128, 128, "Chemical"], [151, 151, "Chemical"], [0, 0, "Disease"], [22, 22, "Disease"], [64, 64, "Disease"], [109, 109, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 22, 22, "CID"], [3, 3, 64, 64, "CID"], [3, 3, 109, 109, "CID"], [28, 28, 0, 0, "CID"], [28, 28, 22, 22, "CID"], [28, 28, 64, 64, "CID"], [28, 28, 109, 109, "CID"], [61, 61, 0, 0, "CID"], [61, 61, 22, 22, "CID"], [61, 61, 64, 64, "CID"], [61, 61, 109, 109, "CID"], [89, 89, 0, 0, "CID"], [89, 89, 22, 22, "CID"], [89, 89, 64, 64, "CID"], [89, 89, 109, 109, "CID"], [106, 106, 0, 0, "CID"], [106, 106, 22, 22, "CID"], [106, 106, 64, 64, "CID"], [106, 106, 109, 109, "CID"], [128, 128, 0, 0, "CID"], [128, 128, 22, 22, "CID"], [128, 128, 64, 64, "CID"], [128, 128, 109, 109, "CID"], [151, 151, 0, 0, "CID"], [151, 151, 22, 22, "CID"], [151, 151, 64, 64, "CID"], [151, 151, 109, 109, "CID"]]], "clusters": [], "translated": " \n<7>癫痫发作</7>与<0>左氧氟沙星</0>相关：案例介绍和文献回顾。目的：我们介绍了一例在开始使用<1>左氧氟沙星</1>治疗后不久发生<8>癫痫发作</8>的患者，并讨论与抑制细胞色素P450（CYP）1A2有关的药物 - 药物相互作用在这种情况下以及<2>左氧氟沙星</2> - 诱发性<9>癫痫发作</9>中的潜在作用。方法：检索了多个生物医学数据库，包括MEDLINE、Cochrane和Ovid。使用的主要搜索词是病例报告和<3>左氧氟沙星</3>。搜索仅限于以英文发表的研究。结果：文献报道了6例<4>左氧氟沙星</4>引起的<10>癫痫发作</10>。与CYP1A2受<5>左氧氟沙星</5>抑制有关的药物 - 药物相互作用很可能与这些病例的临床结局有关。结论：临床医生在开始为患者使用<6>左氧氟沙星</6>治疗时，应密切注意同时使用具有致癫痫特性且为CYP1A2底物的药物的患者。", "revised": true}
{"doc_key": "6292680", "sentences": [["Doxorubicin", "cardiomyopathy", "in", "children", "with", "left", "-", "sided", "Wilms", "tumor", ".", "Two", "children", "with", "Wilms", "tumor", "of", "the", "left", "kidney", "experienced", "severe", "anthracycline", "cardiomyopathy", "after", "irradiation", "to", "the", "tumor", "bed", "and", "conventional", "dosage", "of", "doxorubicin", ".", "The", "cardiomyopathy", "is", "attributed", "1", ")", "to", "the", "fact", "that", "radiation", "fields", "for", "left", "Wilms", "tumor", "include", "the", "lower", "portion", "of", "the", "heart", "and", "2", ")", "to", "the", "interaction", "of", "doxorubicin", "and", "irradiation", "on", "cardiac", "muscle", ".", "It", "is", "recommended", "that", "doxorubicin", "dosage", "be", "sharply", "restricted", "in", "children", "with", "Wilms", "tumor", "of", "the", "left", "kidney", "who", "receive", "postoperative", "irradiation", "."]], "ner": [[[0, 0, "Chemical"], [34, 34, "Chemical"], [66, 66, "Chemical"], [77, 77, "Chemical"], [1, 1, "Disease"], [23, 23, "Disease"], [37, 37, "Disease"], [8, 9, "Disease"], [14, 15, "Disease"], [50, 51, "Disease"], [85, 86, "Disease"], [28, 28, "Disease"], [22, 22, "Chemical"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 23, 23, "CID"], [0, 0, 37, 37, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 23, 23, "CID"], [34, 34, 37, 37, "CID"], [66, 66, 1, 1, "CID"], [66, 66, 23, 23, "CID"], [66, 66, 37, 37, "CID"], [77, 77, 1, 1, "CID"], [77, 77, 23, 23, "CID"], [77, 77, 37, 37, "CID"]]], "clusters": [], "translated": " <0>多柔比星</0><4>心肌病</4>患儿左侧<7>肾母细胞瘤</7>。两个左肾<8>Wilms瘤</8>的患儿，在<11>瘤</11>区照射和<1>多柔比星</1>的常规剂量后，出现了严重的<12>蒽环类药物</12><5>心肌病</5>。 <6>心肌病</6>归因于1）左侧<9>Wilms肿瘤</9>的放射野覆盖了心脏的下部和2）<2>阿霉素</2>和照射对心肌的影响。建议对于左侧肾部<10>Wilms瘤</10>术后接受放疗的患儿，应该严格限制<3>多柔比星</3>的剂量。", "revised": true}
{"doc_key": "20331935", "sentences": [["A", "cross", "-", "sectional", "evaluation", "of", "the", "effect", "of", "risperidone", "and", "selective", "serotonin", "reuptake", "inhibitors", "on", "bone", "mineral", "density", "in", "boys", ".", "OBJECTIVE", ":", "The", "aim", "of", "the", "present", "study", "was", "to", "investigate", "the", "effect", "of", "risperidone", "-", "induced", "hyperprolactinemia", "on", "trabecular", "bone", "mineral", "density", "(", "BMD", ")", "in", "children", "and", "adolescents", ".", "METHOD", ":", "Medically", "healthy", "7", "-", "to", "17", "-", "year", "-", "old", "males", "chronically", "treated", ",", "in", "a", "naturalistic", "setting", ",", "with", "risperidone", "were", "recruited", "for", "this", "cross", "-", "sectional", "study", "through", "child", "psychiatry", "outpatient", "clinics", "between", "November", "2005", "and", "June", "2007", ".", "Anthropometric", "measurements", "and", "laboratory", "testing", "were", "conducted", ".", "The", "clinical", "diagnoses", "were", "based", "on", "chart", "review", ",", "and", "developmental", "and", "treatment", "history", "was", "obtained", "from", "the", "medical", "record", ".", "Volumetric", "BMD", "of", "the", "ultradistal", "radius", "was", "measured", "using", "peripheral", "quantitative", "computed", "tomography", ",", "and", "areal", "BMD", "of", "the", "lumbar", "spine", "was", "estimated", "using", "dual", "-", "energy", "x", "-", "ray", "absorptiometry", ".", "RESULTS", ":", "Hyperprolactinemia", "was", "present", "in", "49", "%", "of", "83", "boys", "(", "n", "=", "41", ")", "treated", "with", "risperidone", "for", "a", "mean", "of", "2", ".", "9", "years", ".", "Serum", "testosterone", "concentration", "increased", "with", "pubertal", "status", "but", "was", "not", "affected", "by", "hyperprolactinemia", ".", "As", "expected", ",", "bone", "mineral", "content", "and", "BMD", "increased", "with", "sexual", "maturity", ".", "After", "adjusting", "for", "the", "stage", "of", "sexual", "development", "and", "height", "and", "BMI", "z", "scores", ",", "serum", "prolactin", "was", "negatively", "associated", "with", "trabecular", "volumetric", "BMD", "at", "the", "ultradistal", "radius", "(", "P", "<", ".", "03", ")", ".", "Controlling", "for", "relevant", "covariates", ",", "we", "also", "found", "treatment", "with", "selective", "serotonin", "reuptake", "inhibitors", "(", "SSRIs", ")", "to", "be", "associated", "with", "lower", "trabecular", "BMD", "at", "the", "radius", "(", "P", "=", ".", "03", ")", "and", "BMD", "z", "score", "at", "the", "lumbar", "spine", "(", "P", "<", ".", "05", ")", ".", "These", "findings", "became", "more", "marked", "when", "the", "analysis", "was", "restricted", "to", "non", "-", "Hispanic", "white", "patients", ".", "Of", "13", "documented", "fractures", ",", "3", "occurred", "after", "risperidone", "and", "SSRIs", "were", "started", ",", "and", "none", "occurred", "in", "patients", "with", "hyperprolactinemia", ".", "CONCLUSIONS", ":", "This", "is", "the", "first", "study", "to", "link", "risperidone", "-", "induced", "hyperprolactinemia", "and", "SSRI", "treatment", "to", "lower", "BMD", "in", "children", "and", "adolescents", ".", "Future", "research", "should", "evaluate", "the", "longitudinal", "course", "of", "this", "adverse", "event", "to", "determine", "its", "temporal", "stability", "and", "whether", "a", "higher", "fracture", "rate", "ensues", "."]], "ner": [[[9, 9, "Chemical"], [36, 36, "Chemical"], [75, 75, "Chemical"], [175, 175, "Chemical"], [320, 320, "Chemical"], [343, 343, "Chemical"], [39, 39, "Disease"], [159, 159, "Disease"], [197, 197, "Disease"], [332, 332, "Disease"], [346, 346, "Disease"], [315, 315, "Disease"], [12, 12, "Chemical"], [258, 258, "Chemical"], [186, 186, "Chemical"]]], "relations": [[[9, 9, 39, 39, "CID"], [9, 9, 159, 159, "CID"], [9, 9, 197, 197, "CID"], [9, 9, 332, 332, "CID"], [9, 9, 346, 346, "CID"], [36, 36, 39, 39, "CID"], [36, 36, 159, 159, "CID"], [36, 36, 197, 197, "CID"], [36, 36, 332, 332, "CID"], [36, 36, 346, 346, "CID"], [75, 75, 39, 39, "CID"], [75, 75, 159, 159, "CID"], [75, 75, 197, 197, "CID"], [75, 75, 332, 332, "CID"], [75, 75, 346, 346, "CID"], [175, 175, 39, 39, "CID"], [175, 175, 159, 159, "CID"], [175, 175, 197, 197, "CID"], [175, 175, 332, 332, "CID"], [175, 175, 346, 346, "CID"], [320, 320, 39, 39, "CID"], [320, 320, 159, 159, "CID"], [320, 320, 197, 197, "CID"], [320, 320, 332, 332, "CID"], [320, 320, 346, 346, "CID"], [343, 343, 39, 39, "CID"], [343, 343, 159, 159, "CID"], [343, 343, 197, 197, "CID"], [343, 343, 332, 332, "CID"], [343, 343, 346, 346, "CID"]]], "clusters": [], "translated": "对男孩骨矿物质密度影响的<0>横断面评估</0>： <0>利培酮</0> 和选择性<12>血清素</12>再摄取抑制剂。目的：本研究旨在探讨<1>利培酮</1>诱发的<6>高泌乳素血症</6>对儿童和青少年骨小梁骨密度（BMD）的影响。方法：在2005年11月至2007年6月期间，通过儿童精神病学门诊诊所招募身体健康的7至17岁男性在自然环境中长期接受<2>利培酮</2>治疗。进行了人体测量和实验室测试，临床诊断基于图表审查，并从病历中获得发育和治疗史。使用外周定量计算机断层扫描测量桡骨最远端的<4>体积BMD</4>，使用双能<4>X射线吸收测定</4>法估计<4>腰椎的面积BMD</4>。结果：<7>高泌乳素血症</7>在接受<3>利培酮</3>治疗的83名男孩(n=41)中占49%，平均为2.9年。血清<14>睾酮</14>浓度随青春期状态而增加，但不受<8>高催乳素血症</8>的影响。正如预期的那样，骨矿物质含量和BMD随着性成熟而增加。在针对性发育阶段和身高以及BMIz评分进行调整后，血清<6>催乳素</6>与桡骨最远端的小梁体积BMD呈负相关(P<.03)。控制相关的协变量，我们还发现<13>SSRIs</13>治疗与较低的桡骨小梁BMD(P=.03)和腰椎BMDz评分(P<.05)。当分析仅限于非西班牙裔白人患者时，这些发现变得更加明显。在记录的13例<11>骨折</11>中，3例发生在<4>利培酮</4>和SSRIs开始后，<9>高催乳素血症</9>患者没有发生骨折。结论：这是第一项将<5>利培酮</5>诱发的<10>高泌乳素血症</10>和SSRI治疗与降低儿童和青少年BMD联系起来的研究。未来的研究应该评估这种不良事件的纵向过程，以确定其时间稳定性以及是否会导致更高的骨折率。", "revised": true}
{"doc_key": "19692487", "sentences": [["Mice", "lacking", "mPGES", "-", "1", "are", "resistant", "to", "lithium", "-", "induced", "polyuria", ".", "Cyclooxygenase", "-", "2", "activity", "is", "required", "for", "the", "development", "of", "lithium", "-", "induced", "polyuria", ".", "However", ",", "the", "involvement", "of", "a", "specific", ",", "terminal", "prostaglandin", "(", "PG", ")", "isomerase", "has", "not", "been", "evaluated", ".", "The", "present", "study", "was", "undertaken", "to", "assess", "lithium", "-", "induced", "polyuria", "in", "mice", "deficient", "in", "microsomal", "prostaglandin", "E", "synthase", "-", "1", "(", "mPGES", "-", "1", ")", ".", "A", "2", "-", "wk", "administration", "of", "LiCl", "(", "4", "mmol", ".", "kg", "(", "-", "1", ")", ".", "day", "(", "-", "1", ")", "ip", ")", "in", "mPGES", "-", "1", "+", "/", "+", "mice", "led", "to", "a", "marked", "polyuria", "with", "hyposmotic", "urine", ".", "This", "was", "associated", "with", "elevated", "renal", "mPGES", "-", "1", "protein", "expression", "and", "increased", "urine", "PGE", "(", "2", ")", "excretion", ".", "In", "contrast", ",", "mPGES", "-", "1", "-", "/", "-", "mice", "were", "largely", "resistant", "to", "lithium", "-", "induced", "polyuria", "and", "a", "urine", "concentrating", "defect", ",", "accompanied", "by", "nearly", "complete", "blockade", "of", "high", "urine", "PGE", "(", "2", ")", "and", "cAMP", "output", ".", "Immunoblotting", ",", "immunohistochemistry", ",", "and", "quantitative", "(", "q", ")", "RT", "-", "PCR", "consistently", "detected", "a", "significant", "decrease", "in", "aquaporin", "-", "2", "(", "AQP2", ")", "protein", "expression", "in", "both", "the", "renal", "cortex", "and", "medulla", "of", "lithium", "-", "treated", "+", "/", "+", "mice", ".", "This", "decrease", "was", "significantly", "attenuated", "in", "the", "-", "/", "-", "mice", ".", "qRT", "-", "PCR", "detected", "similar", "patterns", "of", "changes", "in", "AQP2", "mRNA", "in", "the", "medulla", "but", "not", "in", "the", "cortex", ".", "Similarly", ",", "the", "total", "protein", "abundance", "of", "the", "Na", "-", "K", "-", "2Cl", "cotransporter", "(", "NKCC2", ")", "in", "the", "medulla", "but", "not", "in", "the", "cortex", "of", "the", "+", "/", "+", "mice", "was", "significantly", "reduced", "by", "lithium", "treatment", ".", "In", "contrast", ",", "the", "dowregulation", "of", "renal", "medullary", "NKCC2", "expression", "was", "significantly", "attenuated", "in", "the", "-", "/", "-", "mice", ".", "We", "conclude", "that", "mPGES", "-", "1", "-", "derived", "PGE", "(", "2", ")", "mediates", "lithium", "-", "induced", "polyuria", "likely", "via", "inhibition", "of", "AQP2", "and", "NKCC2", "expression", "."]], "ner": [[[80, 80, "Chemical"], [11, 11, "Disease"], [26, 26, "Disease"], [57, 57, "Disease"], [110, 110, "Disease"], [152, 152, "Disease"], [323, 323, "Disease"], [8, 8, "Chemical"], [23, 23, "Chemical"], [54, 54, "Chemical"], [149, 149, "Chemical"], [209, 209, "Chemical"], [284, 284, "Chemical"], [320, 320, "Chemical"], [37, 37, "Chemical"], [39, 39, "Chemical"], [63, 64, "Chemical"], [129, 132, "Chemical"], [167, 170, "Chemical"], [315, 318, "Chemical"], [257, 257, "Chemical"], [259, 259, "Chemical"], [261, 261, "Chemical"]]], "relations": [[[80, 80, 11, 11, "CID"], [80, 80, 26, 26, "CID"], [80, 80, 57, 57, "CID"], [80, 80, 110, 110, "CID"], [80, 80, 152, 152, "CID"], [80, 80, 323, 323, "CID"]]], "clusters": [], "translated": "缺乏 mPGES-1 的小鼠对 <7>锂</7> 诱导的 <1>多尿</1> 有抵抗力。<8> 锂 </8> 诱导的 <2> 多尿 </2> 的发展需要环氧合酶-2活性。然而，特定的末端<14>前列腺素</14>（<15>PG</15>）异构酶的参与尚未得到评估。本研究旨在评估微粒体<16>前列腺素E</16>合酶-1 (mPGES-1)缺陷小鼠中<9>锂</9>诱导的<3>多尿</3>。在mPGES-1<sub>+ / +</sub>小鼠中连续两周给予<0>LiCl</0>（4 mmol.kg(-1).天(-1)ip）导致显着的<4>多尿</4>低渗尿。这与肾脏mPGES-1蛋白表达升高和尿<17>PGE(2)</17>排泄增加有关。相比之下，mPGES-1<sub>- / -</sub>小鼠对<10>锂</10>诱导的<5>多尿</5>和尿液浓缩缺陷有很大的抵抗力，同时伴有几乎完全阻断高尿<18>PGE(2)</18>和cAMP输出。免疫印迹、免疫组织化学和定量(q)RT-PCR始终检测到<11>锂</11>处理的<sub>+ / +</sub>小鼠的肾皮质和髓质中水通道蛋白-2（AQP2）蛋白表达显着降低。这种减少在<sub>- / -</sub>小鼠中显着减弱。qRT-PCR在髓质而非皮质中检测到AQP2 mRNA的类似变化模式。同样，<20>Na</20>-<21>K</21>-<22>2Cl</22>协同转运蛋白(NKCC2)在髓质中的总蛋白丰度，但在<sup>+ / +</sup>小鼠显着减少<12>锂</12>处理。相反，肾髓质NKCC2表达的下调在<sub>- / -</sub>小鼠中显着减弱。我们得出结论，mPGES-1衍生的<19>PGE(2)</19>介导<13>锂</13>诱导的<6>多尿</6>可能是通过抑制AQP2和NKCC2表达。", "revised": true}
{"doc_key": "11694026", "sentences": [["Tolerability", "of", "nimesulide", "and", "paracetamol", "in", "patients", "with", "NSAID", "-", "induced", "urticaria", "/", "angioedema", ".", "Previous", "studies", "evaluated", "the", "tolerance", "of", "nimesulide", "and", "paracetamol", "in", "subjects", "with", "cutaneous", ",", "respiratory", "and", "anaphylactoid", "reactions", "induced", "by", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", ".", "In", "this", "study", "we", "investigated", "tolerability", "and", "reliability", "of", "nimesulide", "and", "paracetamol", "in", "a", "very", "large", "number", "of", "patients", "with", "an", "exclusive", "well", "-", "documented", "history", "of", "NSAID", "-", "induced", "urticaria", "/", "angioedema", ".", "Furthermore", ",", "we", "evaluated", "whether", "some", "factors", "have", "the", "potential", "to", "increase", "the", "risk", "of", "reaction", "to", "paracetamol", "and", "nimesulide", ".", "A", "single", "-", "placebo", "-", "controlled", "oral", "challenge", "procedure", "with", "nimesulide", "or", "paracetamol", "was", "applied", "to", "829", "patients", "with", "a", "history", "of", "NSAID", "-", "induced", "urticaria", "/", "angioedema", ".", "A", "total", "of", "75", "/", "829", "(", "9", ".", "4", "%", ")", "patients", "experienced", "reactions", "to", "nimesulide", "or", "paracetamol", ".", "Of", "the", "715", "patients", "tested", "with", "nimesulide", "62", "(", "8", ".", "6", "%", ")", "showed", "a", "positive", "test", ",", "while", "of", "114", "subjects", "submitted", "to", "the", "challenge", "with", "paracetamol", ",", "13", "(", "9", ".", "6", "%", ")", "did", "not", "tolerate", "this", "drug", ".", "Furthermore", ",", "18", ".", "28", "%", "of", "patients", "with", "a", "history", "of", "chronic", "urticaria", "and", "11", ".", "8", "%", "of", "subjects", "with", "an", "history", "of", "NSAID", "-", "induced", "urticaria", "/", "angioedema", "or", "angioedema", "alone", "(", "with", "or", "without", "chronic", "urticaria", ")", "resulted", "to", "be", "intolerant", "to", "alternative", "drugs", ".", "Taken", "together", ",", "our", "results", "confirm", "the", "good", "tolerability", "of", "nimesulide", "and", "paracetamol", "in", "patients", "who", "experienced", "urticaria", "/", "angioedema", "caused", "by", "NSAIDs", ".", "However", ",", "the", "risk", "of", "reaction", "to", "these", "alternative", "study", "drugs", "is", "statistically", "increased", "by", "a", "history", "of", "chronic", "urticaria", "and", ",", "above", "all", ",", "by", "a", "history", "of", "NSAID", "-", "induced", "angioedema", "."]], "ner": [[[2, 2, "Chemical"], [21, 21, "Chemical"], [53, 53, "Chemical"], [97, 97, "Chemical"], [109, 109, "Chemical"], [144, 144, "Chemical"], [154, 154, "Chemical"], [250, 250, "Chemical"], [13, 13, "Disease"], [76, 76, "Disease"], [126, 126, "Disease"], [221, 221, "Disease"], [223, 223, "Disease"], [259, 259, "Disease"], [296, 296, "Disease"], [4, 4, "Chemical"], [23, 23, "Chemical"], [55, 55, "Chemical"], [95, 95, "Chemical"], [111, 111, "Chemical"], [146, 146, "Chemical"], [176, 176, "Chemical"], [252, 252, "Chemical"], [8, 8, "Chemical"], [35, 39, "Chemical"], [41, 41, "Chemical"], [71, 71, "Chemical"], [121, 121, "Chemical"], [216, 216, "Chemical"], [262, 262, "Chemical"], [293, 293, "Chemical"], [11, 11, "Disease"], [74, 74, "Disease"], [124, 124, "Disease"], [204, 204, "Disease"], [219, 219, "Disease"], [230, 230, "Disease"], [257, 257, "Disease"], [283, 283, "Disease"]]], "relations": [[[2, 2, 13, 13, "CID"], [2, 2, 76, 76, "CID"], [2, 2, 126, 126, "CID"], [2, 2, 221, 221, "CID"], [2, 2, 223, 223, "CID"], [2, 2, 259, 259, "CID"], [2, 2, 296, 296, "CID"], [21, 21, 13, 13, "CID"], [21, 21, 76, 76, "CID"], [21, 21, 126, 126, "CID"], [21, 21, 221, 221, "CID"], [21, 21, 223, 223, "CID"], [21, 21, 259, 259, "CID"], [21, 21, 296, 296, "CID"], [53, 53, 13, 13, "CID"], [53, 53, 76, 76, "CID"], [53, 53, 126, 126, "CID"], [53, 53, 221, 221, "CID"], [53, 53, 223, 223, "CID"], [53, 53, 259, 259, "CID"], [53, 53, 296, 296, "CID"], [97, 97, 13, 13, "CID"], [97, 97, 76, 76, "CID"], [97, 97, 126, 126, "CID"], [97, 97, 221, 221, "CID"], [97, 97, 223, 223, "CID"], [97, 97, 259, 259, "CID"], [97, 97, 296, 296, "CID"], [109, 109, 13, 13, "CID"], [109, 109, 76, 76, "CID"], [109, 109, 126, 126, "CID"], [109, 109, 221, 221, "CID"], [109, 109, 223, 223, "CID"], [109, 109, 259, 259, "CID"], [109, 109, 296, 296, "CID"], [144, 144, 13, 13, "CID"], [144, 144, 76, 76, "CID"], [144, 144, 126, 126, "CID"], [144, 144, 221, 221, "CID"], [144, 144, 223, 223, "CID"], [144, 144, 259, 259, "CID"], [144, 144, 296, 296, "CID"], [154, 154, 13, 13, "CID"], [154, 154, 76, 76, "CID"], [154, 154, 126, 126, "CID"], [154, 154, 221, 221, "CID"], [154, 154, 223, 223, "CID"], [154, 154, 259, 259, "CID"], [154, 154, 296, 296, "CID"], [250, 250, 13, 13, "CID"], [250, 250, 76, 76, "CID"], [250, 250, 126, 126, "CID"], [250, 250, 221, 221, "CID"], [250, 250, 223, 223, "CID"], [250, 250, 259, 259, "CID"], [250, 250, 296, 296, "CID"], [4, 4, 13, 13, "CID"], [4, 4, 76, 76, "CID"], [4, 4, 126, 126, "CID"], [4, 4, 221, 221, "CID"], [4, 4, 223, 223, "CID"], [4, 4, 259, 259, "CID"], [4, 4, 296, 296, "CID"], [23, 23, 13, 13, "CID"], [23, 23, 76, 76, "CID"], [23, 23, 126, 126, "CID"], [23, 23, 221, 221, "CID"], [23, 23, 223, 223, "CID"], [23, 23, 259, 259, "CID"], [23, 23, 296, 296, "CID"], [55, 55, 13, 13, "CID"], [55, 55, 76, 76, "CID"], [55, 55, 126, 126, "CID"], [55, 55, 221, 221, "CID"], [55, 55, 223, 223, "CID"], [55, 55, 259, 259, "CID"], [55, 55, 296, 296, "CID"], [95, 95, 13, 13, "CID"], [95, 95, 76, 76, "CID"], [95, 95, 126, 126, "CID"], [95, 95, 221, 221, "CID"], [95, 95, 223, 223, "CID"], [95, 95, 259, 259, "CID"], [95, 95, 296, 296, "CID"], [111, 111, 13, 13, "CID"], [111, 111, 76, 76, "CID"], [111, 111, 126, 126, "CID"], [111, 111, 221, 221, "CID"], [111, 111, 223, 223, "CID"], [111, 111, 259, 259, "CID"], [111, 111, 296, 296, "CID"], [146, 146, 13, 13, "CID"], [146, 146, 76, 76, "CID"], [146, 146, 126, 126, "CID"], [146, 146, 221, 221, "CID"], [146, 146, 223, 223, "CID"], [146, 146, 259, 259, "CID"], [146, 146, 296, 296, "CID"], [176, 176, 13, 13, "CID"], [176, 176, 76, 76, "CID"], [176, 176, 126, 126, "CID"], [176, 176, 221, 221, "CID"], [176, 176, 223, 223, "CID"], [176, 176, 259, 259, "CID"], [176, 176, 296, 296, "CID"], [252, 252, 13, 13, "CID"], [252, 252, 76, 76, "CID"], [252, 252, 126, 126, "CID"], [252, 252, 221, 221, "CID"], [252, 252, 223, 223, "CID"], [252, 252, 259, 259, "CID"], [252, 252, 296, 296, "CID"], [8, 8, 13, 13, "CID"], [8, 8, 76, 76, "CID"], [8, 8, 126, 126, "CID"], [8, 8, 221, 221, "CID"], [8, 8, 223, 223, "CID"], [8, 8, 259, 259, "CID"], [8, 8, 296, 296, "CID"], [35, 39, 13, 13, "CID"], [35, 39, 76, 76, "CID"], [35, 39, 126, 126, "CID"], [35, 39, 221, 221, "CID"], [35, 39, 223, 223, "CID"], [35, 39, 259, 259, "CID"], [35, 39, 296, 296, "CID"], [41, 41, 13, 13, "CID"], [41, 41, 76, 76, "CID"], [41, 41, 126, 126, "CID"], [41, 41, 221, 221, "CID"], [41, 41, 223, 223, "CID"], [41, 41, 259, 259, "CID"], [41, 41, 296, 296, "CID"], [71, 71, 13, 13, "CID"], [71, 71, 76, 76, "CID"], [71, 71, 126, 126, "CID"], [71, 71, 221, 221, "CID"], [71, 71, 223, 223, "CID"], [71, 71, 259, 259, "CID"], [71, 71, 296, 296, "CID"], [121, 121, 13, 13, "CID"], [121, 121, 76, 76, "CID"], [121, 121, 126, 126, "CID"], [121, 121, 221, 221, "CID"], [121, 121, 223, 223, "CID"], [121, 121, 259, 259, "CID"], [121, 121, 296, 296, "CID"], [216, 216, 13, 13, "CID"], [216, 216, 76, 76, "CID"], [216, 216, 126, 126, "CID"], [216, 216, 221, 221, "CID"], [216, 216, 223, 223, "CID"], [216, 216, 259, 259, "CID"], [216, 216, 296, 296, "CID"], [262, 262, 13, 13, "CID"], [262, 262, 76, 76, "CID"], [262, 262, 126, 126, "CID"], [262, 262, 221, 221, "CID"], [262, 262, 223, 223, "CID"], [262, 262, 259, 259, "CID"], [262, 262, 296, 296, "CID"], [293, 293, 13, 13, "CID"], [293, 293, 76, 76, "CID"], [293, 293, 126, 126, "CID"], [293, 293, 221, 221, "CID"], [293, 293, 223, 223, "CID"], [293, 293, 259, 259, "CID"], [293, 293, 296, 296, "CID"]]], "clusters": [], "translated": "<0>尼美舒利</0>和<15>对乙酰氨基酚</15>在<23>非甾体抗炎药</23>诱发的<31>荨麻疹</31>/<8>血管性水肿</8>患者中的耐受性。先前的研究评估了<1>尼美舒利</1>和<16>对乙酰氨基酚</16>在<24>非甾体抗炎药</24>引起的皮肤、呼吸和类过敏反应的受试者中的耐受性（<25>非甾体抗炎药</25>）。在这项研究中，我们调查了<2>尼美舒利</2>和<17>扑热息痛</17>在非常多的患者中的耐受性和可靠性-<26>NSAID</26>-诱发<32>荨麻疹</32>/<9>血管性水肿</9>。此外，我们评估了某些因素是否有可能增加对<18>扑热息痛</18>和<3>尼美舒利</3>的反应风险。使用<4>尼美舒利</4>或<19>对乙酰氨基酚</19>的单一安慰剂对照口服激发程序应用于829名有<27>NSAID</27>诱发<33>荨麻疹</33>/<10>血管性水肿</10>病史的患者。共有75/829（9.4%）名患者对<5>尼美舒利</5>或<20>扑热息痛</20>出现反应。在接受<6>尼美舒利</6>测试的715名患者中，有62名（8.6%）显示阳性测试，而在接受<21>扑热息痛</21>挑战的114名受试者中，有13名（9.6%）不能耐受这种药物。此外，18.28%的患者有慢性<34>荨麻疹</34>和11.8%的受试者有<28>NSAID</28>诱发<35>荨麻疹</35>/<11>血管性水肿</11>或<12>血管性水肿</12>单独（有或没有慢性<36>荨麻疹</36>）导致对替代药物不耐受。综上所述，我们的结果证实了<7>尼美舒利</7>和<22>扑热息痛</22>在经历过由以下原因引起的<37>荨麻疹</37>/<13>血管性水肿</13>的患者中的良好耐受性-<29>非甾体抗炎药</29>。然而，慢性<38>荨麻疹</38>病史，尤其是<30>NSAID</30>诱发的<14>血管性水肿</14>病史，对这些替代研究药物产生反应的风险有统计学意义。", "revised": true}
{"doc_key": "11284996", "sentences": [["Calcitonin", "gene", "-", "related", "peptide", "levels", "during", "nitric", "oxide", "-", "induced", "headache", "in", "patients", "with", "chronic", "tension", "-", "type", "headache", ".", "It", "has", "been", "proposed", "that", "nitric", "oxide", "(", "NO", ")", "induced", "headache", "in", "primary", "headaches", "may", "be", "associated", "with", "release", "of", "calcitonin", "gene", "-", "related", "peptide", "(", "CGRP", ")", ".", "In", "the", "present", "study", "we", "aimed", "to", "investigate", "plasma", "levels", "of", "CGRP", "during", "headache", "induced", "by", "the", "NO", "donor", "glyceryl", "trinitrate", "(", "GTN", ")", "in", "16", "patients", "with", "chronic", "tension", "-", "type", "headache", "and", "16", "healthy", "controls", ".", "The", "subjects", "were", "randomly", "allocated", "to", "receive", "0", ".", "5", "microg", "/", "kg", "/", "min", "GTN", "or", "placebo", "over", "20", "min", "on", "two", "headache", "-", "free", "days", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "10", ",", "20", "and", "60", "min", "after", "start", "of", "infusion", ".", "Both", "patients", "and", "controls", "developed", "significantly", "stronger", "immediate", "headache", "on", "the", "GTN", "day", "than", "on", "the", "placebo", "day", "and", "the", "headache", "was", "significantly", "more", "pronounced", "in", "patients", "than", "in", "controls", ".", "There", "was", "no", "difference", "between", "the", "area", "under", "the", "CGRP", "curve", "(", "AUCCGRP", ")", "on", "GTN", "vs", ".", "placebo", "day", "in", "either", "patients", "(", "P", "=", "0", ".", "65", ")", "or", "controls", "(", "P", "=", "0", ".", "48", ")", ".", "The", "AUCCGRP", "recorded", "on", "the", "GTN", "day", "did", "not", "differ", "between", "patients", "and", "controls", "(", "P", "=", "0", ".", "36", ")", ".", "Both", "in", "patients", "and", "controls", ",", "CGRP", "levels", "changed", "significantly", "over", "time", ",", "on", "both", "the", "GTN", "and", "placebo", "days", "(", "P", "<", "0", ".", "05", ")", ".", "The", "present", "study", "indicates", "that", "NO", "-", "induced", "immediate", "headache", "is", "not", "associated", "with", "release", "of", "CGRP", "."]], "ner": [[[7, 8, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [68, 68, "Chemical"], [261, 261, "Chemical"], [11, 11, "Disease"], [32, 32, "Disease"], [64, 64, "Disease"], [112, 112, "Disease"], [143, 143, "Disease"], [155, 155, "Disease"], [265, 265, "Disease"], [70, 71, "Chemical"], [73, 73, "Chemical"], [104, 104, "Chemical"], [146, 146, "Chemical"], [181, 181, "Chemical"], [211, 211, "Chemical"], [244, 244, "Chemical"], [16, 19, "Disease"], [80, 83, "Disease"], [34, 35, "Disease"]]], "relations": [[[7, 8, 11, 11, "CID"], [7, 8, 32, 32, "CID"], [7, 8, 64, 64, "CID"], [7, 8, 112, 112, "CID"], [7, 8, 143, 143, "CID"], [7, 8, 155, 155, "CID"], [7, 8, 265, 265, "CID"], [26, 27, 11, 11, "CID"], [26, 27, 32, 32, "CID"], [26, 27, 64, 64, "CID"], [26, 27, 112, 112, "CID"], [26, 27, 143, 143, "CID"], [26, 27, 155, 155, "CID"], [26, 27, 265, 265, "CID"], [29, 29, 11, 11, "CID"], [29, 29, 32, 32, "CID"], [29, 29, 64, 64, "CID"], [29, 29, 112, 112, "CID"], [29, 29, 143, 143, "CID"], [29, 29, 155, 155, "CID"], [29, 29, 265, 265, "CID"], [68, 68, 11, 11, "CID"], [68, 68, 32, 32, "CID"], [68, 68, 64, 64, "CID"], [68, 68, 112, 112, "CID"], [68, 68, 143, 143, "CID"], [68, 68, 155, 155, "CID"], [68, 68, 265, 265, "CID"], [261, 261, 11, 11, "CID"], [261, 261, 32, 32, "CID"], [261, 261, 64, 64, "CID"], [261, 261, 112, 112, "CID"], [261, 261, 143, 143, "CID"], [261, 261, 155, 155, "CID"], [261, 261, 265, 265, "CID"], [70, 71, 11, 11, "CID"], [70, 71, 32, 32, "CID"], [70, 71, 64, 64, "CID"], [70, 71, 112, 112, "CID"], [70, 71, 143, 143, "CID"], [70, 71, 155, 155, "CID"], [70, 71, 265, 265, "CID"], [73, 73, 11, 11, "CID"], [73, 73, 32, 32, "CID"], [73, 73, 64, 64, "CID"], [73, 73, 112, 112, "CID"], [73, 73, 143, 143, "CID"], [73, 73, 155, 155, "CID"], [73, 73, 265, 265, "CID"], [104, 104, 11, 11, "CID"], [104, 104, 32, 32, "CID"], [104, 104, 64, 64, "CID"], [104, 104, 112, 112, "CID"], [104, 104, 143, 143, "CID"], [104, 104, 155, 155, "CID"], [104, 104, 265, 265, "CID"], [146, 146, 11, 11, "CID"], [146, 146, 32, 32, "CID"], [146, 146, 64, 64, "CID"], [146, 146, 112, 112, "CID"], [146, 146, 143, 143, "CID"], [146, 146, 155, 155, "CID"], [146, 146, 265, 265, "CID"], [181, 181, 11, 11, "CID"], [181, 181, 32, 32, "CID"], [181, 181, 64, 64, "CID"], [181, 181, 112, 112, "CID"], [181, 181, 143, 143, "CID"], [181, 181, 155, 155, "CID"], [181, 181, 265, 265, "CID"], [211, 211, 11, 11, "CID"], [211, 211, 32, 32, "CID"], [211, 211, 64, 64, "CID"], [211, 211, 112, 112, "CID"], [211, 211, 143, 143, "CID"], [211, 211, 155, 155, "CID"], [211, 211, 265, 265, "CID"], [244, 244, 11, 11, "CID"], [244, 244, 32, 32, "CID"], [244, 244, 64, 64, "CID"], [244, 244, 112, 112, "CID"], [244, 244, 143, 143, "CID"], [244, 244, 155, 155, "CID"], [244, 244, 265, 265, "CID"]]], "clusters": [], "translated": "慢性<19>紧张型头痛</19>患者<0>一氧化氮</0>诱发<5>头痛</5>期间降钙素基因相关肽水平。有人提出，<1>一氧化氮</1>（<2>NO</2>）在<21>原发性头痛</21>中引起的<6>头痛</6>可能与降钙素基因相关肽（CGRP）的释放有关。在本研究中，我们旨在研究<3>NO</3>供体<12>甘油三硝酸酯</12>（<13>GTN</13>）引起的<7>头痛</7>期间CGRP的血浆水平，在16名慢性<20>紧张型头痛</20>患者和16名健康对照者中。受试者被随机分配接受0.5微克/千克/分钟<14>GTN</14>或安慰剂，在两个无<8>头痛</8>的日子内服用20分钟。在基线、输注开始后10、20和60分钟收集血样。患者和对照组在<15>GTN</15>日的即刻<9>头痛</9>均比安慰剂日明显更强烈，<10>头痛</10>在患者中明显比在对照组中更显著。在患者（P = 0.65）和对照组（P = 0.48）中，<16>GTN</16>和安慰剂日的CGRP曲线下面积(AUCCGRP)没有差异。在患者和对照组之间，<17>GTN</17>日记录的AUCCGRP没有差异(P = 0.36)。在患者和对照组中，CGRP水平随时间显着变化，在<18>GTN</18>和安慰剂日均如此(P < 0.05)。本研究表明，<4>NO</4>引起的即刻<11>头痛</11>与CGRP的释放无关。", "revised": true}
{"doc_key": "9867728", "sentences": [["Risk", "for", "valvular", "heart", "disease", "among", "users", "of", "fenfluramine", "and", "dexfenfluramine", "who", "underwent", "echocardiography", "before", "use", "of", "medication", ".", "BACKGROUND", ":", "Because", "uncontrolled", "echocardiographic", "surveys", "suggested", "that", "up", "to", "30", "%", "to", "38", "%", "of", "users", "of", "fenfluramine", "and", "dexfenfluramine", "had", "valvular", "disease", ",", "these", "drugs", "were", "withdrawn", "from", "the", "market", ".", "OBJECTIVE", ":", "To", "determine", "the", "risk", "for", "new", "or", "worsening", "valvular", "abnormalities", "among", "users", "of", "fenfluramine", "or", "dexfenfluramine", "who", "underwent", "echocardiography", "before", "they", "began", "to", "take", "these", "medications", ".", "DESIGN", ":", "Cohort", "study", ".", "SETTING", ":", "Academic", "primary", "care", "practices", ".", "PATIENTS", ":", "46", "patients", "who", "used", "fenfluramine", "or", "dexfenfluramine", "for", "14", "days", "or", "more", "and", "had", "echocardiograms", "obtained", "before", "therapy", ".", "MEASUREMENTS", ":", "Follow", "-", "up", "echocardiography", ".", "The", "primary", "outcome", "was", "new", "or", "worsening", "valvulopathy", ",", "defined", "as", "progression", "of", "either", "aortic", "or", "mitral", "regurgitation", "by", "at", "least", "one", "degree", "of", "severity", "and", "disease", "that", "met", "U", ".", "S", ".", "Food", "and", "Drug", "Administration", "criteria", "(", "at", "least", "mild", "aortic", "regurgitation", "or", "moderate", "mitral", "regurgitation", ")", ".", "RESULTS", ":", "Two", "patients", "(", "4", ".", "3", "%", "[", "95", "%", "CI", ",", "0", ".", "6", "%", "to", "14", ".", "8", "%", "]", ")", "receiving", "fenfluramine", "-", "phentermine", "developed", "valvular", "heart", "disease", ".", "One", "had", "baseline", "bicuspid", "aortic", "valve", "and", "mild", "aortic", "regurgitation", "that", "progressed", "to", "moderate", "regurgitation", ".", "The", "second", "patient", "developed", "new", "moderate", "aortic", "insufficiency", ".", "CONCLUSION", ":", "Users", "of", "diet", "medications", "are", "at", "risk", "for", "valvular", "heart", "disease", ".", "However", ",", "the", "incidence", "may", "be", "lower", "than", "that", "reported", "previously", "."]], "ner": [[[8, 8, "Chemical"], [37, 37, "Chemical"], [67, 67, "Chemical"], [99, 99, "Chemical"], [197, 197, "Chemical"], [135, 138, "Disease"], [163, 164, "Disease"], [213, 214, "Disease"], [227, 228, "Disease"], [199, 199, "Chemical"], [2, 4, "Disease"], [41, 42, "Disease"], [62, 63, "Disease"], [128, 128, "Disease"], [201, 203, "Disease"], [240, 242, "Disease"], [10, 10, "Chemical"], [39, 39, "Chemical"], [69, 69, "Chemical"], [101, 101, "Chemical"], [167, 168, "Disease"], [208, 210, "Disease"]]], "relations": [[[8, 8, 135, 138, "CID"], [8, 8, 163, 164, "CID"], [8, 8, 213, 214, "CID"], [8, 8, 227, 228, "CID"], [37, 37, 135, 138, "CID"], [37, 37, 163, 164, "CID"], [37, 37, 213, 214, "CID"], [37, 37, 227, 228, "CID"], [67, 67, 135, 138, "CID"], [67, 67, 163, 164, "CID"], [67, 67, 213, 214, "CID"], [67, 67, 227, 228, "CID"], [99, 99, 135, 138, "CID"], [99, 99, 163, 164, "CID"], [99, 99, 213, 214, "CID"], [99, 99, 227, 228, "CID"], [197, 197, 135, 138, "CID"], [197, 197, 163, 164, "CID"], [197, 197, 213, 214, "CID"], [197, 197, 227, 228, "CID"], [199, 199, 135, 138, "CID"], [199, 199, 163, 164, "CID"], [199, 199, 213, 214, "CID"], [199, 199, 227, 228, "CID"]]], "clusters": [], "translated": "<0>芬氟拉明</0>和<16>右芬氟拉明</16>使用者在用药前接受了超声心动图检查，有发生<10>瓣膜性心脏病</10>的风险。背景：由于不受控制的超声心动图调查表明，高达30%至38%的<1>芬氟拉明</1>和<17>右芬氟拉明</17>使用者患有<11>瓣膜病</11>，这些药物被撤回从市场上。目的：确定<2>芬氟拉明</2>或<18>右芬氟拉明</18>使用者在开始服用这些药物之前进行了超声心动图检查后出现新的或恶化的<12>瓣膜异常</12>的风险。设计：队列研究。地点：学术初级保健实践。患者：46名使用<3>芬氟拉明</3>或<19>右芬氟拉明</19>14天或更长时间且在治疗前获得超声心动图的患者。测量：随访超声心动图。主要结果是新的或恶化的<13>瓣膜病变</13>，定义为<5>主动脉瓣或二尖瓣反流</5>至少达到一个严重程度和疾病的进展程度，满足美国FDA标准（至少有轻度<6>主动脉瓣反流</6>或中度<20>二尖瓣反流</20>）。结果：两名患者（4.3% [95% CI，0.6%至14.8%]）接受<4>芬氟拉明</4>-<9>非那丙胺</9>发展为<14>心脏瓣膜病</14>。一个有基线<21>二尖瓣主动脉瓣</21>和轻度<7>主动脉瓣反流</7>进展到中度反流。第二位患者出现新的中度<8>主动脉瓣关闭不全</8>。结论：减肥药使用者有发生<15>心脏瓣膜病</15>的风险。但是，发生率可能低于以前报道的。", "revised": true}
{"doc_key": "3108839", "sentences": [["Mitomycin", "C", "associated", "hemolytic", "uremic", "syndrome", ".", "Mitomycin", "C", "associated", "Hemolytic", "Uremic", "Syndrome", "(", "HUS", ")", "is", "a", "potentially", "fatal", "but", "uncommon", "condition", "that", "is", "not", "yet", "widely", "recognised", ".", "It", "consists", "of", "microangiopathic", "hemolytic", "anemia", ",", "thrombocytopenia", "and", "progressive", "renal", "failure", "associated", "with", "mitomycin", "C", "treatment", "and", "affects", "about", "10", "%", "of", "patients", "treated", "with", "this", "agent", ".", "The", "renal", "failure", "usually", "develops", "about", "8", "-", "10", "mth", "after", "start", "of", "mitomycin", "C", "treatment", "and", "the", "mortality", "is", "approximately", "60", "%", "from", "renal", "failure", "or", "pulmonary", "edema", ".", "Renal", "lesions", "are", "similar", "to", "those", "seen", "in", "idiopathic", "HUS", "and", "include", "arteriolar", "fibrin", "thrombi", ",", "expanded", "subendothelial", "zones", "in", "glomerular", "capillary", "walls", ",", "ischemic", "wrinkling", "of", "glomerular", "basement", "membranes", "and", "mesangiolysis", ".", "The", "mechanism", "of", "action", "is", "postulated", "as", "mitomycin", "C", "-", "induced", "endothelial", "cell", "damage", ".", "We", "describe", "the", "clinical", "course", "and", "pathological", "findings", "in", "a", "65", "yr", "-", "old", "man", "with", "gastric", "adenocarcinoma", "who", "developed", "renal", "failure", "and", "thrombocytopenia", "while", "on", "treatment", "with", "mitomycin", "C", "and", "died", "in", "pulmonary", "edema", "."]], "ner": [[[0, 1, "Chemical"], [7, 8, "Chemical"], [44, 45, "Chemical"], [72, 73, "Chemical"], [129, 130, "Chemical"], [165, 166, "Chemical"], [3, 5, "Disease"], [10, 12, "Disease"], [14, 14, "Disease"], [98, 98, "Disease"], [40, 41, "Disease"], [60, 61, "Disease"], [83, 84, "Disease"], [89, 90, "Disease"], [157, 158, "Disease"], [34, 35, "Disease"], [37, 37, "Disease"], [160, 160, "Disease"], [86, 87, "Disease"], [170, 171, "Disease"], [103, 103, "Disease"], [113, 113, "Disease"], [153, 154, "Disease"]]], "relations": [[[0, 1, 3, 5, "CID"], [0, 1, 10, 12, "CID"], [0, 1, 14, 14, "CID"], [0, 1, 98, 98, "CID"], [7, 8, 3, 5, "CID"], [7, 8, 10, 12, "CID"], [7, 8, 14, 14, "CID"], [7, 8, 98, 98, "CID"], [44, 45, 3, 5, "CID"], [44, 45, 10, 12, "CID"], [44, 45, 14, 14, "CID"], [44, 45, 98, 98, "CID"], [72, 73, 3, 5, "CID"], [72, 73, 10, 12, "CID"], [72, 73, 14, 14, "CID"], [72, 73, 98, 98, "CID"], [129, 130, 3, 5, "CID"], [129, 130, 10, 12, "CID"], [129, 130, 14, 14, "CID"], [129, 130, 98, 98, "CID"], [165, 166, 3, 5, "CID"], [165, 166, 10, 12, "CID"], [165, 166, 14, 14, "CID"], [165, 166, 98, 98, "CID"], [0, 1, 40, 41, "CID"], [0, 1, 60, 61, "CID"], [0, 1, 83, 84, "CID"], [0, 1, 89, 90, "CID"], [0, 1, 157, 158, "CID"], [7, 8, 40, 41, "CID"], [7, 8, 60, 61, "CID"], [7, 8, 83, 84, "CID"], [7, 8, 89, 90, "CID"], [7, 8, 157, 158, "CID"], [44, 45, 40, 41, "CID"], [44, 45, 60, 61, "CID"], [44, 45, 83, 84, "CID"], [44, 45, 89, 90, "CID"], [44, 45, 157, 158, "CID"], [72, 73, 40, 41, "CID"], [72, 73, 60, 61, "CID"], [72, 73, 83, 84, "CID"], [72, 73, 89, 90, "CID"], [72, 73, 157, 158, "CID"], [129, 130, 40, 41, "CID"], [129, 130, 60, 61, "CID"], [129, 130, 83, 84, "CID"], [129, 130, 89, 90, "CID"], [129, 130, 157, 158, "CID"], [165, 166, 40, 41, "CID"], [165, 166, 60, 61, "CID"], [165, 166, 83, 84, "CID"], [165, 166, 89, 90, "CID"], [165, 166, 157, 158, "CID"]]], "clusters": [], "translated": "<0>丝裂霉素C</0>相关<6>溶血性尿毒症综合征</6>。 <1>丝裂霉素C </1>相关的 <7>溶血性尿毒症综合征</7> (<8>HUS</8>)是一种可能致命但尚未得到广泛认识的罕见病症。它包括与 <2>丝裂霉素C</2>治疗相关的微血管病性<15>溶血性贫血</15>、<16>血小板减少症</16>和进行性<10>肾功能衰竭</10>，影响约10%接受这种药物治疗的患者。<11>肾功能衰竭 </11>通常在<3>丝裂霉素C</3>治疗开始后约8-10个月发生，<12>死亡率约为60%</12>，死因是<18>肺水肿</18>或<13>肾脏病变</13>。<9>肾脏病变</9>与特发性<21>HUS</21>相似，包括小动脉纤维蛋白<20>血栓</20>、肾小球毛细血管壁内皮下区扩张和<21>缺血性</21>肾小球基底膜起皱和系膜溶解。作用机制被假定为<4>丝裂霉素C</4>诱导的内皮细胞损伤。我们描述了一位患有<22>胃腺癌</22>的65岁男性的临床过程和病理学发现，他在接受<5>丝裂霉素C</5>治疗时出现<14>肾功能衰竭</14>和<17>血小板减少症</17>，并死于<19>肺水肿</19>。", "revised": true}
{"doc_key": "18627295", "sentences": [["Doxorubicin", "cardiomyopathy", "-", "induced", "inflammation", "and", "apoptosis", "are", "attenuated", "by", "gene", "deletion", "of", "the", "kinin", "B1", "receptor", ".", "Clinical", "use", "of", "the", "anthracycline", "doxorubicin", "(", "DOX", ")", "is", "limited", "by", "its", "cardiotoxic", "effects", ",", "which", "are", "attributed", "to", "the", "induction", "of", "apoptosis", ".", "To", "elucidate", "the", "possible", "role", "of", "the", "kinin", "B1", "receptor", "(", "B1R", ")", "during", "the", "development", "of", "DOX", "cardiomyopathy", ",", "we", "studied", "B1R", "knockout", "mice", "(", "B1R", "(", "-", "/", "-", ")", ")", "by", "investigating", "cardiac", "inflammation", "and", "apoptosis", "after", "induction", "of", "DOX", "-", "induced", "cardiomyopathy", ".", "DOX", "control", "mice", "showed", "cardiac", "dysfunction", "measured", "by", "pressure", "-", "volume", "loops", "in", "vivo", ".", "This", "was", "associated", "with", "a", "reduced", "activation", "state", "of", "AKT", ",", "as", "well", "as", "an", "increased", "bax", "/", "bcl2", "ratio", "in", "Western", "blots", ",", "indicating", "cardiac", "apoptosis", ".", "Furthermore", ",", "mRNA", "levels", "of", "the", "proinflammatory", "cytokine", "interleukin", "6", "were", "increased", "in", "the", "cardiac", "tissue", ".", "In", "DOX", "B1R", "(", "-", "/", "-", ")", "mice", ",", "cardiac", "dysfunction", "was", "improved", "compared", "to", "DOX", "control", "mice", ",", "which", "was", "associated", "with", "normalization", "of", "the", "bax", "/", "bcl", "-", "2", "ratio", "and", "interleukin", "6", ",", "as", "well", "as", "AKT", "activation", "state", ".", "These", "findings", "suggest", "that", "B1R", "is", "detrimental", "in", "DOX", "cardiomyopathy", "in", "that", "it", "mediates", "the", "inflammatory", "response", "and", "apoptosis", ".", "These", "insights", "might", "have", "useful", "implications", "for", "future", "studies", "utilizing", "B1R", "antagonists", "for", "treatment", "of", "human", "DOX", "cardiomyopathy", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [60, 60, "Chemical"], [85, 85, "Chemical"], [90, 90, "Chemical"], [151, 151, "Chemical"], [166, 166, "Chemical"], [202, 202, "Chemical"], [230, 230, "Chemical"], [1, 1, "Disease"], [61, 61, "Disease"], [88, 88, "Disease"], [203, 203, "Disease"], [231, 231, "Disease"], [4, 4, "Disease"], [79, 79, "Disease"], [31, 31, "Disease"], [94, 95, "Disease"], [130, 131, "Disease"], [160, 161, "Disease"], [22, 22, "Chemical"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 61, 61, "CID"], [0, 0, 88, 88, "CID"], [0, 0, 203, 203, "CID"], [0, 0, 231, 231, "CID"], [23, 23, 1, 1, "CID"], [23, 23, 61, 61, "CID"], [23, 23, 88, 88, "CID"], [23, 23, 203, 203, "CID"], [23, 23, 231, 231, "CID"], [25, 25, 1, 1, "CID"], [25, 25, 61, 61, "CID"], [25, 25, 88, 88, "CID"], [25, 25, 203, 203, "CID"], [25, 25, 231, 231, "CID"], [60, 60, 1, 1, "CID"], [60, 60, 61, 61, "CID"], [60, 60, 88, 88, "CID"], [60, 60, 203, 203, "CID"], [60, 60, 231, 231, "CID"], [85, 85, 1, 1, "CID"], [85, 85, 61, 61, "CID"], [85, 85, 88, 88, "CID"], [85, 85, 203, 203, "CID"], [85, 85, 231, 231, "CID"], [90, 90, 1, 1, "CID"], [90, 90, 61, 61, "CID"], [90, 90, 88, 88, "CID"], [90, 90, 203, 203, "CID"], [90, 90, 231, 231, "CID"], [151, 151, 1, 1, "CID"], [151, 151, 61, 61, "CID"], [151, 151, 88, 88, "CID"], [151, 151, 203, 203, "CID"], [151, 151, 231, 231, "CID"], [166, 166, 1, 1, "CID"], [166, 166, 61, 61, "CID"], [166, 166, 88, 88, "CID"], [166, 166, 203, 203, "CID"], [166, 166, 231, 231, "CID"], [202, 202, 1, 1, "CID"], [202, 202, 61, 61, "CID"], [202, 202, 88, 88, "CID"], [202, 202, 203, 203, "CID"], [202, 202, 231, 231, "CID"], [230, 230, 1, 1, "CID"], [230, 230, 61, 61, "CID"], [230, 230, 88, 88, "CID"], [230, 230, 203, 203, "CID"], [230, 230, 231, 231, "CID"]]], "clusters": [], "translated": " <0>阿霉素</0> <10>心肌病</10>诱导的<15>炎症</15>和细胞凋亡通过激肽B1受体基因缺失得到减弱。<21>蒽环类药物</21><1>阿霉素</1> ( <2>DOX</2> )的临床应用受到其<17>心脏毒性</17>作用的限制，这归因于诱导作用细胞凋亡。为了阐明激肽B1受体(B1R)在<3>DOX</3><11>心肌病</11>发展过程中的可能作用，我们研究了B1R敲除小鼠(B1R(-/-))通过研究心脏<4>DOX</4>诱导<12>心肌病</12>后<16>炎症</16>和细胞凋亡。<5>DOX</5>对照小鼠显示通过体内压力容积环测量<18>心脏功能障碍</18>，这与AKT激活状态降低以及Western印迹中bax/bcl2比率增加有关，表明<19>心脏细胞凋亡</19>。此外，促炎细胞因子白细胞介素6的mRNA水平在心脏组织中增加。在<6>DOX</6>B1R(-/-)小鼠中，与<7>DOX</7>对照小鼠相比，<20>心功能不全</20>得到改善，这与bax/bcl-2比值的正常化、白细胞介素6水平的正常化，以及AKT激活状态有关。这些发现表明B1R在<8>DOX</8><13>心肌病</13>中是有害的，因为它介导炎症反应和细胞凋亡。这些见解可能对利用B1R拮抗剂治疗人类<9>DOX</9><14>心肌病</14>的未来研究具有重要意义。", "revised": true}
{"doc_key": "15638391", "sentences": [["Aging", "process", "of", "epithelial", "cells", "of", "the", "rat", "prostate", "lateral", "lobe", "in", "experimental", "hyperprolactinemia", "induced", "by", "haloperidol", ".", "The", "aim", "of", "the", "study", "was", "to", "examine", "the", "influence", "of", "hyperprolactinemia", ",", "induced", "by", "haloperidol", "(", "HAL", ")", "on", "age", "related", "morphology", "and", "function", "changes", "of", "epithelial", "cells", "in", "rat", "prostate", "lateral", "lobe", ".", "The", "study", "was", "performed", "on", "sexually", "mature", "male", "rats", ".", "Serum", "concentrations", "of", "prolactin", "(", "PRL", ")", "and", "testosterone", "(", "T", ")", "were", "measured", ".", "Tissue", "sections", "were", "evaluated", "with", "light", "and", "electron", "microscopy", ".", "Immunohistochemical", "reactions", "for", "Anti", "-", "Proliferating", "Cell", "Nuclear", "Antigen", "(", "PCNA", ")", "were", "performed", ".", "In", "rats", "of", "the", "experimental", "group", ",", "the", "mean", "concentration", "of", ":", "PRL", "was", "more", "than", "twice", "higher", ",", "whereas", "T", "concentration", "was", "almost", "twice", "lower", "than", "that", "in", "the", "control", "group", ".", "Light", "microscopy", "visualized", "the", "following", ":", "hypertrophy", "and", "epithelium", "hyperplasia", "of", "the", "glandular", "ducts", ",", "associated", "with", "increased", "PCNA", "expression", ".", "Electron", "microscopy", "revealed", "changes", "in", "columnar", "epithelial", "cells", ",", "concerning", "organelles", ",", "engaged", "in", "protein", "synthesis", "and", "secretion", "."]], "ner": [[[16, 16, "Chemical"], [33, 33, "Chemical"], [35, 35, "Chemical"], [13, 13, "Disease"], [29, 29, "Disease"], [68, 68, "Chemical"], [115, 115, "Chemical"], [71, 71, "Chemical"], [73, 73, "Chemical"], [123, 123, "Chemical"], [142, 142, "Disease"], [145, 145, "Disease"]]], "relations": [[[16, 16, 13, 13, "CID"], [16, 16, 29, 29, "CID"], [33, 33, 13, 13, "CID"], [33, 33, 29, 29, "CID"], [35, 35, 13, 13, "CID"], [35, 35, 29, 29, "CID"]]], "clusters": [], "translated": "<0>氟哌啶醇</0>致实验性<3>高泌乳素血症</3>大鼠前列腺外侧叶上皮细胞的衰老过程。本研究旨在探讨由<1>氟哌啶醇</1>（<2>HAL</2>）引起的<4>高泌乳素血症</4>对大鼠前列腺外侧叶上皮细胞年龄相关的形态和功能变化的影响。这项研究是在性成熟的雄性大鼠上进行的。测定了催乳素 (<5>PRL</5>) 和<7>睾酮</7> (<8>T</8>) 的血清浓度。组织切片用光学和电子显微镜进行评估。进行了抗增殖细胞核抗原(PCNA) 的免疫组织化学反应。在实验组的大鼠中，<6>PRL</6> 的平均浓度高于对照组的两倍以上，而<9>T</9> 的浓度几乎是对照组的两倍低。光学显微镜下可视化以下情况：<10>肥大</10>的腺管和上皮<11>增生</11>，与 PCNA表达的增加有关。电子显微镜显示柱状上皮细胞有变化，涉及到参与蛋白质合成和分泌的细胞器。", "revised": true}
{"doc_key": "12745515", "sentences": [["Seizure", "associated", "with", "sleep", "deprivation", "and", "sustained", "-", "release", "bupropion", ".", "This", "case", "report", "describes", "a", "generalized", "seizure", "associated", "with", "sustained", "-", "release", "bupropion", "use", "and", "sleep", "deprivation", ".", "The", "subject", ",", "a", "31", "-", "year", "-", "old", "female", "smoker", ",", "was", "participating", "in", "a", "clinical", "trial", "evaluating", "an", "investigational", "medication", "for", "smoking", "cessation", "that", "used", "sustained", "-", "release", "bupropion", "as", "an", "active", "control", ".", "After", "5", "weeks", "of", "bupropion", "use", ",", "the", "subject", "experienced", "a", "generalized", "tonic", "clonic", "seizure", "after", "staying", "up", "nearly", "all", "night", "packing", "and", "moving", "to", "a", "new", "residence", ".", "The", "patient", "had", "no", "other", "risk", "factors", "for", "seizures", ".", "We", "suggest", "that", "sleep", "deprivation", "may", "add", "to", "the", "risk", "of", "bupropion", "-", "associated", "seizures", "."]], "ner": [[[9, 9, "Chemical"], [23, 23, "Chemical"], [59, 59, "Chemical"], [69, 69, "Chemical"], [115, 115, "Chemical"], [0, 0, "Disease"], [17, 17, "Disease"], [79, 79, "Disease"], [102, 102, "Disease"], [118, 118, "Disease"], [3, 4, "Disease"], [26, 27, "Disease"], [107, 108, "Disease"]]], "relations": [[[9, 9, 0, 0, "CID"], [9, 9, 17, 17, "CID"], [9, 9, 79, 79, "CID"], [9, 9, 102, 102, "CID"], [9, 9, 118, 118, "CID"], [23, 23, 0, 0, "CID"], [23, 23, 17, 17, "CID"], [23, 23, 79, 79, "CID"], [23, 23, 102, 102, "CID"], [23, 23, 118, 118, "CID"], [59, 59, 0, 0, "CID"], [59, 59, 17, 17, "CID"], [59, 59, 79, 79, "CID"], [59, 59, 102, 102, "CID"], [59, 59, 118, 118, "CID"], [69, 69, 0, 0, "CID"], [69, 69, 17, 17, "CID"], [69, 69, 79, 79, "CID"], [69, 69, 102, 102, "CID"], [69, 69, 118, 118, "CID"], [115, 115, 0, 0, "CID"], [115, 115, 17, 17, "CID"], [115, 115, 79, 79, "CID"], [115, 115, 102, 102, "CID"], [115, 115, 118, 118, "CID"]]], "clusters": [], "translated": "<5>癫痫发作</5>与<10>睡眠剥夺</10>和<0>缓释安非他酮</0>相关。本病例报告描述了与持续释放<1>安非他酮</1>使用和<11>睡眠剥夺</11>相关的<6>全身性癫痫发作</6>。该受试者是一名31岁的女性吸烟者，正在参加一项临床试验，该试验评估一种研究性戒烟药物，该试验使用缓释<2>安非他酮</2>作为活性对照。在使用<3>安非他酮</3>5周后，受试者在几乎整夜熬夜收拾行李并搬到新住所后经历了<7>全身性强直-阵挛性癫痫发作</7>。患者没有其他<8>癫痫发作</8>的危险因素。我们建议<12>睡眠剥夺</12>可能会增加<4>安非他酮</4>相关的<9>癫痫发作</9>的风险。", "revised": true}
{"doc_key": "18405372", "sentences": [["Hepatotoxicity", "associated", "with", "sulfasalazine", "in", "inflammatory", "arthritis", ":", "A", "case", "series", "from", "a", "local", "surveillance", "of", "serious", "adverse", "events", ".", "BACKGROUND", ":", "Spontaneous", "reporting", "systems", "for", "adverse", "drug", "reactions", "(", "ADRs", ")", "are", "handicapped", "by", "under", "-", "reporting", "and", "limited", "detail", "on", "individual", "cases", ".", "We", "report", "an", "investigation", "from", "a", "local", "surveillance", "for", "serious", "adverse", "drug", "reactions", "associated", "with", "disease", "modifying", "anti", "-", "rheumatic", "drugs", "that", "was", "triggered", "by", "the", "occurrence", "of", "liver", "failure", "in", "two", "of", "our", "patients", ".", "METHODS", ":", "Serious", "ADR", "reports", "have", "been", "solicited", "from", "local", "clinicians", "by", "regular", "postcards", "over", "the", "past", "seven", "years", ".", "Patients", "'", ",", "who", "had", "hepatotoxicity", "on", "sulfasalazine", "and", "met", "a", "definition", "of", "a", "serious", "ADR", ",", "were", "identified", ".", "Two", "clinicians", "reviewed", "structured", "case", "reports", "and", "assessed", "causality", "by", "consensus", "and", "by", "using", "a", "causality", "assessment", "instrument", ".", "The", "likely", "frequency", "of", "hepatotoxicity", "with", "sulfasalazine", "was", "estimated", "by", "making", "a", "series", "of", "conservative", "assumptions", ".", "RESULTS", ":", "Ten", "cases", "were", "identified", ":", "eight", "occurred", "during", "surveillance", ".", "Eight", "patients", "were", "hospitalised", ",", "two", "in", "hepatic", "failure", "-", "one", "died", "after", "a", "liver", "transplant", ".", "All", "but", "one", "event", "occurred", "within", "6", "weeks", "of", "treatment", ".", "Seven", "patients", "had", "a", "skin", "rash", ",", "three", "eosinophilia", "and", "one", "interstitial", "nephritis", ".", "Five", "patients", "were", "of", "Black", "British", "of", "African", "or", "Caribbean", "descent", ".", "Liver", "enzymes", "showed", "a", "hepatocellular", "pattern", "in", "four", "cases", "and", "a", "mixed", "pattern", "in", "six", ".", "Drug", "-", "related", "hepatotoxicity", "was", "judged", "probable", "or", "highly", "probable", "in", "8", "patients", ".", "The", "likely", "frequency", "of", "serious", "hepatotoxicity", "with", "sulfasalazine", "was", "estimated", "at", "0", ".", "4", "%", "of", "treated", "patients", ".", "CONCLUSION", ":", "Serious", "hepatotoxicity", "associated", "with", "sulfasalazine", "appears", "to", "be", "under", "-", "appreciated", "and", "intensive", "monitoring", "and", "vigilance", "in", "the", "first", "6", "weeks", "of", "treatment", "is", "especially", "important", "."]], "ner": [[[3, 3, "Chemical"], [108, 108, "Chemical"], [146, 146, "Chemical"], [260, 260, "Chemical"], [278, 278, "Chemical"], [0, 0, "Disease"], [106, 106, "Disease"], [144, 144, "Disease"], [242, 242, "Disease"], [258, 258, "Disease"], [275, 275, "Disease"], [6, 6, "Disease"], [73, 74, "Disease"], [176, 177, "Disease"], [201, 202, "Disease"], [205, 205, "Disease"], [208, 209, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 106, 106, "CID"], [3, 3, 144, 144, "CID"], [3, 3, 242, 242, "CID"], [3, 3, 258, 258, "CID"], [3, 3, 275, 275, "CID"], [108, 108, 0, 0, "CID"], [108, 108, 106, 106, "CID"], [108, 108, 144, 144, "CID"], [108, 108, 242, 242, "CID"], [108, 108, 258, 258, "CID"], [108, 108, 275, 275, "CID"], [146, 146, 0, 0, "CID"], [146, 146, 106, 106, "CID"], [146, 146, 144, 144, "CID"], [146, 146, 242, 242, "CID"], [146, 146, 258, 258, "CID"], [146, 146, 275, 275, "CID"], [260, 260, 0, 0, "CID"], [260, 260, 106, 106, "CID"], [260, 260, 144, 144, "CID"], [260, 260, 242, 242, "CID"], [260, 260, 258, 258, "CID"], [260, 260, 275, 275, "CID"], [278, 278, 0, 0, "CID"], [278, 278, 106, 106, "CID"], [278, 278, 144, 144, "CID"], [278, 278, 242, 242, "CID"], [278, 278, 258, 258, "CID"], [278, 278, 275, 275, "CID"]]], "clusters": [], "translated": " <5>肝毒性</5>与<0>柳氮磺胺吡啶</0>在炎症性<11>关节炎</11>中的相关性：来自严重不良事件的局部监测的病例系列。背景：药物不良反应 (ADR) 的自发报告系统因个案报告不足和细节有限而受到阻碍。我们报告了一项当地监测的调查，调查发现与缓解疾病的抗风湿药相关的严重药物不良反应是由我们的两名患者发生<12>肝功能衰竭</12>引起的。方法：在过去七年中，通过定期明信片向当地临床医生征求严重的 ADR 报告。对<1>柳氮磺胺吡啶</1>有<6>肝毒性</6>并符合严重不良反应定义的患者进行了鉴定。两名临床医生审查了结构化病例报告，并通过共识和使用因果关系评估工具评估了因果关系。 <7>肝毒性</7>与<2>柳氮磺胺吡啶</2>的可能发生频率是通过一系列保守假设估计的。结果：确定了 10 个病例：8 个发生在监测期间。八名患者住院，其中两名<13>肝功能衰竭</13>-一名在肝移植后死亡。除了一个事件外，所有事件都发生在治疗的6周内。7例患者出现<14>皮疹</14>，3例<15>嗜酸性粒细胞增多</15>，1例<16>间质性肾炎</16>。五名患者是非洲或加勒比血统的英国黑人。4例肝酶呈肝细胞型，6例呈混合型。在8名患者中，与药物相关的<8>肝毒性</8>被判断为可能或高度可能。<3>柳氮磺胺吡啶</3>引起严重<9>肝毒性</9>的可能频率估计为0.4%的治疗患者。结论：与<4>柳氮磺胺吡啶</4>相关的严重<10>肝毒性</10>似乎被低估了，在治疗的前6周内加强监测和警惕尤为重要。", "revised": true}
{"doc_key": "2466960", "sentences": [["Continuous", "ambulatory", "ECG", "monitoring", "during", "fluorouracil", "therapy", ":", "a", "prospective", "study", ".", "Although", "there", "have", "been", "anecdotal", "reports", "of", "cardiac", "toxicity", "associated", "with", "fluorouracil", "(", "5", "-", "FU", ")", "therapy", ",", "this", "phenomenon", "has", "not", "been", "studied", "in", "a", "systematic", "fashion", ".", "We", "prospectively", "performed", "continuous", "ambulatory", "ECG", "monitoring", "on", "25", "patients", "undergoing", "5", "-", "FU", "infusion", "for", "treatment", "of", "solid", "tumors", "in", "order", "to", "assess", "the", "incidence", "of", "ischemic", "ST", "changes", ".", "Patients", "were", "monitored", "for", "23", "+", "/", "-", "4", "hours", "before", "5", "-", "FU", "infusion", ",", "and", "98", "+", "/", "-", "9", "hours", "during", "5", "-", "FU", "infusion", ".", "Anginal", "episodes", "were", "rare", ":", "only", "one", "patient", "had", "angina", "(", "during", "5", "-", "FU", "infusion", ")", ".", "However", ",", "asymptomatic", "ST", "changes", "(", "greater", "than", "or", "equal", "to", "1", "mm", "ST", "deviation", ")", "were", "common", ":", "six", "of", "25", "patients", "(", "24", "%", ")", "had", "ST", "changes", "before", "5", "-", "FU", "infusion", "v", "17", "(", "68", "%", ")", "during", "5", "-", "FU", "infusion", "(", "P", "less", "than", ".", "002", ")", ".", "The", "incidence", "of", "ischemic", "episodes", "per", "patient", "per", "hour", "was", "0", ".", "05", "+", "/", "-", "0", ".", "02", "prior", "to", "5", "-", "FU", "infusion", "v", "0", ".", "13", "+", "/", "-", "0", ".", "03", "during", "5", "-", "FU", "infusion", "(", "P", "less", "than", ".", "001", ")", ";", "the", "duration", "of", "ECG", "changes", "was", "0", ".", "6", "+", "/", "-", "0", ".", "3", "minutes", "per", "patient", "per", "hour", "before", "5", "-", "FU", "v", "1", ".", "9", "+", "/", "-", "0", ".", "5", "minutes", "per", "patient", "per", "hour", "during", "5", "-", "FU", "(", "P", "less", "than", ".", "01", ")", ".", "ECG", "changes", "were", "more", "common", "among", "patients", "with", "known", "coronary", "artery", "disease", ".", "There", "were", "two", "cases", "of", "sudden", "death", ",", "both", "of", "which", "occurred", "at", "the", "end", "of", "the", "chemotherapy", "course", ".", "We", "conclude", "that", "5", "-", "FU", "infusion", "is", "associated", "with", "a", "significant", "increase", "in", "silent", "ST", "segment", "deviation", "suggestive", "of", "ischemia", ",", "particularly", "among", "patients", "with", "coronary", "artery", "disease", ".", "The", "mechanism", "and", "clinical", "significance", "of", "these", "ECG", "changes", "remain", "to", "be", "determined", "."]], "ner": [[[5, 5, "Chemical"], [23, 23, "Chemical"], [25, 27, "Chemical"], [53, 55, "Chemical"], [84, 86, "Chemical"], [97, 99, "Chemical"], [114, 116, "Chemical"], [151, 153, "Chemical"], [162, 164, "Chemical"], [195, 197, "Chemical"], [210, 212, "Chemical"], [243, 245, "Chemical"], [262, 264, "Chemical"], [309, 311, "Chemical"], [69, 69, "Disease"], [177, 177, "Disease"], [326, 326, "Disease"], [102, 102, "Disease"], [111, 111, "Disease"], [19, 20, "Disease"], [61, 61, "Disease"], [282, 284, "Disease"], [332, 334, "Disease"], [291, 292, "Disease"]]], "relations": [[[5, 5, 69, 69, "CID"], [5, 5, 177, 177, "CID"], [5, 5, 326, 326, "CID"], [23, 23, 69, 69, "CID"], [23, 23, 177, 177, "CID"], [23, 23, 326, 326, "CID"], [25, 27, 69, 69, "CID"], [25, 27, 177, 177, "CID"], [25, 27, 326, 326, "CID"], [53, 55, 69, 69, "CID"], [53, 55, 177, 177, "CID"], [53, 55, 326, 326, "CID"], [84, 86, 69, 69, "CID"], [84, 86, 177, 177, "CID"], [84, 86, 326, 326, "CID"], [97, 99, 69, 69, "CID"], [97, 99, 177, 177, "CID"], [97, 99, 326, 326, "CID"], [114, 116, 69, 69, "CID"], [114, 116, 177, 177, "CID"], [114, 116, 326, 326, "CID"], [151, 153, 69, 69, "CID"], [151, 153, 177, 177, "CID"], [151, 153, 326, 326, "CID"], [162, 164, 69, 69, "CID"], [162, 164, 177, 177, "CID"], [162, 164, 326, 326, "CID"], [195, 197, 69, 69, "CID"], [195, 197, 177, 177, "CID"], [195, 197, 326, 326, "CID"], [210, 212, 69, 69, "CID"], [210, 212, 177, 177, "CID"], [210, 212, 326, 326, "CID"], [243, 245, 69, 69, "CID"], [243, 245, 177, 177, "CID"], [243, 245, 326, 326, "CID"], [262, 264, 69, 69, "CID"], [262, 264, 177, 177, "CID"], [262, 264, 326, 326, "CID"], [309, 311, 69, 69, "CID"], [309, 311, 177, 177, "CID"], [309, 311, 326, 326, "CID"], [5, 5, 102, 102, "CID"], [5, 5, 111, 111, "CID"], [23, 23, 102, 102, "CID"], [23, 23, 111, 111, "CID"], [25, 27, 102, 102, "CID"], [25, 27, 111, 111, "CID"], [53, 55, 102, 102, "CID"], [53, 55, 111, 111, "CID"], [84, 86, 102, 102, "CID"], [84, 86, 111, 111, "CID"], [97, 99, 102, 102, "CID"], [97, 99, 111, 111, "CID"], [114, 116, 102, 102, "CID"], [114, 116, 111, 111, "CID"], [151, 153, 102, 102, "CID"], [151, 153, 111, 111, "CID"], [162, 164, 102, 102, "CID"], [162, 164, 111, 111, "CID"], [195, 197, 102, 102, "CID"], [195, 197, 111, 111, "CID"], [210, 212, 102, 102, "CID"], [210, 212, 111, 111, "CID"], [243, 245, 102, 102, "CID"], [243, 245, 111, 111, "CID"], [262, 264, 102, 102, "CID"], [262, 264, 111, 111, "CID"], [309, 311, 102, 102, "CID"], [309, 311, 111, 111, "CID"]]], "clusters": [], "translated": "<0>氟尿嘧啶</0>治疗期间连续动态心电图监测：一项前瞻性研究。尽管有与<1>氟尿嘧啶</1> (<2>5-FU</2>) 治疗相关的<19>心脏毒性</19>的轶事报道，但尚未对这种现象进行系统的研究。我们前瞻性地对25名接受<3>5-FU</3>输注治疗实体<20>肿瘤</20>的患者进行连续动态心电图监测，以评估<14>缺血性</14> ST 的发生率变化。在<4>5-FU</4>输注前对患者进行23+/-4小时的监测，在<5>5-FU</5>输注期间对患者进行98+/-9小时的监测。<17>心绞痛</17>发作很少见：只有一名患者有<18>心绞痛</18>（在<6>5-FU</6>输注期间）。然而，无症状的ST段改变（大于或等于1毫米ST段偏差）很常见：25名患者中有6名（24%）在<7>5-FU</7>输注之前有ST段改变v17（68%）在<8>5-FU</8>输注（P小于.002）。每名患者每小时<15>缺血性</15>发作的发生率为0.05+/-0.02在<9>5-FU</9>输注前v0.13+/-0.03<10>5-FU</10>输注期间（P小于.001）；心电图变化的持续时间为0.6+/-0.3分钟每位患者每小时在<11>5-FU</11> v1.9+/-0.5分钟每位患者每小时在<12>5-FU</12>期间（P小于.01）。心电图变化在已知<21>冠状动脉疾病</21>的患者中更为常见。<23>猝死</23>2例，均发生在化疗疗程结束时。我们得出结论，<13>5-FU</13>输注与提示<16>缺血</16>的无症状ST段偏差显着增加有关，特别是在患有<22>冠状动脉疾病</22>的患者中。这些心电图变化的机制和临床意义仍有待确定。", "revised": true}
{"doc_key": "19289093", "sentences": [["Identification", "of", "a", "simple", "and", "sensitive", "microplate", "method", "for", "the", "detection", "of", "oversulfated", "chondroitin", "sulfate", "in", "heparin", "products", ".", "Heparin", "is", "a", "commonly", "implemented", "anticoagulant", "used", "to", "treat", "critically", "ill", "patients", ".", "Recently", ",", "a", "number", "of", "commercial", "lots", "of", "heparin", "products", "were", "found", "to", "be", "contaminated", "with", "an", "oversulfated", "chondroitin", "sulfate", "(", "OSCS", ")", "derivative", "that", "could", "elicit", "a", "hypotensive", "response", "in", "pigs", "following", "a", "single", "high", "-", "dose", "infusion", ".", "Using", "both", "contaminated", "heparin", "products", "and", "the", "synthetically", "produced", "derivative", ",", "we", "showed", "that", "the", "OSCS", "produces", "dose", "-", "dependent", "hypotension", "in", "pigs", ".", "The", "no", "observed", "effect", "level", "(", "NOEL", ")", "for", "this", "contaminant", "appears", "to", "be", "approximately", "1mg", "/", "kg", ",", "corresponding", "to", "a", "contamination", "level", "of", "approximately", "3", "%", ".", "We", "also", "demonstrated", "that", "OSCS", "can", "be", "identified", "in", "heparin", "products", "using", "a", "simple", ",", "inexpensive", ",", "commercially", "available", "heparin", "enzyme", "immunoassay", "(", "EIA", ")", "kit", "that", "has", "a", "limit", "of", "detection", "of", "approximately", "0", ".", "1", "%", ",", "well", "below", "the", "NOEL", ".", "This", "kit", "may", "provide", "a", "useful", "method", "to", "test", "heparin", "products", "for", "contamination", "with", "oversulfated", "GAG", "derivatives", "."]], "ner": [[[13, 14, "Chemical"], [50, 51, "Chemical"], [60, 60, "Disease"], [92, 92, "Disease"], [16, 16, "Chemical"], [19, 19, "Chemical"], [40, 40, "Chemical"], [75, 75, "Chemical"], [134, 134, "Chemical"], [144, 144, "Chemical"], [178, 178, "Chemical"]]], "relations": [[[13, 14, 60, 60, "CID"], [13, 14, 92, 92, "CID"], [50, 51, 60, 60, "CID"], [50, 51, 92, 92, "CID"]]], "clusters": [], "translated": "<4>肝素</4>产品中过硫酸化<0>硫酸软骨素</0>的简便灵敏的微孔板法检测的鉴定。 <5>肝素</5>是一种常用的抗凝剂，用于治疗危重病人。最近发现，许多商业批次的<6>肝素</6>产品被过硫酸化的<1>硫酸软骨素</1> (OSCS)衍生物污染，该衍生物可引起单次高剂量输注后猪的<2>低血压</2>反应。使用受污染的<7>肝素</7>产品和合成产生的衍生物，我们发现OSCS在猪体内产生剂量依赖性<3>低血压</3>。该污染物的未观察到效应水平(NOEL)似乎约为1mg/kg，对应于大约3%的污染水平。我们还证明了，可以使用一种简单、廉价、市售的<9>肝素</9>酶免疫测定(EIA)试剂盒来识别<8>肝素</8>产品中的OSCS，该试剂盒的检测限约为0.1%，远低于NOEL。该试剂盒可能提供一种有用的方法，来测试<10>肝素</10>产品是否污染了过硫酸化的GAG衍生物。", "revised": true}
{"doc_key": "16574713", "sentences": [["Memory", "function", "and", "serotonin", "transporter", "promoter", "gene", "polymorphism", "in", "ecstasy", "(", "MDMA", ")", "users", ".", "Although", "3", ",", "4", "-", "methylenedioxymethamphetamine", "(", "MDMA", "or", "ecstasy", ")", "has", "been", "shown", "to", "damage", "brain", "serotonin", "(", "5", "-", "HT", ")", "neurons", "in", "animals", "and", "possibly", "humans", ",", "little", "is", "known", "about", "the", "long", "-", "term", "consequences", "of", "MDMA", "-", "induced", "5", "-", "HT", "neurotoxic", "lesions", "on", "functions", "in", "which", "5", "-", "HT", "is", "involved", ",", "such", "as", "cognitive", "function", ".", "Because", "5", "-", "HT", "transporters", "play", "a", "key", "element", "in", "the", "regulation", "of", "synaptic", "5", "-", "HT", "transmission", "it", "may", "be", "important", "to", "control", "for", "the", "potential", "covariance", "effect", "of", "a", "polymorphism", "in", "the", "5", "-", "HT", "transporter", "promoter", "gene", "region", "(", "5", "-", "HTTLPR", ")", "when", "studying", "the", "effects", "of", "MDMA", "as", "well", "as", "cognitive", "functioning", ".", "The", "aim", "of", "the", "study", "was", "to", "investigate", "the", "effects", "of", "moderate", "and", "heavy", "MDMA", "use", "on", "cognitive", "function", ",", "as", "well", "as", "the", "effects", "of", "long", "-", "term", "abstention", "from", "MDMA", ",", "in", "subjects", "genotyped", "for", "5", "-", "HTTLPR", ".", "A", "second", "aim", "of", "the", "study", "was", "to", "determine", "whether", "these", "effects", "differ", "for", "females", "and", "males", ".", "Fifteen", "moderate", "MDMA", "users", "(", "<", "55", "lifetime", "tablets", ")", ",", "22", "heavy", "MDMA", "+", "users", "(", ">", "55", "lifetime", "tablets", ")", ",", "16", "ex", "-", "MDMA", "+", "users", "(", "last", "tablet", ">", "1", "year", "ago", ")", "and", "13", "controls", "were", "compared", "on", "a", "battery", "of", "neuropsychological", "tests", ".", "DNA", "from", "peripheral", "nuclear", "blood", "cells", "was", "genotyped", "for", "5", "-", "HTTLPR", "using", "standard", "polymerase", "chain", "reaction", "methods", ".", "A", "significant", "group", "effect", "was", "observed", "only", "on", "memory", "function", "tasks", "(", "p", "=", "0", ".", "04", ")", "but", "not", "on", "reaction", "times", "(", "p", "=", "0", ".", "61", ")", "or", "attention", "/", "executive", "functioning", "(", "p", "=", "0", ".", "59", ")", ".", "Heavy", "and", "ex", "-", "MDMA", "+", "users", "performed", "significantly", "poorer", "on", "memory", "tasks", "than", "controls", ".", "In", "contrast", ",", "no", "evidence", "of", "memory", "impairment", "was", "observed", "in", "moderate", "MDMA", "users", ".", "No", "significant", "effect", "of", "5", "-", "HTTLPR", "or", "gender", "was", "observed", ".", "While", "the", "use", "of", "MDMA", "in", "quantities", "that", "may", "be", "considered", "\"", "moderate", "\"", "is", "not", "associated", "with", "impaired", "memory", "functioning", ",", "heavy", "use", "of", "MDMA", "use", "may", "lead", "to", "long", "lasting", "memory", "impairments", ".", "No", "effect", "of", "5", "-", "HTTLPR", "or", "gender", "on", "memory", "function", "or", "MDMA", "use", "was", "observed", "."]], "ner": [[[9, 9, "Chemical"], [11, 11, "Chemical"], [16, 20, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [55, 55, "Chemical"], [129, 129, "Chemical"], [150, 150, "Chemical"], [167, 167, "Chemical"], [197, 197, "Chemical"], [208, 208, "Chemical"], [221, 221, "Chemical"], [310, 310, "Chemical"], [334, 334, "Chemical"], [353, 353, "Chemical"], [374, 374, "Chemical"], [396, 396, "Chemical"], [328, 329, "Disease"], [367, 369, "Disease"], [381, 382, "Disease"], [3, 3, "Chemical"], [32, 32, "Chemical"], [34, 36, "Chemical"], [58, 60, "Chemical"], [67, 69, "Chemical"], [79, 81, "Chemical"], [92, 94, "Chemical"], [112, 114, "Chemical"], [61, 62, "Disease"]]], "relations": [[[9, 9, 328, 329, "CID"], [9, 9, 367, 369, "CID"], [9, 9, 381, 382, "CID"], [11, 11, 328, 329, "CID"], [11, 11, 367, 369, "CID"], [11, 11, 381, 382, "CID"], [16, 20, 328, 329, "CID"], [16, 20, 367, 369, "CID"], [16, 20, 381, 382, "CID"], [22, 22, 328, 329, "CID"], [22, 22, 367, 369, "CID"], [22, 22, 381, 382, "CID"], [24, 24, 328, 329, "CID"], [24, 24, 367, 369, "CID"], [24, 24, 381, 382, "CID"], [55, 55, 328, 329, "CID"], [55, 55, 367, 369, "CID"], [55, 55, 381, 382, "CID"], [129, 129, 328, 329, "CID"], [129, 129, 367, 369, "CID"], [129, 129, 381, 382, "CID"], [150, 150, 328, 329, "CID"], [150, 150, 367, 369, "CID"], [150, 150, 381, 382, "CID"], [167, 167, 328, 329, "CID"], [167, 167, 367, 369, "CID"], [167, 167, 381, 382, "CID"], [197, 197, 328, 329, "CID"], [197, 197, 367, 369, "CID"], [197, 197, 381, 382, "CID"], [208, 208, 328, 329, "CID"], [208, 208, 367, 369, "CID"], [208, 208, 381, 382, "CID"], [221, 221, 328, 329, "CID"], [221, 221, 367, 369, "CID"], [221, 221, 381, 382, "CID"], [310, 310, 328, 329, "CID"], [310, 310, 367, 369, "CID"], [310, 310, 381, 382, "CID"], [334, 334, 328, 329, "CID"], [334, 334, 367, 369, "CID"], [334, 334, 381, 382, "CID"], [353, 353, 328, 329, "CID"], [353, 353, 367, 369, "CID"], [353, 353, 381, 382, "CID"], [374, 374, 328, 329, "CID"], [374, 374, 367, 369, "CID"], [374, 374, 381, 382, "CID"], [396, 396, 328, 329, "CID"], [396, 396, 367, 369, "CID"], [396, 396, 381, 382, "CID"]]], "clusters": [], "translated": "<0>摇头丸</0>(<1>MDMA</1>)使用者的记忆功能和<20>5-羟色胺</20>转运蛋白启动子基因多态性。虽然 <2>3,4-亚甲二氧基甲基苯丙胺</2>（<3>MDMA</3>或<4>摇头丸</4>）已被证明会损害大脑的<21>血清素</21>（<22>5-HT</22>）神经元在动物和可能的人类中，关于<5>MDMA</5>诱导的<23>5-HT</23><28>神经毒性损伤</28>对涉及<24>5-HT</24>的功能，如认知功能知之甚少。因为<25>5-HT</25>转运蛋白在突触 <26>5-HT</26>传输的调节中起着关键作用，所以研究<6>MDMA</6>以及认知功能的影响时，控制潜在协方差效应的多态性很重要，如<27>5-HT</27>转运蛋白启动子基因区（5-HTTLPR）。该研究的目的是调查中度和重度<7>MDMA</7>使用对认知功能的影响，以及长期戒断<8>MDMA</8>对5-HTTLPR基因分型受试者的影响。该研究的第二个目的是确定这些影响对女性和男性是否不同。15名中度<9>MDMA</9>用户（<55 终生药片），22名重度<10>MDMA</10>+用户（> 55 终生药片），16名前-<11>MDMA</11>+用户（最后一片>1年前）和13名对照者在一系列神经心理学测试中进行了比较。使用标准聚合酶链反应方法对来自外周血核细胞的DNA进行<27>5-HT</27>转运蛋白启动子基因（5-HTTLPR）基因分型。仅在记忆功能任务上（p=0.04）观察到显著的群体效应，但在反应时间（p=0.61）或注意力/执行功能（p=0.59）上没有观察到。重度和ex-<12>MDMA</12>+用户在记忆任务上的表现明显低于对照组。相比之下，在中度<13>MDMA</13>使用者中没有观察到<17>记忆障碍</17>的证据。没有观察到5-HTTLPR或性别的显着影响。虽然<14>MDMA</14>的使用量可能被认为是“适度”，与<18>记忆功能受损</18>无关，但大量使用<15>MDMA</15>可能会导致持久的<19>记忆障碍</19>。没有观察到5-HTTLPR或性别对记忆功能或<16>摇头丸</16>使用的影响。", "revised": true}
{"doc_key": "12842176", "sentences": [["Effect", "of", "lindane", "on", "hepatic", "and", "brain", "cytochrome", "P450s", "and", "influence", "of", "P450", "modulation", "in", "lindane", "induced", "neurotoxicity", ".", "Oral", "administration", "of", "lindane", "(", "2", ".", "5", ",", "5", ",", "10", "and", "15", "mg", "/", "kg", ",", "body", "weight", ")", "for", "5", "days", "was", "found", "to", "produce", "a", "dose", "-", "dependent", "increase", "in", "the", "activity", "of", "P450", "dependent", "7", "-", "ethoxyresorufin", "-", "O", "-", "deethylase", "(", "EROD", ")", ",", "7", "-", "pentoxyresorufin", "-", "O", "-", "dealkylase", "(", "PROD", ")", "and", "N", "-", "nitrosodimethylamine", "demethylase", "(", "NDMA", "-", "d", ")", "in", "rat", "brain", "and", "liver", ".", "A", "significant", "increase", "in", "the", "hepatic", "and", "brain", "P450", "monooxygenases", "was", "also", "observed", "when", "the", "duration", "of", "exposure", "of", "low", "dose", "(", "2", ".", "5", "mg", "/", "kg", ")", "of", "lindane", "was", "increased", "from", "5", "days", "to", "15", "or", "21", "days", ".", "As", "observed", "with", "different", "doses", ",", "the", "magnitude", "of", "induction", "in", "the", "activity", "of", "P450", "monooxygenases", "was", "several", "fold", "higher", "in", "liver", "microsomes", "when", "compared", "with", "the", "brain", ".", "Western", "blotting", "studies", "have", "indicated", "that", "the", "increase", "in", "the", "P450", "enzymes", "could", "be", "due", "to", "the", "increase", "in", "the", "expression", "of", "P450", "1A1", "/", "1A2", ",", "2B1", "/", "2B2", "and", "2E1", "isoenzymes", ".", "In", "vitro", "studies", "using", "organic", "inhibitors", "specific", "for", "individual", "P450", "isoenzymes", "and", "antibody", "inhibition", "experiments", "have", "further", "demonstrated", "that", "the", "increase", "in", "the", "activity", "of", "PROD", ",", "EROD", "and", "NDMA", "-", "d", "are", "due", "to", "the", "increase", "in", "the", "levels", "of", "P450", "2B1", "/", "2B2", ",", "1A1", "/", "1A2", "and", "2E1", "isoenzymes", ",", "respectively", ".", "Induction", "studies", "have", "further", "shown", "that", "while", "pretreatment", "of", "3", "-", "methylcholanthrene", "(", "MC", ")", ",", "an", "inducer", "of", "P4501A1", "/", "1A2", ",", "did", "not", "produce", "any", "significant", "effect", "in", "the", "incidence", "of", "lindane", "induced", "convulsions", ",", "pretreatment", "with", "phenobarbital", "(", "PB", ")", ",", "an", "inducer", "of", "P450", "2B1", "/", "2B2", "or", "ethanol", ",", "an", "inducer", "of", "P450", "2E1", "catalysed", "reactions", ",", "significantly", "increased", "the", "incidence", "of", "lindane", "induced", "convulsions", ".", "Similarly", ",", "when", "the", "P450", "-", "mediated", "metabolism", "of", "lindane", "was", "blocked", "by", "cobalt", "chloride", "incidence", "of", "convulsions", "was", "increased", "in", "animals", "treated", "with", "lindane", "indicating", "that", "lindane", "per", "se", "or", "its", "metabolites", "formed", "by", "PB", "or", "ethanol", "inducible", "P450", "isoenzymes", "are", "involved", "in", "its", "neurobehavioral", "toxicity", "."]], "ner": [[[2, 2, "Chemical"], [15, 15, "Chemical"], [22, 22, "Chemical"], [125, 125, "Chemical"], [288, 288, "Chemical"], [322, 322, "Chemical"], [335, 335, "Chemical"], [350, 350, "Chemical"], [353, 353, "Chemical"], [290, 290, "Disease"], [324, 324, "Disease"], [343, 343, "Disease"], [17, 17, "Disease"], [372, 372, "Disease"], [80, 82, "Chemical"], [85, 85, "Chemical"], [229, 229, "Chemical"], [264, 266, "Chemical"], [268, 268, "Chemical"], [294, 294, "Chemical"], [307, 307, "Chemical"], [363, 363, "Chemical"], [339, 340, "Chemical"]]], "relations": [[[2, 2, 290, 290, "CID"], [2, 2, 324, 324, "CID"], [2, 2, 343, 343, "CID"], [15, 15, 290, 290, "CID"], [15, 15, 324, 324, "CID"], [15, 15, 343, 343, "CID"], [22, 22, 290, 290, "CID"], [22, 22, 324, 324, "CID"], [22, 22, 343, 343, "CID"], [125, 125, 290, 290, "CID"], [125, 125, 324, 324, "CID"], [125, 125, 343, 343, "CID"], [288, 288, 290, 290, "CID"], [288, 288, 324, 324, "CID"], [288, 288, 343, 343, "CID"], [322, 322, 290, 290, "CID"], [322, 322, 324, 324, "CID"], [322, 322, 343, 343, "CID"], [335, 335, 290, 290, "CID"], [335, 335, 324, 324, "CID"], [335, 335, 343, 343, "CID"], [350, 350, 290, 290, "CID"], [350, 350, 324, 324, "CID"], [350, 350, 343, 343, "CID"], [353, 353, 290, 290, "CID"], [353, 353, 324, 324, "CID"], [353, 353, 343, 343, "CID"]]], "clusters": [], "translated": "<0>林丹</0>对肝脏和脑细胞色素P450的影响以及P450调节对<1>林丹</1>诱导的<12>神经毒性</12>的影响。口服<2>林丹</2>（2.5、5、10和15mg/kg体重）5天后，发现P450依赖性7-乙氧基试卤灵-O-脱乙基酶（EROD）、7-戊氧基试卤灵-O-脱烷基酶（PROD）和<14>N-亚硝基二甲胺</14>脱甲基酶（<15>NDMA</15>-d）的活性呈剂量依赖性增加在大鼠脑和肝脏中。当接触低剂量（2.5 mg/kg）<3>林丹</3>的时间从5天增加到15或21天时，还观察到肝脏和大脑P450单加氧酶显着增加。正如在不同剂量下所观察到的，与大脑相比，肝微粒体中P450单加氧酶活性的诱导幅度要高几倍。Western blotting研究表明，P450酶的增加可能是由于P450 1A1/1A2、2B1/2B2和2E1同工酶表达增加所致。使用对单个P450同工酶具有特异性的有机抑制剂的体外研究和抗体抑制实验进一步证明，PROD、EROD和<16>NDMA</16>-d活性的增加是由于P450 2B1/2B2、1A1/1A2和2E1分别是同工酶。诱导研究进一步表明，虽然预处理P4501A1/1A2的诱导剂<17>3-甲基胆蒽</17>（<18>MC</18>）对<4>林丹</4>诱发<9>惊厥</9>的发生率没有产生任何显着影响，用<19>苯巴比妥</19>（PB）预处理，P4502B1/2B2的诱导剂或<20>乙醇</20>，P450 2E1催化的反应，明显增加了<5>林丹</5>诱发<10>惊厥</10>的发生率。同样，当<22>氯化钴</22>阻断P450介导的<6>林丹</6>代谢时，<7>林丹</7>的动物发生<11>惊厥</11>的发生率增加，说明<8>林丹</8>本身或其由PB或<21>乙醇</21>诱导的P450同工酶形成的代谢物参与其神经行为<13>毒性</13>。", "revised": true}
{"doc_key": "9154656", "sentences": [["Hepatic", "and", "extrahepatic", "angiotensinogen", "gene", "expression", "in", "rats", "with", "acute", "nephrotic", "syndrome", ".", "Plasma", "concentration", "and", "urine", "excretion", "of", "the", "renin", "-", "angiotensin", "system", "proteins", "are", "altered", "in", "rats", "with", "nephrotic", "syndrome", "(", "NS", ")", ".", "In", "this", "work", "the", "messenger", "ribonucleic", "acid", "(", "mRNA", ")", "levels", "of", "angiotensinogen", "(", "Ao", ")", "were", "analyzed", "with", "the", "slot", "-", "blot", "hybridization", "technique", "in", "liver", "and", "other", "extrahepatic", "tissues", ":", "kidney", ",", "heart", ",", "brain", ",", "and", "adrenal", "gland", "from", "control", ",", "nephrotic", ",", "and", "pair", "-", "fed", "(", "PF", ")", "rats", ".", "NS", "was", "induced", "by", "a", "single", "injection", "of", "puromycin", "amino", "-", "nucleoside", "(", "PAN", ")", ".", "Although", "a", "great", "urinary", "excretion", "and", "half", "-", "normal", "plasma", "levels", "of", "Ao", "were", "observed", "on", "day", "6", "after", "PAN", "injection", ",", "when", "NS", "was", "clearly", "established", ",", "hepatic", "Ao", "mRNA", "levels", "did", "not", "change", ".", "Furthermore", ",", "the", "Ao", "mRNA", "levels", "did", "not", "change", "in", "any", "of", "the", "extrahepatic", "tissues", "studied", "on", "day", "6", ",", "nor", "did", "its", "hepatic", "levels", "at", "days", "1", ",", "3", ",", "5", ",", "or", "7", "after", "PAN", "injection", ".", "These", "data", "suggest", "that", "the", "hepatic", "and", "extrahepatic", "Ao", "mRNA", "levels", "are", "unaltered", "during", "the", "development", "of", "the", "acute", "NS", "induced", "by", "PAN", "."]], "ner": [[[99, 102, "Chemical"], [104, 104, "Chemical"], [126, 126, "Chemical"], [179, 179, "Chemical"], [204, 204, "Chemical"], [10, 11, "Disease"], [30, 31, "Disease"], [33, 33, "Disease"], [80, 80, "Disease"], [91, 91, "Disease"], [130, 130, "Disease"], [201, 201, "Disease"], [22, 22, "Chemical"]]], "relations": [[[99, 102, 10, 11, "CID"], [99, 102, 30, 31, "CID"], [99, 102, 33, 33, "CID"], [99, 102, 80, 80, "CID"], [99, 102, 91, 91, "CID"], [99, 102, 130, 130, "CID"], [99, 102, 201, 201, "CID"], [104, 104, 10, 11, "CID"], [104, 104, 30, 31, "CID"], [104, 104, 33, 33, "CID"], [104, 104, 80, 80, "CID"], [104, 104, 91, 91, "CID"], [104, 104, 130, 130, "CID"], [104, 104, 201, 201, "CID"], [126, 126, 10, 11, "CID"], [126, 126, 30, 31, "CID"], [126, 126, 33, 33, "CID"], [126, 126, 80, 80, "CID"], [126, 126, 91, 91, "CID"], [126, 126, 130, 130, "CID"], [126, 126, 201, 201, "CID"], [179, 179, 10, 11, "CID"], [179, 179, 30, 31, "CID"], [179, 179, 33, 33, "CID"], [179, 179, 80, 80, "CID"], [179, 179, 91, 91, "CID"], [179, 179, 130, 130, "CID"], [179, 179, 201, 201, "CID"], [204, 204, 10, 11, "CID"], [204, 204, 30, 31, "CID"], [204, 204, 33, 33, "CID"], [204, 204, 80, 80, "CID"], [204, 204, 91, 91, "CID"], [204, 204, 130, 130, "CID"], [204, 204, 201, 201, "CID"]]], "clusters": [], "translated": "急性<5>肾病综合征</5>大鼠肝内及肝外血管紧张素基因的表达。肾素-<12>血管紧张素</12>系统蛋白的血浆浓度和尿液排泄在患有<6>肾病综合征</6> (<7>NS</7>) 的大鼠中发生改变。在这项工作中，血管紧张素原 (Ao) 的信使核糖核酸 (mRNA) 水平通过狭缝印迹杂交技术在肝脏和其他肝外组织中进行了分析：肾、心脏、脑和肾上腺，来自对照、<8>肾病</8>和配对喂养 (PF) 大鼠。 <9>NS</9>由单次注射<0>嘌呤霉素氨基核苷</0>(<1>PAN</1>)诱导。虽然在<2>PAN</2>注射后第6天观察到大量尿液排泄和血浆Ao水平的一半，但当<10>NS</10>明确建立时，肝脏Ao mRNA水平没有变化。此外，在注射<3>PAN</3>后第1、3、5或7天研究的任何肝外组织中，Ao mRNA水平都没有变化。这些数据表明，肝脏和肝外Ao mRNA水平在急性<11>NS</11>发展过程中由<4>PAN</4>诱导时没有改变。", "revised": true}
{"doc_key": "9165568", "sentences": [["Neuroleptic", "malignant", "syndrome", "with", "risperidone", ".", "Neuroleptic", "malignant", "syndrome", "is", "thought", "to", "be", "a", "result", "of", "dopamine", "D2", "receptor", "blockade", "in", "the", "striatum", "of", "the", "basal", "ganglia", ".", "Risperidone", ",", "a", "benzisoxazole", "derivative", "antipsychotic", ",", "has", "high", "serotonin", "5", "-", "HT2", "receptor", "blockade", "and", "dose", "-", "related", "D2", "receptor", "blockade", ".", "The", "high", "ratio", "is", "believed", "to", "impart", "the", "low", "frequency", "of", "extrapyramidal", "symptoms", "with", "risperidone", "at", "low", "dosages", ".", "With", "this", "low", "frequency", "of", "extrapyramidal", "symptoms", ",", "it", "was", "thought", "the", "frequency", "of", "neuroleptic", "malignant", "syndrome", "might", "also", "be", "lowered", ".", "A", "73", "-", "year", "-", "old", "woman", "developed", "neuroleptic", "malignant", "syndrome", "after", "monotherapy", "with", "risperidone", ".", "The", "syndrome", "reversed", "after", "discontinuing", "risperidone", "and", "starting", "treatment", "with", "dantrolene", "and", "bromocriptine", ".", "It", "appears", "that", "the", "protection", "from", "extrapyramidal", "side", "effects", "observed", "with", "risperidone", "does", "not", "ensure", "protection", "from", "neuroleptic", "malignant", "syndrome", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [65, 65, "Chemical"], [106, 106, "Chemical"], [113, 113, "Chemical"], [133, 133, "Chemical"], [0, 2, "Disease"], [6, 8, "Disease"], [84, 86, "Disease"], [100, 102, "Disease"], [139, 141, "Disease"], [16, 16, "Chemical"], [31, 31, "Chemical"], [37, 37, "Chemical"], [118, 118, "Chemical"], [120, 120, "Chemical"], [62, 63, "Disease"], [75, 76, "Disease"]]], "relations": [[[4, 4, 0, 2, "CID"], [4, 4, 6, 8, "CID"], [4, 4, 84, 86, "CID"], [4, 4, 100, 102, "CID"], [4, 4, 139, 141, "CID"], [28, 28, 0, 2, "CID"], [28, 28, 6, 8, "CID"], [28, 28, 84, 86, "CID"], [28, 28, 100, 102, "CID"], [28, 28, 139, 141, "CID"], [65, 65, 0, 2, "CID"], [65, 65, 6, 8, "CID"], [65, 65, 84, 86, "CID"], [65, 65, 100, 102, "CID"], [65, 65, 139, 141, "CID"], [106, 106, 0, 2, "CID"], [106, 106, 6, 8, "CID"], [106, 106, 84, 86, "CID"], [106, 106, 100, 102, "CID"], [106, 106, 139, 141, "CID"], [113, 113, 0, 2, "CID"], [113, 113, 6, 8, "CID"], [113, 113, 84, 86, "CID"], [113, 113, 100, 102, "CID"], [113, 113, 139, 141, "CID"], [133, 133, 0, 2, "CID"], [133, 133, 6, 8, "CID"], [133, 133, 84, 86, "CID"], [133, 133, 100, 102, "CID"], [133, 133, 139, 141, "CID"]]], "clusters": [], "translated": "<6>抗精神病药物恶性综合征</6>用<0>利培酮</0>。 <7>抗精神病药物恶性综合征</7>被认为是基底神经节纹状体<11>多巴胺</11>D2受体阻滞的结果。 <1>利培酮</1>，一种<12>苯并异恶唑</12>衍生物抗精神病药，具有高<13>血清素</13>5-HT2受体阻滞作用和剂量相关的D2受体阻滞作用。高比率被认为赋予<16>锥体外系症状</16>低剂量<2>利培酮</2>的低频率。由于<17>锥体外系症状</17>的发生率较低，据认为<8>抗精神病药物恶性综合征</8>的发生率也可能降低。一名73岁的女性在接受<3>利培酮</3>单药治疗后出现了<9>抗精神病药物恶性综合征</9>。在停用<4>利培酮</4>并开始使用<14>丹曲林</14>和<15>溴隐亭</15>治疗后，该综合征得到逆转。看来用<5>利培酮</5>观察到的防止锥体外系副作用并不能确保防止<10>抗精神病药恶性综合征</10>。", "revised": true}
{"doc_key": "18356633", "sentences": [["An", "evaluation", "of", "amikacin", "nephrotoxicity", "in", "the", "hematology", "/", "oncology", "population", ".", "Amikacin", "is", "an", "aminoglycoside", "commonly", "used", "to", "provide", "empirical", "double", "gram", "-", "negative", "treatment", "for", "febrile", "neutropenia", "and", "other", "suspected", "infections", ".", "Strategies", "of", "extended", "-", "interval", "and", "conventional", "dosing", "have", "been", "utilized", "extensively", "in", "the", "general", "medical", "population", ";", "however", ",", "data", "are", "lacking", "to", "support", "a", "dosing", "strategy", "in", "the", "hematology", "/", "oncology", "population", ".", "To", "evaluate", "amikacin", "-", "associated", "nephrotoxicity", "in", "an", "adult", "hematology", "/", "oncology", "population", ",", "a", "prospective", ",", "randomized", ",", "open", "-", "label", "trial", "was", "conducted", "at", "a", "university", "-", "affiliated", "medical", "center", ".", "Forty", "patients", "with", "a", "diagnosis", "consistent", "with", "a", "hematologic", "/", "oncologic", "disorder", "that", "required", "treatment", "with", "an", "aminoglycoside", "were", "randomized", "to", "either", "conventional", "or", "extended", "-", "interval", "amikacin", ".", "The", "occurrence", "of", "nephrotoxicity", "by", "means", "of", "an", "increase", "in", "serum", "creatinine", "and", "evaluation", "of", "efficacy", "via", "amikacin", "serum", "concentrations", "with", "respective", "pathogens", "were", "assessed", ".", "The", "occurrence", "of", "nephrotoxicity", "was", "similar", "between", "the", "conventional", "and", "extended", "-", "interval", "groups", ",", "at", "10", "%", "and", "5", "%", ",", "respectively", "(", "P", "=", "1", ".", "00", ")", ".", "Six", "patients", "in", "the", "conventional", "group", "had", "a", "positive", "culture", ",", "compared", "with", "none", "in", "the", "extended", "-", "interval", "group", "(", "P", "=", "0", ".", "002", ")", ".", "The", "occurrence", "of", "nephrotoxicity", "was", "similar", "between", "the", "two", "dosing", "regimens", ",", "but", "the", "distribution", "of", "risk", "factors", "was", "variable", "between", "the", "two", "groups", ".", "Efficacy", "could", "not", "be", "assessed", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [71, 71, "Chemical"], [129, 129, "Chemical"], [148, 148, "Chemical"], [4, 4, "Disease"], [74, 74, "Disease"], [134, 134, "Disease"], [160, 160, "Disease"], [219, 219, "Disease"], [27, 28, "Disease"], [32, 32, "Disease"], [110, 113, "Disease"], [15, 15, "Chemical"], [119, 119, "Chemical"], [142, 142, "Chemical"]]], "relations": [[[3, 3, 4, 4, "CID"], [3, 3, 74, 74, "CID"], [3, 3, 134, 134, "CID"], [3, 3, 160, 160, "CID"], [3, 3, 219, 219, "CID"], [12, 12, 4, 4, "CID"], [12, 12, 74, 74, "CID"], [12, 12, 134, 134, "CID"], [12, 12, 160, 160, "CID"], [12, 12, 219, 219, "CID"], [71, 71, 4, 4, "CID"], [71, 71, 74, 74, "CID"], [71, 71, 134, 134, "CID"], [71, 71, 160, 160, "CID"], [71, 71, 219, 219, "CID"], [129, 129, 4, 4, "CID"], [129, 129, 74, 74, "CID"], [129, 129, 134, 134, "CID"], [129, 129, 160, 160, "CID"], [129, 129, 219, 219, "CID"], [148, 148, 4, 4, "CID"], [148, 148, 74, 74, "CID"], [148, 148, 134, 134, "CID"], [148, 148, 160, 160, "CID"], [148, 148, 219, 219, "CID"]]], "clusters": [], "translated": "<0>阿米卡星</0><5>肾毒性</5>在血液学/肿瘤学人群中的评估。<1>阿米卡星</1>是一种<13>氨基糖苷类</13>，通常用于为<10>发热性中性粒细胞减少症</10>和其他疑似<11>感染</11>提供经验性双革兰氏阴性治疗。延长间隔和常规剂量的策略已在一般医疗人群中得到广泛应用；然而，缺乏支持血液学/肿瘤学人群剂量策略的数据。为了评估成人血液学/肿瘤学人群中<2>阿米卡星</2>-相关的<6>肾毒性</6>，在大学附属医疗中心进行了一项前瞻性、随机、开放标签试验。40 名诊断为<12>血液学/肿瘤学疾病</12>且需要<14>氨基糖苷类</14>治疗的患者被随机分配到常规或延长间隔<3>阿米卡星</3>组。通过血清<15>肌酐</15>的增加以及评估疗效时考虑到的<4>阿米卡星</4>血清浓度和病原体信息，评估<7>肾毒性</7>的发生情况。常规组和延长间隔组之间<8>肾毒性</8>的发生率相似，分别为 10% 和 5% (P = 1.00)。常规组有6名患者培养呈阳性，而延长间隔组则没有 (P = 0.002)。两种给药方案<9>肾毒性</9>的发生率相似，但危险因素的分布在两组间存在差异。无法评估疗效。", "revised": true}
{"doc_key": "6115999", "sentences": [["Adverse", "reactions", "to", "bendrofluazide", "and", "propranolol", "for", "the", "treatment", "of", "mild", "hypertension", ".", "Report", "of", "Medical", "Research", "Council", "Working", "Party", "on", "Mild", "to", "Moderate", "Hypertension", ".", "Participants", "in", "the", "Medical", "Research", "Council", "treatment", "trial", "for", "mild", "hypertension", "are", "randomly", "allocated", "to", "one", "of", "four", "treatment", "groups", ":", "bendrofluazide", ",", "propranolol", ",", "or", "a", "placebo", "for", "either", "of", "these", "drugs", ".", "The", "trial", "is", "single", "-", "blind", ".", "23", "582", "patient", "-", "years", "of", "observation", "have", "been", "completed", "so", "far", ",", "10", "684", "on", "active", "drugs", "and", "12", "898", "on", "placebos", ".", "The", "results", "show", "an", "association", "between", "bendrofluazide", "treatment", "and", "impotence", ",", "and", "impotence", "also", "occurred", "more", "frequently", "in", "patients", "taking", "propranolol", "than", "in", "those", "taking", "placebos", ".", "Other", "adverse", "reactions", "significantly", "linked", "with", "active", "drugs", "include", "impaired", "glucose", "tolerance", "in", "men", "and", "women", "and", "gout", "in", "men", ",", "associated", "with", "bendrofluazide", "treatment", ",", "and", "Raynaud", "'s", "phenomenon", "and", "dyspnoea", "in", "men", "and", "women", "taking", "propranolol", ".", "No", "corneal", "disease", "is", "known", "to", "have", "occurred", "in", "the", "propranolol", "group", ".", "Mean", "serum", "potassium", "level", "fell", ",", "and", "urea", "and", "uric", "acid", "levels", "rose", ",", "in", "men", "and", "women", "taking", "bendrofluazide", ".", "In", "the", "propranolol", "group", ",", "serum", "potassium", "and", "uric", "acid", "levels", "rose", "in", "both", "sexes", ",", "but", "the", "urea", "level", "rose", "significantly", "in", "women", "only", "."]], "ner": [[[3, 3, "Chemical"], [47, 47, "Chemical"], [97, 97, "Chemical"], [141, 141, "Chemical"], [189, 189, "Chemical"], [100, 100, "Disease"], [103, 103, "Disease"], [127, 129, "Disease"], [135, 135, "Disease"], [5, 5, "Chemical"], [49, 49, "Chemical"], [111, 111, "Chemical"], [155, 155, "Chemical"], [167, 167, "Chemical"], [193, 193, "Chemical"], [145, 147, "Disease"], [149, 149, "Disease"], [11, 11, "Disease"], [24, 24, "Disease"], [36, 36, "Disease"], [158, 159, "Disease"], [172, 172, "Chemical"], [197, 197, "Chemical"], [177, 177, "Chemical"], [209, 209, "Chemical"], [179, 180, "Chemical"], [199, 200, "Chemical"]]], "relations": [[[3, 3, 100, 100, "CID"], [3, 3, 103, 103, "CID"], [47, 47, 100, 100, "CID"], [47, 47, 103, 103, "CID"], [97, 97, 100, 100, "CID"], [97, 97, 103, 103, "CID"], [141, 141, 100, 100, "CID"], [141, 141, 103, 103, "CID"], [189, 189, 100, 100, "CID"], [189, 189, 103, 103, "CID"], [3, 3, 127, 129, "CID"], [47, 47, 127, 129, "CID"], [97, 97, 127, 129, "CID"], [141, 141, 127, 129, "CID"], [189, 189, 127, 129, "CID"], [3, 3, 135, 135, "CID"], [47, 47, 135, 135, "CID"], [97, 97, 135, 135, "CID"], [141, 141, 135, 135, "CID"], [189, 189, 135, 135, "CID"], [5, 5, 100, 100, "CID"], [5, 5, 103, 103, "CID"], [49, 49, 100, 100, "CID"], [49, 49, 103, 103, "CID"], [111, 111, 100, 100, "CID"], [111, 111, 103, 103, "CID"], [155, 155, 100, 100, "CID"], [155, 155, 103, 103, "CID"], [167, 167, 100, 100, "CID"], [167, 167, 103, 103, "CID"], [193, 193, 100, 100, "CID"], [193, 193, 103, 103, "CID"], [5, 5, 145, 147, "CID"], [49, 49, 145, 147, "CID"], [111, 111, 145, 147, "CID"], [155, 155, 145, 147, "CID"], [167, 167, 145, 147, "CID"], [193, 193, 145, 147, "CID"], [5, 5, 149, 149, "CID"], [49, 49, 149, 149, "CID"], [111, 111, 149, 149, "CID"], [155, 155, 149, 149, "CID"], [167, 167, 149, 149, "CID"], [193, 193, 149, 149, "CID"]]], "clusters": [], "translated": "<0>苯氟嘧啶</0>和<9>普萘洛尔</9>治疗轻度<17>高血压</17>的不良反应。轻度至中度<18>高血压医学研究委员会工作组报告</18>。医学研究委员会针对轻度<19>高血压</19>的治疗试验的参与者被随机分配到四个治疗组之一： <1>苯氟嘧啶</1>、 <10>普萘洛尔</10>或是上述药物的安慰剂。试验是单盲的。迄今为止，已经完成了23,582患者年的观察，其中10,684例使用活性药物，12,898例使用安慰剂。结果显示<2>苯氟嘧啶</2>治疗与<5>阳痿</5>之间存在关联，服用<11>普萘洛尔</11>的患者发生<6>阳痿</6>的频率也高于服用安慰剂的患者。与活性药物显著相关的其他不良反应包括男性和女性的<7>糖耐量降低</7>与男性的<8>痛风</8>，与<3>苯氟嘧啶</3>治疗相关，以及<12>普萘洛尔</12>在男性和女性服用时出现的<15>雷诺现象</15>和<16>呼吸困难</16>。<13>普萘洛尔</13>组未发生<20>角膜疾病</20>。平均血清<21>钾</21>水平下降，男性和女性服用<4>苯氟嘧啶</4>时出现<7>糖耐量降低</7>，并且<23>尿素</23>和<25>尿酸</25>水平上升。在<14>普萘洛尔</14>组中，男女两性的血清<22>钾</22>和<26>尿酸</26>水平均升高，但<24>尿素</24>水平升高明显仅限于女性。", "revised": true}
{"doc_key": "8911359", "sentences": [["Cyclophosphamide", "associated", "bladder", "cancer", "-", "-", "a", "highly", "aggressive", "disease", ":", "analysis", "of", "12", "cases", ".", "PURPOSE", ":", "We", "gained", "knowledge", "of", "the", "etiology", ",", "treatment", "and", "prevention", "of", "cyclophosphamide", "associated", "urothelial", "cancer", ".", "MATERIALS", "AND", "METHODS", ":", "The", "medical", "records", "of", "6", "men", "and", "6", "women", "(", "mean", "age", "55", "years", ")", "with", "cyclophosphamide", "associated", "bladder", "cancer", "were", "reviewed", ".", "RESULTS", ":", "All", "tumors", "were", "grade", "3", "or", "4", "transitional", "cell", "carcinoma", ".", "Of", "the", "5", "patients", "initially", "treated", "with", "endoscopic", "resection", "alone", "only", "1", "is", "alive", "without", "disease", ".", "Of", "the", "6", "patients", "who", "underwent", "early", "cystectomy", "4", "were", "alive", "at", "24", "to", "111", "months", ".", "The", "remaining", "patient", "with", "extensive", "cancer", "underwent", "partial", "cystectomy", "for", "palliation", "and", "died", "3", "months", "later", ".", "CONCLUSIONS", ":", "Cyclophosphamide", "associated", "bladder", "tumor", "is", "an", "aggressive", "disease", ".", "However", ",", "long", "-", "term", "survival", "is", "possible", "when", "radical", "cystectomy", "is", "performed", "for", "bladder", "tumors", "with", "any", "sign", "of", "invasion", "and", "for", "recurrent", "high", "grade", "disease", ",", "even", "when", "noninvasive", "."]], "ner": [[[0, 0, "Chemical"], [29, 29, "Chemical"], [54, 54, "Chemical"], [127, 127, "Chemical"], [2, 3, "Disease"], [56, 57, "Disease"], [129, 130, "Disease"], [150, 151, "Disease"], [31, 32, "Disease"], [64, 64, "Disease"], [113, 113, "Disease"], [72, 72, "Disease"]]], "relations": [[[0, 0, 2, 3, "CID"], [0, 0, 56, 57, "CID"], [0, 0, 129, 130, "CID"], [0, 0, 150, 151, "CID"], [29, 29, 2, 3, "CID"], [29, 29, 56, 57, "CID"], [29, 29, 129, 130, "CID"], [29, 29, 150, 151, "CID"], [54, 54, 2, 3, "CID"], [54, 54, 56, 57, "CID"], [54, 54, 129, 130, "CID"], [54, 54, 150, 151, "CID"], [127, 127, 2, 3, "CID"], [127, 127, 56, 57, "CID"], [127, 127, 129, 130, "CID"], [127, 127, 150, 151, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0>相关<4>膀胱癌</4> - 一种高度侵袭性疾病：12例分析。目的：我们获得了<1>环磷酰胺</1>相关<8>尿路上皮癌</8>的病因学、治疗和预防知识。材料和方法：回顾了6名男性和6名女性（平均年龄55岁）<2>环磷酰胺</2>相关<5>膀胱癌</5>的医疗记录。结果：所有<9>肿瘤</9>均为3级或4级的移行细胞<11>癌</11>。在最初仅接受内窥镜切除术治疗的5名患者中，只有1名无病生存。在接受早期膀胱切除术的6名患者中，有4名在24至111个月时仍存活。另一名患有广泛性<10>癌症</10>的患者接受了部分膀胱切除术作为姑息治疗，并在3个月后死亡。结论：<3>环磷酰胺</3>相关<6>膀胱肿瘤</6>是一种侵袭性疾病。然而，如果对有任何浸润迹象的<7>膀胱肿瘤</7>和复发性高级别疾病进行根治性膀胱切除术，即使是无创手术，也有可能获得长期生存。", "revised": true}
{"doc_key": "6381653", "sentences": [["Levodopa", "-", "induced", "dyskinesia", "and", "thalamotomy", ".", "Levodopa", "-", "induced", "dyskinesia", "of", "the", "limbs", "in", "thirteen", "cases", "of", "Parkinsonism", ",", "which", "was", "choreic", ",", "ballistic", "or", "dystonic", "in", "type", ",", "was", "alleviated", "almost", "completely", "by", "stereotaxic", "surgery", "using", "a", "microelectrode", "technique", "for", "the", "ventralis", "oralis", "anterior", "and", "posterior", "nuclei", "of", "the", "thalamus", ",", "but", "much", "less", "by", "the", "ventralis", "intermedius", "nucleus", ".", "Control", "of", "levodopa", "-", "induced", "dyskinesias", "by", "thalamic", "lesions", "in", "the", "course", "of", "routine", "treatment", "of", "Parkinsonism", "is", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [7, 7, "Chemical"], [64, 64, "Chemical"], [3, 3, "Disease"], [10, 10, "Disease"], [67, 67, "Disease"], [18, 18, "Disease"], [78, 78, "Disease"], [26, 26, "Disease"], [69, 70, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 10, 10, "CID"], [0, 0, 67, 67, "CID"], [7, 7, 3, 3, "CID"], [7, 7, 10, 10, "CID"], [7, 7, 67, 67, "CID"], [64, 64, 3, 3, "CID"], [64, 64, 10, 10, "CID"], [64, 64, 67, 67, "CID"]]], "clusters": [], "translated": " <0>左旋多巴</0> - 诱发<3>运动障碍</3>和丘脑切开术。<1>左旋多巴</1> - 在13例<6>帕金森病</6>中诱发<4>肢体运动障碍</4>，其类型为舞蹈病、弹道病或<8>肌张力障碍</8>，通过使用微电极技术对丘脑的口腹肌前核和后核进行立体定向手术几乎完全缓解，但腹中间核的缓解效果要差得多。探讨<7>帕金森症</7>常规治疗过程中<2>左旋多巴</2>所致<5>运动障碍</5>的控制和<9>丘脑损伤</9>。", "revised": true}
{"doc_key": "7059267", "sentences": [["Chlorpropamide", "-", "induced", "optic", "neuropathy", ".", "A", "65", "-", "year", "-", "old", "woman", "with", "adult", "-", "onset", "diabetes", "treated", "with", "chlorpropamide", "(", "Diabenese", ")", "had", "a", "toxic", "optic", "neuropathy", "that", "resolved", "with", "discontinuation", "of", "chlorpropamide", "therapy", ".", "Visual", "loss", "occurs", "in", "diabetics", "for", "a", "variety", "of", "reasons", ",", "and", "accurate", "diagnosis", "is", "necessary", "to", "institute", "appropriate", "therapy", ".", "The", "possibility", "of", "a", "drug", "-", "induced", "optic", "neuropathy", "should", "be", "considered", "in", "the", "differential", "diagnosis", "of", "visual", "loss", "in", "diabetics", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [34, 34, "Chemical"], [3, 4, "Disease"], [26, 28, "Disease"], [65, 66, "Disease"], [14, 17, "Disease"], [37, 38, "Disease"], [75, 76, "Disease"], [41, 41, "Disease"], [78, 78, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 26, 28, "CID"], [0, 0, 65, 66, "CID"], [20, 20, 3, 4, "CID"], [20, 20, 26, 28, "CID"], [20, 20, 65, 66, "CID"], [22, 22, 3, 4, "CID"], [22, 22, 26, 28, "CID"], [22, 22, 65, 66, "CID"], [34, 34, 3, 4, "CID"], [34, 34, 26, 28, "CID"], [34, 34, 65, 66, "CID"]]], "clusters": [], "translated": " <0>氯磺脲</0> - 诱发 <4>视神经病变</4>。一名患有<7>成人型糖尿病</7>并接受<1>氯磺丙脲</1> ( <2>Diabenese</2> ) 治疗的 65 岁女性出现了<5>中毒性视神经病变</5>，停止<3>氯磺丙脲</3>治疗即可解决。<8>视力丧失</8>发生在<10>糖尿病患者</10>中的原因有很多，准确的诊断对于制定适当的治疗是必要的。在<11>糖尿病患者</11>的<9>视力丧失</9>的鉴别诊断中，应考虑药物引起的<6>视神经病变</6>的可能性。", "revised": true}
{"doc_key": "15531665", "sentences": [["Does", "supplemental", "vitamin", "C", "increase", "cardiovascular", "disease", "risk", "in", "women", "with", "diabetes", "?", "BACKGROUND", ":", "Vitamin", "C", "acts", "as", "a", "potent", "antioxidant", ";", "however", ",", "it", "can", "also", "be", "a", "prooxidant", "and", "glycate", "protein", "under", "certain", "circumstances", "in", "vitro", ".", "These", "observations", "led", "us", "to", "hypothesize", "that", "a", "high", "intake", "of", "vitamin", "C", "in", "diabetic", "persons", "might", "promote", "atherosclerosis", ".", "OBJECTIVE", ":", "The", "objective", "was", "to", "examine", "the", "relation", "between", "vitamin", "C", "intake", "and", "mortality", "from", "cardiovascular", "disease", ".", "DESIGN", ":", "We", "studied", "the", "relation", "between", "vitamin", "C", "intake", "and", "mortality", "from", "total", "cardiovascular", "disease", "(", "n", "=", "281", ")", ",", "coronary", "artery", "disease", "(", "n", "=", "175", ")", ",", "and", "stroke", "(", "n", "=", "57", ")", "in", "1923", "postmenopausal", "women", "who", "reported", "being", "diabetic", "at", "baseline", ".", "Diet", "was", "assessed", "with", "a", "food", "-", "frequency", "questionnaire", "at", "baseline", ",", "and", "subjects", "initially", "free", "of", "coronary", "artery", "disease", "were", "prospectively", "followed", "for", "15", "y", ".", "RESULTS", ":", "After", "adjustment", "for", "cardiovascular", "disease", "risk", "factors", ",", "type", "of", "diabetes", "medication", "used", ",", "duration", "of", "diabetes", ",", "and", "intakes", "of", "folate", ",", "vitamin", "E", ",", "and", "beta", "-", "carotene", ",", "the", "adjusted", "relative", "risks", "of", "total", "cardiovascular", "disease", "mortality", "were", "1", ".", "0", ",", "0", ".", "97", ",", "1", ".", "11", ",", "1", ".", "47", ",", "and", "1", ".", "84", "(", "P", "for", "trend", "<", "0", ".", "01", ")", "across", "quintiles", "of", "total", "vitamin", "C", "intake", "from", "food", "and", "supplements", ".", "Adjusted", "relative", "risks", "of", "coronary", "artery", "disease", "were", "1", ".", "0", ",", "0", ".", "81", ",", "0", ".", "99", ",", "1", ".", "26", ",", "and", "1", ".", "91", "(", "P", "for", "trend", "=", "0", ".", "01", ")", "and", "of", "stroke", "were", "1", ".", "0", ",", "0", ".", "52", ",", "1", ".", "23", ",", "2", ".", "22", ",", "and", "2", ".", "57", "(", "P", "for", "trend", "<", "0", ".", "01", ")", ".", "When", "dietary", "and", "supplemental", "vitamin", "C", "were", "analyzed", "separately", ",", "only", "supplemental", "vitamin", "C", "showed", "a", "positive", "association", "with", "mortality", "endpoints", ".", "Vitamin", "C", "intake", "was", "unrelated", "to", "mortality", "from", "cardiovascular", "disease", "in", "the", "nondiabetic", "subjects", "at", "baseline", ".", "CONCLUSION", ":", "A", "high", "vitamin", "C", "intake", "from", "supplements", "is", "associated", "with", "an", "increased", "risk", "of", "cardiovascular", "disease", "mortality", "in", "postmenopausal", "women", "with", "diabetes", "."]], "ner": [[[2, 3, "Chemical"], [15, 16, "Chemical"], [51, 52, "Chemical"], [70, 71, "Chemical"], [86, 87, "Chemical"], [231, 232, "Chemical"], [314, 315, "Chemical"], [322, 323, "Chemical"], [332, 333, "Chemical"], [353, 354, "Chemical"], [5, 6, "Disease"], [76, 77, "Disease"], [93, 94, "Disease"], [160, 161, "Disease"], [194, 195, "Disease"], [340, 341, "Disease"], [365, 366, "Disease"], [11, 11, "Disease"], [54, 54, "Disease"], [124, 124, "Disease"], [167, 167, "Disease"], [173, 173, "Disease"], [372, 372, "Disease"], [58, 58, "Disease"], [101, 103, "Disease"], [145, 147, "Disease"], [243, 245, "Disease"], [111, 111, "Disease"], [278, 278, "Disease"], [178, 178, "Chemical"], [180, 181, "Chemical"], [184, 186, "Chemical"]]], "relations": [[[2, 3, 5, 6, "CID"], [2, 3, 76, 77, "CID"], [2, 3, 93, 94, "CID"], [2, 3, 160, 161, "CID"], [2, 3, 194, 195, "CID"], [2, 3, 340, 341, "CID"], [2, 3, 365, 366, "CID"], [15, 16, 5, 6, "CID"], [15, 16, 76, 77, "CID"], [15, 16, 93, 94, "CID"], [15, 16, 160, 161, "CID"], [15, 16, 194, 195, "CID"], [15, 16, 340, 341, "CID"], [15, 16, 365, 366, "CID"], [51, 52, 5, 6, "CID"], [51, 52, 76, 77, "CID"], [51, 52, 93, 94, "CID"], [51, 52, 160, 161, "CID"], [51, 52, 194, 195, "CID"], [51, 52, 340, 341, "CID"], [51, 52, 365, 366, "CID"], [70, 71, 5, 6, "CID"], [70, 71, 76, 77, "CID"], [70, 71, 93, 94, "CID"], [70, 71, 160, 161, "CID"], [70, 71, 194, 195, "CID"], [70, 71, 340, 341, "CID"], [70, 71, 365, 366, "CID"], [86, 87, 5, 6, "CID"], [86, 87, 76, 77, "CID"], [86, 87, 93, 94, "CID"], [86, 87, 160, 161, "CID"], [86, 87, 194, 195, "CID"], [86, 87, 340, 341, "CID"], [86, 87, 365, 366, "CID"], [231, 232, 5, 6, "CID"], [231, 232, 76, 77, "CID"], [231, 232, 93, 94, "CID"], [231, 232, 160, 161, "CID"], [231, 232, 194, 195, "CID"], [231, 232, 340, 341, "CID"], [231, 232, 365, 366, "CID"], [314, 315, 5, 6, "CID"], [314, 315, 76, 77, "CID"], [314, 315, 93, 94, "CID"], [314, 315, 160, 161, "CID"], [314, 315, 194, 195, "CID"], [314, 315, 340, 341, "CID"], [314, 315, 365, 366, "CID"], [322, 323, 5, 6, "CID"], [322, 323, 76, 77, "CID"], [322, 323, 93, 94, "CID"], [322, 323, 160, 161, "CID"], [322, 323, 194, 195, "CID"], [322, 323, 340, 341, "CID"], [322, 323, 365, 366, "CID"], [332, 333, 5, 6, "CID"], [332, 333, 76, 77, "CID"], [332, 333, 93, 94, "CID"], [332, 333, 160, 161, "CID"], [332, 333, 194, 195, "CID"], [332, 333, 340, 341, "CID"], [332, 333, 365, 366, "CID"], [353, 354, 5, 6, "CID"], [353, 354, 76, 77, "CID"], [353, 354, 93, 94, "CID"], [353, 354, 160, 161, "CID"], [353, 354, 194, 195, "CID"], [353, 354, 340, 341, "CID"], [353, 354, 365, 366, "CID"]]], "clusters": [], "translated": "补充<0>维生素 C</0>会增加患有<17>糖尿病</17>的女性的<10>心血管疾病</10>风险吗？背景：<1>维生素C</1>是一种有效的抗氧化剂；然而，它在体外某些情况下也可以是一种促氧化剂和糖酸盐蛋白。这些观察结果使我们假设，患有<18>糖尿病</18>的人大量摄入<2>维生素 C</2>可能会促进<23>动脉粥样硬化</23>。目的：目的是检查<3>维生素 C</3>摄入量与<11>心血管疾病</11>死亡率之间的关系。设计：我们研究了<4>维生素 C</4>摄入量与总<12>心血管疾病</12>（n=281）、<24>冠状动脉疾病</24>（n=175）和<27>中风</27>（n=57）在1923名报告基线时患有<19>糖尿病</19>的绝经后妇女中。在基线时使用食物频率问卷评估饮食，对最初没有<25>冠状动脉疾病</25>的受试者进行15年的前瞻性随访。结果：调整了<13>心血管疾病</13>危险因素、<20>糖尿病</20>类型、<21>糖尿病</21>病程和<29>叶酸</29>摄入量、<30>维生素E</30>和<31>β-胡萝卜素</31>，总<14>心血管疾病</14>死亡率调整后的相对风险为1.0、0.97、1.11、1.47和1.84（趋势P<0.01）横跨食物和补充剂总<5>维生素 C</5>摄入量的五分位数。调整后<26>冠状动脉疾病</26>的相对风险为1.0、0.81、0.99、1.26和1.91（趋势P=0.01）,<28>中风</28>的相对风险为1.0、0.52、1.23、2.22和2.57（趋势P<0.01）。当分别分析饮食和补充<6>维生素 C</6>时，只有补充<7>维生素 C</7>与死亡率终点呈正相关。<8>维生素 C</8>摄入量与基线时非糖尿病受试者因<15>心血管疾病</15>引起的死亡率无关。结论：对于患有<22>糖尿病</22>的绝经后妇女，从补充剂中摄入大量的<9>维生素 C</9>与<16>心血管疾病</16>死亡率的风险增加有关。", "revised": true}
{"doc_key": "9514561", "sentences": [["Experimental", "cranial", "pain", "elicited", "by", "capsaicin", ":", "a", "PET", "study", ".", "Using", "a", "positron", "emission", "tomography", "(", "PET", ")", "study", "it", "was", "shown", "recently", "that", "in", "migraine", "without", "aura", "certain", "areas", "in", "the", "brain", "stem", "were", "activated", "during", "the", "headache", "state", ",", "but", "not", "in", "the", "headache", "free", "interval", ".", "It", "was", "suggested", "that", "this", "brain", "stem", "activation", "is", "inherent", "to", "the", "migraine", "attack", "itself", "and", "represents", "the", "so", "called", "'", "migraine", "generator", "'", ".", "To", "test", "this", "hypothesis", "we", "performed", "an", "experimental", "pain", "study", "in", "seven", "healthy", "volunteers", ",", "using", "the", "same", "positioning", "in", "the", "PET", "scanner", "as", "in", "the", "migraine", "patients", ".", "A", "small", "amount", "of", "capsaicin", "was", "administered", "subcutaneously", "in", "the", "right", "forehead", "to", "evoke", "a", "burning", "painful", "sensation", "in", "the", "first", "division", "of", "the", "trigeminal", "nerve", ".", "Increases", "of", "regional", "cerebral", "blood", "flow", "(", "rCBF", ")", "were", "found", "bilaterally", "in", "the", "insula", ",", "in", "the", "anterior", "cingulate", "cortex", ",", "the", "cavernous", "sinus", "and", "the", "cerebellum", ".", "Using", "the", "same", "stereotactic", "space", "limits", "as", "in", "the", "above", "mentioned", "migraine", "study", "no", "brain", "stem", "activation", "was", "found", "in", "the", "acute", "pain", "state", "compared", "to", "the", "pain", "free", "state", ".", "The", "increase", "of", "activation", "in", "the", "region", "of", "the", "cavernous", "sinus", "however", ",", "suggests", "that", "this", "structure", "is", "more", "likely", "to", "be", "involved", "in", "trigeminal", "transmitted", "pain", "as", "such", ",", "rather", "than", "in", "a", "specific", "type", "of", "headache", "as", "was", "suggested", "for", "cluster", "headache", "."]], "ner": [[[5, 5, "Chemical"], [108, 108, "Chemical"], [2, 2, "Disease"], [83, 83, "Disease"], [120, 120, "Disease"], [182, 182, "Disease"], [187, 187, "Disease"], [217, 217, "Disease"], [26, 26, "Disease"], [62, 62, "Disease"], [71, 71, "Disease"], [101, 101, "Disease"], [171, 171, "Disease"], [39, 39, "Disease"], [46, 46, "Disease"], [228, 228, "Disease"], [233, 234, "Disease"]]], "relations": [[[5, 5, 2, 2, "CID"], [5, 5, 83, 83, "CID"], [5, 5, 120, 120, "CID"], [5, 5, 182, 182, "CID"], [5, 5, 187, 187, "CID"], [5, 5, 217, 217, "CID"], [108, 108, 2, 2, "CID"], [108, 108, 83, 83, "CID"], [108, 108, 120, 120, "CID"], [108, 108, 182, 182, "CID"], [108, 108, 187, 187, "CID"], [108, 108, 217, 217, "CID"]]], "clusters": [], "translated": "由<0>辣椒素</0>引起的实验性颅骨<2>疼痛</2>：一项PET研究。使用正电子发射断层扫描(PET)研究最近表明，在<8>无先兆偏头痛</8>中，脑干的某些区域在<13>头痛</13>状态期间被激活，但在<14>头痛</14>无间期。有人提出，这种脑干激活是<9>偏头痛</9>发作本身所固有的，代表了所谓的“<10>偏头痛</10>发生器”。为了检验这一假设，我们在7名健康志愿者中进行了实验性<3>疼痛</3>研究，使用与<11>偏头痛</11>患者相同的PET扫描仪定位。在右前额皮下注射少量<1>辣椒素</1>，在三叉神经第一支引起灼痛<4>痛</4>感。双侧脑岛、前扣带皮层、海绵窦和小脑局部脑血流量(rCBF)增加。使用与上述<12>偏头痛</12>研究中相同的立体定向空间限制，与<6>疼痛</6>自由相比，在急性<5>疼痛</5>状态下未发现脑干激活状态。然而，海绵窦区域激活的增加表明该结构更可能涉及三叉神经传递的<7>疼痛</7>本身，而不是特定类型的<15>头痛</15>，如针对<16>丛集性头痛</16>的建议。", "revised": true}
{"doc_key": "2051906", "sentences": [["Reversible", "cholestasis", "with", "bile", "duct", "injury", "following", "azathioprine", "therapy", ".", "A", "case", "report", ".", "A", "67", "-", "year", "-", "old", "patient", ",", "with", "primary", "polymyositis", "and", "without", "previous", "evidence", "of", "liver", "disease", ",", "developed", "clinical", "and", "biochemical", "features", "of", "severe", "cholestasis", "3", "months", "after", "initiation", "of", "azathioprine", "therapy", ".", "Liver", "biopsy", "showed", "cholestasis", "with", "both", "cytological", "and", "architectural", "alterations", "of", "interlobular", "bile", "ducts", ".", "Azathioprine", "withdrawal", "resulted", "after", "7", "weeks", "in", "the", "resolution", "of", "clinical", "and", "biochemical", "abnormalities", ".", "It", "is", "believed", "that", "this", "is", "the", "first", "reported", "case", "of", "reversible", "azathioprine", "-", "induced", "cholestasis", "associated", "with", "histological", "evidence", "of", "bile", "duct", "injury", "."]], "ner": [[[7, 7, "Chemical"], [46, 46, "Chemical"], [64, 64, "Chemical"], [91, 91, "Chemical"], [1, 1, "Disease"], [3, 5, "Disease"], [40, 40, "Disease"], [52, 52, "Disease"], [94, 94, "Disease"], [100, 102, "Disease"], [24, 24, "Disease"], [30, 31, "Disease"]]], "relations": [[[7, 7, 1, 1, "CID"], [7, 7, 3, 5, "CID"], [7, 7, 40, 40, "CID"], [7, 7, 52, 52, "CID"], [7, 7, 94, 94, "CID"], [7, 7, 100, 102, "CID"], [46, 46, 1, 1, "CID"], [46, 46, 3, 5, "CID"], [46, 46, 40, 40, "CID"], [46, 46, 52, 52, "CID"], [46, 46, 94, 94, "CID"], [46, 46, 100, 102, "CID"], [64, 64, 1, 1, "CID"], [64, 64, 3, 5, "CID"], [64, 64, 40, 40, "CID"], [64, 64, 52, 52, "CID"], [64, 64, 94, 94, "CID"], [64, 64, 100, 102, "CID"], [91, 91, 1, 1, "CID"], [91, 91, 3, 5, "CID"], [91, 91, 40, 40, "CID"], [91, 91, 52, 52, "CID"], [91, 91, 94, 94, "CID"], [91, 91, 100, 102, "CID"]]], "clusters": [], "translated": "<0>硫唑嘌呤</0>治疗后可逆性<4>胆汁淤积</4>伴有<5>胆管损伤</5>。个案报告。一位 67 岁的患者，患有原发性<10>多发性肌炎</10>并且之前没有<11>肝脏疾病</11>的证据，在<1>硫唑嘌呤</1>治疗开始后3个月出现了严重<6>胆汁淤积</6>的临床和生化特征。肝活检显示<7>胆汁淤积</7>，伴有小叶间胆管的细胞学和结构改变。<2>硫唑嘌呤</2>停药7周后临床和生化异常得到解决。据信，这是首例报道的可逆性<3>硫唑嘌呤</3>-诱导的<8>胆汁淤积</8>，并伴有<9>胆管损伤</9>的组织学证据。", "revised": true}
{"doc_key": "3950060", "sentences": [["Factors", "associated", "with", "nephrotoxicity", "and", "clinical", "outcome", "in", "patients", "receiving", "amikacin", ".", "Data", "from", "60", "patients", "treated", "with", "amikacin", "were", "analyzed", "for", "factors", "associated", "with", "nephrotoxicity", ".", "In", "42", "of", "these", "patients", ",", "data", "were", "examined", "for", "factors", "associated", "with", "clinical", "outcome", ".", "Variables", "evaluated", "included", "patient", "weight", ",", "age", ",", "sex", ",", "serum", "creatinine", "level", ",", "creatinine", "clearance", ",", "duration", "of", "therapy", ",", "total", "dose", ",", "mean", "daily", "dose", ",", "organism", "minimum", "inhibitory", "concentration", "(", "MIC", ")", ",", "mean", "peak", "levels", ",", "mean", "trough", "levels", ",", "mean", "area", "under", "the", "serum", "concentration", "-", "time", "curve", "(", "AUC", ")", ",", "total", "AUC", ",", "mean", "AUC", "greater", "than", "MIC", ",", "total", "AUC", "greater", "than", "MIC", ",", "mean", "Schumacher", "'s", "intensity", "factor", "(", "IF", ")", ",", "total", "IF", ",", "In", "(", "mean", "maximum", "concentration", "[", "Cmax", "]", "/", "MIC", ")", ".", "Model", "-", "dependent", "pharmacokinetic", "parameters", "were", "calculated", "by", "computer", "based", "on", "a", "one", "-", "compartment", "model", ".", "When", "the", "parameters", "were", "examined", "individually", ",", "duration", "of", "therapy", "and", "total", "AUC", "correlated", "significantly", "(", "P", "less", "than", ".", "05", ")", "with", "nephrotoxicity", ".", "In", "contrast", ",", "a", "stepwise", "discriminant", "function", "analysis", "identified", "only", "duration", "of", "therapy", "(", "P", "less", "than", ".", "001", ")", "as", "an", "important", "factor", ".", "Based", "on", "this", "model", "and", "on", "Bayes", "'", "theorem", ",", "the", "predictive", "accuracy", "of", "identifying", "\"", "nephrotoxic", "\"", "patients", "increased", "from", "0", ".", "17", "to", "0", ".", "39", ".", "When", "examined", "individually", ",", "mean", "IF", ",", "MIC", ",", "total", "dose", ",", "mean", "daily", "dose", ",", "and", "ln", "(", "mean", "Cmax", "/", "MIC", ")", "correlated", "significantly", "(", "P", "less", "than", ".", "05", ")", "with", "cure", ".", "In", "contrast", ",", "a", "simultaneous", "multivariable", "analysis", "identified", "IF", ",", "MIC", ",", "and", "total", "dose", "according", "to", "one", "model", "and", "ln", "(", "mean", "Cmax", "/", "MIC", ")", "according", "to", "a", "second", "statistical", "model", "of", "parameters", "selected", "to", "have", "the", "greatest", "prospective", "value", ".", "Based", "on", "Bayes", "'", "theorem", "and", "the", "first", "model", ",", "the", "predictive", "accuracy", "of", "identifying", "patients", "not", "cured", "increased", "from", "0", ".", "19", "to", "0", ".", "83", ".", "For", "the", "second", "model", ",", "the", "predictive", "accuracy", "increased", "from", "0", ".", "19", "to", "0", ".", "50", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[10, 10, "Chemical"], [18, 18, "Chemical"], [3, 3, "Disease"], [25, 25, "Disease"], [179, 179, "Disease"], [222, 222, "Disease"], [54, 54, "Chemical"], [57, 57, "Chemical"]]], "relations": [[[10, 10, 3, 3, "CID"], [10, 10, 25, 25, "CID"], [10, 10, 179, 179, "CID"], [10, 10, 222, 222, "CID"], [18, 18, 3, 3, "CID"], [18, 18, 25, 25, "CID"], [18, 18, 179, 179, "CID"], [18, 18, 222, 222, "CID"]]], "clusters": [], "translated": "接受<0>阿米卡星</0>治疗的患者<2>肾毒性</2>和临床结果的相关因素。分析了60名接受<1>阿米卡星</1>治疗的患者的数据，以了解与<3>肾毒性</3>相关的因素。在其中42名患者中，检查了与临床结果相关的因素的数据。评估的变量包括患者体重、年龄、性别、血清<6>肌酐</6>水平、<7>肌酐</7>清除率、治疗持续时间、总剂量、平均日剂量、生物体最低抑菌浓度（MIC）、平均峰水平、平均谷水平、平均血清浓度-时间曲线下面积（AUC）、总AUC、平均AUC大于MIC、总AUC大于MIC、平均舒马赫强度因子（IF）、总IF、In（平均最大浓度[Cmax]/MIC）。模型依赖性药代动力学参数是根据单室模型通过计算机计算的。当单独检查参数时，治疗持续时间和总AUC与<4>肾毒性</4>显着相关（P小于.05）。相比之下，逐步判别函数分析仅将治疗持续时间（P小于.001）确定为一个重要因素。基于该模型和贝叶斯定理，识别“<5>肾毒性</5>”患者的预测准确度从0.17增加到0.39。当单独检查时，平均IF、MIC、总剂量、平均日剂量和ln（平均Cmax/MIC）与治愈显着相关（P小于.05）。相比之下，同步多变量分析根据一个模型确定IF、MIC和总剂量，根据选择具有最大预期值的参数的第二个统计模型确定ln（平均Cmax/MIC）。基于贝叶斯定理和第一个模型，识别未治愈患者的预测准确度从0.19增加到0.83。对于第二个模型，预测准确度从0.19增加到0.50。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "1445986", "sentences": [["Cefotetan", "-", "induced", "immune", "hemolytic", "anemia", ".", "Immune", "hemolytic", "anemia", "due", "to", "a", "drug", "-", "adsorption", "mechanism", "has", "been", "described", "primarily", "in", "patients", "receiving", "penicillins", "and", "first", "-", "generation", "cephalosporins", ".", "We", "describe", "a", "patient", "who", "developed", "anemia", "while", "receiving", "intravenous", "cefotetan", ".", "Cefotetan", "-", "dependent", "antibodies", "were", "detected", "in", "the", "patient", "'s", "serum", "and", "in", "an", "eluate", "prepared", "from", "his", "red", "blood", "cells", ".", "The", "eluate", "also", "reacted", "weakly", "with", "red", "blood", "cells", "in", "the", "absence", "of", "cefotetan", ",", "suggesting", "the", "concomitant", "formation", "of", "warm", "-", "reactive", "autoantibodies", ".", "These", "observations", ",", "in", "conjunction", "with", "clinical", "and", "laboratory", "evidence", "of", "extravascular", "hemolysis", ",", "are", "consistent", "with", "drug", "-", "induced", "hemolytic", "anemia", ",", "possibly", "involving", "both", "drug", "-", "adsorption", "and", "autoantibody", "formation", "mechanisms", ".", "This", "case", "emphasizes", "the", "need", "for", "increased", "awareness", "of", "hemolytic", "reactions", "to", "all", "cephalosporins", "."]], "ner": [[[0, 0, "Chemical"], [41, 41, "Chemical"], [43, 43, "Chemical"], [78, 78, "Chemical"], [4, 5, "Disease"], [8, 9, "Disease"], [110, 111, "Disease"], [37, 37, "Disease"], [102, 102, "Disease"], [24, 24, "Chemical"], [29, 29, "Chemical"], [137, 137, "Chemical"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 8, 9, "CID"], [0, 0, 110, 111, "CID"], [41, 41, 4, 5, "CID"], [41, 41, 8, 9, "CID"], [41, 41, 110, 111, "CID"], [43, 43, 4, 5, "CID"], [43, 43, 8, 9, "CID"], [43, 43, 110, 111, "CID"], [78, 78, 4, 5, "CID"], [78, 78, 8, 9, "CID"], [78, 78, 110, 111, "CID"]]], "clusters": [], "translated": "<0>头孢替坦</0>——诱发免疫性<4>溶血性贫血</4>。由于药物吸附机制导致的免疫性<5>溶血性贫血</5>主要发生在接受<9>青霉素</9>和第一代<10>头孢菌素</10>的患者中。我们描述了一名患者，他在接受静脉注射<1>头孢替坦</1>治疗时出现了<7>贫血</7>。 <2>头孢替坦</2>依赖性抗体在患者的血清和从他的红细胞制备的洗脱液中检测到。在<3>头孢替坦</3>不存在的情况下，洗脱液也与红细胞发生微弱反应，表明同时形成了温反应性自身抗体。这些观察结果与临床和实验室证据表明<8>血管外溶血</8>的一致，提示药物诱导的<6>溶血性贫血</6>，可能涉及药物吸附和自身抗体形成机制。该病例强调需要提高对所有<11>头孢菌素</11>溶血反应的认识。", "revised": true}
{"doc_key": "2021202", "sentences": [["Renal", "function", "and", "hemodynamics", "during", "prolonged", "isoflurane", "-", "induced", "hypotension", "in", "humans", ".", "The", "effect", "of", "isoflurane", "-", "induced", "hypotension", "on", "glomerular", "function", "and", "renal", "blood", "flow", "was", "investigated", "in", "20", "human", "subjects", ".", "Glomerular", "filtration", "rate", "(", "GFR", ")", "and", "effective", "renal", "plasma", "flow", "(", "ERPF", ")", "were", "measured", "by", "inulin", "and", "para", "-", "aminohippurate", "(", "PAH", ")", "clearance", ",", "respectively", ".", "Anesthesia", "was", "maintained", "with", "fentanyl", ",", "nitrous", "oxide", ",", "oxygen", ",", "and", "isoflurane", ".", "Hypotension", "was", "induced", "for", "236", ".", "9", "+", "/", "-", "15", ".", "1", "min", "by", "increasing", "the", "isoflurane", "inspired", "concentration", "to", "maintain", "a", "mean", "arterial", "pressure", "of", "59", ".", "8", "+", "/", "-", "0", ".", "4", "mmHg", ".", "GFR", "and", "ERPF", "decreased", "with", "the", "induction", "of", "anesthesia", "but", "not", "significantly", "more", "during", "hypotension", ".", "Postoperatively", ",", "ERPF", "returned", "to", "preoperative", "values", ",", "whereas", "GFR", "was", "higher", "than", "preoperative", "values", ".", "Renal", "vascular", "resistance", "increased", "during", "anesthesia", "but", "decreased", "when", "hypotension", "was", "induced", ",", "allowing", "the", "maintenance", "of", "renal", "blood", "flow", ".", "We", "conclude", "that", "renal", "compensatory", "mechanisms", "are", "preserved", "during", "isoflurane", "-", "induced", "hypotension", "and", "that", "renal", "function", "and", "hemodynamics", "quickly", "return", "to", "normal", "when", "normotension", "is", "resumed", "."]], "ner": [[[6, 6, "Chemical"], [16, 16, "Chemical"], [75, 75, "Chemical"], [94, 94, "Chemical"], [177, 177, "Chemical"], [9, 9, "Disease"], [19, 19, "Disease"], [77, 77, "Disease"], [129, 129, "Disease"], [156, 156, "Disease"], [180, 180, "Disease"], [53, 55, "Chemical"], [57, 57, "Chemical"], [67, 67, "Chemical"], [69, 70, "Chemical"], [72, 72, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 19, 19, "CID"], [6, 6, 77, 77, "CID"], [6, 6, 129, 129, "CID"], [6, 6, 156, 156, "CID"], [6, 6, 180, 180, "CID"], [16, 16, 9, 9, "CID"], [16, 16, 19, 19, "CID"], [16, 16, 77, 77, "CID"], [16, 16, 129, 129, "CID"], [16, 16, 156, 156, "CID"], [16, 16, 180, 180, "CID"], [75, 75, 9, 9, "CID"], [75, 75, 19, 19, "CID"], [75, 75, 77, 77, "CID"], [75, 75, 129, 129, "CID"], [75, 75, 156, 156, "CID"], [75, 75, 180, 180, "CID"], [94, 94, 9, 9, "CID"], [94, 94, 19, 19, "CID"], [94, 94, 77, 77, "CID"], [94, 94, 129, 129, "CID"], [94, 94, 156, 156, "CID"], [94, 94, 180, 180, "CID"], [177, 177, 9, 9, "CID"], [177, 177, 19, 19, "CID"], [177, 177, 77, 77, "CID"], [177, 177, 129, 129, "CID"], [177, 177, 156, 156, "CID"], [177, 177, 180, 180, "CID"]]], "clusters": [], "translated": "长期<0>异氟醚</0>期间的肾功能和血液动力学 - 导致人类<5>低血压</5>。在20名受试者中研究了<1>异氟烷</1>引起的<6>低血压</6>对肾小球功能和肾血流量的影响。分别通过菊糖和<11>对氨基马尿酸</11>(<12>PAH</12>)清除率测定肾小球滤过率(GFR)和有效肾血浆流量(ERPF)。使用<13>芬太尼</13>、<14>一氧化氮</14>、<15>氧气</15>和<2>异氟醚</2>维持麻醉。<7>低血压</7>被诱发了236.9+/-15.1分钟，通过增加<3>异氟醚</3>吸入浓度维持平均动脉压59.8+/-0.4毫米汞柱。GFR和ERPF随麻醉诱导而降低，但在<8>低血压</8>期间没有显着增加。术后，ERPF恢复到术前值，而GFR高于术前值。肾血管阻力在麻醉期间增加，但当<9>低血压</9>被诱导时，肾血管阻力降低，从而维持肾血流。我们得出结论，在<4>异氟醚</4>引起的<10>低血压</10>期间，肾脏代偿机制得以保留，并且当血压恢复正常时，肾功能和血流动力学会迅速恢复正常。", "revised": true}
{"doc_key": "3311455", "sentences": [["Cardiac", "transplantation", ":", "improved", "quality", "of", "survival", "with", "a", "modified", "immunosuppressive", "protocol", ".", "The", "effects", "on", "renal", "function", "on", "two", "different", "immunosuppressive", "protocols", "were", "evaluated", "retrospectively", "in", "two", "subsequent", "groups", "of", "heart", "transplant", "recipients", ".", "In", "group", "I", ",", "cyclosporine", "was", "given", "before", "the", "procedure", "at", "a", "loading", "dose", "of", "17", ".", "5", "mg", "/", "kg", "and", "then", "continued", "after", "the", "procedure", "to", "keep", "a", "whole", "blood", "level", "about", "1000", "ng", "/", "ml", ".", "In", "group", "II", ",", "cyclosporine", "was", "started", "only", "after", "the", "procedure", "at", "a", "lower", "dosage", "and", "was", "complemented", "by", "azathioprine", ",", "which", "was", "used", "for", "the", "first", "postoperative", "week", ".", "Group", "II", "showed", "a", "better", "perioperative", "renal", "function", "as", "determined", "by", "serum", "blood", "urea", "nitrogen", "and", "serum", "creatinine", "levels", ".", "Group", "II", "also", "showed", "a", "significant", "decrease", "of", "chronic", "nephrotoxicity", "secondary", "to", "long", "-", "term", "therapy", "with", "cyclosporine", ".", "Despite", "this", "improvement", "in", "late", "renal", "function", ",", "group", "II", "still", "shows", "a", "slow", "rise", "in", "serum", "creatinine", ".", "We", "think", "that", "even", "these", "lower", "dosages", "of", "cyclosporine", "can", "cause", "chronic", "nephrotoxicity", "and", "that", "further", "modification", "of", "the", "immunosuppressive", "regimen", "is", "required", "to", "completely", "abolish", "this", "toxic", "side", "effect", "."]], "ner": [[[39, 39, "Chemical"], [78, 78, "Chemical"], [141, 141, "Chemical"], [170, 170, "Chemical"], [133, 133, "Disease"], [174, 174, "Disease"], [93, 93, "Chemical"], [117, 118, "Chemical"], [121, 121, "Chemical"], [160, 160, "Chemical"]]], "relations": [[[39, 39, 133, 133, "CID"], [39, 39, 174, 174, "CID"], [78, 78, 133, 133, "CID"], [78, 78, 174, 174, "CID"], [141, 141, 133, 133, "CID"], [141, 141, 174, 174, "CID"], [170, 170, 133, 133, "CID"], [170, 170, 174, 174, "CID"]]], "clusters": [], "translated": "心脏移植：改进的免疫抑制方案提高了生存质量。在随后的两组心脏移植受者中回顾性评估了两种不同免疫抑制方案对肾功能的影响。I组术前给予<0>环孢素</0>负荷剂量 17.5 mg/kg，然后在手术后继续保持全血浓度在1000 ng/ml 左右。在II组中，<1>环孢菌素</1>仅在手术后以较低剂量开始，并辅之以<6>硫唑嘌呤</6>，用于术后第一周。根据血清<7>尿素氮</7>和血清<8>肌酐</8>水平，II组显示出更好的围手术期肾功能。第II组还显示显着降低的慢性<4>肾毒性</4>，这是由于长期接受<2>环孢菌素</2>治疗导致的。尽管II组的晚期肾功能有所改善，但血清<9>肌酐</9>仍然缓慢上升。我们认为，即使是这些较低剂量的<3>环孢菌素</3>也会导致慢性<5>肾毒性</5>，并且需要进一步修改免疫抑制方案以完全消除这种毒副作用。", "revised": true}
{"doc_key": "1848636", "sentences": [["Debrisoquine", "phenotype", "and", "the", "pharmacokinetics", "and", "beta", "-", "2", "receptor", "pharmacodynamics", "of", "metoprolol", "and", "its", "enantiomers", ".", "The", "metabolism", "of", "the", "cardioselective", "beta", "-", "blocker", "metoprolol", "is", "under", "genetic", "control", "of", "the", "debrisoquine", "/", "sparteine", "type", ".", "The", "two", "metabolic", "phenotypes", ",", "extensive", "(", "EM", ")", "and", "poor", "metabolizers", "(", "PM", ")", ",", "show", "different", "stereoselective", "metabolism", ",", "resulting", "in", "apparently", "higher", "beta", "-", "1", "adrenoceptor", "antagonistic", "potency", "of", "racemic", "metoprolol", "in", "EMs", ".", "We", "investigated", "if", "the", "latter", "also", "applies", "to", "the", "beta", "-", "2", "adrenoceptor", "antagonism", "by", "metoprolol", ".", "The", "drug", "effect", "studied", "was", "the", "antagonism", "by", "metoprolol", "of", "terbutaline", "-", "induced", "hypokalemia", ".", "By", "using", "pharmacokinetic", "pharmacodynamic", "modeling", "the", "pharmacodynamics", "of", "racemic", "metoprolol", "and", "the", "active", "S", "-", "isomer", ",", "were", "quantitated", "in", "EMs", "and", "PMs", "in", "terms", "of", "IC50", "values", ",", "representing", "metoprolol", "plasma", "concentrations", "resulting", "in", "half", "-", "maximum", "receptor", "occupancy", ".", "Six", "EMs", "received", "0", ".", "5", "mg", "of", "terbutaline", "s", ".", "c", ".", "on", "two", "different", "occasions", ":", "1", ")", "1", "hr", "after", "administration", "of", "a", "placebo", "and", "2", ")", "1", "hr", "after", "150", "mg", "of", "metoprolol", "p", ".", "o", ".", "Five", "PMs", "were", "studied", "according", "to", "the", "same", "protocol", ",", "except", "for", "a", "higher", "terbutaline", "dose", "(", "0", ".", "75", "mg", ")", "on", "day", "2", ".", "Blood", "samples", "for", "the", "analysis", "of", "plasma", "potassium", ",", "terbutaline", ",", "metoprolol", "(", "racemic", ",", "R", "-", "and", "S", "-", "isomer", ")", ",", "and", "alpha", "-", "hydroxymetoprolol", "concentrations", "were", "taken", "at", "regular", "time", "intervals", ",", "during", "8", "hr", "after", "metoprolol", ".", "In", "PMs", ",", "metoprolol", "increased", "the", "terbutaline", "area", "under", "the", "plasma", "concentration", "vs", ".", "time", "curve", "(", "+", "67", "%", ")", ".", "Higher", "metoprolol", "/", "alpha", "-", "hydroxymetoprolol", "ratios", "in", "PMs", "were", "predictive", "for", "higher", "R", "-", "/", "S", "-", "isomer", "ratios", "of", "unchanged", "drug", ".", "There", "was", "a", "difference", "in", "metoprolol", "potency", "with", "higher", "racemic", "metoprolol", "IC50", "values", "in", "PMs", "(", "72", "+", "/", "-", "7", "ng", ".", "ml", "-", "1", ")", "than", "EMs", "(", "42", "+", "/", "-", "8", "ng", ".", "ml", "-", "1", ",", "P", "less", "than", ".", "001", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[101, 101, "Chemical"], [155, 155, "Chemical"], [202, 202, "Chemical"], [223, 223, "Chemical"], [261, 261, "Chemical"], [104, 104, "Disease"], [0, 0, "Chemical"], [32, 32, "Chemical"], [12, 12, "Chemical"], [25, 25, "Chemical"], [70, 70, "Chemical"], [89, 89, "Chemical"], [99, 99, "Chemical"], [115, 115, "Chemical"], [136, 136, "Chemical"], [183, 183, "Chemical"], [225, 225, "Chemical"], [253, 253, "Chemical"], [258, 258, "Chemical"], [278, 278, "Chemical"], [306, 306, "Chemical"], [311, 311, "Chemical"], [34, 34, "Chemical"], [221, 221, "Chemical"], [238, 240, "Chemical"], [280, 282, "Chemical"]]], "relations": [[[101, 101, 104, 104, "CID"], [155, 155, 104, 104, "CID"], [202, 202, 104, 104, "CID"], [223, 223, 104, 104, "CID"], [261, 261, 104, 104, "CID"]]], "clusters": [], "translated": "<6>Debrisoquine</6>表型和<8>美托洛尔</8>及其对映异构体的药代动力学和β-2受体药效学。心脏选择性β受体阻滞剂<9>美托洛尔</9>的代谢受<7>debrisoquine</7>/<22>sparteine</22>类型的遗传控制。广泛代谢型（EM）和弱代谢型（PM）这两种代谢表型表现出不同的立体选择性代谢，导致外消旋<10>美托洛尔</10>在EMs中明显更高的β-1肾上腺素能受体拮抗作用。我们调查了后者是否也适用于<11>美托洛尔</11>对β-2肾上腺素能受体的拮抗作用。所研究的药效是<12>美托洛尔</12>对<0>特布他林</0>引起的<5>低钾血症</5>的拮抗作用。通过使用药代动力学药效学模型，外消旋<13>美托洛尔</13>和活性S-异构体的药效学在EMs和PMs中根据IC50值进行定量，代表<14>美托洛尔</14>血浆浓度导致一半-最大受体占用率。六个EM收到0.5毫克<1>特布他林</1>s.c.在两个不同的场合：1）安慰剂给药后1小时和2）150毫克<15>美托洛尔</15>p.o.后1小时。五个PM按照相同的方案研究了，除了在第二天使用更高的<2>特布他林</2>剂量（0.75 mg）外。血样用于分析血浆<23>钾</23>、<3>特布他林</3>、<16>美托洛尔</16>（外消旋，R-和S-异构体）和<24>羟基美托洛尔</24>的浓度，在<17>美托洛尔</17>后8小时内，定期测量。在PM中，<18>美托洛尔</18>增加血浆浓度下的<4>特布他林</4>面积与时间曲线（+67%）。PM中较高的<19>美托洛尔</19>/<25>α-羟​​基美托洛尔</25>比率预示着未变化药物的较高R-/S-异构体比率。<20>美托洛尔</20>的效力存在差异，外消旋<21>美托洛尔</21>IC50值在PMs中（72+/-7 ng.ml-1）高于EMs（42+/-8 ng.ml-1，P小于.001）。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "8111719", "sentences": [["Hallucinations", "and", "ifosfamide", "-", "induced", "neurotoxicity", ".", "BACKGROUND", ":", "Hallucinations", "as", "a", "symptom", "of", "central", "neurotoxicity", "are", "a", "known", "but", "poorly", "described", "side", "effect", "of", "ifosfamide", ".", "Most", "cases", "of", "ifosfamide", "-", "induced", "hallucinations", "have", "been", "reported", "with", "other", "mental", "status", "changes", ".", "METHODS", ":", "The", "authors", "interviewed", "six", "persons", "with", "ifosfamide", "-", "induced", "hallucinations", "in", "the", "presence", "of", "a", "clear", "sensorium", ".", "All", "patients", "were", "receiving", "high", "-", "dose", "ifosfamide", "as", "part", "of", "their", "bone", "marrow", "transplant", "procedure", ".", "RESULTS", ":", "Hallucinations", "occurred", "only", "when", "the", "patient", "'s", "eyes", "were", "closed", "and", ",", "in", "all", "but", "one", "case", ",", "were", "reported", "as", "disturbing", "or", "frightening", ".", "Underreporting", "of", "these", "hallucinations", "by", "patients", "is", "likely", ".", "CONCLUSIONS", ":", "Hallucinations", "may", "be", "the", "sole", "or", "first", "manifestation", "of", "neurotoxicity", ".", "The", "incidence", "may", "be", "dose", "and", "infusion", "-", "time", "related", ".", "The", "clinician", "should", "be", "alerted", "for", "possible", "ifosfamide", "-", "induced", "hallucinations", ",", "which", "may", "occur", "without", "other", "signs", "of", "neurotoxicity", ".", "\"", "Eyes", "-", "closed", "\"", "hallucinatory", "experiences", "appear", "to", "be", "an", "unusual", "feature", "of", "this", "presentation", ".", "Patients", "anxious", "about", "this", "experience", "respond", "well", "to", "support", "and", "education", "about", "this", "occurrence", ".", "Optimal", "pharmacologic", "management", "of", "disturbed", "patients", "is", "unclear", ".", "If", "agitation", "becomes", "marked", ",", "high", "-", "potency", "neuroleptics", "(", "i", ".", "e", ".", ",", "haloperidol", ")", "may", "be", "effective", "."]], "ner": [[[2, 2, "Chemical"], [25, 25, "Chemical"], [30, 30, "Chemical"], [51, 51, "Chemical"], [70, 70, "Chemical"], [147, 147, "Chemical"], [0, 0, "Disease"], [9, 9, "Disease"], [33, 33, "Disease"], [54, 54, "Disease"], [82, 82, "Disease"], [110, 110, "Disease"], [118, 118, "Disease"], [150, 150, "Disease"], [166, 166, "Disease"], [217, 217, "Chemical"], [5, 5, "Disease"], [15, 15, "Disease"], [127, 127, "Disease"], [159, 159, "Disease"], [203, 203, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 9, 9, "CID"], [2, 2, 33, 33, "CID"], [2, 2, 54, 54, "CID"], [2, 2, 82, 82, "CID"], [2, 2, 110, 110, "CID"], [2, 2, 118, 118, "CID"], [2, 2, 150, 150, "CID"], [2, 2, 166, 166, "CID"], [25, 25, 0, 0, "CID"], [25, 25, 9, 9, "CID"], [25, 25, 33, 33, "CID"], [25, 25, 54, 54, "CID"], [25, 25, 82, 82, "CID"], [25, 25, 110, 110, "CID"], [25, 25, 118, 118, "CID"], [25, 25, 150, 150, "CID"], [25, 25, 166, 166, "CID"], [30, 30, 0, 0, "CID"], [30, 30, 9, 9, "CID"], [30, 30, 33, 33, "CID"], [30, 30, 54, 54, "CID"], [30, 30, 82, 82, "CID"], [30, 30, 110, 110, "CID"], [30, 30, 118, 118, "CID"], [30, 30, 150, 150, "CID"], [30, 30, 166, 166, "CID"], [51, 51, 0, 0, "CID"], [51, 51, 9, 9, "CID"], [51, 51, 33, 33, "CID"], [51, 51, 54, 54, "CID"], [51, 51, 82, 82, "CID"], [51, 51, 110, 110, "CID"], [51, 51, 118, 118, "CID"], [51, 51, 150, 150, "CID"], [51, 51, 166, 166, "CID"], [70, 70, 0, 0, "CID"], [70, 70, 9, 9, "CID"], [70, 70, 33, 33, "CID"], [70, 70, 54, 54, "CID"], [70, 70, 82, 82, "CID"], [70, 70, 110, 110, "CID"], [70, 70, 118, 118, "CID"], [70, 70, 150, 150, "CID"], [70, 70, 166, 166, "CID"], [147, 147, 0, 0, "CID"], [147, 147, 9, 9, "CID"], [147, 147, 33, 33, "CID"], [147, 147, 54, 54, "CID"], [147, 147, 82, 82, "CID"], [147, 147, 110, 110, "CID"], [147, 147, 118, 118, "CID"], [147, 147, 150, 150, "CID"], [147, 147, 166, 166, "CID"]]], "clusters": [], "translated": "<6>幻觉</6>和<0>异环磷酰胺</0>引起的<16>神经毒性</16>。背景：作为中枢<17>神经毒性</17>症状的<7>幻觉</7>是<1>异环磷酰胺</1>的一种已知但很少描述的副作用。大多数<2>异环磷酰胺</2>引起的<8>幻觉</8>病例均伴有其他精神状态变化。方法：作者采访了6名患有<3>异环磷酰胺</3>的患者，这些患者在存在清晰感觉的情况下出现<9>幻觉</9>。作为骨髓移植手术的一部分，所有患者都接受了高剂量<4>异环磷酰胺</4>。结果：<10>幻觉</10>仅在患者闭眼时出现，并且在所有病例中均被报告为令人不安或恐惧。患者可能漏报了这些<11>幻觉</11>。结论：<12>幻觉</12>可能是<18>神经毒性</18>的唯一或首发表现。发生率可能与剂量和输注时间有关。临床医生应警惕可能的<5>异环磷酰胺</5>诱发的<13>幻觉</13>，这种幻觉可能在没有其他<19>神经毒性</19>迹象的情况下发生。 “闭眼”<14>幻觉</14>体验似乎是该演示文稿的一个不寻常特征。对这种经历感到焦虑的患者对有关这种情况的支持和教育反应良好。不安患者的最佳药物管理尚不清楚。如果<20>激越</20>变得明显，高效精神安定药（即<15>氟哌啶醇</15>）可能有效。", "revised": true}
{"doc_key": "343678", "sentences": [["Type", "B", "hepatitis", "after", "needle", "-", "stick", "exposure", ":", "prevention", "with", "hepatitis", "B", "immune", "globulin", ".", "Final", "report", "of", "the", "Veterans", "Administration", "Cooperative", "Study", ".", "Hepatitis", "B", "immune", "globulin", "(", "HBIG", ")", "and", "immune", "serum", "globulin", "(", "ISG", ")", "were", "examined", "in", "a", "randomized", ",", "double", "-", "blind", "trial", "to", "assess", "their", "relative", "efficacies", "in", "preventing", "type", "B", "hepatitis", "after", "needle", "-", "stick", "exposure", "to", "hepatitis", "B", "surface", "antigen", "(", "HBsAG", ")", "-", "positive", "donors", ".", "Clinical", "hepatitis", "developed", "in", "1", ".", "4", "%", "of", "HBIG", "and", "in", "5", ".", "9", "%", "of", "ISG", "recipients", "(", "P", "=", "0", ".", "016", ")", ",", "and", "seroconversion", "(", "anti", "-", "HBs", ")", "occurred", "in", "5", ".", "6", "%", "and", "20", ".", "7", "%", "of", "them", "respectively", "(", "P", "less", "than", "0", ".", "001", ")", ".", "Mild", "and", "transient", "side", "-", "effects", "were", "noted", "in", "3", ".", "0", "%", "of", "ISG", "and", "in", "3", ".", "2", "%", "of", "HBIG", "recipients", ".", "Available", "donor", "sera", "were", "examined", "for", "DNA", "polymerase", "(", "DNAP", ")", "and", "e", "antigen", "and", "antibody", "(", "HBeAg", ";", "anti", "-", "HBE", ")", ".", "Both", "DNAP", "and", "HBeAg", "showed", "a", "highly", "statistically", "significant", "correlation", "with", "the", "infectivity", "of", "HBsAg", "-", "positive", "donors", ".", "Hepatitis", "B", "immune", "globulin", "remained", "significantly", "superior", "to", "ISG", "in", "preventing", "type", "B", "hepatitis", "even", "when", "the", "analysis", "was", "confined", "to", "these", "two", "high", "-", "risk", "subgroups", ".", "The", "efficacy", "of", "ISG", "in", "preventing", "type", "B", "hepatitis", "can", "not", "be", "ascertained", "because", "a", "true", "placebo", "group", "was", "not", "included", "."]], "ner": [[[175, 175, "Chemical"], [185, 185, "Chemical"], [0, 2, "Disease"], [11, 12, "Disease"], [25, 26, "Disease"], [56, 58, "Disease"], [201, 202, "Disease"], [212, 214, "Disease"], [235, 237, "Disease"], [65, 68, "Chemical"], [70, 70, "Chemical"], [196, 196, "Chemical"], [77, 77, "Disease"]]], "relations": [[[175, 175, 0, 2, "CID"], [175, 175, 11, 12, "CID"], [175, 175, 25, 26, "CID"], [175, 175, 56, 58, "CID"], [175, 175, 201, 202, "CID"], [175, 175, 212, 214, "CID"], [175, 175, 235, 237, "CID"], [185, 185, 0, 2, "CID"], [185, 185, 11, 12, "CID"], [185, 185, 25, 26, "CID"], [185, 185, 56, 58, "CID"], [185, 185, 201, 202, "CID"], [185, 185, 212, 214, "CID"], [185, 185, 235, 237, "CID"]]], "clusters": [], "translated": " <2>乙型肝炎</2>针刺接触后：用<3>乙型肝炎</3>免疫球蛋白预防。退伍军人管理局合作研究的最终报告。 <4>乙型肝炎</4>免疫球蛋白 (HBIG)和免疫血清球蛋白 (ISG)在一项随机、双盲试验中进行了检查，以评估它们在预防针后<5>乙型肝炎</5>方面的相对功效-坚持接触<9>乙型肝炎表面抗原</9> (<10>HBsAG</10>) 阳性供体。临床<12>肝炎</12>发生于 1.4%的HBIG和5.9%的ISG接受者 (P=0.016)，血清转化（抗-HBs）发生在5.6%和20.7%的接受者，分别为P小于0.001。3.0%的ISG和3.2%的HBIG接受者注意到轻微而短暂的副作用。对可用供体血清进行了DNA聚合酶 (DNAP) 和e抗原和抗体(<0>HBeAg</0>；抗HBE)检查，DNAP和<1>HBeAg</1>均与<11>HBsAg</11>阳性供体的感染性在统计学上具有高度显着相关性。当分析仅限于这两个高危亚组时，<6>乙型肝炎</6>免疫球蛋白在预防<7>乙型肝炎</7>方面仍然有效。无法确定ISG在预防<8>乙型肝炎</8>方面的功效，因为未包括真正的安慰剂组。", "revised": true}
{"doc_key": "8106150", "sentences": [["Effect", "of", "nondopaminergic", "drugs", "on", "L", "-", "dopa", "-", "induced", "dyskinesias", "in", "MPTP", "-", "treated", "monkeys", ".", "A", "group", "of", "four", "monkeys", "was", "rendered", "parkinsonian", "with", "the", "toxin", "MPTP", ".", "They", "were", "then", "treated", "chronically", "with", "L", "-", "DOPA", "/", "benserazide", "50", "/", "12", ".", "5", "mg", "/", "kg", "given", "orally", "daily", "for", "2", "months", ".", "This", "dose", "produced", "a", "striking", "antiparkinsonian", "effect", ",", "but", "all", "animals", "manifested", "dyskinesia", ".", "A", "series", "of", "agents", "acting", "primarily", "on", "neurotransmitters", "other", "than", "dopamine", "were", "then", "tested", "in", "combination", "with", "L", "-", "DOPA", "to", "see", "if", "the", "dyskinetic", "movements", "would", "be", "modified", ".", "Several", "drugs", ",", "including", "clonidine", ",", "physostigmine", ",", "methysergide", ",", "5", "-", "MDOT", ",", "propranolol", ",", "and", "MK", "-", "801", ",", "markedly", "reduced", "the", "dyskinetic", "movements", "but", "at", "the", "cost", "of", "a", "return", "of", "parkinsonian", "symptomatology", ".", "However", ",", "yohimbine", "and", "meperidine", "reduced", "predominantly", "the", "dyskinetic", "movements", ".", "Baclofen", "was", "also", "useful", "in", "one", "monkey", "against", "a", "more", "dystonic", "form", "of", "dyskinesia", ".", "Atropine", "converted", "the", "dystonic", "movements", "into", "chorea", "."]], "ner": [[[36, 40, "Chemical"], [10, 10, "Disease"], [68, 68, "Disease"], [94, 94, "Disease"], [124, 124, "Disease"], [145, 145, "Disease"], [161, 161, "Disease"], [12, 12, "Chemical"], [28, 28, "Chemical"], [24, 24, "Disease"], [134, 134, "Disease"], [5, 7, "Chemical"], [87, 89, "Chemical"], [158, 158, "Disease"], [166, 166, "Disease"], [169, 169, "Disease"], [80, 80, "Chemical"], [104, 104, "Chemical"], [106, 106, "Chemical"], [108, 108, "Chemical"], [114, 114, "Chemical"], [117, 119, "Chemical"], [139, 139, "Chemical"], [141, 141, "Chemical"], [148, 148, "Chemical"], [163, 163, "Chemical"]]], "relations": [[[36, 40, 10, 10, "CID"], [36, 40, 68, 68, "CID"], [36, 40, 94, 94, "CID"], [36, 40, 124, 124, "CID"], [36, 40, 145, 145, "CID"], [36, 40, 161, 161, "CID"], [12, 12, 24, 24, "CID"], [12, 12, 134, 134, "CID"], [28, 28, 24, 24, "CID"], [28, 28, 134, 134, "CID"]]], "clusters": [], "translated": "非多巴胺能药物对<11>左旋多巴</11>引起的<1>运动障碍</1>在<7> MPTP </7>处理过的猴子中的影响。一组四只猴子因毒素<8> MPTP </8>而患上<9>帕金森症</9>。然后用<0>L-DOPA/benserazide</0> 50 / 12对他们进行长期治疗。每天口服 5 毫克/千克，持续2个月。该剂量产生了显着的抗帕金森病作用，但所有动物都表现出<2>运动障碍</2>。然后，将一系列主要作用于<16>多巴胺</16>以外的神经递质的药物与<12>L-DOPA</12>结合进行测试，以观察是否会改善<3>运动障碍</3>运动。几种药物，包括<17>可乐定</17>、<18>毒扁豆碱</18>、<19>麦角新碱</19>、5-MDOT、<20>普萘洛尔</20>和<21>MK-801</21>，显着减少了<4>运动障碍</4>运动，但代价是返回了<10>帕金森病</10>症状。然而，<22>育亨宾</22>和<23>杜冷丁</23>主要减少了<5>运动障碍</5>运动。<24>巴氯芬</24>也可用于一只猴子对抗更<13>肌张力障碍</13>形式的<6>运动障碍</6>。<25>阿托品</25>将<14>肌张力障碍</14>运动转化为<15>舞蹈症</15>。", "revised": true}
{"doc_key": "8607407", "sentences": [["Acute", "blood", "pressure", "elevations", "with", "caffeine", "in", "men", "with", "borderline", "systemic", "hypertension", ".", "Whether", "the", "vasoconstrictive", "actions", "of", "caffeine", "are", "enhanced", "in", "hypertensive", "persons", "has", "not", "been", "demonstrated", ".", "Thus", ",", "caffeine", "(", "3", ".", "3", "mg", "/", "kg", ")", "versus", "placebo", "was", "tested", "in", "48", "healthy", "men", "(", "aged", "20", "to", "35", "years", ")", "selected", "after", "screening", "on", "2", "separate", "occasions", ".", "Borderline", "hypertensive", "men", "(", "n", "=", "24", ")", "were", "selected", "with", "screening", "systolic", "blood", "pressure", "(", "BP", ")", "of", "140", "to", "160", "mm", "Hg", "and", "/", "or", "diastolic", "BP", "90", "to", "99", "mm", "Hg", ".", "Low", "-", "risk", "controls", "(", "n", "=", "24", ")", "reported", "no", "parental", "history", "of", "hypertension", "and", "had", "screening", "BP", "<", "130", "/", "85", "mm", "Hg", ".", "Participants", "were", "then", "tested", "on", "2", "occasions", "after", "12", "-", "hour", "abstinence", "from", "caffeine", "in", "each", "of", "2", "protocols", ";", "this", "required", "a", "total", "of", "4", "laboratory", "visits", ".", "Caffeine", "-", "induced", "changes", "in", "diastolic", "BP", "were", "2", "to", "3", "times", "larger", "in", "borderline", "subjects", "than", "in", "controls", "(", "+", "8", ".", "4", "vs", "+", "3", ".", "8", "mm", "Hg", ",", "p", "<", "0", ".", "0001", ")", ",", "and", "were", "attributable", "to", "larger", "changes", "in", "impedance", "-", "derived", "measures", "of", "systemic", "vascular", "resistance", "(", "+", "135", "vs", "+", "45", "dynes", ".", "s", ".", "cm", "-", "5", ",", "p", "<", "0", ".", "004", ")", ".", "These", "findings", "were", "consistent", "and", "reached", "significance", "in", "both", "protocols", ".", "The", "percentage", "of", "borderline", "subjects", "in", "whom", "diastolic", "BP", "changes", "exceeded", "the", "median", "control", "response", "was", "96", "%", ".", "Consequently", ",", "whereas", "all", "participants", "exhibited", "normotensive", "levels", "during", "the", "resting", "predrug", "baseline", ",", "33", "%", "of", "borderline", "subjects", "achieved", "hypertensive", "BP", "levels", "after", "caffeine", "ingestion", ".", "Thus", ",", "in", "borderline", "hypertensive", "men", ",", "exaggerated", "responses", "to", "caffeine", "were", ":", "selective", "for", "diastolic", "BP", ",", "consistent", "with", "greater", "vasoconstriction", ",", "replicated", "in", "2", "protocols", ",", "and", "representative", "of", "nearly", "all", "borderline", "hypertensives", ".", "We", "suspect", "that", "the", "potential", "for", "caffeine", "to", "stabilize", "high", "resistance", "states", "in", "susceptible", "persons", "suggests", "that", "its", "use", "may", "facilitate", "their", "disease", "progression", ",", "as", "well", "as", "hinder", "accurate", "diagnosis", "and", "treatment", "."]], "ner": [[[5, 5, "Chemical"], [18, 18, "Chemical"], [31, 31, "Chemical"], [137, 137, "Chemical"], [153, 153, "Chemical"], [282, 282, "Chemical"], [295, 295, "Chemical"], [327, 327, "Chemical"], [11, 11, "Disease"], [22, 22, "Disease"], [64, 64, "Disease"], [112, 112, "Disease"], [278, 278, "Disease"], [289, 289, "Disease"], [319, 319, "Disease"]]], "relations": [[[5, 5, 11, 11, "CID"], [5, 5, 22, 22, "CID"], [5, 5, 64, 64, "CID"], [5, 5, 112, 112, "CID"], [5, 5, 278, 278, "CID"], [5, 5, 289, 289, "CID"], [5, 5, 319, 319, "CID"], [18, 18, 11, 11, "CID"], [18, 18, 22, 22, "CID"], [18, 18, 64, 64, "CID"], [18, 18, 112, 112, "CID"], [18, 18, 278, 278, "CID"], [18, 18, 289, 289, "CID"], [18, 18, 319, 319, "CID"], [31, 31, 11, 11, "CID"], [31, 31, 22, 22, "CID"], [31, 31, 64, 64, "CID"], [31, 31, 112, 112, "CID"], [31, 31, 278, 278, "CID"], [31, 31, 289, 289, "CID"], [31, 31, 319, 319, "CID"], [137, 137, 11, 11, "CID"], [137, 137, 22, 22, "CID"], [137, 137, 64, 64, "CID"], [137, 137, 112, 112, "CID"], [137, 137, 278, 278, "CID"], [137, 137, 289, 289, "CID"], [137, 137, 319, 319, "CID"], [153, 153, 11, 11, "CID"], [153, 153, 22, 22, "CID"], [153, 153, 64, 64, "CID"], [153, 153, 112, 112, "CID"], [153, 153, 278, 278, "CID"], [153, 153, 289, 289, "CID"], [153, 153, 319, 319, "CID"], [282, 282, 11, 11, "CID"], [282, 282, 22, 22, "CID"], [282, 282, 64, 64, "CID"], [282, 282, 112, 112, "CID"], [282, 282, 278, 278, "CID"], [282, 282, 289, 289, "CID"], [282, 282, 319, 319, "CID"], [295, 295, 11, 11, "CID"], [295, 295, 22, 22, "CID"], [295, 295, 64, 64, "CID"], [295, 295, 112, 112, "CID"], [295, 295, 278, 278, "CID"], [295, 295, 289, 289, "CID"], [295, 295, 319, 319, "CID"], [327, 327, 11, 11, "CID"], [327, 327, 22, 22, "CID"], [327, 327, 64, 64, "CID"], [327, 327, 112, 112, "CID"], [327, 327, 278, 278, "CID"], [327, 327, 289, 289, "CID"], [327, 327, 319, 319, "CID"]]], "clusters": [], "translated": "<0>咖啡因</0> 在患有临界系统性 <8>高血压</8>的男性中导致急性血压升高。 <1> 咖啡因 </1> 的血管收缩作用是否在<9>高血压</9>人群中得到增强尚未得到证实。因此，在48名健康男性（20-35岁）中，每个人（ 3.3mg/kg）分别接受 <2>咖啡因</2>与安慰剂的测试，在筛选两次后选中。筛选边缘<10>高血压</10>男性（ n = 24）收缩压（BP）为 140 至 160 mm Hg 和/或舒张压 90 至 99 mm Hg。低风险对照（ n = 24）未报告<11>高血压</11>家族史，筛选 BP 在 <130/85mmHg。每种方案中的每个参与者在 12 小时停用 <3> 咖啡因 </3> 后分别接受两次测试，总共需要 4 次实验室访问。边缘受试者<4>咖啡因</4> -引起的舒张压变化是控制组的 2-3 倍（+8.4 vs +3.8 mmHg，p<0.0001），归因于更大的全身血管阻力的阻抗波动（ + 135 vs + 45 dynes.s.cm-5，p < 0.004）。这些发现在两个方案中都是一致的，并且均达到显著性。舒张压变化超过控制反应的中位数的边缘受试者比例为 96%。因此，尽管所有参与者在用药前静息基线期间表现出正常的血压水平，但有 33% 的边缘受试者在接受<5>咖啡因</5> 摄入后达到了<12>高血压</12>水平。因此，在边缘<13>高血压</13>男性中，对<6>咖啡因 </6> 的反应过度：选择舒张压，与更大的血管收缩一致，在两个方案中重复，并代表了几乎所有的边缘<14>高血压</14>。我们怀疑，<7>咖啡因</7>稳定易感人群的高阻力状态的潜力表明其使用可能会促进其疾病进展，同时也会阻碍准确的诊断和治疗。", "revised": true}
{"doc_key": "8686832", "sentences": [["Leg", "and", "back", "pain", "after", "spinal", "anaesthesia", "involving", "hyperbaric", "5", "%", "lignocaine", ".", "Fifty", "-", "four", "patients", ",", "aged", "27", "-", "90", "years", ",", "who", "were", "given", "lignocaine", "5", "%", "in", "6", ".", "8", "%", "glucose", "solution", "for", "spinal", "anaesthesia", "were", "studied", ".", "Thirteen", "of", "these", "patients", "experienced", "pain", "in", "the", "legs", "and", "/", "or", "back", "after", "recovery", "from", "anaesthesia", ".", "The", "patients", "affected", "were", "younger", "(", "p", "<", "0", ".", "05", ")", "and", "the", "site", "of", "the", "dural", "puncture", "was", "higher", "(", "p", "<", "0", ".", "01", ")", "than", "those", "individuals", "without", "pain", ".", "Five", "of", "the", "13", "patients", "(", "38", "%", ")", "with", "pain", "and", "seven", "of", "the", "41", "patients", "(", "17", "%", ")", "without", "pain", "admitted", "to", "a", "high", "alcohol", "intake", ",", "which", "might", "be", "a", "contributing", "factor", ".", "Leg", "and", "/", "or", "back", "pain", "is", "associated", "with", "the", "intrathecal", "use", "of", "hyperbaric", "5", "%", "lignocaine", "."]], "ner": [[[11, 11, "Chemical"], [27, 27, "Chemical"], [148, 148, "Chemical"], [0, 3, "Disease"], [48, 55, "Disease"], [132, 137, "Disease"], [35, 35, "Chemical"], [122, 122, "Chemical"], [93, 93, "Disease"], [105, 105, "Disease"], [117, 117, "Disease"]]], "relations": [[[11, 11, 0, 3, "CID"], [11, 11, 48, 55, "CID"], [11, 11, 132, 137, "CID"], [27, 27, 0, 3, "CID"], [27, 27, 48, 55, "CID"], [27, 27, 132, 137, "CID"], [148, 148, 0, 3, "CID"], [148, 148, 48, 55, "CID"], [148, 148, 132, 137, "CID"]]], "clusters": [], "translated": " <3>腿部和背部疼痛</3>在使用高压 5% <0>利多卡因</0> 脊髓麻醉后往往发生。共研究了 54 名年龄在 27 - 90 岁之间的患者，这些患者在腰麻时使用了 6.8% <6>葡萄糖</6> 溶液和 <1>利多卡因</1> 5%。其中 13 名患者术后恢复后出现了<4>腿部和 / 或背部疼痛</4>。与没有<8>疼痛</8>的患者相比，受影响的患者更年轻（p < 0.05），并且脊膜穿刺部位更高（p < 0.01）。13 名患者中有 5 名患者（38%）出现<9>疼痛</9>，而 41 名患者中有 7 名患者（17%）没有<10>疼痛</10>，他们承认曾饮用大量的<7>酒精</7>，这可能是一个促成因素。<5>腿部和/或背部疼痛</5>是与鞘内使用高压 5% <2>利多卡因</2> 相关的。", "revised": true}
{"doc_key": "982002", "sentences": [["Acute", "renal", "failure", "subsequent", "to", "the", "administration", "of", "rifampicin", ".", "A", "follow", "-", "up", "study", "of", "cases", "reported", "earlier", ".", "A", "clinical", "presentation", "is", "made", "of", "a", "2", "-", "3", "year", "follow", "-", "up", "of", "six", "cases", "of", "acute", "renal", "failure", "that", "have", "been", "reported", "earlier", ".", "The", "patients", "had", "developed", "transient", "renal", "failure", "after", "the", "intermittent", "administration", "of", "rifampicin", ".", "The", "stage", "of", "olig", "-", "anuria", "lasted", "for", "1", "-", "3", "weeks", ",", "and", "five", "of", "the", "patients", "were", "treated", "by", "hemodialysis", ".", "Two", "of", "the", "patients", "died", "due", "to", "unrelated", "causes", "during", "the", "follow", "-", "up", "period", ".", "The", "four", "patients", "re", "-", "examined", "were", "clinically", "cured", ".", "Pathologic", "findings", "by", "light", "microscopy", "and", "immunofluorescence", "at", "biopsy", "were", "scarce", ".", "Nothing", "abnormal", "was", "seen", "by", "electron", "microscopy", "in", "two", "of", "the", "cases", "studied", ".", "Renal", "function", "was", "normal", ".", "In", "three", "cases", "the", "excretion", "at", "131I", "-", "hippuran", "renography", "was", "slightly", "slowed", ".", "Although", "in", "the", "acute", "stage", "the", "renal", "lesions", "histologically", "appeared", "toxic", ",", "evidence", "suggestive", "of", "an", "immunological", "mechanism", "can", "not", "be", "excluded", "."]], "ner": [[[8, 8, "Chemical"], [59, 59, "Chemical"], [0, 2, "Disease"], [38, 40, "Disease"], [52, 53, "Disease"], [66, 66, "Disease"], [161, 162, "Disease"]]], "relations": [[[8, 8, 0, 2, "CID"], [8, 8, 38, 40, "CID"], [59, 59, 0, 2, "CID"], [59, 59, 38, 40, "CID"]]], "clusters": [], "translated": " <2>急性肾功能衰竭</2>继<0>利福平</0>给药后。对先前报告的病例进行后续研究。一份临床报告是由6例<3>急性肾功能衰竭</3>的2-3年随访组成的，这些病例早先已被报道过。患者在间歇服用<1>利福平</1>后出现一过性<4>肾功能衰竭</4>。olig-<5>无尿</5>期持续1-3周，其中5例接受了血液透析治疗。其中2名患者在随访期间因无关原因死亡。复查的4例患者均已临床治愈。活检时光学显微镜和免疫荧光的病理结果很少。在所研究的2个病例中，电子显微镜未见异常。肾功能正常。在3个案例中，131I-hippuran肾造影的排泄略有减慢。虽然在急性期<6>肾脏病变</6>在组织学上表现出毒性，但不能排除免疫学机制的证据。", "revised": true}
{"doc_key": "33969", "sentences": [["Ethopropazine", "and", "benztropine", "in", "neuroleptic", "-", "induced", "parkinsonism", ".", "In", "a", "12", "-", "week", "controlled", "study", "ethopropazine", "was", "compared", "to", "benztropine", "in", "the", "treatment", "of", "parkinsonism", "induced", "by", "fluphenazine", "enanthate", "in", "60", "schizophrenic", "outpatients", ".", "Ethopropazine", "and", "benztropine", "were", "found", "to", "be", "equally", "effective", "in", "controlling", "parkinsonian", "symptoms", "and", "were", "as", "efficacious", "as", "procyclidine", ",", "their", "previous", "antiparkinsonian", "drug", ".", "However", ",", "benztropine", "treated", "patients", "had", "a", "significant", "increase", "in", "tardive", "dyskinesia", "compared", "to", "their", "condition", "during", "procyclindine", "treatment", ",", "and", "significantly", "more", "anxiety", "and", "depression", "than", "ethopropazine", "treated", "patients", ".", "This", "suggests", "that", "benztropine", "is", "not", "the", "anticholinergic", "drug", "of", "choice", "in", "the", "treatment", "of", "neuroleptic", "-", "induced", "parkinsonian", "symptoms", ",", "because", "of", "its", "more", "toxic", "central", "and", "peripheral", "atropinic", "effect", "."]], "ner": [[[2, 2, "Chemical"], [20, 20, "Chemical"], [37, 37, "Chemical"], [62, 62, "Chemical"], [94, 94, "Chemical"], [70, 71, "Disease"], [83, 83, "Disease"], [85, 85, "Disease"], [28, 29, "Chemical"], [7, 7, "Disease"], [25, 25, "Disease"], [46, 47, "Disease"], [109, 110, "Disease"], [0, 0, "Chemical"], [16, 16, "Chemical"], [35, 35, "Chemical"], [87, 87, "Chemical"], [32, 32, "Disease"], [53, 53, "Chemical"], [77, 77, "Chemical"]]], "relations": [[[2, 2, 70, 71, "CID"], [20, 20, 70, 71, "CID"], [37, 37, 70, 71, "CID"], [62, 62, 70, 71, "CID"], [94, 94, 70, 71, "CID"], [2, 2, 83, 83, "CID"], [20, 20, 83, 83, "CID"], [37, 37, 83, 83, "CID"], [62, 62, 83, 83, "CID"], [94, 94, 83, 83, "CID"], [2, 2, 85, 85, "CID"], [20, 20, 85, 85, "CID"], [37, 37, 85, 85, "CID"], [62, 62, 85, 85, "CID"], [94, 94, 85, 85, "CID"], [28, 29, 7, 7, "CID"], [28, 29, 25, 25, "CID"], [28, 29, 46, 47, "CID"], [28, 29, 109, 110, "CID"]]], "clusters": [], "translated": "<13>乙丙哌嗪</13> 和<0>苯甲托品</0> 在抗精神病药诱导的<9>帕金森症</9>中。在一项为期12周的对照研究中，<14>乙丙哌嗪</14>与<1>苯甲托品</1>治疗<8>氟哌嗪琥珀酸酯</8>引起的<10>帕金森症</10>进行了比较，60名<17>精神分裂症</17>门诊病人。 <15>乙丙嗪</15>和<2>苯托品</2>被发现在控制<11>帕金森病症状</11>方面同样有效，并且与<18>丙环己定</18>一样有效，他们之前的抗帕金森病药物。然而，<3>苯甲托品</3>治疗的患者<5>迟发性运动障碍</5>与<19>丙环己定</19>治疗期间的情况相比显着增加，<6>焦虑</6>和<7>抑郁症</7>优于<16>乙丙哌嗪</16>治疗的患者。这表明<4>苯甲托品</4>不是抗胆碱能药物的首选，因为它具有毒性更大的中枢和外周阿托品作用，因此不是治疗精神安定药引起的<12>帕金森症状</12>的首选抗胆碱能药物。", "revised": true}
{"doc_key": "16844102", "sentences": [["Effect", "of", "alpha", "-", "tocopherol", "and", "deferoxamine", "on", "methamphetamine", "-", "induced", "neurotoxicity", ".", "Methamphetamine", "(", "MA", ")", "-", "induced", "dopaminergic", "neurotoxicity", "is", "believed", "to", "be", "associated", "with", "the", "increased", "formation", "of", "free", "radicals", ".", "This", "study", "examined", "the", "effect", "of", "alpha", "-", "tocopherol", "(", "alpha", "-", "TC", ")", ",", "a", "scavenger", "of", "reactive", "oxygen", "species", ",", "and", "deferoxamine", "(", "DFO", ")", ",", "an", "iron", "chelator", ",", "on", "the", "MA", "-", "induced", "neurotoxicity", ".", "Male", "rats", "were", "treated", "with", "MA", "(", "10", "mg", "/", "kg", ",", "every", "2", "h", "for", "four", "injections", ")", ".", "The", "rat", "received", "either", "alpha", "-", "TC", "(", "20", "mg", "/", "kg", ")", "intraperitoneally", "for", "3", "days", "and", "30", "min", "prior", "to", "MA", "administration", "or", "DFO", "(", "50", "mg", "/", "kg", ")", "subcutaneously", "30", "min", "before", "MA", "administration", ".", "The", "concentrations", "of", "dopamine", "(", "DA", ")", ",", "serotonin", "and", "their", "metabolites", "decreased", "significantly", "after", "MA", "administration", ",", "which", "was", "inhibited", "by", "the", "alpha", "-", "TC", "and", "DFO", "pretreatment", ".", "alpha", "-", "TC", "and", "DFO", "attenuated", "the", "MA", "-", "induced", "hyperthermia", "as", "well", "as", "the", "alterations", "in", "the", "locomotor", "activity", ".", "The", "level", "of", "lipid", "peroxidation", "was", "higher", "and", "the", "reduced", "glutathione", "concentration", "was", "lower", "in", "the", "MA", "-", "treated", "rats", ".", "These", "changes", "were", "significantly", "attenuated", "by", "alpha", "-", "TC", "and", "DFO", ".", "This", "suggests", "that", "alpha", "-", "TC", "and", "DFO", "ameliorate", "the", "MA", "-", "induced", "neuronal", "damage", "by", "decreasing", "the", "level", "of", "oxidative", "stress", "."]], "ner": [[[8, 8, "Chemical"], [13, 13, "Chemical"], [15, 15, "Chemical"], [68, 68, "Chemical"], [78, 78, "Chemical"], [115, 115, "Chemical"], [129, 129, "Chemical"], [147, 147, "Chemical"], [169, 169, "Chemical"], [199, 199, "Chemical"], [226, 226, "Chemical"], [172, 172, "Disease"], [229, 230, "Disease"], [2, 4, "Chemical"], [40, 42, "Chemical"], [44, 46, "Chemical"], [97, 99, "Chemical"], [155, 157, "Chemical"], [162, 164, "Chemical"], [210, 212, "Chemical"], [219, 221, "Chemical"], [11, 11, "Disease"], [20, 20, "Disease"], [71, 71, "Disease"], [6, 6, "Chemical"], [57, 57, "Chemical"], [59, 59, "Chemical"], [118, 118, "Chemical"], [159, 159, "Chemical"], [166, 166, "Chemical"], [214, 214, "Chemical"], [223, 223, "Chemical"], [53, 53, "Chemical"], [63, 63, "Chemical"], [135, 135, "Chemical"], [137, 137, "Chemical"], [140, 140, "Chemical"], [193, 193, "Chemical"]]], "relations": [[[8, 8, 172, 172, "CID"], [13, 13, 172, 172, "CID"], [15, 15, 172, 172, "CID"], [68, 68, 172, 172, "CID"], [78, 78, 172, 172, "CID"], [115, 115, 172, 172, "CID"], [129, 129, 172, 172, "CID"], [147, 147, 172, 172, "CID"], [169, 169, 172, 172, "CID"], [199, 199, 172, 172, "CID"], [226, 226, 172, 172, "CID"], [8, 8, 229, 230, "CID"], [13, 13, 229, 230, "CID"], [15, 15, 229, 230, "CID"], [68, 68, 229, 230, "CID"], [78, 78, 229, 230, "CID"], [115, 115, 229, 230, "CID"], [129, 129, 229, 230, "CID"], [147, 147, 229, 230, "CID"], [169, 169, 229, 230, "CID"], [199, 199, 229, 230, "CID"], [226, 226, 229, 230, "CID"]]], "clusters": [], "translated": "<13>α-生育酚</13>和<24>去铁胺</24>对<0>甲基苯丙胺</0> -诱导的<21>神经毒性</21>的影响。<1>甲基苯丙胺</1>（<2>MA</2>）-诱导的多巴胺能<22>神经毒性</22>被认为与自由基形成增加有关。本研究检验了<14>α-生育酚</14>（<15>α-TC</15>）（一种活性<32>氧</32>物质的清除剂）以及<25>去铁胺</25>（<26>DFO</26>）-一种<33>铁</33>螯合剂-对<3>MA</3> -诱导的<23>神经毒性</23>的影响。雄性大鼠用<4>MA</4>（10 mg/kg，每2小时注射四次）治疗。大鼠接受<16>α-TC</16>（20 mg/kg）腹膜内注射3天，并在<5>MA</5>给药前30分钟，或在<6>MA</6>给药前30分钟，皮下注射<27>DFO</27>（50 mg/kg）。<7>MA</7>给药后，<34>多巴胺</34>（<35>DA</35>），<36>5-羟色胺</36>及其代谢物的浓度显着降低，而这被<17>α-TC</17>和<28>DFO</28>预处理所抑制。<18>α-TC</18> 和 <29>DFO</29> 减弱了 <8>MA</8> - 诱导的 <11>高热</11>以及对运动能力的改变。<9>MA</9>处理的大鼠脂质过氧化水平较高，还原型<37>谷胱甘肽</37>浓度较低，而这些变化被<19>α-TC</19>和<30>DFO</30>显著削弱。这表明，<20>α-TC</20>和<31>DFO</31>通过降低氧化应激水平而改善<10>MA</10> -诱导的<12>神经元损伤</12>。", "revised": true}
{"doc_key": "3431591", "sentences": [["Recent", "preclinical", "and", "clinical", "studies", "with", "the", "thymidylate", "synthase", "inhibitor", "N10", "-", "propargyl", "-", "5", ",", "8", "-", "dideazafolic", "acid", "(", "CB", "3717", ")", ".", "CB", "3717", ",", "N10", "-", "propargyl", "-", "5", ",", "8", "-", "dideazafolic", "acid", ",", "is", "a", "tight", "-", "binding", "inhibitor", "of", "thymidylate", "synthase", "(", "TS", ")", "whose", "cytotoxicity", "is", "mediated", "solely", "through", "the", "inhibition", "of", "this", "enzyme", ".", "Recent", "preclinical", "studies", "have", "focused", "on", "the", "intracellular", "formation", "of", "CB", "3717", "polyglutamates", ".", "Following", "a", "12", "-", "hour", "exposure", "of", "L1210", "cells", "to", "50", "microM", "[", "3H", "]", "CB", "3717", ",", "30", "%", "of", "the", "extractable", "radioactivity", "could", "be", "accounted", "for", "as", "CB", "3717", "tetra", "-", "and", "pentaglutamate", ",", "as", "determined", "by", "high", "-", "pressure", "liquid", "chromatography", "(", "HPLC", ")", "analyses", ".", "As", "inhibitors", "of", "isolated", "L1210", "TS", ",", "CB", "3717", "di", "-", ",", "tri", "-", ",", "tetra", "-", "and", "pentaglutamate", "are", "26", "-", ",", "87", "-", ",", "119", "-", "and", "114", "-", "fold", "more", "potent", "than", "CB", "3717", ",", "respectively", ",", "and", "their", "formation", "may", ",", "therefore", ",", "be", "an", "important", "determinant", "of", "CB", "3717", "cytotoxicity", ".", "In", "early", "clinical", "studies", "with", "CB", "3717", ",", "activity", "has", "been", "seen", "in", "breast", "cancer", ",", "ovarian", "cancer", ",", "hepatoma", ",", "and", "mesothelioma", ".", "Toxicities", "included", "hepatotoxicity", ",", "malaise", ",", "and", "dose", "-", "limiting", "nephrotoxicity", ".", "This", "latter", "effect", "is", "thought", "to", "be", "due", "to", "drug", "precipitation", "within", "the", "renal", "tubule", "as", "a", "result", "of", "the", "poor", "solubility", "of", "CB", "3717", "under", "acidic", "conditions", ".", "In", "an", "attempt", "to", "overcome", "this", "problem", ",", "a", "clinical", "trial", "of", "CB", "3717", "administered", "with", "alkaline", "diuresis", "is", "under", "way", ".", "Preliminary", "results", "at", "400", "and", "500", "mg", "/", "m2", "suggest", "that", "a", "reduction", "in", "nephrotoxicity", "may", "have", "been", "achieved", "with", "only", "1", "instance", "of", "renal", "toxicity", "in", "10", "patients", ".", "Hepatotoxicity", "and", "malaise", "are", "again", "the", "most", "frequent", "side", "effects", ".", "Evidence", "of", "antitumor", "activity", "has", "been", "seen", "in", "3", "patients", ".", "Pharmacokinetic", "investigations", "have", "shown", "that", "alkaline", "diuresis", "does", "not", "alter", "CB", "3717", "plasma", "levels", "or", "urinary", "excretion", "and", "that", "satisfactory", "urinary", "alkalinization", "can", "be", "readily", "achieved", "."]], "ner": [[[10, 19, "Chemical"], [21, 22, "Chemical"], [25, 26, "Chemical"], [28, 37, "Chemical"], [73, 74, "Chemical"], [92, 93, "Chemical"], [106, 107, "Chemical"], [161, 162, "Chemical"], [178, 179, "Chemical"], [187, 188, "Chemical"], [241, 242, "Chemical"], [259, 260, "Chemical"], [331, 332, "Chemical"], [208, 208, "Disease"], [299, 299, "Disease"], [210, 210, "Disease"], [301, 301, "Disease"], [216, 216, "Disease"], [283, 283, "Disease"], [293, 294, "Disease"], [52, 52, "Disease"], [180, 180, "Disease"], [206, 206, "Disease"], [195, 196, "Disease"], [198, 199, "Disease"], [201, 201, "Disease"], [204, 204, "Disease"]]], "relations": [[[10, 19, 208, 208, "CID"], [10, 19, 299, 299, "CID"], [21, 22, 208, 208, "CID"], [21, 22, 299, 299, "CID"], [25, 26, 208, 208, "CID"], [25, 26, 299, 299, "CID"], [28, 37, 208, 208, "CID"], [28, 37, 299, 299, "CID"], [73, 74, 208, 208, "CID"], [73, 74, 299, 299, "CID"], [92, 93, 208, 208, "CID"], [92, 93, 299, 299, "CID"], [106, 107, 208, 208, "CID"], [106, 107, 299, 299, "CID"], [161, 162, 208, 208, "CID"], [161, 162, 299, 299, "CID"], [178, 179, 208, 208, "CID"], [178, 179, 299, 299, "CID"], [187, 188, 208, 208, "CID"], [187, 188, 299, 299, "CID"], [241, 242, 208, 208, "CID"], [241, 242, 299, 299, "CID"], [259, 260, 208, 208, "CID"], [259, 260, 299, 299, "CID"], [331, 332, 208, 208, "CID"], [331, 332, 299, 299, "CID"], [10, 19, 210, 210, "CID"], [10, 19, 301, 301, "CID"], [21, 22, 210, 210, "CID"], [21, 22, 301, 301, "CID"], [25, 26, 210, 210, "CID"], [25, 26, 301, 301, "CID"], [28, 37, 210, 210, "CID"], [28, 37, 301, 301, "CID"], [73, 74, 210, 210, "CID"], [73, 74, 301, 301, "CID"], [92, 93, 210, 210, "CID"], [92, 93, 301, 301, "CID"], [106, 107, 210, 210, "CID"], [106, 107, 301, 301, "CID"], [161, 162, 210, 210, "CID"], [161, 162, 301, 301, "CID"], [178, 179, 210, 210, "CID"], [178, 179, 301, 301, "CID"], [187, 188, 210, 210, "CID"], [187, 188, 301, 301, "CID"], [241, 242, 210, 210, "CID"], [241, 242, 301, 301, "CID"], [259, 260, 210, 210, "CID"], [259, 260, 301, 301, "CID"], [331, 332, 210, 210, "CID"], [331, 332, 301, 301, "CID"], [10, 19, 216, 216, "CID"], [10, 19, 283, 283, "CID"], [10, 19, 293, 294, "CID"], [21, 22, 216, 216, "CID"], [21, 22, 283, 283, "CID"], [21, 22, 293, 294, "CID"], [25, 26, 216, 216, "CID"], [25, 26, 283, 283, "CID"], [25, 26, 293, 294, "CID"], [28, 37, 216, 216, "CID"], [28, 37, 283, 283, "CID"], [28, 37, 293, 294, "CID"], [73, 74, 216, 216, "CID"], [73, 74, 283, 283, "CID"], [73, 74, 293, 294, "CID"], [92, 93, 216, 216, "CID"], [92, 93, 283, 283, "CID"], [92, 93, 293, 294, "CID"], [106, 107, 216, 216, "CID"], [106, 107, 283, 283, "CID"], [106, 107, 293, 294, "CID"], [161, 162, 216, 216, "CID"], [161, 162, 283, 283, "CID"], [161, 162, 293, 294, "CID"], [178, 179, 216, 216, "CID"], [178, 179, 283, 283, "CID"], [178, 179, 293, 294, "CID"], [187, 188, 216, 216, "CID"], [187, 188, 283, 283, "CID"], [187, 188, 293, 294, "CID"], [241, 242, 216, 216, "CID"], [241, 242, 283, 283, "CID"], [241, 242, 293, 294, "CID"], [259, 260, 216, 216, "CID"], [259, 260, 283, 283, "CID"], [259, 260, 293, 294, "CID"], [331, 332, 216, 216, "CID"], [331, 332, 283, 283, "CID"], [331, 332, 293, 294, "CID"]]], "clusters": [], "translated": "胸苷酸合酶抑制剂 <0>N10-炔丙基-5, 8-二氮杂叶酸</0> (<1>CB 3717</1>) 的近期临床前和临床研究。<2>CB 3717</2>，<3>N10-炔丙基-5, 8-二氮杂叶酸</3>，是胸苷酸合酶(TS)的紧密结合抑制剂，其<20>细胞毒性</20>是仅通过抑制这种酶来介导。最近的临床前研究集中在<4>CB 3717</4>聚谷氨酸的细胞内形成。将L1210细胞暴露于50 microM [3H]<5>CB 3717</5> 12小时后，30%的可提取放射性可被解释为<6>CB 3717</6>四谷氨酸和五谷氨酸，由高压液相色谱(HPLC)分析确定。作为分离的L1210 TS抑制剂，CB 3717二谷氨酸、三谷氨酸、四谷氨酸和五谷氨酸盐的效力分别比<7>CB 3717</7>高26、87、119和114倍。因此，可能是<8>CB 3717</8><21>细胞毒性</21>的重要决定因素。在<9>CB 3717</9>的早期临床研究中，已在<23>乳腺癌</23>、<24>卵巢癌</24>、<25>肝癌</25>和<26>间皮瘤</26>。 <22>毒性</22>包括<13>肝毒性</13>、<15>不适</15>和剂量限制性的<17>肾毒性</17>。后一种效应被认为是由于<10>CB 3717</10>在酸性条件下溶解度差导致药物在肾小管内沉淀。为了克服这个问题，一项使用碱性利尿剂辅助<11>CB 3717</11>的临床试验正在进行中。初步结果表明，400和500 mg/m2剂量下，可能达到了<18>肾毒性</18>的降低，但仅在10名患者中出现了1例<19>肾毒性</19>。<14>肝毒性</14>和<16>不适</16>仍是最常见的副作用。在3名患者中发现了抗肿瘤活性的证据。药代动力学研究表明，碱性利尿不会改变<12>CB 3717</12>血浆水平或尿液排泄，并且很容易实现令人满意的尿液碱化。", "revised": true}
{"doc_key": "21418164", "sentences": [["CCNU", "(", "lomustine", ")", "toxicity", "in", "dogs", ":", "a", "retrospective", "study", "(", "2002", "-", "07", ")", ".", "OBJECTIVE", ":", "To", "describe", "the", "incidence", "of", "haematological", ",", "renal", ",", "hepatic", "and", "gastrointestinal", "toxicities", "in", "tumour", "-", "bearing", "dogs", "receiving", "1", "-", "(", "2", "-", "chloroethyl", ")", "-", "3", "-", "cyclohexyl", "-", "1", "-", "nitrosourea", "(", "CCNU", ")", ".", "DESIGN", ":", "The", "medical", "records", "of", "206", "dogs", "that", "were", "treated", "with", "CCNU", "at", "the", "Melbourne", "Veterinary", "Specialist", "Centre", "between", "February", "2002", "and", "December", "2007", "were", "retrospectively", "evaluated", ".", "RESULTS", ":", "Of", "the", "206", "dogs", "treated", "with", "CCNU", ",", "185", "met", "the", "inclusion", "criteria", "for", "at", "least", "one", "class", "of", "toxicity", ".", "CCNU", "was", "used", "most", "commonly", "in", "the", "treatment", "of", "lymphoma", ",", "mast", "cell", "tumour", ",", "brain", "tumour", ",", "histiocytic", "tumours", "and", "epitheliotropic", "lymphoma", ".", "Throughout", "treatment", ",", "56", ".", "9", "%", "of", "dogs", "experienced", "neutropenia", ",", "34", ".", "2", "%", "experienced", "anaemia", "and", "14", ".", "2", "%", "experienced", "thrombocytopenia", ".", "Gastrointestinal", "toxicosis", "was", "detected", "in", "37", ".", "8", "%", "of", "dogs", ",", "the", "most", "common", "sign", "of", "which", "was", "vomiting", "(", "24", ".", "3", "%", ")", ".", "Potential", "renal", "toxicity", "and", "elevated", "alanine", "transaminase", "(", "ALT", ")", "concentration", "were", "reported", "in", "12", ".", "2", "%", "and", "48", ".", "8", "%", "of", "dogs", ",", "respectively", ".", "The", "incidence", "of", "hepatic", "failure", "was", "1", ".", "2", "%", ".", "CONCLUSIONS", ":", "CCNU", "-", "associated", "toxicity", "in", "dogs", "is", "common", ",", "but", "is", "usually", "not", "life", "threatening", "."]], "ner": [[[0, 0, "Chemical"], [2, 2, "Chemical"], [38, 52, "Chemical"], [54, 54, "Chemical"], [69, 69, "Chemical"], [94, 94, "Chemical"], [109, 109, "Chemical"], [227, 227, "Chemical"], [24, 31, "Disease"], [159, 160, "Disease"], [143, 143, "Disease"], [150, 150, "Disease"], [157, 157, "Disease"], [178, 178, "Disease"], [217, 218, "Disease"], [4, 4, "Disease"], [107, 107, "Disease"], [188, 188, "Disease"], [230, 230, "Disease"], [118, 118, "Disease"], [130, 131, "Disease"], [120, 122, "Disease"], [124, 125, "Disease"], [127, 128, "Disease"], [191, 191, "Chemical"]]], "relations": [[[0, 0, 24, 31, "CID"], [2, 2, 24, 31, "CID"], [38, 52, 24, 31, "CID"], [54, 54, 24, 31, "CID"], [69, 69, 24, 31, "CID"], [94, 94, 24, 31, "CID"], [109, 109, 24, 31, "CID"], [227, 227, 24, 31, "CID"], [0, 0, 159, 160, "CID"], [2, 2, 159, 160, "CID"], [38, 52, 159, 160, "CID"], [54, 54, 159, 160, "CID"], [69, 69, 159, 160, "CID"], [94, 94, 159, 160, "CID"], [109, 109, 159, 160, "CID"], [227, 227, 159, 160, "CID"], [0, 0, 143, 143, "CID"], [2, 2, 143, 143, "CID"], [38, 52, 143, 143, "CID"], [54, 54, 143, 143, "CID"], [69, 69, 143, 143, "CID"], [94, 94, 143, 143, "CID"], [109, 109, 143, 143, "CID"], [227, 227, 143, 143, "CID"], [0, 0, 150, 150, "CID"], [2, 2, 150, 150, "CID"], [38, 52, 150, 150, "CID"], [54, 54, 150, 150, "CID"], [69, 69, 150, 150, "CID"], [94, 94, 150, 150, "CID"], [109, 109, 150, 150, "CID"], [227, 227, 150, 150, "CID"], [0, 0, 157, 157, "CID"], [2, 2, 157, 157, "CID"], [38, 52, 157, 157, "CID"], [54, 54, 157, 157, "CID"], [69, 69, 157, 157, "CID"], [94, 94, 157, 157, "CID"], [109, 109, 157, 157, "CID"], [227, 227, 157, 157, "CID"], [0, 0, 178, 178, "CID"], [2, 2, 178, 178, "CID"], [38, 52, 178, 178, "CID"], [54, 54, 178, 178, "CID"], [69, 69, 178, 178, "CID"], [94, 94, 178, 178, "CID"], [109, 109, 178, 178, "CID"], [227, 227, 178, 178, "CID"], [0, 0, 217, 218, "CID"], [2, 2, 217, 218, "CID"], [38, 52, 217, 218, "CID"], [54, 54, 217, 218, "CID"], [69, 69, 217, 218, "CID"], [94, 94, 217, 218, "CID"], [109, 109, 217, 218, "CID"], [227, 227, 217, 218, "CID"]]], "clusters": [], "translated": " <0>CCNU</0>（<1>洛莫司汀</1>）<15>毒性</15>对狗：一项回顾性研究（2002-07）。目的：描述<8>血液学、肾脏、肝脏和胃肠道毒性</8>在接受<2>1-(2-氯乙基)-3-环己基-1-亚硝基脲</2>（<3>CCNU</3>）治疗的荷瘤犬中的发生率。设计：对2002年2月至2007年12月期间在墨尔本兽医专家中心接受<4>CCNU</4>治疗的206只狗的病历进行回顾性评估。结果：在接受<5>CCNU</5>治疗的206只狗中，185只符合至少一类<16>毒性</16>的纳入标准。<6>CCNU</6>最常用于治疗<19>淋巴瘤</19>、<21>肥大细胞瘤</21>、<22>脑瘤</22>、<23>组织细胞瘤肿瘤</23>和<20>上皮性淋巴瘤</20>。整个治疗过程中，56.9%的狗出现<10>中性粒细胞减少症</10>，34.2%经历过<11>贫血</11>，和14.2%经历过<12>血小板减少症</12>。<9>胃肠道毒性</9>检出37.8%的狗，其中最常见的体征是<13> 呕吐</13>(24.3%)。潜在的<17>肾毒性</17>和升高的<24>丙氨酸</24>转氨酶(ALT)浓度在12.2%和48.8%的狗中被报道。发生<14>肝功能衰竭</14>的发生率为1.2%。结论：<7>CCNU</7>相关的<18>毒性</18>在狗中很常见，但通常不会危及生命。", "revised": true}
{"doc_key": "14633084", "sentences": [["Use", "of", "dexamethasone", "with", "mesna", "for", "the", "prevention", "of", "ifosfamide", "-", "induced", "hemorrhagic", "cystitis", ".", "AIM", ":", "Hemorrhagic", "cystitis", "(", "HC", ")", "is", "a", "limiting", "side", "-", "effect", "of", "chemotherapy", "with", "ifosfamide", "(", "IFS", ")", ".", "In", "the", "study", "presented", "here", ",", "we", "investigated", "the", "use", "of", "dexamethasone", "in", "combination", "with", "mesna", "for", "the", "prevention", "of", "IFS", "-", "induced", "HC", ".", "METHODS", ":", "Male", "Wistar", "rats", "(", "150", "-", "200", "g", ";", "6", "rats", "per", "group", ")", "were", "treated", "with", "saline", "or", "mesna", "5", "min", "(", "i", ".", "p", ".", ")", "before", "and", "2", "and", "6", "h", "after", "(", "v", ".", "o", ".", ")", "administration", "of", "IFS", ".", "One", ",", "two", "or", "three", "doses", "of", "mesna", "were", "replaced", "with", "dexamethasone", "alone", "or", "with", "dexamethasone", "plus", "mesna", ".", "Cystitis", "was", "evaluated", "24", "h", "after", "its", "induction", "by", "the", "changes", "in", "bladder", "wet", "weight", "and", "by", "macroscopic", "and", "microscopic", "analysis", ".", "RESULTS", ":", "The", "replacement", "of", "the", "last", "dose", "or", "the", "last", "two", "doses", "of", "mesna", "with", "dexamethasone", "reduced", "the", "increase", "in", "bladder", "wet", "weight", "induced", "by", "IFS", "by", "84", ".", "79", "%", "and", "89", ".", "13", "%", ",", "respectively", ".", "In", "addition", ",", "it", "almost", "abolished", "the", "macroscopic", "and", "microscopic", "alterations", "induced", "by", "IFS", ".", "Moreover", ",", "the", "addition", "of", "dexamethasone", "to", "the", "last", "two", "doses", "of", "mesna", "was", "more", "efficient", "than", "three", "doses", "of", "mesna", "alone", "when", "evaluated", "microscopically", ".", "CONCLUSION", ":", "Dexamethasone", "in", "combination", "with", "mesna", "was", "efficient", "in", "blocking", "IFS", "-", "induced", "HC", ".", "However", ",", "the", "replacement", "of", "last", "two", "doses", "of", "mesna", "with", "saline", "or", "all", "of", "the", "mesna", "doses", "with", "dexamethasone", "did", "not", "prevent", "HC", "."]], "ner": [[[9, 9, "Chemical"], [31, 31, "Chemical"], [33, 33, "Chemical"], [56, 56, "Chemical"], [106, 106, "Chemical"], [175, 175, "Chemical"], [202, 202, "Chemical"], [241, 241, "Chemical"], [12, 13, "Disease"], [17, 18, "Disease"], [20, 20, "Disease"], [59, 59, "Disease"], [244, 244, "Disease"], [269, 269, "Disease"], [127, 127, "Disease"], [2, 2, "Chemical"], [47, 47, "Chemical"], [119, 119, "Chemical"], [123, 123, "Chemical"], [165, 165, "Chemical"], [209, 209, "Chemical"], [232, 232, "Chemical"], [265, 265, "Chemical"], [4, 4, "Chemical"], [51, 51, "Chemical"], [82, 82, "Chemical"], [115, 115, "Chemical"], [125, 125, "Chemical"], [163, 163, "Chemical"], [216, 216, "Chemical"], [224, 224, "Chemical"], [236, 236, "Chemical"], [255, 255, "Chemical"], [262, 262, "Chemical"]]], "relations": [[[9, 9, 12, 13, "CID"], [9, 9, 17, 18, "CID"], [9, 9, 20, 20, "CID"], [9, 9, 59, 59, "CID"], [9, 9, 244, 244, "CID"], [9, 9, 269, 269, "CID"], [31, 31, 12, 13, "CID"], [31, 31, 17, 18, "CID"], [31, 31, 20, 20, "CID"], [31, 31, 59, 59, "CID"], [31, 31, 244, 244, "CID"], [31, 31, 269, 269, "CID"], [33, 33, 12, 13, "CID"], [33, 33, 17, 18, "CID"], [33, 33, 20, 20, "CID"], [33, 33, 59, 59, "CID"], [33, 33, 244, 244, "CID"], [33, 33, 269, 269, "CID"], [56, 56, 12, 13, "CID"], [56, 56, 17, 18, "CID"], [56, 56, 20, 20, "CID"], [56, 56, 59, 59, "CID"], [56, 56, 244, 244, "CID"], [56, 56, 269, 269, "CID"], [106, 106, 12, 13, "CID"], [106, 106, 17, 18, "CID"], [106, 106, 20, 20, "CID"], [106, 106, 59, 59, "CID"], [106, 106, 244, 244, "CID"], [106, 106, 269, 269, "CID"], [175, 175, 12, 13, "CID"], [175, 175, 17, 18, "CID"], [175, 175, 20, 20, "CID"], [175, 175, 59, 59, "CID"], [175, 175, 244, 244, "CID"], [175, 175, 269, 269, "CID"], [202, 202, 12, 13, "CID"], [202, 202, 17, 18, "CID"], [202, 202, 20, 20, "CID"], [202, 202, 59, 59, "CID"], [202, 202, 244, 244, "CID"], [202, 202, 269, 269, "CID"], [241, 241, 12, 13, "CID"], [241, 241, 17, 18, "CID"], [241, 241, 20, 20, "CID"], [241, 241, 59, 59, "CID"], [241, 241, 244, 244, "CID"], [241, 241, 269, 269, "CID"], [9, 9, 127, 127, "CID"], [31, 31, 127, 127, "CID"], [33, 33, 127, 127, "CID"], [56, 56, 127, 127, "CID"], [106, 106, 127, 127, "CID"], [175, 175, 127, 127, "CID"], [202, 202, 127, 127, "CID"], [241, 241, 127, 127, "CID"]]], "clusters": [], "translated": "使用<15>地塞米松</15>与<23>美司钠</23>联合预防<0>异环磷酰胺</0>诱发的<8>出血性膀胱炎</8>。目的：化疗药物<1>异环磷酰胺</1>（<2>IFS</2>）引发的<9>出血性膀胱炎</9>（<10>HC</10>）是一个限制化疗的副作用。本研究调查了联合应用<16>地塞米松</16>和<24>美司钠</24>预防<3>IFS</3> - 引起的<11>HC</11>。方法：雄性Wistar大鼠（150-200g；每组6只）在<4>IFS</4>给药前5分钟（i.p.）和给药后2小时和6小时（v.o.）用生理盐水或<25>美司钠</25>治疗。一剂、两剂或三剂<26>美司钠</26>被<17>单用地塞米松</17>或替换为<18>地塞米松</18>和<27>美司钠</27>。通过膀胱湿重变化、宏观和微观分析评估了<14>膀胱炎</14> 24小时。结果：用<19>地塞米松</19>替代最后一剂或最后两剂<28>美司钠</28>，可分别使由<5>IFS</5>引起的膀胱湿重增加减少84.79%和89.13%。此外，它几乎消除了由<6>IFS</6>引起的宏观和微观变化。此外，当在最后两剂<29>美司钠</29>中加入<20>地塞米松</20>时，在显微镜下评估时与单独使用三剂<30>美司钠</30>相比更有效。结论：<21>地塞米松</21>与<31>美司钠</31>联合应用可有效阻断<7>IFS</7>引发的<12>HC</12>。然而，用生理盐水替换最后两剂<32>美司钠</32>或替换所有<33>美司钠</33>剂量为<22>地塞米松</22>均不能预防<13>HC</13>。", "revised": true}
{"doc_key": "7785794", "sentences": [["Refractory", "cardiogenic", "shock", "and", "complete", "heart", "block", "after", "verapamil", "SR", "and", "metoprolol", "treatment", ".", "A", "case", "report", ".", "A", "seventy", "-", "eight", "-", "year", "-", "old", "woman", "presented", "with", "complete", "heart", "block", "and", "refractory", "hypotension", "two", "days", "after", "a", "therapeutic", "dose", "of", "sustained", "-", "release", "verapamil", "with", "concomitant", "use", "of", "metoprolol", ".", "The", "patient", "continued", "to", "remain", "hypotensive", "with", "complete", "heart", "block", ",", "even", "with", "multiple", "uses", "of", "intravenous", "atropine", "as", "well", "as", "high", "doses", "of", "pressor", "agents", "such", "as", "dopamine", "and", "dobutamine", ".", "However", ",", "shortly", "after", "the", "use", "of", "intravenous", "calcium", "chloride", ",", "the", "refractory", "hypotension", "and", "complete", "heart", "block", "resolved", "."]], "ner": [[[8, 8, "Chemical"], [45, 45, "Chemical"], [5, 6, "Disease"], [30, 31, "Disease"], [60, 61, "Disease"], [100, 101, "Disease"], [11, 11, "Chemical"], [50, 50, "Chemical"], [34, 34, "Disease"], [57, 57, "Disease"], [97, 97, "Disease"], [1, 2, "Disease"], [69, 69, "Chemical"], [80, 80, "Chemical"], [82, 82, "Chemical"], [92, 93, "Chemical"]]], "relations": [[[8, 8, 5, 6, "CID"], [8, 8, 30, 31, "CID"], [8, 8, 60, 61, "CID"], [8, 8, 100, 101, "CID"], [45, 45, 5, 6, "CID"], [45, 45, 30, 31, "CID"], [45, 45, 60, 61, "CID"], [45, 45, 100, 101, "CID"], [11, 11, 5, 6, "CID"], [11, 11, 30, 31, "CID"], [11, 11, 60, 61, "CID"], [11, 11, 100, 101, "CID"], [50, 50, 5, 6, "CID"], [50, 50, 30, 31, "CID"], [50, 50, 60, 61, "CID"], [50, 50, 100, 101, "CID"], [8, 8, 34, 34, "CID"], [8, 8, 57, 57, "CID"], [8, 8, 97, 97, "CID"], [45, 45, 34, 34, "CID"], [45, 45, 57, 57, "CID"], [45, 45, 97, 97, "CID"], [11, 11, 34, 34, "CID"], [11, 11, 57, 57, "CID"], [11, 11, 97, 97, "CID"], [50, 50, 34, 34, "CID"], [50, 50, 57, 57, "CID"], [50, 50, 97, 97, "CID"]]], "clusters": [], "translated": "<0>维拉帕米</0> SR 和 <6>美托洛尔</6> 治疗后难治性 <11>心源性休克</11> 和完全性 <2>心脏传导阻滞</2>。个案报告。一名78岁的女性在服用治疗剂量的缓释<1>维拉帕米</1>后两天出现完全性<3>心脏传导阻滞</3>和难治性<8>低血压</8>，伴随使用<7>美托洛尔</7>。患者继续保持<9>低血压</9>并伴有完全<4>心脏传导阻滞</4>，即使多次使用静脉内<12>阿托品</12>以及高剂量的升压剂如<13>多巴胺</13>和<14>多巴酚丁胺</14>。然而，在使用静脉注射<15>氯化钙</15>后不久，难治性<10>低血压</10>和完全性<5>心脏传导阻滞</5>得到解决。", "revised": true}
{"doc_key": "8888541", "sentences": [["Serotonin", "syndrome", "from", "venlafaxine", "-", "tranylcypromine", "interaction", ".", "Excessive", "stimulation", "of", "serotonin", "5HT1A", "receptors", "causes", "a", "syndrome", "of", "serotonin", "excess", "that", "consists", "of", "shivering", ",", "muscle", "rigidity", ",", "salivation", ",", "confusion", ",", "agitation", "and", "hyperthermia", ".", "The", "most", "common", "cause", "of", "this", "syndrome", "is", "an", "interaction", "between", "a", "monoamine", "oxidase", "inhibitor", "(", "MAOI", ")", "and", "a", "specific", "serotonin", "reuptake", "inhibitor", ".", "Venlafaxine", "is", "a", "new", "antidepressant", "agent", "that", "inhibits", "the", "reuptake", "of", "serotonin", "and", "norepinephrine", ".", "We", "report", "a", "venlafaxine", "-", "MAOI", "interaction", "that", "resulted", "in", "the", "serotonin", "syndrome", "in", "a", "23", "-", "y", "-", "old", "male", "who", "was", "taking", "tranylcypromine", "for", "depression", ".", "He", "had", "been", "well", "until", "the", "morning", "of", "presentation", "when", "he", "took", "1", "/", "2", "tab", "of", "venlafaxine", ".", "Within", "2", "h", "he", "became", "confused", "with", "jerking", "movements", "of", "his", "extremities", ",", "tremors", "and", "rigidity", ".", "He", "was", "brought", "directly", "to", "a", "hospital", "where", "he", "was", "found", "to", "be", "agitated", "and", "confused", "with", "shivering", ",", "myoclonic", "jerks", ",", "rigidity", ",", "salivation", "and", "diaphoresis", ".", "His", "pupils", "were", "7", "mm", "and", "sluggishly", "reactive", "to", "light", ".", "Vital", "signs", "were", ":", "blood", "pressure", "120", "/", "67", "mm", "Hg", ",", "heart", "rate", "127", "/", "min", ",", "respiratory", "rate", "28", "/", "min", ",", "and", "temperature", "97", "F", ".", "After", "180", "mg", "of", "diazepam", "i", ".", "v", ".", "he", "remained", "tremulous", "with", "muscle", "rigidity", "and", "clenched", "jaws", ".", "He", "was", "intubated", "for", "airway", "protection", "and", "because", "of", "hypoventilation", ",", "and", "was", "paralyzed", "to", "control", "muscle", "rigidity", ".", "His", "subsequent", "course", "was", "remarkable", "for", "non", "-", "immune", "thrombocytopenia", "which", "resolved", ".", "The", "patient", "'s", "maximal", "temperature", "was", "101", ".", "2", "F", "and", "his", "CPK", "remained", "<", "500", "units", "/", "L", "with", "no", "other", "evidence", "of", "rhabdomyolysis", ".", "His", "mental", "status", "normalized", "and", "he", "was", "transferred", "to", "a", "psychiatry", "ward", ".", "This", "patient", "survived", "without", "sequelae", "due", "to", "the", "aggressive", "sedation", "and", "neuromuscular", "paralysis", "."]], "ner": [[[3, 3, "Chemical"], [61, 61, "Chemical"], [79, 79, "Chemical"], [121, 121, "Chemical"], [0, 1, "Disease"], [87, 88, "Disease"], [5, 5, "Chemical"], [100, 100, "Chemical"], [25, 26, "Disease"], [138, 138, "Disease"], [162, 162, "Disease"], [221, 222, "Disease"], [243, 244, "Disease"], [28, 28, "Disease"], [164, 164, "Disease"], [30, 30, "Disease"], [34, 34, "Disease"], [136, 136, "Disease"], [159, 160, "Disease"], [255, 255, "Disease"], [11, 11, "Chemical"], [18, 18, "Chemical"], [57, 57, "Chemical"], [72, 72, "Chemical"], [74, 74, "Chemical"], [212, 212, "Chemical"], [32, 32, "Disease"], [102, 102, "Disease"], [236, 236, "Disease"], [240, 240, "Disease"], [310, 310, "Disease"], [283, 283, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [3, 3, 87, 88, "CID"], [61, 61, 0, 1, "CID"], [61, 61, 87, 88, "CID"], [79, 79, 0, 1, "CID"], [79, 79, 87, 88, "CID"], [121, 121, 0, 1, "CID"], [121, 121, 87, 88, "CID"], [5, 5, 0, 1, "CID"], [5, 5, 87, 88, "CID"], [100, 100, 0, 1, "CID"], [100, 100, 87, 88, "CID"], [3, 3, 25, 26, "CID"], [3, 3, 138, 138, "CID"], [3, 3, 162, 162, "CID"], [3, 3, 221, 222, "CID"], [3, 3, 243, 244, "CID"], [61, 61, 25, 26, "CID"], [61, 61, 138, 138, "CID"], [61, 61, 162, 162, "CID"], [61, 61, 221, 222, "CID"], [61, 61, 243, 244, "CID"], [79, 79, 25, 26, "CID"], [79, 79, 138, 138, "CID"], [79, 79, 162, 162, "CID"], [79, 79, 221, 222, "CID"], [79, 79, 243, 244, "CID"], [121, 121, 25, 26, "CID"], [121, 121, 138, 138, "CID"], [121, 121, 162, 162, "CID"], [121, 121, 221, 222, "CID"], [121, 121, 243, 244, "CID"], [3, 3, 28, 28, "CID"], [3, 3, 164, 164, "CID"], [61, 61, 28, 28, "CID"], [61, 61, 164, 164, "CID"], [79, 79, 28, 28, "CID"], [79, 79, 164, 164, "CID"], [121, 121, 28, 28, "CID"], [121, 121, 164, 164, "CID"], [3, 3, 30, 30, "CID"], [61, 61, 30, 30, "CID"], [79, 79, 30, 30, "CID"], [121, 121, 30, 30, "CID"], [3, 3, 34, 34, "CID"], [61, 61, 34, 34, "CID"], [79, 79, 34, 34, "CID"], [121, 121, 34, 34, "CID"], [3, 3, 136, 136, "CID"], [61, 61, 136, 136, "CID"], [79, 79, 136, 136, "CID"], [121, 121, 136, 136, "CID"], [3, 3, 159, 160, "CID"], [61, 61, 159, 160, "CID"], [79, 79, 159, 160, "CID"], [121, 121, 159, 160, "CID"], [3, 3, 255, 255, "CID"], [61, 61, 255, 255, "CID"], [79, 79, 255, 255, "CID"], [121, 121, 255, 255, "CID"], [5, 5, 25, 26, "CID"], [5, 5, 138, 138, "CID"], [5, 5, 162, 162, "CID"], [5, 5, 221, 222, "CID"], [5, 5, 243, 244, "CID"], [100, 100, 25, 26, "CID"], [100, 100, 138, 138, "CID"], [100, 100, 162, 162, "CID"], [100, 100, 221, 222, "CID"], [100, 100, 243, 244, "CID"], [5, 5, 28, 28, "CID"], [5, 5, 164, 164, "CID"], [100, 100, 28, 28, "CID"], [100, 100, 164, 164, "CID"], [5, 5, 30, 30, "CID"], [100, 100, 30, 30, "CID"], [5, 5, 34, 34, "CID"], [100, 100, 34, 34, "CID"], [5, 5, 136, 136, "CID"], [100, 100, 136, 136, "CID"], [5, 5, 159, 160, "CID"], [100, 100, 159, 160, "CID"], [5, 5, 255, 255, "CID"], [100, 100, 255, 255, "CID"]]], "clusters": [], "translated": "<4>5-羟色胺综合征</4>来自<0>文拉法辛</0>-<6>反苯环丙胺</6>相互作用。过度刺激<20>血清素</20> 5HT1A 受体会导致<21>血清素</21>过量综合征，包括寒战、<8>肌肉僵硬</8> 、<13>流涎</13>、<15>意识模糊</15>、<26>激动</26>和<16>体温过高</16>。该综合征最常见的原因是单胺氧化酶抑制剂 ( MAOI ) 和特定的<22>5-羟色胺</22> 再摄取抑制剂之间的相互作用。 <1>文拉法辛</1>是一种新型抗抑郁药，可抑制<23>血清素</23>和<24>去甲肾上腺素</24>的再摄取。我们报告了<2>文拉法辛</2> - MAOI 相互作用导致 <5>5-羟色胺综合征</5>在一名服用<7>反苯环丙胺</7>治疗<27>抑郁症的23岁男性</27>。直到就诊那天早上服用 1/2 片<3>文拉法辛</3>之前，他一直很好。在 2 小时内，他变得对四肢的抽搐运动、<17>震颤</17>和<9>僵硬</9>感到困惑。他被直接送往医院，在那里发现他烦躁不安，并伴有颤抖、<18>肌阵挛性抽搐</18>、<10>强直</10>、<14>流涎</14>和出汗。他的瞳孔为7毫米，对光反应迟钝。生命体征为：血压 120/67 mm Hg，心率 127/分钟，呼吸频率28/分钟，体温 97 F。在注射180 mg<25>地西泮</25>后，他因<11>肌肉僵硬</11>和咬紧牙关而一直颤抖。由于<28>通气不足</28>，他被插管以保护气道，<29>瘫痪</29>以控制<12>肌肉僵硬</12>。他随后的非免疫性<19>血小板减少症</19>病程非常显着，该病已痊愈。患者的最高体温为101.2F，他的CPK保持<500单位/升，没有其他<31>横纹肌溶解症</31>的证据。他的精神状态恢复正常，并被转移到精神病房。由于积极镇静和<30>神经肌肉麻痹</30>，这名患者没有留下后遗症。", "revised": true}
{"doc_key": "2557556", "sentences": [["Involvement", "of", "the", "mu", "-", "opiate", "receptor", "in", "peripheral", "analgesia", ".", "The", "intradermal", "injection", "of", "mu", "(", "morphine", ",", "Tyr", "-", "D", "-", "Ala", "-", "Gly", "-", "NMe", "-", "Phe", "-", "Gly", "-", "ol", "and", "morphiceptin", ")", ",", "kappa", "(", "trans", "-", "3", ",", "4", "-", "dichloro", "-", "N", "-", "methyl", "-", "N", "[", "2", "-", "(", "1", "-", "pyrrolidinyl", ")", "cyclohexyl", "]", "benzeneactemide", ")", "and", "delta", "(", "[", "D", "-", "Pen2", ".", "5", "]", "-", "enkephalin", "and", "[", "D", "-", "Ser2", "]", "-", "[", "Leu", "]", "enkephalin", "-", "Thr", ")", "selective", "opioid", "-", "agonists", ",", "by", "themselves", ",", "did", "not", "significantly", "affect", "the", "mechanical", "nociceptive", "threshold", "in", "the", "hindpaw", "of", "the", "rat", ".", "Intradermal", "injection", "of", "mu", ",", "but", "not", "delta", "or", "kappa", "opioid", "-", "agonists", ",", "however", ",", "produced", "dose", "-", "dependent", "inhibition", "of", "prostaglandin", "E2", "-", "induced", "hyperalgesia", ".", "The", "analgesic", "effect", "of", "the", "mu", "-", "agonist", "morphine", "was", "dose", "-", "dependently", "antagonized", "by", "naloxone", "and", "prevented", "by", "co", "-", "injection", "of", "pertussis", "toxin", ".", "Morphine", "did", "not", ",", "however", ",", "alter", "the", "hyperalgesia", "induced", "by", "8", "-", "bromo", "cyclic", "adenosine", "monophosphate", ".", "We", "conclude", "that", "the", "analgesic", "action", "of", "opioids", "on", "the", "peripheral", "terminals", "of", "primary", "afferents", "is", "via", "a", "binding", "site", "with", "characteristics", "of", "the", "mu", "-", "opioid", "receptor", "and", "that", "this", "action", "is", "mediated", "by", "inhibition", "of", "the", "cyclic", "adenosine", "monophosphate", "second", "messenger", "system", "."]], "ner": [[[136, 137, "Chemical"], [140, 140, "Disease"], [176, 176, "Disease"], [179, 184, "Chemical"], [17, 17, "Chemical"], [150, 150, "Chemical"], [168, 168, "Chemical"], [9, 9, "Disease"], [19, 33, "Chemical"], [35, 35, "Chemical"], [40, 63, "Chemical"], [68, 76, "Chemical"], [78, 89, "Chemical"], [157, 157, "Chemical"], [224, 226, "Chemical"]]], "relations": [[[136, 137, 140, 140, "CID"], [136, 137, 176, 176, "CID"], [179, 184, 140, 140, "CID"], [179, 184, 176, 176, "CID"]]], "clusters": [], "translated": "μ-阿片受体参与外周<7>镇痛</7>。皮内注射 mu (<4>吗啡</4>、<8>Tyr-D-Ala-Gly-NMe-Phe-Gly-ol</8> 和 <9>吗啡肽</9>)、kappa (<10>反式-3,4-二氯-N-甲基-N[2-(1-吡咯烷基)环己基]苯乙酰胺</10>) 和 δ (<11>[D-Pen2.5]-脑啡肽</11> 和 <12>[D-Ser2]-[Leu]脑啡肽-Thr</12>) 选择性阿片类激动剂本身不会显着影响大鼠后爪的机械伤害性阈值。然而，皮内注射 mu 而不是 delta 或 kappa 阿片类激动剂对 <0>前列腺素E2</0>诱导的<1>痛觉过敏</1>产生剂量依赖性抑制。μ-激动剂<5>吗啡</5>的镇痛作用被<13>纳洛酮</13>剂量依赖性地拮抗，并被共同注射的百日咳毒素所阻止。<6>吗啡</6>并没有改变<3>8-溴环磷酸腺苷</3>引起的<2>痛觉过敏</2>。我们得出结论，阿片类药物对初级传入神经末梢的镇痛作用是通过具有 mu- 阿片受体特征的结合位点实现的，并且该作用是通过抑制<14>环磷酸腺苷</14>第二信使介导的系统。", "revised": true}
{"doc_key": "18674790", "sentences": [["High", "fat", "diet", "-", "fed", "obese", "rats", "are", "highly", "sensitive", "to", "doxorubicin", "-", "induced", "cardiotoxicity", ".", "Often", ",", "chemotherapy", "by", "doxorubicin", "(", "Adriamycin", ")", "is", "limited", "due", "to", "life", "threatening", "cardiotoxicity", "in", "patients", "during", "and", "posttherapy", ".", "Recently", ",", "we", "have", "shown", "that", "moderate", "diet", "restriction", "remarkably", "protects", "against", "doxorubicin", "-", "induced", "cardiotoxicity", ".", "This", "cardioprotection", "is", "accompanied", "by", "decreased", "cardiac", "oxidative", "stress", "and", "triglycerides", "and", "increased", "cardiac", "fatty", "-", "acid", "oxidation", ",", "ATP", "synthesis", ",", "and", "upregulated", "JAK", "/", "STAT3", "pathway", ".", "In", "the", "current", "study", ",", "we", "investigated", "whether", "a", "physiological", "intervention", "by", "feeding", "40", "%", "high", "fat", "diet", "(", "HFD", ")", ",", "which", "induces", "obesity", "in", "male", "Sprague", "-", "Dawley", "rats", "(", "250", "-", "275", "g", ")", ",", "sensitizes", "to", "doxorubicin", "-", "induced", "cardiotoxicity", ".", "A", "LD", "(", "10", ")", "dose", "(", "8", "mg", "doxorubicin", "/", "kg", ",", "ip", ")", "administered", "on", "day", "43", "of", "the", "HFD", "feeding", "regimen", "led", "to", "higher", "cardiotoxicity", ",", "cardiac", "dysfunction", ",", "lipid", "peroxidation", ",", "and", "80", "%", "mortality", "in", "the", "obese", "(", "OB", ")", "rats", "in", "the", "absence", "of", "any", "significant", "renal", "or", "hepatic", "toxicity", ".", "Doxorubicin", "toxicokinetics", "studies", "revealed", "no", "change", "in", "accumulation", "of", "doxorubicin", "and", "doxorubicinol", "(", "toxic", "metabolite", ")", "in", "the", "normal", "diet", "-", "fed", "(", "ND", ")", "and", "OB", "hearts", ".", "Mechanistic", "studies", "revealed", "that", "OB", "rats", "are", "sensitized", "due", "to", ":", "(", "1", ")", "higher", "oxyradical", "stress", "leading", "to", "upregulation", "of", "uncoupling", "proteins", "2", "and", "3", ",", "(", "2", ")", "downregulation", "of", "cardiac", "peroxisome", "proliferators", "activated", "receptor", "-", "alpha", ",", "(", "3", ")", "decreased", "plasma", "adiponectin", "levels", ",", "(", "4", ")", "decreased", "cardiac", "fatty", "-", "acid", "oxidation", "(", "666", ".", "9", "+", "/", "-", "14", ".", "0", "nmol", "/", "min", "/", "g", "heart", "in", "ND", "versus", "400", ".", "2", "+", "/", "-", "11", ".", "8", "nmol", "/", "min", "/", "g", "heart", "in", "OB", ")", ",", "(", "5", ")", "decreased", "mitochondrial", "AMP", "-", "alpha2", "protein", "kinase", ",", "and", "(", "6", ")", "86", "%", "drop", "in", "cardiac", "ATP", "levels", "accompanied", "by", "decreased", "ATP", "/", "ADP", "ratio", "after", "doxorubicin", "administration", ".", "Decreased", "cardiac", "erythropoietin", "and", "increased", "SOCS3", "further", "downregulated", "the", "cardioprotective", "JAK", "/", "STAT3", "pathway", ".", "In", "conclusion", ",", "HFD", "-", "induced", "obese", "rats", "are", "highly", "sensitized", "to", "doxorubicin", "-", "induced", "cardiotoxicity", "by", "substantially", "downregulating", "cardiac", "mitochondrial", "ATP", "generation", ",", "increasing", "oxidative", "stress", "and", "downregulating", "the", "JAK", "/", "STAT3", "pathway", "."]], "ner": [[[1, 1, "Chemical"], [99, 99, "Chemical"], [5, 5, "Disease"], [107, 107, "Disease"], [169, 169, "Disease"], [171, 171, "Disease"], [211, 211, "Disease"], [218, 218, "Disease"], [306, 306, "Disease"], [363, 363, "Disease"], [11, 11, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [49, 49, "Chemical"], [123, 123, "Chemical"], [137, 137, "Chemical"], [185, 185, "Chemical"], [194, 194, "Chemical"], [339, 339, "Chemical"], [369, 369, "Chemical"], [157, 158, "Disease"], [14, 14, "Disease"], [30, 30, "Disease"], [52, 52, "Disease"], [126, 126, "Disease"], [155, 155, "Disease"], [372, 372, "Disease"], [180, 183, "Disease"], [64, 64, "Chemical"], [73, 73, "Chemical"], [329, 329, "Chemical"], [334, 334, "Chemical"], [378, 378, "Chemical"], [196, 196, "Chemical"], [314, 314, "Chemical"], [336, 336, "Chemical"]]], "relations": [[[1, 1, 5, 5, "CID"], [1, 1, 107, 107, "CID"], [1, 1, 169, 169, "CID"], [1, 1, 171, 171, "CID"], [1, 1, 211, 211, "CID"], [1, 1, 218, 218, "CID"], [1, 1, 306, 306, "CID"], [1, 1, 363, 363, "CID"], [99, 99, 5, 5, "CID"], [99, 99, 107, 107, "CID"], [99, 99, 169, 169, "CID"], [99, 99, 171, 171, "CID"], [99, 99, 211, 211, "CID"], [99, 99, 218, 218, "CID"], [99, 99, 306, 306, "CID"], [99, 99, 363, 363, "CID"], [11, 11, 157, 158, "CID"], [20, 20, 157, 158, "CID"], [22, 22, 157, 158, "CID"], [49, 49, 157, 158, "CID"], [123, 123, 157, 158, "CID"], [137, 137, 157, 158, "CID"], [185, 185, 157, 158, "CID"], [194, 194, 157, 158, "CID"], [339, 339, 157, 158, "CID"], [369, 369, 157, 158, "CID"]]], "clusters": [], "translated": "高<0>脂肪</0>饮食喂养的<2>肥胖</2>大鼠对<10>多柔比星</10>诱导的<21>心脏毒性</21>高度敏感。通常，<11>多柔比星</11>（<12>阿霉素</12>）化疗在治疗期间和治疗后会因危及生命的<22>心脏毒性</22>而受到限制。最近，我们已经证明适度的饮食限制可以显着防止<13>阿霉素</13>引起的<23>心脏毒性</23>。这种心脏保护作用伴随着心脏氧化应激和<28>甘油三酯</28>的减少以及心脏脂肪酸氧化、<29>ATP</29>合成的增加以及 JAK/STAT3 通路的上调。在当前的研究中，我们调查了通过喂养40%高<1>脂肪</1>饮食 (HFD)，使雄性 Sprague-Dawley 大鼠 (250-275g)发生<3>肥胖</3>, 是否会导致对<14>多柔比星</14>诱导的<24>心脏毒性</24>敏感。在 HFD 喂养方案的第43天给予LD（10）剂量（8 mg <15>阿霉素</15>/kg，ip），在没有任何显着的<27>肾或肝毒性</27>情况下，导致更高的<25>心脏毒性</25>、<20>心脏功能障碍</20>、脂质过氧化和 80%的死亡率在<4>肥胖</4> (<5>OB</5>) 大鼠中。在正常饮食喂养（ND）和<6>OB</6>心脏中，<16>阿霉素</16>毒代动力学研究表明<17>阿霉素</17>和<33>阿霉素ol</33>（毒性代谢物）的积累没有变化。机制研究表明，由于以下原因，<7> OB </7>大鼠变得敏感：（1）较高的氧自由基压力导致解偶联蛋白2和3的上调，（2）心脏过氧化物酶体增殖物激活受体 -α的下调，（3）血浆脂联素水平降低，（4）心脏脂肪酸氧化降低（666.9 +/- 14.0 nmol/min/g心脏在ND对比400.2 +/- 11.8 nmol/min/g心脏在<8>OB</8>），（5）线粒体<34>AMP</34>-alpha2蛋白激酶减少，(6)在<18>多柔比星</18>给药后心脏<30>ATP</30>水平下降86％，并伴随着<31>ATP</31>/<35>ADP</35>比率的降低。心脏促红细胞生成素减少和增加SOCS3进一步下调心脏保护性 JAK/STAT3 通路。总之，HFD 诱导的<9>肥胖</9>大鼠对<19>多柔比星</19>诱导的<26>心脏毒性</26>高度敏感，通过显着下调心脏线粒体<32>ATP</32>生成、增加氧化应激和下调JAK/STAT3通路。", "revised": true}
{"doc_key": "7905523", "sentences": [["The", "safety", "and", "efficacy", "of", "combination", "N", "-", "butyl", "-", "deoxynojirimycin", "(", "SC", "-", "48334", ")", "and", "zidovudine", "in", "patients", "with", "HIV", "-", "1", "infection", "and", "200", "-", "500", "CD4", "cells", "/", "mm3", ".", "We", "conducted", "a", "double", "-", "blind", ",", "randomized", "phase", "II", "study", "to", "evaluate", "the", "safety", "and", "activity", "of", "combination", "therapy", "with", "N", "-", "butyl", "-", "deoxynojirimycin", "(", "SC", "-", "48334", ")", "(", "an", "alpha", "-", "glucosidase", "I", "inhibitor", ")", "and", "zidovudine", "versus", "zidovudine", "alone", ".", "Patients", "with", "200", "to", "500", "CD4", "cells", "/", "mm3", "who", "tolerated", "<", "or", "=", "12", "weeks", "of", "prior", "zidovudine", "therapy", "received", "SC", "-", "48334", "(", "1000", "mg", "every", "8", "h", ")", "and", "zidovudine", "(", "100", "mg", "every", "8", "h", ")", "or", "zidovudine", "and", "placebo", ".", "Sixty", "patients", "received", "combination", "therapy", "and", "58", ",", "zidovudine", "and", "placebo", ".", "Twenty", "-", "three", "patients", "(", "38", "%", ")", "and", "15", "(", "26", "%", ")", ",", "in", "the", "combination", "and", "zidovudine", "groups", ",", "respectively", ",", "discontinued", "therapy", "(", "p", "=", "0", ".", "15", ")", ".", "The", "mean", "SC", "-", "48334", "steady", "-", "state", "trough", "level", "(", "4", ".", "04", "+", "/", "-", "0", ".", "99", "micrograms", "/", "ml", ")", "was", "below", "the", "in", "vitro", "inhibitory", "concentration", "for", "human", "immunodeficiency", "virus", "(", "HIV", ")", ".", "The", "mean", "increase", "in", "CD4", "cells", "at", "week", "4", "was", "73", ".", "8", "cells", "/", "mm3", "and", "52", ".", "4", "cells", "/", "mm3", "for", "the", "combination", "and", "zidovudine", "groups", ",", "respectively", "(", "p", ">", "0", ".", "36", ")", ".", "For", "patients", "with", "prior", "zidovudine", "therapy", ",", "the", "mean", "change", "in", "CD4", "cells", "in", "the", "combination", "and", "zidovudine", "groups", "was", "63", ".", "7", "cells", "/", "mm3", "and", "4", ".", "9", "cells", "/", "mm3", "at", "week", "8", "and", "6", ".", "8", "cells", "/", "mm3", "and", "-", "45", ".", "1", "cells", "/", "mm3", "at", "week", "16", ",", "respectively", ".", "The", "number", "of", "patients", "with", "suppression", "of", "HIV", "p24", "antigenemia", "in", "the", "combination", "and", "zidovudine", "groups", "was", "six", "(", "40", "%", ")", "and", "two", "(", "11", "%", ")", "at", "week", "4", "(", "p", "=", "0", ".", "10", ")", "and", "five", "(", "45", "%", ")", "and", "two", "(", "14", "%", ")", "at", "week", "24", "(", "p", "=", "0", ".", "08", ")", ",", "respectively", ".", "Diarrhea", ",", "flatulence", ",", "abdominal", "pain", ",", "and", "weight", "loss", "were", "common", "for", "combination", "recipients", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[6, 10, "Chemical"], [12, 14, "Chemical"], [55, 59, "Chemical"], [61, 63, "Chemical"], [100, 102, "Chemical"], [172, 174, "Chemical"], [368, 368, "Disease"], [370, 370, "Disease"], [372, 373, "Disease"], [376, 377, "Disease"], [17, 17, "Chemical"], [74, 74, "Chemical"], [76, 76, "Chemical"], [97, 97, "Chemical"], [111, 111, "Chemical"], [120, 120, "Chemical"], [132, 132, "Chemical"], [155, 155, "Chemical"], [236, 236, "Chemical"], [252, 252, "Chemical"], [265, 265, "Chemical"], [319, 319, "Chemical"], [21, 24, "Disease"], [203, 203, "Disease"]]], "relations": [[[6, 10, 368, 368, "CID"], [12, 14, 368, 368, "CID"], [55, 59, 368, 368, "CID"], [61, 63, 368, 368, "CID"], [100, 102, 368, 368, "CID"], [172, 174, 368, 368, "CID"], [6, 10, 370, 370, "CID"], [12, 14, 370, 370, "CID"], [55, 59, 370, 370, "CID"], [61, 63, 370, 370, "CID"], [100, 102, 370, 370, "CID"], [172, 174, 370, 370, "CID"], [6, 10, 372, 373, "CID"], [12, 14, 372, 373, "CID"], [55, 59, 372, 373, "CID"], [61, 63, 372, 373, "CID"], [100, 102, 372, 373, "CID"], [172, 174, 372, 373, "CID"], [6, 10, 376, 377, "CID"], [12, 14, 376, 377, "CID"], [55, 59, 376, 377, "CID"], [61, 63, 376, 377, "CID"], [100, 102, 376, 377, "CID"], [172, 174, 376, 377, "CID"], [17, 17, 368, 368, "CID"], [74, 74, 368, 368, "CID"], [76, 76, 368, 368, "CID"], [97, 97, 368, 368, "CID"], [111, 111, 368, 368, "CID"], [120, 120, 368, 368, "CID"], [132, 132, 368, 368, "CID"], [155, 155, 368, 368, "CID"], [236, 236, 368, 368, "CID"], [252, 252, 368, 368, "CID"], [265, 265, 368, 368, "CID"], [319, 319, 368, 368, "CID"], [17, 17, 370, 370, "CID"], [74, 74, 370, 370, "CID"], [76, 76, 370, 370, "CID"], [97, 97, 370, 370, "CID"], [111, 111, 370, 370, "CID"], [120, 120, 370, 370, "CID"], [132, 132, 370, 370, "CID"], [155, 155, 370, 370, "CID"], [236, 236, 370, 370, "CID"], [252, 252, 370, 370, "CID"], [265, 265, 370, 370, "CID"], [319, 319, 370, 370, "CID"], [17, 17, 372, 373, "CID"], [74, 74, 372, 373, "CID"], [76, 76, 372, 373, "CID"], [97, 97, 372, 373, "CID"], [111, 111, 372, 373, "CID"], [120, 120, 372, 373, "CID"], [132, 132, 372, 373, "CID"], [155, 155, 372, 373, "CID"], [236, 236, 372, 373, "CID"], [252, 252, 372, 373, "CID"], [265, 265, 372, 373, "CID"], [319, 319, 372, 373, "CID"], [17, 17, 376, 377, "CID"], [74, 74, 376, 377, "CID"], [76, 76, 376, 377, "CID"], [97, 97, 376, 377, "CID"], [111, 111, 376, 377, "CID"], [120, 120, 376, 377, "CID"], [132, 132, 376, 377, "CID"], [155, 155, 376, 377, "CID"], [236, 236, 376, 377, "CID"], [252, 252, 376, 377, "CID"], [265, 265, 376, 377, "CID"], [319, 319, 376, 377, "CID"]]], "clusters": [], "translated": "<0>N-丁基-脱氧野尻霉素</0>（<1>SC-48334</1>）和<10>齐多夫定</10>联合治疗<22>HIV-1感染</22>和200-500个CD4细胞/mm3。我们进行了一项双盲、随机II期研究，以评估与<2>N-丁基脱氧野尻霉素</2>（<3>SC-48334</3>）（一种α-葡萄糖苷酶I抑制剂）和<11>齐多夫定</11>联合治疗的安全性和活性对比单独使用<12>齐多夫定</12>。CD4细胞数为200至500/mm3且耐受≤12周之前<13>齐多夫定</13>治疗的患者接受了<4>SC-48334</4>（每8小时1000毫克）和<14>齐多夫定</14>（每8小时100毫克）或<15>齐多夫定</15>和安慰剂。60名患者接受联合治疗，58名<16>齐多夫定</16>和安慰剂。联合用药组和<17>齐多夫定</17>组分别有23名（38%）和15名（26%）患者停止了治疗（p=0.15）。平均<5>SC-48334</5>稳态谷水平（4.04+/-0.99微克/毫升）低于人类<23>免疫缺陷</23> 病毒的体外抑制浓度（HIV）。第4周时CD4细胞的平均增加为73.8个细胞/mm3，分别为联合组和<18>齐多夫定</18>组的52.4个细胞/mm3（p>0.36）。对于先前接受过<19>齐多夫定</19>治疗的患者，联合治疗组和<20>齐多夫定</20>治疗组的CD4细胞平均变化为63.7个细胞/mm3和4.9个细胞/mm3，在第8周和第16周分别为9个细胞/mm3和6.8个细胞/mm3和-45.1个细胞/mm3。第4周（p=0.10)和<21>齐多夫定</21>组中抑制HIV p24抗原血症的患者人数分别为六名（40%）和两名（11%）,第24周分别为五名（45%）和两名（14%）（p=0.08）。<6>腹泻</6>、<7>胃肠胀气</7>、<8>腹痛</8>和<9>体重减轻</9>在联合接受者中很常见。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "9431903", "sentences": [["Effect", "of", "glyceryl", "trinitrate", "on", "the", "sphincter", "of", "Oddi", "spasm", "evoked", "by", "prostigmine", "-", "morphine", "administration", ".", "OBJECTIVE", ":", "In", "this", "study", "the", "effect", "of", "glyceryl", "trinitrate", "on", "the", "prostigmine", "-", "morphine", "-", "induced", "sphincter", "of", "Oddi", "spasm", "was", "evaluated", "in", "nine", "female", "patients", "with", "sphincter", "of", "Oddi", "dyskinesia", ".", "METHOD", ":", "Sphincter", "of", "Oddi", "spasm", "was", "induced", "by", "prostigmine", "-", "morphine", "administration", "(", "0", ".", "5", "mg", "prostigmine", "intramuscularly", "and", "10", "mg", "morphine", "subcutaneously", ")", "and", "visualized", "by", "quantitative", "hepatobiliary", "scintigraphy", ".", "The", "entire", "procedure", "was", "repeated", "during", "glyceryl", "trinitrate", "infusion", "(", "Nitrolingual", "1", "microg", "/", "kg", "/", "min", "for", "120", "min", ")", ".", "RESULTS", ":", "Prostigmine", "-", "morphine", "provocation", "caused", "significant", "increases", "in", "the", "time", "to", "peak", "activity", "(", "Tmax", ")", "over", "the", "hepatic", "hilum", "(", "HH", ":", "34", ".", "33", "+", "/", "-", "5", ".", "05", "vs", ".", "22", ".", "77", "+", "/", "-", "3", ".", "26", ")", "and", "the", "common", "bile", "duct", "(", "CBD", ":", "60", ".", "44", "+", "/", "-", "5", ".", "99", "vs", ".", "40", ".", "0", "+", "/", "-", "2", ".", "88", ")", "and", "in", "the", "half", "-", "time", "of", "excretion", "(", "T1", "/", "2", ")", "over", "the", "liver", "parenchyma", "(", "LP", ":", "120", ".", "04", "+", "/", "-", "16", ".", "01", "vs", ".", "27", ".", "37", "+", "/", "-", "2", ".", "19", ")", ",", "HH", "(", "117", ".", "61", "+", "/", "-", "14", ".", "71", "vs", ".", "31", ".", "85", "+", "/", "-", "3", ".", "99", ")", "and", "CBD", "(", "158", ".", "11", "+", "/", "-", "9", ".", "18", "vs", ".", "40", ".", "1", "+", "/", "-", "6", ".", "24", ")", ",", "indicating", "a", "complete", "spasm", "at", "the", "level", "of", "the", "sphincter", "of", "Oddi", ".", "Glyceryl", "trinitrate", "infusion", "completely", "normalized", "the", "prostigmine", "-", "morphine", "-", "induced", "alterations", "in", "these", "quantitative", "parameters", "(", "TmaX", "over", "the", "LP", ":", "11", ".", "33", "+", "/", "-", "1", ".", "13", ";", "over", "the", "HH", ":", "18", ".", "88", "+", "/", "-", "1", ".", "48", ";", "and", "over", "the", "CBD", ":", "36", ".", "22", "+", "/", "-", "1", ".", "92", ";", "and", "T1", "/", "2", "over", "the", "LP", ":", "28", ".", "21", "+", "/", "-", "1", ".", "83", ";", "over", "the", "HH", ":", "33", ".", "42", "+", "/", "-", "3", ".", "10", ";", "and", "over", "the", "CBD", ":", "41", ".", "66", "+", "/", "-", "6", ".", "33", ")", ",", "suggesting", "an", "effective", "sphincter", "-", "relaxing", "effect", "of", "glyceryl", "trinitrate", ".", "CONCLUSION", ":", "These", "results", "provide", "the", "first", "evidence", "of", "the", "effectiveness", "of", "glyceryl", "trinitrate", "on", "the", "morphine", "-", "induced", "sphincter", "of", "Oddi", "spasm", "in", "humans", ".", "Since", "glyceryl", "trinitrate", "is", "able", "to", "overcome", "even", "the", "drastic", "effect", "of", "morphine", ",", "it", "might", "be", "of", "relevance", "in", "the", "treatment", "of", "sphincter", "of", "Oddi", "dyskinesia", "."]], "ner": [[[12, 12, "Chemical"], [29, 29, "Chemical"], [59, 59, "Chemical"], [68, 68, "Chemical"], [107, 107, "Chemical"], [289, 289, "Chemical"], [6, 9, "Disease"], [34, 37, "Disease"], [45, 48, "Disease"], [52, 55, "Disease"], [422, 425, "Disease"], [452, 455, "Disease"], [14, 14, "Chemical"], [31, 31, "Chemical"], [61, 61, "Chemical"], [73, 73, "Chemical"], [109, 109, "Chemical"], [291, 291, "Chemical"], [419, 419, "Chemical"], [441, 441, "Chemical"], [273, 273, "Disease"], [2, 3, "Chemical"], [25, 26, "Chemical"], [89, 90, "Chemical"], [93, 93, "Chemical"], [283, 284, "Chemical"], [400, 401, "Chemical"], [415, 416, "Chemical"], [430, 431, "Chemical"]]], "relations": [[[12, 12, 6, 9, "CID"], [12, 12, 34, 37, "CID"], [12, 12, 45, 48, "CID"], [12, 12, 52, 55, "CID"], [12, 12, 422, 425, "CID"], [12, 12, 452, 455, "CID"], [29, 29, 6, 9, "CID"], [29, 29, 34, 37, "CID"], [29, 29, 45, 48, "CID"], [29, 29, 52, 55, "CID"], [29, 29, 422, 425, "CID"], [29, 29, 452, 455, "CID"], [59, 59, 6, 9, "CID"], [59, 59, 34, 37, "CID"], [59, 59, 45, 48, "CID"], [59, 59, 52, 55, "CID"], [59, 59, 422, 425, "CID"], [59, 59, 452, 455, "CID"], [68, 68, 6, 9, "CID"], [68, 68, 34, 37, "CID"], [68, 68, 45, 48, "CID"], [68, 68, 52, 55, "CID"], [68, 68, 422, 425, "CID"], [68, 68, 452, 455, "CID"], [107, 107, 6, 9, "CID"], [107, 107, 34, 37, "CID"], [107, 107, 45, 48, "CID"], [107, 107, 52, 55, "CID"], [107, 107, 422, 425, "CID"], [107, 107, 452, 455, "CID"], [289, 289, 6, 9, "CID"], [289, 289, 34, 37, "CID"], [289, 289, 45, 48, "CID"], [289, 289, 52, 55, "CID"], [289, 289, 422, 425, "CID"], [289, 289, 452, 455, "CID"], [14, 14, 6, 9, "CID"], [14, 14, 34, 37, "CID"], [14, 14, 45, 48, "CID"], [14, 14, 52, 55, "CID"], [14, 14, 422, 425, "CID"], [14, 14, 452, 455, "CID"], [31, 31, 6, 9, "CID"], [31, 31, 34, 37, "CID"], [31, 31, 45, 48, "CID"], [31, 31, 52, 55, "CID"], [31, 31, 422, 425, "CID"], [31, 31, 452, 455, "CID"], [61, 61, 6, 9, "CID"], [61, 61, 34, 37, "CID"], [61, 61, 45, 48, "CID"], [61, 61, 52, 55, "CID"], [61, 61, 422, 425, "CID"], [61, 61, 452, 455, "CID"], [73, 73, 6, 9, "CID"], [73, 73, 34, 37, "CID"], [73, 73, 45, 48, "CID"], [73, 73, 52, 55, "CID"], [73, 73, 422, 425, "CID"], [73, 73, 452, 455, "CID"], [109, 109, 6, 9, "CID"], [109, 109, 34, 37, "CID"], [109, 109, 45, 48, "CID"], [109, 109, 52, 55, "CID"], [109, 109, 422, 425, "CID"], [109, 109, 452, 455, "CID"], [291, 291, 6, 9, "CID"], [291, 291, 34, 37, "CID"], [291, 291, 45, 48, "CID"], [291, 291, 52, 55, "CID"], [291, 291, 422, 425, "CID"], [291, 291, 452, 455, "CID"], [419, 419, 6, 9, "CID"], [419, 419, 34, 37, "CID"], [419, 419, 45, 48, "CID"], [419, 419, 52, 55, "CID"], [419, 419, 422, 425, "CID"], [419, 419, 452, 455, "CID"], [441, 441, 6, 9, "CID"], [441, 441, 34, 37, "CID"], [441, 441, 45, 48, "CID"], [441, 441, 52, 55, "CID"], [441, 441, 422, 425, "CID"], [441, 441, 452, 455, "CID"], [12, 12, 273, 273, "CID"], [29, 29, 273, 273, "CID"], [59, 59, 273, 273, "CID"], [68, 68, 273, 273, "CID"], [107, 107, 273, 273, "CID"], [289, 289, 273, 273, "CID"], [14, 14, 273, 273, "CID"], [31, 31, 273, 273, "CID"], [61, 61, 273, 273, "CID"], [73, 73, 273, 273, "CID"], [109, 109, 273, 273, "CID"], [291, 291, 273, 273, "CID"], [419, 419, 273, 273, "CID"], [441, 441, 273, 273, "CID"]]], "clusters": [], "translated": "效应<21>三硝酸甘油酯</21>对<0>前列斯的明</0> - <12>吗啡</12>引起的<6>Oddi 括约肌痉挛</6>的影响。目的：本研究旨在探讨<22>三硝酸甘油酯</22>对<1>前列明</1> - <13>吗啡</13>诱发的<7>Oddi 括约肌痉挛</7>的影响。在9名患有<8> Oddi括约肌运动障碍</8> 的女性患者中进行了评估。方法：<9>Oddi 括约肌痉挛</9>由<2>前列的明</2> - <14>吗啡</14>给药引起（0.5mg<3>前列的明</3>肌肉注射和10mg<15>吗啡</15>皮下注射），并通过定量肝胆闪烁显像观察。在<23>甘油三硝酸酯</23>输注期间重复整个过程（<24>硝基舌</24> 1微克/千克/分钟，持续120分钟）。结果：<4>前列明</4> - <16>吗啡</16>激发导致肝门活性峰值时间(Tmax) 显着增加（HH: 34.33 +/- 5.05对比22.77 +/- 3.26）和胆总管（CBD: 60.44 +/- 5.99对比40.0 +/- 2.88）和排泄的一半时间(T1/2)肝实质上方（LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19），HH（117.61 +/- 14.71 vs. 31.85 +/- 3.99）和CBD（158.11 +/- 9.18对比40.1 +/- 6.24），表明Oddi括约肌水平的完全<20>痉挛</20>。<25>甘油三硝酸酯</25>输注完全正常化<5>前列明</5> - <17>吗啡</17> - 诱导的这些定量参数的改变（TmaX:<11>  LP：11.33+/-1.13；在HH上：18.88+/-1.48；在CBD上：36.22+/-1.92；在LP上的T1/2：28.21+/-1.83；高于HH：33.42+/-3.10；高于CBD：41.66+/-6.33），表明<26>甘油三硝酸酯</26>具有有效的括约肌松弛作用。结论：这些结果首次证明了<27>三硝酸甘油酯</27>对<18>吗啡</18>诱发的人类<10>Oddi括约肌痉挛</10>的有效性。由于<28>三硝酸甘油酯</28>甚至可以克服<19>吗啡</19>的剧烈作用，因此可能对<11>Oddi括约肌运动障碍</11>的治疗具有相关性。", "revised": true}
{"doc_key": "11999899", "sentences": [["Behavioral", "effects", "of", "MK", "-", "801", "on", "reserpine", "-", "treated", "mice", ".", "The", "effects", "of", "dizocilpine", "(", "MK", "-", "801", ")", ",", "a", "noncompetitive", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "antagonist", ",", "were", "studied", "on", "dopamine", "-", "related", "behaviors", "induced", "by", "reserpine", "treatments", ".", "This", "study", "focuses", "on", "behavioral", "syndromes", "that", "may", "used", "as", "models", "for", "Parkinson", "'s", "disease", ",", "or", "tardive", "dyskinesia", ",", "and", "its", "response", "after", "glutamatergic", "blockage", ".", "Reserpine", "(", "1", "mg", "/", "kg", ")", ",", "administered", "once", "every", "other", "day", "for", "4", "days", ",", "produced", "increases", "in", "orofacial", "dyskinesia", ",", "tongue", "protrusion", "and", "vacuous", "chewing", "in", "mice", ",", "which", "are", "signs", "indicative", "of", "tardive", "dyskinesia", ".", "Reserpine", "also", "produced", "tremor", "and", "catalepsy", ",", "which", "are", "signs", "suggestive", "of", "Parkinson", "'s", "disease", ".", "MK", "-", "801", "(", "0", ".", "1", "mg", "/", "kg", ")", ",", "administered", "30", "min", "before", "the", "observation", "test", ",", "prevented", "the", "vacuous", "chewing", "movements", ",", "tongue", "protrusions", "and", "catalepsy", "induced", "by", "reserpine", ".", "However", ",", "MK", "-", "801", "injection", "produced", "a", "significant", "increase", "of", "tremor", "in", "reserpine", "-", "treated", "mice", ".", "Reserpine", "(", "1", "mg", "/", "kg", ")", ",", "administered", "90", "min", "before", "the", "test", "and", "followed", "by", "apomophine", "injection", "(", "0", ".", "1", "mg", "/", "kg", ")", "5", "min", "before", "the", "test", ",", "did", "not", "produce", "oral", "dyskinesia", "in", "mice", ".", "On", "the", "other", "hand", ",", "reserpine", "induced", "increases", "in", "tremor", "and", "catalepsy", "compared", "to", "control", "mice", ".", "MK", "-", "801", "(", "0", ".", "1", "mg", "/", "kg", ")", "administration", "attenuated", "the", "catalepsy", "and", "tremor", "induced", "by", "reserpine", ".", "Pretreatment", "with", "reserpine", "(", "1", "mg", "/", "kg", ")", "24", "h", "before", "the", "observation", "test", "produced", "increases", "in", "vacuous", "chewing", "movements", "and", "tongue", "protrusion", ",", "as", "well", "as", "increases", "in", "tremor", "and", "catalepsy", ",", "whereas", "MK", "-", "801", "(", "0", ".", "1", "mg", "/", "kg", ")", "injection", "90", "min", "before", "the", "test", "reversed", "the", "effects", "of", "reserpine", ".", "These", "results", "show", "that", "reserpine", "produces", "different", "and", "abnormal", "movements", ",", "which", "are", "related", "to", "dose", "and", "schedule", "employed", "and", "can", "be", "considered", "as", "parkinsonian", "-", "like", "and", "tardive", "dsykinesia", "signs", ".", "The", "glutamatergic", "blockage", "produced", "by", "NMDA", "can", "restore", "these", "signs", ",", "such", "as", "vacuous", "chewing", "movements", ",", "tongue", "protrusions", ",", "catalepsy", "and", "tremor", "according", "to", "the", "employed", "model", "."]], "ner": [[[7, 7, "Chemical"], [46, 46, "Chemical"], [76, 76, "Chemical"], [115, 115, "Chemical"], [163, 163, "Chemical"], [178, 178, "Chemical"], [183, 183, "Chemical"], [229, 229, "Chemical"], [260, 260, "Chemical"], [264, 264, "Chemical"], [318, 318, "Chemical"], [324, 324, "Chemical"], [66, 67, "Disease"], [112, 113, "Disease"], [328, 329, "Disease"], [348, 349, "Disease"], [118, 118, "Disease"], [176, 176, "Disease"], [233, 233, "Disease"], [257, 257, "Disease"], [292, 292, "Disease"], [374, 374, "Disease"], [120, 120, "Disease"], [160, 160, "Disease"], [235, 235, "Disease"], [255, 255, "Disease"], [294, 294, "Disease"], [372, 372, "Disease"], [3, 5, "Chemical"], [15, 15, "Chemical"], [17, 19, "Chemical"], [131, 133, "Chemical"], [167, 169, "Chemical"], [241, 243, "Chemical"], [297, 299, "Chemical"], [61, 63, "Disease"], [127, 129, "Disease"], [344, 344, "Disease"], [96, 97, "Disease"], [219, 220, "Disease"], [24, 30, "Chemical"], [32, 32, "Chemical"], [357, 357, "Chemical"], [40, 40, "Chemical"], [200, 200, "Chemical"]]], "relations": [[[7, 7, 66, 67, "CID"], [7, 7, 112, 113, "CID"], [7, 7, 328, 329, "CID"], [7, 7, 348, 349, "CID"], [46, 46, 66, 67, "CID"], [46, 46, 112, 113, "CID"], [46, 46, 328, 329, "CID"], [46, 46, 348, 349, "CID"], [76, 76, 66, 67, "CID"], [76, 76, 112, 113, "CID"], [76, 76, 328, 329, "CID"], [76, 76, 348, 349, "CID"], [115, 115, 66, 67, "CID"], [115, 115, 112, 113, "CID"], [115, 115, 328, 329, "CID"], [115, 115, 348, 349, "CID"], [163, 163, 66, 67, "CID"], [163, 163, 112, 113, "CID"], [163, 163, 328, 329, "CID"], [163, 163, 348, 349, "CID"], [178, 178, 66, 67, "CID"], [178, 178, 112, 113, "CID"], [178, 178, 328, 329, "CID"], [178, 178, 348, 349, "CID"], [183, 183, 66, 67, "CID"], [183, 183, 112, 113, "CID"], [183, 183, 328, 329, "CID"], [183, 183, 348, 349, "CID"], [229, 229, 66, 67, "CID"], [229, 229, 112, 113, "CID"], [229, 229, 328, 329, "CID"], [229, 229, 348, 349, "CID"], [260, 260, 66, 67, "CID"], [260, 260, 112, 113, "CID"], [260, 260, 328, 329, "CID"], [260, 260, 348, 349, "CID"], [264, 264, 66, 67, "CID"], [264, 264, 112, 113, "CID"], [264, 264, 328, 329, "CID"], [264, 264, 348, 349, "CID"], [318, 318, 66, 67, "CID"], [318, 318, 112, 113, "CID"], [318, 318, 328, 329, "CID"], [318, 318, 348, 349, "CID"], [324, 324, 66, 67, "CID"], [324, 324, 112, 113, "CID"], [324, 324, 328, 329, "CID"], [324, 324, 348, 349, "CID"], [7, 7, 118, 118, "CID"], [7, 7, 176, 176, "CID"], [7, 7, 233, 233, "CID"], [7, 7, 257, 257, "CID"], [7, 7, 292, 292, "CID"], [7, 7, 374, 374, "CID"], [46, 46, 118, 118, "CID"], [46, 46, 176, 176, "CID"], [46, 46, 233, 233, "CID"], [46, 46, 257, 257, "CID"], [46, 46, 292, 292, "CID"], [46, 46, 374, 374, "CID"], [76, 76, 118, 118, "CID"], [76, 76, 176, 176, "CID"], [76, 76, 233, 233, "CID"], [76, 76, 257, 257, "CID"], [76, 76, 292, 292, "CID"], [76, 76, 374, 374, "CID"], [115, 115, 118, 118, "CID"], [115, 115, 176, 176, "CID"], [115, 115, 233, 233, "CID"], [115, 115, 257, 257, "CID"], [115, 115, 292, 292, "CID"], [115, 115, 374, 374, "CID"], [163, 163, 118, 118, "CID"], [163, 163, 176, 176, "CID"], [163, 163, 233, 233, "CID"], [163, 163, 257, 257, "CID"], [163, 163, 292, 292, "CID"], [163, 163, 374, 374, "CID"], [178, 178, 118, 118, "CID"], [178, 178, 176, 176, "CID"], [178, 178, 233, 233, "CID"], [178, 178, 257, 257, "CID"], [178, 178, 292, 292, "CID"], [178, 178, 374, 374, "CID"], [183, 183, 118, 118, "CID"], [183, 183, 176, 176, "CID"], [183, 183, 233, 233, "CID"], [183, 183, 257, 257, "CID"], [183, 183, 292, 292, "CID"], [183, 183, 374, 374, "CID"], [229, 229, 118, 118, "CID"], [229, 229, 176, 176, "CID"], [229, 229, 233, 233, "CID"], [229, 229, 257, 257, "CID"], [229, 229, 292, 292, "CID"], [229, 229, 374, 374, "CID"], [260, 260, 118, 118, "CID"], [260, 260, 176, 176, "CID"], [260, 260, 233, 233, "CID"], [260, 260, 257, 257, "CID"], [260, 260, 292, 292, "CID"], [260, 260, 374, 374, "CID"], [264, 264, 118, 118, "CID"], [264, 264, 176, 176, "CID"], [264, 264, 233, 233, "CID"], [264, 264, 257, 257, "CID"], [264, 264, 292, 292, "CID"], [264, 264, 374, 374, "CID"], [318, 318, 118, 118, "CID"], [318, 318, 176, 176, "CID"], [318, 318, 233, 233, "CID"], [318, 318, 257, 257, "CID"], [318, 318, 292, 292, "CID"], [318, 318, 374, 374, "CID"], [324, 324, 118, 118, "CID"], [324, 324, 176, 176, "CID"], [324, 324, 233, 233, "CID"], [324, 324, 257, 257, "CID"], [324, 324, 292, 292, "CID"], [324, 324, 374, 374, "CID"], [7, 7, 120, 120, "CID"], [7, 7, 160, 160, "CID"], [7, 7, 235, 235, "CID"], [7, 7, 255, 255, "CID"], [7, 7, 294, 294, "CID"], [7, 7, 372, 372, "CID"], [46, 46, 120, 120, "CID"], [46, 46, 160, 160, "CID"], [46, 46, 235, 235, "CID"], [46, 46, 255, 255, "CID"], [46, 46, 294, 294, "CID"], [46, 46, 372, 372, "CID"], [76, 76, 120, 120, "CID"], [76, 76, 160, 160, "CID"], [76, 76, 235, 235, "CID"], [76, 76, 255, 255, "CID"], [76, 76, 294, 294, "CID"], [76, 76, 372, 372, "CID"], [115, 115, 120, 120, "CID"], [115, 115, 160, 160, "CID"], [115, 115, 235, 235, "CID"], [115, 115, 255, 255, "CID"], [115, 115, 294, 294, "CID"], [115, 115, 372, 372, "CID"], [163, 163, 120, 120, "CID"], [163, 163, 160, 160, "CID"], [163, 163, 235, 235, "CID"], [163, 163, 255, 255, "CID"], [163, 163, 294, 294, "CID"], [163, 163, 372, 372, "CID"], [178, 178, 120, 120, "CID"], [178, 178, 160, 160, "CID"], [178, 178, 235, 235, "CID"], [178, 178, 255, 255, "CID"], [178, 178, 294, 294, "CID"], [178, 178, 372, 372, "CID"], [183, 183, 120, 120, "CID"], [183, 183, 160, 160, "CID"], [183, 183, 235, 235, "CID"], [183, 183, 255, 255, "CID"], [183, 183, 294, 294, "CID"], [183, 183, 372, 372, "CID"], [229, 229, 120, 120, "CID"], [229, 229, 160, 160, "CID"], [229, 229, 235, 235, "CID"], [229, 229, 255, 255, "CID"], [229, 229, 294, 294, "CID"], [229, 229, 372, 372, "CID"], [260, 260, 120, 120, "CID"], [260, 260, 160, 160, "CID"], [260, 260, 235, 235, "CID"], [260, 260, 255, 255, "CID"], [260, 260, 294, 294, "CID"], [260, 260, 372, 372, "CID"], [264, 264, 120, 120, "CID"], [264, 264, 160, 160, "CID"], [264, 264, 235, 235, "CID"], [264, 264, 255, 255, "CID"], [264, 264, 294, 294, "CID"], [264, 264, 372, 372, "CID"], [318, 318, 120, 120, "CID"], [318, 318, 160, 160, "CID"], [318, 318, 235, 235, "CID"], [318, 318, 255, 255, "CID"], [318, 318, 294, 294, "CID"], [318, 318, 372, 372, "CID"], [324, 324, 120, 120, "CID"], [324, 324, 160, 160, "CID"], [324, 324, 235, 235, "CID"], [324, 324, 255, 255, "CID"], [324, 324, 294, 294, "CID"], [324, 324, 372, 372, "CID"]]], "clusters": [], "translated": "<28> MK-801 </28>对<0> 利血平 </0>治疗小鼠的行为影响。 <29> 地佐西平 </29>（<30> MK-801 </30>）的作用，一种非竞争性<40> N-甲基-D-天冬氨酸 </40>（<41> NMDA </41>）受体拮抗剂，对<43> 多巴胺 </43>相关行为进行了研究，该行为由<1> 利血平 </1>治疗引起。本研究重点关注可用作<35> 帕金森病 </35>或<12> 迟发性运动障碍 </12>模型的行为综合征及其在谷氨酸能阻断后的反应。<2> 利血平 </2>(1 mg/kg)，每隔一天给药一次，持续4天，在小鼠中产生<38>口面部运动障碍</38>、舌头突出和咀嚼无力的增加，这些迹象表明<13>迟发性运动障碍</13>。<3> 利血平 </3>还产生了<16>震颤</16>和<22>僵直</22>，这些都是提示<36>帕金森病</36>的体征。<31> MK-801 </31>(0.1 mg/kg)，在观察试验前30分钟给药，可防止<4>利血平</4>引起的空洞咀嚼运动、舌头突出和<23>强直性昏厥</23>。然而，<32> MK-801 </32>注射剂在<5>利血平</5>处理的小鼠中产生了显着增加的<17>震颤</17>。<6> 利血平 </6>（1 mg/kg），试验前90分钟给药，试验前5分钟注射<44> 阿朴啡 </44>（0.1 mg/kg），未产生<39>口腔运动障碍</39>小鼠。另一方面，与对照小鼠相比，<7>利血平</7>诱导<18>震颤</18>和<24> 僵直性昏厥 </24>增加。<33> MK-801 </33> (0.1 mg/kg)给药可减轻<8>利血平</8>引起的<25> 僵直 </25>和<19>震颤</19>。在观察试验前24小时用<9> 利血平 </9>(1 mg/kg)预处理产生空洞咀嚼运动和舌头突出的增加，以及<20> 震颤 </20>和<26> 僵直的增加</26>，而在试验前90分钟注射<34> MK-801 </34>(0.1 mg/kg)可逆转<10> 利血平 </10>的作用。这些结果表明<11> 利血平 </11>产生不同的和<14>异常运动</14>，这与使用的剂量和时间表有关，可以被认为是<37>帕金森病</37>-样和<15>迟发性运动障碍</15>体征。根据所采用的模型，<42> NMDA </42>产生的谷氨酸能阻滞可以恢复这些体征，例如空洞的咀嚼运动、舌头突出、<27>强直性昏厥</27>和<21> 震颤 </21>。", "revised": true}
{"doc_key": "8958188", "sentences": [["A", "phase", "I", "clinical", "study", "of", "the", "antipurine", "antifolate", "lometrexol", "(", "DDATHF", ")", "given", "with", "oral", "folic", "acid", ".", "Lometrexol", "is", "an", "antifolate", "which", "inhibits", "glycinamide", "ribonucleotide", "formyltransferase", "(", "GARFT", ")", ",", "an", "enzyme", "essential", "for", "de", "novo", "purine", "synthesis", ".", "Extensive", "experimental", "and", "limited", "clinical", "data", "have", "shown", "that", "lometrexol", "has", "activity", "against", "tumours", "which", "are", "refractory", "to", "other", "drugs", ",", "notably", "methotrexate", ".", "However", ",", "the", "initial", "clinical", "development", "of", "lometrexol", "was", "curtailed", "because", "of", "severe", "and", "cumulative", "antiproliferative", "toxicities", ".", "Preclinical", "murine", "studies", "demonstrated", "that", "the", "toxicity", "of", "lometrexol", "can", "be", "prevented", "by", "low", "dose", "folic", "acid", "administration", ",", "i", ".", "e", ".", "for", "7", "days", "prior", "to", "and", "7", "days", "following", "a", "single", "bolus", "dose", ".", "This", "observation", "prompted", "a", "Phase", "I", "clinical", "study", "of", "lometrexol", "given", "with", "folic", "acid", "supplementation", "which", "has", "confirmed", "that", "the", "toxicity", "of", "lometrexol", "can", "be", "markedly", "reduced", "by", "folic", "acid", "supplementation", ".", "Thrombocytopenia", "and", "mucositis", "were", "the", "major", "toxicities", ".", "There", "was", "no", "clear", "relationship", "between", "clinical", "toxicity", "and", "the", "extent", "of", "plasma", "folate", "elevation", ".", "Associated", "studies", "demonstrated", "that", "lometrexol", "plasma", "pharmacokinetics", "were", "not", "altered", "by", "folic", "acid", "administration", "indicating", "that", "supplementation", "is", "unlikely", "to", "reduce", "toxicity", "by", "enhancing", "lometrexol", "plasma", "clearance", ".", "The", "work", "described", "in", "this", "report", "has", "identified", "for", "the", "first", "time", "a", "clinically", "acceptable", "schedule", "for", "the", "administration", "of", "a", "GARFT", "inhibitor", ".", "This", "information", "will", "facilitate", "the", "future", "evaluation", "of", "this", "class", "of", "compounds", "in", "cancer", "therapy", "."]], "ner": [[[9, 9, "Chemical"], [11, 11, "Chemical"], [19, 19, "Chemical"], [50, 50, "Chemical"], [72, 72, "Chemical"], [91, 91, "Chemical"], [129, 129, "Chemical"], [142, 142, "Chemical"], [180, 180, "Chemical"], [200, 200, "Chemical"], [152, 152, "Disease"], [154, 154, "Disease"], [7, 7, "Chemical"], [54, 54, "Disease"], [241, 241, "Disease"], [81, 81, "Disease"], [89, 89, "Disease"], [140, 140, "Disease"], [158, 158, "Disease"], [167, 167, "Disease"], [197, 197, "Disease"], [16, 17, "Chemical"], [98, 99, "Chemical"], [132, 133, "Chemical"], [148, 149, "Chemical"], [173, 173, "Chemical"], [187, 188, "Chemical"], [25, 26, "Chemical"], [38, 38, "Chemical"], [63, 63, "Chemical"]]], "relations": [[[9, 9, 152, 152, "CID"], [11, 11, 152, 152, "CID"], [19, 19, 152, 152, "CID"], [50, 50, 152, 152, "CID"], [72, 72, 152, 152, "CID"], [91, 91, 152, 152, "CID"], [129, 129, 152, 152, "CID"], [142, 142, 152, 152, "CID"], [180, 180, 152, 152, "CID"], [200, 200, 152, 152, "CID"], [9, 9, 154, 154, "CID"], [11, 11, 154, 154, "CID"], [19, 19, 154, 154, "CID"], [50, 50, 154, 154, "CID"], [72, 72, 154, 154, "CID"], [91, 91, 154, 154, "CID"], [129, 129, 154, 154, "CID"], [142, 142, 154, 154, "CID"], [180, 180, 154, 154, "CID"], [200, 200, 154, 154, "CID"]]], "clusters": [], "translated": "<12>抗嘌呤</12>抗叶酸<0>洛美曲索</0>(<1>DDATHF</1>)与口服<21>叶酸</21>的I期临床研究。<2>Lometrexol</2>是一种抗叶酸药，可抑制<27>甘氨酰胺核糖核苷酸</27>甲酰基转移酶(GARFT)，后者是<28>嘌呤</28>从头合成所必需的一种酶。广泛的实验和有限的临床数据表明，<3>洛美曲索</3>具有抗<13>肿瘤</13>的活性，而其他药物尤其是<29>甲氨蝶呤</29>难以治疗。然而，<4>洛美曲索</4>的初始临床开发因严重和累积的抗增殖<15>毒性</15>而受到限制。临床前小鼠研究表明，<5>洛美曲索</5>的<16>毒性</16>可以通过低剂量<22>叶酸</22>给药来预防，即为单次推注给药前7天和给药后7天。这一观察结果促成了<6>洛美曲索</6>与<23>叶酸</23>补充剂的I期临床研究，该研究证实了<7>洛美曲索</7>的<17>毒性</17>可通过<24>叶酸</24>补充剂显着降低。<10>血小板减少症</10>和<11>粘膜炎</11>是主要的<18>毒性</18>。临床<19>毒性</19>与血浆<25>叶酸</25>升高程度之间没有明确的关系。相关研究表明，<8>洛美曲索</8>血浆药代动力学未被<26>叶酸</26>给药改变，表明补充不太可能通过增强<9>洛美曲索</9>的清除血浆来降低<20>毒性</20>。本报告中描述的工作首次确定了临床上可接受的GARFT抑制剂给药时间表。此信息将有助于将来评估这类化合物在<14>癌症</14>治疗中的作用。", "revised": true}
{"doc_key": "9121607", "sentences": [["Neuroactive", "steroids", "protect", "against", "pilocarpine", "-", "and", "kainic", "acid", "-", "induced", "limbic", "seizures", "and", "status", "epilepticus", "in", "mice", ".", "Several", "structurally", "related", "metabolites", "of", "progesterone", "(", "3", "alpha", "-", "hydroxy", "pregnane", "-", "20", "-", "ones", ")", "and", "deoxycorticosterone", "(", "3", "alpha", "-", "hydroxy", "pregnane", "-", "21", "-", "diol", "-", "20", "-", "ones", ")", "and", "their", "3", "beta", "-", "epimers", "were", "evaluated", "for", "protective", "activity", "against", "pilocarpine", "-", ",", "kainic", "acid", "-", "and", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "-", "induced", "seizures", "in", "mice", ".", "Steroids", "with", "the", "3", "-", "hydroxy", "group", "in", "the", "alpha", "-", "position", "and", "5", "-", "H", "in", "the", "alpha", "-", "or", "beta", "-", "configurations", "were", "highly", "effective", "in", "protecting", "against", "pilocarpine", "(", "416", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", "-", "induced", "limbic", "motor", "seizures", "and", "status", "epilepticus", "(", "ED50", "values", ",", "7", ".", "0", "-", "18", ".", "7", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "The", "corresponding", "epimers", "with", "the", "3", "-", "hydroxy", "group", "in", "the", "beta", "-", "position", "were", "also", "effective", "but", "less", "potent", "(", "ED50", "values", ",", "33", ".", "8", "-", "63", ".", "5", ",", "i", ".", "p", ".", ")", ".", "Although", "the", "neuroactive", "steroids", "were", "considerably", "less", "potent", "than", "the", "benzodiazepine", "clonazepam", "in", "protecting", "against", "pilocarpine", "seizures", ",", "steroids", "with", "the", "5", "alpha", ",", "3", "alpha", "-", "configuration", "had", "comparable", "or", "higher", "protective", "index", "values", "(", "TD50", "for", "motor", "impairment", "divided", "by", "ED50", "for", "seizure", "protection", ")", "than", "clonazepam", ",", "indicating", "that", "some", "neuroactive", "steroids", "may", "have", "lower", "relative", "toxicity", ".", "Steroids", "with", "the", "5", "alpha", ",", "3", "alpha", "-", "or", "5", "beta", ",", "3", "alpha", "-", "configurations", "also", "produced", "a", "dose", "-", "dependent", "delay", "in", "the", "onset", "of", "limbic", "seizures", "induced", "by", "kainic", "acid", "(", "32", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", ",", "but", "did", "not", "completely", "protect", "against", "the", "seizures", ".", "However", ",", "when", "a", "second", "dose", "of", "the", "steroid", "was", "administered", "1", "hr", "after", "the", "first", "dose", ",", "complete", "protection", "from", "the", "kainic", "acid", "-", "induced", "limbic", "seizures", "and", "status", "epilepticus", "was", "obtained", ".", "The", "steroids", "also", "caused", "a", "dose", "-", "dependent", "delay", "in", "NMDA", "(", "257", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", "-", "induced", "lethality", ",", "but", "did", "not", "completely", "protect", "against", "NMDA", "seizures", "or", "lethality", ".", "We", "conclude", "that", "neuroactive", "steroids", "are", "highly", "effective", "in", "protecting", "against", "pilocarpine", "-", "and", "kainic", "acid", "-", "induced", "seizures", "and", "status", "epilepticus", "in", "mice", ",", "and", "may", "be", "of", "utility", "in", "the", "treatment", "of", "some", "forms", "of", "status", "epilepticus", "in", "humans", "."]], "ner": [[[4, 4, "Chemical"], [65, 65, "Chemical"], [118, 118, "Chemical"], [212, 212, "Chemical"], [395, 395, "Chemical"], [12, 12, "Disease"], [84, 84, "Disease"], [134, 134, "Disease"], [213, 213, "Disease"], [241, 241, "Disease"], [287, 287, "Disease"], [311, 311, "Disease"], [340, 340, "Disease"], [380, 380, "Disease"], [402, 402, "Disease"], [14, 15, "Disease"], [136, 137, "Disease"], [342, 343, "Disease"], [404, 405, "Disease"], [421, 422, "Disease"], [7, 8, "Chemical"], [68, 69, "Chemical"], [290, 291, "Chemical"], [335, 336, "Chemical"], [398, 399, "Chemical"], [1, 1, "Chemical"], [88, 88, "Chemical"], [200, 200, "Chemical"], [215, 215, "Chemical"], [251, 251, "Chemical"], [258, 258, "Chemical"], [321, 321, "Chemical"], [348, 348, "Chemical"], [388, 388, "Chemical"], [256, 256, "Disease"], [24, 24, "Chemical"], [26, 34, "Chemical"], [37, 37, "Chemical"], [39, 51, "Chemical"], [72, 78, "Chemical"], [80, 80, "Chemical"], [357, 357, "Chemical"], [379, 379, "Chemical"], [207, 207, "Chemical"], [208, 208, "Chemical"], [245, 245, "Chemical"]]], "relations": [[[4, 4, 12, 12, "CID"], [4, 4, 84, 84, "CID"], [4, 4, 134, 134, "CID"], [4, 4, 213, 213, "CID"], [4, 4, 241, 241, "CID"], [4, 4, 287, 287, "CID"], [4, 4, 311, 311, "CID"], [4, 4, 340, 340, "CID"], [4, 4, 380, 380, "CID"], [4, 4, 402, 402, "CID"], [65, 65, 12, 12, "CID"], [65, 65, 84, 84, "CID"], [65, 65, 134, 134, "CID"], [65, 65, 213, 213, "CID"], [65, 65, 241, 241, "CID"], [65, 65, 287, 287, "CID"], [65, 65, 311, 311, "CID"], [65, 65, 340, 340, "CID"], [65, 65, 380, 380, "CID"], [65, 65, 402, 402, "CID"], [118, 118, 12, 12, "CID"], [118, 118, 84, 84, "CID"], [118, 118, 134, 134, "CID"], [118, 118, 213, 213, "CID"], [118, 118, 241, 241, "CID"], [118, 118, 287, 287, "CID"], [118, 118, 311, 311, "CID"], [118, 118, 340, 340, "CID"], [118, 118, 380, 380, "CID"], [118, 118, 402, 402, "CID"], [212, 212, 12, 12, "CID"], [212, 212, 84, 84, "CID"], [212, 212, 134, 134, "CID"], [212, 212, 213, 213, "CID"], [212, 212, 241, 241, "CID"], [212, 212, 287, 287, "CID"], [212, 212, 311, 311, "CID"], [212, 212, 340, 340, "CID"], [212, 212, 380, 380, "CID"], [212, 212, 402, 402, "CID"], [395, 395, 12, 12, "CID"], [395, 395, 84, 84, "CID"], [395, 395, 134, 134, "CID"], [395, 395, 213, 213, "CID"], [395, 395, 241, 241, "CID"], [395, 395, 287, 287, "CID"], [395, 395, 311, 311, "CID"], [395, 395, 340, 340, "CID"], [395, 395, 380, 380, "CID"], [395, 395, 402, 402, "CID"], [4, 4, 14, 15, "CID"], [4, 4, 136, 137, "CID"], [4, 4, 342, 343, "CID"], [4, 4, 404, 405, "CID"], [4, 4, 421, 422, "CID"], [65, 65, 14, 15, "CID"], [65, 65, 136, 137, "CID"], [65, 65, 342, 343, "CID"], [65, 65, 404, 405, "CID"], [65, 65, 421, 422, "CID"], [118, 118, 14, 15, "CID"], [118, 118, 136, 137, "CID"], [118, 118, 342, 343, "CID"], [118, 118, 404, 405, "CID"], [118, 118, 421, 422, "CID"], [212, 212, 14, 15, "CID"], [212, 212, 136, 137, "CID"], [212, 212, 342, 343, "CID"], [212, 212, 404, 405, "CID"], [212, 212, 421, 422, "CID"], [395, 395, 14, 15, "CID"], [395, 395, 136, 137, "CID"], [395, 395, 342, 343, "CID"], [395, 395, 404, 405, "CID"], [395, 395, 421, 422, "CID"], [7, 8, 12, 12, "CID"], [7, 8, 84, 84, "CID"], [7, 8, 134, 134, "CID"], [7, 8, 213, 213, "CID"], [7, 8, 241, 241, "CID"], [7, 8, 287, 287, "CID"], [7, 8, 311, 311, "CID"], [7, 8, 340, 340, "CID"], [7, 8, 380, 380, "CID"], [7, 8, 402, 402, "CID"], [68, 69, 12, 12, "CID"], [68, 69, 84, 84, "CID"], [68, 69, 134, 134, "CID"], [68, 69, 213, 213, "CID"], [68, 69, 241, 241, "CID"], [68, 69, 287, 287, "CID"], [68, 69, 311, 311, "CID"], [68, 69, 340, 340, "CID"], [68, 69, 380, 380, "CID"], [68, 69, 402, 402, "CID"], [290, 291, 12, 12, "CID"], [290, 291, 84, 84, "CID"], [290, 291, 134, 134, "CID"], [290, 291, 213, 213, "CID"], [290, 291, 241, 241, "CID"], [290, 291, 287, 287, "CID"], [290, 291, 311, 311, "CID"], [290, 291, 340, 340, "CID"], [290, 291, 380, 380, "CID"], [290, 291, 402, 402, "CID"], [335, 336, 12, 12, "CID"], [335, 336, 84, 84, "CID"], [335, 336, 134, 134, "CID"], [335, 336, 213, 213, "CID"], [335, 336, 241, 241, "CID"], [335, 336, 287, 287, "CID"], [335, 336, 311, 311, "CID"], [335, 336, 340, 340, "CID"], [335, 336, 380, 380, "CID"], [335, 336, 402, 402, "CID"], [398, 399, 12, 12, "CID"], [398, 399, 84, 84, "CID"], [398, 399, 134, 134, "CID"], [398, 399, 213, 213, "CID"], [398, 399, 241, 241, "CID"], [398, 399, 287, 287, "CID"], [398, 399, 311, 311, "CID"], [398, 399, 340, 340, "CID"], [398, 399, 380, 380, "CID"], [398, 399, 402, 402, "CID"], [7, 8, 14, 15, "CID"], [7, 8, 136, 137, "CID"], [7, 8, 342, 343, "CID"], [7, 8, 404, 405, "CID"], [7, 8, 421, 422, "CID"], [68, 69, 14, 15, "CID"], [68, 69, 136, 137, "CID"], [68, 69, 342, 343, "CID"], [68, 69, 404, 405, "CID"], [68, 69, 421, 422, "CID"], [290, 291, 14, 15, "CID"], [290, 291, 136, 137, "CID"], [290, 291, 342, 343, "CID"], [290, 291, 404, 405, "CID"], [290, 291, 421, 422, "CID"], [335, 336, 14, 15, "CID"], [335, 336, 136, 137, "CID"], [335, 336, 342, 343, "CID"], [335, 336, 404, 405, "CID"], [335, 336, 421, 422, "CID"], [398, 399, 14, 15, "CID"], [398, 399, 136, 137, "CID"], [398, 399, 342, 343, "CID"], [398, 399, 404, 405, "CID"], [398, 399, 421, 422, "CID"]]], "clusters": [], "translated": "具有神经活性的<25>类固醇</25>可防止<0>毛果芸香碱</0>-和<20>红藻氨酸</20>-诱导的边缘系统<5>癫痫发作</5>和<15>癫痫持续状态</15>在老鼠身上。<35>孕酮</35>（<36>3α-羟基孕烷-20-</36>one）和<37>脱氧皮质酮</37>（<38>3α-羟基孕烷-21-二醇-20-ones</38>）及其3个β-差向异构体被评估了对<1>毛果芸香碱</1>-、<21>红藻氨酸</21>-和<39>N-甲基-D-天门冬氨酸</39>(<40>NMDA</40>)-诱导小鼠<6>癫痫发作</6>的保护活性。<26>类固醇</26>在α-位具有3-羟基且在α-或β-构型具有5-H，在预防<2>毛果芸香碱</2>方面非常有效（416mg/kg，s.c.）诱发边缘运动<7>癫痫发作</7>和<16>癫痫持续状态</16>（ED50值，7.0-18.7mg/kg，i.p.）。在β位带有3-羟基的相应差向异构体也有效但效力较低（ED50值，33.8-63.5 ，i.p.）。尽管神经活性<27>类固醇</27>在预防<3>毛果芸香碱</3><8>癫痫发作</8>方面远低于<43>苯二氮卓类药物</43><44>氯硝西泮</44>，<28>类固醇</28>与5alpha，3alpha-配置具有相当或更高的保护指数值（运动障碍的TD50除以<9>癫痫发作</9>保护的ED50）与<45>氯硝西泮</45>，表明一些具有神经活性的<29>类固醇</29>可能具有较低的相对<34>毒性</34>。<30>类固醇</30>具有5alpha，3alpha - 或5beta，3alpha - 配置也产生了由<22>红藻氨酸</22>(32mg/kg，s.c.) 诱导的边缘<10>癫痫发作</10>的剂量依赖性延迟，但不能完全防止<11>癫痫发作</11>。然而，当在第一剂后1小时给予第二剂<31>类固醇</31>时，完全保护免受<23>红藻氨酸</23>-诱导的边缘<12>癫痫发作</12>和<17>癫痫持续状态</17>获得。<32>类固醇</32> 还在<41>NMDA</41>(257mg/kg，s.c.)诱导的致死中引起剂量依赖性延迟，但没有完全防止<42>NMDA</42> <13>癫痫发作</13>或致死率。我们得出结论，神经活性<33>类固醇</33>在预防<4>毛果芸香碱</4>和<24>红藻氨酸</24>诱导的<14>癫痫发作</14>和<18>癫痫持续状态</18>在小鼠身上非常有效，并且可能对治疗人类的某些形式的<19>癫痫持续状态</19>有用。", "revised": true}
{"doc_key": "15580403", "sentences": [["Adequate", "timing", "of", "ribavirin", "reduction", "in", "patients", "with", "hemolysis", "during", "combination", "therapy", "of", "interferon", "and", "ribavirin", "for", "chronic", "hepatitis", "C", ".", "BACKGROUND", ":", "Hemolytic", "anemia", "is", "one", "of", "the", "major", "adverse", "events", "of", "the", "combination", "therapy", "of", "interferon", "and", "ribavirin", ".", "Because", "of", "ribavirin", "-", "related", "hemolytic", "anemia", ",", "dose", "reduction", "is", "a", "common", "event", "in", "this", "therapy", ".", "In", "this", "clinical", "retrospective", "cohort", "study", "we", "have", "examined", "the", "suitable", "timing", "of", "ribavirin", "reduction", "in", "patients", "with", "hemolysis", "during", "combination", "therapy", ".", "METHODS", ":", "Thirty", "-", "seven", "of", "160", "patients", "who", "had", "HCV", "-", "genotype", "1b", ",", "had", "high", "virus", "load", ",", "and", "received", "24", "-", "week", "combination", "therapy", "developed", "anemia", "with", "hemoglobin", "level", "<", "10", "g", "/", "dl", "or", "anemia", "-", "related", "signs", "during", "therapy", ".", "After", "that", ",", "these", "37", "patients", "were", "reduced", "one", "tablet", "of", "ribavirin", "(", "200", "mg", ")", "per", "day", ".", "After", "reduction", "of", "ribavirin", ",", "27", "of", "37", "patients", "could", "continue", "combination", "therapy", "for", "a", "total", "of", "24", "weeks", "(", "group", "A", ")", ".", "However", ",", "10", "of", "37", "patients", "with", "reduction", "of", "ribavirin", "could", "not", "continue", "combination", "therapy", "because", "their", "<", "8", ".", "5", "g", "/", "dl", "hemoglobin", "values", "decreased", "to", "or", "anemia", "-", "related", "severe", "side", "effects", "occurred", "(", "group", "B", ")", ".", "We", "assessed", "the", "final", "efficacy", "and", "safety", "after", "reduction", "of", "ribavirin", "in", "groups", "A", "and", "B", ".", "RESULTS", ":", "A", "sustained", "virological", "response", "(", "SVR", ")", "was", "29", ".", "6", "%", "(", "8", "/", "27", ")", "in", "group", "A", "and", "10", "%", "(", "1", "/", "10", ")", "in", "group", "B", ",", "respectively", ".", "A", "34", ".", "4", "%", "(", "12", "/", "27", ")", "of", "SVR", "+", "biological", "response", "in", "group", "A", "was", "higher", "than", "10", "%", "(", "1", "/", "10", ")", "in", "group", "B", "(", "P", "=", "0", ".", "051", ")", ",", "with", "slight", "significance", ".", "With", "respect", "to", "hemoglobin", "level", "at", "the", "time", "of", "ribavirin", "reduction", ",", "a", "rate", "of", "continuation", "of", "therapy", "in", "patients", "with", ">", "or", "=", "10", "g", "/", "dl", "hemoglobin", "was", "higher", "than", "that", "in", "patients", "with", "<", "10", "g", "/", "dl", "(", "P", "=", "0", ".", "036", ")", ".", "CONCLUSIONS", ":", "Reduction", "of", "ribavirin", "at", "hemoglobin", "level", ">", "or", "=", "10", "g", "/", "dl", "is", "suitable", "in", "terms", "of", "efficacy", "and", "side", "effects", "."]], "ner": [[[3, 3, "Chemical"], [15, 15, "Chemical"], [39, 39, "Chemical"], [43, 43, "Chemical"], [72, 72, "Chemical"], [138, 138, "Chemical"], [149, 149, "Chemical"], [179, 179, "Chemical"], [221, 221, "Chemical"], [316, 316, "Chemical"], [360, 360, "Chemical"], [23, 24, "Disease"], [46, 47, "Disease"], [13, 13, "Chemical"], [37, 37, "Chemical"], [8, 8, "Disease"], [77, 77, "Disease"], [17, 19, "Disease"], [110, 110, "Disease"], [120, 120, "Disease"], [199, 199, "Disease"]]], "relations": [[[3, 3, 23, 24, "CID"], [3, 3, 46, 47, "CID"], [15, 15, 23, 24, "CID"], [15, 15, 46, 47, "CID"], [39, 39, 23, 24, "CID"], [39, 39, 46, 47, "CID"], [43, 43, 23, 24, "CID"], [43, 43, 46, 47, "CID"], [72, 72, 23, 24, "CID"], [72, 72, 46, 47, "CID"], [138, 138, 23, 24, "CID"], [138, 138, 46, 47, "CID"], [149, 149, 23, 24, "CID"], [149, 149, 46, 47, "CID"], [179, 179, 23, 24, "CID"], [179, 179, 46, 47, "CID"], [221, 221, 23, 24, "CID"], [221, 221, 46, 47, "CID"], [316, 316, 23, 24, "CID"], [316, 316, 46, 47, "CID"], [360, 360, 23, 24, "CID"], [360, 360, 46, 47, "CID"], [13, 13, 23, 24, "CID"], [13, 13, 46, 47, "CID"], [37, 37, 23, 24, "CID"], [37, 37, 46, 47, "CID"]]], "clusters": [], "translated": "<13>干扰素</13>和<1>利巴韦林</1>联合治疗<17>慢性肝炎</17>期间<0>利巴韦林</0>减少<15>溶血</15>患者的适当时机。背景：<11>溶血性贫血</11>是<14>干扰素</14>和<2>利巴韦林</2>联合治疗的主要不良反应之一。由于<3>利巴韦林</3>相关的<12>溶血性贫血</12>，剂量减少是该疗法的常见事件。在这项临床回顾性队列研究中，我们检查了联合治疗期间<4>利巴韦林</4>减少<16>溶血</16>患者的合适时机。方法：160名HCV基因型1b、病毒载量高并接受24周联合治疗的患者中有37名出现<18>贫血</18>，血红蛋白水平<10 g/dl或<19>治疗期间的贫血症状</19>。之后，这37例患者减少每天1片<5>利巴韦林</5>(200mg)。<6>利巴韦林</6>减量后，37例患者中有27例可以继续联合治疗共24周（A组）。然而，37例<7>利巴韦林</7>减量的患者中有10例不能继续联合治疗，因为他们的血红蛋白值<8.5 g/dl下降或<20>贫血</20>相关的严重副作用发生（B组）。我们评估了A组和B组<8>利巴韦林</8>减量后的最终疗效和安全性。结果：A组持续病毒学应答(SVR)为29.6%(8/27)，B组为10%(1/10)。A组SVR+生物学反应的34.4%(12/27)高于B组10%(1/10)(P=0.051)，差异有轻微意义。关于<9>利巴韦林</9>减量时的血红蛋白水平，血红蛋白≥10 g/dl的患者继续治疗的比率高于<10 g/dl的患者（P=0.036）。结论：<10>利巴韦林</10>在血红蛋白水平>或=10 g/dl时的疗效和副作用是合适的。", "revised": true}
{"doc_key": "8267029", "sentences": [["Penicillamine", "-", "induced", "rapidly", "progressive", "glomerulonephritis", "in", "a", "patient", "with", "rheumatoid", "arthritis", ".", "A", "67", "-", "year", "-", "old", "woman", "with", "rheumatoid", "arthritis", "presented", "rapidly", "progressive", "glomerulonephritis", "(", "RPGN", ")", "after", "5", "months", "of", "D", "-", "penicillamine", "(", "250", "mg", "/", "day", ")", "treatment", ".", "Light", "microscopy", "study", "showed", "severe", "glomerulonephritis", "with", "crescent", "formation", "in", "60", "%", "of", "the", "glomeruli", "and", "infiltration", "of", "inflammatory", "cells", "in", "the", "wall", "of", "an", "arteriole", ".", "Immunofluorescence", "revealed", "scanty", "granular", "IgG", ",", "IgA", "and", "C3", "deposits", "along", "the", "capillary", "walls", "and", "mesangium", ".", "The", "patient", "was", "treated", "with", "steroid", "pulse", ",", "plasmapheresis", ",", "cyclophosphamide", "and", "antiplatelet", "agents", ".", "A", "complete", "recovery", "of", "renal", "function", "was", "achieved", "in", "a", "few", "weeks", ".", "This", "new", "case", "of", "RPGN", "in", "the", "course", "of", "D", "-", "penicillamine", "treatment", "emphasizes", "the", "need", "for", "frequent", "monitoring", "of", "renal", "function", "and", "evaluation", "of", "urinary", "sediment", "and", "proteinuria", "in", "these", "patients", ".", "The", "prompt", "discontinuation", "of", "D", "-", "penicillamine", "and", "vigorous", "treatment", "measures", "could", "allow", "for", "a", "good", "prognosis", "as", "in", "this", "case", "."]], "ner": [[[0, 0, "Chemical"], [34, 36, "Chemical"], [126, 128, "Chemical"], [154, 156, "Chemical"], [5, 5, "Disease"], [26, 26, "Disease"], [28, 28, "Disease"], [50, 50, "Disease"], [121, 121, "Disease"], [10, 11, "Disease"], [21, 22, "Disease"], [145, 145, "Disease"], [94, 94, "Chemical"], [99, 99, "Chemical"], [101, 102, "Chemical"]]], "relations": [[[0, 0, 5, 5, "CID"], [0, 0, 26, 26, "CID"], [0, 0, 28, 28, "CID"], [0, 0, 50, 50, "CID"], [0, 0, 121, 121, "CID"], [34, 36, 5, 5, "CID"], [34, 36, 26, 26, "CID"], [34, 36, 28, 28, "CID"], [34, 36, 50, 50, "CID"], [34, 36, 121, 121, "CID"], [126, 128, 5, 5, "CID"], [126, 128, 26, 26, "CID"], [126, 128, 28, 28, "CID"], [126, 128, 50, 50, "CID"], [126, 128, 121, 121, "CID"], [154, 156, 5, 5, "CID"], [154, 156, 26, 26, "CID"], [154, 156, 28, 28, "CID"], [154, 156, 50, 50, "CID"], [154, 156, 121, 121, "CID"]]], "clusters": [], "translated": " \n\n<0>青霉胺</0> - 在<9>类风湿性关节炎</9>患者中诱发了快速进展的<4>肾小球肾炎</4>。一名患有<10>类风湿性关节炎</10>的67岁女性在服用<1>D-青霉胺</1>（250毫克/天）治疗5个月后出现快速进展的<5>肾小球肾炎</5>（<6>RPGN</6>）。光镜检查显示严重的<7>肾小球肾炎</7>，60%的肾小球形成新月体，小动脉壁有炎性细胞浸润。免疫荧光显示毛细血管壁和系膜上有少量颗粒状IgG、IgA和C3沉积物。患者接受<12>类固醇</12>冲击、血浆置换、<13>环磷酰胺</13>和<14>抗血小板药物</14>治疗。数周后肾功能完全恢复。这例在<2>D-青霉胺</2>治疗过程中发生的<8>RPGN</8>的新病例强调了经常监测肾功能和评估尿沉渣和<11>蛋白尿</11>的必要性在这些患者中。及时停用<3>D-青霉胺</3>并采取积极的治疗措施，本例预后良好。", "revised": true}
{"doc_key": "15075188", "sentences": [["Increased", "expression", "and", "apical", "targeting", "of", "renal", "ENaC", "subunits", "in", "puromycin", "aminonucleoside", "-", "induced", "nephrotic", "syndrome", "in", "rats", ".", "Nephrotic", "syndrome", "is", "often", "accompanied", "by", "sodium", "retention", "and", "generalized", "edema", ".", "However", ",", "the", "molecular", "basis", "for", "the", "decreased", "renal", "sodium", "excretion", "remains", "undefined", ".", "We", "hypothesized", "that", "epithelial", "Na", "channel", "(", "ENaC", ")", "subunit", "dysregulation", "may", "be", "responsible", "for", "the", "increased", "sodium", "retention", ".", "An", "experimental", "group", "of", "rats", "was", "treated", "with", "puromycin", "aminonucleoside", "(", "PAN", ";", "180", "mg", "/", "kg", "iv", ")", ",", "whereas", "the", "control", "group", "received", "only", "vehicle", ".", "After", "7", "days", ",", "PAN", "treatment", "induced", "significant", "proteinuria", ",", "hypoalbuminemia", ",", "decreased", "urinary", "sodium", "excretion", ",", "and", "extensive", "ascites", ".", "The", "protein", "abundance", "of", "alpha", "-", "ENaC", "and", "beta", "-", "ENaC", "was", "increased", "in", "the", "inner", "stripe", "of", "the", "outer", "medulla", "(", "ISOM", ")", "and", "in", "the", "inner", "medulla", "(", "IM", ")", "but", "was", "not", "altered", "in", "the", "cortex", ".", "gamma", "-", "ENaC", "abundance", "was", "increased", "in", "the", "cortex", ",", "ISOM", ",", "and", "IM", ".", "Immunoperoxidase", "brightfield", "-", "and", "laser", "-", "scanning", "confocal", "fluorescence", "microscopy", "demonstrated", "increased", "targeting", "of", "alpha", "-", "ENaC", ",", "beta", "-", "ENaC", ",", "and", "gamma", "-", "ENaC", "subunits", "to", "the", "apical", "plasma", "membrane", "in", "the", "distal", "convoluted", "tubule", "(", "DCT2", ")", ",", "connecting", "tubule", ",", "and", "cortical", "and", "medullary", "collecting", "duct", "segments", ".", "Immunoelectron", "microscopy", "further", "revealed", "an", "increased", "labeling", "of", "alpha", "-", "ENaC", "in", "the", "apical", "plasma", "membrane", "of", "cortical", "collecting", "duct", "principal", "cells", "of", "PAN", "-", "treated", "rats", ",", "indicating", "enhanced", "apical", "targeting", "of", "alpha", "-", "ENaC", "subunits", ".", "In", "contrast", ",", "the", "protein", "abundances", "of", "Na", "(", "+", ")", "/", "H", "(", "+", ")", "exchanger", "type", "3", "(", "NHE3", ")", ",", "Na", "(", "+", ")", "-", "K", "(", "+", ")", "-", "2Cl", "(", "-", ")", "cotransporter", "(", "BSC", "-", "1", ")", ",", "and", "thiazide", "-", "sensitive", "Na", "(", "+", ")", "-", "Cl", "(", "-", ")", "cotransporter", "(", "TSC", ")", "were", "decreased", ".", "Moreover", ",", "the", "abundance", "of", "the", "alpha", "(", "1", ")", "-", "subunit", "of", "the", "Na", "-", "K", "-", "ATPase", "was", "decreased", "in", "the", "cortex", "and", "ISOM", ",", "but", "it", "remained", "unchanged", "in", "the", "IM", ".", "In", "conclusion", ",", "the", "increased", "or", "sustained", "expression", "of", "ENaC", "subunits", "combined", "with", "increased", "apical", "targeting", "in", "the", "DCT2", ",", "connecting", "tubule", ",", "and", "collecting", "duct", "are", "likely", "to", "play", "a", "role", "in", "the", "sodium", "retention", "associated", "with", "PAN", "-", "induced", "nephrotic", "syndrome", ".", "The", "decreased", "abundance", "of", "NHE3", ",", "BSC", "-", "1", ",", "TSC", ",", "and", "Na", "-", "K", "-", "ATPase", "may", "play", "a", "compensatory", "role", "to", "promote", "sodium", "excretion", "."]], "ner": [[[10, 11, "Chemical"], [73, 74, "Chemical"], [76, 76, "Chemical"], [97, 97, "Chemical"], [244, 244, "Chemical"], [396, 396, "Chemical"], [14, 15, "Disease"], [19, 20, "Disease"], [399, 400, "Disease"], [101, 101, "Disease"], [103, 103, "Disease"], [112, 112, "Disease"], [29, 29, "Disease"], [25, 25, "Chemical"], [40, 40, "Chemical"], [49, 49, "Chemical"], [62, 62, "Chemical"], [107, 107, "Chemical"], [266, 266, "Chemical"], [282, 282, "Chemical"], [307, 307, "Chemical"], [337, 337, "Chemical"], [392, 392, "Chemical"], [415, 415, "Chemical"], [427, 427, "Chemical"], [271, 271, "Chemical"], [287, 287, "Chemical"], [339, 339, "Chemical"], [417, 417, "Chemical"], [292, 292, "Chemical"], [312, 312, "Chemical"], [304, 304, "Chemical"]]], "relations": [[[10, 11, 14, 15, "CID"], [10, 11, 19, 20, "CID"], [10, 11, 399, 400, "CID"], [73, 74, 14, 15, "CID"], [73, 74, 19, 20, "CID"], [73, 74, 399, 400, "CID"], [76, 76, 14, 15, "CID"], [76, 76, 19, 20, "CID"], [76, 76, 399, 400, "CID"], [97, 97, 14, 15, "CID"], [97, 97, 19, 20, "CID"], [97, 97, 399, 400, "CID"], [244, 244, 14, 15, "CID"], [244, 244, 19, 20, "CID"], [244, 244, 399, 400, "CID"], [396, 396, 14, 15, "CID"], [396, 396, 19, 20, "CID"], [396, 396, 399, 400, "CID"], [10, 11, 101, 101, "CID"], [73, 74, 101, 101, "CID"], [76, 76, 101, 101, "CID"], [97, 97, 101, 101, "CID"], [244, 244, 101, 101, "CID"], [396, 396, 101, 101, "CID"], [10, 11, 103, 103, "CID"], [73, 74, 103, 103, "CID"], [76, 76, 103, 103, "CID"], [97, 97, 103, 103, "CID"], [244, 244, 103, 103, "CID"], [396, 396, 103, 103, "CID"], [10, 11, 112, 112, "CID"], [73, 74, 112, 112, "CID"], [76, 76, 112, 112, "CID"], [97, 97, 112, 112, "CID"], [244, 244, 112, 112, "CID"], [396, 396, 112, 112, "CID"]]], "clusters": [], "translated": "在<0>嘌呤霉素氨基核苷</0>诱导的大鼠<6>肾病综合征</6>中，肾ENaC亚基的表达和顶端靶向增加。 <7>肾病综合征</7>常伴有<13>钠</13>潴留和全身性<12>水肿</12>。然而，肾脏<14>钠</14>排泄减少的分子基础仍未明确。我们假设上皮<15>Na</15>通道（ENaC）亚基失调可能是导致<16>钠</16>滞留增加的原因。实验组大鼠用<1>嘌呤霉素氨基核苷</1>（<2>PAN</2>; 180 mg/kg iv）治疗，而对照组仅接受载体。7天后，<3>PAN</3>治疗引起明显的<9>蛋白尿</9>、<10>低白蛋白血症</10>、尿<17>钠</17>排泄减少和广泛的<11>腹水</11>. alpha-ENaC 和beta-ENaC的蛋白质丰度在外髓质内条纹(ISOM)和内髓质(IM)中增加，但在皮质中没有改变。皮质、ISOM和IM中的gamma-ENaC丰度增加。免疫过氧化物酶明场和激光扫描共聚焦荧光显微镜显示alpha-ENaC、beta-ENaC和gamma-ENaC亚基在远曲小管(DCT2)、连接小管、皮质和髓质集合管的顶端质膜上的靶向增加。免疫电子显微镜进一步显示<4>PAN</4>处理大鼠皮质集合管主细胞顶端质膜中alpha-ENaC标记增加，表明alpha-ENaC亚基顶端靶向增强。相比之下，<18>Na</18>(+)/<25>H</25>(+)交换器类型3(NHE3)、<19>Na</19>(+)-<26>K</26>(+)-<29>2Cl</29>(-)协同转运蛋白(BSC-1)和<31>噻嗪类</31>-敏感<20>Na</20>(+)-<30>Cl</30>(-)协同转运蛋白(TSC)减少。此外，<21>Na</21>-<27>K</27>-ATPase的α(1)-亚基的丰度在皮质和ISOM中降低，但在IM中保持不变。总之，ENaC亚基的增加或持续表达与DCT2、连接小管和集合管中顶端靶向的增加可能在<22>钠</22>滞留中发挥作用，与<5>PAN</5>-诱发<8>肾病综合征</8>。NHE3、BSC-1、TSC和<23>Na</23>-<28>K</28>-ATP酶丰度的降低可能起到代偿作用，促进<24>钠</24>排泄。", "revised": true}
{"doc_key": "17263743", "sentences": [["Cardiac", "arrest", "in", "a", "child", "with", "cerebral", "palsy", "undergoing", "sevoflurane", "induction", "of", "anesthesia", "after", "preoperative", "clonidine", ".", "Clonidine", "is", "a", "frequently", "administered", "alpha2", "-", "adrenergic", "agonist", "which", "can", "decrease", "heart", "rate", "and", "blood", "pressure", ".", "We", "present", "a", "case", "of", "a", "5", "-", "year", "-", "old", "child", "with", "cerebral", "palsy", "and", "seizure", "disorder", ",", "receiving", "clonidine", "for", "restlessness", ",", "who", "presented", "for", "placement", "of", "a", "baclofen", "pump", ".", "Without", "the", "knowledge", "of", "the", "medical", "personnel", ",", "the", "patient", "'s", "mother", "administered", "three", "doses", "of", "clonidine", "during", "the", "evening", "before", "and", "morning", "of", "surgery", "to", "reduce", "anxiety", ".", "During", "induction", "of", "anesthesia", ",", "the", "patient", "developed", "bradycardia", "and", "hypotension", "requiring", "cardiac", "resuscitation", ".", "There", "are", "no", "previous", "reports", "of", "clonidine", "-", "associated", "cardiac", "arrest", "in", "a", "child", "undergoing", "induction", "of", "anesthesia", "."]], "ner": [[[15, 15, "Chemical"], [17, 17, "Chemical"], [55, 55, "Chemical"], [84, 84, "Chemical"], [118, 118, "Chemical"], [0, 1, "Disease"], [121, 122, "Disease"], [105, 105, "Disease"], [107, 107, "Disease"], [9, 9, "Chemical"], [65, 65, "Chemical"], [6, 7, "Disease"], [48, 49, "Disease"], [51, 52, "Disease"], [57, 57, "Disease"], [95, 95, "Disease"]]], "relations": [[[15, 15, 0, 1, "CID"], [15, 15, 121, 122, "CID"], [17, 17, 0, 1, "CID"], [17, 17, 121, 122, "CID"], [55, 55, 0, 1, "CID"], [55, 55, 121, 122, "CID"], [84, 84, 0, 1, "CID"], [84, 84, 121, 122, "CID"], [118, 118, 0, 1, "CID"], [118, 118, 121, 122, "CID"], [15, 15, 105, 105, "CID"], [17, 17, 105, 105, "CID"], [55, 55, 105, 105, "CID"], [84, 84, 105, 105, "CID"], [118, 118, 105, 105, "CID"], [15, 15, 107, 107, "CID"], [17, 17, 107, 107, "CID"], [55, 55, 107, 107, "CID"], [84, 84, 107, 107, "CID"], [118, 118, 107, 107, "CID"]]], "clusters": [], "translated": "<5>心脏骤停</5>在一名<11>脑瘫</11>患儿接受<9>七氟醚</9>麻醉诱导后，术中因术前<0>可乐定</0>使用。 <1>可乐定</1>是一种经常使用的α2-肾上腺素能激动剂，可降低心率和血压。我们介绍了一名接受<2>可乐定</2>治疗<14>躁动</14>的5岁<12>脑瘫</12>和<13>癫痫发作</13>患儿，此次患儿接受了<10>巴氯芬</10>泵的置入手术。手术前一天晚上和手术早上，在医务人员不知情的情况下，患者的母亲给患儿服用了三剂<3>可乐定</3>，以减轻<15>焦虑</15>。麻醉诱导期间，患者出现<7>心动过缓</7>和<8>低血压</8>，需要进行心脏复苏。以前没有关于接受麻醉诱导的<4>可乐定</4>相关<6>心脏骤停</6>的报道。", "revised": true}
{"doc_key": "133615", "sentences": [["Progestational", "agents", "and", "blood", "coagulation", ".", "VII", ".", "Thromboembolic", "and", "other", "complications", "of", "oral", "contraceptive", "therapy", "in", "relationship", "to", "pretreatment", "levels", "of", "blood", "coagulation", "factors", ":", "summary", "report", "of", "a", "ten", "-", "year", "study", ".", "During", "a", "ten", "-", "year", "period", ",", "348", "women", "were", "studied", "for", "a", "total", "of", "5", ",", "877", "patient", "months", "in", "four", "separate", "studies", "relating", "oral", "contraceptives", "to", "changes", "in", "hematologic", "parameters", ".", "Significant", "increases", "in", "certain", "factors", "of", "the", "blood", "coagulation", "and", "fibrinolysin", "systems", "(", "factors", "I", ",", "II", ",", "VII", ",", "VIII", ",", "IX", ",", "and", "X", "and", "plasminogen", ")", "were", "observed", "in", "the", "treated", "groups", ".", "Severe", "complications", "developed", "in", "four", "patients", ".", "All", "four", "had", "an", "abnormal", "blood", "coagulation", "profile", ",", "suggesting", "\"", "hypercoagulability", "\"", "before", "initiation", "of", "therapy", ".", "Some", "of", "these", "findings", "represented", "the", "most", "extreme", "abnormalities", "seen", "in", "the", "entire", "group", "of", "patients", ";", "some", "increased", "further", "during", "therapy", ".", "One", "of", "these", "patients", "developed", "a", "myocardial", "infarction", "before", "receiving", "any", "medication", ",", "shortly", "after", "the", "base", "-", "line", "values", "were", "obtained", ".", "One", "patient", "developed", "retinopathy", "19", "months", "after", "she", "began", "therapy", ",", "and", "another", "developed", "thrombophlebitis", "after", "27", "months", "of", "therapy", ".", "The", "fourth", "patient", "developed", "thrombophlebitis", "14", "days", "after", "initiation", "of", "contraceptive", "therapy", ".", "All", "four", "patients", "were", "of", "the", "A", "or", "AB", "blood", "group", ".", "Previous", "studies", "suggested", "the", "possiblility", "of", "increased", "propensity", "for", "thromboembolic", "episodes", "in", "patients", "possessing", "the", "A", "antigen", ".", "It", "appears", "from", "these", "data", "that", "hematologic", "work", "-", "ups", "may", "be", "useful", "in", "women", "who", "are", "about", "to", "start", "long", "-", "term", "oral", "contraceptive", "therapy", "."]], "ner": [[[13, 14, "Chemical"], [60, 61, "Chemical"], [262, 263, "Chemical"], [3, 4, "Disease"], [22, 23, "Disease"], [75, 76, "Disease"], [116, 117, "Disease"], [158, 159, "Disease"], [178, 178, "Disease"], [189, 189, "Disease"], [200, 200, "Disease"], [8, 8, "Disease"], [230, 231, "Disease"], [122, 122, "Disease"]]], "relations": [[[13, 14, 3, 4, "CID"], [13, 14, 22, 23, "CID"], [13, 14, 75, 76, "CID"], [13, 14, 116, 117, "CID"], [60, 61, 3, 4, "CID"], [60, 61, 22, 23, "CID"], [60, 61, 75, 76, "CID"], [60, 61, 116, 117, "CID"], [262, 263, 3, 4, "CID"], [262, 263, 22, 23, "CID"], [262, 263, 75, 76, "CID"], [262, 263, 116, 117, "CID"], [13, 14, 158, 159, "CID"], [60, 61, 158, 159, "CID"], [262, 263, 158, 159, "CID"], [13, 14, 178, 178, "CID"], [60, 61, 178, 178, "CID"], [262, 263, 178, 178, "CID"], [13, 14, 189, 189, "CID"], [13, 14, 200, 200, "CID"], [60, 61, 189, 189, "CID"], [60, 61, 200, 200, "CID"], [262, 263, 189, 189, "CID"], [262, 263, 200, 200, "CID"]]], "clusters": [], "translated": "促孕剂和<3>凝血</3>。七。<11>血栓栓塞</11>和<0>口服避孕药</0>治疗的其他并发症与治疗前<4>凝血</4>因素水平的关系：十年研究总结报告。在10年的时间里，共有348名女性参与了四项关于<1>口服避孕药</1>与血液学参数变化相关的独立研究，共计研究了5,877个患者月。观察到<5>血液凝血</5>和纤维蛋白的某些因子（因子I、II、VII、VIII、IX、X和纤溶酶原）在治疗组中显着升高。四名患者出现了严重并发症，而这四名患者的<6>血液凝血</6>情况均异常，这表明在治疗开始前呈现“<13>高凝状态</13>”。这些发现中有些代表整个患者组中最极端的异常情况，而有些在治疗期间进一步加重。其中一名患者在接受药物治疗之前发生了<7>心肌梗塞</7>，基线值获得后不久。一名患者在治疗开始 19 个月后出现<8>视网膜病变</8>，而另一名患者在治疗 27 个月后出现<9>血栓性静脉炎</9>。第四名患者在开始避孕治疗后14天出现<10>血栓性静脉炎</10>。所有四名患者均属于A或AB血型，先前的研究表明在具有A抗原的患者中，<12>血栓栓塞发作</12>的可能性增加。从这些数据看来，在即将开始长期<2>口服避孕药</2>治疗的女性中，血液学检查可能很有用。", "revised": true}
{"doc_key": "384871", "sentences": [["Bilateral", "optic", "neuropathy", "due", "to", "combined", "ethambutol", "and", "isoniazid", "treatment", ".", "The", "case", "of", "a", "40", "-", "year", "-", "old", "patient", "who", "underwent", "an", "unsuccessful", "cadaver", "kidney", "transplantation", "and", "was", "treated", "with", "ethambutol", "and", "isoniazid", "is", "reported", ".", "A", "bilateral", "retrobulbar", "neuropathy", "with", "an", "unusual", "central", "bitemporal", "hemianopic", "scotoma", "was", "found", ".", "Ethambutol", "was", "stopped", "and", "only", "small", "improvement", "of", "the", "visual", "acuity", "followed", ".", "Isoniazid", "was", "discontinued", "later", ",", "followed", "by", "a", "dramatic", "improvement", "in", "the", "visual", "acuity", ".", "The", "hazards", "of", "optic", "nerve", "toxicity", "due", "to", "ethambutol", "are", "known", ".", "We", "emphasize", "the", "potential", "danger", "in", "the", "use", "of", "ethambutol", "and", "isoniazid", "."]], "ner": [[[6, 6, "Chemical"], [32, 32, "Chemical"], [52, 52, "Chemical"], [88, 88, "Chemical"], [101, 101, "Chemical"], [0, 2, "Disease"], [39, 41, "Disease"], [8, 8, "Chemical"], [34, 34, "Chemical"], [65, 65, "Chemical"], [103, 103, "Chemical"], [48, 48, "Disease"], [85, 85, "Disease"]]], "relations": [[[6, 6, 0, 2, "CID"], [6, 6, 39, 41, "CID"], [32, 32, 0, 2, "CID"], [32, 32, 39, 41, "CID"], [52, 52, 0, 2, "CID"], [52, 52, 39, 41, "CID"], [88, 88, 0, 2, "CID"], [88, 88, 39, 41, "CID"], [101, 101, 0, 2, "CID"], [101, 101, 39, 41, "CID"], [8, 8, 0, 2, "CID"], [8, 8, 39, 41, "CID"], [34, 34, 0, 2, "CID"], [34, 34, 39, 41, "CID"], [65, 65, 0, 2, "CID"], [65, 65, 39, 41, "CID"], [103, 103, 0, 2, "CID"], [103, 103, 39, 41, "CID"], [6, 6, 48, 48, "CID"], [32, 32, 48, 48, "CID"], [52, 52, 48, 48, "CID"], [88, 88, 48, 48, "CID"], [101, 101, 48, 48, "CID"], [8, 8, 48, 48, "CID"], [34, 34, 48, 48, "CID"], [65, 65, 48, 48, "CID"], [103, 103, 48, 48, "CID"]]], "clusters": [], "translated": "<5>双侧视神经病变</5>由于<0>乙胺丁醇</0>和<7>异烟肼</7>联合治疗。报道了一名40岁的患者，其进行了一次无法成功的尸体肾移植并接受了<1>乙胺丁醇</1>和<8>异烟肼</8>的治疗。发现<6>双侧球后神经病变</6>伴有一个异常的中央双侧偏盲<11>暗点</11>。停用<2>乙胺丁醇</2>后，视力仅略微改善。<9>异烟肼</9>随后停用，随后视力迅速改善。已知使用<3>乙胺丁醇</3>会存在视神经<12>毒性</12>的危害。我们强调使用<4>乙胺丁醇</4>和<10>异烟肼</10>的潜在危险。", "revised": true}
{"doc_key": "14745746", "sentences": [["Does", "hormone", "therapy", "for", "the", "treatment", "of", "breast", "cancer", "have", "a", "detrimental", "effect", "on", "memory", "and", "cognition", "?", "A", "pilot", "study", ".", "This", "pilot", "study", "examines", "whether", "hormone", "therapy", "for", "breast", "cancer", "affects", "cognition", ".", "Patients", "participating", "in", "a", "randomised", "trial", "of", "anastrozole", ",", "tamoxifen", "alone", "or", "combined", "(", "ATAC", ")", "(", "n", "=", "94", ")", "and", "a", "group", "of", "women", "without", "breast", "cancer", "(", "n", "=", "35", ")", "completed", "a", "battery", "of", "neuropsychological", "measures", ".", "Compared", "with", "the", "control", "group", ",", "the", "patients", "were", "impaired", "on", "a", "processing", "speed", "task", "(", "p", "=", "0", ".", "032", ")", "and", "on", "a", "measure", "of", "immediate", "verbal", "memory", "(", "p", "=", "0", ".", "026", ")", "after", "controlling", "for", "the", "use", "of", "hormone", "replacement", "therapy", "in", "both", "groups", ".", "Patient", "group", "performance", "was", "not", "significantly", "related", "to", "length", "of", "treatment", "or", "measures", "of", "psychological", "morbidity", ".", "The", "results", "showed", "specific", "impairments", "in", "processing", "speed", "and", "verbal", "memory", "in", "women", "receiving", "hormonal", "therapy", "for", "the", "treatment", "of", "breast", "cancer", ".", "Verbal", "memory", "may", "be", "especially", "sensitive", "to", "changes", "in", "oestrogen", "levels", ",", "a", "finding", "commonly", "reported", "in", "studies", "of", "hormone", "replacement", "therapy", "in", "healthy", "women", ".", "In", "view", "of", "the", "increased", "use", "of", "hormone", "therapies", "in", "an", "adjuvant", "and", "preventative", "setting", "their", "impact", "on", "cognitive", "functioning", "should", "be", "investigated", "more", "thoroughly", "."]], "ner": [[[42, 42, "Chemical"], [11, 16, "Disease"], [44, 44, "Chemical"], [7, 8, "Disease"], [30, 31, "Disease"], [62, 63, "Disease"], [163, 164, "Disease"], [175, 175, "Chemical"]]], "relations": [[[42, 42, 11, 16, "CID"], [44, 44, 11, 16, "CID"]]], "clusters": [], "translated": "用于治疗<3>乳腺癌</3>的激素疗法是否对<1>记忆和认知产生不利影响</1>？一项试点研究。这项试点研究检查了<4>乳腺癌</4>的激素疗法是否会影响认知。参加随机试验的患者<0>阿那曲唑</0>，<2>他莫昔芬</2>单独或联合使用(ATAC)(n=94)和一组未患<5>乳腺癌</5>的女性(n=35)完成了一组神经心理测量。与对照组相比，在控制两组激素替代疗法的使用后，患者在处理速度任务(<0>p=0.032</0>)和即时语言记忆测量(<1>p=0.026</1>)上均受损。患者组的表现与治疗时间或心理发病率指标没有显着相关性。结果显示，接受激素治疗以治疗<6>乳腺癌</6>的女性在处理速度和语言记忆方面存在特定障碍。语言记忆可能对<7>雌激素</7>水平的变化特别敏感，这一发现在健康女性的激素替代疗法研究中普遍报道。鉴于激素疗法在辅助和预防环境中的使用增加，应更彻底地研究它们对认知功能的影响。", "revised": true}
{"doc_key": "11195262", "sentences": [["Contribution", "of", "sodium", "valproate", "to", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", ".", "We", "report", "the", "case", "of", "a", "62", "-", "year", "-", "old", "man", "who", "was", "administered", "sodium", "valproate", "(", "VPA", ")", "and", "who", "subsequently", "developed", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", ".", "He", "had", "been", "taking", "VPA", "for", "treatment", "of", "idiopathic", "generalized", "tonic", "-", "clonic", "convulsions", "since", "he", "was", "56", "years", "old", ".", "After", "substituting", "VPA", "with", "zonisamide", ",", "the", "serum", "sodium", "level", "returned", "to", "normal", ".", "We", "consider", "this", "episode", "of", "SIADH", "to", "be", "the", "result", "of", "a", "combination", "of", "factors", "including", "a", "weakness", "of", "the", "central", "nervous", "system", "and", "the", "long", "-", "term", "administration", "of", "VPA", "."]], "ner": [[[2, 3, "Chemical"], [29, 30, "Chemical"], [32, 32, "Chemical"], [54, 54, "Chemical"], [73, 73, "Chemical"], [115, 115, "Chemical"], [6, 12, "Disease"], [39, 45, "Disease"], [47, 47, "Disease"], [90, 90, "Disease"], [60, 63, "Disease"], [102, 107, "Disease"], [75, 75, "Chemical"], [79, 79, "Chemical"]]], "relations": [[[2, 3, 6, 12, "CID"], [2, 3, 39, 45, "CID"], [2, 3, 47, 47, "CID"], [2, 3, 90, 90, "CID"], [29, 30, 6, 12, "CID"], [29, 30, 39, 45, "CID"], [29, 30, 47, 47, "CID"], [29, 30, 90, 90, "CID"], [32, 32, 6, 12, "CID"], [32, 32, 39, 45, "CID"], [32, 32, 47, 47, "CID"], [32, 32, 90, 90, "CID"], [54, 54, 6, 12, "CID"], [54, 54, 39, 45, "CID"], [54, 54, 47, 47, "CID"], [54, 54, 90, 90, "CID"], [73, 73, 6, 12, "CID"], [73, 73, 39, 45, "CID"], [73, 73, 47, 47, "CID"], [73, 73, 90, 90, "CID"], [115, 115, 6, 12, "CID"], [115, 115, 39, 45, "CID"], [115, 115, 47, 47, "CID"], [115, 115, 90, 90, "CID"]]], "clusters": [], "translated": "<0>丙戊酸钠</0>对<6>抗利尿激素异常分泌综合征</6>的贡献。我们报告了一名 62 岁男性的病例，他服用了<1>丙戊酸钠</1>（<2>VPA</2>），随后出现了<7>抗利尿激素分泌不当综合征</7>（<8>SIADH</8>）。他从56岁起就一直服用<3>VPA</3>治疗特发性全身性<10>强直-阵挛性惊厥</10>。用<12>唑尼沙胺</12>替代<4>VPA</4>后，血清<13>钠</13>水平恢复正常。我们认为这次<9>SIADH</9>是多种因素共同作用的结果，包括<11>中枢神经系统虚弱</11>和长期服用<5>VPA</5>。", "revised": true}
{"doc_key": "9201797", "sentences": [["The", "attenuating", "effect", "of", "carteolol", "hydrochloride", ",", "a", "beta", "-", "adrenoceptor", "antagonist", ",", "on", "neuroleptic", "-", "induced", "catalepsy", "in", "rats", ".", "It", "is", "known", "that", "beta", "-", "adrenoceptor", "antagonists", "are", "effective", "in", "the", "treatment", "of", "akathisia", ",", "one", "of", "the", "extrapyramidal", "side", "effects", "that", "occur", "during", "neuroleptic", "treatment", ".", "Neuroleptic", "-", "induced", "catalepsy", ",", "a", "model", "of", "neuroleptic", "-", "induced", "extrapyramidal", "side", "effects", ",", "was", "considered", "suitable", "as", "a", "model", "for", "predicting", "neuroleptic", "-", "induced", "akathisia", "in", "humans", ",", "although", "neuroleptic", "-", "induced", "catalepsy", "was", "not", "considered", "a", "specific", "test", "for", "neuroleptic", "-", "induced", "akathisia", ".", "Therefore", ",", "the", "effects", "of", "carteolol", ",", "a", "beta", "-", "adrenoceptor", "antagonist", ",", "on", "haloperidol", "-", "induced", "catalepsy", "in", "rats", "were", "behaviorally", "studied", "and", "compared", "with", "those", "of", "propranolol", "and", "biperiden", ",", "a", "muscarinic", "receptor", "antagonist", ".", "Carteolol", ",", "as", "well", "as", "propranolol", "and", "biperiden", ",", "inhibited", "the", "haloperidol", "-", "induced", "catalepsy", ".", "The", "inhibitory", "effect", "of", "carteolol", "was", "almost", "comparable", "to", "that", "of", "propranolol", ",", "but", "was", "weaker", "than", "that", "of", "biperiden", ".", "Carteolol", "did", "not", "evoke", "postsynaptic", "dopamine", "receptor", "-", "stimulating", "behavioral", "signs", "such", "as", "stereotypy", "and", "hyperlocomotion", "in", "rats", ".", "Carteolol", "did", "not", "antagonize", "the", "inhibitory", "effects", "of", "haloperidol", "on", "apomorphine", "-", "induced", "stereotypy", "and", "locomotor", "activity", "in", "rats", ".", "In", "addition", ",", "carteolol", "did", "not", "evoke", "5", "-", "HT1A", "receptor", "-", "stimulating", "behavioral", "signs", "such", "as", "flat", "body", "posture", "and", "forepaw", "treading", "and", "did", "not", "inhibit", "5", "-", "hydroxytryptophan", "-", "induced", "head", "twitch", "in", "rats", ".", "Finally", ",", "carteolol", "did", "not", "inhibit", "physostigmine", "-", "induced", "lethality", "in", "rats", ".", "These", "results", "strongly", "suggest", "that", "carteolol", "improves", "haloperidol", "-", "induced", "catalepsy", "via", "its", "beta", "-", "adrenoceptor", "antagonistic", "activity", "and", "is", "expected", "to", "be", "effective", "in", "the", "treatment", "of", "akathisia", "without", "attenuating", "neuroleptic", "-", "induced", "antipsychotic", "effects", "due", "to", "its", "postsynaptic", "dopamine", "receptor", "antagonistic", "activity", "."]], "ner": [[[110, 110, "Chemical"], [144, 144, "Chemical"], [197, 197, "Chemical"], [266, 266, "Chemical"], [17, 17, "Disease"], [52, 52, "Disease"], [83, 83, "Disease"], [113, 113, "Disease"], [147, 147, "Disease"], [269, 269, "Disease"], [4, 5, "Chemical"], [101, 101, "Chemical"], [133, 133, "Chemical"], [153, 153, "Chemical"], [170, 170, "Chemical"], [189, 189, "Chemical"], [212, 212, "Chemical"], [248, 248, "Chemical"], [264, 264, "Chemical"], [35, 35, "Disease"], [75, 75, "Disease"], [94, 94, "Disease"], [287, 287, "Disease"], [185, 185, "Disease"], [124, 124, "Chemical"], [138, 138, "Chemical"], [160, 160, "Chemical"], [126, 126, "Chemical"], [140, 140, "Chemical"], [168, 168, "Chemical"], [175, 175, "Chemical"], [299, 299, "Chemical"], [199, 199, "Chemical"], [236, 238, "Chemical"], [252, 252, "Chemical"]]], "relations": [[[110, 110, 17, 17, "CID"], [110, 110, 52, 52, "CID"], [110, 110, 83, 83, "CID"], [110, 110, 113, 113, "CID"], [110, 110, 147, 147, "CID"], [110, 110, 269, 269, "CID"], [144, 144, 17, 17, "CID"], [144, 144, 52, 52, "CID"], [144, 144, 83, 83, "CID"], [144, 144, 113, 113, "CID"], [144, 144, 147, 147, "CID"], [144, 144, 269, 269, "CID"], [197, 197, 17, 17, "CID"], [197, 197, 52, 52, "CID"], [197, 197, 83, 83, "CID"], [197, 197, 113, 113, "CID"], [197, 197, 147, 147, "CID"], [197, 197, 269, 269, "CID"], [266, 266, 17, 17, "CID"], [266, 266, 52, 52, "CID"], [266, 266, 83, 83, "CID"], [266, 266, 113, 113, "CID"], [266, 266, 147, 147, "CID"], [266, 266, 269, 269, "CID"]]], "clusters": [], "translated": "<10>盐酸卡替洛尔</10>，一种β-肾上腺素能受体拮抗剂，对大鼠抗精神病药引起的<4>强直性昏厥</4>的减弱作用。众所周知，β-肾上腺素能受体拮抗剂可有效治疗<19>静坐不能</19>，这是神经安定药治疗期间发生的锥体外系副作用之一。抗精神病药引起的<5>强直性昏厥</5>，一种抗精神病药引起的锥体外系副作用的模型，被认为适合作为预测人类抗精神病药引起的<20>静坐不能</20>的模型，尽管抗精神病药引起的<6>强直性昏厥</6>不被认为是抗精神病药物引起的<21>静坐不能</21>的特定测试。因此，在行为学上研究了β-肾上腺素能受体拮抗剂<11>卡替洛尔</11>对<0>氟哌啶醇</0>诱导的<7>僵直</7>大鼠的影响，并与<24>普萘洛尔</24>和<27>比哌立登</27>，一种毒蕈碱受体拮抗剂。 <12>卡替洛尔</12>以及<25>普萘洛尔</25>和<28>比哌立登</28>抑制<1>氟哌啶醇</1> - 诱导的<8>强直性昏厥</8>。 <13>卡替洛尔</13>的抑制作用与<26>普萘洛尔</26>几乎相当，但弱于<29>比哌立登</29>。 <14>卡替洛尔</14>不会在大鼠中引起突触后<30>多巴胺</30>受体刺激行为迹象，例如刻板印象和<23>过度运动</23>。 <15>卡替洛尔</15>不拮抗<2>氟哌啶醇</2>对<32>阿朴吗啡</32>诱导的大鼠刻板行为和自发活动的抑制作用。此外，<16>卡替洛尔</16>不会引起5-HT1A受体刺激性行为体征，如平身姿势和前爪踩踏，也不会抑制<33>5-羟色氨酸</33>-诱导的大鼠头部抽搐。最后，<17>卡替洛尔</17>不抑制<34>毒扁豆碱</34>引起的大鼠致死。这些结果强烈表明，<18>卡替洛尔</18>通过其β-肾上腺素能受体拮抗活性改善了<3>氟哌啶醇</3>诱导的<9>僵直</9>，并有望有效治疗<22>静坐不能</22>。由于其突触后<31>多巴胺</31>受体拮抗活性，不会减弱抗精神病药物诱导的抗精神病作用。", "revised": true}
{"doc_key": "10728962", "sentences": [["Vasopressin", "in", "the", "treatment", "of", "milrinone", "-", "induced", "hypotension", "in", "severe", "heart", "failure", ".", "The", "use", "of", "phosphodiesterase", "inhibitors", "such", "as", "milrinone", "in", "the", "treatment", "of", "severe", "heart", "failure", "is", "frequently", "restricted", "because", "they", "cause", "vasodilation", "and", "hypotension", ".", "In", "patients", "with", "decompensated", "heart", "failure", "with", "hypotension", "after", "treatment", "with", "milrinone", ",", "low", "doses", "of", "vasopressin", "restored", "blood", "pressure", "without", "inhibiting", "the", "inotropic", "effect", "of", "milrinone", "."]], "ner": [[[0, 0, "Chemical"], [55, 55, "Chemical"], [8, 8, "Disease"], [37, 37, "Disease"], [46, 46, "Disease"], [5, 5, "Chemical"], [21, 21, "Chemical"], [50, 50, "Chemical"], [65, 65, "Chemical"], [11, 12, "Disease"], [27, 28, "Disease"], [43, 44, "Disease"]]], "relations": [[[0, 0, 8, 8, "CID"], [0, 0, 37, 37, "CID"], [0, 0, 46, 46, "CID"], [55, 55, 8, 8, "CID"], [55, 55, 37, 37, "CID"], [55, 55, 46, 46, "CID"], [5, 5, 8, 8, "CID"], [5, 5, 37, 37, "CID"], [5, 5, 46, 46, "CID"], [21, 21, 8, 8, "CID"], [21, 21, 37, 37, "CID"], [21, 21, 46, 46, "CID"], [50, 50, 8, 8, "CID"], [50, 50, 37, 37, "CID"], [50, 50, 46, 46, "CID"], [65, 65, 8, 8, "CID"], [65, 65, 37, 37, "CID"], [65, 65, 46, 46, "CID"]]], "clusters": [], "translated": " <0>加压素</0>治疗<5>米力农</5>引起的<2>低血压</2>在严重<9>心力衰竭</9>的治疗方面具有很高的应用价值。磷酸二酯酶抑制剂如<6>米力农</6>在治疗严重<10>心力衰竭</10>时其使用常常受到限制，因为会导致血管扩张和<3>低血压</3>。在进行治疗后，失代偿性的<11>心力衰竭</11>患者伴有<4>低血压</4>症状，而在使用<7>米力农</7>治疗后，低剂量的<1>加压素</1>可以恢复患者的血压，这种方法不会影响到 <8>米力农</8> 的正性肌力作用。", "revised": true}
{"doc_key": "14982270", "sentences": [["Methimazole", "-", "induced", "cholestatic", "jaundice", ".", "Methimazole", "is", "a", "widely", "used", "and", "generally", "well", "-", "tolerated", "antithyroid", "agent", ".", "A", "43", "-", "year", "-", "old", "woman", "had", "severe", "jaundice", "and", "itching", "1", "month", "after", "receiving", "methimazole", "(", "10", "mg", "tid", ")", "and", "propranolol", "(", "20", "mg", "tid", ")", "for", "treatment", "of", "hyperthyroidism", ".", "The", "patient", "continued", "treatment", "for", "another", "4", "days", "after", "the", "appearance", "of", "jaundice", "until", "she", "finished", "both", "medications", ".", "When", "seen", "at", "the", "emergency", "department", "2", "weeks", "later", ",", "she", "still", "had", "severe", "icterus", ",", "pruritus", ",", "and", "hyperbilirubinemia", ",", "formed", "mainly", "of", "the", "conjugated", "fraction", ".", "Methimazole", "-", "induced", "cholestasis", "was", "diagnosed", ",", "and", "propranolol", "therapy", "was", "resumed", ".", "Over", "the", "following", "9", "days", ",", "the", "symptoms", "improved", "and", "plasma", "bilirubin", "levels", "were", "normal", "after", "12", "weeks", "without", "methimazole", ".", "In", "rare", "cases", "within", "the", "first", "few", "weeks", "of", "therapy", ",", "this", "drug", "can", "cause", "severe", "and", "reversible", "cholestatic", "jaundice", ".", "Physicians", "and", "patients", "should", "be", "aware", "of", "this", "adverse", "effect", "so", "that", ",", "upon", "occurrence", ",", "they", "can", "discontinue", "methimazole", "therapy", "and", "avoid", "unnecessary", "invasive", "procedures", "."]], "ner": [[[0, 0, "Chemical"], [6, 6, "Chemical"], [35, 35, "Chemical"], [100, 100, "Chemical"], [132, 132, "Chemical"], [174, 174, "Chemical"], [3, 4, "Disease"], [152, 153, "Disease"], [30, 30, "Disease"], [88, 88, "Disease"], [91, 91, "Disease"], [28, 28, "Disease"], [65, 65, "Disease"], [86, 86, "Disease"], [51, 51, "Disease"], [103, 103, "Disease"], [42, 42, "Chemical"], [108, 108, "Chemical"], [124, 124, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 152, 153, "CID"], [6, 6, 3, 4, "CID"], [6, 6, 152, 153, "CID"], [35, 35, 3, 4, "CID"], [35, 35, 152, 153, "CID"], [100, 100, 3, 4, "CID"], [100, 100, 152, 153, "CID"], [132, 132, 3, 4, "CID"], [132, 132, 152, 153, "CID"], [174, 174, 3, 4, "CID"], [174, 174, 152, 153, "CID"], [0, 0, 30, 30, "CID"], [0, 0, 88, 88, "CID"], [6, 6, 30, 30, "CID"], [6, 6, 88, 88, "CID"], [35, 35, 30, 30, "CID"], [35, 35, 88, 88, "CID"], [100, 100, 30, 30, "CID"], [100, 100, 88, 88, "CID"], [132, 132, 30, 30, "CID"], [132, 132, 88, 88, "CID"], [174, 174, 30, 30, "CID"], [174, 174, 88, 88, "CID"], [0, 0, 91, 91, "CID"], [6, 6, 91, 91, "CID"], [35, 35, 91, 91, "CID"], [100, 100, 91, 91, "CID"], [132, 132, 91, 91, "CID"], [174, 174, 91, 91, "CID"]]], "clusters": [], "translated": "<0>甲巯咪唑</0>——诱发<6>胆汁淤积性黄疸</6>。 <1>甲巯咪唑</1>是一种广泛使用且通常耐受性良好的抗甲状腺药物。一名 43 岁的女性在接受 <2>甲巯咪唑</2>（10 mg tid）和 <16>普萘洛尔</16>（20 mg tid）用于治疗<14>甲亢</14>后 1 个月出现严重的<11>黄疸</11>和<8>瘙痒</8>。患者在出现<12>黄疸</12>后继续治疗4天，直至她完成两种药物治疗。 2 周后在急诊室就诊时，她仍有严重的<13>黄疸</13>、<9>瘙痒</9>和主要由结合部分组成的<10>高胆红素血症</10>。诊断出 <3>甲巯咪唑</3>诱发的<15>胆汁淤积</15>，恢复<17>普萘洛尔</17>治疗。在接下来的9天里，症状得到改善，血浆<18>胆红素</18>水平在未使用<4>甲巯咪唑</4>的12周后恢复正常。在极少数情况下，在治疗的最初几周内，该药物可引起严重且可逆的<7>胆汁淤积性黄疸</7>。医生和患者应该意识到这种不良反应，一旦发生，他们可以停止<5>甲巯咪唑</5>治疗并避免不必要的侵入性操作。", "revised": true}
{"doc_key": "12911170", "sentences": [["Ciprofloxacin", "-", "induced", "acute", "interstitial", "nephritis", "and", "autoimmune", "hemolytic", "anemia", ".", "Ciprofloxacin", "has", "been", "associated", "with", "several", "side", "effects", "including", "interstitial", "nephritis", "and", "hemolytic", "anemia", ".", "The", "combination", "of", "both", "side", "effects", "is", "extremely", "rare", ".", "In", "this", "report", ",", "we", "describe", "a", "case", "of", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "and", "autoimmune", "hemolytic", "anemia", ".", "Hemolytic", "anemia", "improved", "after", "stopping", "the", "drug", "and", "initiation", "of", "steroid", "therapy", ".", "Unfortunately", ",", "acute", "interstitial", "nephritis", "was", "irreversible", "and", "the", "patient", "developed", "end", "-", "stage", "renal", "disease", "."]], "ner": [[[0, 0, "Chemical"], [11, 11, "Chemical"], [45, 45, "Chemical"], [4, 5, "Disease"], [20, 21, "Disease"], [48, 49, "Disease"], [71, 72, "Disease"], [23, 24, "Disease"], [55, 56, "Disease"], [79, 83, "Disease"], [7, 9, "Disease"], [51, 53, "Disease"], [65, 65, "Chemical"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 20, 21, "CID"], [0, 0, 48, 49, "CID"], [0, 0, 71, 72, "CID"], [11, 11, 4, 5, "CID"], [11, 11, 20, 21, "CID"], [11, 11, 48, 49, "CID"], [11, 11, 71, 72, "CID"], [45, 45, 4, 5, "CID"], [45, 45, 20, 21, "CID"], [45, 45, 48, 49, "CID"], [45, 45, 71, 72, "CID"], [0, 0, 23, 24, "CID"], [0, 0, 55, 56, "CID"], [11, 11, 23, 24, "CID"], [11, 11, 55, 56, "CID"], [45, 45, 23, 24, "CID"], [45, 45, 55, 56, "CID"], [0, 0, 79, 83, "CID"], [11, 11, 79, 83, "CID"], [45, 45, 79, 83, "CID"]]], "clusters": [], "translated": "<0>环丙沙星</0>诱发急性<3>间质性肾炎</3>和<10>自身免疫性溶血性贫血</10>。 <1>环丙沙星</1>与多种副作用相关，包括<4>间质性肾炎</4>和<7>溶血性贫血</7>。两种副作用的组合极为罕见。在本报告中，我们描述了一例<2>环丙沙星</2>诱发的<5>间质性肾炎</5>和<11>自身免疫性溶血性贫血</11>。 <8>溶血性贫血</8>在停药和开始<12>类固醇</12>治疗后得到改善。不幸的是，急性<6>间质性肾炎</6>是不可逆转的，患者发展为<9>终末期肾病</9>。", "revised": true}
{"doc_key": "2907585", "sentences": [["Reversal", "of", "neuroleptic", "-", "induced", "catalepsy", "by", "novel", "aryl", "-", "piperazine", "anxiolytic", "drugs", ".", "The", "novel", "anxiolytic", "drug", ",", "buspirone", ",", "reverses", "catalepsy", "induced", "by", "haloperidol", ".", "A", "series", "of", "aryl", "-", "piperazine", "analogues", "of", "buspirone", "and", "other", "5", "-", "hydroxytryptaminergic", "agonists", "were", "tested", "for", "their", "ability", "to", "reverse", "haloperidol", "induced", "catalepsy", ".", "Those", "drugs", "with", "strong", "affinity", "for", "5", "-", "hydroxytryptamine1a", "receptors", "were", "able", "to", "reverse", "catalepsy", ".", "Drugs", "with", "affinity", "for", "other", "5", "-", "HT", "receptors", "or", "weak", "affinity", "were", "ineffective", ".", "However", ",", "inhibition", "of", "postsynaptic", "5", "-", "HT", "receptors", "neither", "inhibited", "nor", "potentiated", "reversal", "of", "catalepsy", "and", "leaves", "open", "the", "question", "as", "to", "the", "site", "or", "mechanism", "for", "this", "effect", "."]], "ner": [[[25, 25, "Chemical"], [49, 49, "Chemical"], [5, 5, "Disease"], [22, 22, "Disease"], [51, 51, "Disease"], [67, 67, "Disease"], [99, 99, "Disease"], [19, 19, "Chemical"], [35, 35, "Chemical"], [38, 41, "Chemical"], [59, 61, "Chemical"], [74, 76, "Chemical"], [89, 91, "Chemical"]]], "relations": [[[25, 25, 5, 5, "CID"], [25, 25, 22, 22, "CID"], [25, 25, 51, 51, "CID"], [25, 25, 67, 67, "CID"], [25, 25, 99, 99, "CID"], [49, 49, 5, 5, "CID"], [49, 49, 22, 22, "CID"], [49, 49, 51, 51, "CID"], [49, 49, 67, 67, "CID"], [49, 49, 99, 99, "CID"]]], "clusters": [], "translated": "通过新型芳基-哌嗪抗焦虑药物逆转抗精神病药引起的<2>强直性昏厥</2>。新型抗焦虑药<7>丁螺环酮</7>可逆转<3>强直性昏厥</3>由<0>氟哌啶醇</0>引起。测试了<8>丁螺环酮</8>和其他<9>5-羟色胺能激动剂</9>的一系列芳基-哌嗪类似物逆转<1>氟哌啶醇</1>诱导的<4>僵直</4>。对<10>5-羟色胺1a</10>受体具有强亲和力的药物能够逆转<5>强直性昏厥</5>。对其他<11>5-HT</11>受体有亲和力或亲和力弱的药物无效。然而，抑制<12>5-HT</12>突触后受体既不会抑制也不会增强<6>强直性昏厥</6>的逆转，并留下关于这种效应的部位或机制的问题。", "revised": true}
{"doc_key": "4038130", "sentences": [["Rat", "extraocular", "muscle", "regeneration", ".", "Repair", "of", "local", "anesthetic", "-", "induced", "damage", ".", "Local", "anesthetics", "that", "are", "commonly", "used", "in", "ophthalmic", "surgery", "(", "0", ".", "75", "%", "bupivacaine", "hydrochloride", ",", "2", ".", "0", "%", "mepivacaine", "hydrochloride", ",", "and", "2", ".", "0", "%", "lidocaine", "hydrochloride", "plus", "1", ":", "100", ",", "000", "epinephrine", ")", "were", "injected", "into", "the", "retrobulbar", "area", "of", "rat", "eyes", ".", "Controls", "were", "injected", "with", "physiological", "saline", ".", "All", "three", "anesthetics", "produced", "massive", "degeneration", "of", "the", "extraocular", "muscles", ".", "Muscle", "degeneration", "is", "followed", "by", "regeneration", "of", "the", "damaged", "muscle", "fibers", ".", "In", "addition", "to", "muscle", "damage", ",", "severe", "damage", "was", "also", "seen", "in", "harderian", "glands", ",", "especially", "after", "exposure", "to", "mepivacaine", "and", "lidocaine", "plus", "epinephrine", ".", "With", "these", "findings", "in", "rats", ",", "it", "is", "hypothesized", "that", "the", "temporary", "diplopia", "sometimes", "seen", "in", "patients", "after", "ophthalmic", "surgery", "might", "be", "due", "to", "anesthetic", "-", "induced", "damage", "to", "the", "extraocular", "muscles", "."]], "ner": [[[27, 28, "Chemical"], [80, 81, "Disease"], [95, 96, "Disease"], [34, 35, "Chemical"], [111, 111, "Chemical"], [42, 43, "Chemical"], [113, 113, "Chemical"], [129, 129, "Disease"], [50, 50, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[27, 28, 80, 81, "CID"], [27, 28, 95, 96, "CID"], [34, 35, 80, 81, "CID"], [34, 35, 95, 96, "CID"], [111, 111, 80, 81, "CID"], [111, 111, 95, 96, "CID"], [42, 43, 80, 81, "CID"], [42, 43, 95, 96, "CID"], [113, 113, 80, 81, "CID"], [113, 113, 95, 96, "CID"]]], "clusters": [], "translated": "大鼠眼外肌再生。修复局麻药引起的损伤。眼科手术常用的局麻药（0.75% <0>盐酸布比卡因</0>，2.0% <3>盐酸甲哌卡因</3>，2.0% <5>盐酸利多卡因</5>加1:100,000 <8>肾上腺素</8>）注入大鼠眼球后区。对照组注射生理盐水。这三种麻醉剂都会导致眼外肌发生大量退化。<1>肌肉退化</1>之后是受损肌肉纤维的再生。除了<2>肌肉损伤</2>外，哈氏腺体也出现严重损伤，尤其是接触<4>盐酸甲哌卡因</4>和<6>盐酸利多卡因</6>加<9>肾上腺素</9>。根据大鼠的这些发现，可以假设眼科手术后患者有时出现的暂时性<7>复视</7>可能是由于麻醉剂引起的眼外肌损伤。", "revised": true}
{"doc_key": "17241657", "sentences": [["Effects", "of", "UMB24", "and", "(", "+", "/", "-", ")", "-", "SM", "21", ",", "putative", "sigma2", "-", "preferring", "antagonists", ",", "on", "behavioral", "toxic", "and", "stimulant", "effects", "of", "cocaine", "in", "mice", ".", "Earlier", "studies", "have", "demonstrated", "that", "antagonism", "of", "sigma1", "receptors", "attenuates", "the", "convulsive", ",", "lethal", ",", "locomotor", "stimulatory", "and", "rewarding", "actions", "of", "cocaine", "in", "mice", ".", "In", "contrast", ",", "the", "contribution", "of", "sigma2", "receptors", "is", "unclear", "because", "experimental", "tools", "to", "selectively", "target", "this", "subtype", "are", "unavailable", ".", "To", "begin", "addressing", "this", "need", ",", "we", "characterized", "UMB24", "(", "1", "-", "(", "2", "-", "phenethyl", ")", "-", "4", "-", "(", "2", "-", "pyridyl", ")", "-", "piperazine", ")", "and", "(", "+", "/", "-", ")", "-", "SM", "21", "(", "3alpha", "-", "tropanyl", "-", "2", "-", "(", "4", "-", "chorophenoxy", ")", "butyrate", ")", "in", "receptor", "binding", "and", "behavioral", "studies", ".", "Receptor", "binding", "studies", "confirmed", "that", "UMB24", "and", "(", "+", "/", "-", ")", "-", "SM", "21", "display", "preferential", "affinity", "for", "sigma2", "over", "sigma1", "receptors", ".", "In", "behavioral", "studies", ",", "pretreatment", "of", "Swiss", "Webster", "mice", "with", "UMB24", "or", "(", "+", "/", "-", ")", "-", "SM", "21", "significantly", "attenuated", "cocaine", "-", "induced", "convulsions", "and", "locomotor", "activity", ",", "but", "not", "lethality", ".", "When", "administered", "alone", ",", "(", "+", "/", "-", ")", "-", "SM", "21", "produced", "no", "significant", "effects", "compared", "to", "control", "injections", "of", "saline", ",", "but", "UMB24", "had", "locomotor", "depressant", "actions", ".", "Together", ",", "the", "data", "suggest", "that", "sigma2", "receptor", "antagonists", "have", "the", "potential", "to", "attenuate", "some", "of", "the", "behavioral", "effects", "of", "cocaine", ",", "and", "further", "development", "of", "more", "selective", ",", "high", "affinity", "ligands", "are", "warranted", "."]], "ner": [[[26, 26, "Chemical"], [51, 51, "Chemical"], [180, 180, "Chemical"], [242, 242, "Chemical"], [41, 41, "Disease"], [183, 183, "Disease"], [2, 2, "Chemical"], [84, 84, "Chemical"], [86, 102, "Chemical"], [139, 139, "Chemical"], [168, 168, "Chemical"], [216, 216, "Chemical"], [10, 11, "Chemical"], [111, 112, "Chemical"], [114, 125, "Chemical"], [147, 148, "Chemical"], [176, 177, "Chemical"], [202, 203, "Chemical"]]], "relations": [[[26, 26, 41, 41, "CID"], [26, 26, 183, 183, "CID"], [51, 51, 41, 41, "CID"], [51, 51, 183, 183, "CID"], [180, 180, 41, 41, "CID"], [180, 180, 183, 183, "CID"], [242, 242, 41, 41, "CID"], [242, 242, 183, 183, "CID"]]], "clusters": [], "translated": "<6>UMB24</6> 和 (+/-)-<12>SM 21</12> 推定的 sigma2 偏好拮抗剂对小鼠 <0>可卡因</0> 的行为毒性和兴奋作用的影响。早期研究表明，拮抗 sigma1 受体可减弱小鼠<1>可卡因</1>的 <4>惊厥</4>、致死、运动刺激和奖赏作用。相比之下，由于缺乏选择性靶向该亚型的实验工具，sigma2 受体的作用尚不清楚。为了开始满足这一需求，我们对这些受体做了结合和行为研究，观察 <7>UMB24</7>（<8>1-(2-苯乙基)-4-(2-吡啶基)-哌嗪</8>）和（+/-）-<13>SM 21</13>（<14>3alpha- 调旋型 -2- (4-氯苯氧基)丁酸</14>）的特征。受体结合研究证实，<9>UMB24</9> 和 (+/-)-<15>SM 21</15> 的亲和力优先作用于 sigma2 受体。行为研究中，用 <10>UMB24</10> 或 (+/-)-<16>SM 21</16> 预处理瑞士韦伯斯特小鼠可显著减轻 <2>可卡因</2> - 诱发的 <5>抽搐</5> 和自发活动，但不是杀伤力。当单独给药时，(+/-)-<17>SM 21</17> 与对照盐水注射相比没有产生显著的效果，但<11>UMB24</11> 具有运动抑制作用。总之，数据表明 sigma2 受体的拮抗剂有可能减弱<3>可卡因</3>的某些行为影响，因此有必要进一步开发更具选择性、高亲和力的配体。", "revised": true}
{"doc_key": "4090988", "sentences": [["Induction", "by", "paracetamol", "of", "bladder", "and", "liver", "tumours", "in", "the", "rat", ".", "Effects", "on", "hepatocyte", "fine", "structure", ".", "Groups", "of", "male", "and", "female", "inbred", "Leeds", "strain", "rats", "were", "fed", "diets", "containing", "either", "0", ".", "5", "%", "or", "1", ".", "0", "%", "paracetamol", "by", "weight", "for", "up", "to", "18", "months", ".", "At", "the", "1", ".", "0", "%", "dosage", "level", ",", "20", "%", "of", "rats", "of", "both", "sexes", "developed", "neoplastic", "nodules", "of", "the", "liver", ",", "a", "statistically", "significant", "incidence", ".", "These", "rats", "also", "showed", "gross", "enlargement", "of", "their", "livers", "and", "an", "increase", "in", "foci", "of", "cellular", "alteration", ",", "the", "latter", "also", "being", "observed", "in", "the", "low", "dosage", "male", "rats", ".", "Papillomas", "of", "the", "transitional", "epithelium", "of", "the", "bladder", "developed", "in", "all", "paracetamol", "-", "treated", "groups", ",", "and", "three", "rats", "bore", "bladder", "carcinomas", ".", "However", ",", "significant", "yields", "of", "bladder", "tumours", "were", "only", "obtained", "from", "low", "dosage", "females", "and", "high", "dosage", "males", ".", "Additionally", ",", "20", "to", "25", "%", "of", "paracetamol", "-", "treated", "rats", "developed", "hyperplasia", "of", "the", "bladder", "epithelium", ",", "which", "was", "not", "coincident", "with", "the", "presence", "of", "bladder", "calculi", ".", "A", "low", "yield", "of", "tumours", "at", "various", "other", "sites", "also", "arose", "following", "paracetamol", "feeding", ".", "An", "electron", "microscope", "study", "of", "the", "livers", "of", "paracetamol", "-", "treated", "rats", "revealed", "ultrastructural", "changes", "in", "the", "hepatocytes", "that", "resemble", "those", "that", "result", "from", "exposure", "to", "a", "variety", "of", "known", "hepatocarcinogens", "."]], "ner": [[[2, 2, "Chemical"], [41, 41, "Chemical"], [119, 119, "Chemical"], [157, 157, "Chemical"], [191, 191, "Chemical"], [202, 202, "Chemical"], [4, 7, "Disease"], [128, 129, "Disease"], [136, 137, "Disease"], [224, 224, "Disease"], [162, 162, "Disease"], [108, 108, "Disease"], [176, 177, "Disease"], [183, 183, "Disease"]]], "relations": [[[2, 2, 4, 7, "CID"], [2, 2, 128, 129, "CID"], [2, 2, 136, 137, "CID"], [41, 41, 4, 7, "CID"], [41, 41, 128, 129, "CID"], [41, 41, 136, 137, "CID"], [119, 119, 4, 7, "CID"], [119, 119, 128, 129, "CID"], [119, 119, 136, 137, "CID"], [157, 157, 4, 7, "CID"], [157, 157, 128, 129, "CID"], [157, 157, 136, 137, "CID"], [191, 191, 4, 7, "CID"], [191, 191, 128, 129, "CID"], [191, 191, 136, 137, "CID"], [202, 202, 4, 7, "CID"], [202, 202, 128, 129, "CID"], [202, 202, 136, 137, "CID"], [2, 2, 224, 224, "CID"], [41, 41, 224, 224, "CID"], [119, 119, 224, 224, "CID"], [157, 157, 224, 224, "CID"], [191, 191, 224, 224, "CID"], [202, 202, 224, 224, "CID"], [2, 2, 162, 162, "CID"], [41, 41, 162, 162, "CID"], [119, 119, 162, 162, "CID"], [157, 157, 162, 162, "CID"], [191, 191, 162, 162, "CID"], [202, 202, 162, 162, "CID"]]], "clusters": [], "translated": "<0>对乙酰氨基酚</0>诱导大鼠<6>膀胱和肝脏肿瘤</6>。对肝细胞精细结构的影响。将几组雄性和雌性近交系利兹品系大鼠喂食含有0.5%或1.0%<1>扑热息痛</1>按重量计长达18个月。在1.0%剂量水平，20%的雌性和雄性大鼠发生肝肿瘤结节，发生率有统计学意义。这些大鼠还表现出肝脏明显增大和细胞改变灶增加，后者也在低剂量雄性大鼠中观察到。<11>膀胱移行上皮乳头状瘤</11>在所有<2>对乙酰氨基酚</2>治疗组中均发生，三只大鼠患<7>膀胱癌</7>。然而，<8>膀胱肿瘤</8>的显着产量仅来自低剂量雌性和高剂量雄性。此外，20%至25%的<3>对乙酰氨基酚</3>治疗的大鼠出现膀胱上皮细胞的<10>增生</10>，这与<12>膀胱结石</12>的存在不一致。在<4>对乙酰氨基酚</4>喂食后，其他各个部位的<13>肿瘤</13>也出现了低产量。对用<5>扑热息痛</5>处理的大鼠肝脏进行的电子显微镜研究显示，肝细胞的超微结构变化类似于因暴露于各种已知的<9>肝癌物质</9>而导致的变化。", "revised": true}
{"doc_key": "2528969", "sentences": [["Nature", ",", "time", "course", "and", "dose", "dependence", "of", "zidovudine", "-", "related", "side", "effects", ":", "results", "from", "the", "Multicenter", "Canadian", "Azidothymidine", "Trial", ".", "To", "characterize", "the", "nature", ",", "time", "course", "and", "dose", "dependency", "of", "zidovudine", "-", "related", "side", "effects", ",", "we", "undertook", "a", "multicenter", ",", "prospective", ",", "dose", "-", "range", "finding", "study", ".", "Our", "study", "group", "consisted", "of", "74", "HIV", "-", "positive", "homosexual", "men", "belonging", "to", "groups", "II", "B", ",", "III", "and", "IV", "C2", "from", "the", "Centers", "for", "Disease", "Control", "(", "CDC", ")", "classification", "of", "HIV", "disease", ".", "Following", "a", "3", "-", "week", "observation", "period", ",", "volunteers", "were", "treated", "with", "zidovudine", "600", "mg", "/", "day", "for", "18", "weeks", ",", "900", "mg", "/", "day", "for", "9", "weeks", "and", "1200", "mg", "/", "day", "for", "9", "weeks", ",", "followed", "by", "a", "washout", "period", "of", "6", "weeks", "after", "which", "they", "were", "re", "-", "started", "on", "1200", "mg", "/", "day", "or", "the", "highest", "tolerated", "dose", "at", "8", "-", "hourly", "intervals", ".", "Subjects", "were", "randomly", "assigned", "to", "4", "-", "hourly", "or", "8", "-", "hourly", "regimens", "within", "CDC", "groups", "while", "taking", "600", "and", "1200", "mg", "/", "day", ".", "Clinical", "and", "laboratory", "evaluations", "were", "performed", "at", "3", "-", "week", "intervals", ".", "Symptomatic", "adverse", "effects", "were", "present", "in", "96", "%", "of", "subjects", ",", "most", "commonly", "nausea", "(", "64", "%", ")", ",", "fatigue", "(", "55", "%", ")", "and", "headache", "(", "49", "%", ")", ".", "These", "were", "generally", "self", "-", "limited", ",", "reappearing", "briefly", "at", "each", "dose", "increment", ".", "A", "decrease", "in", "hemoglobin", "occurred", "shortly", "after", "initiation", "of", "therapy", ".", "This", "was", "not", "dose", "dependent", "and", "reversed", "rapidly", "upon", "discontinuation", "of", "treatment", ".", "A", "red", "blood", "cell", "count", "decrease", ",", "a", "mean", "cell", "volume", "increase", "and", "a", "granulocyte", "count", "decrease", "developed", "early", "in", "a", "dose", "-", "independent", "fashion", ",", "reverting", "at", "least", "partially", "during", "the", "washout", "phase", ".", "The", "decrease", "in", "reticulocyte", "count", "was", "dose", "related", "between", "600", "and", "900", "mg", "/", "day", "with", "no", "further", "change", "when", "the", "dose", "was", "escalated", "to", "1200", "mg", "/", "day", ".", "Bone", "marrow", "changes", "occurred", "rapidly", "as", "demonstrated", "by", "megaloblastosis", "in", "95", "%", "of", "65", "specimens", "at", "week", "18", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[8, 8, "Chemical"], [19, 19, "Chemical"], [33, 33, "Chemical"], [99, 99, "Chemical"], [205, 205, "Disease"], [211, 211, "Disease"], [217, 217, "Disease"], [84, 85, "Disease"]]], "relations": [[[8, 8, 205, 205, "CID"], [19, 19, 205, 205, "CID"], [33, 33, 205, 205, "CID"], [99, 99, 205, 205, "CID"], [8, 8, 211, 211, "CID"], [19, 19, 211, 211, "CID"], [33, 33, 211, 211, "CID"], [99, 99, 211, 211, "CID"], [8, 8, 217, 217, "CID"], [19, 19, 217, 217, "CID"], [33, 33, 217, 217, "CID"], [99, 99, 217, 217, "CID"]]], "clusters": [], "translated": "<0>齐多夫定</0>相关副作用的性质、时程和剂量依赖性：来自加拿大多中心<1>叠氮胸苷</1>试验的结果。为表征<2>齐多夫定</2>相关副作用的性质、时程和剂量依赖性，我们进行了一项多中心、前瞻性、剂量范围探索研究。我们的研究组由 74 名属于疾病控制中心 (<7>CDC</7>) 分类的 II B、III 和 IV C2 组的 HIV 阳性男同性恋者组成。经过 3 周的观察期后，志愿者接受 <3>齐多夫定</3> 600 毫克/天治疗 18 周， 900 毫克/天治疗 9 周和 1200 毫克/天治疗 9 周，随后是清除期 6 周后，他们以 1200 毫克/天或以 8 小时为间隔的最高耐受剂量重新开始。受试者被随机分配到 CDC 组内的 4 小时或 8 小时方案，同时服用 600 和 1200 毫克/天。临床和实验室评估每 3 周进行一次。 96% 的受试者出现有症状的不良反应，最常见的是<4>恶心</4> (64%)，<5>疲劳</5> (55%) 和<6>头痛</6> (49%)。这些通常是自限性的，每次增加剂量时都会短暂出现。治疗开始后不久血红蛋白下降。这与剂量无关，并在停止治疗后迅速逆转。红细胞计数减少、平均细胞体积增加和粒细胞计数减少以剂量依赖性方式早期出现，在清除阶段至少部分恢复。网织红细胞计数的减少在 600 至 900 毫克/天之间与剂量相关，当剂量增加至 1200 毫克/天时没有进一步变化。第 18 周时，65 个标本中的 95% 出现了巨幼红细胞增多症，表明骨髓变化迅速发生。（摘要被截断为 250 个单词）", "revised": true}
{"doc_key": "11208990", "sentences": [["Association", "of", "nitric", "oxide", "production", "and", "apoptosis", "in", "a", "model", "of", "experimental", "nephropathy", ".", "BACKGROUND", ":", "In", "recent", "studies", "increased", "amounts", "of", "nitric", "oxide", "(", "NO", ")", "and", "apoptosis", "have", "been", "implicated", "in", "various", "pathological", "conditions", "in", "the", "kidney", ".", "We", "have", "studied", "the", "role", "of", "NO", "and", "its", "association", "with", "apoptosis", "in", "an", "experimental", "model", "of", "nephrotic", "syndrome", "induced", "by", "a", "single", "injection", "of", "adriamycin", "(", "ADR", ")", ".", "METHODS", ":", "The", "alteration", "in", "the", "NO", "pathway", "was", "assessed", "by", "measuring", "nitrite", "levels", "in", "serum", "/", "urine", "and", "by", "evaluating", "the", "changes", "in", "vascular", "reactivity", "of", "the", "isolated", "perfused", "rat", "kidney", "(", "IPRK", ")", "system", ".", "Rats", "were", "stratified", "into", "control", "groups", "and", "ADR", "-", "induced", "nephropathy", "groups", ".", "These", "two", "groups", "were", "then", "divided", "into", ":", "group", "1", ",", "animals", "receiving", "saline", ";", "and", "group", "2", ",", "animals", "receiving", "aminoguanidine", "(", "AG", ")", "which", "is", "a", "specific", "inhibitor", "of", "inducible", "-", "NO", "synthase", ".", "On", "day", "21", ",", "rats", "were", "sacrificed", "after", "obtaining", "material", "for", "biochemical", "analysis", ".", "RESULTS", ":", "Histopathological", "examination", "of", "the", "kidneys", "of", "rats", "treated", "with", "ADR", "revealed", "focal", "areas", "of", "mesangial", "proliferation", "and", "mild", "tubulointerstitial", "inflammation", ".", "They", "also", "had", "significantly", "higher", "levels", "of", "proteinuria", "compared", "with", "control", "and", "treatment", "groups", "(", "P", "<", "0", ".", "05", ")", ".", "Urine", "nitrite", "levels", "were", "significantly", "increased", "in", "the", "ADR", "-", "nephropathy", "group", "(", "P", "<", "0", ".", "05", ")", ".", "In", "the", "IPRK", "phenylephrine", "and", "acetylcholine", "related", "responses", "were", "significantly", "impaired", "in", "the", "ADR", "-", "nephropathy", "group", ".", "Apoptosis", "was", "not", "detected", "in", "controls", ".", "However", ",", "in", "the", "ADR", "-", "nephropathy", "group", ",", "numerous", "apoptotic", "cells", "were", "identified", "in", "the", "tubulointerstitial", "areas", ".", "Double", "staining", "revealed", "numerous", "interstitial", "apoptotic", "cells", "to", "stain", "for", "ED1", ",", "a", "marker", "for", "monocytes", "/", "macrophages", ".", "Treatment", "with", "AG", "prevented", "the", "impairment", "of", "renal", "vascular", "bed", "responses", "and", "reduced", "both", "urine", "nitrite", "levels", "and", "apoptosis", "to", "control", "levels", ".", "CONCLUSION", ":", "We", "suggest", "that", "interactions", "between", "NO", "and", "apoptosis", "are", "important", "in", "the", "pathogenesis", "of", "the", "ADR", "-", "induced", "nephrosis", "."]], "ner": [[[65, 65, "Chemical"], [67, 67, "Chemical"], [114, 114, "Chemical"], [181, 181, "Chemical"], [223, 223, "Chemical"], [248, 248, "Chemical"], [264, 264, "Chemical"], [338, 338, "Chemical"], [57, 58, "Disease"], [200, 200, "Disease"], [2, 3, "Chemical"], [22, 23, "Chemical"], [25, 25, "Chemical"], [46, 46, "Chemical"], [76, 76, "Chemical"], [153, 153, "Chemical"], [328, 328, "Chemical"], [12, 12, "Disease"], [117, 117, "Disease"], [225, 225, "Disease"], [250, 250, "Disease"], [266, 266, "Disease"], [186, 187, "Disease"], [190, 191, "Disease"], [341, 341, "Disease"], [82, 82, "Chemical"], [216, 216, "Chemical"], [313, 313, "Chemical"], [141, 141, "Chemical"], [143, 143, "Chemical"], [300, 300, "Chemical"], [238, 238, "Chemical"], [240, 240, "Chemical"]]], "relations": [[[65, 65, 57, 58, "CID"], [67, 67, 57, 58, "CID"], [114, 114, 57, 58, "CID"], [181, 181, 57, 58, "CID"], [223, 223, 57, 58, "CID"], [248, 248, 57, 58, "CID"], [264, 264, 57, 58, "CID"], [338, 338, 57, 58, "CID"], [65, 65, 200, 200, "CID"], [67, 67, 200, 200, "CID"], [114, 114, 200, 200, "CID"], [181, 181, 200, 200, "CID"], [223, 223, 200, 200, "CID"], [248, 248, 200, 200, "CID"], [264, 264, 200, 200, "CID"], [338, 338, 200, 200, "CID"]]], "clusters": [], "translated": "实验性<17>肾病</17>模型中<10>一氧化氮</10>产生和细胞凋亡的关联。背景：在最近的研究中，增加的<11>一氧化氮</11> (<12>NO</12>)和细胞凋亡与肾脏的各种病理状况有关。我们在单次注射<0>阿霉素</0> (<1>ADR</1>) 诱导的<8>肾病综合征</8>实验模型中研究了<13>NO</13>的作用及其与细胞凋亡的关系。方法：通过测量血清/尿液中的<25>亚硝酸盐</25>水平和评估离体灌注大鼠肾脏 (IPRK) 系统的血管反应性变化来评估<14>NO</14>通路的改变。大鼠分为对照组和<2>ADR</2>诱发的<18>肾病</18>组。然后将这两组分成：第1组，接受生理盐水的动物；第2组动物接受<28>氨基胍</28> (<29>AG</29>)，这是一种特异性的诱导型<15>NO</15>合酶抑制剂。第21天，取材后处死大鼠进行生化分析。结果：对用<3>ADR</3>治疗的大鼠肾脏进行组织病理学检查，发现局灶性区域有<22>系膜增生</22>和轻度<23>肾小管间质炎症</23>。与对照组和治疗组相比，他们的<9>蛋白尿</9>水平也显着升高 (P < 0.05)。 <4>ADR</4>-<19>肾病</19>组尿<26>亚硝酸盐</26>水平显着升高 (P < 0.05)。在IPRK中，<31>酚肾上腺素</31>和<32>乙酰胆碱</32>相关反应在<5>ADR</5>-<20>肾病</20>组明显受损。对照组未检测到细胞凋亡。而<6>ADR</6>-<21>肾病</21>组肾小管间质可见大量凋亡细胞。双染色显示大量间质凋亡细胞对ED1染色，ED1是单核细胞/巨噬细胞的标记物。<30>AG</30>治疗可防止肾血管床反应受损，并将尿液<27>亚硝酸盐</27>水平和细胞凋亡降低至对照水平。结论：我们认为<16>NO</16>与细胞凋亡之间的相互作用在<7>ADR</7>诱导的<24>肾病</24>的发病机制中起重要作用。", "revised": true}
{"doc_key": "2334179", "sentences": [["D", "-", "penicillamine", "in", "the", "treatment", "of", "localized", "scleroderma", ".", "Localized", "scleroderma", "has", "no", "recognized", "internal", "organ", "involvement", "but", "may", "be", "disfiguring", "and", "disabling", "when", "the", "cutaneous", "lesions", "are", "extensive", "or", "affect", "children", ".", "There", "is", "no", "accepted", "or", "proven", "treatment", "for", "localized", "scleroderma", ".", "Case", "reports", "of", "11", "patients", "with", "severe", ",", "extensive", "localized", "scleroderma", "who", "were", "treated", "with", "D", "-", "penicillamine", "are", "summarized", "in", "this", "article", ".", "This", "drug", "was", "judged", "to", "have", "a", "favorable", "effect", "on", "the", "disease", "course", "in", "7", "(", "64", "%", ")", "of", "11", "patients", ".", "Improvement", "began", "within", "3", "to", "6", "months", "and", "consisted", "of", "cessation", "of", "active", "cutaneous", "lesions", "in", "all", "7", "patients", ",", "skin", "softening", "in", "5", ",", "and", "more", "normal", "growth", "of", "the", "affected", "limb", "in", "2", "of", "3", "children", ".", "Joint", "stiffness", "and", "contractures", "also", "improved", ".", "The", "dose", "of", "D", "-", "penicillamine", "associated", "with", "a", "favorable", "response", "was", "as", "low", "as", "2", "to", "5", "mg", "/", "kg", "per", "day", "given", "over", "a", "period", "ranging", "from", "15", "to", "53", "months", ".", "D", "-", "Penicillamine", "caused", "nephrotic", "syndrome", "in", "1", "patient", "and", "milder", "reversible", "proteinuria", "in", "3", "other", "patients", ";", "none", "developed", "renal", "insufficiency", ".", "These", "data", "suggest", "that", "D", "-", "penicillamine", "may", "be", "effective", "in", "severe", "cases", "of", "localized", "scleroderma", "."]], "ner": [[[0, 2, "Chemical"], [60, 62, "Chemical"], [141, 143, "Chemical"], [172, 174, "Chemical"], [199, 201, "Chemical"], [176, 177, "Disease"], [184, 184, "Disease"], [7, 8, "Disease"], [10, 11, "Disease"], [42, 43, "Disease"], [54, 55, "Disease"], [209, 210, "Disease"], [134, 134, "Disease"], [192, 193, "Disease"]]], "relations": [[[0, 2, 176, 177, "CID"], [60, 62, 176, 177, "CID"], [141, 143, 176, 177, "CID"], [172, 174, 176, 177, "CID"], [199, 201, 176, 177, "CID"], [0, 2, 184, 184, "CID"], [60, 62, 184, 184, "CID"], [141, 143, 184, 184, "CID"], [172, 174, 184, 184, "CID"], [199, 201, 184, 184, "CID"]]], "clusters": [], "translated": "<0>D-青霉胺</0>治疗<7>局限性硬皮病</7>。 <8>局限性硬皮病</8>没有公认的内脏器官受累，但当皮肤病变广泛或影响儿童时可能会毁容和致残。 <9>局限性硬皮病</9>尚无公认或有效的治疗方法。本文总结了11例严重、广泛的<10>局限性硬皮病</10>患者接受<1>D-青霉胺</1>治疗的病例报告。11名患者中有7名（64%）被判定该药物对疾病进程有有利影响。改善在3到6个月内开始出现，包括所有7名患者的活动性皮肤损伤停止，5名患者皮肤变软，3名儿童中有2名患肢的生长更加正常。关节僵硬和<12>挛缩</12>也得到改善。与良好反应相关的<2>D-青霉胺</2>剂量低至每天2至5mg/kg，给药时间为15至53个月。<3>D-青霉胺</3>引起1例<5>肾病综合征</5>，3例出现较轻的可逆性<6>蛋白尿</6>；没有发生<13>肾功能不全</13>。这些数据表明，<4>D-青霉胺</4>可能对严重的<11>局限性硬皮病</11>有效。", "revised": true}
{"doc_key": "19761039", "sentences": [["Effect", "of", "Hibiscus", "rosa", "sinensis", "on", "reserpine", "-", "induced", "neurobehavioral", "and", "biochemical", "alterations", "in", "rats", ".", "Effect", "of", "methanolic", "extract", "of", "Hibiscus", "rosa", "sinensis", "(", "100", "-", "300", "mg", "/", "kg", ")", "was", "studied", "on", "reserpine", "-", "induced", "orofacial", "dyskinesia", "and", "neurochemical", "alterations", ".", "The", "rats", "were", "treated", "with", "intraperitoneal", "reserpine", "(", "1", "mg", "/", "kg", ",", "ip", ")", "for", "3", "days", "every", "other", "day", ".", "On", "day", "5", ",", "vacuous", "chewing", "movements", "and", "tongue", "protrusions", "were", "counted", "for", "5", "min", ".", "Reserpine", "treated", "rats", "significantly", "developed", "vacuous", "chewing", "movements", "and", "tongue", "protrusions", "however", ",", "coadministration", "of", "Hibiscus", "rosa", "sinensis", "roots", "extract", "(", "100", ",", "200", "and", "300", "mg", "/", "kg", ",", "per", "orally", ")", "attenuated", "the", "effects", ".", "Biochemical", "analysis", "of", "brain", "revealed", "that", "the", "reserpine", "treatment", "significantly", "increased", "lipid", "peroxidation", "and", "decreased", "levels", "of", "superoxide", "dismutase", "(", "SOD", ")", ",", "catalase", "(", "CAT", ")", "and", "glutathione", "reductase", "(", "GSH", ")", ",", "an", "index", "of", "oxidative", "stress", "process", ".", "Coadministration", "of", "extract", "significantly", "reduced", "the", "lipid", "peroxidation", "and", "reversed", "the", "decrease", "in", "brain", "SOD", ",", "CAT", "and", "GSH", "levels", ".", "The", "results", "of", "the", "present", "study", "suggested", "that", "Hibiscus", "rosa", "sinensis", "had", "a", "protective", "role", "against", "reserpine", "-", "induced", "orofacial", "dyskinesia", "and", "oxidative", "stress", "."]], "ner": [[[6, 6, "Chemical"], [35, 35, "Chemical"], [50, 50, "Chemical"], [82, 82, "Chemical"], [126, 126, "Chemical"], [197, 197, "Chemical"], [39, 39, "Disease"], [201, 201, "Disease"], [2, 4, "Chemical"], [21, 23, "Chemical"], [97, 99, "Chemical"], [189, 191, "Chemical"], [136, 136, "Chemical"], [147, 147, "Chemical"]]], "relations": [[[6, 6, 39, 39, "CID"], [6, 6, 201, 201, "CID"], [35, 35, 39, 39, "CID"], [35, 35, 201, 201, "CID"], [50, 50, 39, 39, "CID"], [50, 50, 201, 201, "CID"], [82, 82, 39, 39, "CID"], [82, 82, 201, 201, "CID"], [126, 126, 39, 39, "CID"], [126, 126, 201, 201, "CID"], [197, 197, 39, 39, "CID"], [197, 197, 201, 201, "CID"]]], "clusters": [], "translated": "<8> Hibiscus rosa sinensis </8> 对 <0>利血平</0> 诱导的大鼠神经行为和生化改变的影响。研究了<9> Hibiscus rosa sinensis </9>甲醇提取物（100-300 mg/kg）对<1>利血平</1>诱发的口面部<6>运动障碍</6>和神经化学改变的影响。大鼠腹腔注射<2>利血平</2>（1 mg/kg，ip），连续3天，隔日给药。第5天，记录5分钟的无意义咀嚼运动和舌头伸出。 <3>利血平</3>处理的大鼠显着出现空洞的咀嚼运动和舌头突出，但是，<10> Hibiscus rosa sinensis </10>根提取物的共同给药（100, 200和300 mg/kg，口服）减弱了效果。大脑的生化分析表明，<4>利血平</4>处理显着增加了脂质过氧化作用，降低了<12>超氧化物</12>歧化酶（SOD）、过氧化氢酶（CAT）和<13>谷胱甘肽</13>还原酶（GSH），氧化应激过程的指标。提取物的联合给药显着降低了脂质过氧化作用，并逆转了大脑SOD、CAT和GSH水平的下降。本研究结果表明，<11> Hibiscus rosa sinensis </11>对<5>利血平</5>引起的口面部<7>运动障碍</7>和氧化应激具有保护作用。", "revised": true}
{"doc_key": "1700207", "sentences": [["Antiarrhythmic", "effects", "of", "optical", "isomers", "of", "cibenzoline", "on", "canine", "ventricular", "arrhythmias", ".", "Antiarrhythmic", "effects", "of", "(", "+", ")", "-", "cibenzoline", "and", "(", "-", ")", "-", "cibenzoline", "were", "examined", "using", "two", "canine", "ventricular", "arrhythmia", "models", ".", "Digitalis", "arrhythmia", ",", "which", "is", "suppressed", "by", "Na", "channel", "blockers", ",", "was", "induced", "by", "intermittent", "intravenous", "(", "i", ".", "v", ".", ")", "injection", "of", "ouabain", "in", "pentobarbital", "-", "anesthetized", "dogs", ".", "Adrenaline", "arrhythmia", ",", "which", "is", "suppressed", "by", "Ca", "channel", "blockers", ",", "was", "induced", "by", "adrenaline", "infusion", "in", "halothane", "-", "anesthetized", "dogs", ".", "Ten", "and", "5", "mg", "/", "kg", "i", ".", "v", ".", "(", "+", ")", "-", "cibenzoline", "suppressed", "digitalis", "-", "and", "adrenaline", "-", "induced", "arrhythmias", ",", "respectively", ".", "The", "minimum", "effective", "plasma", "concentrations", "of", "(", "+", ")", "-", "cibenzoline", "for", "digitalis", "-", "and", "adrenaline", "-", "induced", "arrhythmias", "were", "1", ".", "4", "+", "/", "-", "0", ".", "4", "and", "2", ".", "0", "+", "/", "-", "0", ".", "6", "micrograms", "/", "ml", ",", "respectively", "(", "mean", "+", "/", "-", "SD", ",", "n", "=", "6", ")", ".", "A", "lower", "dose", "of", "1", "mg", "/", "kg", "i", ".", "v", ".", "of", "(", "-", ")", "-", "cibenzoline", "suppressed", "the", "digitalis", "-", "induced", "arrhythmia", ",", "whereas", "5", "mg", "/", "kg", "i", ".", "v", ".", "was", "needed", "to", "suppress", "adrenaline", "-", "induced", "arrhythmias", ".", "The", "minimum", "effective", "plasma", "concentrations", "of", "(", "-", ")", "-", "cibenzoline", "for", "digitalis", "-", "and", "adrenaline", "-", "induced", "arrhythmia", "were", "0", ".", "06", "+", "/", "-", "0", ".", "04", "and", "0", ".", "7", "+", "/", "-", "0", ".", "1", "micrograms", "/", "ml", ",", "respectively", "(", "mean", "+", "/", "-", "SD", ",", "n", "=", "6", ")", ".", "The", "stronger", "antiarrhythmic", "effect", "of", "(", "-", ")", "-", "cibenzoline", "indicates", "that", "(", "-", ")", "-", "isomer", "may", "have", "an", "effect", "nearly", "5", "-", "20", "times", "stronger", "in", "suppressing", "Na", "channels", ",", "but", "effects", "of", "both", "drugs", "on", "Ca", "channels", "may", "be", "almost", "equipotent", "."]], "ner": [[[59, 59, "Chemical"], [9, 10, "Disease"], [31, 32, "Disease"], [36, 36, "Disease"], [66, 67, "Disease"], [110, 110, "Disease"], [132, 132, "Disease"], [193, 193, "Disease"], [211, 211, "Disease"], [231, 231, "Disease"], [80, 80, "Chemical"], [107, 107, "Chemical"], [129, 129, "Chemical"], [208, 208, "Chemical"], [228, 228, "Chemical"], [6, 6, "Chemical"], [19, 19, "Chemical"], [25, 25, "Chemical"], [102, 102, "Chemical"], [124, 124, "Chemical"], [187, 187, "Chemical"], [223, 223, "Chemical"], [278, 278, "Chemical"], [35, 35, "Chemical"], [104, 104, "Chemical"], [126, 126, "Chemical"], [190, 190, "Chemical"], [225, 225, "Chemical"], [42, 42, "Chemical"], [298, 298, "Chemical"], [61, 61, "Chemical"], [73, 73, "Chemical"], [307, 307, "Chemical"], [83, 83, "Chemical"]]], "relations": [[[59, 59, 9, 10, "CID"], [59, 59, 31, 32, "CID"], [59, 59, 36, 36, "CID"], [59, 59, 66, 67, "CID"], [59, 59, 110, 110, "CID"], [59, 59, 132, 132, "CID"], [59, 59, 193, 193, "CID"], [59, 59, 211, 211, "CID"], [59, 59, 231, 231, "CID"], [80, 80, 9, 10, "CID"], [80, 80, 31, 32, "CID"], [80, 80, 36, 36, "CID"], [80, 80, 66, 67, "CID"], [80, 80, 110, 110, "CID"], [80, 80, 132, 132, "CID"], [80, 80, 193, 193, "CID"], [80, 80, 211, 211, "CID"], [80, 80, 231, 231, "CID"], [107, 107, 9, 10, "CID"], [107, 107, 31, 32, "CID"], [107, 107, 36, 36, "CID"], [107, 107, 66, 67, "CID"], [107, 107, 110, 110, "CID"], [107, 107, 132, 132, "CID"], [107, 107, 193, 193, "CID"], [107, 107, 211, 211, "CID"], [107, 107, 231, 231, "CID"], [129, 129, 9, 10, "CID"], [129, 129, 31, 32, "CID"], [129, 129, 36, 36, "CID"], [129, 129, 66, 67, "CID"], [129, 129, 110, 110, "CID"], [129, 129, 132, 132, "CID"], [129, 129, 193, 193, "CID"], [129, 129, 211, 211, "CID"], [129, 129, 231, 231, "CID"], [208, 208, 9, 10, "CID"], [208, 208, 31, 32, "CID"], [208, 208, 36, 36, "CID"], [208, 208, 66, 67, "CID"], [208, 208, 110, 110, "CID"], [208, 208, 132, 132, "CID"], [208, 208, 193, 193, "CID"], [208, 208, 211, 211, "CID"], [208, 208, 231, 231, "CID"], [228, 228, 9, 10, "CID"], [228, 228, 31, 32, "CID"], [228, 228, 36, 36, "CID"], [228, 228, 66, 67, "CID"], [228, 228, 110, 110, "CID"], [228, 228, 132, 132, "CID"], [228, 228, 193, 193, "CID"], [228, 228, 211, 211, "CID"], [228, 228, 231, 231, "CID"]]], "clusters": [], "translated": "<15>西苯唑啉</15>光学异构体对犬<1>室性心律失常</1>的抗心律失常作用。 (+)-<16>西苯唑啉</16>和(-)-<17>西苯唑啉</17>的抗心律失常作用用两种犬<2>室性心律失常</2>模型进行了检查。<23>洋地黄</23><3>心律失常</3>由<28>Na</28>通道阻滞剂抑制，间歇性静脉内(i.v.)注射<0>哇巴因</0>在<30>戊巴比妥</30>-麻醉狗中诱发。<4>肾上腺素心律失常</4>可被<31>Ca</31>通道阻滞剂抑制，<10>肾上腺素</10>输注在<33>氟烷</33>-麻醉的犬中可引起心律失常。10和5毫克/公斤i.v.的(+) -<18>西苯唑啉</18>分别抑制<24>洋地黄</24>-和<11>肾上腺素</11>-诱导的<5>心律失常</5>。(+)-<19>西苯唑啉</19>对<25>洋地黄</25>和<12>肾上腺素</12>引起的<6>心律失常</6>的最低有效血浆浓度为1 . 4+/-0 . 4和2 . 0+/-0 . 6微克/毫升(平均值+/-标准差,n=6)。<20>负西苯唑啉</20>的较低剂量1mg/kg i.v.抑制<26>洋地黄</26>-诱导的<7>心律失常</7>，而5mg/kg i.v.需要抑制<13>肾上腺素</13>引起的<8>心律失常</8>。(-)-<21>西苯唑啉</21>对<27>洋地黄</27>和<14>肾上腺素</14>引起的<9>心律失常</9>的最低有效血浆浓度为0.06+/-0.04和0.7+/-0.1微克/毫升(平均值+/-标准差,n=6)。( - )-<22>西苯唑啉</22>更强的抗心律失常作用表明(-)-异构体在抑制<29>Na</29>通道方面的作用可能强近5-20倍，但两者的对<32>Ca</32>通道的药效可能几乎相等。", "revised": true}
{"doc_key": "2894433", "sentences": [["Diazepam", "facilitates", "reflex", "bradycardia", "in", "conscious", "rats", ".", "The", "effects", "of", "diazepam", "on", "cardiovascular", "function", "were", "assessed", "in", "conscious", "rats", ".", "Intravenous", "administration", "of", "diazepam", "(", "1", "-", "30", "mg", "kg", "-", "1", ")", "produced", "a", "dose", "-", "dependent", "decrease", "in", "both", "the", "mean", "arterial", "pressure", "and", "the", "heart", "rate", ".", "Also", ",", "reflex", "bradycardia", "was", "produced", "in", "rats", "by", "intravenous", "infusion", "of", "adrenaline", "(", "1", ".", "25", "-", "2", ".", "5", "micrograms", "kg", "-", "1", ")", ".", "Intravenous", "pretreatment", "of", "the", "rats", "with", "diazepam", ",", "although", "causing", "no", "change", "in", "the", "adrenaline", "-", "induced", "pressor", "effect", ",", "did", "enhance", "the", "adrenaline", "-", "induced", "reflex", "bradycardia", ".", "However", ",", "the", "diazepam", "enhancement", "of", "adrenaline", "-", "induced", "reflex", "bradycardia", "was", "antagonized", "by", "pretreatment", "of", "rats", "with", "an", "intravenous", "dose", "of", "picrotoxin", "(", "an", "agent", "blocks", "chloride", "channels", "by", "binding", "to", "sites", "associated", "with", "the", "benzodiazepine", "-", "GABA", "-", "chloride", "channel", "macromolecular", "complex", ")", ".", "The", "data", "indicate", "that", "diazepam", "acts", "through", "the", "benzodiazepine", "-", "GABA", "-", "chloride", "channel", "macromolecular", "complex", "within", "the", "central", "nervous", "system", "to", "facilitate", "reflex", "bradycardia", "mediated", "through", "baroreceptor", "reflexes", "in", "response", "to", "an", "acute", "increase", "in", "arterial", "pressure", "."]], "ner": [[[0, 0, "Chemical"], [11, 11, "Chemical"], [24, 24, "Chemical"], [84, 84, "Chemical"], [110, 110, "Chemical"], [157, 157, "Chemical"], [3, 3, "Disease"], [54, 54, "Disease"], [105, 105, "Disease"], [117, 117, "Disease"], [177, 177, "Disease"], [63, 63, "Chemical"], [92, 92, "Chemical"], [101, 101, "Chemical"], [113, 113, "Chemical"], [129, 129, "Chemical"], [134, 134, "Chemical"], [147, 147, "Chemical"], [165, 165, "Chemical"], [143, 143, "Chemical"], [161, 161, "Chemical"], [145, 145, "Chemical"], [163, 163, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 54, 54, "CID"], [0, 0, 105, 105, "CID"], [0, 0, 117, 117, "CID"], [0, 0, 177, 177, "CID"], [11, 11, 3, 3, "CID"], [11, 11, 54, 54, "CID"], [11, 11, 105, 105, "CID"], [11, 11, 117, 117, "CID"], [11, 11, 177, 177, "CID"], [24, 24, 3, 3, "CID"], [24, 24, 54, 54, "CID"], [24, 24, 105, 105, "CID"], [24, 24, 117, 117, "CID"], [24, 24, 177, 177, "CID"], [84, 84, 3, 3, "CID"], [84, 84, 54, 54, "CID"], [84, 84, 105, 105, "CID"], [84, 84, 117, 117, "CID"], [84, 84, 177, 177, "CID"], [110, 110, 3, 3, "CID"], [110, 110, 54, 54, "CID"], [110, 110, 105, 105, "CID"], [110, 110, 117, 117, "CID"], [110, 110, 177, 177, "CID"], [157, 157, 3, 3, "CID"], [157, 157, 54, 54, "CID"], [157, 157, 105, 105, "CID"], [157, 157, 117, 117, "CID"], [157, 157, 177, 177, "CID"], [63, 63, 3, 3, "CID"], [63, 63, 54, 54, "CID"], [63, 63, 105, 105, "CID"], [63, 63, 117, 117, "CID"], [63, 63, 177, 177, "CID"], [92, 92, 3, 3, "CID"], [92, 92, 54, 54, "CID"], [92, 92, 105, 105, "CID"], [92, 92, 117, 117, "CID"], [92, 92, 177, 177, "CID"], [101, 101, 3, 3, "CID"], [101, 101, 54, 54, "CID"], [101, 101, 105, 105, "CID"], [101, 101, 117, 117, "CID"], [101, 101, 177, 177, "CID"], [113, 113, 3, 3, "CID"], [113, 113, 54, 54, "CID"], [113, 113, 105, 105, "CID"], [113, 113, 117, 117, "CID"], [113, 113, 177, 177, "CID"]]], "clusters": [], "translated": " <0>地西泮</0>促进清醒大鼠的反射<6>心动过缓</6>。在有意识的大鼠中评估了<1>地西泮</1>对心血管功能的影响。静脉注射<2>地西泮</2> (1-30 mg kg-1) 可使平均动脉压和心率均呈剂量依赖性降低。此外，通过静脉输注<11>肾上腺素</11>（1.25-2.5微克kg-1）在大鼠中产生反射性<7>心动过缓</7>。用<3>地西泮</3>对大鼠进行静脉内预处理，虽然对<12>肾上腺素</12>诱导的升压作用没有改变，但确实增强了<13>肾上腺素</13>诱导的反射<8>心动过缓</8>。然而，<4>地西泮</4>增强<14>肾上腺素</14>诱导的反射<9>心动过缓</9>被静脉注射剂量的大鼠<15>印防己毒素</15>所拮抗（一种药物通过结合到与<19>苯二氮卓</19> - <21>GABA</21> - <17>氯</17>通道大分子复合物相关的位点来阻断<16>氯</16>通道）。数据表明，<5>地西泮</5>通过中枢神经系统内的<20>苯二氮卓</20> - <22>GABA</22> - <18>氯</18>通道大分子复合物作用于促进反射<10>心动过缓</10>，通过压力感受器反射介导以应对动脉压的急剧升高。", "revised": true}
{"doc_key": "19300240", "sentences": [["5", "flourouracil", "-", "induced", "apical", "ballooning", "syndrome", ":", "a", "case", "report", ".", "The", "apical", "ballooning", "syndrome", "(", "ABS", ")", "is", "a", "recently", "described", "stress", "-", "mediated", "acute", "cardiac", "syndrome", "characterized", "by", "transient", "wall", "-", "motion", "abnormalities", "involving", "the", "apex", "and", "midventricle", "with", "hyperkinesis", "of", "the", "basal", "left", "ventricular", "(", "LV", ")", "segments", "without", "obstructive", "epicardial", "coronary", "disease", ".", "Cardiotoxicity", "is", "not", "an", "uncommon", "adverse", "effect", "of", "chemotherapeutic", "agents", ".", "However", ",", "there", "are", "no", "reports", "of", "ABS", "secondary", "to", "chemotherapeutic", "agents", ".", "We", "describe", "the", "case", "of", "a", "woman", "who", "developed", "the", "syndrome", "after", "chemotherapy", "for", "metastatic", "cancer", ".", "A", "79", "-", "year", "-", "old", "woman", "presented", "with", "typical", "ischemic", "chest", "pain", ",", "elevated", "cardiac", "enzymes", "with", "significant", "ST", "-", "segment", "abnormalities", "on", "her", "electrocardiogram", ".", "She", "underwent", "recent", "chemotherapy", "with", "fluorouracil", "for", "metastatic", "colorectal", "cancer", ".", "Echocardiography", "revealed", "a", "wall", "-", "motion", "abnormality", "involving", "the", "apical", "and", "periapical", "segments", "which", "appeared", "akinetic", ".", "Coronary", "angiography", "revealed", "no", "obstructive", "coronary", "lesions", ".", "The", "patient", "was", "stabilized", "with", "medical", "therapy", ".", "Four", "weeks", "later", "she", "remained", "completely", "asymptomatic", ".", "Echocardiogram", "revealed", "a", "normal", "ejection", "fraction", "and", "a", "resolution", "of", "the", "apical", "akinesis", ".", "Pathogenetic", "mechanisms", "of", "cardiac", "complications", "in", "cancer", "patients", "undergoing", "chemotherapy", "include", "coronary", "vasospasm", ",", "endothelial", "damage", "and", "consequent", "thrombus", "formation", ".", "In", "our", "patient", ",", "both", "supraphysiologic", "levels", "of", "plasma", "catecholamines", "and", "stress", "related", "neuropeptides", "caused", "by", "cancer", "diagnosis", "as", "well", "as", "chemotherapy", "may", "have", "contributed", "the", "development", "of", "ABS", "."]], "ner": [[[0, 1, "Chemical"], [131, 131, "Chemical"], [4, 6, "Disease"], [13, 15, "Disease"], [17, 17, "Disease"], [76, 76, "Disease"], [241, 241, "Disease"], [110, 111, "Disease"], [26, 28, "Disease"], [42, 42, "Disease"], [54, 56, "Disease"], [58, 58, "Disease"], [97, 97, "Disease"], [198, 198, "Disease"], [229, 229, "Disease"], [109, 109, "Disease"], [134, 135, "Disease"], [152, 152, "Disease"], [190, 190, "Disease"], [195, 196, "Disease"], [203, 204, "Disease"], [210, 210, "Disease"], [222, 222, "Chemical"]]], "relations": [[[0, 1, 4, 6, "CID"], [0, 1, 13, 15, "CID"], [0, 1, 17, 17, "CID"], [0, 1, 76, 76, "CID"], [0, 1, 241, 241, "CID"], [131, 131, 4, 6, "CID"], [131, 131, 13, 15, "CID"], [131, 131, 17, 17, "CID"], [131, 131, 76, 76, "CID"], [131, 131, 241, 241, "CID"], [0, 1, 110, 111, "CID"], [131, 131, 110, 111, "CID"]]], "clusters": [], "translated": " <0>5氟尿嘧啶</0> -诱发的<2>心尖球形综合征</2>：一例报告。 <3>心尖球形综合征</3> (<4>ABS</4>) 是最近描述的一种应激介导的<8>急性心脏综合征</8>，其特征是涉及心尖和心室的短暂室壁运动异常伴<9>基底左心室 (LV) 节段无阻塞性</9><10>心外膜冠状动脉疾病</10>。 <11>化疗药物</11>的一种常见不良反应是<19>心脏并发症</19>。然而，尚未报道化疗药物继发<5>ABS</5>。我们报道了一名女性，在转移性<12>癌症</12>化疗后出现该综合征的情况。一名79岁女性出现典型的<15>缺血性</15><7>胸痛</7>，心肌酶升高和其电囊图上出现明显的ST段异常。她最近接受了<1>5氟尿嘧啶</1>治疗转移性<16>结直肠癌</16>。超声心动图显示涉及心尖和心尖周节段的室壁运动异常，<17>似乎</17><17>运动不能</17>。冠状动脉造影显示没有阻塞性冠状动脉病变。患者通过药物治疗得到了稳定。四个星期后，她仍然完全没有症状。超声心动图显示射血分数正常，消退了心尖<18>运动不能</18>现象。<13>癌症</13>化疗患者出现<19>心脏并发症</19>的发病机制包括<20>冠状动脉痉挛</20>、内皮损伤以及继发的<21>血栓</21>形成。在我们的病例中，由于<14>癌症</14>诊断以及常规化疗引起的超生理水平的血浆<22>儿茶酚胺</22>和应激相关神经肽可能有助于<6>ABS</6>的发生。", "revised": true}
{"doc_key": "18006530", "sentences": [["Reduction", "of", "pain", "during", "induction", "with", "target", "-", "controlled", "propofol", "and", "remifentanil", ".", "BACKGROUND", ":", "Pain", "on", "injection", "of", "propofol", "is", "unpleasant", ".", "We", "hypothesized", "that", "propofol", "infusion", "pain", "might", "be", "prevented", "by", "infusing", "remifentanil", "before", "starting", "the", "propofol", "infusion", "in", "a", "clinical", "setting", "where", "target", "-", "controlled", "infusions", "(", "TCI", ")", "of", "both", "drugs", "were", "used", ".", "A", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "was", "performed", "to", "determine", "the", "effect", "-", "site", "concentration", "(", "Ce", ")", "of", "remifentanil", "to", "prevent", "the", "pain", "without", "producing", "complications", ".", "METHODS", ":", "A", "total", "of", "128", "patients", "undergoing", "general", "surgery", "were", "randomly", "allocated", "to", "receive", "normal", "saline", "(", "control", ")", "or", "remifentanil", "to", "a", "target", "Ce", "of", "2", "ng", "ml", "(", "-", "1", ")", "(", "R2", ")", ",", "4", "ng", "ml", "(", "-", "1", ")", "(", "R4", ")", ",", "or", "6", "ng", "ml", "(", "-", "1", ")", "(", "R6", ")", "administered", "via", "TCI", ".", "After", "the", "target", "Ce", "was", "achieved", ",", "the", "infusion", "of", "propofol", "was", "started", ".", "Remifentanil", "-", "related", "complications", "were", "assessed", "during", "the", "remifentanil", "infusion", ",", "and", "pain", "caused", "by", "propofol", "was", "evaluated", "using", "a", "four", "-", "point", "scale", "during", "the", "propofol", "infusion", ".", "RESULTS", ":", "The", "incidence", "of", "pain", "was", "significantly", "lower", "in", "Groups", "R4", "and", "R6", "than", "in", "the", "control", "and", "R2", "groups", "(", "12", "/", "32", "and", "6", "/", "31", "vs", "26", "/", "31", "and", "25", "/", "32", ",", "respectively", ",", "P", "<", "0", ".", "001", ")", ".", "Pain", "was", "less", "severe", "in", "Groups", "R4", "and", "R6", "than", "in", "the", "control", "and", "R2", "groups", "(", "P", "<", "0", ".", "001", ")", ".", "However", ",", "both", "incidence", "and", "severity", "of", "pain", "were", "not", "different", "between", "Groups", "R4", "and", "R6", ".", "No", "significant", "complications", "were", "observed", "during", "the", "study", ".", "CONCLUSIONS", ":", "During", "induction", "of", "anaesthesia", "with", "TCI", "of", "propofol", "and", "remifentanil", ",", "a", "significant", "reduction", "in", "propofol", "infusion", "pain", "was", "achieved", "without", "significant", "complications", "by", "prior", "administration", "of", "remifentanil", "at", "a", "target", "Ce", "of", "4", "ng", "ml", "(", "-", "1", ")", "."]], "ner": [[[9, 9, "Chemical"], [19, 19, "Chemical"], [26, 26, "Chemical"], [38, 38, "Chemical"], [167, 167, "Chemical"], [186, 186, "Chemical"], [197, 197, "Chemical"], [306, 306, "Chemical"], [314, 314, "Chemical"], [2, 2, "Disease"], [15, 15, "Disease"], [28, 28, "Disease"], [88, 88, "Disease"], [183, 183, "Disease"], [205, 205, "Disease"], [247, 247, "Disease"], [278, 278, "Disease"], [316, 316, "Disease"], [11, 11, "Chemical"], [34, 34, "Chemical"], [84, 84, "Chemical"], [114, 114, "Chemical"], [171, 171, "Chemical"], [179, 179, "Chemical"], [308, 308, "Chemical"], [326, 326, "Chemical"]]], "relations": [[[9, 9, 2, 2, "CID"], [9, 9, 15, 15, "CID"], [9, 9, 28, 28, "CID"], [9, 9, 88, 88, "CID"], [9, 9, 183, 183, "CID"], [9, 9, 205, 205, "CID"], [9, 9, 247, 247, "CID"], [9, 9, 278, 278, "CID"], [9, 9, 316, 316, "CID"], [19, 19, 2, 2, "CID"], [19, 19, 15, 15, "CID"], [19, 19, 28, 28, "CID"], [19, 19, 88, 88, "CID"], [19, 19, 183, 183, "CID"], [19, 19, 205, 205, "CID"], [19, 19, 247, 247, "CID"], [19, 19, 278, 278, "CID"], [19, 19, 316, 316, "CID"], [26, 26, 2, 2, "CID"], [26, 26, 15, 15, "CID"], [26, 26, 28, 28, "CID"], [26, 26, 88, 88, "CID"], [26, 26, 183, 183, "CID"], [26, 26, 205, 205, "CID"], [26, 26, 247, 247, "CID"], [26, 26, 278, 278, "CID"], [26, 26, 316, 316, "CID"], [38, 38, 2, 2, "CID"], [38, 38, 15, 15, "CID"], [38, 38, 28, 28, "CID"], [38, 38, 88, 88, "CID"], [38, 38, 183, 183, "CID"], [38, 38, 205, 205, "CID"], [38, 38, 247, 247, "CID"], [38, 38, 278, 278, "CID"], [38, 38, 316, 316, "CID"], [167, 167, 2, 2, "CID"], [167, 167, 15, 15, "CID"], [167, 167, 28, 28, "CID"], [167, 167, 88, 88, "CID"], [167, 167, 183, 183, "CID"], [167, 167, 205, 205, "CID"], [167, 167, 247, 247, "CID"], [167, 167, 278, 278, "CID"], [167, 167, 316, 316, "CID"], [186, 186, 2, 2, "CID"], [186, 186, 15, 15, "CID"], [186, 186, 28, 28, "CID"], [186, 186, 88, 88, "CID"], [186, 186, 183, 183, "CID"], [186, 186, 205, 205, "CID"], [186, 186, 247, 247, "CID"], [186, 186, 278, 278, "CID"], [186, 186, 316, 316, "CID"], [197, 197, 2, 2, "CID"], [197, 197, 15, 15, "CID"], [197, 197, 28, 28, "CID"], [197, 197, 88, 88, "CID"], [197, 197, 183, 183, "CID"], [197, 197, 205, 205, "CID"], [197, 197, 247, 247, "CID"], [197, 197, 278, 278, "CID"], [197, 197, 316, 316, "CID"], [306, 306, 2, 2, "CID"], [306, 306, 15, 15, "CID"], [306, 306, 28, 28, "CID"], [306, 306, 88, 88, "CID"], [306, 306, 183, 183, "CID"], [306, 306, 205, 205, "CID"], [306, 306, 247, 247, "CID"], [306, 306, 278, 278, "CID"], [306, 306, 316, 316, "CID"], [314, 314, 2, 2, "CID"], [314, 314, 15, 15, "CID"], [314, 314, 28, 28, "CID"], [314, 314, 88, 88, "CID"], [314, 314, 183, 183, "CID"], [314, 314, 205, 205, "CID"], [314, 314, 247, 247, "CID"], [314, 314, 278, 278, "CID"], [314, 314, 316, 316, "CID"]]], "clusters": [], "translated": "使用目标控制的<0>异丙酚</0>和<18>瑞芬太尼</18>减少诱导期间的<9>疼痛</9>。背景：注射<1>异丙酚</1>时<10>疼痛</10>令人不快。我们假设在临床环境中开始输注<3>异丙酚</3>之前输注<19>瑞芬太尼</19>可以预防<2>异丙酚</2>输注<11>疼痛</11>，使用两种药物的靶控输注（TCI）。进行了一项前瞻性、随机、双盲、安慰剂对照试验，以确定<20>瑞芬太尼</20>在不产生并发症的情况下预防<12>疼痛</12>的作用部位浓度（Ce）。方法：共有128名接受普外科手术的患者被随机分配接受生理盐水（对照）或<21>瑞芬太尼</21>，目标Ce为2 ng ml (-1)（R2）、4 ng ml (-1)（R4）或6 ng ml (-1)（R6）通过TCI给药。达到目标Ce后，开始输注<4>异丙酚</4>。<22>瑞芬太尼</22>相关并发症在<23>瑞芬太尼</23>输注过程中进行评估，<5>异丙酚</5>引起的<13>疼痛</13>使用四点刻度在<6>异丙酚</6>输注期间进行评估。结果：<14>疼痛</14>的发生率在R4和R6组中显着低于对照组和R2组（分别为12/32和6/31 vs 26/31和25/32，P<0.001）。<15>疼痛</15>在R4和R6组中比在对照组和R2组中更轻（P<0.001）。然而，<16>疼痛</16>的发生率和严重程度在R4组和R6组之间没有差异。研究期间未观察到明显的并发症。结论：<7>异丙酚</7>和<24>瑞芬太尼</24>TCI诱导麻醉期间，<8>异丙酚</8>输注<17>疼痛</17>显着减少，在4 ng ml (-1)的目标Ce下预先使用<25>瑞芬太尼</25>没有显着并发症。", "revised": true}
{"doc_key": "15974569", "sentences": [["Two", "prodrugs", "of", "potent", "and", "selective", "GluR5", "kainate", "receptor", "antagonists", "actives", "in", "three", "animal", "models", "of", "pain", ".", "Amino", "acids", "5", "and", "7", ",", "two", "potent", "and", "selective", "competitive", "GluR5", "KA", "receptor", "antagonists", ",", "exhibited", "high", "GluR5", "receptor", "affinity", "over", "other", "glutamate", "receptors", ".", "Their", "ester", "prodrugs", "6", "and", "8", "were", "orally", "active", "in", "three", "models", "of", "pain", ":", "reversal", "of", "formalin", "-", "induced", "paw", "licking", ",", "carrageenan", "-", "induced", "thermal", "hyperalgesia", ",", "and", "capsaicin", "-", "induced", "mechanical", "hyperalgesia", "."]], "ner": [[[67, 67, "Chemical"], [70, 71, "Disease"], [77, 78, "Disease"], [74, 74, "Chemical"], [7, 7, "Chemical"], [30, 30, "Chemical"], [16, 16, "Disease"], [57, 57, "Disease"], [41, 41, "Chemical"], [61, 61, "Chemical"]]], "relations": [[[67, 67, 70, 71, "CID"], [67, 67, 77, 78, "CID"], [74, 74, 70, 71, "CID"], [74, 74, 77, 78, "CID"]]], "clusters": [], "translated": "两种有效且选择性的GluR5<4>红藻氨酸</4>受体拮抗剂前药在三种<6>疼痛</6>动物模型中具有活性。氨基酸5和7是两种有效且具有选择性的竞争性GluR5<5>KA</5>受体拮抗剂，与其他<8>谷氨酸</8>受体相比表现出更高的GluR5受体亲和力。它们的酯前体药物6和8在三种<7>疼痛</7>模型中具有口服活性：逆转<9>福尔马林</9>诱导的爪子舔，<0>角叉菜胶</0>诱导的<1>热痛觉过敏</1>，和<3>辣椒素</3>诱导的<2>机械痛觉过敏</2>。", "revised": true}
{"doc_key": "11704023", "sentences": [["Comparison", "of", "aqueous", "and", "gellan", "ophthalmic", "timolol", "with", "placebo", "on", "the", "24", "-", "hour", "heart", "rate", "response", "in", "patients", "on", "treatment", "for", "glaucoma", ".", "PURPOSE", ":", "Topical", "beta", "-", "blocker", "treatment", "is", "routine", "therapy", "in", "the", "management", "of", "patients", "with", "glaucoma", ".", "Therapy", "results", "in", "systemic", "absorption", ",", "however", ",", "the", "degree", "of", "reduction", "of", "resting", "and", "peak", "heart", "rate", "has", "not", "been", "quantified", ".", "DESIGN", ":", "This", "trial", "evaluated", "the", "effect", "of", "placebo", ",", "0", ".", "5", "%", "aqueous", "timolol", "(", "timolol", "solution", ")", "and", "a", "0", ".", "5", "%", "timolol", "suspension", "that", "forms", "a", "gel", "on", "application", "to", "the", "conjunctiva", "(", "timolol", "gellan", ")", "on", "the", "24", "-", "hour", "heart", "rate", "in", "patients", "currently", "being", "treated", "for", "glaucoma", "to", "quantify", "the", "reduction", "in", "mean", "heart", "rate", ".", "METHODS", ":", "Forty", "-", "three", "Caucasian", "patients", "with", "primary", "open", "-", "angle", "glaucoma", "or", "ocular", "hypertension", "with", "a", "mean", "(", "+", "/", "-", "SD", ")", "age", "of", "63", "(", "+", "/", "-", "8", ")", "years", "were", "randomized", "and", "crossed", "over", "in", "a", "double", "-", "masked", "manner", "to", "14", "days", "of", "treatment", "with", "placebo", "(", "morning", "and", "evening", "in", "both", "eyes", ")", ",", "timolol", "solution", "(", "morning", "and", "evening", "in", "both", "eyes", ")", ",", "or", "timolol", "gellan", "(", "morning", "in", "both", "eyes", "with", "placebo", "in", "the", "evening", ")", ".", "On", "the", "13th", "day", "of", "each", "period", ",", "heart", "rate", "was", "recorded", "continuously", "during", "a", "typical", ",", "ambulant", "24", "-", "hour", "period", ".", "RESULTS", ":", "Both", "timolol", "solution", "and", "timolol", "gellan", "reduced", "the", "mean", "24", "-", "hour", "heart", "rate", "compared", "with", "placebo", "(", "P", "<", "or", "=", ".", "001", ")", ",", "and", "this", "reduction", "was", "most", "pronounced", "during", "the", "daytime", "(", "-", "7", ".", "5", "%", "change", "in", "mean", "heart", "rate", ",", "-", "5", ".", "7", "beats", "/", "min", ")", ".", "Timolol", "gellan", "showed", "a", "numerically", "but", "not", "significantly", "smaller", "reduction", "in", "24", "-", "hour", "heart", "rate", ",", "compared", "with", "timolol", "solution", ".", "During", "the", "night", ",", "the", "mean", "12", "-", "hour", "heart", "rate", "on", "placebo", "and", "timolol", "gellan", "were", "both", "significantly", "less", "than", "on", "timolol", "solution", ";", "the", "difference", "between", "solution", "and", "gellan", "treatments", "was", "statistically", "significant", "(", "P", "=", ".", "01", ")", ".", "CONCLUSIONS", ":", "Both", "timolol", "solution", "and", "timolol", "gellan", "decrease", "the", "mean", "24", "-", "hour", "heart", "rate", "compared", "with", "placebo", ".", "This", "response", "was", "most", "pronounced", "during", "the", "active", "daytime", "period", ".", "These", "data", "quantify", "the", "modest", "bradycardia", "associated", "with", "ophthalmic", "beta", "-", "blocker", "therapy", "in", "a", "typical", "patient", "population", "on", "therapy", "for", "glaucoma", ".", "Although", "exercise", "performance", "was", "not", "assessed", "in", "this", "trial", ",", "reductions", "of", "this", "magnitude", "should", "not", "have", "substantial", "clinical", "consequences", "."]], "ner": [[[6, 6, "Chemical"], [80, 80, "Chemical"], [82, 82, "Chemical"], [91, 91, "Chemical"], [103, 103, "Chemical"], [191, 191, "Chemical"], [203, 203, "Chemical"], [243, 243, "Chemical"], [246, 246, "Chemical"], [298, 298, "Chemical"], [317, 317, "Chemical"], [334, 334, "Chemical"], [342, 342, "Chemical"], [365, 365, "Chemical"], [368, 368, "Chemical"], [398, 398, "Disease"], [22, 22, "Disease"], [40, 40, "Disease"], [119, 119, "Disease"], [414, 414, "Disease"], [138, 141, "Disease"], [143, 144, "Disease"]]], "relations": [[[6, 6, 398, 398, "CID"], [80, 80, 398, 398, "CID"], [82, 82, 398, 398, "CID"], [91, 91, 398, 398, "CID"], [103, 103, 398, 398, "CID"], [191, 191, 398, 398, "CID"], [203, 203, 398, 398, "CID"], [243, 243, 398, 398, "CID"], [246, 246, 398, 398, "CID"], [298, 298, 398, 398, "CID"], [317, 317, 398, 398, "CID"], [334, 334, 398, 398, "CID"], [342, 342, 398, 398, "CID"], [365, 365, 398, 398, "CID"], [368, 368, 398, 398, "CID"]]], "clusters": [], "translated": "眼药水和结冷胶<0>噻吗洛尔</0>与安慰剂对治疗<16>青光眼</16>患者24小时心率反应的比较。目的：局部β受体阻滞剂治疗是<17>青光眼</17>患者的常规治疗。治疗导致全身吸收，但是静息心率和峰值心率的降低程度尚未量化。设计：本试验评估安慰剂的效果，0.5%<1>噻吗洛尔</1>水溶液（<2>噻吗洛尔</2>溶液）和0.5%<3>噻吗洛尔</3> 混悬液在结膜上形成凝胶（<4>噻吗洛尔</4>结冷胶）对目前正在接受<18>青光眼</18>治疗的患者24小时心率的影响，量化平均心率的降低。方法：43名患有原发性<20>开角型青光眼</20>或<21>高眼压症</21>的白种人患者，平均(+/-SD)年龄为63(+/-8)岁，随机化并以双盲方式交叉进行为期14天的安慰剂治疗（双眼早晚），<5>噻吗洛尔</5>溶液（双眼早晚），或<6>噻吗洛尔</6>结冷胶（双眼早上服用，晚上服用安慰剂）。在每个周期的第13天，在典型的24小时移动周期内连续记录心率。结果：与安慰剂相比，<7>噻吗洛尔</7>溶液和<8>噻吗洛尔</8>结冷胶均降低了平均24小时心率（P ≤ .001），这种降低在治疗期间最为明显。白天（平均心率变化-7.5%，-5.7次/分钟）。与<10>噻吗洛尔</10>溶液相比，<9>噻吗洛尔</9>结冷胶在24小时心率方面的降幅在数值上并不显着较小。在夜间，服用安慰剂和<11>噻吗洛尔</11>结冷胶的平均12小时心率均显着低于<12>噻吗洛尔</12>溶液；溶液处理和结冷胶处理之间的差异具有统计学意义（P = .01）。结论：与安慰剂相比，<13>噻吗洛尔</13>溶液和<14>噻吗洛尔</14>结冷胶均能降低平均24小时心率。这种反应在活跃的白天期间最为明显。这些数据量化了在接受<19>青光眼</19>治疗的典型患者群体中与眼科β受体阻滞剂治疗相关的适度<15>心动过缓</15>。虽然在该试验中未评估运动表现，但这种幅度的减少不会产生实质性的临床后果。", "revised": true}
{"doc_key": "17702969", "sentences": [["Prenatal", "exposure", "to", "fluoxetine", "induces", "fetal", "pulmonary", "hypertension", "in", "the", "rat", ".", "RATIONALE", ":", "Fluoxetine", "is", "a", "selective", "serotonin", "reuptake", "inhibitor", "antidepressant", "widely", "used", "by", "pregnant", "women", ".", "Epidemiological", "data", "suggest", "that", "fluoxetine", "exposure", "prenatally", "increases", "the", "prevalence", "of", "persistent", "pulmonary", "hypertension", "syndrome", "of", "the", "newborn", ".", "The", "mechanism", "responsible", "for", "this", "effect", "is", "unclear", "and", "paradoxical", ",", "considering", "the", "current", "evidence", "of", "a", "pulmonary", "hypertension", "protective", "fluoxetine", "effect", "in", "adult", "rodents", ".", "OBJECTIVES", ":", "To", "evaluate", "the", "fluoxetine", "effect", "on", "fetal", "rat", "pulmonary", "vascular", "smooth", "muscle", "mechanical", "properties", "and", "cell", "proliferation", "rate", ".", "METHODS", ":", "Pregnant", "rats", "were", "treated", "with", "fluoxetine", "(", "10", "mg", "/", "kg", ")", "from", "Day", "11", "through", "Day", "21", "of", "gestation", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "Fetuses", "were", "delivered", "by", "cesarean", "section", ".", "As", "compared", "with", "controls", ",", "fluoxetine", "exposure", "resulted", "in", "fetal", "pulmonary", "hypertension", "as", "evidenced", "by", "an", "increase", "in", "the", "weight", "ratio", "of", "the", "right", "ventricle", "to", "the", "left", "ventricle", "plus", "septum", "(", "P", "=", "0", ".", "02", ")", "and", "by", "an", "increase", "in", "pulmonary", "arterial", "medial", "thickness", "(", "P", "<", "0", ".", "01", ")", ".", "Postnatal", "mortality", "was", "increased", "among", "experimental", "animals", ",", "and", "arterial", "oxygen", "saturation", "was", "96", "+", "/", "-", "1", "%", "in", "1", "-", "day", "-", "old", "control", "animals", "and", "significantly", "lower", "(", "P", "<", "0", ".", "01", ")", "in", "fluoxetine", "-", "exposed", "pups", "(", "79", "+", "/", "-", "2", "%", ")", ".", "In", "vitro", ",", "fluoxetine", "induced", "pulmonary", "arterial", "muscle", "contraction", "in", "fetal", ",", "but", "not", "adult", ",", "animals", "(", "P", "<", "0", ".", "01", ")", "and", "reduced", "serotonin", "-", "induced", "contraction", "at", "both", "ages", "(", "P", "<", "0", ".", "01", ")", ".", "After", "in", "utero", "exposure", "to", "a", "low", "fluoxetine", "concentration", "the", "pulmonary", "arterial", "smooth", "muscle", "cell", "proliferation", "rate", "was", "significantly", "increased", "in", "fetal", ",", "but", "not", "adult", ",", "cells", "(", "P", "<", "0", ".", "01", ")", ".", "CONCLUSIONS", ":", "In", "contrast", "to", "the", "adult", ",", "fluoxetine", "exposure", "in", "utero", "induces", "pulmonary", "hypertension", "in", "the", "fetal", "rat", "as", "a", "result", "of", "a", "developmentally", "regulated", "increase", "in", "pulmonary", "vascular", "smooth", "muscle", "proliferation", "."]], "ner": [[[3, 3, "Chemical"], [14, 14, "Chemical"], [32, 32, "Chemical"], [67, 67, "Chemical"], [78, 78, "Chemical"], [101, 101, "Chemical"], [134, 134, "Chemical"], [222, 222, "Chemical"], [238, 238, "Chemical"], [283, 283, "Chemical"], [320, 320, "Chemical"], [5, 7, "Disease"], [138, 140, "Disease"], [40, 42, "Disease"], [64, 65, "Disease"], [325, 326, "Disease"], [18, 18, "Chemical"], [261, 261, "Chemical"], [194, 194, "Chemical"]]], "relations": [[[3, 3, 5, 7, "CID"], [3, 3, 138, 140, "CID"], [14, 14, 5, 7, "CID"], [14, 14, 138, 140, "CID"], [32, 32, 5, 7, "CID"], [32, 32, 138, 140, "CID"], [67, 67, 5, 7, "CID"], [67, 67, 138, 140, "CID"], [78, 78, 5, 7, "CID"], [78, 78, 138, 140, "CID"], [101, 101, 5, 7, "CID"], [101, 101, 138, 140, "CID"], [134, 134, 5, 7, "CID"], [134, 134, 138, 140, "CID"], [222, 222, 5, 7, "CID"], [222, 222, 138, 140, "CID"], [238, 238, 5, 7, "CID"], [238, 238, 138, 140, "CID"], [283, 283, 5, 7, "CID"], [283, 283, 138, 140, "CID"], [320, 320, 5, 7, "CID"], [320, 320, 138, 140, "CID"], [3, 3, 40, 42, "CID"], [3, 3, 64, 65, "CID"], [3, 3, 325, 326, "CID"], [14, 14, 40, 42, "CID"], [14, 14, 64, 65, "CID"], [14, 14, 325, 326, "CID"], [32, 32, 40, 42, "CID"], [32, 32, 64, 65, "CID"], [32, 32, 325, 326, "CID"], [67, 67, 40, 42, "CID"], [67, 67, 64, 65, "CID"], [67, 67, 325, 326, "CID"], [78, 78, 40, 42, "CID"], [78, 78, 64, 65, "CID"], [78, 78, 325, 326, "CID"], [101, 101, 40, 42, "CID"], [101, 101, 64, 65, "CID"], [101, 101, 325, 326, "CID"], [134, 134, 40, 42, "CID"], [134, 134, 64, 65, "CID"], [134, 134, 325, 326, "CID"], [222, 222, 40, 42, "CID"], [222, 222, 64, 65, "CID"], [222, 222, 325, 326, "CID"], [238, 238, 40, 42, "CID"], [238, 238, 64, 65, "CID"], [238, 238, 325, 326, "CID"], [283, 283, 40, 42, "CID"], [283, 283, 64, 65, "CID"], [283, 283, 325, 326, "CID"], [320, 320, 40, 42, "CID"], [320, 320, 64, 65, "CID"], [320, 320, 325, 326, "CID"]]], "clusters": [], "translated": "产前接触<0>氟西汀</0>会在大鼠中诱发<11>胎儿肺动脉高压</11>。理由：<1>氟西汀</1>是一种选择性<16>5-羟色胺</16>再摄取抑制剂抗抑郁药，广泛用于孕妇。流行病学数据表明，产前<2>氟西汀</2>暴露会增加新生儿持续性<13>肺动脉高压综合征</13>的患病率。考虑到目前在成年啮齿动物中 <14>肺动脉高压</14>保护性<3>氟西汀</3>作用的证据，造成这种作用的机制尚不清楚且自相矛盾。目的：评价<4>氟西汀</4>对胎鼠肺血管平滑肌力学性能和细胞增殖率的影响。方法：妊娠大鼠从妊娠第11天到第21天接受<5>氟西汀</5>（10 mg/kg）治疗。测量指标和主要结果：胎儿通过剖宫产分娩。与对照组相比，<6>氟西汀</6>暴露导致<12>胎儿肺动脉高压</12>，表现为右心室与左心室加隔膜的重量比增加（P = 0.02）和肺动脉内侧厚度的增加（P < 0.01）。实验动物的出生后死亡率增加，1日龄对照动物的动脉<18>氧</18>饱和度为96 +/- 1 %，<7>氟西汀</7> - 暴露的幼崽动脉<18>氧</18>饱和度显著降低(P < 0.01)。在体外，<8>氟西汀</8>诱导胎儿而非成年动物的肺动脉肌肉收缩(P < 0.01)，并且减少<17>血清素</17> - 诱导的收缩(P < 0.01)。在子宫内暴露于低浓度<9>氟西汀</9>后，胎儿的肺动脉平滑肌细胞增殖率显着增加，而成人细胞则没有(P < 0.01)。结论：与成年相比，<10>氟西汀</10>在子宫内的暴露会在胎鼠中诱发<15>肺动脉高压</15>，这是肺血管平滑肌增殖受发育调节增加的结果。", "revised": true}
{"doc_key": "16826348", "sentences": [["Peripheral", "neuropathy", "caused", "by", "high", "-", "dose", "cytosine", "arabinoside", "treatment", "in", "a", "patient", "with", "acute", "myeloid", "leukemia", ".", "The", "central", "nervous", "system", "toxicity", "of", "high", "-", "dose", "cytosine", "arabinoside", "is", "well", "recognized", ",", "but", "the", "toxicity", "of", "cytosine", "arabinoside", "in", "the", "peripheral", "nervous", "system", "has", "been", "infrequently", "reported", ".", "A", "49", "-", "year", "-", "old", "Japanese", "man", "was", "diagnosed", "with", "acute", "myeloid", "leukemia", ".", "After", "he", "achieved", "complete", "remission", ",", "he", "received", "high", "-", "dose", "cytosine", "arabinoside", "treatment", "(", "2", "g", "/", "m2", "twice", "a", "day", "for", "5", "days", ";", "total", ",", "20", "g", "/", "m2", ")", "as", "consolidation", "therapy", ".", "The", "first", "course", "of", "high", "-", "dose", "cytosine", "arabinoside", "resulted", "in", "no", "unusual", "symptoms", ",", "but", "on", "day", "21", "of", "the", "second", "course", "of", "treatment", ",", "the", "patient", "complained", "of", "numbness", "in", "his", "right", "foot", ".", "Electromyogram", "and", "nerve", "-", "conduction", "studies", "showed", "peripheral", "neuropathy", "in", "both", "peroneal", "nerves", ".", "This", "neuropathy", "was", "gradually", "resolving", ";", "however", ",", "after", "the", "patient", "received", "allogeneic", "bone", "marrow", "transplantation", ",", "the", "symptoms", "worsened", ",", "with", "the", "development", "of", "graft", "-", "versus", "-", "host", "disease", ",", "and", "the", "symptoms", "subsequently", "responded", "to", "methylprednisolone", ".", "Although", "the", "mechanisms", "of", "peripheral", "neuropathy", "are", "still", "unclear", ",", "high", "-", "dose", "cytosine", "arabinoside", "is", "a", "therapy", "that", "is", "potentially", "toxic", "to", "the", "peripheral", "nervous", "system", ",", "and", "auto", "/", "alloimmunity", "may", "play", "an", "important", "role", "in", "these", "mechanisms", "."]], "ner": [[[7, 8, "Chemical"], [27, 28, "Chemical"], [37, 38, "Chemical"], [75, 76, "Chemical"], [108, 109, "Chemical"], [204, 205, "Chemical"], [0, 1, "Disease"], [144, 145, "Disease"], [195, 196, "Disease"], [189, 189, "Chemical"], [14, 16, "Disease"], [60, 62, "Disease"], [22, 22, "Disease"], [35, 35, "Disease"], [131, 131, "Disease"], [152, 152, "Disease"], [176, 181, "Disease"]]], "relations": [[[7, 8, 0, 1, "CID"], [7, 8, 144, 145, "CID"], [7, 8, 195, 196, "CID"], [27, 28, 0, 1, "CID"], [27, 28, 144, 145, "CID"], [27, 28, 195, 196, "CID"], [37, 38, 0, 1, "CID"], [37, 38, 144, 145, "CID"], [37, 38, 195, 196, "CID"], [75, 76, 0, 1, "CID"], [75, 76, 144, 145, "CID"], [75, 76, 195, 196, "CID"], [108, 109, 0, 1, "CID"], [108, 109, 144, 145, "CID"], [108, 109, 195, 196, "CID"], [204, 205, 0, 1, "CID"], [204, 205, 144, 145, "CID"], [204, 205, 195, 196, "CID"]]], "clusters": [], "translated": "<10>急性髓性白血病</10>患者因大剂量<0>阿糖胞苷</0>治疗引起的<6>周围神经病变</6>。高剂量<1>阿糖胞苷</1>的<12>中枢神经系统毒性</12>是公认的，但<2>阿糖胞苷</2>在<13>周围神经系统</13>的<13>毒性</13>很少见报道。一名49岁的日本男子被诊断出患有<11>急性髓性白血病</11>。完全缓解后，接受大剂量<3>阿糖胞苷</3>治疗（2g/m2，每日2次，共5天；总计20g/m2）作为巩固治疗。第一疗程大剂量<4>阿糖胞苷</4>无异常症状，但第二疗程第21天，患者主诉右足<14>麻木</14>。肌电图和神经传导研究显示双侧腓神经<7>周围神经病变</7>。这种<15>神经病</15>正在逐渐消退；但患者接受同种异体骨髓移植后，症状加重，发展为<16>移植物抗宿主病</16>，随后对<9>甲基强的松龙</9>症状缓解。虽然<8>周围神经病变</8>的机制尚不清楚，但大剂量<5>阿糖胞苷</5>是一种对<8>周围神经系统</8>有潜在毒性的疗法，自身/同种免疫可能发挥重要作用这些机制的作用。", "revised": true}
{"doc_key": "11282081", "sentences": [["Effects", "of", "verapamil", "on", "atrial", "fibrillation", "and", "its", "electrophysiological", "determinants", "in", "dogs", ".", "BACKGROUND", ":", "Atrial", "tachycardia", "-", "induced", "remodeling", "promotes", "the", "occurrence", "and", "maintenance", "of", "atrial", "fibrillation", "(", "AF", ")", "and", "decreases", "L", "-", "type", "Ca", "(", "2", "+", ")", "current", ".", "There", "is", "also", "a", "clinical", "suggestion", "that", "acute", "L", "-", "type", "Ca", "(", "2", ")", "channel", "blockade", "can", "promote", "AF", ",", "consistent", "with", "an", "AF", "promoting", "effect", "of", "Ca", "(", "2", "+", ")", "channel", "inhibition", ".", "METHODS", ":", "To", "evaluate", "the", "potential", "mechanisms", "of", "AF", "promotion", "by", "Ca", "(", "2", "+", ")", "channel", "blockers", ",", "we", "administered", "verapamil", "to", "morphine", "-", "chloralose", "anesthetized", "dogs", ".", "Diltiazem", "was", "used", "as", "a", "comparison", "drug", "and", "autonomic", "blockade", "with", "atropine", "and", "nadolol", "was", "applied", "in", "some", "experiments", ".", "Epicardial", "mapping", "with", "240", "epicardial", "electrodes", "was", "used", "to", "evaluate", "activation", "during", "AF", ".", "RESULTS", ":", "Verapamil", "caused", "AF", "promotion", "in", "six", "dogs", ",", "increasing", "mean", "duration", "of", "AF", "induced", "by", "burst", "pacing", ",", "from", "8", "+", "/", "-", "4", "s", "(", "mean", "+", "/", "-", "S", ".", "E", ".", ")", "to", "95", "+", "/", "-", "39", "s", "(", "P", "<", "0", ".", "01", "vs", ".", "control", ")", "at", "a", "loading", "dose", "of", "0", ".", "1", "mg", "/", "kg", "and", "228", "+", "/", "-", "101", "s", "(", "P", "<", "0", ".", "0005", "vs", ".", "control", ")", "at", "a", "dose", "of", "0", ".", "2", "mg", "/", "kg", ".", "Underlying", "electrophysiological", "mechanisms", "were", "studied", "in", "detail", "in", "five", "additional", "dogs", "under", "control", "conditions", "and", "in", "the", "presence", "of", "the", "higher", "dose", "of", "verapamil", ".", "In", "these", "experiments", ",", "verapamil", "shortened", "mean", "effective", "refractory", "period", "(", "ERP", ")", "from", "122", "+", "/", "-", "5", "to", "114", "+", "/", "-", "4", "ms", "(", "P", "<", "0", ".", "02", ")", "at", "a", "cycle", "length", "of", "300", "ms", ",", "decreased", "ERP", "heterogeneity", "(", "from", "15", "+", "/", "-", "1", "to", "10", "+", "/", "-", "1", "%", ",", "P", "<", "0", ".", "05", ")", ",", "heterogeneously", "accelerated", "atrial", "conduction", "and", "decreased", "the", "cycle", "length", "of", "AF", "(", "94", "+", "/", "-", "4", "to", "84", "+", "/", "-", "3", "ms", ",", "P", "<", "0", ".", "005", ")", ".", "Diltiazem", "did", "not", "affect", "ERP", ",", "AF", "cycle", "length", "or", "AF", "duration", ",", "but", "produced", "conduction", "acceleration", "similar", "to", "that", "caused", "by", "verapamil", "(", "n", "=", "5", ")", ".", "In", "the", "presence", "of", "autonomic", "blockade", ",", "verapamil", "failed", "to", "promote", "AF", "and", "increased", ",", "rather", "than", "decreasing", ",", "refractoriness", ".", "Neither", "verapamil", "nor", "diltiazem", "affected", "atrial", "conduction", "in", "the", "presence", "of", "autonomic", "blockade", ".", "Epicardial", "mapping", "suggested", "that", "verapamil", "promoted", "AF", "by", "increasing", "the", "number", "of", "simultaneous", "wavefronts", "reflected", "by", "separate", "zones", "of", "reactivation", "in", "each", "cycle", ".", "CONCLUSIONS", ":", "Verapamil", "promotes", "AF", "in", "normal", "dogs", "by", "promoting", "multiple", "circuit", "reentry", ",", "an", "effect", "dependent", "on", "intact", "autonomic", "tone", "and", "not", "shared", "by", "diltiazem", "."]], "ner": [[[2, 2, "Chemical"], [100, 100, "Chemical"], [144, 144, "Chemical"], [258, 258, "Chemical"], [264, 264, "Chemical"], [380, 380, "Chemical"], [394, 394, "Chemical"], [409, 409, "Chemical"], [426, 426, "Chemical"], [448, 448, "Chemical"], [4, 5, "Disease"], [26, 27, "Disease"], [29, 29, "Disease"], [62, 62, "Disease"], [67, 67, "Disease"], [87, 87, "Disease"], [140, 140, "Disease"], [146, 146, "Disease"], [156, 156, "Disease"], [336, 336, "Disease"], [364, 364, "Disease"], [368, 368, "Disease"], [398, 398, "Disease"], [428, 428, "Disease"], [450, 450, "Disease"], [15, 16, "Disease"], [36, 36, "Chemical"], [54, 54, "Chemical"], [71, 71, "Chemical"], [90, 90, "Chemical"], [102, 102, "Chemical"], [104, 104, "Chemical"], [108, 108, "Chemical"], [358, 358, "Chemical"], [411, 411, "Chemical"], [471, 471, "Chemical"], [119, 119, "Chemical"], [121, 121, "Chemical"]]], "relations": [[[2, 2, 4, 5, "CID"], [2, 2, 26, 27, "CID"], [2, 2, 29, 29, "CID"], [2, 2, 62, 62, "CID"], [2, 2, 67, 67, "CID"], [2, 2, 87, 87, "CID"], [2, 2, 140, 140, "CID"], [2, 2, 146, 146, "CID"], [2, 2, 156, 156, "CID"], [2, 2, 336, 336, "CID"], [2, 2, 364, 364, "CID"], [2, 2, 368, 368, "CID"], [2, 2, 398, 398, "CID"], [2, 2, 428, 428, "CID"], [2, 2, 450, 450, "CID"], [100, 100, 4, 5, "CID"], [100, 100, 26, 27, "CID"], [100, 100, 29, 29, "CID"], [100, 100, 62, 62, "CID"], [100, 100, 67, 67, "CID"], [100, 100, 87, 87, "CID"], [100, 100, 140, 140, "CID"], [100, 100, 146, 146, "CID"], [100, 100, 156, 156, "CID"], [100, 100, 336, 336, "CID"], [100, 100, 364, 364, "CID"], [100, 100, 368, 368, "CID"], [100, 100, 398, 398, "CID"], [100, 100, 428, 428, "CID"], [100, 100, 450, 450, "CID"], [144, 144, 4, 5, "CID"], [144, 144, 26, 27, "CID"], [144, 144, 29, 29, "CID"], [144, 144, 62, 62, "CID"], [144, 144, 67, 67, "CID"], [144, 144, 87, 87, "CID"], [144, 144, 140, 140, "CID"], [144, 144, 146, 146, "CID"], [144, 144, 156, 156, "CID"], [144, 144, 336, 336, "CID"], [144, 144, 364, 364, "CID"], [144, 144, 368, 368, "CID"], [144, 144, 398, 398, "CID"], [144, 144, 428, 428, "CID"], [144, 144, 450, 450, "CID"], [258, 258, 4, 5, "CID"], [258, 258, 26, 27, "CID"], [258, 258, 29, 29, "CID"], [258, 258, 62, 62, "CID"], [258, 258, 67, 67, "CID"], [258, 258, 87, 87, "CID"], [258, 258, 140, 140, "CID"], [258, 258, 146, 146, "CID"], [258, 258, 156, 156, "CID"], [258, 258, 336, 336, "CID"], [258, 258, 364, 364, "CID"], [258, 258, 368, 368, "CID"], [258, 258, 398, 398, "CID"], [258, 258, 428, 428, "CID"], [258, 258, 450, 450, "CID"], [264, 264, 4, 5, "CID"], [264, 264, 26, 27, "CID"], [264, 264, 29, 29, "CID"], [264, 264, 62, 62, "CID"], [264, 264, 67, 67, "CID"], [264, 264, 87, 87, "CID"], [264, 264, 140, 140, "CID"], [264, 264, 146, 146, "CID"], [264, 264, 156, 156, "CID"], [264, 264, 336, 336, "CID"], [264, 264, 364, 364, "CID"], [264, 264, 368, 368, "CID"], [264, 264, 398, 398, "CID"], [264, 264, 428, 428, "CID"], [264, 264, 450, 450, "CID"], [380, 380, 4, 5, "CID"], [380, 380, 26, 27, "CID"], [380, 380, 29, 29, "CID"], [380, 380, 62, 62, "CID"], [380, 380, 67, 67, "CID"], [380, 380, 87, 87, "CID"], [380, 380, 140, 140, "CID"], [380, 380, 146, 146, "CID"], [380, 380, 156, 156, "CID"], [380, 380, 336, 336, "CID"], [380, 380, 364, 364, "CID"], [380, 380, 368, 368, "CID"], [380, 380, 398, 398, "CID"], [380, 380, 428, 428, "CID"], [380, 380, 450, 450, "CID"], [394, 394, 4, 5, "CID"], [394, 394, 26, 27, "CID"], [394, 394, 29, 29, "CID"], [394, 394, 62, 62, "CID"], [394, 394, 67, 67, "CID"], [394, 394, 87, 87, "CID"], [394, 394, 140, 140, "CID"], [394, 394, 146, 146, "CID"], [394, 394, 156, 156, "CID"], [394, 394, 336, 336, "CID"], [394, 394, 364, 364, "CID"], [394, 394, 368, 368, "CID"], [394, 394, 398, 398, "CID"], [394, 394, 428, 428, "CID"], [394, 394, 450, 450, "CID"], [409, 409, 4, 5, "CID"], [409, 409, 26, 27, "CID"], [409, 409, 29, 29, "CID"], [409, 409, 62, 62, "CID"], [409, 409, 67, 67, "CID"], [409, 409, 87, 87, "CID"], [409, 409, 140, 140, "CID"], [409, 409, 146, 146, "CID"], [409, 409, 156, 156, "CID"], [409, 409, 336, 336, "CID"], [409, 409, 364, 364, "CID"], [409, 409, 368, 368, "CID"], [409, 409, 398, 398, "CID"], [409, 409, 428, 428, "CID"], [409, 409, 450, 450, "CID"], [426, 426, 4, 5, "CID"], [426, 426, 26, 27, "CID"], [426, 426, 29, 29, "CID"], [426, 426, 62, 62, "CID"], [426, 426, 67, 67, "CID"], [426, 426, 87, 87, "CID"], [426, 426, 140, 140, "CID"], [426, 426, 146, 146, "CID"], [426, 426, 156, 156, "CID"], [426, 426, 336, 336, "CID"], [426, 426, 364, 364, "CID"], [426, 426, 368, 368, "CID"], [426, 426, 398, 398, "CID"], [426, 426, 428, 428, "CID"], [426, 426, 450, 450, "CID"], [448, 448, 4, 5, "CID"], [448, 448, 26, 27, "CID"], [448, 448, 29, 29, "CID"], [448, 448, 62, 62, "CID"], [448, 448, 67, 67, "CID"], [448, 448, 87, 87, "CID"], [448, 448, 140, 140, "CID"], [448, 448, 146, 146, "CID"], [448, 448, 156, 156, "CID"], [448, 448, 336, 336, "CID"], [448, 448, 364, 364, "CID"], [448, 448, 368, 368, "CID"], [448, 448, 398, 398, "CID"], [448, 448, 428, 428, "CID"], [448, 448, 450, 450, "CID"]]], "clusters": [], "translated": "<0>维拉帕米</0>对犬<10>房颤</10>的影响及其电生理决定因素。背景：<25>房性心动过速</25>诱发的重构促进 <11>心房颤动</11> （<12>AF</12>）的发生和维持，降低 L 型 <26>Ca</26>（2+）电流。也有临床提示急性 L 型 <27>Ca</27>（2）通道阻滞可促进 <13>AF</13>，与 <14>AF</14> 促进作用一致，即 <28>Ca</28>（2+）通道抑制。方法：为了评估 <29>Ca</29>（2+）通道阻滞剂促进 <15>AF</15> 的潜在机制，我们在 <30>吗啡</30> - <31>氯醛糖</31> 麻醉狗中给予 <1>维拉帕米</1>。将 <32>地尔硫卓</32> 作为一个对照药， 并在一些实验中使用 <36>阿托品</36> 和 <37>纳多洛尔</37> 进行自主神经阻滞。使用了 240 个心外膜电极的心外膜映射来评估 <16>AF</16> 期间的激活。结果：在 6 只狗中，<2>维拉帕米</2> 促进 <17>AF</17>，负荷剂量为 0.1 毫克/千克时，将突发爆发引起的 <18>AF</18> 的平均持续时间从8 +/- 4 秒（平均 +/ - S.E.）增加至 95 +/- 39 s（P <0.01 vs.对照），将剂量增加至 0.2 毫克/千克时，增加至 228 +/- 101 s（P <0.0005 vs.对照）。在控制条件下和存在较高剂量 <3>维拉帕米</3> 的情况下，我们对另外五只狗详细研究了潜在的电生理机制。在这些实验中，<4>维拉帕米</4>将平均有效不应期（ERP）从 122 +/- 5 缩短到114 +/- 4 毫秒（P <0.02），周期长度为300 毫秒，降低了ERP异质性（从 15 +/- 1 降至 10 +/- 1 %，P <0.05），不均匀加速心房传导并减少了 <19>AF</19> 的周期长度（94 +/- 4 缩短至 84 +/- 3 毫秒，P <0.005）。 <33>地尔硫卓</33> 不影响 ERP、<20>AF</20> 周期长度或 <21>AF</21> 持续时间，但产生类似于 <5>维拉帕米</5> 引起的传导加速（n = 5）。在存在自主神经阻滞的情况下，<6>维拉帕米</6> 未能促进 <22>AF</22>，并增加而不是减少不应性。<7>维拉帕米</7> 和 <34>地尔硫卓</34> 均不影响存在自主神经阻滞的心房传导。心外膜映射表明，<8> 维拉帕米 </8> 通过增加每个周期中不同的再激活区反射的同时波前的数量来促进 <23>AF</23>。结论：<9>维拉帕米</9> 通过促进多回路折返来促进正常犬的<24>AF</24>，这种作用依赖于完好的自主神经张力，而<35>地尔硫卓</35>不具有此类作用。", "revised": true}
{"doc_key": "2790457", "sentences": [["Chronic", "carbamazepine", "inhibits", "the", "development", "of", "local", "anesthetic", "seizures", "kindled", "by", "cocaine", "and", "lidocaine", ".", "The", "effects", "of", "carbamazepine", "(", "CBZ", ")", "treatment", "on", "local", "anesthetic", "-", "kindled", "seizures", "and", "lethality", "were", "evaluated", "in", "different", "stages", "of", "the", "kindling", "process", "and", "under", "different", "methods", "of", "CBZ", "administration", ".", "Chronic", "oral", "CBZ", "inhibited", "the", "development", "of", "both", "lidocaine", "-", "and", "cocaine", "-", "induced", "seizures", ",", "but", "had", "little", "effect", "on", "the", "fully", "developed", "local", "anesthetic", "seizures", ".", "Chronic", "CBZ", "also", "decreased", "the", "incidence", "of", "seizure", "-", "related", "mortality", "in", "the", "cocaine", "-", "injected", "rats", ".", "Acute", "CBZ", "over", "a", "range", "of", "doses", "(", "15", "-", "50", "mg", "/", "kg", ")", "had", "no", "effect", "on", "completed", "lidocaine", "-", "kindled", "or", "acute", "cocaine", "-", "induced", "seizures", ".", "Repeated", "i", ".", "p", ".", "injection", "of", "CBZ", "(", "15", "mg", "/", "kg", ")", "also", "was", "without", "effect", "on", "the", "development", "of", "lidocaine", "-", "or", "cocaine", "-", "kindled", "seizures", ".", "The", "differential", "effects", "of", "CBZ", "depending", "upon", "stage", "of", "seizure", "development", "suggest", "that", "distinct", "mechanisms", "underlie", "the", "development", "versus", "maintenance", "of", "local", "anesthetic", "-", "kindled", "seizures", ".", "The", "effectiveness", "of", "chronic", "but", "not", "repeated", ",", "intermittent", "injections", "of", "CBZ", "suggests", "that", "different", "biochemical", "consequences", "result", "from", "the", "different", "treatment", "regimens", ".", "The", "possible", "utility", "of", "chronic", "CBZ", "in", "preventing", "the", "development", "of", "toxic", "side", "effects", "in", "human", "cocaine", "users", "is", "suggested", "by", "these", "data", ",", "but", "remains", "to", "be", "directly", "evaluated", "."]], "ner": [[[11, 11, "Chemical"], [59, 59, "Chemical"], [89, 89, "Chemical"], [119, 119, "Chemical"], [149, 149, "Chemical"], [221, 221, "Chemical"], [8, 8, "Disease"], [28, 28, "Disease"], [62, 62, "Disease"], [74, 74, "Disease"], [83, 83, "Disease"], [122, 122, "Disease"], [152, 152, "Disease"], [163, 163, "Disease"], [179, 179, "Disease"], [13, 13, "Chemical"], [56, 56, "Chemical"], [114, 114, "Chemical"], [146, 146, "Chemical"], [1, 1, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [45, 45, "Chemical"], [50, 50, "Chemical"], [77, 77, "Chemical"], [95, 95, "Chemical"], [131, 131, "Chemical"], [158, 158, "Chemical"], [192, 192, "Chemical"], [210, 210, "Chemical"]]], "relations": [[[11, 11, 8, 8, "CID"], [11, 11, 28, 28, "CID"], [11, 11, 62, 62, "CID"], [11, 11, 74, 74, "CID"], [11, 11, 83, 83, "CID"], [11, 11, 122, 122, "CID"], [11, 11, 152, 152, "CID"], [11, 11, 163, 163, "CID"], [11, 11, 179, 179, "CID"], [59, 59, 8, 8, "CID"], [59, 59, 28, 28, "CID"], [59, 59, 62, 62, "CID"], [59, 59, 74, 74, "CID"], [59, 59, 83, 83, "CID"], [59, 59, 122, 122, "CID"], [59, 59, 152, 152, "CID"], [59, 59, 163, 163, "CID"], [59, 59, 179, 179, "CID"], [89, 89, 8, 8, "CID"], [89, 89, 28, 28, "CID"], [89, 89, 62, 62, "CID"], [89, 89, 74, 74, "CID"], [89, 89, 83, 83, "CID"], [89, 89, 122, 122, "CID"], [89, 89, 152, 152, "CID"], [89, 89, 163, 163, "CID"], [89, 89, 179, 179, "CID"], [119, 119, 8, 8, "CID"], [119, 119, 28, 28, "CID"], [119, 119, 62, 62, "CID"], [119, 119, 74, 74, "CID"], [119, 119, 83, 83, "CID"], [119, 119, 122, 122, "CID"], [119, 119, 152, 152, "CID"], [119, 119, 163, 163, "CID"], [119, 119, 179, 179, "CID"], [149, 149, 8, 8, "CID"], [149, 149, 28, 28, "CID"], [149, 149, 62, 62, "CID"], [149, 149, 74, 74, "CID"], [149, 149, 83, 83, "CID"], [149, 149, 122, 122, "CID"], [149, 149, 152, 152, "CID"], [149, 149, 163, 163, "CID"], [149, 149, 179, 179, "CID"], [221, 221, 8, 8, "CID"], [221, 221, 28, 28, "CID"], [221, 221, 62, 62, "CID"], [221, 221, 74, 74, "CID"], [221, 221, 83, 83, "CID"], [221, 221, 122, 122, "CID"], [221, 221, 152, 152, "CID"], [221, 221, 163, 163, "CID"], [221, 221, 179, 179, "CID"], [13, 13, 8, 8, "CID"], [13, 13, 28, 28, "CID"], [13, 13, 62, 62, "CID"], [13, 13, 74, 74, "CID"], [13, 13, 83, 83, "CID"], [13, 13, 122, 122, "CID"], [13, 13, 152, 152, "CID"], [13, 13, 163, 163, "CID"], [13, 13, 179, 179, "CID"], [56, 56, 8, 8, "CID"], [56, 56, 28, 28, "CID"], [56, 56, 62, 62, "CID"], [56, 56, 74, 74, "CID"], [56, 56, 83, 83, "CID"], [56, 56, 122, 122, "CID"], [56, 56, 152, 152, "CID"], [56, 56, 163, 163, "CID"], [56, 56, 179, 179, "CID"], [114, 114, 8, 8, "CID"], [114, 114, 28, 28, "CID"], [114, 114, 62, 62, "CID"], [114, 114, 74, 74, "CID"], [114, 114, 83, 83, "CID"], [114, 114, 122, 122, "CID"], [114, 114, 152, 152, "CID"], [114, 114, 163, 163, "CID"], [114, 114, 179, 179, "CID"], [146, 146, 8, 8, "CID"], [146, 146, 28, 28, "CID"], [146, 146, 62, 62, "CID"], [146, 146, 74, 74, "CID"], [146, 146, 83, 83, "CID"], [146, 146, 122, 122, "CID"], [146, 146, 152, 152, "CID"], [146, 146, 163, 163, "CID"], [146, 146, 179, 179, "CID"]]], "clusters": [], "translated": "慢性<19>卡马西平</19>抑制由<0>可卡因</0>和<15>利多卡因</15>引起的局部麻醉剂<6>癫痫发作</6>的发展。评估了<20>卡马西平</20>（<21>CBZ</21>）治疗局部麻醉药引发的<7>癫痫发作</7>和致死率在引发过程的不同阶段和不同方法下的影响<22>CBZ</22>管理。慢性口服<23>CBZ</23>抑制<16>利多卡因</16>-和<1>可卡因</1>-诱发的<8>癫痫发作</8>的发展，但对充分发展的局部麻醉剂<9>癫痫发作</9>。慢性<24>CBZ</24>还降低了<2>可卡因</2>注射大鼠的<10>癫痫发作</10>相关死亡率。剂量范围（15-50mg/kg）的急性<25>CBZ</25>对完全点燃的<17>利多卡因</17>或急性<3>可卡因</3>-诱导的<11>癫痫发作</11>没有影响。重复i.p.注射<26>CBZ</26>（15mg/kg）对<18>利多卡因</18>或<4>可卡因</4>点燃的<12>癫痫发作</12>的发展也没有影响。<27>CBZ</27>的不同作用取决于<13>癫痫发作</13>的发展阶段，这表明不同的机制是局部麻醉剂引起的<14>癫痫发作</14>发展与维持的基础。长期但不重复、间歇注射<28>CBZ</28>的有效性表明，不同的治疗方案会导致不同的生化结果。这些数据表明慢性<29>CBZ</29>在预防人类<5>可卡因</5>使用者毒副作用发展方面的可能效用，但仍有待直接评估。", "revised": true}
{"doc_key": "16820346", "sentences": [["Atorvastatin", "prevented", "and", "reversed", "dexamethasone", "-", "induced", "hypertension", "in", "the", "rat", ".", "To", "assess", "the", "antioxidant", "effects", "of", "atorvastatin", "(", "atorva", ")", "on", "dexamethasone", "(", "dex", ")", "-", "induced", "hypertension", ",", "60", "male", "Sprague", "-", "Dawley", "rats", "were", "treated", "with", "atorva", "30", "mg", "/", "kg", "/", "day", "or", "tap", "water", "for", "15", "days", ".", "Dex", "increased", "systolic", "blood", "pressure", "(", "SBP", ")", "from", "109", "+", "/", "-", "1", ".", "8", "to", "135", "+", "/", "-", "0", ".", "6", "mmHg", "and", "plasma", "superoxide", "(", "5711", "+", "/", "-", "284", ".", "9", "saline", ",", "7931", "+", "/", "-", "392", ".", "8", "U", "/", "ml", "dex", ",", "P", "<", "0", ".", "001", ")", ".", "In", "this", "prevention", "study", ",", "SBP", "in", "the", "atorva", "+", "dex", "group", "was", "increased", "from", "115", "+", "/", "-", "0", ".", "4", "to", "124", "+", "/", "-", "1", ".", "5", "mmHg", ",", "but", "this", "was", "significantly", "lower", "than", "in", "the", "dex", "-", "only", "group", "(", "P", "'", "<", "0", ".", "05", ")", ".", "Atorva", "reversed", "dex", "-", "induced", "hypertension", "(", "129", "+", "/", "-", "0", ".", "6", "mmHg", ",", "vs", ".", "135", "+", "/", "-", "0", ".", "6", "mmHg", "P", "'", "<", "0", ".", "05", ")", "and", "decreased", "plasma", "superoxide", "(", "7931", "+", "/", "-", "392", ".", "8", "dex", ",", "1187", "+", "/", "-", "441", ".", "2", "atorva", "+", "dex", ",", "P", "<", "0", ".", "0001", ")", ".", "Plasma", "nitrate", "/", "nitrite", "(", "NOx", ")", "was", "decreased", "in", "dex", "-", "treated", "rats", "compared", "to", "saline", "-", "treated", "rats", "(", "11", ".", "2", "+", "/", "-", "1", ".", "08", "microm", ",", "15", ".", "3", "+", "/", "-", "1", ".", "17", "microm", ",", "respectively", ",", "P", "<", "0", ".", "05", ")", ".", "Atorva", "affected", "neither", "plasma", "NOx", "nor", "thymus", "weight", ".", "Thus", ",", "atorvastatin", "prevented", "and", "reversed", "dexamethasone", "-", "induced", "hypertension", "in", "the", "rat", "."]], "ner": [[[4, 4, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [54, 54, "Chemical"], [102, 102, "Chemical"], [121, 121, "Chemical"], [151, 151, "Chemical"], [166, 166, "Chemical"], [209, 209, "Chemical"], [220, 220, "Chemical"], [239, 239, "Chemical"], [296, 296, "Chemical"], [7, 7, "Disease"], [29, 29, "Disease"], [169, 169, "Disease"], [299, 299, "Disease"], [0, 0, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [40, 40, "Chemical"], [119, 119, "Chemical"], [164, 164, "Chemical"], [218, 218, "Chemical"], [281, 281, "Chemical"], [292, 292, "Chemical"], [81, 81, "Chemical"], [200, 200, "Chemical"], [230, 230, "Chemical"], [232, 232, "Chemical"]]], "relations": [[[4, 4, 7, 7, "CID"], [4, 4, 29, 29, "CID"], [4, 4, 169, 169, "CID"], [4, 4, 299, 299, "CID"], [23, 23, 7, 7, "CID"], [23, 23, 29, 29, "CID"], [23, 23, 169, 169, "CID"], [23, 23, 299, 299, "CID"], [25, 25, 7, 7, "CID"], [25, 25, 29, 29, "CID"], [25, 25, 169, 169, "CID"], [25, 25, 299, 299, "CID"], [54, 54, 7, 7, "CID"], [54, 54, 29, 29, "CID"], [54, 54, 169, 169, "CID"], [54, 54, 299, 299, "CID"], [102, 102, 7, 7, "CID"], [102, 102, 29, 29, "CID"], [102, 102, 169, 169, "CID"], [102, 102, 299, 299, "CID"], [121, 121, 7, 7, "CID"], [121, 121, 29, 29, "CID"], [121, 121, 169, 169, "CID"], [121, 121, 299, 299, "CID"], [151, 151, 7, 7, "CID"], [151, 151, 29, 29, "CID"], [151, 151, 169, 169, "CID"], [151, 151, 299, 299, "CID"], [166, 166, 7, 7, "CID"], [166, 166, 29, 29, "CID"], [166, 166, 169, 169, "CID"], [166, 166, 299, 299, "CID"], [209, 209, 7, 7, "CID"], [209, 209, 29, 29, "CID"], [209, 209, 169, 169, "CID"], [209, 209, 299, 299, "CID"], [220, 220, 7, 7, "CID"], [220, 220, 29, 29, "CID"], [220, 220, 169, 169, "CID"], [220, 220, 299, 299, "CID"], [239, 239, 7, 7, "CID"], [239, 239, 29, 29, "CID"], [239, 239, 169, 169, "CID"], [239, 239, 299, 299, "CID"], [296, 296, 7, 7, "CID"], [296, 296, 29, 29, "CID"], [296, 296, 169, 169, "CID"], [296, 296, 299, 299, "CID"]]], "clusters": [], "translated": "<16>阿托伐他汀</16>预防和逆转<0>地塞米松</0>诱导的大鼠<12>高血压</12>。评估<17>阿托伐他汀</17>（<18>atorva</18>）对<1>地塞米松</1>（<2>dex</2>）诱导的<13>高血压</13>，60只雄性Sprague-Dawley大鼠用<19>atorva</19> 30mg/kg/天或自来水处理15天。 <3>dex</3>使收缩压(SBP) 从109 +/- 1增加。8至135+/-0.6mmHg和血浆<25>超氧化物</25>（5711+/-284.9生理盐水，7931+/-392.8U/ml <4>dex</4>，P<0.001）。在这项预防研究中，<20>atorva</20>+<5>dex</5>组的SBP从115+/-0.4增加。4至124+/-1.5mmHg，但这显着低于仅<6>dex</6>组(P'<0.05)。<21>atorva</21>逆转<7>dex</7>诱发的<14>高血压</14>（129+/-0.6mmHg，对比135+/-0.6mmHg P'<0.05）和减少血浆<26>超氧化物</26>（7931+/-392.8<8>dex</8>，1187+/-441.2<22>atorva</22>+<9>dex</9>，P<0.0001）。血浆<27>硝酸盐</27>/<28>亚硝酸盐</28>(NOx) 在<10>dex</10>处理的大鼠中比盐水处理的大鼠减少(11.2+/-1.08微米，15.3+/-1.17微米，分别，P<0.05)。<23>atorva</23>既不影响血浆NOx也不影响胸腺重量。因此，<24>阿托伐他汀</24>可预防和逆转<11>地塞米松</11>诱导的大鼠<15>高血压</15>。", "revised": true}
{"doc_key": "7647582", "sentences": [["Halogenated", "anesthetics", "form", "liver", "adducts", "and", "antigens", "that", "cross", "-", "react", "with", "halothane", "-", "induced", "antibodies", ".", "Two", "halogenated", "anesthetics", ",", "enflurane", "and", "isoflurane", ",", "have", "been", "associated", "with", "an", "allergic", "-", "type", "hepatic", "injury", "both", "alone", "and", "following", "previous", "exposure", "to", "halothane", ".", "Halothane", "hepatitis", "appears", "to", "involve", "an", "aberrant", "immune", "response", ".", "An", "antibody", "response", "to", "a", "protein", "-", "bound", "biotransformation", "product", "(", "trifluoroacetyl", "adduct", ")", "has", "been", "detected", "on", "halothane", "hepatitis", "patients", ".", "This", "study", "was", "performed", "to", "determine", "cross", "-", "reactivity", "between", "enflurane", "and", "isoflurane", "with", "the", "hypersensitivity", "induced", "by", "halothane", ".", "The", "subcellular", "and", "lobular", "production", "of", "hepatic", "neoantigens", "recognized", "by", "halothane", "-", "induced", "antibodies", "following", "enflurane", "and", "isoflurane", ",", "and", "the", "biochemical", "nature", "of", "these", "neoantigens", "was", "investigated", "in", "two", "animal", "models", ".", "Enflurane", "administration", "resulted", "in", "neoantigens", "detected", "in", "both", "the", "microsomal", "and", "cytosolic", "fraction", "of", "liver", "homogenates", "and", "in", "the", "centrilobular", "region", "of", "the", "liver", ".", "In", "the", "same", "liver", ",", "biochemical", "analysis", "detected", "fluorinated", "liver", "adducts", "that", "were", "up", "to", "20", "-", "fold", "greater", "in", "guinea", "pigs", "than", "in", "rats", ".", "This", "supports", "and", "extends", "previous", "evidence", "for", "a", "mechanism", "by", "which", "enflurane", "and", "/", "or", "isoflurane", "could", "produce", "a", "hypersensitivity", "condition", "similar", "to", "that", "of", "halothane", "hepatitis", "either", "alone", "or", "subsequent", "to", "halothane", "administration", ".", "The", "guinea", "pig", "would", "appear", "to", "be", "a", "useful", "model", "for", "further", "investigations", "of", "the", "immunological", "response", "to", "these", "antigens", "."]], "ner": [[[12, 12, "Chemical"], [42, 42, "Chemical"], [44, 44, "Chemical"], [72, 72, "Chemical"], [94, 94, "Chemical"], [106, 106, "Chemical"], [205, 205, "Chemical"], [212, 212, "Chemical"], [33, 34, "Disease"], [45, 45, "Disease"], [73, 73, "Disease"], [206, 206, "Disease"], [21, 21, "Chemical"], [86, 86, "Chemical"], [111, 111, "Chemical"], [129, 129, "Chemical"], [191, 191, "Chemical"], [23, 23, "Chemical"], [88, 88, "Chemical"], [113, 113, "Chemical"], [195, 195, "Chemical"], [91, 91, "Disease"], [199, 199, "Disease"], [65, 65, "Chemical"]]], "relations": [[[12, 12, 33, 34, "CID"], [12, 12, 45, 45, "CID"], [12, 12, 73, 73, "CID"], [12, 12, 206, 206, "CID"], [42, 42, 33, 34, "CID"], [42, 42, 45, 45, "CID"], [42, 42, 73, 73, "CID"], [42, 42, 206, 206, "CID"], [44, 44, 33, 34, "CID"], [44, 44, 45, 45, "CID"], [44, 44, 73, 73, "CID"], [44, 44, 206, 206, "CID"], [72, 72, 33, 34, "CID"], [72, 72, 45, 45, "CID"], [72, 72, 73, 73, "CID"], [72, 72, 206, 206, "CID"], [94, 94, 33, 34, "CID"], [94, 94, 45, 45, "CID"], [94, 94, 73, 73, "CID"], [94, 94, 206, 206, "CID"], [106, 106, 33, 34, "CID"], [106, 106, 45, 45, "CID"], [106, 106, 73, 73, "CID"], [106, 106, 206, 206, "CID"], [205, 205, 33, 34, "CID"], [205, 205, 45, 45, "CID"], [205, 205, 73, 73, "CID"], [205, 205, 206, 206, "CID"], [212, 212, 33, 34, "CID"], [212, 212, 45, 45, "CID"], [212, 212, 73, 73, "CID"], [212, 212, 206, 206, "CID"], [21, 21, 33, 34, "CID"], [21, 21, 45, 45, "CID"], [21, 21, 73, 73, "CID"], [21, 21, 206, 206, "CID"], [86, 86, 33, 34, "CID"], [86, 86, 45, 45, "CID"], [86, 86, 73, 73, "CID"], [86, 86, 206, 206, "CID"], [111, 111, 33, 34, "CID"], [111, 111, 45, 45, "CID"], [111, 111, 73, 73, "CID"], [111, 111, 206, 206, "CID"], [129, 129, 33, 34, "CID"], [129, 129, 45, 45, "CID"], [129, 129, 73, 73, "CID"], [129, 129, 206, 206, "CID"], [191, 191, 33, 34, "CID"], [191, 191, 45, 45, "CID"], [191, 191, 73, 73, "CID"], [191, 191, 206, 206, "CID"], [23, 23, 33, 34, "CID"], [23, 23, 45, 45, "CID"], [23, 23, 73, 73, "CID"], [23, 23, 206, 206, "CID"], [88, 88, 33, 34, "CID"], [88, 88, 45, 45, "CID"], [88, 88, 73, 73, "CID"], [88, 88, 206, 206, "CID"], [113, 113, 33, 34, "CID"], [113, 113, 45, 45, "CID"], [113, 113, 73, 73, "CID"], [113, 113, 206, 206, "CID"], [195, 195, 33, 34, "CID"], [195, 195, 45, 45, "CID"], [195, 195, 73, 73, "CID"], [195, 195, 206, 206, "CID"]]], "clusters": [], "translated": "卤化麻醉剂形成肝加合物和与<0>氟烷</0>诱导的抗体发生交叉反应的抗原。两种卤化麻醉剂，<12>恩氟烷</12>和<17>异氟烷</17>，与过敏型<8>肝损伤</8>有关，无论是单独使用还是在之前暴露于<1>氟烷</1>后。<2>氟烷</2><9>肝炎</9>似乎与异常的免疫反应有关。已在<3>氟烷</3><10>肝炎</10>患者身上检测到对蛋白质结合生物转化产物（<23>三氟乙酰</23> 加合物）的抗体反应。本研究旨在确定<13>恩氟烷</13>和<18>异氟烷</18>与<4>氟烷</4>引起的<21>超敏反应</21>之间的交叉反应。在<14>恩氟烷</14>和<19>异氟烷</19>后，<5>氟烷</5>诱导的抗体识别肝脏新抗原的亚细胞和小叶产生，并研究了这些新抗原的生化性质，两个动物模型。给予<15>恩氟烷</15>后，肝脏匀浆的微粒体和胞质部分以及肝脏的小叶中心区域都检测到新抗原。在同一个肝脏中，生化分析检测到氟化肝加合物在豚鼠中比在大鼠中高出20倍。这支持并扩展了先前关于<16>恩氟烷</16>和/或<20>异氟烷</20>可能产生类似于<6>氟烷</6><11>肝炎</11>单独或在<7>氟烷</7>给药后产生的<22>超敏反应</22>的机制的证据。豚鼠似乎是进一步研究对这些抗原的免疫反应的有用模型。", "revised": true}
{"doc_key": "11079278", "sentences": [["Effect", "of", "intravenous", "metoprolol", "or", "intravenous", "metoprolol", "plus", "glucagon", "on", "dobutamine", "-", "induced", "myocardial", "ischemia", ".", "STUDY", "OBJECTIVE", ":", "To", "determine", "the", "effect", "of", "metoprolol", "on", "dobutamine", "stress", "testing", "with", "technetium", "-", "99m", "sestamibi", "single", "-", "photon", "emission", "computed", "tomography", "imaging", "and", "ST", "-", "segment", "monitoring", ",", "and", "to", "assess", "the", "impact", "of", "intravenous", "glucagon", "on", "metoprolol", "'s", "effects", ".", "DESIGN", ":", "Randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", ".", "SETTING", ":", "Community", "hospital", ".", "PATIENTS", ":", "Twenty", "-", "two", "patients", "with", "known", "reversible", "perfusion", "defects", ".", "INTERVENTION", ":", "Patients", "underwent", "dobutamine", "stress", "tests", "per", "standard", "protocol", ".", "Before", "dobutamine", "was", "begun", ",", "no", "therapy", "was", "given", "during", "the", "first", "visit", ",", "and", "patients", "were", "randomized", "on", "subsequent", "visits", "to", "receive", "metoprolol", "or", "metoprolol", "plus", "glucagon", "1", "mg", ".", "Metoprolol", "was", "dosed", "to", "achieve", "a", "resting", "predobutamine", "heart", "rate", "below", "65", "beats", "/", "minute", "or", "a", "total", "intravenous", "dose", "of", "20", "mg", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "Metoprolol", "reduced", "maximum", "heart", "rate", "31", "%", ",", "summed", "stress", "scores", "29", "%", ",", "and", "summed", "difference", "scores", "43", "%", "versus", "control", ".", "Metoprolol", "plus", "glucagon", "also", "reduced", "the", "maximum", "heart", "rate", "29", "%", "versus", "control", ".", "Summed", "stress", "and", "summed", "difference", "scores", "were", "not", "significantly", "reduced", ",", "although", "they", "were", "18", "%", "and", "30", "%", "lower", ",", "respectively", ",", "than", "control", ".", "No", "significant", "differences", "were", "found", "in", "any", "parameter", "between", "metoprolol", "and", "metoprolol", "-", "glucagon", ".", "CONCLUSION", ":", "During", "dobutamine", "stress", "testing", ",", "metoprolol", "attenuates", "or", "eliminates", "evidence", "of", "myocardial", "ischemia", ".", "Glucagon", "1", "mg", ",", "although", "somewhat", "effective", ",", "does", "not", "correct", "this", "effect", "to", "the", "extent", "that", "it", "can", "be", "administered", "clinically", "."]], "ner": [[[10, 10, "Chemical"], [26, 26, "Chemical"], [94, 94, "Chemical"], [102, 102, "Chemical"], [242, 242, "Chemical"], [13, 14, "Disease"], [252, 253, "Disease"], [3, 3, "Chemical"], [6, 6, "Chemical"], [24, 24, "Chemical"], [56, 56, "Chemical"], [124, 124, "Chemical"], [126, 126, "Chemical"], [132, 132, "Chemical"], [161, 161, "Chemical"], [184, 184, "Chemical"], [233, 233, "Chemical"], [235, 235, "Chemical"], [246, 246, "Chemical"], [30, 33, "Chemical"]]], "relations": [[[10, 10, 13, 14, "CID"], [10, 10, 252, 253, "CID"], [26, 26, 13, 14, "CID"], [26, 26, 252, 253, "CID"], [94, 94, 13, 14, "CID"], [94, 94, 252, 253, "CID"], [102, 102, 13, 14, "CID"], [102, 102, 252, 253, "CID"], [242, 242, 13, 14, "CID"], [242, 242, 252, 253, "CID"]]], "clusters": [], "translated": "静脉注射<7>美托洛尔</7> 或静脉注射<8>美托洛尔</8> 加胰高血糖素对<0>多巴酚丁胺</0> 引起的<5>心肌缺血</5> 的影响。研究目的: 确定<9>美托洛尔</9> 对 <1>多巴酚丁胺</1> 压力测试的影响，使用<19>锝 - 99m sestamibi</19>单光子发射计算机断层扫描成像和 ST 段监测，并评估静脉注射胰高血糖素对<10>美托洛尔</10> 的影响。设计：随机、双盲、安慰剂对照试验。地点：社区医院。患者：22 名已知可逆性灌注缺陷的患者。干预：根据标准方案，患者接受了<2>多巴酚丁胺</2> 压力测试。在<3>多巴酚丁胺</3> 开始之前，第一次就诊期间未给予治疗，患者在随后的就诊中随机接受<11>美托洛尔</11> 或<12>美托洛尔</12> 加胰高血糖素 1 毫克。<13>美托洛尔</13> 的给药是为了使静息前多巴酚丁胺心率低于 65 次/分钟或总静脉剂量为 20 mg。测量和主要结果：<14>美托洛尔</14> 减少最高心率 31 %，和对照相比，压力总分降低了 29%，差异总分降低了 43%。 <15>美托洛尔</15> 加上胰高血糖素也减少了最高心率 29%。尽管压力总和和差异总分分别比对照组低 18% 和 30%，但没有显着降低。在<16>美托洛尔</16> 和<17>美托洛尔</17>-胰高血糖素之间没有发现任何参数的显着差异。结论：在<4>多巴酚丁胺</4> 负荷试验中，<18>美托洛尔</18> 减弱或消除了 <6>心肌缺血</6> 的证据。虽然胰高血糖素 1 mg 有一定效果，但不能将其临床使用的效果纠正到足够的程度。", "revised": true}
{"doc_key": "11243580", "sentences": [["The", "role", "of", "nitrergic", "system", "in", "lidocaine", "-", "induced", "convulsion", "in", "the", "mouse", ".", "The", "effects", "of", "N", "-", "nitro", "-", "L", "-", "arginine", "-", "methyl", "ester", "(", "L", "-", "NAME", ")", "a", "nitric", "oxide", "(", "NO", ")", "synthase", "inhibitor", "and", "L", "-", "arginine", ",", "a", "NO", "precursor", ",", "were", "investigated", "on", "lidocaine", "-", "induced", "convulsions", ".", "In", "the", "first", "experiment", ",", "four", "groups", "of", "mice", "received", "physiological", "saline", "(", "0", ".", "9", "%", ")", ",", "L", "-", "arginine", "(", "300", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ",", "L", "-", "NAME", "(", "100", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "and", "diazepam", "(", "2", "mg", "/", "kg", ")", ",", "respectively", ".", "Thirty", "minutes", "after", "these", "injections", ",", "all", "mice", "received", "lidocaine", "(", "50", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "In", "the", "second", "experiment", ",", "four", "groups", "of", "mice", "received", "similar", "treatment", "in", "the", "first", "experiment", ",", "and", "30", "min", "after", "these", "injections", ",", "all", "mice", "received", "a", "higher", "dose", "of", "lidocaine", "(", "80", "mg", "/", "kg", ")", ".", "L", "-", "NAME", "(", "100", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "and", "diazepam", "(", "2", "mg", "/", "kg", ")", "significantly", "decreased", "the", "incidence", "of", "lidocaine", "(", "50", "mg", "/", "kg", ")", "-", "induced", "convulsions", ".", "In", "contrast", ",", "the", "L", "-", "arginine", "treatment", "increased", "the", "incidence", "of", "lidocaine", "(", "80", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "-", "induced", "convulsions", "significantly", ".", "These", "results", "may", "suggest", "that", "NO", "is", "a", "proconvulsant", "mediator", "in", "lidocaine", "-", "induced", "convulsions", "."]], "ner": [[[6, 6, "Chemical"], [52, 52, "Chemical"], [125, 125, "Chemical"], [169, 169, "Chemical"], [204, 204, "Chemical"], [227, 227, "Chemical"], [255, 255, "Chemical"], [9, 9, "Disease"], [55, 55, "Disease"], [213, 213, "Disease"], [241, 241, "Disease"], [258, 258, "Disease"], [17, 26, "Chemical"], [28, 30, "Chemical"], [91, 93, "Chemical"], [177, 179, "Chemical"], [33, 34, "Chemical"], [36, 36, "Chemical"], [46, 46, "Chemical"], [249, 249, "Chemical"], [41, 43, "Chemical"], [76, 78, "Chemical"], [219, 221, "Chemical"], [106, 106, "Chemical"], [192, 192, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 55, 55, "CID"], [6, 6, 213, 213, "CID"], [6, 6, 241, 241, "CID"], [6, 6, 258, 258, "CID"], [52, 52, 9, 9, "CID"], [52, 52, 55, 55, "CID"], [52, 52, 213, 213, "CID"], [52, 52, 241, 241, "CID"], [52, 52, 258, 258, "CID"], [125, 125, 9, 9, "CID"], [125, 125, 55, 55, "CID"], [125, 125, 213, 213, "CID"], [125, 125, 241, 241, "CID"], [125, 125, 258, 258, "CID"], [169, 169, 9, 9, "CID"], [169, 169, 55, 55, "CID"], [169, 169, 213, 213, "CID"], [169, 169, 241, 241, "CID"], [169, 169, 258, 258, "CID"], [204, 204, 9, 9, "CID"], [204, 204, 55, 55, "CID"], [204, 204, 213, 213, "CID"], [204, 204, 241, 241, "CID"], [204, 204, 258, 258, "CID"], [227, 227, 9, 9, "CID"], [227, 227, 55, 55, "CID"], [227, 227, 213, 213, "CID"], [227, 227, 241, 241, "CID"], [227, 227, 258, 258, "CID"], [255, 255, 9, 9, "CID"], [255, 255, 55, 55, "CID"], [255, 255, 213, 213, "CID"], [255, 255, 241, 241, "CID"], [255, 255, 258, 258, "CID"]]], "clusters": [], "translated": "氮能系统在<0>利多卡因</0>诱发小鼠<7>惊厥</7>中的作用。 <12>N-硝基-L-精氨酸-甲酯</12>（<13>L-NAME</13>）——一种<16>一氧化氮</16>（<17>NO</17>）合成酶抑制剂和<20>L-精氨酸</20>——一种<18>NO</18>前体，被用来研究<1> 利多卡因</1>诱导的<8>惊厥</8>。在第一个实验中，四组小鼠分别注射生理盐水（0.9%）、<21>L-精氨酸</21>（300mg/kg,i.p.）、<14>L-NAME</14> (100mg/kg,i.p.) 和 <23>地西泮</23>（2mg/kg）。注射后30分钟，所有小鼠均接受<2>利多卡因</2>（50mg/kg,i.p）。在第二个实验中，四组小鼠接受与第一个实验相似的处理，注射后30分钟，所有小鼠接受更高剂量的 <3>利多卡因</3>（80mg/kg）。 <15>L-NAME</15> (100mg/kg,i.p.) 和 <24>地西泮</24> (2mg/kg)显着降低<4>利多卡因</4>（50mg/kg）-诱发<9>抽搐</9>的发生率。相比之下，<22>L-精氨酸</22>治疗显着增加了<5>利多卡因</5>（80mg/kg，i.p.）诱发的<10>抽搐</10>的发生率。这些结果可能表明，<19>NO</19>是<6>利多卡因</6>诱导的<11>惊厥</11>中的促惊厥介质。", "revised": true}
{"doc_key": "10533019", "sentences": [["Rapid", "reversal", "of", "life", "-", "threatening", "diltiazem", "-", "induced", "tetany", "with", "calcium", "chloride", ".", "We", "describe", "a", "patient", "who", "developed", "tetany", "with", "sudden", "respiratory", "arrest", "after", "the", "infusion", "of", "intravenous", "diltiazem", ".", "The", "administration", "of", "calcium", "chloride", "rapidly", "resolved", "the", "patient", "'s", "tetany", "with", "prompt", "recovery", "of", "respiratory", "function", ",", "averting", "the", "need", "for", "more", "aggressive", "airway", "management", "and", "ventilatory", "support", ".", "The", "emergency", "physician", "should", "be", "aware", "that", "life", "-", "threatening", "tetany", "may", "accompany", "the", "administration", "of", "intravenous", "diltiazem", "and", "that", "calcium", "chloride", "may", "be", "a", "rapid", "and", "effective", "remedy", "."]], "ner": [[[6, 6, "Chemical"], [30, 30, "Chemical"], [79, 79, "Chemical"], [9, 9, "Disease"], [20, 20, "Disease"], [42, 42, "Disease"], [72, 72, "Disease"], [23, 24, "Disease"], [11, 12, "Chemical"], [35, 36, "Chemical"], [82, 83, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 20, 20, "CID"], [6, 6, 42, 42, "CID"], [6, 6, 72, 72, "CID"], [30, 30, 9, 9, "CID"], [30, 30, 20, 20, "CID"], [30, 30, 42, 42, "CID"], [30, 30, 72, 72, "CID"], [79, 79, 9, 9, "CID"], [79, 79, 20, 20, "CID"], [79, 79, 42, 42, "CID"], [79, 79, 72, 72, "CID"]]], "clusters": [], "translated": "用 <8> 氯化钙 </8> 快速逆转危及生命的<0>地尔硫卓</0>引起的<3>手足抽搐</3>。我们描述了一名患者，他在静脉输注<1>地尔硫卓</1>后出现<4>手足抽搐</4>，并突然出现<7>呼吸窘迫</7>。 <9>氯化钙</9>的给药迅速解决了患者的<5>手足抽搐症</5>，呼吸功能迅速恢复，避免了更积极的气道管理和通气支持的需要。急诊医师应该意识到，危及生命的<6>手足抽搐</6>可能伴随静脉注射<2>地尔硫卓</2>而<10>氯化钙</10>可能是一种快速有效的补救措施。", "revised": true}
{"doc_key": "8268147", "sentences": [["A", "case", "of", "polymyositis", "in", "a", "patient", "with", "primary", "biliary", "cirrhosis", "treated", "with", "D", "-", "penicillamine", ".", "Although", "D", "-", "penicillamine", "has", "been", "used", "for", "many", "rheumatologic", "diseases", ",", "toxicity", "limits", "its", "usefulness", "in", "many", "patients", ".", "Polymyositis", "/", "dermatomyositis", "can", "develop", "as", "one", "of", "the", "autoimmune", "complications", "of", "D", "-", "penicillamine", "treatment", ",", "but", "its", "exact", "pathogenesis", "remains", "unclear", ".", "We", "report", "a", "patient", "with", "primary", "biliary", "cirrhosis", ",", "who", "developed", "polymyositis", "while", "receiving", "D", "-", "penicillamine", "therapy", ".", "We", "described", "the", "special", "clinical", "course", "of", "the", "patient", ".", "Patients", "receiving", "D", "-", "penicillamine", "therapy", "should", "be", "followed", "carefully", "for", "the", "development", "of", "autoimmune", "complications", "like", "polymyositis", "/", "dermatomyositis", "."]], "ner": [[[13, 15, "Chemical"], [18, 20, "Chemical"], [49, 51, "Chemical"], [75, 77, "Chemical"], [92, 94, "Chemical"], [3, 3, "Disease"], [37, 37, "Disease"], [72, 72, "Disease"], [107, 107, "Disease"], [8, 10, "Disease"], [66, 68, "Disease"], [26, 27, "Disease"], [29, 29, "Disease"], [39, 39, "Disease"], [109, 109, "Disease"]]], "relations": [[[13, 15, 3, 3, "CID"], [13, 15, 37, 37, "CID"], [13, 15, 72, 72, "CID"], [13, 15, 107, 107, "CID"], [18, 20, 3, 3, "CID"], [18, 20, 37, 37, "CID"], [18, 20, 72, 72, "CID"], [18, 20, 107, 107, "CID"], [49, 51, 3, 3, "CID"], [49, 51, 37, 37, "CID"], [49, 51, 72, 72, "CID"], [49, 51, 107, 107, "CID"], [75, 77, 3, 3, "CID"], [75, 77, 37, 37, "CID"], [75, 77, 72, 72, "CID"], [75, 77, 107, 107, "CID"], [92, 94, 3, 3, "CID"], [92, 94, 37, 37, "CID"], [92, 94, 72, 72, "CID"], [92, 94, 107, 107, "CID"]]], "clusters": [], "translated": "用<0>D-青霉胺</0>治疗<9>原发性胆汁性肝硬化</9>的<5>多发性肌炎</5>一例。尽管<1>D-青霉胺</1>已用于许多<11>风湿病</11>，但<12>毒性</12>限制了它在许多患者中的应用。<6>多发性肌炎</6>/<13>皮肌炎</13>是<2>D-青霉胺</2>治疗的自身免疫性并发症之一，但其确切发病机制尚不清楚。我们报告了一位患有<10>原发性胆汁性肝硬化</10>的患者，该患者在接受<3>D-青霉胺</3>治疗期间发展为<7>多发性肌炎</7>。我们描述了患者的特殊临床过程。接受<4>D-青霉胺</4>治疗的患者应密切关注自身免疫并发症的发生，如<8>多发性肌炎</8>/<14>皮肌炎</14>。", "revised": true}
{"doc_key": "8251368", "sentences": [["Photodistributed", "nifedipine", "-", "induced", "facial", "telangiectasia", ".", "Five", "months", "after", "starting", "nifedipine", "(", "Adalat", ")", ",", "two", "patients", "developed", "photodistributed", "facial", "telangiectasia", ",", "which", "became", "more", "noticeable", "with", "time", ".", "Neither", "patient", "complained", "of", "photosensitivity", "or", "flushing", ".", "Both", "patients", "reported", "a", "significant", "cosmetic", "improvement", "after", "discontinuing", "the", "drug", ".", "One", "commenced", "the", "closely", "related", "drug", "amlodipine", "3", "years", "later", ",", "with", "recurrence", "of", "telangiectasia", ".", "The", "photodistribution", "of", "the", "telangiectasia", "suggests", "a", "significant", "drug", "/", "light", "interaction", "."]], "ner": [[[1, 1, "Chemical"], [11, 11, "Chemical"], [13, 13, "Chemical"], [5, 5, "Disease"], [21, 21, "Disease"], [64, 64, "Disease"], [70, 70, "Disease"], [56, 56, "Chemical"], [36, 36, "Disease"]]], "relations": [[[1, 1, 5, 5, "CID"], [1, 1, 21, 21, "CID"], [1, 1, 64, 64, "CID"], [1, 1, 70, 70, "CID"], [11, 11, 5, 5, "CID"], [11, 11, 21, 21, "CID"], [11, 11, 64, 64, "CID"], [11, 11, 70, 70, "CID"], [13, 13, 5, 5, "CID"], [13, 13, 21, 21, "CID"], [13, 13, 64, 64, "CID"], [13, 13, 70, 70, "CID"], [56, 56, 5, 5, "CID"], [56, 56, 21, 21, "CID"], [56, 56, 64, 64, "CID"], [56, 56, 70, 70, "CID"]]], "clusters": [], "translated": "光分布<0>硝苯地平</0>诱导的面部<3>毛细血管扩张</3>。在开始使用<1>硝苯地平</1> (<2>Adalat</2>)五个月后，两名患者出现光分布面部<4>毛细血管扩张</4>，随着时间的推移变得更加明显。没有患者抱怨光敏性或<8>潮红</8>。两名患者都报告说在停药后美容效果显着改善。一位患者开始使用密切相关的药物<7>氨氯地平</7>，3年后，<5>毛细血管扩张</5>复发。<6>毛细血管扩张</6>的光分布表明存在显着的药物/光相互作用。", "revised": true}
{"doc_key": "12851669", "sentences": [["Absolute", "and", "attributable", "risk", "of", "venous", "thromboembolism", "in", "women", "on", "combined", "cyproterone", "acetate", "and", "ethinylestradiol", ".", "OBJECTIVE", ":", "To", "achieve", "absolute", "risk", "estimates", "of", "venous", "thromboembolism", "(", "VTE", ")", "among", "women", "on", "cyproterone", "acetate", "plus", "ethinylestradiol", "(", "CPA", "/", "EE", ")", ",", "and", "among", "women", "on", "combined", "oral", "contraceptives", "(", "COCs", ")", ".", "METHODS", ":", "From", "the", "Danish", "National", "Register", "of", "Patients", "(", "NRP", ")", ",", "1996", "to", "1998", ",", "the", "records", "of", "1", ".", "1", "million", "Danish", "women", ",", "ages", "15", "to", "44", "years", ",", "were", "searched", "for", "evidence", "of", "VTE", ".", "COC", "use", "was", "ascertained", "through", "mailed", "questionnaires", ".", "Sales", "statistics", "of", "COCs", "and", "CPA", "/", "EE", "were", "provided", "through", "Danish", "Drug", "Statistics", ".", "RESULTS", ":", "During", "the", "time", "frame", "of", "the", "study", ",", "330", "women", "were", "found", "to", "have", "had", "VTE", "while", "on", "COCs", ".", "Of", "these", "women", ",", "67", "were", "on", "levonorgestrel", "-", "containing", "COCs", ".", "Eleven", "were", "on", "CPA", "/", "EE", ".", "The", "corresponding", "absolute", "risk", "of", "VTE", "was", "3", ".", "4", "(", "range", ",", "3", ".", "1", "-", "3", ".", "8", ")", "per", "10", "000", "women", "years", "among", "the", "women", "on", "COCs", ",", "4", ".", "2", "(", "range", ",", "3", ".", "2", "-", "5", ".", "2", ")", "per", "10", "000", "women", "years", "among", "women", "on", "levonorgestrel", "-", "containing", "COCs", ",", "and", "3", ".", "1", "(", "range", ",", "1", ".", "3", "-", "4", ".", "9", ")", "per", "10", "000", "women", "years", "among", "the", "women", "on", "CPA", "/", "EE", ".", "CONCLUSION", ":", "Our", "results", "suggest", "the", "absolute", "risk", "of", "VTE", "among", "Danish", "women", "on", "COCs", "is", "similar", "to", "that", "among", "women", "taking", "CPA", "/", "EE", "."]], "ner": [[[46, 48, "Chemical"], [50, 50, "Chemical"], [93, 93, "Chemical"], [104, 104, "Chemical"], [136, 136, "Chemical"], [148, 148, "Chemical"], [187, 187, "Chemical"], [214, 214, "Chemical"], [258, 258, "Chemical"], [5, 6, "Disease"], [24, 25, "Disease"], [27, 27, "Disease"], [91, 91, "Disease"], [133, 133, "Disease"], [162, 162, "Disease"], [253, 253, "Disease"], [11, 12, "Chemical"], [32, 33, "Chemical"], [37, 37, "Chemical"], [106, 106, "Chemical"], [153, 153, "Chemical"], [240, 240, "Chemical"], [266, 266, "Chemical"], [14, 14, "Chemical"], [35, 35, "Chemical"], [39, 39, "Chemical"], [108, 108, "Chemical"], [155, 155, "Chemical"], [242, 242, "Chemical"], [268, 268, "Chemical"], [145, 145, "Chemical"], [211, 211, "Chemical"]]], "relations": [[[46, 48, 5, 6, "CID"], [46, 48, 24, 25, "CID"], [46, 48, 27, 27, "CID"], [46, 48, 91, 91, "CID"], [46, 48, 133, 133, "CID"], [46, 48, 162, 162, "CID"], [46, 48, 253, 253, "CID"], [50, 50, 5, 6, "CID"], [50, 50, 24, 25, "CID"], [50, 50, 27, 27, "CID"], [50, 50, 91, 91, "CID"], [50, 50, 133, 133, "CID"], [50, 50, 162, 162, "CID"], [50, 50, 253, 253, "CID"], [93, 93, 5, 6, "CID"], [93, 93, 24, 25, "CID"], [93, 93, 27, 27, "CID"], [93, 93, 91, 91, "CID"], [93, 93, 133, 133, "CID"], [93, 93, 162, 162, "CID"], [93, 93, 253, 253, "CID"], [104, 104, 5, 6, "CID"], [104, 104, 24, 25, "CID"], [104, 104, 27, 27, "CID"], [104, 104, 91, 91, "CID"], [104, 104, 133, 133, "CID"], [104, 104, 162, 162, "CID"], [104, 104, 253, 253, "CID"], [136, 136, 5, 6, "CID"], [136, 136, 24, 25, "CID"], [136, 136, 27, 27, "CID"], [136, 136, 91, 91, "CID"], [136, 136, 133, 133, "CID"], [136, 136, 162, 162, "CID"], [136, 136, 253, 253, "CID"], [148, 148, 5, 6, "CID"], [148, 148, 24, 25, "CID"], [148, 148, 27, 27, "CID"], [148, 148, 91, 91, "CID"], [148, 148, 133, 133, "CID"], [148, 148, 162, 162, "CID"], [148, 148, 253, 253, "CID"], [187, 187, 5, 6, "CID"], [187, 187, 24, 25, "CID"], [187, 187, 27, 27, "CID"], [187, 187, 91, 91, "CID"], [187, 187, 133, 133, "CID"], [187, 187, 162, 162, "CID"], [187, 187, 253, 253, "CID"], [214, 214, 5, 6, "CID"], [214, 214, 24, 25, "CID"], [214, 214, 27, 27, "CID"], [214, 214, 91, 91, "CID"], [214, 214, 133, 133, "CID"], [214, 214, 162, 162, "CID"], [214, 214, 253, 253, "CID"], [258, 258, 5, 6, "CID"], [258, 258, 24, 25, "CID"], [258, 258, 27, 27, "CID"], [258, 258, 91, 91, "CID"], [258, 258, 133, 133, "CID"], [258, 258, 162, 162, "CID"], [258, 258, 253, 253, "CID"]]], "clusters": [], "translated": "服用<16>醋酸环丙孕酮</16>和<23>炔雌醇</23>的女性发生<9>静脉血栓栓塞</9>的绝对和归因风险。目的：在服用<17>醋酸环丙孕酮</17>加<24>炔雌醇</24>（<18>CPA</18>/<25>EE</25>）以及在服用<0>复方口服避孕药</0>（<1>COCs</1>）的女性中，达到<10>静脉血栓栓塞</10>（<11>VTE</11>）的绝对风险估计。方法：从丹麦国家患者登记处（NRP）1996至1998年的记录中，筛选15至44岁，共有1.1百万名丹麦女性，寻找<12>VTE</12>证据。通过邮寄问卷确认使用<2>COC</2>。<3>COCs</3>和<19>CPA</19>/<26>EE</26>的销售统计数据由丹麦药品统计提供。结果：在研究期间，330名使用<4>COCs</4>的女性发生了<13>VTE</13>，其中67名服用含有<30>左炔诺孕酮</30>的<5>COCs</5>，11名服用<20>CPA</20>/<27>EE</27>。相应的<14>VTE</14>绝对风险为3.4（范围3.1-3.8）每10,000名女性年服用<6>COCs</6>，4.2（范围3.2-5.2）每10,000名女性年服用<31>左炔诺孕酮</31>的女性-含有<7>COCs</7>，以及3.1（范围1.3-4.9）每10,000名女性年服用<21>CPA</21>/<28>EE</28>。结论：我们的结果表明，服用<8>COCs</8>的丹麦女性和服用<22>CPA</22>/<29>EE</29>的女性发生<15>VTE</15>的绝对风险相似。", "revised": true}
{"doc_key": "10414674", "sentences": [["Effects", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "on", "hemostasis", "in", "patients", "with", "aneurysmal", "subarachnoid", "hemorrhage", ".", "Platelet", "function", "is", "impaired", "by", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "with", "prominent", "anti", "-", "inflammatory", "properties", ".", "Their", "safety", "in", "patients", "undergoing", "intracranial", "surgery", "is", "under", "debate", ".", "Patients", "with", "aneurysmal", "subarachnoid", "hemorrhage", "(", "SAH", ")", "were", "randomized", "to", "receive", "either", "ketoprofen", ",", "100", "mg", ",", "three", "times", "a", "day", "(", "ketoprofen", "group", ",", "n", "=", "9", ")", "or", "a", "weak", "NSAID", ",", "acetaminophen", ",", "1", "g", ",", "three", "times", "a", "day", "(", "acetaminophen", "group", ",", "n", "=", "9", ")", "starting", "immediately", "after", "the", "diagnosis", "of", "aneurysmal", "SAH", ".", "Treatment", "was", "continued", "for", "3", "days", "postoperatively", ".", "Test", "blood", "samples", "were", "taken", "before", "treatment", "and", "surgery", "as", "well", "as", "on", "the", "first", ",", "third", ",", "and", "fifth", "postoperative", "mornings", ".", "Maximal", "platelet", "aggregation", "induced", "by", "6", "microM", "of", "adenosine", "diphosphate", "decreased", "after", "administration", "of", "ketoprofen", ".", "Aggregation", "was", "lower", "(", "P", "<", ".", "05", ")", "in", "the", "ketoprofen", "group", "than", "in", "the", "acetaminophen", "group", "just", "before", "surgery", "and", "on", "the", "third", "postoperative", "day", ".", "In", "contrast", ",", "maximal", "platelet", "aggregation", "increased", "in", "the", "acetaminophen", "group", "on", "the", "third", "postoperative", "day", "as", "compared", "with", "the", "pretreatment", "platelet", "aggregation", "results", "(", "P", "<", ".", "05", ")", ".", "One", "patient", "in", "the", "ketoprofen", "group", "developed", "a", "postoperative", "intracranial", "hematoma", ".", "Coagulation", "(", "prothrombin", "time", "[", "PT", "]", ",", "activated", "partial", "thromboplastin", "time", "[", "APPT", "]", ",", "fibrinogen", "concentration", ",", "and", "antithrombin", "III", "[", "AT", "III", "]", ")", "was", "comparable", "between", "the", "two", "groups", ".", "Ketoprofen", "but", "not", "acetaminophen", "impaired", "platelet", "function", "in", "patients", "with", "SAH", ".", "If", "ketoprofen", "is", "used", "before", "surgery", "on", "cerebral", "artery", "aneurysms", ",", "it", "may", "pose", "an", "additional", "risk", "factor", "for", "hemorrhage", "."]], "ner": [[[60, 60, "Chemical"], [70, 70, "Chemical"], [153, 153, "Chemical"], [166, 166, "Chemical"], [218, 218, "Chemical"], [260, 260, "Chemical"], [273, 273, "Chemical"], [140, 141, "Disease"], [187, 188, "Disease"], [204, 205, "Disease"], [224, 224, "Disease"], [12, 14, "Disease"], [49, 51, "Disease"], [53, 53, "Disease"], [106, 106, "Disease"], [270, 270, "Disease"], [82, 82, "Chemical"], [92, 92, "Chemical"], [171, 171, "Chemical"], [192, 192, "Chemical"], [263, 263, "Chemical"], [147, 148, "Chemical"], [105, 105, "Disease"], [280, 281, "Disease"], [291, 291, "Disease"]]], "relations": [[[60, 60, 140, 141, "CID"], [60, 60, 187, 188, "CID"], [60, 60, 204, 205, "CID"], [70, 70, 140, 141, "CID"], [70, 70, 187, 188, "CID"], [70, 70, 204, 205, "CID"], [153, 153, 140, 141, "CID"], [153, 153, 187, 188, "CID"], [153, 153, 204, 205, "CID"], [166, 166, 140, 141, "CID"], [166, 166, 187, 188, "CID"], [166, 166, 204, 205, "CID"], [218, 218, 140, 141, "CID"], [218, 218, 187, 188, "CID"], [218, 218, 204, 205, "CID"], [260, 260, 140, 141, "CID"], [260, 260, 187, 188, "CID"], [260, 260, 204, 205, "CID"], [273, 273, 140, 141, "CID"], [273, 273, 187, 188, "CID"], [273, 273, 204, 205, "CID"], [60, 60, 224, 224, "CID"], [70, 70, 224, 224, "CID"], [153, 153, 224, 224, "CID"], [166, 166, 224, 224, "CID"], [218, 218, 224, 224, "CID"], [260, 260, 224, 224, "CID"], [273, 273, 224, 224, "CID"]]], "clusters": [], "translated": "非甾体抗炎药对<11>动脉瘤性蛛网膜下腔出血</11>止血效果的影响。具有显着抗炎特性的非甾体类抗炎药 (NSAID)会损害血小板功能。它们对接受颅内手术的患者的安全性存在争议。<12>动脉瘤性蛛网膜下腔出血</12> (<13>SAH</13>)患者随机接受<0>酮洛芬</0>100 mg，每天三次(<1>酮洛芬</1>组, n=9) 或弱NSAID，<16>对乙酰氨基酚</16>，1 g，每天3次(<17>对乙酰氨基酚</17>组, n=9)诊断后立即开始<22>动脉瘤性</22><14>蛛网膜下腔出血</14>。术后继续治疗3天。在治疗和手术前以及术后第一个、第三个和第五个早晨采集测试血样。服用<2>酮洛芬</2>后，6 microM <21>二磷酸腺苷</21>诱导的最大<7>血小板聚集</7>减少。就在手术前和术后第三天，<3>酮洛芬</3>组的聚集低于<18>对乙酰氨基酚</18>组(P<.05)。相比之下，<19>对乙酰氨基酚</19>组在术后第三天最大<8>血小板聚集</8>增加(P<.05)，与治疗前<9>血小板聚集</9>结果相比。 <4>酮洛芬</4>组1例患者术后出现颅内<10>血肿</10>。两组之间的凝血功能(凝血酶原时间[PT]、活化部分凝血活酶时间[APPT]、纤维蛋白原浓度和抗凝血酶III[AT III])具有可比性。<5>酮洛芬</5>而不是<20>对乙酰氨基酚</20>对<15>SAH</15>患者血小板功能的损害。如果在脑<23>动脉瘤</23>手术前使用<6>酮洛芬</6>，可能会造成<24>出血</24>的额外危险因素。", "revised": true}
{"doc_key": "9523850", "sentences": [["Value", "of", "methylprednisolone", "in", "prevention", "of", "the", "arthralgia", "-", "myalgia", "syndrome", "associated", "with", "the", "total", "dose", "infusion", "of", "iron", "dextran", ":", "a", "double", "blind", "randomized", "trial", ".", "The", "safety", "and", "efficacy", "of", "total", "dose", "infusion", "(", "TDI", ")", "of", "iron", "dextran", "has", "been", "well", "documented", ".", "In", "40", "%", "of", "treated", "patients", ",", "an", "arthralgia", "-", "myalgia", "syndrome", "develops", ".", "The", "purpose", "of", "this", "randomized", ",", "double", "-", "blind", ",", "prospective", "study", "was", "to", "investigate", "whether", "intravenous", "(", "i", ".", "v", ".", ")", "administration", "of", "methylprednisolone", "(", "MP", ")", "prevents", "this", "complication", ".", "Sixty", "-", "five", "patients", ",", "34", "women", "and", "31", "men", ",", "ages", "36", "to", "80", "years", ",", "received", "either", "normal", "saline", "before", "and", "after", "TDI", "(", "group", "1", ")", ",", "125", "mg", "i", ".", "v", ".", "MP", "before", "and", "saline", "after", "TDI", "(", "group", "2", ")", ",", "or", "125", "mg", "i", ".", "v", ".", "MP", "before", "and", "after", "TDI", "(", "group", "3", ")", ".", "Patients", "were", "observed", "for", "72", "hours", "and", "reactions", "were", "recorded", "and", "graded", "according", "to", "severity", ".", "Fifty", "-", "eight", "percent", "of", "group", "1", "patients", ",", "33", "%", "of", "group", "2", ",", "and", "26", "%", "of", "group", "3", "had", "reactions", "to", "TDI", ".", "The", "severity", "of", "reactions", "(", "minimal", ",", "mild", ",", "and", "moderate", ",", "respectively", ")", "was", "as", "follows", ":", "group", "1", "-", "-", "6", ",", "6", ",", "and", "2", ";", "group", "2", "-", "-", "1", ",", "5", ",", "and", "0", ";", "group", "3", "-", "-", "5", ",", "1", ",", "and", "0", ".", "Data", "were", "analyzed", "by", "the", "two", "-", "sided", "Fisher", "'s", "exact", "test", "using", "95", "%", "confidence", "intervals", "with", "the", "approximation", "of", "Woolf", ".", "These", "data", "demonstrate", "that", "administration", "of", "MP", "before", "and", "after", "TDI", "reduces", "the", "frequency", "and", "severity", "of", "the", "arthralgia", "-", "myalgia", "syndrome", ".", "We", "conclude", "that", "125", "mg", "i", ".", "v", ".", "MP", "should", "be", "given", "routinely", "before", "and", "after", "TDI", "of", "iron", "dextran", "."]], "ner": [[[18, 19, "Chemical"], [39, 40, "Chemical"], [315, 316, "Chemical"], [7, 7, "Disease"], [54, 54, "Disease"], [291, 291, "Disease"], [2, 2, "Chemical"], [85, 85, "Chemical"], [87, 87, "Chemical"], [129, 129, "Chemical"], [147, 147, "Chemical"], [279, 279, "Chemical"], [305, 305, "Chemical"], [9, 9, "Disease"], [56, 56, "Disease"], [293, 293, "Disease"]]], "relations": [[[18, 19, 7, 7, "CID"], [18, 19, 54, 54, "CID"], [18, 19, 291, 291, "CID"], [39, 40, 7, 7, "CID"], [39, 40, 54, 54, "CID"], [39, 40, 291, 291, "CID"], [315, 316, 7, 7, "CID"], [315, 316, 54, 54, "CID"], [315, 316, 291, 291, "CID"]]], "clusters": [], "translated": "<6>甲泼尼龙</6>预防<3>关节痛</3>-<13>肌痛</13>综合征与<0>右旋糖酐铁</0>输注总剂量相关的价值：a双盲随机试验。 <1>右旋糖酐铁</1>的总剂量输注 (TDI)的安全性和有效性已得到充分证明。40%接受治疗的患者会出现<4>关节痛</4>-<14>肌痛</14>综合征。这项随机、双盲、前瞻性研究的目的是调查静脉内 (i.v.)给药<7>甲泼尼龙</7> (<8>MP</8>) 是否可以预防这种并发症。65 名患者，34 名女性和 31 名男性，年龄在 36 至 80 岁之间，在 TDI 前后接受生理盐水（第 1 组），125 mg i 。诉。 <9>MP</9>之前和生理盐水<span class =\"del\"><10>之后</10></span><span class =\"ins\"><10>之后的甲泼尼龙</10></span>（第2组），或 125 mg i 。诉。 <span class =\"ins\"><10>甲泼尼龙</10></span><span class =\"del\"><10>MP</10></span> TDI前后（第3组）。观察患者 72 小时，记录反应并根据严重程度分级。58%的组1患者、33%的组2和26%的组3对 TDI 有反应。反应的严重程度（分别为轻微、轻微和中度）如下：组1---6、6和2；第2组---1、5和0；第3组---5、1和0。使用95%置信区间和 Woolf 近似值，通过双侧 Fisher 精确检验分析数据。这些数据表明，在 TDI 之前和之后 <span class =\"ins\">服用<11>甲泼尼龙</11></span><span class =\"del\">用<11>MP</11></span>可降低<span class =\"del\"><5>关节痛</5>-<15>肌痛</15></span><span class =\"ins\"><5>关节痛</5> - <15>肌痛</15></span>综合征的发生频率和严重程度。我们得出的结论是125 mg i 。诉。<span class =\"ins\"><12>甲泼尼龙 </12></span><span class =\"del\"><12>MP</12></span>应在<2>右旋糖酐铁</2>TDI前后常规给药。", "revised": true}
{"doc_key": "7542793", "sentences": [["Nephrotoxicity", "of", "cyclosporin", "A", "and", "FK506", ":", "inhibition", "of", "calcineurin", "phosphatase", ".", "Cyclosporin", "A", "(", "CsA", ";", "50", "mg", "/", "kg", ")", "and", "Fujimycine", "(", "FK506", ";", "5", "mg", "/", "kg", ")", ",", "but", "not", "the", "related", "macrolide", "immunosuppressant", "rapamycin", "(", "5", "mg", "/", "kg", ")", ",", "caused", "a", "reduction", "of", "glomerular", "filtration", "rate", ",", "degenerative", "changes", "of", "proximal", "tubular", "epithelium", ",", "and", "hypertrophy", "of", "the", "juxtaglomerular", "apparatus", "in", "male", "Wistar", "rats", "when", "given", "for", "10", "days", ".", "The", "molecular", "mechanisms", "of", "CsA", "and", "FK506", "toxicity", "were", "investigated", ".", "Cyclophilin", "A", "and", "FK506", "-", "binding", "protein", ",", "the", "main", "intracytoplasmic", "receptors", "for", "CsA", "and", "FK506", ",", "respectively", ",", "were", "each", "detected", "in", "renal", "tissue", "extract", ".", "In", "the", "kidney", ",", "high", "levels", "of", "immunoreactive", "and", "enzymatically", "active", "calcineurin", "were", "found", "which", "were", "inhibited", "by", "the", "immunosuppressants", "CsA", "and", "FK506", ",", "but", "not", "by", "rapamycin", ".", "Finally", ",", "specific", "immunophilin", "-", "drug", "-", "calcineurin", "complexes", "formed", "only", "in", "the", "presence", "of", "CsA", "and", "FK506", ",", "but", "not", "rapamycin", ".", "These", "results", "suggest", "that", "the", "nephrotoxic", "effects", "of", "CsA", "and", "FK506", "is", "likely", "mediated", "through", "binding", "to", "renal", "immunophilin", "and", "inhibiting", "calcineurin", "phosphatase", "."]], "ner": [[[2, 3, "Chemical"], [12, 13, "Chemical"], [15, 15, "Chemical"], [82, 82, "Chemical"], [102, 102, "Chemical"], [136, 136, "Chemical"], [160, 160, "Chemical"], [176, 176, "Chemical"], [0, 0, "Disease"], [173, 173, "Disease"], [5, 5, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [84, 84, "Chemical"], [92, 92, "Chemical"], [104, 104, "Chemical"], [138, 138, "Chemical"], [162, 162, "Chemical"], [178, 178, "Chemical"], [37, 37, "Chemical"], [39, 39, "Chemical"], [143, 143, "Chemical"], [166, 166, "Chemical"], [63, 63, "Disease"], [85, 85, "Disease"]]], "relations": [[[2, 3, 0, 0, "CID"], [2, 3, 173, 173, "CID"], [12, 13, 0, 0, "CID"], [12, 13, 173, 173, "CID"], [15, 15, 0, 0, "CID"], [15, 15, 173, 173, "CID"], [82, 82, 0, 0, "CID"], [82, 82, 173, 173, "CID"], [102, 102, 0, 0, "CID"], [102, 102, 173, 173, "CID"], [136, 136, 0, 0, "CID"], [136, 136, 173, 173, "CID"], [160, 160, 0, 0, "CID"], [160, 160, 173, 173, "CID"], [176, 176, 0, 0, "CID"], [176, 176, 173, 173, "CID"], [5, 5, 0, 0, "CID"], [5, 5, 173, 173, "CID"], [23, 23, 0, 0, "CID"], [23, 23, 173, 173, "CID"], [25, 25, 0, 0, "CID"], [25, 25, 173, 173, "CID"], [84, 84, 0, 0, "CID"], [84, 84, 173, 173, "CID"], [92, 92, 0, 0, "CID"], [92, 92, 173, 173, "CID"], [104, 104, 0, 0, "CID"], [104, 104, 173, 173, "CID"], [138, 138, 0, 0, "CID"], [138, 138, 173, 173, "CID"], [162, 162, 0, 0, "CID"], [162, 162, 173, 173, "CID"], [178, 178, 0, 0, "CID"], [178, 178, 173, 173, "CID"]]], "clusters": [], "translated": "<0>环孢菌素A</0>和<10>FK506</10>的<8>肾毒性</8>：神经钙蛋白磷酸酶的抑制作用。<1>环孢菌素A</1>（<2>CsA</2>;50 mg/kg）和<11>富士霉素</11>（<12>FK506</12>;5 mg/kg），但不是相关的<19>大环内酯</19>免疫抑制剂<20>雷帕霉素</20>（5 mg/kg），引起肾小球滤过率降低，近端肾小管上皮退行性改变，<23>肾小球旁器官肥大</23>，给药10天后雄性Wistar大鼠肾中的变化。探讨了<3>CsA</3>和<13>FK506</13><24>毒性</24>的分子机制。环孢菌素A和<14>FK506</14>结合蛋白，分别是<4>CsA</4>和<15>FK506</15>的主要胞质内受体，在肾组织提取物中各有检测。在肾脏中发现与免疫反应性和酶促活性的神经钙蛋白高水平，这些水平被免疫抑制剂<5>CsA</5>和<16>FK506</16> 抑制，但不受<21>雷帕霉素</21>抑制。最后，特异性免疫亲和素-药物-神经钙蛋白复合物只存在于<6>CsA</6>和<17>FK506</17>存在的情况下，而<22>雷帕霉素</22>不存在。这些结果表明，<7>CsA</7>和<18>FK506</18>的<9>肾毒性</9>作用可能是通过与肾免疫亲和素结合并抑制神经钙蛋白磷酸酶介导的。", "revised": true}
{"doc_key": "11583940", "sentences": [["Sirolimus", "and", "mycophenolate", "mofetil", "for", "calcineurin", "-", "free", "immunosuppression", "in", "renal", "transplant", "recipients", ".", "Calcineurin", "inhibitors", ",", "such", "as", "cyclosporine", "and", "tacrolimus", ",", "have", "been", "available", "for", "almost", "20", "years", ".", "Although", "these", "drugs", "are", "highly", "effective", "and", "represent", "the", "mainstay", "of", "transplant", "immunosuppression", ",", "they", "are", "associated", "with", "acute", "and", "chronic", "nephrotoxicity", ".", "Acute", "nephrotoxicity", ",", "which", "occurs", "in", "the", "early", "period", "after", "transplantation", ",", "leads", "to", "a", "higher", "rate", "of", "dialysis", ",", "and", "chronic", "nephrotoxicity", "may", "eventually", "result", "in", "graft", "loss", ".", "Acute", "and", "chronic", "nephrotoxicity", "is", "becoming", "more", "common", "as", "the", "use", "of", "marginal", "kidneys", "for", "transplantation", "increases", ".", "Two", "recently", "available", "immunosuppressive", "agents", ",", "mycophenolate", "mofetil", "and", "sirolimus", "(", "rapamycin", ")", ",", "have", "no", "nephrotoxicity", ".", "The", "use", "of", "these", "drugs", "in", "combination", "with", "other", "agents", "has", "led", "to", "the", "development", "of", "new", "paradigms", "of", "immunosuppressive", "therapy", ".", "This", "paper", "reviews", "the", "results", "of", "clinical", "trials", "that", "have", "investigated", "these", "new", "approaches", "to", "immunosuppression", "in", "renal", "transplant", "recipients", "."]], "ner": [[[19, 19, "Chemical"], [52, 52, "Disease"], [55, 55, "Disease"], [76, 76, "Disease"], [87, 87, "Disease"], [118, 118, "Disease"], [21, 21, "Chemical"], [0, 0, "Chemical"], [111, 111, "Chemical"], [113, 113, "Chemical"], [2, 3, "Chemical"], [108, 109, "Chemical"]]], "relations": [[[19, 19, 52, 52, "CID"], [19, 19, 55, 55, "CID"], [19, 19, 76, 76, "CID"], [19, 19, 87, 87, "CID"], [19, 19, 118, 118, "CID"], [21, 21, 52, 52, "CID"], [21, 21, 55, 55, "CID"], [21, 21, 76, 76, "CID"], [21, 21, 87, 87, "CID"], [21, 21, 118, 118, "CID"]]], "clusters": [], "translated": "<7>西罗莫司</7>和<10>吗替麦考酚酯</10>用于肾移植受者的无神经钙蛋白免疫抑制。钙调神经磷酸酶抑制剂，如<0>环孢菌素</0>和<6>他克莫司</6>，已经上市近20年。尽管这些药物非常有效并且是移植免疫抑制的主要药物，但它们与急性和慢性<1>肾毒性</1>有关。急性<2>肾毒性</2>发生在移植后早期，导致较高的透析率，而<3>慢性肾毒性</3>则可能最终导致移植物失功。随着边缘肾用于移植的增加，急性和慢性<4>肾毒性</4>变得越来越普遍。最近上市的两种免疫抑制剂<11>吗替麦考酚酯</11>和<8>西罗莫司</8>（<9>雷帕霉素</9>）没有<5>肾毒性</5>。这些药物与其他药物的联合使用导致了免疫抑制治疗新范式的发展。本文回顾了在肾移植受者中研究这些免疫抑制新方法的临床试验结果。", "revised": true}
{"doc_key": "7337133", "sentences": [["Massive", "cerebral", "edema", "associated", "with", "fulminant", "hepatic", "failure", "in", "acetaminophen", "overdose", ":", "possible", "role", "of", "cranial", "decompression", ".", "Cerebral", "edema", "may", "complicate", "the", "course", "of", "fulminant", "hepatic", "failure", ".", "Response", "to", "conventional", "therapy", "has", "been", "disappointing", ".", "We", "present", "a", "patient", "with", "fatal", "acetaminophen", "-", "induced", "fulminant", "hepatic", "failure", ",", "with", "signs", "and", "symptoms", "of", "cerebral", "edema", ",", "unresponsive", "to", "conventional", "medical", "therapy", ".", "Cranial", "decompression", "was", "carried", "out", ".", "A", "justification", "of", "the", "need", "for", "further", "evaluation", "of", "cranial", "decompression", "in", "such", "patients", "is", "presented", "."]], "ner": [[[9, 9, "Chemical"], [43, 43, "Chemical"], [1, 2, "Disease"], [18, 19, "Disease"], [55, 56, "Disease"], [6, 7, "Disease"], [25, 27, "Disease"], [46, 48, "Disease"], [10, 10, "Disease"]]], "relations": [[[9, 9, 1, 2, "CID"], [9, 9, 18, 19, "CID"], [9, 9, 55, 56, "CID"], [43, 43, 1, 2, "CID"], [43, 43, 18, 19, "CID"], [43, 43, 55, 56, "CID"], [9, 9, 6, 7, "CID"], [9, 9, 25, 27, "CID"], [9, 9, 46, 48, "CID"], [43, 43, 6, 7, "CID"], [43, 43, 25, 27, "CID"], [43, 43, 46, 48, "CID"]]], "clusters": [], "translated": "大量<2>脑水肿</2>与<0>对乙酰氨基酚</0><8>过量</8>中的暴发性<5>肝功能衰竭</5>相关：颅骨减压的可能作用。 <3>脑水肿</3>可能使<6>暴发性肝功能衰竭</6>的病程复杂化。对常规疗法的反应令人失望。我们介绍了一名患有致命性<1>对乙酰氨基酚</1>诱发的<7>暴发性肝功能衰竭</7>的患者，其体征和症状为<4>脑水肿</4>，对常规药物治疗无反应。进行了颅骨减压。提出了对此类患者进行颅骨减压术进一步评估的必要性的理由。", "revised": true}
{"doc_key": "3780697", "sentences": [["Post", "-", "operative", "rigidity", "after", "fentanyl", "administration", ".", "A", "case", "of", "thoraco", "-", "abdominal", "rigidity", "leading", "to", "respiratory", "failure", "is", "described", "in", "the", "post", "-", "operative", "period", "in", "an", "elderly", "patient", "who", "received", "a", "moderate", "dose", "of", "fentanyl", ".", "This", "was", "successfully", "reversed", "by", "naloxone", ".", "The", "mechanisms", "possibly", "implicated", "in", "this", "accident", "are", "discussed", "."]], "ner": [[[5, 5, "Chemical"], [37, 37, "Chemical"], [3, 3, "Disease"], [14, 14, "Disease"], [44, 44, "Chemical"], [17, 18, "Disease"]]], "relations": [[[5, 5, 3, 3, "CID"], [5, 5, 14, 14, "CID"], [37, 37, 3, 3, "CID"], [37, 37, 14, 14, "CID"]]], "clusters": [], "translated": "<0>芬太尼</0>给药后的术后<2>僵硬</2>。一例胸腹<3>强直</3>导致<5>呼吸衰竭</5>的病例描述于接受中等剂量<1>芬太尼</1>的老年患者术后期间。这被成功逆转使用<4>纳洛酮</4>。讨论了可能与这次事故有关的机制。", "revised": true}
{"doc_key": "4069770", "sentences": [["Gentamicin", "nephropathy", "in", "a", "neonate", ".", "The", "clinical", "and", "autopsy", "findings", "in", "a", "premature", "baby", "who", "died", "of", "acute", "renal", "failure", "after", "therapy", "with", "gentamicin", "(", "5", "mg", "/", "kg", "/", "day", ")", "and", "penicillin", "are", "presented", ".", "The", "serum", "gentamicin", "concentration", "had", "reached", "toxic", "levels", "when", "anuria", "developed", ".", "Numerous", "periodic", "acid", "Schiff", "(", "PAS", ")", "positive", ",", "diastase", "resistant", "cytoplasmic", "inclusion", "bodies", "which", "appeared", "as", "myelin", "figures", "in", "cytosegresomes", "under", "the", "electron", "microscope", "were", "identified", "in", "the", "proximal", "convoluted", "tubules", ".", "The", "pathological", "changes", "induced", "by", "gentamicin", "in", "the", "human", "neonatal", "kidneys", "have", "not", "been", "previously", "reported", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [40, 40, "Chemical"], [88, 88, "Chemical"], [18, 20, "Disease"], [1, 1, "Disease"], [47, 47, "Disease"], [34, 34, "Chemical"], [51, 52, "Chemical"]]], "relations": [[[0, 0, 18, 20, "CID"], [24, 24, 18, 20, "CID"], [40, 40, 18, 20, "CID"], [88, 88, 18, 20, "CID"]]], "clusters": [], "translated": "<0>庆大霉素</0><5>新生儿肾病</5>。 <1>庆大霉素</1> (5 mg/kg/天) 和 <7>青霉素</7> 治疗后死于 <4>急性肾功能衰竭</4> 的早产儿的临床和尸检结果被提出。发生 <6>无尿</6> 时，血清 <2>庆大霉素</2> 浓度已达到中毒水平。近曲小管内可见大量 <8>高碘酸希夫</8>（PAS）阳性、耐淀粉酶的胞浆包涵体，电镜下胞质分离体呈髓鞘状。 <3>庆大霉素</3> 引起的人新生儿肾脏病理改变以前未见报道。", "revised": true}
{"doc_key": "8665051", "sentences": [["Effects", "of", "acute", "steroid", "administration", "on", "ventilatory", "and", "peripheral", "muscles", "in", "rats", ".", "Occasional", "case", "reports", "have", "shown", "that", "acute", "myopathy", "may", "occur", "in", "patients", "treated", "with", "massive", "doses", "of", "corticosteroids", ".", "The", "mechanism", "of", "this", "myopathy", "is", "poorly", "understood", ".", "Therefore", ",", "60", "male", "rats", "were", "randomly", "assigned", "to", "receive", "daily", "injection", "of", "saline", "(", "C", ")", ",", "methylprednisolone", "(", "M", ")", ",", "or", "triamcinolone", "(", "T", ")", "80", "mg", "/", "kg", "/", "d", "for", "5", "d", ".", "Nutritional", "intake", ",", "measured", "daily", "in", "15", "animals", ",", "showed", "a", "significant", "reduction", "of", "food", "intake", "in", "the", "steroid", "-", "treated", "groups", "(", "-", "50", "and", "-", "79", "%", "in", "M", "and", "T", ",", "respectively", ")", ".", "This", "was", "associated", "with", "a", "similar", "loss", "in", "body", "weight", ".", "In", "the", "45", "remaining", "animals", ",", "diaphragm", "contractility", "and", "histopathologic", "features", "of", "several", "muscles", "were", "studied", ".", "Weights", "of", "respiratory", "and", "peripheral", "muscles", "were", "similarly", "decreased", "after", "steroid", "treatment", ".", "Maximal", "twitches", "of", "the", "diaphragm", "were", "lower", "in", "the", "C", "group", "(", "653", "+", "/", "-", "174", "g", "/", "cm", "(", "2", ")", ")", "than", "in", "the", "M", "group", "(", "837", "+", "/", "-", "171", "g", "/", "cm", "(", "2", ")", ";", "p", "<", "0", ".", "05", ")", "and", "the", "T", "group", "(", "765", "+", "/", "-", "145", "g", "/", "cm", "(", "2", ")", ",", "NS", ")", ".", "Half", "-", "relaxation", "time", "was", "prolonged", "in", "both", "steroid", "groups", ",", "and", "time", "to", "peak", "tension", "was", "longer", "with", "M", ",", "whereas", "tetanic", "tensions", "were", "similar", ".", "Steroid", "treatment", "also", "induced", "a", "leftward", "shift", "of", "the", "force", "-", "frequency", "curve", "at", "25", "and", "50", "Hz", "when", "compared", "with", "saline", "treatment", "(", "p", "<", "0", ".", "05", ")", ".", "ATPase", "staining", "of", "the", "diaphragm", ",", "scalenus", "medius", ",", "and", "gastrocnemius", "showed", "type", "IIb", "fiber", "atrophy", "in", "the", "steroid", "groups", "and", "also", "diaphragmatic", "type", "IIa", "atrophy", "with", "T", ",", "whereas", "histologic", "examinations", "revealed", "a", "normal", "muscular", "pattern", "with", "absence", "of", "necrosis", ".", "Finally", ",", "a", "pair", "-", "fed", "(", "PF", ")", "study", ",", "performed", "in", "18", "rats", "(", "C", ",", "T", ",", "and", "PF", ")", ",", "showed", "that", "muscle", "atrophy", "was", "considerably", "less", "pronounced", "in", "PF", "animals", "than", "in", "T", "-", "treated", "animals", ".", "We", "conclude", "that", "(", "1", ")", "short", "-", "term", "treatment", "with", "massive", "doses", "of", "steroids", "induced", "severe", "respiratory", "and", "limb", "muscle", "wasting", ";", "(", "2", ")", "both", "types", "of", "steroids", "induced", "predominantly", "type", "IIb", "atrophy", ",", "resulting", "in", "the", "expected", "alterations", "in", "diaphragm", "contractile", "properties", ";", "(", "3", ")", "neither", "steroid", "caused", "muscle", "necrosis", ";", "(", "4", ")", "type", "IIb", "atrophy", "was", "not", "caused", "by", "acute", "nutritional", "deprivation", "alone", "."]], "ner": [[[59, 59, "Chemical"], [61, 61, "Chemical"], [109, 109, "Chemical"], [184, 184, "Chemical"], [244, 244, "Chemical"], [91, 94, "Disease"], [122, 125, "Disease"], [298, 298, "Disease"], [308, 308, "Disease"], [351, 352, "Disease"], [427, 427, "Disease"], [65, 65, "Chemical"], [67, 67, "Chemical"], [111, 111, "Chemical"], [207, 207, "Chemical"], [310, 310, "Chemical"], [343, 343, "Chemical"], [362, 362, "Chemical"], [3, 3, "Chemical"], [97, 97, "Chemical"], [154, 154, "Chemical"], [233, 233, "Chemical"], [252, 252, "Chemical"], [301, 301, "Chemical"], [381, 381, "Chemical"], [396, 396, "Chemical"], [417, 417, "Chemical"], [20, 20, "Disease"], [36, 36, "Disease"], [247, 247, "Disease"], [323, 323, "Disease"], [420, 420, "Disease"], [401, 401, "Disease"], [30, 30, "Chemical"]]], "relations": [[[59, 59, 91, 94, "CID"], [61, 61, 91, 94, "CID"], [109, 109, 91, 94, "CID"], [184, 184, 91, 94, "CID"], [244, 244, 91, 94, "CID"], [59, 59, 122, 125, "CID"], [61, 61, 122, 125, "CID"], [109, 109, 122, 125, "CID"], [184, 184, 122, 125, "CID"], [244, 244, 122, 125, "CID"], [59, 59, 298, 298, "CID"], [59, 59, 308, 308, "CID"], [59, 59, 351, 352, "CID"], [59, 59, 427, 427, "CID"], [61, 61, 298, 298, "CID"], [61, 61, 308, 308, "CID"], [61, 61, 351, 352, "CID"], [61, 61, 427, 427, "CID"], [109, 109, 298, 298, "CID"], [109, 109, 308, 308, "CID"], [109, 109, 351, 352, "CID"], [109, 109, 427, 427, "CID"], [184, 184, 298, 298, "CID"], [184, 184, 308, 308, "CID"], [184, 184, 351, 352, "CID"], [184, 184, 427, 427, "CID"], [244, 244, 298, 298, "CID"], [244, 244, 308, 308, "CID"], [244, 244, 351, 352, "CID"], [244, 244, 427, 427, "CID"], [65, 65, 91, 94, "CID"], [67, 67, 91, 94, "CID"], [111, 111, 91, 94, "CID"], [207, 207, 91, 94, "CID"], [310, 310, 91, 94, "CID"], [343, 343, 91, 94, "CID"], [362, 362, 91, 94, "CID"], [65, 65, 122, 125, "CID"], [67, 67, 122, 125, "CID"], [111, 111, 122, 125, "CID"], [207, 207, 122, 125, "CID"], [310, 310, 122, 125, "CID"], [343, 343, 122, 125, "CID"], [362, 362, 122, 125, "CID"], [65, 65, 298, 298, "CID"], [65, 65, 308, 308, "CID"], [65, 65, 351, 352, "CID"], [65, 65, 427, 427, "CID"], [67, 67, 298, 298, "CID"], [67, 67, 308, 308, "CID"], [67, 67, 351, 352, "CID"], [67, 67, 427, 427, "CID"], [111, 111, 298, 298, "CID"], [111, 111, 308, 308, "CID"], [111, 111, 351, 352, "CID"], [111, 111, 427, 427, "CID"], [207, 207, 298, 298, "CID"], [207, 207, 308, 308, "CID"], [207, 207, 351, 352, "CID"], [207, 207, 427, 427, "CID"], [310, 310, 298, 298, "CID"], [310, 310, 308, 308, "CID"], [310, 310, 351, 352, "CID"], [310, 310, 427, 427, "CID"], [343, 343, 298, 298, "CID"], [343, 343, 308, 308, "CID"], [343, 343, 351, 352, "CID"], [343, 343, 427, 427, "CID"], [362, 362, 298, 298, "CID"], [362, 362, 308, 308, "CID"], [362, 362, 351, 352, "CID"], [362, 362, 427, 427, "CID"]]], "clusters": [], "translated": "急性<18>类固醇</18>给药对大鼠通气和外周肌肉的影响。偶有病例报告显示，接受大剂量<33>皮质类固醇</33>治疗的患者可能会发生急性<27>肌病</27>。这种<28>肌病</28>的机制尚不清楚。因此，60只雄性大鼠被随机分配接受每天注射生理盐水（C），<0>甲泼尼龙</0>（<1>M</1>），或<11>去炎松</11>（<12>T</12>）80 mg/kg/d，连续5 d。每天测量15只动物的营养摄入量，显示<19>类固醇</19>治疗组的食物摄入量显着<5>减少</5>（<2>M</2>和<13>T</13>-50%和-79%，分别）。这与类似的<6>体重减轻</6>相关。在剩下的45只动物中，对几种肌肉的横膈膜收缩力和组织病理学特征进行了研究。<20>类固醇</20>治疗后，呼吸肌和外周肌的重量同样下降。C组（653+/-174 g/cm(2)）的膈肌最大抽搐低于<3>M</3>组（837+/-171 g/cm(2)；p < 0.05）和<14>T</14>组（765+/-145 g/cm(2)，NS）。两个<21>类固醇</21>组的半弛豫时间均延长，<4>M</4>组达到峰值张力的时间更长，而<29>强直</29>张力相似。与生理盐水治疗相比，<22>类固醇</22>治疗还导致力-频率曲线在25和50 Hz处向左移动（p < 0.05）。横膈膜、斜角肌和腓肠肌的ATPase染色显示<23>类固醇</23>组的IIb型纤维<7>萎缩</7>以及<15>T</15>的IIa型横膈膜<8>萎缩</8>，而组织学检查显示正常的肌肉模式，没有<30>坏死</30>。最后，在18只大鼠（C，<16>T</16>和PF）中进行的配对喂养(PF)研究表明，与PF动物相比，<9>肌肉萎缩</9>明显不明显在<17>T</17>处理的动物中。我们的结论是：（1）使用大剂量<24>类固醇</24>进行短期治疗会导致严重的呼吸和肢体肌肉萎缩；(2)两种类型的<25>类固醇</25>主要诱导IIb型<32>萎缩</32>，导致横膈膜收缩特性的预期改变；(3)<26>类固醇</26>均未引起肌肉<31>坏死</31>；(4)IIb型<10>萎缩</10>并非单纯由急性营养剥夺所致。", "revised": true}
{"doc_key": "3686155", "sentences": [["Postpartum", "psychosis", "induced", "by", "bromocriptine", ".", "Two", "multigravida", "patients", "with", "no", "prior", "psychiatric", "history", "were", "seen", "with", "postpartum", "psychosis", ",", "having", "received", "bromocriptine", "for", "inhibition", "of", "lactation", ".", "Bromocriptine", "given", "in", "high", "doses", "has", "been", "associated", "with", "psychosis", "in", "patients", "receiving", "the", "drug", "for", "Parkinson", "'s", "disease", ".", "These", "cases", "demonstrate", "that", "bromocriptine", "may", "cause", "psychosis", "even", "when", "given", "in", "low", "doses", "."]], "ner": [[[4, 4, "Chemical"], [22, 22, "Chemical"], [28, 28, "Chemical"], [52, 52, "Chemical"], [1, 1, "Disease"], [18, 18, "Disease"], [37, 37, "Disease"], [55, 55, "Disease"], [12, 12, "Disease"], [24, 26, "Disease"], [44, 46, "Disease"]]], "relations": [[[4, 4, 1, 1, "CID"], [4, 4, 18, 18, "CID"], [4, 4, 37, 37, "CID"], [4, 4, 55, 55, "CID"], [22, 22, 1, 1, "CID"], [22, 22, 18, 18, "CID"], [22, 22, 37, 37, "CID"], [22, 22, 55, 55, "CID"], [28, 28, 1, 1, "CID"], [28, 28, 18, 18, "CID"], [28, 28, 37, 37, "CID"], [28, 28, 55, 55, "CID"], [52, 52, 1, 1, "CID"], [52, 52, 18, 18, "CID"], [52, 52, 37, 37, "CID"], [52, 52, 55, 55, "CID"]]], "clusters": [], "translated": "<0>溴隐亭</0>致产后<4>精神病</4>。两名既往没有<8>精神病</8>病史的多胎孕妇出现产后<5>精神病</5>，并接受<1>溴隐亭</1>治疗<9>抑制泌乳</9>。<2>溴隐亭</2>高剂量与接受药物治疗<10>帕金森病</10>的患者的<6>精神病</6>相关。这些病例表明，<3>溴隐亭</3>即使是低剂量也可能引起<7>精神病</7>。", "revised": true}
{"doc_key": "8384253", "sentences": [["Long", "-", "term", "effects", "of", "vincristine", "on", "the", "peripheral", "nervous", "system", ".", "Forty", "patients", "with", "Non", "-", "Hodgkin", "'s", "Lymphoma", "treated", "with", "vincristine", "between", "1984", "and", "1990", "(", "cumulative", "dose", "12", "mg", "in", "18", "-", "24", "weeks", ")", "were", "investigated", "in", "order", "to", "evaluate", "the", "long", "term", "effects", "of", "vincristine", "on", "the", "peripheral", "nervous", "system", ".", "The", "patients", "were", "interviewed", "with", "emphasis", "on", "neuropathic", "symptoms", ".", "Physical", "and", "quantitative", "sensory", "examination", "with", "determination", "of", "vibratory", "perception", "and", "thermal", "discrimination", "thresholds", "were", "performed", ",", "four", "to", "77", "months", "(", "median", "34", "months", ")", "after", "vincristine", "treatment", ".", "Twenty", "-", "seven", "patients", "reported", "neuropathic", "symptoms", ".", "In", "13", "of", "these", "27", "patients", "symptoms", "were", "still", "present", "at", "the", "time", "of", "examination", ".", "In", "these", "patients", "sensory", "signs", "and", "symptoms", "predominated", ".", "In", "the", "other", "14", "patients", "symptoms", "had", "been", "present", "in", "the", "past", ".", "Symptoms", "persisted", "maximally", "40", "months", "since", "cessation", "of", "therapy", ".", "There", "was", "no", "age", "difference", "between", "patients", "with", "and", "without", "complaints", "at", "the", "time", "of", "examination", ".", "Normal", "reflexes", "were", "found", "in", "two", "third", "of", "patients", ".", "Neuropathic", "complaints", "were", "not", "very", "troublesome", "on", "the", "long", "term", ".", "It", "is", "concluded", "that", "with", "the", "above", "mentioned", "vincristine", "dose", "schedule", "signs", "and", "symptoms", "of", "vincristine", "neuropathy", "are", "reversible", "for", "a", "great", "deal", "and", "prognosis", "is", "fairly", "good", "."]], "ner": [[[5, 5, "Chemical"], [22, 22, "Chemical"], [49, 49, "Chemical"], [93, 93, "Chemical"], [198, 198, "Chemical"], [205, 205, "Chemical"], [63, 64, "Disease"], [101, 102, "Disease"], [15, 19, "Disease"], [206, 206, "Disease"]]], "relations": [[[5, 5, 63, 64, "CID"], [5, 5, 101, 102, "CID"], [22, 22, 63, 64, "CID"], [22, 22, 101, 102, "CID"], [49, 49, 63, 64, "CID"], [49, 49, 101, 102, "CID"], [93, 93, 63, 64, "CID"], [93, 93, 101, 102, "CID"], [198, 198, 63, 64, "CID"], [198, 198, 101, 102, "CID"], [205, 205, 63, 64, "CID"], [205, 205, 101, 102, "CID"]]], "clusters": [], "translated": "<0>长春新碱</0>对周围神经系统的长期影响。对 1984 年至 1990 年间接受 <1>长春新碱</1>治疗的 40 名<8>非霍奇金淋巴瘤</8>患者进行了调查（18 - 24 周内累积剂量为 12 毫克） ，以评估长期疗效<2>长春新碱</2>对周围神经系统的影响。患者的访谈重点是<6>神经性症状</6>。在<3>长春新碱</3>治疗后4至77个月（中位数34个月），进行了物理和定量感官检查，确定振动知觉和热辨别阈值。27名患者报告了<7>神经性症状</7>。在这27名患者中，有13名在检查时症状仍然存在。在这些患者中，感觉体征和症状占主导地位。其他14名患者过去曾出现过症状。停止治疗后症状最长持续40个月。在检查时有和没有主诉的患者之间没有年龄差异。三分之二的患者反射正常。从长远来看，神经病的抱怨并不是很麻烦。结论：采用上述<4>长春新碱</4>剂量方案，<5>长春新碱</5><9>神经病变</9>的体征和症状在很大程度上是可逆的，预后较好。", "revised": true}
{"doc_key": "3780814", "sentences": [["Anti", "-", "carcinogenic", "action", "of", "phenobarbital", "given", "simultaneously", "with", "diethylnitrosamine", "in", "the", "rat", ".", "The", "present", "work", "has", "been", "planned", "in", "order", "to", "elucidate", "the", "effect", "of", "phenobarbital", "(", "PB", ":", "15", "mg", "per", "rat", "of", "ingested", "dose", ")", "on", "carcinogenesis", "when", "it", "is", "administered", "simultaneously", "with", "diethylnitrosamine", "(", "DEN", ":", "10", "mg", "/", "kg", "/", "day", ")", ".", "Wistar", "rats", "(", "180", "g", ")", "were", "treated", "by", "DEN", "alone", "or", "by", "DEN", "+", "PB", "during", "2", ",", "4", "and", "6", "weeks", "according", "to", "our", "schedule", "for", "hepatocarcinogenesis", ".", "After", "the", "end", "of", "the", "treatment", ",", "the", "number", "and", "the", "size", "of", "induced", "PAS", "positive", "preneoplastic", "foci", "was", "significantly", "reduced", "when", "PB", "was", "given", "simultaneously", "with", "DEN", "for", "4", "and", "6", "weeks", ".", "The", "mitotic", "inhibition", "and", "the", "production", "of", "micronuclei", "normally", "observed", "after", "partial", "hepatectomy", "in", "DEN", "treated", "rats", "were", "also", "significantly", "decreased", "in", "DEN", "+", "PB", "treated", "rats", ".", "When", "the", "treatment", "last", "only", "2", "weeks", ",", "the", "presence", "of", "PB", "did", "not", "change", "significantly", "the", "last", "parameters", ".", "In", "DEN", "+", "PB", "treated", "rats", ",", "the", "survival", "was", "prolonged", "and", "the", "tumor", "incidence", "decreased", "as", "compared", "with", "the", "results", "obtained", "by", "DEN", "alone", ".", "It", "is", "concluded", "that", "PB", ",", "which", "promotes", "carcinogenesis", "when", "administered", "after", "the", "DEN", "treatment", ",", "reduces", "the", "carcinogen", "effect", "when", "given", "simultaneously", "with", "DEN", ".", "This", "'", "anti", "-", "carcinogen", "'", "effect", "acts", "on", "the", "initiation", "as", "well", "as", "on", "the", "promotion", "of", "the", "precancerous", "lesions", ".", "Biochemical", "investigations", "are", "in", "progress", "to", "obtain", "more", "information", "about", "this", "'", "paradoxical", "'", "PB", "effect", "."]], "ner": [[[9, 9, "Chemical"], [47, 47, "Chemical"], [49, 49, "Chemical"], [68, 68, "Chemical"], [72, 72, "Chemical"], [116, 116, "Chemical"], [137, 137, "Chemical"], [145, 145, "Chemical"], [172, 172, "Chemical"], [194, 194, "Chemical"], [210, 210, "Chemical"], [221, 221, "Chemical"], [105, 106, "Disease"], [242, 243, "Disease"], [5, 5, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [74, 74, "Chemical"], [111, 111, "Chemical"], [147, 147, "Chemical"], [162, 162, "Chemical"], [174, 174, "Chemical"], [201, 201, "Chemical"], [259, 259, "Chemical"], [2, 2, "Disease"], [40, 40, "Disease"], [87, 87, "Disease"], [205, 205, "Disease"], [184, 184, "Disease"]]], "relations": [[[9, 9, 105, 106, "CID"], [9, 9, 242, 243, "CID"], [47, 47, 105, 106, "CID"], [47, 47, 242, 243, "CID"], [49, 49, 105, 106, "CID"], [49, 49, 242, 243, "CID"], [68, 68, 105, 106, "CID"], [68, 68, 242, 243, "CID"], [72, 72, 105, 106, "CID"], [72, 72, 242, 243, "CID"], [116, 116, 105, 106, "CID"], [116, 116, 242, 243, "CID"], [137, 137, 105, 106, "CID"], [137, 137, 242, 243, "CID"], [145, 145, 105, 106, "CID"], [145, 145, 242, 243, "CID"], [172, 172, 105, 106, "CID"], [172, 172, 242, 243, "CID"], [194, 194, 105, 106, "CID"], [194, 194, 242, 243, "CID"], [210, 210, 105, 106, "CID"], [210, 210, 242, 243, "CID"], [221, 221, 105, 106, "CID"], [221, 221, 242, 243, "CID"]]], "clusters": [], "translated": "<14>苯巴比妥</14>与<0>二乙基亚硝胺</0>同时给予大鼠的抗<24>致癌</24>作用。目前的工作是为了阐明<15>苯巴比妥</15>（<16> PB </16>：每只大鼠摄入剂量为15 mg）对<25>致癌作用</25>的影响，当与<1>二乙基亚硝胺</1>同时给药（<2>DEN</2>：10 mg/kg/天）时。根据我们<26>肝癌发生</26>的计划进行了2、4和6周的<3>DEN</3>治疗大鼠或同时给予<4>DEN</4>+<17>PB</17>的治疗。治疗结束后，当<18>PB</18>与<5>DEN</5>同时给药时，诱导的PAS阳性<12>癌前病灶</12>的数量和大小在4和6周时显着减少。在<6>DEN</6>治疗大鼠的部分肝切除术后通常观察到的有丝分裂抑制和微核产生在<7>DEN</7>+<19>PB</19>处理的大鼠中也显着降低。当治疗仅持续2周时，<20>PB</20>的存在并未显着改变最后的参数。<8>DEN</8>+<21>PB</21>处理的大鼠中，与<9>DEN</9>独自给药获得的结果相比，存活时间延长，<28>肿瘤</28>的发生率降低。得出的结论是，<22>PB</22>在<10>DEN</10>治疗后给予时会促进<27>致癌作用</27>，但当与<11>DEN</11>同时给药时表现为“抗致癌物”作用。这种作用可引发和促进<13>癌前病变</13>。生化研究正在进行中，以获取有关这种“矛盾的”<23>PB</23>效应的更多信息。", "revised": true}
{"doc_key": "10910842", "sentences": [["Prednisolone", "-", "induced", "muscle", "dysfunction", "is", "caused", "more", "by", "atrophy", "than", "by", "altered", "acetylcholine", "receptor", "expression", ".", "Large", "doses", "of", "glucocorticoids", "can", "alter", "muscle", "physiology", "and", "susceptibility", "to", "neuromuscular", "blocking", "drugs", "by", "mechanisms", "not", "clearly", "understood", ".", "We", "investigated", "the", "effects", "of", "moderate", "and", "large", "doses", "of", "prednisolone", "on", "muscle", "function", "and", "pharmacology", ",", "and", "their", "relationship", "to", "changes", "in", "muscle", "size", "and", "acetylcholine", "receptor", "(", "AChR", ")", "expression", ".", "With", "institutional", "approval", ",", "35", "Sprague", "-", "Dawley", "rats", "were", "randomly", "allocated", "to", "receive", "daily", "subcutaneous", "doses", "of", "10", "mg", "/", "kg", "prednisolone", "(", "P10", "group", ")", ",", "100", "mg", "/", "kg", "prednisolone", "(", "P100", "group", ")", ",", "or", "an", "equal", "volume", "of", "saline", "(", "S", "group", ")", "for", "7", "days", ".", "A", "fourth", "group", "of", "rats", "was", "pair", "fed", "(", "food", "restricted", ")", "with", "the", "P100", "rats", "for", "7", "days", "(", "FR", "group", ")", ".", "On", "Day", "8", ",", "the", "nerve", "-", "evoked", "peak", "twitch", "tensions", ",", "tetanic", "tensions", ",", "and", "fatigability", ",", "and", "the", "dose", "-", "response", "curves", "of", "d", "-", "tubocurarine", "in", "the", "tibialis", "cranialis", "muscle", "were", "measured", "in", "vivo", "and", "related", "to", "muscle", "mass", "or", "expression", "of", "AChRs", ".", "Rate", "of", "body", "weight", "gain", "was", "depressed", "in", "the", "P100", ",", "FR", ",", "and", "P10", "groups", "compared", "with", "the", "S", "group", ".", "Tibialis", "muscle", "mass", "was", "smaller", "in", "the", "P100", "group", "than", "in", "the", "P10", "or", "S", "groups", ".", "The", "evoked", "peak", "twitch", "and", "tetanic", "tensions", "were", "less", "in", "the", "P100", "group", "than", "in", "the", "P10", "or", "S", "groups", ",", "however", ",", "tension", "per", "milligram", "of", "muscle", "mass", "was", "greater", "in", "the", "P100", "group", "than", "in", "the", "S", "group", ".", "The", "50", "%", "effective", "dose", "of", "d", "-", "tubocurarine", "(", "microg", "/", "kg", ")", "in", "the", "tibialis", "muscle", "was", "smaller", "in", "the", "P10", "(", "33", ".", "6", "+", "/", "-", "5", ".", "4", ")", "than", "in", "the", "S", "(", "61", ".", "9", "+", "/", "-", "5", ".", "0", ")", "or", "the", "P100", "(", "71", ".", "3", "+", "/", "-", "9", ".", "6", ")", "groups", ".", "AChR", "expression", "was", "less", "in", "the", "P10", "group", "than", "in", "the", "S", "group", ".", "The", "evoked", "tensions", "correlated", "with", "muscle", "mass", "(", "r", "(", "2", ")", "=", "0", ".", "32", ",", "P", "<", "0", ".", "001", ")", ",", "however", ",", "not", "with", "expression", "of", "AChR", ".", "The", "50", "%", "effective", "dose", "of", "d", "-", "tubocurarine", "did", "not", "correlate", "with", "muscle", "mass", "or", "AChR", "expression", ".", "Our", "results", "suggest", "that", "the", "neuromuscular", "dysfunction", "after", "prednisolone", "is", "dose", "-", "dependent", ",", "and", "derives", "primarily", "from", "muscle", "atrophy", "and", "derives", "less", "so", "from", "changes", "in", "AChR", "expression", ".", "IMPLICATIONS", ":", "The", "mechanisms", "by", "which", "chronic", "glucocorticoid", "therapy", "alters", "neuromuscular", "physiology", "and", "pharmacology", "are", "unclear", ".", "We", "suggest", "that", "the", "observed", "effects", "are", "dose", "-", "dependent", "and", "derive", "primarily", "from", "muscle", "atrophy", "and", "derive", "less", "from", "changes", "in", "acetylcholine", "receptor", "expression", "."]], "ner": [[[0, 0, "Chemical"], [47, 47, "Chemical"], [92, 92, "Chemical"], [102, 102, "Chemical"], [411, 411, "Chemical"], [3, 4, "Disease"], [421, 422, "Disease"], [464, 465, "Disease"], [9, 9, "Disease"], [158, 158, "Disease"], [237, 237, "Disease"], [408, 409, "Disease"], [13, 13, "Chemical"], [63, 63, "Chemical"], [472, 472, "Chemical"], [171, 173, "Chemical"], [279, 281, "Chemical"], [390, 392, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [47, 47, 3, 4, "CID"], [92, 92, 3, 4, "CID"], [102, 102, 3, 4, "CID"], [411, 411, 3, 4, "CID"], [0, 0, 421, 422, "CID"], [0, 0, 464, 465, "CID"], [47, 47, 421, 422, "CID"], [47, 47, 464, 465, "CID"], [92, 92, 421, 422, "CID"], [92, 92, 464, 465, "CID"], [102, 102, 421, 422, "CID"], [102, 102, 464, 465, "CID"], [411, 411, 421, 422, "CID"], [411, 411, 464, 465, "CID"]]], "clusters": [], "translated": "<0>泼尼松龙</0>引起的<5>肌肉功能障碍</5>更多是由<8>萎缩</8>引起的，而不是由<12>乙酰胆碱</12>受体表达改变引起的。大剂量糖皮质激素可通过尚不清楚的机制改变肌肉生理学和对神经肌肉阻断药物的敏感性。我们研究了中等和大剂量<1>泼尼松龙</1>对肌肉功能和药理学的影响，以及它们与肌肉大小和<13>乙酰胆碱</13>受体(AChR)表达变化的关系。经机构批准，35只Sprague-Dawley大鼠被随机分配接受每天皮下注射10 mg/kg <2>泼尼松龙</2> （P10组），100 mg/kg <3>泼尼松龙</3> （P100组），或等量生理盐水（S组）7天。第四组大鼠与P100大鼠配对喂养（限制食物）7天（FR组）。第8天，在胫骨颅肌中测量了神经诱发的峰值抽搐张力、<9>强直</9>张力和易疲劳性，并在体内测量了<15>d-筒箭毒碱</15>剂量反应曲线与与肌肉质量或AChRs的表达有关。与S组相比，P100、FR和P10组的体重增加率降低。P100组的胫骨肌质量小于P10或S组。 P100组诱发的峰值抽搐和<10>强直</10>张力低于P10或S组，但P100组每毫克肌肉质量的张力高于S组。<16>d-筒箭毒碱</16>的50%有效剂量(μg/kg)在P10组(33.6+/-5.4)小于S组(61.9+/-5.0)或P100组(71.3+/-9.6)。 P10组AChR表达低于S组。诱发的紧张与肌肉质量相关(r(2)=0.32，P<0.001)，但与AChR的表达无关。<17>d-筒箭毒碱</17>的50%有效剂量与肌肉质量或AChR表达无关。我们的结果表明，<4>泼尼松龙</4>后的<11>神经肌肉功能障碍</11>具有剂量依赖性，主要源于<6>肌肉萎缩</6>，较少源于AChR表达的变化。意义：慢性糖皮质激素治疗改变神经肌肉生理学和药理学的机制尚不清楚。我们认为，观察到的影响是剂量依赖性的，主要来自<7>肌肉萎缩</7>，较少来自<14>乙酰胆碱</14>受体表达的变化。", "revised": true}
{"doc_key": "20304337", "sentences": [["Brainstem", "dysgenesis", "in", "an", "infant", "prenatally", "exposed", "to", "cocaine", ".", "Many", "authors", "described", "the", "effects", "on", "the", "fetus", "of", "maternal", "cocaine", "abuse", "during", "pregnancy", ".", "Vasoconstriction", "appears", "to", "be", "the", "common", "mechanism", "of", "action", "leading", "to", "a", "wide", "range", "of", "fetal", "anomalies", ".", "We", "report", "on", "an", "infant", "with", "multiple", "cranial", "-", "nerve", "involvement", "attributable", "to", "brainstem", "dysgenesis", ",", "born", "to", "a", "cocaine", "-", "addicted", "mother", "."]], "ner": [[[8, 8, "Chemical"], [49, 53, "Disease"], [20, 21, "Disease"], [62, 64, "Disease"], [40, 41, "Disease"]]], "relations": [[[8, 8, 49, 53, "CID"]]], "clusters": [], "translated": "产前接触 <0>可卡因</0> 的婴儿脑干发育不全。许多作者描述了孕期母亲<2>可卡因滥用</2>对胎儿的影响。血管收缩似乎是导致<4>范围广泛的胎儿异常</4>的常见作用机制。我们报告了一名<1>多发颅神经受累</1>的婴儿，该婴儿可归因于脑干发育不全，其母亲是<3>可卡因成瘾者</3>。", "revised": true}
{"doc_key": "458486", "sentences": [["Tiapride", "in", "levodopa", "-", "induced", "involuntary", "movements", ".", "Tiapride", ",", "a", "substituted", "benzamide", "derivative", "closely", "related", "to", "metoclopramide", ",", "reduced", "levodopa", "-", "induced", "peak", "dose", "involuntary", "movements", "in", "16", "patients", "with", "idiopathic", "Parkinson", "'s", "disease", ".", "However", ",", "an", "unacceptable", "increase", "in", "disability", "from", "Parkinsonism", "with", "aggravation", "of", "end", "-", "of", "-", "dose", "akinesia", "led", "to", "its", "cessation", "in", "14", "patients", ".", "Tiapride", "had", "no", "effect", "on", "levodopa", "-", "induced", "early", "morning", "of", "\"", "off", "-", "period", "\"", "segmental", "dystonia", ".", "These", "results", "fail", "to", "support", "the", "notion", "that", "levodopa", "-", "induced", "dyskinesias", "are", "caused", "by", "overstimulation", "of", "a", "separate", "group", "of", "dopamine", "receptors", "."]], "ner": [[[2, 2, "Chemical"], [20, 20, "Chemical"], [67, 67, "Chemical"], [89, 89, "Chemical"], [5, 6, "Disease"], [25, 26, "Disease"], [53, 53, "Disease"], [92, 92, "Disease"], [0, 0, "Chemical"], [8, 8, "Chemical"], [62, 62, "Chemical"], [31, 34, "Disease"], [44, 44, "Disease"], [79, 79, "Disease"], [12, 12, "Chemical"], [17, 17, "Chemical"], [102, 102, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 25, 26, "CID"], [2, 2, 53, 53, "CID"], [2, 2, 92, 92, "CID"], [20, 20, 5, 6, "CID"], [20, 20, 25, 26, "CID"], [20, 20, 53, 53, "CID"], [20, 20, 92, 92, "CID"], [67, 67, 5, 6, "CID"], [67, 67, 25, 26, "CID"], [67, 67, 53, 53, "CID"], [67, 67, 92, 92, "CID"], [89, 89, 5, 6, "CID"], [89, 89, 25, 26, "CID"], [89, 89, 53, 53, "CID"], [89, 89, 92, 92, "CID"]]], "clusters": [], "translated": "<8>噻必利</8> 在<0>左旋多巴</0>诱发的<4>不自主运动</4>。 <9>噻必利</9>，一种取代的<14>苯甲酰胺</14>衍生物，与<15>甲氧氯普胺</15>密切相关，减少了16名患有<11>特发性帕金森病</11>的患者<1>左旋多巴</1>-诱发的峰值剂量<5>不自主运动</5>。然而，剂量结束时<6>运动不能</6>加重导致<12>帕金森综合症</12>残疾不可接受，因此有14名患者停药。 <10>噻必利</10>对<2>左旋多巴</2>诱发的早期“关闭期”节段性<13>肌张力障碍</13>无影响。这些结果不支持<3>左旋多巴</3>-诱发的<7>运动障碍</7>是由一组单独的<16>多巴胺</16>受体过度刺激引起的观点。", "revised": true}
{"doc_key": "2004015", "sentences": [["Sensitivity", "of", "erythroid", "progenitor", "colonies", "to", "erythropoietin", "in", "azidothymidine", "treated", "immunodeficient", "mice", ".", "The", "anaemia", "induced", "by", "3", "'", "-", "azido", "-", "3", "'", "dideoxythymidine", "(", "AZT", ")", "is", "poorly", "understood", ".", "We", "have", "used", "a", "murine", "model", "of", "AIDS", ",", "infection", "of", "female", "C57BL", "/", "6", "mice", "with", "LP", "-", "BM5", "murine", "leukaemia", "(", "MuLV", ")", "virus", ",", "to", "determine", "if", "AZT", "-", "induced", "anaemia", "is", "due", ",", "in", "part", ",", "to", "decreased", "responsiveness", "of", "erythropoietic", "precursors", "(", "BFU", "-", "e", ")", "to", "erythropoietin", "(", "EPO", ")", ".", "Mice", "in", "the", "early", "stage", "of", "LP", "-", "BM5", "MuLV", "disease", "were", "given", "AZT", "in", "their", "drinking", "water", "at", "1", ".", "0", "and", "2", ".", "5", "mg", "/", "ml", ".", "AZT", "produced", "anaemia", "in", "both", "groups", ",", "in", "a", "dose", "-", "dependent", "fashion", ".", "Despite", "the", "anaemia", ",", "the", "number", "of", "splenic", "and", "bone", "marrow", "BFU", "-", "e", "in", "AZT", "treated", "mice", "increased", "up", "to", "five", "-", "fold", "over", "levels", "observed", "in", "infected", "untreated", "animals", "after", "15", "d", "of", "treatment", ".", "Colony", "formation", "by", "splenic", "and", "bone", "marrow", "BFUe", "was", "stimulated", "at", "lower", "concentrations", "of", "EPO", "in", "mice", "receiving", "AZT", "for", "15", "d", "than", "for", "infected", ",", "untreated", "mice", ".", "By", "day", "30", ",", "sensitivity", "of", "both", "splenic", "and", "bone", "marrow", "BFU", "-", "e", "of", "treated", "animals", "returned", "to", "that", "observed", "from", "cells", "of", "infected", "untreated", "animals", ".", "The", "mean", "plasma", "levels", "of", "EPO", "observed", "in", "AZT", "treated", "mice", "were", "appropriate", "for", "the", "degree", "of", "anaemia", "observed", "when", "compared", "with", "phenylhydrazine", "(", "PHZ", ")", "treated", "mice", ".", "The", "numbers", "of", "BFU", "-", "e", "and", "the", "percentage", "of", "bone", "marrow", "erythroblasts", "observed", "were", "comparable", "in", "AZT", "and", "PHZ", "treated", "mice", "with", "similar", "degrees", "of", "anaemia", ".", "However", ",", "reticulocytosis", "was", "inappropriate", "for", "the", "degree", "of", "anaemia", "observed", "in", "AZT", "treated", "infected", "mice", ".", "AZT", "-", "induced", "peripheral", "anaemia", "in", "the", "face", "of", "increased", "numbers", "of", "BFU", "-", "e", "and", "increased", "levels", "of", "plasma", "EPO", "suggest", "a", "lesion", "in", "terminal", "differentiation", "."]], "ner": [[[8, 8, "Chemical"], [17, 24, "Chemical"], [26, 26, "Chemical"], [62, 62, "Chemical"], [102, 102, "Chemical"], [119, 119, "Chemical"], [148, 148, "Chemical"], [188, 188, "Chemical"], [235, 235, "Chemical"], [273, 273, "Chemical"], [296, 296, "Chemical"], [301, 301, "Chemical"], [14, 14, "Disease"], [65, 65, "Disease"], [121, 121, "Disease"], [135, 135, "Disease"], [244, 244, "Disease"], [282, 282, "Disease"], [293, 293, "Disease"], [305, 305, "Disease"], [10, 10, "Disease"], [39, 39, "Disease"], [41, 41, "Disease"], [53, 53, "Disease"], [286, 286, "Disease"], [249, 249, "Chemical"], [251, 251, "Chemical"], [275, 275, "Chemical"]]], "relations": [[[8, 8, 14, 14, "CID"], [8, 8, 65, 65, "CID"], [8, 8, 121, 121, "CID"], [8, 8, 135, 135, "CID"], [8, 8, 244, 244, "CID"], [8, 8, 282, 282, "CID"], [8, 8, 293, 293, "CID"], [8, 8, 305, 305, "CID"], [17, 24, 14, 14, "CID"], [17, 24, 65, 65, "CID"], [17, 24, 121, 121, "CID"], [17, 24, 135, 135, "CID"], [17, 24, 244, 244, "CID"], [17, 24, 282, 282, "CID"], [17, 24, 293, 293, "CID"], [17, 24, 305, 305, "CID"], [26, 26, 14, 14, "CID"], [26, 26, 65, 65, "CID"], [26, 26, 121, 121, "CID"], [26, 26, 135, 135, "CID"], [26, 26, 244, 244, "CID"], [26, 26, 282, 282, "CID"], [26, 26, 293, 293, "CID"], [26, 26, 305, 305, "CID"], [62, 62, 14, 14, "CID"], [62, 62, 65, 65, "CID"], [62, 62, 121, 121, "CID"], [62, 62, 135, 135, "CID"], [62, 62, 244, 244, "CID"], [62, 62, 282, 282, "CID"], [62, 62, 293, 293, "CID"], [62, 62, 305, 305, "CID"], [102, 102, 14, 14, "CID"], [102, 102, 65, 65, "CID"], [102, 102, 121, 121, "CID"], [102, 102, 135, 135, "CID"], [102, 102, 244, 244, "CID"], [102, 102, 282, 282, "CID"], [102, 102, 293, 293, "CID"], [102, 102, 305, 305, "CID"], [119, 119, 14, 14, "CID"], [119, 119, 65, 65, "CID"], [119, 119, 121, 121, "CID"], [119, 119, 135, 135, "CID"], [119, 119, 244, 244, "CID"], [119, 119, 282, 282, "CID"], [119, 119, 293, 293, "CID"], [119, 119, 305, 305, "CID"], [148, 148, 14, 14, "CID"], [148, 148, 65, 65, "CID"], [148, 148, 121, 121, "CID"], [148, 148, 135, 135, "CID"], [148, 148, 244, 244, "CID"], [148, 148, 282, 282, "CID"], [148, 148, 293, 293, "CID"], [148, 148, 305, 305, "CID"], [188, 188, 14, 14, "CID"], [188, 188, 65, 65, "CID"], [188, 188, 121, 121, "CID"], [188, 188, 135, 135, "CID"], [188, 188, 244, 244, "CID"], [188, 188, 282, 282, "CID"], [188, 188, 293, 293, "CID"], [188, 188, 305, 305, "CID"], [235, 235, 14, 14, "CID"], [235, 235, 65, 65, "CID"], [235, 235, 121, 121, "CID"], [235, 235, 135, 135, "CID"], [235, 235, 244, 244, "CID"], [235, 235, 282, 282, "CID"], [235, 235, 293, 293, "CID"], [235, 235, 305, 305, "CID"], [273, 273, 14, 14, "CID"], [273, 273, 65, 65, "CID"], [273, 273, 121, 121, "CID"], [273, 273, 135, 135, "CID"], [273, 273, 244, 244, "CID"], [273, 273, 282, 282, "CID"], [273, 273, 293, 293, "CID"], [273, 273, 305, 305, "CID"], [296, 296, 14, 14, "CID"], [296, 296, 65, 65, "CID"], [296, 296, 121, 121, "CID"], [296, 296, 135, 135, "CID"], [296, 296, 244, 244, "CID"], [296, 296, 282, 282, "CID"], [296, 296, 293, 293, "CID"], [296, 296, 305, 305, "CID"], [301, 301, 14, 14, "CID"], [301, 301, 65, 65, "CID"], [301, 301, 121, 121, "CID"], [301, 301, 135, 135, "CID"], [301, 301, 244, 244, "CID"], [301, 301, 282, 282, "CID"], [301, 301, 293, 293, "CID"], [301, 301, 305, 305, "CID"]]], "clusters": [], "translated": "<0>叠氮胸苷</0>处理的<20>免疫缺陷</20>小鼠中红细胞祖细胞集落对促红细胞生成素的敏感性。<1>3'-叠氮基-3'双脱氧胸苷</1>（<2>AZT</2>）引起的<12>贫血</12>知之甚少。我们使用<21>AIDS</21>，<22>感染</22>雌性C57BL/6小鼠LP-BM5小鼠<23>白血病</23>(MuLV)病毒模型，来确定如果<3>AZT</3>诱发<13>贫血</13>部分是由于红细胞生成前体（BFU-e）对促红细胞生成素（EPO）的反应性降低。在LP-BM5 MuLV病早期小鼠中，给予1.0和2.5毫克/毫升的<4>AZT</4>于饮用水中。<5>AZT</5>以剂量依赖的方式在两组中产生了<14>贫血</14>。尽管<15>贫血</15>，但在<6>AZT</6>处理的小鼠中脾脏和骨髓BFU-e的数量在处理15天后比在未处理的感染动物中观察到的水平高出五倍。在接受<7>AZT</7>治疗15天的小鼠中，与未受感染的未治疗小鼠相比，在较低浓度的EPO下刺激脾脏和骨髓BFUe的集落形成。到第30天，接受治疗的动物的脾脏和骨髓BFU-e的敏感性恢复到从受感染的未治疗动物的细胞中观察到的水平。与<25>苯肼</25>相比，<8>AZT</8>治疗小鼠观察到的EPO平均血浆水平与观察到的<16>贫血</16>程度相符（<26>PHZ</26>治疗小鼠）。在<9>AZT</9>和<27>PHZ</27>治疗的具有相似程度<17>贫血</17>的小鼠中，观察到的BFU-e数量和骨髓成红细胞百分比相当。然而，<24>网织红细胞增多症</24>与在<10>AZT</10>处理的感染小鼠中观察到的<18>贫血</18>程度不相称。<11>AZT</11>诱导的外周血<19>贫血</19>面对BFU-e数量的增加和血浆EPO水平的增加表明终末分化的损伤。", "revised": true}
{"doc_key": "21294084", "sentences": [["Effects", "of", "the", "hippocampal", "deep", "brain", "stimulation", "on", "cortical", "epileptic", "discharges", "in", "penicillin", "-", "induced", "epilepsy", "model", "in", "rats", ".", "AIM", ":", "Experimental", "and", "clinical", "studies", "have", "revealed", "that", "hippocampal", "DBS", "can", "control", "epileptic", "activity", ",", "but", "the", "mechanism", "of", "action", "is", "obscure", "and", "optimal", "stimulation", "parameters", "are", "not", "clearly", "defined", ".", "The", "aim", "was", "to", "evaluate", "the", "effects", "of", "high", "frequency", "hippocampal", "stimulation", "on", "cortical", "epileptic", "activity", "in", "penicillin", "-", "induced", "epilepsy", "model", ".", "MATERIAL", "AND", "METHODS", ":", "Twenty", "-", "five", "Sprague", "-", "Dawley", "rats", "were", "implanted", "DBS", "electrodes", ".", "In", "group", "-", "1", "(", "n", "=", "10", ")", "hippocampal", "DBS", "was", "off", "and", "in", "the", "group", "-", "2", "(", "n", "=", "10", ")", "hippocampal", "DBS", "was", "on", "(", "185", "Hz", ",", "0", ".", "5V", ",", "1V", ",", "2V", ",", "and", "5V", "for", "60", "sec", ")", "following", "penicillin", "G", "injection", "intracortically", ".", "In", "the", "control", "group", "hippocampal", "DBS", "was", "on", "following", "8", "l", "saline", "injection", "intracortically", ".", "EEG", "recordings", "were", "obtained", "before", "and", "15", "minutes", "following", "penicillin", "-", "G", "injection", ",", "and", "at", "10th", "minutes", "following", "each", "stimulus", "for", "analysis", "in", "terms", "of", "frequency", ",", "amplitude", ",", "and", "power", "spectrum", ".", "RESULTS", ":", "High", "frequency", "hippocampal", "DBS", "suppressed", "the", "acute", "penicillin", "-", "induced", "cortical", "epileptic", "activity", "independent", "from", "stimulus", "intensity", ".", "In", "the", "control", "group", ",", "hippocampal", "stimulation", "alone", "lead", "only", "to", "diffuse", "slowing", "of", "cerebral", "bioelectrical", "activity", "at", "5V", "stimulation", ".", "CONCLUSION", ":", "Our", "results", "revealed", "that", "continuous", "high", "frequency", "stimulation", "of", "the", "hippocampus", "suppressed", "acute", "cortical", "epileptic", "activity", "effectively", "without", "causing", "secondary", "epileptic", "discharges", ".", "These", "results", "are", "important", "in", "terms", "of", "defining", "the", "optimal", "parameters", "of", "hippocampal", "DBS", "in", "patients", "with", "epilepsy", "."]], "ner": [[[138, 139, "Chemical"], [167, 169, "Chemical"], [9, 9, "Disease"], [15, 15, "Disease"], [33, 33, "Disease"], [66, 66, "Disease"], [72, 72, "Disease"], [205, 205, "Disease"], [249, 249, "Disease"], [255, 255, "Disease"], [275, 275, "Disease"], [12, 12, "Chemical"], [69, 69, "Chemical"], [201, 201, "Chemical"]]], "relations": [[[138, 139, 9, 9, "CID"], [138, 139, 15, 15, "CID"], [138, 139, 33, 33, "CID"], [138, 139, 66, 66, "CID"], [138, 139, 72, 72, "CID"], [138, 139, 205, 205, "CID"], [138, 139, 249, 249, "CID"], [138, 139, 255, 255, "CID"], [138, 139, 275, 275, "CID"], [167, 169, 9, 9, "CID"], [167, 169, 15, 15, "CID"], [167, 169, 33, 33, "CID"], [167, 169, 66, 66, "CID"], [167, 169, 72, 72, "CID"], [167, 169, 205, 205, "CID"], [167, 169, 249, 249, "CID"], [167, 169, 255, 255, "CID"], [167, 169, 275, 275, "CID"]]], "clusters": [], "translated": "海马深部脑刺激对<11>青霉素</11>致<3>癫痫</3>大鼠皮层<2>癫痫</2>放电的影响。目的：实验和临床研究表明，海马DBS可控制<4>癫痫</4>活动，但作用机制尚不明确，最佳刺激参数尚不明确。目的是评估高频海马刺激对<12>青霉素</12>诱发的<6>癫痫</6>模型皮层<5>癫痫</5>活动的影响。材料和方法：25 只 Sprague-Dawley 大鼠被植入 DBS 电极。在第 1 组（n = 10）海马 DBS 关闭，第 2 组（n = 10）海马 DBS 打开（185 Hz、0.5V、1V、2V 和 5V，持续60秒）<0>青霉素 G</0>皮内注射。对照组海马DBS在皮层注射8升生理盐水后打开。在<1>青霉素-G</1>注射前和注射后15分钟以及每次刺激后第10分钟获得脑电图记录，以分析频率、振幅和功率谱。结果：高频海马DBS抑制急性<13>青霉素</13>诱导的皮层<7>癫痫</7>活动，与刺激强度无关。在对照组中，海马刺激单独导致大脑生物电活动在5V刺激下弥漫性减慢。结论：我们的研究结果表明，持续高频刺激海马体可有效抑制急性皮层<8>癫痫</8>活动，且不会引起继发性<9>癫痫</9>放电。这些结果对于确定<10>癫痫</10>患者海马DBS的最佳参数非常重要。", "revised": true}
{"doc_key": "20533999", "sentences": [["Dopamine", "is", "not", "essential", "for", "the", "development", "of", "methamphetamine", "-", "induced", "neurotoxicity", ".", "It", "is", "widely", "believed", "that", "dopamine", "(", "DA", ")", "mediates", "methamphetamine", "(", "METH", ")", "-", "induced", "toxicity", "to", "brain", "dopaminergic", "neurons", ",", "because", "drugs", "that", "interfere", "with", "DA", "neurotransmission", "decrease", "toxicity", ",", "whereas", "drugs", "that", "increase", "DA", "neurotransmission", "enhance", "toxicity", ".", "However", ",", "temperature", "effects", "of", "drugs", "that", "have", "been", "used", "to", "manipulate", "brain", "DA", "neurotransmission", "confound", "interpretation", "of", "the", "data", ".", "Here", "we", "show", "that", "the", "recently", "reported", "ability", "of", "L", "-", "dihydroxyphenylalanine", "to", "reverse", "the", "protective", "effect", "of", "alpha", "-", "methyl", "-", "para", "-", "tyrosine", "on", "METH", "-", "induced", "DA", "neurotoxicity", "is", "also", "confounded", "by", "drug", "effects", "on", "body", "temperature", ".", "Further", ",", "we", "show", "that", "mice", "genetically", "engineered", "to", "be", "deficient", "in", "brain", "DA", "develop", "METH", "neurotoxicity", ",", "as", "long", "as", "the", "thermic", "effects", "of", "METH", "are", "preserved", ".", "In", "addition", ",", "we", "demonstrate", "that", "mice", "genetically", "engineered", "to", "have", "unilateral", "brain", "DA", "deficits", "develop", "METH", "-", "induced", "dopaminergic", "deficits", "that", "are", "of", "comparable", "magnitude", "on", "both", "sides", "of", "the", "brain", ".", "Taken", "together", ",", "these", "findings", "demonstrate", "that", "DA", "is", "not", "essential", "for", "the", "development", "of", "METH", "-", "induced", "dopaminergic", "neurotoxicity", "and", "suggest", "that", "mechanisms", "independent", "of", "DA", "warrant", "more", "intense", "investigation", "."]], "ner": [[[8, 8, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [101, 101, "Chemical"], [131, 131, "Chemical"], [141, 141, "Chemical"], [161, 161, "Chemical"], [193, 193, "Chemical"], [11, 11, "Disease"], [105, 105, "Disease"], [132, 132, "Disease"], [197, 197, "Disease"], [0, 0, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [40, 40, "Chemical"], [49, 49, "Chemical"], [67, 67, "Chemical"], [104, 104, "Chemical"], [129, 129, "Chemical"], [158, 158, "Chemical"], [185, 185, "Chemical"], [204, 204, "Chemical"], [29, 29, "Disease"], [43, 43, "Disease"], [52, 52, "Disease"], [164, 165, "Disease"], [84, 86, "Chemical"], [93, 99, "Chemical"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 105, 105, "CID"], [8, 8, 132, 132, "CID"], [8, 8, 197, 197, "CID"], [23, 23, 11, 11, "CID"], [23, 23, 105, 105, "CID"], [23, 23, 132, 132, "CID"], [23, 23, 197, 197, "CID"], [25, 25, 11, 11, "CID"], [25, 25, 105, 105, "CID"], [25, 25, 132, 132, "CID"], [25, 25, 197, 197, "CID"], [101, 101, 11, 11, "CID"], [101, 101, 105, 105, "CID"], [101, 101, 132, 132, "CID"], [101, 101, 197, 197, "CID"], [131, 131, 11, 11, "CID"], [131, 131, 105, 105, "CID"], [131, 131, 132, 132, "CID"], [131, 131, 197, 197, "CID"], [141, 141, 11, 11, "CID"], [141, 141, 105, 105, "CID"], [141, 141, 132, 132, "CID"], [141, 141, 197, 197, "CID"], [161, 161, 11, 11, "CID"], [161, 161, 105, 105, "CID"], [161, 161, 132, 132, "CID"], [161, 161, 197, 197, "CID"], [193, 193, 11, 11, "CID"], [193, 193, 105, 105, "CID"], [193, 193, 132, 132, "CID"], [193, 193, 197, 197, "CID"]]], "clusters": [], "translated": "<12>多巴胺</12> 对于<0>甲基苯丙胺</0>诱导的<8>神经毒性</8>的发展不是必需的。人们普遍认为<13>多巴胺</13>（<14>DA</14>）介导<1>甲基苯丙胺</1>（<2>METH</2>）诱导的<23>毒性</23>对大脑多巴胺能神经元，因为干扰<15>DA</15>神经传递的药物会降低<24>毒性</24>，而增加<16>DA</16>神经传递的药物会增强<25>毒性</25>。然而，用于控制大脑<17>DA</17>神经传递的药物的温度影响混淆了对数据的解释。在这里，我们表明最近报道的<27>L-二羟基苯丙氨酸</27>能够逆转<28>α-甲基-对-酪氨酸</28>对<3>METH</3>的保护作用诱导<18>DA</18> <9>神经毒性</9>也被药物对体温的影响所混淆。此外，我们表明只要<5>METH</5>的热效应存在，基因工程小鼠大脑<19>DA</19>发展<4>METH</4><10>神经毒性</10>。此外，我们证明基因工程处理的单侧脑部<20>DA</20>缺陷小鼠会出现<6>METH</6>-诱导的<26>多巴胺能缺陷</26>，两侧的程度相当的大脑。综上所述，这些发现表明<21>DA</21>对于<7>METH</7>诱导的多巴胺能<11>神经毒性</11>的发展不是必需的，并表明独立于<22>DA</22>的机制需要进行更深入的调查。", "revised": true}
{"doc_key": "19674115", "sentences": [["Recurrent", "dysosmia", "induced", "by", "pyrazinamide", ".", "Pyrazinamide", "can", "have", "adverse", "effects", "such", "as", "hepatic", "toxicity", ",", "hyperuricemia", "or", "digestive", "disorders", ".", "In", "rare", "cases", ",", "alterations", "in", "taste", "and", "smell", "function", "have", "been", "reported", "for", "pyrazinamide", "when", "combined", "with", "other", "drugs", ".", "We", "report", "a", "case", "of", "reversible", "olfactory", "disorder", "related", "to", "pyrazinamide", "in", "a", "woman", ",", "with", "a", "positive", "rechallenge", ".", "The", "patient", "presented", "every", "day", "a", "sensation", "of", "smelling", "something", "burning", "15", "min", "after", "drug", "intake", ".", "Dysosmia", "disappeared", "completely", "after", "pyrazinamide", "withdrawal", "and", "recurred", "after", "its", "rechallenge", ".", "The", "case", "was", "reported", "to", "the", "Tunisian", "Centre", "of", "Pharmacovigilance", "."]], "ner": [[[4, 4, "Chemical"], [6, 6, "Chemical"], [35, 35, "Chemical"], [52, 52, "Chemical"], [83, 83, "Chemical"], [1, 1, "Disease"], [48, 49, "Disease"], [79, 79, "Disease"], [13, 14, "Disease"], [16, 16, "Disease"]]], "relations": [[[4, 4, 1, 1, "CID"], [4, 4, 48, 49, "CID"], [4, 4, 79, 79, "CID"], [6, 6, 1, 1, "CID"], [6, 6, 48, 49, "CID"], [6, 6, 79, 79, "CID"], [35, 35, 1, 1, "CID"], [35, 35, 48, 49, "CID"], [35, 35, 79, 79, "CID"], [52, 52, 1, 1, "CID"], [52, 52, 48, 49, "CID"], [52, 52, 79, 79, "CID"], [83, 83, 1, 1, "CID"], [83, 83, 48, 49, "CID"], [83, 83, 79, 79, "CID"]]], "clusters": [], "translated": "<0>吡嗪酰胺</0>引起的反复<5>嗅觉障碍</5>。<1>吡嗪酰胺</1>可产生不良反应，如<8>肝毒性</8>、<9>高尿酸血症</9>或消化系统紊乱。在极少数情况下，<2>吡嗪酰胺</2>与其他药物联合使用时，味觉和嗅觉功能会发生改变。我们报告了一例与<3>吡嗪酰胺</3>相关的可逆性<6>嗅觉障碍</6>的女性患者，并进行了积极的再挑战。患者每天服药15分钟后均有闻到烧灼感。<7>嗅觉障碍</7>在<4>吡嗪酰胺</4>停药后完全消失，再次服用后又复发。该病例已报告给突尼斯药物警戒中心。", "revised": true}
{"doc_key": "2709684", "sentences": [["Phlorizin", "-", "induced", "glycosuria", "does", "not", "prevent", "gentamicin", "nephrotoxicity", "in", "rats", ".", "Because", "rats", "with", "streptozotocin", "-", "induced", "diabetes", "mellitus", "(", "DM", ")", "have", "a", "high", "solute", "diuresis", "(", "glycosuria", "of", "10", "to", "12", "g", "/", "day", ")", ",", "we", "have", "suggested", "that", "this", "may", "in", "part", "be", "responsible", "for", "their", "resistance", "to", "gentamicin", "-", "induced", "acute", "renal", "failure", "(", "ARF", ")", ".", "The", "protection", "from", "gentamicin", "nephrotoxicity", "was", "studied", "in", "non", "-", "diabetic", "rats", "with", "chronic", "solute", "diuresis", "induced", "by", "blockage", "of", "tubular", "glucose", "reabsorption", "with", "phlorizin", "(", "P", ")", ".", "DM", "rats", "with", "mild", "glycosuria", "(", "similar", "in", "degree", "to", "that", "of", "the", "P", "treated", "animals", ")", "were", "also", "studied", ".", "Unanesthetized", "adult", "female", ",", "Sprague", "-", "Dawley", "rats", "were", "divided", "in", "four", "groups", "and", "studied", "for", "15", "days", ".", "Group", "1", "(", "P", "alone", ")", "received", "P", ",", "360", "mg", "/", "day", ",", "for", "15", "days", ";", "Group", "II", "(", "P", "+", "gentamicin", ")", ";", "Group", "III", "(", "gentamicin", "alone", ")", "and", "Group", "IV", "(", "mild", "DM", "+", "gentamicin", ")", ".", "Nephrotoxic", "doses", "(", "40", "mg", "/", "kg", "body", "wt", "/", "day", ")", "of", "gentamicin", "were", "injected", "during", "the", "last", "nine", "days", "of", "study", "to", "the", "animals", "of", "groups", "II", "to", "IV", ".", "In", "Group", "I", ",", "P", "induced", "a", "moderate", "and", "stable", "glycosuria", "(", "3", ".", "9", "+", "/", "-", "0", ".", "1", "g", "/", "day", ",", "SE", ")", ",", "and", "no", "functional", "or", "morphologic", "evidence", "of", "renal", "dysfunction", "(", "baseline", "CCr", "2", ".", "1", "+", "/", "-", "0", ".", "1", "ml", "/", "min", ",", "undetectable", "lysozymuria", ")", "or", "damage", "(", "tubular", "necrosis", "score", "[", "maximum", "4", "]", ",", "zero", ")", ".", "In", "Group", "II", ",", "P", "did", "not", "prevent", "gentamicin", "-", "ARF", "(", "maximal", "decrease", "in", "CCr", "at", "day", "9", ".", "89", "%", ",", "P", "less", "than", "0", ".", "001", ";", "peak", "lysozymuria", ",", "1863", "+", "/", "-", "321", "micrograms", "/", "day", ";", "and", "tubular", "necrosis", "score", ",", "3", ".", "9", "+", "/", "-", "0", ".", "1", ")", ".", "These", "values", "were", "not", "different", "from", "those", "of", "Group", "III", ":", "maximal", "decrease", "in", "CCr", "73", "%", "(", "P", "less", "than", "0", ".", "001", ")", ";", "lysozymuria", ",", "2147", "+", "/", "-", "701", "micrograms", "/", "day", ";", "tubular", "necrosis", "score", ",", "3", ".", "8", "+", "/", "-", "0", ".", "1", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[7, 7, "Chemical"], [53, 53, "Chemical"], [66, 66, "Chemical"], [155, 155, "Chemical"], [161, 161, "Chemical"], [171, 171, "Chemical"], [187, 187, "Chemical"], [284, 284, "Chemical"], [56, 58, "Disease"], [60, 60, "Disease"], [286, 286, "Disease"], [15, 15, "Chemical"], [18, 19, "Disease"], [21, 21, "Disease"], [73, 73, "Disease"], [92, 92, "Disease"], [169, 169, "Disease"], [0, 0, "Chemical"], [87, 87, "Chemical"], [89, 89, "Chemical"], [105, 105, "Chemical"], [135, 135, "Chemical"], [139, 139, "Chemical"], [153, 153, "Chemical"], [210, 210, "Chemical"], [280, 280, "Chemical"], [299, 299, "Chemical"], [352, 352, "Chemical"], [3, 3, "Disease"], [29, 29, "Disease"], [96, 96, "Disease"], [216, 216, "Disease"], [8, 8, "Disease"], [67, 67, "Disease"], [174, 174, "Disease"], [241, 242, "Disease"], [265, 266, "Disease"], [319, 320, "Disease"], [371, 372, "Disease"], [84, 84, "Chemical"]]], "relations": [[[7, 7, 56, 58, "CID"], [7, 7, 60, 60, "CID"], [7, 7, 286, 286, "CID"], [53, 53, 56, 58, "CID"], [53, 53, 60, 60, "CID"], [53, 53, 286, 286, "CID"], [66, 66, 56, 58, "CID"], [66, 66, 60, 60, "CID"], [66, 66, 286, 286, "CID"], [155, 155, 56, 58, "CID"], [155, 155, 60, 60, "CID"], [155, 155, 286, 286, "CID"], [161, 161, 56, 58, "CID"], [161, 161, 60, 60, "CID"], [161, 161, 286, 286, "CID"], [171, 171, 56, 58, "CID"], [171, 171, 60, 60, "CID"], [171, 171, 286, 286, "CID"], [187, 187, 56, 58, "CID"], [187, 187, 60, 60, "CID"], [187, 187, 286, 286, "CID"], [284, 284, 56, 58, "CID"], [284, 284, 60, 60, "CID"], [284, 284, 286, 286, "CID"], [15, 15, 18, 19, "CID"], [15, 15, 21, 21, "CID"], [15, 15, 73, 73, "CID"], [15, 15, 92, 92, "CID"], [15, 15, 169, 169, "CID"]]], "clusters": [], "translated": "<17>根皮苷</17>诱导的<28>糖尿</28>不能预防大鼠的<0>庆大霉素</0><32>肾毒性</32>。因为<11>链脲佐菌素</11>诱导的<12>糖尿病</12>大鼠（<13>DM</13>）具有高溶质利尿（<29>糖尿</29>为10~12 g/天），我们认为这可能部分是他们对<1>庆大霉素</1>诱导的<8>急性肾功能衰竭</8>（<9>ARF</9>）产生耐药性的原因。在非<14>糖尿病</14>大鼠中研究了<2>庆大霉素</2>的<33>肾毒性</33>保护作用，慢性溶质利尿由肾小管<39>葡萄糖</39>阻塞引起用<18>根皮苷</18>（<19>P</19>）重吸收。还对具有轻度<30>糖尿</30>（与<20>P</20>治疗动物的程度相似）的<15>DM</15>大鼠进行了研究。未麻醉的成年雌性Sprague-Dawley大鼠被分成四组并研究15天。第1组（单独使用<21>P</21>）接受<22>P</22>，每天360毫克，持续15天；II组（<23>P</23>+<3>庆大霉素</3>）；第三组（单独<4>庆大霉素</4>）和第四组（轻度<16>DM</16>+<5>庆大霉素</5>）。<34>肾毒性</34>剂量（40毫克/千克体重/天）<6>庆大霉素</6>在研究的最后9天被注射到组II至IV的动物。在第I组中，<24>P</24>引起中度和稳定的<31>糖尿</31>（3.9+/-0.1 g/天，SE），并且没有功能或形态学证据<35>肾功能不全</35>（基线CCr2.1+/-0.1毫升/分钟，溶菌尿检测不到）或损害（<36>肾小管坏死</36>评分[最大值4]，零）。在第II组中，<25>P</25>没有阻止<7>庆大霉素</7> - <10>ARF</10>（第9天CCr的最大下降89%，<26>P</26>小于0.001；峰值溶菌酶，1863+/-321微克/天；<37>肾小管坏死</37>评分，3.9+/-0.1）。这些值与组III的值没有差异：CCr的最大降低73%（<27>P</27>小于0.001）；溶菌尿，2147+/-701微克/天；<38>肾小管坏死</38>评分，3.8+/-0.1。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "20727411", "sentences": [["Neural", "correlates", "of", "S", "-", "ketamine", "induced", "psychosis", "during", "overt", "continuous", "verbal", "fluency", ".", "The", "glutamatergic", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "has", "been", "implicated", "in", "the", "pathophysiology", "of", "schizophrenia", ".", "Administered", "to", "healthy", "volunteers", ",", "a", "subanesthetic", "dose", "of", "the", "non", "-", "competitive", "NMDA", "receptor", "antagonist", "ketamine", "leads", "to", "psychopathological", "symptoms", "similar", "to", "those", "observed", "in", "schizophrenia", ".", "In", "patients", "with", "schizophrenia", ",", "ketamine", "exacerbates", "the", "core", "symptoms", "of", "illness", ",", "supporting", "the", "hypothesis", "of", "a", "glutamatergic", "dysfunction", ".", "In", "a", "counterbalanced", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", "design", ",", "healthy", "subjects", "were", "administered", "a", "continuous", "subanesthetic", "S", "-", "ketamine", "infusion", "while", "differences", "in", "BOLD", "responses", "measured", "with", "fMRI", "were", "detected", ".", "During", "the", "scanning", "period", ",", "subjects", "performed", "continuous", "overt", "verbal", "fluency", "tasks", "(", "phonological", ",", "lexical", "and", "semantic", ")", ".", "Ketamine", "-", "induced", "psychopathological", "symptoms", "were", "assessed", "with", "the", "Positive", "and", "Negative", "Syndrome", "Scale", "(", "PANSS", ")", ".", "Ketamine", "elicited", "psychosis", "like", "psychopathology", ".", "Post", "-", "hoc", "t", "-", "tests", "revealed", "significant", "differences", "between", "placebo", "and", "ketamine", "for", "the", "amounts", "of", "words", "generated", "during", "lexical", "and", "semantic", "verbal", "fluency", ",", "while", "the", "phonological", "domain", "remained", "unaffected", ".", "Ketamine", "led", "to", "enhanced", "cortical", "activations", "in", "supramarginal", "and", "frontal", "brain", "regions", "for", "phonological", "and", "lexical", "verbal", "fluency", ",", "but", "not", "for", "semantic", "verbal", "fluency", ".", "Ketamine", "induces", "activation", "changes", "in", "healthy", "subjects", "similar", "to", "those", "observed", "in", "patients", "with", "schizophrenia", ",", "particularly", "in", "frontal", "and", "temporal", "brain", "regions", ".", "Our", "results", "provide", "further", "support", "for", "the", "hypothesis", "of", "an", "NMDA", "receptor", "dysfunction", "in", "the", "pathophysiology", "of", "schizophrenia", "."]], "ner": [[[52, 52, "Chemical"], [69, 69, "Chemical"], [141, 141, "Chemical"], [159, 159, "Chemical"], [177, 177, "Chemical"], [198, 198, "Chemical"], [224, 224, "Chemical"], [7, 7, "Disease"], [161, 161, "Disease"], [16, 22, "Chemical"], [24, 24, "Chemical"], [49, 49, "Chemical"], [258, 258, "Chemical"], [34, 34, "Disease"], [62, 62, "Disease"], [67, 67, "Disease"], [238, 238, "Disease"], [265, 265, "Disease"], [82, 83, "Disease"]]], "relations": [[[52, 52, 7, 7, "CID"], [52, 52, 161, 161, "CID"], [69, 69, 7, 7, "CID"], [69, 69, 161, 161, "CID"], [141, 141, 7, 7, "CID"], [141, 141, 161, 161, "CID"], [159, 159, 7, 7, "CID"], [159, 159, 161, 161, "CID"], [177, 177, 7, 7, "CID"], [177, 177, 161, 161, "CID"], [198, 198, 7, 7, "CID"], [198, 198, 161, 161, "CID"], [224, 224, 7, 7, "CID"], [224, 224, 161, 161, "CID"]]], "clusters": [], "translated": "S-氯胺酮的神经相关性在明显连续的语言流利期间诱发<7>精神病</7>。谷氨酸能<9>N-甲基-D-天冬氨酸</9> (<10>NMDA</10>) 受体与<13>精神分裂症</13>的病理生理学有关。对健康志愿者进行亚麻醉剂量的非竞争性<11>NMDA</11>受体拮抗剂<0>氯胺酮</0>会导致类似于<14>精神分裂症</14>中观察到的精神病理学症状。在<15>精神分裂症</15>患者中，<1>氯胺酮</1>加剧了疾病的核心症状，支持了<18>谷氨酸能功能障碍</18>的假说。在一项平衡、安慰剂对照、双盲研究设计中，健康受试者接受连续亚麻醉S-氯胺酮输注，同时检测到用fMRI测量的BOLD反应的差异。在扫描期间，受试者执行连续的明显语言流畅性任务（语音、词汇和语义）。<2>氯胺酮</2>诱发的精神病理学症状采用阳性和阴性症状量表(PANSS)进行评估。<3>氯胺酮</3>引发<8>精神病</8>样精神病理学。事后t检验显示安慰剂和<4>氯胺酮</4>在词汇和语义语言流畅性期间产生的单词量方面存在显着差异，而语音领域保持不受影响。<5>氯胺酮</5>导致超边缘和额叶大脑区域的皮质激活增强，以提高语音和词汇的流畅性，但不会增强语义的流畅性。<6>氯胺酮</6>在健康受试者中引起的激活变化与在<16>精神分裂症</16>患者中观察到的相似，特别是在额叶和颞叶脑区。我们的结果进一步支持了<12>NMDA</12>受体功能障碍在<17>精神分裂症</17>病理生理学中的假设。", "revised": true}
{"doc_key": "20103708", "sentences": [["The", "protective", "role", "of", "Nrf2", "in", "streptozotocin", "-", "induced", "diabetic", "nephropathy", ".", "OBJECTIVE", ":", "Diabetic", "nephropathy", "is", "one", "of", "the", "major", "causes", "of", "renal", "failure", ",", "which", "is", "accompanied", "by", "the", "production", "of", "reactive", "oxygen", "species", "(", "ROS", ")", ".", "Nrf2", "is", "the", "primary", "transcription", "factor", "that", "controls", "the", "antioxidant", "response", "essential", "for", "maintaining", "cellular", "redox", "homeostasis", ".", "Here", ",", "we", "report", "our", "findings", "demonstrating", "a", "protective", "role", "of", "Nrf2", "against", "diabetic", "nephropathy", ".", "RESEARCH", "DESIGN", "AND", "METHODS", ":", "We", "explore", "the", "protective", "role", "of", "Nrf2", "against", "diabetic", "nephropathy", "using", "human", "kidney", "biopsy", "tissues", "from", "diabetic", "nephropathy", "patients", ",", "a", "streptozotocin", "-", "induced", "diabetic", "nephropathy", "model", "in", "Nrf2", "(", "-", "/", "-", ")", "mice", ",", "and", "cultured", "human", "mesangial", "cells", ".", "RESULTS", ":", "The", "glomeruli", "of", "human", "diabetic", "nephropathy", "patients", "were", "under", "oxidative", "stress", "and", "had", "elevated", "Nrf2", "levels", ".", "In", "the", "animal", "study", ",", "Nrf2", "was", "demonstrated", "to", "be", "crucial", "in", "ameliorating", "streptozotocin", "-", "induced", "renal", "damage", ".", "This", "is", "evident", "by", "Nrf2", "(", "-", "/", "-", ")", "mice", "having", "higher", "ROS", "production", "and", "suffering", "from", "greater", "oxidative", "DNA", "damage", "and", "renal", "injury", "compared", "with", "Nrf2", "(", "+", "/", "+", ")", "mice", ".", "Mechanistic", "studies", "in", "both", "in", "vivo", "and", "in", "vitro", "systems", "showed", "that", "the", "Nrf2", "-", "mediated", "protection", "against", "diabetic", "nephropathy", "is", ",", "at", "least", ",", "partially", "through", "inhibition", "of", "transforming", "growth", "factor", "-", "beta1", "(", "TGF", "-", "beta1", ")", "and", "reduction", "of", "extracellular", "matrix", "production", ".", "In", "human", "renal", "mesangial", "cells", ",", "high", "glucose", "induced", "ROS", "production", "and", "activated", "expression", "of", "Nrf2", "and", "its", "downstream", "genes", ".", "Furthermore", ",", "activation", "or", "overexpression", "of", "Nrf2", "inhibited", "the", "promoter", "activity", "of", "TGF", "-", "beta1", "in", "a", "dose", "-", "dependent", "manner", ",", "whereas", "knockdown", "of", "Nrf2", "by", "siRNA", "enhanced", "TGF", "-", "beta1", "transcription", "and", "fibronectin", "production", ".", "CONCLUSIONS", ":", "This", "work", "clearly", "indicates", "a", "protective", "role", "of", "Nrf2", "in", "diabetic", "nephropathy", ",", "suggesting", "that", "dietary", "or", "therapeutic", "activation", "of", "Nrf2", "could", "be", "used", "as", "a", "strategy", "to", "prevent", "or", "slow", "down", "the", "progression", "of", "diabetic", "nephropathy", "."]], "ner": [[[6, 6, "Chemical"], [100, 100, "Chemical"], [153, 153, "Chemical"], [9, 10, "Disease"], [14, 15, "Disease"], [71, 72, "Disease"], [87, 88, "Disease"], [95, 96, "Disease"], [103, 104, "Disease"], [127, 128, "Disease"], [212, 213, "Disease"], [310, 311, "Disease"], [335, 336, "Disease"], [23, 24, "Disease"], [156, 157, "Disease"], [182, 183, "Disease"], [34, 34, "Chemical"], [247, 247, "Chemical"]]], "relations": [[[6, 6, 9, 10, "CID"], [6, 6, 14, 15, "CID"], [6, 6, 71, 72, "CID"], [6, 6, 87, 88, "CID"], [6, 6, 95, 96, "CID"], [6, 6, 103, 104, "CID"], [6, 6, 127, 128, "CID"], [6, 6, 212, 213, "CID"], [6, 6, 310, 311, "CID"], [6, 6, 335, 336, "CID"], [100, 100, 9, 10, "CID"], [100, 100, 14, 15, "CID"], [100, 100, 71, 72, "CID"], [100, 100, 87, 88, "CID"], [100, 100, 95, 96, "CID"], [100, 100, 103, 104, "CID"], [100, 100, 127, 128, "CID"], [100, 100, 212, 213, "CID"], [100, 100, 310, 311, "CID"], [100, 100, 335, 336, "CID"], [153, 153, 9, 10, "CID"], [153, 153, 14, 15, "CID"], [153, 153, 71, 72, "CID"], [153, 153, 87, 88, "CID"], [153, 153, 95, 96, "CID"], [153, 153, 103, 104, "CID"], [153, 153, 127, 128, "CID"], [153, 153, 212, 213, "CID"], [153, 153, 310, 311, "CID"], [153, 153, 335, 336, "CID"]]], "clusters": [], "translated": "Nrf2对<0>链脲佐菌素</0>诱导的<3>糖尿病肾病</3>的保护作用。目的：<4>糖尿病肾病</4>是<13>肾功能衰竭</13>的主要原因之一，并伴有活性<16>氧</16>物质（ROS）的产生。Nrf2 是控制维持细胞氧化还原稳态所必需的抗氧化反应的主要转录因子。在这里，我们报告了我们的发现，证明 Nrf2 对<5>糖尿病肾病</5>具有保护作用。研究设计和方法：我们使用来自<7>糖尿病肾病</7>患者的人肾活检组织探索Nrf2对<6>糖尿病肾病</6>的保护作用，<1>链脲佐菌素</1> -诱导<8>糖尿病肾病</8>Nrf2(-/-)小鼠模型，培养人系膜细胞。结果：人类<9>糖尿病肾病</9>患者的肾小球处于氧化应激状态，Nrf2水平升高。在动物研究中，Nrf2被证明对改善<2>链脲佐菌素</2>-诱导的<14>肾损伤</14>至关重要。与Nrf2（+/+）小鼠相比，Nrf2（-/-）小鼠具有更高的ROS产生并遭受更大的氧化DNA损伤和<15>肾损伤</15>，这一点很明显。体内和体外系统的机制研究表明，Nrf2介导的对<10>糖尿病肾病</10>的保护至少部分是通过抑制转化生长因子-beta1（TGF-beta1）和减少细胞外基质生产。在人肾系膜细胞中，高<17>葡萄糖</17>诱导ROS产生并激活Nrf2及其下游基因的表达。此外，Nrf2的激活或过表达以剂量依赖性方式抑制TGF-beta1的启动子活性，而通过siRNA敲低Nrf2可增强TGF-beta1的转录和纤连蛋白的产生。结论：这项工作清楚地表明Nrf2在<11>糖尿病肾病</11>中的保护作用，表明Nrf2的饮食或治疗激活可用作预防或减缓<12>糖尿病肾病</12>进展的策略。", "revised": true}
{"doc_key": "10411803", "sentences": [["Severe", "immune", "hemolytic", "anemia", "associated", "with", "prophylactic", "use", "of", "cefotetan", "in", "obstetric", "and", "gynecologic", "procedures", ".", "Second", "-", "and", "third", "-", "generation", "cephalosporins", ",", "especially", "cefotetan", ",", "are", "increasingly", "associated", "with", "severe", ",", "sometimes", "fatal", "immune", "hemolytic", "anemia", ".", "We", "noticed", "that", "10", "of", "our", "35", "cases", "of", "cefotetan", "-", "induced", "hemolytic", "anemias", "were", "in", "patients", "who", "had", "received", "cefotetan", "prophylactically", "for", "obstetric", "and", "gynecologic", "procedures", ".", "Eight", "of", "these", "cases", "of", "severe", "immune", "hemolytic", "anemia", "are", "described", "."]], "ner": [[[9, 9, "Chemical"], [25, 25, "Chemical"], [48, 48, "Chemical"], [59, 59, "Chemical"], [2, 3, "Disease"], [36, 37, "Disease"], [51, 52, "Disease"], [74, 75, "Disease"], [22, 22, "Chemical"]]], "relations": [[[9, 9, 2, 3, "CID"], [9, 9, 36, 37, "CID"], [9, 9, 51, 52, "CID"], [9, 9, 74, 75, "CID"], [25, 25, 2, 3, "CID"], [25, 25, 36, 37, "CID"], [25, 25, 51, 52, "CID"], [25, 25, 74, 75, "CID"], [48, 48, 2, 3, "CID"], [48, 48, 36, 37, "CID"], [48, 48, 51, 52, "CID"], [48, 48, 74, 75, "CID"], [59, 59, 2, 3, "CID"], [59, 59, 36, 37, "CID"], [59, 59, 51, 52, "CID"], [59, 59, 74, 75, "CID"]]], "clusters": [], "translated": "严重的免疫性<4>溶血性贫血</4>与在妇产科手术中预防性使用<0>头孢替坦</0>有关。第二代和第三代<8>头孢菌素</8>，尤其是<1>头孢替坦</1>，越来越多地与严重的、有时是致命的免疫性<5>溶血性贫血</5>相关。我们注意到，在我们的 35 例<2>头孢替坦</2>引起的<6>溶血性贫血</6>中，有 10 例患者在妇产科手术中预防性接受了<3>头孢替坦</3>。描述了其中八例严重免疫性<7>溶血性贫血</7>。", "revised": true}
{"doc_key": "12907924", "sentences": [["Methylphenidate", "-", "induced", "obsessive", "-", "compulsive", "symptoms", "in", "an", "elderly", "man", ".", "An", "82", "-", "year", "-", "old", "man", "with", "treatment", "-", "resistant", "depression", "and", "early", "Alzheimer", "'s", "disease", "was", "started", "on", "methylphenidate", ".", "Significant", "obsessive", "-", "compulsive", "behavior", "ensued", "but", "diminished", "over", "several", "weeks", "when", "methylphenidate", "was", "replaced", "by", "fluvoxamine", ".", "The", "patient", "had", "no", "prior", "psychiatric", "history", ",", "but", "he", "had", "a", "sister", "with", "obsessive", "-", "compulsive", "disorder", ".", "It", "appears", "that", "methylphenidate", "precipitated", "the", "patient", "'s", "pathological", "behavior", "."]], "ner": [[[0, 0, "Chemical"], [32, 32, "Chemical"], [46, 46, "Chemical"], [74, 74, "Chemical"], [3, 6, "Disease"], [35, 38, "Disease"], [66, 69, "Disease"], [20, 23, "Disease"], [26, 28, "Disease"], [57, 57, "Disease"], [50, 50, "Chemical"]]], "relations": [[[0, 0, 3, 6, "CID"], [0, 0, 35, 38, "CID"], [0, 0, 66, 69, "CID"], [32, 32, 3, 6, "CID"], [32, 32, 35, 38, "CID"], [32, 32, 66, 69, "CID"], [46, 46, 3, 6, "CID"], [46, 46, 35, 38, "CID"], [46, 46, 66, 69, "CID"], [74, 74, 3, 6, "CID"], [74, 74, 35, 38, "CID"], [74, 74, 66, 69, "CID"]]], "clusters": [], "translated": "<0>哌醋甲酯</0>在一位老人身上引起<4>强迫症状</4>。一名患有<7>难治性抑郁症</7>和早期<8>阿尔茨海默病</8>的82岁男性开始服用<1>哌醋甲酯</1>。明显的<5>强迫行为</5>随之而来，但在数周内有所减轻，当<2>哌醋甲酯</2>被<10>氟伏沙明</10> 取代后。患者既往无<9>精神病</9>病史，但其姐姐有<6>强迫症</6>。看来<3>哌醋甲酯</3>促成了患者的病理行为。", "revised": true}
{"doc_key": "16132524", "sentences": [["Intracavitary", "chemotherapy", "(", "paclitaxel", "/", "carboplatin", "liquid", "crystalline", "cubic", "phases", ")", "for", "recurrent", "glioblastoma", "-", "-", "clinical", "observations", ".", "Human", "malignant", "brain", "tumors", "have", "a", "poor", "prognosis", "in", "spite", "of", "surgery", "and", "radiation", "therapy", ".", "Cubic", "phases", "consist", "of", "curved", "biocontinuous", "lipid", "bilayers", ",", "separating", "two", "congruent", "networks", "of", "water", "channels", ".", "Used", "as", "a", "host", "for", "cytotoxic", "drugs", ",", "the", "gel", "-", "like", "matrix", "can", "easily", "be", "applied", "to", "the", "walls", "of", "a", "surgical", "resection", "cavity", ".", "For", "human", "glioblastoma", "recurrences", ",", "the", "feasibility", ",", "safety", ",", "and", "short", "-", "term", "effects", "of", "a", "surgical", "intracavitary", "application", "of", "paclitaxel", "and", "carboplatin", "encapsulated", "by", "liquid", "crystalline", "cubic", "phases", "are", "examined", "in", "a", "pilot", "study", ".", "A", "total", "of", "12", "patients", "with", "a", "recurrence", "of", "a", "glioblastoma", "multiforme", "underwent", "re", "-", "resection", "and", "received", "an", "intracavitary", "application", "of", "paclitaxel", "and", "carboplatin", "cubic", "phases", "in", "different", "dosages", ".", "Six", "of", "the", "patients", "received", "more", "than", "15", "mg", "paclitaxel", "and", "suffered", "from", "moderate", "to", "severe", "brain", "edema", ",", "while", "the", "remaining", "patients", "received", "only", "a", "total", "of", "15", "mg", "paclitaxel", ".", "In", "the", "latter", "group", ",", "brain", "edema", "was", "markedly", "reduced", "and", "dealt", "medically", ".", "Intracavitary", "chemotherapy", "in", "recurrent", "glioblastoma", "using", "cubic", "phases", "is", "feasible", "and", "safe", ",", "yet", "the", "clinical", "benefit", "remains", "to", "be", "examined", "in", "a", "clinical", "phase", "II", "study", "."]], "ner": [[[3, 3, "Chemical"], [99, 99, "Chemical"], [137, 137, "Chemical"], [155, 155, "Chemical"], [176, 176, "Chemical"], [162, 163, "Disease"], [183, 184, "Disease"], [13, 13, "Disease"], [80, 80, "Disease"], [125, 125, "Disease"], [196, 196, "Disease"], [21, 22, "Disease"], [5, 5, "Chemical"], [101, 101, "Chemical"], [139, 139, "Chemical"]]], "relations": [[[3, 3, 162, 163, "CID"], [3, 3, 183, 184, "CID"], [99, 99, 162, 163, "CID"], [99, 99, 183, 184, "CID"], [137, 137, 162, 163, "CID"], [137, 137, 183, 184, "CID"], [155, 155, 162, 163, "CID"], [155, 155, 183, 184, "CID"], [176, 176, 162, 163, "CID"], [176, 176, 183, 184, "CID"]]], "clusters": [], "translated": "腔内化疗（<0>紫杉醇</0>/<12>卡铂</12>液晶立方相）用于复发性<7>胶质母细胞瘤</7>-临床观察。人类恶性<11>脑肿瘤</11>尽管进行了手术和放射治疗，但预后很差。立方相由弯曲的生物连续脂质双层组成，将两个全等的水通道网络分开。作为细胞毒性药物的宿主，凝胶状基质可以很容易地应用于手术切除腔的壁上。对于人类<8>胶质母细胞瘤</8>复发，手术腔内应用<1>紫杉醇</1>和<13>卡铂</13>液晶立方体包封的可行性、安全性和近期效果在一项试点研究中检查阶段。共12例复发的<9>胶质母细胞瘤</9>多形性肿瘤再次切除，腔内应用<2>紫杉醇</2>和<14>卡铂</14>不同立方相剂量。其中六名患者接受了超过15毫克<3>紫杉醇</3>并出现中度至重度<5>脑水肿</5>，而其余患者仅接受了总共15毫克<4>紫杉醇</4>。在后一组中，<6>脑水肿</6>明显减轻并进行了药物治疗。复发性<10>胶质母细胞瘤</10>的腔内化疗采用立方相是可行和安全的，但其临床获益仍有待临床II期研究检验。", "revised": true}
{"doc_key": "19139001", "sentences": [["Longitudinal", "assessment", "of", "air", "conduction", "audiograms", "in", "a", "phase", "III", "clinical", "trial", "of", "difluoromethylornithine", "and", "sulindac", "for", "prevention", "of", "sporadic", "colorectal", "adenomas", ".", "A", "phase", "III", "clinical", "trial", "assessed", "the", "recurrence", "of", "adenomatous", "polyps", "after", "treatment", "for", "36", "months", "with", "difluoromethylornithine", "(", "DFMO", ")", "plus", "sulindac", "or", "matched", "placebos", ".", "Temporary", "hearing", "loss", "is", "a", "known", "toxicity", "of", "treatment", "with", "DFMO", ",", "thus", "a", "comprehensive", "approach", "was", "developed", "to", "analyze", "serial", "air", "conduction", "audiograms", ".", "The", "generalized", "estimating", "equation", "method", "estimated", "the", "mean", "difference", "between", "treatment", "arms", "with", "regard", "to", "change", "in", "air", "conduction", "pure", "tone", "thresholds", "while", "accounting", "for", "within", "-", "subject", "correlation", "due", "to", "repeated", "measurements", "at", "frequencies", ".", "Based", "on", "290", "subjects", ",", "there", "was", "an", "average", "difference", "of", "0", ".", "50", "dB", "between", "subjects", "treated", "with", "DFMO", "plus", "sulindac", "compared", "with", "those", "treated", "with", "placebo", "(", "95", "%", "confidence", "interval", ",", "-", "0", ".", "64", "to", "1", ".", "63", "dB", ";", "P", "=", "0", ".", "39", ")", ",", "adjusted", "for", "baseline", "values", ",", "age", ",", "and", "frequencies", ".", "In", "the", "normal", "speech", "range", "of", "500", "to", "3", ",", "000", "Hz", ",", "an", "estimated", "difference", "of", "0", ".", "99", "dB", "(", "-", "0", ".", "17", "to", "2", ".", "14", "dB", ";", "P", "=", "0", ".", "09", ")", "was", "detected", ".", "Dose", "intensity", "did", "not", "add", "information", "to", "models", ".", "There", "were", "14", "of", "151", "(", "9", ".", "3", "%", ")", "in", "the", "DFMO", "plus", "sulindac", "group", "and", "4", "of", "139", "(", "2", ".", "9", "%", ")", "in", "the", "placebo", "group", "who", "experienced", "at", "least", "15", "dB", "hearing", "reduction", "from", "baseline", "in", "2", "or", "more", "consecutive", "frequencies", "across", "the", "entire", "range", "tested", "(", "P", "=", "0", ".", "02", ")", ".", "Follow", "-", "up", "air", "conduction", "done", "at", "least", "6", "months", "after", "end", "of", "treatment", "showed", "an", "adjusted", "mean", "difference", "in", "hearing", "thresholds", "of", "1", ".", "08", "dB", "(", "-", "0", ".", "81", "to", "2", ".", "96", "dB", ";", "P", "=", "0", ".", "26", ")", "between", "treatment", "arms", ".", "There", "was", "no", "significant", "difference", "in", "the", "proportion", "of", "subjects", "in", "the", "DFMO", "plus", "sulindac", "group", "who", "experienced", "clinically", "significant", "hearing", "loss", "compared", "with", "the", "placebo", "group", ".", "The", "estimated", "attributable", "risk", "of", "ototoxicity", "from", "exposure", "to", "the", "drug", "is", "8", ".", "4", "%", "(", "95", "%", "confidence", "interval", ",", "-", "2", ".", "0", "%", "to", "18", ".", "8", "%", ";", "P", "=", "0", ".", "12", ")", ".", "There", "is", "a", "<", "2", "dB", "difference", "in", "mean", "threshold", "for", "patients", "treated", "with", "DFMO", "plus", "sulindac", "compared", "with", "those", "treated", "with", "placebo", "."]], "ner": [[[15, 15, "Chemical"], [45, 45, "Chemical"], [132, 132, "Chemical"], [237, 237, "Chemical"], [344, 344, "Chemical"], [414, 414, "Chemical"], [51, 52, "Disease"], [350, 351, "Disease"], [13, 13, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [60, 60, "Chemical"], [130, 130, "Chemical"], [235, 235, "Chemical"], [342, 342, "Chemical"], [412, 412, "Chemical"], [20, 21, "Disease"], [32, 33, "Disease"], [56, 56, "Disease"], [363, 363, "Disease"]]], "relations": [[[15, 15, 51, 52, "CID"], [15, 15, 350, 351, "CID"], [45, 45, 51, 52, "CID"], [45, 45, 350, 351, "CID"], [132, 132, 51, 52, "CID"], [132, 132, 350, 351, "CID"], [237, 237, 51, 52, "CID"], [237, 237, 350, 351, "CID"], [344, 344, 51, 52, "CID"], [344, 344, 350, 351, "CID"], [414, 414, 51, 52, "CID"], [414, 414, 350, 351, "CID"]]], "clusters": [], "translated": "<8>二氟甲基鸟氨酸</8>和<0>舒林酸</0>预防散发性<16>结直肠腺瘤</16>的III期临床试验中气导听力图的纵向评估。一项 III 期临床试验评估了<17>腺瘤性息肉</17>在使用<9>二氟甲基鸟氨酸</9>（<10>DFMO</10>）加<1>舒林酸</1>治疗36个月后的复发情况或匹配的安慰剂。暂时性<6>听力损失</6>是<11>DFMO</11>治疗的已知<18>毒性</18>，因此开发了一种综合方法来分析系列气导听力图。广义估计方程法估计了治疗组之间在气导纯音阈值变化方面的平均差异，同时考虑了由于在频率上重复测量而导致的受试者内部相关性。基于290名受试者，平均差异为0.50 dB，<12>DFMO</12>加<2>舒林酸</2>治疗组与安慰剂治疗组相比，在<0>肺毒性</0><16>结直肠腺瘤</16>方面的区别不具有统计学意义（95%置信区间，-0.64 至 1.63 dB；P = 0 . 39），调整了基线值、年龄和频率。在500Hz至3,000Hz的<7>正常语音范围内</7>，检测到的差异为0.99 dB，（-0.17 至 2.14 dB；P = 0.09）。剂量强度没有增加模型的信息。<13>DFMO</13>加<3>舒林酸</3>组151人中有14人（9.3%），安慰剂组139人中有4人（2.9%），他们经历了至少15dB基线听力降低，在整个测试范围内的2个或更多连续频率（P = 0.02）。治疗结束后至少6个月进行的随访气导显示听力阈值的调整平均差为1.08分贝，（-0.81 至 2.96 dB；P = 0.26）治疗臂之间。与安慰剂组相比，<14>DFMO</14>加<4>舒林酸</4>组出现临床显着听力损失的受试者比例没有显着差异。接触药物引起的<19>耳毒性</19>的估计归因风险为8.4% （95%置信区间，-2.0%至18.8%；P = 0.12）。与接受安慰剂治疗的患者相比，接受<15>DFMO</15>加<5>舒林酸</5>治疗的患者的平均阈值差异不超过2dB。", "revised": true}
{"doc_key": "3137399", "sentences": [["A", "prospective", "study", "on", "the", "dose", "dependency", "of", "cardiotoxicity", "induced", "by", "mitomycin", "C", ".", "Since", "1975", "mitomycin", "C", "(", "MMC", ")", "has", "been", "suggested", "to", "be", "cardiotoxic", ",", "especially", "when", "combined", "with", "or", "given", "following", "doxorubicin", ".", "Data", "on", "dose", "dependency", "or", "incidence", "concerning", "this", "side", "effect", "were", "not", "known", ".", "We", "have", "initiated", "a", "prospective", "study", "to", "obtain", "some", "more", "data", "on", "these", "subjects", ".", "Forty", "-", "four", "MMC", "-", "treated", "patients", "were", "studied", ",", "37", "of", "them", "could", "be", "evaluated", ".", "All", "patients", "were", "studied", "by", "repeated", "physical", "examinations", ",", "chest", "X", "-", "rays", ",", "electro", "-", "and", "echocardiography", "and", "radionuclide", "left", "ventricular", "ejection", "fraction", "(", "EF", ")", "determinations", ".", "The", "results", "were", "evaluated", "per", "cumulative", "dose", "level", ".", "One", "of", "the", "patients", "developed", "cardiac", "failure", "after", "30", "mg", "m", "-", "2", "MMC", "and", "only", "150", "mg", "m", "-", "2", "doxorubicin", ".", "The", "cardiac", "failure", "was", "predicted", "by", "a", "drop", "in", "EF", "determined", "during", "a", "cold", "pressor", "test", ".", "None", "of", "the", "other", "patients", "developed", "clinical", "cardiotoxicity", ",", "nor", "did", "the", "studied", "parameters", "change", ".", "The", "literature", "on", "this", "subject", "was", "also", "reviewed", ".", "Based", "on", "the", "combined", "data", "from", "the", "present", "study", "and", "the", "literature", ",", "we", "suggest", "that", "MMC", "-", "related", "cardiotoxicity", "is", "dose", "dependent", ",", "occurring", "at", "cumulative", "dose", "levels", "of", "30", "mg", "m", "-", "2", "or", "more", ",", "mainly", "in", "patients", "also", "(", "previously", "or", "simultaneously", ")", "treated", "with", "doxorubicin", ".", "The", "incidence", "is", "likely", "to", "be", "less", "than", "10", "%", "even", "for", "this", "risk", "group", "."]], "ner": [[[11, 12, "Chemical"], [16, 17, "Chemical"], [19, 19, "Chemical"], [69, 69, "Chemical"], [134, 134, "Chemical"], [202, 202, "Chemical"], [126, 127, "Disease"], [145, 146, "Disease"], [35, 35, "Chemical"], [142, 142, "Chemical"], [235, 235, "Chemical"], [8, 8, "Disease"], [26, 26, "Disease"], [168, 168, "Disease"], [205, 205, "Disease"]]], "relations": [[[11, 12, 126, 127, "CID"], [11, 12, 145, 146, "CID"], [16, 17, 126, 127, "CID"], [16, 17, 145, 146, "CID"], [19, 19, 126, 127, "CID"], [19, 19, 145, 146, "CID"], [69, 69, 126, 127, "CID"], [69, 69, 145, 146, "CID"], [134, 134, 126, 127, "CID"], [134, 134, 145, 146, "CID"], [202, 202, 126, 127, "CID"], [202, 202, 145, 146, "CID"], [35, 35, 126, 127, "CID"], [35, 35, 145, 146, "CID"], [142, 142, 126, 127, "CID"], [142, 142, 145, 146, "CID"], [235, 235, 126, 127, "CID"], [235, 235, 145, 146, "CID"]]], "clusters": [], "translated": "<0>丝裂霉素C</0>致<11>心脏毒性</11>剂量依赖性的前瞻性研究。自 1975 年以来，<1>丝裂霉素C</1> ( <2>MMC</2> ) 被认为具有<12>心脏毒性</12>，尤其是当与<8>阿霉素</8>联合使用或在其后使用时。有关此副作用的剂量依赖性或发生率的数据尚不清楚。我们已经启动了一项前瞻性研究，以获得有关这些主题的更多数据。研究了44名接受<3>MMC</3>治疗的患者，其中37名可以进行评估。所有患者均通过反复体格检查、胸部X光检查、心电图和超声心动图以及放射性核素左心室射血分数 (EF) 测定进行研究。结果按累积剂量水平进行评估。其中一名患者在服用30 mg m - 2 <4>MMC</4> 和仅服用150 mg m - 2 <9>多柔比星</9>后出现<6>心力衰竭</6>。 <7>心力衰竭</7>是通过冷加压试验期间确定的EF下降来预测的。其他患者均未出现临床<13>心脏毒性</13>，所研究的参数也未发生变化。还回顾了有关该主题的文献。根据本研究和文献的综合数据，我们认为<5>MMC</5>相关的<14>心脏毒性</14>是剂量依赖性的，发生在累积剂量水平为30 mg m-2或更多，主要发生在还（之前或同时）接受<10>阿霉素</10>治疗的患者中。即使对于这个高危人群，发病率也可能低于10%。", "revised": true}
{"doc_key": "17344330", "sentences": [["Syncope", "and", "QT", "prolongation", "among", "patients", "treated", "with", "methadone", "for", "heroin", "dependence", "in", "the", "city", "of", "Copenhagen", ".", "BACKGROUND", ":", "Methadone", "is", "prescribed", "to", "heroin", "addicts", "to", "decrease", "illicit", "opioid", "use", ".", "Prolongation", "of", "the", "QT", "interval", "in", "the", "ECG", "of", "patients", "with", "torsade", "de", "pointes", "(", "TdP", ")", "has", "been", "reported", "in", "methadone", "users", ".", "As", "heroin", "addicts", "sometimes", "faint", "while", "using", "illicit", "drugs", ",", "doctors", "might", "attribute", "too", "many", "episodes", "of", "syncope", "to", "illicit", "drug", "use", "and", "thereby", "underestimate", "the", "incidence", "of", "TdP", "in", "this", "special", "population", ",", "and", "the", "high", "mortality", "in", "this", "population", "may", ",", "in", "part", ",", "be", "caused", "by", "the", "proarrhythmic", "effect", "of", "methadone", ".", "METHODS", ":", "In", "this", "cross", "-", "sectional", "study", "interview", ",", "ECGs", "and", "blood", "samples", "were", "collected", "in", "a", "population", "of", "adult", "heroin", "addicts", "treated", "with", "methadone", "or", "buprenorphine", "on", "a", "daily", "basis", ".", "Of", "the", "patients", "at", "the", "Drug", "Addiction", "Service", "in", "the", "municipal", "of", "Copenhagen", ",", "450", "(", "approximately", "52", "%", ")", "were", "included", ".", "The", "QT", "interval", "was", "estimated", "from", "12", "lead", "ECGs", ".", "All", "participants", "were", "interviewed", "about", "any", "experience", "of", "syncope", ".", "The", "association", "between", "opioid", "dose", "and", "QT", ",", "and", "methadone", "dose", "and", "reporting", "of", "syncope", "was", "assessed", "using", "multivariate", "linear", "regression", "and", "logistic", "regression", ",", "respectively", ".", "RESULTS", ":", "Methadone", "dose", "was", "associated", "with", "longer", "QT", "interval", "of", "0", ".", "140", "ms", "/", "mg", "(", "p", "=", "0", ".", "002", ")", ".", "No", "association", "between", "buprenorphine", "and", "QTc", "was", "found", ".", "Among", "the", "subjects", "treated", "with", "methadone", ",", "28", "%", "men", "and", "32", "%", "women", "had", "prolonged", "QTc", "interval", ".", "None", "of", "the", "subjects", "treated", "with", "buprenorphine", "had", "QTc", "interval", ">", "0", ".", "440", "s", "(", "(", "1", "/", "2", ")", ")", ".", "A", "50", "mg", "higher", "methadone", "dose", "was", "associated", "with", "a", "1", ".", "2", "(", "95", "%", "CI", "1", ".", "1", "to", "1", ".", "4", ")", "times", "higher", "odds", "for", "syncope", ".", "CONCLUSIONS", ":", "Methadone", "is", "associated", "with", "QT", "prolongation", "and", "higher", "reporting", "of", "syncope", "in", "a", "population", "of", "heroin", "addicts", "."]], "ner": [[[8, 8, "Chemical"], [20, 20, "Chemical"], [53, 53, "Chemical"], [109, 109, "Chemical"], [136, 136, "Chemical"], [196, 196, "Chemical"], [216, 216, "Chemical"], [253, 253, "Chemical"], [294, 294, "Chemical"], [323, 323, "Chemical"], [0, 0, "Disease"], [73, 73, "Disease"], [185, 185, "Disease"], [201, 201, "Disease"], [319, 319, "Disease"], [333, 333, "Disease"], [2, 3, "Disease"], [263, 265, "Disease"], [327, 328, "Disease"], [10, 10, "Chemical"], [24, 24, "Chemical"], [57, 57, "Chemical"], [132, 132, "Chemical"], [338, 338, "Chemical"], [138, 138, "Chemical"], [242, 242, "Chemical"], [273, 273, "Chemical"], [43, 45, "Disease"], [47, 47, "Disease"], [84, 84, "Disease"]]], "relations": [[[8, 8, 0, 0, "CID"], [8, 8, 73, 73, "CID"], [8, 8, 185, 185, "CID"], [8, 8, 201, 201, "CID"], [8, 8, 319, 319, "CID"], [8, 8, 333, 333, "CID"], [20, 20, 0, 0, "CID"], [20, 20, 73, 73, "CID"], [20, 20, 185, 185, "CID"], [20, 20, 201, 201, "CID"], [20, 20, 319, 319, "CID"], [20, 20, 333, 333, "CID"], [53, 53, 0, 0, "CID"], [53, 53, 73, 73, "CID"], [53, 53, 185, 185, "CID"], [53, 53, 201, 201, "CID"], [53, 53, 319, 319, "CID"], [53, 53, 333, 333, "CID"], [109, 109, 0, 0, "CID"], [109, 109, 73, 73, "CID"], [109, 109, 185, 185, "CID"], [109, 109, 201, 201, "CID"], [109, 109, 319, 319, "CID"], [109, 109, 333, 333, "CID"], [136, 136, 0, 0, "CID"], [136, 136, 73, 73, "CID"], [136, 136, 185, 185, "CID"], [136, 136, 201, 201, "CID"], [136, 136, 319, 319, "CID"], [136, 136, 333, 333, "CID"], [196, 196, 0, 0, "CID"], [196, 196, 73, 73, "CID"], [196, 196, 185, 185, "CID"], [196, 196, 201, 201, "CID"], [196, 196, 319, 319, "CID"], [196, 196, 333, 333, "CID"], [216, 216, 0, 0, "CID"], [216, 216, 73, 73, "CID"], [216, 216, 185, 185, "CID"], [216, 216, 201, 201, "CID"], [216, 216, 319, 319, "CID"], [216, 216, 333, 333, "CID"], [253, 253, 0, 0, "CID"], [253, 253, 73, 73, "CID"], [253, 253, 185, 185, "CID"], [253, 253, 201, 201, "CID"], [253, 253, 319, 319, "CID"], [253, 253, 333, 333, "CID"], [294, 294, 0, 0, "CID"], [294, 294, 73, 73, "CID"], [294, 294, 185, 185, "CID"], [294, 294, 201, 201, "CID"], [294, 294, 319, 319, "CID"], [294, 294, 333, 333, "CID"], [323, 323, 0, 0, "CID"], [323, 323, 73, 73, "CID"], [323, 323, 185, 185, "CID"], [323, 323, 201, 201, "CID"], [323, 323, 319, 319, "CID"], [323, 323, 333, 333, "CID"], [8, 8, 2, 3, "CID"], [8, 8, 263, 265, "CID"], [8, 8, 327, 328, "CID"], [20, 20, 2, 3, "CID"], [20, 20, 263, 265, "CID"], [20, 20, 327, 328, "CID"], [53, 53, 2, 3, "CID"], [53, 53, 263, 265, "CID"], [53, 53, 327, 328, "CID"], [109, 109, 2, 3, "CID"], [109, 109, 263, 265, "CID"], [109, 109, 327, 328, "CID"], [136, 136, 2, 3, "CID"], [136, 136, 263, 265, "CID"], [136, 136, 327, 328, "CID"], [196, 196, 2, 3, "CID"], [196, 196, 263, 265, "CID"], [196, 196, 327, 328, "CID"], [216, 216, 2, 3, "CID"], [216, 216, 263, 265, "CID"], [216, 216, 327, 328, "CID"], [253, 253, 2, 3, "CID"], [253, 253, 263, 265, "CID"], [253, 253, 327, 328, "CID"], [294, 294, 2, 3, "CID"], [294, 294, 263, 265, "CID"], [294, 294, 327, 328, "CID"], [323, 323, 2, 3, "CID"], [323, 323, 263, 265, "CID"], [323, 323, 327, 328, "CID"]]], "clusters": [], "translated": " <10>晕厥</10>和<16>QT间期延长</16>在哥本哈根市因<19>海洛因</19>依赖而接受<0>美沙酮</0>治疗的患者。背景：<1>美沙酮</1>用于<20>海洛因</20>成瘾者，以减少非法使用阿片类药物。在<2>美沙酮</2>使用者中，患有<27>尖端扭转型室性心动过速</27>(<28>TdP</28>)的患者心电图显示出QT间期延长。由于<21>海洛因</21>成瘾者有时会在使用非法药物时晕倒，医生可能会将过多的<11>晕厥</11>归因于非法药物使用，从而低估了在这一特殊人群中<29>TdP</29>的发生率，而该人群的高死亡率可能部分是由于<3>美沙酮</3>的促心律失常作用所致。方法：在这一横断面研究中，对成年<22>海洛因</22>成瘾者进行访谈、心电图和血样收集，这些患者每天接受<4>美沙酮</4>或<24>布洛芬酰胺</24>治疗。在哥本哈根市的药物成瘾服务中心的患者中，有 450 名（约 52%）被纳入研究。 QT 间期是根据 12 个导联心电图估计的。所有参与者都接受了有关<12>晕厥</12>经历的访谈。阿片类药物剂量与QT之间的关联，以及<5>美沙酮</5>剂量与<13>晕厥</13>报告之间的关联分别使用多元线性回归和逻辑回归进行评估。结果：<6>美沙酮</6>剂量与QT间期延长0.140ms/毫克相关(p = 0.002)。未发现<25>布洛芬酰胺</25>与QTc之间存在关联。在接受<7>美沙酮</7>治疗的受试者中，28%的男性和32%的女性有<17>延长的QTc间期</17>。接受<26>布洛芬酰胺</26>治疗的受试者均未出现>0.440秒的QTc间期（(1/2)）。50mg更高的<8>美沙酮</8>剂量与<14>晕厥</14>的报告率高达1.2(95% CI 1.1至1.4)倍。结论：<9>美沙酮</9>与<18>QT间期延长</18>和<15>晕厥</15>的较高报告率在<23>海洛因</23>成瘾人群中有关联。", "revised": true}
{"doc_key": "18239197", "sentences": [["Increased", "mental", "slowing", "associated", "with", "the", "APOE", "epsilon4", "allele", "after", "trihexyphenidyl", "oral", "anticholinergic", "challenge", "in", "healthy", "elderly", ".", "OBJECTIVES", ":", "The", "objectives", "of", "this", "study", "were", "to", "examine", "the", "relationship", "between", "APOE", "epsilon4", "and", "subjective", "effects", "of", "trihexyphenidyl", "on", "measures", "reflecting", "sedation", "and", "confusion", "and", "to", "investigate", "the", "relationship", "between", "trihexyphenidyl", "-", "induced", "subjective", "effects", "and", "objective", "memory", "performance", ".", "METHODS", ":", "This", "study", "comprised", "24", "cognitively", "intact", ",", "health", "elderly", "adults", "(", "12", "APOE", "epsilon4", "carriers", ")", "at", "an", "outpatient", "geriatric", "psychiatry", "research", "clinic", ".", "This", "was", "a", "randomized", ",", "double", "blind", ",", "placebo", "-", "controlled", ",", "three", "-", "way", ",", "crossover", "experimental", "design", ".", "All", "participants", "received", "1", ".", "0", "mg", "or", "2", ".", "0", "mg", "trihexyphenidyl", "or", "placebo", "administered", "in", "counterbalanced", "sequences", "over", "a", "period", "of", "three", "consecutive", "weeks", ".", "Bond", "and", "Lader", "'s", "visual", "analog", "scales", "and", "alternate", "versions", "of", "the", "Buschke", "Selective", "Reminding", "Test", "were", "administered", "in", "a", "repeated", "measures", "design", "at", "baseline", ",", "1", ",", "2", ".", "5", ",", "and", "5", "hours", "postdrug", "administration", ".", "RESULTS", ":", "A", "2", ".", "0", "-", "mg", "oral", "dose", "of", "trihexyphenidyl", "resulted", "in", "increased", "subjective", "ratings", "of", "mental", "slowness", "in", "carriers", "of", "the", "APOE", "epsilon4", "allele", "only", ".", "Drug", "effects", "as", "determined", "by", "difference", "scores", "between", "2", ".", "0", "mg", "trihexyphenidyl", "and", "placebo", "on", "ratings", "of", "mental", "slowness", "significantly", "correlated", "with", "total", "and", "delayed", "recall", "on", "the", "Buschke", "Selective", "Reminding", "Test", "in", "carriers", "of", "the", "APOE", "epsilon4", "allele", "only", ".", "However", ",", "no", "significant", "effects", "were", "found", "with", "other", "visual", "analog", "scales", "reflecting", "subjective", "sedation", "and", "clear", "-", "headedness", ".", "CONCLUSION", ":", "The", "epsilon4", "allele", "in", "healthy", "elderly", "was", "associated", "with", "increased", "subjective", "mental", "slowing", "after", "trihexyphenidyl", "anticholinergic", "challenge", "."]], "ner": [[[10, 10, "Chemical"], [37, 37, "Chemical"], [50, 50, "Chemical"], [118, 118, "Chemical"], [182, 182, "Chemical"], [212, 212, "Chemical"], [278, 278, "Chemical"], [1, 2, "Disease"], [189, 190, "Disease"], [218, 219, "Disease"], [275, 276, "Disease"], [43, 43, "Disease"]]], "relations": [[[10, 10, 1, 2, "CID"], [10, 10, 189, 190, "CID"], [10, 10, 218, 219, "CID"], [10, 10, 275, 276, "CID"], [37, 37, 1, 2, "CID"], [37, 37, 189, 190, "CID"], [37, 37, 218, 219, "CID"], [37, 37, 275, 276, "CID"], [50, 50, 1, 2, "CID"], [50, 50, 189, 190, "CID"], [50, 50, 218, 219, "CID"], [50, 50, 275, 276, "CID"], [118, 118, 1, 2, "CID"], [118, 118, 189, 190, "CID"], [118, 118, 218, 219, "CID"], [118, 118, 275, 276, "CID"], [182, 182, 1, 2, "CID"], [182, 182, 189, 190, "CID"], [182, 182, 218, 219, "CID"], [182, 182, 275, 276, "CID"], [212, 212, 1, 2, "CID"], [212, 212, 189, 190, "CID"], [212, 212, 218, 219, "CID"], [212, 212, 275, 276, "CID"], [278, 278, 1, 2, "CID"], [278, 278, 189, 190, "CID"], [278, 278, 218, 219, "CID"], [278, 278, 275, 276, "CID"]]], "clusters": [], "translated": "在健康老年人中<0>苯海索</0>口服抗胆碱能刺激后，与APOE epsilon4等位基因相关的<7>智力减慢</7>增加。目的：本研究的目的是检查APOE epsilon4与<1>苯海索</1>对反映镇静和<11>混乱</11>的主观影响之间的关系，并调查<2>苯海索诱发的主观影响和客观记忆表现</2>。方法：这项研究包括24名认知完整、健康的老年人（12名APOE epsilon4携带者），他们在门诊老年精神病学研究诊所就诊。这是一项随机、双盲、安慰剂对照、三向交叉实验设计。所有参与者收到1.0毫克或2.0毫克<3>苯海索</3>或安慰剂，在连续三周内以平衡顺序给药。Bond和Lader的视觉模拟量表和Buschke选择性提醒测试的替代版本在基线、1、2.5和5小时给药后进行了重复测量设计的管理。结果：A 2.0-mg口服剂量的<4>苯海索</4>仅导致APOE epsilon4等位基因携带者对<8>智力迟钝</8>的主观评价增加。药物效应由2.0毫克<5>苯海索</5>和安慰剂对<9>智力迟钝</9>的评级之间的差异分数确定，在仅APOE epsilon4等位基因携带者的Buschke选择性提醒测试中与总和和延迟回忆显着相关。然而，没有发现其他反映主观镇静和头脑清醒的视觉模拟量表有显着影响。结论：健康老年人中的epsilon4等位基因与<6>苯海索</6>抗胆碱能刺激后主观<10>智力减慢</10>增加有关。", "revised": true}
{"doc_key": "9549528", "sentences": [["Cortical", "motor", "overactivation", "in", "parkinsonian", "patients", "with", "L", "-", "dopa", "-", "induced", "peak", "-", "dose", "dyskinesia", ".", "We", "have", "studied", "the", "regional", "cerebral", "blood", "flow", "(", "rCBF", ")", "changes", "induced", "by", "the", "execution", "of", "a", "finger", "-", "to", "-", "thumb", "opposition", "motor", "task", "in", "the", "supplementary", "and", "primary", "motor", "cortex", "of", "two", "groups", "of", "parkinsonian", "patients", "on", "L", "-", "dopa", "medication", ",", "the", "first", "one", "without", "L", "-", "dopa", "induced", "dyskinesia", "(", "n", "=", "23", ")", "and", "the", "other", "with", "moderate", "peak", "-", "dose", "dyskinesia", "(", "n", "=", "15", ")", ",", "and", "of", "a", "group", "of", "14", "normal", "subjects", ".", "Single", "photon", "emission", "tomography", "with", "i", ".", "v", ".", "133Xe", "was", "used", "to", "measure", "the", "rCBF", "changes", ".", "The", "dyskinetic", "parkinsonian", "patients", "exhibited", "a", "pattern", "of", "response", "which", "was", "markedly", "different", "from", "those", "of", "the", "normal", "subjects", "and", "non", "-", "dyskinetic", "parkinsonian", "patients", ",", "with", "a", "significant", "overactivation", "in", "the", "supplementary", "motor", "area", "and", "the", "ipsi", "-", "and", "contralateral", "primary", "motor", "areas", ".", "These", "results", "are", "compatible", "with", "the", "hypothesis", "that", "an", "hyperkinetic", "abnormal", "involuntary", "movement", ",", "like", "L", "-", "dopa", "-", "induced", "peak", "dose", "dyskinesia", ",", "is", "due", "to", "a", "disinhibition", "of", "the", "primary", "and", "associated", "motor", "cortex", "secondary", "to", "an", "excessive", "outflow", "of", "the", "pallidothalamocortical", "motor", "loop", "."]], "ner": [[[7, 9, "Chemical"], [57, 59, "Chemical"], [66, 68, "Chemical"], [178, 180, "Chemical"], [15, 15, "Disease"], [70, 70, "Disease"], [84, 84, "Disease"], [119, 119, "Disease"], [140, 140, "Disease"], [173, 175, "Disease"], [185, 185, "Disease"], [4, 4, "Disease"], [54, 54, "Disease"], [120, 120, "Disease"], [141, 141, "Disease"], [172, 172, "Disease"]]], "relations": [[[7, 9, 15, 15, "CID"], [7, 9, 70, 70, "CID"], [7, 9, 84, 84, "CID"], [7, 9, 119, 119, "CID"], [7, 9, 140, 140, "CID"], [7, 9, 173, 175, "CID"], [7, 9, 185, 185, "CID"], [57, 59, 15, 15, "CID"], [57, 59, 70, 70, "CID"], [57, 59, 84, 84, "CID"], [57, 59, 119, 119, "CID"], [57, 59, 140, 140, "CID"], [57, 59, 173, 175, "CID"], [57, 59, 185, 185, "CID"], [66, 68, 15, 15, "CID"], [66, 68, 70, 70, "CID"], [66, 68, 84, 84, "CID"], [66, 68, 119, 119, "CID"], [66, 68, 140, 140, "CID"], [66, 68, 173, 175, "CID"], [66, 68, 185, 185, "CID"], [178, 180, 15, 15, "CID"], [178, 180, 70, 70, "CID"], [178, 180, 84, 84, "CID"], [178, 180, 119, 119, "CID"], [178, 180, 140, 140, "CID"], [178, 180, 173, 175, "CID"], [178, 180, 185, 185, "CID"]]], "clusters": [], "translated": "<11>帕金森病</11>患者的皮层运动过度激活，<0>左旋多巴</0> - 诱发峰值剂量<4>运动障碍</4>。我们研究了两组<12>帕金森病</12>患者在<1> L-多巴</1>药物的辅助和初级运动皮层中执行手指对拇指对立运动任务引起的局部脑血流（rCBF）变化，第一个没有<2>L-多巴</2>引起的<5>运动障碍</5>（n = 23），另一个有中等峰值剂量<6>运动障碍</6>（n = 15），以及一组14名正常受试者。单光子发射断层扫描与i.v. ^133Xe被用来测量rCBF的变化。表现<7>运动障碍</7><13>帕金森病</13>患者的反应模式明显不同于正常受者和非-<8>运动障碍</8><14>帕金森病</14>患者，辅助运动区和同侧及对侧初级运动区明显过度激活。这些结果符合以下假设：<15>多动症</15><9>异常不自主运动</9>，如<3>L-多巴</3>-诱发峰值剂量<10>运动障碍</10>，是由于继发于苍白丘脑皮质运动回路过度流出的初级和相关运动皮层的去抑制。", "revised": true}
{"doc_key": "7803371", "sentences": [["Cognitive", "deterioration", "from", "long", "-", "term", "abuse", "of", "dextromethorphan", ":", "a", "case", "report", ".", "Dextromethorphan", "(", "DM", ")", ",", "the", "dextrorotatory", "isomer", "of", "3", "-", "hydroxy", "-", "N", "-", "methylmorphinan", ",", "is", "the", "main", "ingredient", "in", "a", "number", "of", "widely", "available", ",", "over", "-", "the", "-", "counter", "antitussives", ".", "Initial", "studies", "(", "Bornstein", "1968", ")", "showed", "that", "it", "possessed", "no", "respiratory", "suppressant", "effects", "and", "no", "addiction", "liability", ".", "Subsequently", ",", "however", ",", "several", "articles", "reporting", "abuse", "of", "this", "drug", "have", "appeared", "in", "the", "literature", ".", "The", "drug", "is", "known", "to", "cause", "a", "variety", "of", "acute", "toxic", "effects", ",", "ranging", "from", "nausea", ",", "restlessness", ",", "insomnia", ",", "ataxia", ",", "slurred", "speech", "and", "nystagmus", "to", "mood", "changes", ",", "perceptual", "alterations", ",", "inattention", ",", "disorientation", "and", "aggressive", "behavior", "(", "Rammer", "et", "al", "1988", ";", "Katona", "and", "Watson", "1986", ";", "Isbell", "and", "Fraser", "1953", ";", "Devlin", "et", "al", "1985", ";", "McCarthy", "1971", ";", "Dodds", "and", "Revai", "1967", ";", "Degkwitz", "1964", ";", "Hildebrand", "et", "al", "1989", ")", ".", "There", "have", "also", "been", "two", "reported", "fatalities", "from", "DM", "overdoses", "(", "Fleming", "1986", ")", ".", "However", ",", "there", "are", "no", "reports", "describing", "the", "effects", "of", "chronic", "abuse", ".", "This", "report", "describes", "a", "case", "of", "cognitive", "deterioration", "resulting", "from", "prolonged", "use", "of", "DM", "."]], "ner": [[[8, 8, "Chemical"], [14, 14, "Chemical"], [16, 16, "Chemical"], [171, 171, "Chemical"], [204, 204, "Chemical"], [0, 1, "Disease"], [197, 198, "Disease"], [23, 29, "Chemical"], [100, 100, "Disease"], [102, 102, "Disease"], [104, 104, "Disease"], [106, 106, "Disease"], [111, 111, "Disease"], [123, 124, "Disease"]]], "relations": [[[8, 8, 0, 1, "CID"], [8, 8, 197, 198, "CID"], [14, 14, 0, 1, "CID"], [14, 14, 197, 198, "CID"], [16, 16, 0, 1, "CID"], [16, 16, 197, 198, "CID"], [171, 171, 0, 1, "CID"], [171, 171, 197, 198, "CID"], [204, 204, 0, 1, "CID"], [204, 204, 197, 198, "CID"]]], "clusters": [], "translated": "长期滥用<0>右美沙芬</0>导致<5>认知能力下降</5>：一例报告。 <1>右美沙芬</1>（<2>DM</2>）是<7>3-羟基-N-甲基吗啡喃</7>的右旋异构体，是许多广泛使用的药物的主要成分，超过-柜台镇咳药。初步研究（Bornstein 1968）表明它没有呼吸抑制作用，也没有成瘾倾向。然而，随后，文献中出现了几篇报道这种药物滥用的文章。已知该药物会引起多种急性毒性作用，包括<8>恶心</8>、<9>烦躁</9>、<10>失眠</10>、<11>共济失调</11>、言语不清和<12>眼球震颤</12>导致情绪变化、知觉改变、注意力不集中、定向障碍和<13>攻击行为</13>（Rammer等人1988年；Katona和Watson1986年；Isbell和Fraser1953年；Devlin等人1985年；McCarthy1971年；Dodds和Revai1967年；Degkwitz1964年；Hildebrand等人1989年）。还有两起因<3>DM</3>过量服用而死亡的报道（Fleming 1986年）。然而，没有报告描述长期滥用的影响。本报告描述了一个因长期使用<4>DM</4>而导致<6>认知能力下降</6>的病例。", "revised": true}
{"doc_key": "17194457", "sentences": [["Behavioral", "effects", "of", "pubertal", "anabolic", "androgenic", "steroid", "exposure", "in", "male", "rats", "with", "low", "serotonin", ".", "The", "goal", "of", "this", "study", "was", "to", "assess", "the", "interactive", "effects", "of", "chronic", "anabolic", "androgenic", "steroid", "(", "AAS", ")", "exposure", "and", "brain", "serotonin", "(", "5", "-", "hydroxytryptamine", ",", "5", "-", "HT", ")", "depletion", "on", "behavior", "of", "pubertal", "male", "rats", ".", "Serotonin", "was", "depleted", "beginning", "on", "postnatal", "day", "26", "with", "parachlorophenylalanine", "(", "PCPA", "100", "mg", "/", "kg", ",", "every", "other", "day", ")", ";", "controls", "received", "saline", ".", "At", "puberty", "(", "P40", ")", ",", "half", "the", "PCPA", "-", "treated", "rats", "and", "half", "the", "saline", "-", "treated", "rats", "began", "treatment", "with", "testosterone", "(", "T", ",", "5", "mg", "/", "kg", ",", "5", "days", "/", "week", ")", ".", "Behavioral", "measures", "included", "locomotion", ",", "irritability", ",", "copulation", ",", "partner", "preference", ",", "and", "aggression", ".", "Animals", "were", "tested", "for", "aggression", "in", "their", "home", "cage", ",", "both", "with", "and", "without", "physical", "provocation", "(", "mild", "tail", "pinch", ")", ".", "Brain", "levels", "of", "5", "-", "HT", "and", "its", "metabolite", ",", "5", "-", "hydroxyindoleacetic", "acid", "(", "5", "-", "HIAA", ")", ",", "were", "determined", "using", "HPLC", ".", "PCPA", "significantly", "and", "substantially", "depleted", "5", "-", "HT", "and", "5", "-", "HIAA", "in", "all", "brain", "regions", "examined", ".", "Chronic", "T", "treatment", "significantly", "decreased", "5", "-", "HT", "and", "5", "-", "HIAA", "in", "certain", "brain", "areas", ",", "but", "to", "a", "much", "lesser", "extent", "than", "PCPA", ".", "Chronic", "exposure", "to", "PCPA", "alone", "significantly", "decreased", "locomotor", "activity", "and", "increased", "irritability", "but", "had", "no", "effect", "on", "sexual", "behavior", ",", "partner", "preference", ",", "or", "aggression", ".", "T", "alone", "had", "no", "effect", "on", "locomotion", ",", "irritability", ",", "or", "sexual", "behavior", "but", "increased", "partner", "preference", "and", "aggression", ".", "The", "most", "striking", "effect", "of", "combining", "T", "+", "PCPA", "was", "a", "significant", "increase", "in", "attack", "frequency", "as", "well", "as", "a", "significant", "decrease", "in", "the", "latency", "to", "attack", ",", "particularly", "following", "physical", "provocation", ".", "Based", "on", "these", "data", ",", "it", "can", "be", "speculated", "that", "pubertal", "AAS", "users", "with", "low", "central", "5", "-", "HT", "may", "be", "especially", "prone", "to", "exhibit", "aggressive", "behavior", "."]], "ner": [[[103, 103, "Chemical"], [105, 105, "Chemical"], [199, 199, "Chemical"], [250, 250, "Chemical"], [276, 276, "Chemical"], [123, 123, "Disease"], [131, 131, "Disease"], [137, 137, "Disease"], [235, 235, "Disease"], [248, 248, "Disease"], [258, 258, "Disease"], [268, 268, "Disease"], [328, 329, "Disease"], [6, 6, "Chemical"], [30, 30, "Chemical"], [13, 13, "Chemical"], [37, 37, "Chemical"], [39, 41, "Chemical"], [43, 45, "Chemical"], [55, 55, "Chemical"], [158, 160, "Chemical"], [185, 187, "Chemical"], [203, 205, "Chemical"], [319, 321, "Chemical"], [165, 168, "Chemical"], [170, 172, "Chemical"], [189, 191, "Chemical"], [207, 209, "Chemical"]]], "relations": [[[103, 103, 123, 123, "CID"], [103, 103, 131, 131, "CID"], [103, 103, 137, 137, "CID"], [103, 103, 235, 235, "CID"], [103, 103, 248, 248, "CID"], [103, 103, 258, 258, "CID"], [103, 103, 268, 268, "CID"], [103, 103, 328, 329, "CID"], [105, 105, 123, 123, "CID"], [105, 105, 131, 131, "CID"], [105, 105, 137, 137, "CID"], [105, 105, 235, 235, "CID"], [105, 105, 248, 248, "CID"], [105, 105, 258, 258, "CID"], [105, 105, 268, 268, "CID"], [105, 105, 328, 329, "CID"], [199, 199, 123, 123, "CID"], [199, 199, 131, 131, "CID"], [199, 199, 137, 137, "CID"], [199, 199, 235, 235, "CID"], [199, 199, 248, 248, "CID"], [199, 199, 258, 258, "CID"], [199, 199, 268, 268, "CID"], [199, 199, 328, 329, "CID"], [250, 250, 123, 123, "CID"], [250, 250, 131, 131, "CID"], [250, 250, 137, 137, "CID"], [250, 250, 235, 235, "CID"], [250, 250, 248, 248, "CID"], [250, 250, 258, 258, "CID"], [250, 250, 268, 268, "CID"], [250, 250, 328, 329, "CID"], [276, 276, 123, 123, "CID"], [276, 276, 131, 131, "CID"], [276, 276, 137, 137, "CID"], [276, 276, 235, 235, "CID"], [276, 276, 248, 248, "CID"], [276, 276, 258, 258, "CID"], [276, 276, 268, 268, "CID"], [276, 276, 328, 329, "CID"]]], "clusters": [], "translated": "青春期合成代谢雄激素<13>类固醇</13>暴露于低<15>血清素</15>雄性大鼠的行为影响。本研究的目的是评估慢性合成代谢雄激素<14>类固醇</14>（AAS）暴露和大脑<16>血清素</16>（<17>5-羟色胺</17>，<18>5-HT</18>）消耗对青春期雄性大鼠行为的影响。<19>血清素</19>从产后第26天开始用对氯苯丙氨酸（PCPA 100 mg/kg，每隔一天）耗尽；对照组接受生理盐水。在青春期（P40），一半的PCPA处理的大鼠和一半的生理盐水处理的大鼠开始用<0>睾酮</0>（<1>T</1>，5 mg/kg，5天/周）治疗。行为测量包括运动、<5>易怒</5>、交配、伴侣偏好和<6>攻击性</6>。动物在笼子里有无身体刺激（轻度夹尾）下测试<7>攻击性</7>。使用HPLC测定了<20>5-HT</20>及其代谢物<24>5-羟基吲哚乙酸</24>（<25>5-HIAA</25>）的脑水平。PCPA显着和实质性地耗尽了所有检查的大脑区域中的<21>5-HT</21>和<26>5-HIAA</26>。慢性<2>T</2>治疗显着降低了某些脑区的<22>5-HT</22>和<27>5-HIAA</27>，但程度远低于PCPA。单独长期接触PCPA会显着降低自发活动并增加<8>烦躁</8>，但对性行为、伴侣偏好或<9>攻击性</9>没有影响。<3>T</3>单独对运动、<10>烦躁</10>或性行为没有影响，但会增加伴侣偏好和<11>攻击性</11>。 <4>T</4>+PCPA组合的最显着效果是攻击频率显着增加以及攻击延迟显着减少，尤其是在身体挑衅之后。基于这些数据，可以推测具有低中枢<23>5-HT</23>的青春期AAS使用者可能特别容易表现出<12>攻击行为</12>。", "revised": true}
{"doc_key": "3411101", "sentences": [["Quinidine", "phenylethylbarbiturate", "-", "induced", "fulminant", "hepatitis", "in", "a", "pregnant", "woman", ".", "A", "case", "report", ".", "We", "report", "the", "case", "of", "a", "19", "-", "year", "-", "old", "Laotian", "patient", "affected", "by", "fulminant", "hepatitis", "during", "the", "third", "trimester", "of", "her", "pregnancy", "after", "a", "1", "-", "month", "administration", "of", "quinidine", "phenylethylbarbiturate", ".", "After", "delivery", ",", "the", "patient", "underwent", "orthotopic", "liver", "transplantation", ".", "The", "patient", "was", "in", "good", "condition", "16", "months", "after", "liver", "transplantation", ".", "Quinidine", "itself", "or", "phenylethylbarbiturate", "may", "be", "responsible", "for", "fulminant", "hepatitis", "in", "this", "patient", "."]], "ner": [[[0, 1, "Chemical"], [46, 47, "Chemical"], [74, 74, "Chemical"], [5, 5, "Disease"], [31, 31, "Disease"], [80, 80, "Disease"], [71, 71, "Chemical"]]], "relations": [[[0, 1, 5, 5, "CID"], [0, 1, 31, 31, "CID"], [0, 1, 80, 80, "CID"], [46, 47, 5, 5, "CID"], [46, 47, 31, 31, "CID"], [46, 47, 80, 80, "CID"], [74, 74, 5, 5, "CID"], [74, 74, 31, 31, "CID"], [74, 74, 80, 80, "CID"]]], "clusters": [], "translated": " <0> 苯乙基巴比妥酸奎尼丁 </0> - 在孕妇中诱发暴发性<3> 肝炎 </3>。个案报告。我们报告了一名 19 岁的老挝患者在服用<1> 苯乙基巴比妥酸奎尼丁 </1>1个月后，在妊娠晚期患上暴发性<4> 肝炎 </4>的病例。分娩后，患者接受了原位肝移植。肝移植术后16个月，患者情况良好。<6> 奎尼丁 </6>本身或<2> 苯乙基巴比妥酸盐 </2>可能是导致该患者发生暴发性<5> 肝炎 </5>的原因。", "revised": true}
{"doc_key": "10225068", "sentences": [["Cauda", "equina", "syndrome", "after", "spinal", "anaesthesia", "with", "hyperbaric", "5", "%", "lignocaine", ":", "a", "review", "of", "six", "cases", "of", "cauda", "equina", "syndrome", "reported", "to", "the", "Swedish", "Pharmaceutical", "Insurance", "1993", "-", "1997", ".", "Six", "cases", "of", "cauda", "equina", "syndrome", "with", "varying", "severity", "were", "reported", "to", "the", "Swedish", "Pharmaceutical", "Insurance", "during", "the", "period", "1993", "-", "1997", ".", "All", "were", "associated", "with", "spinal", "anaesthesia", "using", "hyperbaric", "5", "%", "lignocaine", ".", "Five", "cases", "had", "single", "-", "shot", "spinal", "anaesthesia", "and", "one", "had", "a", "repeat", "spinal", "anaesthetic", "due", "to", "inadequate", "block", ".", "The", "dose", "of", "hyperbaric", "5", "%", "lignocaine", "administered", "ranged", "from", "60", "to", "120", "mg", ".", "Three", "of", "the", "cases", "were", "most", "likely", "caused", "by", "direct", "neurotoxicity", "of", "hyperbaric", "5", "%", "lignocaine", ".", "In", "the", "other", "3", "cases", ",", "direct", "neurotoxicity", "was", "also", "probable", ",", "but", "unfortunately", "radiological", "investigations", "were", "not", "done", "to", "definitely", "exclude", "a", "compressive", "aetiology", ".", "All", "cases", "sustained", "permanent", "neurological", "deficits", ".", "We", "recommend", "that", "hyperbaric", "lignocaine", "should", "be", "administered", "in", "concentrations", "not", "greater", "than", "2", "%", "and", "at", "a", "total", "dose", "preferably", "not", "exceeding", "60", "mg", "."]], "ner": [[[10, 10, "Chemical"], [64, 64, "Chemical"], [92, 92, "Chemical"], [116, 116, "Chemical"], [155, 155, "Chemical"], [0, 2, "Disease"], [18, 20, "Disease"], [34, 36, "Disease"], [111, 111, "Disease"], [125, 125, "Disease"], [148, 149, "Disease"]]], "relations": [[[10, 10, 0, 2, "CID"], [10, 10, 18, 20, "CID"], [10, 10, 34, 36, "CID"], [64, 64, 0, 2, "CID"], [64, 64, 18, 20, "CID"], [64, 64, 34, 36, "CID"], [92, 92, 0, 2, "CID"], [92, 92, 18, 20, "CID"], [92, 92, 34, 36, "CID"], [116, 116, 0, 2, "CID"], [116, 116, 18, 20, "CID"], [116, 116, 34, 36, "CID"], [155, 155, 0, 2, "CID"], [155, 155, 18, 20, "CID"], [155, 155, 34, 36, "CID"]]], "clusters": [], "translated": " <5>马尾综合征</5> 5% <0>利多卡因</0> 脊髓麻醉后：瑞典医药保险公司报告的 6 例 <6>马尾综合征</6> 回顾 1993 - 1997 年。1993 年至 1997 年期间，瑞典医药保险公司报告了 6 例严重程度不同的 <7>马尾神经综合征</7>。所有患者均使用高压 5% <1>利多卡因</1> 进行脊髓麻醉。5 例行单次腰麻，1 例因阻滞不充分再次行腰麻。高压 5% <2>利多卡因</2> 的给药剂量范围为 60 至 120 毫克。其中 3 例很可能是由高压 5% <3>利多卡因</3> 的直接<8>神经毒性</8> 引起的。在其他 3 例中，也可能存在直接 <9>神经毒性</9>，但不幸的是，并未进行放射学检查以明确排除压迫性病因。所有病例都持续存在永久性 <10>神经功能缺损</10>。我们建议高压 <4>利多卡因</4> 的浓度不超过 2%，总剂量最好不超过 60 毫克。", "revised": true}
{"doc_key": "12139551", "sentences": [["Cardiac", "arrest", "after", "intravenous", "metoclopramide", "-", "a", "case", "of", "five", "repeated", "injections", "of", "metoclopramide", "causing", "five", "episodes", "of", "cardiac", "arrest", ".", "We", "describe", "a", "patient", "where", "intravenous", "injection", "of", "metoclopramide", "was", "immediately", "followed", "by", "asystole", "repeatedly", ".", "The", "patient", "received", "metoclopramide", "10", "mg", "i", ".", "v", ".", "five", "times", "during", "48", "h", ".", "After", "interviewing", "the", "attending", "nurses", "and", "reviewing", "the", "written", "documentation", ",", "it", "is", "clear", "that", "every", "administration", "of", "metoclopramide", "was", "immediately", "(", "within", "s", ")", "followed", "by", "asystole", ".", "The", "asystole", "lasted", "15", "-", "30", "s", "on", "four", "occasions", ",", "on", "one", "occasion", "it", "lasted", "2", "min", ".", "The", "patient", "received", "atropine", "0", ".", "5", "-", "1", "mg", "and", "chest", "compressions", ",", "before", "sinus", "rhythm", "again", "took", "over", ".", "We", "interpret", "this", "as", "episodes", "of", "cardiac", "arrest", "caused", "by", "metoclopramide", ".", "The", "rapid", "injection", "via", "the", "central", "venous", "route", "and", "the", "concomitant", "tapering", "of", "dopamine", "infusion", "might", "have", "contributed", "in", "precipitating", "the", "adverse", "drug", "reaction", "."]], "ner": [[[4, 4, "Chemical"], [13, 13, "Chemical"], [29, 29, "Chemical"], [40, 40, "Chemical"], [71, 71, "Chemical"], [132, 132, "Chemical"], [0, 1, "Disease"], [18, 19, "Disease"], [34, 34, "Disease"], [80, 80, "Disease"], [83, 83, "Disease"], [128, 129, "Disease"], [104, 104, "Chemical"], [147, 147, "Chemical"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 18, 19, "CID"], [4, 4, 34, 34, "CID"], [4, 4, 80, 80, "CID"], [4, 4, 83, 83, "CID"], [4, 4, 128, 129, "CID"], [13, 13, 0, 1, "CID"], [13, 13, 18, 19, "CID"], [13, 13, 34, 34, "CID"], [13, 13, 80, 80, "CID"], [13, 13, 83, 83, "CID"], [13, 13, 128, 129, "CID"], [29, 29, 0, 1, "CID"], [29, 29, 18, 19, "CID"], [29, 29, 34, 34, "CID"], [29, 29, 80, 80, "CID"], [29, 29, 83, 83, "CID"], [29, 29, 128, 129, "CID"], [40, 40, 0, 1, "CID"], [40, 40, 18, 19, "CID"], [40, 40, 34, 34, "CID"], [40, 40, 80, 80, "CID"], [40, 40, 83, 83, "CID"], [40, 40, 128, 129, "CID"], [71, 71, 0, 1, "CID"], [71, 71, 18, 19, "CID"], [71, 71, 34, 34, "CID"], [71, 71, 80, 80, "CID"], [71, 71, 83, 83, "CID"], [71, 71, 128, 129, "CID"], [132, 132, 0, 1, "CID"], [132, 132, 18, 19, "CID"], [132, 132, 34, 34, "CID"], [132, 132, 80, 80, "CID"], [132, 132, 83, 83, "CID"], [132, 132, 128, 129, "CID"]]], "clusters": [], "translated": " <6>甲氧氯普胺</6><0>静脉注射</0>后<6>心脏骤停</6> - 五次重复注射<1>甲氧氯普胺</1>导致五次<7>心脏骤停</7>的病例。我们描述了一名患者，其中<2>甲氧氯普胺</2>的静脉注射立即被重复的<8>心搏停止</8>。患者接受<3>甲氧氯普胺</3> 10 mg i.v.五次在48小时内。在采访了主治护士并审查了书面文件后，很明显每次服用<4>甲氧氯普胺</4>后立即（在s内）紧随<9>心搏停止</9>。<10>心脏停搏</10>4次持续15-30秒，1次持续2分钟。患者接受了<12>阿托品</12> 0.5-1毫克和胸部按压，在窦性心律再次接管之前。我们将此解释为由<5>甲氧氯普胺</5>引起的<11>心脏骤停</11>发作。通过中心静脉途径的快速注射和伴随的<13>多巴胺</13>输注逐渐减量可能促进了不良药物反应。", "revised": true}
{"doc_key": "6496797", "sentences": [["Complete", "heart", "block", "following", "a", "single", "dose", "of", "trazodone", ".", "Forty", "minutes", "after", "receiving", "a", "single", "starting", "dose", "of", "trazodone", ",", "a", "patient", "developed", "complete", "heart", "block", ".", "The", "case", "illustrates", "that", ",", "despite", "the", "results", "of", "earlier", "studies", ",", "trazodone", "'s", "effect", "on", "cardiac", "conduction", "may", "be", "severe", "in", "individuals", "at", "risk", "for", "conduction", "delay", "."]], "ner": [[[8, 8, "Chemical"], [19, 19, "Chemical"], [40, 40, "Chemical"], [1, 2, "Disease"], [25, 26, "Disease"]]], "relations": [[[8, 8, 1, 2, "CID"], [8, 8, 25, 26, "CID"], [19, 19, 1, 2, "CID"], [19, 19, 25, 26, "CID"], [40, 40, 1, 2, "CID"], [40, 40, 25, 26, "CID"]]], "clusters": [], "translated": "单剂量<0>曲唑酮</0>后完全<3>心脏传导阻滞</3>。接受单次起始剂量<1>曲唑酮</1>四十分钟后，一名患者出现完全性<4>心脏传导阻滞</4>。该案例表明，尽管有早期研究的结果，<2>曲唑酮</2>对有传导延迟风险的个体的心脏传导可能影响严重。", "revised": true}
{"doc_key": "1415380", "sentences": [["Hemolytic", "-", "uremic", "syndrome", "associated", "with", "ingestion", "of", "quinine", ".", "Hemolytic", "-", "uremic", "syndrome", "following", "quinine", "ingestion", "is", "a", "newly", "described", "phenomenon", ",", "with", "just", "two", "previous", "descriptions", "of", "4", "cases", "in", "the", "literature", ".", "We", "describe", "a", "5th", "case", ".", "The", "reaction", "may", "be", "mediated", "by", "the", "presence", "of", "antibodies", "reactive", "against", "platelets", "in", "the", "presence", "of", "quinine", ".", "Treatment", "has", "included", "use", "of", "plasma", "exchange", ",", "prednisone", ",", "aspirin", ",", "and", "dipyridamole", ".", "The", "patients", "have", "all", "regained", "some", "degree", "of", "renal", "function", ".", "However", ",", "it", "is", "unclear", "whether", "pharmacological", "treatment", "or", "spontaneous", "resolution", "is", "responsible", "for", "the", "improvement", ".", "Quinine", "-", "associated", "hemolytic", "-", "uremic", "syndrome", "probably", "occurs", "more", "often", "than", "is", "recognized", ".", "It", "is", "important", "to", "recognize", "this", "reaction", "when", "it", "occurs", "and", "to", "avoid", "further", "quinine", "exposure", ",", "since", "the", "reaction", "seems", "to", "be", "recurrent", "."]], "ner": [[[8, 8, "Chemical"], [15, 15, "Chemical"], [58, 58, "Chemical"], [103, 103, "Chemical"], [132, 132, "Chemical"], [0, 3, "Disease"], [10, 13, "Disease"], [106, 109, "Disease"], [68, 68, "Chemical"], [70, 70, "Chemical"], [73, 73, "Chemical"]]], "relations": [[[8, 8, 0, 3, "CID"], [8, 8, 10, 13, "CID"], [8, 8, 106, 109, "CID"], [15, 15, 0, 3, "CID"], [15, 15, 10, 13, "CID"], [15, 15, 106, 109, "CID"], [58, 58, 0, 3, "CID"], [58, 58, 10, 13, "CID"], [58, 58, 106, 109, "CID"], [103, 103, 0, 3, "CID"], [103, 103, 10, 13, "CID"], [103, 103, 106, 109, "CID"], [132, 132, 0, 3, "CID"], [132, 132, 10, 13, "CID"], [132, 132, 106, 109, "CID"]]], "clusters": [], "translated": "<5>溶血性尿毒症综合征</5>与摄入<0>奎宁</0>有关。 <1> 奎宁 </1>摄入后的<6>溶血性尿毒症综合征 </6>是一种新描述的现象，之前文献中仅描述了4例。我们描述第5种情况。在<2>奎宁</2>存在的情况下，抗体的存在可能会介导该反应。治疗包括使用血浆置换、<8>泼尼松</8>、<9>阿司匹林</9>和<10>双嘧达莫</10>。患者都在一定程度上恢复了肾功能。然而，尚不清楚药物治疗或自发消退是否对改善负责。<3>奎宁</3>相关的<7>溶血性尿毒症综合征</7>发生的频率可能比人们认识的要高。重要的是在这种反应发生时识别它并避免进一步<4>奎宁</4>暴露，因为这种反应似乎是反复发生的。", "revised": true}
{"doc_key": "1255900", "sentences": [["Pyeloureteral", "filling", "defects", "associated", "with", "systemic", "anticoagulation", ":", "a", "case", "report", ".", "The", "etiology", "of", "pyeloureteritis", "cystica", "has", "long", "been", "attributed", "to", "chronic", "infection", "and", "inflammation", ".", "A", "case", "is", "presented", "that", "is", "unique", "in", "that", "the", "acute", "onset", "and", "the", "rapid", "resolution", "of", "pyeloureteral", "filling", "defects", "in", "this", "patient", "were", "documented", "by", "radiography", ".", "There", "is", "no", "evidence", "of", "antecedent", "or", "concurrent", "infection", "in", "this", "patient", ".", "The", "disease", "occurred", "subsequent", "to", "the", "initiation", "of", "heparin", "therapy", "for", "suspected", "pelvic", "thrombophlebitis", "and", "cleared", "rapidly", "subsequent", "to", "its", "discontinuation", ".", "The", "rate", "of", "resolution", "of", "the", "radiographic", "findings", "may", "be", "helpful", "in", "distinguishing", "between", "true", "pyeloureteritis", "cystica", "and", "submucosal", "hemorrhage", "."]], "ner": [[[76, 76, "Chemical"], [15, 16, "Disease"], [105, 106, "Disease"], [23, 23, "Disease"], [63, 63, "Disease"], [25, 25, "Disease"], [81, 81, "Disease"], [108, 109, "Disease"]]], "relations": [[[76, 76, 15, 16, "CID"], [76, 76, 105, 106, "CID"]]], "clusters": [], "translated": "与全身性抗凝相关的<1>肾盂输尿管充盈缺陷</1>：病例报告。 <1>囊性肾盂输尿管炎</1>的病因长期以来被归于慢性<3>感染</3>和<5>炎症</5>。介绍了一个独特的案例，因为该患者的<1>肾盂输尿管充盈缺损</1>的急性发作和快速消退通过放射线照相记录。没有证据表明该患者存在先前或并发的<4>感染</4>。该疾病发生在因疑似盆腔<6>血栓性静脉炎</6>而开始<0>肝素</0>治疗后，并在停药后迅速消失。影像学检查结果的消退率可能有助于区分真正的<2>囊性肾盂输尿管炎</2>和<7>黏膜下出血</7>。", "revised": true}
{"doc_key": "7437994", "sentences": [["Long", "-", "term", "lithium", "treatment", "and", "the", "kidney", ".", "Interim", "report", "on", "fifty", "patients", ".", "This", "is", "a", "report", "on", "the", "first", "part", "of", "our", "study", "of", "the", "effects", "of", "long", "-", "term", "lithium", "treatment", "on", "the", "kidney", ".", "Creatinine", "clearance", ",", "maximum", "urinary", "osmolality", "and", "24", "hour", "urine", "volume", "have", "been", "tested", "in", "50", "affectively", "ill", "patients", "who", "have", "been", "on", "long", "-", "term", "lithium", "for", "more", "than", "one", "year", ".", "These", "findings", "have", "been", "compared", "with", "norms", "and", "with", "values", "of", "the", "same", "tests", "from", "screening", "prior", "to", "lithium", ",", "available", "for", "most", "of", "our", "patients", ".", "No", "evidence", "was", "found", "for", "any", "reduction", "of", "glomerular", "filtration", "during", "lithium", "treatment", ".", "Low", "clearance", "values", "found", "in", "several", "patients", "could", "be", "accounted", "for", "by", "their", "age", "and", "their", "pre", "-", "lithium", "values", ".", "Urinary", "concentration", "defect", "appeared", "frequent", "but", "the", "extent", "of", "the", "impairment", "is", "difficult", "to", "assess", "because", "of", "the", "uncertainty", "about", "the", "norms", "applicable", "to", "this", "group", "of", "patients", ".", "The", "concentration", "defect", "appeared", "reversible", ",", "at", "least", "in", "part", ".", "Polyuria", "above", "3", "litres", "/", "24", "hours", "was", "found", "in", "10", "%", "of", "patients", ".", "An", "attempt", "is", "made", "to", "draw", "practical", "conclusions", "from", "the", "preliminary", "findings", "."]], "ner": [[[3, 3, "Chemical"], [33, 33, "Chemical"], [65, 65, "Chemical"], [90, 90, "Chemical"], [110, 110, "Chemical"], [131, 131, "Chemical"], [174, 174, "Disease"], [39, 39, "Chemical"]]], "relations": [[[3, 3, 174, 174, "CID"], [33, 33, 174, 174, "CID"], [65, 65, 174, 174, "CID"], [90, 90, 174, 174, "CID"], [110, 110, 174, 174, "CID"], [131, 131, 174, 174, "CID"]]], "clusters": [], "translated": "长期<0>锂</0>治疗与肾脏有关。五十名患者的中期报告。这是我们研究长期<1>锂</1>治疗对肾脏影响的第一部分报告。<7>肌酐</7>清除率、最大尿渗透压和24小时尿量已对50名长期服用<2>锂</2>一年以上的情感疾病患者进行了检测。已将这些发现与正常值以及<3>锂</3>之前筛选的相同测试值进行了比较，这些测试适用于我们的大多数患者。在<4>锂</4>治疗期间，没有发现任何肾小球滤过减少的证据。在几名患者中发现的低清除率值可以通过他们的年龄和他们的<5>锂</5>前值来解释。尿液浓度缺陷经常出现，但由于不确定适用于该组患者的标准，因此难以评估损害的程度。浓度缺陷似乎是可逆的，至少是部分可逆的。<6>多尿</6>超过3升/24小时的患者占10%。试图从初步调查结果中得出实际结论。", "revised": true}
{"doc_key": "85485", "sentences": [["Changes", "in", "peroxisomes", "in", "preneoplastic", "liver", "and", "hepatoma", "of", "mice", "induced", "by", "alpha", "-", "benzene", "hexachloride", ".", "Peroxisomes", "in", "hepatomas", "and", "hyperplastic", "preneoplastic", "liver", "lesions", "induced", "in", "mice", "by", "500", "ppm", "alpha", "-", "benzene", "hexachloride", "were", "examined", "histochemically", "and", "electron", "microscopically", ".", "Although", "most", "of", "the", "hepatomas", "were", "well", "-", "differentiated", "tumors", "and", "contained", "a", "considerable", "number", "of", "peroxisomes", ",", "the", "tumor", "cells", "did", "not", "respond", "to", "ethyl", "-", "alpha", "-", "p", "-", "chlorophenoxyisobutyrate", "with", "proliferation", "of", "peroxisomes", ".", "At", "the", "16th", "week", "of", "carcinogen", "feeding", ",", "hyperplastic", "nodules", "appeared", "and", "advanced", "to", "further", "stages", ".", "A", "majority", "of", "the", "nodules", "showed", "a", "considerable", "number", "of", "peroxisomes", "and", "the", "inductive", "proliferation", "of", "peroxisomes", ".", "Within", "the", "nodules", ",", "foci", "of", "proliferation", "of", "the", "cells", "that", "showed", "no", "inducibility", "of", "proliferation", "of", "peroxisomes", "appeared", ".", "These", "cells", "proliferated", "further", ",", "replacing", "the", "most", "part", "of", "the", "nodules", ",", "and", "with", "this", "process", "hepatomas", "appeared", "to", "have", "been", "formed", ".", "No", "abnormal", "matrical", "inclusions", "of", "peroxisomes", "were", "formed", "in", "the", "cells", "of", "hyperplastic", "nodules", "by", "ethyl", "-", "alpha", "-", "p", "-", "chlorophenoxyisobutyrate", "unlike", "in", "the", "case", "of", "rats", "."]], "ner": [[[12, 15, "Chemical"], [31, 34, "Chemical"], [7, 7, "Disease"], [19, 19, "Disease"], [46, 46, "Disease"], [151, 151, "Disease"], [67, 73, "Chemical"], [173, 179, "Chemical"], [23, 24, "Disease"], [51, 51, "Disease"], [61, 61, "Disease"]]], "relations": [[[12, 15, 7, 7, "CID"], [12, 15, 19, 19, "CID"], [12, 15, 46, 46, "CID"], [12, 15, 151, 151, "CID"], [31, 34, 7, 7, "CID"], [31, 34, 19, 19, "CID"], [31, 34, 46, 46, "CID"], [31, 34, 151, 151, "CID"]]], "clusters": [], "translated": "<0>α-六氯化苯</0>致小鼠癌前肝及<2>肝细胞瘤</2>过氧化物酶体的变化。对500 ppm <1>α-六氯化苯</1>诱导的小鼠<3>肝细胞瘤</3>和增生性癌前病变<8>肝损伤</8>的过氧化物酶体进行了组织化学和电子显微镜检查。尽管大多数<4>肝细胞瘤</4>是分化良好的<9>肿瘤</9>并含有相当数量的过氧化物酶体，但<10>肿瘤</10>细胞对<6>乙基-α-对氯苯氧基异丁酸酯</6>没有反应，不出现过氧化物酶体增殖。致癌物喂养第16周，出现增生性结节并进一步发展。大多数结节显示有相当数量的过氧化物酶体和过氧化物酶体的诱导增殖。结节内出现对过氧化物酶体增殖无诱导作用的细胞增殖灶。这些细胞进一步增殖，取代了大部分结节，并且在这个过程中<5>肝细胞瘤</5>似乎已经形成。与大鼠的情况不同，<7>乙基-α-对氯苯氧基异丁酸酯</7>在增生性结节细胞中没有形成过氧化物酶体的异常基质包涵体。", "revised": true}
{"doc_key": "19274460", "sentences": [["DSMM", "XI", "study", ":", "dose", "definition", "for", "intravenous", "cyclophosphamide", "in", "combination", "with", "bortezomib", "/", "dexamethasone", "for", "remission", "induction", "in", "patients", "with", "newly", "diagnosed", "myeloma", ".", "A", "clinical", "trial", "was", "initiated", "to", "evaluate", "the", "recommended", "dose", "of", "cyclophosphamide", "in", "combination", "with", "bortezomib", "and", "dexamethasone", "as", "induction", "treatment", "before", "stem", "cell", "transplantation", "for", "younger", "patients", "with", "newly", "diagnosed", "multiple", "myeloma", "(", "MM", ")", ".", "Thirty", "patients", "were", "treated", "with", "three", "21", "-", "day", "cycles", "of", "bortezomib", "1", ".", "3", "mg", "/", "m", "(", "2", ")", "on", "days", "1", ",", "4", ",", "8", ",", "and", "11", "plus", "dexamethasone", "40", "mg", "on", "the", "day", "of", "bortezomib", "injection", "and", "the", "day", "after", "plus", "cyclophosphamide", "at", "900", ",", "1", ",", "200", ",", "or", "1", ",", "500", "mg", "/", "m", "(", "2", ")", "on", "day", "1", ".", "The", "maximum", "tolerated", "dose", "of", "cyclophosphamide", "was", "defined", "as", "900", "mg", "/", "m", "(", "2", ")", ".", "At", "this", "dose", "level", ",", "92", "%", "of", "patients", "achieved", "at", "least", "a", "partial", "response", ".", "The", "overall", "response", "rate", "[", "complete", "response", "(", "CR", ")", "plus", "partial", "response", "(", "PR", ")", "]", "across", "all", "dose", "levels", "was", "77", "%", ",", "with", "a", "10", "%", "CR", "rate", ".", "No", "patient", "experienced", "progressive", "disease", ".", "The", "most", "frequent", "adverse", "events", "were", "hematological", "and", "gastrointestinal", "toxicities", "as", "well", "as", "neuropathy", ".", "The", "results", "suggest", "that", "bortezomib", "in", "combination", "with", "cyclophosphamide", "at", "900", "mg", "/", "m", "(", "2", ")", "and", "dexamethasone", "is", "an", "effective", "induction", "treatment", "for", "patients", "with", "newly", "diagnosed", "MM", "that", "warrants", "further", "investigation", "."]], "ner": [[[8, 8, "Chemical"], [36, 36, "Chemical"], [108, 108, "Chemical"], [135, 135, "Chemical"], [224, 224, "Chemical"], [207, 210, "Disease"], [214, 214, "Disease"], [12, 12, "Chemical"], [40, 40, "Chemical"], [73, 73, "Chemical"], [101, 101, "Chemical"], [220, 220, "Chemical"], [14, 14, "Chemical"], [42, 42, "Chemical"], [94, 94, "Chemical"], [234, 234, "Chemical"], [23, 23, "Disease"], [56, 57, "Disease"], [59, 59, "Disease"], [245, 245, "Disease"]]], "relations": [[[8, 8, 207, 210, "CID"], [36, 36, 207, 210, "CID"], [108, 108, 207, 210, "CID"], [135, 135, 207, 210, "CID"], [224, 224, 207, 210, "CID"], [8, 8, 214, 214, "CID"], [36, 36, 214, 214, "CID"], [108, 108, 214, 214, "CID"], [135, 135, 214, 214, "CID"], [224, 224, 214, 214, "CID"], [12, 12, 207, 210, "CID"], [40, 40, 207, 210, "CID"], [73, 73, 207, 210, "CID"], [101, 101, 207, 210, "CID"], [220, 220, 207, 210, "CID"], [12, 12, 214, 214, "CID"], [40, 40, 214, 214, "CID"], [73, 73, 214, 214, "CID"], [101, 101, 214, 214, "CID"], [220, 220, 214, 214, "CID"], [14, 14, 207, 210, "CID"], [42, 42, 207, 210, "CID"], [94, 94, 207, 210, "CID"], [234, 234, 207, 210, "CID"], [14, 14, 214, 214, "CID"], [42, 42, 214, 214, "CID"], [94, 94, 214, 214, "CID"], [234, 234, 214, 214, "CID"]]], "clusters": [], "translated": "DSMM XI 研究：静脉内<0>环磷酰胺</0>联合<7>硼替佐米</7>/<12>地塞米松</12>用于新诊断<16>骨髓瘤</16>患者缓解诱导的剂量定义。启动了一项临床试验，以评估<1>环磷酰胺</1>联合<8>硼替佐米</8>和<13>地塞米松</13>作为初诊<17>多发性骨髓瘤</17>（<18>MM</18>）年轻患者干细胞移植前诱导治疗的推荐剂量。30名患者接受了三个21天周期的<9>硼替佐米</9> 1.3mg/m(2)治疗。第1、4、8、11天加<10>硼替佐米</10>注射当天40mg的<14>地塞米松</14>，加900、1,200或1,500mg/m(2)的<2>环磷酰胺</2>。最大耐受剂量的<3>环磷酰胺</3>定义为900mg/m(2)。在此剂量水平下，92%的患者至少达到了部分反应。所有剂量水平的总体缓解率[完全缓解(CR)加部分缓解(PR)]为77%，其中CR率为10%。没有患者出现疾病进展。最常见的不良事件是<5>血液学和胃肠道毒性</5>，以及<6>神经病变</6>。结果表明，<11>硼替佐米</11>联合900mg/m(2)的<4>环磷酰胺</4>和<15>地塞米松</15>是初诊<19>MM</19>患者的有效诱导治疗，值得进一步调查。", "revised": true}
{"doc_key": "6308526", "sentences": [["Naloxazone", "pretreatment", "modifies", "cardiorespiratory", ",", "temperature", ",", "and", "behavioral", "effects", "of", "morphine", ".", "Behavioral", "and", "cardiorespiratory", "responses", "to", "a", "lethal", "dose", "of", "morphine", "were", "evaluated", "in", "rats", "pretreated", "with", "saline", "or", "naloxazone", ",", "an", "antagonist", "of", "high", "-", "affinity", "mu", "1", "opioid", "receptors", ".", "Pretreatment", "with", "naloxazone", "significantly", "blocked", "morphine", "analgesia", ",", "catalepsy", "and", "hypothermia", "at", "a", "dose", "which", "completely", "eliminated", "high", "-", "affinity", "binding", "in", "brain", "membranes", ".", "Moreover", ",", "naloxazone", "significantly", "attenuated", "the", "morphine", "-", "induced", "hypotension", "and", "respiratory", "depression", ",", "whereas", "morphine", "-", "induced", "bradycardia", "was", "less", "affected", ".", "Results", "indicate", "that", "subpopulations", "of", "mu", "receptors", "may", "mediate", "selective", "behavioral", "and", "cardiorespiratory", "responses", "to", "morphine", "."]], "ner": [[[11, 11, "Chemical"], [22, 22, "Chemical"], [49, 49, "Chemical"], [75, 75, "Chemical"], [84, 84, "Chemical"], [107, 107, "Chemical"], [52, 52, "Disease"], [54, 54, "Disease"], [78, 78, "Disease"], [87, 87, "Disease"], [0, 0, "Chemical"], [31, 31, "Chemical"], [46, 46, "Chemical"], [71, 71, "Chemical"], [50, 50, "Disease"], [80, 81, "Disease"]]], "relations": [[[11, 11, 52, 52, "CID"], [22, 22, 52, 52, "CID"], [49, 49, 52, 52, "CID"], [75, 75, 52, 52, "CID"], [84, 84, 52, 52, "CID"], [107, 107, 52, 52, "CID"], [11, 11, 54, 54, "CID"], [22, 22, 54, 54, "CID"], [49, 49, 54, 54, "CID"], [75, 75, 54, 54, "CID"], [84, 84, 54, 54, "CID"], [107, 107, 54, 54, "CID"], [11, 11, 78, 78, "CID"], [22, 22, 78, 78, "CID"], [49, 49, 78, 78, "CID"], [75, 75, 78, 78, "CID"], [84, 84, 78, 78, "CID"], [107, 107, 78, 78, "CID"], [11, 11, 87, 87, "CID"], [22, 22, 87, 87, "CID"], [49, 49, 87, 87, "CID"], [75, 75, 87, 87, "CID"], [84, 84, 87, 87, "CID"], [107, 107, 87, 87, "CID"]]], "clusters": [], "translated": "<10>纳洛沙酮</10>预处理改变了<0>吗啡</0>的心肺、温度和行为效应。在用生理盐水或高亲和力μ1阿片受体拮抗剂<11>纳洛沙酮</11>预处理的大鼠中，评估了对致死剂量<1>吗啡</1>的行为和心肺反应。预处理用<12>纳洛沙酮</12>显着阻断了<2>吗啡</2><14>镇痛</14>、<6>僵直</6>和<7>低温</7>，其剂量完全消除了脑膜中的高亲和力结合。此外，<13>纳洛沙酮</13>显着减轻了<3>吗啡</3>引起的<8>低血压</8>和<15>呼吸抑制</15>，而<4>吗啡</4>引起的<9>心动过缓</9>受影响较小。结果表明，μ受体亚群可能介导对<5>吗啡</5>的选择性行为和心肺反应。", "revised": true}
{"doc_key": "48362", "sentences": [["Quinidine", "hepatitis", ".", "Long", "-", "term", "administration", "of", "quinidine", "was", "associated", "with", "persistent", "elevation", "of", "serum", "concentrations", "of", "SGOT", ",", "lactic", "acid", "dehydrogenase", ",", "and", "alkaline", "phosphatase", ".", "Liver", "biopsy", "showed", "active", "hepatitis", ".", "Discontinuance", "of", "quinidine", "therapy", "led", "to", "normalization", "of", "liver", "function", "tests", ".", "A", "challenge", "dose", "of", "quinidine", "caused", "clinical", "symptoms", "and", "abrupt", "elevation", "of", "SGOT", ",", "alkaline", "phosphatase", ",", "and", "lactic", "acid", "dehydrogenase", "values", ".", "We", "concluded", "that", "this", "patient", "had", "quinidine", "hepatotoxicity", "and", "believe", "that", "this", "is", "the", "first", "case", "reported", "with", "liver", "biopsy", "documentation", ".", "This", "report", "also", "suggests", "that", ",", "even", "after", "long", "-", "term", "administration", ",", "the", "hepatic", "toxicity", "is", "reversible", "."]], "ner": [[[0, 0, "Chemical"], [8, 8, "Chemical"], [36, 36, "Chemical"], [50, 50, "Chemical"], [75, 75, "Chemical"], [1, 1, "Disease"], [32, 32, "Disease"], [76, 76, "Disease"], [105, 106, "Disease"], [20, 21, "Chemical"], [64, 65, "Chemical"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 32, 32, "CID"], [0, 0, 76, 76, "CID"], [0, 0, 105, 106, "CID"], [8, 8, 1, 1, "CID"], [8, 8, 32, 32, "CID"], [8, 8, 76, 76, "CID"], [8, 8, 105, 106, "CID"], [36, 36, 1, 1, "CID"], [36, 36, 32, 32, "CID"], [36, 36, 76, 76, "CID"], [36, 36, 105, 106, "CID"], [50, 50, 1, 1, "CID"], [50, 50, 32, 32, "CID"], [50, 50, 76, 76, "CID"], [50, 50, 105, 106, "CID"], [75, 75, 1, 1, "CID"], [75, 75, 32, 32, "CID"], [75, 75, 76, 76, "CID"], [75, 75, 105, 106, "CID"]]], "clusters": [], "translated": "<0>奎尼丁</0> <5>肝炎</5> .长期服用<1>奎尼丁</1>与血清SGOT、<9>乳酸脱氢酶</9>和碱性磷酸酶浓度持续升高有关。肝活检示活动性<6>肝炎</6>。停止<2>奎尼丁</2>治疗导致肝功能检查正常化。<3>奎尼丁</3>的挑战剂量引起临床症状和SGOT、碱性磷酸酶和<10>乳酸脱氢酶</10>值的突然升高。我们得出结论，该患者有<4>奎尼丁</4><7>肝毒性</7>，并相信这是第一例有肝活检记录的病例报告。该报告还表明，即使在长期给药后，<8>肝毒性</8>也是可逆的。", "revised": true}
{"doc_key": "11337188", "sentences": [["Cutaneous", "leucocytoclastic", "vasculitis", "associated", "with", "oxacillin", ".", "A", "67", "-", "year", "-", "old", "man", "who", "was", "treated", "with", "oxacillin", "for", "one", "week", "because", "of", "Staphylococcus", "aureus", "bacteremia", ",", "developed", "renal", "failure", "and", "diffuse", ",", "symmetric", ",", "palpable", "purpuric", "lesions", "on", "his", "feet", ".", "Necrotic", "blisters", "were", "noted", "on", "his", "fingers", ".", "Skin", "biopsies", "showed", "findings", "diagnostic", "of", "leucocytoclastic", "vasculitis", ".", "Oxacillin", "was", "discontinued", "and", "patient", "was", "treated", "with", "corticosteroids", ".", "The", "rash", "disappeared", "after", "three", "weeks", "and", "renal", "function", "returned", "to", "normal", ".", "Leucocytoclastic", "vasculitis", "presents", "as", "palpable", "purpura", "of", "the", "lower", "extremities", "often", "accompanied", "by", "abdominal", "pain", ",", "arthralgia", ",", "and", "renal", "involvement", ".", "Etiologic", "factors", "or", "associated", "disorders", "include", "infections", ",", "medications", ",", "collagen", "vascular", "disease", "and", "neoplasia", ".", "However", ",", "in", "half", "of", "the", "cases", "no", "etiologic", "factor", "is", "identified", ".", "Usually", "it", "is", "a", "self", "-", "limited", "disorder", ",", "but", "corticosteroid", "therapy", "may", "be", "needed", "in", "life", "-", "threatening", "cases", "since", "early", "treatment", "with", "corticosteroids", "in", "severe", "cases", "can", "prevent", "complications", ".", "Oxacillin", "should", "be", "included", "among", "the", "drugs", "that", "can", "cause", "leucocytoclastic", "vasculitis", "."]], "ner": [[[5, 5, "Chemical"], [18, 18, "Chemical"], [60, 60, "Chemical"], [166, 166, "Chemical"], [0, 2, "Disease"], [57, 58, "Disease"], [83, 84, "Disease"], [176, 177, "Disease"], [68, 68, "Chemical"], [144, 144, "Chemical"], [158, 158, "Chemical"], [29, 30, "Disease"], [24, 26, "Disease"], [37, 38, "Disease"], [88, 88, "Disease"], [43, 44, "Disease"], [71, 71, "Disease"], [96, 97, "Disease"], [99, 99, "Disease"], [102, 103, "Disease"], [111, 111, "Disease"], [115, 117, "Disease"], [119, 119, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 57, 58, "CID"], [5, 5, 83, 84, "CID"], [5, 5, 176, 177, "CID"], [18, 18, 0, 2, "CID"], [18, 18, 57, 58, "CID"], [18, 18, 83, 84, "CID"], [18, 18, 176, 177, "CID"], [60, 60, 0, 2, "CID"], [60, 60, 57, 58, "CID"], [60, 60, 83, 84, "CID"], [60, 60, 176, 177, "CID"], [166, 166, 0, 2, "CID"], [166, 166, 57, 58, "CID"], [166, 166, 83, 84, "CID"], [166, 166, 176, 177, "CID"], [68, 68, 0, 2, "CID"], [68, 68, 57, 58, "CID"], [68, 68, 83, 84, "CID"], [68, 68, 176, 177, "CID"], [144, 144, 0, 2, "CID"], [144, 144, 57, 58, "CID"], [144, 144, 83, 84, "CID"], [144, 144, 176, 177, "CID"], [158, 158, 0, 2, "CID"], [158, 158, 57, 58, "CID"], [158, 158, 83, 84, "CID"], [158, 158, 176, 177, "CID"], [5, 5, 29, 30, "CID"], [18, 18, 29, 30, "CID"], [60, 60, 29, 30, "CID"], [166, 166, 29, 30, "CID"], [68, 68, 29, 30, "CID"], [144, 144, 29, 30, "CID"], [158, 158, 29, 30, "CID"]]], "clusters": [], "translated": " <4>皮肤白细胞破碎性血管炎</4>与<0>苯唑西林</0>有关。一名 67 岁男性因<12>金黄色葡萄球菌菌血症</12>接受<1>苯唑西林</1>治疗一周，出现<11>肾功能衰竭</11>和弥漫性、对称性、可触及的<13>紫癜性病变</13>。在他的手指上发现了<15>坏死性水泡</15>。皮肤活检结果显示诊断为<5>白细胞破碎性血管炎</5>。 <2>苯唑西林</2>停用，患者接受<8>皮质类固醇</8> 治疗。三周后<16>皮疹</16>消失，肾功能恢复正常。<6>白细胞破碎性血管炎</6>表现为下肢可触及的<14>紫癜</14>，常伴有<17>腹痛</17>、<18>关节痛</18>、<19>肾脏受累</19>。病因或相关疾病包括<20>感染</20>、药物、<21>胶原血管病</21>和<22>瘤形成</22>。然而，在半数病例中，未发现病因。通常它是一种自限性疾病，但危及生命的病例可能需要<9>皮质类固醇</9>治疗，因为在严重病例中早期使用<10>皮质类固醇</10>治疗可以预防并发症。<3>苯唑西林</3>应列入可引起<7>白细胞破碎性血管炎</7>的药物。", "revised": true}
{"doc_key": "18201582", "sentences": [["Results", "of", "a", "comparative", ",", "phase", "III", ",", "12", "-", "week", ",", "multicenter", ",", "prospective", ",", "randomized", ",", "double", "-", "blind", "assessment", "of", "the", "efficacy", "and", "tolerability", "of", "a", "fixed", "-", "dose", "combination", "of", "telmisartan", "and", "amlodipine", "versus", "amlodipine", "monotherapy", "in", "Indian", "adults", "with", "stage", "II", "hypertension", ".", "OBJECTIVE", ":", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "the", "efficacy", "and", "tolerability", "of", "a", "new", "fixed", "-", "dose", "combination", "(", "FDC", ")", "of", "telmisartan", "40", "mg", "+", "amlodipine", "5", "mg", "(", "T", "+", "A", ")", "compared", "with", "amlodipine", "5", "-", "mg", "monotherapy", "(", "A", ")", "in", "adult", "Indian", "patients", "with", "stage", "II", "hypertension", ".", "METHODS", ":", "This", "comparative", ",", "Phase", "III", ",", "12", "-", "week", ",", "multicenter", ",", "prospective", ",", "randomized", ",", "double", "-", "blind", "study", "was", "conducted", "in", "Indian", "patients", "aged", "18", "to", "65", "years", "with", "established", "stage", "II", "hypertension", ".", "Patients", "were", "treated", "with", "oral", "FDC", "of", "T", "+", "A", "or", "A", "QD", "before", "breakfast", "for", "12", "weeks", ";", "blood", "pressure", "(", "BP", ")", "and", "heart", "rate", "were", "measured", "in", "the", "sitting", "position", ".", "Primary", "efficacy", "end", "points", "were", "reduction", "in", "clinical", "systolic", "BP", "(", "SBP", ")", "/", "diastolic", "BP", "(", "DBP", ")", "from", "baseline", "to", "study", "end", "and", "number", "of", "responders", "(", "ie", ",", "patients", "who", "achieved", "target", "SBP", "/", "DBP", "<", "130", "/", "<", "80", "mm", "Hg", ")", "at", "end", "of", "study", ".", "Tolerability", "was", "assessed", "by", "treatment", "-", "emergent", "adverse", "events", ",", "identified", "using", "physical", "examination", ",", "laboratory", "analysis", ",", "and", "electrocardiography", ".", "RESULTS", ":", "A", "total", "of", "210", "patients", "were", "enrolled", "in", "the", "study", ";", "203", "patients", "(", "143", "men", ",", "60", "women", ")", "completed", "the", "study", "while", "7", "were", "lost", "to", "follow", "-", "up", "(", "4", "patients", "in", "the", "T", "+", "A", "group", "and", "3", "in", "the", "A", "group", ")", "and", "considered", "with", "-", "drawn", ".", "At", "study", "end", ",", "statistically", "significant", "percentage", "reductions", "from", "baseline", "within", "groups", "and", "between", "groups", "were", "observed", "in", "SBP", "(", "T", "+", "A", "[", "-", "27", ".", "4", "%", "]", ";", "A", "[", "-", "16", ".", "6", "%", "]", ")", "and", "DBP", "(", "T", "+", "A", "[", "-", "20", ".", "1", "%", "]", ";", "A", "[", "-", "13", ".", "3", "%", "]", ")", "(", "all", ",", "P", "<", "0", ".", "05", ")", ".", "Response", "rates", "were", "87", ".", "3", "%", "(", "89", "/", "102", ")", "in", "the", "T", "+", "A", "group", "and", "69", ".", "3", "%", "(", "70", "/", "101", ")", "in", "the", "A", "group", "(", "P", "<", "0", ".", "05", ")", ".", "The", "prevalences", "of", "adverse", "events", "were", "not", "significantly", "different", "between", "the", "2", "treatment", "groups", "(", "T", "+", "A", ",", "16", ".", "0", "%", "[", "17", "/", "106", "]", ";", "A", ",", "15", ".", "4", "%", "[", "16", "/", "104", "]", ")", ".", "Peripheral", "edema", "was", "reported", "in", "8", ".", "5", "%", "patients", "(", "9", "/", "106", ")", "in", "the", "T", "+", "A", "group", "compared", "with", "13", ".", "5", "%", "(", "14", "/", "104", ")", "in", "the", "A", "group", ",", "and", "cough", "was", "reported", "in", "3", ".", "8", "%", "patients", "(", "4", "/", "106", ")", "in", "the", "T", "+", "A", "group", "and", "1", ".", "0", "%", "(", "1", "/", "104", ")", "patients", "in", "the", "A", "group", ";", "these", "differences", "did", "not", "reach", "statistical", "significance", ".", "The", "incidences", "of", "headache", ",", "dizziness", ",", "and", "diarrhea", "were", "similar", "between", "the", "2", "groups", ".", "CONCLUSIONS", ":", "Among", "these", "Indian", "patients", "with", "stage", "II", "hypertension", ",", "the", "FDC", "of", "T", "+", "A", "was", "found", "to", "be", "significantly", "more", "effective", ",", "with", "regard", "to", "BP", "reductions", ",", "than", "A", ",", "and", "both", "treatments", "were", "well", "tolerated", "."]], "ner": [[[34, 34, "Chemical"], [73, 73, "Chemical"], [459, 459, "Disease"], [496, 496, "Disease"], [543, 543, "Disease"], [545, 545, "Disease"], [548, 548, "Disease"], [36, 36, "Chemical"], [38, 38, "Chemical"], [77, 77, "Chemical"], [87, 87, "Chemical"], [46, 46, "Disease"], [102, 102, "Disease"], [140, 140, "Disease"], [565, 565, "Disease"]]], "relations": [[[34, 34, 459, 459, "CID"], [73, 73, 459, 459, "CID"], [34, 34, 496, 496, "CID"], [73, 73, 496, 496, "CID"], [34, 34, 543, 543, "CID"], [73, 73, 543, 543, "CID"], [34, 34, 545, 545, "CID"], [73, 73, 545, 545, "CID"], [34, 34, 548, 548, "CID"], [73, 73, 548, 548, "CID"], [36, 36, 459, 459, "CID"], [38, 38, 459, 459, "CID"], [77, 77, 459, 459, "CID"], [87, 87, 459, 459, "CID"], [36, 36, 496, 496, "CID"], [38, 38, 496, 496, "CID"], [77, 77, 496, 496, "CID"], [87, 87, 496, 496, "CID"], [36, 36, 543, 543, "CID"], [38, 38, 543, 543, "CID"], [77, 77, 543, 543, "CID"], [87, 87, 543, 543, "CID"], [36, 36, 545, 545, "CID"], [38, 38, 545, 545, "CID"], [77, 77, 545, 545, "CID"], [87, 87, 545, 545, "CID"], [36, 36, 548, 548, "CID"], [38, 38, 548, 548, "CID"], [77, 77, 548, 548, "CID"], [87, 87, 548, 548, "CID"]]], "clusters": [], "translated": "<0>替米沙坦</0>和<7>氨氯地平</7>的固定剂量组合的疗效和耐受性的比较性、III期、12周、多中心、前瞻性、随机、双盲评估结果与<8>氨氯地平</8>单药治疗II期<11>高血压</11>的印度成人相比。目的：本研究的目的是评估<1>替米沙坦</1>40mg+<9>氨氯地平</9>5mg的新型固定剂量组合（FDC）的疗效和耐受性（T+A）与<10>氨氯地平</10>5mg单药治疗（A）在成年印度<12>高血压</12>患者中的比较。方法：这项III期、为期12周、多中心、前瞻性、随机、双盲的比较研究是在年龄在18至65岁的患有II期<13>高血压</13>的印度患者中进行的。患者在早餐前接受口服FDC T+A或AQD治疗12周；血压（BP）和心率是在坐姿下测量的。主要疗效终点是从基线到研究结束时临床收缩压（SBP）/舒张压（DBP）的降低，以及研究结束时有反应者的数量（即达到目标收缩压/DBP＜130/＜80mmHg的患者）。耐受性是通过治疗中出现的不良事件来评估的，这些不良事件是通过身体检查、实验室分析和心电图来确定的。结果：共有210名患者被纳入研究；203名患者（143名男性，60名女性）完成了研究，而7名患者失访（T+A组4名患者，A组3名患者）并考虑退出。在研究结束时，观察到SBP（T+A[-27.4%]; A[-16.6%]）和DBP（T+A[-20.1%]；A[-13.3%]）（全部，P＜0.05）。回应率为87.3%（89/102）在T+A组和69.3%（70/101）在A组（P<0.05）。不良事件的发生率在两个治疗组之间没有显着差异（T+A，16.0%[17/106]；A，15.4%[16/104]）。外周<2>水肿</2>报告了8例。T+A组中有5%的患者（9/106）与13.5%（14/104）在A组中，<3>咳嗽</3>在3.8%的患者（4/106）在T+A组和1.0%（1/104）患者在A组；这些差异没有达到统计学意义。两组间<4>头痛</4>、<5>头晕</5>和<6>腹泻</6>的发生率相似。结论：在这些患有II期<14>高血压</14>的印度患者中，发现FDC的T+A在降压方面明显比A更有效，并且两种治疗的耐受性都很好。", "revised": true}
{"doc_key": "2598570", "sentences": [["The", "epidemiology", "of", "the", "acute", "flank", "pain", "syndrome", "from", "suprofen", ".", "Suprofen", ",", "a", "new", "nonsteroidal", "anti", "-", "inflammatory", "drug", ",", "was", "marketed", "in", "early", "1986", "as", "an", "analgesic", "agent", ".", "Until", "physicians", "began", "reporting", "an", "unusual", "acute", "flank", "pain", "syndrome", "to", "the", "spontaneous", "reporting", "system", ",", "700", ",", "000", "persons", "used", "the", "drug", "in", "the", "United", "States", ".", "Through", "August", "1986", ",", "a", "total", "of", "163", "cases", "of", "this", "syndrome", "were", "reported", ".", "To", "elucidate", "the", "epidemiology", "of", "the", "syndrome", ",", "a", "case", "-", "control", "study", "was", "performed", ",", "comparing", "62", "of", "the", "case", "patients", "who", "had", "been", "reported", "to", "the", "spontaneous", "reporting", "system", "to", "185", "suprofen", "-", "exposed", "control", "subjects", "who", "did", "not", "have", "the", "syndrome", ".", "Case", "patients", "were", "more", "likely", "to", "be", "men", "(", "odds", "ratio", ",", "3", ".", "8", ";", "95", "%", "confidence", "interval", ",", "1", ".", "2", "-", "12", ".", "1", ")", ",", "suffer", "from", "hay", "fever", "and", "asthma", "(", "odds", "ratio", ",", "3", ".", "4", ";", "95", "%", "confidence", "interval", ",", "1", ".", "0", "-", "11", ".", "9", ")", ";", "to", "participate", "in", "regular", "exercise", "(", "odds", "ratio", ",", "5", ".", "9", ";", "95", "%", "confidence", "interval", ",", "1", ".", "1", "-", "30", ".", "7", ")", ",", "especially", "in", "the", "use", "of", "Nautilus", "equipment", "(", "p", "=", "0", ".", "02", ")", ";", "and", "to", "use", "alcohol", "(", "odds", "ratio", ",", "4", ".", "4", ";", "95", "%", "confidence", "interval", ",", "1", ".", "1", "-", "17", ".", "5", ")", ".", "Possible", "risk", "factors", "included", "young", "age", ",", "concurrent", "use", "of", "other", "analgesic", "agents", "(", "especially", "ibuprofen", ")", ",", "preexisting", "renal", "disease", ",", "a", "history", "of", "kidney", "stones", ",", "a", "history", "of", "gout", ",", "a", "recent", "increase", "in", "activity", ",", "a", "recent", "increase", "in", "sun", "exposure", ",", "and", "residence", "in", "the", "Sunbelt", ".", "These", "were", "findings", "that", "were", "suggestive", "but", "did", "not", "reach", "conventional", "statistical", "significance", ".", "These", "findings", "are", "consistent", "with", "the", "postulated", "mechanism", "for", "this", "unusual", "syndrome", ":", "acute", "diffuse", "crystallization", "of", "uric", "acid", "in", "renal", "tubules", "."]], "ner": [[[9, 9, "Chemical"], [11, 11, "Chemical"], [107, 107, "Chemical"], [5, 6, "Disease"], [38, 39, "Disease"], [222, 222, "Chemical"], [260, 260, "Chemical"], [328, 329, "Chemical"], [151, 152, "Disease"], [154, 154, "Disease"], [264, 265, "Disease"], [270, 271, "Disease"], [276, 276, "Disease"]]], "relations": [[[9, 9, 5, 6, "CID"], [9, 9, 38, 39, "CID"], [11, 11, 5, 6, "CID"], [11, 11, 38, 39, "CID"], [107, 107, 5, 6, "CID"], [107, 107, 38, 39, "CID"]]], "clusters": [], "translated": "<0>舒洛芬</0>引起的急性<3>腰痛</3>综合征的流行病学。<1>舒洛芬</1>是一种新型非甾体类抗炎药，于1986年初作为镇痛剂上市。在医生开始向自发报告系统报告不寻常的急性<4>腰痛</4>综合征之前，美国有700,000人使用了该药物。到1986年8月，共报告了163例该综合征病例。为了阐明该综合征的流行病学，进行了一项病例对照研究，比较了62名已向自发报告系统报告的病例患者与185名<2>舒洛芬</2>暴露的对照受试者，他们没有综合症。病例患者更有可能是男性（比值比，3.8；95%置信区间，1.2-12.1），患有<8>花粉症</8>和<9>哮喘</9>（比值比，3.4；95%置信区间，1.0-11.9）；参加定期锻炼（比值比，5.9；95%置信区间，1.1-30.7），尤其是使用Nautilus设备（p=0.02）；并使用<5>酒精</5>（比值比，4.4；95%置信区间，1.1-17.5）。可能的危险因素包括年轻、同时使用其他镇痛药（尤其是<6>布洛芬</6>）、既往有<10>肾病</10>、<11>肾结石</11>病史、<12>痛风病史</12>，近期活动量增加，近期日光照射增加，居住在阳光带。这些发现具有启发性，但未达到常规统计显着性。这些发现与这种不寻常综合征的假设机制一致：<7>尿酸</7>在肾小管中急性弥漫性结晶。", "revised": true}
{"doc_key": "2594614", "sentences": [["Protective", "effect", "of", "a", "specific", "platelet", "-", "activating", "factor", "antagonist", ",", "BN", "52021", ",", "on", "bupivacaine", "-", "induced", "cardiovascular", "impairments", "in", "rats", ".", "Administration", "of", "the", "local", "anaesthetic", "bupivacaine", "(", "1", ".", "5", "or", "2", "mg", "/", "kg", ",", "i", ".", "v", ".", ")", "to", "rats", "elicited", "a", "marked", "decrease", "of", "mean", "arterial", "blood", "pressure", "(", "MBP", ")", "and", "heart", "rate", "(", "HR", ")", "leading", "to", "death", "(", "in", "67", "%", "or", "90", "%", "of", "animals", "respectively", ")", ".", "Intravenous", "injection", "of", "the", "specific", "platelet", "-", "activating", "factor", "(", "PAF", ")", "antagonist", "BN", "52021", "(", "10", "mg", "/", "kg", ")", ",", "30", "min", "before", "bupivacaine", "administration", "(", "2", "mg", "/", "kg", "i", ".", "v", ".", ")", "suppressed", "both", "the", "decrease", "of", "MBP", "and", "HR", ".", "In", "contrast", ",", "doses", "of", "1", "mg", "/", "kg", "BN", "52021", "given", "30", "min", "before", "or", "10", "mg", "/", "kg", "administered", "5", "min", "before", "i", ".", "v", ".", "injection", "of", "bupivacaine", "were", "ineffective", ".", "When", "BN", "52021", "(", "20", "mg", "/", "kg", "i", ".", "v", ".", ")", "was", "injected", "immediately", "after", "bupivacaine", "(", "2", "mg", "/", "kg", ")", ",", "a", "partial", "reversion", "of", "the", "decrease", "of", "MBP", "and", "HR", "was", "observed", ",", "whereas", "the", "dose", "of", "10", "mg", "/", "kg", "was", "ineffective", ".", "A", "partial", "recovery", "of", "bupivacaine", "-", "induced", "ECG", "alterations", "was", "observed", "after", "pretreatment", "of", "the", "rats", "with", "BN", "52021", ".", "Since", "the", "administration", "of", "BN", "52021", ",", "at", "all", "doses", "studied", ",", "did", "not", "alter", "MBP", "and", "HR", "at", "the", "doses", "used", ",", "the", "bulk", "of", "these", "results", "clearly", "demonstrate", "a", "protective", "action", "of", "BN", "52021", ",", "a", "specific", "antagonist", "of", "PAF", ",", "against", "bupivacaine", "-", "induced", "cardiovascular", "toxicity", ".", "Thus", ",", "consistent", "with", "its", "direct", "effect", "on", "heart", ",", "PAF", "appears", "to", "be", "implicated", "in", "bupivacaine", "-", "induced", "cardiovascular", "alterations", "."]], "ner": [[[15, 15, "Chemical"], [28, 28, "Chemical"], [104, 104, "Chemical"], [155, 155, "Chemical"], [176, 176, "Chemical"], [212, 212, "Chemical"], [272, 272, "Chemical"], [294, 294, "Chemical"], [49, 63, "Disease"], [119, 123, "Disease"], [189, 193, "Disease"], [11, 12, "Chemical"], [92, 93, "Chemical"], [134, 135, "Chemical"], [160, 161, "Chemical"], [225, 226, "Chemical"], [232, 233, "Chemical"], [262, 263, "Chemical"], [18, 19, "Disease"], [275, 276, "Disease"], [297, 298, "Disease"]]], "relations": [[[15, 15, 49, 63, "CID"], [15, 15, 119, 123, "CID"], [15, 15, 189, 193, "CID"], [28, 28, 49, 63, "CID"], [28, 28, 119, 123, "CID"], [28, 28, 189, 193, "CID"], [104, 104, 49, 63, "CID"], [104, 104, 119, 123, "CID"], [104, 104, 189, 193, "CID"], [155, 155, 49, 63, "CID"], [155, 155, 119, 123, "CID"], [155, 155, 189, 193, "CID"], [176, 176, 49, 63, "CID"], [176, 176, 119, 123, "CID"], [176, 176, 189, 193, "CID"], [212, 212, 49, 63, "CID"], [212, 212, 119, 123, "CID"], [212, 212, 189, 193, "CID"], [272, 272, 49, 63, "CID"], [272, 272, 119, 123, "CID"], [272, 272, 189, 193, "CID"], [294, 294, 49, 63, "CID"], [294, 294, 119, 123, "CID"], [294, 294, 189, 193, "CID"]]], "clusters": [], "translated": "特异性血小板活化因子拮抗剂<11>BN 52021</11>对大鼠<0>布比卡因</0>诱导的<18>心血管损伤</18>的保护作用。对大鼠施用局部麻醉剂<1>布比卡因</1>（1.5或2 mg/kg，i.v.）引起平均动脉血压(MBP)和心率(HR)显着<8>下降</8>导致死亡（分别在67%或90%的动物中）。静脉注射特异性血小板活化因子(PAF)拮抗剂<12>BN 52021</12>（10 mg/kg），在<2>布比卡因</2>给药前30分钟（2 mg/kg i.v.）抑制了<9>MBP和HR的降低</9>。相反，在i前30分钟给予1 mg/kg<13>BN 52021</13>剂量或在i前5分钟给予10 mg/kg剂量。注射<3>布比卡因</3>均无效。<14>BN 52021</14> (20 mg/kg i.v.)在<4>布比卡因</4> (2 mg/kg)后立即注射，部分逆转了<10>MBP和HR的降低</10>，而10mg/kg剂量无效。用<15>BN 52021</15>预处理大鼠后观察到<5>布比卡因</5>引起的心电图改变部分恢复。由于<16>BN 52021</16>的给药在所有研究剂量下均未改变所用剂量的MBP和HR，因此这些结果中的大部分清楚地证明了<17>BN 52021</17>的保护作用，PAF的特异性拮抗剂，对抗<6>布比卡因</6>引起的<19>心血管毒性</19>。因此，与其对心脏的直接作用一致，PAF似乎与<7>布比卡因</7>诱导的<20>心血管改变</20>有关。", "revised": true}
{"doc_key": "8278214", "sentences": [["Hyperalgesia", "and", "myoclonus", "in", "terminal", "cancer", "patients", "treated", "with", "continuous", "intravenous", "morphine", ".", "Eight", "cancer", "patients", "in", "the", "terminal", "stages", "of", "the", "disease", "treated", "with", "high", "doses", "of", "intravenous", "morphine", "developed", "hyperalgesia", ".", "All", "cases", "were", "retrospectively", "sampled", "from", "three", "different", "hospitals", "in", "Copenhagen", ".", "Five", "patients", "developed", "universal", "hyperalgesia", "and", "hyperesthesia", "which", "in", "2", "cases", "were", "accompanied", "by", "myoclonus", ".", "In", "3", "patients", "a", "pre", "-", "existing", "neuralgia", "increased", "to", "excruciating", "intensity", "and", "in", "2", "of", "these", "cases", "myoclonus", "occurred", "simultaneously", ".", "Although", "only", "few", "clinical", "descriptions", "of", "the", "relationship", "between", "hyperalgesia", "/", "myoclonus", "and", "high", "doses", "of", "morphine", "are", "available", ",", "experimental", "support", "from", "animal", "studies", "indicates", "that", "morphine", ",", "or", "its", "metabolites", ",", "plays", "a", "causative", "role", "for", "the", "observed", "behavioural", "syndrome", ".", "The", "possible", "mechanisms", "are", "discussed", "and", "treatment", "proposals", "given", "suggesting", "the", "use", "of", "more", "efficacious", "opioids", "with", "less", "excitatory", "potency", "in", "these", "situations", "."]], "ner": [[[11, 11, "Chemical"], [29, 29, "Chemical"], [99, 99, "Chemical"], [110, 110, "Chemical"], [0, 0, "Disease"], [31, 31, "Disease"], [49, 49, "Disease"], [92, 92, "Disease"], [2, 2, "Disease"], [59, 59, "Disease"], [79, 79, "Disease"], [94, 94, "Disease"], [51, 51, "Disease"], [68, 68, "Disease"], [5, 5, "Disease"], [14, 14, "Disease"]]], "relations": [[[11, 11, 0, 0, "CID"], [11, 11, 31, 31, "CID"], [11, 11, 49, 49, "CID"], [11, 11, 92, 92, "CID"], [29, 29, 0, 0, "CID"], [29, 29, 31, 31, "CID"], [29, 29, 49, 49, "CID"], [29, 29, 92, 92, "CID"], [99, 99, 0, 0, "CID"], [99, 99, 31, 31, "CID"], [99, 99, 49, 49, "CID"], [99, 99, 92, 92, "CID"], [110, 110, 0, 0, "CID"], [110, 110, 31, 31, "CID"], [110, 110, 49, 49, "CID"], [110, 110, 92, 92, "CID"], [11, 11, 2, 2, "CID"], [11, 11, 59, 59, "CID"], [11, 11, 79, 79, "CID"], [11, 11, 94, 94, "CID"], [29, 29, 2, 2, "CID"], [29, 29, 59, 59, "CID"], [29, 29, 79, 79, "CID"], [29, 29, 94, 94, "CID"], [99, 99, 2, 2, "CID"], [99, 99, 59, 59, "CID"], [99, 99, 79, 79, "CID"], [99, 99, 94, 94, "CID"], [110, 110, 2, 2, "CID"], [110, 110, 59, 59, "CID"], [110, 110, 79, 79, "CID"], [110, 110, 94, 94, "CID"], [11, 11, 51, 51, "CID"], [29, 29, 51, 51, "CID"], [99, 99, 51, 51, "CID"], [110, 110, 51, 51, "CID"], [11, 11, 68, 68, "CID"], [29, 29, 68, 68, "CID"], [99, 99, 68, 68, "CID"], [110, 110, 68, 68, "CID"]]], "clusters": [], "translated": "<4>痛觉过敏</4>和<8>肌阵挛</8>末期<14>癌症</14>患者持续静脉注射<0>吗啡</0>。八名<15>癌症</15>患者在接受高剂量静脉注射<1>吗啡</1>治疗后，在疾病晚期出现了<5>痛觉过敏</5>。所有病例均从哥本哈根的三个不同医院进行回顾性抽样。5例患者出现全身<6>痛觉过敏</6>和<12>感觉过敏</12>，其中2例伴有<9>肌阵挛</9>。在3名患者中，预先存在的<13>神经痛</13>增加到难以忍受的强度，其中2名患者同时出现<10>肌阵挛</10>。尽管<7>痛觉过敏</7>/<11>肌阵挛</11>与高剂量<2>吗啡</2>之间关系的临床描述很少，但动物研究的实验支持表明<3>吗啡</3>，或其代谢物，对观察到的行为综合症起着致病作用。讨论了可能的机制并给出了治疗建议，建议在这些情况下使用更有效的兴奋性效力较低的阿片类药物。", "revised": true}
{"doc_key": "11900788", "sentences": [["Nicotine", "potentiation", "of", "morphine", "-", "induced", "catalepsy", "in", "mice", ".", "In", "the", "present", "study", ",", "effects", "of", "nicotine", "on", "catalepsy", "induced", "by", "morphine", "in", "mice", "have", "been", "investigated", ".", "Morphine", "but", "not", "nicotine", "induced", "a", "dose", "-", "dependent", "catalepsy", ".", "The", "response", "of", "morphine", "was", "potentiated", "by", "nicotine", ".", "Intraperitoneal", "administration", "of", "atropine", ",", "naloxone", ",", "mecamylamine", ",", "and", "hexamethonium", "to", "mice", "reduced", "catalepsy", "induced", "by", "a", "combination", "of", "morphine", "with", "nicotine", ".", "Intracerebroventricular", "injection", "of", "atropine", ",", "hexamethonium", ",", "and", "naloxone", "also", "decreased", "catalepsy", "induced", "by", "morphine", "plus", "nicotine", ".", "Intraperitoneal", "administration", "of", "atropine", ",", "but", "not", "intraperitoneal", "or", "intracerebroventricular", "injection", "of", "hexamethonium", ",", "decreased", "the", "effect", "of", "a", "single", "dose", "of", "morphine", ".", "It", "was", "concluded", "that", "morphine", "catalepsy", "can", "be", "elicited", "by", "opioid", "and", "cholinergic", "receptors", ",", "and", "the", "potentiation", "of", "morphine", "induced", "by", "nicotine", "may", "also", "be", "mediated", "through", "cholinergic", "receptor", "mechanisms", "."]], "ner": [[[0, 0, "Chemical"], [17, 17, "Chemical"], [32, 32, "Chemical"], [47, 47, "Chemical"], [71, 71, "Chemical"], [89, 89, "Chemical"], [137, 137, "Chemical"], [6, 6, "Disease"], [19, 19, "Disease"], [38, 38, "Disease"], [63, 63, "Disease"], [84, 84, "Disease"], [120, 120, "Disease"], [3, 3, "Chemical"], [22, 22, "Chemical"], [29, 29, "Chemical"], [43, 43, "Chemical"], [69, 69, "Chemical"], [87, 87, "Chemical"], [113, 113, "Chemical"], [119, 119, "Chemical"], [134, 134, "Chemical"], [52, 52, "Chemical"], [76, 76, "Chemical"], [94, 94, "Chemical"], [54, 54, "Chemical"], [81, 81, "Chemical"], [56, 56, "Chemical"], [59, 59, "Chemical"], [78, 78, "Chemical"], [103, 103, "Chemical"]]], "relations": [[[0, 0, 6, 6, "CID"], [0, 0, 19, 19, "CID"], [0, 0, 38, 38, "CID"], [0, 0, 63, 63, "CID"], [0, 0, 84, 84, "CID"], [0, 0, 120, 120, "CID"], [17, 17, 6, 6, "CID"], [17, 17, 19, 19, "CID"], [17, 17, 38, 38, "CID"], [17, 17, 63, 63, "CID"], [17, 17, 84, 84, "CID"], [17, 17, 120, 120, "CID"], [32, 32, 6, 6, "CID"], [32, 32, 19, 19, "CID"], [32, 32, 38, 38, "CID"], [32, 32, 63, 63, "CID"], [32, 32, 84, 84, "CID"], [32, 32, 120, 120, "CID"], [47, 47, 6, 6, "CID"], [47, 47, 19, 19, "CID"], [47, 47, 38, 38, "CID"], [47, 47, 63, 63, "CID"], [47, 47, 84, 84, "CID"], [47, 47, 120, 120, "CID"], [71, 71, 6, 6, "CID"], [71, 71, 19, 19, "CID"], [71, 71, 38, 38, "CID"], [71, 71, 63, 63, "CID"], [71, 71, 84, 84, "CID"], [71, 71, 120, 120, "CID"], [89, 89, 6, 6, "CID"], [89, 89, 19, 19, "CID"], [89, 89, 38, 38, "CID"], [89, 89, 63, 63, "CID"], [89, 89, 84, 84, "CID"], [89, 89, 120, 120, "CID"], [137, 137, 6, 6, "CID"], [137, 137, 19, 19, "CID"], [137, 137, 38, 38, "CID"], [137, 137, 63, 63, "CID"], [137, 137, 84, 84, "CID"], [137, 137, 120, 120, "CID"], [3, 3, 6, 6, "CID"], [3, 3, 19, 19, "CID"], [3, 3, 38, 38, "CID"], [3, 3, 63, 63, "CID"], [3, 3, 84, 84, "CID"], [3, 3, 120, 120, "CID"], [22, 22, 6, 6, "CID"], [22, 22, 19, 19, "CID"], [22, 22, 38, 38, "CID"], [22, 22, 63, 63, "CID"], [22, 22, 84, 84, "CID"], [22, 22, 120, 120, "CID"], [29, 29, 6, 6, "CID"], [29, 29, 19, 19, "CID"], [29, 29, 38, 38, "CID"], [29, 29, 63, 63, "CID"], [29, 29, 84, 84, "CID"], [29, 29, 120, 120, "CID"], [43, 43, 6, 6, "CID"], [43, 43, 19, 19, "CID"], [43, 43, 38, 38, "CID"], [43, 43, 63, 63, "CID"], [43, 43, 84, 84, "CID"], [43, 43, 120, 120, "CID"], [69, 69, 6, 6, "CID"], [69, 69, 19, 19, "CID"], [69, 69, 38, 38, "CID"], [69, 69, 63, 63, "CID"], [69, 69, 84, 84, "CID"], [69, 69, 120, 120, "CID"], [87, 87, 6, 6, "CID"], [87, 87, 19, 19, "CID"], [87, 87, 38, 38, "CID"], [87, 87, 63, 63, "CID"], [87, 87, 84, 84, "CID"], [87, 87, 120, 120, "CID"], [113, 113, 6, 6, "CID"], [113, 113, 19, 19, "CID"], [113, 113, 38, 38, "CID"], [113, 113, 63, 63, "CID"], [113, 113, 84, 84, "CID"], [113, 113, 120, 120, "CID"], [119, 119, 6, 6, "CID"], [119, 119, 19, 19, "CID"], [119, 119, 38, 38, "CID"], [119, 119, 63, 63, "CID"], [119, 119, 84, 84, "CID"], [119, 119, 120, 120, "CID"], [134, 134, 6, 6, "CID"], [134, 134, 19, 19, "CID"], [134, 134, 38, 38, "CID"], [134, 134, 63, 63, "CID"], [134, 134, 84, 84, "CID"], [134, 134, 120, 120, "CID"]]], "clusters": [], "translated": " <0>尼古丁</0>增强<13>吗啡</13>诱导的小鼠<7>强直性昏厥</7>。本研究考察了<1>尼古丁</1>对<14>吗啡</14>诱发的小鼠<8>强直性昏厥</8>的影响。<15>吗啡</15>但不是<2>尼古丁</2>诱发剂量依赖性<9>强直性昏厥</9>。<16>吗啡</16>的反应被<3>尼古丁</3>增强。给小鼠腹腔注射<22>阿托品</22>，<25>纳洛酮</25>，<27>美卡拉明</27>和<28>六甲铵</28>可减轻由<17>吗啡</17>和<4>尼古丁</4>的组合引起的<10>强直性昏厥</10>。脑室内注射<23>阿托品</23>，<29>六甲铵</29>和<26>纳洛酮</26>也可降低加上<5>尼古丁</5>的<18>吗啡</18>引起的<11>强直性昏厥</11>。腹腔注射<24>阿托品</24>，而不是腹膜内或脑室内注射<30>六甲铵</30>，会降低单个剂量<19>吗啡</19>的作用。结论是<20>吗啡</20>的<12>强直性昏厥</12>可由阿片样物质和胆碱能受体诱发，<6>尼古丁</6>可增强<21>吗啡</21>的诱发。<6>尼古丁</6> 也可能通过胆碱能受体机制介导。", "revised": true}
{"doc_key": "6817363", "sentences": [["Effects", "of", "the", "novel", "compound", "aniracetam", "(", "Ro", "13", "-", "5057", ")", "upon", "impaired", "learning", "and", "memory", "in", "rodents", ".", "The", "effect", "of", "aniracetam", "(", "Ro", "13", "-", "5057", ",", "1", "-", "anisoyl", "-", "2", "-", "pyrrolidinone", ")", "was", "studied", "on", "various", "forms", "of", "experimentally", "impaired", "cognitive", "functions", "(", "learning", "and", "memory", ")", "in", "rodents", "and", "produced", "the", "following", "effects", ":", "(", "1", ")", "almost", "complete", "prevention", "of", "the", "incapacity", "to", "learn", "a", "discrete", "escape", "response", "in", "rats", "exposed", "to", "sublethal", "hypercapnia", "immediately", "before", "the", "acquisition", "session", ";", "(", "2", ")", "partial", "(", "rats", ")", "or", "complete", "(", "mice", ")", "prevention", "of", "the", "scopolamine", "-", "induced", "short", "-", "term", "amnesia", "for", "a", "passive", "avoidance", "task", ";", "(", "3", ")", "complete", "protection", "against", "amnesia", "for", "a", "passive", "avoidance", "task", "in", "rats", "submitted", "to", "electroconvulsive", "shock", "immediately", "after", "avoidance", "acquisition", ";", "(", "4", ")", "prevention", "of", "the", "long", "-", "term", "retention", "-", "or", "retrieval", "-", "deficit", "for", "a", "passive", "avoidance", "task", "induced", "in", "rats", "and", "mice", "by", "chloramphenicol", "or", "cycloheximide", "administered", "immediately", "after", "acquisition", ";", "(", "5", ")", "reversal", ",", "when", "administered", "as", "late", "as", "1", "h", "before", "the", "retention", "test", ",", "of", "the", "deficit", "in", "retention", "or", "retrieval", "of", "a", "passive", "avoidance", "task", "induced", "by", "cycloheximide", "injected", "2", "days", "previously", ";", "(", "6", ")", "prevention", "of", "the", "deficit", "in", "the", "retrieval", "of", "an", "active", "avoidance", "task", "induced", "in", "mice", "by", "subconvulsant", "electroshock", "or", "hypercapnia", "applied", "immediately", "before", "retrieval", "testing", "(", "24", "h", "after", "acquisition", ")", ".", "These", "improvements", "or", "normalizations", "of", "impaired", "cognitive", "functions", "were", "seen", "at", "oral", "aniracetam", "doses", "of", "10", "-", "100", "mg", "/", "kg", ".", "Generally", ",", "the", "dose", "-", "response", "curves", "were", "bell", "-", "shaped", ".", "The", "mechanisms", "underlying", "the", "activity", "of", "aniracetam", "and", "its", "'", "therapeutic", "window", "'", "are", "unknown", ".", "Piracetam", ",", "another", "pyrrolidinone", "derivative", "was", "used", "for", "comparison", ".", "It", "was", "active", "only", "in", "six", "of", "nine", "tests", "and", "had", "about", "one", "-", "tenth", "the", "potency", "of", "aniracetam", ".", "The", "results", "indicate", "that", "aniracetam", "improves", "cognitive", "functions", "which", "are", "impaired", "by", "different", "procedure", "and", "in", "different", "phases", "of", "the", "learning", "and", "memory", "process", "."]], "ner": [[[165, 165, "Chemical"], [13, 16, "Disease"], [167, 167, "Chemical"], [204, 204, "Chemical"], [103, 103, "Chemical"], [109, 109, "Disease"], [122, 122, "Disease"], [5, 5, "Chemical"], [7, 10, "Chemical"], [23, 23, "Chemical"], [25, 28, "Chemical"], [30, 36, "Chemical"], [257, 257, "Chemical"], [285, 285, "Chemical"], [323, 323, "Chemical"], [329, 329, "Chemical"], [45, 47, "Disease"], [250, 252, "Disease"], [81, 81, "Disease"], [232, 232, "Disease"], [295, 295, "Chemical"], [298, 298, "Chemical"]]], "relations": [[[165, 165, 13, 16, "CID"], [167, 167, 13, 16, "CID"], [204, 204, 13, 16, "CID"], [103, 103, 109, 109, "CID"], [103, 103, 122, 122, "CID"]]], "clusters": [], "translated": "新型化合物<7>阿尼西坦</7> (<8>Ro 13-5057</8>) 对啮齿类动物<1>学习记忆障碍</1>的影响。 <9>阿尼西坦</9> (<10>Ro 13-5057</10>，<11>1-苯甲酰基-2-吡咯烷酮</11>) 对各种形式的实验性<16>受损认知功能</16>（学习与记忆）进行了研究，并产生了以下影响：<br>（1）几乎完全阻止了大鼠学习离散逃避反应的能力，该反应在获得任务的前一刻暴露于潜在亚致死水平的<18>高碳酸血症</18>之前。<br>（2）部分（大鼠）或完全（小鼠）预防了<4>东莨菪碱</4>诱发的被动回避任务的短时<5>遗忘</5>。<br>（3）在大鼠获得回避任务后立即进行电惊厥，完全防止<6>遗忘</6>被动回避任务。<br>（4）在大鼠和小鼠学习收获之后立即施用<0>氯霉素</0>或<2>环己酰亚胺 </2>可预防长期存储或检索缺陷被动回避任务所引起的损失。<br>（5）最迟在保留测试前1小时给予<3>环己酰亚胺</3>，可逆转2天前注射的药物所引起的<5>遗忘</5>被动回避任务的保留或恢复缺陷。<br>（6）预防因亚惊厥电击或将<19>高碳酸血症</19>施加至检测现场（获得24小时后）而在小鼠中诱导的主动回避任务的恢复缺陷。<br>这些改善或正常化<17> 受损认知功能</17> 的效果可观察到，口服<12>阿尼西坦</12>剂量为10-100mg/kg，其量效曲线呈钟形。目前尚不清楚<13>阿尼西坦</13>活性及其“治疗窗口”的潜在机制。还使用了另一种<21>吡咯烷酮的</21>衍生物，<20>吡拉西坦</20>，进行比较。它仅在9项测试中的6项中有效，其效力约为<14>阿尼西坦</14>的十分之一。结果表明，<15>阿尼西坦</15>可改善因不同操作、不同阶段的学习记忆过程而受损的<16>认知功能</16>。", "revised": true}
{"doc_key": "19996135", "sentences": [["High", "-", "dose", "tranexamic", "Acid", "is", "associated", "with", "nonischemic", "clinical", "seizures", "in", "cardiac", "surgical", "patients", ".", "BACKGROUND", ":", "In", "2", "separate", "centers", ",", "we", "observed", "a", "notable", "increase", "in", "the", "incidence", "of", "postoperative", "convulsive", "seizures", "from", "1", ".", "3", "%", "to", "3", ".", "8", "%", "in", "patients", "having", "undergone", "major", "cardiac", "surgical", "procedures", ".", "These", "events", "were", "temporally", "coincident", "with", "the", "initial", "use", "of", "high", "-", "dose", "tranexamic", "acid", "(", "TXA", ")", "therapy", "after", "withdrawal", "of", "aprotinin", "from", "general", "clinical", "usage", ".", "The", "purpose", "of", "this", "review", "was", "to", "perform", "a", "retrospective", "analysis", "to", "examine", "whether", "there", "was", "a", "relation", "between", "TXA", "usage", "and", "seizures", "after", "cardiac", "surgery", ".", "METHODS", ":", "An", "in", "-", "depth", "chart", "review", "was", "undertaken", "in", "all", "24", "patients", "who", "developed", "perioperative", "seizures", ".", "Electroencephalographic", "activity", "was", "recorded", "in", "11", "of", "these", "patients", ",", "and", "all", "patients", "had", "a", "formal", "neurological", "evaluation", "and", "brain", "imaging", "studies", ".", "RESULTS", ":", "Twenty", "-", "one", "of", "the", "24", "patients", "did", "not", "have", "evidence", "of", "new", "cerebral", "ischemic", "injury", ",", "but", "seizures", "were", "likely", "due", "to", "ischemic", "brain", "injury", "in", "3", "patients", ".", "All", "patients", "with", "seizures", "did", "not", "have", "permanent", "neurological", "abnormalities", ".", "All", "24", "patients", "with", "seizures", "received", "high", "doses", "of", "TXA", "intraoperatively", "ranging", "from", "61", "to", "259", "mg", "/", "kg", ",", "had", "a", "mean", "age", "of", "69", ".", "9", "years", ",", "and", "21", "of", "24", "had", "undergone", "open", "chamber", "rather", "than", "coronary", "bypass", "procedures", ".", "All", "but", "one", "patient", "were", "managed", "using", "cardiopulmonary", "bypass", ".", "No", "evidence", "of", "brain", "ischemic", ",", "metabolic", ",", "or", "hyperthermia", "-", "induced", "causes", "for", "their", "seizures", "was", "apparent", ".", "CONCLUSION", ":", "Our", "results", "suggest", "that", "use", "of", "high", "-", "dose", "TXA", "in", "older", "patients", "in", "conjunction", "with", "cardiopulmonary", "bypass", "and", "open", "-", "chamber", "cardiac", "surgery", "is", "associated", "with", "clinical", "seizures", "in", "susceptible", "patients", "."]], "ner": [[[3, 4, "Chemical"], [67, 68, "Chemical"], [70, 70, "Chemical"], [101, 101, "Chemical"], [203, 203, "Chemical"], [278, 278, "Chemical"], [10, 10, "Disease"], [33, 33, "Disease"], [34, 34, "Disease"], [104, 104, "Disease"], [126, 126, "Disease"], [171, 171, "Disease"], [186, 186, "Disease"], [198, 198, "Disease"], [263, 263, "Disease"], [297, 297, "Disease"], [166, 168, "Disease"], [176, 178, "Disease"], [191, 192, "Disease"], [251, 252, "Disease"], [257, 257, "Disease"]]], "relations": [[[3, 4, 10, 10, "CID"], [3, 4, 33, 33, "CID"], [3, 4, 34, 34, "CID"], [3, 4, 104, 104, "CID"], [3, 4, 126, 126, "CID"], [3, 4, 171, 171, "CID"], [3, 4, 186, 186, "CID"], [3, 4, 198, 198, "CID"], [3, 4, 263, 263, "CID"], [3, 4, 297, 297, "CID"], [67, 68, 10, 10, "CID"], [67, 68, 33, 33, "CID"], [67, 68, 34, 34, "CID"], [67, 68, 104, 104, "CID"], [67, 68, 126, 126, "CID"], [67, 68, 171, 171, "CID"], [67, 68, 186, 186, "CID"], [67, 68, 198, 198, "CID"], [67, 68, 263, 263, "CID"], [67, 68, 297, 297, "CID"], [70, 70, 10, 10, "CID"], [70, 70, 33, 33, "CID"], [70, 70, 34, 34, "CID"], [70, 70, 104, 104, "CID"], [70, 70, 126, 126, "CID"], [70, 70, 171, 171, "CID"], [70, 70, 186, 186, "CID"], [70, 70, 198, 198, "CID"], [70, 70, 263, 263, "CID"], [70, 70, 297, 297, "CID"], [101, 101, 10, 10, "CID"], [101, 101, 33, 33, "CID"], [101, 101, 34, 34, "CID"], [101, 101, 104, 104, "CID"], [101, 101, 126, 126, "CID"], [101, 101, 171, 171, "CID"], [101, 101, 186, 186, "CID"], [101, 101, 198, 198, "CID"], [101, 101, 263, 263, "CID"], [101, 101, 297, 297, "CID"], [203, 203, 10, 10, "CID"], [203, 203, 33, 33, "CID"], [203, 203, 34, 34, "CID"], [203, 203, 104, 104, "CID"], [203, 203, 126, 126, "CID"], [203, 203, 171, 171, "CID"], [203, 203, 186, 186, "CID"], [203, 203, 198, 198, "CID"], [203, 203, 263, 263, "CID"], [203, 203, 297, 297, "CID"], [278, 278, 10, 10, "CID"], [278, 278, 33, 33, "CID"], [278, 278, 34, 34, "CID"], [278, 278, 104, 104, "CID"], [278, 278, 126, 126, "CID"], [278, 278, 171, 171, "CID"], [278, 278, 186, 186, "CID"], [278, 278, 198, 198, "CID"], [278, 278, 263, 263, "CID"], [278, 278, 297, 297, "CID"]]], "clusters": [], "translated": "高剂量<0>氨甲环酸</0>与心脏手术患者的非缺血性临床<6>癫痫发作</6>有关。背景：在2个独立的中心，我们观察到术后<7>惊厥</7><8>癫痫发作</8>的发生率从1.3%到3.8%的患者接受过重大心脏外科手术。这些事件在时间上与抑肽酶从一般临床使用中撤出后开始使用高剂量<1>氨甲环酸</1> (<2>TXA</2>)治疗暂时一致。本次审查的目的是进行回顾性分析，以检查心脏手术后<3>TXA</3>的使用与<9>癫痫发作</9>之间是否存在关联。方法：对所有24名出现围手术期<10>癫痫发作</10>的患者进行了深入的图表回顾。其中11名患者记录了脑电图活动，所有患者都进行了正式的神经学评估和脑成像研究。结果：24例患者中有21例没有新的<16>脑缺血性损伤</16>证据，但<11>癫痫发作</11>可能是由于<17>缺血性脑损伤</17>所致的3个病人。所有发生<12>癫痫发作</12>的患者都没有永久性<18>神经系统异常</18>。所有24例<13>癫痫发作</13>患者在术中均接受了61至259mg/kg的高剂量<4>TXA</4>，平均年龄为69.9年，24人中有21人接受了开腔手术而不是冠状动脉旁路手术。除一名患者外，所有患者均使用体外循环进行治疗。没有证据表明<19>脑缺血</19>、代谢或<20>体温过高</20>导致其<14>癫痫发作</14>的原因很明显。结论：我们的结果表明，在老年患者中使用高剂量<5>TXA</5>联合体外循环和开腔心脏手术与易感患者的临床<15>癫痫发作</15>相关。", "revised": true}
{"doc_key": "3934126", "sentences": [["A", "prospective", "study", "of", "adverse", "reactions", "associated", "with", "vancomycin", "therapy", ".", "A", "prospective", "evaluation", "of", "the", "efficacy", "and", "safety", "of", "vancomycin", "was", "conducted", "in", "54", "consecutive", "patients", "over", "a", "16", "-", "month", "period", ".", "Vancomycin", "was", "curative", "in", "95", "%", "of", "43", "patients", "with", "proven", "infection", ".", "Drugs", "were", "ceased", "in", "six", "patients", "because", "of", "adverse", "reactions", ";", "in", "three", "of", "these", "vancomycin", "was", "considered", "the", "likely", "cause", ".", "Reactions", "included", "thrombophlebitis", "(", "20", "of", "54", "patients", ")", ",", "rash", "(", "4", "of", "54", ")", ",", "nephrotoxicity", "(", "4", "of", "50", ")", ",", "proteinuria", "(", "1", "of", "50", ")", "and", "ototoxicity", "(", "1", "of", "11", "patients", "tested", "by", "audiometry", ")", ".", "Thrombophlebitis", "occurred", "only", "with", "infusion", "through", "peripheral", "cannulae", ";", "nephrotoxicity", "and", "ototoxicity", "were", "confined", "to", "patients", "receiving", "an", "aminoglycoside", "plus", "vancomycin", ".", "We", "conclude", "that", "vancomycin", ",", "administered", "appropriately", ",", "constitutes", "safe", ",", "effective", "therapy", "for", "infections", "caused", "by", "susceptible", "bacteria", "."]], "ner": [[[8, 8, "Chemical"], [20, 20, "Chemical"], [34, 34, "Chemical"], [62, 62, "Chemical"], [131, 131, "Chemical"], [136, 136, "Chemical"], [71, 71, "Disease"], [111, 111, "Disease"], [79, 79, "Disease"], [93, 93, "Disease"], [100, 100, "Disease"], [122, 122, "Disease"], [45, 45, "Disease"], [147, 147, "Disease"], [86, 86, "Disease"], [120, 120, "Disease"], [129, 129, "Chemical"]]], "relations": [[[8, 8, 71, 71, "CID"], [8, 8, 111, 111, "CID"], [20, 20, 71, 71, "CID"], [20, 20, 111, 111, "CID"], [34, 34, 71, 71, "CID"], [34, 34, 111, 111, "CID"], [62, 62, 71, 71, "CID"], [62, 62, 111, 111, "CID"], [131, 131, 71, 71, "CID"], [131, 131, 111, 111, "CID"], [136, 136, 71, 71, "CID"], [136, 136, 111, 111, "CID"], [8, 8, 79, 79, "CID"], [20, 20, 79, 79, "CID"], [34, 34, 79, 79, "CID"], [62, 62, 79, 79, "CID"], [131, 131, 79, 79, "CID"], [136, 136, 79, 79, "CID"], [8, 8, 93, 93, "CID"], [20, 20, 93, 93, "CID"], [34, 34, 93, 93, "CID"], [62, 62, 93, 93, "CID"], [131, 131, 93, 93, "CID"], [136, 136, 93, 93, "CID"], [8, 8, 100, 100, "CID"], [8, 8, 122, 122, "CID"], [20, 20, 100, 100, "CID"], [20, 20, 122, 122, "CID"], [34, 34, 100, 100, "CID"], [34, 34, 122, 122, "CID"], [62, 62, 100, 100, "CID"], [62, 62, 122, 122, "CID"], [131, 131, 100, 100, "CID"], [131, 131, 122, 122, "CID"], [136, 136, 100, 100, "CID"], [136, 136, 122, 122, "CID"]]], "clusters": [], "translated": "<0>万古霉素</0>治疗相关不良反应的前瞻性研究。在 16 个月的时间里，对 54 名连续患者进行了一项关于 <1>万古霉素</1> 疗效和安全性的前瞻性评估。<2>万古霉素</2> 对 43 名证实有<12>感染</12>的患者中的95%有治愈作用。6例因不良反应停药；其中三个<3>万古霉素</3>被认为是可能的原因。反应包括<6>血栓性静脉炎</6>（54 名患者中的 20 名），<8>皮疹</8>（54 名患者中的 4 名），<14>肾毒性</14>（50 名患者中的 4 名），<9>蛋白尿</9>（50 人中有 1 人）和<10>耳毒性</10>（11 名患者中有 1 人接受了听力测试）。<7>血栓性静脉炎</7>仅在通过外周插管输液时发生；<15>肾毒性</15>和<11>耳毒性</11>仅限于接受<16>氨基糖苷类</16>加<4>万古霉素</4>治疗的患者。我们的结论是，<5>万古霉素</5>，如果使用得当，可以安全、有效地治疗由敏感细菌引起的<13>感染</13>。", "revised": true}
{"doc_key": "10840460", "sentences": [["Cyclophosphamide", "-", "induced", "cystitis", "in", "freely", "-", "moving", "conscious", "rats", ":", "behavioral", "approach", "to", "a", "new", "model", "of", "visceral", "pain", ".", "PURPOSE", ":", "To", "develop", "a", "model", "of", "visceral", "pain", "in", "rats", "using", "a", "behavioral", "approach", ".", "Cyclophosphamide", "(", "CP", ")", ",", "an", "antitumoral", "agent", "known", "to", "produce", "toxic", "effects", "on", "the", "bladder", "wall", "through", "its", "main", "toxic", "metabolite", "acrolein", ",", "was", "used", "to", "induce", "cystitis", ".", "MATERIALS", "AND", "METHODS", ":", "CP", "was", "administered", "at", "doses", "of", "50", ",", "100", "and", "200", "mg", ".", "/", "kg", ".", "i", ".", "p", ".", "to", "male", "rats", ",", "and", "their", "behavior", "observed", "and", "scored", ".", "The", "effects", "of", "morphine", "(", "0", ".", "5", "to", "4", "mg", ".", "/", "kg", ".", "i", ".", "v", ".", ")", "on", "CP", "-", "induced", "behavioral", "modifications", "were", "tested", "administered", "alone", "and", "after", "naloxone", "(", "1", "mg", ".", "/", "kg", ".", "s", ".", "c", ".", ")", ".", "In", "addition", ",", "90", "minutes", "after", "CP", "injection", ",", "that", "is", ",", "at", "the", "time", "of", "administration", "of", "morphine", ",", "the", "bladder", "was", "removed", "in", "some", "rats", "for", "histological", "examination", ".", "Finally", ",", "to", "show", "that", "the", "bladder", "is", "essential", "for", "the", "CP", "-", "induced", "behavioral", "modifications", ",", "female", "rats", "also", "received", "CP", "at", "doses", "of", "200", "mg", ".", "/", "kg", ".", "i", ".", "p", ".", "and", "of", "20", "mg", ".", "by", "the", "intravesical", "route", ",", "and", "acrolein", "at", "doses", "of", "0", ".", "5", "mg", ".", "by", "the", "intravesical", "route", "and", "of", "5", "mg", ".", "/", "kg", ".", "i", ".", "v", ".", "RESULTS", ":", "CP", "dose", "-", "relatedly", "induced", "marked", "behavioral", "modifications", "in", "male", "rats", ":", "breathing", "rate", "decrease", ",", "closing", "of", "the", "eyes", "and", "occurrence", "of", "specific", "postures", ".", "Morphine", "dose", "-", "dependently", "reversed", "these", "behavioral", "disorders", ".", "A", "dose", "of", "0", ".", "5", "mg", ".", "/", "kg", ".", "produced", "a", "reduction", "of", "almost", "50", "%", "of", "the", "behavioral", "score", "induced", "by", "CP", "200", "mg", ".", "/", "kg", ".", "This", "effect", "was", "completely", "prevented", "by", "pretreatment", "with", "naloxone", ".", "At", "the", "time", "of", "administration", "of", "morphine", ",", "histological", "modifications", "of", "the", "bladder", "wall", ",", "such", "as", "chorionic", "and", "muscle", "layer", "edema", ",", "were", "observed", ".", "In", "female", "rats", ",", "CP", "200", "mg", ".", "/", "kg", ".", "i", ".", "p", ".", "produced", "the", "same", "marked", "behavioral", "modifications", "as", "those", "observed", "in", "male", "rats", ".", "Administered", "at", "the", "dose", "of", "20", "mg", ".", "intravesically", ",", "CP", "did", "not", "produce", "any", "behavioral", "effects", ",", "whereas", "acrolein", "at", "0", ".", "5", "mg", ".", "intravesically", "induced", "behavioral", "modifications", "identical", "to", "those", "under", "CP", "200", "mg", ".", "/", "kg", ".", "i", ".", "p", ".", ",", "with", "the", "same", "maximal", "levels", ".", "Conversely", ",", "acrolein", "5", "mg", ".", "/", "kg", ".", "i", ".", "v", ".", "did", "not", "produce", "any", "behavioral", "effects", "at", "all", ".", "CONCLUSIONS", ":", "Overall", ",", "these", "results", "indicate", "that", "this", "experimental", "model", "of", "CP", "-", "induced", "cystitis", "may", "be", "an", "interesting", "new", "behavioral", "model", "of", "inflammatory", "visceral", "pain", ",", "allowing", "a", "better", "understanding", "of", "these", "painful", "syndromes", "and", "thus", "a", "better", "therapeutic", "approach", "to", "them", "."]], "ner": [[[0, 0, "Chemical"], [37, 37, "Chemical"], [39, 39, "Chemical"], [71, 71, "Chemical"], [123, 123, "Chemical"], [154, 154, "Chemical"], [190, 190, "Chemical"], [200, 200, "Chemical"], [252, 252, "Chemical"], [311, 311, "Chemical"], [358, 358, "Chemical"], [392, 392, "Chemical"], [416, 416, "Chemical"], [468, 468, "Chemical"], [3, 3, "Disease"], [65, 65, "Disease"], [471, 471, "Disease"], [490, 491, "Disease"], [59, 59, "Chemical"], [225, 225, "Chemical"], [401, 401, "Chemical"], [436, 436, "Chemical"], [18, 19, "Disease"], [28, 29, "Disease"], [481, 482, "Disease"], [284, 285, "Disease"], [349, 349, "Disease"], [105, 105, "Chemical"], [166, 166, "Chemical"], [278, 278, "Chemical"], [334, 334, "Chemical"], [134, 134, "Chemical"], [326, 326, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 65, 65, "CID"], [0, 0, 471, 471, "CID"], [37, 37, 3, 3, "CID"], [37, 37, 65, 65, "CID"], [37, 37, 471, 471, "CID"], [39, 39, 3, 3, "CID"], [39, 39, 65, 65, "CID"], [39, 39, 471, 471, "CID"], [71, 71, 3, 3, "CID"], [71, 71, 65, 65, "CID"], [71, 71, 471, 471, "CID"], [123, 123, 3, 3, "CID"], [123, 123, 65, 65, "CID"], [123, 123, 471, 471, "CID"], [154, 154, 3, 3, "CID"], [154, 154, 65, 65, "CID"], [154, 154, 471, 471, "CID"], [190, 190, 3, 3, "CID"], [190, 190, 65, 65, "CID"], [190, 190, 471, 471, "CID"], [200, 200, 3, 3, "CID"], [200, 200, 65, 65, "CID"], [200, 200, 471, 471, "CID"], [252, 252, 3, 3, "CID"], [252, 252, 65, 65, "CID"], [252, 252, 471, 471, "CID"], [311, 311, 3, 3, "CID"], [311, 311, 65, 65, "CID"], [311, 311, 471, 471, "CID"], [358, 358, 3, 3, "CID"], [358, 358, 65, 65, "CID"], [358, 358, 471, 471, "CID"], [392, 392, 3, 3, "CID"], [392, 392, 65, 65, "CID"], [392, 392, 471, 471, "CID"], [416, 416, 3, 3, "CID"], [416, 416, 65, 65, "CID"], [416, 416, 471, 471, "CID"], [468, 468, 3, 3, "CID"], [468, 468, 65, 65, "CID"], [468, 468, 471, 471, "CID"], [0, 0, 490, 491, "CID"], [37, 37, 490, 491, "CID"], [39, 39, 490, 491, "CID"], [71, 71, 490, 491, "CID"], [123, 123, 490, 491, "CID"], [154, 154, 490, 491, "CID"], [190, 190, 490, 491, "CID"], [200, 200, 490, 491, "CID"], [252, 252, 490, 491, "CID"], [311, 311, 490, 491, "CID"], [358, 358, 490, 491, "CID"], [392, 392, 490, 491, "CID"], [416, 416, 490, 491, "CID"], [468, 468, 490, 491, "CID"], [59, 59, 490, 491, "CID"], [225, 225, 490, 491, "CID"], [401, 401, 490, 491, "CID"], [436, 436, 490, 491, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0> - 在自由活动的有意识大鼠中诱发<14>膀胱炎</14>: <22>内脏痛</22>新模型的行为方法。目的：使用行为学方法建立大鼠<23>内脏痛</23>模型。<1>环磷酰胺</1>（<2>CP</2>），是一种抗肿瘤药物，已知通过其主要毒性代谢物<18>丙烯醛</18>对膀胱壁产生毒性作用，用于诱导<15>膀胱炎</15>。材料和方法：<3>CP</3>的给药剂量为50、100和200 mg/kg.i.p.对雄性大鼠，对其行为进行观察和评分。<27>吗啡</27>（0.5至4 mg/kg.i.v.）对<4>CP</4>诱导的行为改变的影响进行了单独给药和<31>纳洛酮</31>给药后的测试（1 mg./kg.s.c.）。此外，在<5>CP</5>注射后90分钟，即<28>吗啡</28>给药时，部分大鼠摘除膀胱进行组织学检查。最后，为了表明膀胱对于<6>CP</6>诱导的行为改变至关重要，雌性大鼠还接受了200 mg剂量的<7>CP</7>/kg.i.p.和20毫克。通过膀胱内途径，<19>丙烯醛</19>剂量为0.5毫克。通过膀胱内途径和5毫克。 /公斤。我。诉。结果：<8>CP</8>剂量相关地诱导雄性大鼠显着的行为改变：呼吸频率降低、闭眼和出现特定姿势。<29>吗啡</29>剂量依赖性地逆转了这些<25>行为障碍</25>。剂量为0.5 mg./kg.的<9>CP</9>200 mg。/kg。引起的行为评分减少了近50％。用<32>纳洛酮</32>预处理完全阻止了这种作用。在给予<30>吗啡</30>时，观察到膀胱壁的组织学改变，例如绒毛膜和肌肉层<26>水肿</26>。在雌性大鼠中，<10>CP</10>200 mg。/公斤。我。p.产生了与在雄性大鼠中观察到的相同的显着行为改变。以20毫克的剂量给药。膀胱内，<11>CP</11>没有产生任何行为影响，而<20>丙烯醛</20>为0.5毫克。膀胱内诱导的行为改变与<12>CP</12>200 mg下的相同。/公斤。我。p.，具有相同的最大水平。反之，<21>丙烯醛</21>5毫克。/公斤。我。诉。根本没有产生任何行为影响。总之，这些结果表明，这种<13>CP</13>-诱导的<16>膀胱炎</16>的实验模型可能是一种有趣的新的炎症<24>内脏痛</24>的行为模型，允许更好地了解这些<17>疼痛综合征</17>，从而更好地治疗它们。", "revised": true}
{"doc_key": "1687392", "sentences": [["Blockade", "of", "both", "D", "-", "1", "and", "D", "-", "2", "dopamine", "receptors", "may", "induce", "catalepsy", "in", "mice", ".", "1", ".", "The", "catalepsy", "induced", "by", "dopamine", "antagonists", "has", "been", "tested", "and", "the", "possible", "dopamine", "subtypes", "involved", "in", "catalepsy", "was", "determined", ".", "2", ".", "Dopamine", "antagonist", "fluphenazine", ",", "D", "-", "1", "antagonist", "SCH", "23390", "or", "D", "-", "2", "antagonist", "sulpiride", "induced", "catalepsy", ".", "The", "effect", "of", "fluphenazine", "and", "sulpiride", "was", "dose", "-", "dependent", ".", "Combination", "of", "SCH", "23390", "with", "sulpiride", "did", "not", "induce", "catalepsy", "potentiation", ".", "3", ".", "D", "-", "1", "agonist", "SKF", "38393", "or", "D", "-", "2", "agonist", "quinpirole", "decreased", "the", "catalepsy", "induced", "by", "fluphenazine", ",", "SCH", "23390", "or", "sulpiride", ".", "4", ".", "Combination", "of", "SKF", "38393", "with", "quinpirole", "did", "not", "cause", "potentiated", "inhibitory", "effect", "on", "catalepsy", "induced", "by", "dopamine", "antagonists", ".", "5", ".", "The", "data", "may", "indicate", "that", "although", "D", "-", "2", "receptor", "blockade", "is", "involved", "in", "catalepsy", ",", "the", "D", "-", "1", "receptor", "may", "plan", "a", "role", "."]], "ner": [[[44, 44, "Chemical"], [64, 64, "Chemical"], [103, 103, "Chemical"], [14, 14, "Disease"], [21, 21, "Disease"], [36, 36, "Disease"], [59, 59, "Disease"], [81, 81, "Disease"], [100, 100, "Disease"], [125, 125, "Disease"], [147, 147, "Disease"], [50, 51, "Chemical"], [74, 75, "Chemical"], [105, 106, "Chemical"], [57, 57, "Chemical"], [66, 66, "Chemical"], [77, 77, "Chemical"], [108, 108, "Chemical"], [10, 10, "Chemical"], [24, 24, "Chemical"], [32, 32, "Chemical"], [42, 42, "Chemical"], [128, 128, "Chemical"], [90, 91, "Chemical"], [114, 115, "Chemical"], [97, 97, "Chemical"], [117, 117, "Chemical"]]], "relations": [[[44, 44, 14, 14, "CID"], [44, 44, 21, 21, "CID"], [44, 44, 36, 36, "CID"], [44, 44, 59, 59, "CID"], [44, 44, 81, 81, "CID"], [44, 44, 100, 100, "CID"], [44, 44, 125, 125, "CID"], [44, 44, 147, 147, "CID"], [64, 64, 14, 14, "CID"], [64, 64, 21, 21, "CID"], [64, 64, 36, 36, "CID"], [64, 64, 59, 59, "CID"], [64, 64, 81, 81, "CID"], [64, 64, 100, 100, "CID"], [64, 64, 125, 125, "CID"], [64, 64, 147, 147, "CID"], [103, 103, 14, 14, "CID"], [103, 103, 21, 21, "CID"], [103, 103, 36, 36, "CID"], [103, 103, 59, 59, "CID"], [103, 103, 81, 81, "CID"], [103, 103, 100, 100, "CID"], [103, 103, 125, 125, "CID"], [103, 103, 147, 147, "CID"], [50, 51, 14, 14, "CID"], [50, 51, 21, 21, "CID"], [50, 51, 36, 36, "CID"], [50, 51, 59, 59, "CID"], [50, 51, 81, 81, "CID"], [50, 51, 100, 100, "CID"], [50, 51, 125, 125, "CID"], [50, 51, 147, 147, "CID"], [74, 75, 14, 14, "CID"], [74, 75, 21, 21, "CID"], [74, 75, 36, 36, "CID"], [74, 75, 59, 59, "CID"], [74, 75, 81, 81, "CID"], [74, 75, 100, 100, "CID"], [74, 75, 125, 125, "CID"], [74, 75, 147, 147, "CID"], [105, 106, 14, 14, "CID"], [105, 106, 21, 21, "CID"], [105, 106, 36, 36, "CID"], [105, 106, 59, 59, "CID"], [105, 106, 81, 81, "CID"], [105, 106, 100, 100, "CID"], [105, 106, 125, 125, "CID"], [105, 106, 147, 147, "CID"], [57, 57, 14, 14, "CID"], [57, 57, 21, 21, "CID"], [57, 57, 36, 36, "CID"], [57, 57, 59, 59, "CID"], [57, 57, 81, 81, "CID"], [57, 57, 100, 100, "CID"], [57, 57, 125, 125, "CID"], [57, 57, 147, 147, "CID"], [66, 66, 14, 14, "CID"], [66, 66, 21, 21, "CID"], [66, 66, 36, 36, "CID"], [66, 66, 59, 59, "CID"], [66, 66, 81, 81, "CID"], [66, 66, 100, 100, "CID"], [66, 66, 125, 125, "CID"], [66, 66, 147, 147, "CID"], [77, 77, 14, 14, "CID"], [77, 77, 21, 21, "CID"], [77, 77, 36, 36, "CID"], [77, 77, 59, 59, "CID"], [77, 77, 81, 81, "CID"], [77, 77, 100, 100, "CID"], [77, 77, 125, 125, "CID"], [77, 77, 147, 147, "CID"], [108, 108, 14, 14, "CID"], [108, 108, 21, 21, "CID"], [108, 108, 36, 36, "CID"], [108, 108, 59, 59, "CID"], [108, 108, 81, 81, "CID"], [108, 108, 100, 100, "CID"], [108, 108, 125, 125, "CID"], [108, 108, 147, 147, "CID"]]], "clusters": [], "translated": "阻断 D-1 和 D-2 <18>多巴胺</18> 受体可诱发小鼠 <3>强直性昏厥</3>。1. 对 <19>多巴胺</19>拮抗剂诱发的<4>强直性昏厥</4>进行了检测，并确定了可能涉及<20>多巴胺</20>亚型的<5>强直性昏厥</5>。2. <21>多巴胺</21>拮抗剂<0>氟奋乃静</0>、D-1拮抗剂<11>SCH 23390</11>或D-2拮抗剂<14>舒必利</14>引起了<6>强直性昏厥</6>。<1>氟奋乃静</1>和<15>舒必利</15>的作用呈剂量依赖性。联用<12>SCH 23390</12>和<16>舒必利</16>不会增强<7>强直性昏厥</7>。3. D-1激动剂<23>SKF 38393</23>或D-2激动剂<25>喹吡罗</25>减轻了由<2>氟奋乃静</2>、<13>SCH 23390</13>或<17>舒必利</17>诱导的<8>强直性昏厥</8>。4.<24>SKF 38393</24>与<26>喹吡罗</26>联用不会增强<9>多巴胺</9>拮抗剂诱导的<22>强直性昏厥</22>的抑制作用。5.数据可能表明，尽管 D-2受体阻断与<10>强直性昏厥</10>有关，但D-1受体可能也发挥了一定的作用。", "revised": true}
{"doc_key": "7843916", "sentences": [["Dexamethasone", "-", "induced", "ocular", "hypertension", "in", "perfusion", "-", "cultured", "human", "eyes", ".", "PURPOSE", ":", "Glucocorticoid", "administration", "can", "lead", "to", "the", "development", "of", "ocular", "hypertension", "and", "corticosteroid", "glaucoma", "in", "a", "subset", "of", "the", "population", "through", "a", "decrease", "in", "the", "aqueous", "humor", "outflow", "facility", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "glucocorticoid", "treatment", "can", "directly", "affect", "the", "outflow", "facility", "of", "isolated", ",", "perfusion", "-", "cultured", "human", "eyes", ".", "METHODS", ":", "The", "anterior", "segments", "of", "human", "donor", "eyes", "from", "regional", "eye", "banks", "were", "placed", "in", "a", "constant", "flow", ",", "variable", "pressure", "perfusion", "culture", "system", ".", "Paired", "eyes", "were", "perfused", "in", "serum", "-", "free", "media", "with", "or", "without", "10", "(", "-", "7", ")", "M", "dexamethasone", "for", "12", "days", ".", "Intraocular", "pressure", "was", "monitored", "daily", ".", "After", "incubation", ",", "the", "eyes", "were", "morphologically", "characterized", "by", "light", "microscopy", ",", "transmission", "and", "scanning", "electron", "microscopy", ",", "and", "scanning", "laser", "confocal", "microscopy", ".", "RESULTS", ":", "A", "significant", "increase", "in", "intraocular", "pressure", "developed", "in", "13", "of", "the", "44", "pairs", "of", "eyes", "perfused", "with", "dexamethasone", "with", "an", "average", "pressure", "rise", "of", "17", ".", "5", "+", "/", "-", "3", ".", "8", "mm", "Hg", "after", "12", "days", "of", "dexamethasone", "exposure", ".", "The", "contralateral", "control", "eyes", ",", "which", "did", "not", "receive", "dexamethasone", ",", "maintained", "a", "stable", "intraocular", "pressure", "during", "the", "same", "period", ".", "The", "outflow", "pathway", "of", "the", "untreated", "eyes", "appeared", "morphologically", "normal", ".", "In", "contrast", ",", "the", "dexamethasone", "-", "treated", "hypertensive", "eyes", "had", "thickened", "trabecular", "beams", ",", "decreased", "intertrabecular", "spaces", ",", "thickened", "juxtacanalicular", "tissue", ",", "activated", "trabecular", "meshwork", "cells", ",", "and", "increased", "amounts", "of", "amorphogranular", "extracellular", "material", ",", "especially", "in", "the", "juxtacanalicular", "tissue", "and", "beneath", "the", "endothelial", "lining", "of", "the", "canal", "of", "Schlemm", ".", "The", "dexamethasone", "-", "treated", "nonresponder", "eyes", "appeared", "to", "be", "morphologically", "similar", "to", "the", "untreated", "eyes", ",", "although", "several", "subtle", "dexamethasone", "-", "induced", "morphologic", "changes", "were", "evident", ".", "CONCLUSION", ":", "Dexamethasone", "treatment", "of", "isolated", ",", "perfusion", "-", "cultured", "human", "eyes", "led", "to", "the", "generation", "of", "ocular", "hypertension", "in", "approximately", "30", "%", "of", "the", "dexamethasone", "-", "treated", "eyes", ".", "Steroid", "treatment", "resulted", "in", "morphologic", "changes", "in", "the", "trabecular", "meshwork", "similar", "to", "those", "reported", "for", "corticosteroid", "glaucoma", "and", "open", "angle", "glaucoma", ".", "This", "system", "may", "provide", "an", "acute", "model", "in", "which", "to", "study", "the", "pathogenic", "mechanisms", "involved", "in", "steroid", "glaucoma", "and", "primary", "open", "angle", "glaucoma", "."]], "ner": [[[0, 0, "Chemical"], [113, 113, "Chemical"], [167, 167, "Chemical"], [189, 189, "Chemical"], [201, 201, "Chemical"], [228, 228, "Chemical"], [276, 276, "Chemical"], [294, 294, "Chemical"], [304, 304, "Chemical"], [327, 327, "Chemical"], [3, 4, "Disease"], [22, 23, "Disease"], [231, 232, "Disease"], [319, 320, "Disease"], [25, 26, "Disease"], [347, 348, "Disease"], [370, 371, "Disease"], [350, 352, "Disease"], [373, 376, "Disease"], [332, 332, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 22, 23, "CID"], [0, 0, 231, 232, "CID"], [0, 0, 319, 320, "CID"], [113, 113, 3, 4, "CID"], [113, 113, 22, 23, "CID"], [113, 113, 231, 232, "CID"], [113, 113, 319, 320, "CID"], [167, 167, 3, 4, "CID"], [167, 167, 22, 23, "CID"], [167, 167, 231, 232, "CID"], [167, 167, 319, 320, "CID"], [189, 189, 3, 4, "CID"], [189, 189, 22, 23, "CID"], [189, 189, 231, 232, "CID"], [189, 189, 319, 320, "CID"], [201, 201, 3, 4, "CID"], [201, 201, 22, 23, "CID"], [201, 201, 231, 232, "CID"], [201, 201, 319, 320, "CID"], [228, 228, 3, 4, "CID"], [228, 228, 22, 23, "CID"], [228, 228, 231, 232, "CID"], [228, 228, 319, 320, "CID"], [276, 276, 3, 4, "CID"], [276, 276, 22, 23, "CID"], [276, 276, 231, 232, "CID"], [276, 276, 319, 320, "CID"], [294, 294, 3, 4, "CID"], [294, 294, 22, 23, "CID"], [294, 294, 231, 232, "CID"], [294, 294, 319, 320, "CID"], [304, 304, 3, 4, "CID"], [304, 304, 22, 23, "CID"], [304, 304, 231, 232, "CID"], [304, 304, 319, 320, "CID"], [327, 327, 3, 4, "CID"], [327, 327, 22, 23, "CID"], [327, 327, 231, 232, "CID"], [327, 327, 319, 320, "CID"]]], "clusters": [], "translated": "<0>地塞米松</0>在灌注培养的人眼中引起<10>高眼压</10>。目的：糖皮质激素给药可导致部分人群发生<11>高眼压症</11>和<14>皮质类固醇性青光眼</14>，原因是房水流出设施减少。本研究的目的是确定糖皮质激素治疗是否可以直接影响离体、灌注培养的人眼的流出设施。方法：将来自区域眼库的人类供体眼的眼前节置于恒流、变压灌注培养系统中。配对的眼睛在有或没有10(-7) M <1>地塞米松</1>的无血清培养基中灌注12天。每天监测眼压。孵育后，通过光学显微镜、透射和扫描电子显微镜以及扫描激光共聚焦显微镜对眼睛进行形态学表征。结果：灌注<2>地塞米松</2>的44对眼中有13对眼压明显升高，平均升高17.5 ± 3.8 mm Hg，<3>地塞米松</3>暴露12天后。未给予<4>地塞米松</4>的对侧对照眼同期眼压保持稳定。未治疗眼的流出通路形态正常。相比之下，<5>地塞米松</5>治疗<12>高血压眼</12>的小梁梁变厚，小梁间隙减少，小梁旁组织增厚，小梁网细胞活化，无形颗粒细胞外物质增加，尤其是在juxtacanalicular组织和Schlemm管的内皮衬里下面。 <6>地塞米松</6>治疗后无反应的眼睛在形态上与未治疗的眼睛相似，尽管一些细微的<7>地塞米松</7>诱导的形态学变化很明显。结论：<8>地塞米松</8>治疗离体、灌注培养的人眼导致约30%的<9>地塞米松</9>治疗眼产生<13>高眼压症</13>。<19>类固醇</19>治疗导致小梁网的形态学变化类似于<15>皮质类固醇性青光眼</15>和<17>开角型青光眼</17>的报道。该系统可提供一个急性模型，用于研究<16>类固醇性青光眼</16>和<18>原发性开角型青光眼</18>的致病机制。", "revised": true}
{"doc_key": "19719056", "sentences": [["Dextran", "-", "etodolac", "conjugates", ":", "synthesis", ",", "in", "vitro", "and", "in", "vivo", "evaluation", ".", "Etodolac", "(", "E", ")", ",", "is", "a", "non", "-", "narcotic", "analgesic", "and", "antiinflammatory", "drug", ".", "A", "biodegradable", "polymer", "dextran", "has", "been", "utilized", "as", "a", "carrier", "for", "synthesis", "of", "etodolac", "-", "dextran", "conjugates", "(", "ED", ")", "to", "improve", "its", "aqueous", "solubility", "and", "reduce", "gastrointestinal", "side", "effects", ".", "An", "activated", "moiety", ",", "i", ".", "e", ".", "N", "-", "acylimidazole", "derivative", "of", "etodolac", "(", "EAI", ")", ",", "was", "condensed", "with", "the", "polysaccharide", "polymer", "dextran", "of", "different", "molecular", "weights", "(", "40000", ",", "60000", ",", "110000", "and", "200000", ")", ".", "IR", "spectral", "data", "confirmed", "formation", "of", "ester", "bonding", "in", "the", "conjugates", ".", "Etodolac", "contents", "were", "evaluated", "by", "UV", "-", "spectrophotometric", "analysis", ".", "The", "molecular", "weights", "were", "determined", "by", "measuring", "viscosity", "using", "the", "Mark", "-", "Howink", "-", "Sakurada", "equation", ".", "In", "vitro", "hydrolysis", "of", "ED", "was", "done", "in", "aqueous", "buffers", "(", "pH", "1", ".", "2", ",", "7", ".", "4", ",", "9", ")", "and", "in", "80", "%", "(", "v", "/", "v", ")", "human", "plasma", "(", "pH", "7", ".", "4", ")", ".", "At", "pH", "9", ",", "a", "higher", "rate", "of", "etodolac", "release", "from", "ED", "was", "observed", "as", "compared", "to", "aqueous", "buffer", "of", "pH", "7", ".", "4", "and", "80", "%", "human", "plasma", "(", "pH", "7", ".", "4", ")", ",", "following", "first", "-", "order", "kinetics", ".", "In", "vivo", "investigations", "were", "performed", "in", "animals", ".", "Acute", "analgesic", "and", "antiinflammatory", "activities", "were", "ascertained", "using", "acetic", "acid", "induced", "writhing", "model", "(", "mice", ")", "and", "carrageenan", "-", "induced", "rat", "paw", "edema", "model", ",", "respectively", ".", "In", "comparison", "to", "control", ",", "E", "and", "ED1", "-", "ED4", "showed", "highly", "significant", "analgesic", "and", "antiinflammatory", "activities", "(", "p", "<", "0", ".", "001", ")", ".", "Biological", "evaluation", "suggested", "that", "conjugates", "(", "ED1", "-", "ED4", ")", "retained", "comparable", "analgesic", "and", "antiinflammatory", "activities", "with", "remarkably", "reduced", "ulcerogenicity", "as", "compared", "to", "their", "parent", "drug", "-", "-", "etodolac", "."]], "ner": [[[245, 245, "Chemical"], [239, 239, "Disease"], [250, 250, "Disease"], [0, 0, "Chemical"], [32, 32, "Chemical"], [44, 44, "Chemical"], [84, 84, "Chemical"], [2, 2, "Chemical"], [14, 14, "Chemical"], [16, 16, "Chemical"], [42, 42, "Chemical"], [73, 73, "Chemical"], [111, 111, "Chemical"], [186, 186, "Chemical"], [260, 260, "Chemical"], [308, 308, "Chemical"], [236, 237, "Chemical"]]], "relations": [[[245, 245, 239, 239, "CID"], [245, 245, 250, 250, "CID"]]], "clusters": [], "translated": "<3>葡聚糖</3>-<7>依托度酸</7>偶联物：合成、体外和体内评价。<8>依托度酸</8>(<9>E</9>)，是一种非麻醉性镇痛抗炎药。一种可生物降解的聚合物<4>葡聚糖</4>已被用作合成<10>依托度酸</10>-<5>葡聚糖</5>偶联物(ED)的载体，以提高其水溶性并减少胃肠道副作用影响。一个激活的部分，即<11>依托度酸</11>(EAI)的N-酰基咪唑衍生物与不同分子量(<6>40000、60000、110000和200000</6>)的多糖聚合物<6>葡聚糖</6>缩合而成。红外光谱数据证实了缀合物中酯键的形成。<12>依托度酸</12>的含量通过紫外分光光度法分析进行评估。分子量是通过使用Mark-Howink-Sakurada方程测量粘度来确定的。ED的体外水解在水性缓冲液(pH 1.2、7.4、9)和80%(v/v)人血浆(pH 7.4)中进行。在pH 9时，观察到从ED中释放出更高速率的<13>依托度酸</13>与pH 7.4的水性缓冲液和80%人血浆(pH 7.4)相比，遵循一级动力学。在动物身上进行了体内研究。使用<16>乙酸</16>诱导的<1>扭体</1>模型（小鼠）和<0>角叉菜胶</0>诱导的大鼠爪<2>水肿</2>模型，分别确定急性镇痛和抗炎活性。与对照相比，<14>E</14>和ED1-ED4显示出高度显着的镇痛和抗炎活性(p < 0.001)。生物学评估表明，与其母体药物- -<15>依托度酸</15>相比，结合物(ED1-ED4)保留了相当的镇痛和抗炎活性，同时显着降低了溃疡形成。", "revised": true}
{"doc_key": "15266362", "sentences": [["Hypersensitivity", "myocarditis", "complicating", "hypertrophic", "cardiomyopathy", "heart", ".", "The", "present", "report", "describes", "a", "case", "of", "eosinophilic", "myocarditis", "complicating", "hypertrophic", "cardiomyopathy", ".", "The", "47", "-", "year", "-", "old", "female", "patient", ",", "known", "to", "have", "hypertrophic", "cardiomyopathy", ",", "was", "admitted", "with", "biventricular", "failure", "and", "managed", "aggressively", "with", "dobutamine", "infusion", "and", "other", "drugs", "while", "being", "assessed", "for", "heart", "transplantation", ".", "On", "transthoracic", "echocardiogram", ",", "she", "had", "moderate", "left", "ventricular", "dysfunction", "with", "regional", "variability", "and", "moderate", "mitral", "regurgitation", ".", "The", "recipient", "'s", "heart", "showed", "the", "features", "of", "apical", "hypertrophic", "cardiomyopathy", "and", "myocarditis", "with", "abundant", "eosinophils", ".", "Myocarditis", "is", "rare", "and", "eosinophilic", "myocarditis", "is", "rarer", ".", "It", "is", "likely", "that", "the", "hypersensitivity", "(", "eosinophilic", ")", "myocarditis", "was", "related", "to", "dobutamine", "infusion", "therapy", ".", "Eosinophilic", "myocarditis", "has", "been", "reported", "with", "an", "incidence", "of", "2", ".", "4", "%", "to", "7", ".", "2", "%", "in", "explanted", "hearts", "and", "may", "be", "related", "to", "multidrug", "therapy", "."]], "ner": [[[44, 44, "Chemical"], [113, 113, "Chemical"], [0, 0, "Disease"], [105, 105, "Disease"], [1, 1, "Disease"], [14, 15, "Disease"], [86, 86, "Disease"], [91, 91, "Disease"], [95, 96, "Disease"], [109, 109, "Disease"], [117, 118, "Disease"], [107, 107, "Disease"], [3, 4, "Disease"], [17, 18, "Disease"], [32, 33, "Disease"], [83, 84, "Disease"], [38, 39, "Disease"], [63, 65, "Disease"], [71, 72, "Disease"]]], "relations": [[[44, 44, 0, 0, "CID"], [44, 44, 105, 105, "CID"], [113, 113, 0, 0, "CID"], [113, 113, 105, 105, "CID"], [44, 44, 1, 1, "CID"], [44, 44, 14, 15, "CID"], [44, 44, 86, 86, "CID"], [44, 44, 91, 91, "CID"], [44, 44, 95, 96, "CID"], [44, 44, 109, 109, "CID"], [44, 44, 117, 118, "CID"], [113, 113, 1, 1, "CID"], [113, 113, 14, 15, "CID"], [113, 113, 86, 86, "CID"], [113, 113, 91, 91, "CID"], [113, 113, 95, 96, "CID"], [113, 113, 109, 109, "CID"], [113, 113, 117, 118, "CID"], [44, 44, 107, 107, "CID"], [113, 113, 107, 107, "CID"]]], "clusters": [], "translated": " <2>超敏反应</2><4>心肌炎</4>并发<12>肥厚性心肌病</12>心脏。本报告描述了一例<5>嗜酸性粒细胞性心肌炎</5>并发<13>肥厚性心肌病</13>的病例。这位47岁的女性患者，已知患有<14>肥厚型心肌病</14>，因<16>双心室衰竭</16>入院，并通过输注<0>多巴酚丁胺</0>和其他药物进行积极治疗，同时接受心脏移植评估。经胸超声心动图显示，她有中度<17>左心室功能不全</17>和中度<18>二尖瓣反流</18>，并伴有区域变异性。受者心脏表现为心尖部<15>肥厚型心肌病</15>和<6>心肌炎</6>特征，嗜酸性粒细胞增多。<7>心肌炎</7>少见，<8>嗜酸性粒细胞性心肌炎</8>更为少见。 <3>超敏反应</3>（<11>嗜酸性粒细胞增多</11>）<9>心肌炎</9>可能与<1>多巴酚丁胺</1>输液治疗有关。 <10>嗜酸性粒细胞性心肌炎</10>据报道发病率为2.4%至7.2%在外植心脏中，可能与多药治疗有关。", "revised": true}
{"doc_key": "8045270", "sentences": [["KF17837", ":", "a", "novel", "selective", "adenosine", "A2A", "receptor", "antagonist", "with", "anticataleptic", "activity", ".", "KF17837", "is", "a", "novel", "selective", "adenosine", "A2A", "receptor", "antagonist", ".", "Oral", "administration", "of", "KF17837", "(", "2", ".", "5", ",", "10", ".", "0", "and", "30", ".", "0", "mg", "/", "kg", ")", "significantly", "ameliorated", "the", "cataleptic", "responses", "induced", "by", "intracerebroventricular", "administration", "of", "an", "adenosine", "A2A", "receptor", "agonist", ",", "CGS", "21680", "(", "10", "micrograms", ")", ",", "in", "a", "dose", "-", "dependent", "manner", ".", "KF17837", "also", "reduced", "the", "catalepsy", "induced", "by", "haloperidol", "(", "1", "mg", "/", "kg", "i", ".", "p", ".", ")", "and", "by", "reserpine", "(", "5", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "These", "anticataleptic", "effects", "were", "exhibited", "dose", "dependently", "at", "doses", "from", "0", ".", "625", "and", "2", ".", "5", "mg", "/", "kg", "p", ".", "o", ".", ",", "respectively", ".", "Moreover", ",", "KF17837", "(", "0", ".", "625", "mg", "/", "kg", "p", ".", "o", ".", ")", "potentiated", "the", "anticataleptic", "effects", "of", "a", "subthreshold", "dose", "of", "L", "-", "3", ",", "4", "-", "dihydroxyphenylalanine", "(", "L", "-", "DOPA", ";", "25", "mg", "/", "kg", "i", ".", "p", ".", ")", "plus", "benserazide", "(", "6", ".", "25", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "These", "results", "suggested", "that", "KF17837", "is", "a", "centrally", "active", "adenosine", "A2A", "receptor", "antagonist", "and", "that", "the", "dopaminergic", "function", "of", "the", "nigrostriatal", "pathway", "is", "potentiated", "by", "adenosine", "A2A", "receptor", "antagonists", ".", "Furthermore", ",", "KF17837", "may", "be", "a", "useful", "drug", "in", "the", "treatment", "of", "parkinsonism", "."]], "ner": [[[59, 60, "Chemical"], [46, 46, "Disease"], [77, 77, "Disease"], [80, 80, "Chemical"], [93, 93, "Chemical"], [0, 0, "Chemical"], [13, 13, "Chemical"], [26, 26, "Chemical"], [73, 73, "Chemical"], [134, 134, "Chemical"], [196, 196, "Chemical"], [224, 224, "Chemical"], [234, 234, "Disease"], [5, 5, "Chemical"], [18, 18, "Chemical"], [54, 54, "Chemical"], [201, 201, "Chemical"], [217, 217, "Chemical"], [156, 162, "Chemical"], [164, 166, "Chemical"], [178, 178, "Chemical"]]], "relations": [[[59, 60, 46, 46, "CID"], [59, 60, 77, 77, "CID"], [80, 80, 46, 46, "CID"], [80, 80, 77, 77, "CID"], [93, 93, 46, 46, "CID"], [93, 93, 77, 77, "CID"]]], "clusters": [], "translated": " <5>KF17837</5>：一种新型选择性<13>腺苷</13>A2A受体拮抗剂，具有抗强直作用。 <6>KF17837</6>是一种新型的选择性<14>腺苷</14>A2A受体拮抗剂。口服给予<7>KF17837</7>（2.5、10.0和30.0 mg/kg），在剂量依賴性的条件下，明显减轻了由脑室内给予<15> A2A受体</15>激动剂<0>CGS 21680</0>（10μg/kg）引起的<1>强直反应</1>。<8>KF17837</8>也减少了由<3>氟哌啶醇</3>（1 mg/kg i.p.）和<4>利血平</4>（5mg/kg i.p.）引起的<2>强直反应</2>。这些抗强直作用在不同剂量下表现出剂量依賴性（分别为0.625 mg/kg和2.5 mg/kg口服）。此外，<9>KF17837</9>（0.625 mg/kg口服）加强了低于阈值剂量的<18>L-3，4-二羟基苯丙氨酸</18>（<19>L-DOPA</19>；25 mg/kg i.p.）+<20>苯磺酸多奈哌齐缓释片</20>（6.25mg/kg i.p.）的抗强直作用。这些结果表明，<10>KF17837</10>是一种具有中枢活性的<16>腺苷</16>A2A受体拮抗剂，并且通过增强<17>腺苷</17>A2A受体拮抗剂，黑质纹状体通路的多巴胺能功能。此外，<11>KF17837</11>可能是治疗<12>帕金森症</12>的有效药物。", "revised": true}
{"doc_key": "2576810", "sentences": [["Some", "central", "effects", "of", "repeated", "treatment", "with", "fluvoxamine", ".", "We", "investigated", "the", "effect", "of", "repeated", "treatment", "with", "fluvoxamine", ",", "a", "selective", "serotonin", "uptake", "inhibitor", ",", "on", "behavioral", "effects", "of", "dopaminomimetics", "and", "methoxamine", "and", "on", "the", "animal", "behavior", "in", "the", "\"", "behavioral", "despair", "\"", "test", ".", "A", "repeated", "treatment", "with", "fluvoxamine", "(", "twice", "daily", "for", "14", "days", ")", "potentiated", "in", "mice", "and", "in", "rats", "(", "weaker", ")", "the", "amphetamine", "-", "induced", "hyperactivity", ".", "The", "hyperactivity", "induced", "by", "nomifensine", "in", "mice", "remained", "unaffected", "by", "fluvoxamine", ".", "The", "stimulation", "of", "locomotor", "activity", "by", "intracerebroventricularly", "administered", "methoxamine", "was", "not", "affected", "by", "repeated", "treatment", "with", "fluvoxamine", ".", "Given", "three", "times", "fluvoxamine", "had", "no", "effect", "on", "the", "immobilization", "time", "in", "the", "\"", "behavioral", "despair", "\"", "test", "in", "rats", ".", "The", "results", "indicate", "that", "fluvoxamine", "given", "repeatedly", "acts", "differently", "than", "citalopram", ",", "another", "selective", "serotonin", "uptake", "inhibitor", ",", "and", "differs", "also", "from", "other", "antidepressant", "drugs", "."]], "ner": [[[7, 7, "Chemical"], [17, 17, "Chemical"], [49, 49, "Chemical"], [82, 82, "Chemical"], [100, 100, "Chemical"], [105, 105, "Chemical"], [127, 127, "Chemical"], [70, 70, "Disease"], [73, 73, "Disease"], [31, 31, "Chemical"], [92, 92, "Chemical"], [67, 67, "Chemical"], [76, 76, "Chemical"], [21, 21, "Chemical"], [137, 137, "Chemical"], [133, 133, "Chemical"]]], "relations": [[[7, 7, 70, 70, "CID"], [7, 7, 73, 73, "CID"], [17, 17, 70, 70, "CID"], [17, 17, 73, 73, "CID"], [49, 49, 70, 70, "CID"], [49, 49, 73, 73, "CID"], [82, 82, 70, 70, "CID"], [82, 82, 73, 73, "CID"], [100, 100, 70, 70, "CID"], [100, 100, 73, 73, "CID"], [105, 105, 70, 70, "CID"], [105, 105, 73, 73, "CID"], [127, 127, 70, 70, "CID"], [127, 127, 73, 73, "CID"], [31, 31, 70, 70, "CID"], [31, 31, 73, 73, "CID"], [92, 92, 70, 70, "CID"], [92, 92, 73, 73, "CID"], [67, 67, 70, 70, "CID"], [67, 67, 73, 73, "CID"], [76, 76, 70, 70, "CID"], [76, 76, 73, 73, "CID"]]], "clusters": [], "translated": "<0>氟伏沙明</0>重复治疗的一些中枢作用。我们研究了重复使用<1>氟伏沙明</1>（一种选择性<13>血清素</13>摄取抑制剂）对多巴胺模拟物和<9>甲氧胺</9>的行为影响以及对动物行为的影响“行为绝望”测试。用<2>氟伏沙明</2>重复治疗（每天两次，持续14天）在小鼠和大鼠（较弱）中增强了<11>苯丙胺</11>诱导的<7>多动症</7>。<12>诺米芬辛</12>引起的小鼠<8>多动</8>不受<3>氟伏沙明</3>的影响。脑室内注射<10>甲氧胺</10>对运动活动的刺激不受<4>氟伏沙明</4>重复治疗的影响。给予3次<5>氟伏沙明</5>对大鼠“行为绝望”试验中的固定时间无影响。结果表明，反复给予<6>氟伏沙明</6>与<15>西酞普兰</15>不同，后者是另一种选择性<14>血清素</14>摄取抑制剂，也与其他抗抑郁药不同。", "revised": true}
{"doc_key": "17049862", "sentences": [["Is", "phenytoin", "administration", "safe", "in", "a", "hypothermic", "child", "?", "A", "male", "neonate", "with", "a", "Chiari", "malformation", "and", "a", "leaking", "myelomeningocoele", "underwent", "ventriculoperitoneal", "shunt", "insertion", "followed", "by", "repair", "of", "myelomeningocoele", ".", "During", "anaesthesia", "and", "surgery", ",", "he", "inadvertently", "became", "moderately", "hypothermic", ".", "Intravenous", "phenytoin", "was", "administered", "during", "the", "later", "part", "of", "the", "surgery", "for", "seizure", "prophylaxis", ".", "Following", "phenytoin", "administration", ",", "the", "patient", "developed", "acute", "severe", "bradycardia", ",", "refractory", "to", "atropine", "and", "adrenaline", ".", "The", "cardiac", "depressant", "actions", "of", "phenytoin", "and", "hypothermia", "can", "be", "additive", ".", "Administration", "of", "phenytoin", "in", "the", "presence", "of", "hypothermia", "may", "lead", "to", "an", "adverse", "cardiac", "event", "in", "children", ".", "As", "phenytoin", "is", "a", "commonly", "used", "drug", ",", "clinicians", "need", "to", "be", "aware", "of", "this", "interaction", "."]], "ner": [[[1, 1, "Chemical"], [42, 42, "Chemical"], [57, 57, "Chemical"], [78, 78, "Chemical"], [87, 87, "Chemical"], [104, 104, "Chemical"], [65, 65, "Disease"], [6, 6, "Disease"], [39, 39, "Disease"], [80, 80, "Disease"], [92, 92, "Disease"], [14, 15, "Disease"], [53, 53, "Disease"], [69, 69, "Chemical"], [71, 71, "Chemical"]]], "relations": [[[1, 1, 65, 65, "CID"], [42, 42, 65, 65, "CID"], [57, 57, 65, 65, "CID"], [78, 78, 65, 65, "CID"], [87, 87, 65, 65, "CID"], [104, 104, 65, 65, "CID"]]], "clusters": [], "translated": "<0>苯妥英钠</0>对<7>体温过低</7>儿童安全吗？一名患有<11>Chiari畸形</11>和脊髓脊膜腔渗漏的男性新生儿接受了脑室腹腔分流术插入术，随后修复了脊髓脊膜腔。在麻醉和手术过程中，他不经意地变得中度<8>体温过低</8>。手术后期静脉注射<1>苯妥英</1>以预防<12>癫痫发作</12>。 <2>苯妥英</2>给药后，患者出现急性重度<6>心动过缓</6>，对<13>阿托品</13>和<14>肾上腺素</14>无效。 <3>苯妥英</3>和<9>体温过低</9>的心脏抑制作用可以相加。在<10>体温过低</10>的情况下使用<4>苯妥英</4>可能会导致儿童发生不良心脏事件。由于<5>苯妥英</5>是一种常用药物，临床医生需要注意这种相互作用。", "revised": true}
{"doc_key": "20635749", "sentences": [["Severe", "congestive", "heart", "failure", "patient", "on", "amiodarone", "presenting", "with", "myxedemic", "coma", ":", "a", "case", "report", ".", "This", "is", "a", "case", "report", "of", "myxedema", "coma", "secondary", "to", "amiodarone", "-", "induced", "hypothyroidism", "in", "a", "patient", "with", "severe", "congestive", "heart", "failure", "(", "CHF", ")", ".", "To", "our", "knowledge", "and", "after", "reviewing", "the", "literature", "there", "is", "one", "case", "report", "of", "myxedema", "coma", "during", "long", "term", "amiodarone", "therapy", ".", "Myxedema", "coma", "is", "a", "life", "threatening", "condition", "that", "carries", "a", "mortality", "reaching", "as", "high", "as", "20", "%", "with", "treatment", ".", "The", "condition", "is", "treated", "with", "intravenous", "thyroxine", "(", "T4", ")", "or", "intravenous", "tri", "-", "iodo", "-", "thyronine", "(", "T3", ")", ".", "Patients", "with", "CHF", "on", "amiodarone", "may", "suffer", "serious", "morbidity", "and", "mortality", "from", "hypothyroidism", ",", "and", "thus", "may", "deserve", "closer", "follow", "up", "for", "thyroid", "stimulating", "hormone", "(", "TSH", ")", "levels", ".", "This", "case", "report", "carries", "an", "important", "clinical", "application", "given", "the", "frequent", "usage", "of", "amiodarone", "among", "CHF", "patients", ".", "The", "myriad", "clinical", "presentation", "of", "myxedema", "coma", "and", "its", "serious", "morbidity", "and", "mortality", "stresses", "the", "need", "to", "suspect", "this", "clinical", "syndrome", "among", "CHF", "patients", "presenting", "with", "hypotension", ",", "weakness", "or", "other", "unexplained", "symptoms", "."]], "ner": [[[6, 6, "Chemical"], [26, 26, "Chemical"], [61, 61, "Chemical"], [109, 109, "Chemical"], [148, 148, "Chemical"], [9, 10, "Disease"], [22, 23, "Disease"], [56, 57, "Disease"], [64, 65, "Disease"], [158, 159, "Disease"], [29, 29, "Disease"], [117, 117, "Disease"], [1, 3, "Disease"], [35, 37, "Disease"], [39, 39, "Disease"], [107, 107, "Disease"], [150, 150, "Disease"], [175, 175, "Disease"], [90, 90, "Chemical"], [92, 92, "Chemical"], [96, 100, "Chemical"], [102, 102, "Chemical"], [179, 179, "Disease"], [181, 181, "Disease"]]], "relations": [[[6, 6, 9, 10, "CID"], [6, 6, 22, 23, "CID"], [6, 6, 56, 57, "CID"], [6, 6, 64, 65, "CID"], [6, 6, 158, 159, "CID"], [26, 26, 9, 10, "CID"], [26, 26, 22, 23, "CID"], [26, 26, 56, 57, "CID"], [26, 26, 64, 65, "CID"], [26, 26, 158, 159, "CID"], [61, 61, 9, 10, "CID"], [61, 61, 22, 23, "CID"], [61, 61, 56, 57, "CID"], [61, 61, 64, 65, "CID"], [61, 61, 158, 159, "CID"], [109, 109, 9, 10, "CID"], [109, 109, 22, 23, "CID"], [109, 109, 56, 57, "CID"], [109, 109, 64, 65, "CID"], [109, 109, 158, 159, "CID"], [148, 148, 9, 10, "CID"], [148, 148, 22, 23, "CID"], [148, 148, 56, 57, "CID"], [148, 148, 64, 65, "CID"], [148, 148, 158, 159, "CID"], [6, 6, 29, 29, "CID"], [6, 6, 117, 117, "CID"], [26, 26, 29, 29, "CID"], [26, 26, 117, 117, "CID"], [61, 61, 29, 29, "CID"], [61, 61, 117, 117, "CID"], [109, 109, 29, 29, "CID"], [109, 109, 117, 117, "CID"], [148, 148, 29, 29, "CID"], [148, 148, 117, 117, "CID"]]], "clusters": [], "translated": "严重<12>充血性心力衰竭</12><0>胺碘酮</0>患者出现<5>粘液性昏迷</5>：病例报告。这是一例<6>粘液水肿昏迷</6>继发于<1>胺碘酮</1>-诱发<10>甲状腺功能减退症</10>的病例报告，患者患有严重<13>充血性心力衰竭</13>(<14>CHF</14>)。据我们所知，在查阅文献后，有一例在长期<2>胺碘酮</2>治疗期间的<7>粘液水肿昏迷</7>病例报告。 <8>粘液水肿昏迷</8>是一种危及生命的疾病，治疗后死亡率高达20%。治疗方法是静脉注射<18>甲状腺素</18>(<19>T4</19>)或静脉注射<20>三碘甲状腺素</20>(<21>T3</21>)。<15>CHF</15>服​​用<3>胺碘酮</3>的患者可能会因<11>甲状腺功能减退症</11>而导致严重的发病率和死亡率，因此可能需要更密切地跟踪促甲状腺激素(TSH)水平。考虑到<16>CHF</16>患者频繁使用<4>胺碘酮</4>，该病例报告具有重要的临床应用价值。<9>粘液水肿昏迷</9>的多种临床表现及其严重的发病率和死亡率强调了在<17>CHF</17>患者出现<22>低血压</22>、<23>无力</23>或其他无法解释的症状时需要怀疑这种临床综合症。", "revised": true}
{"doc_key": "11230490", "sentences": [["Reduced", "cardiotoxicity", "and", "preserved", "antitumor", "efficacy", "of", "liposome", "-", "encapsulated", "doxorubicin", "and", "cyclophosphamide", "compared", "with", "conventional", "doxorubicin", "and", "cyclophosphamide", "in", "a", "randomized", ",", "multicenter", "trial", "of", "metastatic", "breast", "cancer", ".", "PURPOSE", ":", "To", "determine", "whether", "Myocet", "(", "liposome", "-", "encapsulated", "doxorubicin", ";", "The", "Liposome", "Company", ",", "Elan", "Corporation", ",", "Princeton", ",", "NJ", ")", "in", "combination", "with", "cyclophosphamide", "significantly", "reduces", "doxorubicin", "cardiotoxicity", "while", "providing", "comparable", "antitumor", "efficacy", "in", "first", "-", "line", "treatment", "of", "metastatic", "breast", "cancer", "(", "MBC", ")", ".", "PATIENTS", "AND", "METHODS", ":", "Two", "hundred", "ninety", "-", "seven", "patients", "with", "MBC", "and", "no", "prior", "chemotherapy", "for", "metastatic", "disease", "were", "randomized", "to", "receive", "either", "60", "mg", "/", "m", "(", "2", ")", "of", "Myocet", "(", "M", ")", "or", "conventional", "doxorubicin", "(", "A", ")", ",", "in", "combination", "with", "600", "mg", "/", "m", "(", "2", ")", "of", "cyclophosphamide", "(", "C", ")", ",", "every", "3", "weeks", "until", "disease", "progression", "or", "unacceptable", "toxicity", ".", "Cardiotoxicity", "was", "defined", "by", "reductions", "in", "left", "-", "ventricular", "ejection", "fraction", ",", "assessed", "by", "serial", "multigated", "radionuclide", "angiography", "scans", ",", "or", "congestive", "heart", "failure", "(", "CHF", ")", ".", "Antitumor", "efficacy", "was", "assessed", "by", "objective", "tumor", "response", "rates", "(", "World", "Health", "Organization", "criteria", ")", ",", "time", "to", "progression", ",", "and", "survival", ".", "RESULTS", ":", "Six", "percent", "of", "MC", "patients", "versus", "21", "%", "(", "including", "five", "cases", "of", "CHF", ")", "of", "AC", "patients", "developed", "cardiotoxicity", "(", "P", "=", ".", "0002", ")", ".", "Median", "cumulative", "doxorubicin", "dose", "at", "onset", "was", "more", "than", "2", ",", "220", "mg", "/", "m", "(", "2", ")", "for", "MC", "versus", "480", "mg", "/", "m", "(", "2", ")", "for", "AC", "(", "P", "=", ".", "0001", ",", "hazard", "ratio", ",", "5", ".", "04", ")", ".", "MC", "patients", "also", "experienced", "less", "grade", "4", "neutropenia", ".", "Antitumor", "efficacy", "of", "MC", "versus", "AC", "was", "comparable", ":", "objective", "response", "rates", ",", "43", "%", "versus", "43", "%", ";", "median", "time", "to", "progression", ",", "5", ".", "1", "%", "versus", "5", ".", "5", "months", ";", "median", "time", "to", "treatment", "failure", ",", "4", ".", "6", "versus", "4", ".", "4", "months", ";", "and", "median", "survival", ",", "19", "versus", "16", "months", ".", "CONCLUSION", ":", "Myocet", "improves", "the", "therapeutic", "index", "of", "doxorubicin", "by", "significantly", "reducing", "cardiotoxicity", "and", "grade", "4", "neutropenia", "and", "provides", "comparable", "antitumor", "efficacy", ",", "when", "used", "in", "combination", "with", "cyclophosphamide", "as", "first", "-", "line", "therapy", "for", "MBC", "."]], "ner": [[[10, 10, "Chemical"], [16, 16, "Chemical"], [35, 35, "Chemical"], [40, 40, "Chemical"], [59, 59, "Chemical"], [111, 111, "Chemical"], [117, 117, "Chemical"], [230, 230, "Chemical"], [341, 341, "Chemical"], [347, 347, "Chemical"], [169, 171, "Disease"], [173, 173, "Disease"], [214, 214, "Disease"], [279, 279, "Disease"], [355, 355, "Disease"], [12, 12, "Chemical"], [18, 18, "Chemical"], [56, 56, "Chemical"], [133, 133, "Chemical"], [367, 367, "Chemical"], [1, 1, "Disease"], [60, 60, "Disease"], [148, 148, "Disease"], [220, 220, "Disease"], [351, 351, "Disease"], [27, 28, "Disease"], [73, 74, "Disease"], [76, 76, "Disease"], [90, 90, "Disease"], [374, 374, "Disease"], [146, 146, "Disease"], [182, 182, "Disease"]]], "relations": [[[10, 10, 169, 171, "CID"], [10, 10, 173, 173, "CID"], [10, 10, 214, 214, "CID"], [16, 16, 169, 171, "CID"], [16, 16, 173, 173, "CID"], [16, 16, 214, 214, "CID"], [35, 35, 169, 171, "CID"], [35, 35, 173, 173, "CID"], [35, 35, 214, 214, "CID"], [40, 40, 169, 171, "CID"], [40, 40, 173, 173, "CID"], [40, 40, 214, 214, "CID"], [59, 59, 169, 171, "CID"], [59, 59, 173, 173, "CID"], [59, 59, 214, 214, "CID"], [111, 111, 169, 171, "CID"], [111, 111, 173, 173, "CID"], [111, 111, 214, 214, "CID"], [117, 117, 169, 171, "CID"], [117, 117, 173, 173, "CID"], [117, 117, 214, 214, "CID"], [230, 230, 169, 171, "CID"], [230, 230, 173, 173, "CID"], [230, 230, 214, 214, "CID"], [341, 341, 169, 171, "CID"], [341, 341, 173, 173, "CID"], [341, 341, 214, 214, "CID"], [347, 347, 169, 171, "CID"], [347, 347, 173, 173, "CID"], [347, 347, 214, 214, "CID"], [10, 10, 279, 279, "CID"], [10, 10, 355, 355, "CID"], [16, 16, 279, 279, "CID"], [16, 16, 355, 355, "CID"], [35, 35, 279, 279, "CID"], [35, 35, 355, 355, "CID"], [40, 40, 279, 279, "CID"], [40, 40, 355, 355, "CID"], [59, 59, 279, 279, "CID"], [59, 59, 355, 355, "CID"], [111, 111, 279, 279, "CID"], [111, 111, 355, 355, "CID"], [117, 117, 279, 279, "CID"], [117, 117, 355, 355, "CID"], [230, 230, 279, 279, "CID"], [230, 230, 355, 355, "CID"], [341, 341, 279, 279, "CID"], [341, 341, 355, 355, "CID"], [347, 347, 279, 279, "CID"], [347, 347, 355, 355, "CID"], [12, 12, 169, 171, "CID"], [12, 12, 173, 173, "CID"], [12, 12, 214, 214, "CID"], [18, 18, 169, 171, "CID"], [18, 18, 173, 173, "CID"], [18, 18, 214, 214, "CID"], [56, 56, 169, 171, "CID"], [56, 56, 173, 173, "CID"], [56, 56, 214, 214, "CID"], [133, 133, 169, 171, "CID"], [133, 133, 173, 173, "CID"], [133, 133, 214, 214, "CID"], [367, 367, 169, 171, "CID"], [367, 367, 173, 173, "CID"], [367, 367, 214, 214, "CID"], [12, 12, 279, 279, "CID"], [12, 12, 355, 355, "CID"], [18, 18, 279, 279, "CID"], [18, 18, 355, 355, "CID"], [56, 56, 279, 279, "CID"], [56, 56, 355, 355, "CID"], [133, 133, 279, 279, "CID"], [133, 133, 355, 355, "CID"], [367, 367, 279, 279, "CID"], [367, 367, 355, 355, "CID"]]], "clusters": [], "translated": "与传统的<1>多柔比星</1>和<16>环磷酰胺</16>相比，脂质体封装的<0>多柔比星</0>和<15>环磷酰胺</15>降低了<20>心脏毒性</20>并保持了抗肿瘤功效，在转移性<25>乳腺癌</25>的随机、多中心试验中。目的：确定<2>Myocet</2>（脂质体包裹的<3>阿霉素</3>;脂质体公司，Elan Corporation，新泽西州普林斯顿）与<17>环磷酰胺</17>联合使用是否显着降低<4>阿霉素</4><21>心脏毒性</21>，同时在转移性<26>乳腺癌</26>（<27>MBC</27>）的一线治疗中提供相当的抗肿瘤疗效。患者和方法：297名<28>MBC</28>且既往未接受过转移性疾病化疗的患者随机接受60mg/m(2)的<5>Myocet</5>（M）或常规<6>多柔比星</6>（A），与600mg/m(2)<18>环磷酰胺</18>（C）联合使用，每3周一次，直至疾病进展或出现不可接受的<30>毒性</30>。<22>心脏毒性</22>定义为左心室射血分数降低（通过连续多门放射性核素血管造影扫描评估）或<10>充血性心力衰竭</10>（<11>CHF</11>）。抗肿瘤疗效通过客观<31>肿瘤</31>反应率（世界卫生组织标准）、进展时间和存活率进行评估。结果：6%的MC患者与21%（包括5例<12>CHF</12>）的AC患者发生了<23>心脏毒性</23>（P=.0002）。MC的中位累积<7>多柔比星</7>剂量超过2,220mg/m(2)而AC为480mg/m(2)（P=.0001，风险比5.04）。MC患者也较少出现4级<13>中性粒细胞减少症</13>。MC与AC的抗肿瘤疗效相当：客观反应率，43%与43%；中位进展时间，5.1%对5.5个月；治疗失败的中位时间，4.6对4.4个月；中位生存期分别为19个月和16个月。结论：<8>Myocet</8>通过显着降低<24>心脏毒性</24>和4级<14>中性粒细胞减少症</14>提高了<9>多柔比星</9>的治疗指数，并提供了相当的抗肿瘤疗效，当与<19>环磷酰胺</19>联合用作<29>MBC</29>的一线治疗时。", "revised": true}
{"doc_key": "2257294", "sentences": [["Benzylacyclouridine", "reverses", "azidothymidine", "-", "induced", "marrow", "suppression", "without", "impairment", "of", "anti", "-", "human", "immunodeficiency", "virus", "activity", ".", "Increased", "extracellular", "concentrations", "of", "uridine", "(", "Urd", ")", "have", "been", "reported", "to", "reduce", ",", "in", "vitro", ",", "azidothymidine", "(", "AZT", ")", "-", "induced", "inhibition", "of", "human", "granulocyte", "-", "macrophage", "progenitor", "cells", "without", "impairment", "of", "its", "antihuman", "immunodeficiency", "virus", "(", "HIV", ")", "activity", ".", "Because", "of", "the", "clinical", "toxicities", "associated", "with", "chronic", "Urd", "administration", ",", "the", "ability", "of", "benzylacyclouridine", "(", "BAU", ")", "to", "effect", ",", "in", "vivo", ",", "AZT", "-", "induced", "anemia", "and", "leukopenia", "was", "assessed", ".", "This", "agent", "inhibits", "Urd", "catabolism", "and", ",", "in", "vivo", ",", "increases", "the", "plasma", "concentration", "of", "Urd", "in", "a", "dose", "-", "dependent", "manner", ",", "without", "Urd", "-", "related", "toxicity", ".", "In", "mice", "rendered", "anemic", "and", "leukopenic", "by", "the", "administration", "of", "AZT", "for", "28", "days", "in", "drinking", "water", "(", "1", ".", "5", "mg", "/", "mL", ")", ",", "the", "continued", "administration", "of", "AZT", "plus", "daily", "BAU", "(", "300", "mg", "/", "kg", ",", "orally", ")", "partially", "reversed", "AZT", "-", "induced", "anemia", "and", "leukopenia", "(", "P", "less", "than", ".", "05", ")", ",", "increased", "peripheral", "reticulocytes", "(", "to", "4", ".", "9", "%", ",", "P", "less", "than", ".", "01", ")", ",", "increased", "cellularity", "in", "the", "marrow", ",", "and", "improved", "megaloblastosis", ".", "When", "coadministered", "with", "AZT", "from", "the", "onset", "of", "drug", "administration", ",", "BAU", "reduced", "AZT", "-", "induced", "marrow", "toxicity", ".", "In", "vitro", ",", "at", "a", "concentration", "of", "100", "mumol", "/", "L", ",", "BAU", "possesses", "minimal", "anti", "-", "HIV", "activity", "and", "has", "no", "effect", "on", "the", "ability", "of", "AZT", "to", "reverse", "the", "HIV", "-", "induced", "cytopathic", "effect", "in", "MT4", "cells", ".", "The", "clinical", "and", "biochemical", "implications", "of", "these", "findings", "are", "discussed", "."]], "ner": [[[2, 2, "Chemical"], [34, 34, "Chemical"], [36, 36, "Chemical"], [84, 84, "Chemical"], [132, 132, "Chemical"], [152, 152, "Chemical"], [166, 166, "Chemical"], [210, 210, "Chemical"], [220, 220, "Chemical"], [253, 253, "Chemical"], [5, 6, "Disease"], [223, 224, "Disease"], [87, 87, "Disease"], [125, 125, "Disease"], [169, 169, "Disease"], [89, 89, "Disease"], [127, 127, "Disease"], [171, 171, "Disease"], [0, 0, "Chemical"], [74, 74, "Chemical"], [76, 76, "Chemical"], [155, 155, "Chemical"], [218, 218, "Chemical"], [238, 238, "Chemical"], [13, 13, "Disease"], [53, 53, "Disease"], [64, 64, "Disease"], [120, 120, "Disease"], [21, 21, "Chemical"], [23, 23, "Chemical"], [68, 68, "Chemical"], [96, 96, "Chemical"], [108, 108, "Chemical"], [117, 117, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 223, 224, "CID"], [34, 34, 5, 6, "CID"], [34, 34, 223, 224, "CID"], [36, 36, 5, 6, "CID"], [36, 36, 223, 224, "CID"], [84, 84, 5, 6, "CID"], [84, 84, 223, 224, "CID"], [132, 132, 5, 6, "CID"], [132, 132, 223, 224, "CID"], [152, 152, 5, 6, "CID"], [152, 152, 223, 224, "CID"], [166, 166, 5, 6, "CID"], [166, 166, 223, 224, "CID"], [210, 210, 5, 6, "CID"], [210, 210, 223, 224, "CID"], [220, 220, 5, 6, "CID"], [220, 220, 223, 224, "CID"], [253, 253, 5, 6, "CID"], [253, 253, 223, 224, "CID"], [2, 2, 87, 87, "CID"], [2, 2, 125, 125, "CID"], [2, 2, 169, 169, "CID"], [34, 34, 87, 87, "CID"], [34, 34, 125, 125, "CID"], [34, 34, 169, 169, "CID"], [36, 36, 87, 87, "CID"], [36, 36, 125, 125, "CID"], [36, 36, 169, 169, "CID"], [84, 84, 87, 87, "CID"], [84, 84, 125, 125, "CID"], [84, 84, 169, 169, "CID"], [132, 132, 87, 87, "CID"], [132, 132, 125, 125, "CID"], [132, 132, 169, 169, "CID"], [152, 152, 87, 87, "CID"], [152, 152, 125, 125, "CID"], [152, 152, 169, 169, "CID"], [166, 166, 87, 87, "CID"], [166, 166, 125, 125, "CID"], [166, 166, 169, 169, "CID"], [210, 210, 87, 87, "CID"], [210, 210, 125, 125, "CID"], [210, 210, 169, 169, "CID"], [220, 220, 87, 87, "CID"], [220, 220, 125, 125, "CID"], [220, 220, 169, 169, "CID"], [253, 253, 87, 87, "CID"], [253, 253, 125, 125, "CID"], [253, 253, 169, 169, "CID"], [2, 2, 89, 89, "CID"], [2, 2, 127, 127, "CID"], [2, 2, 171, 171, "CID"], [34, 34, 89, 89, "CID"], [34, 34, 127, 127, "CID"], [34, 34, 171, 171, "CID"], [36, 36, 89, 89, "CID"], [36, 36, 127, 127, "CID"], [36, 36, 171, 171, "CID"], [84, 84, 89, 89, "CID"], [84, 84, 127, 127, "CID"], [84, 84, 171, 171, "CID"], [132, 132, 89, 89, "CID"], [132, 132, 127, 127, "CID"], [132, 132, 171, 171, "CID"], [152, 152, 89, 89, "CID"], [152, 152, 127, 127, "CID"], [152, 152, 171, 171, "CID"], [166, 166, 89, 89, "CID"], [166, 166, 127, 127, "CID"], [166, 166, 171, 171, "CID"], [210, 210, 89, 89, "CID"], [210, 210, 127, 127, "CID"], [210, 210, 171, 171, "CID"], [220, 220, 89, 89, "CID"], [220, 220, 127, 127, "CID"], [220, 220, 171, 171, "CID"], [253, 253, 89, 89, "CID"], [253, 253, 127, 127, "CID"], [253, 253, 171, 171, "CID"]]], "clusters": [], "translated": " \n\n<18>苄基环尿苷</18>可逆转<0>叠氮胸苷</0>诱导的<10>骨髓抑制</10>而不会损害抗人类<24>免疫缺陷</24>病毒的活性。据报道，增加细胞外浓度的<28>尿苷</28>（<29>Urd</29>）可在体外减少<1>叠氮胸苷</1>（<2>AZT</2>）-诱导抑制人类粒细胞-巨噬细胞祖细胞而不损害其抗人类<25>免疫缺陷</25>病毒（HIV）活性。由于临床<26>毒性</26>与慢性<30>尿苷</30>给药相关，评估了<19>苄基环尿苷</19>（<20>BAU</20>）的作用能力，在体内评估<3>AZT</3>-诱导的<12>贫血</12>和<15>白细胞减少</15>。该药物抑制<31>尿苷</31>分解代谢，并在体内以剂量依赖性方式增加<32>尿苷</32>的血浆浓度，与<33>尿苷</33>无关<27>毒性</27>. 在通过在饮用水中施用<4>AZT</4> 28天 （1.5mg/mL）而导致小鼠<13>贫血</13>和<16>白细胞减少</16>的情况下，继续施用<5>AZT</5>加每日<21>苄基环尿苷</21>（300mg/kg，口服）部分逆转<6>AZT</6>-诱导的<14>贫血</14>和<17>白细胞减少</17>（P小于.05），外周网织红细胞增加（达到4.9%，P小于.01），骨髓细胞增多，巨幼红细胞增多。当与<7>AZT</7>联合给药时，<22>苄基环尿苷</22>降低了<8>AZT</8>诱导的<11>骨髓毒性</11>。在体外，浓度为100mumol/L时，<23>苄基环尿苷</23>具有最小的抗HIV活性，并且对<9>AZT</9>逆转HIV-诱导的细胞病变作用的能力没有影响。讨论了这些发现的临床和生化意义。", "revised": true}
{"doc_key": "19203554", "sentences": [["Proteinase", "3", "-", "antineutrophil", "cytoplasmic", "antibody", "-", "(", "PR3", "-", "ANCA", ")", "positive", "necrotizing", "glomerulonephritis", "after", "restarting", "sulphasalazine", "treatment", ".", "A", "59", "-", "year", "-", "old", "woman", "with", "ulcerative", "colitis", "developed", "red", "eyes", ",", "pleural", "effusion", ",", "eosinophilia", "and", "urinary", "abnormalities", "after", "restarting", "of", "sulphasalazine", "treatment", ".", "Light", "microscopy", "of", "a", "kidney", "biopsy", "revealed", "segmental", "necrotizing", "glomerulonephritis", "without", "deposition", "of", "immunoglobulin", "or", "complement", ".", "Proteinase", "3", "-", "antineutrophil", "cytoplasmic", "antibody", "(", "PR3", "-", "ANCA", ")", "titer", "was", "elevated", "at", "183", "ELISA", "units", "(", "EU", ")", "in", "sera", "(", "normal", "range", "less", "than", "10", "EU", ")", ",", "myeloperoxidase", "-", "ANCA", "was", "negative", ".", "PR3", "-", "ANCA", "titer", "was", "250", "and", "1", ",", "070", "EU", "in", "pleural", "effusions", "on", "right", "and", "left", "side", ",", "respectively", ".", "Although", "cessation", "of", "sulphasalazine", "treatment", "resulted", "in", "improvements", "in", "fever", ",", "red", "eyes", ",", "chest", "pain", ",", "titer", "of", "C", "-", "reactive", "protein", "and", "volume", "of", "the", "pleural", "effusions", ",", "we", "initiated", "steroid", "therapy", ",", "because", "PR3", "-", "ANCA", "titer", "rose", "to", "320", "EU", ",", "eosinophil", "count", "increased", "to", "1", ",", "100", "cells", "/", "microl", ",", "and", "the", "pleural", "effusion", "remained", ".", "One", "month", "after", "steroid", "therapy", ",", "the", "pleural", "effusion", "disappeared", ",", "and", "PR3", "-", "ANCA", "titer", "normalized", "3", "months", "later", ".", "This", "case", "suggests", "that", "sulphasalazine", "can", "induce", "PR3", "-", "ANCA", "-", "positive", "necrotizing", "glomerulonephritis", "."]], "ner": [[[17, 17, "Chemical"], [44, 44, "Chemical"], [127, 127, "Chemical"], [211, 211, "Chemical"], [34, 35, "Disease"], [114, 115, "Disease"], [151, 152, "Disease"], [182, 183, "Disease"], [193, 194, "Disease"], [54, 56, "Disease"], [133, 133, "Disease"], [14, 14, "Disease"], [220, 220, "Disease"], [156, 156, "Chemical"], [189, 189, "Chemical"], [28, 29, "Disease"], [31, 32, "Disease"], [135, 136, "Disease"], [37, 37, "Disease"], [39, 40, "Disease"], [138, 139, "Disease"]]], "relations": [[[17, 17, 34, 35, "CID"], [17, 17, 114, 115, "CID"], [17, 17, 151, 152, "CID"], [17, 17, 182, 183, "CID"], [17, 17, 193, 194, "CID"], [44, 44, 34, 35, "CID"], [44, 44, 114, 115, "CID"], [44, 44, 151, 152, "CID"], [44, 44, 182, 183, "CID"], [44, 44, 193, 194, "CID"], [127, 127, 34, 35, "CID"], [127, 127, 114, 115, "CID"], [127, 127, 151, 152, "CID"], [127, 127, 182, 183, "CID"], [127, 127, 193, 194, "CID"], [211, 211, 34, 35, "CID"], [211, 211, 114, 115, "CID"], [211, 211, 151, 152, "CID"], [211, 211, 182, 183, "CID"], [211, 211, 193, 194, "CID"], [17, 17, 54, 56, "CID"], [44, 44, 54, 56, "CID"], [127, 127, 54, 56, "CID"], [211, 211, 54, 56, "CID"], [17, 17, 133, 133, "CID"], [44, 44, 133, 133, "CID"], [127, 127, 133, 133, "CID"], [211, 211, 133, 133, "CID"]]], "clusters": [], "translated": "重新开始<0>柳氮磺胺吡啶</0>治疗后，蛋白酶3-抗中性粒细胞胞质抗体- (<1>PR3-ANCA</1>) 阳性坏死性<11>肾小球肾炎</11>。一名患有<15>溃疡性结肠炎</15>的 59 岁女性出现<16>红眼</16>、<4>胸腔积液</4>、<18>嗜酸性粒细胞增多</18>和尿液异常<19>，这都是在重新开始<1>柳氮磺胺吡啶</1>治疗后出现的。肾活检的光镜检查显示<9>节段性坏死性肾小球肾炎</9>，但没有免疫球蛋白或补体沉积。血清中蛋白酶 3-抗中性粒细胞胞质抗体 (PR3-ANCA) 滴度升高至 183 ELISA单位 (EU) (正常范围小于 10 EU)，髓过氧化物酶-ANCA为阴性。左右侧<5>胸腔积液</5>PR3-ANCA滴度分别为 250 和 1,070 EU。虽然停止<2>柳氮磺胺吡啶</2>治疗导致<10>发烧</10>、<17>红眼</17>、<20>胸痛</20>、C反应蛋白的滴度和<6>胸腔积液的体积和蛋白质</6>均有所改善，但我们开始<13>类固醇</13>治疗，因为PR3-ANCA滴度升至 320 EU，嗜酸性粒细胞计数增至1,100个细胞/μl，并且<7>胸腔积液</7>仍存。<14>类固醇</14>治疗1个月后，<8>胸腔积液</8>消失，3个月后PR3-ANCA滴度恢复正常。本病例提示<3>柳氮磺胺吡啶</3>可诱发PR3-ANCA阳性坏死性<12>肾小球肾炎</12>。", "revised": true}
{"doc_key": "11827497", "sentences": [["Delayed", "-", "onset", "heparin", "-", "induced", "thrombocytopenia", ".", "BACKGROUND", ":", "Heparin", "-", "induced", "thrombocytopenia", "presents", "5", "to", "12", "days", "after", "heparin", "exposure", ",", "with", "or", "without", "arterial", "or", "venous", "thromboemboli", ".", "Delayed", "recognition", "and", "treatment", "of", "heparin", "-", "induced", "thrombocytopenia", "contribute", "to", "poor", "patient", "outcomes", ".", "OBJECTIVE", ":", "To", "describe", "and", "increase", "awareness", "of", "a", "clinical", "scenario", "in", "which", "the", "onset", "or", "manifestations", "of", "heparin", "-", "induced", "thrombocytopenia", "are", "delayed", ".", "DESIGN", ":", "Retrospective", "case", "series", ".", "SETTING", ":", "Three", "large", "urban", "hospitals", "(", "with", "active", "cardiovascular", "surgery", "programs", ")", ".", "PATIENTS", ":", "14", "patients", "seen", "over", "a", "3", "-", "year", "period", "in", "whom", "heparin", "-", "induced", "thrombocytopenia", "became", "apparent", "on", "delayed", "presentation", "with", "thromboembolic", "complications", ".", "MEASUREMENTS", ":", "Platelet", "counts", ",", "onset", "of", "objectively", "determined", "thromboembolism", ",", "results", "of", "heparin", "-", "induced", "platelet", "factor", "4", "antibody", "tests", ",", "and", "outcomes", ".", "RESULTS", ":", "Patients", "went", "home", "after", "hospitalizations", "that", "had", "included", "heparin", "exposure", "-", "-", "in", "most", "cases", ",", "with", "no", "thrombocytopenia", "recognized", "-", "-", "only", "to", "return", "to", "the", "hospital", "(", "median", ",", "day", "14", ")", "with", "thromboembolic", "complications", ".", "Thromboemboli", "were", "venous", "(", "12", "patients", ",", "7", "with", "pulmonary", "emboli", ")", "or", "arterial", "(", "4", "patients", ")", "or", "both", ".", "Platelet", "counts", "were", "mildly", "decreased", "in", "all", "but", "2", "patients", "on", "second", "presentation", ".", "On", "readmission", ",", "11", "patients", "received", "therapeutic", "heparin", ",", "which", "worsened", "the", "patients", "'", "clinical", "condition", "and", ",", "in", "all", "11", "cases", ",", "decreased", "the", "platelet", "count", "(", "mean", "at", "readmission", ",", "143", "x", "10", "(", "9", ")", "cells", "/", "L", ";", "mean", "nadir", "after", "heparin", "re", "-", "exposure", ",", "39", "x", "10", "(", "9", ")", "cells", "/", "L", ")", ".", "Results", "of", "serologic", "tests", "for", "heparin", "-", "induced", "antibodies", "were", "positive", "in", "all", "patients", ".", "Subsequent", "treatments", "included", "alternative", "anticoagulants", "(", "11", "patients", ")", ",", "thrombolytic", "drugs", "(", "3", "patients", ")", ",", "inferior", "vena", "cava", "filters", "(", "3", "patients", ")", "and", ",", "eventually", ",", "warfarin", "(", "11", "patients", ")", ".", "Three", "patients", "died", ".", "CONCLUSIONS", ":", "Delayed", "-", "onset", "heparin", "-", "induced", "thrombocytopenia", "is", "increasingly", "being", "recognized", ".", "To", "avoid", "disastrous", "outcomes", ",", "physicians", "must", "consider", "heparin", "-", "induced", "thrombocytopenia", "whenever", "a", "recently", "hospitalized", "patient", "returns", "with", "thromboembolism", ";", "therapy", "with", "alternative", "anticoagulants", ",", "not", "heparin", ",", "should", "be", "initiated", "."]], "ner": [[[3, 3, "Chemical"], [10, 10, "Chemical"], [20, 20, "Chemical"], [36, 36, "Chemical"], [64, 64, "Chemical"], [104, 104, "Chemical"], [130, 130, "Chemical"], [152, 152, "Chemical"], [224, 224, "Chemical"], [262, 262, "Chemical"], [283, 283, "Chemical"], [337, 337, "Chemical"], [354, 354, "Chemical"], [373, 373, "Chemical"], [6, 6, "Disease"], [13, 13, "Disease"], [39, 39, "Disease"], [67, 67, "Disease"], [107, 107, "Disease"], [162, 162, "Disease"], [340, 340, "Disease"], [357, 357, "Disease"], [26, 29, "Disease"], [191, 192, "Disease"], [114, 114, "Disease"], [126, 126, "Disease"], [179, 179, "Disease"], [182, 182, "Disease"], [365, 365, "Disease"], [322, 322, "Chemical"]]], "relations": [[[3, 3, 6, 6, "CID"], [3, 3, 13, 13, "CID"], [3, 3, 39, 39, "CID"], [3, 3, 67, 67, "CID"], [3, 3, 107, 107, "CID"], [3, 3, 162, 162, "CID"], [3, 3, 340, 340, "CID"], [3, 3, 357, 357, "CID"], [10, 10, 6, 6, "CID"], [10, 10, 13, 13, "CID"], [10, 10, 39, 39, "CID"], [10, 10, 67, 67, "CID"], [10, 10, 107, 107, "CID"], [10, 10, 162, 162, "CID"], [10, 10, 340, 340, "CID"], [10, 10, 357, 357, "CID"], [20, 20, 6, 6, "CID"], [20, 20, 13, 13, "CID"], [20, 20, 39, 39, "CID"], [20, 20, 67, 67, "CID"], [20, 20, 107, 107, "CID"], [20, 20, 162, 162, "CID"], [20, 20, 340, 340, "CID"], [20, 20, 357, 357, "CID"], [36, 36, 6, 6, "CID"], [36, 36, 13, 13, "CID"], [36, 36, 39, 39, "CID"], [36, 36, 67, 67, "CID"], [36, 36, 107, 107, "CID"], [36, 36, 162, 162, "CID"], [36, 36, 340, 340, "CID"], [36, 36, 357, 357, "CID"], [64, 64, 6, 6, "CID"], [64, 64, 13, 13, "CID"], [64, 64, 39, 39, "CID"], [64, 64, 67, 67, "CID"], [64, 64, 107, 107, "CID"], [64, 64, 162, 162, "CID"], [64, 64, 340, 340, "CID"], [64, 64, 357, 357, "CID"], [104, 104, 6, 6, "CID"], [104, 104, 13, 13, "CID"], [104, 104, 39, 39, "CID"], [104, 104, 67, 67, "CID"], [104, 104, 107, 107, "CID"], [104, 104, 162, 162, "CID"], [104, 104, 340, 340, "CID"], [104, 104, 357, 357, "CID"], [130, 130, 6, 6, "CID"], [130, 130, 13, 13, "CID"], [130, 130, 39, 39, "CID"], [130, 130, 67, 67, "CID"], [130, 130, 107, 107, "CID"], [130, 130, 162, 162, "CID"], [130, 130, 340, 340, "CID"], [130, 130, 357, 357, "CID"], [152, 152, 6, 6, "CID"], [152, 152, 13, 13, "CID"], [152, 152, 39, 39, "CID"], [152, 152, 67, 67, "CID"], [152, 152, 107, 107, "CID"], [152, 152, 162, 162, "CID"], [152, 152, 340, 340, "CID"], [152, 152, 357, 357, "CID"], [224, 224, 6, 6, "CID"], [224, 224, 13, 13, "CID"], [224, 224, 39, 39, "CID"], [224, 224, 67, 67, "CID"], [224, 224, 107, 107, "CID"], [224, 224, 162, 162, "CID"], [224, 224, 340, 340, "CID"], [224, 224, 357, 357, "CID"], [262, 262, 6, 6, "CID"], [262, 262, 13, 13, "CID"], [262, 262, 39, 39, "CID"], [262, 262, 67, 67, "CID"], [262, 262, 107, 107, "CID"], [262, 262, 162, 162, "CID"], [262, 262, 340, 340, "CID"], [262, 262, 357, 357, "CID"], [283, 283, 6, 6, "CID"], [283, 283, 13, 13, "CID"], [283, 283, 39, 39, "CID"], [283, 283, 67, 67, "CID"], [283, 283, 107, 107, "CID"], [283, 283, 162, 162, "CID"], [283, 283, 340, 340, "CID"], [283, 283, 357, 357, "CID"], [337, 337, 6, 6, "CID"], [337, 337, 13, 13, "CID"], [337, 337, 39, 39, "CID"], [337, 337, 67, 67, "CID"], [337, 337, 107, 107, "CID"], [337, 337, 162, 162, "CID"], [337, 337, 340, 340, "CID"], [337, 337, 357, 357, "CID"], [354, 354, 6, 6, "CID"], [354, 354, 13, 13, "CID"], [354, 354, 39, 39, "CID"], [354, 354, 67, 67, "CID"], [354, 354, 107, 107, "CID"], [354, 354, 162, 162, "CID"], [354, 354, 340, 340, "CID"], [354, 354, 357, 357, "CID"], [373, 373, 6, 6, "CID"], [373, 373, 13, 13, "CID"], [373, 373, 39, 39, "CID"], [373, 373, 67, 67, "CID"], [373, 373, 107, 107, "CID"], [373, 373, 162, 162, "CID"], [373, 373, 340, 340, "CID"], [373, 373, 357, 357, "CID"], [3, 3, 26, 29, "CID"], [10, 10, 26, 29, "CID"], [20, 20, 26, 29, "CID"], [36, 36, 26, 29, "CID"], [64, 64, 26, 29, "CID"], [104, 104, 26, 29, "CID"], [130, 130, 26, 29, "CID"], [152, 152, 26, 29, "CID"], [224, 224, 26, 29, "CID"], [262, 262, 26, 29, "CID"], [283, 283, 26, 29, "CID"], [337, 337, 26, 29, "CID"], [354, 354, 26, 29, "CID"], [373, 373, 26, 29, "CID"], [3, 3, 191, 192, "CID"], [10, 10, 191, 192, "CID"], [20, 20, 191, 192, "CID"], [36, 36, 191, 192, "CID"], [64, 64, 191, 192, "CID"], [104, 104, 191, 192, "CID"], [130, 130, 191, 192, "CID"], [152, 152, 191, 192, "CID"], [224, 224, 191, 192, "CID"], [262, 262, 191, 192, "CID"], [283, 283, 191, 192, "CID"], [337, 337, 191, 192, "CID"], [354, 354, 191, 192, "CID"], [373, 373, 191, 192, "CID"]]], "clusters": [], "translated": "迟发性<0>肝素</0>诱导的<14>血小板减少症</14>。背景：<1>肝素</1>诱发的<15>血小板减少症</15>在<2>肝素</2>暴露后5至12天出现，伴有或不伴有<22>动脉或静脉血栓栓塞</22>。对<3>肝素</3>引起的<16>血小板减少症</16>的延迟识别和治疗导致患者预后不佳。目的：描述并提高对<4>肝素</4>诱导的<17>血小板减少症</17>的发作或表现延迟的临床情况的认识。设计：回顾性病例系列。地点：三个大型城市医院（具有积极的心血管外科项目）。患者：14名在3年期间就诊的患者，其中<5>肝素</5>引起的<18>血小板减少症</18>在延迟就诊时变得明显，并伴有<24>血栓栓塞</24>并发症。测量：血小板计数、客观确定的<25>血栓栓塞症</25>的发生、<6>肝素</6>诱导的血小板因子4抗体检测的结果，以及结果。结果：患者在住院后回家，其中包括<7>肝素</7>暴露-在大多数情况下，未发现<19>血小板减少</19>，仅返回医院（中位数，第14天）伴有<26>血栓栓塞</26>并发症。<27>血栓栓塞</27>为静脉（12名患者，7名<23>肺栓塞</23>）或动脉（4名患者）或两者。除2名第二次就诊的患者外，所有患者的血小板计数均轻度下降。再入院时，11名患者接受了治疗性<8>肝素</8>，这使患者的临床状况恶化，并且在所有11名患者中，血小板计数均降低（再入院时平均143 x 10(9)个细胞/L；平均<9>肝素</9>再暴露后的最低点，39 x 10(9)个细胞/L)。<10>肝素</10>诱导抗体的血清学检测结果在所有患者中均呈阳性。随后的治疗包括替代抗凝剂（11名患者）、溶栓药物（3名患者）、下腔静脉滤器（3名患者）以及最终<29>华法林</29>（11名患者）。三名患者死亡。结论：迟发性<11>肝素</11>诱发的<20>血小板减少症</20>越来越受到重视。为避免灾难性后果，每当最近住院的患者因<28>血栓栓塞</28>返回时，医生必须考虑<12>肝素</12>诱导的<21>血小板减少症</21>；应开始使用替代抗凝剂治疗，而不是<13>肝素</13>。", "revised": true}
{"doc_key": "11009181", "sentences": [["Apomorphine", ":", "an", "underutilized", "therapy", "for", "Parkinson", "'s", "disease", ".", "Apomorphine", "was", "the", "first", "dopaminergic", "drug", "ever", "used", "to", "treat", "symptoms", "of", "Parkinson", "'s", "disease", ".", "While", "powerful", "antiparkinsonian", "effects", "had", "been", "observed", "as", "early", "as", "1951", ",", "the", "potential", "of", "treating", "fluctuating", "Parkinson", "'s", "disease", "by", "subcutaneous", "administration", "of", "apomorphine", "has", "only", "recently", "become", "the", "subject", "of", "systematic", "study", ".", "A", "number", "of", "small", "scale", "clinical", "trials", "have", "unequivocally", "shown", "that", "intermittent", "subcutaneous", "apomorphine", "injections", "produce", "antiparkinsonian", "benefit", "close", "if", "not", "identical", "to", "that", "seen", "with", "levodopa", "and", "that", "apomorphine", "rescue", "injections", "can", "reliably", "revert", "off", "-", "periods", "even", "in", "patients", "with", "complex", "on", "-", "off", "motor", "swings", ".", "Continuous", "subcutaneous", "apomorphine", "infusions", "can", "reduce", "daily", "off", "-", "time", "by", "more", "than", "50", "%", "in", "this", "group", "of", "patients", ",", "which", "appears", "to", "be", "a", "stronger", "effect", "than", "that", "generally", "seen", "with", "add", "-", "on", "therapy", "with", "oral", "dopamine", "agonists", "or", "COMT", "inhibitors", ".", "Extended", "follow", "-", "up", "studies", "of", "up", "to", "8", "years", "have", "demonstrated", "long", "-", "term", "persistence", "of", "apomorphine", "efficacy", ".", "In", "addition", ",", "there", "is", "convincing", "clinical", "evidence", "that", "monotherapy", "with", "continuous", "subcutaneous", "apomorphine", "infusions", "is", "associated", "with", "marked", "reductions", "of", "preexisting", "levodopa", "-", "induced", "dyskinesias", ".", "The", "main", "side", "effects", "of", "subcutaneous", "apomorphine", "treatment", "are", "related", "to", "cutaneous", "tolerability", "problems", ",", "whereas", "sedation", "and", "psychiatric", "complications", "play", "a", "lesser", "role", ".", "Given", "the", "marked", "degree", "of", "efficacy", "of", "subcutaneous", "apomorphine", "treatment", "in", "fluctuating", "Parkinson", "'s", "disease", ",", "this", "approach", "seems", "to", "deserve", "more", "widespread", "clinical", "use", "."]], "ner": [[[87, 87, "Chemical"], [197, 197, "Chemical"], [200, 200, "Disease"], [0, 0, "Chemical"], [10, 10, "Chemical"], [50, 50, "Chemical"], [74, 74, "Chemical"], [90, 90, "Chemical"], [112, 112, "Chemical"], [172, 172, "Chemical"], [188, 188, "Chemical"], [208, 208, "Chemical"], [235, 235, "Chemical"], [6, 8, "Disease"], [22, 24, "Disease"], [43, 45, "Disease"], [239, 241, "Disease"], [220, 220, "Disease"], [149, 149, "Chemical"]]], "relations": [[[87, 87, 200, 200, "CID"], [197, 197, 200, 200, "CID"]]], "clusters": [], "translated": " <3>阿泊吗啡</3>：一种未被充分利用的<13>帕金森氏病</13>治疗方法。 <4>阿泊吗啡</4>是第一种用于治疗<14>帕金森氏病</14>症状的多巴胺能药物。虽然早在1951年就观察到了其强大的抗帕金森氏病作用，但通过皮下注射<5>阿泊吗啡</5>治疗波动性<15>帕金森氏病</15>的潜力直到最近才成为系统研究的主题。许多规模较小的临床试验明确表明，间歇性皮下注射<6>阿泊吗啡</6>与<0>左旋多巴</0>和<7>阿泊吗啡</7>所见效果接近，即使不完全相同。挽救注射可以可靠地恢复关闭期，甚至能够在具有复杂的运动起伏的患者中产生作用。连续皮下注射<8>阿泊吗啡</8>可使这组患者的每日停药时间缩短50%以上，这似乎比通过口服<18>多巴胺受体激动剂</18>或COMT抑制剂进行附加疗法的效果更强。长达8年的追踪研究证实了<9>阿泊吗啡</9>的长期疗效。此外，有令人信服的临床证据表明，使用连续皮下注射<10>阿泊吗啡</10>治疗单独的运用是可以显着减少先前存在的<1>左旋多巴</1>-引起的<2>运动障碍</2>。皮下注射<11>阿泊吗啡</11>治疗的主要副作用与皮肤耐受性问题有关，而镇静和<17>精神</17>并发症的作用较小。鉴于皮下注射<12>阿泊吗啡</12>治疗波动性<16>帕金森氏病</16>的显着疗效，这种方法似乎应得到更广泛的临床应用。", "revised": true}
{"doc_key": "14648024", "sentences": [["All", "-", "trans", "-", "retinoic", "acid", "-", "induced", "erythema", "nodosum", "in", "patients", "with", "acute", "promyelocytic", "leukemia", ".", "Erythema", "nodosum", "associated", "with", "all", "-", "trans", "-", "retinoic", "acid", "(", "ATRA", ")", "for", "acute", "promyelocytic", "leukemia", "(", "APL", ")", "is", "very", "rare", ".", "We", "describe", "four", "patients", "with", "classic", "APL", "who", "developed", "erythema", "nodosum", "during", "ATRA", "therapy", ".", "Fever", "and", "subsequent", "multiple", "painful", "erythematous", "nodules", "over", "extremities", "developed", "on", "D11", ",", "D16", ",", "D17", ",", "and", "D19", ",", "respectively", ",", "after", "ATRA", "therapy", ".", "The", "skin", "biopsy", "taken", "from", "each", "patient", "was", "consistent", "with", "erythema", "nodosum", ".", "All", "patients", "received", "short", "course", "of", "steroids", ".", "Fever", "subsided", "rapidly", "and", "the", "skin", "lesions", "regressed", "completely", ".", "All", "patients", "achieved", "complete", "remission", "without", "withdrawal", "of", "ATRA", ".", "ATRA", "seemed", "to", "be", "the", "most", "possible", "etiology", "of", "erythema", "nodosum", "in", "our", "patients", ".", "Short", "-", "term", "use", "of", "steroid", "is", "very", "effective", "in", "ATRA", "-", "induced", "erythema", "nodosum", "."]], "ner": [[[0, 5, "Chemical"], [21, 26, "Chemical"], [28, 28, "Chemical"], [53, 53, "Chemical"], [79, 79, "Chemical"], [121, 121, "Chemical"], [123, 123, "Chemical"], [148, 148, "Chemical"], [8, 9, "Disease"], [17, 18, "Disease"], [50, 51, "Disease"], [61, 62, "Disease"], [92, 93, "Disease"], [132, 133, "Disease"], [151, 152, "Disease"], [56, 56, "Disease"], [103, 103, "Disease"], [13, 15, "Disease"], [31, 33, "Disease"], [35, 35, "Disease"], [47, 47, "Disease"], [60, 60, "Disease"], [101, 101, "Chemical"], [143, 143, "Chemical"]]], "relations": [[[0, 5, 8, 9, "CID"], [0, 5, 17, 18, "CID"], [0, 5, 50, 51, "CID"], [0, 5, 61, 62, "CID"], [0, 5, 92, 93, "CID"], [0, 5, 132, 133, "CID"], [0, 5, 151, 152, "CID"], [21, 26, 8, 9, "CID"], [21, 26, 17, 18, "CID"], [21, 26, 50, 51, "CID"], [21, 26, 61, 62, "CID"], [21, 26, 92, 93, "CID"], [21, 26, 132, 133, "CID"], [21, 26, 151, 152, "CID"], [28, 28, 8, 9, "CID"], [28, 28, 17, 18, "CID"], [28, 28, 50, 51, "CID"], [28, 28, 61, 62, "CID"], [28, 28, 92, 93, "CID"], [28, 28, 132, 133, "CID"], [28, 28, 151, 152, "CID"], [53, 53, 8, 9, "CID"], [53, 53, 17, 18, "CID"], [53, 53, 50, 51, "CID"], [53, 53, 61, 62, "CID"], [53, 53, 92, 93, "CID"], [53, 53, 132, 133, "CID"], [53, 53, 151, 152, "CID"], [79, 79, 8, 9, "CID"], [79, 79, 17, 18, "CID"], [79, 79, 50, 51, "CID"], [79, 79, 61, 62, "CID"], [79, 79, 92, 93, "CID"], [79, 79, 132, 133, "CID"], [79, 79, 151, 152, "CID"], [121, 121, 8, 9, "CID"], [121, 121, 17, 18, "CID"], [121, 121, 50, 51, "CID"], [121, 121, 61, 62, "CID"], [121, 121, 92, 93, "CID"], [121, 121, 132, 133, "CID"], [121, 121, 151, 152, "CID"], [123, 123, 8, 9, "CID"], [123, 123, 17, 18, "CID"], [123, 123, 50, 51, "CID"], [123, 123, 61, 62, "CID"], [123, 123, 92, 93, "CID"], [123, 123, 132, 133, "CID"], [123, 123, 151, 152, "CID"], [148, 148, 8, 9, "CID"], [148, 148, 17, 18, "CID"], [148, 148, 50, 51, "CID"], [148, 148, 61, 62, "CID"], [148, 148, 92, 93, "CID"], [148, 148, 132, 133, "CID"], [148, 148, 151, 152, "CID"], [0, 5, 56, 56, "CID"], [0, 5, 103, 103, "CID"], [21, 26, 56, 56, "CID"], [21, 26, 103, 103, "CID"], [28, 28, 56, 56, "CID"], [28, 28, 103, 103, "CID"], [53, 53, 56, 56, "CID"], [53, 53, 103, 103, "CID"], [79, 79, 56, 56, "CID"], [79, 79, 103, 103, "CID"], [121, 121, 56, 56, "CID"], [121, 121, 103, 103, "CID"], [123, 123, 56, 56, "CID"], [123, 123, 103, 103, "CID"], [148, 148, 56, 56, "CID"], [148, 148, 103, 103, "CID"]]], "clusters": [], "translated": "<0>全反式维甲酸</0>诱发<8>结节性红斑</8>在<17>急性早幼粒细胞白血病</17>患者中相当罕见。与<1>全反式维甲酸</1>（<2>ATRA</2>）相关的<18>急性早幼粒细胞白血病</18>（<19>APL</19>）<9>结节性红斑</9>非常罕见。我们描述了四名典型<20>APL</20>患者，他们在<3>ATRA</3>治疗期间出现了<10>结节性红斑</10>。D11、D16、D17和D19，在<4>ATRA</4>治疗后分别出现了<15>发热</15>和随后的多发性<11>红斑结节</11><21>疼痛</21>。每位患者的皮肤活检均符合<12>结节性红斑</12>。所有患者均接受了短期<22>类固醇</22>疗程。发现<16>发热</16>很快消退，皮肤病变完全消失。所有患者均在未停用<5>ATRA</5>的情况下获得了完全缓解。在我们的患者中，<6>ATRA</6>似乎是最可能引起<13>结节性红斑</13>的病因。短期使用<23>类固醇</23>对于<7>ATRA</7>诱发的<14>结节性红斑</14>非常有效。", "revised": true}
{"doc_key": "8988571", "sentences": [["Fatal", "excited", "delirium", "following", "cocaine", "use", ":", "epidemiologic", "findings", "provide", "new", "evidence", "for", "mechanisms", "of", "cocaine", "toxicity", ".", "We", "describe", "an", "outbreak", "of", "deaths", "from", "cocaine", "-", "induced", "excited", "delirium", "(", "EDDs", ")", "in", "Dade", "County", ",", "Florida", "between", "1979", "and", "1990", ".", "From", "a", "registry", "of", "all", "cocaine", "-", "related", "deaths", "in", "Dade", "County", ",", "Florida", ",", "from", "1969", "-", "1990", ",", "58", "EDDs", "were", "compared", "with", "125", "victims", "of", "accidental", "cocaine", "overdose", "without", "excited", "delirium", ".", "Compared", "with", "controls", ",", "EDDs", "were", "more", "frequently", "black", ",", "male", ",", "and", "younger", ".", "They", "were", "less", "likely", "to", "have", "a", "low", "body", "mass", "index", ",", "and", "more", "likely", "to", "have", "died", "in", "police", "custody", ",", "to", "have", "received", "medical", "treatment", "immediately", "before", "death", ",", "to", "have", "survived", "for", "a", "longer", "period", ",", "to", "have", "developed", "hyperthermia", ",", "and", "to", "have", "died", "in", "summer", "months", ".", "EDDs", "had", "concentrations", "of", "cocaine", "and", "benzoylecgonine", "in", "autopsy", "blood", "that", "were", "similar", "to", "those", "for", "controls", ".", "The", "epidemiologic", "findings", "are", "most", "consistent", "with", "the", "hypothesis", "that", "chronic", "cocaine", "use", "disrupts", "dopaminergic", "function", "and", ",", "when", "coupled", "with", "recent", "cocaine", "use", ",", "may", "precipitate", "agitation", ",", "delirium", ",", "aberrant", "thermoregulation", ",", "rhabdomyolysis", ",", "and", "sudden", "death", "."]], "ner": [[[4, 4, "Chemical"], [15, 15, "Chemical"], [25, 25, "Chemical"], [48, 48, "Chemical"], [72, 72, "Chemical"], [149, 149, "Chemical"], [174, 174, "Chemical"], [185, 185, "Chemical"], [2, 2, "Disease"], [29, 29, "Disease"], [31, 31, "Disease"], [64, 64, "Disease"], [76, 76, "Disease"], [82, 82, "Disease"], [145, 145, "Disease"], [192, 192, "Disease"], [197, 197, "Disease"], [200, 201, "Disease"], [151, 151, "Chemical"], [16, 16, "Disease"], [73, 73, "Disease"], [135, 135, "Disease"], [190, 190, "Disease"]]], "relations": [[[4, 4, 2, 2, "CID"], [4, 4, 29, 29, "CID"], [4, 4, 31, 31, "CID"], [4, 4, 64, 64, "CID"], [4, 4, 76, 76, "CID"], [4, 4, 82, 82, "CID"], [4, 4, 145, 145, "CID"], [4, 4, 192, 192, "CID"], [15, 15, 2, 2, "CID"], [15, 15, 29, 29, "CID"], [15, 15, 31, 31, "CID"], [15, 15, 64, 64, "CID"], [15, 15, 76, 76, "CID"], [15, 15, 82, 82, "CID"], [15, 15, 145, 145, "CID"], [15, 15, 192, 192, "CID"], [25, 25, 2, 2, "CID"], [25, 25, 29, 29, "CID"], [25, 25, 31, 31, "CID"], [25, 25, 64, 64, "CID"], [25, 25, 76, 76, "CID"], [25, 25, 82, 82, "CID"], [25, 25, 145, 145, "CID"], [25, 25, 192, 192, "CID"], [48, 48, 2, 2, "CID"], [48, 48, 29, 29, "CID"], [48, 48, 31, 31, "CID"], [48, 48, 64, 64, "CID"], [48, 48, 76, 76, "CID"], [48, 48, 82, 82, "CID"], [48, 48, 145, 145, "CID"], [48, 48, 192, 192, "CID"], [72, 72, 2, 2, "CID"], [72, 72, 29, 29, "CID"], [72, 72, 31, 31, "CID"], [72, 72, 64, 64, "CID"], [72, 72, 76, 76, "CID"], [72, 72, 82, 82, "CID"], [72, 72, 145, 145, "CID"], [72, 72, 192, 192, "CID"], [149, 149, 2, 2, "CID"], [149, 149, 29, 29, "CID"], [149, 149, 31, 31, "CID"], [149, 149, 64, 64, "CID"], [149, 149, 76, 76, "CID"], [149, 149, 82, 82, "CID"], [149, 149, 145, 145, "CID"], [149, 149, 192, 192, "CID"], [174, 174, 2, 2, "CID"], [174, 174, 29, 29, "CID"], [174, 174, 31, 31, "CID"], [174, 174, 64, 64, "CID"], [174, 174, 76, 76, "CID"], [174, 174, 82, 82, "CID"], [174, 174, 145, 145, "CID"], [174, 174, 192, 192, "CID"], [185, 185, 2, 2, "CID"], [185, 185, 29, 29, "CID"], [185, 185, 31, 31, "CID"], [185, 185, 64, 64, "CID"], [185, 185, 76, 76, "CID"], [185, 185, 82, 82, "CID"], [185, 185, 145, 145, "CID"], [185, 185, 192, 192, "CID"], [4, 4, 197, 197, "CID"], [15, 15, 197, 197, "CID"], [25, 25, 197, 197, "CID"], [48, 48, 197, 197, "CID"], [72, 72, 197, 197, "CID"], [149, 149, 197, 197, "CID"], [174, 174, 197, 197, "CID"], [185, 185, 197, 197, "CID"], [4, 4, 200, 201, "CID"], [15, 15, 200, 201, "CID"], [25, 25, 200, 201, "CID"], [48, 48, 200, 201, "CID"], [72, 72, 200, 201, "CID"], [149, 149, 200, 201, "CID"], [174, 174, 200, 201, "CID"], [185, 185, 200, 201, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>使用后致死性兴奋<8>谵妄</8>：流行病学发现为<1>可卡因</1> <19>毒性</19>机制提供了新证据。我们描述了1979年至1990年间佛罗里达州戴德县因<2>可卡因</2>诱发的兴奋性<9>谵妄</9>（<10>EDDs</10>）而导致的死亡暴发。从1969年至1990年佛罗里达州戴德县所有<3>可卡因</3>相关死亡的登记处，将58名<11>EDD</11>与125名意外<4>可卡因</4>过量<20>无兴奋</20><12>谵妄</12>受害者进行了比较。与对照组相比，<13>EDDs</13>更常见于黑人、男性和年轻人。他们不太可能有低体重指数，更有可能在警察拘留期间死亡，在死亡前立即接受治疗，存活较长时间，发生<21>体温过高</21>，并在夏季死亡。<14>EDDs</14>尸检血液中<5>可卡因</5>和<18>苯甲酰爱康宁</18>的浓度与对照组相似。流行病学研究结果与长期<6>可卡因</6>使用会破坏多巴胺能功能的假设最为一致，并且当与近期<7>可卡因</7>使用相结合时，可能会导致<22>激越</22>、<15>谵妄</15>、体温调节异常、<16>横纹肌溶解</16>和<17>猝死</17>。", "revised": true}
{"doc_key": "11858397", "sentences": [["Torsade", "de", "pointes", "induced", "by", "metoclopramide", "in", "an", "elderly", "woman", "with", "preexisting", "complete", "left", "bundle", "branch", "block", ".", "There", "is", "a", "growing", "list", "of", "drugs", "implicated", "in", "acquired", "long", "QT", "syndrome", "and", "torsade", "de", "pointes", ".", "However", ",", "the", "torsadogenic", "potential", "of", "metoclopramide", ",", "a", "commonly", "used", "antiemetic", "and", "prokinetic", "drug", ",", "has", "not", "been", "reported", "in", "the", "literature", ",", "despite", "its", "chemical", "similarity", "to", "procainamide", ".", "We", "report", "on", "a", "92", "-", "year", "-", "old", "woman", "with", "preexisting", "complete", "left", "bundle", "branch", "block", "who", "developed", "torsade", "de", "pointes", "after", "intravenous", "and", "oral", "administration", "of", "metoclopramide", ".", "This", "patient", "also", "developed", "torsade", "de", "pointes", "when", "cisapride", "and", "erythromycin", "were", "given", "simultaneously", ".", "These", "two", "episodes", "were", "suppressed", "successfully", "after", "discontinuing", "the", "offending", "drugs", "and", "administering", "class", "IB", "drugs", ".", "This", "is", "the", "first", "documentation", "that", "metoclopramide", "provokes", "torsade", "de", "pointes", "clinically", ".", "Metoclopramide", "should", "be", "used", "cautiously", "in", "patients", "with", "a", "risk", "of", "torsade", "de", "pointes", "."]], "ner": [[[5, 5, "Chemical"], [42, 42, "Chemical"], [95, 95, "Chemical"], [135, 135, "Chemical"], [142, 142, "Chemical"], [0, 2, "Disease"], [32, 34, "Disease"], [86, 88, "Disease"], [101, 103, "Disease"], [137, 139, "Disease"], [153, 155, "Disease"], [105, 105, "Chemical"], [107, 107, "Chemical"], [65, 65, "Chemical"], [13, 16, "Disease"], [80, 83, "Disease"], [28, 30, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 32, 34, "CID"], [5, 5, 86, 88, "CID"], [5, 5, 101, 103, "CID"], [5, 5, 137, 139, "CID"], [5, 5, 153, 155, "CID"], [42, 42, 0, 2, "CID"], [42, 42, 32, 34, "CID"], [42, 42, 86, 88, "CID"], [42, 42, 101, 103, "CID"], [42, 42, 137, 139, "CID"], [42, 42, 153, 155, "CID"], [95, 95, 0, 2, "CID"], [95, 95, 32, 34, "CID"], [95, 95, 86, 88, "CID"], [95, 95, 101, 103, "CID"], [95, 95, 137, 139, "CID"], [95, 95, 153, 155, "CID"], [135, 135, 0, 2, "CID"], [135, 135, 32, 34, "CID"], [135, 135, 86, 88, "CID"], [135, 135, 101, 103, "CID"], [135, 135, 137, 139, "CID"], [135, 135, 153, 155, "CID"], [142, 142, 0, 2, "CID"], [142, 142, 32, 34, "CID"], [142, 142, 86, 88, "CID"], [142, 142, 101, 103, "CID"], [142, 142, 137, 139, "CID"], [142, 142, 153, 155, "CID"], [105, 105, 0, 2, "CID"], [105, 105, 32, 34, "CID"], [105, 105, 86, 88, "CID"], [105, 105, 101, 103, "CID"], [105, 105, 137, 139, "CID"], [105, 105, 153, 155, "CID"], [107, 107, 0, 2, "CID"], [107, 107, 32, 34, "CID"], [107, 107, 86, 88, "CID"], [107, 107, 101, 103, "CID"], [107, 107, 137, 139, "CID"], [107, 107, 153, 155, "CID"]]], "clusters": [], "translated": " <5>尖端扭转型室性心动过速</5> 由<0>甲氧氯普胺</0>诱发的一名老年妇女，该妇女先前存在完全性<14>左束支传导阻滞</14>。越来越多的药物与获得性<16>长QT综合征</16>和<6>尖端扭转型室速</6>有关。然而，<1>甲氧氯普胺</1>是一种常用的止吐和促运动药物，尽管其与<13>普鲁卡因胺</13>的化学相似，但尚未在文献中报道其致扭转作用的可能性。我们报告了一名92岁的女性，她之前患有完全性<15>左束支传导阻滞</15>，在静脉和口服<2>甲氧氯普胺</2>后发生了<7>尖端扭转型室性心动过速</7>。当同时给予<11>西沙必利</11>和<12>红霉素</12>时，该患者也出现了<8>尖端扭转型室速</8>。在停用违规药物并给予IB类药物后，这两次发作被成功抑制。这是<3>甲氧氯普胺</3>在临床上第一次被报告引起<9>尖端扭转型室性心动过速</9>。应谨慎使用<4>甲氧氯普胺</4>来治疗存在<10>尖端扭转型室速</10>风险的患者。", "revised": true}
{"doc_key": "16225977", "sentences": [["Amisulpride", "related", "tic", "-", "like", "symptoms", "in", "an", "adolescent", "schizophrenic", ".", "Tic", "disorders", "can", "be", "effectively", "treated", "by", "atypical", "antipsychotics", "such", "as", "risperidone", ",", "olanzapine", "and", "ziprasidone", ".", "However", ",", "there", "are", "two", "case", "reports", "that", "show", "tic", "-", "like", "symptoms", ",", "including", "motor", "and", "phonic", "variants", ",", "occurring", "during", "treatment", "with", "quetiapine", "or", "clozapine", ".", "We", "present", "a", "15", "-", "year", "-", "old", "girl", "schizophrenic", "who", "developed", "frequent", "involuntary", "eye", "-", "blinking", "movements", "after", "5", "months", "of", "amisulpride", "treatment", "(", "1000", "mg", "per", "day", ")", ".", "The", "tic", "-", "like", "symptoms", "resolved", "completely", "after", "we", "reduced", "the", "dose", "of", "amisulpride", "down", "to", "800", "mg", "per", "day", ".", "However", ",", "her", "psychosis", "recurred", "after", "the", "dose", "reduction", ".", "We", "then", "placed", "her", "on", "an", "additional", "100", "mg", "per", "day", "of", "quetiapine", ".", "She", "has", "been", "in", "complete", "remission", "under", "the", "combined", "medications", "for", "more", "than", "one", "year", "and", "maintains", "a", "fair", "role", "function", ".", "No", "more", "tic", "-", "like", "symptoms", "or", "other", "side", "effects", "have", "been", "reported", ".", "Together", "with", "previously", "reported", "cases", ",", "our", "patient", "suggests", "that", "tic", "-", "like", "symptoms", "might", "occur", "in", "certain", "vulnerable", "individuals", "during", "treatment", "with", "atypical", "antipsychotics", "such", "as", "quetiapine", ",", "clozapine", ",", "or", "amisulpride", "."]], "ner": [[[0, 0, "Chemical"], [78, 78, "Chemical"], [100, 100, "Chemical"], [200, 200, "Chemical"], [2, 5, "Disease"], [11, 12, "Disease"], [37, 40, "Disease"], [88, 91, "Disease"], [156, 159, "Disease"], [178, 181, "Disease"], [9, 9, "Disease"], [65, 65, "Disease"], [69, 73, "Disease"], [111, 111, "Disease"], [22, 22, "Chemical"], [24, 24, "Chemical"], [26, 26, "Chemical"], [52, 52, "Chemical"], [130, 130, "Chemical"], [195, 195, "Chemical"], [54, 54, "Chemical"], [197, 197, "Chemical"]]], "relations": [[[0, 0, 2, 5, "CID"], [0, 0, 11, 12, "CID"], [0, 0, 37, 40, "CID"], [0, 0, 88, 91, "CID"], [0, 0, 156, 159, "CID"], [0, 0, 178, 181, "CID"], [78, 78, 2, 5, "CID"], [78, 78, 11, 12, "CID"], [78, 78, 37, 40, "CID"], [78, 78, 88, 91, "CID"], [78, 78, 156, 159, "CID"], [78, 78, 178, 181, "CID"], [100, 100, 2, 5, "CID"], [100, 100, 11, 12, "CID"], [100, 100, 37, 40, "CID"], [100, 100, 88, 91, "CID"], [100, 100, 156, 159, "CID"], [100, 100, 178, 181, "CID"], [200, 200, 2, 5, "CID"], [200, 200, 11, 12, "CID"], [200, 200, 37, 40, "CID"], [200, 200, 88, 91, "CID"], [200, 200, 156, 159, "CID"], [200, 200, 178, 181, "CID"]]], "clusters": [], "translated": " <0>氨磺必利</0>与<4>抽动样症状</4>相关的青少年<10>精神分裂症</10>。 <5>抽动障碍</5>可以通过<14>利培酮</14>、<15>奥氮平</15>和<16>齐拉西酮</16>等非典型抗精神病药有效治疗。然而，有两例病例报告显示<6>抽动样症状</6>，包括运动和发音变异，发生在<17>喹硫平</17>或<20>氯氮平</20>治疗期间。我们介绍了一名15岁的女孩<11>精神分裂症</11>，她在每天服用<1>氨磺必利</1> 1000毫克的治疗5个月后出现频繁的<12>不自主的眨眼运动</12>。在将<2>氨磺必利</2>的剂量降至每天800毫克后，<7>抽动样症状</7>完全消失。然而，她的<13>精神病</13>在剂量减少后复发。之后，我们让她每天额外服用100毫克的<18>喹硫平</18>。联合用药一年多，病情完全缓解，功能正常。没有更多的<8>抽动样症状</8>或其他副作用的报道。结合之前报道的病例，我们的患者表明，某些易受伤害的个体在使用非典型抗精神病药（例如<19>喹硫平</19>、<21>氯氮平</21>）治疗期间可能会出现<9>抽动样症状</9>，或者<3>氨磺必利</3>。", "revised": true}
{"doc_key": "12852481", "sentences": [["Comparison", "of", "developmental", "toxicology", "of", "aspirin", "(", "acetylsalicylic", "acid", ")", "in", "rats", "using", "selected", "dosing", "paradigms", ".", "BACKGROUND", ":", "Analysis", "of", "the", "literature", "for", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "suggests", "that", "a", "low", "incidence", "of", "developmental", "anomalies", "occurs", "in", "rats", "given", "NSAIDs", "on", "specific", "days", "during", "organogenesis", ".", "Aspirin", "(", "acetylsalicylic", "acid", "[", "ASA", "]", ")", ",", "an", "irreversible", "cyclooxygenase", "1", "and", "2", "inhibitor", ",", "induces", "developmental", "anomalies", "when", "administered", "to", "Wistar", "rats", "on", "gestational", "day", "(", "GD", ")", "9", ",", "10", ",", "or", "11", "(", "Kimmel", "CA", ",", "Wilson", "JG", ",", "Schumacher", "HJ", ".", "Teratology", "4", ":", "15", "-", "24", ",", "1971", ")", ".", "There", "are", "no", "published", "ASA", "studies", "using", "the", "multiple", "dosing", "paradigm", "of", "GDs", "6", "to", "17", ".", "Objectives", "of", "the", "current", "study", "were", "to", "compare", "results", "between", "Sprague", "-", "Dawley", "(", "SD", ")", "and", "Wistar", "strains", "when", "ASA", "is", "administered", "on", "GD", "9", ",", "10", ",", "or", "11", ";", "to", "compare", "the", "malformation", "patterns", "following", "single", "and", "multiple", "dosings", "during", "organogenesis", "in", "SD", "rats", ";", "and", "to", "test", "the", "hypothesis", "that", "maternal", "gastrointestinal", "toxicity", "confounds", "the", "detection", "of", "low", "incidence", "malformations", "with", "ASA", "when", "a", "multiple", "dosing", "paradigm", "is", "used", ".", "METHODS", ":", "ASA", "was", "administered", "as", "a", "single", "dose", "on", "GD", "9", "(", "0", ",", "250", ",", "500", ",", "or", "625", "mg", "/", "kg", ")", ",", "10", "(", "0", ",", "500", ",", "625", ",", "or", "750", "mg", "/", "kg", ")", ",", "or", "11", "(", "0", ",", "500", ",", "750", ",", "or", "1000", "mg", "/", "kg", ")", "and", "from", "GD", "6", "to", "GD", "17", "(", "0", ",", "50", ",", "125", ",", "or", "250", "mg", "/", "kg", "a", "day", ")", "in", "the", "multiple", "dose", "study", "to", "SD", "rats", ".", "Animals", "were", "killed", "on", "GD", "21", ",", "and", "fetuses", "were", "examined", "viscerally", ".", "RESULTS", ":", "The", "literature", "evaluation", "suggested", "that", "NSAIDs", "induce", "ventricular", "septal", "defects", "(", "VSDs", ")", "and", "midline", "defects", "(", "MDs", ")", "in", "rats", "and", "diaphragmatic", "hernia", "(", "DH", ")", ",", "MDs", ",", "and", "VSDs", "in", "rabbits", "(", "Cook", "JC", "et", "al", ".", ",", "2003", ")", ";", "hence", ",", "the", "present", "study", "focused", "on", "these", "malformations", ",", "even", "though", "ASA", "induces", "several", "other", "low", "-", "incidence", "malformations", ".", "In", "single", "dose", "studies", ",", "DH", ",", "MD", ",", "and", "VSD", "were", "induced", "on", "GDs", "9", "and", "10", ".", "VSD", "also", "was", "noted", "following", "treatment", "on", "GD", "11", ".", "In", "contrast", ",", "DH", "and", "MD", "were", "noted", "in", "the", "multiple", "dose", "study", "design", "only", "in", "the", "high", "-", "dose", "group", ",", "and", "VSD", "was", "noted", "across", "all", "dose", "groups", ".", "CONCLUSIONS", ":", "High", "concordance", "in", "major", "developmental", "anomalies", "between", "Wistar", "and", "SD", "rats", "were", "noted", "with", "the", "exception", "of", "VSD", "in", "the", "SD", "rats", "and", "hydrocephalus", "in", "the", "Wistar", "rats", ".", "Variations", "and", "malformations", "were", "similar", "when", "ASA", "was", "administered", "as", "a", "single", "dose", "or", "during", "the", "period", "of", "organogenesis", "(", "GDs", "6", "to", "17", ")", ".", "It", "was", "also", "evident", "that", ",", "by", "titrating", "the", "dose", "to", "achieve", "a", "maximum", "tolerated", "dose", ",", "malformations", "that", "normally", "occur", "at", "low", "incidence", ",", "as", "reported", "from", "previous", "single", "dose", "studies", ",", "could", "also", "be", "induced", "with", "ASA", "given", "at", "multiple", "doses", "."]], "ner": [[[5, 5, "Chemical"], [7, 8, "Chemical"], [51, 51, "Chemical"], [53, 54, "Chemical"], [56, 56, "Chemical"], [112, 112, "Chemical"], [145, 145, "Chemical"], [190, 190, "Chemical"], [201, 201, "Chemical"], [357, 357, "Chemical"], [463, 463, "Chemical"], [521, 521, "Chemical"], [38, 39, "Disease"], [69, 70, "Disease"], [188, 188, "Disease"], [353, 353, "Disease"], [364, 364, "Disease"], [432, 433, "Disease"], [459, 459, "Disease"], [500, 500, "Disease"], [308, 310, "Disease"], [312, 312, "Disease"], [332, 332, "Disease"], [376, 376, "Disease"], [385, 385, "Disease"], [418, 418, "Disease"], [445, 445, "Disease"], [323, 324, "Disease"], [326, 326, "Disease"], [371, 371, "Disease"], [398, 398, "Disease"], [180, 181, "Disease"], [315, 316, "Disease"], [318, 318, "Disease"], [329, 329, "Disease"], [373, 373, "Disease"], [400, 400, "Disease"], [451, 451, "Disease"]]], "relations": [[[5, 5, 38, 39, "CID"], [5, 5, 69, 70, "CID"], [5, 5, 188, 188, "CID"], [5, 5, 353, 353, "CID"], [5, 5, 364, 364, "CID"], [5, 5, 432, 433, "CID"], [5, 5, 459, 459, "CID"], [5, 5, 500, 500, "CID"], [7, 8, 38, 39, "CID"], [7, 8, 69, 70, "CID"], [7, 8, 188, 188, "CID"], [7, 8, 353, 353, "CID"], [7, 8, 364, 364, "CID"], [7, 8, 432, 433, "CID"], [7, 8, 459, 459, "CID"], [7, 8, 500, 500, "CID"], [51, 51, 38, 39, "CID"], [51, 51, 69, 70, "CID"], [51, 51, 188, 188, "CID"], [51, 51, 353, 353, "CID"], [51, 51, 364, 364, "CID"], [51, 51, 432, 433, "CID"], [51, 51, 459, 459, "CID"], [51, 51, 500, 500, "CID"], [53, 54, 38, 39, "CID"], [53, 54, 69, 70, "CID"], [53, 54, 188, 188, "CID"], [53, 54, 353, 353, "CID"], [53, 54, 364, 364, "CID"], [53, 54, 432, 433, "CID"], [53, 54, 459, 459, "CID"], [53, 54, 500, 500, "CID"], [56, 56, 38, 39, "CID"], [56, 56, 69, 70, "CID"], [56, 56, 188, 188, "CID"], [56, 56, 353, 353, "CID"], [56, 56, 364, 364, "CID"], [56, 56, 432, 433, "CID"], [56, 56, 459, 459, "CID"], [56, 56, 500, 500, "CID"], [112, 112, 38, 39, "CID"], [112, 112, 69, 70, "CID"], [112, 112, 188, 188, "CID"], [112, 112, 353, 353, "CID"], [112, 112, 364, 364, "CID"], [112, 112, 432, 433, "CID"], [112, 112, 459, 459, "CID"], [112, 112, 500, 500, "CID"], [145, 145, 38, 39, "CID"], [145, 145, 69, 70, "CID"], [145, 145, 188, 188, "CID"], [145, 145, 353, 353, "CID"], [145, 145, 364, 364, "CID"], [145, 145, 432, 433, "CID"], [145, 145, 459, 459, "CID"], [145, 145, 500, 500, "CID"], [190, 190, 38, 39, "CID"], [190, 190, 69, 70, "CID"], [190, 190, 188, 188, "CID"], [190, 190, 353, 353, "CID"], [190, 190, 364, 364, "CID"], [190, 190, 432, 433, "CID"], [190, 190, 459, 459, "CID"], [190, 190, 500, 500, "CID"], [201, 201, 38, 39, "CID"], [201, 201, 69, 70, "CID"], [201, 201, 188, 188, "CID"], [201, 201, 353, 353, "CID"], [201, 201, 364, 364, "CID"], [201, 201, 432, 433, "CID"], [201, 201, 459, 459, "CID"], [201, 201, 500, 500, "CID"], [357, 357, 38, 39, "CID"], [357, 357, 69, 70, "CID"], [357, 357, 188, 188, "CID"], [357, 357, 353, 353, "CID"], [357, 357, 364, 364, "CID"], [357, 357, 432, 433, "CID"], [357, 357, 459, 459, "CID"], [357, 357, 500, 500, "CID"], [463, 463, 38, 39, "CID"], [463, 463, 69, 70, "CID"], [463, 463, 188, 188, "CID"], [463, 463, 353, 353, "CID"], [463, 463, 364, 364, "CID"], [463, 463, 432, 433, "CID"], [463, 463, 459, 459, "CID"], [463, 463, 500, 500, "CID"], [521, 521, 38, 39, "CID"], [521, 521, 69, 70, "CID"], [521, 521, 188, 188, "CID"], [521, 521, 353, 353, "CID"], [521, 521, 364, 364, "CID"], [521, 521, 432, 433, "CID"], [521, 521, 459, 459, "CID"], [521, 521, 500, 500, "CID"], [5, 5, 308, 310, "CID"], [5, 5, 312, 312, "CID"], [5, 5, 332, 332, "CID"], [5, 5, 376, 376, "CID"], [5, 5, 385, 385, "CID"], [5, 5, 418, 418, "CID"], [5, 5, 445, 445, "CID"], [7, 8, 308, 310, "CID"], [7, 8, 312, 312, "CID"], [7, 8, 332, 332, "CID"], [7, 8, 376, 376, "CID"], [7, 8, 385, 385, "CID"], [7, 8, 418, 418, "CID"], [7, 8, 445, 445, "CID"], [51, 51, 308, 310, "CID"], [51, 51, 312, 312, "CID"], [51, 51, 332, 332, "CID"], [51, 51, 376, 376, "CID"], [51, 51, 385, 385, "CID"], [51, 51, 418, 418, "CID"], [51, 51, 445, 445, "CID"], [53, 54, 308, 310, "CID"], [53, 54, 312, 312, "CID"], [53, 54, 332, 332, "CID"], [53, 54, 376, 376, "CID"], [53, 54, 385, 385, "CID"], [53, 54, 418, 418, "CID"], [53, 54, 445, 445, "CID"], [56, 56, 308, 310, "CID"], [56, 56, 312, 312, "CID"], [56, 56, 332, 332, "CID"], [56, 56, 376, 376, "CID"], [56, 56, 385, 385, "CID"], [56, 56, 418, 418, "CID"], [56, 56, 445, 445, "CID"], [112, 112, 308, 310, "CID"], [112, 112, 312, 312, "CID"], [112, 112, 332, 332, "CID"], [112, 112, 376, 376, "CID"], [112, 112, 385, 385, "CID"], [112, 112, 418, 418, "CID"], [112, 112, 445, 445, "CID"], [145, 145, 308, 310, "CID"], [145, 145, 312, 312, "CID"], [145, 145, 332, 332, "CID"], [145, 145, 376, 376, "CID"], [145, 145, 385, 385, "CID"], [145, 145, 418, 418, "CID"], [145, 145, 445, 445, "CID"], [190, 190, 308, 310, "CID"], [190, 190, 312, 312, "CID"], [190, 190, 332, 332, "CID"], [190, 190, 376, 376, "CID"], [190, 190, 385, 385, "CID"], [190, 190, 418, 418, "CID"], [190, 190, 445, 445, "CID"], [201, 201, 308, 310, "CID"], [201, 201, 312, 312, "CID"], [201, 201, 332, 332, "CID"], [201, 201, 376, 376, "CID"], [201, 201, 385, 385, "CID"], [201, 201, 418, 418, "CID"], [201, 201, 445, 445, "CID"], [357, 357, 308, 310, "CID"], [357, 357, 312, 312, "CID"], [357, 357, 332, 332, "CID"], [357, 357, 376, 376, "CID"], [357, 357, 385, 385, "CID"], [357, 357, 418, 418, "CID"], [357, 357, 445, 445, "CID"], [463, 463, 308, 310, "CID"], [463, 463, 312, 312, "CID"], [463, 463, 332, 332, "CID"], [463, 463, 376, 376, "CID"], [463, 463, 385, 385, "CID"], [463, 463, 418, 418, "CID"], [463, 463, 445, 445, "CID"], [521, 521, 308, 310, "CID"], [521, 521, 312, 312, "CID"], [521, 521, 332, 332, "CID"], [521, 521, 376, 376, "CID"], [521, 521, 385, 385, "CID"], [521, 521, 418, 418, "CID"], [521, 521, 445, 445, "CID"], [5, 5, 323, 324, "CID"], [5, 5, 326, 326, "CID"], [5, 5, 371, 371, "CID"], [5, 5, 398, 398, "CID"], [7, 8, 323, 324, "CID"], [7, 8, 326, 326, "CID"], [7, 8, 371, 371, "CID"], [7, 8, 398, 398, "CID"], [51, 51, 323, 324, "CID"], [51, 51, 326, 326, "CID"], [51, 51, 371, 371, "CID"], [51, 51, 398, 398, "CID"], [53, 54, 323, 324, "CID"], [53, 54, 326, 326, "CID"], [53, 54, 371, 371, "CID"], [53, 54, 398, 398, "CID"], [56, 56, 323, 324, "CID"], [56, 56, 326, 326, "CID"], [56, 56, 371, 371, "CID"], [56, 56, 398, 398, "CID"], [112, 112, 323, 324, "CID"], [112, 112, 326, 326, "CID"], [112, 112, 371, 371, "CID"], [112, 112, 398, 398, "CID"], [145, 145, 323, 324, "CID"], [145, 145, 326, 326, "CID"], [145, 145, 371, 371, "CID"], [145, 145, 398, 398, "CID"], [190, 190, 323, 324, "CID"], [190, 190, 326, 326, "CID"], [190, 190, 371, 371, "CID"], [190, 190, 398, 398, "CID"], [201, 201, 323, 324, "CID"], [201, 201, 326, 326, "CID"], [201, 201, 371, 371, "CID"], [201, 201, 398, 398, "CID"], [357, 357, 323, 324, "CID"], [357, 357, 326, 326, "CID"], [357, 357, 371, 371, "CID"], [357, 357, 398, 398, "CID"], [463, 463, 323, 324, "CID"], [463, 463, 326, 326, "CID"], [463, 463, 371, 371, "CID"], [463, 463, 398, 398, "CID"], [521, 521, 323, 324, "CID"], [521, 521, 326, 326, "CID"], [521, 521, 371, 371, "CID"], [521, 521, 398, 398, "CID"]]], "clusters": [], "translated": "使用选定的给药范例比较<0>阿司匹林</0>（<1>乙酰水杨酸</1>）在大鼠中的发育毒理学。背景：对非甾体类抗炎药 (NSAID) 的文献分析表明，在器官形成期间的特定日期给予 NSAID 的大鼠<12>发育异常</12>的发生率较低。 <2>阿司匹林</2>（<3>乙酰水杨酸</3>[<4>ASA</4>]），一种不可逆的环加氧酶 1 和 2 抑制剂，服用后会导致<13>发育异常</13>在妊娠期GD9、10或11对Wistar大鼠进行实验（Kimmel CA，Wilson JG，Schumacher HJ. Teratology 4: 15-24，1971）。没有已发表的<5>ASA</5>研究使用GDs6至17的多次给药范例。当前研究的目的是比较在第9、10或11天施用<6>ASA</6>时Sprague-Dawley（SD）和Wistar菌株的结果；比较SD大鼠器官形成过程中单次和多次给药后的畸形模式；并检验以下假设：当使用多次给药范例时，母体<31>胃肠道毒性</31>会混淆低发生率<14>畸形</14>与<7>ASA</7>的检测。\n\n方法：<8>ASA</8>在GD9（0、250、500或625 mg / kg）、10（0、500、625或750 mg / kg）或11（0、500、750或1000 mg / kg）和从第6天到第17天（每天0、50、125或250 mg / kg a day）对SD大鼠进行多次给药研究。在GD 21处死动物，并对胎儿进行内脏检查。\n\n结果：文献评价提示NSAIDs可引起<20>室间隔缺损</20>（<21>VSDs</21>）和<32>中线缺损</32>（<33>MDs</33>）大鼠和兔子<27>膈疝</27>（<28>DH</28>）、<34>MD</34>和<22>VSD</22>（Cook JC et al.，2003);因此，本研究集中于这些<15>畸形</15>，尽管<9>ASA</9>诱发了其他几种低发生率的<16>畸形</16>。在单剂量研究中，<29>DH</29>、<35>MD</35>和<23>VSD</23>在GDs 9和10上被诱导。<24>VSD</24>在GD 11治疗后也被注意到。相比之下，<30>DH</30>和<36>MD</36>在多剂量研究设计中仅在高剂量组中出现，而<25>VSD</25>在所有剂量组中出现。结果表明，除SD老鼠的<26>VSD</26>和Wistar老鼠的<37>脑积水</37>外，主要的<17>发育异常</17>在Wistar 和SD大鼠之间存在高度一致性。当<10>ASA</10>单次给药或在器官发生期间（GDs6至17）给药时，变异和<18>畸形</18>相似。同时，通过逐步提高剂量至最大耐受剂量，通过给于<11>ASA</11>的多次给药，能够诱发之前单次剂量研究中低发生率发生的<19>畸形</19>。", "revised": true}
{"doc_key": "9067481", "sentences": [["Cholesteryl", "hemisuccinate", "treatment", "protects", "rodents", "from", "the", "toxic", "effects", "of", "acetaminophen", ",", "adriamycin", ",", "carbon", "tetrachloride", ",", "chloroform", "and", "galactosamine", ".", "In", "addition", "to", "its", "use", "as", "a", "stabilizer", "/", "rigidifier", "of", "membranes", ",", "cholesteryl", "hemisuccinate", ",", "tris", "salt", "(", "CS", ")", "administration", "has", "also", "been", "shown", "to", "protect", "rats", "from", "the", "hepatotoxic", "effects", "of", "carbon", "tetrachloride", "(", "CCl4", ")", ".", "To", "further", "our", "understanding", "of", "the", "mechanism", "of", "CS", "cytoprotection", ",", "we", "examined", "in", "rats", "and", "mice", "the", "protective", "abilities", "of", "CS", "and", "the", "non", "-", "hydrolyzable", "ether", "form", "of", "CS", ",", "gamma", "-", "cholesteryloxybutyric", "acid", ",", "tris", "salt", "(", "CSE", ")", "against", "acetaminophen", "-", ",", "adriamycin", "-", ",", "carbon", "tetrachloride", "-", ",", "chloroform", "-", "and", "galactosamine", "-", "induced", "toxicity", ".", "The", "results", "of", "these", "studies", "demonstrated", "that", "CS", "-", "mediated", "protection", "is", "not", "selective", "for", "a", "particular", "species", ",", "organ", "system", "or", "toxic", "chemical", ".", "A", "24", "-", "h", "pretreatment", "of", "both", "rats", "and", "mice", "with", "a", "single", "dose", "of", "CS", "(", "100mg", "/", "kg", ",", "i", ".", "p", ".", ")", ",", "resulted", "in", "significant", "protection", "against", "the", "hepatotoxic", "effects", "of", "CCl4", ",", "CHCl3", ",", "acetaminophen", "and", "galactosamine", "and", "against", "the", "lethal", "(", "and", "presumably", "cardiotoxic", ")", "effect", "of", "adriamycin", "administration", ".", "Maximal", "CS", "-", "mediated", "protection", "was", "observed", "in", "experimental", "animals", "pretreated", "24", "h", "prior", "to", "the", "toxic", "insult", ".", "These", "data", "suggest", "that", "CS", "intervenes", "in", "a", "critical", "cellular", "event", "that", "is", "an", "important", "common", "pathway", "to", "toxic", "cell", "death", ".", "The", "mechanism", "of", "CS", "protection", "does", "not", "appear", "to", "be", "dependent", "on", "the", "inhibition", "of", "chemical", "bioactivation", "to", "a", "toxic", "reactive", "intermediate", "(", "in", "light", "of", "the", "protection", "observed", "against", "galactosamine", "hepatotoxicity", ")", ".", "However", ",", "based", "on", "the", "data", "presented", ",", "we", "can", "not", "exclude", "the", "possibility", "that", "CS", "administration", "inhibits", "chemical", "bioactivation", ".", "Our", "findings", "do", "suggest", "that", "CS", "-", "mediated", "protection", "is", "dependent", "on", "the", "action", "of", "the", "intact", "anionic", "CS", "molecule", "(", "non", "-", "hydrolyzable", "CSE", "was", "as", "protective", "as", "CS", ")", ",", "whose", "mechanism", "has", "yet", "to", "be", "defined", "."]], "ner": [[[10, 10, "Chemical"], [104, 104, "Chemical"], [187, 187, "Chemical"], [52, 52, "Disease"], [180, 180, "Disease"], [276, 276, "Disease"], [12, 12, "Chemical"], [107, 107, "Chemical"], [201, 201, "Chemical"], [197, 197, "Disease"], [14, 15, "Chemical"], [55, 56, "Chemical"], [58, 58, "Chemical"], [110, 111, "Chemical"], [183, 183, "Chemical"], [17, 17, "Chemical"], [114, 114, "Chemical"], [185, 185, "Chemical"], [19, 19, "Chemical"], [117, 117, "Chemical"], [189, 189, "Chemical"], [275, 275, "Chemical"], [0, 1, "Chemical"], [34, 35, "Chemical"], [120, 120, "Disease"], [93, 96, "Chemical"]]], "relations": [[[10, 10, 52, 52, "CID"], [10, 10, 180, 180, "CID"], [10, 10, 276, 276, "CID"], [104, 104, 52, 52, "CID"], [104, 104, 180, 180, "CID"], [104, 104, 276, 276, "CID"], [187, 187, 52, 52, "CID"], [187, 187, 180, 180, "CID"], [187, 187, 276, 276, "CID"], [12, 12, 197, 197, "CID"], [107, 107, 197, 197, "CID"], [201, 201, 197, 197, "CID"], [14, 15, 52, 52, "CID"], [14, 15, 180, 180, "CID"], [14, 15, 276, 276, "CID"], [55, 56, 52, 52, "CID"], [55, 56, 180, 180, "CID"], [55, 56, 276, 276, "CID"], [58, 58, 52, 52, "CID"], [58, 58, 180, 180, "CID"], [58, 58, 276, 276, "CID"], [110, 111, 52, 52, "CID"], [110, 111, 180, 180, "CID"], [110, 111, 276, 276, "CID"], [183, 183, 52, 52, "CID"], [183, 183, 180, 180, "CID"], [183, 183, 276, 276, "CID"], [17, 17, 52, 52, "CID"], [17, 17, 180, 180, "CID"], [17, 17, 276, 276, "CID"], [114, 114, 52, 52, "CID"], [114, 114, 180, 180, "CID"], [114, 114, 276, 276, "CID"], [185, 185, 52, 52, "CID"], [185, 185, 180, 180, "CID"], [185, 185, 276, 276, "CID"], [19, 19, 52, 52, "CID"], [19, 19, 180, 180, "CID"], [19, 19, 276, 276, "CID"], [117, 117, 52, 52, "CID"], [117, 117, 180, 180, "CID"], [117, 117, 276, 276, "CID"], [189, 189, 52, 52, "CID"], [189, 189, 180, 180, "CID"], [189, 189, 276, 276, "CID"], [275, 275, 52, 52, "CID"], [275, 275, 180, 180, "CID"], [275, 275, 276, 276, "CID"]]], "clusters": [], "translated": "<22>胆甾醇半琥珀酸酯</22>治疗可保护啮齿类动物免受<0>对乙酰氨基酚</0>、<6>阿霉素</6>、<10>四氯化碳</10>、<15>氯仿</15>和<18>半乳糖胺</18>等有毒物质的危害。除了用作膜的稳定剂/硬化剂外，给药生产的<23>胆甾醇半琥珀酸酯</23> tris盐（CS）还被展示可保护大鼠免受<3>肝脏毒性</3>作用影响，如<11>四氯化碳</11> (<12>CCl4</12>)。为了进一步了解CS细胞保护机制，我们在大鼠和小鼠中检测了CS和CS的不可水解醚形式<25>γ-胆固醇氧丁酸</25>，tris盐(CSE)对<1>对乙酰氨基酚</1>、<7>阿霉素</7>、<13>四氯化碳</13>、<16>氯仿</16>和<19>半乳糖胺</19>制剂的诱发<24>毒性</24>的保护能力。这些研究结果表明，CS介导的保护作用对于特定物种、器官系统或有毒化学物质没有选择性。在大鼠和小鼠中，通过单个剂量CS（100mg / kg，i.p.）进行24小时预处理，结果显示该处理在<4>肝脏毒性作用</4>、<14>四氯化碳</14>、<17>氯仿</17>、<2>对乙酰氨基酚</2>和<20>半乳糖胺</20>制剂的诱发上具有显著的保护作用，同时也能防止<8>阿霉素的致死作用</8> （可能是<9>心脏毒性</9>）。实验动物在损伤前24小时经预处理，实验结果表明最大的CS介导的保护作用。这些数据表明CS干预了关键的细胞事件，该事件是导致毒性细胞死亡的重要共同途径。 由于观察到与<21>半乳糖胺</21> <5>肝脏毒性</5>相关的保护作用，CS保护机制似乎并不依赖于有毒活性中间体的化学生物活化的抑制。然而，根据提供的数据，不能排除CS给药抑制化学生物活化的可能性。我们的研究结果表明，CS介导的保护作用依赖于-CS分子中的完整阴离子（不可水解的CSE与CS一样具有保护作用），其机制尚未明确。", "revised": true}
{"doc_key": "3952818", "sentences": [["Cardiac", "toxicity", "of", "5", "-", "fluorouracil", ".", "Report", "of", "a", "case", "of", "spontaneous", "angina", ".", "We", "report", "a", "case", "of", "a", "patient", "with", "colon", "carcinoma", "and", "liver", "metastasis", "who", "presented", "chest", "pain", "after", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "administration", ".", "Clinical", "electrocardiographic", "evolution", "was", "similar", "to", "that", "observed", "in", "Prinzmetal", "'s", "angina", ",", "and", "chest", "pain", "promptly", "resolved", "with", "nifedipine", ".", "These", "data", "suggest", "that", "coronary", "spasm", "may", "be", "the", "cause", "of", "cardiotoxicity", "due", "to", "5", "-", "FU", ",", "and", "that", "calcium", "antagonists", "may", "probably", "be", "used", "in", "the", "prevention", "or", "treatment", "of", "5", "-", "FU", "cardiotoxicity", "."]], "ner": [[[3, 5, "Chemical"], [33, 35, "Chemical"], [37, 39, "Chemical"], [78, 80, "Chemical"], [96, 98, "Chemical"], [30, 31, "Disease"], [57, 58, "Disease"], [52, 54, "Disease"], [0, 1, "Disease"], [75, 75, "Disease"], [99, 99, "Disease"], [62, 62, "Chemical"], [84, 84, "Chemical"], [13, 13, "Disease"], [23, 24, "Disease"], [27, 27, "Disease"], [68, 69, "Disease"]]], "relations": [[[3, 5, 30, 31, "CID"], [3, 5, 57, 58, "CID"], [33, 35, 30, 31, "CID"], [33, 35, 57, 58, "CID"], [37, 39, 30, 31, "CID"], [37, 39, 57, 58, "CID"], [78, 80, 30, 31, "CID"], [78, 80, 57, 58, "CID"], [96, 98, 30, 31, "CID"], [96, 98, 57, 58, "CID"], [3, 5, 52, 54, "CID"], [33, 35, 52, 54, "CID"], [37, 39, 52, 54, "CID"], [78, 80, 52, 54, "CID"], [96, 98, 52, 54, "CID"]]], "clusters": [], "translated": "<0>5-氟尿嘧啶</0>的<8>心脏毒性</8>。自发性<13>心绞痛</13>一例报告。我们报告了一例患有<14>结肠癌</14>和肝<15>转移</15>的患者，在给予<1>5-氟尿嘧啶</1>（<2>5-FU</2>）后出现<5>胸痛</5>。临床心电图演变与<7>Prinzmetal心绞痛</7>观察到的类似，<6>胸痛</6>用<11>硝苯地平</11>迅速缓解。这些数据表明<16>冠状动脉痉挛</16>可能是由于<3>5-FU</3><9>心脏毒性</9>的原因，可能可以使用<12>钙</12>拮抗剂预防或治疗<4>5-FU</4><10>心脏毒性</10>。", "revised": true}
{"doc_key": "8841157", "sentences": [["Valsartan", ",", "a", "new", "angiotensin", "II", "antagonist", "for", "the", "treatment", "of", "essential", "hypertension", ":", "a", "comparative", "study", "of", "the", "efficacy", "and", "safety", "against", "amlodipine", ".", "OBJECTIVE", ":", "To", "compare", "the", "antihypertensive", "efficacy", "of", "a", "new", "angiotensin", "II", "antagonist", ",", "valsartan", ",", "with", "a", "reference", "therapy", ",", "amlodipine", ".", "METHODS", ":", "One", "hundred", "sixty", "-", "eight", "adult", "outpatients", "with", "mild", "to", "moderate", "hypertension", "were", "randomly", "allocated", "in", "double", "-", "blind", "fashion", "and", "equal", "number", "to", "receive", "80", "mg", "valsartan", "or", "5", "mg", "amlodipine", "for", "12", "weeks", ".", "After", "8", "weeks", "of", "therapy", ",", "in", "patients", "whose", "blood", "pressure", "remained", "uncontrolled", ",", "5", "mg", "amlodipine", "was", "added", "to", "the", "initial", "therapy", ".", "Patients", "were", "assessed", "at", "4", ",", "8", ",", "and", "12", "weeks", ".", "The", "primary", "efficacy", "variable", "was", "change", "from", "baseline", "in", "mean", "sitting", "diastolic", "blood", "pressure", "at", "8", "weeks", ".", "Secondary", "variables", "included", "change", "in", "sitting", "systolic", "blood", "pressure", "and", "responder", "rates", ".", "RESULTS", ":", "Both", "valsartan", "and", "amlodipine", "were", "effective", "at", "lowering", "blood", "pressure", "at", "4", ",", "8", ",", "and", "12", "weeks", ".", "Similar", "decreases", "were", "observed", "in", "both", "groups", ",", "with", "no", "statistically", "significant", "differences", "between", "the", "groups", "for", "any", "variable", "analyzed", ".", "For", "the", "primary", "variable", "the", "difference", "was", "0", ".", "5", "mm", "Hg", "in", "favor", "of", "valsartan", "(", "p", "=", "0", ".", "68", ";", "95", "%", "confidence", "interval", ",", "-", "2", ".", "7", "to", "1", ".", "7", ")", ".", "Responder", "rates", "at", "8", "weeks", "were", "66", ".", "7", "%", "for", "valsartan", "and", "60", ".", "2", "%", "for", "amlodipine", "(", "p", "=", "0", ".", "39", ")", ".", "Both", "treatments", "were", "well", "tolerated", ".", "The", "incidence", "of", "drug", "-", "related", "dependent", "edema", "was", "somewhat", "higher", "in", "the", "amlodipine", "group", ",", "particularly", "at", "a", "dose", "of", "10", "mg", "per", "day", "(", "2", ".", "4", "%", "for", "80", "mg", "valsartan", ";", "3", ".", "6", "%", "for", "5", "mg", "amlodipine", ";", "0", "%", "for", "valsartan", "plus", "5", "mg", "amlodipine", ";", "14", ".", "3", "%", "for", "10", "mg", "amlodipine", ")", ".", "CONCLUSIONS", ":", "The", "data", "show", "that", "valsartan", "is", "at", "least", "as", "effective", "as", "amlodipine", "in", "the", "treatment", "of", "mild", "to", "moderate", "hypertension", ".", "The", "results", "also", "show", "valsartan", "to", "be", "well", "tolerated", "and", "suggest", "that", "it", "is", "not", "associated", "with", "side", "effects", "characteristic", "of", "this", "comparator", "class", ",", "dihydropyridine", "calcium", "antagonists", "."]], "ner": [[[0, 0, "Chemical"], [39, 39, "Chemical"], [77, 77, "Chemical"], [156, 156, "Chemical"], [210, 210, "Chemical"], [244, 244, "Chemical"], [299, 299, "Chemical"], [313, 313, "Chemical"], [335, 335, "Chemical"], [356, 356, "Chemical"], [273, 273, "Disease"], [23, 23, "Chemical"], [46, 46, "Chemical"], [81, 81, "Chemical"], [102, 102, "Chemical"], [158, 158, "Chemical"], [251, 251, "Chemical"], [279, 279, "Chemical"], [308, 308, "Chemical"], [317, 317, "Chemical"], [326, 326, "Chemical"], [342, 342, "Chemical"], [12, 12, "Disease"], [61, 61, "Disease"], [350, 350, "Disease"], [4, 5, "Chemical"], [35, 36, "Chemical"], [377, 377, "Chemical"], [378, 378, "Chemical"]]], "relations": [[[0, 0, 273, 273, "CID"], [39, 39, 273, 273, "CID"], [77, 77, 273, 273, "CID"], [156, 156, 273, 273, "CID"], [210, 210, 273, 273, "CID"], [244, 244, 273, 273, "CID"], [299, 299, 273, 273, "CID"], [313, 313, 273, 273, "CID"], [335, 335, 273, 273, "CID"], [356, 356, 273, 273, "CID"], [23, 23, 273, 273, "CID"], [46, 46, 273, 273, "CID"], [81, 81, 273, 273, "CID"], [102, 102, 273, 273, "CID"], [158, 158, 273, 273, "CID"], [251, 251, 273, 273, "CID"], [279, 279, 273, 273, "CID"], [308, 308, 273, 273, "CID"], [317, 317, 273, 273, "CID"], [326, 326, 273, 273, "CID"], [342, 342, 273, 273, "CID"]]], "clusters": [], "translated": "<0>缬沙坦</0>，一种治疗原发性<22>高血压</22>的新型<25>血管紧张素Ⅱ</25>拮抗剂：与<11>氨氯地平</11>的疗效和安全性比较研究。目的：比较新型<26>血管紧张素Ⅱ</26>拮抗剂<1>缬沙坦</1>与参考疗法<12>氨氯地平</12>的抗高血压疗效。方法：将168名患有轻度至中度<23>高血压</23>的成年门诊患者以双盲方式随机分配，且人数相等，分别接受80mg<2>缬沙坦</2>或5mg<13>氨氯地平</13>12周。治疗8周后，对于血压仍未控制的患者，在初始治疗基础上加用5mg<14>氨氯地平</14>。在第4、8和12周对患者进行评估。主要疗效变量是8周时平均坐位舒张压相对于基线的变化。次要变量包括坐位收缩压和反应率的变化。结果：<3>缬沙坦</3>和<15>氨氯地平</15>在第4、8和12周时均能有效降低血压。两组均观察到类似的下降，对于所分析的任何变量，两组之间没有统计学上的显着差异。对于主要变量，差异为0.5毫米汞柱有利于<4>缬沙坦</4>（p=0.68；95%置信区间，-2.7至1.7）。反应率在8周时分别为<5>缬沙坦</5>为66.5％，<16>氨氯地平</16>为60.7％（p = 0.39）。两种治疗都具有良好的耐受性。<17>氨氯地平</17>组的药物相关性<10>水肿</10>发生率略高，尤其是在每天10mg的剂量下（80mg<6>缬沙坦</6>;3.6％对于5mg<18>氨氯地平</18> ;0%对于<7>缬沙坦</7>加5mg<19>氨氯地平</19>;14.3%对于10mg<20>氨氯地平</20>）。结论：数据显示<8>缬沙坦</8>在治疗轻中度<24>高血压</24>方面至少与<21>氨氯地平</21>一样有效。结果还显示<9>缬沙坦</9>具有良好的耐受性，并表明它与此类比较剂<27>二氢吡啶</27><28>钙</28>拮抗剂的副作用特征无关。", "revised": true}
{"doc_key": "15686794", "sentences": [["Acute", "low", "back", "pain", "during", "intravenous", "administration", "of", "amiodarone", ":", "a", "report", "of", "two", "cases", ".", "Amiodarone", "represents", "an", "effective", "antiarrhythmic", "drug", "for", "cardioversion", "of", "recent", "-", "onset", "atrial", "fibrillation", "(", "AF", ")", "and", "maintenance", "of", "sinus", "rhythm", ".", "We", "briefly", "describe", "two", "patients", "suffering", "from", "recent", "-", "onset", "atrial", "fibrillation", ",", "who", "experienced", "an", "acute", "devastating", "low", "back", "pain", "a", "few", "minutes", "after", "initiation", "of", "intravenous", "amiodarone", "loading", ".", "Notably", ",", "this", "side", "effect", "has", "not", "been", "ever", "reported", "in", "the", "medical", "literature", ".", "Clinicians", "should", "be", "aware", "of", "this", "reaction", "since", "prompt", "termination", "of", "parenteral", "administration", "leads", "to", "complete", "resolution", "."]], "ner": [[[8, 8, "Chemical"], [16, 16, "Chemical"], [67, 67, "Chemical"], [1, 3, "Disease"], [57, 59, "Disease"], [28, 29, "Disease"], [31, 31, "Disease"], [49, 50, "Disease"]]], "relations": [[[8, 8, 1, 3, "CID"], [8, 8, 57, 59, "CID"], [16, 16, 1, 3, "CID"], [16, 16, 57, 59, "CID"], [67, 67, 1, 3, "CID"], [67, 67, 57, 59, "CID"]]], "clusters": [], "translated": "<0>胺碘酮</0>静脉给药引起急性<3>腰痛</3>2例报告。<1>胺碘酮</1>是一种有效的抗心律失常药物，可用于复律近期发作的<5>心房颤动</5> (<6>AF</6>)和维持窦性心律。我们简要描述了两名近期发作的<7>心房颤动</7>患者，他们在开始静脉注射<2>胺碘酮</2>几分钟后经历了急性破坏性<4>腰痛</4>。值得注意的是，医学文献中从未报道过这种副作用。临床医生应该意识到这种反应，因为迅速终止静脉给药会导致完全消退。", "revised": true}
{"doc_key": "12691807", "sentences": [["Levodopa", "-", "induced", "oromandibular", "dystonia", "in", "progressive", "supranuclear", "palsy", ".", "Levodopa", "-", "induced", "dyskinesias", "have", "been", "reported", "in", "Parkinson", "'s", "disease", "and", "multiple", "system", "atrophy", ".", "Cranial", "dystonias", "are", "rare", "in", "patients", "with", "progressive", "supranuclear", "palsy", "(", "PSP", ")", ".", "In", "this", "report", "we", "describe", "an", "unusual", "case", "of", "reversible", "levodopa", "-", "induced", "Oromandibular", "dystonia", "(", "OMD", ")", "in", "a", "PSP", "patient", "to", "highlight", "the", "importance", "of", "recognizing", "this", "drug", "related", "complication", "in", "the", "management", "of", "PSP", ",", "and", "discuss", "the", "possible", "underlying", "pathophysiology", "."]], "ner": [[[0, 0, "Chemical"], [10, 10, "Chemical"], [50, 50, "Chemical"], [4, 4, "Disease"], [27, 27, "Disease"], [6, 8, "Disease"], [33, 35, "Disease"], [37, 37, "Disease"], [60, 60, "Disease"], [76, 76, "Disease"], [13, 13, "Disease"], [18, 20, "Disease"], [22, 24, "Disease"], [53, 54, "Disease"], [56, 56, "Disease"]]], "relations": [[[0, 0, 4, 4, "CID"], [0, 0, 27, 27, "CID"], [10, 10, 4, 4, "CID"], [10, 10, 27, 27, "CID"], [50, 50, 4, 4, "CID"], [50, 50, 27, 27, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0> - 在<5>进行性核上性麻痹</5>中诱发下颌骨<3>肌张力障碍</3>。 <1>左旋多巴</1>诱发的<10>运动障碍</10>已在<11>帕金森病</11>和<12>多系统萎缩</12>中报道。<4>颅骨肌张力障碍</4>在<6>进行性核上性麻痹</6> (<7>PSP</7>) 的患者很少出现。在本报告中，我们描述了一个不寻常的病例，即<8>PSP</8>患者中可逆性<2>左旋多巴</2>诱导的<13>下颌肌张力障碍</13> (<14>OMD</14>)，以突出认识该药物相关并发症在<9>PSP</9>管理中的重要性，并讨论可能的潜在病理生理学。", "revised": true}
{"doc_key": "6615052", "sentences": [["Heparin", "-", "induced", "thrombocytopenia", ",", "thrombosis", ",", "and", "hemorrhage", ".", "Sixty", "-", "two", "patients", "with", "a", "heparin", "-", "induced", "thrombocytopenia", "are", "reported", ".", "Clinical", "manifestations", "of", "this", "disorder", "include", "hemorrhage", "or", ",", "more", "frequently", ",", "thromboembolic", "events", "in", "patients", "receiving", "heparin", ".", "Laboratory", "testing", "has", "revealed", "a", "falling", "platelet", "count", ",", "increased", "resistance", "to", "heparin", ",", "and", "aggregation", "of", "platelets", "by", "the", "patient", "'s", "plasma", "when", "heparin", "is", "added", ".", "Immunologic", "testing", "has", "demonstrated", "the", "presence", "of", "a", "heparin", "-", "dependent", "platelet", "membrane", "antibody", ".", "The", "20", "deaths", ",", "52", "hemorrhagic", "and", "thromboembolic", "complications", ",", "and", "21", "surgical", "procedures", "to", "manage", "the", "complications", "confirm", "the", "seriousness", "of", "the", "disorder", ".", "Specific", "risk", "factors", "have", "not", "been", "identified", ";", "therefore", ",", "all", "patients", "receiving", "heparin", "should", "be", "monitored", ".", "If", "the", "platelet", "count", "falls", "to", "less", "than", "100", ",", "000", "/", "mm3", ",", "while", "the", "patient", "is", "receiving", "heparin", ",", "platelet", "aggregation", "testing", ",", "using", "the", "patient", "'s", "plasma", ",", "is", "indicated", ".", "Management", "consists", "of", "cessation", "of", "heparin", ",", "platelet", "anti", "-", "aggregating", "agents", ",", "and", "alternate", "forms", "of", "anticoagulation", "when", "indicated", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [40, 40, "Chemical"], [54, 54, "Chemical"], [66, 66, "Chemical"], [78, 78, "Chemical"], [123, 123, "Chemical"], [147, 147, "Chemical"], [167, 167, "Chemical"], [3, 3, "Disease"], [19, 19, "Disease"], [8, 8, "Disease"], [29, 29, "Disease"], [90, 93, "Disease"], [35, 35, "Disease"], [5, 5, "Disease"], [46, 49, "Disease"], [149, 150, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 19, 19, "CID"], [16, 16, 3, 3, "CID"], [16, 16, 19, 19, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 19, 19, "CID"], [54, 54, 3, 3, "CID"], [54, 54, 19, 19, "CID"], [66, 66, 3, 3, "CID"], [66, 66, 19, 19, "CID"], [78, 78, 3, 3, "CID"], [78, 78, 19, 19, "CID"], [123, 123, 3, 3, "CID"], [123, 123, 19, 19, "CID"], [147, 147, 3, 3, "CID"], [147, 147, 19, 19, "CID"], [167, 167, 3, 3, "CID"], [167, 167, 19, 19, "CID"], [0, 0, 8, 8, "CID"], [0, 0, 29, 29, "CID"], [0, 0, 90, 93, "CID"], [16, 16, 8, 8, "CID"], [16, 16, 29, 29, "CID"], [16, 16, 90, 93, "CID"], [40, 40, 8, 8, "CID"], [40, 40, 29, 29, "CID"], [40, 40, 90, 93, "CID"], [54, 54, 8, 8, "CID"], [54, 54, 29, 29, "CID"], [54, 54, 90, 93, "CID"], [66, 66, 8, 8, "CID"], [66, 66, 29, 29, "CID"], [66, 66, 90, 93, "CID"], [78, 78, 8, 8, "CID"], [78, 78, 29, 29, "CID"], [78, 78, 90, 93, "CID"], [123, 123, 8, 8, "CID"], [123, 123, 29, 29, "CID"], [123, 123, 90, 93, "CID"], [147, 147, 8, 8, "CID"], [147, 147, 29, 29, "CID"], [147, 147, 90, 93, "CID"], [167, 167, 8, 8, "CID"], [167, 167, 29, 29, "CID"], [167, 167, 90, 93, "CID"], [0, 0, 35, 35, "CID"], [16, 16, 35, 35, "CID"], [40, 40, 35, 35, "CID"], [54, 54, 35, 35, "CID"], [66, 66, 35, 35, "CID"], [78, 78, 35, 35, "CID"], [123, 123, 35, 35, "CID"], [147, 147, 35, 35, "CID"], [167, 167, 35, 35, "CID"]]], "clusters": [], "translated": "<0>肝素</0> - 诱导的<9>血小板减少症</9>、<15>血栓形成</15>和<11>出血</11>。据报道，有 62 名<1>肝素</1>诱发的<10>血小板减少症</10>患者。这种疾病的临床表现包括接受<2>肝素</2>治疗的患者<12>出血</12>或更常见的<14>血栓栓塞</14>事件。实验室检查显示<16>血小板计数下降</16>，<3>肝素</3>抵抗力增加，添加<4>肝素</4>后患者血浆血小板聚集。免疫学检测表明存在<5>肝素</5>依赖性血小板膜抗体。20 例死亡、52 例<13>出血和血栓栓塞并发症</13>以及 21 例处理并发症的外科手术证实了疾病的严重性。具体风险因素尚未确定；因此，应对所有接受<6>肝素</6>治疗的患者进行监测。如果血小板计数低于 100,000/mm3，而患者正在接受<7>肝素</7>，则需要使用患者的血浆进行<17>血小板聚集</17>检测。处理包括停止使用<8>肝素</8>、血小板抗凝剂，并在有指征时使用其他形式的抗凝剂。", "revised": true}
{"doc_key": "430165", "sentences": [["Transient", "hemiparesis", ":", "a", "rare", "manifestation", "of", "diphenylhydantoin", "toxicity", ".", "Report", "of", "two", "cases", ".", "Among", "the", "common", "side", "effects", "of", "diphenylhydantoin", "(", "DPH", ")", "overdose", ",", "the", "most", "frequently", "encountered", "neurological", "signs", "are", "those", "of", "cerebellar", "dysfunction", ".", "Very", "rarely", ",", "the", "toxic", "neurological", "manifestations", "of", "this", "drug", "are", "of", "cerebral", "origin", ".", "Two", "patients", "are", "presented", "who", "suffered", "progressive", "hemiparesis", "due", "to", "DPH", "overdose", ".", "Both", "had", "brain", "surgery", "before", "DPH", "treatment", ".", "It", "is", "assumed", "that", "patients", "with", "some", "cerebral", "damage", "are", "liable", "to", "manifest", "DPH", "toxicity", "as", "focal", "neurological", "signs", "."]], "ner": [[[7, 7, "Chemical"], [21, 21, "Chemical"], [23, 23, "Chemical"], [64, 64, "Chemical"], [72, 72, "Chemical"], [88, 88, "Chemical"], [1, 1, "Disease"], [61, 61, "Disease"], [25, 25, "Disease"], [65, 65, "Disease"], [36, 37, "Disease"], [8, 8, "Disease"], [89, 89, "Disease"], [82, 83, "Disease"]]], "relations": [[[7, 7, 1, 1, "CID"], [7, 7, 61, 61, "CID"], [21, 21, 1, 1, "CID"], [21, 21, 61, 61, "CID"], [23, 23, 1, 1, "CID"], [23, 23, 61, 61, "CID"], [64, 64, 1, 1, "CID"], [64, 64, 61, 61, "CID"], [72, 72, 1, 1, "CID"], [72, 72, 61, 61, "CID"], [88, 88, 1, 1, "CID"], [88, 88, 61, 61, "CID"], [7, 7, 25, 25, "CID"], [7, 7, 65, 65, "CID"], [21, 21, 25, 25, "CID"], [21, 21, 65, 65, "CID"], [23, 23, 25, 25, "CID"], [23, 23, 65, 65, "CID"], [64, 64, 25, 25, "CID"], [64, 64, 65, 65, "CID"], [72, 72, 25, 25, "CID"], [72, 72, 65, 65, "CID"], [88, 88, 25, 25, "CID"], [88, 88, 65, 65, "CID"], [7, 7, 36, 37, "CID"], [21, 21, 36, 37, "CID"], [23, 23, 36, 37, "CID"], [64, 64, 36, 37, "CID"], [72, 72, 36, 37, "CID"], [88, 88, 36, 37, "CID"]]], "clusters": [], "translated": "一过性<6>偏瘫</6>： <0>二苯乙内酰脲</0> <11>中毒</11> 的罕见表现。两例报告。在<1>二苯乙内酰脲 </1>(<2>DPH</2>)<8>过量服用</8>的常见副作用中，最常见的神经症状是<10>小脑功能障碍</10>。极少数情况下，这种药物的毒性神经学表现是脑源性的。两名患者因<3>DPH</3><9>药物过量</9>而出现进行性<7>偏瘫</7>。两人在<4>DPH</4>治疗前都进行了脑部手术。据推测，一些<13>脑损伤</13>的患者容易出现<5>DPH</5><12>毒性</12>作为局灶性神经体征。", "revised": true}
{"doc_key": "12091028", "sentences": [["Ketamine", "in", "war", "/", "tropical", "surgery", "(", "a", "final", "tribute", "to", "the", "racemic", "mixture", ")", ".", "A", "technique", "of", "continuous", "intravenous", "anaesthesia", "with", "ketamine", "was", "used", "successfully", "during", "the", "Somalia", "civil", "war", "in", "1994", "and", "in", "north", "Uganda", "in", "1999", "for", "64", "operations", "in", "62", "patients", ",", "aged", "from", "6", "weeks", "to", "70", "years", ",", "undergoing", "limb", "and", "abdominal", "surgery", "including", "caesarian", "sections", "and", "interventions", "in", "neonates", ".", "Operations", "lasting", "up", "to", "2h", "could", "be", "performed", "in", "the", "absence", "of", "sophisticated", "equipment", "such", "as", "pulse", "oximeters", "or", "ventilators", "in", "patients", "on", "spontaneous", "ventilation", "breathing", "air", "/", "oxygen", "only", ".", "After", "premedication", "with", "diazepam", ",", "glycopyrrolate", "and", "local", "anaesthesia", ",", "and", "induction", "with", "standard", "doses", "of", "ketamine", ",", "a", "maintenance", "dose", "of", "10", "-", "20", "microg", "/", "kg", "/", "min", "of", "ketamine", "proved", "safe", "and", "effective", ".", "Emphasis", "was", "placed", "on", "bedside", "clinical", "monitoring", ",", "relying", "heavily", "on", "the", "heart", "rate", ".", "Diazepam", ",", "unless", "contraindicated", "or", "risky", ",", "remains", "the", "only", "necessary", "complementary", "drug", "to", "ketamine", "as", "it", "buffers", "its", "cardiovascular", "response", "and", "decreases", "the", "duration", "and", "intensity", "of", "operative", "and", "postoperative", "hallucinations", ".", "Local", "anaesthetic", "blocks", "were", "useful", "in", "decreasing", "the", "requirement", "for", "postoperative", "analgesia", ".", "An", "antisialogue", "was", "usually", "unnecessary", "in", "operations", "lasting", "up", "to", "2", "h", ",", "glycopyrrolate", "being", "the", "best", "choice", "for", "its", "lowest", "psychotropic", "and", "chronotropic", "effects", ",", "especially", "in", "a", "hot", "climate", ".", "Experience", "in", "war", "/", "tropical", "settings", "suggests", "this", "technique", "could", "be", "useful", "in", "civilian", "contexts", "such", "as", "outdoor", "life", "-", "saving", "emergency", "surgery", "or", "in", "mass", "casualties", "where", ",", "e", ".", "g", ".", "amputation", "and", "rapid", "extrication", "were", "required", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [115, 115, "Chemical"], [130, 130, "Chemical"], [165, 165, "Chemical"], [182, 182, "Disease"], [195, 195, "Disease"], [96, 96, "Chemical"], [102, 102, "Chemical"], [151, 151, "Chemical"], [104, 104, "Chemical"], [210, 210, "Chemical"]]], "relations": [[[0, 0, 182, 182, "CID"], [23, 23, 182, 182, "CID"], [115, 115, 182, 182, "CID"], [130, 130, 182, 182, "CID"], [165, 165, 182, 182, "CID"]]], "clusters": [], "translated": "<0>氯胺酮</0>在战争/热带手术中（对外消旋混合物的最后致敬）。1994年索马里内战期间和1999年在乌干达北部成功采用<1>氯胺酮</1>连续静脉麻醉技术对62例年龄6周至70岁的四肢和腹部手术患者进行了64次手术。手术包括剖腹产和新生儿干预。在没有脉搏血氧仪或呼吸机等精密设备的情况下，仅对仅呼吸空气/<7>氧气</7>的自主呼吸患者进行持续长达2小时的手术。用<8>地西泮</8>、<10>格隆溴铵</10>和局部麻醉进行术前给药，并用标准剂量的<2>氯胺酮</2>诱导后，维持剂量为10-20μg/kg/min的<3>氯胺酮</3>被证明是安全有效的。重点放在床边临床监测上，严重依赖于心率。<9>地西泮</9>，除非有禁忌症或风险，否则它仍然是<4>氯胺酮</4>唯一必要的补充药物，因为它可以缓冲其心血管反应并减少手术和术后<5>幻觉</5>的持续时间和强度。局麻药块有助于减少术后<6>镇痛</6>的需求。在长达2小时的手术中通常不需要抗唾液酸，<11>格隆溴铵</11>是最佳选择，因为它具有最低的精神和变时作用，尤其是在炎热的气候下。战争/热带环境中的经验表明，这种技术在民用环境中可能很有用，例如户外救生紧急手术或大规模伤亡，例如G。需要截肢和迅速解救。", "revised": true}
{"doc_key": "16600756", "sentences": [["Nerve", "growth", "factor", "and", "prostaglandins", "in", "the", "urine", "of", "female", "patients", "with", "overactive", "bladder", ".", "PURPOSE", ":", "NGF", "and", "PGs", "in", "the", "bladder", "can", "be", "affected", "by", "pathological", "changes", "in", "the", "bladder", "and", "these", "changes", "can", "be", "detected", "in", "urine", ".", "We", "investigated", "changes", "in", "urinary", "NGF", "and", "PGs", "in", "women", "with", "OAB", ".", "MATERIALS", "AND", "METHODS", ":", "The", "study", "groups", "included", "65", "women", "with", "OAB", "and", "20", "without", "bladder", "symptoms", "who", "served", "as", "controls", ".", "Evaluation", "included", "patient", "history", ",", "urinalysis", ",", "a", "voiding", "diary", "and", "urodynamic", "studies", ".", "Urine", "samples", "were", "collected", ".", "NGF", ",", "PGE2", ",", "PGF2alpha", "and", "PGI2", "were", "measured", "using", "enzyme", "-", "linked", "immunosorbent", "assay", "and", "compared", "between", "the", "groups", ".", "In", "addition", ",", "correlations", "between", "urinary", "NGF", "and", "PG", ",", "and", "urodynamic", "parameters", "in", "patients", "with", "OAB", "were", "examined", ".", "RESULTS", ":", "Urinary", "NGF", ",", "PGE2", "and", "PGF2alpha", "were", "significantly", "increased", "in", "patients", "with", "OAB", "compared", "with", "controls", "(", "p", "<", "0", ".", "05", ")", ".", "However", ",", "urinary", "PGI2", "was", "not", "different", "between", "controls", "and", "patients", "with", "OAB", ".", "In", "patients", "with", "OAB", "urinary", "PGE2", "positively", "correlated", "with", "volume", "at", "first", "desire", "to", "void", "and", "maximum", "cystometric", "capacity", "(", "p", "<", "0", ".", "05", ")", ".", "Urinary", "NGF", ",", "PGF2alpha", "and", "PGI2", "did", "not", "correlate", "with", "urodynamic", "parameters", "in", "patients", "with", "OAB", ".", "CONCLUSIONS", ":", "NGF", "and", "PGs", "have", "important", "roles", "in", "the", "development", "of", "OAB", "symptoms", "in", "female", "patients", ".", "Urinary", "levels", "of", "these", "factors", "may", "be", "used", "as", "markers", "to", "evaluate", "OAB", "symptoms", "."]], "ner": [[[97, 97, "Chemical"], [141, 141, "Chemical"], [181, 181, "Chemical"], [12, 13, "Disease"], [52, 52, "Disease"], [65, 65, "Disease"], [132, 132, "Disease"], [150, 150, "Disease"], [174, 174, "Disease"], [179, 179, "Disease"], [218, 218, "Disease"], [232, 232, "Disease"], [250, 250, "Disease"], [99, 99, "Chemical"], [143, 143, "Chemical"], [206, 206, "Chemical"], [4, 4, "Chemical"], [19, 19, "Chemical"], [48, 48, "Chemical"], [124, 124, "Chemical"], [224, 224, "Chemical"], [101, 101, "Chemical"], [165, 165, "Chemical"], [208, 208, "Chemical"]]], "relations": [[[97, 97, 12, 13, "CID"], [97, 97, 52, 52, "CID"], [97, 97, 65, 65, "CID"], [97, 97, 132, 132, "CID"], [97, 97, 150, 150, "CID"], [97, 97, 174, 174, "CID"], [97, 97, 179, 179, "CID"], [97, 97, 218, 218, "CID"], [97, 97, 232, 232, "CID"], [97, 97, 250, 250, "CID"], [141, 141, 12, 13, "CID"], [141, 141, 52, 52, "CID"], [141, 141, 65, 65, "CID"], [141, 141, 132, 132, "CID"], [141, 141, 150, 150, "CID"], [141, 141, 174, 174, "CID"], [141, 141, 179, 179, "CID"], [141, 141, 218, 218, "CID"], [141, 141, 232, 232, "CID"], [141, 141, 250, 250, "CID"], [181, 181, 12, 13, "CID"], [181, 181, 52, 52, "CID"], [181, 181, 65, 65, "CID"], [181, 181, 132, 132, "CID"], [181, 181, 150, 150, "CID"], [181, 181, 174, 174, "CID"], [181, 181, 179, 179, "CID"], [181, 181, 218, 218, "CID"], [181, 181, 232, 232, "CID"], [181, 181, 250, 250, "CID"], [99, 99, 12, 13, "CID"], [99, 99, 52, 52, "CID"], [99, 99, 65, 65, "CID"], [99, 99, 132, 132, "CID"], [99, 99, 150, 150, "CID"], [99, 99, 174, 174, "CID"], [99, 99, 179, 179, "CID"], [99, 99, 218, 218, "CID"], [99, 99, 232, 232, "CID"], [99, 99, 250, 250, "CID"], [143, 143, 12, 13, "CID"], [143, 143, 52, 52, "CID"], [143, 143, 65, 65, "CID"], [143, 143, 132, 132, "CID"], [143, 143, 150, 150, "CID"], [143, 143, 174, 174, "CID"], [143, 143, 179, 179, "CID"], [143, 143, 218, 218, "CID"], [143, 143, 232, 232, "CID"], [143, 143, 250, 250, "CID"], [206, 206, 12, 13, "CID"], [206, 206, 52, 52, "CID"], [206, 206, 65, 65, "CID"], [206, 206, 132, 132, "CID"], [206, 206, 150, 150, "CID"], [206, 206, 174, 174, "CID"], [206, 206, 179, 179, "CID"], [206, 206, 218, 218, "CID"], [206, 206, 232, 232, "CID"], [206, 206, 250, 250, "CID"]]], "clusters": [], "translated": "<3>膀胱过度活动症</3>女性患者尿液中的神经生长因子和<16>前列腺素</16>。目的：膀胱中的NGF和<17>PG</17>会受到膀胱病理变化的影响，并且可以在尿液中检测到这些变化。我们调查了患有<4>OAB</4>的女性尿NGF和<18>PGs</18>的变化。材料和方法：研究组包括65名患有<5>OAB</5>的女性和20名没有膀胱症状的女性作为对照。评估包括患者病史、尿液分析、排尿日记和尿动力学研究。收集了尿样。采用酶联免疫吸附法测定NGF、<0>PGE2</0>、<13>PGF2alpha</13>和<21>PGI2</21>，并进行组间比较。此外，还检查了患有<6>OAB</6>的患者尿NGF与<19>PG</19>和尿动力学参数之间的相关性。结果：与对照组相比，患有<7>OAB</7>的患者的尿NGF、<1>PGE2</1>和<14>PGF2alpha</14>显着升高(p < 0.05)。然而，尿<22>PGI2</22>在对照组和患有<8>OAB</8>的患者之间没有差异。在患有<9>OAB</9>的患者中，尿液<2>PGE2</2>与首次排尿欲量和最大膀胱容量呈正相关(p < 0.05)。尿NGF、<15>PGF2alpha</15>和<23>PGI2</23>与患有<10>OAB</10>的患者尿动力学参数无关。结论：NGF和<20>PGs</20>在<11>OAB</11>女性患者症状的发生和发展中具有重要作用。这些因素的尿水平可用作评估<12>OAB</12>症状的标志物。", "revised": true}
{"doc_key": "11860495", "sentences": [["Steroid", "structure", "and", "pharmacological", "properties", "determine", "the", "anti", "-", "amnesic", "effects", "of", "pregnenolone", "sulphate", "in", "the", "passive", "avoidance", "task", "in", "rats", ".", "Pregnenolone", "sulphate", "(", "PREGS", ")", "has", "generated", "interest", "as", "one", "of", "the", "most", "potent", "memory", "-", "enhancing", "neurosteroids", "to", "be", "examined", "in", "rodent", "learning", "studies", ",", "with", "particular", "importance", "in", "the", "ageing", "process", ".", "The", "mechanism", "by", "which", "this", "endogenous", "steroid", "enhances", "memory", "formation", "is", "hypothesized", "to", "involve", "actions", "on", "glutamatergic", "and", "GABAergic", "systems", ".", "This", "hypothesis", "stems", "from", "findings", "that", "PREGS", "is", "a", "potent", "positive", "modulator", "of", "N", "-", "methyl", "-", "d", "-", "aspartate", "receptors", "(", "NMDARs", ")", "and", "a", "negative", "modulator", "of", "gamma", "-", "aminobutyric", "acid", "(", "A", ")", "receptors", "(", "GABA", "(", "A", ")", "Rs", ")", ".", "Moreover", ",", "PREGS", "is", "able", "to", "reverse", "the", "amnesic", "-", "like", "effects", "of", "NMDAR", "and", "GABA", "(", "A", ")", "R", "ligands", ".", "To", "investigate", "this", "hypothesis", ",", "the", "present", "study", "in", "rats", "examined", "the", "memory", "-", "altering", "abilities", "of", "structural", "analogs", "of", "PREGS", ",", "which", "differ", "in", "their", "modulation", "of", "NMDAR", "and", "/", "or", "GABA", "(", "A", ")", "R", "function", ".", "The", "analogs", "tested", "were", ":", "11", "-", "ketopregnenolone", "sulphate", "(", "an", "agent", "that", "is", "inactive", "at", "GABA", "(", "A", ")", "Rs", "and", "NMDARs", ")", ",", "epipregnanolone", "(", "[", "3beta", "-", "hydroxy", "-", "5beta", "-", "pregnan", "-", "20", "-", "one", "]", "sulphate", ",", "an", "inhibitor", "of", "both", "GABA", "(", "A", ")", "Rs", "and", "NMDARs", ")", ",", "and", "a", "newly", "synthesized", "(", "-", ")", "PREGS", "enantiomer", "(", "which", "is", "identical", "to", "PREGS", "in", "effects", "on", "GABA", "(", "A", ")", "Rs", "and", "NMDARs", ")", ".", "The", "memory", "-", "enhancing", "effects", "of", "PREGS", "and", "its", "analogs", "were", "tested", "in", "the", "passive", "avoidance", "task", "using", "the", "model", "of", "scopolamine", "-", "induced", "amnesia", ".", "Both", "PREGS", "and", "its", "(", "-", ")", "enantiomer", "blocked", "the", "effects", "of", "scopolamine", ".", "The", "results", "show", "that", ",", "unlike", "PREGS", ",", "11", "-", "ketopregnenolone", "sulphate", "and", "epipregnanolone", "sulphate", "failed", "to", "block", "the", "effect", "of", "scopolamine", ",", "suggesting", "that", "altering", "the", "modulation", "of", "NMDA", "receptors", "diminishes", "the", "memory", "-", "enhancing", "effects", "of", "PREGS", ".", "Moreover", ",", "enantioselectivity", "was", "demonstrated", "by", "the", "ability", "of", "natural", "PREGS", "to", "be", "an", "order", "of", "magnitude", "more", "effective", "than", "its", "synthetic", "enantiomer", "in", "reversing", "scopolamine", "-", "induced", "amnesia", ".", "These", "results", "identify", "a", "novel", "neuropharmacological", "site", "for", "the", "modulation", "of", "memory", "processes", "by", "neuroactive", "steroids", "."]], "ner": [[[286, 286, "Chemical"], [303, 303, "Chemical"], [326, 326, "Chemical"], [370, 370, "Chemical"], [9, 9, "Disease"], [130, 130, "Disease"], [289, 289, "Disease"], [373, 373, "Disease"], [0, 0, "Chemical"], [62, 62, "Chemical"], [390, 390, "Chemical"], [12, 13, "Chemical"], [22, 23, "Chemical"], [25, 25, "Chemical"], [83, 83, "Chemical"], [124, 124, "Chemical"], [164, 164, "Chemical"], [208, 223, "Chemical"], [245, 245, "Chemical"], [252, 252, "Chemical"], [271, 271, "Chemical"], [292, 292, "Chemical"], [311, 311, "Chemical"], [318, 319, "Chemical"], [343, 343, "Chemical"], [355, 355, "Chemical"], [90, 96, "Chemical"], [334, 334, "Chemical"], [106, 109, "Chemical"], [115, 115, "Chemical"], [137, 137, "Chemical"], [176, 176, "Chemical"], [199, 199, "Chemical"], [229, 229, "Chemical"], [256, 256, "Chemical"]]], "relations": [[[286, 286, 9, 9, "CID"], [286, 286, 130, 130, "CID"], [286, 286, 289, 289, "CID"], [286, 286, 373, 373, "CID"], [303, 303, 9, 9, "CID"], [303, 303, 130, 130, "CID"], [303, 303, 289, 289, "CID"], [303, 303, 373, 373, "CID"], [326, 326, 9, 9, "CID"], [326, 326, 130, 130, "CID"], [326, 326, 289, 289, "CID"], [326, 326, 373, 373, "CID"], [370, 370, 9, 9, "CID"], [370, 370, 130, 130, "CID"], [370, 370, 289, 289, "CID"], [370, 370, 373, 373, "CID"]]], "clusters": [], "translated": " <8>类固醇</8> 结构和药理特性决定了<11>孕烯醇酮硫酸盐</11>在大鼠被动回避任务中的抗<4>遗忘</4>作用。<12>孕烯醇酮硫酸盐</12> (<13>PREGS</13>) 作为啮齿动物学习研究中最有效的增强记忆力的神经类固醇之一引起了人们的兴趣，在衰老过程中尤为重要。这种内源性<9>类固醇</9>增强记忆形成的机制被假设涉及对谷氨酸能和GABAergic系统的作用。这一假设源于以下发现：<14>PREGS</14>是 <26>N-甲基-d-天冬氨酸</26>受体 (NMDARs)的有效正调节剂和<28>γ-氨基丁酸的负调节剂</28>(A)受体(<29>GABA</29>(A)Rs)。此外，<15>PREGS</15>能够逆转NMDAR和<30>GABA</30>(A)R配合物的<5>遗忘</5>样作用。为了研究这一假设，本研究在大鼠中检测了<16>PREGS</16>结构类似物的记忆改变能力，它们在调节NMDAR和/或 <31>GABA</31>(A)R函数方面有所不同。测试的类似物是：11-酮孕烯醇酮硫酸盐（一种在<32>GABA</32>(A)Rs和NMDARs处无活性的试剂），<17>epipregnanolone</17>（[3beta-hydroxy-5beta-pregnan-20-one]硫酸盐，<33>GABA</33>(A)Rs和NMDARs的抑制剂）和新合成的(-)<18>PREGS</18>对映异构体（与<19>PREGS</19>在对<34>GABA</34>(A)Rs和NMDARs的影响方面相同）。使用<0>东莨菪碱</0>诱导的<6>遗忘</6>模型，在被动回避任务中测试了<20>PREGS</20>及其类似物的记忆增强作用。<21>PREGS</21>及其(-)对映异构体均能阻断<1>东莨菪碱</1>的作用。结果显示，与<22>PREGS</22>不同，11-ketopregnenolone sulphate和<23>epipregnanolone sulphate</23>未能阻断<2>东莨菪碱</2>的作用，表明改变<27>NMDA</27>受体减弱了<24>PREGS</24>的记忆增强作用。此外，天然<25>PREGS</25>在逆转<3>东莨菪碱</3>诱导的<7>失忆症</7>方面比其合成对映体更有效的能力证明了对映选择性。这些结果确定了神经活性<10>类固醇</10>调节记忆过程的新神经药理学位点。", "revised": true}
{"doc_key": "12600698", "sentences": [["Protective", "effect", "of", "edaravone", "against", "streptomycin", "-", "induced", "vestibulotoxicity", "in", "the", "guinea", "pig", ".", "This", "study", "investigated", "alleviation", "of", "streptomycin", "-", "induced", "vestibulotoxicity", "by", "edaravone", "in", "guinea", "pigs", ".", "Edaravone", ",", "a", "free", "radical", "scavenger", ",", "has", "potent", "free", "radical", "quenching", "action", "and", "is", "used", "in", "clinical", "practice", "to", "treat", "cerebral", "infarction", ".", "Streptomycin", "was", "administered", "to", "the", "inner", "ear", "by", "osmotic", "pump", "for", "24", "h", ",", "and", "edaravone", "(", "n", "=", "8", ")", "or", "saline", "(", "n", "=", "6", ")", "was", "intraperitoneally", "injected", "once", "a", "day", "for", "7", "days", ".", "We", "observed", "horizontal", "vestibulo", "-", "ocular", "reflex", "as", "a", "marker", "of", "postoperative", "vestibular", "function", ".", "Animals", "injected", "with", "saline", "showed", "statistically", "smaller", "gains", "than", "those", "injected", "with", "edaravone", ".", "These", "results", "suggest", "that", "edaravone", "suppresses", "streptomycin", "-", "induced", "vestibulotoxicity", "."]], "ner": [[[5, 5, "Chemical"], [19, 19, "Chemical"], [53, 53, "Chemical"], [126, 126, "Chemical"], [8, 8, "Disease"], [22, 22, "Disease"], [129, 129, "Disease"], [3, 3, "Chemical"], [24, 24, "Chemical"], [29, 29, "Chemical"], [68, 68, "Chemical"], [118, 118, "Chemical"], [124, 124, "Chemical"], [50, 51, "Disease"]]], "relations": [[[5, 5, 8, 8, "CID"], [5, 5, 22, 22, "CID"], [5, 5, 129, 129, "CID"], [19, 19, 8, 8, "CID"], [19, 19, 22, 22, "CID"], [19, 19, 129, 129, "CID"], [53, 53, 8, 8, "CID"], [53, 53, 22, 22, "CID"], [53, 53, 129, 129, "CID"], [126, 126, 8, 8, "CID"], [126, 126, 22, 22, "CID"], [126, 126, 129, 129, "CID"]]], "clusters": [], "translated": "<7>依达拉奉</7>对<0>链霉素</0>引起的<4>豚鼠前庭毒性</4>的保护作用。本研究考察了<8>依达拉奉</8>对豚鼠<1>链霉素</1>诱导的<5>前庭毒性</5>的缓解作用。<9>依达拉奉</9>是一种自由基清除剂，具有强效的自由基猝灭作用，临床上用于治疗<13>脑梗塞</13>。渗透泵内耳给药<2>链霉素</2> 24 h，<10>依达拉奉</10> (n=8) 或生理盐水 (n=6) 腹腔注射，每天 1 次，连续 7 天。我们观察水平前庭眼反射作为术后前庭功能的标志。注射生理盐水的动物在统计学上表现出更小的增益，与注射<11>依达拉奉</11>的动物相比。这些结果表明<12>依达拉奉</12>抑制<3>链霉素</3>诱导的<6>前庭毒性</6>。", "revised": true}
{"doc_key": "12760988", "sentences": [["Postoperative", "myalgia", "after", "succinylcholine", ":", "no", "evidence", "for", "an", "inflammatory", "origin", ".", "A", "common", "side", "effect", "associated", "with", "succinylcholine", "is", "postoperative", "myalgia", ".", "The", "pathogenesis", "of", "this", "myalgia", "is", "still", "unclear", ";", "inflammation", "has", "been", "suggested", "but", "without", "convincing", "evidence", ".", "We", "designed", "the", "present", "study", "to", "investigate", "whether", "an", "inflammatory", "reaction", "contributes", "to", "this", "myalgia", ".", "The", "incidence", "and", "severity", "of", "succinylcholine", "-", "associated", "myalgia", "was", "determined", "in", "64", "patients", "pretreated", "with", "saline", "or", "dexamethasone", "before", "succinylcholine", "(", "n", "=", "32", "for", "each", ")", ".", "Incidence", "and", "severity", "of", "myalgia", "did", "not", "differ", "significantly", "between", "the", "two", "groups", ":", "15", "patients", "in", "the", "dexamethasone", "group", "complained", "of", "myalgia", "compared", "with", "18", "patients", "in", "the", "saline", "group", ",", "and", "severe", "myalgia", "was", "reported", "by", "five", "patients", "and", "three", "patients", ",", "respectively", "(", "not", "significant", ")", ".", "At", "48", "h", "after", "surgery", ",", "12", "patients", "in", "both", "groups", "still", "suffered", "from", "myalgia", "(", "not", "significant", ")", ".", "In", "addition", ",", "interleukin", "-", "6", "(", "IL", "-", "6", ")", "as", "an", "early", "marker", "of", "inflammation", "was", "assessed", "in", "a", "subgroup", "of", "10", "patients", "pretreated", "with", "saline", ".", "We", "found", "an", "increase", "of", "IL", "-", "6", "for", "only", "three", "patients", ",", "but", "only", "one", "patient", "reported", "myalgia", ";", "no", "relationship", "between", "myalgia", "and", "the", "increase", "of", "IL", "-", "6", "was", "found", ".", "In", "conclusion", ",", "there", "is", "no", "evidence", "for", "an", "inflammatory", "origin", "of", "succinylcholine", "-", "associated", "myalgia", ".", "IMPLICATIONS", ":", "Administration", "of", "dexamethasone", "before", "succinylcholine", "was", "not", "effective", "in", "decreasing", "the", "incidence", "or", "the", "severity", "of", "succinylcholine", "-", "induced", "postoperative", "myalgia", ".", "Furthermore", ",", "there", "was", "no", "significant", "relationship", "between", "postoperative", "myalgia", "and", "time", "course", "of", "interleukin", "-", "6", "concentrations", ",", "a", "marker", "of", "inflammation", ".", "Pretreatment", "with", "dexamethasone", "is", "not", "justified", "to", "prevent", "postoperative", "myalgia", "after", "succinylcholine", "."]], "ner": [[[3, 3, "Chemical"], [18, 18, "Chemical"], [62, 62, "Chemical"], [77, 77, "Chemical"], [231, 231, "Chemical"], [242, 242, "Chemical"], [254, 254, "Chemical"], [295, 295, "Chemical"], [0, 1, "Disease"], [20, 21, "Disease"], [257, 258, "Disease"], [268, 269, "Disease"], [292, 293, "Disease"], [27, 27, "Disease"], [55, 55, "Disease"], [65, 65, "Disease"], [90, 90, "Disease"], [108, 108, "Disease"], [120, 120, "Disease"], [150, 150, "Disease"], [203, 203, "Disease"], [208, 208, "Disease"], [234, 234, "Disease"], [75, 75, "Chemical"], [104, 104, "Chemical"], [240, 240, "Chemical"], [286, 286, "Chemical"], [32, 32, "Disease"], [172, 172, "Disease"], [282, 282, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [3, 3, 20, 21, "CID"], [3, 3, 257, 258, "CID"], [3, 3, 268, 269, "CID"], [3, 3, 292, 293, "CID"], [18, 18, 0, 1, "CID"], [18, 18, 20, 21, "CID"], [18, 18, 257, 258, "CID"], [18, 18, 268, 269, "CID"], [18, 18, 292, 293, "CID"], [62, 62, 0, 1, "CID"], [62, 62, 20, 21, "CID"], [62, 62, 257, 258, "CID"], [62, 62, 268, 269, "CID"], [62, 62, 292, 293, "CID"], [77, 77, 0, 1, "CID"], [77, 77, 20, 21, "CID"], [77, 77, 257, 258, "CID"], [77, 77, 268, 269, "CID"], [77, 77, 292, 293, "CID"], [231, 231, 0, 1, "CID"], [231, 231, 20, 21, "CID"], [231, 231, 257, 258, "CID"], [231, 231, 268, 269, "CID"], [231, 231, 292, 293, "CID"], [242, 242, 0, 1, "CID"], [242, 242, 20, 21, "CID"], [242, 242, 257, 258, "CID"], [242, 242, 268, 269, "CID"], [242, 242, 292, 293, "CID"], [254, 254, 0, 1, "CID"], [254, 254, 20, 21, "CID"], [254, 254, 257, 258, "CID"], [254, 254, 268, 269, "CID"], [254, 254, 292, 293, "CID"], [295, 295, 0, 1, "CID"], [295, 295, 20, 21, "CID"], [295, 295, 257, 258, "CID"], [295, 295, 268, 269, "CID"], [295, 295, 292, 293, "CID"], [3, 3, 27, 27, "CID"], [3, 3, 55, 55, "CID"], [3, 3, 65, 65, "CID"], [3, 3, 90, 90, "CID"], [3, 3, 108, 108, "CID"], [3, 3, 120, 120, "CID"], [3, 3, 150, 150, "CID"], [3, 3, 203, 203, "CID"], [3, 3, 208, 208, "CID"], [3, 3, 234, 234, "CID"], [18, 18, 27, 27, "CID"], [18, 18, 55, 55, "CID"], [18, 18, 65, 65, "CID"], [18, 18, 90, 90, "CID"], [18, 18, 108, 108, "CID"], [18, 18, 120, 120, "CID"], [18, 18, 150, 150, "CID"], [18, 18, 203, 203, "CID"], [18, 18, 208, 208, "CID"], [18, 18, 234, 234, "CID"], [62, 62, 27, 27, "CID"], [62, 62, 55, 55, "CID"], [62, 62, 65, 65, "CID"], [62, 62, 90, 90, "CID"], [62, 62, 108, 108, "CID"], [62, 62, 120, 120, "CID"], [62, 62, 150, 150, "CID"], [62, 62, 203, 203, "CID"], [62, 62, 208, 208, "CID"], [62, 62, 234, 234, "CID"], [77, 77, 27, 27, "CID"], [77, 77, 55, 55, "CID"], [77, 77, 65, 65, "CID"], [77, 77, 90, 90, "CID"], [77, 77, 108, 108, "CID"], [77, 77, 120, 120, "CID"], [77, 77, 150, 150, "CID"], [77, 77, 203, 203, "CID"], [77, 77, 208, 208, "CID"], [77, 77, 234, 234, "CID"], [231, 231, 27, 27, "CID"], [231, 231, 55, 55, "CID"], [231, 231, 65, 65, "CID"], [231, 231, 90, 90, "CID"], [231, 231, 108, 108, "CID"], [231, 231, 120, 120, "CID"], [231, 231, 150, 150, "CID"], [231, 231, 203, 203, "CID"], [231, 231, 208, 208, "CID"], [231, 231, 234, 234, "CID"], [242, 242, 27, 27, "CID"], [242, 242, 55, 55, "CID"], [242, 242, 65, 65, "CID"], [242, 242, 90, 90, "CID"], [242, 242, 108, 108, "CID"], [242, 242, 120, 120, "CID"], [242, 242, 150, 150, "CID"], [242, 242, 203, 203, "CID"], [242, 242, 208, 208, "CID"], [242, 242, 234, 234, "CID"], [254, 254, 27, 27, "CID"], [254, 254, 55, 55, "CID"], [254, 254, 65, 65, "CID"], [254, 254, 90, 90, "CID"], [254, 254, 108, 108, "CID"], [254, 254, 120, 120, "CID"], [254, 254, 150, 150, "CID"], [254, 254, 203, 203, "CID"], [254, 254, 208, 208, "CID"], [254, 254, 234, 234, "CID"], [295, 295, 27, 27, "CID"], [295, 295, 55, 55, "CID"], [295, 295, 65, 65, "CID"], [295, 295, 90, 90, "CID"], [295, 295, 108, 108, "CID"], [295, 295, 120, 120, "CID"], [295, 295, 150, 150, "CID"], [295, 295, 203, 203, "CID"], [295, 295, 208, 208, "CID"], [295, 295, 234, 234, "CID"]]], "clusters": [], "translated": "<8>术后肌痛</8> <0>琥珀酰胆碱</0>：无炎症起源的证据。与<1>琥珀酰胆碱</1>相关的常见副作用是<9>术后肌痛</9>。这种<13>肌痛</13>的发病机制尚不清楚；有人提出<27>炎症</27>但没有令人信服的证据。我们设计本研究以调查炎症反应是否会导致这种<14>肌痛</14>。<2>琥珀胆碱</2> - 相关的<15>肌痛</15>的发生率和严重程度在每组32例患者中确定，在<3>琥珀胆碱</3>之前用生理盐水或<23>地塞米松</23>预处理。两组<16>肌痛</16>的发生率和严重程度之间没有显着差异： <24>地塞米松</24>组有15名患者主诉有<17>肌痛</17>，而生理盐水组有18名患者报告<18>严重肌痛</18>，分别有5名和3名患者（无显着性）。术后48 h后，两组仍有12例<19>肌痛</19>（无显着差异）。此外，以白细胞介素-6 (IL-6) 作为<28>炎症</28>的早期标志，对10名接受生理盐水预处理的患者进行了评估。我们发现仅3名患者的IL-6增加，但只有1名患者报告<20>肌痛</20>；未发现<21>肌痛</21>和IL-6增加之间的关系。总之，没有证据表明<4>琥珀酰胆碱</4> - 相关的<22>肌痛</22>是由炎症引起的。意义是：<5>琥珀胆碱</5>之前给予<25>地塞米松</25>不能有效降低<6>琥珀胆碱</6>引起的<10>术后肌痛</10>的发生率或严重程度。此外，<11>术后肌痛</11>和白细胞介素-6浓度的时间进程之间没有显着关系，白细胞介素6浓度是<29>炎症</29>的标志物。预处理<26>地塞米松</26>不能预防<7>琥珀胆碱</7>后<12>术后肌痛</12>。", "revised": true}
{"doc_key": "20394767", "sentences": [["Fear", "-", "potentiated", "startle", ",", "but", "not", "light", "-", "enhanced", "startle", ",", "is", "enhanced", "by", "anxiogenic", "drugs", ".", "RATIONALE", "AND", "OBJECTIVES", ":", "The", "light", "-", "enhanced", "startle", "paradigm", "(", "LES", ")", "is", "suggested", "to", "model", "anxiety", ",", "because", "of", "the", "non", "-", "specific", "cue", "and", "the", "long", "-", "term", "effect", ".", "In", "contrast", ",", "the", "fear", "-", "potentiated", "startle", "(", "FPS", ")", "is", "suggested", "to", "model", "conditioned", "fear", ".", "However", ",", "the", "pharmacological", "profiles", "of", "these", "two", "paradigms", "are", "very", "similar", ".", "The", "present", "study", "investigated", "the", "effects", "of", "putative", "anxiogenic", "drugs", "on", "LES", "and", "FPS", "and", "aimed", "at", "determining", "the", "sensitivity", "of", "LES", "for", "anxiogenic", "drugs", "and", "to", "potentially", "showing", "a", "pharmacological", "differentiation", "between", "these", "two", "paradigms", ".", "METHODS", ":", "Male", "Wistar", "rats", "received", "each", "dose", "of", "the", "alpha", "(", "2", ")", "-", "adrenoceptor", "antagonist", "yohimbine", "(", "0", ".", "25", "-", "1", ".", "0mg", "/", "kg", ")", ",", "the", "5", "-", "HT", "(", "2C", ")", "receptor", "agonist", "m", "-", "chlorophenylpiperazine", "(", "mCPP", ",", "0", ".", "5", "-", "2", ".", "0mg", "/", "kg", ")", "or", "the", "GABA", "(", "A", ")", "inverse", "receptor", "agonist", "pentylenetetrazole", "(", "PTZ", ",", "3", "-", "30mg", "/", "kg", ")", "and", "were", "subsequently", "tested", "in", "either", "LES", "or", "FPS", ".", "RESULTS", ":", "None", "of", "the", "drugs", "enhanced", "LES", ",", "whereas", "mCPP", "increased", "percentage", "FPS", "and", "yohimbine", "increased", "absolute", "FPS", "values", ".", "Furthermore", ",", "yohimbine", "increased", "baseline", "startle", "amplitude", "in", "the", "LES", ",", "while", "mCPP", "suppressed", "baseline", "startle", "in", "both", "the", "LES", "and", "FPS", "and", "PTZ", "suppressed", "baseline", "startle", "in", "the", "FPS", ".", "CONCLUSIONS", ":", "In", "contrast", "to", "findings", "in", "the", "FPS", "paradigm", ",", "none", "of", "the", "drugs", "were", "able", "to", "exacerbate", "the", "LES", "response", ".", "Thus", ",", "a", "clear", "pharmacological", "differentiation", "was", "found", "between", "LES", "and", "FPS", "."]], "ner": [[[136, 136, "Chemical"], [218, 218, "Chemical"], [226, 226, "Chemical"], [3, 3, "Disease"], [10, 10, "Disease"], [26, 26, "Disease"], [58, 58, "Disease"], [229, 229, "Disease"], [239, 239, "Disease"], [250, 250, "Disease"], [158, 160, "Chemical"], [162, 162, "Chemical"], [213, 213, "Chemical"], [236, 236, "Chemical"], [183, 183, "Chemical"], [185, 185, "Chemical"], [247, 247, "Chemical"], [150, 152, "Chemical"], [176, 176, "Chemical"], [35, 35, "Disease"]]], "relations": [[[136, 136, 3, 3, "CID"], [136, 136, 10, 10, "CID"], [136, 136, 26, 26, "CID"], [136, 136, 58, 58, "CID"], [136, 136, 229, 229, "CID"], [136, 136, 239, 239, "CID"], [136, 136, 250, 250, "CID"], [218, 218, 3, 3, "CID"], [218, 218, 10, 10, "CID"], [218, 218, 26, 26, "CID"], [218, 218, 58, 58, "CID"], [218, 218, 229, 229, "CID"], [218, 218, 239, 239, "CID"], [218, 218, 250, 250, "CID"], [226, 226, 3, 3, "CID"], [226, 226, 10, 10, "CID"], [226, 226, 26, 26, "CID"], [226, 226, 58, 58, "CID"], [226, 226, 229, 229, "CID"], [226, 226, 239, 239, "CID"], [226, 226, 250, 250, "CID"], [158, 160, 3, 3, "CID"], [158, 160, 10, 10, "CID"], [158, 160, 26, 26, "CID"], [158, 160, 58, 58, "CID"], [158, 160, 229, 229, "CID"], [158, 160, 239, 239, "CID"], [158, 160, 250, 250, "CID"], [162, 162, 3, 3, "CID"], [162, 162, 10, 10, "CID"], [162, 162, 26, 26, "CID"], [162, 162, 58, 58, "CID"], [162, 162, 229, 229, "CID"], [162, 162, 239, 239, "CID"], [162, 162, 250, 250, "CID"], [213, 213, 3, 3, "CID"], [213, 213, 10, 10, "CID"], [213, 213, 26, 26, "CID"], [213, 213, 58, 58, "CID"], [213, 213, 229, 229, "CID"], [213, 213, 239, 239, "CID"], [213, 213, 250, 250, "CID"], [236, 236, 3, 3, "CID"], [236, 236, 10, 10, "CID"], [236, 236, 26, 26, "CID"], [236, 236, 58, 58, "CID"], [236, 236, 229, 229, "CID"], [236, 236, 239, 239, "CID"], [236, 236, 250, 250, "CID"], [183, 183, 3, 3, "CID"], [183, 183, 10, 10, "CID"], [183, 183, 26, 26, "CID"], [183, 183, 58, 58, "CID"], [183, 183, 229, 229, "CID"], [183, 183, 239, 239, "CID"], [183, 183, 250, 250, "CID"], [185, 185, 3, 3, "CID"], [185, 185, 10, 10, "CID"], [185, 185, 26, 26, "CID"], [185, 185, 58, 58, "CID"], [185, 185, 229, 229, "CID"], [185, 185, 239, 239, "CID"], [185, 185, 250, 250, "CID"], [247, 247, 3, 3, "CID"], [247, 247, 10, 10, "CID"], [247, 247, 26, 26, "CID"], [247, 247, 58, 58, "CID"], [247, 247, 229, 229, "CID"], [247, 247, 239, 239, "CID"], [247, 247, 250, 250, "CID"]]], "clusters": [], "translated": "恐惧增强的<6>惊吓</6>，而不是光增强的<5>惊吓</5>，是由抗焦虑药物增强的。<3>惊吓</3>的强化作用，但不是<4>光增强惊吓</4>的强化作用，是由抗焦虑药物增强的。 基本原理和目标:鉴于非特异刺激和长时间影响的影响，光增强<5>惊吓</5>（LES）范例被认为是模拟<19>焦虑</19>的。相比之下， 恐惧增强的<6>惊吓</6>（FPS）被认为是模拟条件性恐惧的。然而，这两种范式的药物作用特征非常类似。 本研究旨在调查假设的致焦虑药物对 LES 和 FPS 的作用，并旨在确定 LES 对致焦虑药物的灵敏性，并可能显示这两种范式之间的药理差异。 方法： Wistar 雄性大鼠接受了每个剂量的α (2)-肾上腺素能受体拮抗剂<0>育亨宾</0>（0.25 -1.0mg/kg），<17> 5-HT </17>(2C)受体激动剂<10>间-氯苯基哌嗪</10> (<11> mCPP </11>，0.5-2.0mg/kg) 或<18> GABA </18> (A) 反向受体激动剂<14>戊四唑</14> (<15> PTZ </15>，3-30mg/kg) ，然后在 LES 或 FPS 中进行了测试。 结果：所有药物均未增强 LES 的效果，而<12> mCPP </12> 增加了 FPS 百分比，而<1>育亨宾</1> 增加了 FPS 的绝对值效果。此外，<2>育亨宾</2>增加 LES 中的基线<7>惊吓</7>振幅，而<13> mCPP </13> 抑制了 LES 和 FPS 中的基线<8>惊吓</8>，<16> PTZ </16> 抑制了 FPS 中的基线<9>惊吓</9> 。结论：与 FPS 范式中的结果相反，没有一种药物能够加剧 LES 的效果。因此， LES 和 FPS 之间存在明显的药理差异。", "revised": true}
{"doc_key": "7197363", "sentences": [["REM", "sleep", "deprivation", "changes", "behavioral", "response", "to", "catecholaminergic", "and", "serotonergic", "receptor", "activation", "in", "rats", ".", "The", "effects", "of", "REM", "sleep", "deprivation", "(", "REMD", ")", "on", "apomorphine", "-", "induced", "aggressiveness", "and", "quipazine", "-", "induced", "head", "twitches", "in", "rats", "were", "determined", ".", "Forty", "-", "eight", "hr", "of", "REMD", "increased", "apomorphine", "-", "induced", "aggressiveness", ",", "and", "reduced", "(", "immediately", "after", "completing", "of", "REMD", ")", "or", "increased", "(", "96", "hr", "after", "completing", "of", "REMD", ")", "quipazine", "-", "induced", "head", "twitches", ".", "Results", "are", "discussed", "in", "terms", "of", "similarity", "to", "pharmacological", "effects", "of", "other", "antidepressive", "treatments", "."]], "ner": [[[25, 25, "Chemical"], [47, 47, "Chemical"], [28, 28, "Disease"], [50, 50, "Disease"], [30, 30, "Chemical"], [71, 71, "Chemical"], [33, 34, "Disease"], [74, 75, "Disease"], [0, 2, "Disease"], [18, 20, "Disease"], [22, 22, "Disease"], [45, 45, "Disease"], [59, 59, "Disease"], [69, 69, "Disease"]]], "relations": [[[25, 25, 28, 28, "CID"], [25, 25, 50, 50, "CID"], [47, 47, 28, 28, "CID"], [47, 47, 50, 50, "CID"], [30, 30, 33, 34, "CID"], [30, 30, 74, 75, "CID"], [71, 71, 33, 34, "CID"], [71, 71, 74, 75, "CID"]]], "clusters": [], "translated": " <8>REM睡眠剥夺</8> 改变了大鼠对儿茶酚能和血清素能受体激活的行为反应。 <9>REM睡眠剥夺</9>（<10>REMD</10>）对 <0>阿扑吗啡</0> - 诱导的<2>攻击性</2>和 <4>喹哌嗪</4> - 诱导的 <6>头部抽搐</6> 在大鼠身上进行了测定。 四十八小时的 <11>REMD</11> 增加了 <1>阿扑吗啡</1> - 诱导的 <3>攻击性</3> ，并在完成 <12>REMD</12> 立即减少或在完成 <13>REMD</13> 后 96 小时增加 <5>喹哌嗪</5> - 诱导的 <7>头部抽搐</7> 。结果根据与其他抗抑郁治疗的药理作用的相似性进行讨论。", "revised": true}
{"doc_key": "10354657", "sentences": [["Effect", "of", "lithium", "maintenance", "therapy", "on", "thyroid", "and", "parathyroid", "function", ".", "OBJECTIVES", ":", "To", "assess", "changes", "induced", "by", "lithium", "maintenance", "therapy", "on", "the", "incidence", "of", "thyroid", ",", "parathyroid", "and", "ion", "alterations", ".", "These", "were", "evaluated", "with", "respect", "to", "the", "duration", "of", "lithium", "therapy", ",", "age", ",", "sex", ",", "and", "family", "history", "(", "whether", "or", "not", "the", "patient", "had", "a", "first", "-", "degree", "relative", "with", "thyroid", "disease", ")", ".", "DESIGN", ":", "Prospective", "study", ".", "SETTING", ":", "Affective", "Disorders", "Clinic", "at", "St", ".", "Mary", "'s", "Hospital", ",", "Montreal", ".", "PATIENTS", ":", "One", "hundred", "and", "one", "patients", "(", "28", "men", "and", "73", "women", ")", "with", "bipolar", "disorder", "receiving", "lithium", "maintenance", "therapy", "ranging", "from", "1", "year", "'s", "to", "32", "years", "'", "duration", ".", "The", "control", "group", "consisted", "of", "82", "patients", "with", "no", "psychiatric", "or", "endocrinological", "diagnoses", "from", "the", "hospital", "'s", "out", "-", "patient", "clinics", ".", "OUTCOME", "MEASURES", ":", "Laboratory", "analyses", "of", "calcium", ",", "magnesium", "and", "thyroid", "-", "stimulating", "hormone", "levels", "performed", "before", "beginning", "lithium", "therapy", "and", "at", "biannual", "follow", "-", "up", ".", "RESULTS", ":", "Hypothyroidism", "developed", "in", "40", "patients", ",", "excluding", "8", "patients", "who", "were", "hypothyroid", "at", "baseline", ".", "All", "patients", "having", "first", "-", "degree", "relatives", "affected", "by", "thyroid", "illness", "had", "accelerated", "onset", "of", "hypothyroidism", "(", "3", ".", "7", "years", "after", "onset", "of", "lithium", "therapy", ")", "compared", "with", "patients", "without", "a", "family", "history", "(", "8", ".", "6", "years", "after", "onset", "of", "lithium", "therapy", ")", ".", "Women", "over", "60", "years", "of", "age", "were", "more", "often", "affected", "by", "hypothyroidism", "than", "women", "under", "60", "years", "of", "age", "(", "34", ".", "6", "%", "versus", "31", ".", "9", "%", ")", ".", "Magnesium", "levels", "in", "patients", "on", "lithium", "treatment", "were", "unchanged", "from", "baseline", "levels", ".", "After", "lithium", "treatment", ",", "calcium", "levels", "were", "higher", "than", "either", "baseline", "levels", "or", "control", "levels", ".", "Thus", ",", "lithium", "treatment", "counteracted", "the", "decrease", "in", "plasma", "calcium", "levels", "associated", "with", "aging", ".", "CONCLUSIONS", ":", "Familial", "thyroid", "illness", "is", "a", "risk", "factor", "for", "hypothyroidism", "and", "hypercalcemia", "during", "lithium", "therapy", "."]], "ner": [[[2, 2, "Chemical"], [18, 18, "Chemical"], [41, 41, "Chemical"], [105, 105, "Chemical"], [159, 159, "Chemical"], [209, 209, "Chemical"], [227, 227, "Chemical"], [267, 267, "Chemical"], [276, 276, "Chemical"], [293, 293, "Chemical"], [320, 320, "Chemical"], [170, 170, "Disease"], [181, 181, "Disease"], [200, 200, "Disease"], [242, 242, "Disease"], [316, 316, "Disease"], [64, 65, "Disease"], [194, 195, "Disease"], [309, 310, "Disease"], [102, 103, "Disease"], [128, 128, "Disease"], [318, 318, "Disease"], [147, 147, "Chemical"], [279, 279, "Chemical"], [300, 300, "Chemical"], [149, 149, "Chemical"], [262, 262, "Chemical"]]], "relations": [[[2, 2, 170, 170, "CID"], [2, 2, 181, 181, "CID"], [2, 2, 200, 200, "CID"], [2, 2, 242, 242, "CID"], [2, 2, 316, 316, "CID"], [18, 18, 170, 170, "CID"], [18, 18, 181, 181, "CID"], [18, 18, 200, 200, "CID"], [18, 18, 242, 242, "CID"], [18, 18, 316, 316, "CID"], [41, 41, 170, 170, "CID"], [41, 41, 181, 181, "CID"], [41, 41, 200, 200, "CID"], [41, 41, 242, 242, "CID"], [41, 41, 316, 316, "CID"], [105, 105, 170, 170, "CID"], [105, 105, 181, 181, "CID"], [105, 105, 200, 200, "CID"], [105, 105, 242, 242, "CID"], [105, 105, 316, 316, "CID"], [159, 159, 170, 170, "CID"], [159, 159, 181, 181, "CID"], [159, 159, 200, 200, "CID"], [159, 159, 242, 242, "CID"], [159, 159, 316, 316, "CID"], [209, 209, 170, 170, "CID"], [209, 209, 181, 181, "CID"], [209, 209, 200, 200, "CID"], [209, 209, 242, 242, "CID"], [209, 209, 316, 316, "CID"], [227, 227, 170, 170, "CID"], [227, 227, 181, 181, "CID"], [227, 227, 200, 200, "CID"], [227, 227, 242, 242, "CID"], [227, 227, 316, 316, "CID"], [267, 267, 170, 170, "CID"], [267, 267, 181, 181, "CID"], [267, 267, 200, 200, "CID"], [267, 267, 242, 242, "CID"], [267, 267, 316, 316, "CID"], [276, 276, 170, 170, "CID"], [276, 276, 181, 181, "CID"], [276, 276, 200, 200, "CID"], [276, 276, 242, 242, "CID"], [276, 276, 316, 316, "CID"], [293, 293, 170, 170, "CID"], [293, 293, 181, 181, "CID"], [293, 293, 200, 200, "CID"], [293, 293, 242, 242, "CID"], [293, 293, 316, 316, "CID"], [320, 320, 170, 170, "CID"], [320, 320, 181, 181, "CID"], [320, 320, 200, 200, "CID"], [320, 320, 242, 242, "CID"], [320, 320, 316, 316, "CID"]]], "clusters": [], "translated": "<0>锂</0>维持治疗对甲状腺和甲状旁腺功能的影响。目的：评估<1>锂</1>维持治疗引起的甲状腺、甲状旁腺和离子改变发生率的变化。评估对象包括<2>锂</2>治疗的持续时间、年龄、性别和家族史（患者是否有一级亲属患有<16>甲状腺疾病</16>）。\n设计：前瞻性研究。地点：蒙特利尔圣玛丽医院的情感障碍诊所。\n患者：101 名<19>双相情感障碍</19>患者（28 名男性和 73 名女性），接受为期 1 年至 32 年的<3>锂</3>维持治疗。对照组包括 82 名来自医院门诊的没有<20>精神病学</20>或内分泌学诊断的患者。\n结果测量：在开始<4>锂</4>治疗之前和每两年一次的随访中进行了<22>钙</22>、<25>镁</25>和促甲状腺激素水平的实验室分析。\n\n结果：40 名患者出现<11>甲状腺功能减退</11>，排除了 8 名基线时<12>甲状腺功能减退</12>的患者。所有有患有<17>甲状腺疾病</17>的一级亲属的患者都加速了<13>甲状腺功能减退症</13>的发作（<5>锂</5>治疗开始后3.7 年），而没有家族史的患者则是<6>锂</6>治疗开始后8.6 年。60 岁以上的女性比 60 岁以下的女性更容易患<14>甲状腺功能减退症</14>（分别为 34.6% 和 31.9%）。接受<7>锂</7>治疗的患者的<26>镁</26>水平与基线水平相比没有变化。<8>锂</8>治疗后，<23>钙</23>水平高于基线水平或对照水平。因此，<9>锂</9>治疗抵消了与衰老相关的血浆<24>钙</24>水平下降。\n\n结论：家族性<18>甲状腺疾病</18>是<10>锂</10>治疗期间<15>甲状腺功能减退</15>和<21>高钙血症</21>的危险因素。", "revised": true}
{"doc_key": "3973521", "sentences": [["Time", "course", "alterations", "of", "QTC", "interval", "due", "to", "hypaque", "76", ".", "Sequential", "measurement", "of", "QT", "interval", "during", "left", "ventricular", "angiography", "was", "made", "30", "seconds", "and", "one", ",", "three", ",", "five", "and", "ten", "minutes", "after", "injection", "of", "hypaque", "76", ".", "The", "subjects", "were", "ten", "patients", "found", "to", "have", "normal", "left", "ventricles", "and", "coronary", "arteries", ".", "Significant", "QTC", "prolongation", "occurred", "in", "30", "seconds", "to", "one", "minute", "in", "association", "with", "marked", "hypotension", "and", "elevation", "of", "cardiac", "output", "."]], "ner": [[[8, 9, "Chemical"], [36, 37, "Chemical"], [55, 56, "Disease"], [68, 68, "Disease"]]], "relations": [[[8, 9, 55, 56, "CID"], [36, 37, 55, 56, "CID"], [8, 9, 68, 68, "CID"], [36, 37, 68, 68, "CID"]]], "clusters": [], "translated": "由于<0>hypaque 76</0>引起的QTC间期的时程变化。在注射<1>hypaque 76</1>后30秒和1、3、5和10分钟，在左心室造影期间连续测量QT间期。受试者是十名左心室和冠状动脉正常的患者。显着的<2>QTC延长</2>发生在30秒到1分钟内，并伴有显着的<3>低血压</3>和心输出量升高。", "revised": true}
{"doc_key": "7161250", "sentences": [["Extrapyramidal", "side", "effects", "and", "oral", "haloperidol", ":", "an", "analysis", "of", "explanatory", "patient", "and", "treatment", "characteristics", ".", "The", "incidence", "of", "extrapyramidal", "side", "effects", "(", "EPS", ")", "was", "evaluated", "in", "98", "patients", "treated", "with", "haloperidol", ".", "The", "incidence", "of", "parkinsonism", "was", "higher", "at", "higher", "doses", "of", "haloperidol", "and", "in", "younger", "patients", ".", "Prophylactic", "antiparkinsonian", "medication", "was", "effective", "in", "younger", "but", "not", "in", "older", "patients", ".", "However", ",", "these", "medications", "were", "more", "effective", "in", "both", "young", "and", "old", "patients", "when", "given", "after", "parkinsonism", "developed", ".", "Akathisia", "was", "controlled", "by", "the", "benzodiazepine", "lorazepam", "in", "14", "out", "of", "16", "patients", ",", "while", "prophylactic", "antiparkinsonians", "were", "ineffective", ".", "The", "present", "study", "points", "to", "patient", "characteristics", "that", "may", "be", "of", "significance", "in", "the", "development", "of", "EPS", "due", "to", "haloperidol", "."]], "ner": [[[5, 5, "Chemical"], [32, 32, "Chemical"], [44, 44, "Chemical"], [121, 121, "Chemical"], [37, 37, "Disease"], [79, 79, "Disease"], [82, 82, "Disease"], [87, 87, "Chemical"], [88, 88, "Chemical"]]], "relations": [[[5, 5, 37, 37, "CID"], [5, 5, 79, 79, "CID"], [32, 32, 37, 37, "CID"], [32, 32, 79, 79, "CID"], [44, 44, 37, 37, "CID"], [44, 44, 79, 79, "CID"], [121, 121, 37, 37, "CID"], [121, 121, 79, 79, "CID"]]], "clusters": [], "translated": "锥体外系副作用和口服<0>氟哌啶醇</0>：对解释性患者和治疗特征的分析。在 98 名接受<1>氟哌啶醇</1>治疗的患者中，评估了锥体外系副作用（EPS）的发生率。发现<4>帕金森症</4>发生率在较高剂量的<2>氟哌啶醇</2>和较年轻的患者中较高。预防性抗帕金森病药物对年轻患者有效，但对老年患者无效。然而，这些药物在<5>帕金森综合症</5>发生后给予年轻和老年患者都更有效。<6>静坐不能</6>在16例患者中有14例通过<7>苯二氮卓类药物</7><8>劳拉西泮</8>得到控制，而预防性抗帕金森病药物无效。本研究指出了可能对<3>氟哌啶醇</3>导致的EPS发展具有重要意义的患者特征。", "revised": true}
{"doc_key": "10328196", "sentences": [["Systemic", "toxicity", "following", "administration", "of", "sirolimus", "(", "formerly", "rapamycin", ")", "for", "psoriasis", ":", "association", "of", "capillary", "leak", "syndrome", "with", "apoptosis", "of", "lesional", "lymphocytes", ".", "BACKGROUND", ":", "Sirolimus", "(", "formerly", "rapamycin", ")", "is", "an", "immunosuppressive", "agent", "that", "interferes", "with", "T", "-", "cell", "activation", ".", "After", "2", "individuals", "with", "psoriasis", "developed", "a", "capillary", "leak", "syndrome", "following", "treatment", "with", "oral", "sirolimus", "lesional", "skin", "cells", "and", "activated", "peripheral", "blood", "cells", "were", "analyzed", "for", "induction", "of", "apoptosis", ".", "OBSERVATIONS", ":", "A", "keratome", "skin", "specimen", "from", "1", "patient", "with", "sirolimus", "-", "induced", "capillary", "leak", "syndrome", "had", "a", "2", ".", "3", "-", "fold", "increase", "in", "percentage", "of", "apoptotic", "cells", "(", "to", "48", "%", ")", "compared", "with", "an", "unaffected", "sirolimus", "-", "treated", "patient", "with", "psoriasis", "(", "21", "%", ")", ".", "Activated", "peripheral", "blood", "T", "cells", "from", "patients", "with", "psoriasis", "tended", "to", "exhibit", "greater", "spontaneous", "or", "dexamethasone", "-", "induced", "apoptosis", "than", "did", "normal", "T", "cells", ",", "particularly", "in", "the", "presence", "of", "sirolimus", ".", "CONCLUSIONS", ":", "Severe", "adverse", "effects", "of", "sirolimus", "include", "fever", ",", "anemia", ",", "and", "capillary", "leak", "syndrome", ".", "These", "symptoms", "may", "be", "the", "result", "of", "drug", "-", "induced", "apoptosis", "of", "lesional", "leukocytes", ",", "especially", "activated", "T", "lymphocytes", ",", "and", "possibly", "release", "of", "inflammatory", "mediators", ".", "Because", "patients", "with", "severe", "psoriasis", "may", "develop", "capillary", "leak", "from", "various", "systemic", "therapies", ",", "clinical", "monitoring", "is", "advisable", "for", "patients", "with", "inflammatory", "diseases", "who", "are", "treated", "with", "immune", "modulators", "."]], "ner": [[[5, 5, "Chemical"], [8, 8, "Chemical"], [26, 26, "Chemical"], [29, 29, "Chemical"], [57, 57, "Chemical"], [83, 83, "Chemical"], [111, 111, "Chemical"], [152, 152, "Chemical"], [160, 160, "Chemical"], [15, 17, "Disease"], [50, 52, "Disease"], [86, 88, "Disease"], [167, 169, "Disease"], [205, 206, "Disease"], [1, 1, "Disease"], [137, 137, "Chemical"], [11, 11, "Disease"], [47, 47, "Disease"], [116, 116, "Disease"], [130, 130, "Disease"], [202, 202, "Disease"], [162, 162, "Disease"], [164, 164, "Disease"], [219, 220, "Disease"]]], "relations": [[[5, 5, 15, 17, "CID"], [5, 5, 50, 52, "CID"], [5, 5, 86, 88, "CID"], [5, 5, 167, 169, "CID"], [5, 5, 205, 206, "CID"], [8, 8, 15, 17, "CID"], [8, 8, 50, 52, "CID"], [8, 8, 86, 88, "CID"], [8, 8, 167, 169, "CID"], [8, 8, 205, 206, "CID"], [26, 26, 15, 17, "CID"], [26, 26, 50, 52, "CID"], [26, 26, 86, 88, "CID"], [26, 26, 167, 169, "CID"], [26, 26, 205, 206, "CID"], [29, 29, 15, 17, "CID"], [29, 29, 50, 52, "CID"], [29, 29, 86, 88, "CID"], [29, 29, 167, 169, "CID"], [29, 29, 205, 206, "CID"], [57, 57, 15, 17, "CID"], [57, 57, 50, 52, "CID"], [57, 57, 86, 88, "CID"], [57, 57, 167, 169, "CID"], [57, 57, 205, 206, "CID"], [83, 83, 15, 17, "CID"], [83, 83, 50, 52, "CID"], [83, 83, 86, 88, "CID"], [83, 83, 167, 169, "CID"], [83, 83, 205, 206, "CID"], [111, 111, 15, 17, "CID"], [111, 111, 50, 52, "CID"], [111, 111, 86, 88, "CID"], [111, 111, 167, 169, "CID"], [111, 111, 205, 206, "CID"], [152, 152, 15, 17, "CID"], [152, 152, 50, 52, "CID"], [152, 152, 86, 88, "CID"], [152, 152, 167, 169, "CID"], [152, 152, 205, 206, "CID"], [160, 160, 15, 17, "CID"], [160, 160, 50, 52, "CID"], [160, 160, 86, 88, "CID"], [160, 160, 167, 169, "CID"], [160, 160, 205, 206, "CID"]]], "clusters": [], "translated": "<14>全身性</14> <14>毒性</14> 后使用<0>西罗莫司</0>（以前的<1>雷帕霉素</1>) 治疗<16>银屑病</16>： <9>毛细血管渗漏综合征</9> 与病变淋巴细胞凋亡有关。背景： <2>西罗莫司</2>（原名<3>雷帕霉素</3>）是一种干扰T细胞活化的免疫抑制剂。2名患有<17>银屑病</17>的患者在接受口服<4>西罗莫司</4>治疗后出现了<10>毛细血管渗漏综合征</10>，因此对损伤的皮肤细胞和活化的外周血细胞进行分析以诱导细胞凋亡。观察结果：使用<5>西罗莫司</5>诱导<11>毛细血管渗漏综合征</11>的1名患者的角膜刀皮肤样本中，凋亡细胞的百分比增加了2.3倍（48%），相比之下未受影响的使用<6>西罗莫司</6>治疗的<18>银屑病</18>患者只有21%。与正常T细胞相比，患有<19>银屑病</19>的患者的活化外周血T细胞倾向于表现出较大的自发或经<15>地塞米松</15>诱导的凋亡，特别是在<7>西罗莫司</7>存在的情况下。结论： <8>西罗莫司</8> 的严重不良反应包括<21>发热</21>、<22>贫血</22>和<12>毛细血管渗漏综合征</12>。这些症状可能是药物诱导病变白细胞凋亡，特别是活化的T淋巴细胞凋亡，并可能释放炎症介质的结果。由于重度<20>银屑病</20>患者可能会因全身治疗而发生<13>毛细血管渗漏</13>，因此建议对接受免疫调节剂治疗的<23>炎症性疾病</23>患者进行临床监测。", "revised": true}
{"doc_key": "7053705", "sentences": [["Hepatic", "veno", "-", "occlusive", "disease", "caused", "by", "6", "-", "thioguanine", ".", "Clinically", "reversible", "veno", "-", "occlusive", "disease", "of", "the", "liver", "developed", "in", "a", "23", "-", "year", "-", "old", "man", "with", "acute", "lymphocytic", "leukemia", "after", "10", "months", "of", "maintenance", "therapy", "with", "6", "-", "thioguanine", ".", "Serial", "liver", "biopsies", "showed", "the", "development", "and", "resolution", "of", "intense", "sinusoidal", "engorgement", ".", "Although", "this", "disease", "was", "clinically", "reversible", ",", "some", "subintimal", "fibrosis", "about", "the", "terminal", "hepatic", "veins", "persisted", ".", "This", "case", "presented", "a", "unique", "opportunity", "to", "observe", "the", "histologic", "features", "of", "clinically", "reversible", "hepatic", "veno", "-", "occlusive", "disease", "over", "time", ",", "and", "may", "be", "the", "first", "case", "of", "veno", "-", "occlusive", "related", "solely", "to", "6", "-", "thioguanine", "."]], "ner": [[[7, 9, "Chemical"], [40, 42, "Chemical"], [109, 111, "Chemical"], [0, 4, "Disease"], [13, 19, "Disease"], [88, 92, "Disease"], [30, 32, "Disease"], [66, 66, "Disease"]]], "relations": [[[7, 9, 0, 4, "CID"], [7, 9, 13, 19, "CID"], [7, 9, 88, 92, "CID"], [40, 42, 0, 4, "CID"], [40, 42, 13, 19, "CID"], [40, 42, 88, 92, "CID"], [109, 111, 0, 4, "CID"], [109, 111, 13, 19, "CID"], [109, 111, 88, 92, "CID"]]], "clusters": [], "translated": "由<0>6-硫鸟嘌呤</0>引起的<3>肝静脉闭塞症</3>。一名患有<6>急性淋巴细胞白血病</6>的23岁男性在接受<1>6-硫鸟嘌呤</1>维持治疗10个月后，发生了临床可逆性的<4>肝静脉闭塞性疾病</4>。系列肝活检显示肝窦充血的发展和消退。虽然这种疾病在临床上是可逆的，但终末肝静脉的一些内膜下<7>纤维化</7>仍然存在。该病例提供了一个独特的机会来观察随着时间的推移，临床可逆性<5>肝静脉闭塞性疾病</5>的组织学特征，并且可能是第一例仅与<2>6-硫鸟嘌呤</2>相关的静脉闭塞病例。", "revised": true}
{"doc_key": "2840807", "sentences": [["A", "dystonia", "-", "like", "syndrome", "after", "neuropeptide", "(", "MSH", "/", "ACTH", ")", "stimulation", "of", "the", "rat", "locus", "ceruleus", ".", "The", "movement", "disorder", "investigated", "in", "these", "studies", "has", "some", "features", "in", "common", "with", "human", "idiopathic", "dystonia", ",", "and", "information", "obtained", "in", "these", "studies", "may", "be", "of", "potential", "clinical", "benefit", ".", "The", "present", "experimental", "results", "indicated", "that", "peptidergic", "stimulation", "of", "the", "LC", "resulted", "in", "a", "NE", "-", "mediated", "inhibition", "of", "cerebellar", "Purkinje", "cells", "located", "at", "terminals", "of", "the", "ceruleo", "-", "cerebellar", "pathway", ".", "However", ",", "it", "is", "not", "certain", "as", "to", "the", "following", ":", "(", "a", ")", "what", "receptors", "were", "stimulated", "by", "the", "ACTH", "N", "-", "terminal", "fragments", "at", "the", "LC", "that", "resulted", "in", "this", "disorder", ";", "(", "b", ")", "whether", "NE", ",", "released", "onto", "Purkinje", "cell", "synapses", "located", "at", "terminals", "of", "the", "ceruleo", "-", "cerebellar", "pathway", ",", "did", "indeed", "cause", "the", "long", "-", "term", "depression", "at", "Purkinje", "cell", "synapses", "(", "previously", "described", "by", "others", ")", "that", "resulted", "in", "the", "long", "duration", "of", "the", "movement", "disorder", ";", "(", "c", ")", "whether", "the", "inhibition", "of", "inhibitory", "Purkinje", "cells", "resulted", "in", "disinhibition", "or", "increased", "excitability", "of", "the", "unilateral", "cerebellar", "fastigial", "or", "interpositus", "nuclei", ",", "the", "output", "targets", "of", "the", "Purkinje", "cell", "axons", ",", "that", "may", "have", "been", "an", "important", "contributing", "factor", "to", "this", "disorder", ".", "These", "questions", "are", "currently", "being", "investigated", "."]], "ner": [[[8, 8, "Chemical"], [1, 1, "Disease"], [34, 34, "Disease"], [10, 10, "Chemical"], [101, 101, "Chemical"], [20, 21, "Disease"], [162, 163, "Disease"], [143, 143, "Disease"]]], "relations": [[[8, 8, 1, 1, "CID"], [8, 8, 34, 34, "CID"], [10, 10, 1, 1, "CID"], [10, 10, 34, 34, "CID"], [101, 101, 1, 1, "CID"], [101, 101, 34, 34, "CID"]]], "clusters": [], "translated": "神经肽(<0>MSH</0>/<3>ACTH</3>)刺激大鼠蓝斑后出现<1>肌张力障碍</1>样综合征。这些研究中调查的<5>运动障碍</5>与人类特发性<2>肌张力障碍</2>有一些共同特征，这些研究中获得的信息可能具有潜在的临床益处。目前的实验结果表明，LC的肽能刺激导致 NE 介导的对位于蓝-小脑通路末端的小脑浦肯野细胞的抑制。但是，以下问题尚不确定：(a) 哪些受体受到LC上的<4>ACTH</4> N 末端片段的刺激，导致了这种疾病；(b) NE，释放到位于小脑小脑通路末端的浦肯野细胞突触上，是否确实引起了浦肯野细胞突触的长期<7>抑制</7>，从而导致 <6>运动障碍</6> 持续时间长；(c) 抑制性浦肯野细胞的抑制是否会导致单侧小脑顶核或间核（浦肯野细胞轴突的输出目标）的抑制解除或增加兴奋性，这可能是导致这种疾病的一个重要因素。目前正在调查这些问题。", "revised": true}
{"doc_key": "6402369", "sentences": [["Treatment", "of", "ifosfamide", "-", "induced", "urothelial", "toxicity", "by", "oral", "administration", "of", "sodium", "2", "-", "mercaptoethane", "sulphonate", "(", "MESNA", ")", "to", "patients", "with", "inoperable", "lung", "cancer", ".", "The", "protective", "effect", "of", "oral", "administration", "of", "the", "thiol", "compound", "sodium", "2", "-", "mercaptoethane", "sulphonate", "(", "MESNA", ")", "against", "urothelial", "toxicity", "induced", "by", "ifosfamide", "(", "IF", ")", "was", "tested", "in", "a", "group", "of", "45", "patients", "with", "inoperable", "lung", "cancer", "under", "treatment", "with", "IF", "(", "2250", "mg", "/", "m2", "on", "days", "2", "-", "5", ")", "as", "part", "of", "a", "polychemotherapy", "regimen", "repeated", "in", "a", "4", "-", "week", "cycle", ".", "MESNA", "was", "given", "orally", "on", "the", "days", "of", "treatment", "with", "IF", "in", "3", "doses", "of", "840", "mg", "/", "m2", ",", "each", "administered", "at", "0", "hr", "(", "=", "injection", "of", "IF", ")", ",", "4", "hr", "and", "8", "hr", "p", ".", "i", ".", "Out", "of", "a", "total", "of", "88", "courses", "of", "this", "treatment", "we", "observed", "10", "episodes", "of", "asymptomatic", "microscopic", "haematuria", "and", "no", "episodes", "of", "gross", "haematuria", ".", "In", "this", "group", "of", "45", "patients", "under", "protection", "with", "MESNA", "there", "were", "5", "complete", "remissions", "and", "9", "partial", "remissions", "(", "total", "31", "%", ")", ".", "A", "further", "group", "of", "25", "patients", "under", "polychemotherapy", "with", "IF", "were", "treated", "by", "conventional", "prophylactic", "measures", "(", "raised", "fluid", "intake", "and", "forced", "diuresis", ")", ".", "In", "this", "group", "there", "were", "1", "complete", "and", "5", "partial", "remissions", "(", "total", "24", "%", ")", ",", "but", "nearly", "all", "patients", "developed", "either", "gross", "haematuria", "and", "/", "or", "symptoms", "of", "bladder", "irritation", "(", "cystitis", "and", "pollakisuria", ")", ".", "There", "were", "no", "appreciable", "differences", "between", "the", "MESNA", "series", "and", "the", "conventional", "prophylaxis", "series", "with", "respect", "to", "either", "haematological", "or", "systemic", "toxicity", "of", "the", "cytostatic", "treatment", ".", "Our", "results", "support", "the", "view", "that", "MESNA", ",", "given", "orally", "in", "conjunction", "with", "combined", "cytostatic", "regimens", "which", "include", "IF", ",", "simplifies", "the", "treatment", "and", "provides", "optimum", "protection", "for", "the", "urinary", "epithelium", ".", "Protection", "with", "oral", "MESNA", "is", "particularly", "suitable", "for", "outpatients", "."]], "ner": [[[2, 2, "Chemical"], [49, 49, "Chemical"], [51, 51, "Chemical"], [68, 68, "Chemical"], [104, 104, "Chemical"], [123, 123, "Chemical"], [194, 194, "Chemical"], [293, 293, "Chemical"], [5, 6, "Disease"], [45, 46, "Disease"], [240, 241, "Disease"], [23, 24, "Disease"], [63, 64, "Disease"], [152, 152, "Disease"], [158, 158, "Disease"], [234, 234, "Disease"], [243, 243, "Disease"], [245, 245, "Disease"], [269, 269, "Disease"], [11, 15, "Chemical"], [17, 17, "Chemical"], [36, 40, "Chemical"], [42, 42, "Chemical"], [94, 94, "Chemical"], [169, 169, "Chemical"], [255, 255, "Chemical"], [281, 281, "Chemical"], [310, 310, "Chemical"], [34, 34, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 45, 46, "CID"], [2, 2, 240, 241, "CID"], [49, 49, 5, 6, "CID"], [49, 49, 45, 46, "CID"], [49, 49, 240, 241, "CID"], [51, 51, 5, 6, "CID"], [51, 51, 45, 46, "CID"], [51, 51, 240, 241, "CID"], [68, 68, 5, 6, "CID"], [68, 68, 45, 46, "CID"], [68, 68, 240, 241, "CID"], [104, 104, 5, 6, "CID"], [104, 104, 45, 46, "CID"], [104, 104, 240, 241, "CID"], [123, 123, 5, 6, "CID"], [123, 123, 45, 46, "CID"], [123, 123, 240, 241, "CID"], [194, 194, 5, 6, "CID"], [194, 194, 45, 46, "CID"], [194, 194, 240, 241, "CID"], [293, 293, 5, 6, "CID"], [293, 293, 45, 46, "CID"], [293, 293, 240, 241, "CID"]]], "clusters": [], "translated": "口服<19>2-巯基乙烷磺酸钠</19>（<20>MESNA</20>）治疗<0>异环磷酰胺</0>引起的<8>尿路上皮毒性</8>（不能手术的<11>肺癌</11>）。在一组接受综合化疗的不能手术的<12>肺癌</12>患者中，测试了口服<28>硫醇</28>化合物<21>2-巯基乙烷磺酸钠</21>（<22>美司钠</22>）对<1>异环磷酰胺</1>（<2>IF</2>）引起的<9>尿路上皮毒性</9>的保护作用。<3>IF</3>（2250mg/m2在第2~5天）作为以4周为周期重复的综合化疗方案的一部分。 <23>MESNA</23>在接受<4>IF</4>治疗的当天口服，分3剂每剂840mg/m2，每剂在0小时给药（=<5>IF</5>注射），4小时和8小时p.i.。在总共88个疗程中，我们观察到10次无症状镜下<13>血尿</13>和没有发生肉眼<14>血尿</14>。在这组接受<24>MESNA</24>保护的45名患者中，有5名完全缓解和9名部分缓解（总计31%）。另一组接受<6>IF</6>综合化疗的25名患者接受常规预防措施（增加液体摄入量和强制利尿）。在该组中，有1例完全缓解和5例部分缓解（总计24%），但几乎所有患者都出现了肉眼<15>血尿</15>和/或<10>膀胱刺激</10>症状（<16>膀胱炎</16>和<17>尿频</17>）。 <25>MESNA</25>系列和常规预防系列在细胞抑制治疗的血液学或全身<18>毒性</18>方面没有明显差异。我们的结果支持这样的观点，即口服<26>MESNA</26>结合包括<7>IF</7>在内的联合细胞生长抑制剂方案，可简化治疗并为尿道上皮提供最佳保护。口服<27>MESNA</27>的保护特别适合门诊患者。", "revised": true}
{"doc_key": "3084782", "sentences": [["Toxicity", "due", "to", "remission", "inducing", "drugs", "in", "rheumatoid", "arthritis", ".", "Association", "with", "HLA", "-", "B35", "and", "Cw4", "antigens", ".", "Twenty", "-", "five", "patients", "with", "rheumatoid", "arthritis", "(", "RA", ")", "who", "developed", "toxicity", "while", "taking", "remission", "inducing", "drugs", "and", "30", "without", "toxicity", "were", "studied", "for", "possible", "associations", "with", "class", "I", "and", "II", "HLA", "antigens", ".", "A", "strong", "association", "has", "been", "found", "between", "nephritis", "and", "dermatitis", "due", "to", "Tiopronin", "(", "a", "D", "-", "Penicillamine", "like", "compound", ")", "and", "class", "I", "antigens", "B35", "-", "Cw4", ",", "and", "between", "dermatitis", "due", "to", "gold", "thiosulphate", "and", "B35", ".", "Compared", "to", "healthy", "controls", "a", "lower", "DR5", "frequency", "was", "observed", "in", "patients", "with", "RA", "except", "for", "the", "Tiopronin", "related", "nephritis", "group", "."]], "ner": [[[66, 66, "Chemical"], [110, 110, "Chemical"], [61, 61, "Disease"], [112, 112, "Disease"], [63, 63, "Disease"], [85, 85, "Disease"], [88, 88, "Chemical"], [0, 0, "Disease"], [31, 31, "Disease"], [40, 40, "Disease"], [69, 71, "Chemical"], [7, 8, "Disease"], [24, 25, "Disease"], [27, 27, "Disease"], [106, 106, "Disease"]]], "relations": [[[66, 66, 61, 61, "CID"], [66, 66, 112, 112, "CID"], [110, 110, 61, 61, "CID"], [110, 110, 112, 112, "CID"], [66, 66, 63, 63, "CID"], [66, 66, 85, 85, "CID"], [110, 110, 63, 63, "CID"], [110, 110, 85, 85, "CID"], [88, 88, 63, 63, "CID"], [88, 88, 85, 85, "CID"]]], "clusters": [], "translated": "输出: <7>毒性</7> 由于在<11>类风湿性关节炎</11>中诱导缓解药物。与 HLA-B35 和 Cw4 抗原结合。25 名<12>类风湿性关节炎</12>（<13>RA</13>）患者在服用缓解诱导药物时出现<8>毒性</8>，而30名未出现<9>毒性</9>者的HLA I类和II类抗原的关联性研究。 由于一种<10>D-青霉胺</10>类似化合物<0>硫普罗宁</0>，<2>肾炎</2> 和<4>皮炎</4>与I类抗原B35-Cw4之间存在密切关系，<6>硫代硫酸盐</6>引起的<5>皮炎</5>与B35之间存在密切关系。与健康对照组相比，患有<14>RA</14>的患者DR5频率较低，但<1>硫普罗宁</1>相关的<3>肾炎</3>组除外。", "revised": true}
{"doc_key": "2055425", "sentences": [["The", "ability", "of", "insulin", "treatment", "to", "reverse", "or", "prevent", "the", "changes", "in", "urinary", "bladder", "function", "caused", "by", "streptozotocin", "-", "induced", "diabetes", "mellitus", ".", "1", ".", "The", "effects", "of", "insulin", "treatment", "on", "in", "vivo", "and", "in", "vitro", "urinary", "bladder", "function", "in", "streptozotocin", "-", "diabetic", "rats", "were", "investigated", ".", "2", ".", "Diabetes", "of", "2", "months", "duration", "resulted", "in", "decreases", "in", "body", "weight", "and", "increases", "in", "fluid", "consumption", ",", "urine", "volume", ",", "frequency", "of", "micturition", ",", "and", "average", "volume", "per", "micturition", ";", "effects", "which", "were", "prevented", "by", "insulin", "treatment", ".", "3", ".", "Insulin", "treatment", "also", "prevented", "the", "increases", "in", "contractile", "responses", "of", "bladder", "body", "strips", "from", "diabetic", "rats", "to", "nerve", "stimulation", ",", "ATP", ",", "and", "bethanechol", ".", "4", ".", "Diabetes", "of", "4", "months", "duration", "also", "resulted", "in", "decreases", "in", "body", "weight", ",", "and", "increases", "in", "fluid", "consumption", ",", "urine", "volume", ",", "frequency", "of", "micturition", ",", "and", "average", "volume", "per", "micturition", ",", "effects", "which", "were", "reversed", "by", "insulin", "treatment", "for", "the", "final", "2", "months", "of", "the", "study", ".", "5", ".", "Insulin", "treatment", "reversed", "the", "increases", "in", "contractile", "responses", "of", "bladder", "body", "strips", "from", "diabetic", "rats", "to", "nerve", "stimulation", ",", "ATP", ",", "and", "bethanechol", ".", "6", ".", "The", "data", "indicate", "that", "the", "effects", "of", "streptozotocin", "-", "induced", "diabetes", "on", "urinary", "bladder", "function", "are", "both", "prevented", "and", "reversed", "by", "insulin", "treatment", "."]], "ner": [[[17, 17, "Chemical"], [40, 40, "Chemical"], [199, 199, "Chemical"], [20, 21, "Disease"], [42, 42, "Disease"], [49, 49, "Disease"], [103, 103, "Disease"], [116, 116, "Disease"], [179, 179, "Disease"], [202, 202, "Disease"], [109, 109, "Chemical"], [185, 185, "Chemical"], [112, 112, "Chemical"], [188, 188, "Chemical"]]], "relations": [[[17, 17, 20, 21, "CID"], [17, 17, 42, 42, "CID"], [17, 17, 49, 49, "CID"], [17, 17, 103, 103, "CID"], [17, 17, 116, 116, "CID"], [17, 17, 179, 179, "CID"], [17, 17, 202, 202, "CID"], [40, 40, 20, 21, "CID"], [40, 40, 42, 42, "CID"], [40, 40, 49, 49, "CID"], [40, 40, 103, 103, "CID"], [40, 40, 116, 116, "CID"], [40, 40, 179, 179, "CID"], [40, 40, 202, 202, "CID"], [199, 199, 20, 21, "CID"], [199, 199, 42, 42, "CID"], [199, 199, 49, 49, "CID"], [199, 199, 103, 103, "CID"], [199, 199, 116, 116, "CID"], [199, 199, 179, 179, "CID"], [199, 199, 202, 202, "CID"]]], "clusters": [], "translated": "胰岛素治疗逆转或预防由<0>链脲佐菌素</0>诱发的<3>糖尿病</3>引起的膀胱功能改变的能力。1.研究胰岛素治疗对<1>链脲佐菌素</1>诱发的<4>糖尿病</4>大鼠体内外膀胱功能的影响。2.<5>糖尿病</5>持续2个月导致体重下降，液体消耗量、尿量、排尿频率和平均每次排尿量增加；胰岛素治疗可预防这些影响。3.胰岛素治疗还阻止了<6>糖尿病</6>大鼠膀胱体条对神经刺激、<10>ATP</10>和<12>氨甲酰甲胆碱</12>的收缩反应增加。4.<7>糖尿病</7>持续4个月导致体重下降，液体消耗量、尿量、排尿频率和平均每次排尿量增加；胰岛素治疗最后2个月可将这些影响逆转。5.胰岛素治疗可逆转<8>糖尿病</8>大鼠膀胱体条对神经刺激、<11>ATP</11>和<13>氨甲酰甲胆碱</13>的收缩反应增加。6.数据表明，<2>链脲佐菌素</2>诱发的<9>糖尿病</9>对膀胱功能的影响可通过胰岛素治疗得到预防和逆转。", "revised": true}
{"doc_key": "2343592", "sentences": [["Seizure", "activity", "with", "imipenem", "therapy", ":", "incidence", "and", "risk", "factors", ".", "Two", "elderly", "patients", "with", "a", "history", "of", "either", "cerebral", "vascular", "accident", "(", "CVA", ")", "or", "head", "trauma", "and", "no", "evidence", "of", "renal", "disease", "developed", "seizures", "while", "receiving", "maximum", "doses", "of", "imipenem", "/", "cilastatin", ".", "Neither", "patient", "had", "reported", "previous", "seizures", "or", "seizure", "-", "like", "activity", "nor", "was", "receiving", "anticonvulsant", "agents", ".", "All", "seizures", "were", "controlled", "with", "therapeutic", "doses", "of", "phenytoin", ".", "Both", "patients", "had", "received", "maximum", "doses", "of", "other", "beta", "-", "lactam", "antibiotics", "without", "evidence", "of", "seizure", "activity", "."]], "ner": [[[41, 43, "Chemical"], [0, 0, "Disease"], [35, 35, "Disease"], [50, 50, "Disease"], [52, 52, "Disease"], [63, 63, "Disease"], [87, 87, "Disease"], [3, 3, "Chemical"], [70, 70, "Chemical"], [80, 82, "Chemical"], [19, 21, "Disease"], [23, 23, "Disease"], [26, 27, "Disease"], [32, 33, "Disease"]]], "relations": [[[41, 43, 0, 0, "CID"], [41, 43, 35, 35, "CID"], [41, 43, 50, 50, "CID"], [41, 43, 52, 52, "CID"], [41, 43, 63, 63, "CID"], [41, 43, 87, 87, "CID"]]], "clusters": [], "translated": " <1> 癫痫发作 </1> 与 <7> 亚胺培南 </7> 治疗相关：发生率和危险因素。两名有<10> 脑血管意外 </10>（<11> CVA </11>）或<12> 头部外伤 </12>病史且没有<13> 肾病 </13>证据的老年患者，在接受最大剂量的<0> 亚胺培南/西司他丁 </0>时出现<2> 癫痫发作 </2>。既往没有患者报告过<3> 癫痫发作 </3>或<4> 癫痫样发作 </4>，也未接受抗惊厥药物治疗。所有<5> 癫痫发作 </5>均通过治疗剂量的<8> 苯妥英 </8>得到控制。两名患者都曾接受过其他<9> β-内酰胺 </9>类抗生素的最大剂量，且没有<6>  癫痫发作 </6>活动的证据。", "revised": true}
{"doc_key": "15897593", "sentences": [["Dexrazoxane", "protects", "against", "myelosuppression", "from", "the", "DNA", "cleavage", "-", "enhancing", "drugs", "etoposide", "and", "daunorubicin", "but", "not", "doxorubicin", ".", "PURPOSE", ":", "The", "anthracyclines", "daunorubicin", "and", "doxorubicin", "and", "the", "epipodophyllotoxin", "etoposide", "are", "potent", "DNA", "cleavage", "-", "enhancing", "drugs", "that", "are", "widely", "used", "in", "clinical", "oncology", ";", "however", ",", "myelosuppression", "and", "cardiac", "toxicity", "limit", "their", "use", ".", "Dexrazoxane", "(", "ICRF", "-", "187", ")", "is", "recommended", "for", "protection", "against", "anthracycline", "-", "induced", "cardiotoxicity", ".", "EXPERIMENTAL", "DESIGN", ":", "Because", "of", "their", "widespread", "use", ",", "the", "hematologic", "toxicity", "following", "coadministration", "of", "dexrazoxane", "and", "these", "three", "structurally", "different", "DNA", "cleavage", "enhancers", "was", "investigated", ":", "Sensitivity", "of", "human", "and", "murine", "blood", "progenitor", "cells", "to", "etoposide", ",", "daunorubicin", ",", "and", "doxorubicin", "+", "/", "-", "dexrazoxane", "was", "determined", "in", "granulocyte", "-", "macrophage", "colony", "forming", "assays", ".", "Likewise", ",", "in", "vivo", ",", "B6D2F1", "mice", "were", "treated", "with", "etoposide", ",", "daunorubicin", ",", "and", "doxorubicin", ",", "with", "or", "without", "dexrazoxane", "over", "a", "wide", "range", "of", "doses", ":", "posttreatment", ",", "a", "full", "hematologic", "evaluation", "was", "done", ".", "RESULTS", ":", "Nontoxic", "doses", "of", "dexrazoxane", "reduced", "myelosuppression", "and", "weight", "loss", "from", "daunorubicin", "and", "etoposide", "in", "mice", "and", "antagonized", "their", "antiproliferative", "effects", "in", "the", "colony", "assay", ";", "however", ",", "dexrazoxane", "neither", "reduced", "myelosuppression", ",", "weight", "loss", ",", "nor", "the", "in", "vitro", "cytotoxicity", "from", "doxorubicin", ".", "CONCLUSION", ":", "Although", "our", "findings", "support", "the", "observation", "that", "dexrazoxane", "reduces", "neither", "hematologic", "activity", "nor", "antitumor", "activity", "from", "doxorubicin", "clinically", ",", "the", "potent", "antagonism", "of", "daunorubicin", "activity", "raises", "concern", ";", "a", "possible", "interference", "with", "anticancer", "efficacy", "certainly", "would", "call", "for", "renewed", "attention", ".", "Our", "data", "also", "suggest", "that", "significant", "etoposide", "dose", "escalation", "is", "perhaps", "possible", "by", "the", "use", "of", "dexrazoxane", ".", "Clinical", "trials", "in", "patients", "with", "brain", "metastases", "combining", "dexrazoxane", "and", "high", "doses", "of", "etoposide", "is", "ongoing", "with", "the", "aim", "of", "improving", "efficacy", "without", "aggravating", "hematologic", "toxicity", ".", "If", "successful", ",", "this", "represents", "an", "exciting", "mechanism", "for", "pharmacologic", "regulation", "of", "side", "effects", "from", "cytotoxic", "chemotherapy", "."]], "ner": [[[11, 11, "Chemical"], [28, 28, "Chemical"], [106, 106, "Chemical"], [136, 136, "Chemical"], [177, 177, "Chemical"], [257, 257, "Chemical"], [282, 282, "Chemical"], [80, 81, "Disease"], [293, 294, "Disease"], [172, 173, "Disease"], [197, 198, "Disease"], [13, 13, "Chemical"], [22, 22, "Chemical"], [108, 108, "Chemical"], [138, 138, "Chemical"], [175, 175, "Chemical"], [233, 233, "Chemical"], [16, 16, "Chemical"], [24, 24, "Chemical"], [111, 111, "Chemical"], [141, 141, "Chemical"], [206, 206, "Chemical"], [226, 226, "Chemical"], [0, 0, "Chemical"], [54, 54, "Chemical"], [56, 58, "Chemical"], [85, 85, "Chemical"], [115, 115, "Chemical"], [146, 146, "Chemical"], [168, 168, "Chemical"], [192, 192, "Chemical"], [217, 217, "Chemical"], [267, 267, "Chemical"], [277, 277, "Chemical"], [3, 3, "Disease"], [46, 46, "Disease"], [170, 170, "Disease"], [195, 195, "Disease"], [48, 49, "Disease"], [68, 68, "Disease"], [204, 204, "Disease"], [275, 275, "Disease"], [21, 21, "Chemical"], [65, 65, "Chemical"], [27, 27, "Chemical"]]], "relations": [[[11, 11, 80, 81, "CID"], [11, 11, 293, 294, "CID"], [28, 28, 80, 81, "CID"], [28, 28, 293, 294, "CID"], [106, 106, 80, 81, "CID"], [106, 106, 293, 294, "CID"], [136, 136, 80, 81, "CID"], [136, 136, 293, 294, "CID"], [177, 177, 80, 81, "CID"], [177, 177, 293, 294, "CID"], [257, 257, 80, 81, "CID"], [257, 257, 293, 294, "CID"], [282, 282, 80, 81, "CID"], [282, 282, 293, 294, "CID"], [11, 11, 172, 173, "CID"], [11, 11, 197, 198, "CID"], [28, 28, 172, 173, "CID"], [28, 28, 197, 198, "CID"], [106, 106, 172, 173, "CID"], [106, 106, 197, 198, "CID"], [136, 136, 172, 173, "CID"], [136, 136, 197, 198, "CID"], [177, 177, 172, 173, "CID"], [177, 177, 197, 198, "CID"], [257, 257, 172, 173, "CID"], [257, 257, 197, 198, "CID"], [282, 282, 172, 173, "CID"], [282, 282, 197, 198, "CID"], [13, 13, 80, 81, "CID"], [13, 13, 293, 294, "CID"], [22, 22, 80, 81, "CID"], [22, 22, 293, 294, "CID"], [108, 108, 80, 81, "CID"], [108, 108, 293, 294, "CID"], [138, 138, 80, 81, "CID"], [138, 138, 293, 294, "CID"], [175, 175, 80, 81, "CID"], [175, 175, 293, 294, "CID"], [233, 233, 80, 81, "CID"], [233, 233, 293, 294, "CID"], [13, 13, 172, 173, "CID"], [13, 13, 197, 198, "CID"], [22, 22, 172, 173, "CID"], [22, 22, 197, 198, "CID"], [108, 108, 172, 173, "CID"], [108, 108, 197, 198, "CID"], [138, 138, 172, 173, "CID"], [138, 138, 197, 198, "CID"], [175, 175, 172, 173, "CID"], [175, 175, 197, 198, "CID"], [233, 233, 172, 173, "CID"], [233, 233, 197, 198, "CID"], [16, 16, 80, 81, "CID"], [16, 16, 293, 294, "CID"], [24, 24, 80, 81, "CID"], [24, 24, 293, 294, "CID"], [111, 111, 80, 81, "CID"], [111, 111, 293, 294, "CID"], [141, 141, 80, 81, "CID"], [141, 141, 293, 294, "CID"], [206, 206, 80, 81, "CID"], [206, 206, 293, 294, "CID"], [226, 226, 80, 81, "CID"], [226, 226, 293, 294, "CID"], [16, 16, 172, 173, "CID"], [16, 16, 197, 198, "CID"], [24, 24, 172, 173, "CID"], [24, 24, 197, 198, "CID"], [111, 111, 172, 173, "CID"], [111, 111, 197, 198, "CID"], [141, 141, 172, 173, "CID"], [141, 141, 197, 198, "CID"], [206, 206, 172, 173, "CID"], [206, 206, 197, 198, "CID"], [226, 226, 172, 173, "CID"], [226, 226, 197, 198, "CID"]]], "clusters": [], "translated": "<23>右雷佐生</23>防止<34>骨髓抑制</34>来自 DNA 切割增强药物<0>依托泊苷</0>和<11>柔红霉素</11>，但不是<17>多柔比星</17>。目的：<42>蒽环类药物</42>中，<12>柔红霉素</12>和<18>阿霉素</18>以及<44>鬼臼毒素</44>中的<1>依托泊苷</1>是有效的 DNA 裂解剂，在临床肿瘤学中广泛应用；然而，<35>骨髓抑制</35>和<38>心脏毒性</38>限制了它们的使用。<24>右雷佐生</24> (<25>ICRF-187</25>)被推荐用于预防<43>蒽环类药物</43>引起的<39>心脏毒性</39>。实验设计中，研究了在共同使用<26>右雷佐生</26>和这三种结构不同的 DNA 裂解剂增强剂后，<7>造血毒性</7>会如何受到影响: 在粒细胞-巨噬细胞集落形成试验中，确定了人类和小鼠血液祖细胞对于<2>依托泊苷</2>、<13>柔红霉素</13>和<19>多柔比星</19>+/-<27>右雷佐生</27>的敏感性。同样，在小鼠体内，使用不同剂量的<3>依托泊苷</3>、<14>柔红霉素</14>和<20>阿霉素</20>，有或没有<28>右雷佐生</28>治疗，治疗后进行全面的血液学评估。结果：在小鼠中，无毒剂量的<29>右雷佐生</29>减少了由<15>柔红霉素</15>和<4>依托泊苷</4>引发的<36>骨髓抑制</36>和<9>体重减轻</9>，并拮抗它们在菌落试验中的抗增殖作用。然而，<30>右雷佐生</30>既没有减少<37>骨髓抑制</37>，<10>体重减轻</10>，也没有减少<21>阿霉素</21>的体外<40>细胞毒性</40>。结论：尽管我们的研究结果支持观察结果，即<31>右雷佐生</31>在临床上既不降低<22>阿霉素</22>的血液学活性，也不降低其抗肿瘤活性，但对<16>柔红霉素</16>活性的强拮抗作用引起了人们的关注；对抗癌功效的可能干扰肯定会引起新的关注。我们的数据还表明，使用<32>右雷佐生</32>可能会显着增加<5>依托泊苷</5>的剂量。正在进行的患有脑部<41>转移瘤</41>的病人的临床试验联合<33>右雷佐生</33>和高剂量的<6>依托泊苷</6>，旨在提高疗效但不加重<8>血液学毒性</8>。如果成功，这代表了一种令人兴奋的药物调节细胞毒性化疗副作用的机制。", "revised": true}
{"doc_key": "9630698", "sentences": [["Contribution", "of", "the", "glycine", "site", "of", "NMDA", "receptors", "in", "rostral", "and", "intermediate", "-", "caudal", "parts", "of", "the", "striatum", "to", "the", "regulation", "of", "muscle", "tone", "in", "rats", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "assess", "the", "contribution", "of", "the", "glycine", "site", "of", "NMDA", "receptors", "in", "the", "striatum", "to", "the", "regulation", "of", "muscle", "tone", ".", "Muscle", "tone", "was", "examined", "using", "a", "combined", "mechanoand", "electromyographic", "method", ",", "which", "measured", "simultaneously", "the", "muscle", "resistance", "(", "MMG", ")", "of", "the", "rat", "'s", "hind", "foot", "to", "passive", "extension", "and", "flexion", "in", "the", "ankle", "joint", "and", "the", "electromyographic", "activity", "(", "EMG", ")", "of", "the", "antagonistic", "muscles", "of", "that", "joint", ":", "gastrocnemius", "and", "tibialis", "anterior", ".", "Muscle", "rigidity", "was", "induced", "by", "haloperidol", "(", "2", ".", "5", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "5", ",", "7", "-", "dichlorokynurenic", "acid", "(", "5", ",", "7", "-", "DCKA", ")", ",", "a", "selective", "glycine", "site", "antagonist", ",", "injected", "in", "doses", "of", "2", ".", "5", "and", "4", ".", "5", "microg", "/", "0", ".", "5", "microl", "bilaterally", ",", "into", "the", "rostral", "region", "of", "the", "striatum", ",", "decreased", "both", "the", "haloperidol", "-", "induced", "muscle", "rigidity", "(", "MMG", ")", "and", "the", "enhanced", "electromyographic", "activity", "(", "EMG", ")", ".", "5", ",", "7", "-", "DCKA", "injected", "bilaterally", "in", "a", "dose", "of", "4", ".", "5", "microg", "/", "0", ".", "5", "microl", "into", "the", "intermediate", "-", "caudal", "region", "of", "the", "striatum", "of", "rats", "not", "pretreated", "with", "haloperidol", "had", "no", "effect", "on", "the", "muscle", "tone", ".", "The", "present", "results", "suggest", "that", "blockade", "of", "the", "glycine", "site", "of", "NMDA", "receptors", "in", "the", "rostral", "part", "of", "the", "striatum", "may", "be", "mainly", "responsible", "for", "the", "antiparkinsonian", "action", "of", "this", "drug", "."]], "ner": [[[115, 115, "Chemical"], [179, 179, "Chemical"], [230, 230, "Chemical"], [110, 111, "Disease"], [182, 183, "Disease"], [3, 3, "Chemical"], [40, 40, "Chemical"], [145, 145, "Chemical"], [247, 247, "Chemical"], [6, 6, "Chemical"], [43, 43, "Chemical"], [250, 250, "Chemical"], [129, 134, "Chemical"], [136, 140, "Chemical"], [196, 200, "Chemical"]]], "relations": [[[115, 115, 110, 111, "CID"], [115, 115, 182, 183, "CID"], [179, 179, 110, 111, "CID"], [179, 179, 182, 183, "CID"], [230, 230, 110, 111, "CID"], [230, 230, 182, 183, "CID"]]], "clusters": [], "translated": "纹状体头侧和中间 - 尾部<9> NMDA </9>受体的<5>甘氨酸</5>位点对大鼠肌张力调节的贡献。本研究的目的是评估纹状体中<10> NMDA </10>受体的<6>甘氨酸</6>位点对肌肉张力调节的作用。肌肉张力采用机械和肌电图相结合的方法检测，该方法同时测量大鼠后足对踝关节被动伸展和屈曲的肌肉阻力（MMG）和该关节拮抗肌的肌电活动（EMG） ：腓肠肌和胫骨前肌。<3>肌肉僵硬</3>是由<0>氟哌啶醇</0>（2.5 mg/kg i.p.）引起的。<12>5,7-二氯犬尿酸</12>（<13>5,7-DCKA</13>），选择性<7>甘氨酸</7>位点拮抗剂，在注射剂量分别为2.5和4.5微克/0.5微升双侧进入纹状体头侧区域，降低了<1>氟哌啶醇</1>诱导的<4>肌肉僵硬</4>（MMG）和增强的肌电图活性（EMG）。<14>5,7-DCKA</14>注射剂量为4.5微克/0.5微升，双侧进入大鼠纹状体中间 - 尾部区域，未使用<2>氟哌啶醇</2>预处理，对肌张力无影响。目前的结果表明，在纹状体头部区域阻断<11>NMDA</11>受体的<8>甘氨酸</8>位点可能是该药物抗帕金森病作用的主要原因。", "revised": true}
{"doc_key": "1595783", "sentences": [["Amiodarone", "pulmonary", "toxicity", ".", "Amiodarone", "is", "an", "effective", "antiarrhythmic", "agent", "whose", "utility", "is", "limited", "by", "many", "side", "-", "effects", ",", "the", "most", "problematic", "being", "pneumonitis", ".", "The", "pulmonary", "toxicity", "of", "amiodarone", "is", "thought", "to", "result", "from", "direct", "injury", "related", "to", "the", "intracellular", "accumulation", "of", "phospholipid", "and", "T", "cell", "-", "mediated", "hypersensitivity", "pneumonitis", ".", "The", "clinical", "and", "radiographic", "features", "of", "amiodarone", "-", "induced", "pulmonary", "toxicity", "are", "characteristic", "but", "nonspecific", ".", "The", "diagnosis", "depends", "on", "exclusion", "of", "other", "entities", ",", "such", "as", "heart", "failure", ",", "infection", ",", "and", "malignancy", ".", "While", "withdrawal", "of", "amiodarone", "leads", "to", "clinical", "improvement", "in", "majority", "of", "cases", ",", "this", "is", "not", "always", "possible", "or", "advisable", ".", "Dose", "reduction", "or", "concomitant", "steroid", "therapy", "may", "have", "a", "role", "in", "selected", "patients", "."]], "ner": [[[0, 0, "Chemical"], [4, 4, "Chemical"], [30, 30, "Chemical"], [59, 59, "Chemical"], [91, 91, "Chemical"], [24, 24, "Disease"], [50, 51, "Disease"], [1, 2, "Disease"], [27, 28, "Disease"], [62, 63, "Disease"], [80, 81, "Disease"], [83, 83, "Disease"], [86, 86, "Disease"], [113, 113, "Chemical"]]], "relations": [[[0, 0, 24, 24, "CID"], [4, 4, 24, 24, "CID"], [30, 30, 24, 24, "CID"], [59, 59, 24, 24, "CID"], [91, 91, 24, 24, "CID"], [0, 0, 50, 51, "CID"], [4, 4, 50, 51, "CID"], [30, 30, 50, 51, "CID"], [59, 59, 50, 51, "CID"], [91, 91, 50, 51, "CID"]]], "clusters": [], "translated": " <0>胺碘酮</0> <7>肺毒性</7>。 <1>胺碘酮</1> 是一种有效的抗心律失常药，其效用受到许多副作用的限制，最成问题的是<5>肺炎</5> 。<2>胺碘酮</2>的<8>肺毒性</8>被认为是与细胞内磷脂积累和T细胞介导的<6>过敏性肺炎</6>相关的直接损伤所致。 <3>胺碘酮</3> 引起的<9>肺毒性</9>的临床和影像学特征具有特征性但非特异性。诊断取决于排除其他疾病，例如<10>心力衰竭</10>、<11>感染</11>和<12>恶性肿瘤</12>。虽然停用<4>胺碘酮</4>可使大多数病例的临床症状有所改善，但这并不总是可行或不可取的。剂量减少或伴随<13>类固醇</13>治疗可能对选定的患者起作用。", "revised": true}
{"doc_key": "2569282", "sentences": [["Dexmedetomidine", ",", "acting", "through", "central", "alpha", "-", "2", "adrenoceptors", ",", "prevents", "opiate", "-", "induced", "muscle", "rigidity", "in", "the", "rat", ".", "The", "highly", "-", "selective", "alpha", "-", "2", "adrenergic", "agonist", "dexmedetomidine", "(", "D", "-", "MED", ")", "is", "capable", "of", "inducing", "muscle", "flaccidity", "and", "anesthesia", "in", "rats", "and", "dogs", ".", "Intense", "generalized", "muscle", "rigidity", "is", "an", "undesirable", "side", "effect", "of", "potent", "opiate", "agonists", ".", "Although", "the", "neurochemistry", "of", "opiate", "-", "induced", "rigidity", "has", "yet", "to", "be", "fully", "elucidated", ",", "recent", "work", "suggests", "a", "role", "for", "a", "central", "adrenergic", "mechanism", ".", "In", "the", "present", "study", ",", "the", "authors", "determined", "if", "treatment", "with", "D", "-", "MED", "prevents", "the", "muscle", "rigidity", "caused", "by", "high", "-", "dose", "alfentanil", "anesthesia", "in", "the", "rat", ".", "Animals", "(", "n", "=", "42", ")", "were", "treated", "intraperitoneally", "with", "one", "of", "the", "following", "six", "regimens", ":", "1", ")", "L", "-", "MED", "(", "the", "inactive", "L", "-", "isomer", "of", "medetomidine", ")", ",", "30", "micrograms", "/", "kg", ";", "2", ")", "D", "-", "MED", ",", "10", "micrograms", "/", "kg", ";", "3", ")", "D", "-", "MED", ",", "30", "micrograms", "/", "kg", ";", "4", ")", "D", "-", "MED", "[", "30", "micrograms", "/", "kg", "]", "and", "the", "central", "-", "acting", "alpha", "-", "2", "antagonist", ",", "idazoxan", "[", "10", "mg", "/", "kg", "]", ";", "5", ")", "D", "-", "MED", "[", "30", "micrograms", "/", "kg", "]", "and", "the", "peripheral", "-", "acting", "alpha", "-", "2", "antagonist", "DG", "-", "5128", "[", "10", "mg", "/", "kg", "]", ",", "or", ";", "6", ")", "saline", ".", "Baseline", "electromyographic", "activity", "was", "recorded", "from", "the", "gastrocnemius", "muscle", "before", "and", "after", "drug", "treatment", ".", "Each", "rat", "was", "then", "injected", "with", "alfentanil", "(", "ALF", ",", "0", ".", "5", "mg", "/", "kg", "sc", ")", ".", "ALF", "injection", "resulted", "in", "a", "marked", "increase", "in", "hindlimb", "EMG", "activity", "in", "the", "L", "-", "MED", "treatment", "group", "which", "was", "indistinguishable", "from", "that", "seen", "in", "animals", "treated", "with", "saline", ".", "In", "contrast", ",", "D", "-", "MED", "prevented", "alfentanil", "-", "induced", "muscle", "rigidity", "in", "a", "dose", "-", "dependent", "fashion", ".", "The", "small", "EMG", "values", "obtained", "in", "the", "high", "-", "dose", "D", "-", "MED", "group", "were", "comparable", "with", "those", "recorded", "in", "earlier", "studies", "from", "control", "animals", "not", "given", "any", "opiate", ".", "The", "high", "-", "dose", "D", "-", "MED", "animals", "were", "flaccid", ",", "akinetic", ",", "and", "lacked", "a", "startle", "response", "during", "the", "entire", "experimental", "period", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[111, 111, "Chemical"], [262, 262, "Chemical"], [264, 264, "Chemical"], [275, 275, "Chemical"], [312, 312, "Chemical"], [14, 15, "Disease"], [50, 51, "Disease"], [69, 69, "Disease"], [104, 105, "Disease"], [315, 316, "Disease"], [0, 0, "Chemical"], [29, 29, "Chemical"], [31, 33, "Chemical"], [99, 101, "Chemical"], [156, 158, "Chemical"], [167, 169, "Chemical"], [178, 180, "Chemical"], [207, 209, "Chemical"], [308, 310, "Chemical"], [334, 336, "Chemical"], [358, 360, "Chemical"], [39, 40, "Disease"], [365, 365, "Disease"], [370, 370, "Disease"], [146, 146, "Chemical"], [197, 197, "Chemical"], [225, 227, "Chemical"]]], "relations": [[[111, 111, 14, 15, "CID"], [111, 111, 50, 51, "CID"], [111, 111, 69, 69, "CID"], [111, 111, 104, 105, "CID"], [111, 111, 315, 316, "CID"], [262, 262, 14, 15, "CID"], [262, 262, 50, 51, "CID"], [262, 262, 69, 69, "CID"], [262, 262, 104, 105, "CID"], [262, 262, 315, 316, "CID"], [264, 264, 14, 15, "CID"], [264, 264, 50, 51, "CID"], [264, 264, 69, 69, "CID"], [264, 264, 104, 105, "CID"], [264, 264, 315, 316, "CID"], [275, 275, 14, 15, "CID"], [275, 275, 50, 51, "CID"], [275, 275, 69, 69, "CID"], [275, 275, 104, 105, "CID"], [275, 275, 315, 316, "CID"], [312, 312, 14, 15, "CID"], [312, 312, 50, 51, "CID"], [312, 312, 69, 69, "CID"], [312, 312, 104, 105, "CID"], [312, 312, 315, 316, "CID"]]], "clusters": [], "translated": "<10>右美托咪定</10>通过中枢 alpha-2 肾上腺素能受体发挥作用，可防止大鼠因阿片类药物引起的<5>肌肉僵硬</5>。高选择性 α-2 肾上腺素能激动剂<11>右美托咪定</11>（<12>D-MED</12>）能够诱导大鼠和犬的<21>肌肉松弛</21>和麻醉。强烈的全身性<6>肌肉僵硬</6>是强效阿片类激动剂的不良副作用。尽管阿片类药物引起的<7>僵硬</7>的神经化学机制尚未完全阐明，但最近的研究表明中枢肾上腺素能机制发挥了作用。在本研究中，作者确定了<13>D-MED</13>治疗是否可以防止大鼠因高剂量<0>阿芬太尼</0>麻醉引起的<8>肌肉僵硬</8>。动物（n=42）接受以下六种方案之一的腹膜内治疗：1）L-MED（<24>美托咪定</24>的无活性 L-异构体），30 微克/千克；2）<14>D-MED</14>，10微克/公斤；3）<15>D-MED</15>，30 微克/公斤；4）<16>D-MED</16>[30 微克/公斤]和中枢作用 α-2 拮抗剂<25>咪唑生</25>[10 毫克/公斤]；5）<17>D-MED</17>[30 微克/公斤]和外周作用的 α-2 拮抗剂<26>DG-5128</26>[10 毫克/公斤]，或；6）生理盐水。在药物治疗前后记录腓肠肌的基线肌电图活动。然后给每只大鼠注射<1>阿芬太尼</1>（<2>ALF</2>，0.5 mg/kg sc）。<3>ALF</3>注射导致 L-MED 治疗组后肢 EMG 活动显着增加，这与用生理盐水治疗的动物中观察到的没有区别。相反，<18>D-MED</18>以剂量依赖的方式预防<4>阿芬太尼</4>引起的<9>肌肉僵硬</9>。在高剂量<19>D-MED</19>组中获得的小 EMG 值与早期研究中未给予任何阿片类药物的对照动物记录的值相当。高剂量<20>D-MED</20>动物在整个实验期间均表现出松弛、<22>运动不能</22>、<23>惊吓</23>反应。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "18513945", "sentences": [["The", "hemodynamics", "of", "oxytocin", "and", "other", "vasoactive", "agents", "during", "neuraxial", "anesthesia", "for", "cesarean", "delivery", ":", "findings", "in", "six", "cases", ".", "Oxytocin", "is", "a", "commonly", "used", "uterotonic", "that", "can", "cause", "significant", "and", "even", "fatal", "hypotension", ",", "particularly", "when", "given", "as", "a", "bolus", ".", "The", "resulting", "hypotension", "can", "be", "produced", "by", "a", "decrease", "in", "systemic", "vascular", "resistance", "or", "cardiac", "output", "through", "a", "decrease", "in", "venous", "return", ".", "Parturients", "with", "normal", "volume", "status", ",", "heart", "valves", "and", "pulmonary", "vasculature", "most", "often", "respond", "to", "this", "hypotension", "with", "a", "compensatory", "increase", "in", "heart", "rate", "and", "stroke", "volume", ".", "Oxytocin", "-", "induced", "hypotension", "at", "cesarean", "delivery", "may", "be", "incorrectly", "attributed", "to", "blood", "loss", ".", "Pulse", "power", "analysis", "(", "also", "called", "\"", "pulse", "contour", "analysis", "\"", ")", "of", "an", "arterial", "pressure", "wave", "form", "allows", "continuous", "evaluation", "of", "systemic", "vascular", "resistance", "and", "cardiac", "output", "in", "real", "time", ",", "thereby", "elucidating", "the", "causative", "factors", "behind", "changes", "in", "blood", "pressure", ".", "Pulse", "power", "analysis", "was", "conducted", "in", "six", "cases", "of", "cesarean", "delivery", "performed", "under", "neuraxial", "anesthesia", ".", "Hypotension", "in", "response", "to", "oxytocin", "was", "associated", "with", "a", "decrease", "in", "systemic", "vascular", "resistance", "and", "a", "compensatory", "increase", "in", "stroke", "volume", ",", "heart", "rate", "and", "cardiac", "output", ".", "Pulse", "power", "analysis", "may", "be", "helpful", "in", "determining", "the", "etiology", "of", "and", "treating", "hypotension", "during", "cesarean", "delivery", "under", "neuraxial", "anesthesia", "."]], "ner": [[[3, 3, "Chemical"], [20, 20, "Chemical"], [93, 93, "Chemical"], [171, 171, "Chemical"], [33, 33, "Disease"], [44, 44, "Disease"], [81, 81, "Disease"], [96, 96, "Disease"], [167, 167, "Disease"], [208, 208, "Disease"], [90, 90, "Disease"], [186, 186, "Disease"], [105, 106, "Disease"]]], "relations": [[[3, 3, 33, 33, "CID"], [3, 3, 44, 44, "CID"], [3, 3, 81, 81, "CID"], [3, 3, 96, 96, "CID"], [3, 3, 167, 167, "CID"], [3, 3, 208, 208, "CID"], [20, 20, 33, 33, "CID"], [20, 20, 44, 44, "CID"], [20, 20, 81, 81, "CID"], [20, 20, 96, 96, "CID"], [20, 20, 167, 167, "CID"], [20, 20, 208, 208, "CID"], [93, 93, 33, 33, "CID"], [93, 93, 44, 44, "CID"], [93, 93, 81, 81, "CID"], [93, 93, 96, 96, "CID"], [93, 93, 167, 167, "CID"], [93, 93, 208, 208, "CID"], [171, 171, 33, 33, "CID"], [171, 171, 44, 44, "CID"], [171, 171, 81, 81, "CID"], [171, 171, 96, 96, "CID"], [171, 171, 167, 167, "CID"], [171, 171, 208, 208, "CID"]]], "clusters": [], "translated": "<0>催产素</0>和其他血管活性药物在剖宫产椎管内麻醉期间的血流动力学：6例研究结果。<1>催产素</1>是一种常用的子宫收缩剂，可导致显着甚至致命的<4>低血压</4>，尤其是作为推注给药时。由此产生的<5>低血压</5>可由全身血管阻力降低或通过静脉回流减少引起的<8>心输出量</8>产生。容量状态、心脏瓣膜和肺血管系统正常的产妇最常对这种<6>低血压</6>做出反应，心率和<10>每搏量</10>代偿性增加。<2>催产素</2>引起的剖宫产<7>低血压</7>可能被错误地归因于<12>失血</12>。脉搏功率分析（也称为“脉搏轮廓分析”）的动脉压波形允许实时连续评估全身血管阻力和心输出量，从而阐明血压变化背后的致病因素。对6例椎管内麻醉剖宫产进行了脉搏功率分析。对<3>催产素</3>引起的<8>低血压</8>的反应与全身血管阻力的降低和代偿性增加的<11>每搏量、心率和心输出量</11>有关。脉搏功率分析可能有助于确定椎管内麻醉下剖宫产过程中<9>低血压</9>的病因和治疗。", "revised": true}
{"doc_key": "19893084", "sentences": [["Dynamic", "response", "of", "blood", "vessel", "in", "acute", "renal", "failure", ".", "In", "this", "study", "we", "postulated", "that", "during", "acute", "renal", "failure", "induced", "by", "gentamicin", "the", "transient", "or", "dynamic", "response", "of", "blood", "vessels", "could", "be", "affected", ",", "and", "that", "antioxidants", "can", "prevent", "the", "changes", "in", "dynamic", "responses", "of", "blood", "vessels", ".", "The", "new", "approach", "to", "ex", "vivo", "blood", "vessel", "experiments", "in", "which", "not", "only", "the", "end", "points", "of", "vessels", "response", "within", "the", "time", "interval", "is", "considered", ",", "but", "also", "dynamics", "of", "this", "response", ",", "was", "used", "in", "this", "paper", ".", "Our", "results", "confirm", "the", "alteration", "in", "dynamic", "response", "of", "blood", "vessels", "during", "the", "change", "of", "pressure", "in", "gentamicin", "-", "treated", "animals", ".", "The", "beneficial", "effects", "of", "vitamin", "C", "administration", "to", "gentamicin", "-", "treated", "animals", "are", "also", "confirmed", "through", ":", "lower", "level", "of", "blood", "urea", "and", "creatinine", "and", "higher", "level", "of", "potassium", ".", "The", "pressure", "dynamic", "responses", "of", "isolated", "blood", "vessels", "show", "a", "faster", "pressure", "change", "in", "gentamicin", "-", "treated", "animals", "(", "8", ".", "07", "+", "/", "-", "1", ".", "7", "s", "vs", ".", "5", ".", "64", "+", "/", "-", "0", ".", "18", "s", ")", ".", "Vitamin", "C", "administration", "induced", "slowdown", "of", "pressure", "change", "back", "to", "the", "control", "values", ".", "The", "pressure", "dynamic", "properties", ",", "quantitatively", "defined", "by", "comparative", "pressure", "dynamic", "and", "total", "pressure", "dynamic", ",", "confirm", "the", "alteration", "in", "dynamic", "response", "of", "blood", "vessels", "during", "the", "change", "of", "pressure", "in", "gentamicin", "-", "treated", "animals", "and", "beneficial", "effects", "of", "vitamin", "C", "administration", "."]], "ner": [[[22, 22, "Chemical"], [105, 105, "Chemical"], [118, 118, "Chemical"], [154, 154, "Chemical"], [228, 228, "Chemical"], [6, 8, "Disease"], [17, 19, "Disease"], [114, 115, "Chemical"], [183, 184, "Chemical"], [236, 237, "Chemical"], [131, 131, "Chemical"], [133, 133, "Chemical"], [138, 138, "Chemical"]]], "relations": [[[22, 22, 6, 8, "CID"], [22, 22, 17, 19, "CID"], [105, 105, 6, 8, "CID"], [105, 105, 17, 19, "CID"], [118, 118, 6, 8, "CID"], [118, 118, 17, 19, "CID"], [154, 154, 6, 8, "CID"], [154, 154, 17, 19, "CID"], [228, 228, 6, 8, "CID"], [228, 228, 17, 19, "CID"]]], "clusters": [], "translated": "血管在<5>急性肾功能衰竭</5>中的动态反应。在这项研究中，我们假设在<0>庆大霉素</0>引起的<6>急性肾功能衰竭</6>期间，血管的瞬时或动态反应可能受到影响，而抗氧化剂可以阻止血管动态反应的改变。本文采用了离体血管实验的新方法，其中不仅考虑了时间间隔内血管反应的终点，而且还考虑了这种反应的动力学。我们的结果证实了<1>庆大霉素</1>处理的动物在压力变化过程中血管动态响应的改变。<7>维生素C</7>对<2>庆大霉素</2>治疗动物的有益作用也通过以下方式得到证实：血液中<10>尿素</10>和<11>肌酐水平</11>和更高水平的<12>钾</12>。离体血管的压力动态反应显示在<3>庆大霉素</3>处理的动物中压力变化更快（8.07+/-1.7s vs.5.64+/-0.18s)。<8>维生素C</8>给药诱导压力变化减缓回到控制值。通过比较压力动态和总压力动态定量定义的压力动态特性证实了<4>庆大霉素</4>治疗动物在压力变化过程中血管动态响应的改变以及<9>维生素C</9>的有益作用。", "revised": true}
{"doc_key": "8480959", "sentences": [["Efficacy", "and", "tolerability", "of", "lovastatin", "in", "3390", "women", "with", "moderate", "hypercholesterolemia", ".", "OBJECTIVE", ":", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "lovastatin", "in", "women", "with", "moderate", "hypercholesterolemia", ".", "DESIGN", ":", "The", "Expanded", "Clinical", "Evaluation", "of", "Lovastatin", "(", "EXCEL", ")", "Study", ",", "a", "multicenter", ",", "double", "-", "blind", ",", "diet", "-", "and", "placebo", "-", "controlled", "trial", ",", "in", "which", "participants", "were", "randomly", "assigned", "to", "receive", "placebo", "or", "lovastatin", "at", "doses", "of", "20", "or", "40", "mg", "once", "daily", ",", "or", "20", "or", "40", "mg", "twice", "daily", "for", "48", "weeks", ".", "SETTING", ":", "Ambulatory", "patients", "recruited", "by", "362", "participating", "centers", "throughout", "the", "United", "States", ".", "PATIENTS", ":", "Women", "(", "n", "=", "3390", ")", "from", "the", "total", "cohort", "of", "8245", "volunteers", ".", "MEASUREMENTS", ":", "Plasma", "total", ",", "low", "-", "density", "lipoprotein", "(", "LDL", ")", ",", "and", "high", "-", "density", "lipoprotein", "(", "HDL", ")", "cholesterol", ",", "and", "triglycerides", ";", "and", "laboratory", "and", "clinical", "evidence", "of", "adverse", "events", "monitored", "periodically", "throughout", "the", "study", ".", "RESULTS", ":", "Among", "women", ",", "lovastatin", "(", "20", "to", "80", "mg", "/", "d", ")", "produced", "sustained", "(", "12", "-", "to", "48", "-", "week", ")", ",", "dose", "-", "related", "changes", "(", "P", "<", "0", ".", "001", ")", ":", "decreases", "in", "LDL", "cholesterol", "(", "24", "%", "to", "40", "%", ")", "and", "triglycerides", "(", "9", "%", "to", "18", "%", ")", ",", "and", "increases", "in", "HDL", "cholesterol", "(", "6", ".", "7", "%", "to", "8", ".", "6", "%", ")", ".", "Depending", "on", "the", "dose", ",", "from", "82", "%", "to", "95", "%", "of", "lovastatin", "-", "treated", "women", "achieved", "the", "National", "Cholesterol", "Education", "Program", "goal", "of", "LDL", "cholesterol", "levels", "less", "than", "4", ".", "14", "mmol", "/", "L", "(", "160", "mg", "/", "dL", ")", ",", "and", "40", "%", "to", "87", "%", "achieved", "the", "goal", "of", "3", ".", "36", "mmol", "/", "L", "(", "130", "mg", "/", "dL", ")", ".", "Successive", "transaminase", "elevations", "greater", "than", "three", "times", "the", "upper", "limit", "of", "normal", "occurred", "in", "0", ".", "1", "%", "of", "women", "and", "were", "dose", "dependent", "above", "the", "20", "-", "mg", "dose", ".", "Myopathy", ",", "defined", "as", "muscle", "symptoms", "with", "creatine", "kinase", "elevations", "greater", "than", "10", "times", "the", "upper", "limit", "of", "normal", ",", "was", "rare", "and", "associated", "with", "the", "highest", "recommended", "daily", "dose", "of", "lovastatin", "(", "80", "mg", ")", ".", "Estrogen", "-", "replacement", "therapy", "appeared", "to", "have", "no", "effect", "on", "either", "the", "efficacy", "or", "safety", "profile", "of", "lovastatin", ".", "CONCLUSION", ":", "Lovastatin", "is", "highly", "effective", "and", "generally", "well", "tolerated", "as", "therapy", "for", "primary", "hypercholesterolemia", "in", "women", "."]], "ner": [[[4, 4, "Chemical"], [21, 21, "Chemical"], [35, 35, "Chemical"], [66, 66, "Chemical"], [163, 163, "Chemical"], [245, 245, "Chemical"], [360, 360, "Chemical"], [383, 383, "Chemical"], [387, 387, "Chemical"], [329, 329, "Disease"], [10, 10, "Disease"], [26, 26, "Disease"], [399, 399, "Disease"], [139, 139, "Chemical"], [198, 198, "Chemical"], [220, 220, "Chemical"], [252, 252, "Chemical"], [258, 258, "Chemical"], [142, 142, "Chemical"], [207, 207, "Chemical"], [336, 336, "Chemical"]]], "relations": [[[4, 4, 329, 329, "CID"], [21, 21, 329, 329, "CID"], [35, 35, 329, 329, "CID"], [66, 66, 329, 329, "CID"], [163, 163, 329, 329, "CID"], [245, 245, 329, 329, "CID"], [360, 360, 329, 329, "CID"], [383, 383, 329, 329, "CID"], [387, 387, 329, 329, "CID"]]], "clusters": [], "translated": "<0>洛伐他汀</0>对 3390 名中度<10>高胆固醇血症</10>女性的疗效和耐受性。目标：评价<1>洛伐他汀</1>治疗中度<11>高胆固醇血症</11>女性的疗效和安全性。设计：<2>洛伐他汀</2>（EXCEL）研究的扩展临床评估，一项多中心、双盲、饮食和安慰剂对照试验，参与者被随机分配接受安慰剂或<3>洛伐他汀</3>剂量为20或40毫克，每天一次，或20或40毫克，每天两次，持续48周。地点：由全美362个参与中心招募的门诊患者。患者：来自8245名志愿者的总队列中的女性（n = 3390）。测量：血浆总量、低密度脂蛋白（LDL）和高密度脂蛋白（HDL）<13>胆固醇</13>和<18>甘油三酯</18>；在整个研究过程中定期监测不良事件的实验室和临床证据。结果：在女性中，<4>洛伐他汀</4>（20至80毫克/天）产生持续的（12至48周），剂量相关变化（P <0 . 001）: LDL<14>降低胆固醇</14>（24%至40%）和<19>甘油三酯</19>（9%至18%），以及高密度脂蛋白<15>胆固醇</15>（6.7%至8.6%）。根据剂量的不同，82%到95%的<5>洛伐他汀</5>治疗妇女达到了国家<16>胆固醇</16>教育计划的目标，即低密度脂蛋白<17>胆固醇</17>水平低于4.14毫摩尔/升（160毫克/分升），40%到87%达到了3.36毫摩尔/升（130毫克/分升）的目标。连续转氨酶升高超过正常上限的三倍发生在0.1%的女性身上，这种升高呈剂量依赖性，且是在20毫克剂量以上发生的。<9>肌病</9>，定义为<20>肌酸</20>激酶升高超过正常上限10倍的肌肉症状，很少见，与<6>洛伐他汀</6>的最高推荐日剂量相关（80毫克）。雌激素替代疗法似乎对<7>洛伐他汀</7>的疗效或安全性没有影响。结论：<8>洛伐他汀</8>治疗女性原发性<12>高胆固醇血症</12>非常有效且耐受性良好。", "revised": true}
{"doc_key": "804391", "sentences": [["Light", "chain", "proteinuria", "and", "cellular", "mediated", "immunity", "in", "rifampin", "treated", "patients", "with", "tuberculosis", ".", "Light", "chain", "proteinuria", "was", "found", "in", "9", "of", "17", "tuberculosis", "patients", "treated", "with", "rifampin", ".", "Concomitant", "assay", "of", "cellular", "mediated", "immunity", "in", "these", "patients", "using", "skin", "test", "antigen", "and", "a", "lymphokine", "in", "vitro", "test", "provided", "results", "that", "were", "different", ".", "Response", "to", "Varidase", "skin", "test", "antigen", "was", "negative", "for", "all", "eight", "tuberculosis", "patients", "tested", ",", "but", "there", "occurred", "a", "hyper", "-", "responsiveness", "of", "the", "lymphocytes", "of", "these", "eight", "patients", "to", "phytomitogen", "(", "PHA", "-", "P", ")", ".", "as", "well", "as", "of", "those", "of", "seven", "other", "tuberculous", "patients", ".", "This", "last", "finding", "may", "be", "related", "to", "time", "of", "testing", "and", "/", "or", "endogenous", "serum", "binding", "of", "rifampin", "which", "could", "have", "inhibited", "mitogen", "activity", "for", "the", "lymphocyte", "."]], "ner": [[[8, 8, "Chemical"], [27, 27, "Chemical"], [119, 119, "Chemical"], [2, 2, "Disease"], [16, 16, "Disease"], [12, 12, "Disease"], [23, 23, "Disease"], [65, 65, "Disease"], [99, 99, "Disease"]]], "relations": [[[8, 8, 2, 2, "CID"], [8, 8, 16, 16, "CID"], [27, 27, 2, 2, "CID"], [27, 27, 16, 16, "CID"], [119, 119, 2, 2, "CID"], [119, 119, 16, 16, "CID"]]], "clusters": [], "translated": "<0>利福平</0>治疗<5>肺结核</5>患者的轻链<3>蛋白尿</3>和细胞介导免疫。在接受<1>利福平</1>治疗的17例<6>肺结核</6>患者中，有9例出现轻链<4>蛋白尿</4>。对这些患者进行的细胞介导免疫伴随测定使用皮肤试验抗原和淋巴因子体外试验提供了不同的结果。接受测试的8名<7>结核病</7>患者Varidase 皮试抗原的反应均为阴性，但这8名患者的淋巴细胞对植物有丝分裂原(PHA-P)出现了高反应性，而其他七名<8>结核病</8>患者也是如此。最后一项发现可能与测试时间和/或<2>利福平</2>的内源性血清结合有关，后者可能抑制了淋巴细胞的有丝分裂原活性。", "revised": true}
{"doc_key": "18483878", "sentences": [["Exaggerated", "expression", "of", "inflammatory", "mediators", "in", "vasoactive", "intestinal", "polypeptide", "knockout", "(", "VIP", "-", "/", "-", ")", "mice", "with", "cyclophosphamide", "(", "CYP", ")", "-", "induced", "cystitis", ".", "Vasoactive", "intestinal", "polypeptide", "(", "VIP", ")", "is", "an", "immunomodulatory", "neuropeptide", "distributed", "in", "micturition", "pathways", ".", "VIP", "(", "-", "/", "-", ")", "mice", "exhibit", "altered", "bladder", "function", "and", "neurochemical", "properties", "in", "micturition", "pathways", "after", "cyclophosphamide", "(", "CYP", ")", "-", "induced", "cystitis", ".", "Given", "VIP", "'s", "role", "as", "an", "anti", "-", "inflammatory", "mediator", ",", "we", "hypothesized", "that", "VIP", "(", "-", "/", "-", ")", "mice", "would", "exhibit", "enhanced", "inflammatory", "mediator", "expression", "after", "cystitis", ".", "A", "mouse", "inflammatory", "cytokine", "and", "receptor", "RT2", "profiler", "array", "was", "used", "to", "determine", "regulated", "transcripts", "in", "the", "urinary", "bladder", "of", "wild", "type", "(", "WT", ")", "and", "VIP", "(", "-", "/", "-", ")", "mice", "with", "or", "without", "CYP", "-", "induced", "cystitis", "(", "150", "mg", "/", "kg", ";", "i", ".", "p", ".", ";", "48", "h", ")", ".", "Four", "binary", "comparisons", "were", "made", ":", "WT", "control", "versus", "CYP", "treatment", "(", "48", "h", ")", ",", "VIP", "(", "-", "/", "-", ")", "control", "versus", "CYP", "treatment", "(", "48", "h", ")", ",", "WT", "control", "versus", "VIP", "(", "-", "/", "-", ")", "control", ",", "and", "WT", "with", "CYP", "treatment", "(", "48", "h", ")", "versus", "VIP", "(", "-", "/", "-", ")", "with", "CYP", "treatment", "(", "48", "h", ")", ".", "The", "genes", "presented", "represent", "(", "1", ")", "greater", "than", "1", ".", "5", "-", "fold", "change", "in", "either", "direction", "and", "(", "2", ")", "the", "p", "value", "is", "less", "than", "0", ".", "05", "for", "the", "comparison", "being", "made", ".", "Several", "regulated", "genes", "were", "validated", "using", "enzyme", "-", "linked", "immunoassays", "including", "IL", "-", "1beta", "and", "CXCL1", ".", "CYP", "treatment", "significantly", "(", "p", "<", "or", "=", "0", ".", "001", ")", "increased", "expression", "of", "CXCL1", "and", "IL", "-", "1beta", "in", "the", "urinary", "bladder", "of", "WT", "and", "VIP", "(", "-", "/", "-", ")", "mice", ",", "but", "expression", "in", "VIP", "(", "-", "/", "-", ")", "mice", "with", "CYP", "treatment", "was", "significantly", "(", "p", "<", "or", "=", "0", ".", "001", ")", "greater", "(", "4", ".", "2", "-", "to", "13", "-", "fold", "increase", ")", "than", "that", "observed", "in", "WT", "urinary", "bladder", "(", "3", ".", "6", "-", "to", "5", "-", "fold", "increase", ")", ".", "The", "data", "suggest", "that", "in", "VIP", "(", "-", "/", "-", ")", "mice", "with", "bladder", "inflammation", ",", "inflammatory", "mediators", "are", "increased", "above", "that", "observed", "in", "WT", "with", "CYP", ".", "This", "shift", "in", "balance", "may", "contribute", "to", "increased", "bladder", "dysfunction", "in", "VIP", "(", "-", "/", "-", ")", "mice", "with", "bladder", "inflammation", "and", "altered", "neurochemical", "expression", "in", "micturition", "pathways", "."]], "ner": [[[18, 18, "Chemical"], [20, 20, "Chemical"], [59, 59, "Chemical"], [61, 61, "Chemical"], [133, 133, "Chemical"], [161, 161, "Chemical"], [176, 176, "Chemical"], [197, 197, "Chemical"], [211, 211, "Chemical"], [272, 272, "Chemical"], [318, 318, "Chemical"], [388, 388, "Chemical"], [24, 24, "Disease"], [65, 65, "Disease"], [95, 95, "Disease"], [136, 136, "Disease"], [375, 376, "Disease"], [398, 399, "Disease"], [409, 410, "Disease"]]], "relations": [[[18, 18, 24, 24, "CID"], [18, 18, 65, 65, "CID"], [18, 18, 95, 95, "CID"], [18, 18, 136, 136, "CID"], [20, 20, 24, 24, "CID"], [20, 20, 65, 65, "CID"], [20, 20, 95, 95, "CID"], [20, 20, 136, 136, "CID"], [59, 59, 24, 24, "CID"], [59, 59, 65, 65, "CID"], [59, 59, 95, 95, "CID"], [59, 59, 136, 136, "CID"], [61, 61, 24, 24, "CID"], [61, 61, 65, 65, "CID"], [61, 61, 95, 95, "CID"], [61, 61, 136, 136, "CID"], [133, 133, 24, 24, "CID"], [133, 133, 65, 65, "CID"], [133, 133, 95, 95, "CID"], [133, 133, 136, 136, "CID"], [161, 161, 24, 24, "CID"], [161, 161, 65, 65, "CID"], [161, 161, 95, 95, "CID"], [161, 161, 136, 136, "CID"], [176, 176, 24, 24, "CID"], [176, 176, 65, 65, "CID"], [176, 176, 95, 95, "CID"], [176, 176, 136, 136, "CID"], [197, 197, 24, 24, "CID"], [197, 197, 65, 65, "CID"], [197, 197, 95, 95, "CID"], [197, 197, 136, 136, "CID"], [211, 211, 24, 24, "CID"], [211, 211, 65, 65, "CID"], [211, 211, 95, 95, "CID"], [211, 211, 136, 136, "CID"], [272, 272, 24, 24, "CID"], [272, 272, 65, 65, "CID"], [272, 272, 95, 95, "CID"], [272, 272, 136, 136, "CID"], [318, 318, 24, 24, "CID"], [318, 318, 65, 65, "CID"], [318, 318, 95, 95, "CID"], [318, 318, 136, 136, "CID"], [388, 388, 24, 24, "CID"], [388, 388, 65, 65, "CID"], [388, 388, 95, 95, "CID"], [388, 388, 136, 136, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0> (<1>CYP</1>) 诱导的<12>膀胱炎</12> 血管活性肠多肽敲除 (VIP-/-) 小鼠炎症介质表达增高。血管活性肠多肽 (VIP) 是一种分布于排尿通路的免疫调节神经肽。VIP (-/-) 小鼠在<2>环磷酰胺</2> (<3>CYP</3>) 诱导的<13>膀胱炎</13> 后表现出改变的膀胱功能和排尿通路的神经化学特性。鉴于 VIP 作为抗炎介质的作用，我们假设 VIP (-/-) 小鼠在<14>膀胱炎</14> 后会表现出增强的炎症介质表达。小鼠炎症细胞因子和受体 RT2 分析器阵列用于确定野生型 (WT) 和 VIP (-/-) 小鼠膀胱中的调节转录物，有或没有<4>环磷酰胺</4>诱导的<15>膀胱炎</15> (150 mg/kg；i.p.；48h)。进行了四项二元比较：WT 对照与<5>CYP</5>处理 (48 小时)、VIP (-/-) 对照与<6>CYP</6>处理 (48 小时)、WT 对照与 VIP (-/-) 对照，WT 用<7>CYP</7>处理 (48 小时) 对比 VIP (-/-) 用<8>CYP</8>处理 (48 小时)。所呈现的基因代表 (1) 大于 1.5 倍任一方向变化且 (2) p 值小于 0.05 进行比较。使用包括 IL-1beta 和 CXCL1 在内的酶联免疫测定验证了几个受调节的基因。<9>CYP</9>治疗显着 (p ≤ 0.001) 增加 WT 和 VIP (-/-) 小鼠膀胱中 CXCL1 和 IL-1beta 的表达，但在 VIP (-/-) 用<10>CYP</10>治疗的小鼠显着 (p ≤ 0.001) 比在 WT 膀胱中观察到的 (3.6-至5倍数增加)。数据表明，在患有<16>膀胱炎症</16>的 VIP (-/-) 小鼠中，炎症介质的增加高于在具有<11>CYP</11>的 WT 中观察到的。这种平衡的转变可能导致患有<18>膀胱炎症</18>的 VIP (-/-) 小鼠的<17>膀胱功能障碍</17>和排尿通路中神经化学表达的改变。", "revised": true}
{"doc_key": "12734532", "sentences": [["Case", "report", ":", "Dexatrim", "(", "Phenylpropanolamine", ")", "as", "a", "cause", "of", "myocardial", "infarction", ".", "Phenylpropanolamine", "(", "PPA", ")", "is", "a", "sympathetic", "amine", "used", "in", "over", "-", "the", "-", "counter", "cold", "remedies", "and", "weight", "-", "control", "preparations", "worldwide", ".", "Its", "use", "has", "been", "associated", "with", "hypertensive", "episodes", "and", "hemorrhagic", "strokes", "in", "younger", "women", ".", "Several", "reports", "have", "linked", "the", "abuse", "of", "PPA", "with", "myocardial", "injury", ",", "especially", "when", "overdose", "is", "involved", ".", "We", "report", "here", "the", "first", "case", "of", "Dexatrim", "(", "PPA", ")", "-", "induced", "myocardial", "injury", "in", "a", "young", "woman", "who", "was", "using", "it", "at", "recommended", "doses", "for", "weight", "control", ".", "In", "addition", ",", "we", "review", "the", "7", "other", "cases", "of", "PPA", "related", "myocardial", "injury", "that", "have", "been", "reported", "so", "far", ".", "Physicians", "and", "patients", "should", "be", "alert", "to", "the", "potential", "cardiac", "risk", "associated", "with", "the", "use", "of", "PPA", ",", "even", "at", "doses", "generally", "considered", "to", "be", "safe", "."]], "ner": [[[3, 3, "Chemical"], [5, 5, "Chemical"], [14, 14, "Chemical"], [16, 16, "Chemical"], [60, 60, "Chemical"], [78, 78, "Chemical"], [80, 80, "Chemical"], [111, 111, "Chemical"], [138, 138, "Chemical"], [11, 12, "Disease"], [44, 44, "Disease"], [47, 48, "Disease"], [62, 63, "Disease"], [84, 85, "Disease"], [113, 114, "Disease"], [67, 67, "Disease"], [21, 21, "Chemical"]]], "relations": [[[3, 3, 11, 12, "CID"], [5, 5, 11, 12, "CID"], [14, 14, 11, 12, "CID"], [16, 16, 11, 12, "CID"], [60, 60, 11, 12, "CID"], [78, 78, 11, 12, "CID"], [80, 80, 11, 12, "CID"], [111, 111, 11, 12, "CID"], [138, 138, 11, 12, "CID"]]], "clusters": [], "translated": "病例报告：<0>右旋糖苷</0>（<1>苯丙醇胺</1>）作为<9>心肌梗塞</9>的原因。<2> Phenylpropanolamine</2> (<3> PPA </3>) 是一种交感神经<16>胺</16>，在全球范围内用于非处方感冒药和体重控制制剂。它的使用与年轻女性的<10>高血压</10>发作和<11>出血性中风</11>有关。一些报告将<4>PPA</4>的滥用与<12>心肌损伤</12>联系起来，尤其是当涉及<15>过量服用</15>时。我们在这里报告了第一例<5>Dexatrim</5>（<6>PPA</6>）-诱发<13>心肌损伤</13>的一名年轻女性，该女性以推荐剂量使用它来控制体重。此外，我们回顾了迄今为止报道的其他7例<7>PPA</7>相关<14>心肌损伤</14>。医生和患者应警惕与使用<8>PPA</8>相关的潜在心脏风险，即使使用的剂量通常被认为是安全的。", "revised": true}
{"doc_key": "12013711", "sentences": [["Risperidone", "-", "associated", ",", "benign", "transient", "visual", "disturbances", "in", "schizophrenic", "patients", "with", "a", "past", "history", "of", "LSD", "abuse", ".", "Two", "schizophrenic", "patients", ",", "who", "had", "a", "prior", "history", "of", "LSD", "abuse", "and", "who", "had", "previously", "developed", "EPS", "with", "classic", "antipsychotics", ",", "were", "successfully", "treated", "with", "risperidone", ".", "They", "both", "reported", "short", "episodes", "of", "transient", "visual", "disturbances", ",", "which", "appeared", "immediately", "after", "starting", "treatment", "with", "risperidone", ".", "This", "imagery", "resembled", "visual", "disturbances", "previously", "experienced", "as", "\"", "flashbacks", "\"", "related", "to", "prior", "LSD", "consumption", ".", "Risperidone", "administration", "was", "continued", "and", "the", "visual", "disturbances", "gradually", "wore", "off", ".", "During", "a", "six", "-", "month", "follow", "-", "up", "period", ",", "there", "was", "no", "recurrence", "of", "visual", "disturbances", ".", "This", "phenomenon", "may", "be", "interpreted", "as", "a", "benign", ",", "short", "-", "term", "and", "self", "-", "limiting", "side", "effect", "which", "does", "not", "contraindicate", "the", "use", "of", "risperidone", "or", "interfere", "with", "treatment", ".", "Conclusions", "based", "on", "two", "case", "reports", "should", "be", "taken", "with", "appropriate", "caution", "."]], "ner": [[[0, 0, "Chemical"], [45, 45, "Chemical"], [64, 64, "Chemical"], [83, 83, "Chemical"], [138, 138, "Chemical"], [6, 7, "Disease"], [54, 55, "Disease"], [69, 70, "Disease"], [89, 90, "Disease"], [110, 111, "Disease"], [9, 9, "Disease"], [20, 20, "Disease"], [36, 36, "Disease"], [16, 16, "Chemical"], [29, 29, "Chemical"], [80, 80, "Chemical"]]], "relations": [[[0, 0, 6, 7, "CID"], [0, 0, 54, 55, "CID"], [0, 0, 69, 70, "CID"], [0, 0, 89, 90, "CID"], [0, 0, 110, 111, "CID"], [45, 45, 6, 7, "CID"], [45, 45, 54, 55, "CID"], [45, 45, 69, 70, "CID"], [45, 45, 89, 90, "CID"], [45, 45, 110, 111, "CID"], [64, 64, 6, 7, "CID"], [64, 64, 54, 55, "CID"], [64, 64, 69, 70, "CID"], [64, 64, 89, 90, "CID"], [64, 64, 110, 111, "CID"], [83, 83, 6, 7, "CID"], [83, 83, 54, 55, "CID"], [83, 83, 69, 70, "CID"], [83, 83, 89, 90, "CID"], [83, 83, 110, 111, "CID"], [138, 138, 6, 7, "CID"], [138, 138, 54, 55, "CID"], [138, 138, 69, 70, "CID"], [138, 138, 89, 90, "CID"], [138, 138, 110, 111, "CID"]]], "clusters": [], "translated": "<0>利培酮</0>相关的良性短暂性<5>视觉障碍</5>在<10>精神分裂症</10>有<13>LSD</13>滥用史的患者中。两名<11>精神分裂症</11>患者，他们有<14>LSD</14>滥用史，并且之前曾使用经典抗精神病药物治疗过<12>EPS</12>，并通过<1>利培酮</1>成功治疗。他们都报告了短暂的<6>视觉障碍</6>，这些障碍在开始使用<2>利培酮</2>治疗后立即出现。此图像类似于之前经历过的“闪回”，<7>视觉障碍</7>与先前<15>LSD</15>消费有关。<3>利培酮</3>的使用被继续，并且<8>视觉障碍</8>逐渐消失。在六个月的随访期间，<9>视觉障碍</9>没有复发。这种现象可能被解释为一种良性、短期和自限性的副作用，它并不禁忌使用<4>利培酮</4>或干扰治疗。应谨慎对待基于两个病例报告的结论。", "revised": true}
{"doc_key": "15096016", "sentences": [["Pallidal", "stimulation", ":", "an", "alternative", "to", "pallidotomy", "?", "A", "resurgence", "of", "interest", "in", "the", "surgical", "treatment", "of", "Parkinson", "'s", "disease", "(", "PD", ")", "came", "with", "the", "rediscovery", "of", "posteroventral", "pallidotomy", "by", "Laitinen", "in", "1985", ".", "Laitinen", "'s", "procedure", "improved", "most", "symptoms", "in", "drug", "-", "resistant", "PD", ",", "which", "engendered", "wide", "interest", "in", "the", "neurosurgical", "community", ".", "Another", "lesioning", "procedure", ",", "ventrolateral", "thalamotomy", ",", "has", "become", "a", "powerful", "alternative", "to", "stimulate", "the", "nucleus", "ventralis", "intermedius", ",", "producing", "high", "long", "-", "term", "success", "rates", "and", "low", "morbidity", "rates", ".", "Pallidal", "stimulation", "has", "not", "met", "with", "the", "same", "success", ".", "According", "to", "the", "literature", "pallidotomy", "improves", "the", "\"", "on", "\"", "symptoms", "of", "PD", ",", "such", "as", "dyskinesias", ",", "as", "well", "as", "the", "\"", "off", "\"", "symptoms", ",", "such", "as", "rigidity", ",", "bradykinesia", ",", "and", "on", "-", "off", "fluctuations", ".", "Pallidal", "stimulation", "improves", "bradykinesia", "and", "rigidity", "to", "a", "minor", "extent", ";", "however", ",", "its", "strength", "seems", "to", "be", "in", "improving", "levodopa", "-", "induced", "dyskinesias", ".", "Stimulation", "often", "produces", "an", "improvement", "in", "the", "hyper", "-", "or", "dyskinetic", "upper", "limbs", ",", "but", "increases", "the", "\"", "freezing", "\"", "phenomenon", "in", "the", "lower", "limbs", "at", "the", "same", "time", ".", "Considering", "the", "small", "increase", "in", "the", "patient", "'s", "independence", ",", "the", "high", "costs", "of", "bilateral", "implants", ",", "and", "the", "difficulty", "most", "patients", "experience", "in", "handling", "the", "devices", ",", "the", "question", "arises", "as", "to", "whether", "bilateral", "pallidal", "stimulation", "is", "a", "real", "alternative", "to", "pallidotomy", "."]], "ner": [[[156, 156, "Chemical"], [113, 113, "Disease"], [159, 159, "Disease"], [168, 171, "Disease"], [17, 19, "Disease"], [21, 21, "Disease"], [45, 45, "Disease"], [109, 109, "Disease"], [126, 126, "Disease"], [141, 141, "Disease"], [128, 128, "Disease"], [139, 139, "Disease"]]], "relations": [[[156, 156, 113, 113, "CID"], [156, 156, 159, 159, "CID"], [156, 156, 168, 171, "CID"]]], "clusters": [], "translated": "苍白球刺激：苍白球切开术的替代方法？随着 1985 年 Laitinen 重新发现后腹侧苍白球切开术，<4>帕金森病</4>（<5>PD</5>）的外科治疗重新引起人们的兴趣。Laitinen 的手术改善了耐药性<6>PD</6>的大部分症状，这引起了神经外科界的广泛兴趣。另一种损伤手术，腹外侧丘脑切开术，已成为刺激腹中间核的有力替代方法，可产生高长期成功率和低发病率。苍白球刺激并没有取得同样的成功。根据文献，苍白球切开术改善了<7>PD</7>的“开”症状，例如<1>运动障碍</1>，以及“关”症状，例如<8>强直</8>、<10>运动迟缓</10>和开关波动。苍白球刺激可轻微改善<11>运动迟缓</11>和<9>强直</9>；然而，它的优势似乎在于改善<0>左旋多巴</0>引起的<2>运动障碍</2>。刺激通常会改善上肢的<3>运动过度或运动障碍 </3>，但同时会增加下肢的“僵硬”现象。考虑到患者独立性的小幅增加、双侧植入物的高成本以及大多数患者在操作设备时遇到的困难，问题是双侧苍白球刺激是否是苍白球切开术的真正替代方案。", "revised": true}
{"doc_key": "10692744", "sentences": [["Acetazolamide", "-", "induced", "Gerstmann", "syndrome", ".", "Acute", "confusion", "induced", "by", "acetazolamide", "is", "a", "well", "known", "adverse", "drug", "reaction", "in", "patients", "with", "renal", "impairment", ".", "We", "report", "a", "case", "of", "acetazolamide", "-", "induced", "Gerstmann", "syndrome", "in", "a", "patient", "with", "normal", "renal", "function", ",", "to", "highlight", "predisposing", "factors", "that", "are", "frequently", "overlooked", "."]], "ner": [[[0, 0, "Chemical"], [10, 10, "Chemical"], [29, 29, "Chemical"], [3, 4, "Disease"], [32, 33, "Disease"], [7, 7, "Disease"], [21, 22, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 32, 33, "CID"], [10, 10, 3, 4, "CID"], [10, 10, 32, 33, "CID"], [29, 29, 3, 4, "CID"], [29, 29, 32, 33, "CID"]]], "clusters": [], "translated": " <0>乙酰唑胺</0>诱发的<3>格斯特曼综合征</3>。<1>乙酰唑胺</1>引起的急性<5>意识模糊</5>，是<6>肾功能不全</6>患者众所周知的药物不良反应。我们报告了一例肾功能正常患者<2>乙酰唑胺</2>诱发<4>格斯特曼综合征</4>的病例，以强调经常被忽视的诱发因素。", "revised": true}
{"doc_key": "28952", "sentences": [["Initial", "potassium", "loss", "and", "hypokalaemia", "during", "chlorthalidone", "administration", "in", "patients", "with", "essential", "hypertension", ":", "the", "influence", "of", "dietary", "sodium", "restriction", ".", "To", "investigate", "the", "initial", "potassium", "loss", "and", "development", "of", "hypokalaemia", "during", "the", "administration", "of", "an", "oral", "diuretic", ",", "metabolic", "balance", "studies", "were", "performed", "in", "ten", "patients", "with", "essential", "hypertension", "who", "had", "shown", "hypokalaemia", "under", "prior", "oral", "diuretic", "treatment", ".", "Chlorthalidone", "(", "50", "mg", "daily", ")", "was", "given", "for", "14", "days", ".", "Six", "patients", "received", "a", "normal", "-", "sodium", "diet", "and", "four", "a", "low", "-", "sodium", "(", "17", "mmol", "/", "day", ")", "diet", ".", "All", "patients", "had", "a", "normal", "initial", "total", "body", "potassium", "(", "40K", ")", ".", "The", "electrolyte", "balances", ",", "weight", ",", "bromide", "space", ",", "plasma", "renin", "activity", ",", "and", "aldosterone", "secretion", "rate", "were", "measured", ".", "In", "both", "groups", "a", "potassium", "deficit", "developed", ",", "with", "proportionally", "larger", "losses", "from", "the", "extracellular", "than", "from", "the", "intracellular", "compartment", ".", "In", "the", "normal", "-", "sodium", "group", "the", "highest", "mean", "potassium", "deficit", "was", "176", "mmol", "on", "day", "9", ",", "after", "which", "some", "potassium", "was", "regained", ";", "in", "the", "low", "-", "sodium", "group", "the", "highest", "deficit", "was", "276", "mmol", "on", "day", "13", ".", "The", "normal", "-", "sodium", "group", "showed", "an", "immediate", "but", "temporary", "rise", "of", "the", "renin", "and", "aldosterone", "levels", ";", "in", "the", "low", "-", "sodium", "group", "renin", "and", "aldosterone", "increased", "more", "slowly", "but", "remained", "elevated", ".", "It", "is", "concluded", "that", "dietary", "sodium", "restriction", "increases", "diuretic", "-", "induced", "potassium", "loss", ",", "presumably", "by", "an", "increased", "activity", "of", "the", "renin", "-", "angiotensin", "-", "aldosterone", "system", ",", "while", "sodium", "delivery", "to", "the", "distal", "renal", "tubules", "remains", "sufficiently", "high", "to", "allow", "increased", "potassium", "secretion", "."]], "ner": [[[6, 6, "Chemical"], [60, 60, "Chemical"], [4, 4, "Disease"], [30, 30, "Disease"], [53, 53, "Disease"], [1, 1, "Chemical"], [25, 25, "Chemical"], [102, 102, "Chemical"], [131, 131, "Chemical"], [157, 157, "Chemical"], [169, 169, "Chemical"], [234, 234, "Chemical"], [265, 265, "Chemical"], [12, 12, "Disease"], [49, 49, "Disease"], [18, 18, "Chemical"], [78, 78, "Chemical"], [85, 85, "Chemical"], [152, 152, "Chemical"], [177, 177, "Chemical"], [192, 192, "Chemical"], [211, 211, "Chemical"], [228, 228, "Chemical"], [252, 252, "Chemical"], [121, 121, "Chemical"], [204, 204, "Chemical"], [215, 215, "Chemical"], [248, 248, "Chemical"], [246, 246, "Chemical"]]], "relations": [[[6, 6, 4, 4, "CID"], [6, 6, 30, 30, "CID"], [6, 6, 53, 53, "CID"], [60, 60, 4, 4, "CID"], [60, 60, 30, 30, "CID"], [60, 60, 53, 53, "CID"]]], "clusters": [], "translated": "原发性<13>高血压</13>患者服用<0>氯噻酮</0>期间初始<5>钾</5>丢失和<2>低钾血症</2>：饮食<15>钠</15>限制的影响。为研究口服利尿剂给药期间初始<6>钾</6>丢失和<3>低钾血症</3>的发展，对10名原发性<14>高血压</14>患者进行了代谢平衡研究，这些患者在先前的口服利尿剂治疗下表现出<4>低钾血症</4>。每日服用<1>氯噻酮</1>（50mg），连续14天。其中6名患者接受正常的<16>钠</16>饮食，4名患者接受低<17>钠</17>（17mmol/日）饮食。所有患者的初始总体<7>钾</7>（40K）均正常。测量电解质平衡、体重、溴空间、血浆肾素活性和<24>醛固酮</24>分泌率。两组均出现<8>钾</8>缺乏，细胞外的损失比例大于细胞内的损失。在正常-<18>钠</18>组中，第9天的最高平均<9>钾</9>缺乏量为176mmol，之后有些<10>钾</10>又恢复了；在低-<19>钠</19>组中，第13天的最高钾缺乏量为276mmol。正常-<20>钠</20>组肾素和<25>醛固酮</25>水平立即但暂时升高；低-<21>钠</21>组肾素和<26>醛固酮</26>升高较慢，但仍保持升高。得出的结论是，限制饮食<22>钠</22>会增加利尿剂引起的<11>钾</11>流失，这可能是由于肾素-<28>血管紧张素</28>-<27>醛固酮</27>活性增加所致的系统，而<23>钠</23>输送到远端肾小管仍然足够高，以允许增加<12>钾</12>分泌。", "revised": true}
{"doc_key": "11861791", "sentences": [["Activation", "of", "poly", "(", "ADP", "-", "ribose", ")", "polymerase", "contributes", "to", "development", "of", "doxorubicin", "-", "induced", "heart", "failure", ".", "Activation", "of", "the", "nuclear", "enzyme", "poly", "(", "ADP", "-", "ribose", ")", "polymerase", "(", "PARP", ")", "by", "oxidant", "-", "mediated", "DNA", "damage", "is", "an", "important", "pathway", "of", "cell", "dysfunction", "and", "tissue", "injury", "in", "conditions", "associated", "with", "oxidative", "stress", ".", "Increased", "oxidative", "stress", "is", "a", "major", "factor", "implicated", "in", "the", "cardiotoxicity", "of", "doxorubicin", "(", "DOX", ")", ",", "a", "widely", "used", "antitumor", "anthracycline", "antibiotic", ".", "Thus", ",", "we", "hypothesized", "that", "the", "activation", "of", "PARP", "may", "contribute", "to", "the", "DOX", "-", "induced", "cardiotoxicity", ".", "Using", "a", "dual", "approach", "of", "PARP", "-", "1", "suppression", ",", "by", "genetic", "deletion", "or", "pharmacological", "inhibition", "with", "the", "phenanthridinone", "PARP", "inhibitor", "PJ34", ",", "we", "now", "demonstrate", "the", "role", "of", "PARP", "in", "the", "development", "of", "cardiac", "dysfunction", "induced", "by", "DOX", ".", "PARP", "-", "1", "+", "/", "+", "and", "PARP", "-", "1", "-", "/", "-", "mice", "received", "a", "single", "injection", "of", "DOX", "(", "25", "mg", "/", "kg", "i", ".", "p", ")", ".", "Five", "days", "after", "DOX", "administration", ",", "left", "ventricular", "performance", "was", "significantly", "depressed", "in", "PARP", "-", "1", "+", "/", "+", "mice", ",", "but", "only", "to", "a", "smaller", "extent", "in", "PARP", "-", "1", "-", "/", "-", "ones", ".", "Similar", "experiments", "were", "conducted", "in", "BALB", "/", "c", "mice", "treated", "with", "PJ34", "or", "vehicle", ".", "Treatment", "with", "a", "PJ34", "significantly", "improved", "cardiac", "dysfunction", "and", "increased", "the", "survival", "of", "the", "animals", ".", "In", "addition", "PJ34", "significantly", "reduced", "the", "DOX", "-", "induced", "increase", "in", "the", "serum", "lactate", "dehydrogenase", "and", "creatine", "kinase", "activities", "but", "not", "metalloproteinase", "activation", "in", "the", "heart", ".", "Thus", ",", "PARP", "activation", "contributes", "to", "the", "cardiotoxicity", "of", "DOX", ".", "PARP", "inhibitors", "may", "exert", "protective", "effects", "against", "the", "development", "of", "severe", "cardiac", "complications", "associated", "with", "the", "DOX", "treatment", "."]], "ner": [[[13, 13, "Chemical"], [69, 69, "Chemical"], [71, 71, "Chemical"], [94, 94, "Chemical"], [137, 137, "Chemical"], [158, 158, "Chemical"], [172, 172, "Chemical"], [242, 242, "Chemical"], [272, 272, "Chemical"], [290, 290, "Chemical"], [16, 17, "Disease"], [2, 7, "Chemical"], [24, 29, "Chemical"], [67, 67, "Disease"], [97, 97, "Disease"], [270, 270, "Disease"], [133, 134, "Disease"], [226, 227, "Disease"], [285, 286, "Disease"], [78, 78, "Chemical"], [120, 120, "Chemical"], [216, 216, "Chemical"], [223, 223, "Chemical"], [238, 238, "Chemical"], [249, 249, "Chemical"], [252, 252, "Chemical"]]], "relations": [[[13, 13, 16, 17, "CID"], [69, 69, 16, 17, "CID"], [71, 71, 16, 17, "CID"], [94, 94, 16, 17, "CID"], [137, 137, 16, 17, "CID"], [158, 158, 16, 17, "CID"], [172, 172, 16, 17, "CID"], [242, 242, 16, 17, "CID"], [272, 272, 16, 17, "CID"], [290, 290, 16, 17, "CID"]]], "clusters": [], "translated": "<11>聚(ADP-核糖)</11>聚合酶的激活有助于<0>多柔比星</0>诱导的<10>心力衰竭</10>的发展。由氧化剂介导的DNA损伤激活核酶<12>聚(ADP-核糖)</12>聚合酶 (PARP)是与氧化应激相关的条件下细胞功能障碍和组织损伤的重要途径。氧化应激增加是与<1>阿霉素</1> (<2>DOX</2>)的<13>心脏毒性</13>相关的主要因素，阿霉素是一种广泛使用的抗肿瘤<19>蒽环类药物</19>抗生素。因此，我们假设PARP的激活可能有助于<3>DOX</3>诱导的<14>心脏毒性</14>。使用PARP-1抑制的双重方法，通过基因缺失或菲啶酮PARP抑制剂<20>PJ34</20>的药物抑制，我们现在证明了PARP在<4>DOX</4>诱导的<16>心功能障碍</16>发展中的作用。PARP-1+/+和PARP-1-/-小鼠单次注射<5>DOX</5> (25 mg/kg i.p)。 <6>DOX</6>给药5天后，PARP-1+/+小鼠的左心室性能明显下降，但PARP-1-/-小鼠的程度较小。在用<21>PJ34</21>或载体处理的BALB/c小鼠中进行了类似的实验。用<22>PJ34</22>治疗显著改善了<17>心脏功能障碍</17>并增加了动物的存活率。此外，<23>PJ34</23>显着降低<7>DOX</7>-诱导的血清<24>乳酸</24>脱氢酶和<25>肌酸</25>激酶活性增加，但金属蛋白酶没有增加心中激活。因此，PARP激活有助于<8>DOX</8>的<15>心脏毒性</15>。PARP抑制剂可能对<9>DOX</9>治疗相关的严重<18>心脏并发症</18>的发展发挥保护作用。", "revised": true}
{"doc_key": "11022397", "sentences": [["Probing", "peripheral", "and", "central", "cholinergic", "system", "responses", ".", "OBJECTIVE", ":", "The", "pharmacological", "response", "to", "drugs", "that", "act", "on", "the", "cholinergic", "system", "of", "the", "iris", "has", "been", "used", "to", "predict", "deficits", "in", "central", "cholinergic", "functioning", "due", "to", "diseases", "such", "as", "Alzheimer", "'s", "disease", ",", "yet", "correlations", "between", "central", "and", "peripheral", "responses", "have", "not", "been", "properly", "studied", ".", "This", "study", "assessed", "the", "effect", "of", "normal", "aging", "on", "(", "1", ")", "the", "tropicamide", "-", "induced", "increase", "in", "pupil", "diameter", ",", "and", "(", "2", ")", "the", "reversal", "of", "this", "effect", "with", "pilocarpine", ".", "Scopolamine", "was", "used", "as", "a", "positive", "control", "to", "detect", "age", "-", "dependent", "changes", "in", "central", "cholinergic", "functioning", "in", "the", "elderly", ".", "DESIGN", ":", "Randomized", "double", "-", "blind", "controlled", "trial", ".", "PARTICIPANTS", ":", "Ten", "healthy", "elderly", "(", "mean", "age", "70", ")", "and", "9", "young", "(", "mean", "age", "33", ")", "volunteers", ".", "INTERVENTIONS", ":", "Pupil", "diameter", "was", "monitored", "using", "a", "computerized", "infrared", "pupillometer", "over", "4", "hours", ".", "The", "study", "involved", "4", "sessions", ".", "In", "1", "session", ",", "tropicamide", "(", "20", "microL", ",", "0", ".", "01", "%", ")", "was", "administered", "to", "one", "eye", "and", "placebo", "to", "the", "other", ".", "In", "another", "session", ",", "tropicamide", "(", "20", "microL", ",", "0", ".", "01", "%", ")", "was", "administered", "to", "both", "eyes", ",", "followed", "23", "minutes", "later", "by", "the", "application", "of", "pilocarpine", "(", "20", "microL", ",", "0", ".", "1", "%", ")", "to", "one", "eye", "and", "placebo", "to", "the", "other", ".", "All", "eye", "drops", "were", "given", "in", "a", "randomized", "order", ".", "In", "2", "separate", "sessions", ",", "a", "single", "dose", "of", "scopolamine", "(", "0", ".", "5", "mg", ",", "intravenously", ")", "or", "placebo", "was", "administered", ",", "and", "the", "effects", "on", "word", "recall", "were", "measured", "using", "the", "Buschke", "Selective", "Reminding", "Test", "over", "2", "hours", ".", "OUTCOME", "MEASURES", ":", "Pupil", "size", "at", "time", "points", "after", "administration", "of", "tropicamide", "and", "pilocarpine", ";", "scopolamine", "-", "induced", "impairment", "in", "word", "recall", ".", "RESULTS", ":", "There", "was", "no", "significant", "difference", "between", "elderly", "and", "young", "volunteers", "in", "pupillary", "response", "to", "tropicamide", "at", "any", "time", "point", "(", "p", ">", "0", ".", "05", ")", ".", "The", "elderly", "group", "had", "a", "significantly", "greater", "pilocarpine", "-", "induced", "net", "decrease", "in", "pupil", "size", "85", ",", "125", ",", "165", "and", "215", "minutes", "after", "administration", ",", "compared", "with", "the", "young", "group", "(", "p", "<", "0", ".", "05", ")", ".", "Compared", "with", "the", "young", "group", ",", "the", "elderly", "group", "had", "greater", "scopolamine", "-", "induced", "impairment", "in", "word", "recall", "60", ",", "90", "and", "120", "minutes", "after", "administration", "(", "p", "<", "0", ".", "05", ")", ".", "CONCLUSION", ":", "There", "is", "an", "age", "-", "related", "pupillary", "response", "to", "pilocarpine", "that", "is", "not", "found", "with", "tropicamide", ".", "Thus", ",", "pilocarpine", "may", "be", "useful", "to", "assess", "variations", "in", "central", "cholinergic", "function", "in", "elderly", "patients", "."]], "ner": [[[89, 89, "Chemical"], [251, 251, "Chemical"], [298, 298, "Chemical"], [385, 385, "Chemical"], [301, 304, "Disease"], [388, 391, "Disease"], [69, 69, "Chemical"], [164, 164, "Chemical"], [189, 189, "Chemical"], [294, 294, "Chemical"], [322, 322, "Chemical"], [425, 425, "Chemical"], [39, 41, "Disease"], [87, 87, "Chemical"], [213, 213, "Chemical"], [296, 296, "Chemical"], [342, 342, "Chemical"], [419, 419, "Chemical"], [429, 429, "Chemical"]]], "relations": [[[89, 89, 301, 304, "CID"], [89, 89, 388, 391, "CID"], [251, 251, 301, 304, "CID"], [251, 251, 388, 391, "CID"], [298, 298, 301, 304, "CID"], [298, 298, 388, 391, "CID"], [385, 385, 301, 304, "CID"], [385, 385, 388, 391, "CID"]]], "clusters": [], "translated": "输出: 探测外周和中央胆碱能系统的反应。目的：对作用于虹膜胆碱能系统的药物的药理学反应已被用于预测由<12>阿尔茨海默氏病</12>等疾病引起的中枢胆碱能功能缺陷，以及中枢反应和外周反应之间的相关性没有得到适当的研究。本研究评估了正常衰老对(1)<6>托吡卡胺</6>诱导的瞳孔直径增加的影响，以及(2)用<13>毛果芸香碱</13>逆转这种影响。<0>东莨菪碱</0>被用作阳性对照来检测老年人中枢胆碱能功能的年龄依赖性变化。设计：随机双盲对照试验。参与者：10名健康老人（平均年龄70岁）和9名年轻（平均年龄33岁）志愿者。干预措施：使用计算机红外瞳孔计监测瞳孔直径超过4小时。该研究涉及4个疗程。在一个疗程中，一只眼睛服用了<7>托吡卡胺</7>（20微升，0.01%），另一只眼睛服用了安慰剂。在另一个疗程中，<8>托吡卡胺</8>（20微升，0.01%）被施用于双眼，23分钟后使用<14>毛果芸香碱</14>（20微升，0.1%）给一只眼睛，安慰剂给另一只眼睛。所有滴眼液均以随机顺序给药。在2个独立的疗程中，给予单剂量<1>东莨菪碱</1>（0.5毫克，静脉内）或安慰剂，并使用Buschke选择性提醒测试在2小时内测量对单词回忆的影响。结果测量：服用<9>托吡卡胺</9>和<15>毛果芸香碱</15>后各时间点的瞳孔大小；<2>东莨菪碱</2>-诱导<4>单词记忆障碍</4>。结果：在任何时间点，老年和青年志愿者对<10>托吡卡胺</10>的瞳孔反应无显着差异(p > 0.05)。与年轻组相比，老年组在给药后85、125、165和215分钟时<16>毛果芸香碱</16>诱导的瞳孔大小净减少明显更大(p < 0.05)。与年轻组相比，老年组在给药后60、90和120分钟<3>东莨菪碱</3>诱发的<5>单词记忆障碍</5>明显(p < 0.05)。结论：<17>毛果芸香碱</17>存在与年龄相关的瞳孔反应，而<11>托吡卡胺</11>则没有。因此，<18>毛果芸香碱</18>可能有助于评估老年患者中枢胆碱能功能的变化。", "revised": true}
{"doc_key": "17923537", "sentences": [["Intraocular", "pressure", "in", "patients", "with", "uveitis", "treated", "with", "fluocinolone", "acetonide", "implants", ".", "OBJECTIVE", ":", "To", "report", "the", "incidence", "and", "management", "of", "elevated", "intraocular", "pressure", "(", "IOP", ")", "in", "patients", "with", "uveitis", "treated", "with", "the", "fluocinolone", "acetonide", "(", "FA", ")", "intravitreal", "implant", ".", "DESIGN", ":", "Pooled", "data", "from", "3", "multicenter", ",", "double", "-", "masked", ",", "randomized", ",", "controlled", ",", "phase", "2b", "/", "3", "clinical", "trials", "evaluating", "the", "safety", "and", "efficacy", "of", "the", "0", ".", "59", "-", "mg", "or", "2", ".", "1", "-", "mg", "FA", "intravitreal", "implant", "or", "standard", "therapy", "were", "analyzed", ".", "RESULTS", ":", "During", "the", "3", "-", "year", "follow", "-", "up", ",", "71", ".", "0", "%", "of", "implanted", "eyes", "had", "an", "IOP", "increase", "of", "10", "mm", "Hg", "or", "more", "than", "baseline", "and", "55", ".", "1", "%", ",", "24", ".", "7", "%", ",", "and", "6", ".", "2", "%", "of", "eyes", "reached", "an", "IOP", "of", "30", "mm", "Hg", "or", "more", ",", "40", "mm", "Hg", "or", "more", ",", "and", "50", "mm", "Hg", "or", "more", ",", "respectively", ".", "Topical", "IOP", "-", "lowering", "medication", "was", "administered", "in", "74", ".", "8", "%", "of", "implanted", "eyes", ",", "and", "IOP", "-", "lowering", "surgeries", ",", "most", "of", "which", "were", "trabeculectomies", "(", "76", ".", "2", "%", ")", ",", "were", "performed", "on", "36", ".", "6", "%", "of", "implanted", "eyes", ".", "Intraocular", "pressure", "-", "lowering", "surgeries", "were", "considered", "a", "success", "(", "postoperative", "IOP", "of", "6", "-", "21", "mm", "Hg", "with", "or", "without", "additional", "IOP", "-", "lowering", "medication", ")", "in", "85", ".", "1", "%", "of", "eyes", "at", "1", "year", ".", "The", "rate", "of", "hypotony", "(", "IOP", "<", "/", "=", "5", "mm", "Hg", ")", "following", "IOP", "-", "lowering", "surgery", "(", "42", ".", "5", "%", ")", "was", "not", "different", "from", "that", "of", "implanted", "eyes", "not", "subjected", "to", "surgery", "(", "35", ".", "4", "%", ")", "(", "P", "=", ".", "09", ")", ".", "CONCLUSION", ":", "Elevated", "IOP", "is", "a", "significant", "complication", "with", "the", "FA", "intravitreal", "implant", "but", "may", "be", "controlled", "with", "medication", "and", "surgery", "."]], "ner": [[[8, 9, "Chemical"], [34, 35, "Chemical"], [37, 37, "Chemical"], [82, 82, "Chemical"], [21, 23, "Disease"], [5, 5, "Disease"], [30, 30, "Disease"], [250, 250, "Disease"]]], "relations": [[[8, 9, 21, 23, "CID"], [34, 35, 21, 23, "CID"], [37, 37, 21, 23, "CID"], [82, 82, 21, 23, "CID"]]], "clusters": [], "translated": "<5> 葡萄膜炎 </5>患者的眼内压<0>氟轻松</0>植入物治疗。目的：报告接受<1>氟轻松</1>（<2>FA</2>）玻璃体内植入物的<6>葡萄膜炎</6>患者中<4>眼内压升高</4>（IOP）的发生和处理情况。设计：分析评估0.59毫克或2.1毫克<3>FA</3>玻璃体内植入物或标准疗法的三项多中心、双盲、随机、对照、2b/3期临床试验的汇总数据。结果：随访三年期间，71.0％的植入眼的眼内压比基线增加了10毫米汞柱或更高，其中55.1％、24.7％和6.2％的眼睛IOP分别达到了30毫米汞柱或更高、40毫米汞柱或更高和50毫米汞柱或更高。 74.8%的植入眼接受了局部眼压降低药物治疗。 36.6％的植入眼接受了降眼压手术，其中大部分是小梁切除术（76.2％）。眼内压降低手术被认为是成功的（术后眼压为6-21毫米汞柱，有或没有额外的眼压降低药物）的眼睛占85.1％，在1年内<7>眼压低</7>（IOP<=5 mmHg）的发生率（42.5％）与未接受手术的植入眼（35.4％）没有差异（P=.09）。结论：眼内压升高是FA玻璃体内植入物的严重并发症，但可以通过药物和手术加以控制。", "revised": true}
{"doc_key": "8617710", "sentences": [["Absence", "of", "effect", "of", "sertraline", "on", "time", "-", "based", "sensitization", "of", "cognitive", "impairment", "with", "haloperidol", ".", "This", "double", "-", "blind", ",", "randomized", ",", "placebo", "-", "controlled", "study", "evaluated", "the", "effects", "of", "haloperidol", "alone", "and", "haloperidol", "plus", "sertraline", "on", "cognitive", "and", "psychomotor", "function", "in", "24", "healthy", "male", "subjects", ".", "METHOD", ":", "All", "subjects", "received", "placebo", "on", "Day", "1", "and", "haloperidol", "2", "mg", "on", "Days", "2", "and", "25", ".", "From", "Days", "9", "to", "25", ",", "subjects", "were", "randomly", "assigned", "to", "either", "sertraline", "(", "12", "subjects", ")", "or", "placebo", "(", "12", "subjects", ")", ";", "the", "sertraline", "dose", "was", "titrated", "from", "50", "to", "200", "mg", "/", "day", "from", "Days", "9", "to", "16", ",", "and", "remained", "at", "200", "mg", "/", "day", "for", "the", "final", "10", "days", "of", "the", "drug", "administration", "period", ".", "Cognitive", "function", "testing", "was", "performed", "before", "dosing", "and", "over", "a", "24", "-", "hour", "period", "after", "dosing", "on", "Days", "1", ",", "2", ",", "and", "25", ".", "RESULTS", ":", "Impairment", "of", "cognitive", "function", "was", "observed", "6", "to", "8", "hours", "after", "administration", "of", "haloperidol", "on", "Day", "2", "but", "was", "not", "evident", "23", "hours", "after", "dosing", ".", "When", "single", "-", "dose", "haloperidol", "was", "given", "again", "25", "days", "later", ",", "greater", "impairment", "with", "earlier", "onset", "was", "noted", "in", "several", "tests", "in", "both", "treatment", "groups", ",", "suggesting", "enhancement", "of", "this", "effect", ".", "There", "was", "no", "indication", "that", "sertraline", "exacerbated", "the", "impairment", "produced", "by", "haloperidol", "since", "an", "equivalent", "effect", "also", "occurred", "in", "the", "placebo", "group", ".", "Three", "subjects", "(", "2", "on", "sertraline", "and", "1", "on", "placebo", ")", "withdrew", "from", "the", "study", "because", "of", "side", "effects", ".", "Ten", "subjects", "in", "each", "group", "reported", "side", "effects", "related", "to", "treatment", ".", "The", "side", "effect", "profiles", "of", "sertraline", "and", "of", "placebo", "were", "similar", ".", "CONCLUSION", ":", "Haloperidol", "produced", "a", "clear", "profile", "of", "cognitive", "impairment", "that", "was", "not", "worsened", "by", "concomitant", "sertraline", "administration", "."]], "ner": [[[14, 14, "Chemical"], [31, 31, "Chemical"], [34, 34, "Chemical"], [58, 58, "Chemical"], [167, 167, "Chemical"], [184, 184, "Chemical"], [224, 224, "Chemical"], [282, 282, "Chemical"], [11, 12, "Disease"], [154, 157, "Disease"], [288, 289, "Disease"], [4, 4, "Chemical"], [36, 36, "Chemical"], [79, 79, "Chemical"], [92, 92, "Chemical"], [218, 218, "Chemical"], [241, 241, "Chemical"], [273, 273, "Chemical"], [296, 296, "Chemical"]]], "relations": [[[14, 14, 11, 12, "CID"], [14, 14, 154, 157, "CID"], [14, 14, 288, 289, "CID"], [31, 31, 11, 12, "CID"], [31, 31, 154, 157, "CID"], [31, 31, 288, 289, "CID"], [34, 34, 11, 12, "CID"], [34, 34, 154, 157, "CID"], [34, 34, 288, 289, "CID"], [58, 58, 11, 12, "CID"], [58, 58, 154, 157, "CID"], [58, 58, 288, 289, "CID"], [167, 167, 11, 12, "CID"], [167, 167, 154, 157, "CID"], [167, 167, 288, 289, "CID"], [184, 184, 11, 12, "CID"], [184, 184, 154, 157, "CID"], [184, 184, 288, 289, "CID"], [224, 224, 11, 12, "CID"], [224, 224, 154, 157, "CID"], [224, 224, 288, 289, "CID"], [282, 282, 11, 12, "CID"], [282, 282, 154, 157, "CID"], [282, 282, 288, 289, "CID"]]], "clusters": [], "translated": "<11>舍曲林</11>对<8>认知障碍</8>与<0>氟哌啶醇</0>的基于时间的敏化没有影响。这项双盲、随机、安慰剂对照研究评估了单独使用<1>氟哌啶醇</1>和<2>氟哌啶醇</2>加<12>舍曲林</12>对24名健康男性受试者的认知和精神运动功能的影响。方法：所有受试者在第1天接受安慰剂，在第2天和第25天接受<3>氟哌啶醇</3> 2mg。从第9天到第25天，受试者被随机分配到<13>舍曲林</13>（12名受试者）或安慰剂组（12名受试者）;<14>舍曲林</14>的剂量从第9天到第16天从50毫克/天逐渐增加到200毫克/天，并在给药期的最后10天保持在200毫克/天。在给药前和给药后24小时内进行认知功能测试。结果：第2天<4>氟哌啶醇</4>给药后6~8小时观察到<9>认知功能损害</9>，但给药后23小时不明显。当25天后再次给予单剂量<5>氟哌啶醇</5>时，在两个治疗组的几项测试中都注意到更早发作的更大损害，表明这种效果有所增强。没有迹象表明<15>舍曲林</15>会加剧<6>氟哌啶醇</6>产生的损害，因为在安慰剂组中也出现了相同的效果。三名受试者（2名服用<16>舍曲林</16>和1名服用安慰剂）因为副作用退出了研究。每组中有10名受试者报告了与治疗相关的副作用。<17>舍曲林</17>和安慰剂的副作用相似。结论：<7>氟哌啶醇</7>产生了明确的<10>认知障碍</10>特征，同时服用<18>舍曲林</18>不会使认知障碍恶化。", "revised": true}
{"doc_key": "11302406", "sentences": [["Fluconazole", "-", "induced", "torsade", "de", "pointes", ".", "OBJECTIVE", ":", "To", "present", "a", "case", "of", "fluconazole", "-", "associated", "torsade", "de", "pointes", "(", "TDP", ")", "and", "discuss", "fluconazole", "'s", "role", "in", "causing", "TDP", ".", "CASE", "SUMMARY", ":", "A", "68", "-", "year", "-", "old", "white", "woman", "with", "Candida", "glabrata", "isolated", "from", "a", "presacral", "abscess", "developed", "TDP", "eight", "days", "after", "commencing", "oral", "fluconazole", "The", "patient", "had", "no", "other", "risk", "factors", "for", "TDP", ",", "including", "coronary", "artery", "disease", ",", "cardiomyopathy", ",", "congestive", "heart", "failure", ",", "and", "electrolyte", "abnormalities", "There", "was", "a", "temporal", "association", "between", "the", "initiation", "of", "fluconazole", "and", "TDP", ".", "The", "TDP", "resolved", "when", "fluconazole", "was", "discontinued", ";", "however", ",", "the", "patient", "continued", "to", "have", "premature", "ventricular", "contractions", "and", "nonsustained", "ventricular", "tachycardia", "(", "NSVT", ")", "until", "six", "days", "after", "drug", "cessation", "DISCUSSION", ":", "Use", "of", "the", "Naranjo", "probability", "scale", "indicates", "a", "probable", "relationship", "between", "the", "use", "of", "fluconazole", "and", "the", "development", "of", "TDP", ".", "The", "possible", "mechanism", "is", "depression", "of", "rapidly", "activating", "delayed", "rectifier", "potassium", "currents", ".", "In", "our", "patient", ",", "there", "was", "no", "other", "etiology", "identified", "that", "could", "explain", "QT", "prolongation", "or", "TDP", "The", "complete", "disappearance", "of", "NSVT", "and", "premature", "ventricular", "contractions", "followed", "by", "normalization", "of", "QT", "interval", "after", "the", "drug", "was", "stopped", "strongly", "suggests", "fluconazole", "as", "the", "etiology", ".", "CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "that", "fluconazole", ",", "even", "at", "low", "doses", ",", "may", "cause", "prolongation", "of", "the", "QT", "interval", ",", "leading", "to", "TDP", ".", "Serial", "electrocardiographic", "monitoring", "may", "be", "considered", "when", "fluconazole", "is", "administered", "in", "patients", "who", "are", "at", "risk", "for", "ventricular", "arrhythmias", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [25, 25, "Chemical"], [58, 58, "Chemical"], [92, 92, "Chemical"], [100, 100, "Chemical"], [143, 143, "Chemical"], [202, 202, "Chemical"], [214, 214, "Chemical"], [240, 240, "Chemical"], [3, 5, "Disease"], [17, 19, "Disease"], [21, 21, "Disease"], [30, 30, "Disease"], [52, 52, "Disease"], [67, 67, "Disease"], [94, 94, "Disease"], [97, 97, "Disease"], [148, 148, "Disease"], [179, 179, "Disease"], [231, 231, "Disease"], [70, 72, "Disease"], [74, 74, "Disease"], [76, 78, "Disease"], [111, 113, "Disease"], [186, 188, "Disease"], [116, 117, "Disease"], [119, 119, "Disease"], [184, 184, "Disease"], [154, 154, "Disease"], [176, 177, "Disease"], [223, 227, "Disease"], [250, 251, "Disease"], [160, 160, "Chemical"]]], "relations": [[[0, 0, 3, 5, "CID"], [0, 0, 17, 19, "CID"], [0, 0, 21, 21, "CID"], [0, 0, 30, 30, "CID"], [0, 0, 52, 52, "CID"], [0, 0, 67, 67, "CID"], [0, 0, 94, 94, "CID"], [0, 0, 97, 97, "CID"], [0, 0, 148, 148, "CID"], [0, 0, 179, 179, "CID"], [0, 0, 231, 231, "CID"], [14, 14, 3, 5, "CID"], [14, 14, 17, 19, "CID"], [14, 14, 21, 21, "CID"], [14, 14, 30, 30, "CID"], [14, 14, 52, 52, "CID"], [14, 14, 67, 67, "CID"], [14, 14, 94, 94, "CID"], [14, 14, 97, 97, "CID"], [14, 14, 148, 148, "CID"], [14, 14, 179, 179, "CID"], [14, 14, 231, 231, "CID"], [25, 25, 3, 5, "CID"], [25, 25, 17, 19, "CID"], [25, 25, 21, 21, "CID"], [25, 25, 30, 30, "CID"], [25, 25, 52, 52, "CID"], [25, 25, 67, 67, "CID"], [25, 25, 94, 94, "CID"], [25, 25, 97, 97, "CID"], [25, 25, 148, 148, "CID"], [25, 25, 179, 179, "CID"], [25, 25, 231, 231, "CID"], [58, 58, 3, 5, "CID"], [58, 58, 17, 19, "CID"], [58, 58, 21, 21, "CID"], [58, 58, 30, 30, "CID"], [58, 58, 52, 52, "CID"], [58, 58, 67, 67, "CID"], [58, 58, 94, 94, "CID"], [58, 58, 97, 97, "CID"], [58, 58, 148, 148, "CID"], [58, 58, 179, 179, "CID"], [58, 58, 231, 231, "CID"], [92, 92, 3, 5, "CID"], [92, 92, 17, 19, "CID"], [92, 92, 21, 21, "CID"], [92, 92, 30, 30, "CID"], [92, 92, 52, 52, "CID"], [92, 92, 67, 67, "CID"], [92, 92, 94, 94, "CID"], [92, 92, 97, 97, "CID"], [92, 92, 148, 148, "CID"], [92, 92, 179, 179, "CID"], [92, 92, 231, 231, "CID"], [100, 100, 3, 5, "CID"], [100, 100, 17, 19, "CID"], [100, 100, 21, 21, "CID"], [100, 100, 30, 30, "CID"], [100, 100, 52, 52, "CID"], [100, 100, 67, 67, "CID"], [100, 100, 94, 94, "CID"], [100, 100, 97, 97, "CID"], [100, 100, 148, 148, "CID"], [100, 100, 179, 179, "CID"], [100, 100, 231, 231, "CID"], [143, 143, 3, 5, "CID"], [143, 143, 17, 19, "CID"], [143, 143, 21, 21, "CID"], [143, 143, 30, 30, "CID"], [143, 143, 52, 52, "CID"], [143, 143, 67, 67, "CID"], [143, 143, 94, 94, "CID"], [143, 143, 97, 97, "CID"], [143, 143, 148, 148, "CID"], [143, 143, 179, 179, "CID"], [143, 143, 231, 231, "CID"], [202, 202, 3, 5, "CID"], [202, 202, 17, 19, "CID"], [202, 202, 21, 21, "CID"], [202, 202, 30, 30, "CID"], [202, 202, 52, 52, "CID"], [202, 202, 67, 67, "CID"], [202, 202, 94, 94, "CID"], [202, 202, 97, 97, "CID"], [202, 202, 148, 148, "CID"], [202, 202, 179, 179, "CID"], [202, 202, 231, 231, "CID"], [214, 214, 3, 5, "CID"], [214, 214, 17, 19, "CID"], [214, 214, 21, 21, "CID"], [214, 214, 30, 30, "CID"], [214, 214, 52, 52, "CID"], [214, 214, 67, 67, "CID"], [214, 214, 94, 94, "CID"], [214, 214, 97, 97, "CID"], [214, 214, 148, 148, "CID"], [214, 214, 179, 179, "CID"], [214, 214, 231, 231, "CID"], [240, 240, 3, 5, "CID"], [240, 240, 17, 19, "CID"], [240, 240, 21, 21, "CID"], [240, 240, 30, 30, "CID"], [240, 240, 52, 52, "CID"], [240, 240, 67, 67, "CID"], [240, 240, 94, 94, "CID"], [240, 240, 97, 97, "CID"], [240, 240, 148, 148, "CID"], [240, 240, 179, 179, "CID"], [240, 240, 231, 231, "CID"]]], "clusters": [], "translated": "<0>氟康唑</0> - 诱发<10>尖端扭转型室速</10>。目的：介绍一例<1>氟康唑</1> - 相关的<11>尖端扭转型室速</11> (<12>TDP</12>) 并讨论<2>氟康唑</2>的作用造成<13>TDP</13>。病例总结：一名 68 岁的白人女性患有从骶前脓肿分离出的光滑念珠菌，在开始口服<3>氟康唑</3>八天后发生<14>TDP</14>。该患者没有其他危险因素<15>TDP</15>，包括<21>冠状动脉疾病</21>、<22>心肌病</22>、<23>充血性心力衰竭</23>和电解质异常。在<4>氟康唑</4>的使用和<16>TDP</16>之间存在时间关联。 <17>TDP</17>在停用<5>氟康唑</5>后得到解决；然而，患者在停药后6天仍继续出现<24>室性早搏</24>和非持续性<26>室性心动过速</26> (<27>NSVT</27>)。讨论：Naranjo的使用概率量表表明<6>氟康唑</6>的使用与<18>TDP</18>的发展之间可能存在关系。可能的机制是<29>抑制</29>快速激活的延迟整流器<33>钾</33>电流。在我们的患者中，没有发现其他病因可以解释<30>QT延长</30>或<19>TDP</19>。停药后<28>NSVT</28>和<25>室性早搏的完全消失</25>，QT间期正常化强烈提示<7>氟康唑</7>是病因。结论：临床医生应该意识到<8>氟康唑</8>，即使是低剂量，也可能引起<31>QT间期延长</31>，导致<20>TDP</20>。对有<32>室性心律失常</32>风险的患者使用<9>氟康唑</9>时，可考虑连续进行心电图监测。", "revised": true}
{"doc_key": "7565311", "sentences": [["Acute", "renal", "failure", "in", "high", "dose", "carboplatin", "chemotherapy", ".", "Carboplatin", "has", "been", "reported", "to", "cause", "acute", "renal", "failure", "when", "administered", "in", "high", "doses", "to", "adult", "patients", ".", "We", "report", "a", "4", "1", "/", "2", "-", "year", "-", "old", "girl", "who", "was", "treated", "with", "high", "-", "dose", "carboplatin", "for", "metastatic", "parameningeal", "embryonal", "rhabdomyosarcoma", ".", "Acute", "renal", "failure", "developed", "followed", "by", "a", "slow", "partial", "recovery", "of", "renal", "function", ".", "Possible", "contributing", "factors", "are", "discussed", "."]], "ner": [[[6, 6, "Chemical"], [9, 9, "Chemical"], [46, 46, "Chemical"], [0, 2, "Disease"], [15, 17, "Disease"], [53, 55, "Disease"], [50, 51, "Disease"]]], "relations": [[[6, 6, 0, 2, "CID"], [6, 6, 15, 17, "CID"], [6, 6, 53, 55, "CID"], [9, 9, 0, 2, "CID"], [9, 9, 15, 17, "CID"], [9, 9, 53, 55, "CID"], [46, 46, 0, 2, "CID"], [46, 46, 15, 17, "CID"], [46, 46, 53, 55, "CID"]]], "clusters": [], "translated": "<3>急性肾功能衰竭</3>在高剂量<0>卡铂</0>化疗时出现。据报道，成人患者服用大剂量<1>卡铂</1>会导致<4>急性肾功能衰竭</4>。我们报告了一名4 1/2岁的女孩因转移性脑膜旁<6>胚胎性横纹肌肉瘤</6>接受了高剂量<2>卡铂</2>治疗。随后出现了<5>急性肾功能衰竭</5>，肾功能得到了缓慢的部分恢复。讨论了可能的影响因素。", "revised": true}
{"doc_key": "8494478", "sentences": [["Ciprofloxacin", "-", "induced", "nephrotoxicity", "in", "patients", "with", "cancer", ".", "Nephrotoxicity", "associated", "with", "ciprofloxacin", "is", "uncommon", ".", "Five", "patients", "with", "cancer", "who", "developed", "acute", "renal", "failure", "that", "followed", "treatment", "with", "ciprofloxacin", "are", "described", "and", "an", "additional", "15", "cases", "reported", "in", "the", "literature", "are", "reviewed", ".", "Other", "than", "elevation", "of", "serum", "creatinine", "levels", ",", "characteristic", "clinical", "manifestations", "and", "abnormal", "laboratory", "findings", "are", "not", "frequently", "present", ".", "Allergic", "interstitial", "nephritis", "is", "believed", "to", "be", "the", "underlying", "pathological", "-", "process", ".", "Definitive", "diagnosis", "requires", "performance", "of", "renal", "biopsy", ",", "although", "this", "is", "not", "always", "feasible", ".", "An", "improvement", "in", "renal", "function", "that", "followed", "the", "discontinuation", "of", "the", "offending", "antibiotic", "supports", "the", "presumptive", "diagnosis", "of", "ciprofloxacin", "-", "induced", "acute", "renal", "failure", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [29, 29, "Chemical"], [110, 110, "Chemical"], [22, 24, "Disease"], [113, 115, "Disease"], [3, 3, "Disease"], [9, 9, "Disease"], [7, 7, "Disease"], [19, 19, "Disease"], [65, 66, "Disease"], [49, 49, "Chemical"]]], "relations": [[[0, 0, 22, 24, "CID"], [0, 0, 113, 115, "CID"], [12, 12, 22, 24, "CID"], [12, 12, 113, 115, "CID"], [29, 29, 22, 24, "CID"], [29, 29, 113, 115, "CID"], [110, 110, 22, 24, "CID"], [110, 110, 113, 115, "CID"]]], "clusters": [], "translated": " <0>环丙沙星</0> - 在<8>癌症</8>患者中引起的<6>肾毒性</6>。与<1>环丙沙星</1>相关的<7>肾毒性</7>并不常见。描述了5名<9>癌症</9>患者，他们在<2>环丙沙星</2>治疗后出现<4>急性肾功能衰竭</4>，并回顾了文献中报道的另外15例。除了血清<11>肌酐</11>水平升高外，特征性临床表现和异常实验室检查结果并不常见。过敏性<10>间质性肾炎</10>被认为是潜在的病理过程。明确诊断需要进行肾活检，尽管这并不总是可行的。停用致病抗生素后，肾功能改善支持<3>环丙沙星</3>诱发的<5>急性肾功能衰竭</5>的推定诊断。", "revised": true}
{"doc_key": "7650771", "sentences": [["Cholinergic", "toxicity", "resulting", "from", "ocular", "instillation", "of", "echothiophate", "iodide", "eye", "drops", ".", "A", "patient", "developed", "a", "severe", "cholinergic", "syndrome", "from", "the", "use", "of", "echothiophate", "iodide", "ophthalmic", "drops", ",", "presented", "with", "profound", "muscle", "weakness", "and", "was", "initially", "given", "the", "diagnosis", "of", "myasthenia", "gravis", ".", "Red", "blood", "cell", "and", "serum", "cholinesterase", "levels", "were", "severely", "depressed", "and", "symptoms", "resolved", "spontaneously", "following", "discontinuation", "of", "the", "eye", "drops", "."]], "ner": [[[7, 8, "Chemical"], [23, 24, "Chemical"], [31, 32, "Disease"], [1, 1, "Disease"], [40, 41, "Disease"]]], "relations": [[[7, 8, 31, 32, "CID"], [23, 24, 31, 32, "CID"]]], "clusters": [], "translated": "胆碱能<3>毒性</3>由眼部滴入的<0>碘化乙硫磷</0>滴眼液引起。一名患者因使用<1>碘化乙硫磷</1>滴眼液而出现严重的胆碱能综合征，表现为严重的<2>肌肉无力</2>，最初被诊断为<4>重症肌无力</4>。红细胞和血清中胆碱酯酶水平严重下降，停用滴眼液后症状自发消退。", "revised": true}
{"doc_key": "8475949", "sentences": [["Case", "report", ":", "pentamidine", "and", "polymorphic", "ventricular", "tachycardia", "revisited", ".", "Pentamidine", "isethionate", "has", "been", "associated", "with", "ventricular", "tachyarrhythmias", ",", "including", "torsade", "de", "pointes", ".", "This", "article", "reports", "two", "cases", "of", "this", "complication", "and", "reviews", "all", "reported", "cases", "to", "date", ".", "Pentamidine", "-", "induced", "torsade", "de", "pointes", "may", "be", "related", "to", "serum", "magnesium", "levels", "and", "hypomagnesemia", "may", "synergistically", "induce", "torsade", ".", "Torsade", "de", "pointes", "occurred", "after", "an", "average", "of", "10", "days", "of", "treatment", "with", "pentamidine", ".", "In", "these", "patients", ",", "no", "other", "acute", "side", "effects", "of", "pentamidine", "were", "observed", ".", "Torsade", "de", "pointes", "can", "be", "treated", "when", "recognized", "early", ",", "possibly", "without", "discontinuation", "of", "pentamidine", ".", "When", "QTc", "interval", "prolongation", "is", "observed", ",", "early", "magnesium", "supplementation", "is", "advocated", "."]], "ner": [[[3, 3, "Chemical"], [10, 11, "Chemical"], [40, 40, "Chemical"], [73, 73, "Chemical"], [85, 85, "Chemical"], [103, 103, "Chemical"], [20, 22, "Disease"], [43, 45, "Disease"], [60, 62, "Disease"], [89, 91, "Disease"], [6, 7, "Disease"], [16, 17, "Disease"], [54, 54, "Disease"], [106, 108, "Disease"], [51, 51, "Chemical"], [113, 113, "Chemical"]]], "relations": [[[3, 3, 20, 22, "CID"], [3, 3, 43, 45, "CID"], [3, 3, 60, 62, "CID"], [3, 3, 89, 91, "CID"], [10, 11, 20, 22, "CID"], [10, 11, 43, 45, "CID"], [10, 11, 60, 62, "CID"], [10, 11, 89, 91, "CID"], [40, 40, 20, 22, "CID"], [40, 40, 43, 45, "CID"], [40, 40, 60, 62, "CID"], [40, 40, 89, 91, "CID"], [73, 73, 20, 22, "CID"], [73, 73, 43, 45, "CID"], [73, 73, 60, 62, "CID"], [73, 73, 89, 91, "CID"], [85, 85, 20, 22, "CID"], [85, 85, 43, 45, "CID"], [85, 85, 60, 62, "CID"], [85, 85, 89, 91, "CID"], [103, 103, 20, 22, "CID"], [103, 103, 43, 45, "CID"], [103, 103, 60, 62, "CID"], [103, 103, 89, 91, "CID"]]], "clusters": [], "translated": "病例报告：<0>喷他脒</0>和多形性<10>室性心动过速</10>再访。 <1>喷他脒羟乙磺酸盐</1>与<11>室性心动过速</11>有关，包括<6>尖端扭转型室性心动过速</6>。本文报告了该并发症的两例，并回顾了迄今为止报道的所有病例。 <2>喷他脒</2>诱发的<7>尖端扭转型室速</7>可能与血清<14>镁</14>水平有关，<12>低镁血症</12>可能协同诱发扭转型室速。 <8>尖端扭转型室性心动过速</8>发生在使用<3>喷他脒</3>治疗平均10天后。在这些患者中，未观察到<4>喷他脒</4>的其他急性副作用。<9>尖端扭转型室性心动过速</9>可以在早期识别时进行治疗，可能无需停用<5>喷他脒</5>。当被观察到<13>QTc间期延长</13>时，提倡尽早补充<15>镁</15>。", "revised": true}
{"doc_key": "10565806", "sentences": [["Hypomania", "-", "like", "syndrome", "induced", "by", "olanzapine", ".", "We", "report", "a", "female", "patient", "with", "a", "diagnosis", "of", "a", "not", "otherwise", "specified", "psychotic", "disorder", "(", "DSM", "-", "IV", ")", "who", "developed", "hypomania", "shortly", "after", "the", "introduction", "of", "olanzapine", "treatment", "."]], "ner": [[[6, 6, "Chemical"], [36, 36, "Chemical"], [0, 0, "Disease"], [30, 30, "Disease"], [21, 22, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 30, 30, "CID"], [36, 36, 0, 0, "CID"], [36, 36, 30, 30, "CID"]]], "clusters": [], "translated": "<2>由<1>奥氮平</1>引起的<0>轻躁狂</0>样综合征</2>。我们报告了一名女性患者，她被诊断为未另行指定的<4>精神障碍</4>（DSM-IV），在引入<1>奥氮平</1>治疗后不久出现了<3>轻躁狂</3>。", "revised": true}
{"doc_key": "9061311", "sentences": [["Neutrophil", "superoxide", "and", "hydrogen", "peroxide", "production", "in", "patients", "with", "acute", "liver", "failure", ".", "Defects", "in", "superoxide", "and", "hydrogen", "peroxide", "production", "may", "be", "implicated", "in", "the", "high", "incidence", "of", "bacterial", "infections", "in", "patients", "with", "acute", "liver", "failure", "(", "ALF", ")", ".", "In", "the", "present", "study", ",", "oxygen", "radical", "production", "in", "patients", "with", "ALF", "due", "to", "paracetamol", "overdose", "was", "compared", "with", "that", "of", "healthy", "volunteers", ".", "Neutrophils", "from", "14", "ALF", "patients", "were", "stimulated", "via", "the", "complement", "receptors", "using", "zymosan", "opsonized", "with", "ALF", "or", "control", "serum", ".", "Superoxide", "and", "hydrogen", "peroxide", "production", "by", "ALF", "neutrophils", "stimulated", "with", "zymosan", "opsonized", "with", "ALF", "serum", "was", "significantly", "reduced", "compared", "with", "the", "control", "subjects", "(", "P", "<", "0", ".", "01", ")", ".", "This", "defect", "persisted", "when", "zymosan", "opsonized", "by", "control", "serum", "was", "used", "(", "P", "<", "0", ".", "05", ")", ".", "Superoxide", "and", "hydrogen", "peroxide", "production", "in", "neutrophils", "stimulated", "with", "formyl", "-", "methionyl", "-", "leucyl", "-", "phenylalanine", "(", "fMLP", ")", "from", "a", "further", "18", "ALF", "patients", "was", "unaffected", "compared", "with", "control", "neutrophils", ".", "Serum", "C3", "complement", "levels", "were", "significantly", "reduced", "in", "ALF", "patients", "compared", "with", "control", "subjects", "(", "P", "<", "0", ".", "0005", ")", ".", "These", "results", "demonstrate", "a", "neutrophil", "defect", "in", "ALF", "due", "to", "paracetamol", "overdose", ",", "that", "is", "complement", "dependent", "but", "independent", "of", "serum", "complement", ",", "possibly", "connected", "to", "the", "complement", "receptor", "."]], "ner": [[[54, 54, "Chemical"], [198, 198, "Chemical"], [9, 11, "Disease"], [33, 35, "Disease"], [37, 37, "Disease"], [51, 51, "Disease"], [67, 67, "Disease"], [79, 79, "Disease"], [90, 90, "Disease"], [97, 97, "Disease"], [157, 157, "Disease"], [174, 174, "Disease"], [195, 195, "Disease"], [1, 1, "Chemical"], [15, 15, "Chemical"], [84, 84, "Chemical"], [134, 134, "Chemical"], [28, 29, "Disease"], [55, 55, "Disease"], [199, 199, "Disease"], [3, 4, "Chemical"], [17, 18, "Chemical"], [86, 87, "Chemical"], [136, 137, "Chemical"], [45, 45, "Chemical"], [143, 149, "Chemical"], [151, 151, "Chemical"]]], "relations": [[[54, 54, 9, 11, "CID"], [54, 54, 33, 35, "CID"], [54, 54, 37, 37, "CID"], [54, 54, 51, 51, "CID"], [54, 54, 67, 67, "CID"], [54, 54, 79, 79, "CID"], [54, 54, 90, 90, "CID"], [54, 54, 97, 97, "CID"], [54, 54, 157, 157, "CID"], [54, 54, 174, 174, "CID"], [54, 54, 195, 195, "CID"], [198, 198, 9, 11, "CID"], [198, 198, 33, 35, "CID"], [198, 198, 37, 37, "CID"], [198, 198, 51, 51, "CID"], [198, 198, 67, 67, "CID"], [198, 198, 79, 79, "CID"], [198, 198, 90, 90, "CID"], [198, 198, 97, 97, "CID"], [198, 198, 157, 157, "CID"], [198, 198, 174, 174, "CID"], [198, 198, 195, 195, "CID"]]], "clusters": [], "translated": "<2>急性肝功能衰竭</2>患者中性粒细胞<13>超氧化物</13>和<20>过氧化氢</20>的产生。<14>超氧化物</14>和<21>过氧化氢</21>产生的缺陷可能与<3>急性肝功能衰竭</3> 患者的<17>细菌感染</17>高发有关 (<4>ALF</4>)。在本研究中，<5>ALF</5>患者因<0>对乙酰氨基酚</0><18>过量服用</18>而产生的<24>氧</24>自由基与健康志愿者进行了比较。通过补体受体刺激，使用用<7>ALF</7>或对照血清对葡萄糖酵母的聚集素化，来自14名<6>ALF</6>患者的中性粒细胞。经<9>ALF</9>血清调理刺激的<8>ALF</8>中性粒细胞，其<15>超氧化物</15>和<22>过氧化氢</22>的产生与对照相比显著减少(P < 0.01)。当使用对照血清调理的聚糖酵母时，这种缺陷仍然存在(P < 0.05)。<16>超氧化物</16>和<23>过氧化氢</23> 在中性粒细胞的产生，经<25>甲酰-甲硫氨酰-亮氨酰-苯丙氨酸</25>(<26>fMLP</26>)刺激后，与另外18个<10>ALF</10>患者和对照组相比没有影响。与对照组相比，<11>ALF</11>患者的血清C3补体水平显著降低(P<0.0005)。这些结果表明，<12>ALF</12>中的中性粒细胞缺陷是由于<1>对乙酰氨基酚</1><19>过量服用</19>，这是补体依赖性但与血清补体无关，可能与补体受体有关。", "revised": true}
{"doc_key": "3183120", "sentences": [["Reversible", "cerebral", "lesions", "associated", "with", "tiazofurin", "usage", ":", "MR", "demonstration", ".", "Tiazofurin", "is", "an", "experimental", "chemotherapeutic", "agent", "currently", "undergoing", "clinical", "evaluation", ".", "We", "report", "our", "results", "with", "magnetic", "resonance", "(", "MR", ")", "in", "demonstrating", "reversible", "cerebral", "abnormalities", "concurrent", "with", "the", "use", "of", "this", "drug", ".", "The", "abnormalities", "on", "MR", "were", "correlated", "with", "findings", "on", "CT", "as", "well", "as", "with", "cerebral", "angiography", ".", "The", "utility", "of", "MR", "in", "the", "evaluation", "of", "patients", "receiving", "this", "new", "agent", "is", "illustrated", "."]], "ner": [[[5, 5, "Chemical"], [11, 11, "Chemical"], [1, 2, "Disease"], [35, 36, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 35, 36, "CID"], [11, 11, 1, 2, "CID"], [11, 11, 35, 36, "CID"]]], "clusters": [], "translated": "与<0>噻唑呋林</0>使用相关的可逆性<2>脑损伤</2>：MR演示。<1>噻唑呋林</1>是目前正在进行临床评价的实验性化疗药物。我们通过磁共振(MR)报告我们的结果，证明在使用该药物的同时出现可逆的<3>大脑异常</3>。MR异常与CT和脑血管造影结果相关。说明了MR在评估接受这种新药的患者中的效用。", "revised": true}
{"doc_key": "6454943", "sentences": [["Effect", "of", "captopril", "on", "pre", "-", "existing", "and", "aminonucleoside", "-", "induced", "proteinuria", "in", "spontaneously", "hypertensive", "rats", ".", "Proteinuria", "is", "a", "side", "effect", "of", "captopril", "treatment", "in", "hypertensive", "patients", ".", "The", "possibility", "of", "reproducing", "the", "same", "renal", "abnormality", "with", "captopril", "was", "examined", "in", "SHR", ".", "Oral", "administration", "of", "captopril", "at", "100", "mg", "/", "kg", "for", "14", "days", "failed", "to", "aggravate", "proteinuria", "pre", "-", "existing", "in", "SHR", ".", "Also", ",", "captopril", "treatment", "failed", "to", "potentiate", "or", "facilitate", "development", "of", "massive", "proteinuria", "invoked", "by", "puromycin", "aminonucleoside", "in", "SHR", ".", "Captopril", "had", "little", "or", "no", "demonstrable", "effects", "on", "serum", "electrolyte", "concentrations", ",", "excretion", "of", "urine", ",", "sodium", "and", "potassium", ",", "endogenous", "creatinine", "clearance", ",", "body", "weight", ",", "and", "food", "and", "water", "consumption", ".", "However", ",", "ketone", "bodies", "were", "consistently", "present", "in", "urine", "and", "several", "lethalities", "occurred", "during", "multiple", "dosing", "of", "captopril", "in", "SHR", "."]], "ner": [[[8, 8, "Chemical"], [81, 82, "Chemical"], [11, 11, "Disease"], [17, 17, "Disease"], [59, 59, "Disease"], [78, 78, "Disease"], [2, 2, "Chemical"], [23, 23, "Chemical"], [38, 38, "Chemical"], [47, 47, "Chemical"], [68, 68, "Chemical"], [86, 86, "Chemical"], [136, 136, "Chemical"], [14, 14, "Disease"], [26, 26, "Disease"], [35, 36, "Disease"], [102, 102, "Chemical"], [104, 104, "Chemical"], [107, 107, "Chemical"], [121, 121, "Chemical"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 17, 17, "CID"], [8, 8, 59, 59, "CID"], [8, 8, 78, 78, "CID"], [81, 82, 11, 11, "CID"], [81, 82, 17, 17, "CID"], [81, 82, 59, 59, "CID"], [81, 82, 78, 78, "CID"]]], "clusters": [], "translated": "<6>卡托普利</6>对自发性<13>高血压</13>大鼠已有的和<0>氨基核苷</0>诱导的<2>蛋白尿</2>的影响。 <3>蛋白尿</3>是<7>卡托普利</7>治疗<14>高血压</14>患者的副作用。在 SHR 中检查了使用 <8> 卡托普利 </8> 重现相同<15>肾异常</15>的可能性。口服 <9>卡托普利</9> 100 mg/kg 14天未能加重 SHR 中预先存在的<4>蛋白尿</4> 。此外，<10>卡托普利</10>治疗未能加强或促进 SHR 中<1>嘌呤霉素氨基核苷</1>引起的大量<5>蛋白尿</5>的发展。<11>卡托普利</11>对血清电解质浓度、尿液排泄、<16>钠</16>和<17>钾</17>、内源性<18>肌酐</18>清除率、体重以及食物和水的消耗量几乎没有或没有明显影响。然而，<19>酮</19>体一直存在于尿液中，并且在 SHR 中多次给予<12>卡托普利</12>期间发生了几例致死事件。", "revised": true}
{"doc_key": "6153967", "sentences": [["Epileptogenic", "properties", "of", "enflurane", "and", "their", "clinical", "interpretation", ".", "Three", "cases", "of", "EEG", "changes", "induced", "by", "single", "exposure", "to", "enflurane", "anesthesia", "are", "reported", ".", "In", "one", "patient", ",", "enflurane", "administered", "during", "a", "donor", "nephrectomy", "resulted", "in", "unexpected", "partial", "motor", "seizures", ".", "Until", "the", "cause", "of", "the", "seizures", "was", "correctly", "identified", ",", "the", "patient", "was", "inappropriately", "treated", "with", "anticonvulsants", ".", "Two", "other", "patients", "suffered", "from", "partial", ",", "complex", "and", "generalized", "seizures", "uncontrolled", "by", "medication", ".", "Epileptic", "foci", "delineated", "and", "activated", "by", "enflurane", "were", "surgically", "ablated", "and", "the", "patients", "are", "now", "seizure", "-", "free", ".", "Previous", "exposures", "to", "enflurane", "have", "to", "be", "disclosed", "to", "avoid", "mistakes", "in", "clinical", "interpretation", "of", "the", "EEG", ".", "On", "the", "other", "hand", ",", "enflurane", "may", "prove", "to", "be", "a", "safe", "fast", "acting", "activator", "of", "epileptic", "foci", "during", "corticography", "or", "depth", "electrode", "intraoperative", "recordings", "."]], "ner": [[[3, 3, "Chemical"], [19, 19, "Chemical"], [28, 28, "Chemical"], [80, 80, "Chemical"], [96, 96, "Chemical"], [116, 116, "Chemical"], [39, 39, "Disease"], [46, 46, "Disease"], [69, 69, "Disease"], [89, 89, "Disease"], [74, 74, "Disease"], [127, 127, "Disease"]]], "relations": [[[3, 3, 39, 39, "CID"], [3, 3, 46, 46, "CID"], [3, 3, 69, 69, "CID"], [3, 3, 89, 89, "CID"], [19, 19, 39, 39, "CID"], [19, 19, 46, 46, "CID"], [19, 19, 69, 69, "CID"], [19, 19, 89, 89, "CID"], [28, 28, 39, 39, "CID"], [28, 28, 46, 46, "CID"], [28, 28, 69, 69, "CID"], [28, 28, 89, 89, "CID"], [80, 80, 39, 39, "CID"], [80, 80, 46, 46, "CID"], [80, 80, 69, 69, "CID"], [80, 80, 89, 89, "CID"], [96, 96, 39, 39, "CID"], [96, 96, 46, 46, "CID"], [96, 96, 69, 69, "CID"], [96, 96, 89, 89, "CID"], [116, 116, 39, 39, "CID"], [116, 116, 46, 46, "CID"], [116, 116, 69, 69, "CID"], [116, 116, 89, 89, "CID"]]], "clusters": [], "translated": "<0>恩氟烷</0> 的致癫痫特性及其临床解释。报道了三例因单次暴露于<1>安氟烷</1>麻醉引起的脑电图变化。在一名患者中，<2>恩氟烷</2>在供体肾切除术期间给药导致意外的部分运动性<6>癫痫发作</6>。在正确确定<7>癫痫发作</7>的原因之前，该患者一直在接受不恰当的抗惊厥药治疗。另外两名患者患有药物无法控制的部分性、复杂性和全身性<8>癫痫发作</8>。<10>癫痫</10>病灶由<3>恩氟烷</3>描绘和激活，手术切除，患者现在<9>癫痫发作</9>自由。必须披露以前接触过<4>恩氟烷</4>以避免脑电图临床解释错误。另一方面，<5>恩氟烷</5>可能被证明是一种安全的快速作用激活剂，可在皮质造影或深度电极术中记录期间激活<11>癫痫</11>病灶。", "revised": true}
{"doc_key": "7710775", "sentences": [["Time", "dependence", "of", "plasma", "malondialdehyde", ",", "oxypurines", ",", "and", "nucleosides", "during", "incomplete", "cerebral", "ischemia", "in", "the", "rat", ".", "Incomplete", "cerebral", "ischemia", "(", "30", "min", ")", "was", "induced", "in", "the", "rat", "by", "bilaterally", "clamping", "the", "common", "carotid", "arteries", ".", "Peripheral", "venous", "blood", "samples", "were", "withdrawn", "from", "the", "femoral", "vein", "four", "times", "(", "once", "every", "5", "min", ")", "before", "ischemia", "(", "0", "time", ")", "and", "5", ",", "15", ",", "and", "30", "min", "after", "ischemia", ".", "Plasma", "extracts", "were", "analyzed", "by", "a", "highly", "sensitive", "high", "-", "performance", "liquid", "chromatographic", "method", "for", "the", "direct", "determination", "of", "malondialdehyde", ",", "oxypurines", ",", "and", "nucleosides", ".", "During", "ischemia", ",", "a", "time", "-", "dependent", "increase", "of", "plasma", "oxypurines", "and", "nucleosides", "was", "observed", ".", "Plasma", "malondialdehyde", ",", "which", "was", "present", "in", "minimal", "amount", "at", "zero", "time", "(", "0", ".", "058", "mumol", "/", "liter", "plasma", ";", "SD", "0", ".", "015", ")", ",", "increased", "after", "5", "min", "of", "ischemia", ",", "resulting", "in", "a", "fivefold", "increase", "after", "30", "min", "of", "carotid", "occlusion", "(", "0", ".", "298", "mumol", "/", "liter", "plasma", ";", "SD", "0", ".", "078", ")", ".", "Increased", "plasma", "malondialdehyde", "was", "also", "recorded", "in", "two", "other", "groups", "of", "animals", "subjected", "to", "the", "same", "experimental", "model", ",", "one", "receiving", "20", "mg", "/", "kg", "b", ".", "w", ".", "of", "the", "cyclooxygenase", "inhibitor", "acetylsalicylate", "intravenously", "immediately", "before", "ischemia", ",", "the", "other", "receiving", "650", "micrograms", "/", "kg", "b", ".", "w", ".", "of", "the", "hypotensive", "drug", "nitroprusside", "at", "a", "flow", "rate", "of", "103", "microliters", "/", "min", "intravenously", "during", "ischemia", ",", "although", "in", "this", "latter", "group", "malondialdehyde", "was", "significantly", "higher", ".", "The", "present", "data", "indicate", "that", "the", "determination", "of", "malondialdehyde", ",", "oxypurines", ",", "and", "nucleosides", "in", "peripheral", "blood", ",", "may", "be", "used", "to", "monitor", "the", "metabolic", "alterations", "of", "tissues", "occurring", "during", "ischemic", "phenomena", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[4, 4, "Chemical"], [92, 92, "Chemical"], [116, 116, "Chemical"], [177, 177, "Chemical"], [248, 248, "Chemical"], [261, 261, "Chemical"], [12, 13, "Disease"], [19, 20, "Disease"], [57, 57, "Disease"], [71, 71, "Disease"], [100, 100, "Disease"], [147, 147, "Disease"], [212, 212, "Disease"], [241, 241, "Disease"], [283, 283, "Disease"], [227, 227, "Disease"], [9, 9, "Chemical"], [97, 97, "Chemical"], [111, 111, "Chemical"], [266, 266, "Chemical"], [208, 208, "Chemical"], [229, 229, "Chemical"]]], "relations": [[[4, 4, 12, 13, "CID"], [4, 4, 19, 20, "CID"], [92, 92, 12, 13, "CID"], [92, 92, 19, 20, "CID"], [116, 116, 12, 13, "CID"], [116, 116, 19, 20, "CID"], [177, 177, 12, 13, "CID"], [177, 177, 19, 20, "CID"], [248, 248, 12, 13, "CID"], [248, 248, 19, 20, "CID"], [261, 261, 12, 13, "CID"], [261, 261, 19, 20, "CID"]]], "clusters": [], "translated": "大鼠不完全性<6>脑缺血</6>期间血浆<0>丙二醛</0>、氧嘌呤和<16>核苷</16>的时间依赖性。通过双侧夹闭颈总动脉在大鼠中诱导不完全<7>脑缺血</7>（30分钟）。在<8>缺血</8>前（0次）和<9>缺血</9>后5、15、30分钟分别从股静脉抽取外周静脉血4次（每5分钟一次）。血浆提取物采用高灵敏度高效液相色谱法进行分析，可直接测定<1>丙二醛</1>、氧嘌呤和<17>核苷</17>。在<10>局部缺血</10>期间，观察到血浆氧嘌呤和<18>核苷</18>随时间增加。血浆<2>丙二醛</2>，在零时以最小量存在（0.058 mumol/升血浆；SD 0.015），在<11>局部缺血</11>5分钟后增加，导致颈动脉闭塞30分钟后增加了五倍（0.298 μmol/升血浆；SD 0.078）。在接受相同实验模型的另外两组动物中也记录到血浆<3>丙二醛</3>增加，其中一组接受20 mg/kg b.w.的环加氧酶抑制剂<20>乙酰水杨酸盐</20>在<12>局部缺血</12>前立即静脉注射，另接受650 微克/千克b.w.的<15>降压</15>药物<21>硝普钠</21>在<13>局部缺血</13>期间以103 微升/分钟的流速静脉注射，尽管在后一组<4>丙二醛</4>明显偏高。目前的数据表明，外周血中<5>丙二醛</5>、氧化嘌呤和<19>核苷</19>的测定可用于监测<14>缺血</14>现象期间发生的组织代谢变化。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "3120485", "sentences": [["Antagonism", "of", "diazepam", "-", "induced", "sedative", "effects", "by", "Ro15", "-", "1788", "in", "patients", "after", "surgery", "under", "lumbar", "epidural", "block", ".", "A", "double", "-", "blind", "placebo", "-", "controlled", "investigation", "of", "efficacy", "and", "safety", ".", "The", "aim", "of", "this", "study", "was", "to", "assess", "the", "efficacy", "of", "Ro15", "-", "1788", "and", "a", "placebo", "in", "reversing", "diazepam", "-", "induced", "effects", "after", "surgery", "under", "epidural", "block", ",", "and", "to", "evaluate", "the", "local", "tolerance", "and", "general", "safety", "of", "Ro15", "-", "1788", ".", "Fifty", "-", "seven", "patients", "were", "sedated", "with", "diazepam", "for", "surgery", "under", "epidural", "anaesthesia", ".", "Antagonism", "of", "diazepam", "-", "induced", "effects", "by", "Ro15", "-", "1788", "was", "investigated", "postoperatively", "in", "a", "double", "-", "blind", "placebo", "-", "controlled", "trial", ".", "The", "patient", "'s", "subjective", "assessment", "of", "mood", "rating", ",", "an", "objective", "test", "of", "performance", ",", "a", "test", "for", "amnesia", ",", "and", "vital", "signs", "were", "recorded", "for", "up", "to", "300", "min", "after", "administration", "of", "the", "trial", "drug", ".", "No", "significant", "differences", "between", "the", "two", "groups", "were", "observed", "for", "mood", "rating", ",", "amnesia", ",", "or", "vital", "signs", ".", "The", "Ro15", "-", "1788", "group", "showed", "a", "significant", "improvement", "in", "the", "performance", "test", "up", "to", "120", "min", "after", "administration", "of", "the", "drug", ".", "There", "was", "no", "evidence", "of", "reaction", "at", "the", "injection", "site", "."]], "ner": [[[2, 2, "Chemical"], [52, 52, "Chemical"], [83, 83, "Chemical"], [92, 92, "Chemical"], [131, 131, "Disease"], [163, 163, "Disease"], [8, 10, "Chemical"], [44, 46, "Chemical"], [72, 74, "Chemical"], [97, 99, "Chemical"], [170, 172, "Chemical"]]], "relations": [[[2, 2, 131, 131, "CID"], [2, 2, 163, 163, "CID"], [52, 52, 131, 131, "CID"], [52, 52, 163, 163, "CID"], [83, 83, 131, 131, "CID"], [83, 83, 163, 163, "CID"], [92, 92, 131, 131, "CID"], [92, 92, 163, 163, "CID"]]], "clusters": [], "translated": "腰椎硬膜外阻滞术后<6>Ro15-1788</6>拮抗<0>地西泮</0>引起的镇静作用。本研究的目的是评估<7> Ro15 - 1788 </7>和安慰剂在逆转硬膜外阻滞手术后诱导的<1>地西泮</1>作用中的疗效，并评估局部耐受性和<8> Ro15 - 1788 </8>的一般安全性。57例患者在硬膜外麻醉下接受<2>地西泮</2>镇静。在双盲安慰剂对照试验中研究了术后<9>Ro15-1788</9>对<3>地西泮</3>诱导作用的拮抗作用。在服用试验药物后长达300分钟内记录患者的<4>情绪评分</4>主观评估、客观表现测试、健忘症测试和生命体征。在情绪评分、<5>健忘症</5>或生命体征方面，两组之间没有显着差异。<10>Ro15-1788</10>组在给药后长达120分钟的性能测试中表现出显着改善。注射部位没有反应迹象。", "revised": true}
{"doc_key": "1079693", "sentences": [["Ocular", "manifestations", "of", "juvenile", "rheumatoid", "arthritis", ".", "We", "followed", "210", "cases", "of", "juvenile", "rheumatoid", "arthritis", "closely", "for", "eleven", "years", ".", "Thirty", "-", "six", "of", "the", "210", "patients", "(", "17", ".", "2", "%", ")", "developed", "iridocyclitis", ".", "Iridocyclitis", "was", "seen", "most", "frequently", "in", "young", "female", "patients", "(", "0", "to", "4", "years", ")", "with", "the", "monoarticular", "or", "pauciatricular", "form", "of", "the", "arthritis", ".", "However", ",", "30", "%", "of", "the", "patients", "developed", "uveitis", "after", "16", "years", "of", "age", ".", "Although", "61", "%", "of", "patients", "had", "a", "noncontributory", "ocular", "history", "on", "entry", ",", "42", "%", "had", "active", "uveitis", "on", "entry", ".", "Our", "approach", "was", "effective", "in", "detecting", "uveitis", "in", "new", "cases", "and", "exacerbations", "of", "uveitis", "in", "established", "cases", ".", "Forty", "-", "four", "percent", "of", "patients", "with", "uveitis", "had", "one", "or", "more", "identifiable", "signs", "or", "symptoms", ",", "such", "as", "red", "eye", ",", "ocular", "pain", ",", "decreased", "visual", "acuity", ",", "or", "photophobia", ",", "in", "order", "of", "decreasing", "frequency", ".", "Even", "after", "early", "detection", "and", "prompt", "treatment", ",", "41", "%", "of", "cases", "of", "uveitis", "did", "not", "respond", "to", "more", "than", "six", "months", "of", "intensive", "topical", "treatment", "with", "corticosteroids", "and", "mydriatics", ".", "Despite", "this", ",", "there", "was", "a", "dramatic", "decrease", "in", "the", "50", "%", "incidence", "of", "blinding", "complications", "of", "uveitis", "cited", "in", "earlier", "studies", ".", "Cataract", "and", "band", "keratopathy", "occurred", "in", "only", "22", "and", "13", "%", "of", "our", "group", ",", "respectively", ".", "We", "used", "chloroquine", "or", "hydroxychloroquine", "in", "173", "of", "210", "cases", "and", "found", "only", "one", "case", "of", "chorioretinopathy", "attributable", "to", "these", "drugs", ".", "Systemically", "administered", "corticosteroids", "were", "used", "in", "75", "of", "210", "cases", ";", "a", "significant", "number", "of", "posterior", "subcapsular", "cataracts", "was", "found", ".", "Typical", "keratoconjunctivitis", "sicca", "developed", "in", "three", "of", "the", "uveitis", "cases", ".", "This", "association", "with", "uveitis", "and", "JRA", "was", "not", "noted", "previously", ".", "Surgical", "treatment", "of", "cataracts", ",", "band", "keratopathy", ",", "and", "glaucoma", "achieved", "uniformly", "discouraging", "results", "."]], "ner": [[[228, 228, "Chemical"], [240, 240, "Disease"], [180, 180, "Chemical"], [248, 248, "Chemical"], [3, 5, "Disease"], [12, 14, "Disease"], [226, 226, "Chemical"], [34, 34, "Disease"], [36, 36, "Disease"], [59, 59, "Disease"], [69, 69, "Disease"], [93, 93, "Disease"], [103, 103, "Disease"], [110, 110, "Disease"], [122, 122, "Disease"], [166, 166, "Disease"], [201, 201, "Disease"], [275, 275, "Disease"], [281, 281, "Disease"], [137, 138, "Disease"], [140, 142, "Disease"], [145, 145, "Disease"], [207, 207, "Disease"], [263, 263, "Disease"], [292, 292, "Disease"], [209, 210, "Disease"], [294, 295, "Disease"], [268, 268, "Disease"], [298, 298, "Disease"]]], "relations": [[[228, 228, 240, 240, "CID"]]], "clusters": [], "translated": "<4>幼年型类风湿性关节炎的眼部表现</4>。我们对 210 例 <5>幼年型类风湿性关节炎</5> 进行了长达 11 年的密切随访。 210 例患者中有 36 例 (17.2%) 发生<7>虹膜睫状体炎</7>。 <8>虹膜睫状体炎</8> 最常见于患有 <9>关节炎</9> 的单关节或少足形式的年轻女性患者（0 至 4 岁）。然而，30% 的患者在 16 岁以后发生<10>葡萄膜炎</10>。尽管 61% 的患者在入组时没有眼部病史，但 42% 的患者在入组时有活动性<11>葡萄膜炎</11>。我们的方法可有效检测新病例中的<12>葡萄膜炎</12>和既定病例中<13>葡萄膜炎</13>的恶化。44% 的<14>葡萄膜炎</14>患者有一种或多种可识别的体征或症状，例如红眼、 <19>眼痛</19> 、<20>视力下降</20>或<21>畏光</21>，频率从高到低。即使经过早期发现和及时治疗，41% 的<15>葡萄膜炎</15>病例对超过六个月的<2>皮质类固醇</2>和散瞳强化局部治疗没有反应。尽管如此，早期研究中提到的<16>葡萄膜炎</16>致盲并发症的 50% 发生率显着降低。<22>白内障</22>和<25>带状角膜病</25>分别仅在我们组的 22% 和 13% 发生。我们在 210 例病例中的 173 例中使用了<6>氯喹</6>或<0>羟氯喹</0>，仅发现一例因这些药物引起的<1>脉络膜视网膜病变</1>。210 例中有 75 例使用了全身性<3>皮质类固醇</3>；发现大量后囊下<23>白内障</23>。典型的<27>干燥性角膜结膜炎</27>发生在 3 例<17>葡萄膜炎</17>病例中。这种与<18>葡萄膜炎</18>和 JRA 的关联以前没有注意到。<24>白内障</24>、<26>带状角膜病</26>和<28>青光眼</28>的手术治疗均取得了令人沮丧的结果。", "revised": true}
{"doc_key": "803783", "sentences": [["Water", "intoxication", "associated", "with", "oxytocin", "administration", "during", "saline", "-", "induced", "abortion", ".", "Four", "cases", "of", "water", "intoxication", "in", "connection", "with", "oxytocin", "administration", "during", "saline", "-", "induced", "abortions", "are", "described", ".", "The", "mechanism", "of", "water", "intoxication", "is", "discussed", "in", "regard", "to", "these", "cases", ".", "Oxytocin", "administration", "during", "midtrimester", "-", "induced", "abortions", "is", "advocated", "only", "if", "it", "can", "be", "carried", "out", "under", "careful", "observations", "of", "an", "alert", "nursing", "staff", ",", "aware", "of", "the", "symptoms", "of", "water", "intoxication", "and", "instructed", "to", "watch", "the", "diuresis", "and", "report", "such", "early", "signs", "of", "the", "syndrome", "as", "asthenia", ",", "muscular", "irritability", ",", "or", "headaches", ".", "The", "oxytocin", "should", "be", "given", "only", "in", "Ringers", "lactate", "or", ",", "alternately", ",", "in", "Ringers", "lactate", "and", "a", "5", "per", "cent", "dextrose", "and", "water", "solutions", ".", "The", "urinary", "output", "should", "be", "monitored", "and", "the", "oxytocin", "administration", "discontinued", "and", "the", "serum", "electrolytes", "checked", "if", "the", "urinary", "output", "decreases", ".", "The", "oxytocin", "should", "not", "be", "administered", "in", "excess", "of", "36", "hours", ".", "If", "the", "patient", "has", "not", "aborted", "by", "then", "the", "oxytocin", "should", "be", "discontinued", "for", "10", "to", "12", "hours", "in", "order", "to", "perform", "electrolyte", "determinations", "and", "correct", "any", "electrolyte", "imbalance", "."]], "ner": [[[4, 4, "Chemical"], [20, 20, "Chemical"], [43, 43, "Chemical"], [99, 99, "Chemical"], [132, 132, "Chemical"], [147, 147, "Chemical"], [167, 167, "Chemical"], [0, 1, "Disease"], [15, 16, "Disease"], [33, 34, "Disease"], [73, 74, "Disease"], [106, 106, "Chemical"], [113, 113, "Chemical"], [119, 119, "Chemical"], [10, 10, "Disease"], [26, 26, "Disease"], [49, 49, "Disease"], [90, 90, "Disease"], [93, 93, "Disease"], [96, 96, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 15, 16, "CID"], [4, 4, 33, 34, "CID"], [4, 4, 73, 74, "CID"], [20, 20, 0, 1, "CID"], [20, 20, 15, 16, "CID"], [20, 20, 33, 34, "CID"], [20, 20, 73, 74, "CID"], [43, 43, 0, 1, "CID"], [43, 43, 15, 16, "CID"], [43, 43, 33, 34, "CID"], [43, 43, 73, 74, "CID"], [99, 99, 0, 1, "CID"], [99, 99, 15, 16, "CID"], [99, 99, 33, 34, "CID"], [99, 99, 73, 74, "CID"], [132, 132, 0, 1, "CID"], [132, 132, 15, 16, "CID"], [132, 132, 33, 34, "CID"], [132, 132, 73, 74, "CID"], [147, 147, 0, 1, "CID"], [147, 147, 15, 16, "CID"], [147, 147, 33, 34, "CID"], [147, 147, 73, 74, "CID"], [167, 167, 0, 1, "CID"], [167, 167, 15, 16, "CID"], [167, 167, 33, 34, "CID"], [167, 167, 73, 74, "CID"]]], "clusters": [], "translated": " <7>水中毒</7>与<0>催产素</0>在盐水诱导<14>流产</14>期间给药有关。描述了4例<8>水中毒</8>与<1>催产素</1>在盐水诱导的<15>流产</15>中给药有关。<9>水中毒</9>的机制针对这些案例进行了讨论。<2>催产素</2>在妊娠中期引起的<16>流产</16>期间给予催产素只有在警觉的护理人员仔细观察下进行时才提倡，注意<10>水中毒</10>并指示观察利尿情况并报告该综合征的早期体征，如<17>虚弱</17>、肌肉<18>易激怒</18>或<19>头痛</19>。<3>催产素</3>应仅以林格氏<11>乳酸盐</11>或，交替地，以林格氏<12>乳酸盐</12>和5%的<13>葡萄糖</13>和水溶液的形式给予。应监测尿量，如果尿量减少，则停止使用<4>催产素</4>并检查血清电解质。<5>催产素</5>的给药时间不应超过36小时。如果患者到那时还没有流产，则应停用<6>催产素</6>10至12小时，以便进行电解质测定并纠正任何电解质失衡。", "revised": true}
{"doc_key": "7421734", "sentences": [["Endometrial", "carcinoma", "after", "Hodgkin", "disease", "in", "childhood", ".", "A", "34", "-", "year", "-", "old", "patient", "developed", "metastic", "endometrial", "carcinoma", "after", "Hodgkin", "disease", "in", "childhood", ".", "She", "had", "ovarian", "failure", "after", "abdominal", "irradiation", "and", "chemotherapy", "for", "Hodgkin", "disease", ",", "and", "received", "exogenous", "estrogens", ",", "a", "treatment", "implicated", "in", "the", "development", "of", "endometrial", "cancer", "in", "menopausal", "women", ".", "Young", "women", "on", "replacement", "estrogens", "for", "ovarian", "failure", "after", "cancer", "therapy", "may", "also", "have", "increased", "risk", "of", "endometrial", "carcinoma", "and", "should", "be", "examined", "periodically", "."]], "ner": [[[41, 41, "Chemical"], [60, 60, "Chemical"], [0, 1, "Disease"], [17, 18, "Disease"], [50, 51, "Disease"], [73, 74, "Disease"], [3, 4, "Disease"], [20, 21, "Disease"], [35, 36, "Disease"], [27, 28, "Disease"], [62, 63, "Disease"], [65, 65, "Disease"]]], "relations": [[[41, 41, 0, 1, "CID"], [41, 41, 17, 18, "CID"], [41, 41, 50, 51, "CID"], [41, 41, 73, 74, "CID"], [60, 60, 0, 1, "CID"], [60, 60, 17, 18, "CID"], [60, 60, 50, 51, "CID"], [60, 60, 73, 74, "CID"]]], "clusters": [], "translated": "<2> 儿童期 </2><6> 霍奇金病 </6>后的<6> 子宫内膜癌 </6>。一名34岁的患者因童年<7> 霍奇金病 </7>而发展为转移性<3> 子宫内膜癌 </3>。在因<8> 霍奇金病 </8>进行腹部放疗和化疗后，她出现了<9> 卵巢功能衰竭 </9>，并接受了外源性<0> 雌激素 </0>治疗，该治疗与绝经期妇女<4> 子宫内膜癌 </4>的发生有关。在<11> 癌症 </11>治疗后因<10> 卵巢功能衰竭 </10>而接受<1> 雌激素 </1>替代治疗的年轻女性也可能增加<5> 子宫内膜癌 </5>的风险，应该定期检查。", "revised": true}
{"doc_key": "2886572", "sentences": [["Enhanced", "stimulus", "-", "induced", "neurotransmitter", "overflow", "in", "epinephrine", "-", "induced", "hypertensive", "rats", "is", "not", "mediated", "by", "prejunctional", "beta", "-", "adrenoceptor", "activation", ".", "The", "present", "study", "examines", "the", "effect", "of", "6", "-", "day", "epinephrine", "treatment", "(", "100", "micrograms", "/", "kg", "per", "h", ",", "s", ".", "c", ".", ")", "on", "stimulus", "-", "induced", "(", "1", "Hz", ")", "endogenous", "neurotransmitter", "overflow", "from", "the", "isolated", "perfused", "kidney", "of", "vehicle", "-", "and", "epinephrine", "-", "treated", "rats", ".", "Renal", "catecholamine", "stores", "and", "stimulus", "-", "induced", "overflow", "in", "the", "vehicle", "-", "treated", "group", "consisted", "of", "norepinephrine", "only", ".", "However", ",", "epinephrine", "treatment", "resulted", "in", "the", "incorporation", "of", "epinephrine", "into", "renal", "catecholamine", "stores", "such", "that", "approximately", "40", "%", "of", "the", "catecholamine", "present", "was", "epinephrine", "while", "the", "norepinephrine", "content", "was", "reduced", "by", "a", "similar", "degree", ".", "Total", "tissue", "catecholamine", "content", "of", "the", "kidney", "on", "a", "molar", "basis", "was", "unchanged", ".", "Stimulus", "-", "induced", "fractional", "overflow", "of", "neurotransmitter", "from", "the", "epinephrine", "-", "treated", "kidneys", "was", "approximately", "twice", "normal", "and", "consisted", "of", "both", "norepinephrine", "and", "epinephrine", "in", "proportions", "similar", "to", "those", "found", "in", "the", "kidney", ".", "This", "difference", "in", "fractional", "overflow", "between", "groups", "was", "not", "affected", "by", "neuronal", "and", "extraneuronal", "uptake", "blockade", ".", "Propranolol", "had", "no", "effect", "on", "stimulus", "-", "induced", "overflow", "in", "either", "group", ".", "Phentolamine", "increased", "stimulus", "-", "induced", "overflow", "in", "both", "groups", "although", "the", "increment", "in", "overflow", "was", "greater", "in", "the", "epinephrine", "-", "treated", "group", ".", "In", "conclusion", ",", "chronic", "epinephrine", "treatment", "results", "in", "enhanced", "fractional", "neurotransmitter", "overflow", ".", "However", ",", "neither", "alterations", "in", "prejunctional", "beta", "-", "adrenoceptor", "influences", "nor", "alterations", "in", "neuronal", "and", "extraneuronal", "uptake", "mechanisms", "appear", "to", "be", "responsible", "for", "this", "alteration", ".", "Furthermore", ",", "data", "obtained", "with", "phentolamine", "alone", "do", "not", "suggest", "alpha", "-", "adrenoceptor", "desensitization", "as", "the", "cause", "of", "the", "enhanced", "neurotransmitter", "overflow", "after", "epinephrine", "treatment", "."]], "ner": [[[7, 7, "Chemical"], [32, 32, "Chemical"], [67, 67, "Chemical"], [93, 93, "Chemical"], [100, 100, "Chemical"], [115, 115, "Chemical"], [150, 150, "Chemical"], [164, 164, "Chemical"], [223, 223, "Chemical"], [232, 232, "Chemical"], [290, 290, "Chemical"], [10, 10, "Disease"], [73, 73, "Chemical"], [103, 103, "Chemical"], [112, 112, "Chemical"], [129, 129, "Chemical"], [88, 88, "Chemical"], [118, 118, "Chemical"], [162, 162, "Chemical"], [192, 192, "Chemical"], [205, 205, "Chemical"], [272, 272, "Chemical"]]], "relations": [[[7, 7, 10, 10, "CID"], [32, 32, 10, 10, "CID"], [67, 67, 10, 10, "CID"], [93, 93, 10, 10, "CID"], [100, 100, 10, 10, "CID"], [115, 115, 10, 10, "CID"], [150, 150, 10, 10, "CID"], [164, 164, 10, 10, "CID"], [223, 223, 10, 10, "CID"], [232, 232, 10, 10, "CID"], [290, 290, 10, 10, "CID"]]], "clusters": [], "translated": "<0>肾上腺素</0>诱导的<11>高血压</11>大鼠中增强的刺激诱导的神经递质溢出不是由prejunctional β-肾上腺素能受体激活介导的。本研究检查了6天<1>肾上腺素</1>治疗（100微克/kg每小时,s.c.）对刺激诱导的（1 Hz）内源性神经递质从分离灌注肾脏的载体和<2>肾上腺素</2>治疗的大鼠溢出的影响。载体处理组中的肾脏<12>儿茶酚胺</12>储存和刺激引起的溢出仅由<16>去甲肾上腺素</16>组成。然而，<3>肾上腺素</3>治疗导致<4>肾上腺素</4>进入肾脏<13>儿茶酚胺</13>储存，因此大约40%的<14>儿茶酚胺</14>中存在<5>肾上腺素</5>，而<17>去甲肾上腺素</17>的含量也有类似程度的降低。以摩尔为基础，肾脏的总组织<15>儿茶酚胺</15>含量没有变化。刺激诱导的<6>肾上腺素</6>神经递质溢出分数—处理的肾脏大约是正常的两倍，并且由<18>去甲肾上腺素</18>和<7>肾上腺素</7>组成，比例与那些相似发现于肾脏。这种组间分数溢出的差异不受神经元和神经元外摄取阻断的影响。<19>普萘洛尔</19>对两组中刺激引起的溢出均无影响。<20>酚妥拉明</20>增加了两组中刺激引起的溢流，尽管<8>肾上腺素</8>治疗组的溢流增量更大。总之，慢性<9>肾上腺素</9>治疗会导致部分神经递质溢出增加。然而，无论是prejunctional β-肾上腺素能受体影响的改变还是神经元和神经元外摄取机制的改变似乎都不是造成这种改变的原因。此外，单独使用<21>酚妥拉明</21>获得的数据并未表明α-肾上腺素能受体脱敏是<10>肾上腺素</10>治疗后神经递质溢出增强的原因。", "revised": true}
{"doc_key": "3461217", "sentences": [["Production", "of", "autochthonous", "prostate", "cancer", "in", "Lobund", "-", "Wistar", "rats", "by", "treatments", "with", "N", "-", "nitroso", "-", "N", "-", "methylurea", "and", "testosterone", ".", "More", "than", "50", "%", "of", "Lobund", "-", "Wistar", "(", "L", "-", "W", ")", "strain", "rats", "developed", "large", ",", "palpable", "prostate", "adenocarcinomas", "(", "PAs", ")", "following", "treatments", "with", "N", "-", "nitroso", "-", "N", "-", "methylurea", "(", "CAS", ":", "684", "-", "93", "-", "5", ")", "and", "testosterone", "propionate", "[", "(", "TP", ")", "CAS", ":", "57", "-", "85", "-", "2", "]", ",", "and", "most", "of", "the", "tumor", "-", "bearing", "rats", "manifested", "metastatic", "lesions", ".", "The", "incubation", "periods", "averaged", "10", ".", "6", "months", ".", "Within", "the", "same", "timeframe", ",", "no", "L", "-", "W", "rat", "developed", "a", "similar", "palpable", "PA", "when", "treated", "only", "with", "TP", ".", "In", "L", "-", "W", "rats", ",", "TP", "acted", "as", "a", "tumor", "enhancement", "agent", ",", "with", "primary", "emphasis", "on", "the", "development", "of", "prostate", "cancer", "."]], "ner": [[[13, 19, "Chemical"], [50, 56, "Chemical"], [3, 4, "Disease"], [42, 43, "Disease"], [45, 45, "Disease"], [117, 117, "Disease"], [145, 146, "Disease"], [67, 68, "Chemical"], [71, 71, "Chemical"], [122, 122, "Chemical"], [130, 130, "Chemical"], [21, 21, "Chemical"], [86, 86, "Disease"], [134, 134, "Disease"]]], "relations": [[[13, 19, 3, 4, "CID"], [13, 19, 42, 43, "CID"], [13, 19, 45, 45, "CID"], [13, 19, 117, 117, "CID"], [13, 19, 145, 146, "CID"], [50, 56, 3, 4, "CID"], [50, 56, 42, 43, "CID"], [50, 56, 45, 45, "CID"], [50, 56, 117, 117, "CID"], [50, 56, 145, 146, "CID"], [67, 68, 3, 4, "CID"], [67, 68, 42, 43, "CID"], [67, 68, 45, 45, "CID"], [67, 68, 117, 117, "CID"], [67, 68, 145, 146, "CID"], [71, 71, 3, 4, "CID"], [71, 71, 42, 43, "CID"], [71, 71, 45, 45, "CID"], [71, 71, 117, 117, "CID"], [71, 71, 145, 146, "CID"], [122, 122, 3, 4, "CID"], [122, 122, 42, 43, "CID"], [122, 122, 45, 45, "CID"], [122, 122, 117, 117, "CID"], [122, 122, 145, 146, "CID"], [130, 130, 3, 4, "CID"], [130, 130, 42, 43, "CID"], [130, 130, 45, 45, "CID"], [130, 130, 117, 117, "CID"], [130, 130, 145, 146, "CID"]]], "clusters": [], "translated": "<0>N-亚硝基-N-甲基脲</0>和<11>睾酮</11>处理 Lobund-Wistar 大鼠体内<2>前列腺癌</2>的发生。超过50%的 Lobund-Wistar (L-W) 品系大鼠，在用<1>N-亚硝基-N-甲基脲</1> (CAS:684-93-5) 和<7>丙酸睾酮</7> [(<8>TP</8>) CAS:57-85-2] 后，出现了可触及的大的<3>前列腺腺癌</3> (<4>PA</4>)，大多数<12>携带瘤的</12>大鼠也发生了转移性病变。潜伏期平均为10.6个月。在同一时间范围内，当只用<9>TP</9>治疗时，没有L-W大鼠出现类似的可触及的<5>前列腺腺癌</5> (<6>PA</6>)。在L-W大鼠中，<10>TP</10>作为<13>肿瘤</13>增强剂，主要强调<6>前列腺癌</6>的发展。", "revised": true}
{"doc_key": "1969772", "sentences": [["Preservation", "of", "renal", "blood", "flow", "during", "hypotension", "induced", "with", "fenoldopam", "in", "dogs", ".", "The", "introduction", "of", "drugs", "that", "could", "induce", "hypotension", "with", "different", "pharmacological", "actions", "would", "be", "advantageous", "because", "side", "effects", "unique", "to", "a", "specific", "drug", "could", "be", "minimized", "by", "selecting", "appropriate", "therapy", ".", "Specific", "dopamine", "-", "1", ",", "(", "DA1", ")", "and", "dopamine", "-", "2", "(", "DA2", ")", "receptor", "agonists", "are", "now", "under", "clinical", "investigation", ".", "Fenoldopam", "mesylate", "is", "a", "specific", "DA1", "receptor", "agonist", "that", "lowers", "blood", "pressure", "by", "vasodilatation", ".", "The", "hypothesis", "that", "fenoldopam", "could", "be", "used", "to", "induce", "hypotension", "and", "preserve", "blood", "flow", "to", "the", "kidney", "was", "tested", ".", "Systemic", "aortic", "blood", "pressure", "and", "renal", "blood", "flow", "were", "measured", "continuously", "with", "a", "carotid", "arterial", "catheter", "and", "an", "electromagnetic", "flow", "probe", "respectively", ",", "in", "order", "to", "compare", "the", "cardiovascular", "and", "renal", "vascular", "effects", "of", "fenoldopam", "and", "sodium", "nitroprusside", "in", "ten", "dogs", "under", "halothane", "general", "anaesthesia", ".", "Mean", "arterial", "pressure", "was", "decreased", "30", "+", "/", "-", "8", "per", "cent", "from", "control", "with", "infusion", "of", "fenoldopam", "(", "3", ".", "4", "+", "/", "-", "2", ".", "0", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", ")", "and", "34", "+", "/", "-", "4", "per", "cent", "with", "infusion", "of", "sodium", "nitroprusside", "(", "5", ".", "9", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", ")", "(", "NS", ")", ".", "Renal", "blood", "flow", "(", "RBF", ")", "increased", "during", "fenoldopam", "-", "induced", "hypotension", "11", "+", "/", "-", "7", "per", "cent", "and", "decreased", "21", "+", "/", "-", "8", "per", "cent", "during", "sodium", "nitroprusside", "-", "induced", "hypotension", "(", "P", "less", "than", "0", ".", "01", ")", ".", "Sodium", "nitroprusside", "is", "a", "non", "-", "selective", "arteriolar", "and", "venous", "vasodilator", "that", "can", "produce", "redistribution", "of", "blood", "flow", "away", "from", "the", "kidney", "during", "induced", "hypotension", ".", "Fenoldopam", "is", "a", "selective", "dopamine", "-", "1", "(", "DA1", ")", "receptor", "agonist", "that", "causes", "vasodilatation", "to", "the", "kidney", "and", "other", "organs", "with", "DA1", "receptors", "and", "preserves", "blood", "flow", "to", "the", "kidney", "during", "induced", "hypotension", "."]], "ner": [[[9, 9, "Chemical"], [67, 68, "Chemical"], [85, 85, "Chemical"], [136, 136, "Chemical"], [165, 165, "Chemical"], [225, 225, "Chemical"], [6, 6, "Disease"], [20, 20, "Disease"], [91, 91, "Disease"], [228, 228, "Disease"], [250, 250, "Disease"], [284, 284, "Disease"], [319, 319, "Disease"], [139, 139, "Chemical"], [198, 198, "Chemical"], [247, 247, "Chemical"], [261, 261, "Chemical"], [144, 144, "Chemical"], [45, 45, "Chemical"], [50, 50, "Chemical"], [53, 53, "Chemical"], [57, 57, "Chemical"], [290, 290, "Chemical"], [138, 138, "Chemical"], [197, 197, "Chemical"], [246, 246, "Chemical"]]], "relations": [[[9, 9, 6, 6, "CID"], [9, 9, 20, 20, "CID"], [9, 9, 91, 91, "CID"], [9, 9, 228, 228, "CID"], [9, 9, 250, 250, "CID"], [9, 9, 284, 284, "CID"], [9, 9, 319, 319, "CID"], [67, 68, 6, 6, "CID"], [67, 68, 20, 20, "CID"], [67, 68, 91, 91, "CID"], [67, 68, 228, 228, "CID"], [67, 68, 250, 250, "CID"], [67, 68, 284, 284, "CID"], [67, 68, 319, 319, "CID"], [85, 85, 6, 6, "CID"], [85, 85, 20, 20, "CID"], [85, 85, 91, 91, "CID"], [85, 85, 228, 228, "CID"], [85, 85, 250, 250, "CID"], [85, 85, 284, 284, "CID"], [85, 85, 319, 319, "CID"], [136, 136, 6, 6, "CID"], [136, 136, 20, 20, "CID"], [136, 136, 91, 91, "CID"], [136, 136, 228, 228, "CID"], [136, 136, 250, 250, "CID"], [136, 136, 284, 284, "CID"], [136, 136, 319, 319, "CID"], [165, 165, 6, 6, "CID"], [165, 165, 20, 20, "CID"], [165, 165, 91, 91, "CID"], [165, 165, 228, 228, "CID"], [165, 165, 250, 250, "CID"], [165, 165, 284, 284, "CID"], [165, 165, 319, 319, "CID"], [225, 225, 6, 6, "CID"], [225, 225, 20, 20, "CID"], [225, 225, 91, 91, "CID"], [225, 225, 228, 228, "CID"], [225, 225, 250, 250, "CID"], [225, 225, 284, 284, "CID"], [225, 225, 319, 319, "CID"], [139, 139, 6, 6, "CID"], [139, 139, 20, 20, "CID"], [139, 139, 91, 91, "CID"], [139, 139, 228, 228, "CID"], [139, 139, 250, 250, "CID"], [139, 139, 284, 284, "CID"], [139, 139, 319, 319, "CID"], [198, 198, 6, 6, "CID"], [198, 198, 20, 20, "CID"], [198, 198, 91, 91, "CID"], [198, 198, 228, 228, "CID"], [198, 198, 250, 250, "CID"], [198, 198, 284, 284, "CID"], [198, 198, 319, 319, "CID"], [247, 247, 6, 6, "CID"], [247, 247, 20, 20, "CID"], [247, 247, 91, 91, "CID"], [247, 247, 228, 228, "CID"], [247, 247, 250, 250, "CID"], [247, 247, 284, 284, "CID"], [247, 247, 319, 319, "CID"], [261, 261, 6, 6, "CID"], [261, 261, 20, 20, "CID"], [261, 261, 91, 91, "CID"], [261, 261, 228, 228, "CID"], [261, 261, 250, 250, "CID"], [261, 261, 284, 284, "CID"], [261, 261, 319, 319, "CID"], [144, 144, 6, 6, "CID"], [144, 144, 20, 20, "CID"], [144, 144, 91, 91, "CID"], [144, 144, 228, 228, "CID"], [144, 144, 250, 250, "CID"], [144, 144, 284, 284, "CID"], [144, 144, 319, 319, "CID"]]], "clusters": [], "translated": "在<0>甲磺酸非诺多泮</0>引起的犬<6>低血压</6>期间保持肾血流。引入具有不同药理作用的可引起<7>低血压</7>的药物将是有利的，因为通过选择适当的疗法可以将特定药物特有的副作用降至最低。特异性<18>多巴胺-1</18> (<19>DA1</19>) 和<20>多巴胺-2</20> (<21>DA2</21>) 受体激动剂目前正在临床研究中。<1> 非诺多泮 </1>是一种特异性DA1受体激动剂，可通过血管扩张来降低血压。假设 <2> 非诺多泮 </2> 可用于诱导 <8> 低血压 </8> 并保持肾脏血流。分别用颈动脉导管和电磁流量探头连续测量全身主动脉血压和肾血流量，以比较 <3> 非诺多泮 </3> 和<23>硝普钠 </23><13> (NaNO</13><14>PO</14><24>4</24><15>) </15>对心血管和肾血管的影响。在<17> 氟烷 </17>全身麻醉下的十只狗。平均动脉压降低了 30 +/- 8%从对照组的 4% 输注 <4> 非诺多泮 </4> (3.4 +/- 2.0 微克.kg-1.min-1) 和 34 +/- 5.9 微克.kg-1.min-1) (NS)。肾血流量(RBF) 在<5> 非诺多泮 </5>期间增加，诱导 <9>低血压</9> 11 +/- 7%，在<25>硝普钠 </25><13>(NaNO</13><14>PO</14><24>4</24><15>)</15> 引起的<10> 低血压 </10> 期间减少21 +/-8%(P小于0.01)。<16>硝普钠 </16> 是一种非选择性小动脉和静脉血管扩张剂，可在诱导的<11> 低血压 </11>期间重新分配远离肾脏的血流。 <22> 多巴胺-1 </22>(DA1) 受体选择性激动剂显著扩张肾脏和其他具有 DA1 受体的器官，可在诱发的<12>低血压</12>期间保持流向肾脏的血流。", "revised": true}
{"doc_key": "6732043", "sentences": [["Induction", "of", "the", "obstructive", "sleep", "apnea", "syndrome", "in", "a", "woman", "by", "exogenous", "androgen", "administration", ".", "We", "documented", "airway", "occlusion", "during", "sleep", "and", "an", "abnormally", "high", "supraglottic", "resistance", "while", "awake", "in", "a", "54", "-", "yr", "-", "old", "woman", "who", "had", "developed", "physical", "changes", "and", "the", "syndrome", "of", "obstructive", "sleep", "apnea", "while", "being", "administered", "exogenous", "androgens", ".", "When", "the", "androgens", "were", "withdrawn", ",", "the", "patient", "'s", "physical", "changes", ",", "symptoms", ",", "sleep", "study", ",", "and", "supraglottic", "resistance", "all", "returned", "to", "normal", ".", "A", "rechallenge", "with", "androgen", "produced", "symptoms", "of", "obstructive", "sleep", "apnea", "that", "abated", "upon", "withdrawal", "of", "the", "hormone", ".", "Previous", "reports", "have", "favored", "a", "role", "of", "androgens", "in", "the", "pathogenesis", "of", "sleep", "apnea", ".", "Our", "report", "provides", "direct", "evidence", "for", "this", "role", ".", "Structural", "and", "functional", "measurements", "indicate", "that", "androgens", "exert", "a", "permissive", "or", "necessary", "action", "on", "the", "structural", "configuration", "of", "the", "oropharynx", "that", "predisposes", "to", "obstruction", "during", "sleep", ".", "Development", "of", "the", "obstructive", "sleep", "apnea", "syndrome", "must", "be", "considered", "a", "possible", "side", "effect", "of", "androgen", "therapy", "."]], "ner": [[[12, 12, "Chemical"], [53, 53, "Chemical"], [57, 57, "Chemical"], [83, 83, "Chemical"], [105, 105, "Chemical"], [128, 128, "Chemical"], [164, 164, "Chemical"], [3, 6, "Disease"], [44, 48, "Disease"], [87, 89, "Disease"], [152, 155, "Disease"], [110, 111, "Disease"]]], "relations": [[[12, 12, 3, 6, "CID"], [12, 12, 44, 48, "CID"], [12, 12, 87, 89, "CID"], [12, 12, 152, 155, "CID"], [53, 53, 3, 6, "CID"], [53, 53, 44, 48, "CID"], [53, 53, 87, 89, "CID"], [53, 53, 152, 155, "CID"], [57, 57, 3, 6, "CID"], [57, 57, 44, 48, "CID"], [57, 57, 87, 89, "CID"], [57, 57, 152, 155, "CID"], [83, 83, 3, 6, "CID"], [83, 83, 44, 48, "CID"], [83, 83, 87, 89, "CID"], [83, 83, 152, 155, "CID"], [105, 105, 3, 6, "CID"], [105, 105, 44, 48, "CID"], [105, 105, 87, 89, "CID"], [105, 105, 152, 155, "CID"], [128, 128, 3, 6, "CID"], [128, 128, 44, 48, "CID"], [128, 128, 87, 89, "CID"], [128, 128, 152, 155, "CID"], [164, 164, 3, 6, "CID"], [164, 164, 44, 48, "CID"], [164, 164, 87, 89, "CID"], [164, 164, 152, 155, "CID"]]], "clusters": [], "translated": "通过外源性<0>雄激素</0>给药诱导女性<7>阻塞性睡眠呼吸暂停综合征</7>。我们记录了一名54岁女性，在睡眠期间出现气道阻塞现象，清醒时则声门上阻力异常高，而此女性则在接受外源性<1>雄激素</1>时出现变化和<8>阻塞性睡眠呼吸暂停综合征</8>。停用<2>雄激素</2>后，患者的身体变化、症状、睡眠检查和声门上阻力均恢复正常。重新使用<3>雄激素</3>后出现了<9>阻塞性睡眠呼吸暂停</9>的症状，但该症状在停用激素后减轻。以前的报告支持<4>雄激素</4>在<11>睡眠呼吸暂停</11>的发病机制中扮演一定作用。我们的报告为这一作用提供了直接证据。结构和功能测量表明<5>雄激素</5>在咽部结构构成上具有允许或必要的作用，从而容易感染睡眠期间的阻塞。必须考虑<10>阻塞性睡眠呼吸暂停综合征</10>的发展可能是<6>雄激素</6>治疗的副作用。", "revised": true}
{"doc_key": "11058428", "sentences": [["High", "-", "dose", "methylprednisolone", "may", "do", "more", "harm", "for", "spinal", "cord", "injury", ".", "Because", "of", "the", "National", "Acute", "Spinal", "Cord", "Injury", "Studies", "(", "NASCIS", ")", ",", "high", "-", "dose", "methylprednisolone", "became", "the", "standard", "of", "care", "for", "the", "acute", "spinal", "cord", "injury", ".", "In", "the", "NASCIS", ",", "there", "was", "no", "mention", "regarding", "the", "possibility", "of", "acute", "corticosteroid", "myopathy", "that", "high", "-", "dose", "methylprednisolone", "may", "cause", ".", "The", "dosage", "of", "methylprednisolone", "recommended", "by", "the", "NASCIS", "3", "is", "the", "highest", "dose", "of", "steroids", "ever", "being", "used", "during", "a", "2", "-", "day", "period", "for", "any", "clinical", "condition", ".", "We", "hypothesize", "that", "it", "may", "cause", "some", "damage", "to", "the", "muscle", "of", "spinal", "cord", "injury", "patients", ".", "Further", ",", "steroid", "myopathy", "recovers", "naturally", "and", "the", "neurological", "improvement", "shown", "in", "the", "NASCIS", "may", "be", "just", "a", "recording", "of", "this", "natural", "motor", "recovery", "from", "the", "steroid", "myopathy", ",", "instead", "of", "any", "protection", "that", "methylprednisolone", "offers", "to", "the", "spinal", "cord", "injury", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "discussion", "considering", "the", "possibility", "that", "the", "methylprednisolone", "recommended", "by", "NASCIS", "may", "cause", "acute", "corticosteroid", "myopathy", "."]], "ner": [[[3, 3, "Chemical"], [29, 29, "Chemical"], [61, 61, "Chemical"], [68, 68, "Chemical"], [145, 145, "Chemical"], [167, 167, "Chemical"], [56, 56, "Disease"], [101, 104, "Disease"], [114, 114, "Disease"], [138, 138, "Disease"], [175, 175, "Disease"], [9, 11, "Disease"], [18, 20, "Disease"], [38, 40, "Disease"], [106, 108, "Disease"], [149, 151, "Disease"], [55, 55, "Chemical"], [174, 174, "Chemical"], [79, 79, "Chemical"], [113, 113, "Chemical"], [137, 137, "Chemical"]]], "relations": [[[3, 3, 56, 56, "CID"], [3, 3, 101, 104, "CID"], [3, 3, 114, 114, "CID"], [3, 3, 138, 138, "CID"], [3, 3, 175, 175, "CID"], [29, 29, 56, 56, "CID"], [29, 29, 101, 104, "CID"], [29, 29, 114, 114, "CID"], [29, 29, 138, 138, "CID"], [29, 29, 175, 175, "CID"], [61, 61, 56, 56, "CID"], [61, 61, 101, 104, "CID"], [61, 61, 114, 114, "CID"], [61, 61, 138, 138, "CID"], [61, 61, 175, 175, "CID"], [68, 68, 56, 56, "CID"], [68, 68, 101, 104, "CID"], [68, 68, 114, 114, "CID"], [68, 68, 138, 138, "CID"], [68, 68, 175, 175, "CID"], [145, 145, 56, 56, "CID"], [145, 145, 101, 104, "CID"], [145, 145, 114, 114, "CID"], [145, 145, 138, 138, "CID"], [145, 145, 175, 175, "CID"], [167, 167, 56, 56, "CID"], [167, 167, 101, 104, "CID"], [167, 167, 114, 114, "CID"], [167, 167, 138, 138, "CID"], [167, 167, 175, 175, "CID"]]], "clusters": [], "translated": "高剂量<0>甲基强的松龙</0>可能对<11>脊髓损伤</11>造成更大的伤害。由于国家急性<12>脊髓损伤</12>研究（NASCIS），大剂量<1>甲泼尼龙</1>成为急性<13>脊髓损伤</13>的标准治疗。在NASCIS中，没有提及大剂量<2>甲泼尼龙</2>可能引起急性<16>皮质类固醇</16><10>肌病</10>的可能性。NASCIS 3推荐的<3>甲基强的松龙</3>剂量是在2天内用于任何临床病症的最高剂量<18>类固醇</18>。我们推测它可能会对<14>脊髓损伤</14>患者的肌肉造成一些<7>损伤</7>。此外,<19>类固醇</19><8>肌病</8>自然恢复，NASCIS中显示的神经改善可能只是<9>这种自然运动恢复的记录</9><20>而不是</20><4>甲基强的松龙</4>对<15>脊髓损伤</15>提供的任何保护。据我们所知，这是第一次考虑到NASCIS推荐的<5>甲基强的松龙</5>可能导致急性<17>皮质类固醇</17><6>肌病</6>的可能性。", "revised": true}
{"doc_key": "11245434", "sentences": [["Erythropoietin", "restores", "the", "anemia", "-", "induced", "reduction", "in", "cyclophosphamide", "cytotoxicity", "in", "rat", "tumors", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "the", "impact", "of", "anemia", "prevention", "by", "recombinant", "human", "erythropoietin", "(", "rHuEPO", ")", "treatment", "on", "the", "cytotoxicity", "of", "cyclophosphamide", "in", "solid", "experimental", "tumors", ".", "Anemia", "was", "induced", "using", "a", "single", "dose", "of", "carboplatin", "(", "50", "mg", "/", "kg", "i", ".", "v", ".", ")", "resulting", "in", "a", "long", "-", "lasting", "reduction", "(", "30", "%", ")", "of", "the", "hemoglobin", "concentration", ".", "In", "a", "second", "group", ",", "the", "development", "of", "anemia", "was", "prevented", "by", "rHuEPO", "(", "1000", "IU", "/", "kg", ")", "administered", "s", ".", "c", ".", "three", "times", "/", "week", "starting", "7", "days", "before", "carboplatin", "application", ".", "Four", "days", "after", "carboplatin", "treatment", ",", "tumors", "(", "DS", "-", "sarcoma", "of", "the", "rat", ")", "were", "implanted", "s", ".", "c", ".", "onto", "the", "hind", "food", "dorsum", ".", "Neither", "carboplatin", "nor", "rHuEPO", "treatment", "influenced", "tumor", "growth", "rate", "per", "se", ".", "When", "tumors", "were", "treated", "with", "a", "single", "dose", "of", "cyclophosphamide", "(", "60", "mg", "/", "kg", "i", ".", "p", ".", ")", "5", "days", "after", "implantation", ",", "a", "growth", "delay", "with", "a", "subsequent", "regrowth", "of", "the", "tumors", "was", "observed", ".", "In", "the", "anemia", "group", ",", "the", "growth", "delay", "was", "significantly", "shorter", "compared", "with", "nonanemic", "controls", "(", "13", ".", "3", "days", "versus", "8", ".", "6", "days", ")", ".", "In", "the", "group", "where", "anemia", "was", "prevented", "by", "rHuEPO", "treatment", ",", "growth", "delay", "was", "comparable", "with", "that", "of", "nonanemic", "controls", "(", "13", ".", "3", "days", ")", ".", "These", "results", "suggest", "that", "chemotherapy", "-", "induced", "anemia", "reduces", "cytotoxicity", "of", "cyclophosphamide", "in", "tumors", ",", "whereas", "correction", "of", "anemia", "by", "rHuEPO", "treatment", "(", "epoetin", "alpha", ")", "increases", "the", "sensitivity", ",", "probably", "as", "a", "result", "of", "an", "improved", "oxygen", "supply", "to", "tumor", "tissue", "."]], "ner": [[[53, 53, "Chemical"], [112, 112, "Chemical"], [118, 118, "Chemical"], [143, 143, "Chemical"], [3, 3, "Disease"], [25, 25, "Disease"], [45, 45, "Disease"], [88, 88, "Disease"], [194, 194, "Disease"], [223, 223, "Disease"], [253, 253, "Disease"], [264, 264, "Disease"], [8, 8, "Chemical"], [39, 39, "Chemical"], [163, 163, "Chemical"], [257, 257, "Chemical"], [283, 283, "Chemical"], [9, 9, "Disease"], [37, 37, "Disease"], [255, 255, "Disease"], [12, 12, "Disease"], [43, 43, "Disease"], [121, 121, "Disease"], [148, 148, "Disease"], [155, 155, "Disease"], [188, 188, "Disease"], [259, 259, "Disease"], [286, 286, "Disease"], [125, 125, "Disease"]]], "relations": [[[53, 53, 3, 3, "CID"], [53, 53, 25, 25, "CID"], [53, 53, 45, 45, "CID"], [53, 53, 88, 88, "CID"], [53, 53, 194, 194, "CID"], [53, 53, 223, 223, "CID"], [53, 53, 253, 253, "CID"], [53, 53, 264, 264, "CID"], [112, 112, 3, 3, "CID"], [112, 112, 25, 25, "CID"], [112, 112, 45, 45, "CID"], [112, 112, 88, 88, "CID"], [112, 112, 194, 194, "CID"], [112, 112, 223, 223, "CID"], [112, 112, 253, 253, "CID"], [112, 112, 264, 264, "CID"], [118, 118, 3, 3, "CID"], [118, 118, 25, 25, "CID"], [118, 118, 45, 45, "CID"], [118, 118, 88, 88, "CID"], [118, 118, 194, 194, "CID"], [118, 118, 223, 223, "CID"], [118, 118, 253, 253, "CID"], [118, 118, 264, 264, "CID"], [143, 143, 3, 3, "CID"], [143, 143, 25, 25, "CID"], [143, 143, 45, 45, "CID"], [143, 143, 88, 88, "CID"], [143, 143, 194, 194, "CID"], [143, 143, 223, 223, "CID"], [143, 143, 253, 253, "CID"], [143, 143, 264, 264, "CID"]]], "clusters": [], "translated": "促红细胞生成素恢复<4>贫血</4>诱导大鼠<20>肿瘤</20>中<12>环磷酰胺</12>的<17>细胞毒性</17>的减少。本研究的目的是在固体实验中检验重组人促红细胞生成素 (rHuEPO) 治疗对<13>环磷酰胺</13>的<18>细胞毒性</18>预防<5>贫血</5>的影响<21>肿瘤</21>。使用单剂量<0>卡铂</0>（50 mg/kg i.v.）诱导<6>贫血</6>，导致血红蛋白浓度长期持续降低（30％）。在第二组中，给予rHuEPO (1000 IU/kg)防止<7>贫血</7>的发展，每周s.c.3次，自<1>卡铂</1>应用前7天起。在治疗<2>卡铂</2>4天后，<28>大鼠肉瘤</28>的<22>肿瘤</22>被s.c.植入到后脚背部。<23>肿瘤</23>的生长速率均不受<3>卡铂</3>和rHuEPO处理影响。当<24>肿瘤</24>在植入后5天使用单剂量<14>环磷酰胺</14>（60 mg/kg i.p.）进行治疗时，观察到生长延迟和随后的<25>肿瘤</25>再生长。在<8>贫血</8>组中，生长延迟明显短于非贫血对照组（13.3天对8.6天）。在通过rHuEPO治疗预防<9>贫血</9>的组中，生长延迟与非贫血对照组相当（13.3天）。这些结果表明，化疗引起的<10>贫血</10>降低了<26>肿瘤</26>中<15>环磷酰胺</15>的<19>细胞毒性</19>，而通过rHuEPO治疗纠正<11>贫血</11>（epoetin alpha）增加了敏感性，可能是由于改善了<27>肿瘤</27>组织的<16>氧</16>供应。", "revised": true}
{"doc_key": "3220106", "sentences": [["Receptor", "mechanisms", "of", "nicotine", "-", "induced", "locomotor", "hyperactivity", "in", "chronic", "nicotine", "-", "treated", "rats", ".", "Rats", "were", "pretreated", "with", "saline", "or", "nicotine", "(", "1", ".", "5", "mg", "/", "kg", "per", "day", ")", "by", "subcutaneously", "implanting", "each", "animal", "with", "an", "Alzet", "osmotic", "mini", "-", "pump", "which", "continuously", "released", "saline", "or", "nicotine", "for", "1", ",", "5", "and", "14", "days", ".", "At", "the", "end", "of", "each", "pretreatment", "period", ",", "animals", "were", "used", "for", "(", "i", ")", "determining", "their", "locomotor", "response", "to", "acutely", "injected", "nicotine", "(", "0", ".", "2", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", "and", "(", "ii", ")", "measuring", "the", "density", "of", "L", "-", "[", "3H", "]", "nicotine", "and", "[", "3H", "]", "spiperone", "binding", "sites", "in", "the", "striatum", ".", "We", "observed", "no", "changes", "in", "nicotine", "-", "induced", "locomotor", "response", ",", "striatal", "L", "-", "[", "3H", "]", "nicotine", "and", "[", "3H", "]", "spiperone", "binding", "in", "the", "animals", "pretreated", "with", "nicotine", "for", "1", "day", ".", "In", "rats", "which", "were", "pretreated", "with", "nicotine", "for", "5", "days", ",", "there", "was", "a", "significant", "increase", "in", "the", "nicotine", "-", "stimulated", "locomotor", "response", "which", "was", "associated", "with", "an", "increase", "in", "the", "number", "of", "L", "-", "[", "3H", "]", "nicotine", "binding", "sites", "and", "also", "with", "an", "elevated", "dopamine", "(", "DA", ")", "level", "in", "the", "striatum", ".", "The", "number", "of", "striatal", "[", "3H", "]", "spiperone", "binding", "sites", "was", "not", "affected", ".", "In", "animals", "pretreated", "with", "nicotine", "for", "14", "days", ",", "the", "nicotine", "-", "induced", "locomotor", "response", "remained", "to", "be", "potentiated", ".", "However", ",", "this", "response", "was", "correlated", "with", "an", "elevated", "number", "of", "striatal", "[", "3H", "]", "spiperone", "binding", "sites", ",", "whereas", "the", "number", "of", "striatal", "L", "-", "[", "3H", "]", "nicotine", "binding", "sites", "and", "the", "striatal", "DA", "level", "were", "normal", ".", "These", "results", "suggest", "that", "chronic", "nicotine", "-", "treated", "rats", "develop", "locomotor", "hyperactivity", "in", "response", "to", "nicotine", "initially", "due", "to", "increases", "of", "both", "the", "density", "of", "nicotinic", "receptors", "and", "DA", "concentration", ",", "followed", "by", "inducing", "DA", "receptor", "supersensitivity", "in", "the", "striatum", "."]], "ner": [[[3, 3, "Chemical"], [10, 10, "Chemical"], [21, 21, "Chemical"], [49, 49, "Chemical"], [80, 80, "Chemical"], [107, 107, "Chemical"], [124, 124, "Chemical"], [136, 136, "Chemical"], [148, 148, "Chemical"], [159, 159, "Chemical"], [171, 171, "Chemical"], [191, 191, "Chemical"], [226, 226, "Chemical"], [232, 232, "Chemical"], [271, 271, "Chemical"], [287, 287, "Chemical"], [297, 297, "Chemical"], [6, 7, "Disease"], [292, 293, "Disease"], [112, 112, "Chemical"], [141, 141, "Chemical"], [215, 215, "Chemical"], [257, 257, "Chemical"], [199, 199, "Chemical"], [201, 201, "Chemical"], [277, 277, "Chemical"], [310, 310, "Chemical"], [316, 316, "Chemical"]]], "relations": [[[3, 3, 6, 7, "CID"], [3, 3, 292, 293, "CID"], [10, 10, 6, 7, "CID"], [10, 10, 292, 293, "CID"], [21, 21, 6, 7, "CID"], [21, 21, 292, 293, "CID"], [49, 49, 6, 7, "CID"], [49, 49, 292, 293, "CID"], [80, 80, 6, 7, "CID"], [80, 80, 292, 293, "CID"], [107, 107, 6, 7, "CID"], [107, 107, 292, 293, "CID"], [124, 124, 6, 7, "CID"], [124, 124, 292, 293, "CID"], [136, 136, 6, 7, "CID"], [136, 136, 292, 293, "CID"], [148, 148, 6, 7, "CID"], [148, 148, 292, 293, "CID"], [159, 159, 6, 7, "CID"], [159, 159, 292, 293, "CID"], [171, 171, 6, 7, "CID"], [171, 171, 292, 293, "CID"], [191, 191, 6, 7, "CID"], [191, 191, 292, 293, "CID"], [226, 226, 6, 7, "CID"], [226, 226, 292, 293, "CID"], [232, 232, 6, 7, "CID"], [232, 232, 292, 293, "CID"], [271, 271, 6, 7, "CID"], [271, 271, 292, 293, "CID"], [287, 287, 6, 7, "CID"], [287, 287, 292, 293, "CID"], [297, 297, 6, 7, "CID"], [297, 297, 292, 293, "CID"]]], "clusters": [], "translated": "<0>尼古丁</0>-诱导的受体机制<17>运动机能亢进</17>在慢性<1>尼古丁</1>治疗的大鼠中。大鼠用生理盐水或<2>尼古丁</2>（每天1.5 mg/kg）预处理，方法是在每只动物皮下植入一个Alzet微型渗透泵，持续释放生理盐水或<3>尼古丁</3> 1、5 和 14 天。在每个预处理期结束时，动物被用于 ( i ) 确定它们对急性注射<4>尼古丁</4>（0.2 mg/kg，s.c.）的运动反应和（ii）测量密度L-[3H]<5>尼古丁</5>和[3H]<19>spiperone</19>在纹状体中的结合位点。我们观察到<6>尼古丁</6>诱导的运动反应、纹状体 L - [ 3H ] <7>尼古丁</7> 和 [3H]<20>spiperone</20>在预处理的动物中没有变化<8>尼古丁</8> 1天。在用<9>尼古丁</9>预处理 5 天的大鼠中，<10>尼古丁</10> - 刺激的运动反应显着增加，这与 L -[3H]<11>尼古丁</11>结合位点以及纹状体中升高的<23>多巴胺</23>（<24>DA</24>）水平。纹状体[3H]<21>spiperone</21>结合位点的数量不受影响。在用<12>尼古丁</12>预处理 14 天的动物中，<13>尼古丁</13>诱导的运动反应仍有待加强。然而，这种反应与纹状体[3H]<22>spiperone</22>结合位点数量增加相关，而纹状体 L - [3H]<14>尼古丁</14>结合位点数量和纹状体<25>DA</25>水平均正常。这些结果表明，慢性<15>尼古丁</15>治疗的大鼠在对<16>尼古丁</16>的反应中出现<18>运动过度活跃</18>，最初是由于烟碱受体密度和<26>DA</26>浓度的增加，然后在纹状体中诱导<27>DA</27>受体超敏。", "revised": true}
{"doc_key": "15673851", "sentences": [["The", "activation", "of", "spinal", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", "may", "contribute", "to", "degeneration", "of", "spinal", "motor", "neurons", "induced", "by", "neuraxial", "morphine", "after", "a", "noninjurious", "interval", "of", "spinal", "cord", "ischemia", ".", "We", "investigated", "the", "relationship", "between", "the", "degeneration", "of", "spinal", "motor", "neurons", "and", "activation", "of", "N", "-", "methyl", "-", "d", "-", "aspartate", "(", "NMDA", ")", "receptors", "after", "neuraxial", "morphine", "following", "a", "noninjurious", "interval", "of", "aortic", "occlusion", "in", "rats", ".", "Spinal", "cord", "ischemia", "was", "induced", "by", "aortic", "occlusion", "for", "6", "min", "with", "a", "balloon", "catheter", ".", "In", "a", "microdialysis", "study", ",", "10", "muL", "of", "saline", "(", "group", "C", ";", "n", "=", "8", ")", "or", "30", "mug", "of", "morphine", "(", "group", "M", ";", "n", "=", "8", ")", "was", "injected", "intrathecally", "(", "IT", ")", "0", ".", "5", "h", "after", "reflow", ",", "and", "30", "mug", "of", "morphine", "(", "group", "SM", ";", "n", "=", "8", ")", "or", "10", "muL", "of", "saline", "(", "group", "SC", ";", "n", "=", "8", ")", "was", "injected", "IT", "0", ".", "5", "h", "after", "sham", "operation", ".", "Microdialysis", "samples", "were", "collected", "preischemia", ",", "before", "IT", "injection", ",", "and", "at", "2", ",", "4", ",", "8", ",", "24", ",", "and", "48", "h", "of", "reperfusion", "(", "after", "IT", "injection", ")", ".", "Second", ",", "we", "investigated", "the", "effect", "of", "IT", "MK", "-", "801", "(", "30", "mug", ")", "on", "the", "histopathologic", "changes", "in", "the", "spinal", "cord", "after", "morphine", "-", "induced", "spastic", "paraparesis", ".", "After", "IT", "morphine", ",", "the", "cerebrospinal", "fluid", "(", "CSF", ")", "glutamate", "concentration", "was", "increased", "in", "group", "M", "relative", "to", "both", "baseline", "and", "group", "C", "(", "P", "<", "0", ".", "05", ")", ".", "This", "increase", "persisted", "for", "8", "hrs", ".", "IT", "MK", "-", "801", "significantly", "reduced", "the", "number", "of", "dark", "-", "stained", "alpha", "-", "motoneurons", "after", "morphine", "-", "induced", "spastic", "paraparesis", "compared", "with", "the", "saline", "group", ".", "These", "data", "indicate", "that", "IT", "morphine", "induces", "spastic", "paraparesis", "with", "a", "concomitant", "increase", "in", "CSF", "glutamate", ",", "which", "is", "involved", "in", "NMDA", "receptor", "activation", ".", "We", "suggest", "that", "opioids", "may", "be", "neurotoxic", "in", "the", "setting", "of", "spinal", "cord", "ischemia", "via", "NMDA", "receptor", "activation", "."]], "ner": [[[23, 23, "Chemical"], [60, 60, "Chemical"], [108, 108, "Chemical"], [134, 134, "Chemical"], [222, 222, "Chemical"], [230, 230, "Chemical"], [283, 283, "Chemical"], [299, 299, "Chemical"], [225, 226, "Disease"], [286, 287, "Disease"], [301, 302, "Disease"], [4, 10, "Chemical"], [47, 53, "Chemical"], [55, 55, "Chemical"], [315, 315, "Chemical"], [334, 334, "Chemical"], [29, 31, "Disease"], [71, 73, "Disease"], [330, 332, "Disease"], [66, 67, "Disease"], [77, 78, "Disease"], [325, 325, "Disease"], [206, 208, "Chemical"], [268, 270, "Chemical"], [238, 238, "Chemical"], [309, 309, "Chemical"]]], "relations": [[[23, 23, 225, 226, "CID"], [23, 23, 286, 287, "CID"], [23, 23, 301, 302, "CID"], [60, 60, 225, 226, "CID"], [60, 60, 286, 287, "CID"], [60, 60, 301, 302, "CID"], [108, 108, 225, 226, "CID"], [108, 108, 286, 287, "CID"], [108, 108, 301, 302, "CID"], [134, 134, 225, 226, "CID"], [134, 134, 286, 287, "CID"], [134, 134, 301, 302, "CID"], [222, 222, 225, 226, "CID"], [222, 222, 286, 287, "CID"], [222, 222, 301, 302, "CID"], [230, 230, 225, 226, "CID"], [230, 230, 286, 287, "CID"], [230, 230, 301, 302, "CID"], [283, 283, 225, 226, "CID"], [283, 283, 286, 287, "CID"], [283, 283, 301, 302, "CID"], [299, 299, 225, 226, "CID"], [299, 299, 286, 287, "CID"], [299, 299, 301, 302, "CID"]]], "clusters": [], "translated": "在<16>脊髓缺血</16>的无损伤间隔后，脊髓<11>N-甲基-D-天冬氨酸</11>受体的激活可能有助于椎管内<0>吗啡</0>诱导的脊髓运动神经元退化。我们研究了椎管内<1>吗啡</1>后脊髓运动神经元的退化与<12>N-甲基-d-天冬氨酸</12>(<13>NMDA</13>)受体激活之间的关系大鼠<19>主动脉闭塞</19>的无损伤间隔。 <17>脊髓缺血</17>通过球囊导管<20>主动脉闭塞</20>6分钟诱导。在微透析研究中，10 μL 生理盐水（C 组；n = 8）或 30 μg <2>吗啡</2>（M 组；n = 8）鞘内注射 (IT) 0.回流后零点五小时，30 μg <3>吗啡</3>（SM组；n=8）或10μL生理盐水（SC组；n=8）鞘内(IT)注射，假手术后0.5 h。在缺血前、IT 注射前和再灌注 2、4、8、24 和 48 小时（IT 注射后）收集微透析样本。其次，我们研究了 IT <22>MK-801</22>（30 μg）对<4>吗啡</4>引起的<8>痉挛性截瘫</8>后脊髓组织病理学变化的影响。IT<5>吗啡</5>后，与基线和C组相比，M组脑脊液(CSF)<24>谷氨酸</24>浓度升高(P<0. 05)。这种增加持续了 8 小时。IT<23>MK-801</23>显着减少了<6>吗啡</6>诱发的<9>痉挛性轻瘫</9>后深色α-运动神经元的数量与生理盐水组相比。这些数据表明 IT <7>吗啡</7>诱发<10>痉挛性轻瘫</10>并伴随 CSF <25>谷氨酸</25> 增加，后者参与<14>NMDA</14>受体激活。我们认为阿片类药物可能在<18>脊髓缺血</18>的情况下具有<21>神经毒性</21>，通过<15>NMDA</15>受体激活。", "revised": true}
{"doc_key": "20195852", "sentences": [["Risk", "of", "nephropathy", "after", "consumption", "of", "nonionic", "contrast", "media", "by", "children", "undergoing", "cardiac", "angiography", ":", "a", "prospective", "study", ".", "Despite", "increasing", "reports", "on", "nonionic", "contrast", "media", "-", "induced", "nephropathy", "(", "CIN", ")", "in", "hospitalized", "adult", "patients", "during", "cardiac", "procedures", ",", "the", "studies", "in", "pediatrics", "are", "limited", ",", "with", "even", "less", "focus", "on", "possible", "predisposing", "factors", "and", "preventive", "measures", "for", "patients", "undergoing", "cardiac", "angiography", ".", "This", "prospective", "study", "determined", "the", "incidence", "of", "CIN", "for", "two", "nonionic", "contrast", "media", "(", "CM", ")", ",", "iopromide", "and", "iohexol", ",", "among", "80", "patients", "younger", "than", "18", "years", "and", "compared", "the", "rates", "for", "this", "complication", "in", "relation", "to", "the", "type", "and", "dosage", "of", "CM", "and", "the", "presence", "of", "cyanosis", ".", "The", "80", "patients", "in", "the", "study", "consecutively", "received", "either", "iopromide", "(", "group", "A", ",", "n", "=", "40", ")", "or", "iohexol", "(", "group", "B", ",", "n", "=", "40", ")", ".", "Serum", "sodium", "(", "Na", ")", ",", "potassium", "(", "K", ")", ",", "and", "creatinine", "(", "Cr", ")", "were", "measured", "24", "h", "before", "angiography", "as", "baseline", "values", ",", "then", "measured", "again", "at", "12", "-", ",", "24", "-", ",", "and", "48", "-", "h", "intervals", "after", "CM", "use", ".", "Urine", "samples", "for", "Na", "and", "Cr", "also", "were", "checked", "at", "the", "same", "intervals", ".", "Risk", "of", "renal", "failure", ",", "Injury", "to", "the", "kidney", ",", "Failure", "of", "kidney", "function", ",", "Loss", "of", "kidney", "function", ",", "and", "End", "-", "stage", "renal", "damage", "(", "RIFLE", "criteria", ")", "were", "used", "to", "define", "CIN", "and", "its", "incidence", "in", "the", "study", "population", ".", "Accordingly", ",", "among", "the", "15", "CIN", "patients", "(", "18", ".", "75", "%", ")", ",", "7", ".", "5", "%", "of", "the", "patients", "in", "group", "A", "had", "increased", "risk", "and", "3", ".", "75", "%", "had", "renal", "injury", ",", "whereas", "5", "%", "of", "group", "B", "had", "increased", "risk", "and", "2", ".", "5", "%", "had", "renal", "injury", ".", "Whereas", "33", ".", "3", "%", "of", "the", "patients", "with", "CIN", "were", "among", "those", "who", "received", "the", "proper", "dosage", "of", "CM", ",", "the", "percentage", "increased", "to", "66", ".", "6", "%", "among", "those", "who", "received", "larger", "doses", ",", "with", "a", "significant", "difference", "in", "the", "incidence", "of", "CIN", "related", "to", "the", "different", "dosages", "of", "CM", "(", "p", "=", "0", ".", "014", ")", ".", "Among", "the", "15", "patients", "with", "CIN", ",", "6", "had", "cyanotic", "congenital", "heart", "diseases", ",", "but", "the", "incidence", "did", "not", "differ", "significantly", "from", "that", "for", "the", "noncyanotic", "patients", "(", "p", "=", "0", ".", "243", ")", ".", "Although", "clinically", "silent", ",", "CIN", "is", "not", "rare", "in", "pediatrics", ".", "The", "incidence", "depends", "on", "dosage", "but", "not", "on", "the", "type", "of", "consumed", "nonionic", "CM", ",", "nor", "on", "the", "presence", "of", "cyanosis", ",", "and", "although", "CIN", "usually", "is", "reversible", ",", "more", "concern", "is", "needed", "for", "the", "prevention", "of", "such", "a", "complication", "in", "children", "."]], "ner": [[[7, 8, "Chemical"], [24, 25, "Chemical"], [75, 76, "Chemical"], [78, 78, "Chemical"], [107, 107, "Chemical"], [185, 185, "Chemical"], [318, 318, "Chemical"], [350, 350, "Chemical"], [418, 418, "Chemical"], [2, 2, "Disease"], [28, 28, "Disease"], [30, 30, "Disease"], [71, 71, "Disease"], [226, 227, "Disease"], [236, 236, "Disease"], [250, 250, "Disease"], [308, 308, "Disease"], [343, 343, "Disease"], [364, 364, "Disease"], [398, 398, "Disease"], [429, 429, "Disease"], [81, 81, "Chemical"], [123, 123, "Chemical"], [83, 83, "Chemical"], [133, 133, "Chemical"], [144, 144, "Chemical"], [146, 146, "Chemical"], [191, 191, "Chemical"], [149, 149, "Chemical"], [151, 151, "Chemical"], [155, 155, "Chemical"], [157, 157, "Chemical"], [193, 193, "Chemical"], [112, 112, "Disease"], [425, 425, "Disease"], [204, 205, "Disease"], [212, 215, "Disease"], [217, 220, "Disease"], [207, 210, "Disease"], [278, 279, "Disease"], [296, 297, "Disease"], [369, 371, "Disease"]]], "relations": [[[7, 8, 2, 2, "CID"], [7, 8, 28, 28, "CID"], [7, 8, 30, 30, "CID"], [7, 8, 71, 71, "CID"], [7, 8, 226, 227, "CID"], [7, 8, 236, 236, "CID"], [7, 8, 250, 250, "CID"], [7, 8, 308, 308, "CID"], [7, 8, 343, 343, "CID"], [7, 8, 364, 364, "CID"], [7, 8, 398, 398, "CID"], [7, 8, 429, 429, "CID"], [24, 25, 2, 2, "CID"], [24, 25, 28, 28, "CID"], [24, 25, 30, 30, "CID"], [24, 25, 71, 71, "CID"], [24, 25, 226, 227, "CID"], [24, 25, 236, 236, "CID"], [24, 25, 250, 250, "CID"], [24, 25, 308, 308, "CID"], [24, 25, 343, 343, "CID"], [24, 25, 364, 364, "CID"], [24, 25, 398, 398, "CID"], [24, 25, 429, 429, "CID"], [75, 76, 2, 2, "CID"], [75, 76, 28, 28, "CID"], [75, 76, 30, 30, "CID"], [75, 76, 71, 71, "CID"], [75, 76, 226, 227, "CID"], [75, 76, 236, 236, "CID"], [75, 76, 250, 250, "CID"], [75, 76, 308, 308, "CID"], [75, 76, 343, 343, "CID"], [75, 76, 364, 364, "CID"], [75, 76, 398, 398, "CID"], [75, 76, 429, 429, "CID"], [78, 78, 2, 2, "CID"], [78, 78, 28, 28, "CID"], [78, 78, 30, 30, "CID"], [78, 78, 71, 71, "CID"], [78, 78, 226, 227, "CID"], [78, 78, 236, 236, "CID"], [78, 78, 250, 250, "CID"], [78, 78, 308, 308, "CID"], [78, 78, 343, 343, "CID"], [78, 78, 364, 364, "CID"], [78, 78, 398, 398, "CID"], [78, 78, 429, 429, "CID"], [107, 107, 2, 2, "CID"], [107, 107, 28, 28, "CID"], [107, 107, 30, 30, "CID"], [107, 107, 71, 71, "CID"], [107, 107, 226, 227, "CID"], [107, 107, 236, 236, "CID"], [107, 107, 250, 250, "CID"], [107, 107, 308, 308, "CID"], [107, 107, 343, 343, "CID"], [107, 107, 364, 364, "CID"], [107, 107, 398, 398, "CID"], [107, 107, 429, 429, "CID"], [185, 185, 2, 2, "CID"], [185, 185, 28, 28, "CID"], [185, 185, 30, 30, "CID"], [185, 185, 71, 71, "CID"], [185, 185, 226, 227, "CID"], [185, 185, 236, 236, "CID"], [185, 185, 250, 250, "CID"], [185, 185, 308, 308, "CID"], [185, 185, 343, 343, "CID"], [185, 185, 364, 364, "CID"], [185, 185, 398, 398, "CID"], [185, 185, 429, 429, "CID"], [318, 318, 2, 2, "CID"], [318, 318, 28, 28, "CID"], [318, 318, 30, 30, "CID"], [318, 318, 71, 71, "CID"], [318, 318, 226, 227, "CID"], [318, 318, 236, 236, "CID"], [318, 318, 250, 250, "CID"], [318, 318, 308, 308, "CID"], [318, 318, 343, 343, "CID"], [318, 318, 364, 364, "CID"], [318, 318, 398, 398, "CID"], [318, 318, 429, 429, "CID"], [350, 350, 2, 2, "CID"], [350, 350, 28, 28, "CID"], [350, 350, 30, 30, "CID"], [350, 350, 71, 71, "CID"], [350, 350, 226, 227, "CID"], [350, 350, 236, 236, "CID"], [350, 350, 250, 250, "CID"], [350, 350, 308, 308, "CID"], [350, 350, 343, 343, "CID"], [350, 350, 364, 364, "CID"], [350, 350, 398, 398, "CID"], [350, 350, 429, 429, "CID"], [418, 418, 2, 2, "CID"], [418, 418, 28, 28, "CID"], [418, 418, 30, 30, "CID"], [418, 418, 71, 71, "CID"], [418, 418, 226, 227, "CID"], [418, 418, 236, 236, "CID"], [418, 418, 250, 250, "CID"], [418, 418, 308, 308, "CID"], [418, 418, 343, 343, "CID"], [418, 418, 364, 364, "CID"], [418, 418, 398, 398, "CID"], [418, 418, 429, 429, "CID"], [81, 81, 2, 2, "CID"], [81, 81, 28, 28, "CID"], [81, 81, 30, 30, "CID"], [81, 81, 71, 71, "CID"], [81, 81, 226, 227, "CID"], [81, 81, 236, 236, "CID"], [81, 81, 250, 250, "CID"], [81, 81, 308, 308, "CID"], [81, 81, 343, 343, "CID"], [81, 81, 364, 364, "CID"], [81, 81, 398, 398, "CID"], [81, 81, 429, 429, "CID"], [123, 123, 2, 2, "CID"], [123, 123, 28, 28, "CID"], [123, 123, 30, 30, "CID"], [123, 123, 71, 71, "CID"], [123, 123, 226, 227, "CID"], [123, 123, 236, 236, "CID"], [123, 123, 250, 250, "CID"], [123, 123, 308, 308, "CID"], [123, 123, 343, 343, "CID"], [123, 123, 364, 364, "CID"], [123, 123, 398, 398, "CID"], [123, 123, 429, 429, "CID"], [83, 83, 2, 2, "CID"], [83, 83, 28, 28, "CID"], [83, 83, 30, 30, "CID"], [83, 83, 71, 71, "CID"], [83, 83, 226, 227, "CID"], [83, 83, 236, 236, "CID"], [83, 83, 250, 250, "CID"], [83, 83, 308, 308, "CID"], [83, 83, 343, 343, "CID"], [83, 83, 364, 364, "CID"], [83, 83, 398, 398, "CID"], [83, 83, 429, 429, "CID"], [133, 133, 2, 2, "CID"], [133, 133, 28, 28, "CID"], [133, 133, 30, 30, "CID"], [133, 133, 71, 71, "CID"], [133, 133, 226, 227, "CID"], [133, 133, 236, 236, "CID"], [133, 133, 250, 250, "CID"], [133, 133, 308, 308, "CID"], [133, 133, 343, 343, "CID"], [133, 133, 364, 364, "CID"], [133, 133, 398, 398, "CID"], [133, 133, 429, 429, "CID"]]], "clusters": [], "translated": "接受心脏血管造影术的儿童服用非离子型<0>造影剂</0>后发生<9>肾病</9>的风险：一项前瞻性研究。尽管关于非离子 <1> 造影剂 </1> 诱发的 <10> 肾病 </10> ( <11> CIN </11> ) 在心脏手术期间住院的成人患者中的报道越来越多，但在儿科的研究是有限的，更不用说对接受心脏血管造影术的患者可能的诱发因素和预防措施的关注。这项前瞻性研究确定了两种非离子型 <2> 造影剂 </2> ( <3> CM </3> )、<21> 碘普罗胺 </21> 和<12> CIN </12> 发生率<23>碘海醇 </23>，在 80 名 18 岁以下的患者中，比较了与 <4> CM </4> 的类型和剂量以及是否存在 <33> 紫绀 </33> 相关的该并发症的发生率。研究中的 80 名患者连续接受<22>碘普罗胺</22>（A 组，n = 40）或<24>碘海醇</24>（B 组，n = 40）。血清<25>钠</25>（<26>Na</26>）、<28>钾</28>（<29>K</29>）和<30>肌酐</30>（<31>Cr</31>)在血管造影前24小时测量作为基线值，然后在<5>CM</5>使用后每隔12、24和48小时再次测量。尿液样本中的 <27> Na </27> 和 <32> Cr </32> 也以相同的时间间隔进行检查。 <35>肾功能衰竭</35>的风险、<38>肾脏损伤</38>、<36>肾功能衰竭</36>、<37>肾功能丧失</37>和结束-阶段<13>肾损伤</13>（RIFLE标准）用于定义<14>CIN</14>及其在研究人群中的发病率。据此，在15例<15>CIN</15>患者中（18. 75%），7． A 组 5 % 的患者风险增加，3 . 75 % 有 <39> 肾损伤 </39>，而 B 组有 5 % 的风险增加，2 . 5% 有<40>肾损伤</40>。而 33。 3%的<16>CIN</16>患者接受了适当剂量的<6>CM</6>，该百分比增加到66。 6%的人接受较大剂量，<17>CIN</17>的发生率与<7>CM</7>的不同剂量有显着差异(p = 0. 014)。 15例<18>CIN</18>患者中，6例有紫绀型<41>先天性心脏病</41>，但与非紫绀型患者的发病率无显着差异(p=0. 243)。 <19>CIN</19>虽然在临床上很少见，但在儿科并不罕见。发病率取决于剂量，但不取决于消耗的非离子 <8> CM </8> 的类型，也不取决于是否存在 <34> 紫绀 </34>，尽管 <20> CIN </20> 通常是可逆的，需要更多关注预防儿童的此类并发症。", "revised": true}
{"doc_key": "1711760", "sentences": [["Delayed", "institution", "of", "hypertension", "during", "focal", "cerebral", "ischemia", ":", "effect", "on", "brain", "edema", ".", "The", "effect", "of", "induced", "hypertension", "instituted", "after", "a", "2", "-", "h", "delay", "following", "middle", "cerebral", "artery", "occlusion", "(", "MCAO", ")", "on", "brain", "edema", "formation", "and", "histochemical", "injury", "was", "studied", ".", "Under", "isoflurane", "anesthesia", ",", "the", "MCA", "of", "14", "spontaneously", "hypertensive", "rats", "was", "occluded", ".", "In", "the", "control", "group", "(", "n", "=", "7", ")", ",", "the", "mean", "arterial", "pressure", "(", "MAP", ")", "was", "not", "manipulated", ".", "In", "the", "hypertensive", "group", "(", "n", "=", "7", ")", ",", "the", "MAP", "was", "elevated", "by", "25", "-", "30", "mm", "Hg", "beginning", "2", "h", "after", "MCAO", ".", "Four", "hours", "after", "MCAO", ",", "the", "rats", "were", "killed", "and", "the", "brains", "harvested", ".", "The", "brains", "were", "sectioned", "along", "coronal", "planes", "spanning", "the", "distribution", "of", "ischemia", "produced", "by", "MCAO", ".", "Specific", "gravity", "(", "SG", ")", "was", "determined", "in", "the", "subcortex", "and", "in", "two", "sites", "in", "the", "cortex", "(", "core", "and", "periphery", "of", "the", "ischemic", "territory", ")", ".", "The", "extent", "of", "neuronal", "injury", "was", "determined", "by", "2", ",", "3", ",", "5", "-", "triphenyltetrazolium", "staining", ".", "In", "the", "ischemic", "core", ",", "there", "was", "no", "difference", "in", "SG", "in", "the", "subcortex", "and", "cortex", "in", "the", "two", "groups", ".", "In", "the", "periphery", "of", "the", "ischemic", "territory", ",", "SG", "in", "the", "cortex", "was", "greater", "(", "less", "edema", "accumulation", ")", "in", "the", "hypertensive", "group", "(", "1", ".", "041", "+", "/", "-", "0", ".", "001", "vs", "1", ".", "039", "+", "/", "-", "0", ".", "001", ",", "P", "less", "than", "0", ".", "05", ")", ".", "The", "area", "of", "histochemical", "injury", "(", "as", "a", "percent", "of", "the", "cross", "-", "sectional", "area", "of", "the", "hemisphere", ")", "was", "less", "in", "the", "hypertensive", "group", "(", "33", "+", "/", "-", "3", "%", "vs", "21", "+", "/", "-", "2", "%", ",", "P", "less", "than", "0", ".", "05", ")", ".", "The", "data", "indicate", "that", "phenylephrine", "-", "induced", "hypertension", "instituted", "2", "h", "after", "MCAO", "does", "not", "aggravate", "edema", "in", "the", "ischemic", "core", ",", "that", "it", "improves", "edema", "in", "the", "periphery", "of", "the", "ischemic", "territory", ",", "and", "that", "it", "reduces", "the", "area", "of", "histochemical", "neuronal", "dysfunction", "."]], "ner": [[[304, 304, "Chemical"], [3, 3, "Disease"], [18, 18, "Disease"], [53, 53, "Disease"], [81, 81, "Disease"], [221, 221, "Disease"], [275, 275, "Disease"], [307, 307, "Disease"], [45, 45, "Chemical"], [170, 176, "Chemical"], [6, 7, "Disease"], [11, 12, "Disease"], [35, 36, "Disease"], [27, 30, "Disease"], [32, 32, "Disease"], [103, 103, "Disease"], [108, 108, "Disease"], [133, 133, "Disease"], [312, 312, "Disease"], [130, 130, "Disease"], [158, 158, "Disease"], [181, 181, "Disease"], [205, 205, "Disease"], [319, 319, "Disease"], [331, 331, "Disease"], [165, 166, "Disease"], [342, 343, "Disease"], [216, 216, "Disease"], [316, 316, "Disease"], [325, 325, "Disease"]]], "relations": [[[304, 304, 3, 3, "CID"], [304, 304, 18, 18, "CID"], [304, 304, 53, 53, "CID"], [304, 304, 81, 81, "CID"], [304, 304, 221, 221, "CID"], [304, 304, 275, 275, "CID"], [304, 304, 307, 307, "CID"]]], "clusters": [], "translated": "局灶性<10>脑缺血</10>期间<1>高血压</1>的延迟发生：对<11>脑水肿</11>的影响。研究了<13>大脑中动脉闭塞</13>（<14>MCAO</14>）延迟2小时后诱发的<2>高血压</2>对<12>脑水肿</12>形成和组织化学损伤的影响。在<8>异氟烷</8>麻醉下，14只自发性<3>高血压</3>大鼠的MCA被闭塞。在对照组（n=7）中，平均动脉压（MAP）没有被操纵。在<4>高血压</4>组（n=7）中，从<15>MCAO</15>后2小时开始，MAP升高25-30 mm Hg。在<16>MCAO</16>后4小时，处死大鼠并收获大脑。大脑沿着冠状面切片，横跨<17>MCAO</17>产生的<19>缺血</19>的分布。在皮质下和皮质的两个部位（<20>缺血</20>区域的核心和外围）测定比重（SG）。<25>神经元损伤的程度</25>通过<9>2，3，5-三苯基四氮唑</9>染色来确定。在<21>缺血性</21>核心中，两组皮质下和皮质的SG没有差异。在<22>缺血性</22>区域的外围，<5>高血压</5>组皮质中的SG更大（<27>水肿</27>积聚较少）（1.041+/-0.001 vs 1.039+/-0.001，P小于0.05）。<6>高血压</6>组的组织化学损伤面积（占半球横截面积的百分比）较小（33+/-3%对21+/-2%，P＜0.05）。数据表明，<18>MCAO</18>后2小时开始的<0>苯肾上腺素</0>诱导的<7>高血压</7>不会加重<23>缺血性</23>核心的<28>水肿</28>，它改善了<24>缺血性</24>区域外围的<29>水肿</29>，并减少了组织化学<26>神经元功能障碍的面积</26>。”", "revised": true}
{"doc_key": "12571256", "sentences": [["Nephrotoxic", "effects", "in", "high", "-", "risk", "patients", "undergoing", "angiography", ".", "BACKGROUND", ":", "The", "use", "of", "iodinated", "contrast", "medium", "can", "result", "in", "nephropathy", ".", "Whether", "iso", "-", "osmolar", "contrast", "medium", "is", "less", "nephrotoxic", "than", "low", "-", "osmolar", "contrast", "medium", "in", "high", "-", "risk", "patients", "is", "uncertain", ".", "METHODS", ":", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "prospective", ",", "multicenter", "study", "comparing", "the", "nephrotoxic", "effects", "of", "an", "iso", "-", "osmolar", ",", "dimeric", ",", "nonionic", "contrast", "medium", ",", "iodixanol", ",", "with", "those", "of", "a", "low", "-", "osmolar", ",", "nonionic", ",", "monomeric", "contrast", "medium", ",", "iohexol", ".", "The", "study", "involved", "129", "patients", "with", "diabetes", "with", "serum", "creatinine", "concentrations", "of", "1", ".", "5", "to", "3", ".", "5", "mg", "per", "deciliter", "who", "underwent", "coronary", "or", "aortofemoral", "angiography", ".", "The", "primary", "end", "point", "was", "the", "peak", "increase", "from", "base", "line", "in", "the", "creatinine", "concentration", "during", "the", "three", "days", "after", "angiography", ".", "Other", "end", "points", "were", "an", "increase", "in", "the", "creatinine", "concentration", "of", "0", ".", "5", "mg", "per", "deciliter", "or", "more", ",", "an", "increase", "of", "1", ".", "0", "mg", "per", "deciliter", "or", "more", ",", "and", "a", "change", "in", "the", "creatinine", "concentration", "from", "day", "0", "to", "day", "7", ".", "RESULTS", ":", "The", "creatinine", "concentration", "increased", "significantly", "less", "in", "patients", "who", "received", "iodixanol", ".", "From", "day", "0", "to", "day", "3", ",", "the", "mean", "peak", "increase", "in", "creatinine", "was", "0", ".", "13", "mg", "per", "deciliter", "in", "the", "iodixanol", "group", "and", "0", ".", "55", "mg", "per", "deciliter", "in", "the", "iohexol", "group", "(", "P", "=", "0", ".", "001", ";", "the", "increase", "with", "iodixanol", "minus", "the", "increase", "with", "iohexol", ",", "-", "0", ".", "42", "mg", "per", "deciliter", "[", "95", "percent", "confidence", "interval", ",", "-", "0", ".", "73", "to", "-", "0", ".", "22", "]", ")", ".", "Two", "of", "the", "64", "patients", "in", "the", "iodixanol", "group", "(", "3", "percent", ")", "had", "an", "increase", "in", "the", "creatinine", "concentration", "of", "0", ".", "5", "mg", "per", "deciliter", "or", "more", ",", "as", "compared", "with", "17", "of", "the", "65", "patients", "in", "the", "iohexol", "group", "(", "26", "percent", ")", "(", "P", "=", "0", ".", "002", ";", "odds", "ratio", "for", "such", "an", "increase", "in", "the", "iodixanol", "group", ",", "0", ".", "09", "[", "95", "percent", "confidence", "interval", ",", "0", ".", "02", "to", "0", ".", "41", "]", ")", ".", "No", "patient", "receiving", "iodixanol", "had", "an", "increase", "of", "1", ".", "0", "mg", "per", "deciliter", "or", "more", ",", "but", "10", "patients", "in", "the", "iohexol", "group", "(", "15", "percent", ")", "did", ".", "The", "mean", "change", "in", "the", "creatinine", "concentration", "from", "day", "0", "to", "day", "7", "was", "0", ".", "07", "mg", "per", "deciliter", "in", "the", "iodixanol", "group", "and", "0", ".", "24", "mg", "per", "deciliter", "in", "the", "iohexol", "group", "(", "P", "=", "0", ".", "003", ";", "value", "in", "the", "iodixanol", "group", "minus", "the", "value", "in", "the", "iohexol", "group", ",", "-", "0", ".", "17", "mg", "per", "deciliter", "[", "95", "percent", "confidence", "interval", ",", "-", "0", ".", "34", "to", "-", "0", ".", "07", "]", ")", ".", "CONCLUSIONS", ":", "Nephropathy", "induced", "by", "contrast", "medium", "may", "be", "less", "likely", "to", "develop", "in", "high", "-", "risk", "patients", "when", "iodixanol", "is", "used", "rather", "than", "a", "low", "-", "osmolar", ",", "nonionic", "contrast", "medium", "."]], "ner": [[[93, 93, "Chemical"], [239, 239, "Chemical"], [256, 256, "Chemical"], [323, 323, "Chemical"], [388, 388, "Chemical"], [429, 429, "Chemical"], [448, 448, "Chemical"], [0, 0, "Disease"], [21, 21, "Disease"], [31, 31, "Disease"], [63, 63, "Disease"], [478, 478, "Disease"], [77, 77, "Chemical"], [204, 204, "Chemical"], [228, 228, "Chemical"], [251, 251, "Chemical"], [290, 290, "Chemical"], [344, 344, "Chemical"], [369, 369, "Chemical"], [418, 418, "Chemical"], [441, 441, "Chemical"], [495, 495, "Chemical"], [104, 104, "Chemical"], [137, 137, "Chemical"], [154, 154, "Chemical"], [183, 183, "Chemical"], [195, 195, "Chemical"], [218, 218, "Chemical"], [301, 301, "Chemical"], [401, 401, "Chemical"], [101, 101, "Disease"]]], "relations": [[[93, 93, 0, 0, "CID"], [93, 93, 21, 21, "CID"], [93, 93, 31, 31, "CID"], [93, 93, 63, 63, "CID"], [93, 93, 478, 478, "CID"], [239, 239, 0, 0, "CID"], [239, 239, 21, 21, "CID"], [239, 239, 31, 31, "CID"], [239, 239, 63, 63, "CID"], [239, 239, 478, 478, "CID"], [256, 256, 0, 0, "CID"], [256, 256, 21, 21, "CID"], [256, 256, 31, 31, "CID"], [256, 256, 63, 63, "CID"], [256, 256, 478, 478, "CID"], [323, 323, 0, 0, "CID"], [323, 323, 21, 21, "CID"], [323, 323, 31, 31, "CID"], [323, 323, 63, 63, "CID"], [323, 323, 478, 478, "CID"], [388, 388, 0, 0, "CID"], [388, 388, 21, 21, "CID"], [388, 388, 31, 31, "CID"], [388, 388, 63, 63, "CID"], [388, 388, 478, 478, "CID"], [429, 429, 0, 0, "CID"], [429, 429, 21, 21, "CID"], [429, 429, 31, 31, "CID"], [429, 429, 63, 63, "CID"], [429, 429, 478, 478, "CID"], [448, 448, 0, 0, "CID"], [448, 448, 21, 21, "CID"], [448, 448, 31, 31, "CID"], [448, 448, 63, 63, "CID"], [448, 448, 478, 478, "CID"]]], "clusters": [], "translated": "<7> 肾毒性</7> 对接受血管造影术的高危患者的影响。背景：使用含碘造影剂可导致<8>肾病</8>。对于高危患者，等渗造影剂<9>肾毒性</9>是否低于低渗造影剂尚不确定。方法：我们进行了一项随机、双盲、前瞻性、多中心研究，比较了等渗、二聚、非离子造影剂 <12> 碘克沙醇 </12> 与一种低渗、非离子、单体造影剂，<0>碘海醇</0>的<10>肾毒性效应</10>。该研究涉及 129 名<30>糖尿病</30>患者，血清<22>肌酐</22>浓度为 1 。 5比3。接受冠状动脉或主动脉股血管造影术的患者每分升 5 毫克。主要终点是血管造影后三天内<23>肌酐</23>浓度相对于基线的峰值增加。其他终点是 <24> 肌酐 </24> 浓度增加 0 。每分升5毫克以上，增加1。 0 毫克/分升或更多，以及从第 0 天到第 7 天 <25> 肌酐</25> 浓度的变化。结果：接受<13>碘克沙醇</13>治疗的患者<26>肌酐</26>浓度增加明显较少。从第 0 天到第 3 天，<27>肌酐</27>的平均峰值增加为 0 。 <14> 碘克沙醇 </14> 组为 13 mg/dL，0 . <1> 碘海醇 </1> 组每分升 55 毫克（ P = 0 . 001 ；<15> 碘克沙醇 </15> 的增加减去 <2> 碘海醇 </2> 的增加，- 0 . 42毫克每分升 [95% 置信区间，-0. 73 至 - 0. 22]）。 <16>碘克沙醇</16>组的 64 名患者中有两名 (3%) 的<28>肌酐</28>浓度增加了 0 . 5 mg/dL 或更多，与 <3> 碘海醇 </3> 组 65 名患者中的 17 名（ 26 % ）相比（ P = 0 . 002 ；<17> 碘克沙醇 <17 增加的比值比 </17> 组，0.09 [95% 置信区间，0.02 至 0.41])。接受 <18> 碘克沙醇 </18> 治疗的患者没有增加 1 。 0 毫克/分升或更多，但 <4> 碘海醇</4> 组中有 10 名患者 (15%) 这样做了。从第 0 天到第 7 天，<29> 肌酐 </29> 浓度的平均变化为 0 。 <19>碘克沙醇</19>组07 mg/dL，0 . <5>碘海醇</5>组24 mg/dL（P=0 . 003；<20>碘克沙醇</20>组减去<6>碘海醇</6>组的值，- 0 . 17 毫克每分升 [95% 置信区间，- 0 . 34 至 - 0 . 07])。结论：当使用<21>碘克沙醇</21>而不是低渗非离子造影剂时，造影剂引起的<11>肾病</11>在高危患者中发生的可能性较小。", "revised": true}
{"doc_key": "11752998", "sentences": [["Preliminary", "efficacy", "assessment", "of", "intrathecal", "injection", "of", "an", "American", "formulation", "of", "adenosine", "in", "humans", ".", "BACKGROUND", ":", "Preclinical", "studies", "of", "intrathecal", "adenosine", "suggest", "it", "may", "be", "effective", "in", "the", "treatment", "of", "acute", "and", "chronic", "pain", "in", "humans", ",", "and", "preliminary", "studies", "in", "volunteers", "and", "patients", "with", "a", "Swedish", "formulation", "of", "adenosine", "suggests", "it", "may", "be", "effective", "in", "hypersensitivity", "states", "but", "not", "with", "acute", "noxious", "stimulation", ".", "The", "purpose", "of", "this", "study", "was", "to", "screen", "for", "efficacy", "of", "a", "different", "formulation", "of", "adenosine", "marketed", "in", "the", "US", ",", "using", "both", "acute", "noxious", "stimulation", "and", "capsaicin", "-", "evoked", "mechanical", "hypersensitivity", ".", "METHODS", ":", "Following", "Food", "and", "Drug", "Administration", "and", "institutional", "review", "board", "approval", "and", "written", "informed", "consent", ",", "65", "volunteers", "were", "studied", "in", "two", "trials", ":", "an", "open", "-", "label", ",", "dose", "-", "escalating", "trial", "with", "intrathecal", "adenosine", "doses", "of", "0", ".", "25", "-", "2", ".", "0", "mg", "and", "a", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "of", "adenosine", ",", "2", "mg", ".", "Cerebrospinal", "fluid", "was", "obtained", "for", "pharmacokinetic", "analysis", ",", "and", "pain", "ratings", "in", "response", "to", "acute", "heat", "stimuli", "and", "areas", "of", "mechanical", "hyperalgesia", "and", "allodynia", "after", "intradermal", "capsaicin", "injection", "were", "determined", ".", "RESULTS", ":", "Adenosine", "produced", "no", "effect", "on", "pain", "report", "to", "acute", "noxious", "thermal", "or", "chemical", "stimulation", "but", "reduced", "mechanical", "hyperalgesia", "and", "allodynia", "from", "intradermal", "capsaicin", "injection", "for", "at", "least", "24", "h", ".", "In", "contrast", ",", "residence", "time", "of", "adenosine", "in", "cerebrospinal", "fluid", "was", "short", "(", "<", "4", "h", ")", ".", "CONCLUSIONS", ":", "These", "results", "show", "selective", "inhibition", "by", "intrathecal", "adenosine", "of", "hypersensitivity", ",", "presumed", "to", "reflect", "central", "sensitization", "in", "humans", "after", "peripheral", "capsaicin", "injection", ".", "The", "long", "-", "lasting", "effect", "is", "consistent", "with", "that", "observed", "in", "preliminary", "reports", "of", "patients", "with", "chronic", "neuropathic", "pain", "and", "is", "not", "due", "to", "prolonged", "residence", "of", "adenosine", "in", "cerebrospinal", "fluid", "."]], "ner": [[[93, 93, "Chemical"], [188, 188, "Chemical"], [217, 217, "Chemical"], [265, 265, "Chemical"], [182, 183, "Disease"], [185, 185, "Disease"], [211, 212, "Disease"], [214, 214, "Disease"], [11, 11, "Chemical"], [21, 21, "Chemical"], [50, 50, "Chemical"], [81, 81, "Chemical"], [135, 135, "Chemical"], [157, 157, "Chemical"], [195, 195, "Chemical"], [231, 231, "Chemical"], [252, 252, "Chemical"], [295, 295, "Chemical"], [31, 34, "Disease"], [57, 57, "Disease"], [97, 97, "Disease"], [254, 254, "Disease"], [171, 171, "Disease"], [200, 200, "Disease"], [285, 286, "Disease"]]], "relations": [[[93, 93, 182, 183, "CID"], [93, 93, 185, 185, "CID"], [93, 93, 211, 212, "CID"], [93, 93, 214, 214, "CID"], [188, 188, 182, 183, "CID"], [188, 188, 185, 185, "CID"], [188, 188, 211, 212, "CID"], [188, 188, 214, 214, "CID"], [217, 217, 182, 183, "CID"], [217, 217, 185, 185, "CID"], [217, 217, 211, 212, "CID"], [217, 217, 214, 214, "CID"], [265, 265, 182, 183, "CID"], [265, 265, 185, 185, "CID"], [265, 265, 211, 212, "CID"], [265, 265, 214, 214, "CID"]]], "clusters": [], "translated": "“鞘内注射<8>腺苷</8>美国制剂对人体的初步疗效评估。背景：鞘内<9>腺苷</9>的临床前研究表明，它可能对治疗人类<18>急性和慢性疼痛</18>有效，对志愿者和使用瑞典<10>腺苷</10>制剂的患者的初步研究表明，其可能对<19>超敏</19>状态有效，但对急性伤害性刺激无效。本研究的目的是筛选在美国销售的不同配方的<11>腺苷</11>的疗效，同时使用急性毒性刺激和<0>辣椒素</0>诱发的机械性<20>超敏反应</20>。方法：根据美国食品药品监督管理局和机构审查委员会的批准和书面知情同意书，65名志愿者在两项试验中进行了研究：一项开放标签、剂量递增试验，鞘内注射<12>腺苷</12>剂量为0。25 - 2 . 0 mg和<13>腺苷</13>2 mg的双盲安慰剂对照试验。获得脑脊液进行药代动力学分析，并确定对急性热刺激的<22>疼痛</22>评分，以及皮内注射<1>辣椒素</1>后<4>机械痛觉过敏</4>和<5>异常性疼痛</5>的区域。结果：<14>腺苷</14>对急性伤害性热刺激或化学刺激的<23>疼痛</23>报告没有影响，但减少了皮内注射<2>辣椒素</2>至少24小时的<6>机械性痛觉过敏</6>和<7>异常性疼痛</7>。相反，<15>腺苷</15>在脑脊液中的停留时间较短（<4小时）。结论：这些结果显示鞘内<16>腺苷</16>对<21>超敏反应</21>的选择性抑制作用，被认为反映了外周<3>辣椒素</3>注射后人类的中枢敏化作用。这种持久的影响与慢性<24>神经性疼痛</24>患者的初步报告中观察到的效果一致，而不是由于<17>腺苷</17>在脑脊液中的长期停留", "revised": true}
